[{"article": "We're sorry, but Newspapers.com doesn't work properly without JavaScript enabled. You will need to enable Javascript by changing your browser settings. Learn how to enable it.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article interviews only the president of the company that is developing the drug. The article includes no information from independent sources.\u00a0 ", "answer": 0}, {"article": "We could not find the requested page.\n\nPlease visit our home page to explore our services.", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We are told that \u201cthis work was supported in part by the National Institutes of Health and in part by the Paul and Irma Milstein Family Foundation and the American Skin Association.\u201d", "answer": 1}, {"article": "Steroids as a class of drugs are one of the most effective medications in the treatment of ALL.\nThe high-dose methotrexate protocol outlined in the study - along with a parallel finding that the steroid decadron is beneficial for younger (but not older) patients - has quickly become the standard practice for the treatment of high-risk ALL patients in North America, the researchers report in the April XX issue of the Journal of Clinical Oncology.\nPrior to the release of the initial study results, which were first presented last year at the annual meeting of the American Society of Clinical Oncology (ASCO), the standard of care for high-risk ALL patients in North America was escalating methotrexate.\n\"One of the improvements in outcome for ALL overall has been using methotrexate in a more intense fashion, by giving higher doses,\" said senior investigator William L. Carroll, MD, the Julie and Edward J. Minskoff Professor of Pediatrics, director of the Stephen D. Hassenfeld Children's Center for Cancer and Blood Disorders at NYU Langone and director emeritus of NYU Langone's Perlmutter Cancer Center.\n\"The improvement in cure rates for ALL over the last few decades, for the most part, has not come through the introduction of new medications, but through using existing medications in new ways, in terms of their dose and schedule,\" Dr. Carroll said.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "While the release does say that this clinical trial was run by the Children\u2019s Oncology Group, which is funded by the National Cancer Institute and the National Institutes of Health, it makes no mention of possible conflicts of interest.\u00a0 Compounding that is the fact that the published study says, \u201cDisclosures provided by the authors are available with this article at www.jco.org,\u201d but that information is behind the journal\u2019s paywall for most readers, so it\u2019s unknown if there is, or is not, a conflict. It appears as though five of the authors (out of a total of about 20) have some conflicts of interest, mostly from several types of drug company payments.", "answer": 0}, {"article": "A flu drug \u2014 shown to reduce the duration of symptoms \u2014 could upend treatment in U.S.\n\nNext winter, there may be a new drug for people who contract influenza \u2014 one that appears to be able to shut down infection quickly and, unlike anything else on the market, can be taken as a single dose.\n\nThe Food and Drug Administration on Tuesday said that it would give the drug, baloxavir marboxil, a priority review, and approval has the potential to upend the way influenza is treated.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article includes two sources: Mark Eisner, Genentech\u2019s VP of product development for immunology, infectious diseases and ophthalmology and Richard Webby, head of the World Health Organization\u2019s influenza collaborating center at St. Jude Children\u2019s Research Hospital in Memphis.\nEisner\u2019s affiliation with Genentech, the drug\u2019s manufacturer, is clearly noted. Webby does not appear to have any conflicts of interest. The article would have been stronger if it had included a third source who commented on what\u2013if anything\u2013is known about whether reducing the duration of symptoms leads to reduced levels of transmission that result in fewer people contracting the flu and fewer deaths.", "answer": 1}, {"article": "In a separate analysis published in the same issue of JAMA Cardiology, researchers used data from the PARADIGM-HF trial to model the health consequences and cost-effectiveness of Entresto over a 30-year time period.3 They compared Entresto to the ACE-inhibitor enalapril and found Entresto was associated with more than a year longer average survival time, and that it was cost-effective compared to enalapril when these medications were used with other standard of care therapies.3 For every 1,000 patients treated with Entresto vs. enalapril, potentially 59.7 HF hospital admissions could be averted per each year alive in the model.3 In addition, Entresto increased life expectancy at an incremental cost-effectiveness ratio consistent with other high-value widely accepted cardiovascular interventions such as implantable cardioverter defibrillators (ICDs) and cholesterol-lowering statins before they became generic.3\n\nAbout Heart Failure\n\nHeart failure is a debilitating and life-threatening condition, which impacts nearly 6 million Americans and is the leading cause of hospitalization among Americans over the age of 65.4,8 About half of people with heart failure have heart failure with reduced ejection fraction (HFrEF).5 Reduced ejection fraction means the heart does not contract with enough force, so less blood is pumped out.9 Heart failure presents a major and growing health-economic burden that currently exceeds $30 billion in the United States, which accounts for both direct and indirect costs.10\n\nAbout Entresto\n\nEntresto is a twice-a-day medicine that reduces the strain on the failing heart.\nThe target treatment dose of Entresto is 97/103 mg twice daily.11\n\nNovartis is committed to providing patients with affordable access and resources through Entresto Central.\nIt does this by enhancing the protective neurohormonal systems (Natriuretic Peptide system) while simultaneously inhibiting the harmful effects of the overactive renin-angiotensin-aldosterone system (RAAS).11 Other heart failure medicines only block the harmful effects of the overactive RAAS.12 Entresto contains the neprilysin inhibitor sacubitril, and the angiotensin receptor blocker (ARB) valsartan.11\n\nEntresto is indicated in the US to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.11 Entresto is usually administered in conjunction with other heart failure therapies, in place of an Angiotensin Converting Enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB).11 Entresto film-coated tablets are available in three dosage strengths: 24/26 mg, 49/51 mg, and 97/103 mg (sacubitril/valsartan).11 These doses are referred to as 50 mg, 100 mg, and 200 mg in the clinical trial literature including the New England Journal of Medicine publication of the results of PARADIGM-HF.\n2016;1(6):1-4. doi:10.1001/jamacardio.2016.1724\n\u2022 Yancy CW, Jessup M, Bozkurt B, Butler J, Casey Jr DE, Colvin MM, Drazner, MH, Filippatos G, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride, PE, Peterson PN, Stevenson LW, Westlake C, 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure, Journal of the American College of Cardiology (2016), doi: 10.1016/j.jacc.2016.05.011.\nHCUP facts and figures: statistics on hospital-based care in , 2009. : Agency for Healthcare Research and Quality, 2011.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release is coming from the manufacturer of the drug, Entresto, so the conflict of interest is clear. However, we would have liked it better if the release had identified, as the study did, that the principal author of the study receives grant support from Novartis, and several other authors are employees of Novartis.", "answer": 0}, {"article": "The Ache: The bathroom scale shows how much you\u2019ve gained or lost in pounds, but gives no information about whether the change is fat or muscle.\n\nThe Claim: A whole-body scan, called Dual-Energy X-ray Absorptiometry, or DXA for short, gives a detailed snapshot of your body composition, including how your body weight breaks down into fat, bone and lean tissue.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are multiple sources here with conflicts of interest, but they are all clearly identified \u2014 and the story includes at least two sources who appear to have no conflict of interest. However, it would not have been difficult to find someone with a much more skeptical take on this technology, and we wish that perspective had been included.", "answer": 1}, {"article": "\"At age 11, I developed this condition, called alopecia areata, where I lost my hair,\" says Velasquez-Manoff, a science writer in Berkeley, Calif. \"It started in patches, but eventually I lost it all.\"\nYou see, the worms don't shut down the immune system completely \u2014 just enough so that the immune cells won't attack the worm.\nThe first study to finish was a big one in Europe that looked to see if pig whipworms helped with Crohn's disease.\nIt's unclear why the worms haven't worked in these trials, Loke says.\nHe says the benefits of the worms definitely didn't outweigh the bad side effects.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story uses several sources with various points of view, and we couldn\u2019t find any outright conflicts of interest.", "answer": 1}, {"article": "It\u2019s not the first study to show a potential anticancer effect of aspirin and other similar painkillers \u2014 a class of medications known and nonsteroidal anti-inflammatory drugs, or NSAIDs.\nEach case was compared to 10 matched controls who did not develop the disease.\n\u201cAlso, this potential cancer-protective effect should be taken into account when discussing benefits and harms of NSAID use.\u201d\n\nAlice Park is a writer at TIME.\nOverall, 18,532 cases of skin cancer were included in the study.\n\u201cWe hope that the potential cancer-protective effect of NSAIDs will inspire more research on skin cancer prevention,\u201d Johannesdottir said in a statement.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources were quoted. An independent voice could have helped address some of the unanswered questions.", "answer": 0}, {"article": "The blood test that millions of men undergo each year to check for prostate cancer leads to so much unnecessary anxiety, surgery and complications that doctors should stop testing elderly men, and it remains unclear whether the screening is worthwhile for younger men, a federal task force concluded yesterday.\n\"The benefit of screening at this time is uncertain, and if there is a benefit, it's likely to be small,\" said Ned Calonge, who chairs the 16-member U.S. Preventive Services Task Force.\n\"We have seen a dramatic drop in mortality,\" said J. Brantley Thrasher, chairman of the urology department at the University of Kansas and a spokesman for the American Urological Association.\nThe guidelines address perhaps the most important and contentious issue in men's health, and were praised by officials at several leading medical groups, including the National Cancer Institute and the American Cancer Society.\nIn fact, there are several ways in which screening can actually be harmful,\" said Howard L. Parnes of the National Cancer Institute.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included comments from a number of individuals with relevant expertise. \u00a0The story did not do an adequate job of indicating whether those quoted served on the recommendation task force other than for Ned Calonge, who was mentioned as chair of the US Preventive Services Task Force.", "answer": 1}, {"article": "Migraines are characterised by an intense, throbbing headache, sensitivity to light and noise, nausea, vomiting, low energy, and visual disturbances.\nThe research revealed that by months four to six, at least a 50% reduction in mean migraine days per month was achieved for just over 43% of patients injected under the skin with 70-mg of erenumab each month, while half of patients injected with the higher dose of 140-mg had such results.\n\u201cThe results of Strive represent a real transition for migraine patients from poorly understood, re-purposed treatments, to a specific migraine-designed therapy.\u201d\n\nSimon Evans, chief executive of the charity Migraine Action, said: \u201cMigraine is too often trivialised as just a headache when, in reality, it can be a debilitating, chronic condition that can destroy lives.\nThe condition is linked to depression and sick days caused by migraine are estimated to cost the UK economy more than \u00a32bn per year.\n\u201cThis is probably the first example of a migraine preventing drug that was rationally designed, rather than serendipitously found,\u201d he added.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Many news stories fail this test, but this one shines: Not only does the article cite an expert who wasn\u2019t involved in the study, but it also discloses that the drugmakers of erenumab \u2014 Amgen and Novartis \u2014 funded the study, supplied the drug, and did the data analyses. (One thing the story missed, though: The first draft of the study was put together by a company-funded writer.)", "answer": 1}, {"article": "\"The issue is, can you detect these in patients that don't have advanced cancer?\" Venook said. \"The answer is, we don't know.\" The numbers tested by the MD Anderson researchers -- 251 patients with pancreatic cancer (five of whom had very early lesions), 32 with chronic pancreatitis and 120 healthy controls -- aren't nearly large enough to draw such conclusions. And getting a clear answer, Venook said, would probably require lengthy and expensive studies on very large populations.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "In addition to quoting from the study in Nature\u00a0and an editorial published alongside it,\u00a0the article includes an independent expert who provides a measured and objective assessment of the finding which helps put the study in better context. While stating that the research is \u201ca cool observation,\u201d he added that \u201cthis is not a biomarker yet\u201d since the study was too small to draw a conclusion.", "answer": 1}, {"article": "Does it cross her mind what would have happened if she didn't have the ultrasound?\nAnd it's an important story, because about half of women under the age of 50 are found to have dense breast tissue when they get their mammograms.\nIn today's study of about 2,809 women with dense tissue and other risk factors, mammography alone found only half of the cancers.\n\"It's just very difficult to be able to pick out the boundaries of that mass.\"\n\"This could have gone on for years before anybody found it, and it could have been a whole different story,\" she said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only physician or expert interviewed in the story was someone who only commented on how ultrasound works \u2013 not on the findings of the study. So the merits of the study were taken at face value without any independent expert perspective.\u00a0 \n", "answer": 0}, {"article": "CHICAGO (Reuters) - Radiation from CT scans done in 2007 will cause 29,000 cancers and kill nearly 15,000 Americans, researchers said on Monday.\nThe researchers said efforts need to be taken to minimize CT radiation exposure, including reducing the number of unnecessary tests, cutting the dose per study, and standardizing the doses across facilities.\nThey found radiation dosage varied widely between different types of CT studies, from a median or midpoint of 2 millisieverts for a routine head CT scan to 31 millisieverts for a scan of the abdomen and pelvis, which often involves taking multiple images of the same organ.\nThat is a lot of excess deaths.\u201d\n\nCT scans give doctors a view inside the body, often eliminating the need for exploratory surgery.\n\u201cWhat we learned is there is a significant amount of radiation with these CT scans, more than what we thought, and there is a significant number of cancers,\u201d said Dr. Rita Redberg, editor of the Archives of Internal Medicine, where the studies were published.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not quote sources other than the authors of the study and the journal editor. The story should have quoted independent experts who could have provided some perspective on the importance of these results.", "answer": 0}, {"article": "But she cautioned that longer trials are needed to fully assess the drug.\n\u201cOverall, these are the most exciting data we\u2019ve seen in asthma in 20 years,\u201d said Dr. Sally Wenzel, lead investigator for the 104-patient study of dupilumab, an injectable treatment being developed by Regeneron Pharmaceuticals Inc and French drugmaker Sanofi.\n\u201cWe do not know whether dupilumab will be effective in other patient populations,\u201d the editorial said, including patients that stay on their standard therapies and who do not have high levels of eosinophils.\n\u201cThis asthma data and the data we already have in atopic dermatitis really raises the possibility the scientific community has finally hit upon the key pathway across all these allergic diseases,\u201d George Yancopoulos, Regeneron\u2019s research chief, said in an interview.\n\u201cWe have been treating asthma with sort of Band-Aid therapies that didn\u2019t get at the underlying causes,\u201d Wenzel said in an interview, adding that dupilumab could be an important step in going to the root of the problem.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There was too much reliance on sources connected to the trial. The very first quote is from the lead researcher, effusing: \u201cOverall, these are the most exciting data we\u2019ve seen in asthma in 20 years,\u201d said Dr. Sally Wenzel, lead investigator for the 104-patient study of dupilumab, an injectable treatment being developed by Regeneron Pharmaceuticals Inc and French drugmaker Sanofi. The only other person quoted is George Yancopoulos, Regeneron\u2019s research chief. At the very end, an anonymous editorial is quoted with some words of caution that most readers won\u2019t even get to.\nAt one point the story said \u201cresearchers expressed optimism.\u201d\u00a0 Which researchers?\u00a0 Those funded to do the study?", "answer": 0}, {"article": "The drug briakinumab reduced psoriasis symptoms by at least 75 percent in nearly 82 percent of those taking it, compared to just 40 percent of those on methotrexate.\n\"Very high levels of response\" were observed and maintained throughout the study period, said lead researcher Dr. Kristian Reich, a professor of dermatology at the University of Gottingen and a managing partner at Dermatologikum Hamburg, both in Germany.\nBriakinumab works by dampening the immune system response that causes psoriasis, said Bruce Bebo, director of research and medical programs for the National Psoriasis Foundation, based in Portland, Ore.\n\nMore serious infections were seen in people taking briakinumab (2.6 percent) vs. those taking methotrexate (1.8 percent).\nThere were also two cases of cancer in people taking briakinumab and none in the methotrexate group.\nThe study volunteers had had psoriasis for at least six months, and the condition affected at least 10 percent of their bodies.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did state that Abbott Labs had funded the study and it did get an independent comment from the National Psoriasis Foundation.\nBut we judge this to be unsatisfactory because the story did not disclose what is clearly disclosed in the journal article \u2013 that the principal investigator:\nIt also didn\u2019t disclose what the journal article disclosed, that Abbott personnel helped write the manuscript and helped with the statistical analyses.\nThe Statement of Principles of the Association of Health Care Journalists includes these clauses:\n\u00a0", "answer": 0}, {"article": "\"The challenge in prostate cancer is how to look at all of these patterns within a cell, but hone in on the gene activity that suggests cancer, and not only this, what type of cancer - dangerous or manageable?\nThey were able to do this using a computer algorithm, which left the team with 17 possible genetic markers for prostate cancer.\nThis is part of the normal functioning of the human body and can tell individuals apart, but the process can sometimes go wrong, resulting in various diseases.\nIt is now understood that to find the different levels of cancer, scientists have to identify genes that have been altered in different cancer types.\nIt is believed that success rates could be hindered as a result of treating all prostate cancers in the same way.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "All funding sources were listed at the bottom of the release.", "answer": 1}, {"article": "I'll Be Me ,\" Saturday, November 7, at 8 p.m.\nAntioxidant may be most effective in combination\n\nThis is one of the first studies to look not only at these biomarkers, but also the metabolites of resveratrol in spinal fluid, to show that resveratrol is probably getting into the brain, said Dr. Giulio M. Pasinetti, who is the Saunders Family Chair and professor in neurology at the Icahn School of Medicine at Mount Sinai.\n\"The study is encouraging enough that we should certainly go ahead and do a [larger] clinical trial because we showed that it is safe and does have significant effects on Alzheimer's biomarkers,\" said Dr. R. Scott Turner, professor of neurology at Georgetown University Medical Center and lead investigator of the study, which was published on Friday in the journal Neurology.\nThe main goal of the current study, which included 119 patients, was to find out whether high doses of resveratrol could be safe.\nThe only small concern they found was that patients taking resveratrol lost about two pounds during the one-year study, and weight loss is already a problem with Alzheimer's, Turner said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes input from two outside sources who provided important insight into the work. The story is much stronger thanks to the input of these two sources, who addressed the novelty of the work, the need for additional research, and how resveratrol could potentially become part of a multifaceted treatment regimen. The story doesn\u2019t mention who funded the research (NIH), which would have been good. And while the story doesn\u2019t mention that several study authors had ties to pharmaceutical companies, it\u2019s not clear that those companies have any ties to the research.\nSo the overall rating here is Satisfactory, although we did notice the spokesperson from the Alzheimer\u2019s Association mentioned that the currently available cholinseterase inhibitors slow progression of disease, which they do not \u2014 they treat symptoms in a minority of patients for a short period of time. He also opined that eventually the likelihood is that treatment will take a combination of several drugs (and lifestyle measures). Both lines are consistent with the huge amount of pharma money pumped in to the Alzheimer\u2019s Association.\nSimilarly, the other source apparently holds a patent on the use of a grape seed extract to treat Alzheimer\u2019s and Parkinsons \u2014 an interest that could impact his views on this similar approach.", "answer": 1}, {"article": "This measure of metabolic health is called \u201cinsulin sensitivity,\u201d and it is one of many metabolic functions that goes awry in people with obesity. In those who develop type 2 diabetes, sensitivity to insulin becomes so impaired that the body is tricked into believing less insulin is needed, and it pares back its production. The insulin-producing cells in the pancreas will often atrophy and die in response. As a person\u2019s insulin production declines, an external supply of insulin is needed to control blood sugar and deliver fuel to muscles and organs.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes a physician-researcher who was not involved in the study.", "answer": 1}, {"article": "In a statement, she said the trial would help address how the procedure, if approved by federal regulators, \u201cshould be appropriately managed to minimize complications.\u201d\n\nSome experts have speculated that the adverse effects were dose-related.\nHe added that the study also confirmed how quickly physicians had adopted the proteins both for approved and unapproved uses.\nFederal and state investigators are conducting separate investigations to determine whether either company illegally promoted off-label use of their products for procedures including cervical fusions.\nInfuse is also at the center of a controversy in which Army officials have accused a Medtronic consultant who was a former military doctor of falsifying data in a study about the product.\nDr. Kevin S. Cahill, a neurosurgeon at Brigham and Women\u2019s, who led the study released Tuesday, said he believed the complication rates for the cervical fusion procedures were actually higher than those reported in the study because complications often occurred after a patient left the hospital.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\n \nThe story includes comments from two independent experts, as well as a study author and a spokeswoman for a manufacturer. ", "answer": 1}, {"article": "TORONTO, May 22, 2018 - A non-surgical procedure, called percutaneous coronary intervention (PCI), along with prescribed medication, is better than medication alone as initial treatment for people who have the most common form of heart disease, suggests an analysis of an international clinical trial co-led by St. Michael's Hospital.\n\"We used pressure measurements inside the heart arteries to find coronary arteries that should be widened,\" said Dr. Bernard De Bruyne, an interventional cardiologist at the Cardiovascular Center Aalst in Belgium and the Principal Investigator of the trial.\nWhile the FAME 2 trial showed that PCI reduced urgent hospital admissions and revascularizations and likely reduced heart attacks, it did not provide evidence for a difference between PCI and medication alone in the prevention of deaths.\nIn situations where the heart's arteries narrow less suddenly and do not cause a heart attack but induce chest pain during exercise - a condition known as stable coronary artery disease - it has remained unclear whether PCI in addition to medication was better than medication alone in preventing future heart attacks.\nThe medication used in the FAME 2 trial consisted of a combination of aspirin, cholesterol-lowering and blood pressure-lowering drugs as required by current treatment guidelines.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does well to\u00a0notify readers that the study was initially sponsored by St. Jude Medical, a global medical device company. However, it should also have noted that many of the study authors individually have financial relationships with stent makers including St. Jude Medical, Boston Scientific, and Abbott.", "answer": 0}, {"article": "\"We wouldn't want to be encouraging people to drink that much [coffee], without people considering the other risks factors,\" Hashibe says.\nIt\u2019s not exactly known why coffee may help prevent these cancers.\nEditor's Note: Medical news is a popular but sensitive subject rooted in science.\n\"Like many things, the evidence changes over time,\" says Hensrud.\nResearchers found that regular coffee drinkers \u2013 those who drank more than four cups of coffee a day \u2013 had a 39 percent decreased risk of two types of head and neck cancer: oral cavity and pharynx cancers.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One of the researchers and two independent sources were interviewed \u2013 something WebMD didn\u2019t do. ", "answer": 1}, {"article": "Panel Says Aspirin Lowers Heart Attack Risk For Some\n\nMillions of Americans take baby aspirin every day to prevent a heart attack or stroke.\nPeople should talk with their health care provider to find out if they have health problems that would justify taking aspirin, according to Dr. Douglas Owens, a professor of medicine at Stanford University and a member of the task force.\n\"It's just not prudent or safe,\" he says, noting that bleeding in the abdomen or brain is extremely dangerous and can be fatal.\nPeople who don't really need to should not be taking aspirin every day, says Nissen.\nOne physician with major concerns is Steven Nissen, chairman of cardiovascular medicine at the Cleveland Clinic, in Cleveland, Ohio.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story doesn\u2019t delve into potential conflicts of interest, but it does point out that the task force is an independent panel, and interviewed Dr. Nissen who is not part of the panel.", "answer": 1}, {"article": "For both drugs, \"we were able to show a reduction in total nicotine self-administered,\" Schmidt said; however, there was a caveat.\n\"We're very interested in screening potential efficacy of anti-addiction medications in our models,\" said Schmidt, a professor in Penn's School of Nursing and Perelman School of Medicine.\nSpecifically, research from Caryn Lerman, CIRNA's director and the Mary W. Calkins Professor in Psychiatry, concluded that people who quit smoking often report a decrease in what's commonly called their executive functions.\nThere's no data to suggest that a clinician treating a smoker should prescribe one of these AChEIs now.\n\"At the doses shown to reduce nicotine self-administration, the AChEIs did not make our animals sick,\" Schmidt said.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t explicitly state who funded the study or if there were any conflicts of interest. However, it\u2019s strongly inferred that Penn\u2019s Center for Interdisciplinary Research on Nicotine Addiction is the main sponsor. The study itself states that the research received funding from several government and non-profit research organizations and that there were no conflicts of interest. This is not a major omission but must be rated Not Satisfactory.", "answer": 0}, {"article": "\u201cThis makes sense, but we\u2019ll see if it holds up in future studies.\u201d\n\nFuture studies should look at the habits, activities and nutrition that affect lifestyle and glaucoma risks, said Idan Hecht of Tel-Aviv University in Israel, who wasn\u2019t involved in the research.\n\u201cPatients can and should be involved and take an active role in the management of their ailments,\u201d Hecht said.\nThe research team found no associations between coffee, iced tea, decaffeinated tea or soft drink consumption and the likelihood of having glaucoma.\nAlmost half of participants reported drinking coffee often, but less than 10 percent drank hot tea daily.\n\u201cIn the past few years, there has been a tremendous increase in interest, and subsequently research, into the ways lifestyle changes can influence diseases,\u201d Hecht told Reuters Health by email.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two opthalmologists who weren\u2019t involved in the study were interviewed, and we could detect no conflicts of interest.", "answer": 1}, {"article": "A compound in raspberries is being touted as the next new fat burner. But people looking to lose a few pounds may not want to go running to the produce aisle just yet. Scientists say there are no major human studies to support the idea that a berry holds the secret to weight loss.\n\nRaspberry ketones, the organic compounds that give raspberries their aroma, raised hopes as a weight-loss aid after a 2005 study by Japanese researchers found the ketones boosted fat-burning processes in rat cells in a laboratory as long as those...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story recruits three independent experts to bat down\u00a0unfounded claims about raspberry ketones.", "answer": 1}, {"article": "He cites clinical data showing stroke and death rates of more than 10 percent within one year among those getting stents -- not much different from the results in the same study for surgery.\nDr. Alberts and some other doctors say that both procedures are done too often and that the advent of carotid stenting seems to be making the problem of over-treatment worse.\nMeanwhile, patient demand for stents is growing.\nDr. John J. Ricotta, the chairman of surgery at Stony Brook University Hospital, on Long Island, sought training in the stenting procedure last April, to be able to give patients more options.\nA government- and industry-sponsored test comparing surgery with Guidant's stent system, the trial started in 2000 after three years of planning.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Good job pointing out medical turf battle over ownership of this procedure, and \nindustry sponsorship of symposium. ", "answer": 1}, {"article": "When treating a patient suffering from depression, Brent Forester considers which anti-depressant to prescribe\u2014ideally, one that will ease psychic pain without side effects.\n\nIt can be a tough call.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes outside experts and notes that the principal investigator is an unpaid consultant to the company that makes the test. We\u2019re also told that the study was funded by the maker of the genetic test.", "answer": 1}, {"article": "MONDAY, Nov. 7, 2011 (HealthDay News) -- An investigational drug called pridopidine seems an effective and safe treatment for people with the progressive movement disorder Huntington's disease, researchers report.\nThe study was funded by European pharmaceuticals company NeuroSearch A/S.\nThe only drug currently approved for Huntington's is tetrabenazine, which treats only involuntary movements and can cause serious side effects.\nHuntington's patients have an imbalance in the signaling chemical dopamine.\nThe study included 437 Huntington's disease patients from eight European countries.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Dr. Alessandro Di Rocco from NYU Langone Medical Center is used as an independent source. The story also adds that the study was funded by European pharmaceuticals company NeuroSearch A/S.", "answer": 1}, {"article": "To contact Editor's Note author Mitchell H. Katz, M.D., email mediarelations@jamanetwork.org\nThe authors note a number of limitations in their study including that breast cancer was not the primary end point of the trial for which the women were recruited; the number of observed breast cancer cases was low; the authors do not have information on an individual basis on whether and when women in the trial underwent mammography; and the study cannot establish whether the observed beneficial effect was attributable mainly to the EVOO or to its consumption within the context of the Mediterranean diet.\nThe authors report that women eating a Mediterranean diet supplemented with EVOO showed a 68 percent (multivariable-adjusted hazard ratio of 0.32) relatively lower risk of malignant breast cancer than those allocated to the control diet.\nPlease see the article for additional information, including other authors, author contributions and affiliations, financial disclosures\n\nMedia Advisory: To contact study corresponding author Miguel A. Mart\u00ednez-Gonz\u00e1lez, M.D., email Jesus Diaz at jediaz@unav.es or call +34-636-355-333.\n\"The results of the PREDIMED trial suggest a beneficial effect of a MeDiet [Mediterranean diet] supplemented with EVOO in the primary prevention of breast cancer.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release only offers the following statement as an endnote: \u201cAuthors made conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures.\u201d\u00a0 The paper itself points to numerous connections between the researchers and sponsors which would have an obvious vested interest in the study\u2019s outcome.\u00a0 These include grants as well as free supplies of the foods supplemented in the study.\u00a0 While this doesn\u2019t call the findings into question, disclosing this information in a release of this type provides transparency that readers appreciate and should expect.", "answer": 0}, {"article": "They\u2019re also studying the cost difference.\n\u201cWe are actually not surprised that there isn\u2019t a big difference between the two because both therapies are effective at relaxing the overactive bladder muscles.\u201d\n\nWomen can choose between a surgical procedure, which is more expensive at first, versus regular Botox injections, which are less costly and less invasive but which could add up over time, Amundsen said.\n\u201cPregnancy, childbirth, menopause, and the structure of the female urinary tract account for this difference.\u201d\n\nThe researchers at nine medical centers did a head to head comparison of a single Botox injection to the implanted medical device, assigning 381 women to randomly get one or the other treatment.\nThe Botox injections freed 20 percent of the women in the study of incontinence, compared to 4 percent who had a nerve stimulator implant, Amundesen and colleagues reported in the Journal of the American Medical Association.\n\u201cThe prevalence of this disruptive condition is common and increases with age, from 17 percent of women older than 45 years to 27 percent older than 75 years in the United States,\u201d they wrote.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We didn\u2019t see\u00a0any backstopping of this study by an outside source. Although nonprofit websites are quoted, that material is used for purposes of background \u2014 not to assess the study\u2019s claims. Another significant oversight here is no mention of co-authors\u2019 financial relationships with the products used in both arms of the trial.\u00a0(We give props to a Duke University press release about the study for pointing this out.)\nA quick Google search of the lead author\u2019s name and the term Medtronic reveals that she has been a consultant for the neurostimulator devicemaker, as well as for Allergan, Botox\u2019s manufacturer.", "answer": 0}, {"article": "CHICAGO (Reuters) - A new analysis of evidence used by a U.S. advisory panel to roll back breast cancer screening guidelines suggests it may have ignored evidence that more frequent mammograms save more lives, U.S. researchers said on Tuesday.\n\u201cIt is not a small difference,\u201d said Dr. Mark Helvie of the University of Michigan Health System, who worked on the study published in the February issue of the American Journal of Roentgenology.\nBut Helvie and colleague Edward Hendrick of the University of Colorado wrote that \u201cthe USPSTF chose to ignore the science available to them and overemphasized the potential harms of screening mammography, to the serious detriment of U.S. women who follow their flawed recommendations.\u201d\n\nDr. Carol Lee who chairs the American College of Radiology\u2019s Breast Imaging Commission said the new study highlights the risk of setting policy based on the conclusions of one group of scientists.\nBreast cancer is the second-leading cause of cancer death among U.S. women, after lung cancer.\nThose guidelines recommended against routine mammograms for women in their 40s and said women in their 50s should get mammograms every other year instead of every year.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only independent source quoted in the article is the chair of the Breast Imaging Commission of the American College of Radiology.\u00a0 This source would be biased toward recommending more frequent screening.\nThe article should also have included reactions from members of the USPSTF or from groups that supported the recommendations of the Task Force.\nThe article does not mention that one author of the analysis is a consultant to GE\u00a0Healthcare, a major manufacturer of mammography equipment.\u00a0 The other author of the analysis has received grant support from GE\u00a0Healthcare.", "answer": 0}, {"article": "Campbell said tenecteplase is more effective than alteplase because of differences in the enzymes in each drug.\nTHURSDAY, April 26, 2018 (HealthDay News) -- After a stroke, many patients are given the clot-busting intravenous drug alteplase, but another drug may be more effective, Australian researchers report.\nThe investigators found that 22 percent of the patients treated with tenecteplase had more than 50 percent of blood flow return to the brain, compared with 10 percent of those treated with alteplase.\nFor the new study, which did not receive drug company funding, Campbell and his colleagues randomly assigned 202 stroke patients to either alteplase or tenecteplase before surgery to remove clots.\n\"Tenecteplase is likely to become the preferred medication for clot-dissolving in stroke patients,\" said lead researcher Dr. Bruce Campbell, head of the stroke department at the Royal Melbourne Hospital in Parkville.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story has one independent source.\nIt also says the study didn\u2019t receive drug company funding, which is good to know.\nHowever, some of the researchers or their institutions have accepted financial support from companies that make stroke drugs and devices as well as Stryker, a company that makes vehicles designed to quickly deliver thrombotic therapies to stroke patients.", "answer": 0}, {"article": "The Food and Drug Administration has approved DBS therapy for movement disorders such as Parkinson's disease, tremor and dystonia \u2014 usually in people who haven't responded well to medications.\nFollow her at @elandhuis.\nOne of his patients developed OCD so debilitating that he opted for DBS.\nWhen the urge returns, out comes another slap.\nThey rigged some mice to this intermittent stimulator.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story doesn\u2019t disclose that Casey Halpern, the lead researcher, has accepted payment from the maker of the RNS System device, Neuropace.", "answer": 0}, {"article": "\u201cJust understanding that it\u2019s possible is exciting.\u201d\n\nBut it will take further studies following C-section babies for many years to know to what degree, if any, the method protects them from immune and metabolic problems, he said.\nThey are doing it themselves.\u201d\n\nDr. Brubaker is one of them.\nAs the operations began, the gauze was pulled out and placed in a sterile collector.\nThey were all covered with lactobacilli.\nTo replace these microbes, some parents have turned to a novel procedure called vaginal microbial transfer.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article quotes several outside sources with the comments of Drs. Gilbert and\u00a0Khoruts.", "answer": 1}, {"article": "OAK BROOK, Ill. - A minimally invasive treatment can help restore fertility in women with uterine fibroids, according to a new study published online in the journal Radiology.\n\"Our next step will be a randomized study comparing the results of partial and conventional UFE.\"\nSince the time of writing, there were 12 additional pregnancies.\nThe standard treatment option for such women is myomectomy, or surgical removal of the fibroids.\nAs the fibroids die and begin to shrink, the uterus fully recovers.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources were not mentioned. The research article states there were no conflicts of interest to disclose.", "answer": 0}, {"article": "Overall, the study found, measures of spasticity dropped an average of three points \u2014about 30 percent \u2014 on a 24-point scale when patients smoked marijuana, but didn\u2019t change after they smoked the placebo.\nBefore and after each treatment, an independent rater assessed the patients\u2019 muscle spasticity.\n\u201cBut smoking marijuana does not appear to be a long-term solution, because of the cognitive effects,\u201d he told Reuters Health.\nAnd a new clinical trial suggests they are not just blowing smoke.\nFor some people, a change in the medication dose might help.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One independent perspective was used in the story, and it contributed a great deal to the context and balance.", "answer": 1}, {"article": "\u201cMentally, people feel calmer, sharper, maybe more content.\nWe thought it\u2019s time to see if we could pull all [the literature] together \u2026 to see if there\u2019s enough evidence that the benefits individual people notice can be used to help people with mental illness.\u201d\n\nTheir findings suggest that yoga does in fact have positive effects on mild depression and sleep problems, and it improves the symptoms of psychiatric disorders like schizophrenia and ADHD among patients using medication.\nIf a large national study were done, it could turn out that yoga is just as good and may be a low cost alternative to people with unmet needs.\u201d In the meantime, he says it doesn\u2019t hurt to add yoga to existing treatments so patients can take advantage of any potential benefits.\nFor instance, yoga may influence brain chemicals known as neurotransmitters (boosting levels of feel-good agents like serotonin), lower inflammation, reduce oxidative stress and produce a healthier balance of lipids and growth factors \u2014 just as other forms of exercise do.\n\u201cYoga has also become such a cultural phenomenon that it has become difficult for physicians and consumers to differentiate legitimate claims from hype,\u201d researchers from Duke University Medical Center write in their study, published in the journal Frontiers in Psychiatry.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Researchers tend to be optimistic about the treatments they are studying, and the study author quoted in this story is no different. That\u2019s why it\u2019s always a good idea to include an objective\u00a0perspective from an independent expert \u2014 something this story regrettably lacked.", "answer": 0}, {"article": "He points to a recent meta-analysis published in the journal Addiction that concluded that naltrexone helped reduce heavy drinking and cravings for alcohol.\nBut there's good evidence that the combination of counseling and drugs such as naltrexone can help people cut back on drinking, or move toward abstinence.\nAccording to the NIAAA, \"patients can now receive effective alcohol treatment from their primary care doctors or mental health practitioners by combining the newer medications with a series of brief office visits for support.\"\nAs as long ago as 1997, a published study showed that treatment of alcohol dependence with naltrexone by primary care doctors can be effective; follow-up research has confirmed that the primary care approach not only works, but makes treatment much more accessible.\nThe analysis also found that another drug, acamprosate, is effective at helping people who have already stopped drinking to maintain abstinence, perhaps partly by easing the physical and emotional cravings experienced by heavy drinkers who quit.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included a number of independent sources, and we could detect no potential conflicts of interest that should have been disclosed.", "answer": 1}, {"article": "For more on autism and diagnosis, visit the Autism Society.\nFor her part, Laura Bono, the Durham, N.C.-based former chair of the National Autism Association and member of the board of directors of the autism advocacy group \"Safe Minds,\" expressed a certain amount of hesitancy about the prospects for MRI-driven diagnoses.\nThe current effort, focused on patients already diagnosed with autism, used MRIs to locate areas of the brain where the left and right hemispheres do not communicate properly.\nTHURSDAY, Oct. 14, 2010 (HealthDay News) -- With the aim of catching autism in children at an earlier age than currently possible, scientists are exploring the potential of using MRI scans as a screening tool.\n\"So if there's no targeted treatment to follow up on the results of this kind of scan, then it's just another expensive test for parents who are already barraged with so many tests at diagnosis,\" she said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does, technically, bring in an outside source, but the source is not someone with expertise in diagnosing autism disorders or in radiology. The source is \"Laura Bono, the Durham, N.C.-based former chair of the National Autism Association and member of the board of directors of the autism advocacy group Safe Minds.\" It is good that Bono \"expressed a certain amount of hesitancy about the prospects for MRI-driven diagnoses.\" But she may not be the best source to evaluate the results of this study.", "answer": 0}, {"article": "In addition to retaining its first place ranking for the best hospital in the Twin Cities and second in the State of Minnesota in the U.S. News & World Report's 2016-17 best hospital rankings, Abbott Northwestern has received nursing magnet certification, a recognition earned by only five percent of hospitals nationwide.\nOnly 1.5 percent had positive lymph nodes - indicating the rare possibility of metastatic cancer.\nThey examined the outcomes of 294 patients who were treated between 2001 and 2015.\nThe Institute was founded in 1990 at Abbott Northwestern Hospital.\nFor more information, visit us at allinahealth.org, Facebook, Twitter, YouTube or Healthy Set Go.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding sources are listed in the release. No conflicts of interest are mentioned in the published study.  ", "answer": 1}, {"article": "That's when they learned cocoa compounds named epicatechin monomers enhanced beta cells' ability to secrete insulin.\n\"These results will help us get closer to using these compounds more effectively in foods or supplements to maintain normal blood glucose control and potentially even delay or prevent the onset of type-2 diabetes,\" said study co-author Andrew Neilson, assistant professor of food science at Virginia Tech.\n\"You probably have to eat a lot of cocoa, and you probably don't want it to have a lot of sugar in it,\" said study author Jeffery Tessem, assistant professor of nutrition, dietetics and food science at BYU.\n\"The epicatechin monomers are making the mitochondria in the beta cells stronger, which produces more ATP (a cell's energy source), which then results in more insulin being released.\"\nBut here's the thing: BYU researchers have discovered certain compounds found in cocoa can actually help your body release more insulin and respond to increased blood glucose better.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that, \u201cThis research was funded, in part, thanks to grants from the Diabetes Action Research and Education Foundation and the American Diabetes Association.\u201d The researchers did not list any relevant disclosures in their journal article. The release does not include funding from the \u201cVirginia Agricultural Experiment Station and the Hatch Program of the National Institute of Food and Agriculture, U.S. Department of Agriculture\u201d that is listed in the journal article.", "answer": 1}, {"article": "Although many guidelines rely on self-reports, Hennekens and his collaborators from Baylor College of Medicine and Meharry Medical College, used the Surveillance, Epidemiology, and End Results (SEER) program file linked to the Medicare administrative claims file, which allowed them to identify screening mammography use from 1995 to 2009 from 64,384 non-Hispanic women (4,886 black and 59,498 white).\n\u2022 Similar characteristics were seen in black women as in white women.\n14 \"Top Scientist in the World\" based on his H-index of 173.\nBreast cancer afflicts 1 in 8 women in their lifetime and 1 in 25 die from this disease.\nIn 2013, he received the \"Fries Prize for Improving Health\" and in 2014, he received the Alton Ochsner Award for his pioneering work on smoking and health.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There is no mention of funders or potential conflicts of interest in the release.", "answer": 0}, {"article": "(Reuters) - Johnson & Johnson said its drug, Tremfya, was found to be more effective than a rival medicine from Novartis AG in reducing the severity and affected area in adults with moderate-to-severe plaque psoriasis in a late-stage study.\nWith $2.1 billion in sales in 2017, Cosentyx has become one of the top revenue earners for Novartis and is expected to make up for falling revenue from its blood cancer treatment, Gleevec, whose patent expired two years ago.\nTremfya, first approved in July 2017 as a plaque psoriasis treatment in the United States, is also being tested as a for psoriatic arthritis and Crohn\u2019s disease.\nThat market is expected to double to $21.11 billion by 2022, according to U.S. consultant Grand View Research.\nAbout 7.5 million Americans live with plaque psoriasis, of which 20 percent have moderate-to-severe form of the disease, J&J said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two glaring problems here.\nFirst, the only quote used in this very short story is directly lifted (without attribution) from the news release. No independent sources are included.\nFurthermore, it says it comes from the lead investigator of the study (true), but fails to mention he\u2019s a paid consultant for Janssen.", "answer": 0}, {"article": "The latest advances in Alzheimer\u2019s disease involve people who don\u2019t appear to show any signs of cognitive decline yet.\nIdeally, for example, isolating those with MCI might help doctors to focus in on a group of patients who might be at higher risk of developing Alzheimer\u2019s and therefore might need more intensive and regular testing.\nThe results aren\u2019t conclusive enough yet for doctors to start using them to distinguish people who are more likely to develop Alzheimer\u2019s, but that\u2019s the goal, says Sapkota.\nSome had been diagnosed with Alzheimer\u2019s and some with MCI, while others did not have any neurological conditions.\nPresenting at the meeting, Shraddha Sapkota, a graduate student in neuroscience at University of Alberta, and her colleagues described how they carefully analyzed the saliva of a group of volunteers participating in an aging study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story doesn\u2019t offer independent sources and only paraphrases information from the graduate student/principal investigator.", "answer": 0}, {"article": "(CNN) -- Eating a diet rich in healthy fats and limiting dairy and meat could do more than keep your heart healthier.\nThis study looked at people who had never had a clinical stroke, but may have had smaller strokes that went unnoticed.\nThe participants who followed the Mediterranean diet the least had an increased risk for having strokes that was similar to people with hypertension.\nThe study shows association, not causation, meaning there could be some other factors linking the Mediterranean diet to resilience against this form of brain damage.\nParticipants were asked about their diet and then, about six years later, underwent an MRI.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0The story has a quote from a clinician who does not appear to be associated with the research to be presented that was reported on.", "answer": 1}, {"article": "In a first, U.S. trial to test Cuban lung-cancer vaccine\nH. Jack West, an oncologist at Swedish Medical Center in Seattle, said, \u201cIt is literally practice-changing \u2014 immediately.\u201d\n\nRoy Herbst, an oncologist at Yale Cancer Center said that most lung cancer patients now will be offered immunotherapy in some form much earlier than before.\n\u201cImmunotherapy is rapidly, in combination with other treatments and on its own, dramatically changing the standard of care for lung cancer,\u201d said Leena Gandhi, an oncologist at NYU Langone Health who led the study on the immunotherapy-chemotherapy combination, called Keynote-189.\nThe studies simultaneously were published by the New England Journal of Medicine on a day that some experts called the \u201cSuper Bowl of lung cancer immunotherapy.\u201d\n\nThe reports underscore the increasingly important first-line role that immunotherapy, which unleashes the immune system to destroy cancer cells, is taking against the deadliest cancer.\n\u201cInstead of chemo being the backbone on which to improve, immunotherapy is now the backbone on which we build.\u201d\n\nLung cancer is the second-most-common malignancy in the United States, after breast cancer.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story has one independent source:\n\u201cScientists who weren\u2019t involved in the study agreed that it was highly significant. H. Jack West, an oncologist at Swedish Medical Center in Seattle, said, \u2018It is literally practice-changing \u2014 immediately.\u2019\nHowever, it doesn\u2019t say that the studies were sponsored by the drugmakers and many study leaders as well as another oncologist who\u2019s quoted, Roy Herbst, MD, has received consulting fees for companies that make immunotherapy drugs.", "answer": 0}, {"article": "Incidence of hypercalcemia (the presence of abnormally high levels of calcium in the blood) was lower with abaloparatide (3.4 percent) vs teriparatide (6.4 percent).\nThe way forward for fracture prevention involves not only the development of better therapies to prevent fracture and easier delivery systems but also improved adoption of existing osteoporosis therapies for patients with prior fractures and minimization of adverse effects, particularly those associated with long-term use.\u201d\n\n: Both authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.\nAs a result of its mechanism of action, it has been hypothesized that the drug abaloparatide, a synthetic peptide, would have a more pronounced anabolic (i.e., bone growing) action on bone compared with the osteoporosis drug teriparatide.\n\u201cFurther research is needed to understand the clinical importance of risk difference, the risks and benefits of abaloparatide treatment, and the efficacy of abaloparatide vs other osteoporosis treatments,\u201d the authors write.\nEditorial: Osteoporosis Therapy in Postmenopausal Women With High Risk of Fracture\n\n\u201cUltimately, which therapy is selected for osteoporosis treatment may be less important than identifying and initiating an approved treatment,\u201d write Anne R. Cappola, M.D., Sc.M., of the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, and Associate Editor, JAMA, and Dolores M. Shoback, M.D., of the University of California, San Francisco, in an accompanying editorial.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "To its credit the release quotes two people not associated with the study from an accompanying editorial and explains that the study was funded by Radius Health. But it does not make it clear whether Radius Health is involved in making an osteoporosis drug. Instead, the release directs readers to the full study (which is behind a firewall and available only to journal subscribers) for information on financial disclosures. The disclosure shows that several of the researchers, notably\u00a0Paul Miller, MD, the corresponding author noted in the release, is a member of the scientific advisory board for Radius Health and several other pharmaceutical companies, and received research grants from Radius Health and a dozen other pharmaceutical sponsors.\u00a0We think this information was important enough to include in the release itself. ", "answer": 0}, {"article": "Dr. Bremner said he typically suggests a trial of therapy for up to a year to see if sexual function or other symptoms improve.\nAlthough low hormone levels are widely thought to increase a man\u2019s risk of depression, the researchers found that \u201cpsychological symptoms had little or no association with the testosterone level.\u201d\n\nThere are four main approaches to testosterone therapy available in this country: intramuscular injections every one to three weeks; skin applications through a patch or gel; and pellets implanted under the skin that last for months.\nIn a report on the risks of testosterone therapy, written with Dr. Ernani Luis Rhoden and published in 2004 in The New England Journal of Medicine, Dr. Morgentaler noted that testosterone has widespread effects throughout the body, but he and Dr. Rhoden concluded that with proper monitoring, any looming hazards can be readily detected.\nThe researchers, who published their findings in The New England Journal of Medicine, noted that the deck might have been stacked in favor of a hazardous outcome because study participants, especially the group that received testosterone, had high rates of high blood pressure, diabetes, obesity and elevated blood lipids.\nThe most common reason men seek testosterone therapy is waning sexual desire or performance, although the ability of the hormone to relieve sexual symptoms is unpredictable.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although one source, Dr. Abraham Morgentaler, is identified as the author of a book which promotes testosterone therapy,\u00a0the story\u00a0does not disclose, as indicated\u00a0in these recent CME conference materials,\u00a0that Dr. Morgentaler also receives grant funding and is on the speaker\u2019s bureau of companies which manufacture\u00a0testosterone products. To avoid the appearance of any potential conflict, the story should have alerted readers to these relationships.", "answer": 0}, {"article": "\"The protection started at more than 45 grams [about 1.5 ounces] a week,\" says researcher Susanna C. Larsson, PhD, of the Karolinska Institutet in Stockholm, Sweden.\nWhile other studies have found a link between eating chocolate and reduced stroke risk, this research found a slight difference in protection, depending on type of stroke.\nThe group eating the most chocolate got the most benefit, reducing stroke intake by 20%.\nIn this group, the median intake (half ate more, half less) was about 2.3 ounces a week.\nThose who ate the most chocolate were protected a bit more from strokes caused by hemorrhage than strokes caused by obstruction such as blood clots.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The study includes comments from an expert source not affiliated with the study, who provides valuable context on the\u00a0increased desirability of dark chocolate over milk chocolate.", "answer": 1}, {"article": "Images on paint can display on the left, a cancer free mouse; image on right illustrates how the tumor paint shows cancerous cells even after the cancerous organ has been removed.\n\nWhen treating cancer with surgery, there's nothing as important as making sure that every last bit of the disease has been removed. That's not always possible, since tumors have nasty habits of embedding themselves within healthy tissue and of breaking away and spreading malignancies to other parts of the body. But Researchers at Seattle's Fred Hutchinson Cancer Research Center have come up with an innovative way of giving surgeons the upper hand against these wily tumors. They have created a molecular \"paint\" that coats cancer cells so doctors can see the wayward cells that they may otherwise miss.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only quote is from the senior author of the research study (Cancer Research 2007; 66(14):6882-6888).\u00a0 The story could have provided views of surgeons or other researchers who work with current technologies.\u00a0 How does the National Cancer Institute or a cancer research organization assess this research? ", "answer": 0}, {"article": "Whether it is encouraging people to eat right or to exercise, they said, the hardest part is not getting them to start doing the right things but getting them to keep doing the right things.\nMental skills acquired earlier in life persist well into old age, he said.\nThe study tracked 2,802 healthy adults from diverse backgrounds who were, on average, 73 years old.\nA third group was taught memory skills, which involved remembering word lists and using visualizations and associations as memory aids.\nThe participants in the study ranged from age 65 to their early 90s, but Marsiske said the findings apply to people in their 50s or even younger.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two authors of the study and the author of an editorial on the study were used as sources of information for this story.\u00a0 \n\u00a0\n", "answer": 1}, {"article": "But given the 2013 research suggesting \u201ctoxicity of high coffee doses\u201d in some people, he said, \u201cto me the most reasonable approach would be to keep coffee intake to two to three cups most days.\u201d\n\nSecond Take: STAT knows better than to get between coffee lovers and their cup o\u2019 joe, so if you want to take this study as permission to keep beating a path to your Keurig, we\u2019re not going to slow you down.\nIt \u201csupports the safety and efficacy of even high doses of coffee in non-smokers,\u201d said Dr. Carl Lavie, a cardiologist at Ochsner Health System.\nOther studies have found associations with lower risk of specific conditions, like this on cardiovascular disease (by many of the same authors as the new study), this on stroke, this on heart failure, and this on diabetes.\nIt might mean instead that a third factor \u2014 another behavior, socioeconomic status, even personality or genetics \u2014 might go hand in hand with Behavior A and be the true cause of Outcome B.\nMost research has found the greatest benefits with daily consumption of around three or four cups \u2014 usually 6 to 8 ounces, and without distinguishing regular from decaf.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The STAT story included not just any \u00a0\u201coutside\u201d expert comment, but chose \u00a0a co-author of a seminal 2013 study, whose professional credibility added to the story\u2019s. And unlike the CNN story, it offered details of the ongoing epidemiological studies from which the new data were drawn.", "answer": 1}, {"article": "The VTP treatment is now being reviewed by the European Medicines Agency (EMA) for possible license, but it likely to be several years before it can be offered to patients more widely.\n\u201cThis is truly a huge leap forward.\u201d\n\nThe treatment, called vascular-targeted photodynamic therapy or VTP, was developed by scientists at the Weizmann Institute of Science in Israel in collaboration with the privately-owned STEBA Biotech.\n\u201cThese results are excellent news for men with early localized prostate cancer, offering a treatment that can kill cancer without removing or destroying the prostate,\u201d said Mark Emberton, a University College London consultant urologist who led the trial.\nResults of a trial in 413 patients showed that the drug, which is activated with a laser to destroy tumor tissue in the prostate, was so effective that half the patients went into remission, compared with 13.5 percent in a control group.\n\u201cThe fact that the treatment was performed so successfully by non-specialist centers in various health systems is really remarkable,\u201d Emberton said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story misses the mark on two counts. First, it contains no independent sources. That\u2019s a particularly concerning omission since there\u2019s nothing to counter hyperbolic quotes from the study\u2019s lead researcher that the findings are \u201cexcellent news for men with early localized prostate cancer\u201d and \u201ctruly a huge leap forward.\u201d\nFurther, it says the treatment \u201cwas developed by scientists at the Weizmann Institute of Science in Israel in collaboration with the privately-owned STEBA Biotech.\u201d But it doesn\u2019t say that Steba, which holds the commercial license for the treatment, funded the study, a fact that was in the news release, or that all of the researchers involved in the study were compensated by Steba, which was reported in the study itself.", "answer": 0}, {"article": "If media wish to link to the paper once it's published, they can use the following link, which will go live when the embargo lifts: http://www.thelancet.com/journals/lanres/article/PIIS2213-2600(16)30179-5/abstract\nThe research was funded by Novartis Pharmaceuticals, National Institute for Health Research (NIHR) and the EU (AirPROM), and is described by the lead researcher as \"a game changer for future treatment of asthma.\"\nThe rate in people with moderate-to-severe asthma taking the medication was reduced from an average of 5.4 percent to 1.1 percent over 12 weeks, according to the study published today in the prestigious The Lancet Respiratory Medicine journal.\nThis is the technical name for the five year Europe-wide, EU funded project, which aimed to produce computer and physical models of the whole human airway system for people with asthma and chronic obstructive pulmonary disease (COPD).\nThe NIHR Leicester Respiratory Biomedical Research Unit - a partnership between the University of Leicester and Leicester's Hospitals - focuses on promoting the development of new and effective therapies for the treatment of respiratory diseases including severe asthma and chronic obstructive pulmonary disease (COPD).\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release gets credit for including the funding sources of the study \u2014 Novartis Pharmaceuticals, the National Institute for Health Research in the UK, and the European Union \u2014 but it fails to point out any of the linkages among the study\u2019s authors to pharmaceutical firms. According to the published study disclosures, these relationships include speaking fees, consultancies, grants and full-time employment with Novartis and other companies. This transparency is needed for readers to ascertain bias. ", "answer": 0}, {"article": "And if patients are given a choice of catheterization sites, what factors should they consider?\nThe approach allows patients to sit up immediately afterward and even walk, an impossibility in femoral procedures, which require that they lie flat on their backs for several hours to prevent severe bleeding.\nThe femoral artery, approximately the width of a pinkie, presents a direct route to the heart; to a physician, it's a straight stretch of freeway that can be navigated easily.\nIn the cath lab, he noted, \"time is money\" and radial procedures are \"among the most challenging things we do.\"\nOnly 1 percent of the 1.2 million cardiac catheterizations performed annually in the United States are done through the wrist; the newer approach is often preferred for patients who are extremely obese or have poor leg circulation.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included interview material from clinicians who utilize this technique only rarely as well as those who rely on it extensively. \u00a0In addition, there were several patient quotes that presented the view from the other side of the table.", "answer": 1}, {"article": "The distorted valve functions poorly, its flaps swinging apart.\nIn the new trial, 614 patients with severe heart failure in the United States and Canada were randomly assigned to receive a MitraClip along with standard medical treatment or to continue with standard care alone.\nIn the new study, a device called the MitraClip was used to repair the mitral valve by clipping its two flaps together in the middle.\nThe enlarged organ tugs apart the mitral valve, which controls blood flow from the left atrium into the left ventricle.\nThe leaky mitral valve makes the heart enlarge even more, as it tries to compensate, and heart failure worsens.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did a mixed job.\nOn the plus side, it reported that the maker of the clip, Abbott, funded the study. It also reported that one of the physicians quoted \u201creported no relevant conflicts, but said that Columbia University gets royalties from the sale of the MitraClip.\u201d\nHowever, the story did not say whether other physicians who were quoted have conflicts of interest. At least one had a substantial conflict that we found. Gilbert Tang, MD, received $57,600 in payments from Abbott in 2017.\nMost importantly, all of the physicians quoted had some connection to the trial. The story would have benefited from at least one physician source who wasn\u2019t a cheerleader for this device.", "answer": 0}, {"article": "MONDAY, March 22, 2010 (HealthDay News) -- The anti-clotting drug Plavix is of modest benefit in cutting the odds of death in patients with heart failure and heart attack who don't undergo angioplasty, a new study finds.\nThe study appears online March 23 and in the March 30 print issue of the Journal of the American College of Cardiology.\nA randomized study comparing conventional heart failure therapy with and without Plavix \"is needed urgently,\" the editorial writer concluded.\nDanish researchers analyzed data from more than 31,000 patients hospitalized with heart attack between 2000 and 2005 and divided the patients into four groups: two groups with heart failure (one that received Plavix and one that did not) and two groups without heart failure (one that received Plavix and one that did not).\nThe mean follow-up was 18 months for both heart failure groups and just over two years for both non-heart failure groups.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0The story quotes an editorial writer but did not appear to go beyond a news release for interpretation of the study results.\u00a0 ", "answer": 0}, {"article": "Macular degeneration patients often are advised to take certain vitamin combinations that may help stave off advanced disease.\nThe experimental drug, lampalizumab, aims to slow the destruction of light-sensing cells in the retina, creeping lesions that characterize the stage of dry AMD called \u201cgeographic atrophy.\u201d When those cells die, they can\u2019t grow back \u2014 the vision loss is irreversible.\n\u201cFrom the basic science perspective, it makes a lot of sense.\u201d Macular degeneration tends to occur after age 60, but it sometimes strikes earlier.\nThose are the only patients who appeared to benefit from the drug; they had 44 per cent less eye damage than the untreated patients, the Genentech team reported Wednesday in the journal Science Translational Medicine.\nWhile there\u2019s no treatment for the advanced dry form, the \u201cwet\u201d form occurs when leaky blood vessels grow under the retina \u2014 and there are several therapies that can help those patients preserve vision.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although there are independent sources in the story, we\u2019re not told that one of them\u2013Dr. Rahul N. Khurana\u2013has served as a consultant and speaker for Genentech, the drugmaker behind the study (as disclosed here).\nIn the story, he\u2019s quoted several times, including here:\n\u201cIt\u2019s a very, very exciting study,\u201d said Khurana, the ophthalmologist association\u2019s spokesman, who also wasn\u2019t part of the research. \u201cFrom the basic science perspective, it makes a lot of sense.\u201d", "answer": 0}, {"article": "A capsule of Probiotic Immunity from New Chapter Inc., based in Brattleboro, Vt., contains 1 billion each of 10 different organisms, including Streptococcus salivarius subsp. thermophilus and Lactobacillus acidophilus, two species of bacteria often found in yogurt. Other ingredients include herbs such as cumin, ginger and spinach. Users are instructed to take two capsules each day, preferably one in the morning and one in the evening, on an empty stomach. You can buy a bottle of 90 capsules for about $20 at many health food stores.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Independent sources contributed perspectives to this story.", "answer": 1}, {"article": "Doctors in Seattle cured a late-stage cancer patient after tinkering with his body's defenses against infection, leading to cautious optimism about treating late-stage melanoma, a deadly skin cancer.\n\nThe surprising result, published in this week's issue of the New England Journal of Medicine, is the latest hopeful finding from the 30-year-old field of \"adoptive immunotherapy,\" which theorizes that the body can be taught to fight off its own cancers.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\nThe article quotes two scientists\u2014the lead researcher on the published paper and the chief surgeon at the National Cancer Institute, an investigator involved in another study that the news story mentioned. Neither is an independent source. \n", "answer": 0}, {"article": "She notes that using trastuzumab to selectively treat uterine serous carcinoma that express HER2/neu is part of a broader trend at Johns Hopkins and other cancer centers to use the tools of tailored therapy, or precision medicine, based on the molecular and genetic makeup of tumors and patients.\nThe difference, Fader says, may be that these patients have been heavily treated in the past, are more likely to have overall poorer health and are more likely to have mutated or heterogeneous tumors, or tumors with different levels of HER2 expression.\nOther authors of the paper are Dana M. Roque of the University of Maryland; Paul Celano of Greater Baltimore Medical Center; William Lowery of Walter Reed Medical Center; Eric Siegel of the University of Arkansas for Medical Sciences; Natalia Buza, Pei Hui, Osama Abdelghany, Stefania Bellone, Masoud Azodi, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Peter E. Schwartz and Alessandro D. Santin of the Yale University School of Medicine; Setsuko K. Chambers of the University of Arizona; Angeles Alvarez Secord and Laura Havrilesky of Duke University School of Medicine; David M. O'Malley and Floor Backes of The Ohio State University School of Medicine; Nicole Nevadunsky of Montefiore Medical Center; Babak Edraki of John Muir Medical Center; Dirk Pikaart of the Penrose Cancer Center-St Francis; and Karim S. ElSahwi of Meridian Health.\nThe drug used in this research was also provided by Genentech-Roche, which makes one brand of trastuzumab.\n\"The fact that these tumors grow rapidly, but also have a propensity to spread to lymph nodes and other organs very early, is a double whammy for women,\" says Amanda Fader, M.D., associate professor of gynecology and obstetrics at the Johns Hopkins University School of Medicine, and first author of the new study.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release clearly notes that the study was funded by a company that produces one brand of trastuzumab, which is good. The release also notes that one of the researchers had reported a consulting or advisory role for a pharmaceutical company. Since it mentioned that researcher\u2019s potential conflict of interest, it would be easy to assume that the other researchers (who were not mentioned) did not have potential conflicts of interest. That assumption would be incorrect. The journal article itself makes clear that several other researchers had conflicts of interest, including one researcher with ties to another pharmaceutical company (Genentech) that makes a different brand of trastuzumab.", "answer": 0}, {"article": "\"The results and especially the rapidity of the effects observed in the gantenerumab trial went beyond our expectations,\" Luca Santarelli, MD, study co-author and Roche senior vice president of neuroscience, writes in an email.\nTherefore, it's not known if reducing the amount of them will slow or stop the disease.\nIn the study, patients who received monthly gantenerumab injections showed reductions in such brain plaques.\nThe study is published in the online edition of Archives of Neurology.\nThe experimental compound, known as gantenerumab, is being developed by Roche, the Swiss pharmaceutical company.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story added an important independent perspective and identified the study co-author as being a senior VP of the drug company making the drug.", "answer": 1}, {"article": "\u201cHowever,\u201d she added, \u201cunlike a pill, which always has the same ingredients, acupuncture, like psychotherapy, varies from one provider to the other.\u201d\n\nSo while the specific regimen used in this study appeared effective, Manber said, \u201cI do not think we can say that our study proves that acupuncture is effective for depression during pregnancy.\u201d\n\nIt\u2019s estimated that 3 to 5 percent of pregnant women are diagnosed with depression, Manber and her colleagues note in their report.\nAnother 49 women received control acupuncture and 49 received massage.\nFourteen women who received depression-specific acupuncture reported pain during the needling, as did seven in the control-acupuncture group.\nAfter eight weeks, patients in the depression-specific acupuncture group had a higher rate of response to treatment.\nAcupuncture has been used for more than 2,000 years in Chinese medicine to treat a wide variety of ailments.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent experts were quoted in this story.\u00a0\u00a0 ", "answer": 0}, {"article": "The new awards provide up to $600,000 each over three years to support the work of collab...\n\nUW to test using MDMA to treat PTSD\n\nThe Department of Family Medicine and Community Health of the UW School of Medicine and Public Health will take part in a multisite Food and Drug Administration-approved Phase III trial investigating MDMA as an adjunct to psychotherapy for the tre...\nRyan Coller wins federal challenge for app to help children with complex care needs\n\nA team of researchers at the University of Wisconsin School of Medicine and Public Health and the College of Engineering have won a share of a $100,000 award to develop technology for families caring at home for children with complex medical needs...\nThe search committee for the Science and Medicine Graduate Research Scholars (SciMed) program director position enthusiastically announces four finalists who have been invited to give public presentations.\nView a new year's message from Dean Golden for 2019\n\nPlease take a moment to watch a special message from Robert N. Golden, MD, dean of the University of Wisconsin School of Medicine and Public Health, in which he reflects on 2018 and looks ahead to 2019.\nThomas Mackie to lead new joint innovation initiative between UW Health and School of Medicine and Public Health\n\nUW Health has selected Thomas \u201cRock\u201d Mackie to be the inaugural leader of the health system\u2019s innovation initiative, which it is pursuing in partnership with the UW School of Medicine and Public Health.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release clearly states the study was initiated by Dr. Richard Bowen, an employee of the (now bankrupt) Voyager Pharmaceutical Corporation, and that the company performed the study. But it doesn\u2019t disclose that Bowen also reported owning stock in Voyager\u00a0(he\u2019s previously been described as a \u201cmajor shareholder\u201d), which holds a patent\u00a0covering the use of Lupron for the treatment of Alzheimer\u2019s. Though apparently now in bankruptcy, the company would likely still stand to benefit if this treatment approach gained new attention from researchers or was championed by new investors \u2014 and Bowen might well share in that reward. The news release wasn\u2019t transparent about this.", "answer": 0}, {"article": "\"Weight loss was similar but substantial in both groups we studied, but blood pressure improved more in the low-carb dieters,\" said study author Dr. William Yancy Jr., an associate professor of medicine at Duke University Medical Center and a staff physician at the Department of Veterans Affairs Medical Center in Durham, N.C.\n\n\"There are options out there.\n\"There are many paths to weight loss,\" said registered dietitian Karen Congro, director of the Wellness for Life Program at The Brooklyn Hospital Center in New York City.\nThe researchers found that combining the DASH diet with weight management and exercise resulted in a 16.1 mm Hg drop in systolic blood pressure compared to 11.2 mm Hg on the DASH diet alone.\nInsulin and glucose markers improved only in the low-carb group, and there was a significant drop in blood pressure in the low-carb group compared to the orlistat group -- systolic blood pressure (the top number) dropped by 5.9 mm Hg on the low-carb diet vs. 1.5 mm Hg for the orlistat group.\nMore than one-third of American adults are obese, and the incidence of obesity has gone up 140 percent over the past decade, Kushner notes.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did not mention that two of the researchers on the study have received funding from the Robert C. Atkins Foundation, which promotes research on low-carb diets and is associated\u00a0with the Atkins diet books and products. The story\u00a0did include comments from an independent dietitian,\u00a0which is a strength, but this isn\u2019t\u00a0enough to overcome the omission.", "answer": 0}, {"article": "After her mother unexpectedly died from a tear in the wall of her heart at age 63, Patricia Walters talked to her doctor, Leslie Cho, about how to better monitor her own heart health.\n\nPregnant at the time with her own daughter, Ms. Walters, now 46, says she was \"a nervous wreck\" worrying that she, too, might face serious cardiac risk.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although the story did provide some information about the controversy (\u201cWhile some experts don\u2019t think the hs-CRP test adds much to current cardiovascular risk-prediction strategies,\u2026\u201d) the majority of the comments are made by the principal investigator/inventor and an apparent advocate of the test.\u00a0 We would have liked to have seen more balance in the story.\u00a0 Fewer than 20 words to wave off skepticism, the other 838 words all devoted to those who promote the test. Why, based on what is provided in the story would any expert not believe in the test? The story doesn\u2019t give any space for that perspective.", "answer": 0}, {"article": "\"Great.\nFor years, all Siravo and her husband, David, wanted was a good night's rest \u2013 and now they're finally getting it.\n\"So before we activated the device, we have all sorts of problems\u2026 This is basically your brain saying, 'I'm not breathing.'\nAn estimated 22 million Americans suffer from sleep apnea, putting them at greater risk for diabetes, heart disease, stroke and memory loss.\nA treatment is offering hope for millions of patients with sleep apnea, a disorder that causes people to stop breathing when they're asleep.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites only one expert source \u2014 and fails to tell readers that the source is a consultant for Inspire. In fairness, you won\u2019t find that information on the doctor\u2019s professional website. However, it is disclosed in a 2016 journal article by the doctor and one of his collaborators. If we could find that information (with a minimum of effort), we think its omission is a significant oversight.", "answer": 0}, {"article": "They then measured concentrations of a hormone called the anti-Mullerian Hormone (AMH) that is produced by cells in women\u2019s ovaries.\nThe researchers took two more blood samples at three yearly intervals and also collected information on the women\u2019s socioeconomic background and reproductive history.\nExperts commenting on the work agreed it was promising, but said its findings would need to be confirmed in larger trials.\n\u201cThe possibility of an accurate predictor for menopause is very exciting.\n\u201cWe developed a statistical model for estimating the age at menopause from a single measurement of AMH concentration,\u201d Tehrani explained in a report on the study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story briefly quotes one source other than the study\u2019s lead author.\u00a0 ", "answer": 1}, {"article": "Doctors currently diagnose colds and flus through a patchwork of testing, observation and process of elimination.\nThe test is expected to be used mainly in hospitals and emergency rooms, but doctors can send the swab to a local lab.\nIn the lab, genetic material from the swab is magnified millions of times and then bound to fluorescent markers, which are then read by a machine.\nIt tests for a dozen viruses, including several types of influenza, two types of respiratory syncytial virus, or RSV, three types of parainfluenza, adenovirus and even rhinovirus, which causes the common cold.\nCurrently available tests can yield results in a half hour, though accuracy varies and they typically screen for only one or two viruses.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story draws information from a variety of credible sources, including the FDA, a\u00a0researcher who published results\u00a0indicating that the flu is under-diagnosed in children,\u00a0and an independent emergency room physician.\u00a0 Information from the manufacturer is also given.", "answer": 1}, {"article": "\u201cThere are areas in the brain that become poorly perfused as you age, and that\u2019s believed to be associated with dementia and poor cognition.\u201d\n\nResearchers from the Translational Science Center looked at how dietary nitrates affected 14 adults aged 70 and older over a four-day period.\nOn the second day, after another 10-hour fast, the participants returned to the lab and ate their assigned breakfasts.\nAnd blood tests before and after breakfast confirmed nitrite levels in the body.\nAn hour later, an MRI scan recorded brain flow in each person\u2019s brain.\nThe high-nitrate breakfast included 16 ounces of beet juice.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were no independent sources.\u00a0 All quotes came from a university news release.", "answer": 0}, {"article": "But when you become sicker, laparoscopy is better,\u201d said Oleynikov.\nBut it does suggest that laparoscopy could actually save thousands of dollars for some patients, when all costs \u2014 including physician fees, hospital fees and readmissions \u2014 are considered.\n\u201cSubstantial savings could be seen if open surgery is done in a laparoscopic fashion.\u201d\n\nBut he acknowledged that the study has major limitations.\nBut experiments comparing the two kinds of procedure have yielded mixed outcomes, and some experts remain unconvinced that laparoscopy is worth its higher upfront cost.\nIndeed, those who had laparoscopy were younger and usually had less severe disease, which could have biased the results in favor of the minimally invasive procedure.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There was no independent perspective offered.\u00a0 So, even though the lead researcher offered his own caveats about the limitations of the research, we always wish for an independent expert\u2019s voice to be heard in such stories.", "answer": 0}, {"article": "\u201cIt may provide more of a one-stop shop.\u201d\nThe developer, Ironwood Pharmaceuticals, said the drug, linaclotide, met all the goals in the first late-stage trial testing it as a treatment for the type of irritable bowel syndrome accompanied by constipation.\n\u201cThe exciting thing about the data on linaclotide is that it improves both of those symptoms,\u201d he said.\nAbout one-third of the cases involve constipation, another third diarrhea and the rest both constipation and diarrhea, according to Dr. William D. Chey, an expert at the University of Michigan.\nAs many as 20 percent of American adults have some symptoms of irritable bowel syndrome, according to the National Institutes of Health.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There was no mention of the fact that the study being reported on was conducted and funded by the manufacturer of the drug being tested. In addition, almost all of the\u00a0information in this story came from\u00a0the\u00a0drug manufacturer\u00a0or someone with ties to it. Examples:\nWe think this story could have benefited from an alternative perspective.", "answer": 0}, {"article": "But light was associated with better driving.\n\u201cWe experience severe sleepiness toward the end of the night shift, and this may overlap with our commute time,\u201d said senior study author Dr. Ralph Mistlberger of Simon Fraser University in British Columbia, Canada.\n\u201cThere is evidence that the use of bright light at the office (or even at home directly prior to beginning the work shift) may be beneficial in preventing sleep deprivation-related motor vehicle collisions,\u201d said Russell Griffin, a researcher at the University of Alabama at Birmingham who wasn\u2019t involved in the study.\nBeyond its small size, other limitations of the study include the reliance on lab conditions for sleep deprivation and light exposure, which may not match what shift workers would experience on the job, the authors note.\nSleepiness is a leading risk factor for automobile accidents because it can make drivers less vigilant, slow reaction times and dull cognitive abilities, researchers note in Sleep Medicine.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A strong point of this story is how sources in the story are clearly identified as aligned with or independent of the study, and there were several of them. \u00a0We could find no potential conflicts of interest with the researcher who was interviewed.", "answer": 1}, {"article": "Parents get frustrated with the FDA recommendations not to use cold medicines in kids under the age of 4 because they are left with few options.\n\"The American Academy of Pediatrics says the currently available oral cough and cold medications are not effective for children and have the potential for side effects, \" said Dr. Ian Paul, principal investigator and associate professor of pediatrics and public health sciences, Penn State College of Medicine.\n\"I have found that when used properly it can be a good option for parents who want to relieve some cold symptoms in their children.\n\"This was based in part on some of the studies that we have conducted at Penn State.\nIn the study, funded by an unrestricted research grant from Procter & Gamble, makers of Vicks, researchers took 138 children between the ages of 2 and 11, with symptoms like cough, congestion, runny nose and restless sleep that lasted seven days or more.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\nThe story does include a comment from an independent pediatrician, and the story notes that she works for CNN. It also points out that funding for the trial came from the company that sells VapoRub and that the lead researcher is an advisor to the company.", "answer": 1}, {"article": "They also put tested at against petroleum jelly and regular moisturizer on 22 people with dry, flaky legs.\n\u201cMany people have tried to do this, and the materials that have been available up until this have not had the properties of being flexible, comfortable, nonirritating, and able to conform to the movement of the skin and return to its original shape.\u201d\n\nThey screened about 100 compounds before settling on polysiloxane, a silicone-based gel.\nThe cream\u2019s effects are detailed in a scientific report in the journal Nature Materials, but as part of the school\u2019s close association with the companies, it\u2019s being patented and produced at almost the same time.\n\u201cRubber alone would not be that strong.\u201d\n\nIn this case, the catalyst is platinum-based and it turns the gel into a thin, stretchy sheet.\nA team at the Massachusetts Institute of Technology has developed the cream and licensed it to two companies with close ties to the lab \u2014 one called Living Proof, best known for spinning out MIT inventions to the hair care market, and a second one called Olivo Labs, which will develop it for medical uses, perhaps to deliver drugs to the skin.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does include at least one independent source, although that perspective is buried at the bottom of the story, long after the many potential benefits of the technology have been extensively touted. As as to potential conflicts of interest,\u00a0the story didn\u2019t point out the researchers have equity interest\u00a0in the companies, instead it said they had \u201cclose ties,\u201d which warrants a Not Satisfactory rating.", "answer": 0}, {"article": "Paul's group tested buckwheat honey instead of the lighter, more popular varieties because it's known to have more antioxidant and antimicrobial effects, which have been shown in other studies to help wounds heal.\nUnder the provisions of the grant, the group was not involved in the study or the published results, Paul said.\nHoney also beat out no treatment at all.\n\"(Honey) is a cheap and effective treatment,\" said Dr. Ian Paul, lead investigator for the study.\nHoney has long been used by some parents as an alternative treatment for cough, although it should not be given to children under 1 year old.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does quote an independent expert in addition to the lead author of the study.", "answer": 1}, {"article": "One of the top research universities in the world, MSU focuses its vast resources on creating solutions to some of the world's most pressing challenges, while providing life-changing opportunities to a diverse and inclusive academic community through more than 200 programs of study in 17 degree-granting colleges.\n\"Depression is a very frequent condition associated with Parkinson's, so we became interested in whether an antidepressant could modify how the disease progresses,\" said Tim Collier, lead author of the federally funded study and a neuroscientist at MSU.\n\"We found that those on a certain class of antidepressant, called tricyclics, didn't need the levodopa therapy until much later compared to those who weren't on that type of antidepressant medication,\" Collier said.\nThe idea that this clustering effect is controlled by how fast or slow a protein reconfigures itself is typically not a standard way of thinking in research on proteins, but our work has been able to show these changes.\"\n\"Proteins are constantly moving and changing shape,\" said Lapidus, a professor in the Department of Physics and Astronomy.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release says this about the funding of the study: \u201cThe National Institutes of Health, as well as the Michael J. Fox and St. Mary\u2019s Foundations, funded the study.\u201d But the release does not identify any potential conflicts of interest. In our own reading of the material, we found that two of the study\u2019s authors \u2014 C. Justman and P. Lansbury \u2014 are on staff with a for-profit biotech company, Lysosomal Therapeutics, of Cambridge, Mass.That should have been disclosed in the release.", "answer": 0}, {"article": "The reviewed studies included the use of cannabis extracts delta9-tetrahydrocannabinol, or THC, and cannabidiol, or CBD, in people with MS.\n\n\"We found evidence that combined THC and CBD extracts may provide therapeutic benefit for MS spasticity symptoms,\" Lakhan says in a news release.\nAlthough some objective measures of spasticity noted improvement trends, there were no changes found to be significant in post-treatment assessments.\"\nThe researchers say that many existing therapies for this condition are difficult to obtain, ineffective, or associated with intolerable side effects.\nHowever, side effects also were seen in people in placebo groups.\nSide effects varied greatly and depended on the amount needed to limit spasticity, the researchers write.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A HealthDay story reported: \nBut this WebMD story included no independent perspective \u2013 a major shortcoming. ", "answer": 0}, {"article": "Finally, the researchers note, expenses associated with the procedure\u2014the robot costs at least 1.8 million ($2.6 million) to install, 100,000 ($145,000) a year to run, and 1,500 ($2,200) extra for each surgical case-mean the procedure is \u201cprohibitively\u201d expensive \u201cfor many hospitals and indeed many countries.\u201d\n\nThe researchers conclude: \u201cThe significant learning curve should not be understated, and the expense of this technology continues to restrict access to many patients.\u201d\nYou might want to see a surgeon who has done at least 80 operations for the best results, according to the authors of a new research review.\nIn about one in 250 surgeries, the robot failed to work properly.\nThere was also a lack of data on how well patients functioned after surgery, and how patients with high-risk prostate cancer fared long-term.\nLack of information on outcomes isn\u2019t only a problem for robot-assisted surgery, but \u201cbedevils\u201d the scientific literature on prostate removal overall, the researchers note in the journal European Urology.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0The story does not use any comments from experts in the field without a direct connection to the study reported on.", "answer": 0}, {"article": "However this does not help them to overcome their fear in the long term.\nA proportion of the patients surveyed were found to have other psychological conditions - 37% had high levels of general anxiety and 12% had clinically significant levels of depression.\nProfessor Tim Newton from the Dental Institute at King's College London and lead author of the study said: \"People with dental phobia are most commonly given sedation to allow them to become relaxed enough for a short period of time to have their dental treatment performed.\nThe latest study, published in the British Dental Journal, looked at the characteristics of 130 patients (99 women and 31 men) attending a psychologist-led CBT service and the outcomes of their treatment.\nOur service should be viewed as complementing sedation services rather than as an alternative, the two together providing a comprehensive care pathway for the ultimate benefit of patients.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not explicitly name the funding source for the research, only that the clinic where CBT was provided is run by the King\u2019s College London Dental Institute Health Psychology Service at Guy\u2019s and St Thomas\u2019 NHS Foundation Trust.", "answer": 0}, {"article": "Psoriasis is a chronic autoimmune-related skin condition in which thick, scaly patches appear on the skin.\n\"This study highlights the collaborative spirit of academic medicine, and how our rheumatology and bariatric surgery researchers worked together to not only help our patients directly, but inform the medical community at large,\" says study co-author Jose U. Scher, MD, assistant professor of rheumatology and co-director of the NYU Langone's Psoriatic Arthritis Center.\n\"Psoriasis and psoriatic arthritis are chronic inflammatory conditions that can be quite uncomfortable and often painful for patients, so any treatment that might reduce symptoms may improve quality of life,\" says lead study author Soumya Reddy, MD, an assistant professor of medicine in the division of rheumatology at NYU Langone, and co-director of NYU Langone's Psoriatic Arthritis Center.\nFor the study, Reddy and colleagues reviewed the medical charts of 9,073 weight-loss surgery patients who were treated between 2002 and 2013 at NYU Langone's Weight Management Program.\nIt is estimated that as many as 20 percent of individuals with moderate to severe psoriasis develop psoriatic arthritis in their lifetime.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release discloses that the patient histories that were reviewed came from bariatric surgery patients of NYU Langone, the institution that issued the news release. It states, \u201cFor the study, Reddy and colleagues reviewed the medical charts of 9,073 weight-loss surgery patients who were treated between 2002 and 2013 at NYU Langone\u2019s Weight Management Program.\u201d", "answer": 1}, {"article": "CHICAGO \u2014 Insulin pumps are used by tens of thousands of teenagers worldwide with Type 1 diabetes, but they can be risky and have been linked to injuries and even deaths, a review by federal regulators finds.\n\u201cIt is a constant struggle for a patient who is an adolescent to stay in control of any therapy,\u201d said Steve Sabicer, a spokesman for Minneapolis-based Medtronic Inc., which makes the top-selling insulin pump.\nAt times, the devices malfunctioned, but other times, teens were careless or took risks, the study authors wrote.\nAnd they\u2019re a growing segment of diabetes care, with $1.3 billion in annual sales worldwide, said Kelly Close, a San Francisco-based editor of a patient newsletter.\nThe company stands behind the product\u2019s safety and \u201cthe many years of clinical evidence that support the benefits of insulin pump therapy,\u201d he said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The original AP story included the perspective of an independent expert, the American Diabetes Association\u2019s president for medicine and science.\u00a0 It also included input from the editor of a patient newsletter.\u00a0 But the Pioneer Press deleted these perspectives.\u00a0 Instead, the St. Paul story included a quote from the manufacturer of the top-selling insulin pump. Why?\u00a0 Because it\u2019s a local Twin Cities company?\u00a0 ", "answer": 0}, {"article": "March 29, 2011 -- A minimally invasive procedure that cuts off the blood supply to an enlarged prostate may help when medications fail, and it appears to provide good symptom control without sexual dysfunction, a new study shows.\nDespite the promising results of this small trial, experts said it was far too early to recommend PAE to patients.\nWe really don\u2019t know what the short- and long-term success or complication rates are,\u201d says Anthony Malizia Jr., MD, president and director of the Malizia Clinic, a nonprofit urology specialty center in Atlanta.\n\u201cWe don\u2019t know how well these particles are localized to the prostate or if they\u2019re going to the pelvis or other parts of the body.\u201d\n\nMalizia notes that in one serious complication reported in the study, the particles appeared to migrate and kill a small part of the bladder wall.\nA similar procedure is sometimes used to treat another kind of benign growth, uterine fibroids, in women.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two individuals who seemingly had no connections with the research reported on were interviewed for this story. \u00a0Their comments provide good insight though it was somewhat swamped by the promotional comments about this potential treatment.", "answer": 1}, {"article": "LONDON (Reuters) - A protein in urine could be a strong indicator of prostate cancer risk, according to British scientists who say their findings could one day be developed into a quick and simple test for the disease.\nCommenting on the study, Kate Holmes of the UK\u2019s Prostate Cancer Charity, said they could prove very valuable in future.\nIn Britain, around 35,000 men are diagnosed with it and some 10,000 die from the disease.\nProstate cancer killed an estimated 258,000 men around the world in 2008 and is the second most common cause of cancer death in men in the United States.\nThe scientists took tissue and urine samples from around 350 men both with and without prostate cancer to test MSMB levels.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0The story included comments from two individuals involved with the study reported on as well as an individual with expertise in the field without links to that study.", "answer": 1}, {"article": "Ankle replacement has been around for three decades, but it has been slow to catch on.\n\u201cBut I can\u2019t tell you how many patients come in, and I mention this option they don\u2019t even know exists.\u201d (Dr. Radnay, who says he has performed more than 100 ankle replacements using an Inbone device from Wright Medical Group of Arlington, Tenn., is now a paid consultant to the company, helping to gather data on long-term success rates.)\nStill, Dr. Deland said, \u201cwe\u2019re getting fewer and fewer failures.\u201d\n\nThe new models require that less bone be removed, so the bone to which the device is affixed is stronger.\nThe procedure usually relieves pain, but the patient loses mobility in the ankle, leading to changes in gait and, ultimately, additional wear and tear and arthritic pain in other parts of the ankle.\nThe bodies of many older Americans are practically bionic: more than 770,000 hip and knee replacements are performed each year in the United States.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story clearly indicates that all of the experts interviewed had ties to manufacturers of the joint implants.\u00a0 While this may be expected due to the relatively small number of surgeons who perform this procedure, this is a clear example of conflict of interest.\u00a0 The story should have included comment from an independent unconflicted surgeon or referring physician (non-surgeon) with no stake in this.\u00a0 Disclosure is one thing; providing balance is quite another. ", "answer": 0}, {"article": "New blood tests will speed up diagnosis for the most common GI disorder\n\nLOS ANGELES (May 14, 2015) - Millions of people afflicted by irritable bowel syndrome can now be diagnosed quickly and accurately with two simple blood tests developed by a Cedars-Sinai gastroenterologist.\nThe tests are marketed under the name IBSchek\u2122 and are produced by Commonwealth Laboratories Inc., in Salem, Massachusetts.\nThe blood tests identified the two antibodies associated with IBS -- anti-Cdtb and anti-vinculin -- with greater than 90 percent certainty.\nThe new blood tests identify the presence and amount of specific antibodies reacting to the toxins.\nThe tests, created by Mark Pimentel, MD, director of the GI Motility Program and Laboratory, confirm when a patient has developed IBS because of food poisoning, a major cause of the disorder.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We give the release credit here. It clearly notes that the lead author receives consulting fees from Commonwealth Laboratories \u2014 which is the company marketing these tests. And that\u00a0Cedars-Sinai has a license agreement with the company for patent applications covering the blood tests,", "answer": 1}, {"article": "NeuroVision was formed in 2010 and is headquartered in Sacramento, California.\nHere are several highlights:\n\u2022 The first histologic quantitative analysis of retinal plaque clusters, or \"hot spots,\" containing the most toxic forms of beta-amyloid with specific distribution patterns in superior peripheral regions that were previously unexplored.\n\"As a developmental outgrowth of the central nervous system that shares many of the brain's characteristics, the retina may offer a unique opportunity for us to easily and conveniently detect and monitor Alzheimer's disease,\" said Keith L. Black, M.D., chairman of NeuroVision, chair of the Department of Neurosurgery and director of the Maxine Dunitz Neurosurgical Institute at Cedars-Sinai.\nFindings from this study strongly suggest that retinal imaging can serve as a surrogate biomarker to investigate and monitor Alzheimer's disease,\" said Maya Koronyo-Hamaoui, Ph.D., an associate professor of Neurosurgery and Biomedical Sciences and a research scientist at the Maxine Dunitz Neurosurgical Institute at Cedars-Sinai, and a co-founder, inventor and scientist at NeuroVision.\nThe experimental technology, developed by Cedars-Sinai and NeuroVision, scans the retina using techniques that can identify beta-amyloid protein deposits that mirror those in the brain.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Everyone quoted in the release is affiliated with the company that makes the diagnostic tool that is being tested, and that is made clear. The funding sources are also made very clear. And we were also happy to see this level of detail about the study:\nClinical trials were approved by Quorum Review, Seattle, Washington, (IRB00003226) and the U.S. Department of Health and Human Services (FWA00019841). Human tissues were obtained from the USC Alzheimer\u2019s Disease Research Center (ADRC) Neuropathology Core, Los Angeles, CA (IRB protocol: HS-042071).\nAnimal studies were approved by the Cedars-Sinai Medical Center Institutional Animal Care and Use Committee (IACUC) and the Division on Laboratory Animal Medicine (DLAM) at UCLA.", "answer": 1}, {"article": "They concluded that five different types of prostate cancer were found based on 100 genes.\n\"These findings could lead to more optimized diagnostic testing on all aspects of the prostate cancer diagnosis process and brings full circle the coming approach to cancer being an individual disease based very much on the patient's individual genetic profile,\" said Dr. Samadi.\nPrior research had shown six of the genes were linked to prostate cancer, however researchers noted in the published study that it turns out the other 94 genes had not been associated with prostate cancer until now.\nThis may mean that each type of the disease needs its own approach to screening, diagnosis, treatment and even recurrence,\" noted Dr. Samadi.\nFor men with a family history of the disease, contact Dr. Samadi to learn more about your risk factors and to get a baseline PSA blood test.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "This release isn\u2019t hiding any conflicts since it is openly sponsored and released by the prostate cancer specialist named. However, it almost appears as though the author hijacked a recent study about prostate cancer genetics in order to sell the physician\u2019s services to concerned patients. Details about the study itself are minimal.", "answer": 1}, {"article": "Andersson will be available to the media in an embargoed web briefing on Tuesday, March 7, 2017, at 2 p.m.\nA limitation of the study is that the researchers did not assess the effects of untreated erectile dysfunction, or conversely, the effect of having an active sex life without taking erectile dysfunction drugs.\nThe researchers also were unable to account for socioeconomic status; as a next step, they are planning a larger study that will include more health records and complete information on marital status, educational level and disposable income.\nThe study, which retrospectively tracked more than 43,000 men for an average of 3.3 years, found that men prescribed phosphodiesterase-5 (PDE5) inhibitors--the type of erectile dysfunction drug sold under the names Viagra, Levitra, Cialis and others--after their first heart attack were 33 percent less likely to die from any cause.\nHowever, previous studies have associated the use of PDE5 inhibitors with a decreased blood pressure in the left ventricle, which reduces the amount of work required to pump blood and therefore could help explain why the drugs might benefit people with heart failure.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes the funding source:\u00a0the Stockholm County Council and the Swedish Heart and Lung Foundation. The published study discloses that one of the study authors received \u201cconsultancy honoraria\u201d from Actelion and Pfizer, two manufacturers of ED drugs. This should have been included in the release as well.", "answer": 0}, {"article": "\u201cI don\u2019t think this paper is inconsistent with previous work.\u201d\n\nNichols, who was not involved in the study, said aspirin is clearly beneficial for people who\u2019ve already had heart disease, and that it also seems to help those at high risk.\n\u201cThere is not universal agreement on what is high risk,\u201d he told Reuters Health.\nAbout 100,000 men and women age 45 and up took part in the studies.\nEvery year, heart attacks alone kill some 400,000 Americans.\nThe question then becomes finding out what your risk of heart attack is in the first place, which your doctor can help with.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two independent experts were quoted. And the story noted that the research was funded by Bayer.", "answer": 1}, {"article": "For the work, a cohort of 541 9- to 11-year-olds in China, 54 percent boys and 46 percent girls, completed a questionnaire about how often they consumed fish in the past month, with options ranging from \"never\" to \"at least once per week.\"\nPrevious studies showed a relationship between omega-3s, the fatty acids in many types of fish, and improved intelligence, as well as omega-3s and better sleep.\n\"Doing that could be a lot easier than nudging children about going to bed,\" Raine said.\nIt's emerging,\" said Liu, lead author on the paper and an associate professor of nursing and public health.\n\"It really has to be a concerted effort, especially in a culture where fish is not as commonly served or smelled.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We learn the connections between the funders of the research and the investigators and there is no sense that a conflict of interest exists here.", "answer": 1}, {"article": "After a systematic review of medical research on the subject, experts reported that adding an aromatase inhibitor -- a drug that reduces the amount of estrogen produced in the body -- has clearly been shown to reduce the number of tumor recurrences in postmenopausal women compared with the standard drug tamoxifen, which works by blocking the action of estrogen on cancer tumors that are estrogen-receptor positive.\n\"Are [aromatase inhibitors] better than tamoxifen?\nThe drugs can also cause side effects that need to be taken into account when prescribing.\n\"Aromatase inhibitors are clearly associated with osteoporosis and with bone and joint [conditions].\nBut the [financial] costs are much more expensive.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 0}, {"article": "The Johns Hopkins researchers also calculated the effects of surgery on health costs for the patients.\nThe most common drugs before treatment were metformin, a generic taken by about half of patients, followed by the medicines Avandia and Actos, taken by more than one-third of patients.\nWhile mortality in the hospital was 0.3 percent, some 21 percent of patients had to be admitted to the hospital again for one reason or another within a year of their operations.\nBy year three, the data were only available for 288 patients, about 13 percent of those who got the surgery.\nThe researchers argue that the findings, drawn from data on four years of claims made in seven states, support coverage of bariatric surgery by insurers because of the savings and improvements in patients' health.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThis story does not include comments from independent sources. The researchers did not make any financial disclosures. The study was funded by a public agency, the U.S. Agency for Healthcare Research and Quality. It used data that was originally gathered for an obesity care project funded by a surgery device company and an insurance company.", "answer": 0}, {"article": "Media Advisory: To contact corresponding author Susan L. McElroy, M.D., call Jennifer Pierson at 513-536-0316 or email jennifer.pierson@lindnercenter.org\nThe one-week BE episode response status was improved in the 50- and 70-mg/d treatment groups, and a greater proportion of participants achieved four-week cessation of BE episodes and global improvement of symptom severity with all lisdexamfetamine dosages.\n\"In the primary analysis of this study of adults with moderate to severe BED, lisdexamfetamine dimesylate treatment with 50 and 70 mg/d, but not 30 mg/d, demonstrated a significant decrease (compared with placebo) in weekly BE days per week at week 11.\nResults also indicate the percentage of patients who achieved four-week BE cessation was lower with the placebo group (21.3 percent) compared with the 50-mg/d (42.2 percent) and 70-mg/d (50 percent) treatment groups.\nThe study included 259 and 255 adults with BED in safety and intention-to-treat analyses, respectively.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "A pharmaceutical company is identified as the funder of this study in\u00a0an editor\u2019s note at the bottom of the release, and the release notes that the study authors also disclosed conflicts of interest. Also disclosed is the fact that the sponsor paid a communications company to write\u00a0and edit the manuscript.\nThat\u2019s sufficient for a Satisfactory rating, although we\u2019d add that\u00a0each of the study authors (except one, who works for another company) is heavily involved with industry above and beyond this particular study. The cumulative effects of these commercial aspects is worrisome: Where does one draw the line between experiment and \u201cexperimercial\u201d?", "answer": 1}, {"article": "While the American Cancer Society, the American College of Physicians and other gastroenterology experts recommend virtual screening every five years, the U.S. Preventive Services Task Force, a congressionally mandated but non-federal, independent group of medical experts, concluded the evidence wasn\u2019t strong enough to justify Medicare coverage of the service.\nThat\u2019s a bit of a surprise, given that not all medical experts agree on whether the virtual screen is as reliable as a traditional colonoscopy, in which doctors insert a scope with a small camera into the colon.\nAnd given the relatively low cost of investing in the software and other equipment required to run a virtual scan, more hospitals may be adding the option to their patient services.\nIn the end, it\u2019s a matter of personal preference \u2014 it\u2019s less important how you get screened, just that you do get screened.\nOr, the images can be combined to generate a 3D view of the colon, allowing the doctors to \u201cfly through\u201d the organ looking for any suspicious growths or protrusions.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Quotes only one expert in the story \u2013 a director of a CT center.\nWhile the story discusses what unnamed skeptics say, we should have heard from some directly to balance the story.", "answer": 0}, {"article": "But are they benefiting from acupuncture itself, or just getting a placebo effect?\nFor one thing, they note, patients in both groups received treatment with needles and electrical stimulation; the main difference was that in the sham group, the needles were not inserted as deeply and the stimulation was far shorter in duration.\nActually, patients got significant pain relief from both treatments \u2014 an average reduction of one point on a scale of 1 to 7.\nBut that result has been called into question because the patients in the sham group probably figured out they were not getting the real thing.\n\u201cThere are some things you can\u2019t study the same way we do with drugs,\u201d said Dr. Eleanor M. Walker, director of breast radiation oncology at the Henry Ford Health System.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article quotes many sources \u2013 most of them involved in the research in question.\u00a0 One interviewee appeared to be independent of any of the studies being discussed. ", "answer": 1}, {"article": "The first CT scan was OK.\nSays Henschke: \"This is a way of finding it early and taking it out early, because it is a much better chance of being cured from the disease.\"\nBut a new study proves there may be a better way to detect the disease \u2014 early enough to beat it\n\nBarton Lazarus is one of the lucky ones.\nBut the authors of the study say CT screening can be a cost-effective way of detecting lung cancer \u2014 one that could dramatically lower cancer death rates.\nIf Lazarus hadn't had any studies, says Dr. Harvey Pass of the NYU Medical Center in New York, the tumor would have grown causing pain, cough bleeding and maybe not have been able to be surgically removed.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes the prinicpal investigator of the study about the benefits of screening. Although the story quotes another physician, he only discusses his patient's case, not the concept of lung cancer screening.\u00a0 Some independent perspective was needed on this important topic. ", "answer": 0}, {"article": "\"We believe this may be the most exciting breakthrough in leprosy treatment since multi-drug therapy, the current treatment for leprosy, was launched in the 1980s.\n\"This is a unique example of a vaccine produced by totally synthetic methods.\"\n\"This generation of a vaccine to prevent and possibly treat leprosy is the result of years of research.\nA viable vaccine to prevent and/or treat leprosy is the next step in the effort to bring this disease to an end.\nThe clinical trial is focused on safety, as well as evaluating the immune response to the vaccine.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources are all clearly laid out.", "answer": 1}, {"article": "Men whose prostate cancer comes back after surgery are more likely to survive if, along with the usual radiation, they also take drugs to block male hormones.\n\nThe finding, published Wednesday in The New England Journal of Medicine, comes from a long-running study that experts say will help clarify treatment for many patients.\n\nAfter surgery to remove the prostate, more than 30 percent of men have a recurrence, and until now there has not been clear evidence about the best way to stop the disease from killing them. Most are given radiation, but prescribing drugs to counter the effects of male hormones has been inconsistent.\n\nThe study, paid for by the National Cancer Institute, showed that among men who received radiation and hormonal treatment, 76.3 percent were still alive after 12 years, compared to 71.3 percent who had radiation alone.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two outside sources provided comment, and readers are told the study was funded by the National Cancer Institute, a government-funded organization.\nHowever, and unlike a STAT story on the same study, the Times didn\u2019t mention how AstraZeneca \u2014 a maker of a hormone-blocking drug for men \u2014 was a study sponsor.", "answer": 0}, {"article": "As a nicotine-gum addict, Mike Metzger used to worry about the warning on its label: \"Stop using the nicotine gum at the end of 12 weeks.\"\n\nBut that was before a prominent smoking-cessation scientist, K. Michael Cummings, told him to keep chewing the gum as long as it helped him stay off cigarettes. So 15 years after quitting smoking, Mr. Metzger, a 63-year old retired New York telephone worker, still chews 16 pieces of nicotine gum a day.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quoted one scientist in a story that was ostensibly all about the science. Instead, it spent more time with nicotine gum users and a blogger. We thought that had more space been devoted to independent experts, the evidence would have been more clearly sorted out. We did appreciate, though, that the story took pains to point out the extent of drug industry funded research in this area. It says, for example, \u201cHowever, the study reported no difference in the quit rates of the two groups when they were checked at the one-year mark, revealing the fact that many people began smoking again. The senior author of the study, funded by federal grants, has served as a consultant for GlaxoSmithKline.\u201d", "answer": 1}, {"article": "But at our facility we think it makes caring for a patient much easier.\n\"It's highly likely the reason these patients did better is that they were receiving earlier diagnoses, and they were also empowered to take charge of their own health care more,\" Saxon said.\n\"I'm very encouraged that survival after defibrillator implant is as good as it is for as long as it is,\" co-author Dr. Leslie A. Saxon, chief of the division of cardiovascular medicine at the University of Southern California's Keck School of Medicine in Los Angeles, said in a news release from the American Heart Association.\nThe finding is based on an analysis of nearly 186,000 patients outfitted with either an implantable cardioverter defibrillator (ICD), a cardiac resynchronization therapy device (CRT), or a defibrillator combined with a CRT device (a CRT-D).\nBut, Prystowsky continued, \"this analysis does show two impressive things: one, that patients who are not super-selected for a trial do well with these devices from a mortality standpoint; and two, that patients who had home-monitoring had better outcomes.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does use one independent source, but it fails in another way. It does not point out that the study was funded by the device maker Boston Scientific. Also,\u00a0Dr. Prystowsky notes funding support from Boston Scientific (http://www.theheart.org/article/1050051.do ), but this is not acknowledged.", "answer": 0}, {"article": "Savient expects Krystexxa to be available by prescription later this year.\nThe condition is associated with obesity, high blood pressure, high cholesterol, and diabetes.\nKrystexxa, which is made by Savient Pharmaceuticals Inc. of East Brunswick, N.J., is an enzyme that lowers uric acid levels by metabolizing it into a chemical that does not cause bodily damage and is then passed through the urine.\nThe drug is administered to patients every two weeks as an intravenous infusion.\nGout is more common among men and postmenopausal women, and people with kidney disease.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Inadequate. We weren\u2019t told who funded the research.\u00a0 And why do we have to hear claims of novelty only from a company president, lifted from a news release?\u00a0 That\u2019s inadequate sourcing. ", "answer": 0}, {"article": "People with Type 2 diabetes get an earful of grim lectures about their health prospects and endure much hardship to manage their condition well. But new research offers those who do so a rare reward. A glass of wine every day not only won't hurt, says a new study: It can actually improve cardiac health, help manage cholesterol and foster better sleep.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no quotes or other indications that independent sources were consulted.\u00a0An outside perspective, particularly from someone who could point out that the benefits were very modest clinically, would have been valuable.", "answer": 0}, {"article": "An experimental drug designed by Roche Holding AG's Genentech unit against a new cancer target yielded encouraging results against two rare tumors, researchers said, potentially opening up a new front in the battle against the disease.\n\nIn a small study, the drug, known as GDC-0449, shrank tumors in 18 of 33 patients, or 55%, with an advanced form of a skin cancer called basal cell carcinoma. In addition, the drug had a dramatic, though temporary, effect on a 26-year-old patient who had undergone multiple surgeries, chemotherapy...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story provided comments from co-authors of the two studies, as well as the author of the accompanying editorial. \u00a0 ", "answer": 1}, {"article": "We want to outline health-care pathways that provide the best care for patients.\u201d\n\nThe analysis demonstrated an average cost of $13,389 for the wrist approach with same-day discharge, compared with $17,076 for the groin approach with at least one night of hospitalization, resulting in a cost savings of about $3,700 for outpatients who get the wrist-access procedure.\n\u201cWe have unequivocal evidence and data that show better outcomes when we access the heart\u2019s coronary arteries and perform angioplasty through a blood vessel in the wrist rather than through the femoral artery in the groin,\u201d said first author Amit P. Amin, MD, an assistant professor of medicine.\nNewswise \u2014 Hospitals can improve patient care and reduce costs associated with coronary angioplasty if cardiologists perform more of these procedures through an artery in the wrist and if they take steps to discharge such patients on the same day, according to a new study led by Washington University School of Medicine in St. Louis.\nBut with advances we have in technology and equipment, those challenges are rapidly decreasing.\u201d\n\nThis work was supported by a grant from Vita Solutions, a subsidiary of The Medicines Company, for whom Amin has provided consultation; and by the National Institutes of Health (NIH), grant numbers UL1TR000448, KL2TR000450, TL1TR000449 and 1KM1CA156708-01.\n\u201cThe traditional way has been to go through the bigger femoral artery that is a straight pathway to the heart,\u201d Amin said.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release is to be commended here for how it discloses funding sources and potential conflicts of interest. It includes these disclosures in an end note which doesn\u2019t interfere with the flow of the release. This is what we\u2019d like to see in all news releases.", "answer": 1}, {"article": "This practice isn't totally harmless.\n\"I think there's been a disconnect between the observational studies and the randomized clinical trials to date,\" Manson said.\nBut somehow we've arrived at a point when some physicians are prescribing large doses of Vitamin D supplements for their patients in the hope of preventing cancer, cardiovascular disease, diabetes, autoimmune disorders and other maladies, despite a lack of evidence that this works, according to a new commentary in the Journal of the American Medical Association.\nYou should be consuming 600 international units daily if you're between the ages of 1 and 70, and 800 IU each day if you're 71 or older, according to the Institute of Medicine, the health arm of the National Academcy of Sciences.\nOver the past 15 years, those studies \"have looked promising, and very often they've been reported by the media as suggesting that vitamin D has these benefits.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites only two sources: Dr. Manson and the\u00a0JAMA commentary co-authored by Manson. While Dr. Manson would normally qualify as an independent expert source in any story on vitamin D, here she\u2019s basically being asked to comment on an article that she wrote which is the basis for the story. The story would have been much stronger if it had also included input from someone who didn\u2019t author the JAMA commentary.", "answer": 0}, {"article": "(Reuters Health) - The experimental orphan drug teprotumumab significantly reduces the eye bulging associated with Graves\u2019 disease, according to results of a small trial.\nThe eyes don\u2019t have that bulging appearance, he said, and many of them return to the degree of bulging they had before they got the disease.\nThe typical treatment for Graves\u2019 eyes is glucocorticoids, which are not always effective and also have side effects, the study team notes.\n\u201cIn virtually all the responders, the changes are frequently what anyone would call dramatic,\u201d said lead study author Dr. Terry Smith of the University of Michigan Medical School in Ann Arbor.\nOn Monday, Horizon Pharma announced that it was acquiring River Vision, which paid for the new study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only source quoted in this story was the lead investigator in the trial. No information from other unaffiliated experts was included. The story does mention that River Vision Development Corporation funded the trial, but it doesn\u2019t mention that several investigators reported receiving fees from River Vision Development Corporation separate from the study. \u00a0It does not mention grant support from the National Institutes of Health, National Eye Institute, Research to Prevent Blindness, the Bell Charitable Foundation,\u00a0among others.", "answer": 0}, {"article": "\"Although eight hours of CPAP per night can be difficult to achieve in real-life, our results should provide a strong incentive for anyone with sleep apnea, especially prediabetic individuals, to improve adherence to their treatment for cardio-metabolic risk reduction,\" she said.\nIt has been associated with an increased risk of cardiovascular diseases, such as hypertension and stroke, and may decrease their ability to regulate blood sugar levels.\nFor this study, the researchers recruited 39 middle-aged, overweight or obese volunteers with prediabetes and sleep apnea.\nThe other 13 received a placebo -- a pill containing no medicine -- to be taken 30 minutes before bedtime.\nUsing a simple device for eight hours a night to treat sleep apnea can help people with prediabetes improve their blood sugar levels and may reduce the risk of progressing to diabetes, according to a new study published online in the April 21, 2015, issue of the American Journal of Respiratory and Critical Care Medicine.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release clearly identifies the sources of funding for the study, which were the National Institutes of Health and the University of Chicago\u2019s Diabetes Research and Training Center and Institute for Translational Medicine. The release also quotes two researchers and makes clear that both researchers were authors of the paper describing the work.", "answer": 1}, {"article": "Feb. 2, 2011 -- The human papillomavirus (HPV) vaccine can help stave off genital warts in boys and men, according to a new study in the Feb. 3 issue of the New England Journal of Medicine.\nThe vaccine is used in girls and boys and young adults ages 9 to 26 for prevention of genital warts caused by HPV types 6 and 11.\nHPV, a sexually transmitted disease, can be transmitted through vaginal, anal, and oral sex and has been linked to genital warts as well as cervical, vaginal, vulvar, oral, penile, and anal cancers.\nOf 4,065 boys and men aged 16 to 26 from 18 countries, vaccination with an HPV vaccine that targets four types of HPV infection -- HPV-6, HPV-11, HPV-16, and HPV-18 -- protects against infection with these types of HPV and potentially the development of related external genital warts or lesions.\nThe vaccine is recommended for optional use in boys and men.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The sources included one of the study researchers and additional perspective from the author of an editorial in the New England Journal of Medicine. It did not point out that Merck, the manufacturer of Gardasil, contributed to the money for this study.\u00a0 We\u2019ll call it barely satisfactory.", "answer": 1}, {"article": "When I began training last year for my first marathon, my running partner Dave Freedholm, an experienced amateur distance runner, impressed on me the need to vigilantly avoid dehydration. His drink of choice was Accelerade. Like Gatorade, the original sports drink, it's packed with sugars and sodium to provide energy and replace the electrolytes depleted in sweat. But it also contains protein, which he said would help my muscles repair themselves more quickly after the punishing training runs he took me on.\n\nSure enough, I never felt much pain until after the marathon itself, and even then I recovered within a couple of days...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not quote any sources. The story should have provided some perspective from experts who have no stake in the claims being made.", "answer": 0}, {"article": "As part of a longer term project funded by F. Hoffman-La Roche, the team previously tested a collection of approximately 550 potential tracer molecules and identified six promising tracers, eventually narrowing them down to three to be made and tested as candidate Tau PET radiopharmaceuticals.\nThe third part of the study examined six older controls undergoing whole-body scanning.\nAn additional six older healthy controls were recruited for full-body scanning.\nIt was published in the December 2018 issue of the journal.\nThe authors report no other relevant potential conflict of interest.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes the funding source for the research and addresses conflicts of interest.", "answer": 1}, {"article": "April 18, 2011 -- The FDA has approved a new noninvasive portable device for the treatment of a deadly type of brain tumor. The device uses electrical fields to slow and possibly reverse tumor growth.\n\nThe device, manufactured by Novocure, is called the NovoTTF-100A System and is meant for adults with glioblastoma multiforme that recurs or progresses after chemotherapy and radiation treatment.\n\nGlioblastoma multiforme is a common type of brain cancer, and the tumor is highly resistant to standard treatments, such as surgery, radiation, and chemotherapy, the FDA says in a statement.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "As already stated, no independent source was quoted about the evidence, about the benefits or harms. Even the news-release-lifted quote from the FDA official said only that the approval shows FDA\u2019s \u201ccommitment to innovative new devices that provide patients with other treatment options.\u201d\u00a0 That\u2019s more of a self-promotional statement about FDA than it is a helpful comment about the role of this particular device.\nThis is indeed unfortunate given the availabilty of the information about the pivotal study in toto from the FDA website. But the online story didn\u2019t even link to that information.", "answer": 0}, {"article": "Kite Pharma is racing to get the first FDA approval of an experimental gene therapy to fight cancer.\n\nAn experimental gene therapy that turns a patient\u2019s own blood cells into cancer killers worked in a major study, with more than one-third of very sick lymphoma patients showing no sign of disease six months after a single treatment, its maker said Tuesday.\n\nIn all, 82 percent of patients had their cancer shrink at least by half at some point in the study.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story notes that the study was funded by Kite and it quotes two outside sources. First, Dr. Roy Herbst of the Yale Cancer Center, who has not disclosed any relationship with Kite Pharma. Also quoted is Dr. Steven A. Rosenberg of the National Cancer Institute\u00a0\u201cwho had no role in Kite\u2019s study\u201d but who has had T-Cell immunotherapy research funded by Kite Pharma within the past year (a fact not disclosed in the piece).\nThe story makes a good faith effort to provide independent, objective perspectives on the research. However, to make a point of saying Dr. Rosenberg had no role in \u201cthis\u201d study but not mention he has been funded by Kite Pharma in the past for similar research is enough of a red flag to warrant an unsatisfactory mark for potential conflict of interest.", "answer": 0}, {"article": "A birth-control pill that eliminates women's monthly periods could hit pharmacy shelves later this year, marking the latest effort by a drug company to expand a contraceptive's features beyond preventing pregnancy.\n\nSince \"The Pill\" was introduced nearly a half-century ago, most regimens have mimicked a woman's cycle by having a pill-free week each month when women can have bleeding and other symptoms.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story appears to have relied largely on statements from a representative of the drug manufacturer. An additional expert is cited, but it\u2019s not noted whether this person has any affiliation with the drug maker. ", "answer": 0}, {"article": "Attorney James Tuffin followed his usual daily routine last week: He ran five miles and drove to his office on suburban Long Island. In between, he stopped at Advanced Radiation Centers in North Hills, N.Y. There, he drank a quart of water, lay down on a treatment table and watched as a high-tech linear accelerator rotated around him for 90 seconds, blasting his cancerous prostate with radiation.\n\n\"On a good day, I'm in and out in a half-hour,\" says Mr. Tuffin, 54 years old, who was midway through his scheduled 45...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included comments from a number of individuals, all of whom have a vested interest in the RapidArc (a company spokesperson, a spokesperson for a cancer center that has acquired the technology, a professional society spokesperson, and a patient who has selected this treatment). \u00a0The story should have included comment(s) from someone who could have provided an unbiased evaluation of what, if any, added benefit this approach contributes to the arsenal of available treatment options.", "answer": 0}, {"article": "Obese children who cut sugar from their diets saw improvements in markers of heart disease after just nine days, a study in Atherosclerosis found.\nFor the study, researchers evaluated 37 children ages 9 to 18 who were obese and at high risk for heart disease and Type 2 diabetes.\n\u201cSugar calories are not like other carbohydrate calories,\u201d said Dr. Robert Lustig, a co-author of the study and professor of pediatrics at Benioff Children\u2019s Hospital at the University of California, San Francisco.\nAfter nine days, the researchers found a 33 percent drop in triglycerides, a type of fat tied to heart disease; a 49 percent reduction in a protein called apoC-III that is tied to high triglyceride levels; and large reductions in small, dense LDL cholesterol, a risk factor for heart disease.\nThough this study is small and short-term, it builds on this group\u2019s previous research implicating added sugars as a contributor to metabolic disorders and heart disease.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources\u2013the one person quoted\u00a0is study coauthor, Dr. Robert Lustig, who has a potential conflict of interest. Lustig wrote a book that\u2019s extremely critical of sugar, and has spoken of fructose as \u201cpoison.\u201d", "answer": 0}, {"article": "\u201cOur study shows that there may be some relationship between dietary factors and things like egg quality so one idea may be recommending supplementation with omega 3s to improve fertility.\u201d\n\nExactly how the healthy omega 3 fatty acids are helping the ovary to produce better quality eggs isn\u2019t clear yet.\nThese could then mature into a healthy egg that is fertilized and can lead to a live birth.\n\u201cBut even without that firm answer at this point I don\u2019t see the harm in supplementing.\u201d\nWhen the ovaries were examined even further, Skaznik-Wikiel also found that the quality of the eggs were better among the animals with higher levels of omega 3s.\n\u201cBased on this study, it looks very encouraging that omega 3s can potentially improve fertility,\u201d says Skaznik-Wikiel.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story is brief and includes no sources other than the researcher whose paper is being discussed.", "answer": 0}, {"article": "\"Our findings show that ocrelizumab rapidly suppresses inflammatory activity,\" noted the study authors, led by Dr. Ludwig Kappos from the University Hospital, Basel, Switzerland, in a journal news release.\nThe number of active lesions had dropped 89 percent more among the 600-mg group compared with those getting a placebo.\nThe study authors noted that MS is a progressively debilitating disease that attacks an individual's central nervous system, disrupting the normal brain, spinal cord and optic nerve function.\nThe investigators further noted that even eight months after treatment launch, no serious adverse effects were directly attributable to the new drug.\nAfter 24 weeks, some of the doses were adjusted.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The Mayo expert\u2019s input was the one saving grace of the story.\nThe story also disclosed that two drug companies funded the study.", "answer": 1}, {"article": "\"Powdered fiber, mixed in a water bottle, taken once a day is all we asked the children to change, and we got, what we consider, some pretty exciting results -- it has been fantastic,\" added Raylene A. Reimer, PhD, RD, professor and researcher in the Faculty of Kinesiology at University of Calgary, who led the study.\nThe prebiotic was provided as a white powder, mixed in water.\nCheck out our videos on YouTube.\nClinicaltrials.gov no: NCT02125955.\nThe metabolic and microbial findings from this study provide a foundation for a larger clinical trial in the pediatric population.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources were listed.", "answer": 1}, {"article": "The Society is based in Oak Brook, Ill. (RSNA.org)\n\"The results show that multicentric cancer detected on breast MRI after mammography appears to represent a larger tumor burden in approximately a quarter of patients and can result in potential changes to cancer grade and treatment,\" Dr. Iacconi said.\n\"Patients with clinically insignificant cancers undergoing potential overtreatment versus patients who may be undertreated is at the heart of the controversy surrounding breast MRI,\" said the study's lead author Chiara Iacconi, M.D., from the Breast Unit at USL1 Massa-Carrara in Carrara, Italy.\nOAK BROOK, Ill. - Additional breast cancers found with MRI are sometimes larger and potentially more aggressive than those found on mammography, according to a study published online in the journal Radiology.\n\"In general, it is accepted that radiation can likely treat invasive cancer less than 1 centimeter, but lesions larger than 1 centimeter, especially invasive carcinomas, may not be reliably treated with conservation.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not say how the study was funded. The journal article says the researchers \u201cdisclosed no relevant relationships.\u201d Still, we think it is important to clearly note funding and disclosures in all releases, even when there are no apparent conflicts of interest.", "answer": 0}, {"article": "In a related editorial, Drs.\nCommenting on the study, Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York City, said, \"The findings of this trial are exciting because they will propel eribulin into wider use.\nThe study included 508 women who were given eribulin and 254 women who received treatment of the physician's choice, which was defined as: any single-agent chemotherapy, hormonal or biological treatment approved for cancer treatment; radiotherapy; or symptomatic treatment alone.\nDr. Javier Cortes, of the Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology in Barcelona, Spain, and colleagues published the findings in the March 3 online edition of The Lancet.\n\"It would be interesting to see if the drug offers the same benefit in women that have not been treated with multiple drugs before exposure to eribulin,\" she added.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article includes quotes from an independent expert, Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York City and from a related editorial also published in The Lancet.\nThe story\u00a0points out that the study was funded by the company that markets eribulin but it should have further noted that several of the authors of the study received grants or consultancy fees from Eisai.\u00a0 In addition, five of the study authors are employees of Eisai.\nWe\u2019ll rule this one barely satisfactory.", "answer": 1}, {"article": "Researchers say metabolic abnormalities that eventually lead to type 2 diabetes can be present years before diabetes is diagnosed.\n\"They also raise the possibility that, in selected individuals, these measurements could identify those at highest risk of developing diabetes so that early preventive measures could be instituted.\"\n\"These findings could provide insight into metabolic pathways that are altered very early in the process leading to diabetes,\" says researcher Thomas Wang, MD, of Massachusetts General Hospital's Cardiovascular Research Center, in a news release.\nFor example, insulin resistance, where the body does not use insulin effectively, occurs long before blood sugars reach the level seen in type 2 diabetes.\nResearchers found that blood tests that screened for these amino acids accurately predicted risk of type 2 diabetes in otherwise healthy adults as well as in those with traditional risk factors such as obesity.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources are cited, and the\u00a0study discloses that\u00a0five of the investigators have filed a patent application \u201cpertaining to metabolite predictors of diabetes.\u201d This is crucial information for readers that was missed by the story.", "answer": 0}, {"article": "Researchers found that even though people on the FOLFIRINOX had a longer average survival rate of 11.1 months, versus the gemcitabine group with 6.8 months, the quality of life for patients on FOLFIRINOX was not as good.\nFor most patients, the prognosis is grim.\nIt was funded by the government of France.\nThe purpose of the study was to record the overall survival rates of each group.\nFrench investigators from a private company known as BioMed randomly selected 342 patients with pancreatic cancer.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent source is cited.", "answer": 0}, {"article": "The new study ''adds to the trickle of evidence that cannabis may help some of the patients who are struggling [with pain] at present,\" Henry McQuay, DM, an emeritus fellow at Balliol College, Oxford University, England, writes in a commentary accompanying the study.\nThe research is published in CMAJ, the Canadian Medical Association Journal.\n\"About 10% to 15% of patients attending a chronic pain clinic use cannabis as part of their pain [control] strategy,\" he tells WebMD.\n''It's been known anecdotally,\" says researcher Mark Ware, MD, assistant professor of anesthesia and family medicine at McGill University in Montreal.\nBut Ware's study is more scientific -- a clinical trial in which his team compared placebo with three different doses of cannabis.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 1}, {"article": "Nov. 12, 2012 -- A drug used outside the U.S. to treat osteoporosis may not only lessen the everyday pain associated with knee osteoarthritis, but may even slow down the progression of osteoarthritis, researchers say.\nThe function of cartilage is to reduce friction in the joints and serve as a \"shock absorber.\"\nAnd nearly 19% of women and 14% of men age 45 and older have joint pain, stiffness, and other symptoms of knee osteoarthritis, according to a large 2007 study.\nIn a three-year study of more than 1,300 people with knee osteoarthritis, digital X-rays revealed substantially less loss of cartilage in the joint space in those who took strontium ranelate every day compared with people who took a placebo daily.\nStudy head Jean-Yves Reginster, MD, PhD, presented the findings today at the American College of Rheumatology (ACR) Annual Meeting in Washington, D.C.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story provides comments from a spokesman for the American College of Rheumatology. It also notes that several researchers reported financial ties to drug companies, including Servier Laboratories, which\u00a0makes\u00a0strontium ranelate.\n\u00a0", "answer": 1}, {"article": "Dr. Michael Rosenbaum, the lead investigator, said the 10-week study was too short and too small to determine whether continuous leptin treatments could allow dieters to keep off their weight permanently and effortlessly.\nThey also measured thyroid hormone concentrations in the blood and found that leptin reversed the declines in those levels that occurred with weight loss.\nThe leptin would then serve as a sort of virtual fat.\nThey also usually stop losing weight and often gain back what they have already lost.\nIf people lose weight, they have less leptin.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story provided a quote only from the lead investigator of the \nstudy; the story includes no input from any other independent source. ", "answer": 0}, {"article": "A new generation of treatments for severe eczema is on the horizon, which doctors say could help millions more patients gain relief from chronic outbreaks of the oozing, itchy and sometimes debilitating rashes that come with the disease.\n\nAt least two new eczema medicines could be approved by the U.S. Food and Drug Administration in 2017, and a half-dozen more drugs are being tested in clinical trials.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story makes it clear that several companies are working to develop medicines that can act as immune modulators, and at least one of the doctors appears to be independent of the research.\nIt does not, however, make an effort to link its sources to any of those companies. In at least one case, a dermatology professor on the front lines of eczema treatment research offers information\u00a0in her employer bio\u00a0indicating that she is a consultant for one of the companies featured in this story.", "answer": 0}, {"article": "\u201cPatients readmitted after surgery almost always have a postoperative complication, either medical or surgical,\u201d Drs.\nIt might be harder for patients to get appropriate care at the other hospitals, where they don\u2019t have a pre-existing relationship with a surgeon, and so treatment might be delayed, Dimick and Miller wrote.\n\u201cMost clinicians or surgeons feel like if you take the time to do a big operation on someone, you know the area operated on, how the operations went, if there were complications,\u201d lead author Dr. Benjamin S. Brooke of the University of Utah School of Medicine in Salt Lake City told Reuters Health by phone.\nMore than nine million patients underwent one of 12 such surgeries during the study period, and between six and 22 percent, depending on the surgery, were readmitted to the hospital within a month.\n\u201cA lot of readmissions are patients who have time to be transferred or triaged, if they are not bleeding to death or having a heart attack,\u201d he said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included a quote from the editorial that accompanied the study. But this quote is not very informative.\n\u201cPatients readmitted after surgery almost always have a postoperative complication, either medical or surgical.\u201d\nThe point of this criterion is to encourage critical evaluation of the research, so we\u2019re hesitant to give credit for a quote that\u2019s mostly superfluous. The editorialists did comment on some of the important limitations raised in the quality of evidence domain above, but the story didn\u2019t use any of that text.", "answer": 0}, {"article": "Blitz said debate should be aired publicly, and he is not rattled by opposition to plans for a regional approach.\nThe city's survival rate is 12 percent, and it is expected to improve with a citywide cooling program adopted last July, said Dr. David Keseg, the Columbus EMS medical director.\nFor example, patients treated in large, urban teaching hospitals have better odds than those treated elsewhere, according to research from the University of Pennsylvania School of Medicine published last month.\nThe therapy is targeted to patients stricken by ventricular fibrillation, an electrical disturbance that causes the heart's pumping chambers to quiver instead of pump.\nToday it's used routinely to reduce complications of heart surgeries, and it has shown promise for stroke and spinal injuries.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story provided names and interview material from several clinicians; there was some difference in opinion about the merits for the use of this approach to treatment.\nOne problem with the reporting was that one clinician who was in favor of the use of this technology was only identified at the very end of the story as having received funding from the company that sells the device in question.\u00a0", "answer": 1}, {"article": "What if some women with estrogen-fed tumors do benefit from chemotherapy?\nThe drawback of that study, Dr. Glick notes, is that it was not a large prospective randomized clinical trial, the gold standard in medicine.\nNow Dr. Berry, the M. D. Anderson statistician, and a group of leading cancer researchers have found that the chemotherapy benefits in those clinical trials were concentrated almost exclusively in women whose cancers were impervious to estrogen.\nThe chemotherapy question starts with American and European guidelines that say almost every woman with breast cancer that has gone beyond its earliest stages, when it is confined to the milk duct, should have the treatment.\n\"I don't know that many doctors who are comfortable giving women an option about chemotherapy,\" said Fran Visco, president of the National Breast Cancer Coalition, an advocacy group.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Many sources of information are cited and these are from trusted organizations of cancer research and information (e.g. National Cancer Institute, American Cancer Society). Dr. Berry, the lead author of the main study discussed, receives funding from several pharmaceutical companies, including Eli Lilly, Novartis and Bristol-Myers, however, the study was not funded by these companies. ", "answer": 1}, {"article": "Children have requested colorful designs inspired by superheroes, Disney's \"Frozen,\" and in Wyatt's case, the blue-skinned men from \"Blue Man Group.\"\nEach electronic limb takes about 30 to 50 hours to make and assemble.\nI went over to his house and helped him out with electronics,\" he said.\nClap with two hands.\n\"He doesn't need this,\" she thought.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources. Everyone quoted is involved in some way with the printing of 3-D prosthetics.", "answer": 0}, {"article": "Powerful chemotherapy and radiation treatments for cancer can impair a woman's fertility.\n\"So some of these women will still be able to have more children and avoid menopausal symptoms,\" she said, noting two more pregnancies have been reported to her laboratory since the study's publication.\n\"This procedure is gaining ground worldwide as an optional fertility treatment for fertile female cancer patients who after cancer treatment most likely will be infertile,\" said lead researcher Dr. Annette Jensen, from the Laboratory of Reproductive Biology at Rigshospitalet in Copenhagen.\n\"The pregnancy rate with frozen embryos is close to 50 percent, and results are getting better,\" he said, referring to another option for women hoping for a future pregnancy.\nDr. Avner Hershlag, chief of the Center for Human Reproduction at North Shore University Hospital in Manhasset, N.Y., called the new research \"innovative and exciting.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted two of the authors of the original study, Jensen and Andersen, as well as a third researcher, Hershlag, who appears to be independent of that group. The inclusion of multiple sources is a strong point in the coverage.", "answer": 1}, {"article": "The exams didn\u2019t become more embarrassing or less comfortable, either.\nFor now, she said people can go to the American Academy of Dermatology's website to learn the steps - known as the ABCDEs - of finding melanoma (bit.ly/2h9zl0Y).\n\u201cThere was concern that they might be embarrassed by examining areas of the body that aren\u2019t normally seen close up,\u201d said lead author Dr. June Robinson, of Northwestern University Feinberg School of Medicine in Chicago.\nOverall, the trained group found 51 early melanomas during the study, compared to 18 melanomas found by a comparison group of patients and partners who didn\u2019t receive training.\n\u201cFor example, men can\u2019t see the top of their bald heads or the back of their necks or ears,\u201d Robinson said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only person quoted in the story is the lead author of the study. It is always important to hear from at least one independent expert in order to put new\u00a0results the views of researchers into context. Without hearing from a dispassionate third party,\u00a0it is hard to know how important this new research actually is.", "answer": 0}, {"article": "A variation of a drug commonly given to cancer patients with bone damage appears to be an effective tool for preventing repeat hip fractures in elderly patients, according to a study in the New England Journal of Medicine.\n\nThe study results, which were to be presented yesterday in Hawaii, have potentially big implications because hip fractures are a common and debilitating injury for older people. Most of the 300,000 hip fractures each year in the U.S. are related to osteoporosis in older people, as well as falls, according...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although the story contained information and quotes from the editorial accompanying the published research study, it did not appear to tap into the knowledge base of others in the field to assess the importance of the study results.\nThe story did note that those working on the study had ties to the manufactorer of the drug reported on.", "answer": 1}, {"article": "A new study raised questions about the benefits of a relatively common procedure for heart patients\u2014implanting tiny devices that prop open clogged arteries to relieve chest pain.\n\nThe 200-patient study conducted by U.K. researchers found that patients with stable chest pain, or angina, who received stent devices experienced no significant improvement in exercise time on a treadmill, compared with similar patients who received no stents during sham procedures.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes one of the study authors and authors of an accompanying commentary in the journal, The Lancet. The reporter also sought comment from stent makers, who were mostly critical of the study \u2014 but these potential conflicts were made clear to readers.", "answer": 1}, {"article": "These drugs work by increasing bone thickness, thereby reducing the risk of fractures, the researchers said.\nTUESDAY, Feb. 15, 2011 (HealthDay News) -- People who take drugs called bisphosphonates to prevent bone loss may also reduce their risk of developing colorectal cancer by almost 60 percent compared to those not on the drugs, a new study suggests.\n\"We also found a similar effect last year with risk of breast cancer, which has already been replicated by three other groups,\" Rennert added.\nThe findings in this study show that bisphosphonates are associated with a reduced risk of developing colorectal cancer, but they cannot confirm a causal effect -- that is, the study doesn't prove that the use of bisphosphonates is responsible for the lower risk of colorectal cancer.\nHowever, the lowered risk of colorectal cancer seen with bisphosphonates may be due to the way the drug acts in the body, which is similar to how cholesterol-lowering drugs called statins work, according to Rennert.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Both stories quoted the exact same sources: the lead author and\u00a0Eric Jacobs, Strategic Director of Pharmacoepidemiology at the American Cancer Society. But both stories used their comments in very different ways. The Reuters Health story did not allow Rennert to run wild with enthusiasm. The HealthDay story did. For example, when the story notes that \u201cA randomized trial is needed to prove that bisphosphonates are protective against colorectal cancer, Rennert said.\u201d It follows that sobering bit of news up immediately with, \u201cIt should be relatively easy, as it seems that all that is needed is a year of treatment to see the effect,\u201d he said. Should be relatively easy? Ask any drug company how much time it takes and what it costs to bring a drug to market and no one will tell you that clinical trials are easy. This is especially troubling given that a previous study just last year showed no benefit, and, remember, we are talking about just 41 women who appear to have staved off cancer by taking these drugs.", "answer": 1}, {"article": "But his thoughts were out of control.\n\"I think it's actually one of the biggest advances in psychiatry in a very long time,\" says Dr. Martin Teicher, an associate professor of psychiatry at Harvard Medical School and director of the Developmental Biopsychiatry Research Program at McLean Hospital.\nAnd it has all been possible, he says, because for the past six years he has been taking a drug called ketamine.\nScientists still aren't sure why ketamine works, but there's evidence that it encourages the brain to rewire, to alter the connections between cells.\n\"I think it's having multiple effects, and that means it's probably useful for multiple different disorders,\" Teicher says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only two experts quoted in the story are research collaborators who have long advocated for expanded use of ketamine treatment. One of them, Demitri Papolos, has applied for a patent on a ketamine delivery device. The story should have reported this potential financial interest.", "answer": 0}, {"article": "\"With recent research indicating most babies born after 1980 do not acquire Bifidobacterium at birth, our ability to detect significant levels of Bifidobacterium gives pediatricians and parents an immediate indication of whether or not their baby has this beneficial gut bacteria that set them up for lifelong health.\"\nPoint-of-Care Diagnostic Expert Turns Focus to the Infant Gut\n\nThe development of the prototype is led by Dr. Bethany Henrick, Ph.D., Director of Immunology and Diagnostics for Evivo.\nThe liquid will remain pink if a sample has low levels of acetate and lactate, indicating that Bifidobacterium is missing and that key nutrients from breast milk, human milk oligosaccharides (HMO), are being wasted.\nIn addition to the landmark proof-of-concept trial, Evolve is undertaking further clinical studies to build out its suite of microbiome-based solutions.\nHaving led to the development and commercial launch of products to resolve newborn gut dysbiosis, including Evivo\u00ae for infants, Evolve's discovery platform is now being applied to solving gut dysbiosis throughout the human life cycle.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The Evivo stool test is clearly described as owned by Evolve Biosystems, Inc., and that company\u2019s associations and funding are similarly made clear.", "answer": 1}, {"article": "March 19, 2012 (San Diego) -- Ultrasound treatment can reduce excessive sweating in the underarms by nearly 80%, according to a new study.\n\"Microfocused ultrasound appears to be effective and safe in the treatment of hyperhidrosis,\" Nestor says.\nResearchers used a ''microfocused\" ultrasound to target the sweat glands in 14 men and women, aged 18 to 75, says Mark Nestor, MD, PhD, a dermatologist and voluntary associate professor of dermatology at the University of Miami Miller School of Medicine.\nThe sweating can occur even when the temperature is cool and the person is at rest.\nIt works, he says, by heating and destroying the sweat glands under the arm.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A weak satisfactory grade on this.\nTwo dermatologists were quoted besides the researcher:\u00a0 one really didn\u2019t add much.\u00a0 The other has a connection to a competing technology for hyperhidrosis.\nAnd the story did note that the researcher received a grant from the company making the technology.", "answer": 1}, {"article": "Give these a click:\n\nPersonalized cancer vaccines have already helped treat three patients\n\nSmartwatches might cause cancer, says article based on \u2018expert\u2019 who pushes holistic breast cancer treatments\n\nSun damage keeps happening even after you go inside, new study says\nWhen the latest trial was started, Harrington explained, there was no standard of treatment for melanoma -- so it's compared to a treatment that no one expected to outpace T-VEC.\nNow that other therapies -- ones that target specific mutations in patients' cancer cells -- are showing more success than what was available when the trial was formed, researchers will have to see how T-VEC compares.\nA modified version of the Herpes Simplex 1 virus (known for causing cold sores and some cases of genital herpes) called T-Vec has successfully been used to treat melanoma in a phase III clinical trial.\nBut there's more work to be done to determine just how T-VEC can fit into the cancer-treatment landscape.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Nearly every author on this paper has some association with Amgen, which is disclosed in the paper, but the blog post makes no mention of these affiliations. Only one person is quoted and he is one of the authors of the paper. This story needed the evaluation and comment of someone not involved with the phase III study. Such an unaffiliated expert would have made clear that it is uncertain when this agent should be used compared to other melanoma therapies.", "answer": 0}, {"article": "About 3.3 million people are allergic to peanuts or tree nuts.\nThe findings, presented on Sunday at a meeting of the American Academy of Allergy, Asthma and Immunology in Washington, suggest that a treatment for peanut allergy may be developed in two or three years, said Dr. Wesley Burks, the chief of the division of pediatric allergy and immunology at Duke University Medical Center, who helped conduct the research.\nBecause even a minor exposure can set off a reaction, many people at risk strictly avoid foods that contain an allergen or were prepared in places where nuts or other allergens might have been used.\nNearly half of the 150 deaths attributed to food allergies each year in the United States are caused by peanut allergies, according to Duke University.\nWhile drugs can be used to treat an allergic reaction, there are no approved treatments for food allergies.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only source quoted is Dr. Wesley Burks of Duke University Medical Center, one of the researchers who presented work at the meeting.\nThe reporter fails to disclose that Burks has financial relationships with a number of drug, food and device companies with an interest in allergies. \nThe reporter should have interviewed at least one additional source with deep knowledge of peanut allergies and no connection to the research.\u00a0 ", "answer": 0}, {"article": "\"Without sensory feedback, somebody would have to actually have to look at the prosthetic, look at the cup, start to close the hand, (and) visually see the cup is starting to deform,\" he says.\nThen they waited for the brain to heal, as it adjusted to the presence of the electrodes.\n\"Sometimes it feels, kind of, like electrical and sometimes it's more of a pressure.\"\nFor several years now, people have been able to control robotic arms using thoughts alone.\n\"His hand has been disconnected from his brain because of his spinal cord injury,\" Gaunt says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did not quote anyone outside the Pittsburgh team that collaborated on this project.", "answer": 0}, {"article": "\"LaVonne has had Alzheimer's disease longer than anybody I know, and that sounds negative, but it's really a positive thing because it shows that we're doing something right,\" Moore said.\nBut it's far too early to know whether it has value for people with Alzheimer's, Scharre stressed.\nBut they declined at a slower rate, compared to 96 similar patients whose information was taken from an Alzheimer's research database.\nAnd those issues have a huge impact on daily life, for patients and their caregivers, Scharre added.\nInstead, he said, these findings suggest that deep brain stimulation is \"a reasonable route\" to study in larger clinical trials.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes a useful comment from Keith Fargo, who directs scientific programs and outreach for the Alzheimer\u2019s Association, that it\u2019s \u201cmuch too early\u201d for for patients or caregivers to seek out this device.", "answer": 1}, {"article": "While nivolumab is approved for treating metastatic NSCLC, for example, that indication calls for using it if the disease continues to progress either during or after chemotherapy.\nAnd when the scientists studied the blood of the people receiving the immunotherapy, they discovered a close match between the types of immune cells in the blood and certain targets on the tumor cells, suggesting that nivolumab had released the immune system to pump out the appropriate cells it needed to tackle the cancer.\n\u201cThe magnitude of benefit was unexpected and great to see,\u201d says Dr. Leena Gandhi, associate professor of medicine at NYU Langone Medical Center and co-author of the study.\nThe medications target a protein called PD-1, its related PD-L1, or CTLA-4, which protect the body\u2019s cells from being killed by immune cells; because tumors are normal cells growing out of control, they take advantage of this molecular security blanket to avoid getting detected by immune cells.\n\u201cTo give you some idea of how significant that is, with chemotherapy we normally see the same degree of response around 20% of the time.\u201d\n\nForde says that the strong response seen in people at the beginning of the disease could suggest that immunotherapies might be useful in re-training the immune system to fight cancer for long periods of time \u2014 possibly even a lifetime.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story would have benefited from at least one independent expert.\nAll of the experts quoted were authors in the studies being reported. Also, all of the sourced reported conflicts of interest from either funding from a drugmaker or a pending patent that weren\u2019t mentioned in the story.", "answer": 0}, {"article": "The idea of a psychiatric evaluation sent chills down the spine of Caroline's mother, Mathy Milling Downing, who believed that her younger daughter, Candace, had committed suicide because of an adverse reaction linked to a psychiatric drug -- the antidepressant Zoloft.\nSoon after her sister committed suicide, Caroline Downing started doing poorly at school.\nIt is safe and effective.'\nOfficials at St. Andrew's Episcopal School in Potomac gently suggested that the high school sophomore get a mental health screening.\nWhen Candace turned 12, the psychiatrist upped the dose on the grounds that it would help her academically.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A number of mental health experts, several of whom served on major organization review panels on this topic.", "answer": 1}, {"article": "Systolic blood pressure \u2014 the top number on a blood pressure reading \u2014 fell by almost six points on average in the placebo group over the 12-week study, but by just over one point in the treatment group.\nQuestions remain about the safety of the fiber supplement over the long term.\nNeither the researchers nor the participants knew who was receiving the seaweed supplement.\nIn terms of calories, flavor and appearance, the placebo and treatment drink were identical.\nOne group was given packets of the gel supplement, containing 15 grams of fiber, and the other got a seaweed-free placebo drink.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two independent sources were quoted.\u00a0 Industry funding for the study was disclosed.", "answer": 1}, {"article": "While it\u2019s not entirely clear why, part of the reason may have to do with the fact that extreme exercise generates body heat, which can be detrimental to sperm health; for marathoners and people training at intense levels, finding ways to dissipate body heat is a major concern.\nThere are already plenty of reasons to exercise, and now better quality sperm is one more worth noting.\nNow, researchers publishing in the journal have found that another lifestyle change\u2014exercise\u2014may also help improve sperm quality.\nSchlegel also says that regular exercise can improve circulation and make the blood vessels healthier, which may benefit the testes, an organ that\u2019s sensitive to and requires good blood flow.\nIn the current study, the men in the moderate intensity, continuous activity program showed the most improvements compared to men in the other two more intense groups.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does provide a quote from an expert unaffiliated with the research team, and we found no conflicts of interest that should have been noted.", "answer": 1}, {"article": "In 2014, a review[2] suggested that there is probable efficacy (a level A recommendation) for short-term rTMS treatment of neuropathic pain, including central post-stroke pain, but did not speak to long-term efficacy.\nIt is believed that the stimulation aids in plasticity, the ability of the brain to gradually form new neural connections to take on functions previously performed by damaged areas.\nHe added that the remaining question to answer is whether the level of the patients\u2019 severe uncontrollable pain would continue to decrease if rTMS continued for several years.\nSince pain relief from rTMS increases a few days after treatment, weekly treatment sessions were selected to try to sustain pain relief at treatment intervals that could be maintained on an outpatient basis.\nThe study reported at the INS 12th World Congress builds on observations that electrical motor cortex stimulation\u2019s effectiveness in relieving central post-stroke pain can be predicted by rTMS, suggesting the techniques share similar pain-relief mechanisms.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release did not report the funding source, which is reported in the study as coming from a Japanese government grant. That would have been helpful information to include, as it bolsters the credibility of the research.", "answer": 0}, {"article": "WEDNESDAY, Aug. 31, 2016 (HealthDay News) -- Weight-loss surgery helps people drop a significant amount of weight, and now a new study confirms that much of the weight appears to stay off for at least 10 years.\nAt 10 years, the researchers had weight information on 564 of the nearly 1,800 patients who had the gastric bypass.\n\"This study suggests that patients interested in bariatric surgery, especially gastric bypass surgery, should be able to lose a significant amount of weight and keep that weight off for a very long time,\" said study researcher Matt Maciejewski.\nNext, the researchers compared three types of weight-loss surgeries: gastric bypass; sleeve gastrectomy; and adjustable gastric banding.\nBased on the new study findings, Gould said, \"I think a patient who is young and who has a long way to go may want to think about these results, and all other things being equal, might pick a gastric bypass for the long-term weight loss.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Sources are clearly identified, along with information about their links to the study itself (one scientist was the study\u2019s lead researcher, and the other quoted in the story was independent).", "answer": 1}, {"article": "Previously, no treatment was available for these patients.\"\nThe success of this trial opens the field for testing drugs in third-line treatment of HCC and provides a rationale to test regorafenib as a first-line treatment or in combination with therapies administered directly into the tumor or diseased liver in patients in an earlier stage of HCC, according to Dr. Llovet.\n\"This study represents a breakthrough in the management of hepatocellular carcinoma, since it provides evidence for clinical benefits in an area that was an unmet medical need,\" said Josep M. Llovet, MD, founder and Director of the Liver Cancer Program and Professor of Medicine and Liver Diseases at the Icahn School of Medicine at Mount Sinai.\nIn January, Bayer announced that the U.S. Food and Drug Administration (FDA) had granted priority review status for Stivarga (regorafenib) as a second-line systemic treatment for patients with hepatocellular carcinoma.\nThis trial provides evidence that regorafenib is the first systemic treatment for patients whose HCC progressed during treatment with sorafenib, the only other drug with proven clinical benefit.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does note that Bayer funded the clinical trial. However, the release doesn\u2019t tell readers that Bayer manufactures regorafenib. We might be able to let this slide, assuming that Bayer\u2019s ties to regorafenib are inferred, but there\u2019s another problem. The journal article makes clear that a number of the researchers involved in the clinical trial have not only received grants from Bayer, but are also paid advisors and/or consultants for Bayer. That sort of potential conflict of interest is important to note.", "answer": 0}, {"article": "The medications, which include Requip (ropinirole), levodopa, Neurontin (gabapentin) and Lyrica (pregabalin), appear to reduce symptoms of the syndrome in more than 60 percent of patients, researchers report.\nThe same is true for levodopa, Wilt said.\n\"This may be due to restless legs syndrome or other conditions.\nIn addition, those taking dopamine agonists slept better and scored higher on measures of quality of life.\n\"We urge caution in extending our conclusions to these individuals,\" he noted.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an outside expert who doesn\u2019t appear to have\u00a0any conflicts of interest related to this topic.", "answer": 1}, {"article": "SAN FRANCISCO \u2014 Tech company developer conferences always feature a wacky demo or three.\nThe watch works through a combination of sensors and AI (artificial intelligence) techniques to potentially detect and monitor symptoms like tremors, stiffness and instability, among others, according to Microsoft.\nBut at Build 2017 in Seattle Wednesday, Microsoft went for the waterworks at the conclusion of CEO Satya Nadella's keynote address: it showcased a prototype watch that temporarily eliminated the arm shaking that often plagues those suffering from the neurological disease Parkinson's.\nEmma Watch remains a prototype, Microsoft says, but the developers are working with a neuroscience research team to undertake trials with a small group of Parkinson's sufferers.\nWatson erupts in tears as she calls her mother to say this is the first time she's been able to write her name in ages.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Readers sorely need the voice of a scientific and medical expert or two, especially one who\u2019s well-versed in treatment methods for Parkinson\u2019s, to assess the concept of this watch and any related research that speaks to its novelty (or lack thereof).", "answer": 0}, {"article": "\"[2]\n\nWriting in a linked Comment, Louise Cullen and William Parsonage from the Royal Brisbane and Women's Hospital, Queensland, Australia, and Martin Than from Christchurch Hospital, New Zealand, say, \"The ultimate validation for the safety and efficacy of discharging patients with cardiac troponin concentrations less than 5 ng/L will be the report of clinical outcomes after this threshold is implemented in routine clinical practice...Finally, what further assessment, if any, is needed for those patients identified as low risk and suitable for early discharge?\nThe overwhelming majority of these patients do not have a heart attack.\nThese patients are therefore potentially suitable for immediate and safe discharge from the emergency department.\nVery high levels of troponin are a sign that a heart attack has occurred.\n\"[2]\n\nOne of the most common causes of hospitalisation worldwide is acute chest pain.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release duly notes funders.", "answer": 1}, {"article": "A new study by researchers at Wake Forest University suggests combining weight training with a low-calorie diet preserves much needed lean muscle mass that can be lost through aerobic workouts.\nPartial support also comes from grants by the National Institute on Aging.\nLoss of lean mass could have important consequences given the high risk of physical disability among the growing population of older adults.\n\"But this research shows that if you're worried about losing muscle, weight training can be the better option.\"\nWeight training or cardio?\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The study funders were disclosed at the bottom of the news release.", "answer": 1}, {"article": "\u201cThat\u2019s the miracle.\u201d\n\u2022 New hope for young patients with rare genetic disease (\u201cCBS Evening News,\u201d 10/16/15)\n\u2022 Follow the Calliope Joy Foundation on Twitter, Facebook and Instagram\nAmy recalled: \u201cShe\u2019s sitting on the bed in her tutu and her colorful sweater, and they\u2019re telling me she\u2019s gonna die.\u201d\n\nMany children with the disorder are dead by the age of 6.\nAnd so we said, \u2018Well, we\u2019ll start selling cupcakes.\u2019\u201d\n\nThe Calliope Joy Foundation was formed in 2013.\nTeichner asked Brad and Amy Price, \u201cYou keep using the word \u2018miracle.\u2019 In what way is all of this a miracle?\u201d\n\n\u201cOur son\u2019s still with us, and Cecilia as well,\u201d they replied.\nTeichner asked, \u201cDo you believe that gene therapy is finally coming into its own?\u201d\n\nThe MLD trial, she thinks, demonstrates what\u2019s possible -- offering promise to the 30 million Americans who suffer from some 7,000 rare diseases.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources quoted. While the story is focused on individuals and families living with the disease, it would not have been difficult to include a single third-party voice. No doubt many other researchers are watching the clinical trial with interest,\u00a0and they may have provided valuable\u00a0context as well as an indication of the quality of the evidence.\nThe trial is funded by GlaxoSmithKline who own the experimental therapy. Again, a quick mention would have been valuable.", "answer": 0}, {"article": "This study is really a proof of concept.\nThe result: The breath test correctly identified all the patients with heart failure, clearly distinguishing them from those cardiac cases where heart failure was not an issue.\nA single breath sample was obtained from each of the patients within 24 hours of admission, as well as from an additional 36 patients with acute decompensated heart failure as an independent point of comparison.\nThe findings were published March 25 in the Journal of the American College of Cardiology.\nThe investigators stressed that their evaluation is based on a small group of participating patients, and that more extensive research will have to be done to confirm their initial success.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are quotes from an independent expert. The journal that published the research reported that it was funded by state and federal grants, and that the researchers did not report any disclosures relevant to this study.", "answer": 1}, {"article": "Each patient completed standardized behavioral rating scales and participated in a semi-structured interview answering five open-ended questions to stimulate conversation, such as \"Do you have hope?\"\nThe study is published in the journal Suicide and Life-Threatening Behavior, a leading journal for suicide research.\nThese results provide strong evidence for using advanced technology as a decision-support tool to help clinicians and caregivers identify and prevent suicidal behavior, says John Pestian, PhD, professor in the divisions of Biomedical Informatics and Psychiatry at Cincinnati Children's Hospital Medical Center and the study's lead author.\n\"These computational approaches provide novel opportunities to apply technological innovations in suicide care and prevention, and it surely is needed,\" says Dr. Pestian.\nCINCINNATI -- Using a person's spoken or written words, new computer tools can identify with great accuracy whether that person is suicidal, mentally ill but not suicidal, or neither.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "This\u00a0isn\u2019t made clear in the release, but it also isn\u2019t clear in the study itself. As one saving grace, though, the lead author \u2014 who is a professor at\u00a0Cincinnati Children\u2019s Hospital Medical Center \u2014 is clearly identified.", "answer": 0}, {"article": "(Reuters) - Merck & Co\u2019s blockbuster drug Keytruda met the main goal of a late-stage trial testing the treatment in patients with cancers of the digestive tract, the U.S. drugmaker said on Wednesday.\nPD-1 or PD-L1 inhibitors work by blocking a mechanism of tumors that allows them to evade detection by cancer-fighting cells.\nKeytruda, among a class of medicines called PD-1 inhibitors, is Merck\u2019s top selling drug and has already been approved to treat several forms of cancer including skin and lung cancer.\nEsophageal cancer is the seventh most commonly diagnosed cancer in the world, the company said.\n\u201cThis marks the sixth tumor type where Keytruda has demonstrated a survival benefit, and represents the first time an anti-PD-1 therapy has achieved overall survival for this patient population,\u201d said Roy Baynes, chief medical officer of Merck Research Laboratories.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were no independent sources quoted in the story \u2013 only Merck statements about Merck\u2019s own drug.", "answer": 0}, {"article": "\"Gardasil has the potential to meet an unmet medical need as the first vaccine to prevent cervical cancer,\" Merck's Dr. Patrick Brill-Edwards told the Vaccine and Related Biological Products advisory committee.\nGardisil is likely to be approved in early June, After that, the vaccine will move into the hands of the Centers for Disease Control, which will have to decide if it should be a mandatory vaccine or just a recommended vaccine, CBS News correspondent Elizabeth Kaledin reports.\nThe drug protects against the two types of human papillomavirus (HPV) believed responsible for about 70 percent of cervical cancer cases.\nThe committee's HPV vaccine workgroup is recommending the vaccine be given to girls 11 and 12, and the committee will consider recommendations for females 13 to 26.\nAdvocates are recommending the vaccine be given to 11- and 12-year-old girls before they become sexually active, but argue that it is not a license to behave promiscuously, Kaledin reports.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Only the president of the American Cancer Society is quoted. Single-source health care stories are insufficient. See explanation at: https://www.healthnewsreview.org/rThemes.php#sss", "answer": 0}, {"article": "Another sensor, just approved by the F.D.A.\nIt has to be placed above the hip or the buttocks, which makes reaching it awkward, and then the wire leading from the sensor has to be connected to a transmitter that wirelessly sends the information to the pump.\nWhen everything was in, I had two catheters and the transmitter all taped to my body, plus the pump hanging on my belt.\nThe sensor has a coated tip that measures the electrical conductivity of the interstitial fluid, the juice floating between fat cells right under the skin.\nThe main problem was that the sensor was simply not as accurate as a blood-glucose tester.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources of information were obtained. In fact, the only information is related anecdotally by only one man, which could be biasing. ", "answer": 0}, {"article": "Tumor cells make PD-L1 turn on PD-1 when immune cells approach.\nLung cancer is the top cancer killer in the U.S. It\u2019s diagnosed in more than 220,000 people a year and it killed nearly 160,000 people last year, according to the National Cancer Institute.\n\"I suspect the findings were significant enough that this will be a practice-changing finding,\" Dr. Pasi Janne, lung cancer specialist at Harvard Medical School and the Dana-Farber Cancer Institute, told NBC News.\nRelated: Keytruda Keeps Some Patients Alive For Three Years\n\n\"Immunotherapy is a whole new way of treating cancer, including lung cancer,\" said Janne, who was not involved in the study.\nThe drug, Keytruda, is the same drug that former president Jimmy Carter says helped stall advanced melanoma that had spread to his brain.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are multiple independent sources quoted in the story.\nHowever, all of the quotes in this story sound like this:\u00a0\u201cI suspect the findings were significant enough that this will be a practice-changing finding.\u201d If there were numbers being released to back up a claim like that, we would be more comfortable with these kinds of quotes. Without more evidence, though, it gives readers the impression that the drug will have a massive impact.", "answer": 1}, {"article": "A Harvard researcher hopes an old arthritis drug, which he read about in a 19th century German medical journal, could be a cheap new treatment for diabetes.\n\nIn the late 1990s, Steven Shoelson's research suggested that the drug, called salsalate, might also help diabetics. The idea sent him into the basement stacks of a Harvard library to see whether anyone else had pursued the notion.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes comments from two individuals who are not directly involved in the specific study to examine whether salsalate improves outcomes for individuals with type 2 diabetes. \u00a0In addition to comments from Dr. Shoelson who is a proponent of expanding the application of salsalate, the story had comments from a researcher with an opposing viewpoint as well a spokesperson from the governmental agency funding the project.", "answer": 1}, {"article": "Red and purple fruits owe their colors to...\nAlthough it's a challenge to eat the raw fruit without getting a mouthful of seeds and astringent pith, pomegranates are everywhere now in the form of juice, concentrates and extracts, all heavily promoted for better health.\nIt pays researchers to study the benefits of pomegranate juice, gives doctors information on positive studies and, of course, sells pomegranate products.\nThe juice is a beautiful wine-red color and tastes delicious.\nMuch of the popularity is the work of a California-based company, Pom Wonderful.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "While pointing out that one company that sells pomegranate products underwrites the costs of some studies done to explore the health benefits of these products, the story failed to inform the reader whether the two studies mentioned were funded by this company as well. The story also didn\u2019t tell readers where the studies were published. While it could have been informative to include material from experts in the field of anti-oxidant, free radical, or polyphenolic compounds, this article is basically an op-ed piece.", "answer": 0}, {"article": "For more information about Hebrew SeniorLife, visit http://www.\nBased in Boston, the non-profit, non-sectarian organization has provided communities and health care for seniors, research into aging, and education for geriatric care providers since 1903.\nThe Institute carries out rigorous studies that discover the mechanisms of age-related disease and disability; lead to the prevention, treatment and cure of disease; advance the standard of care for older people; and inform public decision-making.\n\"Our study highlights the fact that having a bone density test not only tells women about their risk of fracture, but also their long term risk for cardiovascular disease.\n\"We found that that the presence of calcifications increased the likelihood of having cardiovascular disease such as heart attacks, and even the likelihood of cardiovascular deaths and mortality in general.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There are no details in the release about how the authors of this research may or may not be tied to the bone density testing industry. \u00a0But the published report makes it clear that they have ties to Hologic, which makes bone density testing machines:\nDr. Wilson is an employee of Hologic Inc. and reports personal fees, non-financial support and other from Hologic, Inc., during the conduct of the study; personal fees and other from Hologic, Inc., outside the submitted work; In addition, Dr. Wilson has multiple densitometer imaging and reporting patents which may be relevant, US and worldwide, both pending and issued owned by Hologic, Inc.\nThese are the kinds of financial ties that should always be disclosed in news releases.", "answer": 0}, {"article": "Depression affects about 20 percent of people at some point in their lives.\nAn imbalance in serotonin levels is believed to be linked to depression.\nThey were later assessed by experts for their depression levels and the group that received genuine electroacupuncture was found to be a lot happier.\n\u201cWhen the acupoints are stimulated, some brain centres responsible for producing serotonin are stimulated,\u201d explained Ng, a consultant at the department of psychiatry at the Kowloon Hospital in Hong Kong.\nThe electroacupuncture was given in addition to medication that the patients were already taking and meant to augment their treatment, Zhang told a news conference.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent expert perspective was included.", "answer": 0}, {"article": "Organizers of the trial conceded that a major reason Lucentis was chosen was that Genentech, which is now owned by Roche, agreed to provide the drug free of charge and to contribute $9 million in additional financing \u2014 but only if Lucentis were used.\nRetinopathy results from damage to the blood vessels in the eye.\nThe fourth group got laser therapy plus a sham injection.\nBut it is approved for another eye disease, age-related macular degeneration.\nLucentis is not approved as a treatment for macular edema.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0Several experts in the field were quoted in this story.", "answer": 1}, {"article": "What would that look / sound / smell like?\nThe full study, entitled Functional Imagery Training versus Motivational Interviewing for Weight Loss: A randomised controlled trial of brief individual interventions for overweight and obesity is available to view in the International Journal of Obesity (doi: 10.1038/s41366-018-0122-1).\nProfessor Jackie Andrade, Professor in Psychology at the University of Plymouth, is one of the co-creators of FIT, and she explains: \"FIT is based on two decades of research showing that mental imagery is more strongly emotionally charged than other types of thought.\n\"As well as being delighted by the success of the study in the short term, there are very few studies that document weight loss past the end of treatment, so to see that people continued to lose weight despite not having any support shows the sustainability and effectiveness of this intervention.\"\nThe study showed how after six months people who used the FIT intervention lost an average of 4.11kg, compared with an average of 0.74kg among the MI group.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding source is clearly identified. There are no apparent conflicts of interest, though the release would have been stronger if it had addressed this directly.", "answer": 1}, {"article": "Newswise \u2014 Baltimore, Md.\nThe combined School and Medical System (\u201cUniversity of Maryland Medicine\u201d) has a total budget of $5 billion and an economic impact of nearly $15 billion on the state and local community.\nThe center was designed to be a regional resource, providing the same training, privileges and clinical guidelines to physician groups across the region that work side-by-side with MPTC faculty and staff, thus improving efficiency and affordability.\n\u201cEarly research suggests that adding thermal therapy to proton-beam therapy may be associated with an even greater benefit than when combined with standard radiation therapy, and we are excited to be at the forefront of making this combination therapy available to cancer patients,\u201d says Dr. Vujaskovic, an internationally recognized expert in hyperthermic oncology.\nMPTC is the only center in the world to offer these two treatments at the same facility, an advantage to patients because these therapies are typically given within an hour of each other.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release identifies private donors and a foundation that contributed to their hyperthermia system, although they do not list other sources of funding for the proton therapy.", "answer": 1}, {"article": "A popular new type of prenatal test intended to find genetic flaws in a fetus can in rare cases also reveal previously undiagnosed cancer in the mother.\n\nThe unexpected finding emerged in a study involving eight women who initially had abnormal results from the prenatal blood test, but for whom a subsequent assessment showed their babies were normal. When the mothers\u2019 DNA was reanalyzed, researchers said, the anomalies were linked to cancer in each of the women.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story importantly refers\u00a0to \u201congoing debates\u201d within the medical and scientific community about the wider use of the blood tests, and quotes an editorial written by an expert who did not participate in the study itself. However, while the story notes that the study was funded by Illumina, which markets the test, it did not alert readers that Dr. Bianchi, the study author who is quoted in the piece, is a paid advisor to the company. CBS, by contrast, made note of that relationship. We reluctantly grade the story Not Satisfactory based on that omission.", "answer": 0}, {"article": "Doctors numbed the lower half of O'Brien's body.\nThe day of the surgery, Berger has his patients conquer what amounts to a knee-bending obstacle course before they're able to leave \u2014 walking up and down a hallway and up and down a flight of stairs.\nThe new surgery simply moves them to the side in order to fit the knee with titanium and plastic caps \u2014 creating a knee joint free of pain and arthritis.\n\"Therefore the physical therapy is easy to do and it's quick and it's not very painful for them at all.\"\n\"I'll be chipping and putting in three weeks \u2014 maybe four,\" joked O'Brien from the operating table.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Comments from one patient and one surgeon were included in this piece. But there was no comment from any independent source. Since this television story ran an unusually long 5 1/2 minutes, there certainly was time to include data on the use of the device and input from other physicians. A single-source story on a topic like this is troubling. ", "answer": 0}, {"article": "BOSTON (Reuters) - If you\u2019re checking into the hospital for surgery, doctors may soon be swabbing your nose in an effort to prevent an infection from appearing after your operation.\nThe new study, published in the New England Journal of Medicine, used a rapid test to identify which patients, most of whom were scheduled to undergo surgery, had the bacteria in at least one nostril.\nThe research team, led by Dr. Lonneke Bode of Erasmus University Medical Center in Rotterdam, estimated that 250 patients would need to be screened to prevent one infection.\nThe 504 patients treated with the antibiotic nose gel mupirocin, also known as Bactroban, and washed with chlorhexidine, a common ingredient in mouthwash, developed an S. aureus infection 3.4 percent of the time.\nIn a commentary, Dr. Richard Wenzel of the Virginia Commonwealth University in Richmond said the chlorhexidine-alcohol mixture should replace the older disinfectant when scrubbing people for surgery, and the nasal disinfection technique should primarily be used for people undergoing cardiac surgery, receiving an implant, or whose immune system is likely to be affected.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only source\u00a0cited\u00a0outside of study authors is Dr. Richard Wenzel\u2019s quote from his NEJM editorial regarding his opinion on the primary uses of the new technique. We might have graded this satisfactory \u2013 although barely \u2013 were it not for the following omission.\u00a0 \nConflicts of interest were not identified. As reported in the NEJM article, the study was supported by grants from GSK and Molnlycke, the drug companies that make the treatments used in the study,\u00a0Bactroban and\u00a0Hibiscrub.", "answer": 0}, {"article": "Bochner teamed up with Northwestern oncologist Dr. Leo Gordon and colleagues to test if this BTK inhibitor could shut down an enzyme inside cells that is involved when you have an allergic reaction.\nCurrently, the study is being expanded to adults with food allergy to see if their skin test and basophil activation test responses show a similar reduction with just a few doses of ibrutinib and how long such benefits might last.\n\"The hope is that drugs like BTK inhibitors will protect people with food allergies from having anaphylaxis, or at least increase how much of that food they can eat without reacting,\" Bochner said.\nWhile the study was small - only two patients qualified out of about 35 that were screened for allergies - the implications are much larger for later phases of this study.\nIf the results are favorable, the next step would be to get funding to actually test whether taking a BTK inhibitor will improve the ability of food-allergic adults to eat foods they're allergic to.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The study reports that this study was funded by a 2016 Dixon Translational Research Grant. However, it fails to disclose the list of industry connections, patents, stock options and other items the researchers attached to their journal letter. Two of the seven authors have ties to AbbVie, the co-producer of ibrutininib. AbbVie and Northwestern University have also announced a five-year deal to collaborate on cancer research.", "answer": 0}, {"article": "Scientists at a growing number of research centers are pinning their hopes that these images will help them unlock some of the secrets of everything from what causes childhood disorders like Attention Deficit Hyperactivity Disorder to how neurons in the brain process vision and memory.\nThe spectrum is wide and some are destined to be on the mild end and be very talkative, sometimes almost indistinguishable from those without the disorder in some settings, while others will suffer from a more severe form and have trouble being able to speak basic words.\nIn an article published Thursday in the journal Neuron, scientists at the University of California-San Diego have found that children with autism spectrum disorder, or ASD, with good language outcomes have strikingly distinct patterns of brain activation as compared to those with poor language outcomes and typically developing toddlers.\nThe images of the children in the study -- MRIs of the brain -- were taken at 12 to 29 months while their language was assessed one to two years later at 30 to 48 months.\nBrain imaging has become a popular subject of research in recent years as the technology to be able to scan, store and analyze the terabytes of information in the pictures has become more affordable.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The source quotes only one source \u2014 a study co-author. We see this as a drawback since there are numerous autism experts available, many of them holding differing views on autism diagnosis and treatment. As a service to reporters, HealthNewsReview.org maintains a list of independent experts who are willing to comment on studies and related news on health interventions.", "answer": 0}, {"article": "Jan. 6, 2010 -- A new imaging technique that measures the random motion of water within the brain may prove useful for detecting early signs of Alzheimer's disease.\n\"This might help doctors when trying to differentiate between normal aging and diseases like Alzheimer's.\"\nIn a study published in the Jan. 19 issue of Neurology, Carlesimo and colleagues found that DTI scanning predicted declines in memory performance with more accuracy than traditional MRI.\nThe technique, known as diffusion tensor imaging (DTI) or diffusion MRI, is used to assess changes in the white matter regions of the brain.\n\"This type of brain scan appears to be a better way to measure how healthy the brain is in people who are experiencing memory loss,\" Carlesimo says in a news release.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0The story did include a quote from a neurologist who did not appear to be directly connected with the study. \u00a0That said, his comments were general in nature and were not explicitly about the research reported on.", "answer": 1}, {"article": "This page either does not exist or is currently unavailable.\n\nFrom here you can either hit the \"back\" button on your browser to return to the previous page, or visit the ABCNews.com Home Page. You can also search for something on our site below.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "In addition to \nquoting study authors, a quote from an editorial in the journal in which one of the articles was published was provided.", "answer": 1}, {"article": "The research, supported by the European Research Council and titled Potent organo-osmium compound shifts metabolism in epithelial ovarian cancer cells, is published by PNAS.\nOur new compounds work by attacking the energy balance in cancer cells\u201d.\nBy stopping this switch of energy source, the drug causes the cancer cell to die.\nThe new drug works by forcing cancer cells to use their mitochondria, the \u2018power house\u2019 of a cell, to generate the energy necessary to function.\nSimilar results were obtained by the National Cancer Institute USA in tests conducted on 60 cell lines.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding sources were carefully noted in the release.", "answer": 1}, {"article": "Patients were randomised to receive the combination of anti-TNF\u03b1 and anti-IFN?\nFlorence, Italy - 9 July 2016: Immunotherapy reduces cardiovascular risk in patients with rheumatoid arthritis, according to research presented today at Frontiers in CardioVascular Biology (FCVB) 2016 by Professor Aida Babaeva, head of the Department of Internal Medicine, Volgograd State Medical University, Volgograd, Russia.1 The combination of two extra-low dose anticytokine drugs reduced rheumatoid arthritis disease activity and cardiovascular events.\nIn patients with highly active disease, the standard biologics are better at preventing severe complications such as progressive joint destruction and/or systemic manifestations (vasculitis, uveitis, involvement of internal organs).\n\"Rheumatoid arthritis is an autoimmune disease in which cytokines such as tumour necrosis factor (TNF) and interferon (IFN), which normally protect the body, attack healthy cells,\" said Professor Babaeva.\nShe concluded: \"We do not think that all patients with rheumatoid arthritis should be treated with this combination.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We learn that Professor Aida Babaeva, the lead investigator, is the head of the Department of Internal Medicine, Volgograd State Medical University, Volgograd, Russia, but not the degree to which she may have connections to companies making these drugs. Those kind of clarifications are important.", "answer": 2}, {"article": "Collaborating with Dr. Bickelhaupt and Jaeger were Frederik Bernd Laun, Prof. Dr., Wolfgang Lederer, M.D., Heidi Daniel, M.D., Tristan Anselm Kuder, Dr. rer nat, Lorenz Wuesthof, Daniel Paech, M.D., David Bonekamp, M.D., Alexander Radbruch, M.D., Stefan Delorme, Prof. Dr., Heinz-Peter Schlemmer, Prof. Dr., Franziska Steudle, and Klaus H. Maier-Hein, Ph.D.\n\nRadiology is edited by David A. Bluemke, M.D., Ph.D., University of Wisconsin School of Medicine and Public Health, Madison, Wis., and owned and published by the Radiological Society of North America, Inc.\n\nRSNA is an association of over 54,200 radiologists, radiation oncologists, medical physicists and related scientists promoting excellence in patient care and health care delivery through education, research and technologic innovation.\nThe software algorithm makes the assessment reader-independent, ensuring that its accuracy is maintained across different imaging facilities.\nThe women underwent DWI followed by biopsy.\nRadiomics is a rapidly growing field that enables the extraction of a large amount of quantifiable data from images.\nBreast MRI currently is used to screen women at high risk of breast cancer and as a diagnostic adjunct to mammography.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "No statement is made regarding the funding source for the study.", "answer": 0}, {"article": "See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov.\nThe goal of this procedure is to regenerate blood vessels and smooth muscle, parts of the penis that are not functioning properly in this patient population.\nThis news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials, marketing efforts, funding, etc.\nIntracavernous Injections of Bone Marrow Mononucleated Cells for Postradical Prostatectomy Erectile Dysfunction: Final Results of the INSTIN Clinical Trial.Eur Urol Focus.\nCreative Medical Technology Holdings, Inc. is a clinical stage biotechnology company currently trading on the OTCQB under the ticker symbol CELZ.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release says in the second sentence that the trial was sponsored by Creative Medical Technology Holdings, the same company that is marketing the product.\u00a0It\u2019s good that this conflict of interest was disclosed.", "answer": 1}, {"article": "Fish-oil supplements don't appear to help pregnant women prevent post-partum depression or boost the baby's brain development as previously believed, according to a large trial published Tuesday in the Journal of the American Medical Association.\n\nThe 2,400-woman, randomized study complicates the advice for pregnant women. It adds to a body of mixed research on some potential benefits of the popular omega-3 fatty acid known as DHA, or docosahexaenoic acid. DHA, which can move from the mother to the baby during pregnancy, accumulates...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Barely adequate \u2013 in that the story at least cited the views of an editorial writer in addition to those of one of the study authors. ", "answer": 1}, {"article": "(CNN) Corey Thomas admitted to his pharmacist that he hated the blood pressure medications a previous doctor had prescribed for him.\n'Medical mistrust has been an important barrier'\n\nThe study had some limitations, including that it was not blind, because both participants and researchers knew who was assigned to the pharmacist-led program and who was in the control group.\nBy the end of the study, the researchers found that the barbers' role in encouraging the men to monitor and improve their health resulted in a significant reduction in blood pressure, when coupled with medication from the pharmacists.\nThe researchers randomly assigned the men, based on their barbershop, to participate in the pharmacist-led program or to a control group between February 2015 and July 2017.\nThe researchers found that 17.5% of men who received help were screened, compared with 8.4% of those who didn't receive the screening help.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes comments from both a barber-participant in the study and a researcher unconnected to this project.\u00a0 We did not detect any conflicts of interest that should have been disclosed.", "answer": 1}, {"article": "At 6 months, casting resulted in measures of ankle function equivalent to that with surgery.\nAmong older adults with an unstable ankle fracture, the use of a modified casting technique known as close contact casting (a molded below-knee cast with minimal padding) resulted in similar functional outcomes at 6 months compared with surgery, and with fewer wound complications and reduced intervention costs, according to a study appearing in the October 11 issue of JAMA.\n\"Close contact casting was delivered successfully for most participants, substantially reducing the number of patients requiring invasive surgical procedures at the outset and additional operations during a 6-month period,\" the authors write.\nEditor's Note: The author has completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.\nEditor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "No funding sources and conflicts are mentioned in the news release. Instead, readers are referred to the published study for details on \u201cfinancial disclosures, funding and support.\u201d However, the study is only available to JAMA subscribers.", "answer": 0}, {"article": "\"Beta- blocker drugs compete with stress hormones and bind to the same target receptors [on a cellular level], but unlike stress hormones, do not activate cancer cells,\" said Dr. Des Powe, a senior healthcare research scientist at Queen's Medical Centre, Nottingham University Hospital NHS Trust, in Nottingham, England.\n\"I think this study is interesting, but very far from being conclusive,\" said Chung.\nPowe said he plans to do another study to validate the results.\nTo learn more about inflammation and cancer, visit the U.S. National Cancer Institute.\nIt's not known, she said, whether there is a true association or whether it may be due to chance or another factor.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A medical oncologist and the deputy chief medical officer for the American Cancer Society provided independent commentary for this story.\u00a0 ", "answer": 1}, {"article": "For more information, visit acc.org.\nIn an accompanying editorial, Deepak L. Bhatt, M.D., M.P.H., executive director of interventional cardiovascular programs at Brigham and Women's Hospital Heart and Vascular Center and professor of medicine at Harvard Medical School in Boston, said the program is groundbreaking, and follow-up studies to further pinpoint the exact mechanisms by which the program achieved positive effects on young children's health will be vital for implementing the program in other areas and informing the design of future global programs.\nThe study and editorial are part of a comprehensive Population Health Promotion issue of the Journal of the American College of Cardiology focusing on issues that broadly impact public health and the prevention of cardiovascular disease and related conditions.\n\"It may not only be the cardiovascular health information from the program that is helpful but also the cognitive stimulation from and exposure to positive adult role models, which in turn influence personality traits critical for health behavior and habits,\" Bhatt said.\nThe College operates national registries to measure and improve care, provides professional medical education, disseminates cardiovascular research and bestows credentials upon cardiovascular specialists who meet stringent qualifications.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not mention the funding sources for the study, which was supported by government and foundation grants. Although there are no obvious conflicts of interest here, we always ask that news releases provide funding information about studies so that readers and journalists have easy access to this information.", "answer": 0}, {"article": "The drug used in the study was manufactured by Organix Inc. in Woburn, Mass.\nHe also says \u201cPsilocybin therapy may not work for everyone, and some groups, such as people with schizophrenia, as well as adolescents, should not be treated with it.\u201d\n\nBoth the NYU Langone and Johns Hopkins studies were principally funded by the Heffter Research Institute, a non-profit, scientific institution with the principal mission of helping to design, review and fund studies on the use of psilocybin for a wide range of ailments (Ross previously served as a board member).\n\u201cOur results represent the strongest evidence to date of a clinical benefit from psilocybin therapy, with the potential to transform care for patients with cancer-related psychological distress,\u201d says study lead investigator Stephen Ross, MD, director of substance abuse services in the Department of Psychiatry at NYU Langone.\n\u201cAnd if it\u2019s true for cancer care, then it could apply to other stressful medical conditions.\u201d\n\nBossis cautions that patients should not consume psilocybin on their own or without supervision by a physician and a trained counselor.\n\u201cIf larger clinical trials prove successful, then we could ultimately have available a safe, effective, and inexpensive medication \u2014 dispensed under strict control \u2014 to alleviate the distress that increases suicide rates among cancer patients,\u201d says Ross, also an associate professor of psychiatry at NYU School of Medicine.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "This is a strength of the release. It not only tells readers who funded the work, but that one of the funding organizations is focused specifically on research involving psychedelic drugs \u2014 and that one of the researchers previously served on that organization\u2019s board.", "answer": 1}, {"article": "In another 12%, tumors stopped growing for at least six months.\nDec. 15, 2009 (San Antonio) -- A new targeted cancer drug has been shown to shrink tumors in women with metastatic breast cancer after an average of seven other drugs, including Herceptin, failed.\n\"This is the first study looking at women who have failed so many other treatments,\" Krop tells WebMD.\n\"But we think these results are as good as we've ever seen is such a refractory [sick] population,\" he says.\nIt's a Trojan horse approach, where Herceptin homes in on cancer cells and delivers the cancer-killing agent directly to its target.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article includes dramatic quotes from the investigator, that the results were \"unheard of\" and \"as good as we\u2019ve ever seen\" in this population. While a source presumably unrelated to the study was used and confirmed that the results were \"exceptional,\" Edith Perez has received grant funding from Genentech, a sponsor of the Krop study. (Dr. Perez is also the lead author on a Genentech-supported study of trastuzumab presented at the same conference.) Acknowledging this connection, or citing another or an additional specialist without ties to the sponsor, would have added more balance, or at least the appearance of balance, to the claims of efficacy and tolerability, including the interpretation of the death that occurred during the study.", "answer": 0}, {"article": "Handedness (molecular asymmetry) is critical to the function of bio-molecules in the body.\nThe same can be true of molecules, and in some cases, having the wrong handed molecule can have profound biological consequences.\nIn this case, the osmium compound JPC11, with sodium formate, can selectively produce a molecule of a specific 'handedness' - thus manipulating how cancer cells grow.\nImportantly, the development opens up a possibility for a more selective cancer treatment as JPC11 was observed to specifically target the biochemistry of cancer cells, leaving healthy cells largely untouched - another improvement compared to existing platinum-based drugs, which can also attack non-cancerous cells.\nProfessor Martin Wills, catalyst specialist at the University of Warwick, commented:\n\n\"Although asymmetric catalytic hydrogenation processes are well developed in the materials industry, this research provides the first ever example of it being achieved inside cells using a synthetic catalyst.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes the sources of funding for the study. The release does not explicitly state that there are no conflicts of interests, but there do not appear to be competing interests here.", "answer": 1}, {"article": "SUNDAY, Oct. 23, 2011 (HealthDay News) -- Older women who take nonsteroidal anti-inflammatory drugs -- such as aspirin or ibuprofen -- appear to have a lower risk of death from colorectal cancer than women who don't use these medications, a large new study suggests.\nThe findings were slated for presentation on Sunday at the AACR International Conference on Frontiers in Cancer Prevention Research, in Boston.\nThe researchers confirmed 2,119 cases of colorectal cancer and 492 deaths due to the disease.\nWhile the study found an association between NSAID use and a reduced risk of colorectal cancer, it did not prove a cause-and-effect.\nExperts say that for studies presented at medical meetings, data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were no independent sources cited from outside the study. The only comment came from a doctoral student at the University of Washington.", "answer": 0}, {"article": "Accessed October 2013 from http://content.nejm.org/cgi/content/full/361/5/445\n\u201cThe balloon and other technologies may help to fill the therapeutic gaps between diet and exercise and medical therapy, and medical therapy and surgery, where the gaps are quite large.\u201d\n\nPeople with obesity and severe obesity have higher rates of heart disease, diabetes, some cancers, arthritis, sleep apnea, high blood pressure and dozens of other diseases and conditions.\nNewswise \u2014 NEW ORLEANS \u2013 NOV. 4, 2016 \u2013 Patients with obesity who swallowed gas-filled balloon capsules designed to help them eat less, lost 1.9 times more weight than patients who relied on diet, exercise and lifestyle therapy alone, according to new research* presented today at ObesityWeek 2016, the largest international event focused on the basic science, clinical application and prevention and treatment of obesity.\nThe ASMBS estimates about 24 million Americans have severe obesity, which would mean a BMI of 35 or more with an obesity-related condition like diabetes or a BMI of 40.\n\u201cThe significant weight loss achieved with the Obalon 6-Month Balloon System is maintained at 12 months,\u201d said Aurora Pryor, MD, study co-author and Chief Bariatric, Foregut and Advanced GI Surgery, Stony Brook University.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release fails to report that the manufacturer, Obalon Therapeutics, was responsible for the trial or that the \u201cStudy Chair\u201d listed on ClinicalTrials.gov is a company employee.", "answer": 0}, {"article": "Thus, we foresee an exciting, long term relationship that will benefit cancer patients and cancer research.\u201d\n\nIn December 2007, Hitachi was the first company in the U.S. to clear FDA Premarket Notification Special 510(k) for the \u201cPROBEAT\u201d system with its spot scanning irradiation technology.\nThis collaboration, which includes a 10-year maintenance service, marks the first multi-room PBT application in the nation\u2019s capital.\nIn most cases, patients can continue with their normal daily activities while undergoing treatment.\nProtons from a hydrogen atom are extracted and accelerated up to 70% the speed of light.\nProton Beam Therapy (PBT) is an advanced type of cancer radiotherapy.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "It\u2019s clear that the release comes from Hitachi, the PBT system manufacturer and marketer.", "answer": 1}, {"article": "(Weathers noted more than 100 other drug-resistant patients also have been successfully treated with DLA tablets.)\n\"We have done a lot of work to understand the biochemistry of these compounds, which include a number of flavonoids and terpenes, so we can better understand the role they play in the pharmacological activity of the dried leaves,\" Weathers said.\nAnd, in an experiment that accelerated the evolution of the malaria parasite by passing it through up to 49 generations of mice, the parasite showed no signs of resistance to DLA.\nIn addition, while the combination therapy is designed to be less prone to the drug resistance that has rendered previous antimalarial agents ineffective, increasingly the malaria parasite is showing signs of resistance to ACT, particularly in Southeast Asia.\n\"To our knowledge, this is the first report of dried-leaf Artemisia annua controlling ACT-resistant malaria in humans,\" the authors of the Phytomedicine paper note, adding that more comprehensive clinical trials on patients with drug-resistant malaria are warranted.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release is wise to tell us that author Weathers is herself part of a project by the Polytechnic Institute to create processing techniques for the plant under study. But we are confused about patents held by Weathers and some of the other authors. Is there any profit possible for the authors, or WPI, if widespread use of the tablets was to begin?\nIf there is no conflict, the release could have said \u201cThe authors, while they hold patents related to the plant, do not have any potential profits or conflict of interest.\u201d", "answer": 0}, {"article": "Six ounces of canned tuna contains 60 micrograms of mercury compared to just 4 micrograms of mercury in a six-ounce serving of salmon, according to Consumer Reports.\nThe point is that you should have a variety of types of seafood and not limit yourself to one type, and variety includes canned tuna.\u201d\n\nAlice Lichtenstein, senior scientist and director of the Cardiovascular Nutrition Laboratory at Tufts University said the panel hasn\u2019t suggested that pregnant women eat more tuna.\n\u201cSo why would the proposed 2015 dietary guidelines recommend that pregnant women eat more of it?\u201d\n\nBut Dr. Steve Abrams, a panel member involved in the seafood recommendations and medical director of the Neonatal Nutrition Program at Baylor College of Medicine, said that while women need to be aware of the types of fish they are eating, the evidence is strong that fish consumption by mothers is good for the brains of their babies.\nIn the report, the panel argues that albacore tuna is a \u201cspecial case.\u201d They noted that even when women ate double the recommended weekly amount of tuna, the benefits far outweighed the risks.\n\u201cIt may be that the issue is re-evaluated and there is no change.\u201d\n\nMercury levels in our oceans are on the rise due to an increase in industrial mercury emissions.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes only three sources. Two of the sources are members of the Dietary Guidelines Advisory Committee, which released the very report they were asked to comment on. One of those two sources is Alice Lichtenstein. While the story tells readers that Alice Lichtenstein is \u201csenior scientist and director of the Cardiovascular Nutrition Laboratory at Tufts University,\u201d it failed to note that she is also the vice chair of the Dietary Guidelines Advisory Committee. The third source is a co-founder of the Mercury Policy Project, which is a longtime advocate for limiting mercury exposure. Input from an outside expert on prenatal or pediatric nutrition would have been great.", "answer": 0}, {"article": "With the FDA's announcement, drugs like pembrolizumab have also begun to change the way that physicians, patients and government regulators think of cancer. No longer will they see all cancers of the lung, breast, colon, brain, liver, pancreas and prostate as distinct from one another. Instead, they will look for the common genetic mutations that give rise to cancers no matter where they're found. And they'll treat those cancers with a drug that uses that common signature as a homing beacon, either for the immune system or for targeted cancer drugs to attack.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not tell readers anything about who paid for or managed the drug trials. It also does not report that one of the researchers quoted in the story, Dr. Bert Vogelstein, has received payments from pharmaceutical companies related to work on pembrolizumab, and that he also has a patent pending, as he stated in a New England Journal of Medicine disclosure statement.", "answer": 0}, {"article": "Greek researchers offered fresh evidence of the health benefits of the Mediterranean diet, reporting in a large study that it helps improve several risk factors linked to diabetes, obesity and heart disease.\n\nThe Mediterranean diet is high in monounsaturated fats such as olive oil and also relies heavily on whole-grain cereals, fruits and vegetables, fish and low consumption of animal fats. It has been shown in numerous studies and clinical trials to reduce mortality from such causes as cardiovascular disease and cancer.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A quote from an independent source was included in the story commenting on the study and reflections about the benefits of a \u2018Mediterranean diet\u2019.", "answer": 1}, {"article": "\u201cThe high degree of certainty in one report and the extreme caution in the other,\u201d said Rebecca Goldberg, a senior scientist with Environmental Defense, an advocacy group, \u201cwill make people more confused than ever.\u201d\n\nTo the surprise of Institute of Medicine officials, NOAA sponsored the hastily called press conference at which the Harvard report was released, even though that study conflicted with the one prepared by the institute.\nDr. Malden C. Nesheim, chairman of the institute\u2019s committee and a provost emeritus at Cornell, said, \u201cWe are quite cautious because the studies we looked at are not controlled for all the variables, and we can\u2019t distinguish between the effects from omega-3\u2019s or replacement of other foods in the diet.\u201d\n\nThe National Oceanic & Atmospheric Administration had requested the institute\u2019s report because it said consumers were confused about how much and what kind of fish they should eat.\nFor those who eat more fish, both reports advise eating a variety of species to reduce the level of contaminants.\n\u201cAccording to NOAA\u2019s own statistics, per capita consumption of seafood has risen from 14.8 pounds in 2001 to 16.6 pounds in 2004.\u201d\n\nJane Houlihan, the research director of the Environmental Working Group, another advocacy group, said, \u201cThe Harvard study reads like an advertisement for the seafood industry.\u201d\n\nBoth studies reinforce advice from the Food and Drug Administration and the Environmental Protection Agency in 2004, to eat about six ounces of fish a week, preferably high in omega-3\u2019s, with a caveat for women of childbearing age and children under 12 not to eat swordfish, shark, tile fish or king mackerel and to limit their intake of albacore (white meat) tuna to six ounces a week to avoid mercury.\nrecommend.\u201d\n\nDr. Nestle finds the situation so confusing \u201cno rational person can possibly figure out how to make sense of it,\u201d she said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article cites an array of scientific experts, regulatory authorities, industry sources, and representatives of various advocacy groups. It also provides sufficient information to determine their potential conflicts of interest.", "answer": 1}, {"article": "Before Starting A Statin, Talk It Over With Your Doctor\n\nA study published Monday is pushing back against the notion that up to 40 percent of Americans should be taking statin drugs to reduce the risk of heart disease.\nIt's important to note that statin drugs are generally safe, and harms are uncommon.\n\"The elderly do not benefit as much as previous studies might have thought,\" he says.\nThe most common side effect of these drugs is muscle pain, which usually goes away if patients stop taking the medicines.\n\"If you have no coronary calcium, then your chances of having a heart attack over the next 10 years are very low,\" he says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story includes sources that weren\u2019t involved in the study. The study\u2019s authors reported no conflicts of interest.\nThe story could have acknowledged the influence of pharmaceutical companies in creating guidelines for statin use.", "answer": 1}, {"article": "The oral drug targets an enzyme called Syk.\nNow Harvard researcher Michael E. Weinblatt, MD, reports results from a phase II clinical trial in which 457 patients with active rheumatoid arthritis despite methotrexate treatment received R788 or placebo for six months.\n\"Inhibition of the Syk pathway offers a new drug target for rheumatoid arthritis,\" Weinblatt and colleagues conclude.\nWeinblatt reports receiving grants, fees, or honoraria from a number of drug and biomedical companies, including Rigel.\nIt's not clear whether long-term use of R788 will increase cancer risk; longer-term clinical trials will have to evaluate this risk.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources in this story and, indeed, no named sources quoted.\u00a0High in the story, it says\u00a0\"Now Harvard researcher Michael E. Weinblatt, MD, reports results from a phase II clinical trial,\" giving the imprimature of independent, academic reserach. But the\u00a0story includes this helpful paragraph at the end. \"Rigel funded the study, and three of the study\u2019s six authors are Rigel employees. Weinblatt reports receiving grants, fees, or honoraria from a number of drug and biomedical companies, including Rigel.\"", "answer": 0}, {"article": "(Chicago) - Eating a meal of seafood or other foods containing omega-3 fatty acids at least once a week may protect against age-related memory loss and thinking problems in older people, according to a team of researchers at Rush University Medical Center and Wageningen University in the Netherlands.\nThey also had slower rates of decline in a test of perceptual speed, or the ability to quickly compare letters, objects and patterns.\nThe study group also completed annual food frequency questionnaires, allowing the researchers to compare participants' reported seafood intake with changes in their cognitive abilities as measured by the tests.\nThe age-related memory loss and thinking problems of participants in the study who reported eating seafood less than once a week declined more rapidly compared to those who ate at least one seafood meal per week.\nThe questionnaires included four types of seafood: tuna sandwiches; fish sticks, fish cakes and fish sandwiches; fresh fish as a main dish; and shrimp, lobster and crab.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The story clearly and prominently lists the sources of funding for the work, and there are no apparent conflicts of interest.", "answer": 1}, {"article": "An international team of researchers from University Hospitals Leuven (Belgium), Sophia Children's Hospital Rotterdam (The Netherlands), and Stollery Children's Hospital Edmonton (Canada) has now challenged the validity of this common practice.\nThey conducted a randomized controlled trial that involved 1,440 critically ill children.\nCritically ill children in intensive care are unable to eat independently.\nThis common practice is based on the assumption that it will help them recover more quickly.\nThe artificial nutrition is infused directly into the bloodstream.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There\u2019s no information in the release about funding or potential conflicts of interest.", "answer": 0}, {"article": "Accordingly, the 28-day \u201chealing\u201d diet he suggests consists almost entirely of natural, unprocessed foods, especially lean protein foods like light-meat poultry, fish, egg whites and low-fat dairy, beans (combined with whole grains), and nonacidic vegetables and fruits.\nBut while certain common foods \u2014 like raw onions, garlic, citrus juices, coffee and chocolate \u2014 are likely to cause reflux in most people with the condition, Dr. Aviv and other experts emphasize that everyone is different, and trial and error is the most effective way to determine an individual\u2019s trigger foods and drinks.\n\u201cStudies have revealed that 80 percent of Americans may be taking these powerful meds incorrectly,\u201d Dr. Aviv wrote.\nIf adopting the above measures fails to fully control acid reflux, taking a proton pump inhibitor may also be needed.\nA food does not have to be obviously acidic to be troublesome.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only person cited in the story is Jonathan Aviv, who wrote The Acid Watcher Diet. Input from an independent expert would have been a valuable addition.", "answer": 0}, {"article": "Elsevier is a global information analytics company that helps institutions and professionals progress science, advance healthcare and improve performance for the benefit of humanity.\nAmsterdam, July 3, 2017 - Doctors should consider radiosurgery earlier for patients with severe facial pain, according to a new study in the International Journal of Radiation Oncology*Biology*Physics (the \"Red Journal\") - the official journal of the American Society for Radiation Oncology (ASTRO).\nWhile this can reduce the pain, it makes patients drowsy and tired, and they report feeling drunk.\nInternational Journal of Radiation Oncology * Biology * Physics (IJROBP), known in the field as the \"Red Journal,\" is the official journal of the American Society for Radiation Oncology (ASTRO).\n\"We knew radiosurgery results in pain relief, but we didn't know if the patients actually felt better,\" said Dr. Samuel Chao, corresponding author of the study.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t name the funder of the study. There\u2019s also no mention of potential conflicts of interest, other than that Dr. Chao does the procedure.", "answer": 0}, {"article": "Eli Lilly announced promising data on its efforts to have its Cymbalta depression treatment also used as pain medicine, saying a study showed the drug \"significantly\" reduced chronic lower-back pain.\n\nLilly has been looking at the potential of Cymbalta for relieving the discomfort of fibromyalgia and osteoarthritis pain as well as back pain. The company's results of late have been boosted by the antidepressant, whose second-quarter sales jumped 26% to $654.4 million.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent source was interviewed.\u00a0 ", "answer": 0}, {"article": "Otto tracked 755 patients who died from breast cancer from 1995 to 2003 and another 3,739 control patients matched by age and other measures.\nThe greater risk reduction in women aged 70 to 75, Otto said, is probably a result of the long-term good effects of screening participation in the earlier target age group, 50 to 69, before the upper age limit for screening was extended in the Netherlands from 69 to 75.\nThe study findings ''add to the body of evidence supporting the fact that mammography matters in improving detection and survival,\" said Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York City.\n\"Our study adds further to the evidence that mammography screening unambiguously reduces breast cancer mortality,\" said Dr. Suzie Otto, a senior researcher in the department of public health at Erasmus Medical Center in Rotterdam, the Netherlands.\nIt's not clear, for instance, whether the women who died of cancer got less aggressive treatment or refused treatment.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although there is no specific indication of whether or not there is a conflict of interest ,the article is considered satisfactory because it names the source of the study and provides one independent source, Dr. Stephanie Burnik.", "answer": 1}, {"article": "Rheumatoid arthritis, which is felt throughout the whole body, is caused when a person's immune system attacks his or her own tissues.\nFor the study, the investigators analyzed the findings of 40 studies published between January 1990 and December 2011.\nThe studies included arthritis patients aged 18 or older who had hip or knee replacements.\nThe study team found no differences between the two groups of arthritis patients in rates of follow-up surgery, or 90-day blood clot or death risk.\nIn addition, rheumatoid arthritis patients have a higher infection risk after total knee replacement than osteoarthritis patients, the study authors found.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were no independent sources. The story did not include the conflict of interest disclosures that were clearly posted at the top of the journal article online.", "answer": 0}, {"article": "But not a whole lot.\nExactly how well zinc works is a matter of future research, and the one day estimate may well change, the researchers note.\nAlthough the precise estimate is still uncertain, researchers found that people who started taking zinc-loaded lozenges or syrups within 24 hours of showing symptoms \u2014 a sore throat, say, or runny nose \u2014 shortened their cold by one day.\nSingh said the side effects of zinc lozenges, which can be bought for a few dollars in any drug store in the U.S., come down to bad taste and some cases of nausea.\nWhile the episodes usually aren\u2019t serious, the resulting visits to the doctor alone cost the U.S. an annual $7.7 billion, according to the new report.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Our posted criterion doesn\u2019t allow us to give a satisfactory grade to a story that relies on just one source, even a source as smart as Dr. Meenu Singh, the author of this study.", "answer": 0}, {"article": "He was fascinated by certain powerful cells of the immune system \u2014 T cells.\n\"It's a new modality for treating cancer,\" Dr. Samuel Broder, a former director of the National Cancer Institute, says now of Allison's pioneering research.\nIt might be too early to say we're going to cure cancer, Allison says, \"but we're going to cure certain types of cancers.\n\"I've been doing this sort of stuff for years, and I'd never seen anything like that,\" Allison says.\nAllison's long search for this new kind of treatment \u2014 one that has since become a lifesaver for some cancer patients \u2014 began around a decade before Belvin got sick, when Allison was running a lab at the University of California, Berkeley.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes a former director of the National Cancer Institute, which is good. And the story clearly outlines Allison\u2019s search for pharmaceutical industry partners to develop ipilimumab into a drug that can be used in clinical practice.", "answer": 1}, {"article": "Cigarette smoking is the leading preventable cause of disease and death in the United States, killing about 480,000 Americans each year.\n\u201cThe money spent in one year on Tips is less than the amount the tobacco industry spends on advertising and promotion in just 3 days.\u201d\n\nThe most recent Surgeon General\u2019s Report, The Health Consequences of Smoking\u201450 Years of Progress, called for airing effective messages such as the Tips ads with high frequency and exposure for 12 months a year for a decade or more.\nWith a year-round campaign we could save even more lives and money.\u201d\n\nTips, the first federally funded anti-smoking paid media campaign, features former smokers talking about their smoking-related illnesses.\n\u201cThe Tips campaign is an important counter measure to the $1 million that the tobacco industry spends each hour on cigarette advertising and promotion,\u201d said Corinne Graffunder, Dr.P.H., director of CDC\u2019s Office on Smoking and Health.\nThe latest outcomes measuring the impact of CDC\u2019s national tobacco education campaign are as strong as those achieved in its first year, and suggest that three years into the campaign, the ads were still having a significant impact.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release offers very little information about the study \u2014 readers aren\u2019t told who performed the study or who paid for it. Two of the authors are CDC researchers, and the study itself was funded by the CDC. To be clear: neither of those facts is necessarily problematic; what\u2019s problematic is that the release doesn\u2019t share that information with readers.\nHowever, since the study is evaluating a CDC initiative and being published in the CDC\u2019s journal, savvy readers would most likely deduce CDC funding.", "answer": 0}, {"article": "Fetal death, or intrauterine fetal demise (IUFD), affects 30,000 women each year in the United States.\nTo determine whether a woman's endometrium (uterine lining) is healthy and can sustain the embryo, the research team used the endometrial function test (EFT\u00ae), which was created by study co-author Harvey J. Kliman, M.D., director of the Reproductive and Placental Research Unit in the Department of Obstetrics, Gynecology and Reproductive Sciences at Yale School of Medicine.\nThe results are published in the current issue of Fertility & Sterility, the international journal of the American Society for Reproductive Medicine.\n\"We are very pleased to find that these results reinforce the evidence that progesterone could be a very beneficial, inexpensive, and safe treatment for many women with a history of recurrent pregnancy loss,\" said Stephenson.\nFor women who suffer multiple pregnancy losses in the first four to six weeks of gestation, the hormone progesterone could offer hope for a successful birth, according to a new study by Yale School of Medicine researchers and their colleagues at University of Illinois at Chicago.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t mention who funded the study, which is necessary to meet our standard. It does note that the \u201cresearch team used the endometrial function test (EFT\u00ae), which was created by study co-author Harvey J. Kliman, M.D., director of the Reproductive and Placental Research Unit in the Department of Obstetrics, Gynecology and Reproductive Sciences at Yale School of Medicine.\u201d However, the release doesn\u2019t acknowledge an important conflict of interest that is addressed in the study manuscript itself: \u201cH.J.K. is the inventor of a patent related to the monitoring of endometrial glandular development.\u201d", "answer": 0}, {"article": "It also has a very low rate of false positives - it is 98% accurate at ruling out RA.'\nThe Kennedy Institute's Professor Kim Midwood said: 'What is particularly exciting is that when we looked at samples taken from people before their arthritis began, we could see these antibodies to cTNC up to 16 years before the disease occurred - on average the antibodies could be found seven years before the disease appeared.\nThis latest research provides the basis of tests that could improve diagnosis and, importantly, detect disease at a very early stage, with the promise even that people at risk of developing rheumatoid arthritis can be followed before the disease begins.\n'When we looked at results from more than 2000 patients we found that testing for antibodies that target citrullinated tenascin-C (cTNC) could diagnose RA in around 50% of cases, including some cases not identified by CCP.\nWe decided to see if it could be citrullinated and, if so, whether it was a target for the autoantibodies that attack the body in RA.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There\u2019s no mention of the funders in the release.\nAccording to the published study, funding was provided by the Arthritis Research UK, the Kennedy Trust for Rheumatology Research and BT CURE. In addition, it was disclosed that \u201cdata in this manuscript are the subject of a patent filing\u201d and that the lead investigator sits on the board of and is a consultant to Nascient.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/01/17/national/a130050S19.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Story includes perspective from\neditorial writer.", "answer": 1}, {"article": "People who ate that amount ended up with lower blood pressure readings than those who ate white chocolate.\nThe results are interesting but need to be duplicated in larger, more ethnically diverse populations, said Dr. Laura Svetkey, director of Duke University's Hypertension Center.\nThe researchers note that eating a small amount of dark chocolate daily is a dietary change that's \"easy to adhere to,\" reports CBS News partner WebMD.\nUniversity of Cologne researcher Dr. Dirk Taubert, the study's lead author, said the blood pressure reductions with dark chocolate were small but still substantial enough to potentially reduce cardiovascular disease risks, although study volunteers weren't followed long enough to measure that effect.\nChocolate-makers have embraced these findings and have developed new ways to satisfy the sweet tooth and curb the guilt by introducing more varieties of dark chocolates, fortifying them with vitamins and anti-oxidants, reports Miller.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only \"expert\" interview in the story was with the nutrition director of the Center for Science in the Public Interest.\u00a0 But the interview bites they used from her didn\u2019t add much to the piece, so we\u2019re left yearning for some expert interpretation of the findings.\u00a0 ", "answer": 0}, {"article": "Arena then hopes to file its request for market approval with the Food and Drug Administration by the end of 2009.\nThe drug also proved to be highly selective, meaning it hit the intended targets inside the body and did not cause troubling side effects.\nThe higher the dose, the more weight on average the people lost.\nPeople taking the Arena pill experienced significantly more weight loss, at least 5 percent of their weight over 12 weeks, than people taking a placebo, according to the report filed in the journal Obesity.\nArena has conducted safety studies on the drug, and no heart valve problems have been reported.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were no sources of information quoted that were independent of the study or the company developing the drug.", "answer": 0}, {"article": "The study was funded by the Celladon Corp. of La Jolla, Calif.\n\"This is the first time gene therapy has been tested and shown to improve outcomes for patients with advanced heart failure,\" study lead author Dr. Donna Mancini, professor of medicine and the Sudhir Choudhrie professor of cardiology at Columbia University College of Physicians and Surgeons in New York City, said in a university news release.\n\"There are a lot of treatments for heart failure but at some point patients stop responding and then the prognosis is poor,\" said Dr. Rita Redberg, AHA spokeswoman and professor of medicine at the University of California, San Francisco.\n\"The therapy works by replenishing levels of an enzyme necessary for the heart to pump more efficiently by introducing the gene for SERCA2a, which is depressed in these patients.\nThe study authors hope that, if replicated in larger trials, the gene-therapy treatment could actually delay or obviate the need for heart transplants in patients with heart failure.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does quote two independent experts and reports that the trial was funded by the company developing this gene therapy. Unfortunately, those experts\u2019 quotes didn\u2019t add much to help readers evaluate the quality and value of this trial. But it nonetheless gets a barely passing grade on this criterion. ", "answer": 1}, {"article": "At the end of six months, LDL cholesterol was cut 81 milligrams per deciliter (mg/dl) of blood to 45 mg/dl, a reduction of about 40 percent.\nA big study to confirm the results would take four to five years to complete so the drug is still years away from market, said Cannon, who is a cardiologist with Brigham and Women's Hospital in Boston.\n\"I would be more excited [about anacetrapib] if I hadn't seen what happened to its cousin torcetrapib,\" Weintraub said.\nTo assess the safety of the trial, investigators randomly chose 1,623 adults with coronary heart disease who were taking cholesterol-lowering statins to receive either anacetrapib or a placebo for 18 months.\n\"There are a lot of people in the prevention/lipid field that are simultaneously excited and leery,\" said Dr. Howard Weintraub, clinical director of the Center for the Prevention of Cardiovascular Disease at NYU Langone Medical Center in New York City.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although this story includes a strong lineup of independent sources that put the results in context for readers, it fails to report either that the trial was sponsored by the drug company developing anacetrapib or that the researcher quoted in the story has financial ties to that and other drug companies.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070311/19clot.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A neruologist from the National Institute of Neurological Disorders and Stroke and an expert in cardioembolic stroke were quoted and added insights that were helpful to readers.", "answer": 1}, {"article": "\u2022 Even among patients with hypertension, a longer median overall survival was observed among users of NSBBs compared with nonusers (90 months versus 38.2 months).\nThis study builds on a large body of research by principal investigator Anil Sood, M.D., professor in Gynecologic Medical Oncology and Cancer Biology at MD Anderson.\n\"The ability to show improved survival using nonselective agents - which inhibit a specific stress pathway - is the culmination of years of research into ovarian cancer biology and pathogenesis.\"\nThere are currently two clinical trials, one led by MD Anderson, evaluating the combination of chemotherapy and propranolol (a type of NSBB) on cancer biology and on stress modulators in patients with newly diagnosed EOC.\nFurther examination revealed that NSBB users had improved overall survival regardless of the presence of such prognostic factors or comorbidities.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release includes an exhaustive list of funding sources and notes that one of the journal article\u2019s co-authors has received funding from two pharmaceutical companies.", "answer": 1}, {"article": "Fried, a dermatologist and clinical psychologist, points out that psoriasis itself can be associated with mental health problems.\nBecause of these events, the labeling for Siliq will include a Boxed Warning, and the drug will only be available through a restricted REMS (Risk Evaluation and Mitigation Strategy) program.\n\u201cPatients and their health care providers should discuss the benefits and risks of Siliq before considering treatment,\u201d said Dr. Julie Beitz, director of the Office of Drug Evaluation III in the FDA\u2019s Center for Drug Evaluation and Research, in an agency press release.\nValeant Pharmaceuticals, Siliq\u2019s manufacturer, says that pricing information is not available at this time, and expects to begin sales and marketing in the second half of 2017.\nThe most common side effects of the drug were joint and muscle pain, headache, fatigue, diarrhea, throat pain, nausea, flu, low white blood cell count, fungal infections and reactions at the injection site.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does quote two sources, one an FDA official and the other a member of the medical board of the American Psoriasis Foundation. The story also points out that the APF official \u201csays he has no involvement with the drug or the drug company.\u201d However, the foundation lists Valeant, Siliq\u2019s manufacturer, as a corporate partner, and we think those sorts of details are important to disclose.\n", "answer": 0}, {"article": "All of the babies born by C-section were slightly more likely to use an asthma inhaler at age 5: 10.3 percent of planned C-section babies and 10.19 percent of unscheduled C-section babies wound up using an inhaler, compared with 9.6 percent of vaginally born babies.\nNearly 4 percent were born by planned C-section and 17 percent were delivered by emergency surgery.\nThe remaining 252,917 were vaginal births.\nThere were no significant differences in cancer and irritable bowel disease among any of the types of births.\nC-section birth has also been associated with a higher risk for Type 1 diabetes.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several independent experts were quoted.", "answer": 1}, {"article": "Here is how I would think about asking the question instead: What is the easiest way to reduce my chance of death?\nThe ideal measure would combine the length of time spent exercising with the amount of energy expended \u2014 basically, we want to figure out a way to credit people who walk at half the speed for twice as long the same amount as those who walk faster for less time.\nBut since the people in the studies are of different ages, researchers can\u2019t just look to see whether they have, say, a 2 percentage point lower risk of death in a given year, since that lower risk would mean a lot more for someone who is 30 than for someone who is 90.\nConsider, for example, the many posts on The New York Times\u2019 Well blog on the topic (walking versus running, the \u201cright dose of exercise,\u201d \u201cwalk hard, walk easy\u201d), all of which focus on the relative benefits of walking versus jogging versus running.\nBut a closer look at the data suggests that this is probably just a statistical artifact: This intense running group contains only 36 people and two deaths, versus hundreds of people in the more casual running groups.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "In a sense, this story is a data-driven op-ed piece \u2014 there are no quotes from any outside sources. The story does link to all of the relevant source material, which is great, but the story could have been stronger if it had gotten input from, well, anyone in the medical community with relevant expertise that could have helped readers synthesize all of the study data the story cites. For example, it\u2019s possible that a clinical professional would have pointed out the potential harms of running and helped readers sort through the tradeoffs involved \u2014 making the overall coverage more useful.", "answer": 0}, {"article": "For Patients and the General Public:", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The sponsor of the trial is given as QuantumLeap Healthcare Collaborative, a non-profit set up by Silicon Valley entrepreneurs.\nThe manufacturers of neratinib and veliparib \u2014 Puma Biotechnology and Abbvie, respectively \u2014 are listed as \u201cstrategic partners\u201d on the QuantumLeap Healthcare Collaborative website, suggesting potential financial involvement. That\u2019s a financial tie that should have been noted in the news release as well.\nBoth NEJM papers explicitly state that the pharmaceutical companies had no direct involvement in the trials except to provide the drugs.", "answer": 0}, {"article": "The research findings published by PLOS ONE help support their objective.\n\"This is the first paper demonstrating an objective method of diagnosing mTBI that relies on physiologic parameters,\" said Hoffer, who is professor of otolaryngology at the University of Miami Miller School of Medicine.\nThe goal was to identify OVRT performance metrics that differentiated between mTBI and control groups and to create a model that could accurately evaluate mTBI neurologic status in patients.\nAnother benefit for this research was that \"this next generation test has the considerable advantage of not requiring baseline testing,\" said study co-author Carey Balaban, Ph.D., of the University of Pittsburgh.\nA team of researchers from the University of Miami Miller School of Medicine has shown that the I-Portal Neuro Otologic Test, which uses the head-mounted goggle that gauged eye movement through video cameras and computers, can successfully diagnose concussion with 95 percent specificity and 89 percent sensitivity.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There was no mention of funding sources and conflicts of interest in the news release. We find this highly problematic, since the principal investigator of this study is employed by Neuro-Kinetics, the manufacturer of the I-Portal google. Not only is he paid by Neuro-Kinetics, but the company is his sole affiliation (meaning he has no other hospitals or university affiliations), as listed on the PLoS One research article.\nThe news release also did not disclose the funding sources for the study \u2013 which included the National Football League (NFL), Underarmor, General Electric and the Department of Defense \u2013 through the Head Health Challenge II grant.\nFor these reasons, we give the news release a Not Satisfactory rating here.", "answer": 0}, {"article": "(PHILADELPHIA) -- When patients present with neurologic symptoms such as severe headaches or seizures, the symptoms could suggest anything from infection, cancer, or an autoimmune disease of the brain or spinal cord, leaving physicians scrambling to find the cause in a short amount of time.\n\u201cMoving forward, our goal is to formally validate our findings with a larger sample size that includes both adults and children for future use in the clinical arena.\u201d\n\nArticle reference: Danielle Fortuna, D Craig Hooper, Amity L Roberts, Larry A Harshyne, Michelle Nagurney, Mark T Curtis, \u201cPotential role of CSF cytokine profiles in discriminating infectious from non-infectious CNS disorders,\u201d PLOS ONE, DOI: 10.1371/journal.pone.0205501, 2018.\nChanges in cytokine levels of cerebrospinal fluid offer a very early measurable sign of infection.\u201d\n\nDr. Curtis and colleagues decided to see if they could detect patterns within the cytokines that might differentiate infections from other brain diseases or disorders.\n\u201cOnce confirmed with additional research, our test could provide a first, rapid and less invasive way to look at what\u2019s happening in the brain and guide treatment or further testing.\u201d\n\nThe results were published in the journal PLOS ONE on October 31st.\nThe researchers then tested the cerebral spinal fluid (CSF) for the presence of 41 different cytokines and noticed that patients with confirmed infection of the central nervous system had a different cytokine fingerprint from those confirmed as having tumors or autoimmune disease.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources and potential conflicts of interest \u2014 or a lack thereof \u2014 weren\u2019t noted in the release. The published study lists \u201cnone\u201d under its author\u2019s declarations of interest. In a cursory check, we also found no evidence that the authors gained to benefit from widespread use of the Luminex FlexMAP 3D assay system, which is key to the rapid analysis of spinal tap samples.", "answer": 0}, {"article": "A hijab, a turban, a beard: What aren\u2019t you seeing?\nOver 24,000 employees at 116 LI companies were polled on what makes their employers great.\nA former gang member recently recalled when he decided to join the gang.\nFrom a Catholic school uniform to a hijab, LIers talk about their religious clothing.\nHere\u2019s how he got out.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Only one investigator is quoted. The story mentions an NIH meeting without any details that would allow a reader to learn more.", "answer": 0}, {"article": "Researchers at Stanford University have developed a first-of-its-kind blood test that, according to preliminary studies, is able to identify patients with Alzheimer's disease - an ailment that has been notoriously difficult to diagnose.\nThe 18 different molecules are drawn from a phrasebook of chemical chatter that occurs among cells in the body.\nAlthough the studies were small in scale, researchers said the experiment proved that the concept of screening for chemical signals was promising and that the first Alzheimer's blood test might be within reach after further large scale studies.\nIn one experiment using stored blood samples, the test was positive for Alzheimer's disease in 38 out of 42 patients who had been independently diagnosed by clinicians as having the disease - a 90 percent accuracy rate.\nUsing existing laboratory technology, they developed a test that will light up when the 18 molecules are present in a blood sample.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included quotes from two individuals with expertise in the field but no direct connection with the publication discussed or the company which has been established to market the test.", "answer": 1}, {"article": "New stretch marks were also softer and smoother in 54 women who used the cream for three months, says Zoe Draelos, MD, a consulting professor of dermatology at Duke University Medical Center in Durham, N.C. \"The stretch marks did not go away,\" she tells WebMD.\nThe study, funded by Merz Pharmaceuticals, which makes the cream, was presented at the annual meeting of the American Academy of Dermatology.\nOnions contain flavonoids, a type of antioxidant, that have anti-inflammatory properties, Draelos says.\nThe new product also contains pennywort, a plant found in Asia, Africa, and the Americas that has anti-inflammatory properties and is widely used in Indian naturopathic medicine for ulcer healing, she says.\nAnd it has sulfur, which fights bacteria and infection, and a moisturizing cream to help rehydrate the skin, Draelos says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes one independent source and identifies Dr. Draelos, the lead researcher on the study, as a consultant to Merz Pharmaceuticals, which funded the research.", "answer": 1}, {"article": "\u201cMore often than not, it\u2019s not clear-cut which way to go,\u201d explained Barry Rosenstein, professor of radiation oncology at Mt.\nIf you see a radiation oncologist he\u2019ll say oncology.\u201d\n\nDetermining what type of treatment a man should receive is only part of the dilemma of prostate cancer.\nThis kind of work is important not just for prostate cancer, but all cancers.\n\"This is a study that in certain ways is groundbreaking and also elegantly performed,\" Derweesh said.\nWhile there has been greater success in treating cancer, survivors may live many years with side effects after treatment.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article does not clearly identify whether the sources are independent (one is a co-author, the other is not).", "answer": 0}, {"article": "Dec. 7, 2012 -- A drug related to thalidomide may be more potent and less toxic than thalidomide, which is often used to treat lupus skin conditions.\nThe lenalidomide study included 15 women with lupus skin conditions; six had lupus in other areas of the body, too.\nOne patient withdrew from the study after one week due to digestive system side effects.\nSimilar to treatment with thalidomide, most of the patients had a relapse of their skin problems within weeks of stopping the drug.\nAll had received standard treatments, and 14 had been treated with thalidomide previously.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did interview a doctor outside of the current study team who cautioned about the treatment with lenalidomide may not be safe and effective for patients.", "answer": 1}, {"article": "Compared with the 35 stroke patients who got clot-dissolving medicine alone, the 35 who got the two-pronged treatment were nearly twice as likely to regain some neurological function after three days. Imaging results revealed that for those who got both treatments, 100% of the brain tissue initially affected by a clot had blood flowing to it after 24 hours. Among the subjects who only got alteplase, the median level of restored blood flow was 37%.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story provides quotes from two experts in the field, neither of whom appears to be associated with the two NEJM studies. However, one of the sources \u2014 Dr. Sidney Starkman \u2014 has been an unpaid investigator on another trial run by a device manufacturer discussed in the story, and has disclosed in his previous writing that his employer (University of California) holds a patent on a clot removal device. Although it sounds like he stands to benefit if this technology becomes more widely adopted, we\u2019re not really in a position to know the extent of his personal conflict of interest. We\u2019ll give the benefit of the doubt here, with the caveat that it\u2019s always useful to give readers a clear sense of the source\u2019s independence (or lack thereof).", "answer": 1}, {"article": "\"If [Livia] gets more women to know about TENS, then great,\" she said.\nGunter's main question about Livia is whether it will be significantly different from the already available and effective TENS devices, which usually cost around $35.\nNow there's Livia, a medical device that's being marketed as the \"off switch for menstrual pain.\"\nIts conclusion: \"High-frequency nerve stimulation may help relieve painful menstrual cramps.\"\nBased on these studies, Nachum is trying to get Food and Drug Administration approval to market Livia as a menstrual pain reliever.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The comments from an\u00a0independent expert\u00a0help ground the claims made by the company CEO.\u00a0The outside source is the key to balance in this article.", "answer": 1}, {"article": "Kappelmann, N et al.\nThe research was mainly funded by the Wellcome Trust, with further support from the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre.\nDr Golam Khandaker, who led the study, says: \"It's becoming increasingly clear to us that inflammation plays a role in depression, at least for some individuals, and now our review suggests that it may be possible to treat these individuals using some anti-inflammatory drugs.\n\"It's too early to say whether these anti-cytokine drugs can be used in clinical practice for depression, however,\" adds Professor Peter Jones, co-author of the study.\n\"We will need clinical trials to test how effective they are in patients who do not have the chronic conditions for which the drugs have been developed, such as rheumatoid arthritis or Crohn's disease.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding of the review article are clearly stated in the release. However, the potential conflicts of interest among researchers involved in the studies included in the review are not mentioned. Some of the researchers received honoraria from drug companies. That should have been noted in the release.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Taking fish oil may help prevent full-blown psychotic illness in at-risk adolescents and young adults, a study released today hints.\n\u201cFor young people they don\u2019t want to commit themselves to a treatment which they might need to take for the next five to ten years,\u201d he said.\nThe researchers included people who met at least one of the following three criteria: having low-level psychotic symptoms; having transient psychotic symptoms; or having a schizophrenia-like personality disorder or a close relative with schizophrenia, along with a sharp decline in mental function within the past year.\nThey are also key to the proper function of two brain chemical signaling systems, dopamine and serotonin, which have been implicated in schizophrenia.\nThere\u2019s considerable evidence that abnormal fatty acid metabolism may contribute to the development of schizophrenia, Amminger and his team note in the Archives of General Psychiatry.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The main limitation of this story is that it did not provide insights from any independent experts.\u00a0 It only\u00a0interviewed the principal investigator who conducted the research on which the story was based.\u00a0\u00a0\u00a0Independent experts\u00a0could have highlighted the limitations of the research which would have been important to present.\u00a0 ", "answer": 0}, {"article": "Study Limitations: Imbalances caused by matching groups of obese patients for comparison based on age, sex, body mass index and diagnoses of diabetes.\nThe following related elements from this issue of JAMA are also available on the For The Media website:\n\n-- Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss at 5 Years Among Patients With Morbid Obesity\n\n-- Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss in Patients With Morbid Obesity\n\n-- Lifestyle Intervention and Medical Management With vs Without Roux-en-Y Gastric Bypass and Control of Hemoglobin A , LDL Cholesterol, and Systolic Blood Pressure at 5 Years in the Diabetes Surgery Study\n\n-- Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities\n\n-- Editorial: Comparing the Outcomes of Sleeve Gastrectomy and Roux-en-Y Gastric Bypass for Severe Obesity\n\nFor more details and to read the full study, please visit the For The Media website.\nSome previous research has been limited by a number of factors, including the lack of a comparison group of obese patients who did not undergo bariatric surgery.\nPlease see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.\nResults: The rate of death from any cause over about 4.5 years was lower among obese patients who underwent bariatric surgery compared with patients who managed their obesity with nonsurgical care.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources and conflicts of interest are not addressed in the news release. Is is suggested readers consult the original article (link provided) for more information.", "answer": 0}, {"article": "Dr Furyk's research was recently published in the Annals of Emergency Medicine: http://www.annemergmed.com/article/S0196-0644(16)30364-X/abstract\n\nAbout the Emergency Medicine Foundation - EMF is an Australasian non-profit organisation funds innovative, evidence-based emergency medicine research that will improve clinical practices to save lives, as well as deliver significant economic benefits to the healthcare system.\n\"Kidney stones are a bit of a mystery, occur frequently in the community and generally affect young, healthy adults,\" Dr Furyk said.\nPatients with kidney stones were treated with the drug Tamsulosin in an Emergency Medicine Foundation Australasia (EMF) funded clinical trial run across five Australian hospital emergency departments.\n\"Of more than 400 patients in the trial, we found those who received Tamsulosin passed their large kidney stones more often than the placebo group.\n\"This means patients with large stones might not need more complicated treatments including surgeries, and this has potential to improve care and reduce costs.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that the research was funded by Emergency Medicine Foundation Australasia, and that the quoted researcher has received \u201cmore than $270,000\u201d from that group to support his research.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/060723/31robot.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article appropriately obtains various expert opinions about the claims of superiority of this surgical approach. Some experts appropriately point out that there is no evidence that this is superior to other approaches. ", "answer": 1}, {"article": "The other three people served as the control group.\nWEDNESDAY, Jan. 11, 2012 (HealthDay News) -- A new type of stem cell treatment for people with type 1 diabetes appears to help re-educate rogue immune system cells, which allows cells in the pancreas to start producing insulin again.\nThe treatment, which combines a patient's immune system cells with stem cells from a donor's cord blood, even worked in people with long-standing diabetes who were believed to have no insulin-producing ability.\nThe concept is very intriguing, and the treatment seems to be so simple and so safe,\" said Dr. Luca Inverardi, deputy director of translational research at the Diabetes Research Institute, University of Miami School of Medicine.\n\"That means if you stop the autoimmune reaction, you may see beta cell regeneration, or there might be other precursor cells in the pancreas.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story includes important context from an independent source. There is no discussion of any potential conflicts of interest of the researchers, but lacking any clear evidence of conflicts, we will give the story a passing grade. However, at least one online biography of the lead authors mentions that he holds several patents. If he or any of the authors own patents or other rights to treatments ultimately developed from this research, readers should be informed. The story did not report that the trial was funded by the University of Illinois (according to the trial registration: http://clinicaltrials.gov/ct2/show/NCT01350219). While academic institution funding may seem benign, many universities are actively engaged in licensing their discoveries or even creating companies to develop and market products of their labs, so even this source of funding may raise questions about financial entanglements.", "answer": 1}, {"article": "Data from nearly 9,500 people on five continents shows that amyloid can appear 20 to 30 years before symptoms of dementia, that the vast majority of Alzheimer\u2019s patients have amyloid and that the ApoE4 gene, known to increase Alzheimer\u2019s risk, greatly accelerates amyloid accumulation.\nThe findings also confirm that amyloid screening, by PET scan or cerebral spinal fluid test, can help identify people for clinical trials of drugs to prevent Alzheimer\u2019s.\n\u201cThe papers indicate that amyloid imaging is important to be sure that the drugs are being tested on people who have amyloid,\u201d said Dr. Roger Rosenberg, the director of the Alzheimer\u2019s Disease Center at the University of Texas Southwestern Medical Center at Dallas, who wrote an editorial about the studies.\nThe largest analysis to date of amyloid plaques in people\u2019s brains confirms that the presence of the substance can help predict who will develop Alzheimer\u2019s and determine who has the disease.\nExperts say previous trials of anti-amyloid drugs on people with dementia failed because their brains were already too damaged or because some patients, not screened for amyloid, may not have had Alzheimer\u2019s.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This is a strong point of the story. It includes three independent experts in addition to study authors and the author of an editorial about the research.", "answer": 1}, {"article": "Oct. 17, 2010 -- Women aged 65 and older are advised to undergo bone mineral density (BMD) screening every two years, but those with normal results at age 67 may be able to wait 10 years before their next screening test, a new study suggests.\nTheir findings are based on the women's T-score, which is a measure of bone density.\nResearchers say the 10-year interval is OK because the women\u2019s risk of developing the brittle bone disease osteoporosis in that time is low.\nThat was longer than we expected, and it's great news for this group of women.\"\n\"Our study found it would take about 16 years for 10 percent of women in the highest bone density ranges to develop osteoporosis.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 1}, {"article": "TUESDAY, Aug. 11, 2015 (HealthDay News) -- Colonoscopy can save lives, but experts agree that testing rates remain too low.\nHe believes that the scoring system \"was only modestly able to separate people within the risk groups.\"\nSo, patients scoring at the lower end of risk for colon cancer might be able to have less invasive screening tests (such as the fecal occult blood test), while those at higher risk would require a colonoscopy, Imperiale's team concluded.\nThe study found that patients classified under the scoring system as low-risk did, in fact, have far fewer advanced abnormal growths that might develop into cancer, compared to patients classified as high-risk.\nFor now, he said, the data from this study is not strong enough to spur any changes in current screening recommendations.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story contains two independent voices. The perspective they provide is a particular strength\u00a0of the article. We wish that more stories would reach out to experts not affiliated with the studies being reported on for context.", "answer": 1}, {"article": "A rare form of blindness inched closer to a cure, after two groups published preliminary studies on replacing the bad gene that causes the condition. The results are likely to boost the prospects of gene therapy, a technique that shows promise but has yet to prove it can be used to cure many diseases.\n\nAbout 2,000 people in the U.S. have Leber's congenital amaurosis No. 2, caused when a child inherits a certain flawed gene from both parents. Patients with the bad gene can't make a protein that is supposed to nourish the eye's...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "While this\u00a0article accurately states that its sources were two articles published in the New England Journal of Medicine,\u00a0funding sources were not reported in this article.\u00a0\u00a0The journal did report that funding for the research was primarily in the form of national, federal and foundation grants.\u00a0 One co-author on the British study and four authors of the U.S. study reported financial and/or consulting relationships with pharmacuetical companies.\u00a0 In addition, no opinion from an expert not involved in the trial was provided.", "answer": 0}, {"article": "CHICAGO (Reuters) - A computerized brain training program cut the risk of dementia among healthy people by 48 percent, U.S. researchers said on Sunday in reporting an analysis of the results of a 10-year study.\nThe preliminary findings, presented at the Alzheimer\u2019s Association International Conference in Toronto, are the first to show that any kind of intervention could delay the development of dementia in normal, healthy adults.\nThe new analysis was by Dr. Jerri Edwards of the University of South Florida, whose mentor, Dr. Karlene Ball of the University of Alabama at Birmingham, sold her rights to the program to Posit Science.\n\u201cThis may even be clinically relevant.\u201d\n\nIn 2014, a group of nearly 70 neuroscientists and cognitive psychologists led by researchers at Stanford University\u2019s Center on Longevity and the Berlin Max Planck Institute for Human Development signed a letter saying there was \u201clittle evidence\u201d of such results from brain games.\nTo date, cognitive psychologists and neuroscientists have largely rejected evidence that computer-based cognitive-training software or \u201cbrain games\u201d have any effect on cognitive function.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article introduces past and current investigators of the study, and their relationship to the company Posit Science:\n\u201cThe new analysis was by Dr. Jerri Edwards of the University of South Florida, whose mentor, Dr. Karlene Ball of the University of Alabama at Birmingham, sold her rights to the program to Posit Science. Edwards also was a paid consultant for the company for part of 2008.\u201d", "answer": 1}, {"article": "In drafting its updated colon cancer screening guidelines, the USPSTF reviewed data on several screening strategies.\nThis year about 134,000 people in the country will be diagnosed with the disease, and about 49,000 will die from it., the panel said\n\nThe USPSTF is an independent, volunteer panel of experts that makes recommendations about the effectiveness of specific preventive health services.\nFor this older group, the USPSTF recommends that decisions on screening be made during consultations between the patient and his or her doctor.\n\"Evidence convincingly shows screening for colorectal cancer works, but not enough people are taking advantage of this highly effective service,\" said Owens, a general internist at the Veterans Affairs Palo Alto Health Care System and a professor at Stanford University.\nIn its statement, the panel said that \"for some adults ages 76 to 85, the benefits of screening are smaller, and the potential for harm greater.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes comments from a physician who is not on the USPSTF and who expresses a different viewpoint. We won\u2019t mark down the story for not discussing conflicts of interest because the USPSTF is a voluntary, publicly-funded body and none of the members reported any conflicts in their disclosure forms.", "answer": 1}, {"article": "Finzi notes previous studies show between 50 to 60 percent of patients may benefit from the treatment.\n\u201cSo Botox basically inhibits the muscle and calms it down, so it becomes more difficult to feel those negative emotions.\u201d\n\nThe makers of Botox recently announced plans for the final phase of testing it as a treatment for depression.\nCosts vary widely, but the American Society for Aesthetic Plastic Surgery said the average price for a Botox treatment in 2016 was $376.\n\u201cI had less problems with depression.\u201d\n\nEven though the study she took part in is now over, she said she will continue to get Botox injections.\n\u201cWe don\u2019t believe it has anything to do with looks,\u201d says researcher Dr. Eric Finzi of Chevy Chase Cosmetic Center.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites no experts other than Dr. Finzi, author of a published study about the effects of Botox as a treatment for depression. This omission is made worse when you learn that Finzi\u2019s\u00a02014 study was funded by the Chevy Chase Cosmetic Center, where Finzi is medical director and president, that he has received a US patent for the treatment of depression with botox and was a paid consultant for Allergan in the past.\u00a0In other words, the sole interviewee for this story holds\u00a0an approved patent for the treatment in question,\u00a0stands to gain financially if the treatment receives FDA approval, and has been a paid consultant for the company manufacturing the drug.\u00a0Not telling readers\u00a0about these major conflicts of interest\u00a0is irresponsible.", "answer": 0}, {"article": "Those studies are expected to launch later this year, including two at Penn.\n\"There have been a lot of studies looking at different drugs, but researchers have not seen positive results,\" said the study's lead author Evan Alley, MD, PhD, chief of Hematology and Medical Oncology at Penn Presbyterian Hospital.\nThere are multiple studies going on right now to confirm these findings, which the authors note is a necessary step before the drug can become a standard second-line therapy.\n\"One great sign in this study is that none of the patients had to stop treatment because of side-effects,\" Alley said.\n\"This study provides evidence that some patients can have long-term disease control with this drug, which we haven't seen before,\" Alley said.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that the study was funded by the manufacturer (Merck) and that no financial relationship exists between the lead researcher and the manufacturer.\nHowever, according to the study, four of the co-authors do have individual conflicts of interest and three of the seven authors are Merck employees, two of whom own Merck stock options. These relationships go beyond Merck\u2019s funding of the study and should have been mentioned in the news release.", "answer": 0}, {"article": "\"The reason we're seeing these breakthroughs is because we did the basic science research to help us understand how this cancer happens, how it escapes therapy and how it progresses,\" Turnham says.\nPatients with a limited time to live may not be so positive, Turnham says.\nUntil recently, people with advanced melanoma often died within a year of diagnosis, even with chemotherapy.\nOlder melanoma therapies \u2014 including interferon, interleukin-2 and five chemo drugs \u2014 caused much more serious side effects, leaving her too sick to work, Herry says.\nTurnham knew a 19-year-old woman with melanoma who \"woke up bleeding every morning\" because of rashes caused by one of the new drugs, which targets mutations in a gene called MEK.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Adequate sourcing, including important contributions in quotes from the executive director of the Melanoma Research Foundation.", "answer": 1}, {"article": "Buck scientists strive to discover new ways of detecting, preventing and treating age-related diseases such as Alzheimer's and Parkinson's, cancer, cardiovascular disease, macular degeneration, osteoporosis, diabetes and stroke.\nWhile the medication remains the single most effective agent in the management of PD symptoms, long-term use causes its own side effects, among them abnormal involuntary movements or AIMS.\nHowever, this study provides additional evidence on top of prior work from Dr. Andersen's lab and others that lithium may have therapeutic potential in PD, which is a hypothesis that should be tested in clinical trials,\" he said.\nIn earlier studies, Andersen's team found that low-dose lithium was protective in two different mouse models of PD.\nThis study, published online in Brain Research, involved Parkinsonian mice that were given Carbidopa/Levodopa (sold as Sinemet\u00ae), a drug used to boost levels of the neurotransmitter dopamine, which is lost in PD.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding source for the research is clearly identified in the release. \u00a0However, we are not advised that the Buck Institute and the two senior authors of the paper filed a patent application for low-dose lithium in Parkinsons (US20130017274 A1).", "answer": 0}, {"article": "Many studies have documented the lower risk of various cancers among people who eat more fresh produce, and avoid things like red and processed meat.\nIn a study reported in the , they plumbed the Nurses\u2019 Health Study, a massive survey of nurses who filled out questionnaires on their diet and were followed for various health outcomes, including cancer.\nThe added risk of cancer, however, was counterbalanced by a lower risk of heart disease.\nIn the study, Farvid and her team could not find any significant relationship between fruit juice and breast cancer risk; that may be because fruit\u2019s anti-cancer effects may have to do with the fiber found in the whole fruit, which is stripped out of juice.\n\u201cWe recommend whole fruit and not fruit juice,\u201d says Farvid, \u201cbecause maybe one of the most important ways that fruit decreases risk of breast cancer is through fiber, and even natural fruit juice often has no fiber in it.\u201d\n\nIn another study also published in the , a separate group of researchers found that among 22,000 Danish women, those who added two alcoholic drinks a day on average increased their risk of developing breast cancer by 30% over five years.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources were included in the article, nor does it tell readers who funded the study. In this case, the work was supported by the National Institutes of Health, the Breast Cancer Research Foundation, and the Japan Pharmaceutical Manufacturers Association.", "answer": 0}, {"article": "In this study, the average age was about 59 years old - six years younger than the age at which the U.S. Preventive Services Task Force, a government-backed panel, recommends all women begin being screened for osteoporosis.\nThat may spare the patients from additional testing and additional costs.\nI think it will identify patients who are at a higher risk and need more testing,\u201d said Hull, who wasn\u2019t involved with the new research.\n\u201cI don\u2019t think at this point this one test is going to prevent further testing.\nThe disease affects over 12 million Americans over 50.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The perspectives from the editorial writer and from an independent expert were important contributions.", "answer": 1}, {"article": "More than half of patients ultimately die specifically from progressive lung cancer with observation, and 2-year survival is less than 40 percent with either approach,\" write researcher Robert Timmerman, MD, of the University of Texas Southwestern Medical Center, Dallas, and colleagues in the Journal of the American Medical Association.\nThe next step is a clinical trial to evaluate the therapy in a larger number of patients and determine the proper dosage for maximum benefit and minimal risk.\nIn these situations, the lung cancer tumor is deemed inoperable and conventional radiation therapy or observation without cancer treatment is offered.\nThis type of radiation therapy has not yet been approved by the FDA as a lung cancer treatment, but this study brings it one step closer.\nThree years after the treatment, the study showed that 28 participants had a complete response to the therapy and 21 had a partial response.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not quote any sources other than the lead author of the study. Independent experts could have provided some much-needed perspective on the importance\u00a0of the new findings. ", "answer": 0}, {"article": "So what's in blueberries that makes them so good for us?\nBut he says it's important to point out that the women in this study weren't prime candidates for heart attacks anyway.\nIt's certainly not a perfect way to detect how certain foods may influence health, but it identifies important associations.\n\"But nonetheless, for the first time I think we have some evidence that the intake of theses anthocyanins may have a protective effect.\"\nAt the same time, researchers have monitored the nurses' health to see which diseases they go on to develop, or not.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Cardiologist Dr. Robert Eckel is the independent source in the study who talks about a major study limitation. His comments are extremely helpful and bring more perspective to the study.", "answer": 1}, {"article": "The U.S. drugmaker on Monday said patients taking the approved 2 milligram dosage of Keytruda and those taking an experimental 10 milligram dose had longer overall survival compared with those taking docetaxel, a standard treatment for non small cell lung cancer (NSCLC), the most common form of lung cancer.\nMore detailed data from the study will be provided soon, Merck said, adding that it will ask the U.S. Food and Drug Administration later this year to add the new data to the drug\u2019s package insert label.\nThose whose tumors expressed PD-L1, but not at high levels, did not show such a statistically significant benefit in progression-free survival.\nKeytruda and a similar treatment from Bristol-Myers Squibb Co called Opdivo are antibodies designed to block the interaction between PD-L1 and another protein, PD-1, whose natural function is to put checks on the immune system.\nThe approval was contingent on the company providing more detailed data in the future on Keytruda\u2019s safety and effectiveness.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does note that the Keytruda trial information came from Merck, which produces Keytruda. However, the story does not appear to include any input from independent sources.", "answer": 0}, {"article": "'Reduced infancy and childhood epilepsy following hypothermia-treated neonatal encephalopathy' by Xun Liu, Sally Jary, Frances Cowan and Marianne Thoresen in Epilepsia\nThe patients' cognitive performance, life quality and life expectancy is also affected by having the condition.\nAt two years, seven per cent of the children had an epilepsy diagnosis, however, far fewer, only two per cent, were on regular antiepileptic drugs.\nThe research found that babies, born after 2007, who received the cooling treatment, had much less epilepsy than before cooling treatment was introduced.\nCooling babies deprived of oxygen at birth (perinatal asphyxia) can reduce the number of children who develop epilepsy later in childhood, according to a new study published in the journal Epilepsia.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources are noted and there is no apparent conflict of interest.", "answer": 1}, {"article": "To learn more about the Society and the field of endocrinology, visit our site at http://www.\n\"The findings indicate the beneficial effects of growth hormone remained long after the treatment ceased,\" Krantz said.\nIn contrast, the rate of fractures rose four-fold in the control group as some of those women were diagnosed with osteoporosis.\nThe Endocrine Society is based in Washington, DC.\nThe researchers continued to follow up with the women for seven years after the growth hormone treatment was halted to monitor their bone density, fractures and perception of their quality of life.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release provide no information on who funded the study. The research was funded by the University of Gothenburg as well as a variety of public grants. The independent nature of the research was worth mentioning.", "answer": 0}, {"article": "Gelsinger suffered from a genetic liver condition kept under control with pills and diet, but he volunteered for the study to help find a cure for infants with a fatal form of his disorder.\n\u201cWe are probably in the greatest innovative period of understanding human disease and how to make cures ever.\u201d\n\nThe concept of gene therapy is straightforward, beautiful even: Fix an illness caused by a faulty gene by replacing or supplementing a healthy new copy of the gene.\nThe most promising candidate was adeno-associated virus (AAV)\u2014a virus that grows in the presence of adenovirus but is a completely different type.\n\u201cAnd other than gene therapy, there was no other way.\u201d\n\nGene therapy is well-suited for treating inherited brain diseases.\nThe AAV9 therapy is so good at slipping into the brain that one can deliver the drug intravenously into the blood, and it passes through the blood-brain barrier to penetrate all areas of the brain.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The writer devotes a big chunk of the story to a discussion of investor excitement regarding gene therapy.\u00a0 So although we do not learn who is funding specific scientists or studies, we do learn the venture firms are providing many millions of dollars to support the development effort. \u00a0The relationship between investors and scientists included as sources in this story is not clear. The story also would have benefitted from quoting\u00a0researchers who are not part of the studies in question.", "answer": 0}, {"article": "Take this test to see how well you're managing your diabetes\n\nThe researchers looked at over half a million people from 50 previous studies on the Mediterranean diet, which included people in Spain, Greece, the U.S., France, Sweden, Italy and Australia, among other countries.\nEckel said obesity is by far the largest issue responsible for the metabolic syndrome.\nPanagiotakos added that the diet includes all main food groups, but in a balanced way.\nBy now, you've probably heard all the buzz about the Mediterranean diet, or perhaps you've tried it.\nThat translates into 2.9 million young people.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Independent perspective provided by a past president of the American Heart Association.", "answer": 1}, {"article": "The main side effects, Vertex said, were headache, upper respiratory tract infections, nasal congestion, rash and dizziness.\n\u201cI\u2019ve been doing clinical trials for 30 years in C.F.\nVertex has not said how much it will charge for VX-770.\nNow, 22 years later, a drug that tries to compensate for the genetic defect might be nearing the market.\nThe company is hoping that by late May it will win approval to sell a new type of drug for hepatitis C, which analysts expect will be a blockbuster.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 0}, {"article": "MONDAY, Nov. 16, 2015 (HealthDay News) -- Breast-feeding a premature infant may help reduce the risk of a serious eye problem known as retinopathy of prematurity (ROP), new research suggests.\nThe studies included more than 2,200 preterm infants, comparing how often babies had been fed human milk or formula, and whether or not they developed ROP.\nIn re-evaluating the studies, Chen's team found that breast-feeding in any amount appeared to reduce the risk of ROP.\nThe takeaway from this study, Llanos said, is to breast-feed as long as possible, if possible.\n\"Human milk feeding potentially plays a strong role in protecting very preterm newborns from any-stage ROP and severe ROP,\" the international team of study authors wrote.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Thumbs up here for interviewing an independent source, Dr. Adolfo Llanos. Although, we question the choice to end the article with the following\u00a0quote from Dr. Llanos\nThe takeaway from this study, Llanos said, is to breast-feed as long as possible, if possible.\nThat\u2019s slightly puzzling, since the stated conclusion in the original study\u00a0is much more tentative\nBased on current limited evidence, in very preterm newborns, human milk feeding\u00a0potentially plays a protective role in preventing any-stage ROP and severe ROP.\nThe story would have probably done better to omit this source\u2019s simplistic conclusion.", "answer": 1}, {"article": "LONDON, May 17 (Reuters) - Psilocybin, the psychedelic compound in magic mushrooms, may one day be an effective treatment for patients with severe depression who fail to recover using other therapies, scientists said on Tuesday.\nThey all went through a full screening process before being allowed to participate and they were fully supported before, during and after they received psilocybin.\nWe\u2019re just learning how to do this treatment.\u201d\n\nMagic mushrooms grow worldwide and have been used since ancient times, both for recreation and for religious rites.\n\u201cPsychedelic drugs have potent psychological effects and are only given in our research when appropriate safeguards are in place,\u201d he said.\nThe patients were given psilocybin capsules during two dosing sessions, seven days apart.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although the funder was mentioned in the press release, that information was not included in the story.\u00a0There also was no outside commentary.", "answer": 0}, {"article": "In a prime time news conference, Obama said that doctors may think: \" 'You know what?\nThe picture is further clouded because not all children with big tonsils have sleep-disordered breathing or frequent throat infections.\nThere have been very few randomized studies on the effects of tonsillectomy for sleep-disordered breathing.\nThat's a far cry from the 1950s and '60s, when tonsillectomy was used to fight frequent sore throats.\nThe doctor recommended a head X-Ray, and the radiologist said that though Tyler's adenoids were enlarged, they weren't that bad.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quotes one physician, and that source is a surgeon We would have liked to have seen more independent sources tapped \u2013 a pediatrician or family medicine doctor would have been helpful.", "answer": 0}, {"article": "Although these trials showed a small reduction in the average number of night-time urinations with Noctiva compared to placebo, more patients treated with Noctiva were able to at least halve their number of night-time urinations, and patients treated with Noctiva had more nights with one or fewer night-time urinations.\nAlthough there are other FDA-approved medications that also contain desmopressin, none of those medications are approved to treat nocturia.\nThe Agency also is responsible for the safety and security of our nation\u2019s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.\nBecause Noctiva is approved only for adults with nocturia caused by nocturnal polyuria, health care providers should confirm overproduction of urine at night with a 24-hour urine collection, if one has not been obtained previously.\n\u201cToday\u2019s approval provides adults who overproduce urine at night with the first FDA-approved therapeutic option to help reduce the number of times a night they wake up to urinate,\u201d said Hylton V. Joffe, M.D., M.M.Sc., director of the Division of Bone, Reproductive, and Urologic Products in the FDA\u2019s Center for Drug Evaluation and Research.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release doesn\u2019t mention that the efficacy trials for desmopressin to treat nocturnal poluria were sponsored by the manufacturer, Serenity Pharmaceuticals.", "answer": 0}, {"article": "At the molecular level, genes related to the cells lining blood vessels were turned on.\nThe researchers conclude that their study, recently published in the journal Brain Stimulation, provides the first experimental evidence that whole-brain LIPUS therapy markedly improves cognitive dysfunctions without serious side effects by enhancing specific cells related to dementia's pathology.\n\"The LIPUS therapy is a non-invasive physiotherapy that could apply to high-risk elderly patients without the need for surgery or anaesthesia, and could be used repeatedly,\" says Shimokawa.\nBut there are currently no curative treatments available for vascular dementia or Alzheimer's disease, the most common causes of dementia.\nThe team, led by cardiologist Hiroaki Shimokawa, found that applying low-intensity pulsed ultrasound (LIPUS) to the whole brain of the mice improved blood vessel formation and nerve cell regeneration without having obvious side effects.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "In the release, the Japan Agency for Medical Research and Development is listed as the funder. However, we note that the study\u2019s supplementary study materials say the research was supported \u201cin part\u201d by the organization, which suggests there may have been other funding sources (though the authors declared no conflict of interest).", "answer": 1}, {"article": "\"Future studies should examine which people or patients may need to limit their intake of saturated fat,\" assistant professor Simon Nitter Dankel points out, who led the study together with the director of the laboratory clinics, professor Gunnar Mellgren, at Haukeland university hospital in Bergen, Norway.\nRather, the \"good\" cholesterol increased only on the very-high-fat diet.\nBoth groups had similar intakes of energy, proteins, polyunsaturated fatty acids, the food types were the same and varied mainly in quantity, and intake of added sugar was minimized.\nIt may be more important for public health to encourage reductions in processed flour-based products, highly processed fats and foods with added sugar,\" he says.\nBut even with a higher fat intake in the FATFUNC study compared to most comparable studies, the authors found no significant increase in LDL cholesterol.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not list funding sources or provide any statement regarding potential conflicts for the principal investigators.", "answer": 0}, {"article": "In a landmark medical clash pitting the diagnostic merits of fancy tech versus vintage exercise machines, the new toys and old ways finished in a dead heat, cardiologists reported Saturday.\nIt is a real testament to how far we\u2019ve come in the treatment of patients with suspected coronary disease,\" said Dr. Steven Nissen, department chair of cardiovascular medicine at the Cleveland Clinic.\nThe 10,000-plus patients, who visited 193 health centers in the U.S. and Canada, had no prior diagnosis of coronary artery disease.\n\"Traditionally, when you come in with chest pain, some sort of stress test or CT angiogram will be performed,\" Nissen said.\nThe rest took stress tests \u2014 either an exercise electrocardiogram, a stress echocardiography or a nuclear stress test, which uses radioactive dye.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Neither the story nor the original press release indicates the presence of conflicts of interest. \u00a0That may be reasonable, as the research was funded by the National Heart, Lung, and Blood Institute of NIH. \u00a0The one outside scientist quoted in the story is clearly described as independent of the study.", "answer": 1}, {"article": "The P-Cure gantry-less system significantly reduces many factors associated with proton therapy including the capital cost of equipment and construction, the size of a single room center or multi-room expandable center and the time from center planning to treatment.\nIt may also deliver less collateral radiation to sensitive organs while enabling greater accuracy in proton beam delivery,\u201d said Michael Marash, Ph.D., founder and CEO of P-Cure.\nWith P-Cure, oncologists can develop a compact, gantry-less proton center for significantly less capital and operating costs, essentially making proton therapy more widely available and attainable.\nThe P-Cure Patient-Centric solution is a paradigm shifting change from the current method of treatment with the patient in the horizontal position.\nP-Cure works both with the existing and new cancer centers to establish advanced proton therapy capabilities.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "It is clear that the release comes from P-Cure, the company that is producing the proton therapy being touted in the release.", "answer": 1}, {"article": "Australian researchers have completed the world's first randomised control trial (RCT) assessing the efficacy and safety of ketamine as a treatment for depression in elderly patients.\nResearchers monitored for mood and other side-effects after each treatment session.\n\"Elderly patients with severe depression face additional barriers when seeking treatment for the condition.\nRepeated treatments also resulted in a higher likelihood of remission or a longer time to relapse, with an overall response and remission rate of 68.8 percent for the patients receiving ketamine treatment.\nMany medications may cause more side effects or have lower efficacy as the brain ages,\" said co-author Dr Duncan George from UNSW Sydney.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources and presence or absence of conflicts of interest are not mentioned.", "answer": 0}, {"article": "In devising their models, the researchers updated assumptions that have cast doubt on the relevance of existing breast-cancer risk calculators, which relied on the experiences of women who got an earlier generation of screening mammograms and were more likely to die of breast cancer than is currently the case. Here, teams of modelers from Erasmus University in the Netherlands, Albert Einstein College of Medicine in New York and Harvard Pilgrim Healthcare assumed that women were getting digital mammograms, which offer improved cancer detection rates at lower radiation dosages than earlier mammographic methods. They took into account improved rates of breast cancer treatment effectiveness, and changing causes of mortality for women older than 50. They also took account of the fact that breast density decreases in older women.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article quotes only one of the lead investigators of the study, and used the same quote found in the news release (see last criterion). Coverage elsewhere often included comments from cancer clinicians and investigators not affiliated with the study, most of whom emphasize the complexity of the risk calculations and the human factors that drive medical decision making. The journal article also included an editorial by a Johns Hopkins University scientist, which offered good information about the quality of the research and other things. It would have helped to cite it. (Full disclosure: HealthNewsReview.org reviewer Joann Rodgers consults for Hopkins.)\nAn article about a new breast cancer modeling tool that may impact future screening guidelines should definitely include quotes from breast cancer researchers and\u00a0clinicians who are not affiliated with the study.", "answer": 0}, {"article": "Moreover, though resting energy expenditure varies with each individual, this increase would yield almost 1 lb.\nThe company's centers of excellence are located in North America and India, whereas its cGMP and HACCP system-compliant manufacturing operations are located at multiple FDA inspected sites in India.\n\"Because capsaicinoids (the component of hot peppers that gives them heat) are hot, it was imperative that we use an ingredient which the subjects could tolerate,\" said Vijaya Juturu, Ph.D., F.A.C.N., one of the lead researchers on the MR Study.\nA recent paper, Capsaicinoids Enhance Metabolic Rate in Normal Healthy Individuals using a Novel Metabolic Tracker Breezing Device-An Open Label Placebo Controlled Acute Study, published in the journal Obesity Open Access discussed the findings of the Metabolic Rate (MR) Study, which demonstrated that an extract from red hot peppers boosted metabolic rate (Chen, et al., 2017).\n\"Since Capsimax is made using a proprietary beadleting technology, OmniBead, which coats the capsicum extract, releasing it only when it reaches the intestines where it is absorbed without discomfort, we were able to deliver beneficial levels of capsaicinoids to our subjects, which made the MR Study possible.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t list any funding sources or potential conflicts of interest. The study states that researchers have no conflict of interest but then provides conflicting information suggesting that\u2019s not true. The study also notes that one of the researchers involved with the study is an employee of the supplement manufacturer and another holds a patent for the device used to measure metabolic changes and also received funding from the supplement manufacturer. Those are two clear examples of conflicts of interest that should have been mentioned in the release.", "answer": 0}, {"article": "Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.\nIt's unclear why the three remaining patients didn't have good improvement, although Dr. Peled notes that two of the three had had temporal headaches for decades before surgery.\nUsing an incision originally designed for another purpose, surgeons can gain direct access to the nerves involved in some types of chronic temporal headache, according to the report by ASPS Member Surgeon Dr. Ziv M. Peled of Peled Plastic Surgery, San Francisco.\nThe technique is a new use of an approach that many surgeons are already familiar with: the Gillies incision, used for surgical repair of cheekbone fractures.\nThe simplified approach using the Gillies incision combines the advantages of other approaches to chronic temporal headache surgery while minimizing the disadvantages, Dr. Peled believes.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release does a good job of disclosing the fact that Dr. Ziv M. Peled of Peled Plastic Surgery is a Member Surgeon of the American Society of Plastic Surgeons (ASPS). It isn\u2019t clear, but it seems the 19 patients mentioned in the release were Dr. Peled\u2019s private patients.\nAlthough we would have liked this to be explicitly stated, we feel this earns a Satisfactory rating.", "answer": 1}, {"article": "Autism is characterized by difficulties in social interaction, communication, and understanding other people\u2019s emotions and behavior.\n\u201cThese results are the best yet in the search for a biological basis in terms of being able to distinguish those with and without the disease,\u201d said Nicholas Lange of Harvard Medical School, who directs the Neurostatistics Laboratory at McLean Hospital in Belmont, Massachusetts.\nCHICAGO (Reuters) - U.S. researchers are closing in on an accurate test for autism, a finding that could lead to earlier diagnosis and treatment.\n\u201cHowever, it has been shown that in the early stages of development, individuals have been aided by intense one-on-one caring to help them with language, social function with their peers and also with emotional problems,\u201d he said.\nBy measuring six aspects of the brain\u2019s circuitry, the test was able to correctly pick out people who had been diagnosed with autism with 94 percent accuracy.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story has no independent sources, and, worse yet, it gives readers the mistaken impression that the lead author of the study is an independent voice. After the lead and setup, the story says. \u201cThese results are the best yet in the search for a biological basis in terms of being able to distinguish those with and without the disease,\u201d said Nicholas Lange of Harvard Medical School, who directs the Neurostatistics Laboratory at McLean Hospital in Belmont, Massachusetts. Doesn\u2019t that sound like someone outside the study explaining why the findings are important? Unless readers latched on to a passing reference to \u201cresearchers at McLean\u201d they might read the entire story thinking Lange was unaffiliated. As CNN points out in its story, Lange actually helped create the MRI being used and would likely stand to benefit financially from its commercial rollout.", "answer": 0}, {"article": "CHICAGO (Reuters) - The hallucinogen psilocybin \u2014 known by the street name magic mushrooms \u2014 may help ease the anxiety that often accompanies late-stage cancer, U.S. researchers said on Monday.\nEverything had to be shut down,\u201d Grob said in a telephone interview.\n\u201cIt was something of a public health crisis.\n\u201cForty to 45 years ago, the culture was going through tremendous upheaval.\nThe treatments were given in random order and neither the doctors nor the patients were told which compound was administered.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Women who take bone drugs for several years have a slightly increased chance of suffering an unusual type of thigh fracture, according to a large Canadian study.\nAnd one preliminary study, published along with the Canadian findings in JAMA, hints that the common heart medication nitroglycerin might also boost bone health.\n\u201cThe bad news is that overstating the levels of risk of side effects with these drugs \u2014 which the media have been doing for some time now \u2014 has led people to stop the drugs when they should be taking them,\u201d said Dr. Ethel S. Siris, who heads the Toni Stabile Osteoporosis Center at Columbia University in New York.\nThe findings add to earlier concern over the medicines, called bisphosphonates, whose U.S. labels have been required since October to include a warning about the thighbone fracture risk.\n\u201cIf you\u2019re taking the drugs and you\u2019ve been on them for a while, but aren\u2019t sure if you\u2019re at high risk, you should ask your doctor about it,\u201d Park-Wyllie advised.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Reuters gives us two voices in this piece, including a study author and a treating physician. We are not told anything about whether the treating physician has any ties to the industry, but we couldn\u2019t find any in a brief online search.", "answer": 1}, {"article": "San Francisco--A new study, presented today at the Society of NeuroInterventional Surgery's (SNIS) 15th Annual Meeting, found that new stroke imaging technology could decrease delays in care by up to 60 minutes, giving patients a better chance at making a full recovery.\nThis study suggests that in the future, stroke patients can bypass the CT scan or emergency department and go directly to the angiosuite for imaging and proper care.\nThe lead PI on this study, Professor Vitor Mendes Pereira, concluded by saying, \"By reducing intra-facility transfer times, patients can receive EVT treatment sooner, which can significantly impact patient outcomes\".\nThe time required to transfer a patient from their CT scan to the operating room could delay EVT by as long as 60 minutes.\nPreliminary results show that the cone beam imaging software compares favorably with baseline and follow-up CT scans.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not tell readers who funded the research, who developed the software, or whether there are any conflicts of interest among the researchers.", "answer": 0}, {"article": "The efficacy and safety analyses with tramiprosate published in JPAD reveal a therapeutic effect in patients who are carriers of APOE4 after segmenting them from the larger, non-genetically-defined study population in the Phase 3 clinical program, involving more than 2,000 AD patients in North America and Europe.\nPeople who inherit one copy of the \u03b54 allele, APOE4 heterozygotes, have an increased chance of developing the disease; those who inherit two copies of the allele, APOE4 homozygotes, are at even greater risk and tend to have more aggressive disease.\nThe main adverse events were gastrointestinal (nausea, vomiting and weight loss), which were mild or moderate in severity.\nThe \u03b54 allele is significantly overrepresented in the Alzheimer's disease population compared to the general population: up to 65 percent of Alzheimer's patients carry one or two copies of the \u03b54 allele compared to about 25 percent of the general population.\nAPOE encodes for a protein called apolipoprotein E, which combines with fats to form lipoproteins that can be moved throughout the body.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release is clearly labeled as written on behalf of Alzheon, the manufacturer of the compound. The release further identifies the sources quoted as either employees of Alzheon or as investigators at one of the study\u2019s research sites.", "answer": 1}, {"article": "U.S. experts familiar with the study call it interesting but say the treatment needs more study and wonder if it would catch on in the U.S.\nDec. 13, 2010 -- Acupuncture treatments to treat one type of lazy eye proved as good as the traditional patching of the eye used to help the eyes work together, according to a new study.\nSo Dennis Lam, MD, a researcher at the Joint Shantou International Eye Center of Shantou University and Chinese University of Hong Kong, and his colleagues evaluated 88 children, ages 7 to 12, with the condition known as anisometropic amblyopia, in which there is a difference in the degree of nearsightedness or farsightedness between the two eyes.\nBut at 25 weeks, the resolution rates were similar in the two groups: 30% of the patched group and 42% of the acupuncture group.\n''These results suggest that the treatment effect of acupuncture is equivalent to that of patching for anisometropic amblyopia in older children,\" Lam writes.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story brought perspective from two independent experts who helped put the results in the appropriate context.\u00a0Unfortunately, it\u00a0didn\u2019t point out that some of the study investigators may have a financial incentive to promote acupuncture because they are trying to patent needle placement sites related to vision. The competing coverage also\u00a0failed to\u00a0identify this conflict.", "answer": 0}, {"article": "\u201cWill these peptides actually induce tolerance in people?\n\u201cThis technology could be very effective,\u201d says Timothy Coetzee, PhD, chief research officer for the National Multiple Sclerosis Society.\nThe study was funded by grants from the National Institutes of Health, the Myelin Repair Foundation, the Juvenile Diabetes Foundation, and the Australian government.\nWhat remains to be seen is whether the researchers have picked the right proteins that might turn off the disease in humans, he says.\nIt\u2019s rational, but we won\u2019t know until we get it into people,\u201d says Coetzee, who was not involved in the research.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story relies mostly on the two lead researchers on the project, but it does bring in some important context from the chief researcher for the National Multiple Sclerosis Society, who provides a cautious tone at the start of the story. It also explains how the study was funded.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061015/23addict.b.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story included two quotes from investigators\u00a0 involved in investigation of this drug.\u00a0\u00a0", "answer": 1}, {"article": "A large, new study may be reassuring to women considering mastectomies because of a history of breast cancer in their families.\n\nStanford University researchers affirmed that women with mothers and sisters who carry one of the BRCA gene mutations but who aren't carriers themselves don't have an especially heightened risk of breast cancer.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two outside sources were consulted, and there didn\u2019t appear to be any unidentified conflicts of interest.", "answer": 1}, {"article": "But the procedure had never been done in people.\nThe microscopic bubbles \u2014 roughly the size of red blood cells \u2014 had previously been injected into a vein, along with a chemotherapy drug called liposomal doxorubicin and a tracing molecule.\nOn Tuesday, Dr. Todd Mainprize, a neurosurgeon at Sunnybrook Health Sciences Centre and the University of Toronto, announced at a news conference that he had successfully breached the blood-brain barrier in a 56-year-old Canadian woman whose brain tumor, diagnosed six years ago, had recently begun to grow.\nSucceeding in getting drugs across the barrier is \u201ca huge achievement\u201d said Dr. Nathan McDannold, a radiologist at Boston\u2019s Brigham and Women\u2019s Hospital, who has been working to open the barrier with ultrasound since he first accomplished the feat 15 years ago in animals.\nIn the trial at Sunnybrook \u2014 funded by the Virginia-based Focused Ultrasound Foundation \u2014 nine others are slated to receive the same procedure.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several experts who, according to the story, were outside of the group that did the research were quoted. However, two of these sources are\u00a0involved with the funding organization \u2014 the Focused Ultrasound Foundation. These individuals are listed as experts on the foundation website.\nAlthough the funding source is a foundation, it receives support from numerous industry sources (as well as individuals and other sources). In addition, at least one of these experts (Ghanouni) leads other foundation-support research efforts. It\u2019s possible that experts associated with this foundation may have an incentive to cast this foundation-supported research in a positive light. The story could have alerted readers to these links or, even better, tapped into a wider network of independent experts to provide a more critical evaluation of the research.", "answer": 0}, {"article": "March 7, 2011 -- Traditional Chinese acupuncture may be useful in reducing the severity of hot flashes and other symptoms of menopause, a new study suggests.\nHalf of them received traditional acupuncture treatment.\nLevels of estrogen and other hormones were measured before the study and after the first and last acupuncture sessions in both those receiving real and sham treatments.\nThose in the comparison group were treated with shams needles at the same acupuncture points.\nThe rest were treated with \u201csham\u201d acupuncture needles that were blunted and did not penetrate the skin.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No one was quoted.\u00a0 No independent expert evaluation.", "answer": 0}, {"article": "Treatment continued at least until the birth of the baby.\nThe effects seemed to be strongest early on after birth,\" said study senior author Usha Ramakrishnan, an associate professor in the Hubert Department of Global Health at the Rollins School of Public Health at Emory University in Atlanta.\nMONDAY, Aug. 1, 2011 (HealthDay News) -- When women take a supplement of the omega 3 fatty acid DHA during pregnancy, their babies have fewer cold symptoms and shorter illnesses, new research indicates.\nAt times, however, babies in the DHA group experienced longer duration of rashes and vomiting, the study authors noted.\n\"The data suggested that for most of the symptoms we looked at, duration of symptoms was less when mothers received DHA.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story contained a quote from a New York OB/GYN (who did not appear to have a role in the study reported on) indicating that she recommends that her patients take DHA, although her recommendation differed from that used in the study.\nAs the study was about the possible beneficial impact that prenatal supplementation has on the infant during the first months of life, it would have been more useful to include insight from indiviiduals with expertise in infant rather than maternal health.\nIt is a little troubling that the previous studies of the group of infants in the study reported on were not mentioned. \u00a0The outcomes taken together provide a better picture of the impact of supplementation with DHA.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Monitoring high-risk pregnancies with ultrasound tests may help prevent some fetal and newborn deaths, a new research review finds.\nIn some cases, early delivery may be the best course, but it is unclear whether other options \u2014 such as bed rest or tighter blood pressure control in a woman with high blood pressure \u2014 are effective.\n\u201cThere is no evidence to suggest that it should be done in low-risk women,\u201d Alfirevic said.\nHowever, with Doppler an established technique for monitoring high-risk pregnancies, Alfirevic said it is very unlikely that any future studies will test Doppler against no Doppler \u2014 as most studies in this review did.\nThere have been concerns that abnormal findings on Doppler ultrasound may prompt doctors to sometimes unnecessarily intervene \u2014 by, for instance, performing a cesarean section.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\n\n \nThere is no information in the story that appears to come from an independent source. Comments from experts in the field would have helped put the authors\u2019 comments into perspective. \n", "answer": 0}, {"article": "To find out, they studied 79 adults with chronic insomnia.\n\u201cMore consolidated sleep is more refreshing.\u201d\n\nBased on questionnaires and sleep diaries, the researchers found that two out of every three participants receiving the behavioral intervention responded favorably by the end of 4 weeks, while just one out of every four receiving the printed material experienced substantial improvement in their sleep.\nNEW YORK (Reuters Health) - A few short visits and phone calls with a nurse may be enough to help insomniacs get their zzz\u2019s, suggests a new study of sleep-deprived older adults.\nThe key ingredient in the therapy, according to lead researcher Dr. Daniel Buysse of the University of Pittsburgh School of Medicine, was a simple, somewhat counter-intuitive lesson: \u201cWhen you are sleeping poorly, the most important thing you can do is spend less time in bed.\u201d\n\nInsomnia affects about one in every five Americans, rising to one in three among the elderly, and has been linked to a range of physical problems, from accidents to hypertension.\nYet the time and resource-intense strategy \u2014 usually involving between six- and eight hour-long appointments with a clinical psychologist - is not widely available and its cost, generally hundreds of dollars, is prohibitive for many.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\nThe story includes comments from the author of a commentary article that appeared in the Archives of Internal Medicine along with the research article. In the disclosure section of their article, some of the researchers reported ties to pharmaceutical companies, but since this trial tested a non-drug approach and was funded by public agency and academic grants, it seems reasonable to consider the industry links as not being relevant to this study.", "answer": 1}, {"article": "(Boston) -- To date, there are no methods that can quickly and accurately detect pathogens in blood to allow the diagnosis of systemic bloodstream infections that can lead to life-threatening sepsis.\nThe diagnostic assay is built on FcMBL, a genetically engineered pathogen-binding protein previously developed by Ingber and Michael Super, a Wyss Senior Staff Scientist who co-leads the Institute's pathogen-detecting effort.\nWe are currently working to ready it for high-throughput use in clinical and point of care situations and to accelerate it even further,\" said Mark Cartwright, Ph.D., a Staff Scientist at the Wyss Institute and a lead-author on the study.\nAnd it can more specifically identify patients who have excessive inflammation due to systemic infection, rather than other causes,\" said Donald Ingber, M.D., Ph.D., the Wyss Institute's Founding Director, the Judah Folkman Professor of Vascular Biology at Harvard Medical School and the Vascular Biology Program at Boston Children's Hospital, and Professor of Bioengineering at the Harvard John A. Paulson School of Engineering and Applied Sciences.\nNow, a Wyss Institute team led by Donald Ingber reports in eBioMedicine that it has filled this void with a rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes the funding sources for the research. But the release doesn\u2019t mention the financial stake the researchers have in the development and eventual marketing of the test under a start-up called Opsonix. Those ties include equity holdings and patents. According to the published study,\n\u201cD.E.I. and M.S. hold equity in Opsonix Inc., and are members of its scientific advisory board. M.C. is a consultant for Opsonix Inc. D.E.I. also holds equity in Emulate Inc., and chairs its scientific advisory board. D.E.I., M.S., M.C. and M.R. are inventors on patent applications WO2013012924, WO2011090954, WO2015009734, WO2013130875. J.T., and N.G. are inventors on patent application WO2015009734. A.W. is an inventor on patent applications WO2013012924, WO2013130875.\u201d", "answer": 0}, {"article": "The other trial had nearly identical results.\n\"The ability of these potential drugs to treat individuals with a single F508del mutation means that more people than ever before could benefit,\" said Dr. Michael Boyle, senior vice president for therapeutics at the foundation.\nThis is the first time, Rowe said, that CFTR modulator therapy has \"pushed the needle\" for patients with one F508del mutation.\nThen there's the 30 percent of CF patients who carry only one copy of F508del, plus another defect known as a \"minimal-function\" mutation.\nNow the questions are whether the improved lung function can be sustained, and whether the drugs prevent symptom exacerbations and other complications, wrote Dr. Fernando Holguin, of the University of Colorado, Aurora.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story reported that Vertex Pharmaceuticals, Inc. is developing both experimental drugs. However, it didn\u2019t report the full extent of the conflicts of interest involved in these trials. A majority of the study authors \u2014 including one quoted in the story, Steven Rose, MD \u2014 reported receiving grants, personal fees, and other compensation from Vertex Pharmaceuticals during the trial period, according to disclosures filed with the journal. In addition, one of the authors is a Vertex employee who holds a relevant patent.\nIn addition, we think that the story would have benefited greatly from more independent sources to weigh in on the bold claims being made.", "answer": 0}, {"article": "All compared people taking at least 200 milligrams of Vitamin C each day with people taking placebos.\nFor the rest of us, the chances of vitamin C warding off colds is so slight, the lead researcher concludes it \"doesn't make sense to take vitamin C 365 days a year to lessen the chance of catching a cold.\"\nThe federal Centers for Disease Control and Prevention says the best bit of cold prevention involves not taking a pill, but doing simple, if boring, things such as washing your hands, thoroughly and often.\nThe message from the researchers, Senay observed, is that, if your activity profile doesn't match that of people like these, vitamin C won't keep colds away.\nAnd the results, just published by The Cochrane Library, are likely to disappoint people who swear by vitamin C.\n\nAccording to their analysis, daily vitamin C basically had no effect on the incidence of the common cold in the general population, except for very specific groups of people, all of them small groups.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The\u00a0segment accurately\u00a0indicates the\u00a0high crediblity of the Cochrane\u00a0group, and there appear to be no underlying conflicts of interest that would call the conclusions into question. \u00a0", "answer": 1}, {"article": "(CNN) -- Most heart attacks strike with no warning, but doctors now have a clearer picture than ever before of who is most likely to have one, says Dr. Arthur Agatston, a Miami cardiologist and author of the best-selling South Beach diet books.\nHigh-risk patients already receive such aggressive treatment as cholesterol-lowering statin medication, but many doctors don't think low-risk patients need to incur the expense or small dose of radiation that comes with a coronary calcium scan.\n\"One of the best-kept secrets in the country in medicine is the doctors who are practicing aggressive prevention are really seeing heart attacks and strokes disappear from their practices.\nThese new tests give patients a chance to make major changes in their diet and lifestyle, and give doctors an opportunity to treat them with medication.\nAgatston thinks the coronary calcium scan should be routinely scheduled at age 50, like a colonoscopy, or earlier for people with family histories of heart disease.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Considering that the United States Preventive Service Task Force and other major medical groups do not recommend coronary calcium scoring or carotid ultrasound screening for most people, this story should have included comments from someone explaining that consensus opinion.", "answer": 0}, {"article": "But you can't make any conclusions about definite health benefits\" based on the study findings, said lead author Suzanna M. Zick, a naturopathic physician and research associate professor at University of Michigan Medical Center, Ann Arbor.\nThere's more on ginger at the U.S. National Library of Medicine.\nThe amount of ginger in the pills is equivalent to 20 grams of raw ginger root, the authors said.\nIf more funding becomes available, the researchers hope to launch a larger study, Zick said.\nIt's already clear that people with inflammatory conditions such as inflammatory bowel disease are at higher risk of colon cancer, he noted.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One independent source was quoted.", "answer": 1}, {"article": "The procedure, called a prostatic urethral lift, does not improve flow as much as surgery, in which a physician cuts away some of the inside of the prostate to allow better flow. But the lift procedure and recovery are much quicker, with no hospital stay and fewer complications. And patients who get the sutures can always come back for surgery later.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included at least one independent source, and we didn\u2019t detect any conflicts of interest that should have been disclosed. The story was heavy on positive patient anecdotes, which may not be reflective of the typical patient experience.", "answer": 1}, {"article": "\u201cThe big question is, how can we make sure that everybody responds?\u201d\n\nThe Duke team compared their 61 volunteers to similar past patients who did not get the treatment.\nThe medical team used polio viruses already weakened and altered for use in polio vaccines, and genetically engineered them to carry parts of a common cold virus, called a rhinovirus, known to be attracted to glioma cells.\nIt\u2019s no miracle cure \u2014 only about 20 percent of patients with gliomas were helped \u2014 but some are alive six years later, the team reported in the New England Journal of Medicine.\nThe patient who had the hemorrhage suffered aphasia but was still alive more nearly five years later.\nAbout 80,000 people a year are diagnosed with a brain tumor, and about 24,000 of those are malignant.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story has no independent sources, and does not mention that seven study authors have a financial tie with a firm that holds the patent.", "answer": 0}, {"article": "MORE: You Asked: Should I Take Probiotics?\nThose changes in brain activity \u201csupport the notion that this probiotic has anti-depressive properties,\u201d the authors wrote in their paper.\n\u201cWe know that one part of the brain, the amygdala, tends to be red hot in people with depression, and it seemed to cool down with this intervention,\u201d says McIntyre, who was not involved in the new research.\n\u201cThey seem credible to me, and they might hint that there are other mechanisms, besides just inflammation, linking the GI tract to the brain,\u201d he says.\nThat\u2019s why Dr. Roger McIntyre, professor of psychiatry and pharmacology at the University of Toronto, thinks the fMRI findings are the most interesting and important aspect of the new study: they signal that the probiotics may really be working on the brain itself.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There is a discussion early\u00a0in the story that the research was funded by Nestle. The story\u00a0also incorporates opinions from a research scientist who was not involved with the study who provides additional\u00a0insights about the study\u2019s findings.", "answer": 1}, {"article": "The CDC says colonoscopy could reduce the number of colorectal cancer cases by as much as 60 percent.\nSuch highly specific screening may allow doctors to detect more abnormal growths, called polyps, when they are as small as .10 mm, so they can be removed before they become full-blown cancer tumors.\nThis next step in virtual colonoscopy, called \"immersive colonoscopy,\" projects 3D images of the colon large enough to fill the walls of a room.\n\"This will allow the physician to view 100 percent of the surface including lesions, which are hidden behind folds maybe seen on the side and back walls.\"\nThe CDC says colonoscopy may also be recommended for people experiencing stomach pain, aches or cramps that don't go away, unexplained weight loss and blood in the stool.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The CBS story quotes only one source, Dr. Arie Kaufman, and does not disclose the fact that he also happens to have invented the technology. An independent expert, who could have talked about the limitations of virtual colonoscopy and the benefits of traditional colonoscopy, would have been helpful.", "answer": 0}, {"article": "Scientists think testosterone has some protective effect on the heart.\n\"What we can do with these results is to raise a flag with hormone treatments,\" said Mieke Van Hemelrijck, a cancer epidemiologist at King's College in London and the study's lead researcher.\n\"For the vast majority of men, the benefits of hormone therapy are absolutely clear: it can halt the disease or stop it for years,\" she said.\n\"There is no definitive evidence, though the risk of heart problems is definitely something doctors should consider when prescribing hormone treatment,\" Thun said.\nExperts said the findings could make doctors think twice before prescribing the standard hormone treatment to men with prostate cancer, particularly if they are at risk of heart disease.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\n\nThe story included quotes from two independent experts but not much balance therein.\u00a0 One seems to inappropriately exaggerate the potential benefit of hormone therapy and the other seems to minimize the potential for harm from its use.\u00a0 The story should have also noted the sources of funding for the study. According to a news release, the study was funded by the Swedish Research Council, the Stockholm Cancer Society and Cancer Research UK. Nonetheless, the story barely meets the expectation for this criterion. ", "answer": 1}, {"article": "Previous studies have also suggested that beetroot\u2019s blood-pressure-lowering effects may not be as strong in women.\n\u201cThat effect might be even greater over the long term if they are drinking it day upon day.\u201d\n\nResearchers say that drop may seem small, but on a public health level a reduction like that would equate to a 10% reduction in deaths due to heart disease .\nThe study shows that within hours of drinking it, beet juice lowered systolic blood pressure (the top number in a blood pressure reading) by an average of 4-5 points among a small group of healthy men .\n\u201cIt\u2019s promising that we can see an effect from a single dose,\u201d says researcher Leah Coles, PhD, a research fellow at the Baker IDI Heart and Diabetes Institute in Melbourne, Australia.\nIn this case, Coles says it may be partially explained by the fact that the women in the study tended to be older, and many were on prescription medications, such as oral contraceptives.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an expert not affiliated with the study, but this researcher is a well known advocate for increased nitrate consumption from foods. (See this article he wrote on the topic.)\u00a0\u00a0We suggest that\u00a0if only one source was going to be quoted, there were probably better choices for a truly\u00a0objective comment about the results.\nThat issue aside, we must\u00a0flag the story for not mentioning that the research was commercially funded by the\u00a0Sunraysia Natural Beverage Company, which sells beetroot juice.", "answer": 0}, {"article": "\u2022 None New guidelines outline how to handle back pain \n\n\n\nIn the study, 320 adults with moderate to severe back pain received one of three approaches over 12 weeks:\n\u2022 Education about how to cope with back pain\n\n\n\nYoga was just as effective as physical therapy -- and both groups were about 20 percent less likely to use pain medication than patients receiving education alone.\n\"Yoga was as effective as physical therapy for reducing pain intensity,\" Saper said.\n\"I'm much more comfortable with movement,\" she told CBS News.\nDr. Robert Saper at Boston Medical Center is one of the authors.\n\"Perhaps most importantly reducing pain medication use.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources were quoted.", "answer": 0}, {"article": "Welch J, Petti A, Miller C, Fronick C, O\u2019Laughlin M, Fulton R, Wilson R, Baty J, Duncavage E, Tandon B, Lee Y-S, Wartman L, Uy G, Ghobadi A, Tomasson M, Pusic I, Romee R, Fehniger T, Stockerl-Goldstein K, Vig R, Oh S, Abboud C, Cashen A, Schroeder M, Jacoby M, Heath S, Luber K, Janke M, Hantel A, Khan N, Sukanova M, Knoebel R, Stock W, Graubert T, Walter M, Westervelt P, Link D, DiPersio J and Ley T. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes.\n\u201cThe findings need to be validated in a larger trial,\u201d Ley added, \u201cbut they do suggest that TP53 mutations can reliably predict responses to decitabine, potentially prolonging survival in this ultra high-risk group of patients and providing a bridge to transplantation in some patients who might not otherwise be candidates.\u201d\n\nIn an accompanying editorial, Elihu Estey, MD, an AML expert at the University of Washington Medical Center and Fred Hutchinson Cancer Research Center in Seattle, noted that AML is not one disease but many, each driven by different genetic mutations.\nSome people live a year or two and with a good quality of life, because the chemotherapy is not too toxic.\u201d\n\nRoughly 10 percent of AML patients carry TP53 mutations in their leukemia cells.\nThis information opens the door to using decitabine in a more targeted fashion to treat not just older patients, but also younger patients who carry TP53 mutations.\u201d\n\nFirst author John Welch, MD, PhD, an assistant professor of medicine, added: \u201cIt\u2019s important to note that patients with an extremely poor prognosis in this relatively small study had the same survival outcomes as patients facing a better prognosis, which is encouraging.\nThe current study involved 116 patients treated with decitabine at the Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital, and at the University of Chicago.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding sources for this trial are clearly stated. However, the conflicts of interest disclosed in the published paper are not included in the news release. The disclosure states:\n\u201cDr. Uy reports receiving fees for serving on an advisory board and clinical-trial support from Novartis; Dr. Jacoby, receiving consulting fees and fees for end-point adjudication from Quintiles and clinical-trial support from Sunesis Pharmaceuticals; and Dr. Graubert, receiving consulting fees from Agios.\u201d\nEach of the companies mentioned market cancer drugs so its appropriate to include the researchers\u2019 financial ties with them in the release.", "answer": 0}, {"article": "Bangalore said this is critically important because \"compliance is big issue with our patients.\"\nThe idea that ACE inhibitors are more effective than ARBs was based on comparing studies on ACE inhibitors going as far back as the 1980s and into the 1990s with newer studies on ARBs in the 2000s.\nThe one difference they found was that ARBs tend to be better tolerated by patients, meaning that they have fewer side effects or result in fewer adverse events.\n\"The patients in the '80s and '90s were a higher-risk group than those in the 2000s,\" Bangalore explained.\n\"With hypertension they are on these medications for decades, and it's important to choose one that will be the most tolerable,\" he said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The single quoted source in this story is the main author of the study and the story fails to mention that some authors have ties to major pharmaceutical firms which manufacture these kinds of drugs.\u00a0 While that linkage doesn\u2019t mean the research is definitely biased, writers should disclose that information when available.", "answer": 0}, {"article": "PHILADELPHIA - In a finding that suggests the potential for practice change that would reduce the use of antibiotics in dermatology, researchers in the Perelman School of Medicine at the University of Pennsylvania have found the diuretic drug spironolactone may be just as effective as antibiotics for the treatment of women's acne.\nAs a result, some dermatologists use it to treat female acne patients.\nIt blocks the effects of male hormones like androgen, meaning it's not an option to treat acne in men.\nAcne is one of the most common diseases in the world.\nHowever, those same anti-hormonal effects can help prevent acne outbreaks in women.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not provide the name of the study funders.", "answer": 0}, {"article": "For more information about the School of Medicine, see http://www.\nMepolizumab is already approved by the Food and Drug Administration (FDA) to reduce symptom flare-ups and improve quality of life in eosinophilic asthma.\n\"These patients already have been given every treatment we have to offer them and are still having flare-ups that significantly interfere with their quality of life and can lead to deterioration in lung function and higher mortality,\" said Sciurba.\nThe patients with high eosinophil counts who received mepolizumab had a statistically significant 18 percent lower rate of moderate/severe exacerbations (1.4 per year compared to 1.7 per year) than those in the placebo group.\nThe time to the first exacerbation also was higher with mepolizumab than placebo, but only in the high eosinophil group.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release identifies GlaxoSmithKline as the funder of both trials and names numerous GSK employees as authors of the study. The latter makes it possible\u00a0that\u00a0the biases could have been introduced in the writing process.", "answer": 1}, {"article": "In some of the test groups, overall success rates were fairly low, Lerman noted, but the study was conducted during the Great Recession, a time when financial stress may have depressed the chances of succeeding for everyone, regardless of which approach was used.\nBut the patch costs less and has fewer side-effects than varenicline (including nausea, difficulty sleeping and abnormal dreams), so the researchers concluded that slow metabolizers should be put on the patch.\nThe ratio of two metabolites, or byproducts, of the body's processing of nicotine allows easy identification of the two groups.\nThe researchers, led by Caryn Lerman, a professort of psychiatry, divided 1,246 subjects into slow metabolizers of nicotine and normal metabolizers of the addictive chemical, based on the length of time it took for them to rid their bodies of the drug.\nThis may seem like common sense, but no one had ever tested it before, she said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We appreciate that this story took the time to interview one of the study authors, who provided useful context. However, one other perspective, at least, would have been great and might have yielded many of the details we wish this story had included. In addition, the story could have mentioned that the medication used in the study was provided by Pfizer \u2014 a detail noted in this press release.", "answer": 0}, {"article": "Locke said about 13 percent of patients in the trial had a severe side effect known as cytokine release syndrome, which produces high fevers, low blood pressure and other flulike symptoms.\nOnce the modified cells are returned to the patient, their numbers expand exponentially as they become an army of cancer fighters.\nThis type of cancer begins in the immune system and can be fast- or slow-growing, the FDA noted.\nAbout 600 patients in the United States fall into that category every year.\n\u201cThe doctors were saying, 'Go see an attorney and get your life in order,' \" the 64-year-old Realtor recalled.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources in this story. It would have benefited greatly from at least one outside voice commenting on the importance of the findings.", "answer": 0}, {"article": "\"All clinical trials to date have failed due to side effects ranging from stroke, skin fibrosis and cardiovascular issues.\n\"Our compound only locks the collagen -degrading CatK activity, preventing the unregulated breakdown of collagen in bones without any other negative impacts.\"\nUsing a compound derived from red sage, UBC researchers have found a way to selectively block an enzyme called Cathepsin K (CatK), which plays a major role in the breakdown of collagen in bones during osteoporosis.\nMost drugs in development have been so called active site-directed inhibitors, which act like master keys and lock the entire enzyme, blocking both its disease-relevant functions such as collagen degradation and its other normal functions.\n\"CatK is a multifunctional enzyme with important roles in other parts of the body and we think completely blocking it is what causes unexpected side effects in other drugs,\" said Preety Panwar, a research associate in the Br\u00f6mme lab.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "On EurekAlert!, where the news release is hosted, we\u2019re told that the study was funded by Canadian Institutes of Health Research grants and a Canada Research Chair award. We encourage news releases to include funders in the body of the release, too.\nThe authors listed no conflicts of interest in the published study.", "answer": 1}, {"article": "The CDC says the next step is to fully review all the data and begin to develop guidelines for the use of these drugs in heterosexual men and women here in the U.S.\nOn average, patients were followed for a year although some were followed for about three and a half years.\nThe risk of infection was reduced 63% overall, but for participants who actually got the drugs, that risk decreased by 78%.\nIn fact, an interim review of the Partners data on effectiveness was so compelling that the trial was stopped early and the placebo arm was discontinued.\nPartners PrEP and the TDF2 study have now expanded that finding by demonstrating the effectiveness of PrEP in heterosexual women and men.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "At least one independent source is quoted, and there don\u2019t appear to be any conflicts of interest that should have been pointed out to readers.", "answer": 1}, {"article": "For more information, visit http://www.\n\"The aim is to target the thinking abnormality we see in patients with MDD - that of perseverating, ruminating, obsessing, dwelling on the negative - by activating these two nodes (emotion processing and cognitive control) simultaneously.\nThe underlying mechanism for MDD that the intervention targets involves an imbalance in the activity of specific brain regions: individuals with MDD show hyperactivity of neural systems involved in emotion processing, such as the amygdala, coupled with decreased activity of systems involved in cognitive control and emotion regulation, such as the prefrontal cortex.\nErik Lium, PhD, Senior Vice President at MSIP, said, \"We strongly believed in the potential of this technology based on early trials at Mount Sinai, and are pleased with our commercial partnership with Click Therapeutics.\nThe amygdala processes incoming emotionally salient stimuli, whereas the prefrontal cortex, as the executive center of the brain, decides whether the incoming stimuli are noteworthy.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We were glad to see the for-profit entity, Click Therapeutics, clearly labeled as a contributor to the research and employer of at least one of the investigators.\nBut we would have liked a clearer explanation of conflicts. Do any of the study authors participate in patents related to this work? How might\u00a0researchers benefit financially? The study presentation does disclose they hold patent applications.\nExcerpt:\n\u201cMount Sinai Innovation Partners (MSIP), the commercialization-arm of the Icahn School of Medicine at Mount Sinai, has been a key partner in this development.\u201d", "answer": 1}, {"article": "The company said high levels of the protein might spur the immune system to attach the body\u2019s own tissues.\n\u201cThe question was, \u2018Can you prove in a very large trial what we\u2019ve proven here?\u2019 \u201d\n\nThe 865 patients in the trial, who were mainly in Asia, South America and Eastern Europe, received either Benlysta or a placebo in addition to the drugs they were already taking.\n\u201cAnd we are in a field where we haven\u2019t even had anything fair.\u201d\n\nBenlysta, which is given by infusion once every four weeks, inhibits the action of a protein in the body called B-lymphocyte stimulator, which helps B cells in the blood respond to infections.\nOne recent study estimated that 322,000 Americans definitely or probably have systemic lupus erythematosus, the most common form of the disease and the one against which Benlysta was tested.\nIf Benlysta gets to market, it will be the first drug from the company, and one of the first in the industry, to result from genomics.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included quotes from a company spokesperson, a clinician who is a consultant for the company, and a clinician with expertise in lupus who does not appear to have overt ties with the company. \u00a0The story would have been more informative to readers had several clinicians with expertise in treating people with lupus been interviewed as part of this story. \u00a0The comments of those involved with drug development or promotion have limited credibility.", "answer": 1}, {"article": "* Anorexia among most common psychiatric disorders in girls\n\nLONDON, March 7 (Reuters) - Scientists have for the first time reported successful use of a brain-stimulating implant to help patients with severe anorexia whose condition had not improved with other treatments.\nThey implanted electrodes into the area and connected them to a pulse generator under the skin.\nThe patients, all women, were aged between 24 and 57 and had had anorexia for between four and 37 years.\nUnder previous therapies, none had shown progress.\nThe devices were activated 10 days later and researchers measured changes in the patients\u2019 mood and anxiety to help find the correct level of stimulation.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted two independent experts.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070805/13folate.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "In addition to the first author of the study, quotes from several clinicians who were not involved with the present hypothesis paper but who had expertise about folate, were\u00a0included in this story.", "answer": 1}, {"article": "Reductions in pancreas, stomach and brain cancers were difficult to quantify because of smaller numbers of deaths.\nPeter Elwood, an expert on aspirin from Cardiff University\u2019s medical school who was not involved in this study, described aspirin as \u201ca remarkable drug.\u201d\n\n\u201cThis risk of a bleed is so small compared to the benefits,\u201d he told reporters.\nAspirin protected people against gastrointestinal cancers the most, the study found, with rates of death from these cancers around 54 percent lower after five years among those who took aspirin compared to those who did not.\nIn Rothwell\u2019s study, published in The Lancet, researchers found the 20-year risk of death was reduced by about 10 percent for prostate cancer, 30 percent for lung cancer, 40 percent for colorectal or bowel cancer and 60 percent for oesophageal cancer in those taking aspirin.\nPrevious studies have found taking aspirin can cut the risk of developing colon or bowel cancer and suggested it does so by blocking the enzyme cyclooxygenase2 which promotes inflammation and cell division and is found in high levels in tumors.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Technically, this story meets a strict interpretation of the first part of this criterion by including independent experts, even as it grossly violates the spirit. All of the comments are from cheerleaders for aspirin. Experts with a different perspective are left out.\nThe story also fails to report the consulting relationships that some of the study authors have had with pharmaceutical companies.", "answer": 0}, {"article": "[Dear Science: How many germs are actually on a toilet seat \u2014 and should I care?]\nParasites are no joke.\nIt limits its consumption of blood to a few drops a day and doesn't leave its offspring scattered all over its host's gut.\nShe wouldn't go so far as to call parasites good.\nOnly so many people are willing to have a parasite put inside them for science.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources are cited.", "answer": 0}, {"article": "The correlation of the panel blood test results with Gleason Score shows great promise in this regard.\nThe tests are based on the technology platform of Nucleosomics\u00ae, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.\nOther risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic products Volition might develop; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission.\nFor more information about Volition, visit Volition's website https://volitionrx.com/\n\nor connect with us via:\n\nThe contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document.\nCommenting on the results, Principal Investigator, Professor Thierry Roumeguere, Head of Urological Services, Erasme Hospital, Brussels, Belgium said \"A non-invasive test to help in the risk stratification of men with suspected or actual prostate cancer will be a major step forward in the management of this disease.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Although it is clear that this study is funded by a company hoping to market a new blood test and that most of the quotes come from company employees, the release should have explained the relationship between the company and the principal investigator. Did the company just provide funding for the study? Were there direct payments to the researchers, including consulting or lecturing fees outside of the study budget? What was the role of the company in designing the study and reporting the results?", "answer": 0}, {"article": "\"There is a growing sense that VE [vasogenic edema] or ARIA [amyloid-related imaging abnormalities] is a manageable side effect and may actually be a sign that the drug is clearing amyloid from the brain and the blood vessels,\" said Salloway.\n\"I think it is too early to tell from the data from this small Phase 2 safety trial,\" said Ian Murray, an assistant professor of neuroscience and experimental therapeutics at Texas A&M Health Science Center College of Medicine in College Station.\nThe researchers, who said monitoring of bapineuzumab will continue, are now awaiting the results of a larger Phase III trial on the drug.\nAlthough bapineuzumab has shown promise in certain Alzheimer's patients, other research found that patients taking a higher dose of the drug had an increased risk of brain inflammation from water retention.\nWEDNESDAY, July 20 (HealthDay News)-- An experimental drug for treating Alzheimer's disease that previously showed troubling side effects may actually be safe in the long run, researchers report.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included a quote from Dr. Ian Murray who did not appear to have a role in the studies reported on as well as comments from Dr. Salloway, lead author of the study. But we\u2019re going to rule it unsatisfactory because the story should have noted that Dr. Salloway, according to previous disclosures available online, has received research funding and has consulting relationships with numerous drug companies, including Pfizer, which makes bapineuzumab.", "answer": 0}, {"article": "The current study, she added, shows that \u201chigh quality (stroke) care is available in hospitals on the weekends and weekdays.\u201d In fact, care might even be more aggressive on weekends.\nOverall, Kazley added, this study offers \u201cgood news that indicates that the quality of care is similar regardless of when patients present at the hospital for treatment.\nIn this study, weekend admissions for heart attack were associated with much higher death rates, leading the researchers to conclude that more appropriate hospital staffing or regionalized care of heart attack patients may prevent some of these deaths.\nFor example, in one study examining stroke outcomes in Canada, researchers found that patients with stroke admitted to the hospital on weekends were at greater risk of dying than those admitted on weekdays.\nIn a prior US study, researchers found that people who were admitted to the hospital on a weekend for a heart attack were less likely to receive potentially life-saving procedures than their peers who were admitted on a weekday.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "As noted above, the story quotes an independent expert who does not appear to have a conflict of interest regarding this issue.", "answer": 1}, {"article": "Like a patch on faulty software, C.B.T.\nThis further emphasizes the point that many insomniacs aren\u2019t that different from normal sleepers.\nA big part of the difference may be how insomniacs perceive their sleep performance and the negative messages they give themselves about their poor sleep and how it will affect their daily lives.\nIt demonstrated progress \u2014 the nights in which I got only four or five hours of sleep became less common, and, on average, my nights of sleep lengthened by 30 minutes.\nIn this way, unless exacerbated by physical causes \u2014 like sleep apnea or restless leg syndrome \u2014 insomnia is a condition of the mind that then infects the body.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "While the story is a personal one, we think it could have been strengthened with the opinion of a primary care provider who commonly treats insomnia. Any story that makes health claims should have their facts/interpretation run by an expert.", "answer": 0}, {"article": "\"It's protecting against a severe disease, particularly in elderly adults,\" he said, \"so the benefit, I think, is overwhelming that we should be using this because it's recommended.\"\nIn vaccinated individuals, the rate of shingles was 6.4 cases per 1,000 people in a year while it was twice that -- 13 per 1,000 -- in the unvaccinated population, the investigators found.\n\"I think it's a very good vaccine, and it's a safe vaccine, but obviously there needs to be continuing surveillance of usage of the vaccine to make sure there are no adverse effects that are seen in one in a 100 million cases versus one in five or 10,000 people,\" said Sumaya, also a member of CDC's Advisory Committee on Immunization Practices.\n\"People 60 and over can consider talking to their physician about the possibility of receiving the vaccine to reduce their risk, and the doctor can evaluate if they are eligible,\" said Tseng.\n\"Even after the rash has healed, the pain can last for months or even years,\" said lead study author HungFu Tseng, a research scientist at the Kaiser Permanente Division of Research and Evaluation in Pasadena, Calif.\n\nZostavax, as the vaccine is called, was approved in 2006, based on the results of clinical trials.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\nThis story includes more than one independent source. The comments from these sources add valuable perspective on this study and the larger context of shingles vaccination. The story reports that the Kaiser Permanente health plan funded the study. However, it does not tell readers that some of the researchers have received funding from vaccine companies for other studies or consulting.", "answer": 1}, {"article": "But another finding from that study sheds an interesting light on one of 5-Hour Energy\u2019s central claims \u2014 that the energy shot, unlike competitors\u2019, produces \u201cNo Crash Later.\u201d\n\nAccording to the study, 24 percent of test participants who received 5-Hour Energy had reactions similar to a \u201cmoderately severe crash that left them extremely tired and in need of rest, another drink or some other action,\u201d lawsuit filings show.\nWhatever the case, the energy drink boom has come full circle in Asia, the region where it started.\nAsked whether consumers mistakenly believe that the shot does not produce a caffeine-related crash, Ms. Lutz said that the use of the special mark and its explanation were clear.\n\u201cI don\u2019t believe that it is misleading,\u201d said Ms. Lutz, who added that the advertising division of the Council of Better Business Bureaus had approved the \u201cNo Crash Later\u201d claim.\nBut she declined to say why the results of the study, which was apparently conducted five years ago, had not yet appeared.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A number of independent sources are quoted in the story.", "answer": 1}, {"article": "\"I\u2019m hoping this will help the women who need it.\u2019\u2019\n\nOne expert, Andrew Goldstein who runs the Sexual Wellness Center in Annapolis, Md., described a \"huge\u2019\u2019 unmet need for a medical treatment.\n\"There\u2019s a huge economic cost to divorce, and this is often cited as one of the main reasons for a divorce,\u2019\u2019 Goldstein said.\nThe findings show women who took the drug had more sex, wanted more sex and experienced less distress related to lack of desire.\n\"To the extent that the drug may act as an incentive to bring the subject up, that will be a good opportunity,\u2019\u2019 he said.\n\"We have to give women some type of option,\u2019\u2019 said Beverly Whipple, a professor emeritus at Rutgers University and an expert on women\u2019s sexual health.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The information in this story comes primarily from expert interview and quotes from a representative of the drug manufacturer. But there was no comment on whether any of the expert interviewees had financial ties to the drug maker.\u00a0 ", "answer": 0}, {"article": "Elective Caesarean-section deliveries can increase problems for a newborn if done too early -- even when the baby has technically reached full term, according to a large new study.\n\nThe findings could help diminish a widely popular practice -- now about one in every 14 births -- in which mothers choose to schedule c-sections, or surgical removal of the baby. The study, published in the New England Journal of Medicine, found that about a third of elective c-sections are done too early -- before 39 weeks. Although a fetus is considered...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes quotes from only two physicians, the lead researcher and the author of a related editorial.\u00a0\nThat is not sufficient for a story of this importance and length.\u00a0 \nAt minimum, an experienced OB with no connection to the study should have been consulted.\u00a0 ", "answer": 0}, {"article": "Severely premature babies are more likely to live if they receive intensive-care treatments rather than palliative care to keep them comfortable, according to a U.S. government-funded study published Thursday.\n\nWhether babies born at the extreme edge of viability, generally considered to be 22, 23 or 24 weeks of gestation, should be aggressively medically treated is a controversial issue among pediatric experts. These infants often don\u2019t survive and, even if they do, many have substantial long-term health problems.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes Dr. Elizabeth Rogers, a pediatrics professor who wasn\u2019t involved in the study. Her comments help balance the story, bringing the research into perspective, and also help shed light on how other doctors might react to the study\u2019s findings.\nThe article also points out that the research was supported and funded by the National Institutes of Health.", "answer": 1}, {"article": "Screening patients for heart disease with a heart-imaging test prompted greater follow-up care but had little to no effect on the number of heart attacks and other cardiovascular events in those patients, a new study found.\n\nResearchers at Johns Hopkins Hospital in Baltimore led the study, which was published online Monday in the Archives of Internal Medicine.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The first author of the study reported on and the author of the editorial about that study appear to have been interviewed for this piece.", "answer": 1}, {"article": "Then what, Dr. Nigg asked in series of studies, do orthotics actually do?\nBut when it comes to science and rigorous studies, he added, \u201ccomparatively, there isn\u2019t a whole lot of evidence out there.\u201d\n\nIn his studies, he found there was no way to predict the effect of a given orthotic.\nThus a flat foot is not something that is bad per se.\u201d\n\nSo why shouldn\u2019t Jason \u2014 or anyone, for that matter \u2014 just go to a store and buy whatever shoe feels good, without worrying about \u201ccorrecting\u201d a perceived biomechanical defect?\n\u201cI guess the main thing to note is that, as biomechanists, we really do not know how orthotics work.\u201d\n\nOrthotists say Dr. Nigg\u2019s sweeping statement does not take into account the benefits their patients perceive.\n\u201cBut choosing the right one requires a great deal of care.\u201d\n\nYet Scott D. Cummings, president of the American Academy of Orthotists and Prosthetists, says the trade is only now moving toward becoming a science.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article did present the views of several independent sources. However, the article did not address or identify potential financial conflicts among the contributors beyond identifying their organizations or institutions. Both biomechanical research and footwear research rely heavily on industry funding, which may skew the views of researchers. So this is an important issue. And we can\u2019t give a satisfactory score for half a loaf.\n\n \n", "answer": 0}, {"article": "TUESDAY, March 8, 2011 (HealthDay News) -- Acupuncture may help reduce the severity of hot flashes and other symptoms of menopause, according to a small study.\nThe findings were published online March 7 in Acupuncture in Medicine.\nThere were no differences between the two groups in terms of vaginal dryness and urinary tract infection.\nAfter 10 weeks, the women in the traditional acupuncture group had significantly less severe hot flashes and mood swings than those who'd gotten the fake treatment.\nThe U.S. National Women's Health Information Center has more about treating menopause symptoms.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No one was quoted, suggesting that no one was interviewed.", "answer": 0}, {"article": "The Cochrane reviewers selected 15 studies that enrolled a combined 1,360 participants.\nThe first study to show that zinc might be a useful treatment for the common cold was published in 1984, but the research was criticized for its poor methods.\n\u201cOver all, it appears that zinc does have an effect in controlling the common cold,\u201d said Dr. Meenu Singh, the review\u2019s lead author and a professor in the department of pediatrics at the Postgraduate Institute of Medical Education and Research in Chandigarh, India.\nA March 2008 report in The Journal of Infectious Diseases, for example, found that zinc lozenges cut the duration of colds to four days from seven days, and reduced coughing to two days from five.\n\u201cBut there still needs to be consensus about the dose.\u201d\n\nZinc experts say that many over-the-counter zinc products may not be as effective as those studied by researchers because commercial lozenges and syrups often are made with different formulations of zinc and various flavors and binders that can alter the effectiveness of the treatment.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes commentary from the review\u2019s lead author, as well as Dr. Prasad, \u201can early pioneer of research into zinc as an essential mineral.\u201d Two of Dr. Prasad\u2019s many articles were included in the Cochrane Review. Quotes from an independent expert would have been welcomed.\n", "answer": 0}, {"article": "March 5, 2012 (Orlando, Fla.) -- A traditional Chinese herbal remedy known as kampo helped to relieve daily asthma symptoms in nearly all of more than 200 people studied, Japanese researchers report.\nIn kampo medicine, most herbs are taken as a fixed formula.\nThe number of people in the U.S. with asthma is growing.\nThere's much room for improvement, Shimoide says.\nThe study did not look at possible side effects of kampo herbs.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One independent expert was quoted, adding important cautious perspective.", "answer": 1}, {"article": "WEDNESDAY, May 4, 2011 (HealthDay News) -- Among men under 65 with early stage prostate cancer, those who have the prostate gland removed are less likely to die than those who adopt a \"watchful waiting\" approach, according to a new long-term study out of Europe.\nThere was also a benefit in men whose tumors had low-risk characteristics.\nMen whose cancer had moved outside of the prostate gland and who underwent removal of the prostate had a seven times higher risk of dying than men whose tumors hadn't spread.\nThe U.S. National Cancer Institute has more on prostate cancer treatments.\nAlso, he said, erectile dysfunction can also be a factor of aging and can be treated in most cases.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two clinicians who were not involved in the study provided quotes which were used in the story.", "answer": 1}, {"article": "DALLAS, Oct. 20, 2015 -- Botox -- known for reducing facial wrinkles -- may also prevent irregular heart rhythms when injected into fat surrounding the heart after bypass surgery, according to research in the American Heart Association journal Circulation: Arrhythmia and Electrophysiology.\nThe Russian State Research Institute of Circulation Pathology and the Siberian Division of Russian Academy of Medical Sciences funded the study.\nIn two Russian hospitals, researchers randomly assigned 60 patients to receive Botox or saline injections.\nThe results must be replicated in larger studies before Botox injections are routinely used to prevent AF after bypass surgery, researchers said.\n\"This first-in-man study has opened a whole new line of thinking and research,\" Steinberg said.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding sources (The Russian State Research Institute of Circulation Pathology and the Siberian Division of Russian Academy of Medical Sciences) are noted in the release.", "answer": 1}, {"article": "New research by scientists at the University of Maryland School of Medicine has found that esophageal cancer patients treated with proton therapy experienced significantly less toxic side effects than patients treated with older radiation therapies.\nThe results have particular relevance for the University of Maryland School of Medicine; this fall the school will open the Maryland Proton Treatment Center (MPTC).\nOthers include:\n\u2022 Selective Internal Radiation Therapy, a precision modality for treating patients with particularly difficult-to-remove tumors involving the liver such as those from colorectal cancers;\n\u2022 Thermal Therapies, the use of \"heat\" in treating a broad spectrum of malignancies.\nWhile most cancer patients are well served with today's state-of-the-art radiation therapy technology, up to 30 percent are expected to have a greater benefit from the new form of targeted proton beam therapy.\n\"This evidence underscores the precision of proton therapy, and how it can really make a difference in cancer patients' lives,\" said Dr. Chuong.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The University of Maryland release does note that UMD is poised to open its own proton therapy later this year, and that the 110,000 square-foot center cost $200 million to build. The release also lists Mayo Clinic and the MD Anderson Cancer Center as partners in the research being reported. But the release doesn\u2019t note that both Mayo and MD Anderson have also built large, expensive proton therapy centers. In other words, all three institutions have invested heavily in proton therapy and have a strong financial incentive to promote its benefits. There is no information in the release on how the study was funded.", "answer": 0}, {"article": "Error code 404. Something went\n\nwrong and we can't seem to find\n\nthe page you're looking for.\n\n Report a broken link.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The two doctors quoted are both surgeons. The article would have benefited from an expert familiar with a range of treatments for breast cancer-related lymphedema; for example, a lymphedema-certified physical therapist.", "answer": 1}, {"article": "A new scan to help in difficult-to-diagnose cases of Parkinson's disease or other parkinsonian syndromes is available at more than 80 U.S. hospitals, including some in the Chicago area, since receiving federal approval earlier this year.\nAs part of the study, recently diagnosed Parkinson's patients and healthy subjects are tested with DaTscan, and clinical and behavioral assessments are done to identify biomarkers of Parkinson's disease progression.\nDuring the DaTscan test, an imaging drug is injected into a patient's bloodstream and the patient undergoes a single-photon emission computed tomography, or SPECT, scan.\nBefore DaTscan we would watch and wait because there were no other objective tests to use.\nIt allows them to accept treatment earlier,\" Rezak said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\nAll of the experts quoted in the story appear to work at institutions that are promoting their ability to offer the DaTscan test. A truly independent expert source might have raised some of the important issues discussed in our review.\n", "answer": 0}, {"article": "WASHINGTON--A new dietary review of 49 observational and controlled studies finds plant-based vegetarian diets, especially vegan diets, are associated with lower levels of total cholesterol, including lower levels of HDL and LDL cholesterol, compared to omnivorous diets.\nThe study authors hypothesize that the greater risk reduction for total, HDL, and LDL cholesterol levels observed in the longitudinal studies is likely due to long-term adherence to plant-based eating patterns and changes in body composition.\nThe study authors--Yoko Yokoyama, Ph.D., M.P.H., Susan Levin, M.S., R.D., C.S.S.D., and Neal Barnard, M.D., F.A.C.C.--reviewed 30 observational studies and 19 clinical trials, which met their inclusion criteria.\n\"Our goal with studying plasma lipids throughout the lifespan is to capture the net risk reduction of using a vegetarian diet to control lipid levels.\nThe study authors also note hyperlipidemia, or elevated cholesterol and triglycerides, is often underdiagnosed and undertreated.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that the research is funded by the\u00a0Physicians Committee for Responsible Medicine. Reporters will have to dig a little deeper to learn that group supports an activist agenda on behalf of animal rights, which may have a bearing on its health and diet recommendations. But the release meets our minimum standard for a satisfactory grade.", "answer": 1}, {"article": "Sorry. The page you requested is not available", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The reporter draws on the journal article and the accompanying editorial.\nSources interviewed include the primary author, one medical expert representing the National Multiple Sclerosis Society and one clinician who treated some patients in the study but was not an author.\nThis is sufficient sourcing.\nIt is worth pointing out here, however, that Genentech and Biogen Idec, makers of Rituxan, are \u201cCorporate Star\u201d supporters of the National Multiple Sclerosis Society.", "answer": 1}, {"article": "A growing number of doctors are offering an expensive laser procedure they say zaps away a common fungus that causes ugly, discolored nails. Published data on laser treatment for nail fungus is scant, but early results suggest it is a reasonable option for people who don't want the side effects of oral medications.\n\nOnychomycosis, or fungal infection of nails\u2014most often on the toes\u2014affects about 12% of Americans, according to the American Academy of Dermatology. Some people are genetically prone to it. Others, including swimmers...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Everyone quoted in the story had a conflict \u2013 a user, a consultant, a paid advser, someone who owns stock in a device maker, or a company spokesman.\u00a0 But all of those conflicts are acknowledged.\u00a0 And some of these people offer clear caveats about the approaches.", "answer": 1}, {"article": "Actinic keratoses are typically red, scaly skin lesions that can over time develop into a type of skin cancer.\n\u201cThe shorter application period is what makes ingenol mebutate a breakthrough in the treatment of actinic keratosis,\u201d researcher Mark Lebwohl, MD, says in a news release.\nThe new study included 547 people with actinic keratoses on their face or scalp and 458 people with these lesions on their mid-section or arms and legs.\nThe new gel, Picato (ingenol mebutate), is applied once daily for two or three days, depending on the area being treated.\nAt the end of the two-month study, 42% of people in the first group and 34% of those in the second group who got the new gel showed complete clearance of their lesions.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story explained that \u201cThe new study was funded by Picato manufacturer LEO Pharma.\u201d\nBut it didn\u2019t offer any independent perspective.\nAnd it didn\u2019t report that several authors disclosed a variety of ties to the drug maker, including consultant fees, serving on advisory board, fees for being on a speakers bureau \u2013 and that two of the authors are employees of the drug company.", "answer": 0}, {"article": "But the F.D.A.\nDr. Min said in an e-mail message that foam sclerotherapy was \u201cvery safe,\u201d but that \u201cit is associated with higher risks than liquid sclerotherapy.\u201d Foam injections have been blamed as the cause of blood clots in leg veins, he wrote, adding that one known stroke \u201cmay have been caused by foam sclerotherapy.\u201d\n\nBut foam sclerotherapy has been a big relief for some patients.\nThat said, polidocanol was the \u201csecond most commonly used sclerosing agent\u201d because, he said, \u201cmost physicians want to give their patients the best available treatment.\u201d\n\nF.D.A.\nOften the concentrations of polidocanol from compounding pharmacies were \u201cwrong\u201d and had \u201clots of contaminants\u201d that could damage the skin where injected, according to Dr. Robert A. Weiss, a dermatologist who directs the Laser, Skin and Vein Institute.\nYet, he said both are \u201cvery safe and effective, and a heck of a lot better than surgery.\u201d (It entailed ripping out the groin-to-ankle vein with a wire via an incision.)\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although the story gets high marks for tapping a number of expert sources, it should have done more to identify potential conflicts of interest. One expert who supports laser surgery is appropriately identified as the developer of a laser technique, but Dr. Robert Weiss, another\u00a0expert quoted in the story,\u00a0is\u00a0identified only as the director of\u00a0the Maryland Laser, Skin and Vein Institute. If fails to mention that he is also a consultant to Medicis Pharmaceuticals, which manufactures Asclera,\u00a0a\u00a0drug recently approved by the FDA which is discussed in the story.\u00a0To avoid the appearance of any bias, the story should have disclosed this relationship. It also should have tried to get a comment from someone who doesn\u2019t benefit financially from these procedures.\u00a0", "answer": 0}, {"article": "Johnston says the fight against obesity needs creative solutions that help people manage their weight, appetite and hunger by offering socially acceptable food choices.\nThe researchers conclude that afterschool programs and schools can replace energy dense, unhealthy snacks with peanuts to provide a healthier alternative for children (researchers in the study ensured students did not suffer from nut allergies).\nThis is especially true if a student doesn't have access to other meals during the school day.\nThe study acknowledged that snacking is more common during the adolescent years and that the unhealthy eating habit can lead to an unhealthy weight.\n\"We have a lot of kids skipping meals for a whole bunch of reasons,\" he said.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that the participants are part of an ongoing study of obesity interventions, but never says the study was federally funded,\u00a0or how the snacks were paid for (or donated).", "answer": 0}, {"article": "Nov. 22, 2010 -- Exercising to piano music may help improve balance and prevent falls among the elderly.\n\nA new study shows older men and women who participated in a piano-music-based exercise program were less likely to suffer a fall than those who didn't. Those who exercised to piano music also showed improvements in balance and the manner or style of walking.\n\n\u201cEach year, one-third of the population 65 years and older experiences at least one fall, and half of those fall repeatedly,\u201d write researcher Andrea Trombetti, MD, of University Hospitals and Faculty of Medicine of Geneva, Switzerland, and colleagues in the Archives of Internal Medicine. \u201cExercise can counteract key risk factors for falls, such as poor balance, and consequently reduce risk of falling in elderly community-dwelling individuals.\u201d\n\nResearchers say a large proportion of falls in elderly people occur while walking, so improving gait and balance can have a major impact on fall prevention.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There is neither an independent source nor any discussion of potential conflicts of interest.\n", "answer": 0}, {"article": "Why are so few women being treated?\n\u201cWomen and doctors simply are not aware that symptoms can last this long.\u201d\n\nFinally, many women don\u2019t realize that non hormonal options can be safe and effective, she added.\nBut after the initial findings of the Women\u2019s Health Initiative study showed that HRT can increase the risk of breast cancer, stroke and other serious problems, many women stopped using it.\n\u201cThe management of menopause has been relatively similar in the UK, the USA and in Australia.\u201d\n\nUp to half of women in menopause experience so-called vasomotor symptoms, such as hot flashes and night sweats.\n\u201cIt isn\u2019t \u2018grin and bear it for a few months\u2019 and it will all pass, as many women suffer severe symptoms for five-plus years,\u201d she said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes comments from an independent expert, but it doesn\u2019t note that the lead study author is a paid consultant to a company that makes an estrogen therapy. (See the disclosure in this recent Medscape article she co-authored.)", "answer": 0}, {"article": "And there's another potential problem with existing treatments.\nThe side effects, particularly of the treatment component known as interferon, can be \"pretty hard to deal with,\" said Nicholas A. Meanwell, a co-author of the study and a researcher with the Bristol-Myers Squibb pharmaceutical company.\nThe greater possibility of a cure and fewer side effects, in turn, will lead more people who think they have hepatitis C to \"come out of the woodwork,\" said Schiff, who's familiar with the study findings.\nStill, the drug -- or others like it in development -- could add to the power of new drugs in the pipeline that are poised to cure many more people with hepatitis C, said Dr. Eugene R. Schiff, director of the University of Miami's Center for Liver Diseases.\nFor now, much of the attention in the world of liver disease is on two drugs -- telaprevir and boceprevir -- that Schiff expects will become available within the next year and a half.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story leans heavily on the comments of Dr. Eugene Schiff, who is identified only as the director of the University of Miami\u2019s Center for Liver Diseases. However, as a recent disclosure statement from\u00a0a continuing medical education program in which he participated shows, Dr. Schiff is\u00a0a consultant to Bristol Myers Squibb, which is developing BMS-790052, as well\u00a0as Vertex and Schering Plough, which are developing the other two\u00a0experimental drugs mentioned\u00a0in the article.\u00a0We\u00a0feel these relationships should have been disclosed to readers.\u00a0", "answer": 0}, {"article": "\"In Europe, we have been reluctant to recommend that all men get PSA testing as we have felt that there has been a lack of knowledge,\" agreed lead researcher Dr. Jonas Hugosson, a professor of urology at the University of Gothenburg.\nThe argument over whether PSA screening saves men's lives or merely leads to the overdiagnosis of very slow-growing cancers (with attendant worry and overtreatment) has bedeviled the medical world for years.\nFor men at high risk for the disease -- blacks and men who have a father, brother or son found to have prostate cancer at an early age (before 65) -- that discussion should start at age 45.\nIn addition, men in the screened group were more likely to have their cancer diagnosed while it was in an early stage.\nMoreover, the risk of over-diagnosis was less than previously thought, with just 12 men needed to be diagnosed to save one life.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0The story included quotes from several experts.\u00a0 But we\u2019re going to rule the story\u2019s performance on this criterion as unsatisfactory for reasons of balance.\u00a0 It\u2019s possible to have several sources and still have an editorial imbalance in the story.\u00a0 ", "answer": 0}, {"article": "An experimental Alzheimer\u2019s drug showed positive results and raised hopes anew that pharmaceutical companies were moving closer to a medicine that could finally disrupt the disease\u2019s memory-robbing course, though a string of failures shadow the efforts.\n\nAlzheimer\u2019s has proved an especially tough drug target. Approved therapies only relieve symptoms temporarily, and one experimental treatment after another promising to stymie the neurodegeneration has ultimately failed to work. Some pharmaceutical companies, after costly failures,...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "In addition to business analysts, the story quoted Lon S. Schneider, an Alzheimer\u2019s researcher at the University of Southern California\u2019s Keck School of Medicine, who \u201cwarned against reading too much\u201d into the announced results.", "answer": 1}, {"article": "Doctors say it has given them a new weapon in the battle against sleep apnea, and many patients who struggled with C.P.A.P.\n\u201cIt would be incorporated into these dreams where I was tied up, like in the movie \u2018Alien.\u2019 It was more difficult to sleep with that thing on than to just get through the night with the apnea.\u201d\n\nMr. Bleck got rid of the machine after he discovered Provent.\n\u201cAll sleep apnea is not created equal.\u201d\n\nSome people, for example, breathe through the mouth at night, not the nostrils.\nFor decades, the standard treatment has been \u201ccontinuous positive airway pressure.\u201d A mask worn at night pushes air into the nasal passages, enabling easier breathing.\n\u201cI tried it for six months, and I don\u2019t think I had one full night of sleep the whole time.\u201d\n\n\u201cI\u2019m just so happy that I found it,\u201d she said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes from a range of sources, and we give it high marks for that. We are a little troubled that one of the most outspoken boosters of this product is Dr. Joseph Golish, who works for another medical device company, CleveMed. He was also quoted raving about Provent in The Plain Dealer. A mention of his device company work would have been good context.", "answer": 1}, {"article": "It left some doctors at the conference incredulous and uncertain how to treat their patients.\nThe fact that this uncertainty is occurring so long after the 1998 approval of Herceptin \u2014 the paragon of \u201cpersonalized medicine\u201d \u2014 suggests that it will not be so easy to tailor other drugs to patients based on gene or protein tests.\nDr. Soonmyung Paik, who presented the second study at the cancer conference, said the problem might lie not in sloppy testing but rather in the cutoff used to determine which women get Herceptin.\n\u201cTo me, the take-home message is that we don\u2019t have a perfect test, unfortunately,\u201d Dr. Paik said.\nDr. Daniel F. Hayes, a breast cancer specialist at the University of Michigan who helped develop guidelines for Her2 testing, said it would be unwise to start giving Herceptin to Her2-negative women because the drug was expensive and raised the risk of heart failure.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story is balanced in term of sources cited. The story identifies researchers who conducted reviews, oncologists in practice, the physician who designed guidelines for Her2/neu testing, and a representative from Genentech. Clinicians express frustration and confusion about a lack of standardization for determining who should receive Herceptin and similar treatments.", "answer": 1}, {"article": "Visit redrazz.org for more information, and follow us on our social media channels:\nThe NPRC is responsible for marketing processed raspberries in the U.S. and is committed to promoting the growth of the entire industry.\nIn a secondary objective of the blood sugar control study, researchers found that subjects in the PreDM group who reported the highest level of hunger at baseline experienced greater satiety after the control meal compared to raspberry containing meals (p<0.05).\nand Zhu, M. Dietary Red Raspberry Enhances Intestinal Epithelium Repair in Chronic Colitis.\nSeven individual anthocyanins were identified in the samples.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release was transparent about the conflict of interest\u2014it was released by the National Processed Raspberry Council (NPRC). On its website, the NPRC says its mission is to \u201cpromote the consumption of processed raspberries based on research results.\u201d\nThe studies were all funded by the trade group, and that\u2019s noted on the EurekAlert! sidebar, where the release is hosted. \nThe news release also included a blurb at the bottom acknowledging that the NPRC \u201crepresents the processed raspberry industry.\u201d\u00a0\nMany news releases have conflicts of interest\u2014at least the NPRC was honest about it.\u00a0", "answer": 1}, {"article": "As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual grants in cancer research that have the potential for near-term patient benefit.\nThe researchers conducted this study to further clarify the association between metformin use and lung cancer risk.\nThis study was funded by the National Institutes of Health.\nInformation on their diabetes medications was collected from electronic pharmacy records.\nSome laboratory studies and a number of observational studies suggest that metformin may prevent cancer, but the data from human studies, however, are conflicting, explained Sakoda.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release clearly identifies the funding source for the research and also adequately discloses conflicts among the authors of the paper.", "answer": 1}, {"article": "With statins you get toxicity \u2013 with these drugs we don\u2019t see any side effects with the antibody.\u201d\n\nIn an accompanying editorial, authors Dr. Stephen G. Young, and Loren G. Fong, Ph.D. write: \u201cAt this point, the status of PCSK9 therapeutics appears to be full speed ahead.\nSoon, we can expect more human trials in which investigators will dissect the properties of different PCSK9 antibodies and assess the effect of these agents.\u201d\n\nHowever, without long-term safety data and evidence that PCSK9 inhibitors truly help prevent heart disease, Young and Fong caution that it will remain unclear how important this class of drugs will be.\nIf the results are confirmed, \u201cThis is game changing science,\u201d said Dr. Richard A. Stein, a spokesman for the American Heart Association who's not related to the study author or involved in the research.\nNone of the subjects who received REGN727 discontinued the study because of adverse effects, and the subjects who received REGN727 had a striking reduction of 60 to 65% in LDL cholesterol, according to Stein.\nIf these initial results pan out in larger trials, the drug could prove to be more effective than statins, the widely prescribed drugs which have been very successful in lowering levels of LDL - or bad cholesterol.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Mixed bag.\nThe story did quote the editorial writers and did seek comment from an American Heart Association spokesman.\nBut the story did not report, as MedPage Today did, that: \u201cMany of the co-authors were employees of Regeneron, one of whom jointly wrote the paper with Stein.\u201d\nWe\u2019ll give the story the benefit of the doubt.\n\u00a0", "answer": 1}, {"article": "The pain relief could last for weeks.\nFor many years it was widely believed that tendon-overuse injuries were caused by inflammation, said Dr. Karim Khan, a professor at the School of Human Kinetics at the University of British Columbia and the co-author of a commentary in The Lancet accompanying the new review article.\n\u201cBut it\u2019s not.\u201d The pain associated with tendinopathies tends to fall somewhere around a 7 or so on a 10-point scale of pain.\nBut a major new review article, published last Friday in The Lancet, should revive and intensify the doubts about cortisone\u2019s efficacy.\nThe evidence for cortisone as a treatment for other aching tendons, like sore shoulders and Achilles-tendon pain, was slight and conflicting, the review found.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\nThe journalist based the article on two main sources: a systematic review and an editorial from The Lancet. She quoted one of the review authors and one of the editorialists at length.\u00a0 It would have been educational to hear the views of a researcher not involved with either publication. However, this article included a diversity of viewpoints and rates a \u201csatisfactory\u201d on this criterion.\n \n", "answer": 1}, {"article": "A Phase 2 clinical trial of BCG is currently underway at Mass.\nCritics have gone so far as to send letters to newspapers that covered her work apologizing to patients \u201con behalf of Dr. Faustman\u201d for \u201chaving their expectations cruelly raised.\u201d She has also struggled for funding, receiving much of her research support from the private Iacocca Family Foundation, rather than in federal grants.\nWhile the results, from only nine patients, must be replicated in a larger study, said Dr. Joseph Bellanti of Georgetown University Medical Center, \u201cif what they found is true, they really have something here.\u201d Bellanti, who was not involved in the research, said the study\u2019s eight-year follow-up and use of a placebo control arm made him \u201ccautiously optimistic\u201d that two doses of the BCG vaccine \u201ccan decrease levels of A1c,\u201d a measure of blood glucose that predicts the likelihood of serious complications such as stroke and kidney failure.\nIt alters the immune system so as to increase levels of T regulatory cells; T regs keep other immune cells in check, including those that attack the pancreas\u2019s insulin-making cells \u2014 the root cause of type 1 diabetes.\n(The standard of care is a continuous glucose monitor, in which a probe is inserted into the abdomen, plus an insulin pump.)\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The original journal article on which this story was based includes the researchers\u2019 declaration that they had no conflict of interest. The story includes two sources who were not involved in the research, although one of these sources, a researcher from Radboud University Medical Center in the Netherlands, cannot be considered fully independent, because the quote appears to have been copied from a Massachusetts General Hospital news release about the study (see news release criterion, below).\nThe story also noted that two diabetes research centers and \u201cseveral university diabetes centers all declined to speak about Faustman\u2019s results.\u201d This hints at the \u201ccontroversy\u201d noted in the headline, around the possibility of conflicts of interest that can occur when pharma-supported researchers/advocacy groups criticize this type of research. But the story didn\u2019t explore this sufficiently to prove the researcher\u2019s claim that funders aren\u2019t interested because it has low profit potential, as noted in the summary.", "answer": 1}, {"article": "The U.S. National Institute of Diabetes and Digestive and Kidney Diseases has more about diabetes medicines.\nAs for TAK-875, it targets a separate mechanism \"but again, until more is known about short-term and long-term cardiovascular effects, we need to proceed with moderated enthusiasm for each new drug and drug mechanism,\" Wissner Greene said.\nDr. Minisha Sood, endocrinologist at Lenox Hill Hospital in New York City stressed that, \"given the rising global incidence of type 2 diabetes, the medical community is eagerly awaiting the development of novel agents to add to our existing armamentarium of anti-diabetic agents.\"\nShe said that, \"though this study includes a small sample size followed for a short period of time, the results are promising in that TAK-875 appears to be effective for glycemic [blood sugar] control without significant risk for hypoglycemia or weight gain.\nHowever, the incidence of episodes of hypoglycemia was much lower among patients taking TAK-875 (2 percent) than among those taking glimepiride (19 percent) and the same as those taking the placebo (2 percent).\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story says clearly that the study was funded by the company making the drug being studied: \u201cThe study was funded by Takeda Pharmaceutical (which is developing the drug), and appears online Feb. 26 in The Lancet.\u201d The story also includes two valuable comments from independent researchers. Dr. Loren Wissner Green says that, \u201cuntil more is known about short-term and long-term cardiovascular effects, we need to proceed with moderated enthusiasm for each new drug and drug mechanism.\u201d And Dr. Minisha Sood, says that \u201cfurther investigation is warranted, especially including [heart disease] patients.\u201d", "answer": 1}, {"article": "\"This smartphone reader has the potential to improve access and speed up healthcare delivery,\" said Li.\nThe smartphone reader, which includes a portable device, takes a photo of 96 sample wells at once and uses a computer program to carefully analyze color to determine positive or negative results.\nThe work could lead to faster and lower-cost lab results for fast-moving viral and bacterial epidemics, especially in rural or lower-resource regions where laboratory equipment and medical personnel are sometimes not readily available.\nThe researchers tested the device, which is about the size of a hand, with 771 patient samples at Hospital of University of Pennsylvania and found that it provided false positives only about one percent of the time (was 97. to 99.9 percent accurate).\nIf they send results off to a lab in a distant city, the doctors sometimes must wait for days -- by which time the infection may have become widespread.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release reports that the researchers have filed a patent and hope to commercialize their product. It also states that the work was supported by a Washington State University fund to support entrepreneurial endeavors.", "answer": 1}, {"article": "Chronic rhinosinusitis (CRS) affects a sizable minority -- 14 percent to 16 percent -- of U.S. residents.\n\"Some people with stage 1 and 2 diseases may even get cured.\nFollowing the surgery, about 76 percent of patients had \"clinically significant\" improvement in quality of life, as measured by various validated scales.\n\"I don't think it means everyone with CRS should consider surgery.\nThis is a wonderful renewed hope of feeling better.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 1}, {"article": "\u201cTo our knowledge, this is the first systematic review to assess complementary and alternative medicine for premature ejaculation.\u201d\n\nAccording to the International Society for Sexual Medicine, premature ejaculation can be a lifelong problem, and this primary form of the problem is usually defined as ejaculation happening within one minute of initiating vaginal intercourse every time a man has ever had sex.\nIn the current study, researchers evaluated 10 randomized controlled trials that included comparisons either to another type of treatment or to a placebo, or dummy, treatment.\nWhen they were reported, the adverse effects were generally mild, the study team writes.\nFor example, the five Chinese medicine studies tested different substances, including Qilin pills, Yimusake and Uighur.\nIn some instances, a combination of traditional and alternative options was the most effective.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The researchers interviewed don\u2019t appear to have any conflicts of interest, and several independent sources were included.", "answer": 1}, {"article": "For that reason, Dr. Jacobson of Emory gives the prescription drug, \u201coff label,\u201d to cardiac patients, even though the F.D.A.\nThe American College of Cardiology now advises patients with coronary artery disease to increase their consumption of omega-3 acids to one gram a day, but it does not specify if this should be achieved by eating fish or by taking capsules.\n(In the United States, Omacor is licensed only to treat the small number of people with extremely high blood triglyceride levels.)\nBut the landmark Gissi-Prevenzione trial of fish oil had methodological weaknesses: the patients treated with prescription fish oil pills were compared with untreated patients, rather than with patients given a dummy pill.\n\u201cUsing this medicine is very popular here in Italy, I think partly because so many cardiologists in this country participated in the studies and were aware of the results,\u201d said Dr. Maria Franzosi, a researcher at the Mario Negri Institute in Milan.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included input from several individuals expert in cardiology and the role of omega-3 fatty acids for decreasing risk of heart attack. It would have been informative for readers to have someone explain the nature of the information on heart disease and omega-3 fatty acids and why conclusive data was not available.", "answer": 1}, {"article": "\u201cThe earlier we can get biological markers for autism, the earlier intervention can be initiated, and the greater the chance of better outcomes, \u201d said David Kennedy, Ph.D., co-director of the Child and Adolescent NeuroDevelopment Initiative at the University of Massachusetts Medical School.\nIt may also be a mechanism in the development of autism, and it opens up new possibilities for research, she said.\nThe scans showed that 70 percent of high-risk toddlers diagnosed with autism at age 2 had an elevated amount of cerebrospinal fluid around their brains at 6 and 12 months, compared to toddlers who were not diagnosed with autism.\nHe and his colleagues are working on improving accuracy by combining their brain fluid findings with other recent research.\nTwo-thirds of the infants were high risk, having an older sibling with autism.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes quotes from independent researchers, and we did not detect any potential conflicts of interest.", "answer": 1}, {"article": "Ms. Visco said, \"How is it ethical to do that, to make this much hype around something that is not a health emergency, and you can't check their data?\"\nBased on those findings, it is easy to see why raloxifene was declared the winner.\nMany researchers say that results don't count unless they pass the statistical tests.\nShe said she also worried that the announcement might have left the impression that the drugs could prevent breast cancer entirely.\nThe study included nearly 20,000 women 35 and older who were past menopause and had an increased risk of developing breast cancer.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes multiple sources who have differing opinions of the significance of these findings.", "answer": 1}, {"article": "Sept. 28, 2010 -- Intrauterine devices (IUDs) -- used to prevent pregnancy -- may also be an effective treatment for some patients with early-stage uterine cancer who want to preserve their fertility.\n\nIn a small, early study, carefully selected patients with cancer that had not spread beyond the inner lining of the uterus were treated with IUDs that released the hormone progesterone.\n\nThe treatment was found to be as effective as oral hormone therapy, which is the most widely used nonsurgical, fertility-sparing treatment for the cancer.\n\n\u201cOur results show promise for the treatment of younger endometrial cancer patients with early disease who desire pregnancy in the future,\u201d gynecologic oncologist Lucas Minig tells WebMD. \u201cBut patients must be screened very carefully to make sure their disease has not spread.\u201d", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes one independent expert who provides valuable perspective. We are curious, though, why/how this story quotes the same U.S. expert who comments in the competing HealthDay story. ", "answer": 1}, {"article": "THURSDAY, Dec. 9, 2010 (HealthDay News) -- The bone drug zoledronic acid (Zometa), considered a potentially promising weapon against breast cancer recurrence, has flopped in a new study involving more than 3,360 patients.\nAfter five years, about 400 women in each group either died or had recurrences.\nThe focus was on disease-free survival.\n\"The younger patients are getting no benefit,\" Coleman said.\nIn one previous study, the use of the drug was linked with a 32 percent improvement in survival and lowered recurrence in younger women with breast cancer.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article quoted an independent source. It also addressed conflicts-of-interest among the researchers.", "answer": 1}, {"article": "'This is not the end': Using immunotherapy and a genetic glitch to give cancer patients hope\nSo far, with a full year, it doesn\u2019t look like that is happening.\u201d\n\nLindsey George, the lead investigator and a hematologist at Children's Hospital of Philadelphia, said that nine of the 10 men in the trial didn't experience any bleeding episodes after the gene therapy treatment.\n\u201cOne man who came in a wheelchair is now out of a wheelchair and is coaching Little League.\u201d\n\nPeople with hemophilia B inherit a gene mutation on the X chromosome that interferes with their ability to produce normal levels of blood-clotting factor IX.\nFor the current trial, which is being funded by Spark and Pfizer, researchers used a clotting factor that is 8 to 10 times as strong as the normal version.\nThe therapy developed by Spark, a biotech company spun off from the Children's Hospital of Philadelphia in 2013, involves a bioengineered gene designed to prompt the body to produce increased levels of a different clotting factor.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Independent sources are identified in the story, as are the funders. But missing from the text is information describing linkages between the two funders\u2014Spark Therapeutics and Pfizer\u2014and the lead researchers. It\u2019s not clear from the story that there is a financial relationship.", "answer": 0}, {"article": "Millions of Americans suffer from pet allergies that prevent them from enjoying the benefits of owning a dog or a cat.\n\u201cBut now I don\u2019t really feel allergy symptoms anymore.\u201d\n\nTo find a prescribing doctor for Allerdent in your area or to find more information, visit Allovate.com.\n\u201cThe patients who came in were treated for the very things that they were sensitive to, and that included indoor allergens, like dustmite and pet dander, as well as outdoor allergens such as tree pollen, grass pollen, ragweed pollen,\u201d Dr. William Reisacher, an associate professor of otolaryngology and director of allergy services at Weill Cornell Medicine/New York-Presbyterian Hospital, told FoxNews.com.\nI was really uncomfortable and miserable.\u201d\n\nJoyce tried over-the-counter medications but couldn\u2019t find relief.\nThe toothpaste, called Allerdent, works to keep breath fresh and fight cavities while also offering the same benefits as an allergy shot or drops.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources used in this story, just comments from one study participant and the principal investigator.\u00a0 There is no mention of conflicts although a quick web search reveals that the quoted researcher is also \u201cco-founder and chief medical officer\u201d of the company funding the research.\u00a0 It also shows that he has an \u201cequity ownership\u201d in the company, a clear vested interest and potential conflict.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070513/21sunscreen.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The news story quoted two sources from academic institutions. It\u2019s difficult to know whether either individual has a potential conflict of interest.", "answer": 1}, {"article": "For more information, visit http://www.\nThese results, published today online ahead of print in the American Journal of Medicine, with an accompanying editorial by the editor-in-chief, show that Plaque HD\u00ae, produced statistically significant reductions in dental plaque and inflammation throughout the body as measured by hs-CRP.\nIn addition, the product's proprietary formulation contains unique combinations and concentrations of cleaning agents that weaken the core of the plaque structure to help the subject visualize and more effectively remove the plaque.\nThe original research from the landmark Physician's Health Study, in which Hennekens was the founding principal investigator, was the first to demonstrate that hs-CRP predicted future heart attacks and strokes.\nIn this trial, all randomized subjects were given the same brushing protocol and received a 60-day supply of toothpaste containing either Plaque HD\u00ae or an identical non-plaque identifying placebo toothpaste.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release fails to disclose that the trial was funded by TJA Health LLC, the maker of Plaque HD. (The journal article states that the company was not involved in the design, conduct or reporting of the trial.) And while the release devotes considerable attention to the prominent career of senior author, Charles Hennekens, MD, it does not point out that he holds patents related to CRP testing.  ", "answer": 0}, {"article": "But some pain experts defend the value of the diagnostic tests.\nAlmost everyone suffering from back pain says something like, \"I want to feel better, I want to play golf again, or I want to be able to play baseball with my grandkids,\" anesthesiologist and lead author Steve P. Cohen tells Shots.\nDr. Nikolai Bogdu at the Newcastle Bone & Joint Institute in Australia told Reuters that further cost analysis is needed to account for millions of patients who might not get pain relief from the radiofrequency treatment.\nPatients don't care much about the finer points of diagnostic accuracy.\nDoing away with a painkilling injections, or nerve blocks, as a test to determine the root cause of the back pain didn't hurt patients who went on to have their pain treated by zapping nerves with electrodes.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The NPR\u00a0news org can\u2019t be given credit for eliciting an independent source \u2013 only for \"borrowing\" what Reuters reported.\u00a0 Why not get your own source? ", "answer": 0}, {"article": "Early lab-based tests of ICEC0942 were successful in targeting resistant breast cancers and indicated minimal side effects.\nThe discovery of the drug was spurred by an initial meeting between Professor Anthony Barrett, from the Department of Chemistry, and oncologist Professor Charles Coombes from the Department of Surgery & Cancer.\nThe drug may not become available to patients for a number of years yet, but researchers believe that if clinical trials are successful, it could be used to tackle a variety of treatment-resistant cancers.\nProfessor Charles Coombes, from the Department of Surgery & Cancer, said: \"Treatment-resistant tumours represent a significant threat for patients, as once a cancer stops responding to treatments there is increasingly little clinicians can do.\nEarly funding for the study came from the Engineering and Physical Sciences Research Council (EPSRC), and a major contribution of whole-project funding was from Cancer Research UK.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release states:\nEarly funding for the study came from the Engineering and Physical Sciences Research Council (EPSRC), and a major contribution of whole-project funding was from Cancer Research UK. Licensing of the technology to Carrick Therapeutics was led by Cancer Research UK\u2019s Commercial Partnerships Team and Imperial Innovations, the Technology Transfer Office of Imperial, with support from Emory University.\nHowever, the news release doesn\u2019t offer specifics on these financial relationships.\nA look at the manuscript describing this molecule shows the authors are inventors on a patent owned by Imperial College London and that one researcher acted as a consultant for Carrick. Do Imperial College London and Emory University stand to profit from this drug?", "answer": 0}, {"article": "Researchers said they had identified a family of retroviruses in patients with chronic fatigue syndrome, opening up a potentially promising new avenue of treatment for a debilitating disease that afflicts as many as four million Americans and 17 million people world-wide.\n\nThe finding will likely spur patients with the condition to seek treatment with drugs used to fight HIV, the virus that causes AIDS. Although HIV and the newly identified virus group are different, they are both retroviruses.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 0}, {"article": "\u201cShortly after that he told me I could relax and that I did a good job and they had retrieved the clot and just to relax and I immediately started trying to move my arm.\u201d\n\n\u201cA patient will come in, they can't speak, they can't move half their body,\u201d says neurosurgeon Dr. J Mocco, of Mt.\n\u201cThey are destined to be in a nursing home or to be dead and when we re-establish blood flow \u2014 often times right there on the table \u2014 they get better.\u201d\n\nStent retriever therapy is a new procedure experts call the most major advance in stroke treatment in two decades.\n\u201cThe earlier that patients with acute ischemic stroke get to a hospital offering the appropriate treatment, the higher the likelihood is of a good outcome,\u201d said the study\u2019s lead author, Dr. Mayank Goyal of the Hotchkiss Brain Institute at the University of Calgary.\nRoughly 795,000 people suffer a stroke every year in the United States, and it\u2019s the fifth highest cause of death and a leading cause of adult disability, according to the American Heart Association.\nAt the hospital, the first-line therapy, a powerful blood-thinning medication called tissue plasminogen activator or tPA could not dissolve the blood clots in Reisch\u2019s brain.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Independent sources were included, but the story missed an important detail about conflicts of interest: The study was funded by Medtronic, the maker of the device used in the study. \u00a0This detail was easy to find in the published paper about the study, which also provided a list of all the conflicts of interest declared by all the authors.", "answer": 0}, {"article": "Medical-device makers, venture capitalists and surgeons are racing to turn a once-controversial weight-loss procedure into the next big thing in elective surgery.\n\nOnce dismissed by some surgeons as a gimmick, gastric banding -- in which a silicone band is wrapped around the upper stomach to restrict food intake -- is now the focus of a fierce competition pitting consumer-products giant Johnson & Johnson against Botox maker Allergan Inc. Venture-capital-backed outpatient centers are popping up to implant the bands. Growing...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included primary quotes from clinicians, industry spokespersons, and individuals who had undergone gastric banding.", "answer": 1}, {"article": "MONDAY, March 28, 2016 (HealthDay News) -- Acupuncture can help alleviate the often-debilitating hot flashes that afflict many breast cancer patients, new Italian research says.\nThe result: by the end of the treatment period, those in the acupuncture group were found to have hot flash scores that were 50 percent lower than those in the non-acupuncture group.\n\"Anyone who treats breast cancer struggles with this problem in their practice, because the hot flashes that some women experience with anti-hormonal treatment can be profound,\" she said.\nWhich, in the end, may help to encourage insurance companies to their expand coverage so this can become an affordable option for all patients in need.\"\nThere's more on cancer and hot flashes at the U.S. National Cancer Institute.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does cite one independent source, and there don\u2019t appear to be any conflicts of interest.", "answer": 1}, {"article": "Surgeons sometimes fly blind when operating on hard-to-reach anatomical parts or hard-to-see conditions. For visual references inside the brain or body, they often rely on images and scans taken before an operation.\n\nA growing number of hospitals are equipping operating suites with magnetic resonance imaging, CT scanners and other technology that enables surgeons to scan a patient in real time, without having to move them from the operating table.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The two doctors quoted in the story on the value of these real-time imaging surgical techniques are both leaders of high-profile programs that are dedicated to, well, advancing these real-time imaging surgical techniques. The story would have benefited from the input of an independent source.", "answer": 0}, {"article": "Also unknown: Will insurers pay for the expensive test without evidence it leads to better care or saves lives?\nThe results suggest the test could triple the number of men thought to be at such low risk for aggressive disease that monitoring is a clearly safe option.\nUsing one current method, 37 of the 395 men would have been called very low risk and good candidates for monitoring.\n\"We're not giving patients enough information to make their decision,\" said Dr. Peter Carroll, chairman of urology at the University of California, San Francisco.\nA second study of biopsies from 167 patients narrowed it down to 81 genes, and researchers picked 17 that seemed to predict aggressiveness no matter the location in the tumor.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Mixed bag.\nMultiple sources were interviewed \u2013 which was admirable.\nThe story could have explained that two of the experts quoted either had paid consultant arrangements or received research funding from one of the companies mentioned in the story.", "answer": 1}, {"article": "But if you prefer something less invasive but more frequent, you can test your poop every year without feeling like you\u2019re opting for, um, No.\nIncluded on the list are two cheap, at-home poop tests intended to be done annually: the guaiac-based fecal occult blood test (gFOBT) and a more sensitive test called the fecal immunochemical test, or FIT.\n\u201cThey were very clear: We\u2019re going to stick to the evidence, and right now we don\u2019t have evidence for colonoscopy,\u201d said Aasma Shaukat, section chief of gastroenterology in the Minneapolis VA Health Care System.\nThere is indirect evidence it reduces colorectal cancer deaths, in the form of a large study following people who did and didn\u2019t get the test over time.\n\u201cPeople are very motivated to get screened when they hear colorectal cancer is the second-leading cause of cancer-related death and if they know there are tests that are affordable and can be done at home,\u201d said Wender.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes three independent sources for information and the recommendations of agencies from two different governments.\u00a0 There is no suggestion that in a story offering a selection of screening techniques, with no one preferred above another, that there is any issue with conflicts of interest.", "answer": 1}, {"article": "LONDON (Reuters) - British scientists have discovered a \u201crogue gene\u201d which helps cancer spread around the body and say blocking it with the right kind of drugs could stop many types of the disease in their tracks.\nThe culprit gene, called WWP2, is an enzymic bonding agent found inside cancer cells, the researchers explained in their study, published in the journal Oncogene Monday.\nSurinder Soond, who worked on the study, said it was a \u201cnovel and exciting approach to treating cancer and the spread of tumors which holds great potential.\u201d\n\n\u201cThe challenge now is to identify a potent drug that will get inside cancer cells and destroy the activity of the rogue gene,\u201d said Andrew Chantry of UEA\u2019s school of biological sciences, who led the research.\nIf a drug was developed that deactivated WWP2, he said, conventional therapies such as chemotherapy and radiotherapy could be used on primary tumors with no risk of the disease taking hold elsewhere.\nChantry said in a telephone interview the findings mean drugs could be developed in the next 10 years that could be used to halt the aggressive spread of many forms of cancer, including breast cancer, brain, colon and skin cancer.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story uses no independent sources. It quotes just two people: Surinder Soond and Andrew Chantry, the two authors of the paper published in Oncogene. (You need a subscription to view it.)\u00a0 The claims made in this story needed independent analysis.", "answer": 0}, {"article": "The key to making the therapy work?\nThe only treatment is a bone-marrow transplant \u2014 if a compatible donor can be found \u2014 or a transplant with cord blood, if it was saved at birth.\nThe patients were children who had inherited a mutated gene causing a rare disorder, adrenoleukodystrophy, or ALD.\nFor the first time, doctors have used gene therapy to stave off a fatal degenerative brain disease, an achievement that some experts had thought impossible.\nThe disease strikes about one in 20,000 boys; symptoms first occur at an average age of 7.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes input from multiple independent sources, which is good. The story also notes that the relevant study was funded (in part) by Bluebird Bio \u2014 a company that hopes to market the relevant gene therapy.\nHowever, the story does not note that the principal investigator for the study, David Williams, has a conflict of interest. According to an appendix of the journal article, Bluebird Bio also funds other projects by Williams. The company has also licensed one of Williams\u2019 patents. That doesn\u2019t necessarily mean that anything in the study is shady, but conflicts of interest should be acknowledged.", "answer": 1}, {"article": "If it does, Orlistat (xenical) -- currently sold only by prescription -- could be available over-the-counter (OTC) later this year.\nThe company says that 22 million people in 145 countries have taken the drug.\n\"It's very exciting,\" Klein says.\nThat's because Orlistat works by blocking fat absorption in the intestine.\nNor is Orlistat a quick fix for unwanted pounds.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Provides quotes from drug maker, researchers, and public watchdog organization", "answer": 1}, {"article": "\"Our concern is there are so many CT scans being done right now that we should really be starting to think: Do we need to all of these CT scans?\"\nThe radiation and risk from one CT scan is low, but it carries a dose 50 to 100 times greater than a traditional X-ray, reports LaPook.\nThe dose depends on the type of machine and the person - obese people require more radiation than slim ones - and the risk accumulates over a lifetime.\nA previous study by the same scientists in 2001 led the federal Food and Drug Administration to recommend ways to limit scans and risks in children.\nBut they agree with the need to curb these tests particularly in children, who are more susceptible to radiation and more likely to develop cancer from it.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The reporter interviewed two sources in the story.\u00a0 One was the first author of the article being reported on.\u00a0 One appeared not to be involved in the study reported on.\u00a0 It would have been helpful to clearly identify the doctors beyond their names to explain why they were interviewed. ", "answer": 1}, {"article": "Some of the IntelliCare apps include:\n\u2022 Daily Feats: designed to motivate you to add worthwhile and rewarding activities into your day to increase your overall satisfaction in life.\nThe 96 participants who completed the research study reported that they experienced about a 50 percent decrease in the severity of depressive and anxiety symptoms.\nIn the study, 105 participants were enrolled and 96 of them completed the study.\nThe short-term study-related reductions are comparable to results expected in clinical practice using psychotherapy or with that seen using antidepressant medication.\n\"Using digital tools for mental health is emerging as an important part of our future,\" Mohr said.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that the study was funded by the National Institute of Mental Health.", "answer": 1}, {"article": "The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $800 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, transplantation biology and photomedicine.\nSurvival rates and the incidence and type of tumor recurrence all were similar to what has been reported for photon radiotherapy.\nMassachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School.\n\"At experienced centers, proton therapy has a proven track record of treatment success and safety.\"\nAll had previous surgery to remove as much of the tumor as possible, and all received chemotherapy before, during or after proton therapy.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding sources and conflicts are clearly explained.", "answer": 1}, {"article": "The current study compared the use of traditional medical options -- tranexamic acid pills, mefenamic acid (Ponstel), combined estrogen-progestogen and progesterone alone -- to the use of the levonorgestrel intrauterine system.\nThere was no difference in the rates of surgery or sexual activity between the two groups.\nAnother expert said the findings show promise for women bothered by heavy bleeding.\nInsertion of the device may be mildly uncomfortable for some women, she said.\nThe scale goes from 0 to 100, with lower scores indicating more severe symptoms.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There is another doctor who does not appear to be affiliated with the study quoted in the story.", "answer": 1}, {"article": "LONDON -- GlaxoSmithKline PLC said it has produced an effective bird-flu vaccine for humans and could begin producing the shots at year's end, leaving it to governments to decide whether to begin ordering the shots.\n\nGlaxo, the world's second-biggest drug maker by sales behind Pfizer Inc., called the findings a breakthrough but said it needs to gather additional data before it can answer several important questions, including how much of the vaccine it will be able to manufacture.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quotes representatives from the drug company. The story should have quoted other, independent researchers or clinicians who could have provided additional perspectives.", "answer": 0}, {"article": "Then President Richard Nixon declared drugs \u201cpublic enemy No.\n\u201cThose kinds of changes are not delusional, because blinded interviews with family members, friends and work colleagues [confirm these reports].\u201d\n\nSimilar work has shown psilocybin can help treat anxiety associated with cancer, at UCLA and New York University.\nIn the 1950s through the early \u201970s, research began to show that psychedelics like LSD and psilocybin, the active ingredient in magic mushrooms, could be quite effective at treating mental health disorders like addiction.\nIn the past 20 years or so, a small amount of research has once again begun to focus on these chemicals, showing that they have promise for treating a range of conditions, from addiction to depression and anxiety, says Evan Wood, a psychiatric researcher at the University of British Columbia.\nThe same year, Johns Hopkins University physician and researcher Roland Griffiths showed that in healthy volunteers, psilocybin produced lasting benefits like improved mood and peacefulness six months after ingestion.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only expert quoted is the author of the Canadian Medical Association Journal review article that seems to be the news hook for the story. It would have been interesting to hear a second opinion.\nEditor\u2019s note: This review originally stated that that there was no independent source quoted, which is incorrect. The story quotes Dr.\u00a0Charles Grob who was not involved with the review article that\u2019s the launching point for the story. The rating has been changed to Satisfactory.\u00a0\nThere is also no information about the potential conflicts around such research, and even though such conflicts may be unlikely given the source of drugs studied, a sentence to confirm the independence of the research would have raised the credibility of the article.", "answer": 1}, {"article": "\"While ENDS may have the potential to benefit established adult smokers ... [they] should not be used by youth and adult non-tobacco users because of the harmful effects of nicotine and other risk exposures,\" says Tim McAfee, director the Office on Smoking and Health at the U.S. Centers for Disease Control and Prevention.\n\"Exposure to nicotine can harm adolescent brain development.\"\n\"The intent of big tobacco is to sell their product,\" concludes Peruga.\n\"For every 10% increase in tax you have 4% reduction in tobacco consumption,\" says Peruga.\nThat craving is caused by smoking tobacco but is now being increasingly satisfied by e-cigarettes and the trend to \"vape\" instead of smoke.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story showed good initiative in chasing down and quoting a variety of experts.", "answer": 1}, {"article": "This data can be sent to a mobile phone.\n\"The rate of false positive and false negative diagnosis that breath tests give is a real problem in gastroenterology,\" Berean, who is also Chief Technology Officer at Atmo Bioscience, said.\n\"This gives us confidence that our new technology could potentially solve many mysteries of the gut and help the large portion of the population who have not been able to find a useful diagnosis or treatment for their symptoms,\" Kalantar-zadeh said.\nThe findings show the revolutionary gas-sensing capsule developed by researchers at RMIT University in Melbourne, Australia, could surpass breath testing as the benchmark for diagnosing gut disorders, paving the way to solving previously undiagnosed conditions.\nStudy lead and capsule co-inventor Professor Kourosh Kalantar-zadeh said the results showed high sensitivity and signal-to-noise ratio in measuring the concentration of intestinal hydrogen, providing valuable information at the site of intestinal gas production.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "It\u2019s made clear that one of the sources quoted is the capsule co-inventor, and is also the chief technology officer of the company trying to commercialize the capsule.\nHowever, it\u2019s unclear if the second source \u2014 identified as the study lead and a capsule co-inventor \u2014 is also affiliated with the company.", "answer": 1}, {"article": "In the first year of a two-year trial, 5 of the 31 of those on medication developed full-blown psychosis, compared with 11 of 29 of those who were taking dummy pills.\nGood candidates trickled in slowly; and the researchers added several recruitment sites along the way to increase the numbers of people in the study.\n\"It's clear we need more efficacious drugs with milder side effects.\"\nCritics have charged that treating people for a disorder that has not yet been diagnosed is not only premature but stigmatizing, especially for adolescents.\nMild, psychosis-like symptoms are rare in adolescents, and families often wait until symptoms are pronounced before seeking treatment, Dr. McGlashan said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Mentions that Zyprexa is made by Eli Lilly and that the study was partly funded by this manufacturer (also funded by National Institute of Mental Health).", "answer": 1}, {"article": "Abraham is a consultant for the company.\n\"Not only did we see this reduction in events per hour, the patients also rated themselves better on the Epworth Sleepiness Scale (meaning they were less sleepy during the day) and on a global assessment of their overall quality of life,\" Abraham said.\nIn addition to Abraham, Ohio State's Dr. Rami Khayat and Dr. Ralph Augostini participated in this research, making Ohio State one of the high enrolling centers participating in the study worldwide.\n\"This tells us the effects of neurostimulation are clinically relevant and this could be a promising therapy for those with central sleep apnea.\"\nDuring the first six months of evaluation, 68 devices were activated for treatment, while 73 were left inactive as the control group.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release meets this standard with an end note stating that the study was funded by the manufacturer of the device, and that the quoted researcher is a consultant to the manufacturer.\nWe are glad to see news releases beginning to incorporate more transparency and addressing conflicts of interest.", "answer": 1}, {"article": "But such evidence often does not pan out in human studies.\nThe question is whether the rate-of-living theory is operational in mammals.\u201d\n\nPollak says that none of the most exciting possible benefits for the drug have yet been proved in randomized clinical trials of non-diabetics.\n\u201cPlain old metformin given in the same dose as we do for Type 2 diabetes doesn\u2019t seem to be a breakthrough for cancer, at least for pancreatic cancer.\u201d\n\nMany other metformin clinical trials are underway for breast, colorectal, endometrial and other cancers.\nThe author of the study, Niteesh Choudhry, an associate professor of medicine at Harvard Medical School, also found that newly diagnosed Type 2 diabetics who start on metformin are the least likely to need an additional diabetes drug later.\nBut the guidelines do recommend metformin first.\u201d\n\nFor patients with Type 2 whose doctor started them on a drug other than metformin, he said, \u201cI certainly would encourage people to talk with their doctor.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "By and large, this story gives the reader\u00a0reasonable\u00a0information to judge source bias. Scientists employed as sources are clearly identified as leading individual studies, although\u00a0aside from the science journalist whose anecdote begins the story, one is hard-pressed to find sources independent of studies or funders. Underlying funding is not identified for most studies, although a funder is mentioned in one case. We\u2019ll give the benefit of the doubt.", "answer": 1}, {"article": "That heat can then be used to interrupt the troublesome brain connections responsible for the tremor.\n\u201cFor the first time in a randomized controlled trial, we have shown that ultrasound can be precisely delivered through the intact human skull to treat a difficult neurological disease.\u201d\n\nPioneering Tremor TrialThe multi-site clinical trial included 76 participants with moderate to severe essential tremor, a condition that often robs people of their ability to write, feed themselves and carry out their normal daily activities.\nThe paper outlines the results of an international clinical trial, led by Jeff Elias, MD, of the University of Virginia Health System, that evaluated the scalpel-free approach called focused ultrasound for the treatment of essential tremor (ET), a condition that afflicts an estimated 10 million Americans.\nNewswise \u2014 CHARLOTTESVILLE, Va., Aug. 25, 2016 \u2013 A study published today in the prestigious New England Journal of Medicine offers the most in-depth assessment yet of the safety and effectiveness of a high-tech alternative to brain surgery to treat the uncontrollable shaking caused by the most common movement disorder.\n\u201cThe degree of tremor control was very good overall in the study, but the most important aspects were the significant gains in disabilities and quality of life \u2013 that\u2019s what patients really care about,\u201d Elias said.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "This release identifies the funders of the study but fails to point out that the principal investigator has a financial relationship with the manufacturer of the device used in the study.\nIn addition, the published study notes that \u201cRepresentatives of the manufacturer of the focused ultrasound system used in the study (InSightec) provided study oversight and technical support and obtained national regulatory permissions.\u201d Allowing the device manufacturers to have \u201cstudy oversight\u201d suggests a potential for bias when most studies are obligated to keep a firewall between investigators and financial sponsors.", "answer": 0}, {"article": "This was a phase 2 trial.\n\"Phase 2 was quite positive, but we really don't know if this is going to end up benefiting patients until we get to phase 3.\"\nThe findings were enough to generate the interest of Dr. Lisa A. Carey, the co-author of an accompanying editorial.\nA similar drug, in fact, has shown benefit in patients with BRCA 1 or BRCA 2 mutations predisposing them to breast and ovarian cancer.\nAmong them, she said, were the small size of the study group, \"imbalances at baseline\" favoring the iniparib group, and the \"unconventional\" chemotherapy regimen.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article does not include information about Dr. O\u2019Shaugnessy\u2019s funding from the drug company for consulting & travel.\u00a0 Observations from other researchers about the study would have provided needed perspective about the results.", "answer": 0}, {"article": "Publicity in recent years about emotional, cognitive, and memory problems in aging football and hockey players who suffered multiple concussions during their careers has raised the anxiety level around the topic. A lawsuit by thousands of NFL players who claim the league did not keep them well enough informed about the long-term risks of concussion - dementia is one of them - is based in Philadelphia and has raised even higher the profile of what doctors call mild traumatic brain injury.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites several sources and provides their affiliations.", "answer": 1}, {"article": "A study of a proposed diabetes drug, Januvia, from Merck & Co. showed it lowered a key measure of blood sugar when taken in combination with another common diabetes drug.\n\nThe study, due to be presented Thursday at the European Association for the Study of Diabetes in Copenhagen, involved 1,056 patients diagnosed with Type 2 diabetes who hadn't previously been treated with diabetes medications.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not obtain independent comment on the study findings. ", "answer": 0}, {"article": "Also, scar tissue often builds up around intravenous wires, a process that can make removing and replacing them difficult or dangerous.\nIn recent years, the safety of defibrillator wires has come in particular focus because a model made by Medtronic has been prone to fracturing.\nIn the study published Wednesday, Dr. Bardy and others reported that the new device had undergone several successful initial trials, including one in which it was used for a year in about 60 patients.\nBut Dr. Bardy estimated that the device could work in about 25 percent of patients who now get a defibrillator.\nThe device will not be suitable for a significant number of heart patients, particularly those who require units that also include a pacemaker, which regulates a heart that is beating too fast or too slowly.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\nThe story includes an independent source. It points out that the trials of the new device were paid for by the manufacturer and that the lead researcher founded the company.", "answer": 1}, {"article": "Researchers acknowledge immunotherapy's promise is furthest from realization for bulky solid tumors, perhaps too advanced for the immune system to beat.\nAnd at the National Cancer Institute, a mix of cancer-specific T cells and a booster produced unheard-of improvement in patients with advanced melanoma.\nAnderson professor of blood and marrow transplantation.\nNow, because drugs are mostly tested on patients whose cancer has resisted previous treatment, it's usually used on tumors advanced to often fatal stages.\nThe cancer, glioblastoma, typically kills within that time.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two MD Anderson researchers as well as a scientist at the NCI, who provides much needed balance at the end of the story.", "answer": 1}, {"article": "Those are also symptoms of a deficiency of B12, a key nutrient needed to make red blood cells and DNA and keep the nervous system working right.\n\nVitamin B12 deficiency is officially considered rare, affecting about 1 in 1,000 Americans, according to a 2005 study. But the incidence...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were several sources interviewed for the story. However, the one independent source\u2019s insight was greatly overwhelmed by the personal anecdotes without critical evaluation of their statements. Nonetheless, because there was independent perspective, we\u2019ll give the story the benefit of the doubt on this criterion.", "answer": 1}, {"article": "Age-related macular degeneration affects upward of 15 million Americans.\n\u201cThough additional pre-clinical data is needed, our institute is close to a time when we can offer adult stem cells as a promising source for personalized therapies for this and other human diseases.\u201d\n\nNext steps include testing the efficacy and safety of the stem cell injection in preclinical animal studies to provide information for applying for an investigational new drug.\nCedars-Sinai researchers in the Induced Pluripotent Stem Cell (iPSC) Core, directed by Dhruv Sareen, PhD, with support from the David and Janet Polak Foundation Stem Cell Core Laboratory, first converted adult human skin cells into powerful induced pluripotent stem cells (iPSC), which can be expanded indefinitely and then made into any cell of the human body.\n\u201cThese induced neural progenitor stem cells are a novel source of adult-derived cells which should have powerful effects on slowing down vision loss associated with macular degeneration,\u201d said Clive Svendsen, PhD, director of the Board of Governors Regenerative Medicine Institute and contributing author to the study.\nIn this study, these induced pluripotent stem cells were then directed toward a neural progenitor cell fate, known as induced neural progenitor stem cells, or iNPCs.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release includes at the end a listing of funding sources for this research and there is no information to suggest any conflict of interest.\u00a0 The original research paper specifically states there are no conflicts.", "answer": 1}, {"article": "Overall, the investigators said, adding sestamibi SPECT/CT helped identify 7 of 9 benign tumors, and conventional imaging with added sestamibi SPECT/CT outperformed conventional imaging alone, as measured by a statistical analysis that measures tradeoffs between sensitivity and specificity.\nOn this measure, a value of 0.50 indicates that a diagnostic test is no better than chance.\nConventional imaging combined with sestamibi SPECT/CT had a value of 0.85, while conventional imaging alone had a value of 0.60.\nThe remaining 40 were classified as a variety of other tumor types, including malignant renal cell carcinomas.\nPathology results of surgically removed tumors showed that 8 of the 48 were benign.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release didn\u2019t mention a funder.", "answer": 0}, {"article": "Even as a pigtailed child, Ashley Gallagher was self-conscious about a certain fullness in her face.\nBy middle age, Ms. Gallagher, 51, the owner of a pet-sitting business in Torrance, Calif., was avoiding mirrors and considering liposuction, but she worried about the effects of anesthesia and the recovery time.\nThen she discovered another option: a series of fat-reducing injections intended to slim down a double chin.\nAs an adult, she faithfully performed facial exercises purported to tighten the area under the chin.\nShe stood ramrod-straight, head held high, to make the bulge less apparent.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story provides comments from two experts in the field not associated with the clinical trials or the drug company. Compared with the Post\u2019s news-release based coverage, this yields additional depth and perspective regarding patient selection and potential harms. The story also notes that one quoted source is a paid consultant to the company.", "answer": 1}, {"article": "Taking statins the day of a coronary artery bypass operation may significantly improve survival, a study in the Annals of Thoracic Surgery found.\nThe 1,788 who continued statins up to the day of surgery had a risk of death within 30 days of 1.7 percent, compared with 2.9 percent for 452 who stopped one to three days before surgery, and 3.8 percent for 781 who did not take statins or stopped more than 72 hours before their operations.\n\u201cWe already knew that people on statins before surgery had a decreased risk of death,\u201d said a co-author, Dr. Yi Deng, an assistant professor of anesthesiology at Baylor College of Medicine.\nAfter controlling for many preoperative health and behavioral characteristics, they found that compared with other patients, those who took statins on the day of surgery had a 48 percent reduced risk of dying in the next 30 days.\nUnless you have some other reason to stop them, you should take statins right up to the morning of surgery.\u201d\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources quoted in the story. But some perspective from an expert likely would have helped the story by providing some much-needed context on the reasons people may stop taking a statin before surgery, and how to weigh the risks and benefits in light of this new data.", "answer": 0}, {"article": "Among 242 patients (137 intervention, 105 control) initially identified as high risk for caries, only a quarter of the patients remained at high risk in the CAMBRA group at 24 months, while just over half (54 percent) of the control group did.\nDental decay was low in both groups.\nIf not halted or reversed, this leads to a cavity.\nis an evidence-based approach to preventing or treating dental caries at its earliest stages.\nA dentist who uses CAMBRA obtains the patient's dental and medical history and conducts a clinical exam to assess caries early enough to reverse or halt progression and to determine caries risk factors.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding sources are listed, and there are no apparent conflicts.", "answer": 1}, {"article": "Many people have never heard of rotavirus, but it is one of the most common causes of childhood illness -- many ailments that parents or pediatricians describe as \"stomach flu\" are caused by rotavirus infection.\nThe problem occurs naturally, albeit rarely; it showed up at a sharply elevated rate in babies who received RotaShield.\nVirtually every child in the world contracts the virus repeatedly by age 5, gradually building immunity.\nThe vaccine won approval from the Food and Drug Administration on Feb. 3, and some doctors have received supplies of it.\nIt comes nearly seven years after an earlier rotavirus vaccine was withdrawn from the market for causing a potentially life-threatening form of intestinal blockage in some babies.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The author does quote an independent source, an epidemiologist from the CDC.", "answer": 1}, {"article": "No woman who had a mastectomy developed breast cancer during the three years of follow-up testing.\n\u201cThis is the first study to prove women survive longer with these preventive surgeries and shows the importance of genetic testing when there is a family history of early breast or ovarian cancer,\u201d Dr. Virginia Kaklamani of Northwestern University in Chicago wrote in a commentary about the study published in the Journal of the American Medical Association.\nAccording to the American Cancer Society and the International Agency for Research on Cancer, 1.3 million new breast cancer cases are diagnosed around the world every year and it kills 465,000 women annually, making it the leading global cancer killer of women.\nCHICAGO (Reuters) - Women with mutations in the well-known BRCA1 or BRCA2 genes who have their breasts and ovaries removed are much more likely to survive than women who do not get preventive surgery, U.S. researchers said on Tuesday.\n\u201cMost of these women will die of ovarian cancer, so you can save 20 percent of them with the prophylactic surgery,\u201d Kaklamani said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story includes comments from an author of an editorial in the journal and one other expert who was not involved in the study. Although the story does not report financial or other information about the sources, the study was funded by a variety of grants from public agencies and foundations and neither the researchers nor the editorial writers reported any relevant financial disclosures.", "answer": 1}, {"article": "The last update, in 2005, put more emphasis on chest pushes by alternating 30 presses with two quick breaths; those \"unable or unwilling\" to do the breaths could do presses alone.\nHad the situation been reversed, \"I wouldn't have known what to do.\"\nOnly about 6 percent of those who are stricken outside a hospital survive, although rates vary by location.\nHe noted that victims often gasp periodically anyway, drawing in a little air on their own.\nIn these cases, people need mouth-to-mouth to get air into their lungs and bloodstream.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The medical correspondent cites no sources aside from the AHA recommendations. At least one independent expert should have been consulted. ", "answer": 0}, {"article": "Beaumont's center is one of just 28 proton therapy centers in the U.S.\nThe facilities are impressive, clean and welcoming, but the difference is the people \u2013 best hospital staff I've ever encountered.\nThe proton beam is sent to the treatment room through a transport system consisting of magnets, called the beam line, finally arriving in the gantry, a device that rotates around the patient.\nIn his study published in the International Journal of Radiation Oncology, Biology, Physics, he and his colleagues found, \"in circumstances where surgery may result in significant neurologic or organ dysfunction, patients can be treated definitively with radiation therapy alone.\nThe results supported the use of high-dose definitive radiation therapy, via proton beam therapy, for selected patients with unresected spine and sacral chordomas.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "It\u2019s clear the release is from a proton beam therapy provider discussing one patient\u2019s experience with undergoing the therapy. The release is clearly marked as coming from the treatment provider, so the conflict of interest is pretty straightforward. And the lack of new findings being prevented means that there is no funding source to discuss. As such, this earns a satisfactory ranking.", "answer": 1}, {"article": "Safety, tolerability and response were assessed every eight weeks for the first six months and every 12 weeks thereafter.\nDr. Mehnert, who is also a medical oncologist in the Melanoma and Soft Tissue Oncology Program at Rutgers Cancer Institute, shares more about the research:\n\nQ: How was the study structured?A: At the time our abstract was submitted, 22 patients with a diagnosis of advanced or metastatic papillary or follicular thyroid cancer who failed prior standard therapy were accrued from multiple international sites.\nIt\u2019s an exciting time in early phase drug development when we are observing these results in so many different types of cancer.\nQ: How are immunotherapy drugs changing the landscape of cancer treatment?A: Although many patients treated do not respond, when immunotherapy does induce responses in patients with advanced cancers, these responses may be very long lasting in terms of disease control.\nThey target a certain protein that has the ability to shut down T cells \u2013 a part of white blood cells that help the body fight infection and disease naturally.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release contains no description of funding sources or conflicts. Of the multiple authors, the link to the abstract (click the blue words \u201cabstract disclosures\u201d) identifies many connections to Merck which manufactures pembrolizumab.", "answer": 0}, {"article": "Propping open clogged arteries with a tiny wire-mesh tube called a stent is no better at reducing the risk of heart attack or death in patients with stable heart disease than treatment with medications, according to a large new study that challenges routine use of a procedure that rapidly became standard medical practice.\nThey can safely choose to try medical therapy first.\"\n\"We do too many of these procedures.\"\n\"The data are clear.\"\n\"I think we're getting a midcourse correction.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several sources are quoted.\u00a0 ", "answer": 1}, {"article": "This is the experience many women have.\nChanges like this can make a big difference, says Dr. William Camann, the director of obstetric anesthesiology at Brigham and Women's Hospital in Boston and one of the pioneers of the procedure in the U.S. At Brigham and Women's, their version of the family-centered cesarean is called the gentle cesarean.\n\"He was screaming and then I remember that when I started to talk to him he stopped.\n\"It is the first time we have really done anything innovative or creative with changing the C-section procedure in years,\" she says.\n\"It took me a long time even to be able to say that I gave birth to Avery,\" she says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "It seems that all the experts interviewed in the story have ties to the mothers who are advocates for this approach or to the concept of the family-centered cesarean. One of the people interviewed was Dr. William Camann, a pioneer of the procedure in the US. It would have been interesting to hear from a doctor who opts for a traditional C-section instead of a family-centered one, or one who routinely performs C-sections. That would have been a good opportunity to put an independent perspective into the piece and also to expand on the question, \u201cWhy aren\u2019t family-centered cesareans more popular in the US if mothers are so happy with them?\u201d", "answer": 0}, {"article": "Doctor are taking the first steps to move this treatment beyond the world of the elite athlete.\nThey say, 'no pain, no gain.'\nNormally, platelets help the blood to clot \u2014 but they also promote healing.\nHe is one of the few patients to get it so far \u2014 clinical trials are now testing PRP's safety and effectiveness.\nI definitely had some pain, and there was a lot of gain.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Only one physician and only one patient\u2019s experience were highlighted.\u00a0 This story was crying out for some independent perspective. ", "answer": 0}, {"article": "Dr. Susan Huang, a professor of infectious disease at the University of California, Irvine, wrote an editorial accompanying the study.\n\"A lot of patients and families don't realize that there are problems with a urinary catheter, so they may request them because they think it will allow patients to stay in bed,\" Saint said.\n\"Patients and families should request that a catheter not be put in, and if there is one there, the patient should ask every day whether it is still needed,\" Saint suggested.\n\"This program can reduce urinary infections in hospitals if a team is assembled to ensure adoption of best practices and to rapidly correct reasons for failing to comply with these processes,\" she added.\nThe program Saint helped develop -- called the \"bladder bundle\" -- includes protocols, checklists, training and information-sharing that help doctors and nurses reduce catheter use and prevent infections.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The writer included comments from Dr. Huang, an editorial writer in NEJM, which suffices as an independent source.\nBut, we\u2019re not told that Dr. Saint \u2014 the lead author \u2014 is a paid advisory board member for the health services companies Doximity and Jvion.\u00a0This was probably worth mentioning, since Jvion sells a data product to hospitals \u201cthat looks at the patient population and predicts the risk of an illness or condition before symptoms occur\u201d so that \u201cproviders are better able to stop hospital acquired conditions, prevent patient suffering and deterioration, target population health activities, and save resources.\u201d", "answer": 0}, {"article": "(Reuters) - The U.S. Food and Drug Administration (FDA) on Friday expanded the use of Novartis AG\u2019s relapsing multiple sclerosis (MS) drug Gilenya to treat children and adolescents.\n\nMS is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts communication between the brain and other parts of the body and is among the most common causes of neurological disability in young adults.\n\nGilenya is the first FDA-approved drug to treat pediatric patients suffering from relapsing MS, the U.S. health regulator said.\n\nIn a clinical trial 86 percent of patients receiving Gilenya remained relapse-free after 24 months of treatment, compared to 46 percent of those who were administered another MS drug.\n\nGilenya was first approved by the FDA to treat adults with relapsing MS.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were no independent sources, and the fact that Novartis funded the study to support the FDA approval isn\u2019t mentioned.", "answer": 0}, {"article": "The therapy has even been featured on an episode of the TV series \u201cGrey\u2019s Anatomy.\u201d\n\nBut Dr. Ryan, a gastrointestinal oncologist, suggested in an interview that the procedure was being extended to because \u201cyou can\u2019t make a living doing this procedure in appendix cancer patients.\u201d\n\nHe debated the procedure publicly at the recent annual meeting of the American Society of Clinical Oncology.\nThe is looking at it, according to people in the field.\nAnd putting the chemotherapy on top of tumors should be more effective than systematically delivering it through the bloodstream.\nHe then lifted the small intestine out of the body to sift it through his fingers.\nOne lost much of her abdominal wall to infection and just died in misery.\u201d\n\nAnother risk is that the surgery may be done unnecessarily.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Many different voices with different perspectives were heard in the story.", "answer": 1}, {"article": "Did I feel guilty for potentially contributing to the development of a superbug?\nThe studies also noted that the use of antibiotics must be weighed against the risk of antimicrobial resistance, to which prescriptions for childhood maladies such as ear infections are thought to contribute mightily, and against antibiotics' side effects, which can include diarrhea and eczema.\nCurrent practice guidelines for treating kids' mild middle-ear infections -- or acute otitis media -- call for watchful waiting, to be followed by antibiotics only if symptoms worsen or don't cease.\nBoth of the studies, in contrast to earlier research on which the \"watchful waiting\" approach has been based, are considered well-designed, even if they are on the small side.\nOne of the studies noted that while antibiotics -- specifically, amoxicillin paired with clavulanate -- shortened the duration of symptoms, half the children on placebo eventually got better without the aid of those drugs.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story didn\u2019t solicit a comment from any independent expert about the findings. This is a considerable deficit. With a\u00a0complicated issue such as this,\u00a0expert feedback is critical to highlighting the nuances in\u00a0these studies and how they might impact\u00a0decision-making. That the story takes on an authoritative tone when disseminating incomplete information\u00a0exacerbates the failure in this area.", "answer": 0}, {"article": "Sadly, disappointment is part of it, according to Pharr, who typically hears the frustration of people who go through a study that worked for another person but not for them.\n\"Ethical review happens at several levels: at the NIH, at the Food and Drug Administration and most importantly at University Institutional Review Boards at each institution where a faculty member is participating in a trial,\" Glass explained.\n\"It may have had a different effect on someone else,\" she said.\nUnfortunately, the procedure provided no benefit to patients, though it caused substantial pain to two of the study participants.\nBesides, she added, \"you automatically assume anyone with ALS can participate, but not everyone meets the criteria for a particular study.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes quotes from two people who are not involved in the research. However, it does not mention that the study was partly funded by Neuralstem, a biopharmaceutical\u00a0company focused on stem cell technology. In addition, study authors have numerous financial ties that weren\u2019t disclosed.", "answer": 0}, {"article": "(CNN) The first large head-to-head comparison of two opioid addiction medications found that, although they were equally effective in getting people off of high levels of opioids, users had a significantly more difficult time starting a regimen of naltrexone, compared with buprenorphine.\nSo, for example, a person who is actively using opioids and can't manage the withdrawals may be better suited for buprenorphine, while someone coming from a facility where he or she has detoxed and who doesn't want to use opioids may be better suited for naltrexone.\nThe body also produces natural opioids, but the more narcotics a person takes, the less opioids the body naturally produces.\nIf a person takes an opioid while on naltrexone, it is unlikely they will feel any opioid sensation.\n\"Much like you would expect if the doctor told you 'you have cancer' or 'you have diabetes,' then there are different ways you could pursue treatment,\" he said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although the sources are clearly identified, funding information is missing in action, as are any references to possible conflicts of interest. For example, lead author Dr. Joshua Lee has accepted grant money from Alkermes, the manufacturer of Vivitrol. This should have been disclosed.", "answer": 0}, {"article": "By far, the lowest incidence of colorectal cancers was seen in pesco-vegetarians, people who eat fish at least once a month but eschew all other types of meat. Compared to omnivores, pesco-vegetarians were 43% less likely to be diagnosed with these cancers during the course of the study.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no apparent conflicts of interest, but the story does not include input from any independent sources.", "answer": 0}, {"article": "\"The problem,\" Kohler noted, \"is that we don't want to make behavior changes.\nIt's promising news, Bazil added, that there were no serious side effects in this study.\nLearn more about insomnia and good sleep habits from the National Sleep Foundation.\nKohler said cognitive behavioral therapy -- where people learn to change the thoughts and habits that affect their sleep quality -- is a proven way to manage insomnia.\nBazil agreed: \"I look at most people with insomnia as someone who developed bad sleep habits.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two independent sources added needed balance up against the comments of Merck\u2019s director of clinical research.", "answer": 1}, {"article": "Four people taking curcumin, and two taking placebos, experienced mild side effects such as abdominal pain and nausea.\nThe study was supported by the Ahmanson Foundation, the Marshall and Margherite McComb Foundation, the McMahan Foundation, Bob and Marion Wilson, the Fran and Ray Stark Foundation Fund for Alzheimer\u2019s Disease Research, the U.S. Department of Energy and the National Institutes of Health.\nThe paper\u2019s authors, in addition to Small, are Prabha Siddarth, Dr. Zhaoping Li, Karen Miller, Linda Ercoli, Natacha Emerson, Jacqueline Martinez, Koon-Pong Wong, Jie Liu, Dr. David Merrill, Dr. Stephen Chen, Susanne Henning, Nagichettiar Satyamurthy, Sung-Cheng Huang, Dr. David Heber and Jorge Barrio, all of UCLA.\nThe research, published online Jan. 19 in the American Journal of Geriatric Psychiatry, examined the effects of an easily absorbed curcumin supplement on memory performance in people without dementia, as well as curcumin\u2019s potential impact on the microscopic plaques and tangles in the brains of people with Alzheimer\u2019s disease.\nIt also has been suggested as a possible reason that senior citizens in India, where curcumin is a dietary staple, have a lower prevalence of Alzheimer\u2019s disease and better cognitive performance.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release lists funders and notes that \u201cTheravalues Corp. provided the curcumin and placebos for the trial, as well as funds for the laboratory testing and for [lead author] Small\u2019s travel to present preliminary findings at the 2017 Alzheimer\u2019s Association International Conference.\u201d\nWhat isn\u2019t mentioned is that UCLA owns the patent for the amyloid and tau labelling method used in the study, and that the lead author \u2014 as well as three of the co-authors \u2014 invented the method and have a financial interest in the company that sells it (TauMark, LLC). The lead author has financial relationships with a dozen biomedical companies besides Theravalues and TauMark.", "answer": 0}, {"article": "While the study was relatively small, we believe the data suggest that DBS surgery targeting the fornix can be performed safely in this patient population.\nHowever, its use is being researched for a number of conditions, including epilepsy, depression and bipolar disorder.\nWhereas in Parkinson's disease and essential tremor, the target for the electrodes are nodes within the motor circuits, the Alzheimer's study targeted the fornix, which is part of the memory pathway.\n\"There are more than five million Americans living with Alzheimer's, and yet there are few promising pharmacologic treatment options for this progressive disease,\" says Dr. Ponce.\nInitial research took place between 2012 and 2014 at six hospitals throughout the U.S., including Banner Alzheimer's Institute in Phoenix and Banner Sun Health Research Institute in Sun City, as well as one institution in Canada.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There is no mention of the funding sources. ClinicalTrials.gov shows that the trial was sponsored by Functional Neuromodulation, Ltd. the device being studied. At least one author is associated with Functional Neuromodulation, Ltd.", "answer": 0}, {"article": "* Scientists say new drug could have fewer side effects\n\nLONDON, Jan 8 (Reuters) - A drug for bipolar disorder that works like lithium - the most common and effective treatment - but without lithium\u2019s side-effects has been identified by British researchers in tests on mice.\n\u201cThis is one of the first handful of examples of drug repurposing, where a new use has been found for an existing drug,\u201d Vasudevan said.\nBipolar disorder effects around 1 percent of the population worldwide and sufferers can experience moods that swing from one extreme to another, and have periods of depression and mania lasting several weeks or longer.\nThey screened the library for any drugs that blocked an enzyme that is key to lithium\u2019s success and found ebselen was a possible lithium mimic.\nIn a telephone interview Churchill said that in tests, his team found that mice who were made manic with small doses of amphetamines were able to be calmed again with ebselen.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story would have benefited from some independent perspective. The two quoted sources are both researchers involved in the study.\u00a0 This was a story for which independent perspective was sorely needed.", "answer": 0}, {"article": "When it comes to health, I\u2019m skeptical of willpower. Sure, I talk to my students about personal responsibility, but when it comes to the health of populations, I look for big fixes more than for small acts of will.\n\nThat\u2019s why my ears perked up when I heard that two old physician friends had decided to start taking, as a preventive measure, some of the medications often included in what the field has dubbed the \u201cpolypill.\u201d My friends are both top doctors in their 60s, with good diet and lifestyle, and this is now part of their...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story referred to two separate academic papers, but does not cite any researchers, nor any interviews with experts.\u00a0The coverage would have been improved by seeking out and offering other opinions, rather than glossing over the concerns of critics with a two-sentence paraphrase of their arguments.", "answer": 0}, {"article": "But investors had been anticipating a bigger effect.\nThe Victoza trial, known as Leader, had been designed to show Novo\u2019s drug did not increase heart risk, so its superiority is welcome news for the company, especially as Sanofi\u2019s (SASY.PA) rival Lyxumia failed to show heart benefits in an earlier test.\nThe findings, which involved following 9,340 patients for a median 3.8 years, were also published online in the New England Journal of Medicine.\nMads Krogsgaard Thomsen, Novo\u2019s chief science officer, said the results should encourage doctors to use Victoza earlier, since they could now see it offered \u201clife-expanding\u201d treatment.\n\u201cTo me, the impressive thing about this trial is the consistency across clinical endpoints and its robustness,\u201d said John Buse, professor of medicine at the UNC School of Medicine, who worked on the study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No third-party scientist is quoted, although the views of one industry analyst are paraphrased. It\u2019s not clear, however, if this analyst was actually interviewed for the story, and his comments pertain only to the market\u2019s expectations for the drug. We didn\u2019t think this was substantive enough to rate as Satisfactory.\nThe story does mention that Novo Nordisk funded the study and the focus is squarely on the pharmaceutical industry, making the company\u2019s role clear to the reader.", "answer": 0}, {"article": "Bardwell hasn't worked since November because his condition, inherited, makes breathing so difficult.\nThe hope is that such stimulation will modulate nervous system responses, such as toning down the release of hormones that typically occur at times of stress and increasing the flow of blood.\nThere is considerable data showing connections between the brain, nervous system and heart, said Torre, but until now, no one has attempted to take advantage of the relationship therapeutically.\nThe study calls for Torre to implant the system, done through small puncture holes in the lower back, in 20 patients with advanced heart failure, then conducting tests on them after one, two and three months to measure heart function.\n\"This is a new concept that could increase therapeutic efficacy without adding new medications.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes interviews with one of the study researchers and a patient, but it should have tapped someone with no links to the research for an independent take.\u00a0We\u2019ll flag this one as unsatisfactory. \u00a0\u00a0", "answer": 0}, {"article": "He contended that kratom does not act on the brain's opioid receptors the way prescription painkillers and heroin do. But back in 2016, the Journal of the American Chemical Society reported that kratom indeed works this way. Last month, an FDA study found that 22 of the 25 of the most prevalent compounds in kratom do bind to opioid receptors, and so should be considered an opioid. The study also said most deaths did occur in people who used kratom in addition to other drugs, though in one case, only kratom was detected.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story features comments from independent public health and toxicology experts. It notes that some of the research supporting the benefits of kratom was commissioned by a kratom advocacy group. We think including perspective from an independent health expert would have made the story even stronger, but wasn\u2019t critical.", "answer": 1}, {"article": "Ziman said current methods of melanoma detection are expensive and invasive, involving a trip to a clinician, who must biopsy the lesion to discover whether it is cancerous.\nAntibodies \"are easily accessible in the blood, so it provides a fantastic test to identify an early-stage cancer,\" said project lead Professor Mel Ziman, leader of the university's Melanoma Research Group on Monday.\nDr. Jodie Moffat, head of early diagnosis at Cancer Research UK, agreed that a test which finds melanoma earlier could help reduce deaths from the disease, adding that \"melanoma can be more than skin deep, and it's much harder to treat when diagnosed at a late stage after it has spread.\"\nThe problem is particularly serious in Australia, where melanomas were the fourth most commonly diagnosed cancer in 2017 and cause about 1,700 deaths a year, according to the university.\nIn the meantime, \"people can help spot skin cancer early by knowing what's normal for their skin,\" said Moffat.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We did not detect any conflicts of interest that should have been disclosed, though it would have been useful to explain how the study was funded (a grant from the Australian government). The story provides comments from Dr. Moffat, an unaffiliated expert who places the tests and the results in context.", "answer": 1}, {"article": "DOI: 10.4172/2155-6105.1000290 \n\nhttp://www.\nThis is because smoking increases susceptibility to respiratory infections and stopping smoking can be expected to have a positive effect.\nThe on-line survey of 941 respondents assessed subjective changes in respiratory symptoms in smokers who switched to vaping for at least two months.\nThe researchers say that it is not surprising that the survey respondents noticed improvements in their respiratory health.\nSome previous cell and animal studies have been interpreted as suggesting that vaping may increase vulnerability to infection, but these studies did not use realistic exposure levels.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release does not mention that one of the study authors has financial ties to e-cigarette makers and another to pharmaceutical companies making smoking cessation medications.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Taking multivitamins may help women without cardiovascular disease to ward off a heart attack, new research shows.\nThe women ranged in age from 49 to 83 at the study\u2019s outset, and about 60 percent in each group used some type of dietary supplement.\nSimilar studies have been done in men, with some confirming the current findings and others contradicting them, Rautiainen said.\nDuring the observed period, 932 heart attacks occurred among the women without heart disease, while 269 women with existing heart disease had heart attacks.\nFor the women without heart disease at the study\u2019s outset, taking a multivitamin for less than five years reduced heart attack risk by 18 percent compared with non-users of supplements.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0No independent sources appear to have been used to put the current study results in context. \u00a0Comments from experts in the field could have shed valuable light on this topic.", "answer": 0}, {"article": "Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.\nThe authors note some important limitations of the trial, including the lack of long-term outcomes in the nonsurgical group due to the high crossover rate.\nThe implant procedure is minimally invasive, has few complications, and produces significant and lasting improvements in pain, disability, and quality of life.\nThe study is the first randomized controlled trial to directly compare the results of surgical and nonsurgical treatment for SIJ dysfunction.\nThe randomized controlled trial shows superior outcomes in patients undergoing minimally invasive sacroiliac joint (SIJ) fusion using triangular titanium implants, compared to nonsurgical management, according to the new research overseen by Dr. Daniel J. Cher of SI-BONE, Inc., in San Jose, Calif. (The study was sponsored by SI-BONE, manufacturer of the SIJ implants.)\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release states early on that the research was funded by the company that makes the titanium implant but doesn\u2019t mention that the researchers were either employees or consultants to the company. At a minimum, the release should state what sort of financial relationship the authors had\u00a0with the company.", "answer": 0}, {"article": "The most common form of breast cancer uses oestrogen to grow.\nOur study also demonstrates that statins could be a valuable addition to breast cancer treatment, and that this warrants investigation in clinical trials.\u201d\n\nThe research has not yet been tested in humans.\nBut this is early research and greater clinical evidence is now needed to understand the potential risks and benefits of this approach.\u201d\n\nAnother charity, Breast Cancer Care, said the research was promising but needed further trials.\nThe scientists say the findings are boosted by two studies which found the over-activation of certain genes linked to cholesterol production were linked with a poorer response to the anti-cancer drugs.\n\u201cThis early study raises an interesting question of whether cholesterol-reducing treatment, such as statins, could help lower the chances of breast cancer returning for some women who have developed a resistance to hormone therapy,\u201d said Jane Murphy, clinical nurse specialist.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "It states that the research was funded by Breast Cancer Now, the UK\u2019s largest breast cancer charity.\u00a0It also quotes a clinical nurse specialist from an unrelated UK charity, Breast Cancer Care. This is sufficient enough to be Satisfactory.\nHowever, It does not mention funding from the National Institute for Health Research Biomedical Research Centre at the Royal Marsden National Health Service Foundation Trust and the Institute of Cancer Research, also based in the UK.The story could have quoted more outside experts in order to shed light on the challenge of hormone resistance.", "answer": 1}, {"article": "Over the past 15 years, CHOP hematology researchers have performed clinical trials of gene therapy for hemophilia B that have helped define efficacy and dosing levels in humans.\n\"We developed a unique animal model of this disease after identifying dogs with naturally occurring factor VII deficiency,\" said Margaritis.\nThey are most commonly treated with regular infusions of clotting factor.\nFactor VII (FVII) deficiency has a range of severity, with about 40 percent of patients having severe disease.\nThe CHOP team collaborated with scientists at UNC who have a long-established colony of dogs for hematology research.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There were no conflicts identified. All the funding sources were listed.", "answer": 1}, {"article": "This news release is available in French.\n\"Those numbers reflect the population in general,\" says Bacon, who is also director of the Centre de r\u00e9adaptation Jean-Jacques-Gauthier at Hopital du Sacr\u00e9-Coeur.\n\"It would be great to see physicians recommending physical activity to patients with asthma, alongside traditional pharmacological treatments,\" he says.\nIt's something to keep in mind during winter months, when fitness levels tend to drop along with the temperature, and cold air provides another trigger for asthma symptoms.\n\"Our study shows that those who were able to engage in physical activity on a regular basis year-round benefit most,\" says Bacon.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release states the funding sources, which were grants from the Social Science and Humanities Research Council, Fonds de recherche du Quebec \u2013 Sante, the Canadian Institutes of Health Research and the Michel Auger Foundation of Hopital du Sacre-Coeur de Montreal. No conflicts of interests were declared, both in the original journal article and in the news release.", "answer": 1}, {"article": "Researchers then rated them using a well-validated scale that measures aggression and agitation.\nThere are no currently approved treatments for agitation, and we\u2019re very enthusiastic about this finding.\u201d\n\nCorrection: October 8, 2015 \n\nA report in the In Brief column on Sept. 29 about a combination drug that could ease the agitation of Alzheimer\u2019s disease described incorrectly a disorder treated with the combination drug, dextromethorphan and quinidine.\nThe drug is approved for treating pseudobulbar affect, a neurological disorder that involves involuntary crying, laughing and other emotional displays as its main symptom \u2014 not involuntary movement of the facial muscles.\n\u201cFifty-five percent of the people who were on drugs had a 50 percent reduction in their agitation,\u201d said the lead author, Dr. Jeffrey L. Cummings, director of the Cleveland Clinic Lou Ruvo Center for Brain Health.\nDextromethorphan is a cough suppressant commonly found in over-the-counter cough medicines, and quinidine is a drug used to control heart rhythm disorders.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only source quoted was the lead author. He and most of the other authors are listed as consultants to the company that markets the drug and that funded the study (Avanir). Some of the authors are full-time company employees. The company even supplied a writer to \u201cprovide assistance\u201d in writing up the study. The authors clearly have deep financial conflicts here, and it\u2019s well known that sponsor-funded studies come out positive more often than those funded independently. None of this was discussed or disclosed.\nIt would also have been very easy to use the accompanying editorial to provide more balance and context to the story", "answer": 0}, {"article": "By eating bread containing 4% of dried seaweed the overweight men ingested more dietary fiber (4.5 g more fiber per.\nAn important feature is also that the seaweed has umami - the fifth basic taste, which is known to promote satiety and hence regulate food intake in addition to reduce the craving for salt, sugar and fat.\nBut the responsibility should also be shared by society, argues University of Southern Denmark professor of biophysics, Ole G. Mouritsen, who has authored several books on seaweed as food.\nIt is also possible to add seaweed to meat products and thereby provide the consumer with an increased intake of dietary fiber and antioxidants - or maybe the aim is lower cholesterol levels.\nFor example, dried and granulated seaweed can replace some of the flour when producing dry pasta, bread, pizza, snack bars, etc.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The only clue as to why this news release was written comes when it says that the author of the study in question \u201chas authored several books on seaweed as food.\u201d This seems to be promotional material for his books and little more.", "answer": 1}, {"article": "TUESDAY, Jan. 19, 2010 (HealthDay News) -- DNA testing for the human papillomavirus should replace the Pap smear as the main way to screen women for cervical cancer, according to Italian researchers.\nEinstein had a somewhat different take on the findings.\nThis is happening in single-payer health systems which have national screening.\nThis results in many more callbacks for women to undergo further testing.\nThe U.S. Centers for Disease Control and Prevention has more on cervical cancer screening.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes several sources who provide valuable perspectives.", "answer": 1}, {"article": "Many more stroke victims than previously thought can be saved from disability or death if doctors remove blood clots that are choking off circulation to the brain, a new study has shown.\nThe study showed that the time window could be expanded to 16 hours.\nThe researchers used a special type of brain imaging to identify the patients who still had live brain tissue that could be saved if the blood supply was restored.\nTraditional guidelines have set a limit of six hours after stroke symptoms begin, and said after that it would be too late to help.\n\u201cThese striking results will have an immediate impact and save people from lifelong disability or death,\u201d Dr. Walter J. Koroshetz, director of the National Institute of Neurological Disorders and Stroke, said in a statement.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes a statement from an NIH doctor, taken from a news release.\u00a0 No independent sources were quoted.", "answer": 0}, {"article": "In the new study of 24 patients, scores on a standard test measuring the disturbances of memory, language, attention, and other cognitive skills that are hallmark symptoms of Alzheimer's disease dropped an average of slightly more than five points in those treated with IVIG.\nThe IVIG treatment also appeared to slow the rate of brain shrinkage by about 45%, he tells WebMD.\nIt's a form of intravenous immunoglobulin, or IVIG, drugs that are usually used to treat immune system disorders.\nThe findings were presented at the American Academy of Neurology meeting.\nThat compares with a 15-point decline in patients who initially received placebo and switched to IVIG, says Norman Relkin, MD, of Cornell Weill College of Medicine in New York City.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story explained that the study was funded by the drug company that makes the drug being studied.\u00a0 And it did seek opinions from two independent experts. ", "answer": 1}, {"article": "And functional electrical stimulation is using low levels of electricity in order to activate nerves and muscles in order to restore movement,\" explains Dr. Hunter Peckham, director of the Cleveland F.E.S.\nIt was the lowest point of Annette's life; the woman who once trained dogs to assist the disabled would now be relying on one herself.\n\"I've always compared it to being like a toddler learning how to, you know, walk, write, eat.\"\nSo when the implant is turned on, it electrically stimulates the nerves in order to cause the muscles to move in motions, for example, to open and close the hands.\n\"I had these two implanted electrodes here.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two physicians from the clinic that provides the treatment. The story should have quoted other, independent physicians or researchers who could have provided some much needed perspective.", "answer": 0}, {"article": "MONDAY, April 11, 2011 (HealthDay News) -- A new oral medication for the treatment of multiple sclerosis (MS) shows promise in slowing disease progression, limiting brain atrophy and reducing MS relapses, a recently completed two-year clinical trial demonstrates.\nThe findings concern the experimental drug laquinimod, and stem from work with over 1,100 MS patients at 139 medical facilities in 24 countries.\nThe incidence of liver enzyme elevation was higher in patients treated with laquinimod, according to Comi, but he added that the elevations were temporary, reversible and did not lead to any signs of liver problems.\n\"The injectables aren't going to go away,\" commented Dr. Scott S. Zamvil, a professor of neurology and faculty member in the program in immunology at the University of California, San Francisco.\nThe lead study author is Dr. Giancarlo Comi, director of the department of neurology and the Institute of Experimental Neurology at the Scientific Institute and University Vita-Salute San Raffaele in Milan, Italy.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two independent experts, and makes it clear that the study was funded by the maker of the drug being studied. \u201cThe current research was funded by Teva Pharmaceuticals, the maker of laquinimod,\u201d it says.", "answer": 1}, {"article": "Cancer is the No.\nThe genetic sequencing is also expensive right now \u2013 on the order of several thousand dollars for the 30,000 repeats the team did.\nIt was not a slam dunk, but the test found cancer in the blood of more than half the patients who had been diagnosed with stage 1 cancer.\nThere\u2019s a debate over the usefulness of screening for prostate cancer but blood tests and physical exams can indicate some men at high risk.\nAnd then it will have to be shown that using the test allows doctors to intervene sooner and help people.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does include a quote from a National Cancer Institute researcher who wasn\u2019t part of the study team, and it also acknowledges that the lead researcher has patented the technology behind the test and is the principal of a company doing genetic screening.", "answer": 1}, {"article": "Cancer cells remain elusive and tough to locate, but a new crop of nuclear-imaging tests promises to lead to more accurate prognosis and treatment.\n\nThe tests use imaging agents that combine radioactive isotopes with targeted molecules that can spot cancer at the cellular level. The ability to accurately locate the cancers helps physicians make better and earlier diagnoses\u2014and may eventually make possible targeted nuclear-medicine therapies that identify and kill cancer cells, but not the surrounding healthy cells.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two sources independent of the companies\u2019 representative. There do not appear to be conflicts of interest.\u00a0The article needed more information about where the clinical trials were/are underway.", "answer": 1}, {"article": "EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, AUGUST 5, 2015\n\nMedia Advisory: To contact corresponding author Gretchen A. Brenes, Ph.D., call Marguerite Beck at 336-716-2415 or email marbeck@wakehealth.edu.\nThese two trends are inextricably linked in the area of geriatric mental health and our search for better, more effective treatments with greater reach.\u201d\n\nThe author made conflict of interest disclosure.\nThe clinical trial demonstrated both treatments reduced symptoms of worry, depression and GAD, but telephone CBT was superior to telephone NST and resulted in a greater reduction of symptoms.\nHowever, older adults who live in rural areas can face a number of barriers, including living in an area where psychotherapy is not available, so alternate methods of providing treatment could increase utilization, according to the study background.\nPlease see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "An end note points out that this study was funded by the National Institute of Mental Health.\u00a0 There was no indication of any conflicts of interest.", "answer": 1}, {"article": "For this case-control study, researchers recruited 5,307 colonoscopy patients, 60 percent of them men, at two Tennessee hospitals over a seven-year period ending in April 2010.\nAll patients were interviewed about diet, health habits and medical history.\nThey found 2,141 people with polyps, leaving 3,166 polyp-free controls.\nThe analysis appears online in The American Journal of Clinical Nutrition.\nAnimal studies have suggested that omega-3 fatty acids may have anti-cancer effects, but the results from human epidemiological studies have been inconclusive.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent source was quoted.", "answer": 0}, {"article": "Sandoval is alive today because of an experimental form of immunotherapy called CAR-T.\nOn Friday, Moffitt Cancer Center and MD Anderson reported test results of 101 patients with advanced lymphoma who had failed previous therapy and were treated with CAR-T.\n\n\u201cIt puts a GPS navigation on the front of the cell so that when they\u2019re infused back in they know where to go and kill the lymphoma,\u201d said Dr. Frederick Locke, who helped lead the trial.\nWith CAR-T, a patient\u2019s own immune cells are removed from the body, reprogrammed to find and destroy cancer cells, then put back into the bloodstream.\nThe FDA will review these results and could make a decision on approval by the end of the year.\nBeing around for my daughter, my son, my wife.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story is not satisfactory\u00a0on all counts. It does not report that the treatment maker, Kite Pharma, paid for the trial, with additional funding from the Leukemia & Lymphoma Society (which lists Kite Pharma as a Patron level sponsor). The story also does not report that the researcher quoted in the story has disclosed in previous publications about this trial that he has served as an advisory board attendee for Kite Pharma. There are no independent sources noted in this story.", "answer": 0}, {"article": "Treatment usually involves replacing one of the steroids they are unable to produce - called cortisol - with a medication.\nProfessor Brian Walker, Head of the BHF Centre for Cardiovascular Science at the University of Edinburgh, said: \"These findings suggest that corticosterone could provide a safer alternative to traditional cortisol replacement therapy for conditions such as Addison's disease and congenital adrenal hyperplasia.\"\nThe researchers say that, with further research, these findings may one-day lead to improved therapies for other conditions that respond to steroid treatment, including asthma and rheumatoid arthritis.\nDr Mark Nixon, of the BHF Centre for Cardiovascular Science at the University of Edinburgh, said: \"The discovery of this selective corticosterone pump in fat cells could lead to a completely new approach in our search for safer steroid medications.\"\nThe study, published in the journal Science Translational Medicine, was funded by Wellcome, the British Heart Foundation, the Medical Research Council and the Engineering and Physical Sciences Research Council.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The text offers information about funding sources. The reader must infer that the two sources in the release were involved in the research, but their full identifications make that relatively easy to do.\u00a0Possible conflicts of interest are nowhere to be found.", "answer": 1}, {"article": "About 15% of people with MCI develop full-blown Alzheimer's disease each year.\nThere may even be a reason to start for people in their late 30s and up, he says.\nAccording to the findings, people older than 65 who had higher blood levels of caffeine developed Alzheimer's disease two to four years later than their counterparts with lower caffeine levels.\nIn the study, blood levels of caffeine were more than 50% lower among people with MCI who developed Alzheimer's during follow-up, when compared with their counterparts who did not worsen.\n\"There is no reason to stop if you are experiencing memory problems.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An independent expert injects some important cautionary notes, We wish this perspective had been featured more prominently, and that more experts had been consulted.", "answer": 1}, {"article": "\"So many people say `how can cancer screening be harmful?'\nThe results are \"provocative,\" but this type of study can't prove that screening prevents deaths, said Dr. Matthew R. Smith of the Massachusetts General Hospital Cancer Center.\nThe new study was the first big one to examine a newer screening tool, HPV tests, with or without Pap smears in routine practice.\n-For women 30 and over, a test for the virus, HPV, is better than a Pap smear for predicting cervical cancer risk, and those who test negative on both can safely wait three years to be screened again.\n\"The answer is, it could hurt a lot,\" said Dr. Allen Lichter, chief executive of the American Society of Clinical Oncology.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story\u00a0made good use of experts who put the studies\u2019 findings into context. The story also noted the funding behind the studies and one potential conflict of interest, saying, \u201cThe National Cancer Institute, the Swedish Cancer Society and several foundations paid for the work, and one researcher holds patents for two PSA-related tests.\u201d", "answer": 1}, {"article": "So it really is extraordinarily helpful for people.\u201d\nThat needs to be shown.\u201d\n\nThe researchers are in the process of collecting this data; the clinical trial will run until December.\nI can eat like a normal person, doing things that I couldn\u2019t do before.\u201d\n\nIn July, the Food and Drug Administration approved the device being used in the trial.\nIt has been developed by InSightec, which is funding the trial along with the Focused Ultrasound Foundation and the Binational Industrial Research and Development Foundation.\n\u201cAs we make the test lesion, we see a subtle improvement in their tremor and the patients notice it,\u201d said Dr. Rees Cosgrove who is leading the trial at Brigham and Women\u2019s Hospital in Boston.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only fulfills part of our criteria. It does use one independent source, a physician who was not involved in the study. It also accurately reports the trial\u2019s funding sources: InSightec, which developed the device; along with Focused Ultrasound Foundation, which is funded by device makers and philanthropic organizations; and the Binational Industrial Research and Development Foundation, an Israel-U.S. government partnership that receives corporate support.\nHowever, the story falls short because it does not report the fact that nine of the study authors reported conflicts of interest, with most receiving financial compensation of some sort from device makers in the field. Lead researcher G. Rees Cosgrove, M.D. who is quoted in the story, reported receiving consulting fees from InSightec.", "answer": 0}, {"article": "gov.\nCAVEATS Most participants were white.\nAnyone considering changing or beginning treatment of any kind should consult with a physician.\nTHE QUESTION Eating fish can be good for the heart, thanks to the presence of omega-3 fatty acids.\nThose with the lowest levels of omega-3s showed signs of accelerated aging.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent source was quoted. An extra two dozen words may have done the trick.", "answer": 0}, {"article": "\u2022 Delayed surgery with long-course (25x2 Gy) radiotherapy followed by surgery after 4-8 weeks.\nThe study now presented in The Lancet Oncology is based on the claim that the adverse effects of rectal cancer treatment can be reduced by administering more but lower doses of radiation for a longer time, or by increasing the interval between radiotherapy and surgery.\n\"The results of the study will give rise to improved therapeutic strategies, fewer complications with a sustained low incidence of local recurrence, and better survival rates for rectal cancer patients,\" says Professor Martling.\n\"Back then we showed that preoperative radiotherapy reduces the risk of local recurrence by over 50 per cent for patients with rectal cancer,\" says principal investigator Anna Martling, senior consultant surgeon and professor at Karolinska Institutet's Department of Molecular Medicine and Surgery.\nIt also showed that there is no difference between long-course and short-course radiotherapy other than that the former considerably lengthens the time for treatment.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release states that the study was financed by the Swedish Research Council and the Cancer Society in Stockholm, and through the regional ALF agreement between Stockholm County Council and Karolinska Institutet. According to the study, there are no conflicts of interest.", "answer": 1}, {"article": "SUNDAY, March 6, 2011 (HealthDay News) -- A simple blood test may one day offer a safe way to detect Down syndrome during pregnancy, researchers say.\nThe new test eliminates the risk of miscarriage, Patsalis said.\n\"The cost is much lower than the invasive procedures,\" he said.\nHeart defects and other health problems are also common, according to the March of Dimes.\n\"We estimate we can introduce this to clinical practice in a couple of years.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included the perspective of one independent expert.", "answer": 1}, {"article": "\"Although alemtuzumab [Lemtrada] treatment is associated with safety risks, those risks are manageable in most patients,\" Miskin said.\nThe new trial of more than 600 patients with relapsing-remitting MS was funded by Sanofi Genzyme and Bayer HealthCare Pharmaceuticals, the drug's makers.\nBecause of serious side effects, the drug -- Lemtrada (alemtuzumab) -- is approved in the United States only for patients who have failed other treatments.\nAlso, when the immune system rebuilds itself, \"a significant number of people, about 40 percent, will develop another autoimmune disease,\" Giovannoni said.\nAccording to Bruce Bebo, executive vice president for research at the National Multiple Sclerosis Society, \"Restoring lost function is a significant unmet need for people living with MS.\"\n\nThis study examines previous findings related to the reversal of some disability in those receiving alemtuzumab, he said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several potential\u00a0conflicts of interest were not disclosed. From other sources, including here, we see that lead researcher Dr. Giovannoni receives consulting fees from Bayer Schering Healthcare, Biogen Idec, Genzyme, GlaxoSmithKline, GW Pharma, Merck Serono, Novartis, Protein Discovery Laboratoires, Teva-Aventis, Vertex Pharmaceuticals, UCB Pharma, Pfizer.\nAnd as for the source from the National Multiple Sclerosis Society, the society reported receiving nearly $2.6 million from the\u00a0drug\u00a0manufacturers who funded this study (Bayer and Sanofi) in 2015.", "answer": 0}, {"article": "However, Richmond says patients considering viscosupplementation should discuss this as a treatment option with their doctor.\n\"We have an epidemic of osteoarthritis of the knee and we have limited treatment options,\" says Dr. Richmond, who was not affiliated with the analysis but who reviewed the same data it was based on.\n\"This is most effective in relatively younger patients, 40 to 50 to 60 year olds, and...in people with mild to moderate forms of the disease,\" says Richmond.\nThe effect of the injection used in viscosupplementation is to stimulate cells in the knee to increase production of hyaluronic acid.\nThe most common side effects patients undergoing viscosupplementation may endure are flare-ups - where the knee becomes hot and swollen within 24 hours after the injection - and effusions, where excessive joint fluid collects inside the knee.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "While some data (not much) is cited from the Swiss meta-analysis, no one from that research team was interviewed.\nThe only interview weight was given over to a US critic.\u00a0 Why?\u00a0 How was he chosen?\u00a0 Why was he given this platform?", "answer": 0}, {"article": "The researchers did not observe any side effects.\nBut there are a lot of people out there who still have HPV, and nothing protects against all 130 strains of the virus.\n\u201cSeveral therapeutic vaccines have shown great promise in phase 1 and then not panned out in phase 2,\u201d she noted in an e-mail.\nSome women, because of their particular genetic makeup, can clear precancerous lesions on their own and would not need this vaccine.\nEighteen women with high-grade precancerous cervical lesions participated in the phase 1 study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did provide a quote from an independent researcher who was not involved with the current research (and does not appear to be affiliated with the vaccine manufacturer).", "answer": 1}, {"article": "Four trials had used zinc gluconate lozenges and colds were shortened on average by 28%.\nThere is no significant difference between zinc acetate lozenges and zinc gluconate lozenges regarding their efficacy in shortening the duration of common colds according to a meta-analysis published in Journal of the Royal Society of Medicine Open.\nIf that outlier trial was excluded, the difference between the three zinc acetate and the three zinc gluconate trials shrinked to just 2%, i.e., a 40% vs. 38% reduction in common cold duration.\nNevertheless, he also considers that \"the current evidence of efficacy for zinc lozenges is so strong that common cold patients should be encouraged to try them for treating their colds, but the patients should ascertain that the lozenges do not contain citric acid or its salt citrate.\"\nAlthough the binding difference between zinc acetate and zinc gluconate is a fact, it is not evident whether that causes significant differences at the clinical level for treating the common cold.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The source of funding for the study is not identified. We\u2019ll rate this not applicable since a meta analysis of already completed trials is not particularly costly and may not have needed outside funding. The study itself noted there was no funding.\nArguably the more important issue is whether the included studies were funded by zinc manufacturers and conducted by researchers with ties to the supplement industry. While it would have been nice to see that information included, we won\u2019t dock the release for the omission.", "answer": 2}, {"article": "The trial was registered at http://www.\nAbout the Journal of Orthopaedic & Sports Physical Therapy\n\nThe Journal of Orthopaedic & Sports Physical Therapy\u00ae (JOSPT\u00ae) publishes scientifically rigorous, clinically relevant content for physical therapists and others in the health care community to advance musculoskeletal and sports-related practice globally.\nDry needling may be a viable treatment alternative to cortisone injection for patients with chronic, intermittent pain and tenderness on the outside of the hip, thus avoiding the potentially harmful effects of steroids\n\nDry needling may be a viable treatment alternative to cortisone injection for patients with chronic, intermittent pain and tenderness on the outside of the hip, thus avoiding the potentially harmful effects of steroids, according to a new study published in the April 2017 issue of the Journal of Orthopaedic & Sports Physical Therapy\u00ae (JOSPT\u00ae).\n\"Evidence for dry needling of the hip in lieu of steroid injection is in its infancy,\" acknowledges lead author Kindyle L. Brennan, PT, PhD, with Baylor Scott & White Health.\nEpub March 3, 2017. doi:10.2519/jospt.2017.6994\n\nThe study was approved through the Baylor Scott & White Health Institutional Review Board.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release doesn\u2019t mention any conflicts of interest, and none were reported in the study. The release also echoes the study\u2019s statement that funding came from Baylor Scott & White Health, which is a Dallas-based healthcare system.", "answer": 1}, {"article": "\u2022 None 6 things you can do right now to help prevent the flu \n\n\n\nThe drug uses a different approach to fight the flu than other medications.\nOnce inside a cell, it hijacks the cell's machinery, forcing the cell to make copies of the virus.\nThen, the newly copied viruses break out of the cell, spreading to other cells nearby and repeating the process.\nBoth Japanese and American flu patients were included in the trial.\nThe flu virus spreads through the body by invading cells.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "All of the information in the story is attributed to the Wall Street Journal. Not good enough.", "answer": 0}, {"article": "\"How bulging is the eardrum?\nBut here's the rub \u2013 diagnosing ear infections in very young children, who tend to squirm, is not easy.\nIf many children in prior studies didn't really have ear infections, then it's not surprising the antibiotics didn't work for them, says Dr. Jerome Klein of Boston University, who wrote an editorial that accompanies the new studies.\nBoth studies, which appear today in the New England Journal of Medicine, find these kids get over painful ear infections faster, and have less severe symptoms, if they get prompt treatment with Augmentin, an inexpensive antibiotic often used to treat respiratory infections.\nBut Spiro thinks \"the pendulum will swing the other way\" \u2013 that is, toward immediate antibiotic treatment \u2013 because of the new studies.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does a great job using independent experts who provided a reasoned, thoughtful discussion of the findings. The one omission was the failure in the blog post or the radio piece to report that two of the authors on the US study had received funding from the drug company that makes the antibiotic being studied:\u00a0GlaxoSmithKline. However, the drug is available as a generic product (especially the suspension used in kids) and the NIAID funded the study, so we\u2019ll give the story the benefit of the doubt on this criterion.", "answer": 1}, {"article": "Roslin said patients who have other treatments that restrict their ability to eat -- such as bands and bypass operations that reduce the size of the stomach -- often regain lost weight over time.\nThe study lasted a year, but \"we don't know what happens after that,\" Pryor said.\nThe balloon treatment will be available starting in January, but the cost hasn't been announced, Pryor said.\n\"While there is potentially easier insertion that does not require sedation, I still doubt after removal there will be weight loss,\" he said.\nThe device, called the Obalon Balloon System, was approved in September by the U.S. Food and Drug Administration.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One of the strongest aspects of this story is the ample use of independent sources to provide context and point out limitations of the device. However, this criterion demands that sponsors of research be identified, and this story does not tell readers that the trial was sponsored by Obalon Therapeutics.", "answer": 0}, {"article": "By comparison, the only approved long-term prescription weight loss medication available on the market today, Xenical, is associated with a seven-pound weight loss when combined with diet and exercise.\nPhentermine is commonly used as a short-term weight loss treatment, and was previously paired with fenfluramine to make the successful but now-discontinued weight loss drug Fen-phen.\n\"But unless it's paired with aggressive lifestyle changes, it may not be great in the long term.\"\nThe drugs, phentermine and Topamax, in combination with lifestyle and weight-loss counseling were associated with a 18-22 pound weight loss in trial participants, compared with a three-pound weight loss in patients who received counseling alone.\nThe drug also appears to have reduced other obesity-related indicators, such as blood pressure, cholesterol and inflammation levels.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story turned to \u201cDr. Melina Jampolis,\u00a0 CNNHealth\u2019s physician nutrition expert, who is not connected with the study.\u201d\u00a0 We wish the story had given us some background on her expertise.\nIt also stated that \u201cThe study was funded by the pharmaceutical company Vivus.\u201d", "answer": 1}, {"article": "Sharif said the excellent short-term outcomes and 100 percent cure rate of HCV in organ recipients should prompt transplant centers to rethink use of HCV-infected kidneys.\nAnd the average wait time for a non-infected kidney is more than two years, compared to eight months for an HCV-infected kidney.\nAnother study, published in the same journal in July, reported similar success in transplants of HCV-infected kidneys into HCV-infected patients.\nIn a study of 20 uninfected patients, researchers found that transplanting infected kidneys and then treating recipients for HCV resulted in a 100 percent cure rate.\nThough some patients might not want to take the risk associated with an infected kidney, others might consider it a good option, given the high death rates for dialysis patients awaiting transplants, the researchers suggested.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted one source not involved in the study, Adnan Sharif, MD, a consultant transplant nephrologist at Queen Elizabeth Hospital and University of Birmingham in the United Kingdom, who wrote an editorial that accompanied the study.\nMore importantly, the story didn\u2019t inform readers that the study was funded by Merck, maker of the HCV drug combination elbasvir/grazoprevir, which is marketed under the name Zepatier. (Merck stands to profit from HCV-infected kidney donations becoming more common.)\nIt also didn\u2019t mention that six of the study\u2019s physician authors reported relationships with drug companies that make HCV treatments and/or transplant anti-rejection drugs. That included lead researcher Peter Reese, M.D., who is quoted extensively in the story. Reese reported grants from four companies including Merck and another HCV treatment maker, Bristol-Meyers Squibb.", "answer": 0}, {"article": "In contrast, the risk of failure among recently recalled defibrillators has been estimated by the manufacturers at just 0.009 percent to 2.6 percent.\nSome patients \"might want to hang out and wait and see what happens,\" Krahn said.\nA new Canadian study provides the first estimate of the risk of major complications from replacement surgery, important information for patients facing the choice.\n\"That risk is much higher than we initially thought,\" said study co-author Dr. Andrew Krahn of the London Health Sciences Center in Ontario.\nImplantable defibrillators can be as small as a half dollar and are placed surgically under the skin of the upper chest.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Article notes that the quoted expert has financial ties to device manufacturers, and that he asserts that this research was done without funding from the industry. ", "answer": 1}, {"article": "\u201cWhat about long-term safety issues?\u201d he asked.\nFor that reason, the finding that marijuana may actually help improve patients\u2019 sleep, she said, is \u201cparticularly noteworthy.\u201d\n\nThe cannabinoid family, which includes marijuana, is \u201cemerging as an interesting new class of drugs for pain management,\u201d Ware said.\n\u201cThe trial did not last long ... so the authors cannot really say whether any response would be sustained,\u201d Dr. Henry McQuay, who studies pain and pain relief at the University of Oxford, wrote in an editorial accompanying the study.\n\u201cA lot of the treatments that are used for neuropathic pain ...might also be associated with disruptions in sleep,\u201d Dr. Andrea Hohmann, who studies marijuana and pain at the University of Georgia and was not involved with the current study, told Reuters Health.\nNEW YORK (Reuters Health) - In a small study, people who had chronic pain as a result of damage to the nervous system reported feeling less pain, as well as less depression and anxiety, when they smoked marijuana compared to when they smoked a drug-free placebo.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two outside experts, one of whom is completely independent from the study and the journal, Dr Andrea Hohmann. Beyond that, we would bet that the reporter spent more time interviewing Dr. Mark Ware, the lead researcher, or at least asked tougher questions. Because Ware is more measured in this story than in the WebMD story. He even goes so far as to say, \"What about long-term safety issues?\" he asked. \"These need to be considered before the drug becomes prescribable.\" As with the WebMD story, it would have been nice to see who funded the research. Unlike the WebMD story, this one did not point out the conflicts of interest of Dr. Henry McQuay.", "answer": 1}, {"article": "A breakthrough in helping the body to produce more insulin could make tedious injections of the hormone history.\n\u201cThat\u2019s a huge difference.\u201d\n\nWhat\u2019s more, it appears the cells are relatively long-lasting, which could indicate they are robust enough to bring glucose levels in diabetics under control.\nIn theory, if the same results occur in people, it\u2019s possible that those on the verge of developing diabetes might never progress to develop the disease, since the high blood sugar levels that can cause damage to tissues and lead the body to become less responsive to insulin could be avoided.\nJohn Anderson, president of medicine and science for the American Diabetes Association, says \u201cIt\u2019s very promising and opens up new avenues of research, but we are a long way from replacing insulin, or a cure, or even knowing how this [hormone] will work in human tissue.\u201d\n\nThose concerns aren\u2019t lost on Melton, who also recognizes that more research is needed to confirm that betatrophin may benefit patients.\n\u201cWe don\u2019t understand the cause of type 2 diabetes, but everyone agrees that having more beta cells is better,\u201d says Douglas Melton, senior author of the paper and co-director of the Harvard Stem Cell Institute.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story features a useful comment from an American Diabetes Association expert (though we wonder how many people will read far enough down the story to see it). Unfortunately,\u00a0the story didn\u2019t mention that the authors of\u00a0the study already have agreements in place to commercialize their research. Here\u2019s how a press release about the study described these relationships: \u201cWorking with Harvard\u2019s Office of Technology Development, Melton and Yi already have a collaborative agreement with Evotec, a German biotech firm that now has 15 scientists working on betatrophin, and the compound has been licensed to Janssen Pharmaceuticals, a Johnson & Johnson company that now, too, has scientists working to move betatrophin toward the clinic.\u201d", "answer": 0}, {"article": "Hoberman is chief of the general academic pediatrics division at Children's Hospital of Pittsburgh of UPMC.\n\"Given significant concerns regarding overuse of antibiotics and increased antibiotic resistance, we conducted this trial to see if reducing the duration of antibiotic treatment would be equally effective along with decreased antibiotic resistance and fewer adverse reactions,\" Dr. Alejandro Hoberman said in a university news release.\n\"The results of this study clearly show that for treating ear infections in children between 9 and 23 months of age, a five-day course of antibiotic offers no benefit in terms of adverse events or antibiotic resistance,\" Hoberman said.\nThe children ranged in age from 9 months to 23 months, and were randomly selected to receive either a standard 10-day course of antibiotics or a shortened five-day course of antibiotics followed by five days of placebos.\n\"Though we should be rightly concerned about the emergence of resistance overall for this condition, the benefits of the 10-day regimen greatly outweigh the risks,\" he added.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The disclosure form from the New England Journal article tells us that \u201cDrs. Hoberman and Martin report receiving consulting fees from Genocea Biosciences; and Dr. Hoberman, receiving grant support from Ricoh Innovations and holding pending patents related to the development of a reduced clavulanate concentration version of amoxicillin\u2013clavulanate potassium (U.S. patent application serial number, 14/371,731) and the development of a method and apparatus for aiding in the diagnosis of otitis media by classifying tympanic-membrane images (U.S. patent application serial number, 14/418,509). No other potential conflict of interest relevant to this article was reported.\u201d\nThis potential conflict of interest information was not in the\u00a0HealthDay story.", "answer": 0}, {"article": "Nevertheless, accumulating evidence has her urging patients to get their calcium from their diet, rather than reflexively telling them to take 1,200 milligrams of calcium a day.\nDr. Susan V. Bukata, associate professor of orthopaedic surgery at the University of Rochester Medical Center, said that the study really doesn't provide enough information to make a definitive conclusion.\n\"The cautious way forward seems to be to encourage people to obtain their calcium from the diet, rather than from supplements, since food calcium has not been shown to carry this increased risk of heart disease,\" Reid added.\nAnd in an accompanying journal editorial, medical professors Dr. Bo Abrahamsen and Dr. Opinder Sahota wrote that due to study limitations, \"it is not possible to provide reassurance that calcium supplements given with vitamin D do not cause adverse cardiovascular events or to link them with certainty to increased cardiovascular risk.\nBut, as the current authors point out, more than half of the women in that study were already taking their own calcium supplements on top of what they had been prescribed for the trial, which may have clouded the results.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes some good independent sources, including Dr. Philip Houck, assistant professor of internal medicine at Texas A&M Health Science Center College of Medicine, and Dr. Susan V. Bukata, associate professor of orthopaedic surgery at the University of Rochester Medical Center.\n", "answer": 1}, {"article": "Researchers say the number of people with type 2 diabetes is expected to increase by 65% by 2025, reaching an estimated 380 million people worldwide.\nOverall, the studies involved nearly a million participants.\nWhen the information from the individual studies was combined, researchers found each additional cup of coffee drunk per day was associated with a 7% lower risk of diabetes.\nPeople who drank three to four cups per day had about a 25% lower risk than those who drank two or fewer cups per day.\nIn the study, researchers analyzed information from 18 studies on coffee and diabetes and another 13 studies that included data on decaffeinated coffee and tea drinking and diabetes.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0No independent experts in the field were quoted to provide context for the information presented.", "answer": 0}, {"article": "Funding for the study was provided by the Wake Forest Translational Science Institute and Center for Integrative Medicine and the Claude Pepper Older Americans Independence Center of Wake Forest Baptist.\nThe study included the participants' history of falls and their fear of falling, blood tests at the beginning and at end of the trial to measure 25-hydroxyvitamin D (biomarker for vitamin D in blood), and a monthly diary recording falls during the trial period.\nAt the beginning of this pilot study, the research team found that more than half of the participants had insufficient concentrations of vitamin D in the blood (less than 20 ng/ml), while less than a quarter had concentrations in the optimal range (30 ng/ml or more).\nThe study is published in the early online edition (8/16/2015) of the Journal of the American Geriatrics Society.\nThe study showed that the monthly vitamin D supplement was effective in increasing the concentrations of vitamin D in the blood from insufficient to sufficient levels in all but one of the 34 people who received it, and to optimal levels in all but five people.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release cites funding sources. It makes no mention of possible conflicts of interest, but the study itself says none were found.", "answer": 1}, {"article": "(Reuters) - Medtronic Inc, a manufacturer of pacemakers, heart stents and spine products, has developed a device to tackle another common health problem: erectile dysfunction.\nIt was placed in the artery, opening the vessel and allowing for better blood flow.\n\u201cThis is still investigational and requires more research.\nAfter three months the results were promising, the company said.\nIt is the inception of an entirely new way of treating ED that has never been seen before,\u201d he said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent source was quoted \u2013\u00a0 the company-sponsored investigator was the only source quoted.", "answer": 0}, {"article": "However, a pre-planned interim review of the treatment effectiveness after 200 patients were enrolled in the trial led the independent Data Safety Monitoring Board overseeing the study to recommend early termination of the trial, based on pre-defined criteria demonstrating that clot removal provided significant clinical benefit in the studied patients.\nThere was no difference in mortality or other safety end-points between the two groups.\nOnly 13.1 percent of the medication group had a similar decrease.\nThe mantra 'time is brain' still holds true.\"\nThe trial was sponsored by Stryker Corporation, a medical technology company that manufactures the clot removal devices used in the study.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding source \u2014 a device manufacturer \u2014 was disclosed.", "answer": 1}, {"article": "\u201cWe think this is the first (study) to show this.\u201d\n\nMoss said women have often been overlooked in studies of heart disease, which until recently were dominated by men.\n\u201cThis was far greater than expected.\nWomen tend to have smaller hearts than men and Moss said the treatment works better in smaller hearts.\nIt is the leading killer of women in the United States, claiming more women each year than men.\nThe original study, published in 2009 in the New England Journal of Medicine, showed patients fared better with a combination cardiac resynchronization therapy and a defibrillator rather than a defibrillator alone.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources were cited or quoted. \u00a0The story did mention that the study reported on was funded by the manufacturer of the device discussed.", "answer": 0}, {"article": "Pain patches have a number of benefits, Rosenquist and Dombrowski said, not the least of which is convenience.\nThe active ingredients in Salonpas are methyl salicylate and menthol, common components of pain-relieving gels and creams, such as Bengay.\n\"Salonpas is the Western world catching up with Asia,\" said Dr. Rick Rosenquist, a professor of anesthesia and director of pain medicine at the University of Iowa Carver College of Medicine and chairman of the American Society of Anesthesiologists' committee on pain medicine.\n\"You need to pay attention when you put them on, to see if you have any kind of skin reaction to the compounds that are contained in the patch,\" Rosenquist said.\n\"It's a very clever way of getting the medications right where they need to be.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes some independent sources.\u00a0 We just wish the story had made better use of these sources. Why not ask them to help quantify the benefits and harms?\u00a0 Why not have them discuss some of the alternatives to sticking a patch on the affected area?  ", "answer": 1}, {"article": "Frustrations included warning alarms and problems at the insertion point of the device.\n\"The promise in the near term of these technologies is not only to help us reduce significantly the risk of long-term diabetic complications, but also to reduce the risk of having a catastrophic hypoglycemic event, and further help people with diabetes live easier,\" Aaron Kowalski, research director of the JDRF's Artificial Pancreas Project, said during the teleconference.\nA symposium on advances in the technology -- co-sponsored by the American Diabetes Association and the JDRF -- is slated for Sunday as part of the American Diabetes Association's annual meeting, in Orlando, Fla.\n\nFor people with type 1 diabetes, controlling their blood sugar levels is a full-time job.\nThe promise of this emerging technology is to free diabetics from the need to constantly monitor their blood sugar levels by letting a computer program do the job -- constantly adjusting glucose and insulin levels as needed.\n\"We found that the people who did well used a more problem-solving approach and persisted in trying to learn how to use the CGM,\" she said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No sources appear to have been quoted besides those on the teleconference. We don\u2019t know the basis for the call, but it sounds like a press briefing.\nConflicts are mentioned for the people directly involved in the research. But readers can\u2019t know or judge for themselves whether others who were quoted in the story were truly independent sources \u2013 with no funding connection to this research.", "answer": 0}, {"article": "July 30, 2012 -- If it weren't for routine PSA prostate cancer screening, an extra 17,000 Americans each year would learn that they had the worst form of the disease, a new study suggests.\n\"By not using PSA tests in the vast majority of men, you have to accept you are going to increase very serious metastatic disease threefold,\" says study leader Edward Messing, MD, chief of urology at the University of Rochester Medical Center.\nFor example, Kramer says, what if a man got a PSA test when his prostate cancer was in the very earliest stages of metastatic disease?\nIt finds that in the three years before widespread PSA testing (1983-1985), men getting their first diagnosis of prostate cancer were three times more likely to learn they had very late-stage cancer than men diagnosed in the most recent three years for which data is available (2006-2008).\nBut it's not that simple, says Barnett Kramer, MD, MPH, associate director for disease prevention at the National Institutes of Health.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Most stories on this study relied heavily on the study\u2019s lead author, Dr. Edward Messing, a urologist, who, like most of his colleagues believes strongly in the need for more PSA screening. He\u2019s quoted here, too, of course, but the story also shares with readers important context from Dr. Barnett Kramer of the National Institutes of Health. And it includes input from a US Preventive Services Task Force member.", "answer": 1}, {"article": "The older we get, the more likely our circadian rhythms are disrupted.\nIn conclusion, melatonin can be of great value for aged people suffering from hypertension as an adjuvant substance complementing basic medication as it is able to stabilize circadian BP, heart rate profiles and their phase relationships.\nOver the next 2 weeks, the seniors were administered a low dose of melatonin (1.5 mg) each day by night at 10:30 p.m. On the third week data were monitored again.\nThe maximum systolic BP lowering effect of melatonin falls between 3:00 and 8:00 in the morning, the time of the highest risk of heart attacks and strokes.\nNone of these effects was found in 34 placebo treated seniors, thus ruling out the possibility that rhythms could be improved just because of regular schedule and presence of medical personal who took measurements.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release is written as if the lead researchers wrote it themselves since the text contains no citations to sources but does offer the occasional second-person pronoun (\u201cwe\u201d). The text\u00a0contains no references to funding sources or possible conflicts of interest.", "answer": 0}, {"article": "\u201cThe length of statin use, both greater than six months and greater than five years of use was associated with reduction in colorectal cancer risk.\u201d\n\nThe group of statins that showed the greatest effect in reducing risk are classified as lipophilic: atorvastatin (Lipitor), fluvastatin (Lescol), lovastatin (Altocor, Altoprev, Mevacor), pitavastatin (Livalo), and simvastatin (Zocor),\n\nColorectal cancer is the third most common type of cancer in the U.S.; 102,900 new cases of colon cancer are diagnosed in men and women every year, and about 39,670 new cases of rectal cancer are diagnosed annually.\nAlso, the longer patients used statin drugs, the greater their reduction in risk for colorectal cancer.\n\u201cThis effect was largely consistent across study design with both case control and cohort studies showing a strong correlation,\u201d he says in a news release.\nThe analysis shows there was a 12% reduction of colorectal cancer risk among statin users.\n\u201cObservational studies have suggested that long-term use of statins is associated with reduced risk of several cancers, including breast, prostate, lung, pancreas and liver,\u201d says Samadder in the news release.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent expert voices appeared in the story. ", "answer": 0}, {"article": "A diet that includes tomatoes could lower the chance of having a stroke.\n\nA new study shows that men who had the highest levels of lycopene\u2014an antioxidant found in tomatoes\u2014had fewer strokes than men who had the lowest level of lycopene in their blood. Overall, the risk of strokes was reduced by 55%.\n\nThe study, based in Finland, will be published...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does include a comment from an independent expert, who emphasizes that diet and lifestyle factors are important for stroke prevention. However, there was nowhere near the depth of context provided by\u00a0expert sources in the competing coverage by CNN and WebMD.\nAnd if the expert quoted in this story really said that lycopene \u201cprevents blood clots from forming,\u201d as the story suggests, then he is misinformed. There is no evidence that we\u2019re aware of that shows lycopene prevents blood clots.", "answer": 1}, {"article": "MONDAY, Feb. 15, 2016 (HealthDay News) -- Acupuncture may help ease pain and improve quality of life for people with fibromyalgia, a new study suggests.\nMany patients with fibromyalgia have a central nervous system that is unregulated, meaning an abundance of pain signals are sent to the brain, Shrikhande said.\nFor more on fibromyalgia, visit the U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases.\n\"Individualized acupuncture is a safe and good therapeutic option for the treatment of patients with fibromyalgia,\" said lead researcher Dr. Jorge Vas, of the pain treatment unit at Dona Mercedes Primary Health Center in Seville, Spain.\nThe report was published online Feb. 15 in the journal Acupuncture in Medicine.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes\u00a0experts other than those conducting the research, as well as providing additional information from other sources. One of the quoted experts appears not to be an acupuncturist, which is good.\nThe story does not mention any potential conflicts of interest but the research paper itself states there were no conflicts. Readers might have benefited, however, from knowing the funding source for this research, which was The Spanish Ministry of Health and Consumer Affairs and the Andalusian Public Health System, two public agencies.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Hormone replacement therapy may work slightly better than soy at reducing menopausal hot flashes, a new study says.\nThe researchers looked at 19 studies on how a treatment, either hormones or soy, compared to a placebo.\nA month\u2019s supply costs about $12, while a month of hormone tablets runs between $40 and $60.\nAnd not every woman needs treatment, notes Bachmann, who was not involved in the study.\nWomen with severe or frequent hot flashes or whose hot flashes keep them up at night, should consider treatment, she said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One apparently independent expert was quoted in the story.", "answer": 1}, {"article": "For more industry information, health research and recipe ideas, visit =.\n\"While future studies are needed, we're optimistic of the role of miRNAs as biomarkers of disease and prognosis, and may demonstrate a potential therapeutic target for colorectal cancer treatment.\"\nThis is the first study that evaluates whether walnut consumption can cause changes to micro-ribonucleic acids (miRNA), the nucleotides that are involved in altering gene expression.\nThe tumors of mice fed the walnut-containing diet were found to have 10 times the amount of total omega-3 fatty acids, including plant-based alpha-linolenic acid (ALA), in the tissue compared to the mice fed the control diet.\nThe study results found that a smaller tumor size was associated with greater percentage of omega-3s in tumor tissues, suggesting that ALA may provide a protective benefit.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources were identified, netting this release a Satisfactory rating, but when a fundor is integrally related to the substance of the research, that mention belongs higher up in the story or release, rather than tagged onto the end, allowing readers to consider the context of the funding early in their reading of the material.", "answer": 1}, {"article": "Moffitt is the No.\nThe most common adverse events were fatigue, injection site reactions, and chills.\nImportantly, the immune responses among the patients were similar, regardless of the route of vaccine administration.\nTheir approach involves creating the vaccine from immune cells called dendritic cells that are harvested from each individual patient to create a personalized vaccine.\nThe HER2 protein is overexpressed in 20-25% of all breast cancer tumors and is associated with aggressive disease and poor prognosis.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The study states the funding sources of the study. According to the paper, the researchers reported no conflicts of interest.", "answer": 1}, {"article": "\"For all practical purposes, the programs all worked about the same,\" said Kelly D. Brownell, director of Yale University's Rudd Center for Food Policy and Obesity and creator of the Lifestyle, Exercise, Attitudes, Relationships and Nutrition (LEARN) program for weight management, one of the diets studied.\nThe findings confirm, he said, that reducing carbohydrates, \"especially those with refined starch and sugar like that found in the U.S. diet, has metabolic benefits.\"\nAs for weight loss, the goal that concerns dieters the most, none of the groups managed to shed the large numbers of pounds touted by weight-loss programs and television shows such as \"The Biggest Loser.\"\nIt also shows that replacing these carbohydrates with either fat or protein \"can improve blood cholesterol fractions and blood pressure,\" he said.\nThe latest findings add to a growing body of evidence that the high-protein Atkins diet does not cause the harmful heart and artery effects long feared by many researchers.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included interview material with several nutrition scientists who had no connection with the study that was the subject of the story. It also contained critical comments from two individuals whose diet plans were studied.\u00a0 These comments came from respected individuals in the field and are a particularly valuable addition to the content.", "answer": 1}, {"article": "\u201cIt\u2019s very muddy now exactly how long we need to treat patients,\u201d George said.\n\u201cIt looks as if from this trial you at least need to try three weeks and maybe even six weeks before you would give up.\u201d\n\nPatients who got better were prescribed venlafaxine - marketed as Effexor \u2014 and a small dose of lithium, noted George, a combination that\u2019s been shown to help people stay well after their depression has remitted.\nSomething similar is likely happening, he added, with electroconvulsive therapy (ECT), or what is sometimes referred to as \u201celectroshock treatment.\u201d Sixty to 70 percent of depressed people who undergo ECT, in which electrodes placed on the front of the brain induce a convulsion while the patient is anesthetized, will recover.\nIn the May issue of the Archives of General Psychiatry, George and his colleagues report the results of their 190-patient study, the most rigorous investigation of TMS for depression so far.\nBased on the results, George and his team say, it would be necessary to treat 12 depressed patients with TMS in order to have one patient recover.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "As noted above, the story relied on a single source who was also lead investigator on the study being covered.\u00a0 It failed to note that this source has received research grants from, and is an advisor to,\u00a0several different companies involved in the manufacture of TMS-related technology. To avoid the appearance of any conflict of interest, the article should have disclosed these ties.", "answer": 0}, {"article": "To resolve that possibility, a new trial is under way at 20 cancer centers, including M.D.\nIn study results to be presented next week at an annual meeting of cancer doctors, Hassenbusch's treatment \u2014 chemotherapy and a new vaccine \u2014 significantly prolonged survival of patients with glioblastoma, the most common and aggressive brain cancer.\nThe time of survival was also up significantly from the previous average of 14 months, said Sampson, who declined to reveal the exact number until he presents the data June 2 at the American Society of Clinical Oncology meeting in Chicago.\nUnder the trial protocol, some patients received Temodar for the first five days of the month, and some received it for the first 21 days.\nLate Houston surgeon's work may fight cancer that killed him Surgeon's trial study on cancer is hailed\n\nBrain tumor took his life, but his pioneering therapy now may give others hope\n\nThe death of Houston neurosurgeon Samuel Hassenbusch from the brain cancer he treated has been one of 2008's sadder stories.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted two clinicians involved in the current study. \u00a0While it was refreshing to include the comment from the first author of the study that though enthusiastic about the results, he was \"biased\", the story would have been much better if it had included comments from experts in the field who were not involved in the study.\nInclusion of the interview comments from one of the patients who has received the experimental treatment is potentially misleading for readers because there was no framework for understanding the disease.\u00a0 While she is still alive and doing well 2 years after receiving the treatment, it is premature to conclude that this treatment is the reason for her current state of health.", "answer": 0}, {"article": "They also limit saturated fats, which are found in meat and diary products.\n\"The reason we talk about it so much is in the 1960s and 70s, researchers discovered people living there had lower blood pressure problems, cholesterol problems so they started to analyze the diet,\" Dr. Senay told The Early Show co-anchor Julie Chen.\nThe Mediterranean diet can vary from country to country but the foods consumed from Greece to Spain tend to be high in fruits, vegetables, fish, legumes, nuts, bread, pasta, cereals, potatoes and unsaturated fats like olive oil.\n\"Those who moderately adhered to the diet had a 53 percent reduction in risk of developing Alzheimer's disease,\" The Early Show medical contributor Dr. Emily Senay.\n\"The next step would obviously be to do an intervention trial where one group eats the diet, the other eats a traditional American diet and then look at the outcome.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story has a medical editor reporting on the latest study of the Mediterranean diet. It is difficult to tell what sources of information were used. Citing other medical experts would have been very helpful to put the results of this study in perspective and give the public advice on how to adopt aspects of this diet in place of a high-fat, highly processed foods typical of the American diet. ", "answer": 0}, {"article": "Cancer experts said Tuesday that the actress and filmmaker Angelina Jolie Pitt was wise to have had her ovaries and fallopian tubes removed last week because she carries a genetic mutation, BRCA1, that significantly increases the risk of ovarian cancer, a disease so difficult to detect that it is often found only at an advanced, untreatable stage.\nIt is unclear how common the mutations are in other racial and ethnic groups.\nBRCA mutations cause about 5 to 10 percent of breast cancers and 10 to 15 percent of ovarian cancers among white women in the United States.\nThey also said Ms. Jolie Pitt\u2019s decision to discuss her own choices so frankly will encourage women in similar situations to consider their own options.\nHer mother, aunt and grandmother died of cancer.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story provides excellent comments from three experts in the field.\u00a0 No conflicts of interest are apparent.", "answer": 1}, {"article": "He was not involved in the study.\nOver-the-counter multivitamins typically contain 15 to 25 IU of vitamin E.\n\nThe newly-released Physicians Health Study showed an 8 percent reduction in total cancer occurrence for participants taking a multivitamin, but no benefit was seen for rates of prostate cancer, the most common cancer seen among the participants in the study.\n\u201cOur trial took a very commonly used multivitamin that has basically low levels of all the different essential vitamins and minerals.\u201d\n\nThe findings suggest that the biggest health benefit may come from a broad combination of dietary supplements, he said.\n\u201cIt suggests that a balanced multivitamin approach is probably more beneficial than increasing to high levels any one vitamin.\u201d\n\nAbout half of U.S. adults take at least one daily dietary supplement - the most popular being a multivitamin, according to the U.S. Centers for Disease Control and Prevention.\nLOS ANGELES (Reuters) - Swallowing a daily multivitamin can reduce the risk of cancer by at least eight percent in middle-aged and older men and appears to have no dangerous side-effects, according to the first large-scale, randomized study on the subject.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes comments from two experts not involved\u00a0with the research, but its explanation of the funding was not quite as thorough as the competing AP piece. Reuters says that the study was sponsored by NIH, which is true, but it didn\u2019t note that Pfizer supplied\u00a0its Centrum multivitamin free of charge. Since we\u2019re talking about 15,000 men taking pills for 10 years, that\u2019s more than pocket change\u2013and worth pointing out to readers.\nThis is a grey area. Explicitly pointing out the role Pfizer played in the study is important for readers to know.", "answer": 0}, {"article": "For more information about featured studies, as well as a schedule of availability for featured researchers, please visit http://www.\nThe team also reported that endoscopic sleeve gastroplasty patients customarily left the hospital on the same day of treatment, while laparoscopic sleeve gastrectomy patients stayed for about three days and laparoscopic banding patients for a day and a half.\n\"For years, patients seeking weight-loss interventions had limited options because they could not tolerate or did not want surgery, or it was not even an option for them,\" added Dr. Sharaiha.\n\"Obesity continues to be a problem in America and it is an epidemic rapidly spreading around the world,\" said Reem Z. Sharaiha, MD, MSc, assistant professor of medicine at Weill Cornell Medicine and attending physician at New York-Presbyterian/Weill Cornell Medical Center, the study's lead author.\nObesity is associated with heart disease, stroke, diabetes and some cancers, and researchers estimate that it is the second-leading cause of preventable death, after tobacco use.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release includes a reference stating that the researcher actually making the presentation does not have any conflicts of interest to report. However, there is no information on conflicts of interest regarding the other researchers, nor does the release tell readers who funded the research.", "answer": 0}, {"article": "The study of nearly 32,000 people in eight countries boosts hope that early detection by CAT scans may reduce the death toll of lung cancer, much as mammography has done for breast cancer.\nOf that group, 85 percent had small tumors that had not spread.\nIn all, 31,567 people were screened.\nIn the ensuing years, about 27,000 more scans were done, with some people having them annually.\nOnly 15 percent of people with the disease survive five years from the time it is diagnosed.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes multiple independent sources, providing much needed balance in the story.", "answer": 1}, {"article": "First, a bit of background.\nThe good news, we're told, is that there are many things we can do \u2013 or not do \u2013 in our adult lives to lower our risk of developing different types of cancer.\nThe bottom line from the American Cancer Society: While this is an interesting finding, it's not likely to spur any change in recommendations or medical practice.\nA cursory review of the data suggests, for example, that the number of male sexual partners is greatly underreported.\nAs the study's authors point out, \"The mechanism(s) by which circumcision reduced acquisition of an STI [sexually transmitted infection] is thought to be related to the microenvironment of the thin, lightly keratinized mucosal lining of the inner foreskin.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story concludes with a statement attributed to the American Cancer Society suggesting that the findings won\u2019t change medical practice. While this statement is certainly no substitute for an actual conversation with an expert, it\u2019s more context than we see from many similar blog posts about medical studies. We\u2019ll give it a passing grade, though barely.", "answer": 1}, {"article": "For the really Type A personality, here's a chance to measure how well you are relaxing. Makers of home biofeedback devices that monitor your heart rhythms say the devices teach you to combat emotional stress. Psychologists and psychiatrists say the gadgets appear to help their stressed-out patients but warn that there isn't yet strong scientific evidence that they work.\n\nBiofeedback has long been used to treat stress in psychologists' offices -- with an expert who leads the patient in relaxing breathing exercises and...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two sources are quoted who have differing views on the utility of such devices. They offer some reasonable expertise and guidance to potential users.", "answer": 1}, {"article": "Additionally, change in IRLSSGS score was significantly greater for the RLS device (17.22) compared to historic reports for ropinirole versus the placebo (12 versus 8.9 respectively).\nUntil recently, potent drugs including opioids, depressants and dopamine agonists have been used to ease symptoms, but each of these is accompanied by negative side effects such as dizziness, nausea, vomiting and the added risk of addiction.\nDisclosures: Dr Kuhn worked without compensation through Lake Erie Research Institute (LERI) during the 5 years of the study of the device and is now receiving compensation for that work.\nResearchers indicate that the pressure produced by the device may also stimulate a dopamine release, similar to massage therapy or acupressure.\nAbout The Journal of the American Osteopathic Association\n\nThe Journal of the American Osteopathic Association (JAOA) is the official scientific publication of the American Osteopathic Association.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We will give the release credit for clearly noting that one of the authors works with the Lake Erie Research Institute, which developed the foot wrap, and that she is receiving compensation for her research work. The release also points out that further disclosure details are listed in the journal article. However, the release could have also specifically mentioned that the additional disclosure information includes the fact that the institute receives royalties from the company that bought the rights to the foot wrap.", "answer": 1}, {"article": "A study in the United States last year found that routine prostate cancer screening had resulted in more than a million being diagnosed with tumors who might otherwise have suffered no ill effects from them.\nThe study found that the predictive value of screening these men \u2014 expressed as the number of cancers detected relative to the number of tissue samples taken \u2014 was 48 percent, far higher than the 24 percent achieved in population-wide screening.\n\u201cAlthough these are early results, it appears that (prostate cancer) screening is reasonably accurate at predicting potentially aggressive prostate cancer among men at higher risk of the disease due to a genetic predisposition,\u201d said Ros Eeles, who led a research team from Britain\u2019s Institute of Cancer Research (ICR) and Royal Marsden hospital.\nThe findings suggest that by narrowing the focus of prostate cancer screening to those whose genes put them at most risk, doctors would catch more cancers early as well as reducing the potential for costly and damaging overdiagnosis.\nBut fears about overdiagnosis, which can lead to treatments such as surgery, radiation or hormone therapy that can cause serious side-effects such as impotence and incontinence, have so far dissuaded many European countries from nationwide screening.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A major problem with this story is that it only quoted one expert who is one of the researchers on this study, and all comments from him appear to be from the press release. The story could have been greatly improved by quoting another expert who could have provided some valuable perspective on the importance of these results.", "answer": 0}, {"article": "New research from BYU exercise science professors finds that pro-inflammatory molecules actually go down in the knee joint after running.\n\"What we now know is that for young, healthy individuals, exercise creates an anti-inflammatory environment that may be beneficial in terms of long-term joint health,\" said study lead author Robert Hyldahl, BYU assistant professor of exercise science.\nThe researchers found that the specific markers they were looking for in the extracted synovial fluid--two cytokines named GM-CSF and IL-15--decreased in concentration in the subjects after 30 minutes of running.\n\"It flies in the face of intuition,\" said study coauthor Matt Seeley, associate professor of exercise science at BYU.\nHyldahl said the study results indicate running is chondroprotective, which means exercise may help delay the onset of joint degenerative diseases such as osteoarthritis.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There is no funding source listed, but there is also no funding source listed in the paper.\u00a0 The authors do declare in the paper that there is no conflict of interest and what any conflict would be, considering that the \u201ctreatment\u201d discussed is running, is a puzzle.\nOur standard here is to require some discussion of funding sources. Even if no funding was provided, the release should say so.", "answer": 0}, {"article": "But such drugs tend to be extremely expensive.\nDr. John Wagner, the director of pediatric blood and marrow transplantation at the , called the Pennsylvania results \u201cphenomenal\u201d and said they were \u201cwhat we\u2019ve all been working and hoping for but not seeing to this extent.\u201d\n\nA major drug company, , is betting on the Pennsylvania team and has committed $20 million to building a research center on the university\u2019s campus to bring the treatment to market.\nScaling up the procedure should make it even less expensive, he said, but he added, \u201cOur costs do not include any profit margin, facility depreciation costs or other clinical care costs, and other research costs.\u201d\n\nThe research is still in its early stages, and many questions remain.\nWith a pill, you take it, it\u2019s eliminated from your body and you have to take it again.\u201d But T-cells, he said, \u201ccould potentially be given only once, maybe only once or twice or three times.\u201d\n\nThe Pennsylvania researchers said they were surprised to find any big drug company interested in their work, because a new batch of T-cells must be created for each patient \u2014 a far cry from the familiar commercial strategy of developing products like or medicines, in which millions of people take the same drug.\nShe woke up a week later, on May 2, the day she turned 7; the intensive-care staff sang\n\nSince then, the research team has used the same drug, tocilizumab, in several other patients.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several independent experts are quoted in the story, although their input is used primarily to reinforce the \u201cbreakthrough\u201d nature of the findings. The story could have gotten a lot more mileage from these sources had it probed more\u00a0for limitations, caveats, and concerns about the research and its application to larger numbers of patients.\u00a0 The story also noted Novartis\u2019 investment in the work, something not mentioned in the competing Philadelphia Inquirer story.", "answer": 1}, {"article": "Nature publishes broad review articles, called Primers, that cover global aspects of various diseases and describe all aspects from epidemiology, disease mechanisms, diagnosis, screening and prevention, management and quality of life.\nThe researchers also concluded that, \"A novel formulation of peppermint oil, designed to cause sustained release in the small bowel, was superior to placebo in causing a reduction in total symptoms.\"\n\"IBS considerably affects quality of life and places an enormous burden on patients, physicians and the health-care system,\" said Brooks D. Cash, M.D., A.G.A.F., F.A.C.G., F.A.C.P., F.A.S.G.E., Professor of Medicine in the Gastroenterology Division at the University of South Alabama in Mobile, Ala. \"The results of these studies add to the growing body of medical evidence supporting the utility of IBgard\u00ae, a novel formulation of peppermint oil, in improving the symptoms, patient satisfaction and quality of life of patients with IBS.\nIn the section of the article discussing management options for IBS, Dr. Enck and the accompanying panel of researchers stated \"peppermint oil\u2026is beneficial in reducing IBS symptoms.\"\nThe usual adult dose of IBgard\u00ae is 1-2 capsules as needed, up to three times a day, not to exceed 8 capsules per day.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release fails to reveal that the trial of IBgard it highlights was funded by the manufacturer, IM HealthScience, and authored by two employees and a consultant. The release does not reveal that the expert it quotes, Brooks Cash, M.D., is the company consultant.", "answer": 0}, {"article": "For more information, visit http://www.\n\"While older patients represent a large and growing population of medical cannabis users, few studies have addressed how it affects this particular group, which also suffers from dementia, frequent falls, mobility problems, and hearing and visual impairments,\" says Prof. Victor Novack, M.D., a professor of medicine in the BGU Faculty of Health Sciences (FOHS), and head of the Soroka Cannabis Clinical Research Institute.\nThe researchers in the study also include, Ran Abuhasira, a BGU Ph.D. candidate working in the Soroka Clinical Research Center, Lihi Bar-Lev Schleider of \"Tikun Olam,\" and Prof. Raphael Mechoulam of Hebrew University.\nAbout American Associates, Ben-Gurion University of the Negev\n\nAmerican Associates, Ben-Gurion University of the Negev (AABGU) plays a vital role in sustaining David Ben-Gurion's vision: creating a world-class institution of education and research in the Israeli desert, nurturing the Negev community and sharing the University's expertise locally and around the globe.\nMedical Cannabis Significantly Safer for Elderly With Chronic Pain Than Opioids, According to Ben-Gurion University of the Negev Researchers\n\nBEER-SHEVA, Israel...February 13 - Medical cannabis therapy can significantly reduce chronic pain in patients age 65 and older without adverse effects, according to researchers at Ben-Gurion University of the Negev (BGU) and the Cannabis Clinical Research Institute at Soroka University Medical Center.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Although the news release mentions that the subjects surveyed \u201creceived medical cannabis through \u2018Tikun Olam,\u2019 the largest Israeli medical cannabis supplier,\u201d it does not point out the following:\nThis is definitely something readers should know in a news release that implies efficacy in treating nearly a dozen different conditions in the first two paragraphs. It\u2019s quite clear that people over 65 represent a growing target market for medical cannabis.", "answer": 0}, {"article": "The drug is not approved for children \u2013 except a rare few with premature puberty \u2013 because it can impair bone development crucial to growth, said Dr. Gary Berkovitz, chief of pediatric endocrinology at the University of Miami medical school.\nThey have impulses.\nAutistic children are prone to seizures.\n\"These people are preying on the fears of parents.\nGeier could not be reached for comment despite several attempts by phone.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several independent expert sources were quoted. ", "answer": 1}, {"article": "TUESDAY, May 25, 2010 (HealthDay News) --Giving certain breast cancer patients estrogen-lowering drugs before surgery enhances their chances of being able to choose a breast-conserving lumpectomy instead of a full mastectomy, new research suggests.\nAfter the four months of estrogen-lowering therapy, the research team found that 82 percent of those women in the marginal group were, in fact, able to undergo successful breast-conservation surgery.\nThe women were classified into three groups as the study began: \"marginal\", meaning that the women were eligible for a lumpectomy to conserve the breast, but that it would be disfiguring or require several operations; \"mastectomy-only\", meaning a lumpectomy was not considered possible; and \"inoperable\", meaning that doctors believed that even a mastectomy would not completely remove the cancer.\nThe 352 women who participated were monitored for tumor growth before and after being placed on a 16-week regimen of aromatase inhibitors -- estrogen-lowering agents -- before any surgery.\nThe investigation was funded by the American College of Surgeons Oncology Group and led by Dr. Julie A. Margenthaler, an assistant professor of surgery and a breast surgeon at the Siteman Cancer Center at Washington University in St. Louis.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only perspective we receive in this story is that of the investigators with the study, who provide a uniformly positive take on the results. No independent\u00a0views are provided.", "answer": 0}, {"article": "The comparison groups in the experiments varied as well.\nIn the latest look at various treatments, the Cochrane group evaluated studies that examined both pharmaceutical and alternative techniques, including acupuncture, acupressure (a noninvasive variation of acupuncture), ginger, vitamin B-6 and conventional anti-vomiting drugs.\n\"The onus is back to researchers to carry out studies that would stand up\" to rigorous review and that would build on what's already been tested.\nAll too often, Matthews says, researchers in the field seem to forge ahead without paying enough attention to what's been done before.\nWithout enough data that could be pooled together, it wasn't possible for the Cochrane folks to figure out if anything really works reliably and safely.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only source quoted in the article was an author of the study being covered. As we discussed in our review of the competing LA Times piece, one could argue that this criterion should be ruled not applicable in this case since the Cochrane group authors are, by definition, an independent group of evaluators.\u00a0Since\u00a0other experts do sometimes dispute the way in which Cochrane authors analyze the evidence,\u00a0however,\u00a0we feel it would have added value\u00a0to include the voice of another expert who wasn\u2019t affiliated with the study.", "answer": 0}, {"article": "Almost all cases of cervical cancer occur as a result of infection with high risk types of HPV.\nIn the UK, all girls aged 12 to 13 are offered HPV vaccination as part of the NHS childhood vaccination programme.\nProfessor Jack Cuzick of Queen Mary University of London, who co-authored the report and participated in the design and analysis of the study, and served on the Trial Advisory Board, comments: \"This is a significant achievement.\nThe new vaccine offers significantly greater protection than the current vaccine, which protects against only two cancer causing types of HPV.\nMany people infected with HPV clear it from their systems with no lasting health concerns and some types of the virus are low risk, causing warts or verrucas.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release points out that the study was funded by the manufacturer of the vaccine and that Dr. Cuzick was a coauthor of the study.", "answer": 1}, {"article": "Scientists have developed a simple three-in-one blood test they believe could transform treatment of advanced prostate cancer, helping to extend or save lives.\nThey are cheap and simple to use, but most importantly, because they aren\u2019t invasive, they can be employed or applied to routinely monitor patients to spot early if treatment is failing \u2013 offering patients the best chance of surviving their disease.\u201d\n\nThe research was funded by the Prostate Cancer Foundation, Prostate Cancer UK, Movember, Cancer Research UK and the National Institute for Health Research.\n\u201cNot only could the test have a major impact on treatment of prostate cancer, but it could also be adapted to open up the possibility of precision medicine to patients with other types of cancer as well.\u201d\n\nBy testing cancer DNA in the bloodstream, the researchers found they could pick out which men with advanced prostate cancer were likely to benefit from treatment with the drug.\nProf Johann de Bono, Regius professor of cancer research at the ICR, and consultant medical oncologist at the Royal Marsden NHS foundation trust, said: \u201cOur study identifies, for the first time, genetic changes that allow prostate cancer cells to become resistant to the precision medicine olaparib.\nThe liquid biopsy, less invasive than a tissue biopsy, also detects early signs of resistance to olaparib and monitors the cancer\u2019s evolution over time, according to the paper, published in Cancer Discovery on Monday.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two sources: 1) the first author, who\u2019s a researcher at the UK\u2019s Institute of Cancer Research; and 2) the Chief Executive of the very same research institution. No outside sources were mentioned, much less quoted. It was good that\u00a0funding sources were\u00a0mentioned, however.", "answer": 0}, {"article": "(CNN) Jet lag might be the worst part of long-distance travel, especially when it leaves you feeling tired, cranky and off-kilter for days.\nParticipants were able to sleep through the flashes of light without waking.\nThere's still more testing to be done before the technique is available to the public.\nThey then had the volunteers sleep in the lab, where some were exposed to continuous light for an hour and others were exposed to a sequence of flashes of various frequencies for an hour.\nThis time around, researchers tried to further optimize the process.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No outside expert was asked to comment and cast a critical eye on the quality of the evidence and the soundness of the study.", "answer": 0}, {"article": "Most angioplasties not necessary, study finds\n\nNEW ORLEANS \u2014 More than half a million people a year with chest pain are getting an unnecessary or premature procedure to unclog their arteries because drugs are just as effective, suggests a landmark study that challenges one of the most common practices in heart care.\nBut most angioplasties are done on a non-emergency basis, to relieve chest pain caused by clogged arteries crimping the heart's blood supply.\nIf that does not help, they can consider angioplasty or bypass surgery, which unlike angioplasty, does save lives, prevent heart attacks and give lasting chest-pain relief.\nAfter five years, 74 percent of the angioplasty group and 72 percent of the medication group were free of chest pain \u2014 \"no significant difference,\" Boden said.\nIt involved 2,287 patients throughout the U.S. and Canada who had substantial blockages, typically in two arteries, but were medically stable.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included quotes from\u00a0two of the authors of the study as well as the director of the National Heart, Lung, and Blood Institute and the president of the American College of Cardiology.\nIt might have been useful to readers to have a comment from a clinician in primary care.", "answer": 1}, {"article": "Building upon previous research, the study challenges the widely held belief that recovery from a TBI is limited to two years after an injury.\nThe knowledge-based training group learned information about the structure and function of the brain as well as the effects of sleep and exercise on brain performance.\nOver an eight-week period, the strategy-based training group learned strategies to improve attention and reasoning.\n\"People who showed the greatest change in cortical thickness and connectivity, showed the greatest performance increases in our cognitive tasks.\nPrevious studies have shown that cortical thickness and rsFC can be potential markers for training-induced brain changes.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding sources are disclosed at the end of the news release.", "answer": 1}, {"article": "People who were given Flublok Quadrivalent were over 40% less likely to develop culture-confirmed influenza.\n\"This study shows that Flublok\u00ae Quadrivalent, produced with modern recombinant technology can provide better protection against confirmed influenza-like illness among older adults than standard-dose quadrivalent influenza vaccine produced with traditional technology,\" said Lisa Dunkle MD, Chief Medical Officer of Protein Sciences.\nFlublok is an exact copy of the influenza virus coat protein and is not subject to the egg-adapted mutations associated with low vaccine effectiveness (see Skowronski et al.\nThe publication notes that approximately 9,000 people aged 50 and older were enrolled and randomized in an efficacy study designed to compare Flublok Quadrivalent to a traditional quadrivalent vaccine.\nFlublok is the only flu vaccine made without the use of eggs and therefore is not subject to the mutations that are sometimes introduced into the vaccine during the process of egg adaptation that can cause the traditional vaccines to be ineffective (see Skowronski et al.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release is clearly from Protein Sciences Corporation and clearly identifies its own chief medical officer when she is quoted in the piece. The release does not explicitly state that the study was funded by Protein Sciences, but hat can be deduced from the text.\nBut omitting conflicts of interest disclosures in the release is another matter. According to the disclosure in NEJM, journal article authors \u201cDrs. Dunkle, Izikson, and Cox report being employed by and holding stock in Protein Sciences.\u201d That financial connection should have been included in the news release.", "answer": 0}, {"article": "Nothing there, the radiologist assured her.\n\"Not only do the trials not find a benefit, the trials demonstrate harm in terms of increased physician visits and benign breast biopsies,\" said Dr. Nancy Baxter, a University of Toronto surgeon who reviewed the evidence on self-exams for the Canadian Task Force on Preventive Health Care.\nA scientific review, published in August by the\n\n, highlighted the downside of doing breast self-exams: Women taught to perform the monthly ritual wind up having unnecessary biopsies.\n\"By the time a breast cancer is large enough to be detected by self-exam, tumor biology is the most important predictor of outcome, not finding a tumor a few months before it would have become apparent,\" she said.\n\"One danger of pushing breast self-exams on patients is that they may be falsely reassured by it and opt out of their mammograms,\" said Dr. Heidi Nelson, medical director of the\n\nin Portland.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story is based on an update of a report by the Cochrane Collaboration, a credible international group that analyzes bodies of scientific literature to determine overall findings. A range of clinicians put the report and practice of BSE in perspective.\u00a0 Physicians appropriately talk about the revised guidelines for this screening, and note that regular BSE is still an individual woman\u2019s choice.\u00a0 Women should be aware of the harms and lack of sensitivity of the exam.\u00a0 A patient is interviewed for the story, but her story of misdiagnosis seems to undercut the overall message of the piece: women must weigh the pros and potential downsides of regular BSE. ", "answer": 1}, {"article": "(Reuters) - Johnson & Johnson said on Tuesday its blockbuster drug Stelara was found to be effective in treating a chronic bowel disease in a late-stage trial.\nThe patient had no prior history of high blood pressure or cirrhosis, the drugmaker said.\nBoth 6 mg/kg and 130 mg doses of the intravenous treatment showed clinical remission in significantly more patients, compared with those on placebo, after eight weeks, the company said.\nCurrent treatments include Pfizer Inc\u2019s Xelijanz, an oral treatment for adults patients with moderate-to-severe UC, and Merck & Co\u2019s Renflexis.\nStelara, which brought in sales of $1.34 billion in the second quarter of 2018, is also being tested in autoimmune disease lupus.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not incorporate input from anyone not associated with the company or the study in question.", "answer": 0}, {"article": "Prescription drug addicts like Brian have unique problems beating their habit because they see themselves as different from street junkies.\nThis ad came on the radio,\" he said.\nLet's address what's going on.\"\n\"It can be quite powerful when people begin to use it.\n\"By the grace of God, I say it was a higher power.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are several important shortcomings here:", "answer": 0}, {"article": "Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance.\nNOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.\nThe company's flagship product, the Oncotype DX breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer.\n\"The publication of this clinical utility study clearly demonstrates that the Oncotype DX DCIS Score can play a key role in enhancing cancer care for patients with DCIS, and we believe that these results will support expanded adoption of and access to the DCIS Score.\"\n\"These results highlight the need to optimize treatment of this non-invasive, indolent form of breast disease, and the importance of Oncotype DX in helping physicians reduce over- and under-treatment of DCIS.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The original study listed financial conflict of interests among the study authors \u2014 including the fact that several study authors are paid speakers and consultants for Genomic Health, which makes the test. One of the authors is an employee of the company. But the new release did not provide any of this context.", "answer": 0}, {"article": "Allergan Inc. said that two large human tests of its Botox drug, best known for smoothing wrinkles, showed that periodic injections prevent headaches in adults who suffer from chronic migraines.\n\nEven though details of the study weren't released, the announcement, which surprised many physicians and investors, sent Allergan's shares soaring 11%, or $5.95, to $60.53 at 4 p.m. in New York Stock Exchange composite trading. Botox has been used to treat severe headaches for many years, but some researchers have long been skeptical...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes multiple experts who provide valuable persepctive.", "answer": 1}, {"article": "The work was supported with funding from the Conrad N. Hilton Foundation, the National Institutes of Health, the California Community Foundation, the Tom Sherak MS Hope Foundation, the Rhoda Goetz Foundation for Multiple Sclerosis, and other partners of the UCLA Multiple Sclerosis Program.\nThe study is published in the Proceedings of the National Academy of Sciences.\nThey hypothesized that while inflammation causes loss of myelin and synapses, it is the decrease in cholesterol synthesis gene expression in astrocytes that explains why lesions do not repair in MS.\nThey compared gene expression changes between regions that correspond to different disabilities.\nThey treated MS mice with a drug that increased expression in cholesterol synthesis genes - and this resulted in improved walking ability.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release lists the funding sources. The authors declared no conflicts of interest in the published study. ", "answer": 1}, {"article": "USUALLY NOT THE FIRST STEP\n\n\u201cI have a long list of chronic pain patients coming to seek acupuncture,\u201d said Jongbae Park, head of Asian Medicine & Acupuncture Research at the University of North Carolina at Chapel Hill School of Medicine.\nBut, he added, \u201cI would sincerely say more than 75 percent of my patients will see improvement.\u201d\n\nVickers said people who are considering acupuncture should first make sure their acupuncturist is appropriately qualified and licensed.\nSome think it has potential as an add-on or alternative to standard treatment, while others argue any acupuncture-related benefits are likely the result of hopeful patients getting treatment they strongly believe will help them.\n\u201cA doctor who has a patient in pain has a lot of options,\u201d such as medications and physical or talk therapy, said lead author Andrew Vickers, from Memorial Sloan-Kettering Cancer Center in New York.\nThat either means many of the three million Americans that get acupuncture every year are \u201cwasting their time\u201d - or others who forgo it are missing out on potential benefits, Vickers said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story consulted one of the study authors, as well as the head of the department of Asian Medicine & Acupuncture Research at the University of North Carolina at Chapel Hill School of Medicine.\u00a0Both of these sources are biased either by their affiliation with the study or their\u00a0general support\u00a0and belief in the effectiveness of acupuncture. \u00a0(In an admirable display of transparency, the Asian medicine expert\u00a0acknowledges that he is a \u201cbiased clinician.\u201d) The story would have been\u00a0improved with\u00a0the inclusion of comments from an expert\u00a0in pain treatment who is not invested in the study or in acupuncture as a treatment. Such an expert might well be considered biased against acupuncture, but at least readers would\u00a0be getting both sides of the argument.", "answer": 0}, {"article": "Asthma has complicated Todd Anderson's life ever since he was 3 years old. Doing sports\u2014even stairs\u2014had been difficult. Cigarette smoke, pollen, disinfectants or a passing whiff of perfume could set off a severe asthma attack. \"It feels like your chest is clenching up like a fist,\" says Mr. Anderson, a 29-year-old music teacher in the New York City schools.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\n\nIt\u2019s hard to tell whether an independent source is included. There is no doubt that the story fails to inform readers about the financial ties between most of the quoted experts and the company that funded their research and is now marketing the bronchial thermoplasty device. The conflict of interest statement included with the journal article on the key trial is more than a thousand words long, detailing payments from companies, including Asthmatix, the maker of this device (now part of Boston Scientific), to the lead researchers.\nThe story does disclose that the company provided the contact information for all of the patients quoted in the story. It does not say whether any of the control group participants who got the sham treatment were contacted.", "answer": 0}, {"article": "The body naturally synthesizes vitamin D when the skin is exposed to sunlight.\nAt the end of the study, the researchers found no clear difference between the two groups in the average number of days missed from duty due to a respiratory infection \u2014 which included bronchitis, sinus infections, pneumonia, ear infections and sore throat.\n\u201cHowever,\u201d the researcher said, \u201cthere is a lack of clinical studies of the effect of vitamin D supplementation for preventing respiratory infections.\u201d\n\nFor the current study, Laaksi\u2019s team randomly assigned 164 male military recruits to take either 400 international units (IU) of vitamin D or inactive placebo pills every day for six months \u2014 from October to March, covering the months when people\u2019s vitamin D stores typically decline and when respiratory infections typically peak.\nBecause rates of vitamin D insufficiency rise during the winter in many parts of the world, researchers have been interested in whether the vitamin might play a role in people\u2019s susceptibility to colds, flu and other respiratory infections.\nBut whether vitamin D is the reason for the excess risks \u2014 and whether taking supplements can curb those risks \u2014 has yet to be shown.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\n \nAlthough this story refers to the findings of other studies and the recommendations of health agencies and experts, there is no identified independent source to comment on the trial.\n In their journal article, the researchers reported no potential conflicts of interest. It would have been helpful to tell readers that the trial was funded by the Medical Research Fund of Finnish Defence Forces, in order to distinguish this trial from studies funded by supplement manufacturers or others with a vested interest in the results.", "answer": 0}, {"article": "\u201cThis outcome is more than we hoped for.\nWhile the connection between heart disease and cancer may not seem obvious, Ridker says that many people who have had heart problems, like those in the study, are former or current smokers, since smoking is a risk factor for heart attacks.\n\u201cThis all makes sense to me.\u201d Studies have already shown, for example, that inflammation may be a factor in prostate cancer and colon cancer.\nBeginning in 2003, the American Heart Association started to provide guidelines on how doctors should use CRP testing; for patients like those in the current trial, the group did not see any additional benefit to CRP testing since those patients should already be treated with statins, which can lower both cholesterol and inflammation.\nThe drug is not currently approved for any heart conditions, but Novartis will likely look at doing more studies to confirm its effectiveness in treating heart disease.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not disclose that its primary source, Dr. Paul Ridker, has accepted consultancy & speakers fees from Novartis, the funder of the study.", "answer": 0}, {"article": "This data is clinically significant.\nMigraine symptoms, which can be debilitating for many people, are the sixth leading cause of disability, according to the World Health Organization.\n\"For certain patients, treatment options for migraines, such as oral medications, are not effective, well-tolerated or preferred,\" Dr. Starling adds.\nThe U.S. Food and Drug Administration already had approved the sTMS device for the acute treatment of migraine with aura.\nMULTIMEDIA ALERT: Video and audio are avaiable for download on the Mayo Clinic News Network.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "This is a major weakness of the news release.\nNot only is the funding for the study not mentioned (the study was supported by eNeura Inc.) but it\u2019s also not mentioned that 5 of 13 authors have financial conflicts of interest with this manufacturer of portable TMS devices.\nFurthermore, one of the lead authors is chairman of eNeura\u2019s medical advisory board.", "answer": 0}, {"article": "WASHINGTON (Reuters) - Statin drugs may lower the risk of colon cancer by as much as 12 percent, U.S. researchers reported on Monday.\nStatins are not risk-free.\nThe longer people took the highly popular cholesterol-lowering pills, the lower their risk of later developing colon cancer, the researchers told a meeting of the American College of Gastroenterology.\nSamadder\u2019s team did what is known as a meta-analysis, combining the findings of 22 scientific studies with more than 2.5 million volunteers.\nIn May, British researchers reported that patients taking them have a higher risks of liver dysfunction, kidney failure, muscle weakness and cataracts.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only quotes came from the lead researcher, pulled from a university news release. No independent expert was quoted.\u00a0 \n", "answer": 0}, {"article": "Some insurance plans cover EMDR.\nThe idea is that reliving the memories helps remove the sting and that the urgency of the memories can be reduced as the brain begins to move them from short-term to long-term memory.\nThe sound or the eye movement is supposed to activate both sides of the brain in an imitation of REM sleep, when the brain usually converts short-term memories into long-term recollections.\n\u201cIt\u2019s not opening up any fresh wounds.\u201d\n\nAs Henn walked outside into a brisk April evening after her session, there was a new easiness to her, as though something had finally been freed.\n\u201cBut I never felt like I was getting over it.\u201d Random memories could send her spiraling into panic and fear.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There is at least one independent source not connected with the patient\u2019s story. We would have liked to have seen input from a psychiatrist, as well (not just psychologists).", "answer": 1}, {"article": "(CNN) A new blood test may be as accurate as a test requiring a painful spinal tap for differentiating Parkinson's disease from similar disorders, according to a study published Wednesday in Neurology, the medical journal of the American Academy of Neurology.\nWhen validating a new biomarker for disease, \"one should always analyze at least two different (groups of patients and controls) to make sure that the results are reproducible,\" said Hansson, who added that participants should also include both early- and late-stage patients established at different clinics.\n\"This can be very challenging, especially during the early stages of the diseases and if the responsible doctor is not a neurologist specialized in movement disorders,\" said Dr. Oskar Hansson, lead author of the new study, a neurologist and an associate professor at Lund University in Sweden.\n\"A lot of time, people come in and say they or a family member has a tremor, and they believe it's Parkinson's disease,\" said Wright, who also was not involved in the study.\nBecause spinal fluid is not easily obtained by a primary care doctor, this diagnostic test is not very useful, so Hansson developed a blood test and investigated its accuracy in the new study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included two independent sources not connected with the research.\nHowever, several of the authors in the study had connections to companies that work on this kind of test, and that wasn\u2019t disclosed in the story.", "answer": 0}, {"article": "Neither scenario gives doctors an objective indication of the severity of the injury.\n\"This could ultimately change the way we diagnose concussions, not only in children, but in anyone who sustains a head injury,\" said Linda Papa, MD, MSC, an emergency medicine physician and NIH funded researcher at Orlando Health and lead author of the study.\n\"If we could find a simple test that takes the guess work out of diagnosing these kids, that would completely change the way we approach concussions and would certainly give parents greater peace of mind,\" said Papa.\n\"The idea is to get a point-of-care test that could be used on the field, to help the coaches, the trainers and the athletic directors, make a decision then and there about whether the child should go back to play,\" said Papa.\n\"If there was a simple diagnostic tool like a blood test that can tell us quickly and accurately if a brain injury has occurred, and how severe it might be, that would be ideal,\" said Papa.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that the journal article\u2019s lead author receives funding from NIH. The study itself was partially funded by the NIH, a subtle but potentially important distinction. \u00a0Further, the journal article notes that the lead author is a scientific consultant for Banyan Biomarkers, Inc. \u2014 a company that has intellectual property rights to GFAP testing. The journal article also states that the relevant author \u201creceives no stocks or royalties from the company and will not benefit financially from this publication\u201d \u2014 but that potential conflict of interest is still worth mentioning in the release.", "answer": 0}, {"article": "Thanks to members Drs.\nThe lifetime risk of suffering symptomatic knee OA is estimated to be 44.7% and approximately 1 in 11 of the US population is diagnosed with symptomatic knee OA by age 60.\nNewswise \u2014 LEAWOOD, KS \u2014 Osteoarthritis (OA) is one of the leading causes of disability in adults in the United States and knee OA specifically is ranked within the top 10 non-communicable diseases for global disability-adjusted life years.\nWith this knowledge, the American Medical Society for Sports Medicine (AMSSM) has released a new scientific statement that provides guidance for physicians and healthcare professionals who provide care for those patients with knee osteoarthritis.\nThis is different than studies recently published that say the average response differs.\u201d The full report, published ahead of print in the Clinical Journal of Sport Medicince (CJSM) and will appear in the (British Journal of Sports Medicine) BJSM, entitled, AMSSM Scientific Statement Concerning Viscosupplementation Injections for Knee Osteoarthritis Importance for Individual Patient Outcomes, includes the following notable AMSSM recommendations and one suggestion:\n\u2022 AMSSM RECOMMENDS viscosupplementation injections for Kellgren and Lawrence (KL) grade II-III knee osteoarthritis in those patients above the age of 60 based on HIGH quality evidence demonstrating benefit using OMERACT-OARSI Responder Rating but the evidence should be downgraded due to indirectness for those under 60 years of age.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The information is being provided by the American Society for Sports Medicine, a multidisciplinary group of clinicians who specialize in sports medicine. There is a potential for an inherent bias. In case that needs spelling out the potential bias is that the association may be seeking new patients beyond its athlete patient base, and expanding into the aging population of \u201cbaby boomers\u201d who have the greatest incidence of knee osteoarthritis.", "answer": 1}, {"article": "The other is that, for tens of thousands of years, parasites and other infections unusual in modern society were a major problem in humans. The body developed a defense mechanism - inflammation - to fight them. Now, there aren't as many of these infectious diseases for our bodies to deal with, but we still have this defense mechanism. It has begun to target other things, such as allergens in the environment. Immunotherapy helps teach the body to better tolerate these harmless parts of our environment.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The format clearly excludes independent sources commenting on what the expert is saying. The interviewee himself might have quoted another source or two and strengthened his information, but overall, N/A seems reasonable.", "answer": 2}, {"article": "Ultimately, four (27%) achieved the proposed end point, a PSA of 150 ng/dL at 20 months after the start of ADT, which remained undetectable in two patients for 27 and 46 months, respectively.\nSuch results could not have been achieved with any single therapy alone.\nLonger follow-up is needed to determine whether these patients were in fact cured.\nIn recent years, the FDA has approved six drugs for men with metastatic disease, all of which can increase survival.\nIt is expected that an upcoming Phase 2 trial will further test this endpoint and combined modality approach.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t mention who funded the work or whether there were any conflicts of interest.", "answer": 0}, {"article": "\"We've now demonstrated a technology that can enable painless, self-administered flu vaccination,\" said Mark Prausnitz, a professor in the Georgia Tech School of Chemical and Biomolecular Engineering and leader in the research.\nIt is estimated to affect more than 10 percent of the adult population.\nThree months after vaccination, researchers exposed a different group of immunized mice to the flu virus and found that those who received the microneedles did better than those injected by the hypodermic needles.\nHe said his team is working on those diseases but is not as far along.\nInfected with the influenza virus 30 days later, both groups that received the vaccine remained healthy while mice in the control group contracted the flu and died.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two independent sources are interviewed, one of whom provides valuable context regarding the difficulty of replicating mouse studies in humans.", "answer": 1}, {"article": "But he also emphasized the structured nature of the program tested in his study.\n\"It'll be interesting to see whether people can learn mindfulness techniques, then see durable effects,\" he said.\nThe program, Black said, did not specifically address sleep -- a topic that might only stir anxiety in people who are already worried about a lack of sleep.\nThen there's the fact that sleep issues become common as people age, Spira said.\nIn general, \"mindfulness\" practices encourage people to focus their attention on the present moment, instead of the past or future, and to take an objective look at their thoughts and emotions.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "It\u2019s clear that the reporter spent some time reviewing existing research on sleep disorders among older adults and in talking to the two main sources: the author of the study and an independent expert who wrote a commentary about the study. The story would have been even stronger had made the expert\u2019s\u00a0independence abundantly clear.", "answer": 1}, {"article": "But two potential explanations for Harklinikken\u2019s success have little to do with its formula.\n\u201cThere aren\u2019t a lot of options, and I\u2019d love to be able to say to my patients, \u2018This is something you can try that is worth the money.\u2019 But I can\u2019t do that yet.\u201d\n\nHarklinikken\u2019s formula, refined over 20 years, is derived from plants and cow\u2019s milk.\nBut during regular follow-up appointments, Harklinikken uses high-tech equipment to photograph and magnify the scalp and count new hairs and active follicles, which motivates users to adhere to the regimen.\nFor now, Maryanne Senna, a dermatologist and the director of the Hair Academic Innovative Research Unit at Massachusetts General Hospital in Boston, said the best she can tell patients who ask \u2014 and a lot of them do \u2014 is that Harklinikken won\u2019t do any harm.\nOne is how much emphasis the company places on compliance, the major stumbling block in the efficacy of any treatment, said Dr. Senna, an author of studies on the subject.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes a dermatologist and researcher from Massachusetts General Hospital, who says she\u2019s unable to recommend the product to patients because of a lack of data. Given the extensive commitment involved, including nightly applications of six hours, input from a patient who didn\u2019t achieve hair growth from this product would have been a great addition to this story.", "answer": 1}, {"article": "The system is in trials at Harvard Medical School/Beth Israel Deaconess Medical Centre.\nThe study\u2019s results will be submitted for publication in the coming weeks and a follow-up study on 30 patients is planned.\n\u201cIf out of 10 years the patients have left to live we can keep them at home in a relatively mild state of the disease for three, four, five years, it\u2019s a lot.\u201d\n\nAccording to Alvaro Pascual-Leone, director of the hospital\u2019s Berenson-Allen Centre for Non-invasive Brain Stimulation, brain stimulation - or transcranial magnetic stimulation - involves a very low current applied to a specific part of the brain and is approved by the FDA for treatment of a variety of ailments and diagnostic applications.\n\u201cWe see improvement lasting for 9-12 months and the good thing is that patients can return and undergo treatment again,\u201d Baror said.\nThe device, which consists of a chair containing an electronic system and software in the back and a coil placed at the head, has been tested on mild to moderate Alzheimer\u2019s patients who suffer from dementia but are not totally dependent.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quoted the company CEO and Dr. Alvaro Pascual-Leone.\u00a0 But it didn\u2019t disclose that Pascual-Leone is on the company\u2019s scientific advisory board.\nThere was no truly independent perspective in the story.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070805/13knee.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Three different sources fill out this compact story\u2014a spokesperson for the medical society representing the nation\u2019s orthopaedists, a spokesperson for knee implant manufacturer Zimmer, and chief of the knee service at one of the busiest joint replacement centers in the world (who has consulted for one of Zimmer\u2019s chief competitor, the story notes)\u2014a balanced group whose potential conflicts readers can judge for themselves.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070520/28diet.b.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cited one of the study\u2019s authors, but no independent source who might have expressed greater uncertainty about the significance of the study findings.", "answer": 0}, {"article": "THURSDAY, Oct. 12, 2017 (HealthDay News) -- Breast cancer is the second leading cause of cancer death among women in the United States, and routine screenings remain the most reliable way to detect the disease early, a breast cancer expert says.\n\"All women should know how their breasts look and feel so they can recognize any changes in them.\n\"I advise women to speak with their physician to determine what is right for them,\" Evers said.\n\"But just being familiar with your breasts should never take the place of regular screenings and mammograms.\nIn some cases, women never develop any of these symptoms, Evers noted.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources were cited. The article is based almost entirely on a single source in a news release\u00a0issued by Fox Chase cancer center by a mammographer.", "answer": 0}, {"article": "WEDNESDAY, Aug. 18, 2010 (HealthDay News) -- Fibromyalgia sufferers may find relief from the chronic pain condition by doing tai chi, new research finds.\nMost patients, according to background information in the article, remain in pain years after the diagnosis, are aerobically unfit, have poor muscle strength and flexibility, and need medications to control symptoms.\nThe controlled breathing and movements may promote \"mental tranquility,\" according to the study, which could help with pain.\nDoctors will often suggest exercise, sleep hygiene techniques and medications to treat the condition, but often with limited success, said Dr. Gloria Yeh, an assistant professor of medicine at Harvard Medical School, who wrote an accompanying editorial in the journal.\nThe improvements were still evident at 24 weeks, according to the research reported in the Aug. 19 issue of the New England Journal of Medicine.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does cite the opinions of a researcher who wrote an accompanying article in the journal. More outside voices would have been a nice addition. This criterion is barely satisfactory. ", "answer": 1}, {"article": "Newswise \u2014 WINSTON-SALEM, N.C. \u2013 Sept. 28, 2016 \u2013 Hot flashes \u2013 the bane of existence for many women during menopause \u2013 can be reduced in frequency by almost half for about 50 percent of women over eight weeks of acupuncture treatment, according to scientists at Wake Forest Baptist Medical Center.\nHis spouse is the primary shareholder of Chapel Hill Doctors, which is an organization that was subcontracted by Wake Forest School of Medicine as a site for subject recruitment and treatment.\n\u201cWomen bothered by hot flashes and night sweats may want to give acupuncture a try as a relatively low-cost, low-risk treatment,\u201d said Nancy Avis, Ph.D., lead author of the study and professor of Public Health Sciences at Wake Forest School of Medicine, a part of Wake Forest Baptist.\nWomen who had a reduction in their hot flashes saw a benefit beginning after about three to four weeks of weekly treatments.\u201d\n\nThe National Institutes of Health-funded study was designed to examine different patterns of responses to acupuncture.\n\u201cWe had hoped to identify some of the characteristics of the women who benefitted from acupuncture, but like so many treatments, we could not really tell ahead of time who would benefit,\u201d Avis said.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does a nice job here, mentioning how the study was funded and clearly outlining the potential conflicts of interests. One of the co-authors is the primary shareholder of Chapel Hill Doctors which was subcontracted by Wake Forest School of Medicine to recruit volunteers for the trial.", "answer": 1}, {"article": "The paper \"Real-time imaging of the resection bed using a handheld probe to reduce incidence of microscopic positive margins in cancer surgery\" is available online at http://cancerres.\nThe results appear in the journal Cancer Research.\nThe National Institutes of Health supported this work.\nThey look at the structure of the cells and other features of the tissue.\nThat's when this work will be most rewarding,\" Boppart said.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release discloses financial and commercialization interests of the principal investigator.", "answer": 1}, {"article": "Volunteers had the doctored lotion slathered onto one arm and regular moisturizer on the other.\n\u201cIt does open a window for a potential new treatment.\u201d\n\nHealthy skin harbors a different mix of bacteria than skin damaged by disorders such as atopic dermatitis, the most common form of eczema.\nThe study couldn\u2019t address the bigger question of whether exposure to the right mix of protective bacteria might improve atopic dermatitis itself, cautioned Mount Sinai\u2019s Guttman-Yassky.\nIn lab tests and on the surface of animal skin, those substances could selectively kill Staph aureus, and even a drug-resistant strain known as MRSA, without killing neighboring bacteria like regular antibiotics do, the team reported in the journal Science Translational Medicine.\nThis community \u2014 what scientists call the microbiome \u2014 plays critical roles in whether we stay healthy or become more vulnerable to various diseases.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story\u00a0didn\u2019t disclose this important detail about one of the sources, which was disclosed in the news release on this study:\nTeruaki Nakatsuji and Richard L. Gallo are co-inventors of UC San Diego technology related to the bacterial antimicrobial peptides discussed, and Gallo is a cofounder, consultant, chair of the scientific advisory board and holds equity in MatriSys Bioscience, a company that is developing skin bacteriotherapy.", "answer": 0}, {"article": "Cooper and his colleagues looked at 29,507 births to women covered by Medicaid in Tennessee between 1985 and 2000.\nAs a consequence, the labels on nearly all medications carry a statement saying their safety to fetuses has not been established.\nThe agency will consider broadening the \"black box\" warning against taking ACE inhibitors late in pregnancy, he said.\n\"I think it is safe to say that not a lot is known about the options for women in pregnancy,\" said Sandra L. Kweder of the FDA's Center for Drug Evaluation and Research.\nBut this is important enough and impressive enough to tell people about,\" said Robert Temple of the Food and Drug Administration, who spoke to reporters about the findings.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The sources of information appear to be the journal article, an author of the study and spokespersons from the FDA and its Center for Drug Evaluation and Research. ", "answer": 1}, {"article": "To learn more, visit stjude.org or follow St. Jude at @stjuderesearch\nThe paper's other authors are Qifan Zhu, Liqin Zhu, Zhiping Liu, Rajendra Karki, Ankit Malik, Deepika Sharma, Liyuan Li, R.K. Subbarao Malireddi, Prajwal Gurung, Geoffrey Neale, Scott Olsen, Robert Carter, Daniel McGoldrick, Gang Wu, David Finkelstein, Peter Vogel and Richard Gilbertson, all of St. Jude.\nThe team, led by Thirumala-Devi Kanneganti, Ph.D., a member of the St. Jude Department of Immunology, published their findings in a recent issue of the journal Cell.\n'Since reduced AIM2 activity in colorectal cancer patients is associated with poor survival, it might be useful to detect the level of AIM2 expression in polyps taken from colonoscopy and use this as one of the biomarkers for prognosis,' Kanneganti said.\nBoosting the activity of a protective gene and giving patients 'good' gut bacteria could help prevent or slow progression of colorectal cancer, St. Jude Children's Research Hospital scientists have found\n\nMemphis, Tenn., JUNE 19 -- Scientists at St. Jude Children's Research Hospital have discovered how an immune system protein, called AIM2 (Absent in Melanoma 2), plays a role in determining the aggressiveness of colon cancer.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release identifies the primary funding sources as the National Institutes of Health and ALSAC (though readers have to do their own searches to learn that ALSAC stands for the\u00a0 American Lebanese Syrian Associated Charities). However, the release fails to mention that Genentech supplied the Aim2-deficient mice. And neither the release nor the original article in Cell tell readers whether or not there are any financial or other ties between the researchers and Genentech\u2026 or whether any of the researchers hold any patent or royalty rights that are relevant to this work.\nWe\u2019ll give the benefit of the doubt since we did not see any evidence of conflicts of interest, although we would encourage all news releases to make a clear statement regarding the presence or absence of such conflicts. Readers should not be left in the dark to guess about potential conflicts.", "answer": 1}, {"article": "Alzheimer's disease is the most common age-associated neurodegenerative disorder that has no cure.\nAs part of the medical care for transplant recipients, any evidence of memory impairment or dementia is immediately noted and monitored, as it can limit treatment compliance among these patients.\nThe UTMB study data was compared with national data obtained from the 2014 Alzheimer's Association Facts and Figures dataset on age-matched patients to compare the prevalence of Alzheimer's.\nAn early online version of this paper detailing the findings has been published and is scheduled for publication in the July 7 issue of the Journal of Alzheimer's Disease.\n\"These data clearly show that the prevalence of dementia and Alzheimer's in our transplant patient group is significantly lower, in fact almost absent, when compared to national data from the general population,\" said senior author Luca Cicalese, professor in the department of surgery.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding sources are clearly identified. \u00a0The authors disclosed no conflicts of interest in the paper, a fact which the news release could also have shared with readers.", "answer": 1}, {"article": "The scientists then ran each volunteer through a large array of physical and cognitive tests.\nBut science has not been able to establish definitively whether such changes result primarily from the passage of time \u2014 in which case they are inevitable for anyone with birthdays \u2014 or result at least in part from lifestyle, meaning that they are mutable.\nThe findings suggest that many of our expectations about the inevitability of physical decline with advancing years may be incorrect and that how we age is, to a large degree, up to us.\nBut even the oldest cyclists in this study averaged barely 5 seconds for the walk, which is \u201cwell within the norm reported for healthy young adults,\u201d the study authors write.\nThey also had the volunteers complete the so-called Timed Up and Go test, during which someone stands up from a chair without using his or her arms, briskly walks about 10 feet, turns, walks back and sits down again.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We are given no comments by a non-involved source on the value or limitations of this small study. What\u2019s more, the story does not include any independent experts who could put the study results into context. Even a sentence or two of caution could have gone a long way here.", "answer": 0}, {"article": "LONDON (Reuters) - Taking cholesterol-lowering statin drugs such as Pfizer\u2019s Lipitor and AstraZeneca\u2019s Crestor could help prevent people dying from pneumonia, according to a study by British scientists released on Tuesday.\nPrevious studies have suggested statins, which are also available as cheaper generics, may be linked to better outcomes after bacterial infection.\nThey then matched each statin user \u2014 who was aged over 40 when first prescribed a statin between 1995 and 2006 \u2014 with up to five non-statin users for comparison.\n\u201cStatins are safe, cheap, and an easy intervention in terms of delivery,\u201d said Ian Douglas, a lecturer in epidemiology at the LSHTM who led the research.\nSeparate research published in March found that lowering cholesterol levels could help the body\u2019s immune system fight infections, a finding that appears to be supported by Tuesday\u2019s study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only perspective provided comes from the study\u2019s lead researcher, via a press release.", "answer": 0}, {"article": "Secondly, we have shown that treatment with high frequency TMS makes a difference to at least some sufferers, although there is a long way to go before we will know if TMS is the best route to treat these patients in the long-term\".\nCommenting, Professor Andreas Meyer-Lindenberg, Central Institute of Mental Health, Mannheim and member of the ECNP executive board, said: \"This work builds on previous studies that have shown a critical role of excessive activity of subregions of the temporal lobe in the generation of voice hallucinations in schizophrenia.\nThis means two things; firstly it seems that we now can say with some certainty that we have found a specific anatomical area of the brain associated with auditory verbal hallucinations in schizophrenia.\nNOTE: The full title of this release is \"Scientists discover brain area which can be targeted for treatment in patients with schizophrenia who 'hear voices'\" It has been shortened in some versions to comply with Eurekalert title limits.\nThis is the first controlled trial to show an improvement in these patients by targeting a specific area of the brain and using high frequency TMS.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The study funders (French Health Ministry (PHRC) and Basse Normandie Regional Council) are listed on a sidebar of the EurekAlert! site, where the release is hosted. We encourage news release writers to include funders in the text as well. The release doesn\u2019t address whether the researchers had any conflicts of interest. To be clear, we are not claiming that such conflicts of interest exist (it\u2019s impossible to tell, since the release doesn\u2019t tell us the names of all the researchers involved). But a release should make clear whether any such conflicts exist. If there are no conflicts, say so.", "answer": 1}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\nThe four people who got the sham stimulation during both visits consumed the same number of calories from the vending machines on each visit and did not lose weight.\nSpanning the full spectrum of medicine and afflicting people of all ages and ethnic groups, these diseases encompass some of the most common, severe and disabling conditions affecting Americans.\nThe findings suggest a possible intervention for obesity, when combined with healthy eating and exercise.\nParticipants then ate and drank as much as they wanted from computerized vending machines.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The principal investigator in this research is an employee of a federal agency. There does not appear to be any conflict of interest and funding sources are named.", "answer": 1}, {"article": "MONDAY, June 6, 2011 (HealthDay News) -- There's too little evidence to say definitively whether treating early, localized prostate cancer with radiation is a better option than \"watchful waiting,\" new research finds.\nThere was also \"moderate strength evidence\" that a higher external beam radiation was more effective than a lower dose.\nMen and their doctors need to consider what the tumor looks like under the microscope, which can help gauge how aggressive it may be.\nThe National Cancer Institute has more on prostate cancer.\nThey should also consider age and overall health status, including whether or not the patient has other conditions more likely to cause death than the prostate cancer.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story turned to Dr. Durado Brooks of the American Cancer Society for an independent perspective.", "answer": 1}, {"article": "When considering where to give birth, most parents-to-be and doctors in Western nations believe a hospital is the best place.\n\nNot so Jean Stevens, 32, who chose to deliver two children at home in the U.K. She says her two labors were nearly pain-free.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This was a strong point for the story. The story cites multiple sources on both sides of the issue, and clearly notes when a given source has written about the issue and what that source\u2019s position was.", "answer": 1}, {"article": "Imagine plopping six cups of coffee grounds on the heads of patients just before they are wheeled into the operating room to have nose or throat surgery?\n\"The basic assumption is that, after registration, the spatial relationships between the patient's head and the fiducial markers remains constant,\" said Patrick Wellborn, the graduate student who is making the presentation.\nIn fact, previous research has found that when everything goes well, the guidance system produces targeting errors of about 2 millimeters but, in about one operation out of seven, the target error is much larger, forcing the surgeon to redo the registration process.\nThe computer uses this information to combine a CT scan, which provides a detailed 3-D view of the bone and soft tissue hidden inside the patient's head, with the position of the instruments the surgeon is using and displays them together in real time on a monitor in the operating room.\n\"These are very delicate operations and a sophisticated image guidance system has been developed to help the surgeons, but they don't trust the system because sometimes it is spot on and other times it is off the mark,\" said Robert Webster, associate professor of mechanical engineering and otolaryngology, who is developing a surgical robot designed specifically for endonasal surgery.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release says the research was supported by grants from the National Institutes of Health and the National Science Foundation. It states that one of the researchers now works for Eli Lilly and Company, and that the university is seeking a commercial partner to bring the device to market.", "answer": 1}, {"article": "The agency, he added, remains concerned about \u201cthe proliferation and illegal marketing of unapproved CBD-containing products with unproven medical claims.\u201d\n\nIn April, an advisory committee unanimously recommended approval of the drug for the two types of epilepsy.\nThe disorders afflict fewer than 45,000 people in the United States, but experts expect Epidiolex to be prescribed for other types of epilepsy as well.\nGottlieb noted that the action was \u201cnot an approval of marijuana or all of its components\u201d but rather of one specific CBD medication for a particular use.\nHowever, it isn\u2019t clear whether such a reclassification would involve CBD products in general, the CBD formulation used specifically in Epidiolex or something else.\nThe FDA previously cleared medications containing synthetic versions of THC for nausea for patients getting chemotherapy and for other uses, but it had not approved any drug derived from the plant itself.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There is a quote from a neurologist with the American Epilepsy Society, however he consults for drug companies and the society has received substantial donations from a subsidiary of the drugmaker manufacturing this drug. This should have been flagged for readers.", "answer": 0}, {"article": "Results show that there were significant and clinically meaningful improvements in general quality of life and sleep-related quality of life measures after the initiation of PAP therapy for sleep apnea.\nThe study was funded by a scholar award from the Cleveland Clinic Neurological Institute-Center of Research Outcomes and Evaluation and by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH).\nFor a copy of the study, \"Impact of Sleep-Disordered Breathing Treatment on Quality of Life Measures in a Large Clinic-Based Cohort,\" or to arrange an interview with a study author or an AASM spokesperson, please contact the AASM at 630-737-9700 or media@aasm.org.\n\"Quality of life is one of the most vital outcomes for patients and often one of the primary reasons to seek medical attention,\" said lead author and principal investigator Dr. Harneet Walia, assistant professor at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and staff at the Cleveland Clinic's Sleep Disorders Center.\n\"Our study also serves as a basis for targeted efforts to optimize quality of life in younger adults and lower socioeconomic subgroups,\" said Walia.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release did include a section at the bottom describing the funding sources for the study. However, it neglected to note that the first author has ties to two industry companies (Phillips Respironics and ResMed), both of which make money on the sale and upkeep of CPAP machines and supplies. This is an important financial conflict of interest to include.  ", "answer": 0}, {"article": "Despite popular lore, agency won't allow labels to say drink is good for consumers' hearts\n\nWASHINGTON - There is no credible scientific evidence that drinking green tea reduces the risk of heart disease, federal regulators said last week in rejecting a petition that sought to allow tea labels to make that claim.\nIto En Ltd., a Japanese company that bills itself as the world's largest green tea company, and its U.S. subsidiary, Ito En (North America) Inc., petitioned the FDA in June, seeking to make the claim that drinking at least five ounces of green tea a day may reduce the risk of heart disease.\n\"There is no credible evidence to support qualified health claims for green tea or green tea extract and a reduction of a number of risk factors associated with (cardiovascular disease),\" the FDA said on its Web site last week.\nNonetheless, the belief that drinking green tea confers health benefits has driven its popularity over the past decade, the Tea Association of the United States has said.\nA message left for the AAC Consulting Group, a Rockville, Md., company that filed the petition, also was not immediately returned.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story said that spokespersons for the world\u2019s largest green tea company and for the consulting group that filed the petition with the FDA did not respond to messages left for them. But there were no comments from individuals conducting research investigating whether green tea affects heart disease risk.", "answer": 0}, {"article": "She told ABC's \"Good Morning America\" today she always hoped for a medical miracle.\n\"We were worried that there'd be too much scar tissue in the retina itself to be able to deliver the material to the correct spot,\" he said.\n\"It will succeed not only for me, but also for other people with visual problems so that they can have a hope for their future,\" said Manuela.\nFor the first time, researchers have shown that gene therapy can be used to improve vision for blind children and young adults.\n\"It could, in historic terms, be equated to something like the first heart transplant or the first kidney transplant,\" said Bennett.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The\u00a0greatest threat to validity of this story is that all\u00a0experts cited have patents pending on this gene therapy, and this fact is noted in the source article in the New England Journal of Medicine. The story failed to mention this. ", "answer": 0}, {"article": "For more information about Pitt Public Health, visit the school's Web site at http://www.\n\"If a patient who is on an anticoagulant to avoid a stroke has a major bleeding event, doctors are faced with a catch-22: Discontinue the anticoagulant to avoid future bleeding, but again place their patient at increased risk of stroke; or resume the anticoagulant to continue avoiding a stroke, but then have to worry about another bleeding event,\" said lead author Inmaculada Hernandez, Pharm.D., Ph.D., an assistant professor in Pitt's School of Pharmacy, who completed this work as a doctoral student at Pitt's Graduate School of Public Health.\nThe analysis, published today in the journal Stroke, determined that resuming anticoagulation therapy after a person suffers a major bleeding event was associated with a higher likelihood of stroke-free survival than discontinuing anticoagulation.\n\"It causes a lot of uncertainty for physicians, especially because patients at highest risk of recurrent bleeding also are at highest risk of stroke,\" said co-author Yuting Zhang, Ph.D., associate professor of health policy and management at Pitt Public Health, and Hernandez's doctoral dissertation committee chair.\nThe risk of dying from any cause or having a stroke was 23 to 34 percent higher in patients who discontinued anticoagulation therapy compared to those who resumed it.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release states the study\u2019s funding sources: the Commonwealth Foundation, the Agency for Healthcare Research and Quality, the National Institute of Mental Health, and La Caixa foundation. However, it does not state that one of the authors, Samir Saba, M.D., received research support from Boston Scientific, Medtronic, and St. Jude Medical, all of which make mechanical heart valves that require the use of anticoagulants to lower the post-operative risk of complications from blood clots. Since the potential conflict here is not direct, we will give the benefit of the doubt and award a Satisfactory rating.", "answer": 1}, {"article": "DURHAM, N.C. - Most high-risk lung cancer patients might not need annual low-dose computed tomography (LDCT) screenings if they are cleared of disease in their initial test, according to a study led by a Duke Cancer Institute researcher.\n\"This has significant public policy implications,\" said Edward F. Patz, Jr., M.D., the James and Alice Chen Professor of Radiology at Duke and lead author of a study published online March 21, 2016 in The Lancet Oncology journal.\n\"Our analysis suggests that annual screens may not be warranted for patients who have had an initial negative scan, and future risk prediction and cost-effectiveness models could incorporate these data to improve screening guidelines,\" Patz said.\nIn the first year after a negative screen and before the scheduled first annual screen, 17 patients (0.09 percent of all initial negative LDCT participants) were diagnosed with lung cancer.\nThe researchers found that even former heavy smokers appear to have a reduced incidence of lung cancer if their initial LDCT screening is negative, suggesting that less frequent screening might be warranted.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "No funding or conflicts of interest were mentioned in the news release. While changes in lung cancer screening schedules could have benefits for a wide range of people, we\u2019d still like the release to address the issue of sponsorship. We\u2019re not implying there was a conflict (we don\u2019t know if there were outside funders), but if a manufacturer did sponsor such a study it could pose a potential for conflict of interest that readers should be made aware of.", "answer": 0}, {"article": "The average age of children in the study was 7.\nBut the most immediate question for Sobel is \"whether an olfactory impairment is at the heart of the social impairment in autism.\"\n\"The difference in sniffing pattern between the typically developing children and children with autism was simply overwhelming,\" says Noam Sobel of the Weizmann Institute of Science in Israel.\nThe findings suggest that non-verbal tests related to smell might serve as useful early indicators of ASD, the researchers say.\nThe researchers now plan to test whether the sniff-response pattern they've observed is specific to autism or whether it might show up also in people with other neurodevelopmental conditions.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not tell readers who funded the research. The release also doesn\u2019t mention the fact that, as the paper itself states, \u201cThe results of this manuscript are under consideration of patent at the Weizmann Institute Office of Technology Transfer.\u201d That\u2019s worth mentioning, particularly since the release quotes the study\u2019s corresponding author, who is on faculty at the Weizmann Institute of Science. This isn\u2019t an unusual state of affairs for potentially useful research being done at large institutions, but we feel it is something that a release should share with readers.", "answer": 0}, {"article": "Months of recovery are needed while the transplant grows and reconstitutes the patient\u2019s immune system.\n\u201cIt is possibly a cure, that\u2019s for sure, you won\u2019t know for absolute sure until the person dies and undergoes extreme PCR (genetic) analysis of post-mortem tissue.\u201d\n\nThe mutation affects a receptor, a cellular doorway, called CCR5, that the AIDS virus uses to get into the cells it infects.\n\u201cIt\u2019s not practical and it can kill people,\u201d said Dr. Robert Gallo of the Institute of Human Virology at the University of Maryland, who helped discover the human immunodeficiency virus that causes AIDS.\nWASHINGTON (Reuters) - German researchers who used a bone marrow transplant to treat a cancer patient with the AIDS virus, have declared him cured of the virus \u2014 a stunning claim in a field where the word \u201ccure\u201d is barely whispered.\nNearly four years after the transplant, the patient is free of the virus and it does not appear to be hiding anywhere in his body, Thomas Schneider of Berlin Charite hospital and colleagues said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story\u2019s main expert source was\u00a0Dr. Robert Gallo of the Institute of Human Virology at the University of Maryland, who helped discover the human immunodeficiency virus that causes AIDS. His comments offered context and appropriate cautions. While the story does not discuss potential conflicts of interest, the researchers declared in their journal article that they had no competing financial interests and the work was supported by non-commercial institutions. ", "answer": 1}, {"article": "The infants were randomized to 1 of 4 groups: placebo control; video instruction to parents on how to soothe their baby; video plus oral sugar solution; and video, oral sugar solution and lidocaine applied to the skin.\n\"Vaccinations cause acute distress for both infants and their parents, contributing to vaccination avoidance,\" states Dr. Anna Taddio, a pharmacist and senior associate scientist at The Hospital for Sick Children (SickKids) and professor, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario.\n\"We found that, when used consistently during vaccine injections in the first year of life, only liposomal lidocaine combined with parental video instruction and orally administered sucrose showed a benefit on acute pain when compared with placebo, video alone, and video and sucrose together,\" wrote the authors.\n\"The effects of consistent pain management on the development of preprocedural anxiety (fear), hypersensitivity to pain and compliance with future vaccination warrant future investigation,\" they recommend.\nFor babies under age 1 year, lidocaine cream, combined with a small amount of sugar given by mouth and infant soothing, can help relieve pain from routine vaccinations, according to a study in CMAJ (Canadian Medical Association Journal).\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does note that Pfizer funded the research, but you\u2019ll only see that listed on a sidebar of the EurekAlert!-hosted version of the news release. The disclosure isn\u2019t included in the release text, meaning it probably won\u2019t be noted in subsequent reprints of the release or many articles launched by the news release.\nPerhaps more importantly, the release \u2014 unlike the study itself \u2014 doesn\u2019t disclose that the lead author received a research grant from Pfizer, which makes a lidocaine-containing line of products called Lignocaine. This is an important consideration not only in terms of sponsorship transparency; it also raises the question of whether Lignocaine results can be generalized to other lidocaine products.", "answer": 0}, {"article": "In investigating how BCG administration produces its beneficial effects, the research team identified a mechanism never previously seen in humans in response to treatment with any drug - a shifting of the process of glucose metabolism from oxidative phosphorylation, the most common pathway by which cells convert glucose into energy, to aerobic glycolysis, a process that involves significantly greater glucose consumption by cells.\nIn August 2017 the MGH was once again named to the Honor Roll in the U.S. News & World Report list of \"America's Best Hospitals.\"\nThe MGH BCG clinical trial program is entirely funded by private philanthropy from individuals and family foundations, including the Iacocca Foundation.\nThe researchers also found that BCG could reduce blood sugar elevations in mice that were caused by means other than autoimmune attack, raising the possibility that BCG vaccines could also be beneficial against type 2 diabetes.\nParticipants in the placebo group and in a comparison group of patients receiving no treatment experienced consistent HbA1c elevations over the same eight-year time period.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "According to the news release the study \u201cis entirely funded by private philanthropy from individuals and family foundations.\u201d\nNo conflicts of interest are reported in the published study.", "answer": 1}, {"article": "See Full Prescribing Information.\nAll of KVK's products are made in the U.S.A. in a state-of-the-art facility in Newtown, PA. KVK is committed to maintaining its entire business operations in America, as it continues to build strong, lasting relationships with the nation's largest pharmacy chains, wholesalers and distributors.\nAs with all KVK Tech products, Lomaira will be exclusively manufactured and packaged in the United States, in the strictest accordance with FDA, DEA, and DEP guidelines.\nIt has not been established that the primary action of such drugs in treating obesity is one of appetite suppression since other central nervous system actions, or metabolic effects, may also be involved.\nThe limited usefulness of agents of this drug class (anorectics), including Lomaira, should be measured against possible risk factors inherent in their use.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There is no mention of who funded the studies that the FDA would have required for them to approve this use of the drug, nor is there any mention of potential conflicts of interest on the part of any investigators. The study referenced at the end of the release, however, did identify funders and addressed potential conflicts.", "answer": 0}, {"article": "\"There are a lot of pundits who remain skeptical or feel we need to research this ad infinitum before it's ready, which doesn't make sense to me,\" Feifel says.\nAnd in 2006, a team from the National Institute of Mental Health published a landmark study showing that a single intravenous dose of ketamine produced \"robust and rapid antidepressant effects\" within a couple of hours.\n\"It became clear to me that the future of psychiatry was going to include ketamine or derivatives of ketamine,\" says David Feifel, a professor of psychiatry at the University of California, San Diego, who began administering the drug to patients in 2010.\n\"While the science is promising, ketamine is not ready for broad use in the clinic,\" Insel wrote in his blog a few months ago.\nThe decision put him at odds with some prominent psychiatrists, including Tom Insel, director of the National Institute of Mental Health.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story relies almost entirely on a single passionate advocate and a single compelling patient. The story would have been strengthened and balanced by an interview with someone with a contrary opinion. We\u2019ll give the story a pass for featuring a skeptical blog quote from the director of the National Institute of Mental Health. But the story could have done more to highlight experts who are critical of the use of ketamine and feature patients who didn\u2019t respond to the drug.", "answer": 1}, {"article": "Khalsa's article highlights the principles and practices of this 12-minute meditation, with corresponding SPECT scans showing how it successfully activates the posterior cingulate gyrus, an important region of the brain that helps regulate memory and emotional function.\n\"We've been studying the impact of meditation on memory for more than 20 years, and are as encouraged as we've ever been on its powerful role in maximizing brain health,\" said Khalsa, president and medical director of the Alzheimer's Research and Prevention Foundation and a clinical associate professor of integrative medicine at the University of New Mexico School of Medicine.\nWhile preliminary studies have suggested a link between meditation, a sense of spirituality or faith and the risk of Alzheimer's disease, the article's author, Dharma Singh Khalsa, M.D., states that a cultivation of higher levels of psycho-social well-being, such as independence, resilience and life purpose represents \"an important new frontier that deserves further research as it is freely available to anyone, anytime, anywhere.\"\nTUCSON, Ariz., July 15, 2015 /PRNewswire/ -- Meditation and spiritual fitness are key components in reducing the risk of Alzheimer's disease according to a new article, \"Stress, Meditation, and Alzheimer's Prevention: Where the Evidence Stands\", published in an early online version of the Journal of Alzheimer's Disease 48(1).\nThe article reviews decades of research into the impact that various meditation techniques have had on the prevention of Alzheimer's disease, focusing on one evidence-based practice that Khalsa says can be a powerful part of any Alzheimer's prevention and spiritual fitness program, Kirtan Kriya (KK), a meditation technique which has been successfully used to improve memory in studies of people with subjective cognitive decline and mild cognitive impairment.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "It\u2019s clear that the release came from the Alzheimer\u2019s Research & Prevention Foundation, and that the study author is also the Foundation\u2019s president and medical director, Dharma Singh Khalsa, MD. The release states that the\u00a0Foundation supports holistic and lifestyle approaches to dementia prevention, which distinguishes it from the vast majority of prevention/treatment efforts that are based on drugs.", "answer": 1}, {"article": "The study also found other benefits.\nThe paper suggests that the drug may one day offer a nonsurgical alternative to \"vertical sleeve gastrectomies\" that have become popular in the battle against morbid obesity.\nNearly 20 years ago, Evans's lab worked to identify the molecular switch that turns on a whole series of bodily responses to eating, including digestion, absorption, the transfer of nutrients by the bloodstream and increased blood circulation, to name a few.\nResearchers at the Salk Institute for Biological Studies in La Jolla, Calif., reported Monday that they have developed a compound that tricks the metabolism into responding as if a meal has been eaten, causing it to burn fat to make room for new calories.\nIn the meantime, basic weight loss advice remains the same: fewer calories in, more calories expended by physical activity.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story fails readers by withholding the fact that the leading researchers are co-inventors of the molecule. The journal notes that they \u201cmay be entitled to royalties.\u201d This financial interest should have been reported in the story.\nWhat\u2019s more, the story does not include any independent experts who could put the study results into context.", "answer": 0}, {"article": "But if the beta-amyloid plaques that are the disorder's key physical hallmark could be detected before memory loss and cognitive troubles were evident to all, would you want to know?\nLast week, the FDA approved an agent called Florbetapir F 18 injection (to be marketed as Amyvid), which will allow physicians using a positron emissions tomography (PET) scan to detect the presence and extent of amyloid plaques in patients concerned about declining mental function.\nThe FDA says that Amyvid \"is not a test to predict the development of AD-associated dementia\" in those who have no problematic symptoms.\nFor now, says Weiner, there is \"no consensus\" on which patients should get the costly new PET scans that use Amyvid, and large insurers such as Medicare and Medicaid have not made decisions about coverage for such tests.\nThe \"real game-changer,\" he says, will be when one of the many experimental therapies under study for Alzheimer's disease succeeds in blocking or reversing its progress.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an expert source, Dr. Michael Weiner, who was involved in the development of Amyvid, but it does not mention that he has disclosed relationships with a number of pharmaceutical companies, including Eli Lilly, Amyvid\u2019s manufacturer. In addition, the story mentions that Weiner is the leading researcher on the Alzheimer\u2019s Disease Neuroimaging Initiative, but does not disclose that this consortium is partially funded by industry.\nSince the drug had previously been rejected by the FDA\u2019s scientific advisory committee,\u00a0 a dissenting voice would not have been hard to find.", "answer": 0}, {"article": "\"Parents often say that their biggest concern is, 'When is my child going to be back to normal again?'\nIf the experimental test pans out, \"a pediatrician could collect saliva with a swab, send it off to the lab and then be able to call the family the next day,\" says Steven Hicks, an assistant professor of pediatrics at Penn State Hershey.\nAnd microRNAs offer a promising way to assess concussions in adults as well as children, says Bhomia, whose research involves a range of \"biomarkers\" for traumatic brain injury.\n\"When they came to our medical center and received the diagnosis of concussion, we evaluated them with some standard survey-based tools and then we also got a sample of their saliva,\" Hicks says.\nBut up to 25 percent of young patients \"go on to have these prolonged headaches, fatigue, nausea, and those symptoms can last sometimes one to four months,\" Hicks says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story reports that the lead researcher \u201chelped develop the test and consults for a company that hopes to market concussion tests.\u201d It also includes comments from a source who does not appear to be connected with the study, nor have any potential conflicts of interest. Though as we noted above, the way this source\u2019s comments are reported creates confusion about what the study actually looked at.", "answer": 1}, {"article": "\"There was a trend toward less severe psoriasis severity in people taking statins,\" says researcher Adam Perry, a fourth-year medical student at Emory University in Atlanta.\nAnd no one should start taking statins in an attempt to ward off psoriasis symptoms, doctors stress.\nThe study is preliminary and doesn't prove cause and effect.\nIn a study of 232 people taking medication for psoriasis, those who also took statins had fewer of the thick, red, scaly, itchy patches that are the hallmark sign of psoriasis, compared with people who didn't take the cholesterol-lowering drugs.\nAlready linked to a reduced risk of rheumatoid arthritis, diabetes, multiple sclerosis, and cancer, statins also may help to improve symptoms of psoriasis, researchers report.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0Independent sources were used to write this story; there was, however, \u00a0no information about sources of funding for this research.", "answer": 1}, {"article": "What to do?\nThe researchers looked at whether or not women were getting a dual-energy X-ray absorptiometry (DXA) test, which measures bone mineral density.\nHowever, the study also found that those risk factors -- a small body frame, a history of fractures, or taking medications that could thin bones -- had only a slight effect on a woman's decision to get her bones tested.\n\"Health systems should invest in developing electronic health records systems that prompt providers at the point-of-care when screening is needed and when it can be postponed,\" study senior author Joshua Fenton, an associate professor of family and community medicine at UC Davis, said in the news release.\nThe result: Osteoporosis screening rates jumped sharply at age 50, despite guidelines suggesting that screening only begin at age 65, unless a woman has certain risk factors.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story offers no independent voices to put the findings in context. It makes no mention of funding, though there appear to be no conflicts of interest.", "answer": 0}, {"article": "The test isn't ready for prime time, however, and it's not foolproof: a study found that it misses some premature births and incorrectly predicts others.\nIn the new study, the researchers examined blood samples from 80 women who went on to have normal births and 80 who had premature births.\nThe closer to the preterm birth, the more likely you are to have significant changes in the physiology of the woman that is observed in the blood.\"\nThey tried to find signs in the blood that indicate what kind of birth the women would have.\nThe test wasn't as effective at 24 weeks of gestation.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted one independent expert; it could have been improved with more comment from her or from others.", "answer": 1}, {"article": "Those T-cells pick up melanoma cells\u2019 molecular scent and hunt them down before going off in search of tumor cells hiding elsewhere in the body.\n\u201cThe field is exploding, and this would be another arrow in the quiver that oncologists use.\u201d\n\nImlygic is part of a new group of immune-stimulating viral therapies that could change how cancer is treated and managed.\n\u201cAfter that, there were no side effects.\u201d\n\nSuch muted side effects point to a major benefit of this new approach, doctors and patients said.\n\u201cBut short of that, this might be like diabetes, where we can control it and people live normal lives.\u201d\n\nImlygic is based on a form of the herpes simplex virus that commonly causes cold sores.\nIt\u2019s being developed in combination with other immunotherapies, where we think there\u2019s a little more of a commercial opportunity, but we still need to see more data.\u201d\n\nImlygic is approved for skin tumors that are inoperable in patients whose cancer has returned following surgery.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes a number of experts and clearly a lot of legwork went into the reporting. But two of the sources quoted in the story consult for Amgen, the company that will sell this treatment, and they are not so identified. From the description provided in the story, some readers can probably gather that these experts are involved with the company. But it would have been better to state clearly that these are paid consultants. In addition, we wish that any of the sources quoted in the story had raised questions, pointed to limitations, or provided some critical analysis of the research. The overall tone of the piece is optimistic and positive \u2014 overly so in our view.", "answer": 0}, {"article": "The Ache: Common cholesterol-lowering drugs called statins can have unpleasant side effects, including muscle aches and weakness.\n\nThe Claim: An extract from a bitter, fragrant citrus fruit called bergamot, commonly known as a flavoring in Earl Grey tea, can lower cholesterol with minimal side effects, some scientists say. It also boosts good cholesterol, reduces fatty deposits in the liver and lowers blood sugar, they add.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Dr. David Frid, a cardiologist from the Cleveland Clinic, reminds us that the studies need to be reproduced in other populations, and that statins have been show to reduce heart attacks (not just cholesterol).", "answer": 1}, {"article": "Other researchers are more skeptical.\n\u201cThings are moving forward, but it is still a work in progress.\u201d\n\nMedical guidelines in the U.S. already urge people to take low doses of aspirin to prevent heart disease if the predicted benefits outweigh the risk of side effects, or if they have already suffered a heart attack.\nAs a result, doctors may find and remove tumors or precancerous polyps, which could prolong the patient\u2019s life - the idea behind colon cancer screening.\nEarlier this year, an analysis of previous clinical trials showed that people on aspirin were less likely to die of cancer than those not on the medication, with a 37-percent drop in cancer deaths observed from five years onwards.\nIt includes a decade\u2019s worth of data from more than 100,000 men and women in the U.S., most over 60 and all of them non-smokers.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The input from independent expert Dr. Kausik Ray was important.\u00a0 And it pointed out the recommendation of the US Preventive Services Task Force discouraging the use of aspirin \u201cto stave off colorectal cancer in people at average risk for the disease.\u201d", "answer": 1}, {"article": "Doctors and patients\u2019 advocates urged women considering the procedure to go for counseling and take their time before making a decision, noting that other risk-reducing options were available, like tamoxifen therapy for estrogen receptor-positive breast cancer and the use of more sensitive magnetic resonance imaging screening for earlier detection.\n\u201cFewer women are having just one breast removed.\u201d\n\nYounger women, white women and women with a previous cancer diagnosis were more likely to opt for a contralateral prophylactic mastectomy, the study found, as were women who had lobular histology, meaning the cancer started in the lobules or milk-making glands of the breast.\nThough all women with breast cancer are at risk of developing a second cancer in the uninvolved breast, the risk is slightly greater with lobular histology, Dr. Tuttle said, and white women may be more likely to carry genetic mutations associated with an increased risk of developing cancer in the contralateral breast.\n\u201cFor the vast majority of our patients, this does not impact the chances of dying of breast cancer, and that\u2019s the key thing here,\u201d said Dr. Julie R. Gralow, the chairwoman of the communications committee of the American Society of Clinical Oncology and an associate professor of medical oncology at the University of Washington and the Fred Hutchinson Cancer Research Center in Seattle.\nThough the researchers had limited information about the patients, Dr. Tuttle suggested that younger women might be choosing the procedure because their cancers tended to be very aggressive, and they had more years ahead of them in which a second cancer might develop.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites Dr. Tuttle, the lead author of the study; a woman who decided to undergo a bilateral mastectomy, though she only had cancer in one breast; and Dr. Gralow, who questions the trend of prophylactic mastectomies in women who have the option to undergo lumpectomy and radiation, or lumpectomy alone (for DCIS). The story may have been more balanced by interviewing a patient who chose less treatment, along with her rationale.", "answer": 1}, {"article": "TUESDAY, Sept. 11, 2012 (HealthDay News) -- A new device meant to help surgeons determine in the operating room if they have removed all cancerous breast cancer tissue may help reduce repeat surgeries after lumpectomy without compromising cosmetic effects, according to a new study.\nIn June, the radiation-free device won the blessing of a U.S. Food and Drug Administration advisory panel.\nFor the study, Boolbol and her colleagues randomly assigned 495 breast cancer patients to receive the MarginProbe after lumpectomy or not receive it.\nThe study of nearly 500 patients undergoing breast-conserving surgery found little difference in the volume of tissue removed when the device was used compared to traditional detection methods.\nFor those with ductal carcinoma in situ, 13 percent of the probe group needed a repeat surgery, compared to 37 percent of the control group.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "While the story does quote a respected\u00a0independent source about the need for additional studies, the story should have also indicated that the study was funded by Dune Medical Devices, the manufacturer of the MarginProbe device.", "answer": 0}, {"article": "This barrier works to protect the brain from toxins.\nThis study was funded, in part, by The Ben & Catherine Ivy Foundation.\nOne of the fundamental challenges in treating brain cancer with drugs is what is known as the blood-brain barrier that separates circulating blood from the brain extracellular fluid in the central nervous system.\nOnly 5 percent of patients survive more than 5 years.\nSince then, the Foundation has contributed more than $50 million to research in gliomas within the United States and Canada, with the goal of better diagnostics and treatments that offer long-term survival and a high quality of life for patients with brain tumors.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that the research was funded by the Ben & Catherine IVY Foundation and NIH grants.", "answer": 1}, {"article": "Daily aspirin doubles a person's gastrointestinal bleeding risk to about 2 in every 1,000 people a year.\nAnd the latest study, published in The Lancet, suggests aspirin could provide protection against a wide variety of tumors.\n\"This is definitely the first time that research has shown that long-term aspirin use can reduce the risk of deaths due to cancer,\" Dr. Asad Umar of the National Cancer Institute's division of cancer prevention tells Shots.\n\"So I think in the fullness of time, preventing cancer will be seen to be the main reason for taking aspirin in healthy individuals,\" Rothwell says.\nA British study offers compelling -- though not clinching -- evidence that the humble aspirin tablet can prevent death from a variety of cancers, if you take the medicine long enough in middle age.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story makes pretty good use of outside sources. It points out that \u201cthe U.S. Preventive Services Task Force\u2019s currently recommends against taking aspirin to prevent colorectal cancer, the type of cancer for which there is the largest body of scientific work.\u201d At the same time,\u00a0the statement that the effects on cancer are larger than for heart disease is misleading for middle-aged and older adults who are not at high risk for cancer. Heart disease is 10 times more likely in these populations, so even with a lower relative risk reduction, more heart attcaks are going to be prevented than cancers. The story would have been better if it had told readers that although this study received no outside funding, some of the authors have had consulting relationships with pharmaceutical companies. ", "answer": 1}, {"article": "For more information, visit http://www.\nThe USDA Dietary Guidelines for Americans state that people who eat more fruit as part of an overall healthy diet are likely to reduce their risk of some chronic diseases, although little is published on the health outcomes associated with individual fruits, including pears.\nIn addition to discovering a correlation between fresh pear consumers and lower body weight, the study found that pear consumption was associated with higher diet quality (as defined by the Healthy Eating Index).\nA new study, 'Fresh Pear Consumption is Associated with Better Nutrient Intake, Diet Quality, and Weight Parameters in Adults: National Health and Nutrition Examination Survey 2001-2010,' published in Nutrition and Food Science, revealed new information regarding the health benefits of pear consumption.1 Of particular interest given the high rates of obesity in the United States, the study found that adult pear consumers had a lower body weight than non-pear consumers and they were 35 percent less likely to be obese.\nToday, the United States is the third largest pear-producing country in the world, and Oregon and Washington comprise the nation's largest pear growing region with 1,600 growers producing 84% of all fresh pears grown in the United States.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release is transparent in acknowledging that the Pear Bureau is the source of its pear promotion and the \u201ccommissioning\u201d of studies, in this case at the Louisiana State University Agricultural Center.", "answer": 1}, {"article": "What if you could lose weight and reduce your risk of life-threatening disease without any changes in what you eat -- other than a five-day special diet once every few months?\n\"This study provides evidence that people can experience significant health benefits through a periodic, fasting-mimicking diet that is designed to act on the aging process,\" said Valter Longo, director of the USC Longevity Institute and a professor of biological sciences for USC Davis and Dornsife.\n\"Fasting seems to be the most beneficial for patients who have the great risk factors for disease, such as those who have high blood pressure or pre-diabetes or who are obese,\" Longo said.\nThe work was funded by the USC Edna M. Jones Chair in Gerontology fund, as well as through a National Institutes of Health grant to co-author Wendy Mack at the Keck School of Medicine of USC, through the Southern California Clinical and Translational Science Institute.\n\"We saw similar outcomes, which provides further evidence that a fasting-mimicking diet has effects on many metabolic and disease markers.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We applaud the release for including detailed information on the financial conflicts of the lead author and the University of California at Davis. Here is how the release disclosed the financial conflicts:\n\u201cLongo is the founder of L-Nutra, whose food products were used in the study. His interest in L-Nutra has been disclosed and managed per USC\u2019s conflicts of interest policies to assure objectivity and a lack of bias in the conduct and reporting of his research.\nUSC also has an ownership interest in L-Nutra, and the potential to receive royalty payments from L-Nutra. USC\u2019s financial interest in the company has been disclosed and managed under USC\u2019s institutional conflict of interest policies.\u201d", "answer": 1}, {"article": "\u201cThere is a great deal of interest in developing other uses of bimatoprost,\u201d Heather Katt, a spokeswoman for Allergan, wrote in an e-mail message, \u201cand Allergan is exploring ways to pursue that pathway through the F.D.A.\nThough the claim was met with some skepticism by other clinicians, the idea that ACell\u2019s powder, which has been approved by the government, could facilitate new hair growth has breathed new life into the race to clone hair.\napproval process.\u201d\n\nFor those too impatient to wait, there is also the bold and fashionable solution of shaving one\u2019s head.\n\u201cIt was a noticeable difference.\u201d\n\nBut Latisse does not appear to be a silver bullet for hair loss.\n\u201cWe keep on moving back that time, but I think there\u2019s absolutely no doubt that it\u2019s going to be done.\u201d\n\nHe believes hair cloning will be commercially available within 10 years.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We think this one is a wobbler. The story did quote two hair loss specialists. We wish it had gone a little broader in scope and talked with someone who is not currently prescribing Latisse and could speak to the safety and efficacy of an uNPRoven product like this.", "answer": 1}, {"article": "\"A majority of our patients with osteoarthritis of the knee saw significant pain reduction, not only just a few days after the procedure, but a month after as well, making this an accessible treatment for patients looking to improve their quality of life without surgery,\" said Sandeep Bagla, M.D., director of interventional radiology at the Vascular Institute of Virginia and lead author of the study.\nAs an outpatient treatment, GAE does not require open surgery or physical therapy, and takes 45-90 minutes to perform.\nA second randomized controlled clinical trial began in February 2018 and will provide further data on what types of patients are the best candidates for this treatment and how it could move toward clinical practice.\nBut GAE provides another option for patients struggling with pain and may even allow patients to avoid the painful recovery of knee surgery and the need for the kind of opioid pain medications associated with the dangerous epidemic in the United States.\"\nThe Society of Interventional Radiology is holding its Annual Scientific Meeting March 17-22, 2018 at the Los Angeles Convention Center in Los Angeles, Calif. Visit sirmeeting.org.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t note how the study was funded.", "answer": 0}, {"article": "or \"Have you taken your medications yet today?\n\"These are the things that medications usually do, not text messages,\" says Chow, who is also an associate professor at Sydney Medical School at the University of Sydney.\n\"We [as physicians] are always looking for evidence to make sure that we are recommending the right things for our patients, whether it's a drug, a device or a digital product, like an app,\" says Eapen, who is also medical director of the Duke Heart Failure Same-Day Access Clinic.\n\"I have to say, we were pretty surprised that it worked,\" says Clara Chow, lead author of the study and program director of community-based cardiac services at Westmead Hospital in Sydney, Australia.\nMuch of the buzz over mobile health interventions seems to be about how we can use an ever-growing variety of shiny new smartphone apps and sensors to better manage our health.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes input from an outside expert who was not involved with the research. \u00a0The story clearly meets our bar here, although it would have been stronger if it had reached out to at least one more independent source \u2014 preferably one who hadn\u2019t written an editorial that ran in conjunction with the paper in JAMA. Yes, the editorial was independent and provides some insightful commentary. But it also means we already knew where this source stood on the issue. Finding another reputable expert, who hadn\u2019t already weighed in publicly on the work, would have been great.", "answer": 1}, {"article": "Among those taking a placebo, the number of hot flashes dropped to 6.43 per day, a 33 percent decrease of 3.2 fewer hot flashes per day.\nThe study is the first to examine whether there are any racial differences in how well an antidepressant works in alleviating hot flashes.\nBut hormone use plummeted after the federal government's massive Women's Health Initiative shocked women and doctors by concluding the risks of the medication outweighed its benefits.\nA study involving 205 women found those taking the antidepressant Lexapro experienced a 47 percent reduction in number of hot flashes they were experiencing and the hot flashes they did have tended to be less severe, researchers reported in the Journal of the American Medical Association.\nIn the new study, Ellen Freeman of the University of Pennsylvania School of Medicine in Philadelphia and colleagues gave 205 women who were either starting to go through menopause who had already gone through menopause either Lexapro or a placebo for eight weeks.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were no independent sources referenced in this post. In addition, while the story notes that the study was federally funded, it should have pointed out that at least one of the study researchers receives research funding and is a consultant for Forest Laboratories, which makes Lexapro.", "answer": 0}, {"article": "Michael Burk found walking increasingly painful last year. Crossing the street and tying his shoes became challenges, and colleagues noticed he was limping at work.\n\nOn a recent morning, Mr. Burk reported to the Hospital for Joint Diseases, part of NYU Langone Medical Center in New York City, for hip-replacement surgery. His surgeon had promised him a better quality of life, and said both the operation and recovery would be quick.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Excellent job overall. The story had eight doctors, a nurse manager, and three patients commenting for the record. And at least some of them push back, very appropriately, against the story\u2019s general premise that the same-day procedure and anterior approach are better. The story might have clued readers in to the fact that surgeons are likely to speak highly of whatever approach it is they happen to practice. Those with faster operating times may emphasize that fact because\u00a0it\u2019s what separates them\u00a0from others with whom they are competing for business.", "answer": 1}, {"article": "Gaziano and colleagues created a computer simulation to see if giving statins to more people would be worth the risk of side-effects and the extra cost.\nOne of the recommendations was that statins should be prescribed to anyone with a 7.5 percent risk or higher of developing heart disease over the next 10 years.\nThere\u2019s an online tool that people or their doctors can use to calculate their risk of heart disease, which is based on age, sex, blood pressure and cholesterol levels.\n\u201cThere is no longer any question as to whether to offer treatment with statins for patients for primary prevention, and there should now be fewer questions about how to treat and in whom,\u201d Dr. Philip Greenland, an expert in preventive medicine at Northwestern University and a senior editor of the journal, and Dr. Michael Lauer of the National Heart, Lung and Blood Institute wrote in a commentary.\n\u201cYou have to be at extremely low risk before the risk of statins outweighs their significant, profound benefits,\u201d Gaziano said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We were surprised that there were no independent sources quoted in the story. There are a lot of people talking about these studies, and the Times did a better job seeking out independent analysis.", "answer": 0}, {"article": "Currently indicators such as diagnosed prostatomegaly (enlarged prostate) and unusually high PSA levels can lead to recommendations for biopsy if there is a concern that cancer may be prevalent.\nThe positioning of the prostate gland which is very close to the bladder gives the urine profile a different algorithm if the man has cancer.\"\nOur aim is to create a test that avoids this procedure at initial diagnosis by detecting cancer in a non-invasive way by smelling the disease in men's urine.\nA few years ago we did similar work to detect bladder cancer following a discovery that dogs could sniff out cancer.\nAfter further sample testing the next step is to take this technology and put it into a user friendly format.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding sources are stated and the origins of the equipment being used and tested is also made clear in the release.", "answer": 1}, {"article": "A new study confirms that long-acting forms of contraception such as intrauterine devices and implants are better than birth control pills and patches at preventing pregnancies, giving doctors new ammunition to recommend these methods.\n\nThe study, to be published Thursday in the New England Journal of Medicine, involved about 7,500 women in a project promoting long-acting birth control to reduce unintended pregnancies. There are an estimated three million unplanned pregnancies a year in the U.S., often because of incorrect or...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An independent expert is cited and makes clear that effectiveness, while important,\u00a0is only one factor in a woman\u2019s decision about a contraceptive method.\nThe potential for conflict of interest is adequately addressed, noting that one of the researchers is involved in training doctors on how to use one of the implantable methods.", "answer": 1}, {"article": "Your cells might be aging faster than you are, and new tests purport to help you find out.\n\nA few companies are offering mail-order testing to measure the length of people\u2019s telomeres, the protective caps of DNA on the ends of chromosomes that have been likened to the plastic tips that prevent shoelaces from fraying. Telomeres gradually shorten as people age and eventually may disappear, leaving cells vulnerable to disease and death.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story wins points for reaching out to multiple independent experts, including a Nobel Prize winner who helped discover how telomeres protect chromosomes.", "answer": 1}, {"article": "The researchers first tested 142 natural compounds on mouse and human cell lines to see which inhibited prostate cancer cell growth when administered alone or in combination with another nutrient.\n\"The beauty of this study is that we were able to inhibit tumor growth in mice without toxicity.\"\nAdditional authors include Xiyuan Lu, Bo Wang, Enrique Sentandreu, Meghan Collins, all of UT Austin; and Mikhail Kolonin of The Brown Foundation Institute of Molecular Medicine at the University of Texas Health Science Center in Houston.\nThe experiment was designed, analyzed and written up with coauthors Alessia Lodi, John DiGiovanni and Achinto Saha, all of UT Austin.\nNew research from The University of Texas at Austin identifies several natural compounds found in food, including turmeric, apple peels and red grapes, as key ingredients that could thwart the growth of prostate cancer, the most common cancer afflicting U.S. men.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release states that funders include that National Institutes of Health and the University of Texas System, and there were no conflicts of interest that we could find.", "answer": 1}, {"article": "The practical value of the tests depends critically on details like their sensitivity, meaning the proportion of tumors that are detected, and their specificity, meaning how many of the positive results are in fact false alarms.\nProponents of each test note possible weaknesses of the other.\nThe colon-based test may pick up too many of these, sending far too many people in for colonoscopy.\nJust 0.01 percent of the DNA is human, and most of this is normal DNA, not the altered DNA of tumors.\nExact Sciences reported in July that its test was highly sensitive and specific when applied directly to cells taken from tumors.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story relies too heavily on researchers who are connected to the companies developing the cancer screens. Where was the truly independent perspective?", "answer": 0}, {"article": "Researchers used CAR-T to treat a man with brain cancer to some success\n\nGlioblastoma is one of the deadliest cancers \u2014 an illness that responds to few treatment options, and often poorly. But a single case study that uses an experimental immunotherapy to treat these brain tumors might give oncologists a new way to approach the disease.\n\nThe therapy, called CAR-T, is controversial and has faced hurdles in clinical trials. It has shown great promise in treating blood cancers like leukemia and lymphoma \u2014 but has proven challenging in treating other forms of the disease, including solid tumors.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Job well done in quoting sources outside of the City of Hope investigators and putting the findings into cautious perspective throughout the article. If the story was to be done at all (a debatable decision), this article makes the best of the context problem.", "answer": 1}, {"article": "\"Vitamin D supplementation trial in infancy: body composition effects at 3years of age in a prospective follow-up study from Montr\u00e9al\", by T. J. Hazell, S. Gallo, C. A. Vanstone, S. Agellon, C. Rodd, and H. A. Weiler, Pediatric Obesity doi:10.1111/ijpo.12105\nThe researchers achieved this by following up on a 2013 study in which 132 infants in Montr\u00e9al, Qu\u00e9bec, were given a vitamin D3 supplement at one of four different dosages between the ages of 1 month and 12 months.\nFor the first time, a connection was made between the benefits of achieving healthy vitamin D status during a baby's first 12 to 36 months and how muscle mass develops.\nThe researchers found that higher doses did not provide any additional benefit -- at least not in terms of bone development.\nA healthy intake of vitamin D in the first year of life appears to set children up to have more muscle mass and less body fat as toddlers, according to a new study published in the journal Pediatric Obesity.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Even though the researchers did not disclose any conflicts in their journal article and the study was funded by a government agency, the release should have identified the funding source.", "answer": 0}, {"article": "Saturated fats can remain a part of a healthy diet, in limited amounts \u2013 but there are two easy ways to help:\n\u2022 Saturated fats should make up 10 percent of total caloric intake daily.\nIn fact, the study found that the lower the cholesterol, the greater the risk of death.\nAll that is known is the participants had a normal cholesterol levels and normal blood pressure.\nBut even when their cholesterol levels were lowered by the switch from saturated fats, there was no longevity benefit.\nWhether statins have additional properties to reduce risk, in addition to lowering serum cholesterol remain under study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There don\u2019t appear to be any conflicts of interest, and the story includes an independent source.", "answer": 1}, {"article": "Observational studies, which include all people with a condition, can never conclusively prove cause and effect, Keating acknowledged, because \"the thing we can't account for is whether people who are on a treatment are different from those who aren't.\"\n\"One third of men over 65 who don't have surgery or radiation get this therapy,\" she said.\n\"We are beginning to realize that there can be significant problems in terms of cardiovascular risk.\n\"We're not suggesting that men who need hormone deprivation therapy should not have it.\n\"When you can have potentially serious adverse effects, you want to show caution.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0Comments from two clinicians who were not directly associated with the study reported on were included in this story.", "answer": 1}, {"article": "Bushra Imtiaz, Heidi Taipale, Antti Tanskanen, Miia Tiihonen, Miia Kivipelto, Anna-Mari Heikkinen, Jari Tiihonen, Hilkka Soininen, Sirpa Hartikainen, Anna-Maija Tolppanen.\nThe study also showed that the postmenopausal removal of ovaries, uterus or both was not significantly linked to the risk of Alzheimer's disease, irrespective of the indication of surgery or hormone therapy use.\nThe research data was from the MEDALZ (Medication use and Alzheimer's disease), OSTPRE (Kuopio Osteoporosis Risk Factor and Prevention Study) and CAIDE (Cardiovascular Risk Factors, Aging and Dementia) studies.\nThe protective effect of hormonal therapy may depend on the health status of neurons at baseline and may be lost if therapy starts years after menopause,\" Dr Imtiaz concludes.\nShort-term use was not significantly linked to dementia risk, but in one cohort, dementia risk was higher among short-term users who had started hormone therapy in the late postmenopausal period.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not mention any of the funding sources for the studies. It would be preferable if all funding sources were cited, but we don\u2019t penalize releases or stories unless they fail to report industry funding and commercial ties. These reports were funded by government and academic research institutions, and foundations.", "answer": 2}, {"article": "For more information about deep brain stimulation, visit the American Association of Neurological Surgeons\nThe finding introduces the possibility that deep brain stimulation -- a surgical implant that delivers electrical pulses to the brain -- might one day become a treatment for drug-resistant hypertension or lead to clues about the brain's role in regulating blood pressure.\nMONDAY, Jan. 24, 2011 (HealthDay News) -- Doctors administering deep brain stimulation to control a patient's severe pain report that they discovered the treatment consistently lowered the man's hard-to-control high blood pressure.\n\"It's a really interesting paper,\" said Dr. Nicholas D. Schiff, director of the Laboratory of Cognitive Neuromodulation at New York-Presbyterian Hospital/Weill Cornell Medical Center.\n\"I think it's really interesting physiology,\" added Penn, noting that the results would need to be repeated multiple times before a therapy based on it could be developed.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although the story seeks out independent perspectives, it should have alerted readers to the fact that several authors\u00a0have received speaking honoraria and other financial support from companies that make DBS devices. According to coverage of the study at MedPageToday, these disclosures were included in the published article.\nWhile we can\u2019t award a satisfactory,\u00a0this story did a better\u00a0job than WebMD of talking with people who provided a less optimistic take on the implants. For example, the first independent quote in the WebMD story says, \u201cWhat their case report shows is that blood pressure can be reduced in a sustained fashion in a patient with unsuccessful deep brain stimulation for pain\u2026.\u201cI think that\u2019s important because it paves the way for potentially studying patients without chronic pain and offering the treatment sometime in the future to reduce blood pressure.\u201d That is much more supportive of the technology than the first quote in the HealthDay story, which says, \u201cIt\u2019s a really interesting paper. \u2026 I thought it was compelling, though single cases are always questionable\u201d to generalize.", "answer": 0}, {"article": "The Ache: Nearly 5,000 people a year die from choking in the U.S., according to the nonprofit National Safety Council.\n\nThe Claim: Two new easy-to-use devices work like plungers to suck out obstructions in the airway, providing another option if standard treatment\u2014such as abdominal thrusts developed in 1974 by Henry Heimlich\u2014fail to clear the airway, say the companies who sell them.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article does an excellent job presenting opinions from both people involved in the companies and independent stakeholders outside of the companies.\u00a0 These independent sources\u00a0increased the impartiality of the news story.", "answer": 1}, {"article": "However, with breast cancer remaining a major cause of cancer death in women, there is good reason to pursue the search for improved screening methods, according to the study's lead author, Christiane Kuhl, M.D., chair of the Department of Radiology at RWTH Aachen University in Aachen, Germany.\n\"The interval cancer rate in our study was zero percent.\nNot a single cancer was undetected that became palpable,\" she said.\nThe women had normal screening mammograms and, in the case of those with dense breast tissue, normal screening ultrasound.\nThe new study showed that, consistent with previous research, breast MRI can depict these rapidly growing cancers with high reliability.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t name the sponsors.", "answer": 0}, {"article": "March 30, 2011 -- Two highly anticipated hepatitis C drugs are poised to usher in a new era in the treatment of the viral disease as early as this summer, experts say.\nAdding one of the drugs to the current two-drug regimen of peginterferon and ribavirin will make the treatment of hepatitis C more complex, but it will also cure a lot more people, hepatitis C specialist Donald M. Jensen, MD, of the University of Chicago Medical Center, tells WebMD.\nThe drugs will be used in patients with HCV genotype 1 -- the hardest to treat form of the viral infection.\nThe Merck drug boceprevir and Vertex Pharmaceutical\u2019s similar drug telaprevir are expected to win FDA approval within months, following phase III trials showing that both drugs boosted cure rates to around 70% when used with standard therapy.\nResults from two phase III boceprevir trials are published in the New England Journal of Medicine.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "While the story uses independent sources, it fails to note that Merck, the maker of boceprevir, sponsored the two clinical trials published in the New England Journal of Medicine. It also fails to mention that many of the study authors have received funding from Merck.\u00a0\n ", "answer": 1}, {"article": "\u201cThe ability to activate white matter cells in the brain, as shown in this study, opens up an exciting new avenue of therapy development for myelin disorders such as multiple sclerosis,\u201d said Ursula Utz, Ph.D., program director at the NINDS.\nOPCs are found to multiply in the brains of multiple sclerosis patients as if to respond to myelin damage, but for unknown reasons they are not effective in restoring white matter.\nNIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases.\nThey are currently approved for use as creams or powders on the surfaces of the body but their safety administered in other forms, such as injections, in humans is unknown.\nIt is unknown how myelin-producing cells are damaged, but research suggests they may be targeted by malfunctioning immune cells and that multiple sclerosis may start as an autoimmune disorder.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We are told up front that the study was funded by a division within the National Institutes of Health, and there is no\u00a0apparent conflict of interest according to the paper.", "answer": 1}, {"article": "And our brains like rewards.\nUntil a large study comes along using this sort of approach, parents and consumers will have to decide for themselves whether neurofeedback is worth the time and effort.\nShe says it might have been because she and her son spent so much time going to all those sessions together, and had pizza together afterward.\nIn recent years, more people have been trying an alternative approach called neurofeedback, a type of therapy intended to teach the brain to stay calm and focused.\n\"What I noticed in my son was not necessarily that he'd stop losing things at school or do his homework better,\" she says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "In addition to extensive comments from the journalist book author who discusses her experience with neurofeedback, the story quotes a Duke University researcher who is an expert on ADHD and offers some counterbalancing perspective.", "answer": 1}, {"article": "ZURICH (Reuters) - An experimental cancer drug that Novartis hopes will raise the profile of its oncology portfolio cut the risk of death or disease progression by more than a third in breast cancer patients with a hard-to-target gene mutation.\n\u201cThe results of SOLAR-1 are the most encouraging observed to date from a trial evaluating a PI3K inhibitor\u201d for patients with this kind of breast cancer, said Fabrice Andre, a professor at France\u2019s Institut Gustave Roussy.\n\u201cThese data have the potential to allow physicians to address an unmet need in this patient population by using a biomarker-driven treatment to inform their sequencing decisions,\u201d Andre added.\nNovartis plans to file with regulators for approval of the drug this year, Hirawat said, adding he also has strategies to broaden the indication, including tough-to-treat triple-negative breast cancer.\nBut this specific benefit data is being released on Saturday at the European Society for Medical Oncology\u2019s annual conference in Munich.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article quotes Farbrice Andre. It does not mention that Andre is the lead author of the study. It also does not mention that Andre received a grant from Novartis while the study was being conducted, which is noted in the disclosure section of the abstract.\nThe article also quotes the head of cancer drug development at Novartis.\nThere are no quotes from researchers or experts not involved with the study.", "answer": 0}, {"article": "The American Botanical council took issue with the findings, however.\nHe added that, \"as a former practicing naturopathic doctor, I have had the benefit of working with patients and have seen firsthand how ginkgo biloba can be effective in improving cognitive function.\"\nIn a statement, Douglas MacKay, CRN's vice president of scientific and regulatory affairs, said that \"there is a large body of previously published evidence, as well as ongoing trials, which suggest that ginkgo biloba is effective for helping to improve cognitive impairment in older adults.\"\n\"Measuring the effect of ginkgo in a big trial in older people, we didn't see any effect of the drug on slowing down or delaying normal age-related changes of cognition,\" said lead researcher Dr. Steven T. DeKosky, vice president and dean of the University of Virginia School of Medicine in Charlottesville.\n\"Regardless of whether people say 'I take it and I feel better,' you just don't see an effect,\" he said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Yes, the story sought out different perspectives.\u00a0 But oddly, despite the mounting negative evidence, it afforded more space (265 words) to those defending ginkgo biloba than it did to those discussing the evidence raising huge questions about its value (249 words).\u00a0 He said/she said science journalism doesn\u2019t serve anyone well. ", "answer": 0}, {"article": "\"A lot of the time, people have quite painful and challenging experiences revisiting the trauma, and [MDMA] can help them do it without being overwhelmed or numbed out,\" he says.\nThis was the first clinical trial to explore the therapeutic potential of MDMA since the drug was outlawed in 1985, and the researchers required the permission of the National Institutes of Health, the Food and Drug Administration , and the Drug Enforcement Administration.\nThe study, which appears in the Journal of Psychopharmacology, included 20 people with PTSD stemming from traumas such as sexual assault and combat stress.\nThe drug MDMA\u2014better known by its street name, Ecstasy\u2014may be illegal, but a new study suggests that it\u2019s also a promising treatment for post-traumatic stress disorder.\nThe study was funded by the Multidisciplinary Association for Psychedelic Studies, a California-based nonprofit organization that also sponsors research on medical marijuana and psychedelic drugs such as LSD and psilocybin.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "MAPS is a drug legalization organization. In its stated mission, it says, \"We believe that psychedelics and marijuana, when used in proper settings, can be beneficial for such uses as psychotherapeutic treatment, physiological research and treatment, treatment of addiction, pain relief, spiritual exploration, creativity research, shamanic healing, psychic research, brain physiology research and related scientific inquiries\u2026.We also provide psychedelic emergency services at festivals where psychedelics are likely to be used in an effort to model harm reduction techniques in a post\u2013prohibition world.\" There aren\u2019t many purely scientific\u00a0research organizations that sell posters of\u00a0celestial beings\u00a0shooting light rays from their eyes. This is noted nowhere in the story and is important information for the reader to have in deciding how to evaluate the findings. There are no independent sources in this story, and they are sorely needed.", "answer": 0}, {"article": "SUNDAY, Dec. 5, 2010 (HealthDay News) -- Using gene therapy, German researchers report that they managed to \"correct\" a malfunctioning gene responsible for Wiskott-Aldrich syndrome, a rare but devastating childhood disorder that leads to prolonged bleeding from even minor hits or scrapes, and also leaves these children vulnerable to certain cancers and dangerous infections.\nA viral vector is a virus that has been modified to deliver foreign genetic material into a cell.\nThe boy is currently on chemotherapy, the study authors noted.\nHowever, one of the 10 kids in the study developed acute T-cell leukemia, apparently as a result of the viral vector that was used to insert the healthy gene.\n\"They grow up, go to college and they cause problems,\" said Conley.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included interviews with two independent experts who weren\u2019t involved with the study.", "answer": 1}, {"article": "Atrial fibrillation also increases the risk for dementia.\nThe findings strongly suggest that blood thinners reduce the risk for dementia in people with atrial fibrillation, but proving that would not be possible, the Swedish researchers said.\nAt the time they joined the study, about half of the participants were taking oral anticoagulants, such as warfarin, Eliquis (apixaban), Pradaxa (dabigatran), Savaysa (edoxaban) or Xarelto (rivaroxaban).\n\"In order to prove this assumption, randomized placebo-controlled trials would be needed, but such studies cannot be done because of ethical reasons,\" researchers Leif Friberg and Marten Rosenqvist, of the Karolinska Institute in Stockholm, said in a journal news release.\nAlong with not taking blood thinners, the strongest predictors for dementia were age, Parkinson's disease and alcohol abuse, according to the study, published Oct. 25 in the European Heart Journal.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We learn that the researchers came from the Karolinska Institute in Stockholm yet are not given information about any potential financial conflicts between those researchers or their institution to the makers of anticoagulants.\nAs the study itself makes clear, the researchers have financial ties to numerous drug companies that make anticoagulants including Bayer, Pfizer, and Bristol-Myers Squibb.", "answer": 0}, {"article": "The primary efficacy endpoint \u2013 change from baseline to day 28 in MADRS total score \u2013 was assessed among patients who received \u22651 dose of (nasal spray and oral) study medication by mixed-effects model using repeated measures using a one-sided significance level of 0.025.\nWhat makes this even more significant is that the response was rapid and this milestone was achieved in patients deemed to be treatment-resistant.\nA bittering agent was added to placebo to simulate the taste of esketamine, to help mask the treatment assignment.\nIt has a novel mechanism of action, meaning it works differently than currently available therapies for depression.\nThere were no treatment-emergent adverse events reported in >10% of patients in the placebo group.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "It\u2019s clear that the work was funded by Janssen Pharmaceutical Companies, and the affiliation of the experts quoted in the piece is similarly clear.", "answer": 1}, {"article": "And patients may need to continue treatment.\nThe thought that you could lose your vision is very, very depressing,\" Daniel says.\nThere are some rare side effects, including severe inflammation, infection and detached retina.\n\"Instead of seeing a lot of this squiggling, the lines straighten out,\" he says.\nThere's a catch: it's expensive \u2014 about $2,000 per injection \u2014 although Medicare and most insurance companies cover most of it.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quotes one expert. The story should have quoted other researchers or clinicians who could provide more context.", "answer": 0}, {"article": "Driscoll and her research colleagues used data from 6,467 community-dwelling, postmenopausal women aged 65 and older who reported some level of caffeine consumption.\nThe findings come from participants in the Women's Health Initiative Memory Study, which is funded by the National Heart, Lung, and Blood Institute.\n\"The mounting evidence of caffeine consumption as a potentially protective factor against cognitive impairment is exciting given that caffeine is also an easily modifiable dietary factor with very few contraindications,\" said Ira Driscoll, PhD, the study's lead author and a professor of psychology at the University of Wisconsin-Milwaukee.\n\"What is unique about this study is that we had an unprecedented opportunity to examine the relationships between caffeine intake and dementia incidence in a large and well-defined, prospectively-studied cohort of women.\"\nIn 10 years or less of follow-up with annual assessments of cognitive function, 388 of these women received a diagnosis of probable dementia or some form of global cognitive impairment.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that the study was funded by the National Heart, Lung, and Blood Institute, National Institutes of Health.", "answer": 1}, {"article": "To conduct the study, the researchers asked 164 healthy participants with an average age of 30 to wear a wrist actigraph \u2014 a device that monitors sleep \u2014 for one week to establish their baseline sleep habits.\nThe actigraphy measured sleep in a much more accurate way than information researchers get from self-reports, he says.\nThe study is unique because it used objective measures to show that poor sleep habits make people more vulnerable to a cold virus, says Badr, who was not involved in the research.\nThe study provides more evidence of the link between healthy sleeping habits \u2014 which experts say means at least seven hours of sleep each night \u2014 and overall good health.\nThe found the chronic poor sleepers became sick more often: those who slept for five hours or less each night were 4.5 times more likely to catch the cold than people who slept seven hours or more.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes remarks from Dr. M. Safwan Badr, who was not involved with the study. He brings some useful perspective as far as what is new about the study.", "answer": 1}, {"article": "Among iron-deficient adolescent women there is a future risk of maternal iron deficiency and negative effects on infant health.\nQuestions were included on depression, poor attention and daytime sleepiness, symptoms which all have been associated with iron deficiency or iron deficiency anemia, but were not captured in the prior NHANES analyses.\nBlood tests for iron deficiency without anemia have been developed but they are more costly and difficult to obtain in the doctor's office compared to hemoglobin testing for anemia.\nIn the first study, when the researchers analyzed the NHANES study data, 9 percent of females who were 12 to 21 years old had iron deficiency without anemia.\n\"I think we need to establish the optimal timing for an objective assessment of adolescent iron deficiency and anemia.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release identifies the source of grant funding for both journal articles referenced. We wish it had also said \u201cthere are no conflicts of interest.\u201d", "answer": 1}, {"article": "\u201cThe potential for a nutritional lifestyle intervention to counter obesity driven by high-carbohydrate food, though we don\u2019t know yet how significantly, is fascinating,\u201d Arciero says\u2014especially when it\u2019s as simple and delicious as reheating your pasta.\nThese kinds of carbs bypass the small intestine (where most food is digested) and head to the large intestine (also known as the colon) to be metabolized.\nEven if you heat them up again, they retain their new resistant starches.\n\u201cCooking the carbohydrate starch alters the chemical bonds in the food,\u201d Arciero explains.\nThere, they\u2019re fermented and turned into short-chain fatty acids, which the body burns as energy.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There don\u2019t appear to be any conflicts of interest. However, the story does not quote any independent sources, only one of the study authors.", "answer": 0}, {"article": "Reiman wrote a commentary that accompanies the study in Nature.\n\"If that hint of a clinical benefit is confirmed, it would be a game changer in the fight against Alzheimer's disease,\" says Dr. Eric Reiman, executive director of the Banner Alzheimer's Institute in Phoenix.\nThe results are encouraging for pharmaceutical companies that have spent billions of dollars on efforts to come up with the first drug to treat the underlying cause of Alzheimer's.\n\"It was surprising, encouraging and thought-provoking to see such a striking reduction of existing plaques,\" Reiman says.\nOfficials of Biogen, which is developing the drug, were also cautious about interpreting the results of the study, which included 165 patients in the early stages of Alzheimer's disease.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an official from Biogen (which makes the experimental drug) and the author of an accompanying editorial. But we don\u2019t hear from any truly independent sources in the story. The editorialist, Dr. Eric Reiman, is said to be the\u00a0executive director of the Banner Alzheimer\u2019s Institute in Phoenix. It doesn\u2019t explain that the Banner Institute is leading Alzheimer\u2019s Prevention Initiative, an effort to postpone and prevent the disease before it starts. The initiative partners with a number of drug companies, including Roche, Amgen, Genentech, Novartis, on its studies. These relationships merited a mention in the story.", "answer": 0}, {"article": "Barua is with the Kansas City (Mo.)\nFor example, the new VA study excluded men with a history of heart attacks or strokes, although it did include those with existing heart disease.\nThe study team looked at national data on more than 83,000 men with documented low testosterone, all age 50 or above, who received care in VA between 1999 and 2014.\nAccording to the FDA, \"Testosterone products are FDA-approved only for use in men who lack or have low testosterone levels in conjunction with an associated medical condition.\nThey included, for example, age, body mass index, various chronic diseases, LDL cholesterol levels, and the use of aspirin, beta blockers, and statins.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Although the study itself offers\u00a0full disclosure regarding funding and conflicts of interest (the investigators assert no such conflicts), none of this finds its way into the news release.", "answer": 0}, {"article": "So who wouldn't want a pill to fight the doldrums caused by skipping too many time zones too fast?\nIn a statement, Dr. Lesley Russell, Cephalon's chief medical officer, said:\n\nThe most common side effects for Nuvigil, include diarrhea, headache, insomnia and nausea, according to Cephalon.\nThe medicine has also been linked to rare but life-threatening skin rashes, including Stevens-Johnson syndrome, and carries a prominent warning about that risk.\nFinally, it should be said that the Drug Enforcement Administration has made Nuvigil a federally controlled substance because it has the potential for abuse and dependence.\nIn March, the FDA turned down Cephalon's jet-lag application and questioned how good the data supporting it really were.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We always look for an independent perspective.\u00a0 Granted, the story was based on an FDA review.\u00a0 But we really only got a quote from a company statement.", "answer": 0}, {"article": "A drug derived from this bushy sea creature showed modest, preliminary promise as an Alzheimer's treatment.\n\nIn small Alzheimer\u2019s study, hints of modest benefit from unusual drug\n\nA little-known drug company announced modestly encouraging results for its experimental Alzheimer\u2019s drug on Monday, a rare but still preliminary glimmer of hope in a field that has been battered by failure after failure.\n\nA mid-stage study by a tiny company wouldn\u2019t usually attract much attention, but the results unveiled by Neurotrope BioScience have been eagerly anticipated because its drug \u2014 derived from a bushy, hermaphroditic sea creature \u2014 takes a novel approach.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story\u00a0had several independent sources but it didn\u2019t disclose at least one important relationship.\nIt said \u201cDr. Sam Gandy\u2026is not affiliated with Neurotrope.\u201d However, he has worked as a consultant for them, as the \u201cindustry relationships\u201d section of his bio explains.\nUpdate 5/4/2017: STAT has issued a correction at the bottom of their story: \u201cThis story has been corrected to say that Dr. Sam Gandy consults for Neurotrope.\u201d", "answer": 0}, {"article": "He is also the co-founder of Neuro-Luminance Ketamine Infusion Centers.\nThe study also challenges concerns about neurotoxicity and a recent hypothesis that patients must experience hallucinations during ketamine infusion in order to have an anti-depressant benefit.\nEvidence points to the regeneration of brain cells as a critical mechanism for the relief of depression, as published in peer-reviewed journal Neural Regeneration Research, February 2016 issue.\nThe study, \"Practical application of the neuroregenerative properties of ketamine: real world treatment experience,\" addresses key points in the controversy surrounding the use of intravenous ketamine for the treatment of depression.\nWhile controversial in academic settings, Dr. Henderson said his direct experience supports a different strategy for multiple-infusion treatment regimens and his clinical experience shows ketamine can invoke long-lasting effects often with less than six infusions.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release notes that Henderson is co-founder of a center that uses the treatment but the release does not point out for readers the potential conflict of interest. The study even states \u201cnone\u201d in regard to conflict-of-interest which seems implausible.", "answer": 0}, {"article": "Scientists have slowed down the ageing process by implanting stem cells into the brains of animals, raising hopes for new strategies to combat age-related diseases and extend the human lifespan.\n\u201cThe mechanism is partially due to these cells secreting certain miRNAs which help maintain youth, and the loss of these leads to ageing\u201d said Cai, whose study is published in Nature.\nThe work, described as a tour de force and a breakthrough by one leading expert, suggests that ageing across the body is controlled by stem cells that are found in the hypothalamus region of the brain in youth, but which steadily die off until they are almost completely absent in middle age.\nI can see a day when we are implanted with stem cells or treated with stem cell RNAs that improve our health and extend our lives.\nThe stem cells are known to form fresh brain cells in youth, but the process slows down dramatically in adults.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does quote one source unaffiliated with the research and we didn\u2019t detect any conflicts of interest. (The paper itself notes that the authors of the study have no conflicts of interests.)", "answer": 1}, {"article": "NEW YORK (Reuters Health) - A less common form of obesity surgery may spur more weight loss than its far more popular cousin, gastric bypass \u2014 but at the price of greater long-term risks, researchers reported Tuesday.\nIn a study recently published in the Journal of the American Medical Association, Livingston and his colleagues found no survival advantage among severely obese patients who\u2019d undergone weight-loss surgery versus those who hadn\u2019t.\nBut he also questioned the value of weight-loss surgery, in general, for severely obese people who do not have medical conditions that stand to improve or resolve after surgery.\nIn this study, three of the 29 duodenal switch patients developed protein malnutrition, two developed night blindness, and one had a severe iron deficiency that needed to be treated with iron infusions.\nThe surgeon also creates a bypass around the rest of the stomach and a portion of the small intestine, which limits the body\u2019s absorption of food.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "In addition to quoting the lead author of the Annals article, we liked the balance provided by Edward Livingston in his comments about both the duodenal switch procedure and his comments about the value of surgery in general over medical management.", "answer": 1}, {"article": "For more information, click on www.hsrxbiopharmaceutical.com\n\"We demonstrated superior treatment outcomes with our acne product in a head-to-head clinical trial against the market-leader, and now we've done the same with OsteoRx\u2122.\n\"Joint pain associated with normal aging and over-exercising is extremely common,\" said Thomas Sullivan, Jr., Chief Executive Officer of HSRx Biopharmaceutical.\n\"Research funded by U.S. National Academy of Medicine shows that 70 million adults suffer from joint pain, making it the most prevalent source of pain.\nAfter 48 hours, the average pain reduction for OsteoRx\u2122 users was nearly three times greater than for patients using the competing brand.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We aren\u2019t told who sponsored the referenced clinical trial, just that it was performed by an \u201cindependent clinical research organization.\u201d\u00a0 The release should have provided information about where the trial was conducted, by whom, and whether there was any conflict if the study was funded by the manufacturer of the product.", "answer": 0}, {"article": "Newswise \u2014 Lap band surgery has significant benefits for severely obese teenagers and, despite its controversial nature, should still be considered as a first option to manage obesity during adolescence, a new study has found.\nThe study found that weight and BMI improved significantly at all follow-up times following surgery from three months through to 45 months and, in some cases, as long as five years.\n\u201cThe median BMI reduction of 10 kg/m2 with the lap band is a good result when compared to BMI reduction using the few medications available or lifestyle measures, which is around 1-3 kg/m2,\u201d says Dr Pe\u00f1a.\nHowever there is no data available in Australian adolescents beyond 24 months post-surgery.\nLed by University of Adelaide researchers, in collaboration with Flinders Medical Centre, and published in the journal Obesity Surgery, the study is the first to show medium to long-term follow-up (3-5 years) of lap band surgery in Australian adolescents.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funders are not mentioned in the release although that information is provided in the text of the journal article. The study coauthors all claim no conflicts of interest, but that information is not provided either.", "answer": 0}, {"article": "DePaolo pointed out, \u201c[Elagolix] doesn\u2019t have the pronounced side effects some of the other compounds have.\u201d That\u2019s because, he said, it doesn\u2019t drive down estrogen levels as severely.\nMood swings and night sweats were less common, and one woman in the trial died by suicide (though there\u2019s no indication that the medicine was a cause of her death).\nIn severe cases, a doctor may suggest \u201cexcision surgery\u201d to remove the extra tissue.\nMany women in the trial experienced the symptoms of menopause \u2014 hot flashes, headache, insomnia \u2014 and researchers have also found the drug causes bone loss.\nWe have no idea about the long-term effects of taking the drug because there are no trials lasting for longer than a year, or how it stacks up against other painkillers (since the trials only compared it to placebo).\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The scientist who led the two trials is clearly identified as such, but his consulting relationship with the company now marketing the drug is not mentioned, nor is the fact that that company, now positioned to benefit from selling the drug, paid for the studies.", "answer": 0}, {"article": "\"Shireen had the idea, 'Why can't I just test my food and figure out what's in it?'\n\"One of the things that we wanted to make sure we distinguish is that we don't see ourselves as a medical device,\" Sundvor told CBS News.\nThe company, 6SensorLabs, has started taking pre-orders for the device it calls Nima, which can test food for gluten and get rapid results, said co-founder and chief technology officer Scott Sundvor.\nSo we started talking about the idea and we researched the market and realized it's something we could make happen.\"\nMarilyn Grunzweig Geller, chief executive officer of the Celiac Disease Foundation, said she is not familiar with the new gluten-sensing device and was unable to comment on it directly.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Importantly, the article quotes the\u00a0CEO of the Celiac Disease Foundation as skeptical about the value of gluten sensors in general, along with purported \u201ctreatments\u201d for the disorders. And she makes clear that she \u201cwould never comment on a device that\u2019s not FDA-approved.\u201d Bravo!", "answer": 1}, {"article": "On the other hand, Vorona says, \"The last thing I want readers to think is that Dr. Vorona thinks we're facing this obesity epidemic because we're sleep deprived.\nMake sure the room temperature is comfortable.\nInstead, choose whole-wheat crackers, which can control insulin.\nSuch foods will bump up insulin production.\nLower blinds and turn off lights so your room is as dark as possible.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The author cites three independent sources and identifies each of their affiliations.\u00a0", "answer": 1}, {"article": "(Reuters) - Asterias Biotherapeutics Inc said initial data from a small study showed that its lead stem cell therapy could improve mobility in patients paralyzed by a spinal cord injury.\nData showed that the severity of the spinal injury was reduced in the first patient and two other patients were able to resume their rehabilitation programs soon after being injected with the stem cells.\n\u201cIt is important to know that we do not expect patients to get up and play basketball,\u201d he said.\nIn an early-stage study conducted by Geron, the therapy showed potential in repairing spinal injury in four of the five patients tested, without any adverse events.\nThe therapy, AST OPC-1, is the first product derived from human embryos to be tested on humans.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Only the CEO of Asterias is quoted in this article. An independent source \u2013 who could have discussed the limitations and significance of the trial \u2013 would have helped balance the story, bringing a much-needed perspective to readers.", "answer": 0}, {"article": "The use in spine surgery of bone-growth proteins like Medtronic Inc.\u2019s product Infuse has led to widespread nationwide increases in hospital charges ranging from 11% to 41% above conventional surgical costs, researchers found.\n\nThe researchers studied the results of a broad U.S. sample of 328,000 spine surgeries from 2002 through 2006. They report their findings this week in JAMA, the Journal of the American Medical Association.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The study uses only one live source, the study\u2019s lead author. This is insufficient. \nOne or two additional voices would have been able to put these findings in context and help readers understand what they might mean.\u00a0\nHaving said that, the reporter does get extra points for trying to contact a researcher with clear economic motivations to explain his conclusions, which differ from the current study\u2019s. ", "answer": 0}, {"article": "It is the first shingles vaccine to combine a non-live antigen with a specifically designed adjuvant.\nMany vaccines are made from a weakened form of the virus, but Shingrix is made from just a single protein--known as glycoprotein E--that comes from the outer shell of the herpes zoster virus.\n\"This is quite remarkable because there are no other vaccines that perform nearly so well for people in their 70s and their 80s.\n\"The efficacy is approximately 90% for all age groups--even for those over 70 years of age.\nThe research, published in the Journal of Infectious Diseases, shows that Shingrix offers protection for up to four years, but Professor Cunningham believes it will last much longer.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The study was funded by the manufacturer of Shingrix, GlaxoSmithKline, and many of the authors are listed in the study as being GSK employees or having other financial interests in shingles vaccines. None of that is mentioned.", "answer": 0}, {"article": "Previous laboratory research by Borrello and his colleagues showed that activated MILs could selectively target and kill myeloma cells taken from patients and grown in laboratory culture flasks.\nResults of the trial involving a particular type of tumor-targeting T cell, known as marrow-infiltrating lymphocytes (MILs), are described in the May 20 issue of Science Translational Medicine.\nOther types of tumor-infiltrating cells can be used, but they are usually less plentiful in patients' tumors and may not grow as well outside the body, says Borrello.\nFunding for the study was provided by the Commonwealth Fund (5P01 CA015396, P30 CA006973) and the Baca and Morisi Funds.\nThe overall survival was 31.5 months for those with less than 90 percent disease reduction, but this number has not yet been reached in those with better responses.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding sources for this research are listed in an end note in the release.\u00a0 No conflict of interest information is provided in the release, although the research paper discloses no conflicts.", "answer": 1}, {"article": "\"For high-risk people, those with heart disease or [who] have had a stroke who are taking a standard dose of a statin, further reduction in LDL cholesterol will give them extra benefit,\" said Dr. Colin Baigent of the Clinical Trial Service Unit and Epidemiological Studies Unit at University of Oxford in the United Kingdom, who was involved in both studies.\nThe researchers found that in trials comparing statin doses, taking high-dose statins reduced the odds of having a stroke by an additional 15 percent, compared to the usual doses of statins.\nWhen they did an updated analysis of the 21 trials, first major cardiovascular events (such as heart attack and stroke) were lowered by a \"highly significant\" 22 percent for a 1.07 millimole per liter (mmol/L) reduction of LDL cholesterol.\nResearchers also found that rhabdomyolysis -- the most severe form of the muscle disease associated with statins -- was diagnosed in seven participants given 80 mg of Zocor (simvastatin), compared to none who were given 20 mg of simvastatin.\nThe second study is a randomized trial called the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH), led by professor Jane Armitage, also a scientist at the CTSU in Oxford.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included comments from one source beyond those involved in the study and accompanying editorial. The story also mentioned that one study was in part financed by a company that makes one of the statins. \u00a0However, there were no experts quoted providing perspective about the downside of \u00a0high-dose statins. Because this is such an important subject and because the medical community is not as unified in favor of higher dose statins as this story would suggest, we rated this category unsatisfactory.", "answer": 0}, {"article": "Jan. 4, 2013 -- A new study from Australia may offer a new way of identifying people at risk of glaucoma years before vision loss happens.\nNone of the participants had glaucoma when they entered the study.\nIf caught early, though, there are medications and procedures that may help treat glaucoma.\nCompared with the group as a whole, those people who were diagnosed with the eye disease during the following decade were older, had higher blood pressure, and were more likely to be female.\nEarly detection is key, but without regular eye exams, most people don\u2019t know they have a problem, says ophthalmologist Andrew Iwach, MD.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The closing comment from an independent eye surgeon provided some necessary \u2013 albeit late and brief \u2013 perspective.", "answer": 1}, {"article": "\"There is a fear among clinicians that if you ask questions about suicide, you are giving the patient an idea that this could be an option,\" says Espiritu, \"and if you ask about guns or pills, that you are giving them some hints on how they can carry out a plan.\"\nThe rate is five per 100,000 in the organization's general population, which is well below the national average and has remained steady despite an increasing rate of suicide statewide.\nThere's reason to think a full-bore effort to treat depression could reduce health costs, because untreated depression is associated with higher medical bills for chronic illnesses such as diabetes and hypertension.\nBut there are training costs involved, and the Henry Ford system has had to keep its staffing up to be able to provide care for people who need it.\nWhile the homicide rate in the U.S. has dropped 50 percent since the early 1990s, the suicide rate is higher than it was a decade ago.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story doesn\u2019t include input from experts outside of the Henry Ford Health System. The story would have been stronger if third-party experts in mental health or epidemiology had been able to provide some critical context on how effective the \u201cperfect depression care\u201d approach has been.", "answer": 0}, {"article": "Campbell is one of only 14 people in the United States participating in an FDA-approved study of an artificial retina -- a microchip implanted in the eye to stimulate damaged cells.\n\"Patients were able to do things that we would not have anticipated with so few electrodes,\" Mech said.\nThe shape is communicated to the brain -- the idea being that Campbell might one day perceive some semblance of a shape of that tree.\n\"This is an artificial device that essentially stimulates the retina electrically,\" Del Priore said.\nDevices with 100 and 1,000 electrodes are in production, and the hope, Mech said, is that more electrodes will mean more-detailed vision.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story draws on three sources, all of whom are self-interested:\nAt least one independent source should have been consulted. The self-interest of the three sources used should have been explained.", "answer": 0}, {"article": "\u201cThere\u2019s been a longstanding fear of skin testing, and it turns off a lot of allergy sufferers from getting help,\u201d said Dr. Mitchell, the author of \u201cAllergy and Asthma Solution\u201d (Marlowe, 2006), which advocates oral immunotherapy, or allergy drops, instead of shots.\nThe quick turnaround allows doctors to offer a diagnosis and immediate advice.\nThe first generation of blood tests were developed in the 1970s.\nStill, most allergists prefer skin testing.\nIf he requests a blood test, the laboratory gets the fee.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes multiple experts.", "answer": 1}, {"article": "Side effects from antidepressants can include constipation, diarrhea and dizziness.\n\"Primary care clinicians and their patients may not automatically consider alternatives when discussing treatment,\" said Halle Amick, research associate at the RTI International-University of Chapel Hill Evidence-based Practice Center and lead author.\nRTI-UNC Evidence-based Practice Center is a collaboration between RTI and the five health professions schools and the Cecil G. Sheps Center for Health Services Research at UNC.\n\"Bringing psychotherapy into discussions of treatment may also enhance coordination of care between primary care and mental health care providers in addition to addressing the issue of patient-centered care,\" Amick said.\nHowever, the evidence shows that cognitive behavioral therapy can be just as effective, providing important information for patients and their physicians to consider when choosing among available treatment options.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that the Agency for Healthcare Research and Quality (AHRQ) funded the study. AHRQ is a government agency that studies and promotes improved quality in health care.", "answer": 1}, {"article": "At dinner one recent evening at their yellow brick townhouse in the Georgetown neighborhood in Washington, his wife, Pura, admitted to worrying, but said, \u201cWe don\u2019t talk about it a lot.\u201d She served Indian takeout \u2014 saffron rice, tandoori chicken, eggplant.\n\u201cI keep waiting for the day when I have shortness of breath,\u201d he said.\nResearchers\u2019 ignorance of these control regions and what many of them do might doom the effort.\nOr the change might be in a poorly understood region of DNA that controls genes rather than in a gene itself.\nSo he left for the gym before dawn on a recent chilly morning.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A number of qualified experts weigh in regarding the\u00a0significance of this research.", "answer": 1}, {"article": "A California company has developed a genetic test that can predict whether patients treated for early-stage colon cancer are likely to suffer a recurrence of the disease, the third leading cause of cancer deaths in the U.S.\n\nThe results of the test, based on an analysis of seven different genes found in colon-cancer tumors, yield a score that tells whether patients are at low, intermediate or high risk of having the disease come back after it is removed through surgery.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes three sources: \nGiven the fact that [as the story discloses] the study was paid for by the test maker, the lack of independent sources is glaring. \nThe story would have been much stronger if it had comments from a disinterested oncologist who could speak to the test\u2019s practical value in a clinical setting. ", "answer": 0}, {"article": "MONDAY, Oct. 31, 2011 (HealthDay News) -- Doctors who listen to Mozart while performing colonoscopies may spot more precancerous growths, researchers suggest.\n\"Adenoma detection rate is linked to a reduction in colorectal cancer incidence, so it is an important quality indicator for colonoscopy,\" said O'Shea.\nResearchers set out to determine if this phenomenon, called the \"Mozart Effect,\" played a role in the detection rates of precancerous polyps during colonoscopies.\n\"Anything we can do to get those rates up has the potential to save lives.\nHowever, the second doctor had an adenoma detection rate of nearly 37 percent with Mozart and 40 percent without the music, compared with a baseline detection rate of 27 percent.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were no independent sources cited from outside the study. The only comment came from the lead researcher, Dr. Catherine Noelle O\u2019Shea from the University of Texas Health Science Center.", "answer": 0}, {"article": "Another took part in an exercise program.\n\"People need to begin to push themselves in the face of their fatigue, because if you don't, you become deconditioned and you get caught in a cycle which ... makes fatigue worse,\" says Barsky.\nNearly three decades have passed since the debate began about a series of symptoms that have come to be known as chronic fatigue syndrome.\nAnd, like most professionals who treat patients, Bateman eagerly awaits the day when science can finally pinpoint its cause.\nIts cause is still unknown, but over the years, researchers have identified various brain, immune system and energy metabolism irregularities involved.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quoted two people, but we like that it at least attempted to bring in a different view on how to treat chronic fatigue. In talking with Lucinda Bateman at Fatigue Consultation Clinic in Salt Lake City, the story brought out some of the limitations of the study.", "answer": 1}, {"article": "Laxminarayan did not dismiss the notion of this type of use out of hand, however.\n\u201cBut if you can select a group with a high incidence rate of syphilis or chlamydia, and you want to try to reduce the rate of syphilis quite quickly in this group of people, you may think that this strategy could be used for a couple of months.\u201d\n\nRates of syphilis in particular have risen steadily in recent years; the rate in 2015-2016 \u2014 8.7 cases per 100,000 people \u2014 was the highest since 1993, the Centers for Disease Control and Prevention reported.\nThe authors noted, however, that the study length was short and they can\u2019t tell if the strategy would work as well over the long term.\nThere was, however, a 70 percent reduction in chlamydia infections and cases of syphilis decreased by 73 percent.\nThe men were tested regularly for STIs, and in the nine or so months they were followed, the rates of some sexually transmitted infections fell dramatically in the treatment group.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A strength of the story is that it includes multiple independent sources. It reports funding from the Bill & Melinda Gates Foundation. However, the story does not report funding from a French government agency, nor does it refer to the lengthy list of industry financial ties that many of the researchers disclosed. But we will give the story a satisfactory rating because doxycycline is available as a generic drug produced by a number of companies, not just those the researchers have ties to.", "answer": 1}, {"article": "Scientists have also found impulsive behaviour is a factor in leading to food addiction and Ivo Vlaev, of Warwick Business School, plus Myutan Kulendran, Laura Wingfield, Colin Sugden, and Ara Darzi, of Imperial College London, discovered that a drug called Modafinil, usually used for narcolepsy, shift work disorder and excessive daytime sleepiness, can reduce impulsivity and thus food addiction.\nThe tests revealed that those who had taken Modafinil had a significantly reduced level of impulsiveness, whereas Atomoxetine produced no difference compared to the placebo group.\nThe drug, which is sold under a wide variety of brand names around the world, was one of two drugs tested by researchers, the other being Atomoxetine.\nFood addicts suffer from the same neurobiological conditions so we believe it will help food addicts as well and our initial tests have backed up that theory.\n\"It has been shown to reduce impulsiveness in a variety of disorders such as alcohol dependence, schizophrenia and ADHD.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release makes no mention of who funded this study, nor does it mention any potential or possible conflicts of interest on the part of the researchers.", "answer": 0}, {"article": "TUESDAY, June 14, 2011 (HealthDay News) -- Not only do cooler heads prevail, they might also sleep better, according to researchers who say they have developed a cooling cap that, when worn during sleeptime, may help treat insomnia.\n\"It does reduce brain metabolism in the frontal lobes, and it improves sleep.\"\nThe U.S. National Heart, Lung, and Blood Institute has more on insomnia.\n\"It's in the brain where the chemical changes are occurring that lead to sleep,\" he said.\nOf the patients with insomnia, the average age was 45 and nine were women.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One independent sleep researcher was quoted.", "answer": 1}, {"article": "Natural-birth advocates cite a \"cascade of interventions\" caused by hospitals' practice of using the drug Pitocin to stimulate labor.\nThe epidural can then retard contractions and lead to more drugs, fetal stress and the doctor's recommendation of a Caesarean.\nThe drug can cause painful contractions, which doctors treat with an epidural painkiller.\nIf something does go wrong, in the eyes of the courts \"a normal birth is a risk.\nThere are many births in the documentary film \"The Business of Being Born,\" including a scene of former talk-show host Ricki Lake giving birth naked in her tub.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes multiple sources, however only two of them are clinical experts, the others are authors of books or filmmakers.", "answer": 1}, {"article": "PARIS (Reuters) - Sanofi-Aventis\u2019 cabazitaxel candidate prostate cancer drug combined with prednisone reduced the risk of death by 28 percent compared with another treatment, the outcome of a final-stage trial showed.\nThis compared with 1.9 percent using mitoxantrone.\nThe primary endpoint of the so-called Tropic trial was overall survival.\nFiling for approval in the EU has been completed.\nThe FDA\u2019s review should happen in the third quarter, Sanofi said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0No independent sources were quoted to evaluate the claims made by the drug company. ", "answer": 0}, {"article": "\"\nIn his study, doubling the length of treament also doubled the risk of endometrial cancer, which affects the uterine lining, to about 3%.\nOxford funded the study, which included more than 6,800 women from 36 countries, While tamoxifen delays tumor growth in some women, it appears to cure others, Gray says.\n\"If we are going to look at giving women tamoxifen for 10 years, by golly, we better get the partners involved,\" Shockney says.\n\"This is a dream come true for women,\" says V. Craig Jordan, a researcher who led tamoxifen's development, but who wasn't involved in the new study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "THIS IS A CORRECTED COMMENT IN RESPONSE TO A COMPLAINT BY THE REPORTER OF THE STORY \u2013 HER COMMENTS IN THE COMMENTS SECTION BELOW.\nWE INITIALLY SAID THERE WAS NO QUOTE FROM ANY INDEPENDENT EXPERT NOT CONNECTED TO THE STUDY.\u00a0 THAT WAS INCORRECT.\nHOWEVER, OUR CRITERION IN THIS CATEGORY READS: \u201cIn order to get a satisfactory score on this criterion, two things must occur: There must be an independent expert source quoted (someone not directly connected with the research) and there must be some attempt to let the public know about potential conflicts of interest.\u201d\nAND WE POST MORE BACKGROUND ON THIS CRITERION HERE.\nThis story DID NOT include reference to partial funding of the study by AstraZeneca, which produces a brand of tamoxifen. The competing stories by the NY Times and AP did report on AstraZeneca funding. AP went further in pointing out that the study leader \u201chas been a paid speaker for a company that makes one of the drugs.\u201d\u00a0\u00a0\u00a0 So the score remains unsatisfactory despite our initial error (corrected) on the first point.\nThe interview with the administrative director of the Johns Hopkins Cancer Survivorhip Program about her own experience with tamoxifen use added important perspectives. (The reporter apparently missed that we referred to this in a positive note all along.) ", "answer": 0}, {"article": "Available from: http://www.\nThis annual congress is the biggest event in the EASL calendar, attracting scientific and medical experts from around the world to learn about the latest in liver research.\nThis ongoing, open-label study enrolled 90 children aged between six and 11 years with chronic HCV, mostly genotype 1 (n=86).\n\"This study is a breakthrough for the management of children aged six to 11 years old with Hepatitis C, demonstrating that the new DAA regimen is highly efficacious and, more importantly, safe in this group of HCV-infected children\", said Prof Frank Tacke, University Hospital Aachen, Germany, and EASL Governing Board Member.\nThe most common side effects reported in 10% or more of patients were headache, fever, abdominal pain, diarrhoea, vomiting, cough, fatigue, sore throat and nausea.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release says research funding came from the manufacturer, Gilead Sciences, and the National Institutes of Health, and the study authors own stock in Merck. Kudos for transparency.", "answer": 1}, {"article": "(CNN) -- Taking dietary supplements containing essential fatty acids can help reduce the symptoms of premenstrual syndrome, according to the results of study by researchers at a Brazilian university.\nThe study, authored by researchers from the Federal University of Pernambuco, is not the first to address the possible link between PMS and essential fatty acids, substances that play a complicated role in a woman's reproductive system.\nThe supplements taken by women in the study contained 210 mg of gamma linolenic acid, 175 mg of oleic acid, 345 mg of linoleic acid, 250 mg of other polyunsaturated acids and 20 mg of vitamin E, according to researchers.\nThe study, published Monday in the journal Reproductive Health, found that taking capsules containing about 1 gram of a blend of three essential fatty acids produced a significant reduction in PMS symptoms.\nThe researchers do not make any recommendation in their study about whether women who suffer from PMS should increase their intake of essential fatty acids or, instead, consult with their doctor.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "As stated above, this story needed some independent expert comment.\u00a0 There were also no statements made about conflicts of interest. Since the market for PMS is so big, it would have been helpful to know if these scientists had any vested interest in the results.", "answer": 0}, {"article": "Timothy Hardy, Mujdat Zeybel, Christopher P. Day, Christian Dipper, Steven Masson, Stuart McPherson, Elsbeth Henderson, Dina Tiniakos, Steve White, Jeremy French, Derek A. Mann, Quentin M. Anstee and Jelena Mann.\nIt is the first time an epigenetic signature in blood has been discovered which is diagnostic of the severity of fibrosis for people with Non-alcoholic Fatty Liver Disease (NAFLD).\nCirrhosis - the most severe stage, occurring after years of inflammation, where the liver shrinks and becomes scarred and lumpy; this damage is permanent and can lead to liver failure (where the liver stops working properly) and liver cancer\n\nIt can take years for fibrosis or cirrhosis to develop and the presence of this scarring predicts those people with the worse prognosis.\n\"We know that the presence of even mild fibrosis of the liver predicts a worse long-term outcome for patients with NAFLD and so it's important to be able to detect liver scarring at an early stage.\"\nNon-alcoholic steatohepatitis (NASH) - a more serious form of NAFLD, where the liver has become inflamed; this is estimated to affect up to 5% of the UK population \n\n3.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources are clearly identified, as are researchers who are quoted and their affiliations related to the work. There do not appear to be any relevant conflicts of interest.", "answer": 1}, {"article": "But she said she and her colleagues analyzed the data carefully to account for factors that could have influenced the findings, such as the subjects' ages and whether they had other health problems.\nIt is diagnosed in 235,000 U.S. men each year and kills more than 27,000, making it the most common cancer and second-leading cancer killer, after lung cancer, among men.\nThe research, published in today's Journal of the American Medical Association, is the first to directly examine what has become conventional wisdom: that many older men need not treat early prostate cancer because it tends to grow so slowly that they will probably die of something else first.\nSome doctors fear the cancer is being over-treated, particularly in older men, subjecting them to therapies that leave many impotent and incontinent when their cancer would never bother them if left untreated.\n\"We adjusted for as many of those differences as we could,\" Wong said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article provides multiple sources of information, some of whom appear to be independent of the current study.\u00a0 The sources also provide a range of opinions about what the latest study means, which adds balance.\u00a0 ", "answer": 1}, {"article": "Researchers reviewed data on all patients who have been exposed to JCV who are enrolled in TOUCH, the U.S. Food and Drug Administration-mandated Risk Evaluation and Mitigation Strategy (REMS) program for natalizumab that requires manufacturers to document all uses of a medication to ensure that the benefits of a drug outweigh its risks.\nThere have been 756 PML cases reported worldwide as of January 2018, with a global incidence rate of 4.19 per 1,000 PML cases in people treated with natalizumab.\nIn addition to Dr. Zhovtis-Ryerson, Ilya Kister, MD, associate professor of neurology, Judith D. Goldberg, professor of population health and environmental medicine, and Xiaochun Li, PhD, research scientist of biostatistics, were co-authors at NYU Langone Health.\nPatients who test JCV antibody-positive are typically either told to not to start natalizumab, or have had treatment stopped after two years, when risk was deemed to be too high.\nTaking the medication longer than two years, however, may increase risk PML, which is caused by the John Cunningham virus (JCV).\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Although the news release does mention that natalizumab is manufactured by Biogen \u2014 and that Biogen \u201cprovided the researchers access to their data and statistical support\u201d \u2014 it does not mention that the lead author\u00a0receives research support from Biogen, as well as personal compensation from Biogen for speaker and advisory board activities.\nIt\u2019s also not mentioned that half of the 14 coauthors listed for this study\u00a0are employees of \u2014 and own stock and/or stock options \u2014 in Biogen.", "answer": 0}, {"article": "\"A large body of evidence indicates no difference in how effectively the newer antidepressants improve people's moods,\" said Dr. Arterburn's coauthor Gregory Simon, MD, MPH, a Group Health psychiatrist, GHRI senior investigator, and research professor in psychiatry and behavioral sciences at the UW School of Medicine.\n\"All other antidepressants are linked to varying degrees of weight gain.\"\nChan School of Public Health, who used to work at GHRI.\nGrant R01 MH083671 from the National Institute of Mental Health funded this research.\nBupropion is often used to help patients stop smoking.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "That\u2019s pretty well covered, with lots of information about Group Health and the grantors.", "answer": 1}, {"article": "That study enrolled just 62 people, but the results were significant enough for NIH to fund new research _ at Pennsylvania, the University of Texas in Houston, Boston University and other sites _ enrolling about 650 cocaine users to see if modafinil really does work.\nThe main side effect so far: insomnia, not surprising as modafinil is sold today to help narcolepsy patients fend off that neurologic disease's sudden sleep attacks.\nIn addition to blunting cocaine's notorious cravings, modafinil might also counter the damage that cocaine wreaks on users' brain circuits _ damage that in turn fuels the cycle of addiction.\nThe prospect of that double-whammy has the National Institutes of Health spending $10.8 million researching modafinil as a potential cocaine treatment.\n\"We didn't expect that at all,\" Dackis says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story doesn\u2019t mention any potential conflict of interest of the sources cited. Dr. Dackis is a hired speaker for Cephalon, maker of modafinil, though this is not mentioned in the news story. The disclosure is readily available in the source journal article. ", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2009/11/02/financial/f035110S68.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story only includes a quote from the principle investigator, Paul Kwo (not Quo, as written erroneously in the story).\u00a0 ", "answer": 0}, {"article": "Lee believes ibuprofen strips could be useful for sports participants, helping alleviate conditions such as tendonitis, and repetitive strain injuries.\nWe\u2019ve tested them in our polymers with very good results, we\u2019ve been able to get increased loadings of drugs in the polymer and we\u2019ve shown almost across the board that we can get a steady release rate of that drug from the polymer as well.\u201d\n\nThe team says TEPI patches could go on sale within three years, and Medherant is working with some large, unnamed, pharmaceutical companies to get them ready for market.\nWe\u2019re controlling the dosage and we\u2019re keeping it there for a prolonged period of time.\u201d\n\nThe patches could help treat conditions like chronic back pain, neuralgia and arthritis without the need to take potentially damaging doses of the drug orally.\nAccording to Andrew Lee, co-founder of Medherant, \u201cwe\u2019ve only been in the lab about 12 months, but in the 12 months we\u2019ve essentially assessed about 90 percent of the drugs that are currently available as either creams or patches.\n\u201cWhat we do is dissolve the active ibuprofen, for example, into the adhesive so we can have quite a high loading - so up to 30 percent of the adhesive will be the ibuprofen,\u201d said Haddleton.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources were interviewed. The\u00a0two sources that were interviewed\u00a0for this article were\u00a0both disclosed to be affiliated with the company Medherant, producer of the TEPI patches. Since the use of transdermal patches has been around for decades, it should have been relatively easy to identify experts in the field.", "answer": 1}, {"article": "Six months after treatment, the YAG group reported significantly greater improvement in self-reported floater-related visual disturbance (54 percent) compared with sham controls (9 percent).\nChirag P. Shah, M.D., M.P.H., and Jeffrey S. Heier, M.D., of the Ophthalmic Consultants of Boston, randomly assigned 52 patients (52 eyes) to receive YAG laser vitreolysis (n = 36) in one session or a sham (placebo) laser treatment (control; n = 16).\nThree management options exist for floaters: patient education and observation; surgery; and the laser procedure, YAG vitreolysis, of which there are limited published studies on its effectiveness for treating floaters.\nEMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, JULY 20, 2017\n\nThe commentary, \u201cYAG Laser Vitreolysis\u2014Is It as Clear as It Seems?,\u201d by Jennifer I. Lim, M.D., of the University of Illinois at Chicago; and Editor, JAMA Ophthalmology, also is available at the For The Media website.\n\u201cGreater confidence in these outcomes may result from larger confirmatory studies of longer duration,\u201d the authors write.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t name any funders. ClinicalTrials.gov states that Ophthalmic Consultants of Boston sponsored the study. The journal article notes that neither coauthor had conflicts of interest.", "answer": 0}, {"article": "Russo says, \"One of our main findings is that there was no overall relationship between most types of physical activity and the likelihood of becoming pregnant for women who had already had one or two pregnancy losses, except for walking, which was associated with higher likelihood of becoming pregnant among women who were overweight or obese.\"\nThe researchers conclude that \"these findings provide positive evidence for the benefits of physical activity in women attempting pregnancy, especially for walking among those with higher BMI.\nFor the 1,214 women in the study, the association of walking with the ability to become pregnant, known as fecundability, varied significantly by body mass index, the authors report.\nThe researchers also note that the overall generalizability of this work is limited because the study population may not be representative of the general population with regard to fecundability, and exercise habits may differ in women with prior miscarriage compared to those without.\nThe study was conducted by recent graduate Lindsey Russo and her advisor Brian Whitcomb, associate professor of biostatistics and epidemiology in the School of Public Health and Health Sciences at the University of Massachusetts Amherst.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The study funders are listed on a sidebar on the EurekAlert! site, where the release is hosted. We encourage news releases to include funders and any conflicts of interest in the body of the release so that the information is carried over by news organizations or blogs running the release verbatim.\nThe published paper lists no conflicts of interest among the authors.", "answer": 1}, {"article": "Besides M.D.\nOne expert said the study is an important step but definitely needs follow-up work.\nStudy participants were grouped as low, medium or high risk based on how much their CA-125 levels changed over time.\nMore than half of the women in the study came from Houston.\nThat study is due to show results in 2015.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an independent expert from the American Cancer Society who provides much-needed perspective.", "answer": 1}, {"article": "Nov. 30, 2011 (Chicago) -- Older people who eat baked or broiled fish at least once a week may be boosting their brain health.\nIn a new study, imaging scans showed that regular fish-eaters were less likely to have brain cells die off in the area of the brain responsible for short-term memory -- recalling a phone number that was just heard, for example.\nThis benefit is thought to come from the omega-3 fatty acids in fish, although studies of fish oil supplements have produced disappointing results in people who already have Alzheimer's.\nAnd people who ate baked or broiled fish at least weekly and didn't lose brain cells were much less likely to develop Alzheimer's disease or mild mental impairment, says Cyrus Raji, MD, PhD, of the University of Pittsburgh School of Medicine.\n\"More fish, more brain, less Alzheimer's,\" he tells WebMD.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story turned to the chief medical and scientific officer of the Alzheimer\u2019s Association for comment.\u00a0 But the quote used from him didn\u2019t contribute much to an evaluation of the study.\n ", "answer": 1}, {"article": "\"Of concern is that complication rates are still higher than desirable for this procedure, and there was suboptimal use of stroke-preventing anticoagulation [anti-clotting] therapy after the procedure,\" added Fonarow, who was not involved with the study.\nAccording to Dr. Hugh Calkins, \"Atrial fibrillation ablation is a well-established procedure that has imperfect results.\"\nBut the procedure can have complications, which should be considered carefully by doctors and patients, said Arbelo, a senior specialist in the Cardiovascular Institute at the Hospital Clinic of Barcelona in Spain.\n\"Catheter ablation is a valid alternative for the management of atrial fibrillation with a satisfactory success rate,\" said study lead researcher Dr. Elena Arbelo.\nIn addition, 45 percent of patients who had a successful procedure were still taking antiarrhythmia drugs 12 months later.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does quote two cardiologists unconnected to the study, but fails to disclose possible conflicts of interest among the researchers. For example, the lead researcher has accepted money from Biosense Webster, a company that makes medical products for atrial fibrillation treatments.", "answer": 0}, {"article": "In 37 years as a police officer, Edwin Michel coped with a plane crash, a sniper, wildfires and three bullet wounds.\n\nNothing much rattled him until he was diagnosed with prostate cancer in November 2016. His doctor said the cancer wouldn\u2019t kill him but Mr. Michel, now 76 years old, wasn\u2019t entirely reassured. He felt more confident after a genomics test later revealed his prostate cancer was very low risk. The test, known as Oncotype DX, takes a sample from a prostate biopsy and analyzes 17 genes in it to estimate how aggressive...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story uses multiple sources and in one case points out that the source was not part of the study.\u00a0 In another case, the story points out that a source \u201chas been a paid consultant for the makers of Oncotype DX and Decipher, but has no financial interest in the companies.\u201d\u00a0 One quoted source, however, is part of a company \u201cwhose aims include curbing overtreatment,\u201d which using these tests apparently might prevent.", "answer": 1}, {"article": "To automatically receive news releases from UT Southwestern via email, subscribe at http://www.\n\"The high cure rate is striking when compared to the reported five-year cure rates from other approaches like surgery or conventional radiation, which range between 80 to 90 percent, while the side effects of this treatment are comparable to other types of treatment,\" said Dr. Raquibul Hannan, Assistant Professor of Radiation Oncology and lead author for the study.\nIt is a state-of-the-art technology that allows for a concentrated dose to reach the tumor while limiting the radiation dose to surrounding healthy tissue.\nIn addition, the Center's education and training programs support and develop the next generation of cancer researchers and clinicians.\nA range of clinical trials of SBRT therapy are under way at Simmons Cancer Center, including new investigations evaluating use of SBRT for cancers in the breast and larynx.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release provides the funding source (the U.S. Department of Defense) although it does not explicitly comment on the absence of conflict.", "answer": 1}, {"article": "Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting up to 12% of women.\nThey found that teenagers with PCOS had significantly higher irisin levels compared to the control group, and that this was associated with higher levels of the male sex hormone testosterone, a key marker of PCOS.\n\"Whether it's through counselling or medication, girls can manage their symptoms and decrease the risk of further complications such as fertility problems, hirsutism (excessive hair growth) and type-2 diabetes\".\nMeasuring blood levels of the recently discovered hormone irisin may improve diagnosis rates of teenagers with polycystic ovary syndrome, according to research presented today at the 55th Annual European Society for Paediatric Endocrinology Meeting\n\nMeasuring blood levels of the recently discovered hormone irisin may improve diagnosis rates of teenagers with polycystic ovary syndrome, according to research presented today at the 55th Annual European Society for Paediatric Endocrinology Meeting.\nThe findings suggest that irisin could be a marker for PCOS allowing the condition to be diagnosed more easily.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources and conflicts of interest are not mentioned at all. Even when it\u2019s difficult to determine what any conflict of interest might be, it\u2019s important to note where funding for health studies came from.", "answer": 0}, {"article": "itself the first clear and reproducible example of cancer immunotherapy, developed at Fred Hutch ?\nBecause it was the first study of this particular approach, the researchers focused on a high-risk group -- AML patients undergoing bone marrow transplant who had certain genetic or disease characteristics that decrease the chance of long-term transplant success -- \"a hard population of patients,\" Chapuis said, many of whom \"were horribly sick.\"\nThis is the team's first trial of this strategy, which was initially developed in the lab of Dr. Phil Greenberg, one of the study's leaders and the head of Fred Hutch's Program in Immunology.\nOf the 12 AML patients who received this experimental T-cell therapy after a transplant put their disease in remission, all are still in remission after a median follow-up of more than two years.\nThe study was supported by funding from the National Institutes of Health and spinoff Juno Therapeutics, of which Greenberg is a scientific co-founder.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release reports that funding came from the National Institutes of Health and from Juno Therapeutics. It says that one of the researchers is \u201ca scientific co-founder\u201d of Juno Therapeutics. So we will give the release a passing grade on this criterion. However, readers have to have sharp eyes to intuit that this disclosure means that the researcher owns part of the company and so stands to profit from any treatments that result from this work.", "answer": 1}, {"article": "The requested document is forbidden. Please try your operation again .", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Comments from several clinicians were included in this piece to point out some of the potential confounders with the study results.\nIt was mildly amusing that one of the clinicians interviewed stated categorically that there are over\u00a0800 previous studies on robot-assisted prostate -v the majority of which demonstrate superiority. \u00a0This is an awfully large number of studies about a relatively new technology; further, one of the important points of this story is that there are both short term and longer term outcomes to be considered.", "answer": 1}, {"article": "Tim Barham, the vice president of HBB, the maker of Lazy Cakes, said, \u201cWe look at the brownie as a supplement.\u201d\n\nNews reports have classified Lazy Cakes as dietary supplements, but last month, Douglas Karas, an F.D.A.\n\u201cA hangover effect has been reported\u201d with large doses, said Anna Rouse Dulaney, a toxicologist with the Carolinas Poison Center.\nDr. Lewy dismissed the idea that harm might lurk in a melatonin-laced brownie.\nDr. Alfred J. Lewy, a professor of psychiatry at Oregon Health and Science University who has studied melatonin, a neurohormone, estimated that only a third of the population is susceptible to its effects in a supplement.\n\u201cIt\u2019s a colossally bad idea to put melatonin in food,\u201d Dr. Czeisler said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several independent experts \u2013 independent of the product manufacturers \u2013 were quoted.", "answer": 1}, {"article": "LONDON (Reuters) - British liquid biopsy company Angle said its Parsortix blood test had beaten current methods in identifying ovarian cancer, a breakthough that could help women receive the best possible outcome from surgery.\nThe test will enable women with ovarian cancer to be referred to gynaecological surgeons who specialize in the care of women with ovarian cancer, while patients with a benign tumor will not have to travel to specialist centers.\n\u201cThe vision is that a woman who has been diagnosed with having an abnormal pelvic mass will have a simple blood test and from that we will deduce whether or not she has cancer and if she does which drug would be most suitable for her,\u201d he said.\nThe performance of the test would now be validated in another study designed to meet European CE Mark and US FDA regulatory requirements, he said.\nIt also had the potential to identify targets on the tumor that could be used to inform treatment strategies, he said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story\u2019s sole source is clearly identified as the chief executive of the company that appears to have funded the work.\u00a0 But the presence of only that source is a problem, as the text offers no independent viewpoints.", "answer": 0}, {"article": "Ilaris can lower the immune system\u2019s ability to fight infections.\n\u201cFor the first time, patients with TRAPS and HIDS/MKD, two painful and life altering diseases, have access to a treatment that may help improve their quality of life,\u201d said Badrul Chowdhury, M.D., Ph.D, director of the Division of Pulmonary, Allergy and Rheumatology Products in FDA\u2019s Center for Drug Evaluation and Research.\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nThe new indications are for rare and serious auto-inflammatory diseases in adult and pediatric patients:\n\nAll three syndromes are hereditary diseases that are characterized by periodic attacks of fever and inflammation, as well as severe muscle pain.\nThe agency is also responsible for the safety and security of our nation\u2019s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There\u2019s no mention of funding or conflict of interest, but these don\u2019t (or shouldn\u2019t) apply to regulatory approvals. It\u2019s presumed that the studies will have been conducted by the company seeking approval.", "answer": 2}, {"article": ".\nThe authors say capsaicin also possesses antimicrobial properties that \u201cmay indirectly affect the host by altering the gut microbiota.\u201d\n\nThe research corroborates a 2015 study conducted in China and published in the BMJ that found regular consumption of spicy food is associated with a lower risk of death.\nThe researchers note that people who ate hot red chili peppers tended to be \u201cyounger, male, white, Mexican-American, married, and to smoke cigarettes, drink alcohol, and consume more vegetables and meats .\nFor the study, researchers at the Larner College of Medicine at the University of Vermont analyzed data on more than 16,000 Americans using the National Health and Nutritional Examination Survey (NHANES).\nStill, the authors say the study strengthens the growing body of evidence that spicy food may have protective health properties that can lead to a longer life.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites phrases\u00a0from the paper itself, but otherwise the study authors are not quoted. The only true quote is pulled from a 2015 CBS News story about another study in which eating spicy food is linked to lower risk of death; the quote comes from that study\u2019s author. No other\u00a0sources were quoted, which could have given the story much needed context.", "answer": 0}, {"article": "In addition, availability of a blood test for mTBI/concussion will likely reduce the CT scans performed on patients with concussion each year, potentially saving our health care system the cost of often unnecessary neuroimaging tests.\u201d\n\nAccording to the U.S. Centers for Disease Control and Prevention, in 2013 there were approximately 2.8 million TBI-related emergency department visits, hospitalizations and deaths in the U.S. Of these cases, TBI contributed to the deaths of nearly 50,000 people.\nA majority of patients with concussion symptoms have a negative CT scan.\nTest results can be available within 3 to 4 hours.\nBeing able to predict if patients have a low probability of intracranial lesions can help health care professionals in their management of patients and the decision to perform a CT scan.\nThe FDA reviewed and authorized for marketing the Banyan Brain Trauma Indicator in fewer than 6 months as part of its Breakthrough Devices Program.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t name study funders. ", "answer": 0}, {"article": "His \"tactile imaging system\" capitalizes on the fact that cancerous lumps tend to feel harder and less movable than harmless abnormalities such as fluid-filled cysts or fibrous nodules. The fist-sized, $1,000 machine \u2014 with an elastomer probe, a light, and a camera \u2014 acts like ultrasensitive fingertips. It measures the size, elasticity, and mobility of a breast lump, then a computer program converts the data into a score from 1 to 5, with scores under 2 likely to be benign.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources are quoted.\u00a0 The only quotes in the article are from Dr. Won, the engineer who developed the device.", "answer": 0}, {"article": "TUESDAY, Aug. 2, 2011 (HealthDay News) -- There's still no cure for the common cold, but there may be a way to shorten its misery: A new study suggests that higher doses of zinc lozenges in certain formulations may cut the length of colds by more than 40 percent.\n\"When focusing on those studies which have used large daily doses of zinc, there is strong evidence that zinc lozenges shorten the duration of colds.\"\n\"I would tell my patients we still don't have a cure [for the common cold], and we don't know if zinc works.\"\nDespite the popularity of zinc supplements, controversy over their effectiveness has continued since a much-publicized 1984 study first suggested a cold-limiting effect.\nSince then, more than a dozen studies have been carried out, but data on the trace mineral's effectiveness has been mixed.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes the author of the original journal article and one expert. Neither of these appear to have conflicts of interest.", "answer": 1}, {"article": "\u201cWhen it recognizes that it\u2019s gone inside the cell, it says OK, now it\u2019s time to disassemble and give off the RNA.\u201d\n\nIn a phase 1 clinical trial in patients with various types of tumors, the team gave doses of the targeted nanoparticles four times over 21 days in a 30-minute intravenous infusion.\nRNA stands for ribonucleic acid \u2014 a chemical messenger that is emerging as a key player in the disease process.\nBut getting the treatment to the right target in the body has presented a challenge.\n\u201cIn the particle itself, we\u2019ve built what we call a chemical sensor,\u201d Davis said in a telephone interview.\nDavis could not say whether the therapy helped shrink tumors in the patients, but one patient did get a second cycle of treatment, suggesting it might be.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources interviewed in the story. ", "answer": 0}, {"article": "TNT technology has two major components: First is a nanotechnology-based chip designed to deliver cargo to adult cells in the live body.\nThe chip does not stay with you, and the reprogramming of the cell starts.\nIn lab tests, this technology was also shown to reprogram skin cells in the live body into nerve cells that were injected into brain-injured mice to help them recover from stroke.\nWith this technology, we can convert skin cells into elements of any organ with just one touch.\nThis process only takes less than a second and is non-invasive, and then you're off.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release names the funders. The published research letter states researchers have no financial conflicts of interest.", "answer": 1}, {"article": "PITTSBURGH, June 2, 2016 - Surgery to remove the primary tumor in women diagnosed with stage IV breast cancer, followed by the standard combination of therapies, adds months to the patients' lives, compared with standard therapy alone, an international clinical trial led by a University of Pittsburgh Cancer Institute (UPCI) professor revealed.\nNearly 42 percent of the women who received surgery lived to five years after diagnosis, compared with less than 25 percent of the women who did not receive surgery.\nAt about 40 months after diagnosis, the women who received the surgery plus standard therapy lived an average of nine months longer than their counterparts who received standard therapy alone.\nDr. Soran began the trial in 2007, ultimately recruiting a total of 274 women newly diagnosed with stage IV breast cancer from 25 institutions.\n\"Our thinking is similar to how you might approach a battle against two enemies,\" said Dr. Soran.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release mentions who did the study and how it was funded.", "answer": 1}, {"article": "[3]\n\nWriting in a linked Comment, Professor Avan Aihie Sayer from the University of Southampton, Southampton, UK, and Professor Thomas Kirkwood from Newcastle University, Newcastle upon Tyne, UK discuss whether grip strength could be a new biomarker of ageing, writing that, \"This is not a new idea, but findings from PURE add support.\nThe study, published in The Lancet, also found that grip strength is a stronger predictor of death than systolic blood pressure, and the authors suggest that it could be used as a quick, low-cost screening tool by doctors or other healthcare professionals to identify high-risk patients among people who develop major illnesses such as heart failure and stroke.\nThe findings show that every 5kg decline in grip strength [2] was associated with a 16% increased risk of death from any cause; a 17% greater risk of cardiovascular death; a 17% higher risk of non-cardiovascular mortality; and more modest increases in the risk of having a heart attack (7%) or a stroke (9%).\nThe current study followed 139691 adults aged between 35 and 70 years living in 17 countries from The Prospective Urban-Rural Epidemiology (PURE) study for an average (median) of four years.\nLoss of grip strength is unlikely to lie on a single final common pathway for the adverse effects of ageing, but it might be a particularly good marker of underlying ageing processes, perhaps because of the rarity of muscle-specific diseases contributing to change in muscle function.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "This rating is for a sin of omission. It does not appear that any conflicts were hidden, but all news releases should routinely report a summary of funding sources and disclosures.\nThe journal article reports funding sources for the study and lead authors. There are no competing interests reported. The maker of the dynamometer used does not appear to have played any role in the study. But even in cases like this, where it does not appear that there any funding or other conflicts of interest, news releases should routinely include some reference to funding and disclosures by researchers.", "answer": 0}, {"article": "\"The first importance of the trial is that it shows hepatic [liver] targeting of hormonal action,\" Ladenson said.\nHe said that significant reductions of blood levels of those fats were seen in the trial.\nUse as a single drug treatment for elevated cholesterol levels could follow, first in selected patients, then more widely, he said.\n\"But this is a demonstration of lipid-lowering effect without thyroid toxicity.\"\n\"The second exciting part is its impact on lipids other than LDL cholesterol.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Important caveats were included in the independent expert\u2019s views at the end of the story. ", "answer": 1}, {"article": "HOUSTON - For patients with advanced, inoperable stage 3 lung cancer, concurrent chemotherapy and the specialized radiation treatment, proton therapy, offers improved survival compared to historical data for standard of care, according to a new study from The University of Texas MD Anderson Cancer Center.\nThe image quality was poor and didn't include a CT component in most facilities across the country,\" said Chang.\nThe technique uses an intricate network of magnets to aim a narrow proton beam at a tumor and \"paint\" the radiation dose onto it layer by layer.\nThey deposit the bulk of their cancer-fighting energy right at the tumor, thereby reducing the dose to cardiopulmonary structures, which impacts the toxicity, functional status, quality of life and even survival for patients, explained Chang.\nHealthy tissue surrounding the tumor is spared, and side effects are even more reduced than earlier proton delivery, said Chang.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There is no mention of funding or conflicts of interest in this release.", "answer": 0}, {"article": "A number of new multiple-sclerosis medications are beginning to hit the market that promise to make it easier for patients to control flare-ups of the disease and slow its progression.\n\nThe drugs, designed to be taken orally, represent a new generation of treatment for MS. Currently, people with the disease can choose from a range of drugs that are administered by injection.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We get three different physicians from New York University, Mayo Clinic and the MS Society. No conflicts are reported. In future stories, it is always better to state whether a patient who comments is someone whom the drug company provided to the reporter or whether he/she was independent of that. This story gives us a patient but does not explain whether she has ties to Novartis \u2013 makers of Gilenya.", "answer": 1}, {"article": "Feb. 1, 2010 -- Twelve weeks of fish oil pills made teens at high risk of psychosis much less likely to become psychotic for at least one year.\nIt may be that fish oil works better in young people with pre-psychotic conditions than in older people with more established psychiatric disorders.\nThe study suggests that to prevent one case of psychosis, four high-risk young people must be treated.\nThe finding comes from a placebo-controlled clinical trial that enrolled 81 young people -- average age 16 -- teetering on the brink of psychosis.\nThis happened to only two of 41 teens who began the year with 12 weeks of fish oil capsules rich in omega-3 fatty acids.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not include commentary from any independent sources. \u00a0Furthermore, the quote provided by the study authors was pulled directly from the discussion section of the article. ", "answer": 0}, {"article": "Rose Cooper, a microbiologist and honey expert at the University of Wales Institute at Cardiff, remains cautiously optimistic that the increased use of honey dressings will help better information to emerge.\nFrom the time of the ancient Sumerians, who prescribed a mix of river dust and honey for ailing eyes, until the early 20th century, honey was a conventional therapy in fighting infection, but its popularity waned with the advent in the mid-20th century of a potent, naturally occurring antibiotic: the blue-green mold penicillin.\nThe company, which has been developing manuka products since 2005, buys medical-grade honey from Comvita, which receives unprocessed honey from beekeepers in New Zealand.\nOn average, the report said, \"research and development of anti-infective drugs takes 10 to 20 years.\"\nIn 2000, a World Health Organization report warned: \"Since 1970, no new classes of antibacterials have been developed to combat infectious diseases.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although the story quotes multiple researchers, they were all involved in honey research in one way or another. The story should have quoted other, independent researchers/experts (perhaps with infectious disease expertise) who were not related to the research.", "answer": 0}, {"article": "For older people who fracture a hip, the prognosis is grim: a third or more die within a year and only about 1 in 5 return to their pre-injury level of function.\n\nA new approach to care could mean it doesn\u2019t have to be that way.\n\nMore hospitals are putting hip fracture patients on a fast track from the emergency room to the operating room,...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two experts involved with research, but also one more who appears independent of it, as well as a patient.\u00a0There also appear to be no notable conflicts of interest.", "answer": 1}, {"article": "\u201cLike most studies, it probably raises more questions than it answers.\u201d\n\nIn the U.S., kids aged 9 to 13 should get a total of 300 micrograms of folate a day from food and supplements according to the Institute of Medicine\u2019s \u201cDietary Reference Intakes.\u201d Kids 14 and older and adults are urged to get 400 micrograms a day and pregnant women should get 600 micrograms.\nMost of the population is thought to get adequate amounts for that reason.\nFolic acid is naturally present in green, leafy vegetables and legumes.\nThe differences remained even after the researchers accounted for gender, smoking, the mothers\u2019 education and which schools the kids went to.\nBecause a lack of the nutrient during pregnancy can cause severe birth defects in babies, certain foods are fortified with folic acid, also called folate, in North America.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included quotes from independent sources who helped provide context and perspective on the study and its results.", "answer": 1}, {"article": "The study started in August 2010.\nThe high efficacy is in line with the results of the ZOE-50 trial, a study in people over 50 years old which was presented and published last year showing a 97% efficacy (95% confidence interval: 93-99%)2.\nIn addition to older adults, the candidate vaccine is being evaluated in immunocompromised patient populations, including solid and haematological cancer patients, haematopoietic stem cell and renal transplant recipients and HIV-infected people.\nComplications from shingles can include PHN, (the most common complication), scarring, vision complications, secondary infection and nerve palsies3,4.PHN is often defined as a localized pain of significant intensity persisting at least 90 days after the appearance of the acute shingles rash4.\nDr Emmanuel Hanon, Senior Vice President, Vaccines Research and Development, GSK, said: \"This is the first time that such high efficacy has been demonstrated in a vaccine candidate for older people and it is remarkable, as we know that these people frequently have an age-related weakening of their immune system.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release was issued by GSK so it\u2019s assumed that GSK provided the funding for the study.\nThe release makes no mention of numerous potential conflicts of interest between the many researchers involved in the study and GSK. These include holding GSK stock, employment with GSK, serving on a GSK board, grant support, lecture fees, consulting fees, travel fees, honoraria, and royalties from a zoster vaccine patent. ", "answer": 0}, {"article": "She bases this bold claim on her experience with seriously obese patients and a detailed analysis of the best studies yet done showing weight-loss surgery\u2019s ability to reverse the often devastating effects of being extremely overweight on health and quality of life.\n\u201cI haven\u2019t come across a patient yet who wouldn\u2019t recommend it,\u201d Dr. Twells said in an interview.\n\u201cThese patients have lost hundreds of pounds over and over again,\u201d Dr. Twells said.\nIn reviewing studies that followed patients for five to 25 years after weight-loss surgery, Dr. Twells and colleagues found major long-lasting benefits to the patients\u2019 health and quality of life.\n\u201cBariatric surgery is probably the most effective intervention we have in health care,\u201d says Laurie K. Twells, a clinical epidemiologist at Memorial University of Newfoundland.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "All of the sources in the piece are the authors of published papers discussed in the story, though one of the sources is the author of an \u201cinvited commentary,\u201d rather than a study.\nAlso,\u00a0at least one of the sources in this story also had potential conflicts of interest that weren\u2019t disclosed:\u00a0Dr. Stacy Brethauer has worked as a speaker or consultant for several companies that provide products for bariatric surgery.", "answer": 0}, {"article": "To take a trial that involves people at high risk for lung cancer and to extrapolate it and say it\u2019s good for people with intermediate or low risk is not appropriate.\u201d\n\nThe study, called the National Lung Screening Trial, focused on a specific high-risk group: 53,000 current and former heavy smokers, aged 55 to 74, who had smoked for at least 30 pack-years.\n\u201cWe really need to weigh the harms associated with screening,\u201d he said.\n\u201cShe\u2019s the poster person for this test,\u201d he said.\n\u201cA lot of people run out when there is a new announcement and get the new test.\n\u201cIt was sort of ominous to be working Sunday evening in my home office and this thing comes on the radio,\u201d he said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Good sourcing \u2013 including quotes from one who promotes the scans and the study findings and from two who have concerns and are skeptical or worried about the impact.", "answer": 1}, {"article": "Drug list (formulary): To see a list of covered drugs for the plan you\u2019re considering, use the drop-down menus below.\n\nIf your employer is offering coverage, contact HR for the pharmacy plan name.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Journalist notes that the study was \nfunded by Novartis, maker of Femara, and that many of the researchers own stock in this company or in companies for rival \ndrugs. ", "answer": 1}, {"article": "TUESDAY, March 20, 2018 (HealthDay News) -- Tiny pellets could treat arthritic knee pain, delaying the need for knee replacement surgery, a small study has found.\n\"This therapy is very well-targeted to that particular mechanism, and certainly it should be investigated further,\" said Vedantham, who wasn't involved with the study.\nThe small pilot study -- the first U.S. clinical trial of this procedure -- involved 20 patients with moderate to severe arthritis pain.\nOnly 13 had undergone the procedure by the time of Monday's annual meeting, and only eight had made it to the one-month follow-up, Bagla said.\n\"Patients overall were able to improve their physical function in the knee after the procedure, and there were no adverse events related to this treatment,\" said lead researcher Dr. Sandeep Bagla.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story stated that Boston Scientific, maker of the microparticles, funded the study.\nIt also had one independent source, Suresh Vedantham, MD, a professor of radiology and surgery at the Mallinckrodt Institute of Radiology at Washington University in St. Louis. We did not detect any conflicts of interest.", "answer": 1}, {"article": "Researchers Say Common Test For Prostate Cancer May Not Work\n\nMore bad news on the prostate cancer front: A widely used test that's supposed to help doctors and patients predict the outcome of most prostate cancers is basically worthless.\nIt relies on certain signs doctors use to classify how advanced an individual patient's cancer is \u2013 that is, what stage it's in.\nOnce this is sorted out, doctors treating prostate cancer will be less like the blind men who try to guess what kind of creature they're dealing with when they grasp the elephant's trunk or tail.\nThat's according to a study just published in the journal CANCER.\nDr. Gerald Andriole of Washington University, who was not involved in the study, told Shots he wasn't surprised by the results.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An expert in this field without ties to the study reported on was quoted in this story.", "answer": 1}, {"article": "Editor's note: Tune in as Dr. Sanjay Gupta explores the signs, tests and lifestyle changes that could make cardiac problems a thing of the past on \"The Last Heart Attack,\" Saturday, August 27, 8 and 11 p.m.\nTo put the diet to the real-world test, participants received a one-hour counseling session with a dietitian and an illustrated study booklet at the outset and, later, received a 30-40 minute follow up session.\n\"The question one had to address was how does this play out with people in the real world,\" Jenkins said in a telephone interview.\nIn addition to the soy protein, nuts and whole grains, participants in the diet were encouraged to eat peas, beans and lentils.\nA control group advised to eat a vegetarian, low-saturated diet but not with the cholesterol-lowering foods a saw a slight dip in total cholesterol, from 249 to 246, and in LDL, from 167 to 161.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes the lead author of the study, but includes no truly independent\u00a0perspectives. It also does not disclose that many of the study authors have ties to organizations (e.g. Unilever) that might benefit from wider adoption of this diet.", "answer": 0}, {"article": "\u201cAlthough the randomized controlled trial is the gold-standard methodology in comparing between conditions,\u201d said Thomas G. Brown, an assistant professor of psychiatry at McGill University, \u201cit washes out a factor that may be important in potentiating A.A.\u2019s benefits, namely patient choice and preference.\u201d In other words, having a patient choose the form of treatment, rather than being assigned to it as in most studies, could be an important factor.\nThe paper was published last week in The Cochrane Library, a journal devoted to systematic reviews of health care interventions.\nNone of the studies compared A.A. with no treatment at all, and the researchers said that made it more difficult to draw conclusions about effectiveness.\nBut Sarah Zemore, of the Alcohol Research Group of the National Alcohol Research Center, said studies that observed the results of a treatment without setting up randomized control groups could also be informative.\n\u201cSome of the wisdom embodied in A.A., such as the notion of persons, places and things that trigger drinking, are very much a part of cognitive-behavioral therapy, which is a scientifically driven, empirically validated treatment,\u201d Dr. Nunes said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does an excellent job of putting the results of this study in perspective by interviewing experts in the field of addiction treatment and research. ", "answer": 1}, {"article": "Nine rode exercise bikes in a gym to compare the sweat patches\u2019 performance with the decidedly lower-tech method of sweat-testing used today \u2014 taping on absorbent pads and carting the resulting wet samples to a laboratory.\nBy simply looking at a color change, \u201csuch a patch allows people to now have an opportunity to understand their health and how it changes depending on activities.\u201d\n\nIt\u2019s a growing field: Other research groups around the country, including some of Bao\u2019s colleagues, are pursuing wearable biosensors.\n\u201cSweat has biochemical components within it that tell us a lot about physiological health,\u201d said John A. Rogers, who directs Northwestern University\u2019s Center for Bio-Integrated Electronics and led the new research.\nBut eventually with additional research, Rogers envisions more sophisticated use of such devices, such as real-time monitoring of how the body adjusts during military training, or even to screen people for diseases such as diabetes or cystic fibrosis.\nFor simple fitness purposes, it could give an early warning that it\u2019s time to replenish electrolytes before someone starts to feel dehydrated.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes\u00a0an independent source, a researcher who also works in developing biomedical materials. However, there are no medical experts who could comment on how well this technology might work in clinical or athletic settings.\nAnd, the story does not mention that three of the authors are inventors on a patent application that covers \u201cdevices and related methods for epidermal characterization of biofluids.\u201d Nor does it state that two authors are officers and co-founders of MC10, a company that develops wearable, stretchable electronics. Three other researchers are affiliated with cosmetics firm L\u2019Oreal, which began marketing a stretchable patch for UV monitoring this year. L\u2019Oreal was also among the funders of this study.", "answer": 0}, {"article": "The study was funded by the Veterans Health Administration's Health Services Research and Development Service\nThe newly published study did show that one in five veterans randomly assigned to ImPAT or the comparison approach did not actually attend any sessions - likely because of delays in getting the sessions going.\nAll 129 patients in the study, most of them men in their 40s and 50s, were receiving outpatient addiction treatment in a CBT-based, non-abstinence setting at the Ann Arbor VA. Half were randomly assigned to ImPAT sessions, the other half to support groups of peers, led by a therapist, where pain and addiction could be discussed.\nThe sharp rise in opioid addiction in recent years - often among people who started taking the painkillers as treatment for acute or chronic pain -- has made the search for effective non-drug pain treatment options even more urgent, Ilgen notes.\nAnd the study's authors note that the ImPAT approach has the potential to be easily and inexpensively adopted by addiction treatment centers and groups worldwide, through team members trained in standard psychological techniques.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding source is clearly identified. And while the release does not address conflicts of interest, there do not appear to be any conflicts of interest to address.", "answer": 1}, {"article": "In more than 22% of cases, implantable defibrillators are given to heart patients who don\u2019t meet the guidelines for receiving the pricey devices, according to a study just published in JAMA.\n\nThe research, based on 111,707 cases submitted to a national registry over a three-and-a-half-year period, also finds that those patients who didn\u2019t meet the guidelines had a higher risk of dying in the hospital and of complications from the implantation.\n\nICDs, which can cost north of $30,000, monitor the rhythm of the \u2026", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We spent some time on the fence here, but we were ultimately willing to give the story the benefit of the doubt. The blog calls out a link to a much more complete Wall Street Journal story about the study, and it says, \u201cRead the WSJ story to get perspective from Medtronic and Boston Scientific.\u201d But it spends too much time quoting the lead author and does not quote anyone else. It does, however, provide information that was missing in the LA Times and other coverage. \u201cAuthors of the study reported receiving funding from Medtronic and other device- and drug makers.\u201d We thought that context, along with the link and a quote from statement from the Heart Rhythm Society were enough to pass this criteria. As with the LA Times story, though, we don\u2019t understand why the editorial accompanying the journal article wasn\u2019t cited.", "answer": 1}, {"article": "That's the tantalizing premise behind Deplin, a prescription form of the B-vitamin folate. Although it has been on the market since 2006, Deplin is generating growing buzz at psychiatric conferences and among clinicians and patients, particularly those who haven't responded to antidepressants or did for a while only to have their depression return.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Barely satisfactory. The story included comments from a number of sources, including a company-supported investigator, a representative of a mental health advocacy group, and non-affiliated clinicians. It also did a good job of disclosing relationships with Deplin maker Pamlab where necessary. What we wanted to see more of were comments specifically about the studies\u00a0supporting Deplin as a depression treatment. Most of the sources talk only about their clinical experience with the\u00a0supplement or the general concept of using it.\u00a0We\u2019d like to see a higher priority placed on analysis of the evidence\u00a0that Deplin\u00a0works. ", "answer": 1}, {"article": "Led by John Weeks (johnweeks-integrator.com), the Co-founder and past Executive Director of the Academic Collaborative for Integrative Health, JACM publishes controlled trials, observational studies, scientific reviews and leading commentary intended to help medical organizations and governmental organizations optimize the use of integrative products, practices, and practitioners in patient care and in delivery and payment strategies.\nThe study design and results, which suggest further controlled studies of this intervention approach in ASD, are published in the Journal of Alternative and Complementary Medicine (JACM), a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.\nIts biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide.\nIn the article entitled \"A Pilot Observational Study of an Acupressure/Acupuncture Intervention in Children with Autism Spectrum Disorder,\" most parents reported that the intervention had a positive impact on their relationship with their child.\nCoauthors Lana Warren, EdD, OT/L and Patricia Rao, PhD, Kennedy Krieger Institute, Baltimore, MD, and David Paton, DAc, LAc, Starting Point Acupuncture and Health Services, Catonsville, MD, identified the most positive outcome of the study as the high compliance rate, with all parents of the children ages 3-10 completing the intervention.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t mention who funded the work. In this case, the work was funded by Autism Speaks. Many people have strong feelings about Autism Speaks, one way or the other, making the funding organization particularly worth mentioning here. It also doesn\u2019t mention any conflicts of interest but there don\u2019t appear to be any.", "answer": 0}, {"article": "I thought this is so minimal, it\u2019s stupid.\u201d\n\nAfter a few weeks, she said she began to feel better, and after 12 weeks \u201cthe pain had diminished 90 percent.\u201d She has continued tai chi, lost 50 pounds and can walk three to seven miles a day.\n\u201cI wouldn\u2019t say it\u2019s a cure.\n\u201cThere was no joy to life,\u201d she said.\nIt\u2019s defined by what the patient tells you,\u201d he added.\n\u201cFibromyalgia is so common, and we have such a difficult time treating it effectively.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0Most of the quotes in the story are from people not affiliated with the study.", "answer": 1}, {"article": "\u201cThe goal is to develop a blood test, such as this one, that can accurately identify cancers in their earliest stages.\u201d\n\nKlein added: \u201cIt is several steps away and more research is needed, but it could be given to healthy adults of a certain age, such as those over 40, to see if they have early signs of cancer.\u201d\nThe test had particularly good results for ovarian and pancreatic cancers, though the number of cancers detected was small.\nThe test, called a liquid biopsy, screens for cancer by detecting tiny bits of DNA released by cancer cells into blood.\n\u201cNow, as the NHS marks its 70th anniversary, we stand on the cusp of a new era of personalised medicine that will dramatically transform care for cancer and for inherited and rare diseases,\u201d said Stevens.\nThe number of patients in whom cancers were detected was small.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story didn\u2019t disclose that the researchers had significant conflicts of interest. (See disclosures.)", "answer": 0}, {"article": "Genomic Health Inc. has struck a deal to commercialize a new blood test that can help advanced prostate cancer patients decide whether to try costly new-generation drugs or rely on much cheaper traditional chemotherapy to improve their chances for survival.\n\nThe test, developed by closely held Epic Sciences Inc., San Diego, detects a mutation associated with a poor response to two new drugs, Xtandi from Medivation Inc. and Astellas Pharma Inc. of Japan, and Zytiga from Johnson & Johnson.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent expert source is quoted throughout the story. This is problematic not least because representatives of both Epic Sciences and Genomic Health are quoted on the clinical utility of the test, and their claims need to be\u00a0validated or refuted by experts with no skin in the game.\u00a0It would also be important to get an independent take on the study itself, the strength of the evidence and\u00a0whether there were any limitations that should be highlighted.\nAdditionally, next to no information is given about conflicts of interest. While the lead author\u2019s affiliation is\u00a0given as Memorial Sloan-Kettering Cancer Center, the majority of co-authors of the study are employees of Epic Sciences. This surely warrants a mention so readers are not given the false impression that the company had no role in the study. Moreover, the lead author Howard Scher has received research funding, personal fees and non-financial support from all the companies behind\u00a0the prostate cancer drugs in question. Despite the fact that the blood test would theoretically identify patients who would be better off\u00a0not receiving the drugs, Scher has highly relevant conflicts of interest, thus increasing the need for independent expert sources.", "answer": 0}, {"article": "MRI uses a powerful magnetic field and pulses of radiowave energy to create images.\nThough that difference is well established among radiologists, the new study may be of assistance in the general medical community, including general cardiologists, because \"it summarizes the advantages of CT at this point in time,\" he said.\n\"This article holds no surprises whatever,\" said Dr. Uwe Joseph Schoepf, a professor of radiology and cardiology at the Medical University of South Carolina.\nDr. Ricardo Cury, director of cardiac MRI and CT at Baptist Cardiac & Vascular Institute in Miami and a consultant radiologist at Massachusetts General Hospital, said that the \"meta-analysis demonstrates a knowledge that we have accumulated for the past several years.\"\n\"For ruling out coronary artery disease, CT is more accurate than MRI,\" researchers from Humboldt University in Berlin said in a report in the Feb. 2 issue of the Annals of Internal Medicine.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does cite two independent sources who appeared unrelated to the study.\nThe story did not identify any potential conflicts of interest. While the study publication identifies no primary funding sources, the senior author, Marc Dewey,\u00a0reports in his conflict of interest statement financial relationships with\u00a0Toshiba Medical Devices, Bayer-Scherling, and Guerbet, companies that manufacture imaging devices or contrast media used with them. These relationships were disclosed by the medical journal when they published the study \u2013 yet the story makes no menton of them.", "answer": 0}, {"article": "Both Vertex\u2019s telaprevir and Merck\u2019s boceprevir block an enzyme known as protease that is made by the virus.\nThe standard therapy of interferon and ribavirin was given for either 24 weeks or 48 weeks, depending on how the patients were faring after four weeks and 12 weeks.\nSome 2.7 million to 3.9 million Americans are estimated to have hepatitis C, and 12,000 die from it each year, according to a recent report by the Institute of Medicine.\n\u201cThese data support the vision that we have long had for fundamentally changing the treatment for hepatitis C,\u201d Dr. Robert Kauffman, Vertex\u2019s chief medical officer, said in a conference call with securities analysts.\nBut experts hope that eventually several of the pills now in development could be used together, much as AIDS is treated, doing away with the need for interferon.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We would have liked to have seen independent voices inject more context into the story, but the reporter did at a minimum take these results to another legitimate researcher. The reporter also went to a patient advocacy group that, unfortunately, just spat out the standard \"we welcome any cure\" spiel.", "answer": 1}, {"article": "Follow us: facebook.com/mars, twitter.com/marsglobal, youtube.com/mars, linkedin.com/company/mars\n\nDaniela Mastroiacovo, Catherine Kwik-Uribe, Davide Grassi, Stefano Necozione, Angelo Raffaele, Luana Pistacchio, Roberta Righetti, Raffaella Bocale, Maria Carmela Lechiara, Carmine Marini, Claudio Ferri, and Giovambattista Desideri.\nDr. Desideri and his team are already thinking about the next steps: \"It is clear from our latest research and other recent studies that cocoa flavanols have profound effects on the body, and specifically the brain,\" said Desideri.\nThe high- and intermediate-flavanol cocoa drinks were produced using Mars' patented Cocoapro\u00ae process, while the low-flavanol drink was made with a highly processed, alkalized cocoa powder.\nDr. Giovambattista Desideri, lead author on the paper, said, \"The results of this study are encouraging--they support the idea that diet, and specifically a diet rich in cocoa flavanols, can play an important role in maintaining cognitive health as we age.\"\nDr. Catherine Kwik-Uribe, human health and nutrition director at Mars, Incorporated, and co-author on this latest study, said, \"Since the brain is a heavily vascularized tissue, we might also be looking at vascular improvements as underlying the observed improvements in cognitive function.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release was issued by Mars Inc., and it says high up, \u201cThis study, conducted by researchers from Italy\u2019s University of L\u2019Aquila and Mars, Incorporated\u201d. While the release references Mars throughout, and we don\u2019t think any reporter would be confused about who was behind the study, the release could have stated directly that Mars funded the study.", "answer": 1}, {"article": "[11]\n\nEVZIO (naloxone HCl injection) Auto-injector is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.\nAdditionally, there are nearly two times the number of prescription opioid-related deaths as compared to heroin-related deaths.1 On average, 3,300 children five years old and younger are admitted to emergency departments each year due to accidental opioid exposure.\nRICHMOND, Va., March 29, 2016 /PRNewswire/ -- kal\u00e9o, a privately-held pharmaceutical company, today announced that EVZIO\u00ae (naloxone HCl injection) Auto-injectors have been reported to help save more than 1000 lives.\nThe following warnings and precautions should be taken when administering EVZIO:\n\u2022 Due to the duration of action, keep the patient under continued surveillance and repeated doses of naloxone should be administered, as necessary, while awaiting emergency medical assistance.\nOn average, 79 people die from opioids, including prescription opioid analgesics and heroin, everyday in the United States; most occur outside of medical settings, such as in a home.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "If a news release is going to quote the president and CEO of the company that makes the drug, readers can assume he has a financial interest in his statements.\nBut they are left to wonder about the quotes from health professionals. It might have been a good idea to point out whether they, too, have a financial stake in their statements. If they do not, letting the reader know that might have made their statements appear more persuasive.\nBut since we don\u2019t have specific evidence of a conflict of interest among any of the quoted sources, we\u2019ll rate this Satisfactory.", "answer": 1}, {"article": "The result makes sense, since there's some previous evidence suggesting that higher-intensity exercise is tied to improving how the body processes sugar, said Neal Pire, an exercise physiologist who puts together medically based training programs at HNH Fitness in Oradell, N.J., a program of Holy Name Medical Center.\nAt the end of the study, members of all three exercise groups lost an average of about 2 inches from their waist circumference.\nAll the participants were told to keep a food diary and to eat a healthful diet but to keep their calorie intake constant.\nStrength training can also improve glucose tolerance, which is why it's part of the government guidelines, he told Shots.\nNow we have some answers: You may want to go just a tad longer and harder than you'd thought.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an exercise expert who was not affiliated with the study. He provides some useful context on the value of strength training.", "answer": 1}, {"article": "FDA approves first drug aimed at women with inherited breast cancer\n\nU.S. regulators have approved the first drug aimed at women with advanced breast cancer caused by an inherited flawed gene.\n\nThe Food and Drug Administration on Friday approved AstraZeneca PLC\u2019s Lynparza for patients with inherited BRCA gene mutations who have undergone chemotherapy.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not contain any independent sources. Also, it quotes Dr. Susan M. Domchek at the University of Pennsylvania\u2019s Abramson Cancer Center without stating her institution\u2019s role in the clinical trial.", "answer": 0}, {"article": "Newswise \u2014 Faced with the negative quality-of-life effects from surgery and radiation treatments for prostate cancer, low risk patients may instead want to consider active surveillance with their physician, according to a study released Tuesday by the Journal of the American Medical Association (JAMA).\nThe authors also reported that:\n\n- Surgery was associated with fewer urinary irritative symptoms, like weak urine stream or urinary frequency, compared to active surveillance.\n\u201cThis study shows that, despite technological advances in the treatment of prostate cancer, both surgery and radiation still have a negative effect on quality of life,\u201d said co-author David Penson, M.D., MPH, Paul V. Hamilton, M.D., and Virginia E. Howd Professor of Urologic Oncology and professor and chair of the Department of Urologic Surgery.\nSurgery is considered by some to be the most definitive treatment, and there is evidence from other studies that it has better long-term cancer outcomes than radiation for higher-risk cancers, but it has more sexual and urinary side effects than radiation.\n\u201cUrinary incontinence was reported as a moderate or big problem in 14 percent of men three years after surgery compared to 5 percent of men who had radiation,\u201d Barocas said.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release names the grant sources for the research. It would have been better if the release had also stated (as the study did) that there were no conflicts of interest among the authors.", "answer": 1}, {"article": "The study, conducted at the University of Texas M.D.\nPrevious research into diet and breast cancer has shown mixed results, but the authors of this study said the earlier ones were not rigorous.\nThe study focused on more than 3,000 women \u2014 average age 53 \u2014 who had been treated successfully for early-stage breast cancer.\n\"I went into the study expecting to see a difference between the two groups,\" he said.\nCancer recurred in 17 percent of women in the study, regardless of whether they were in the five-serving or nine-serving group.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story included comments from two of the study\u2019s authors but failed to get any independent perspective. ", "answer": 0}, {"article": "Until more research is in, what should a woman with a personal history of breast cancer do?\nWith the MRI screen, \"we found cancer in just over 3 percent of women [with a personal history], which was double [that found in those with a genetic or family history],\" she said.\nMONDAY, Nov. 29, 2010 (HealthDay News) -- Women who have had breast cancer should consider annual screening with breast MRI in addition to an annual mammogram, new research indicates.\n\"The findings are impressive,\" said Dr. Robert Smith, director of cancer screening for the American Cancer Society.\nCurrently, the American Cancer Society recommends annual breast MRI plus mammography for women at very high risk for breast cancer, such as those with a known genetic mutation known as BRCA or those with a very strong family history.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\nThis story does include an independent source. However, it fails to report that the senior researcher involved with this study disclosed that she is a consultant to a manufacturer of MRI scanners and that another researcher has received grant support from the MRI scanner company.\nReference:\nMeeting abstract disclosures \nhttp://rsna2010.rsna.org/program/event_display.cfm?em_id=9006996", "answer": 0}, {"article": "The all-Achillion regimen could hit the U.S. market by 2020 in a conservative scenario, Deutsche Bank\u2019s Alethia Young estimated.\nThe main goal is to achieve a cure, or sustained virological response, 12 weeks after the completion of therapy.\nThe new-generation hepatitis C regimens use a two- to three-drug combination \u2013 a nucleotide analog inhibitor or \u201cnuke\u201d and a NS5A inhibitor in Gilead\u2019s case \u2013 to achieves a cure in about eight to 12 weeks, making them faster and more effective than older treatment options.\nLaunched in October, its sales touched $2.11 billion in the quarter ended Dec. 31.\nGilead\u2019s regimen Harvoni, with its own NS5A inhibitor and Sovaldi as the \u201cnuke\u201d, needs to be taken for at least eight weeks.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Even though this is a business story focused on the market prospects for the drug, the actual efficacy of the drug is key. To that end, an independent expert in hepatitis would have been a welcome addition.", "answer": 0}, {"article": "Where did this Ron DeSantis come from? Florida\u0092s governor surprises everyone but himself.\n\nA month into his term, Gov. Ron DeSantis has shattered assumptions that he would govern exclusively from the right. He has drawn unexpected praise from Republicans and Democrats.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included quotes from a number of physicians involved in the treatment of liver disease and liver transplantation as well as quotes from two mothers of patients and one patient himself.\nThe story would have benefited from having a clinician who would have summarized the big picture for readers.\u00a0", "answer": 1}, {"article": "\"Is it possible with cosmetic use?\nA big reason Botox and its cousins, such as Myobloc, were OK'd was that preclinical testing showed that after being injected, they did not travel along the body's highways\u2014nerve cells\u2014to the brain and spinal cord.\nThe reason countless lab animals have given their lives during the testing of experimental drugs is to allow manufacturers and regulators to see that a compound might be toxic, even deadly, before millions of people use it.\nThat stands in contrast to the findings of earlier studies, which suggested that the neurotoxin is completely broken down at the injection site into innocuous compounds and does not migrate beyond it\u2014or if it does, only into the bloodstream or lymph system.\nThe FDA didn't do much in response, but since then it has been getting new reports of serious adverse reactions in people receiving Botox, and launched a safety review.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included interview material with the author of the rodent study and an excerpt from a comment made by a company spokesperson. \u00a0It should have included comments from independent experts about medical use of botulinum toxin in peple to provide insight into what the compound does, how it works, and the concerns about its use.\u00a0", "answer": 0}, {"article": "UnitedHealthcare's medical policy for TMS says it is unproven for treating depression.\n\"Generally speaking, just because a device, procedure or medication has been approved or is deemed to be safe by some entities does not mean that it is automatically covered,\" BlueCross BlueShield spokeswoman Kelly Allen said.\n\"We had several patients who were headed toward the hospital, who had this treatment and were able to avoid that,\" said Dr. Scott West, a psychiatrist who pioneered the treatment in Nashville 2 and one-half years ago.\n\"I have a room in my house in which I had stacked boxes from when we moved 10 years ago that I wanted to get to, but I couldn't do it,\" the Centerville woman said.\n\"When this large magnet pulses repetitively, it causes an electromagnetic field which then passes through the skull and stimulates the brain tissue itself,\" said West, explaining a cascading effect that results in the interior nerve fibers connecting better.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Besides the glowing comments by a psychiatrist who uses the device and the originator, we do have a comment from a spokesperson from an insurance company who does not as yet provide coverage. Given the controversy in this 15 year old technology, we would have liked to have seen comments from an expert in the field.", "answer": 0}, {"article": "The U.S. Food and Drug Administration today approved Trulance (plecanatide) for the treatment of Chronic Idiopathic Constipation (CIC) in adult patients.\nThe agency also is responsible for the safety and security of our nation\u2019s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\n\u201cNo one medication works for all patients suffering from chronic gastrointestinal disorders,\u201d said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA\u2019s Center for Drug Evaluation and Research.\nParticipants were randomly assigned to receive a placebo or Trulance, once daily.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Although the release notes that Synergy Pharmaceuticals Inc. makes the new drug, it does not say where the clinical trial results were published or what groups supported or carried out the research.", "answer": 0}, {"article": "The subjects were divided into two groups.\nIn fact, most people try 8 to 10 times and this includes quit attempts with standard cessation medications like nicotine patch and gum and prescription drugs like varenicline,\" said Alan Levy, Ph.D., chairman and CEO of Chrono Therapeutics.\nFor example, 75% of all smokers reach for their first cigarette within 30 minutes of waking up.\nThe clinical trial was a randomized, double blinded study of 24 adult males who smoked 11 or more cigarettes per day, indicating a high level of nicotine dependence.\n\"Achieving statistical significance in a 24-subject trial is very striking and happens infrequently in biopharma; so these results are very encouraging,\" noted Wende Hutton, general partner at Canaan Partners and a member of Chrono's board of directors.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Although the news release is fairly clear that Chronos Therapeutics is the main funder of the clinical trial, it fails to mention that the company had received a study grant from the National Institutes of Health. That\u2019s noted on the study abstract. Further, the release quotes only company executives \u2014 the CEO and a member of the board of directors. While we don\u2019t expect a news release to consult an independent source as we would a news story, we\u2019d like to point out that typically, a scientist involved with the research lends more credibility when reporting results.", "answer": 0}, {"article": "They note that as neither treatment completely relieved pain, more research is needed into effective pain relief, especially for more severe pain.\n\"Morphine did not provide superior analgesia, but was associated with significantly more adverse effects, making ibuprofen a better analgesic option,\" write the authors.\nThe study included 154 children aged 5 to 17 years who underwent minor orthopedic surgery, such as keyhole surgery on joints, ligament and tendon repair, suture or hardware removal at London Health Sciences Centre in London, Ontario.\nPain scores for children in both the oral morphine and ibuprofen groups were similar, but the children receiving oral morphine reported more adverse effects, such as nausea, vomiting, drowsiness, dizziness and constipation.\n\"Oral morphine versus ibuprofen administered at home for postoperative orthopedic pain in children: a randomized controlled trial\" is published October 10, 2017.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "On EurekAlert!, where the release is hosted, it\u2019s noted that the research was funded by Western University. We encourage news releases to include funders in the body of the release as well. The original study reports no conflict of interest.", "answer": 1}, {"article": "If a pill could prevent teenagers from taking dangerous risks, would you consider it for your children?\n\nI\u2019d be tempted. My skateboard- and bicycle-riding son was hit by a car\u2014twice\u2014when he was a teenager. I would have welcomed anything that could have averted those dreadful phone calls from the emergency room.\n\nWhile some bumps and scares...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources in the piece, which straddles the line between commentary and news. We found it in the health section where it wasn\u2019t labeled as opinion and the headline reads like a straight news story. But some first-person passages make one wonder if it\u2019s more of an opinion piece.\nRegardless, we would have liked to have seen at least some references to work outside of this one study, since the claim being made is\u00a0significant, while the evidence being given for the claim\u00a0is less so. We want to know: What kind of evidence is required before pediatricians can feel confident saying \u201ctreating ADHD will not only\u00a0take care of\u00a0immediate behaviors, it will create safer behavior as your child grows?\u201d", "answer": 0}, {"article": "Quantity surveyor Alex Laws was part of the Newcastle University clinical trial and is delighted with the results of the study.\n\"The results, which indicate that metformin, a drug commonly used in the treatment of Type 2 diabetes, could also have a powerful effect in people with Type 1 diabetes is unexpected.\nAlex said: \"I was keen to be part of the clinical trial as I know how important research is into helping people with the condition - I previously worked in the medical research field.\nHowever, for the first time, a clinical trial has revealed metformin can promote a patient's ability to repair their own damaged blood vessels by increasing vascular stem cells.\n\"For the first time, this study has shown metformin has additional benefit beyond improving diabetes control when given to patients with relatively well controlled Type 1 diabetes.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release mentions that the study was funded by the Diabetes Research and Wellness Foundation and the Diabetes Research Fund in Gateshead. Neither the news release or published study address potential conflicts of interest. The funding foundation lists only its board of directors and no background information on the group is readily available.", "answer": 1}, {"article": "You've seen high-definition televisions. Now some medical centers are marketing their high-definitioncolonoscopes, which they say will detect more pre-cancerous polyps. Several recent studies have found a small benefit to high-definition colonoscopy over the standard variety, but gastroenterologists say physician technique is more important in detecting polyps than equipment.\n\nColonoscopy, a screening test doctors recommend for most people starting at age 50, allows doctors to remove pre-cancerous growths before they become...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Great job in identifying and calling out conflicts. There is one independent source in the story and more would have been nice. At the same time, though, the reporter pulled together so much good, well balanced information that the independent voices were not as missed as they often are in stories like this.", "answer": 1}, {"article": "For more information, visit http://www.\n\"Treating pregnant women who have influenza with antiviral drugs can have substantial benefit in terms of reducing length of stay in the hospital,\" said Sandra S. Chaves, MD, MSc, of the Centers for Disease Control and Prevention (CDC) and senior author of the study.\nEditor's Note: The study authors' and editorial commentary authors' affiliations, acknowledgments, and disclosures of financial support and potential conflicts of interests are available in the study and the commentary, which are embargoed until 12:01 a.m. EST on Thursday, Feb. 4.\nThe current study, based on data from a nationwide flu surveillance network including 14 states, focused on pregnant women hospitalized with laboratory-confirmed flu over four recent flu seasons, from 2010 to 2014.\nFor expectant mothers hospitalized with flu, early treatment with the influenza antiviral drug oseltamivir may shorten their time in the hospital, especially in severe cases, suggests a new study published in The Journal of Infectious Diseases and available online.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t articulate funding sources or conflicts of interest. We have to assume the study was sponsored by the CDC because the lead author quoted works there. We are sometimes surprised when a news release fails to mention that there were no conflicts of interest. This is important information, and can only improve one\u2019s perception of the research. Why not mention it? When we looked at the published study we read that the study authors have no conflicts to declare.", "answer": 0}, {"article": "Marban and colleagues developed a technique in which they loaded cardiac stem cells with microscopic bits of iron.\n\"Once injected into a patient's artery, many stem cells are lost due to the combination of tissue blood flow, which can wash out stem cells, and cardiac contraction, which can squeeze out stem cells.\nThe strategy appears to make it more likely that the heart will retain the cells, potentially boosting the power of cardiac stem cell therapy.\n\"This remarkably simple method could easily be coupled with current stem cell treatments to enhance their effectiveness.\"\nWe needed to find a way to guide more of the cells directly to the area of the heart that we want to heal.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The source is a medical center news release. And the quotes, from that news release, are from a researcher who is \"founder of a company that has filed patents for the techniques,\" according to the story.\u00a0 So, while, that conflict was disclosed, there is no independent perspective in the story. That\u2019s unsatisfactory in our view.\u00a0 \n\u00a0", "answer": 0}, {"article": "The website for LipoFuze says that the supplement \"increases the metabolic mechanism in your body.\" The site also says the green tea and caffeine will \"rev up your metabolism\" and \"increase energy, focus and physical performance.\" The site features testimonials it says are from users who claim they have lost huge amounts of weight with the help of LipoFuze. One man says he dropped more than 100 pounds, although it's unclear how long that took. A woman says she lost 40 pounds in less than a year, including 20 pounds in her first month.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two independent sources were quoted for context and synthesis of the literature.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061210/18vitamin.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Three researchers with interest in vitamin D were cited as was one researcher who was involved in one of the articles discussed in the story.", "answer": 1}, {"article": "STOCKHOLM (Reuters) - Giving patients with a history of heart attacks a margarine enriched with omega-3 oils in addition to standard drugs appears to make no difference to their chances of having a repeat attack.\nThe margarines used in the study were developed for the researchers by food and consumer goods giant Unilever.\n\u201cWe found the cardiovascular mortality rate in the study population was only half that expected, probably because of their excellent treatment,\u201d he said.\nThe finding raised questions about the benefits of omega-3, which has been shown in previous studies to make for healthier hearts.\nDiabetes patients also showed a possible benefit.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0The story included quotes from one of the authors of the study and a clinician who was not connected with the study.", "answer": 1}, {"article": "\u201cThe decreased risk of breast cancer in this group is something we totally didn\u2019t expect when we started the W.H.I.\nBut the risks of estrogen use were pronounced in older women.\nThe most surprising new finding relates to breast cancer.\nAlthough all the women in the estrogen study stopped using the treatment in 2004, the investigators have continued to monitor their health, as is typical in large clinical trials.\nThe women with hysterectomies who used estrogen alone had a 23 percent lower risk for breast cancer compared with those who had taken a placebo.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story benefits from direct interviews with sources holding different perspectives.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - The inexpensive tests that look for hidden blood in a person\u2019s stool are effective for colon cancer screening, a study out Tuesday confirms.\nA newer version called immunochemical FOBT (iFOBT) is supposed to zero in on colon growths better than an older version known as guaiac FOBT \u2014 which often picked up bleeding originating in the upper digestive tract, such as from a stomach ulcer.\nAnd they can pick from a number of tests that have all been found to cut the risk of dying from colon cancer.\nMore than 50,000 Americans died of the disease in 2010.\n\u201cIt means that almost every case with colon cancer can be identified by iFOBT,\u201d Lee told Reuters Health in an email.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We wish the story had included an interview with a US screening expert or a member of the US Preventive Services Task Force.", "answer": 0}, {"article": "\u2022 The sensitivity of C-Tb was comparable to the IGRA in confirmed TB cases (77 percent vs. 81 percent), indicating similar abilities to detect infection.\nC-Tb combines the field friendliness of the PPD-based Tuberculin Skin Test (TST), with the high specificity of the interferon gamma release assays (IGRA).\nThe TESEC-06 trial included 979 participants from 13 clinical trial sites in Catalonia, Galicia and Basque Country (Spain) with various risk profiles of M.tuberculosis infection.\nThese phase III trial results demonstrate that C-Tb is safe, has comparable diagnostic performance to QFT-GIT and addresses the problem of false positive TST results in BCG vaccinated persons.\nThe study, conducted in South Africa, enrolled 1,090 participants, including 299 patients with HIV and 402 children as young as 28 days.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Unfortunately, the release offers no information on either funding sources for these trials or on any possible conflicts of interest that might affect the researchers.", "answer": 0}, {"article": "(Editing by Jon Loades-Carter)\n\u201cIt demonstrated that the drug has an effect on the pathological hallmark of Alzheimer\u2019s disease,\u201d lead researcher Juha Rinne from Finland\u2019s University of Turku told Reuters.\nCommenting on the results, Sam Gandy from New York\u2019s Mount Sinai School of Medicine said it was too early to say effective disease-modifying drugs were at hand, but the ability to measure plaque in living subjects was \u201csomething of a breakthrough\u201d.\nBapineuzumab \u2014 being developed by Pfizer Inc (PFE.N), Irish drugmaker Elan Corp ELN.I and Johnson & Johnson (JNJ.N) \u2014 is a potential game-changer because it could be the first drug to treat the underlying cause of the degenerative brain disease.\nInvestor confidence in the antibody medicine, however, took a big hit in July 2008 when it failed to meet its main goal in a mid-stage trial and caused brain swelling at higher doses.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0The story included a quote attributed to Sam Gandy at New York\u2019s Mount Sinai School of Medicine without explaining what expertise he might bring. \u00a0Nonetheless, he was enthusiastic about the potential benefit from the measurement technique the study used. \u00a0And though the story was focused on an Alzheimer\u2019s treatment, he mentioned that it\u2019s too early to say anything about effectiveness to treating Alzheimer\u2019s disease.\u00a0 \nThe story did report that the study was funded by the manufacturer of the drug being studied.", "answer": 1}, {"article": "Studies in 2007 and 2008 suggested that stented arteries faced a higher risk of blood clots, potentially triggering heart attack a year or more down the road.\nExperts describe Abbott's device as an important step in finding a better approach to treating the leading cause of death in the U.S.\n\n\"This is presumably a better technology going forward, at least that's the theory, but it will take years to prove,\" said Dr. George Vetrovec, professor emeritus at Virginia Commonwealth University.\n\"The key for the stent market will be whether pricing returns to rational levels and the success of the new bio-absorbable stent platforms,\" states Evercore ISI analyst Vijay Kumar, in an investment note.\nHe says a \"perfect storm of events,\" including safety concerns and the economic downturn led Abbott and competitors Medtronic Inc. and Boston Scientific Corp. to slash prices in recent years.\nThe Food and Drug Administration approved the device Tuesday for patients with coronary artery disease, the artery-narrowing condition that causes about 370,000 U.S. deaths each year, according to government figures.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Both of the sources\u2014one who conducted the research testing the stent and one who advised the FDA\u2014are clearly identified, as is Abbott Labs as the creator and presumed funder of the stent. A financial analyst is also included.\nThis is sufficient for a Satisfactory rating, though none of these sources represent the ideal of what we\u2019re looking for\u2013a medical expert who is independent of the research and the stent\u2019s FDA approval process.", "answer": 1}, {"article": "There\u2019s no reason why women should be caught unaware in the late stages of a pre-eclampsia\nWriting in the journal Hypertension, the researchers said they did a simple study, testing the blood of 60 women who developed pre-eclampsia later in pregnancy and 60 women who did not.\nThe cost of treating mothers with pre-eclampsia is $45 billion a year in the United States, Europe, Asia, Australia and New Zealand, the researchers said.\n\u201cA high caliber predictive test would allow women who are identified at high-risk for pre-eclampsia to seek obstetric care by specialists and to be monitored more vigilantly,\u201d Eleni Tsigas, executive director of the Pre-eclampsia Foundation, said in a statement.\n\u201cIf we can bring the rates of maternal deaths in undeveloped countries down to the rates in developed countries, by being able to determine which women are at the greatest risk for developing pre-eclampsia, then it has that potential to save thousands of lives,\u201d Baker said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article did include a comment from Eleni Tsigas, executive director of the Preeclampsia Foundation. A better source would have been another researcher, perhaps one of the many cited in the article. The article did not mention whether any of the researchers had conflicts of interest regarding the development of the diagnostic test. The study itself says the authors had no disclosures and reports the study to be entirely government funded. Given that at least one outside source was contacted and that there were no obvious conflicts to disclose, we give this one a pass.\n\u00a0\n", "answer": 1}, {"article": "\"I think we need to pause and think about whether the extra information [from CT scans] really helps us make a diagnosis,\" Smith-Bindman says.\nFor the same body part, the doses varied enormously from one hospital to another and even within the same hospital.\nInstead of an annual growth rate of 12 percent in CT scans, it's now about 1 percent, lower than the hospital's annual growth in patient load.\n\"Our experience over the last five years has been rather phenomenal,\" Thrall says.\nThat will require hospitals to feed dose data to a central computer run by the radiology group.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes multiple experts, including the authors of the study, the author of the accompanying editorial and a Radiologist who was not involved with the study.", "answer": 1}, {"article": "Provenge is the first so-called therapeutic cancer vaccine \u2013 meaning it works by training the patient\u2019s immune system to attack the tumor \u2013 to win F.D.A.\nWhile Medicare generally pays for drugs that are approved by the Food and Drug Administration, its debate over paying for Provenge has raised concerns among some cancer patients, doctors and investors who say the government is sending a warning shot that it will not automatically pay for high-priced medicines.\nSome analysts have assumed that Medicare will pay for Provenge when used for the patients specified in the drug\u2019s label \u2013 those with advanced prostate cancer that is resistant to hormone-deprivation therapy but who are experiencing no or minimal symptoms.\nThe review for Medicare said there was insufficient evidence to judge whether Provenge would work if used off-label.\nBut the analysis for Medicare said that there were issues in how the trials were designed that made it difficult to assess how effective Provenge really was.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\n\nAlthough the story uses excerpts of written statements from a financial analyst and the president of a cancer advocacy group, it does not include an independent source who addresses the scientific issues raised by the analysis of Provenge done for Medicare. The story does not tell readers that the cancer advocacy group it cites receives support from and promotes its services to health care corporations, including pharmaceutical companies.\n", "answer": 0}, {"article": "Researchers analyzed the men\u2019s hormones and cholesterol with blood tests at the start and end of the study.\nThe prototype pill\u2014dimethandrolone undecanoate (DMAU)\u2014is somewhat similar to the combined female pill, which contains estrogen and a steroid hormone.\nThe \u201cundecanoate\u201d in DMAU, however, is a long-chain fatty acid that can slow the drug\u2019s journey out of the body, Page said.\n\u201cDespite having low levels of circulating testosterone, very few subjects reported symptoms consistent with testosterone deficiency or excess,\u201d Page said.\nWhile some subjects on all doses experienced mild weight gain and decreases in so-called \"good\" HDL cholesterol, DMAU appeared safe.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not cite any independent sources, nor does it note that two of the study co-authors have ties to pharmaceutical companies \u2014 including a company that focuses on an oral testosterone replacement therapy.", "answer": 0}, {"article": "\"We now feel pretty confident that, in many children with autism, there are alterations either in structure growth or connectivity of the brain, but we really don't understand the implications of that for core features of autism, one of which is problems with communication,\" Amaral said.\n\"This is probably not going to be used for wide-scale screening but it could be used for children who we have some sense that they have autism and want to gather more information,\" said David Amaral, president of the International Society for Autism Research and research director of the University of California Davis MIND Institute.\n\"We're focusing on this earliest time period, when the brain is still developing and still changing,\" explained study author Lisa Eyler, an assistant professor of psychiatry at the University of California, San Diego.\n\"If we could use this with other markers, we could probably identify people early on and, if we could do that, we'd have a much better chance of helping to make sure that their language development is normal.\"\nIn the youngest children, the activation was about equal in both the right and left hemisphere, while in the older children, activity became more pronounced on the left side, which is similar to adult patterns and to be expected, Eyler explained.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The idependent sources were well chosen and well quoted. The researchers themselves are given the proper context, for the most part, too. The story does not identify conflicts of interest. One could see if one of the researchers had an interest in an fMRI machine manufacturer, but everyone involved and not involved seems to agree that we are a long way from a marketable product.", "answer": 1}, {"article": "\"Why is a higher adherence to the MedDiet related to slowing down the rate of cognitive decline?\nThe main foods in the Mediterranean diet (MedDiet) include plant foods, such as leafy greens, fresh fruit and vegetables, cereals, beans, seeds, nuts, and legumes.\n\"These include reducing inflammatory responses, increasing micronutrients, improving vitamin and mineral imbalances, changing lipid profiles by using olive oils as the main source of dietary fats, maintaining weight and potentially reducing obesity, improving polyphenols in the blood, improving cellular energy metabolism and maybe changing the gut micro-biota, although this has not been examined to a larger extent yet.\"\nMoreover, the benefits to cognition afforded by the MedDiet were not exclusive to older individuals.\n\"I would therefore recommend people to try to adhere or switch to a MedDiet, even at an older age,\" Hardman added.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Although the published study indicates that none of the principal investigators received funding to conduct this study, presumably minimizing conflicts of interest, the news release doesn\u2019t address these issues. That\u2019s unfortunate, since the investigators\u2019 independence would be\u00a0a strength of the study.", "answer": 0}, {"article": "The results were presented Thursday at the American College of Neuropsychopharmacology annual meeting in Hollywood, Fla.\n\"We saw a robust, rapid-acting, long-lasting effect,\" said lead researcher Joseph Moskal, a research professor of biomedical engineering at Northwestern's McCormick School of Engineering and Applied Science and director of the school's Falk Center for Molecular Therapeutics.\nThe drug was so well received by patients that many who were in the trial have called asking to be in any further trials, Moskal said.\nCurrently, the most popular drugs to treat depression are called selective serotonin reuptake inhibitors, or SSRIs.\nFRIDAY, Dec. 7, 2012 (HealthDay News) -- An experimental antidepressant that targets the brain in a different way appears to both act fast and last long, researchers say.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Dr. Bryan Bruno is the independent expert in this story. It would have been helpful if he could have talked more about the study\u2019s limitations, but he does mention that long-term effects of the drug need to be studied before it can be used regularly in clinical practice. The article does an excellent job in bringing up a potential conflict of interest. The study\u2019s lead researcher is the founder and chief scientific officer of the biotechnology firm Naurex Inc., which \u201cdiscover and develop compounds that modulate the NMDA receptor in a new way,\u201d according to the firm\u2019s website. Naurex conducted the clinical study.", "answer": 1}, {"article": "When planning a day at the beach, should you add Polypodium leucotomos to your picnic basket? The company that sells the natural fern extract says a daily dose can help protect against sunburn, sun-related aging and even genetic mutations that cause skin cancer. Dermatologists say preliminary evidence suggests the extract does protect against the sun -- but don't throw away your sunscreen yet.\n\nEvery year, 36% of U.S. adults get at least one sunburn, according to the federal Centers for Disease Control and Prevention....", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two physicians, one of whom is the lead author on the articles and was funded by the manufacturer of the product. It would have been preferable to quote a spokesperson for an academic society or non-profit organization to provide some additional perspectives.", "answer": 1}, {"article": "\"Migraine patients tend to be underdiagnosed and undertreated and inappropriately treated.\"\nA nasal spray is available, as is an injection, but many patients aren't comfortable with these options, Khan and Waltman noted.\nTo complicate matters, many migraine sufferers can also experience severe bouts of nausea and vomiting.\nNuPathe CEO Armando Anido told Bloomberg News, \"We anticipate the product will be available for sale in the fourth quarter of this year.\"\nOne study found that 18 percent of patients using the patch were headache-free after two hours, compared with 9 percent of those using an inactive placebo.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Based on a brief Web search, the two expert sources quoted in the story don\u2019t seem to have any\u00a0conflicts of interest related to this issue.", "answer": 1}, {"article": "Lipton directs the Montefiore Headache Center at the Albert Einstein College of Medicine in the Bronx.\n\"There is a lot of unmet medical need out there in the treatment of migraine,\" he says.\nDrugs commonly used in the treatment of severe headaches are generally not considered effective in the aura phase of migraine attacks, and many patients want to treat their migraines without using drugs, neurologist and headache specialist Richard B. Lipton, MD, tells WebMD.\n\"Some people don't tolerate the drug treatments very well and others just want to avoid them.\"\nAbout 35 million Americans have migraines, according to the American Headache Society, and about 20% to 30% of these patients have headaches that are preceded by visual or other sensory warning signs.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story did at least include comments from the editorial writer who injected some cautionary notes into the discussion. And it did point out the conflicts of interest associated with the trial. This study was funded by Neurolieve, the company that makes the device used in the trial. Furthermore, the lead author of the study owns stock in this company.\u00a0\u00a0 ", "answer": 1}, {"article": "Based on the overall results, Devinsky believes CBD should be evaluated for epilepsy types beyond Dravet syndrome, which is caused by a genetic mutation and affects about one in 20,000 to 40,000 children in the United States.\nShe added that the new study is \"critically important\" for the epilepsy community, which believes a CBD-based medical product would be a first-in-class therapeutic option.\n\"If future clinical trials confirm these promising results, then appropriate regulation will enable the drug to be safely used for medical purposes,\" he said.\nDespite the generally positive results, most study participants reported side effects that included vomiting, fatigue, diarrhea and some liver issues.\n\"Tiredness (somnolence or fatigue) was most common; others were decreased appetite, diarrhea and vomiting,\" Devinsky explained.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes four independent sources, a very high number for a story about a study like this. It also explains that the study was partially funded by a drug company trying to commercialize a cannabis-based drug.", "answer": 1}, {"article": "U.S.News & World Report consistently names Cleveland Clinic as one of the nation's best hospitals in its annual \"America's Best Hospitals\" survey.\nThe findings, published in the Journal of Nutrition today, suggest that whole grains can be a key regulator of blood pressure, and could provide an effective nutritional strategy to reduce cardiovascular-related deaths and disorders.\nThis research shows that eating whole grains reduces the risk of heart disease,\" said John Kirwan, Ph.D., principal investigator and director of the Metabolic Translational Research Center, which is part of Cleveland Clinic's Endocrinology & Metabolism Institute.\nIn the study, a group of 33 overweight and obese adults followed a whole grain diet (intervention) or a refined grain diet (control) for two eight-week periods.\n\"This level of control can only be performed for small numbers and provides the essential empirical data that cannot be obtained from large observational studies.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release identifies the funders of this research as both the National Institutes of Health and the\u00a0Nestl\u00e9 Corporation and points out that\u00a0Solon and Cereal Partners Worldwide provided \u201cthe study meals and foods.\u201d However, it does not mention, as the published study does, that three of the authors work for Nestl\u00e9.", "answer": 0}, {"article": "The Food and Drug Administration approved a new drug on Tuesday to treat serious cases of eczema.\n\u201cScratching leads to swelling, cracking, weeping clear fluid, and finally, coarsening and thickening of the skin.\u201d\n\nThere are many treatments out there now, from simple skin lotions to steroid creams and immune suppressant drugs like tacrolimus.\n\u201cThe most common side effects include injection site reactions; cold sores in the mouth or on the lips; and eye and eyelid inflammation, including redness, swelling and itching,\u201d the FDA notes.\nIt\u2019ll cost $37,000 a year but the drug\u2019s makers, Regeneron Pharmaceuticals and Sanofi, have stressed that\u2019s the wholesale price and make a point of saying there will be programs to help people pay for it.\n\u201cOf the adults with uncontrolled moderate to severe atopic dermatitis in the United States, it is estimated that 300,000 are most in need of new treatment options,\u201d Regeneron said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story lacks independent sources. It uses a quote from the head of the National Eczema Association without mentioning that the association lists the manufacturers of this drug as among its top funders. According to the group\u2019s web site, the companies are \u201csapphire\u201d level sponsors, which have contributed $50,000 or more.\nThe video also doesn\u2019t disclose that Dr. Paul Yamauchi of UCLA, who calls the drug a \u201cgame-changer,\u201d has been hired by the manufacturers of this drug as an investigator as well as an advisor and/or speaker, according to public disclosures.", "answer": 0}, {"article": "SUNDAY, Sept. 19, 2010 (HealthDay News) -- For asthma patients whose condition is not controlled with standard inhaled steroids, the addition of Spiriva -- a medication already approved for lung disease -- appears to improve breathing, a new study finds.\nThe results need to be confirmed in a much larger pool of patients, Peters said, and he noted that the patients were not followed long enough to see if Spiriva was able to reduce the severity of asthma attacks and hospitalizations.\nThe report, funded by the U.S. National Heart, Lung, and Blood Institute, is published in the Sept. 19 online edition of the New England Journal of Medicine.\nThat's important, Peters said, because there have been some safety concerns raised about long-acting beta agonists.\n\"This is a good foundation to design a trial where you would look at Spiriva plus steroids versus doubling the dose of steroids in a large number of asthmatics who are poorly controlled and then you follow them long-term,\" Shafazand said, but right now there is no data on long-term efficacy and safety.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article cites an independent source who was not, apparently, related to the study. The funding of the study was also mentioned. \nThe AP article we reviewed digs into\u00a0further conflicts of interest for the study investigators. As an aside to our review, that article also probes the\u00a0controversy over the fact that a drug company didn\u2019t donate some of the drugs used in this study.", "answer": 1}, {"article": "Elizabeth Loder, chief of headache at Brigham and Women's Hospital in Boston, points out that because CGRP constricts blood vessels, there may be potential long-term effects on blood pressure or other cardiovascular function.\nThey struck a few times a week and I thought they were normal headaches.\nAbortive medications still work, except when they don't.\nSo, four pharmaceutical companies rejiggered their approach.\nRight now, the longest patients have been on one of these new therapies is one to two years.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two physicians who don\u2019t appear to have interests in promoting these treatments are quoted.", "answer": 1}, {"article": "The Brennans' pediatrician, Dr. Lawrence Rosen, explains, \"Elderberry contains chemicals which are flavonoids which are anti-inflammatory agents.\"\n\"There is not enough research about whether [elderberry] works in children and there is also isn't enough information about the proper dose in children,\" Dr. Anna Minta of Johns Hopkins Children's Center told CBS News.\nThe Brennan family in Glen Rock, New Jersey, believes it works..\n\n\"So we give the kids, and we take it ourselves, elderberry every morning right after breakfast,\" Kevin Brennan told CBS News.\nThe University of Maryland Medical Center says European elder, also called black elder, is the variety most often used for medicinal purposes.\n\"The duration and the severity of how they get sick is much less and they get healthy quicker,\" he said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We will give this story a passing grade here because it does include a quote from a physician skeptical of elderberry extract. However, there is no mention of whether the trials of elderberry extract have been done by independent researchers or just manufacturers or others with a financial interest in the results. At least one study we\u2019re aware of cites Razei Bar, a manufacturer of elderberry extract, as its sole sponsor.", "answer": 1}, {"article": "The designer of that treatment, Dr. Katherine A.\nIf all goes well, a genetic treatment for hemophilia B \u201ccould be available for widespread use in a couple of years.\u201d\n\nIn a trial in 2006, a patient injected with a corrective gene produced his own Factor IX but only for 10 weeks.\nTreating a patient with concentrate costs $300,000 a year, with a possible lifetime cost of $20 million, but the single required injection of the new delivery virus costs just $30,000, Dr. Katherine P. Ponder of the Washington University School of Medicine in St. Louis notes in her commentary in The New England Journal of Medicine, calling the trial \u201ca landmark study.\u201d\n\nThe patients have continued to produce their own Factor IX for up to 22 months, said Dr. Edward G. D. Tuddenham, director of the Hemophilia Center at the Royal Free Hospital in London.\nThe delivery virus, carrying a good version of the human gene for the clotting agent known as Factor IX, was prepared by researchers at St. Jude Children\u2019s Research Hospital in Memphis.\nThe virus used by Dr. Nathwani\u2019s team, known as adeno-associated virus-8, generally stays outside the chromosomes, so it should not present this problem.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an editorial writer calling the trial \u201ca landmark study.\u201d\u00a0 But that editorial writer had much more to say in that editorial \u2013 including raising specific concerns on potential harms.\nThe one independent expert quoted only called it a \u201cterrific advance\u201d but wasn\u2019t quoted giving a specific analysis of the research \u2013 what it means or what it may not mean.\nA second external voice was included \u2013 but that was a researcher who, although a competitor, was nonetheless listed as a co-author of the paper because her lab helped monitor the patients.", "answer": 1}, {"article": "We can't find the page you're looking for. Try one of these options.\n\nAre you sure this is the right web address? Let us know.", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "No funding sources are mentioned in the news release regarding the DigniCap clinical study. We find this problematic, since the makers of DigniCap collaborated with Target Health, a clinical research organization (CRO), to conduct the clinical trial and prepare the FDA application.\nAccording to its website, Target Health is\u00a0a privately held, New York City-based full-service contract research organization (CRO) committed to serving the pharmaceutical community with knowledge regarding regulatory affairs, clinical research, biostatistics, data management and Internet-based clinical trials.\nAs a result, we rate this Not Satisfactory.", "answer": 0}, {"article": "Medical researchers are well aware that the dummy pills used in clinical trials often provide as much relief as the actual drugs being tested. This is what's known as the placebo effect, and it's quite common in people with Parkinson's, a movement disorder that causes tremors, stiffness and balance problems. A 2008 meta-analysis found that placebos used in clinical trials of Parkinson's treatments improved symptoms by an average of 16%.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story ends with a quote from an accompanying editorial by experts not affiliated with the study. Although the quote in question doesn\u2019t really add to our understanding of the results \u2014 it merely reinforces the study authors\u2019s conclusions \u2014 we\u2019ll rate this as satisfactory. We would ideally have liked for the story to have interviewed an expert, or at least called attention to comments from the editorial that provide some critical analysis of the results.", "answer": 1}, {"article": "Is that a good thing?\nFor the past 50 years, hyperbaric therapy has been approved by the Food and Drug Administration as a treatment for non-healing wounds, carbon monoxide poisoning, burns and decompression sickness.\nBetween 2009 and 2015, Cifu oversaw three studies for the Department of Veterans Affairs \u2014 reportedly at a taxpayer cost of about $70 million \u2014 of about 60 active-duty service members with post-concussion syndrome.\n\"It's very difficult to get funding for studies on this topic,\" Harch said.\nCook, who lives in Baltimore, began to suffer from debilitating symptoms: She had problems with her short-term memory; she had constant headaches and couldn't concentrate; her vision became blurry and dark; and her hearing was altered, so that all sounds were jumbled and very loud.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "It should have been made more clear that the research supporting positive outcomes \u2014 as well as the two glowing anecdotes \u2014 came from physicians who run hyperbaric therapy clinics.\nHaving said that, we appreciated the inclusion of Dr. Cifu\u2019s skepticism, as well as the cautionary last paragraph regarding anecdotes, and that more research is clearly needed in this area.", "answer": 0}, {"article": "Guyuron, chair of plastic surgery at University Hospitals Case Medical Center in Cleveland, went on to identify four common \"trigger sites\" and publish studies showing that, in selected patients, surgical decompression of nerves in one or more of these sites provides lasting migraine relief. He has also taught 250 plastic surgeons around the world (none in the Philadelphia area) to perform the outpatient operation, which costs an average of $10,000 and is not covered by many insurers.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story takes far too long to bring in independent experts, and their voices, while strongly in opposition to surgery, may be drowned out by all the space devoted go Guyuron and his patients, who claim to have been miraculously cured. One has to wonder why a quote like this would not have made the newspaper have doubts about publishing the story: \u201c\u2019I know most of the headache experts in the country and they don\u2019t support\u2019 migraine surgery, said neurologist Stephen Silberstein, director of Thomas Jefferson University\u2019s Headache Center, one of the nation\u2019s leading programs. \u2018I certainly wouldn\u2019t recommend it, or say insurance should cover it\u2019 at this point. Neither would the American Headache Society, whose board includes Jefferson neurologist William Young.\u201d", "answer": 1}, {"article": "Many smokers already had sought out spiral CTs, even though the American Cancer Society hasn't recommended the test - citing a lack of clear evidence that they work - and most insurance doesn't cover the $300 to $400 cost.\nIt is most often diagnosed at advanced stages, and the average five-year survival rate is just 15 percent.\nThe NCI said it is not clear that all smokers should get the scans, which are not risk-free.\nAbout 200,000 new lung cancers are diagnosed in the U.S. each year, and the disease kills about 159,000 people annually.\nLetters being mailed to study participants advise them to discuss with their doctors whether they should have additional scans or not.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\nThere is no independent source quoted.\u00a0 (Please note: later versions of AP stories carried independent perspectives but we reviewed the first version we found.) ", "answer": 0}, {"article": "\"I hope that people will respect the rigorous methodology used in this blinded, randomized, controlled trial and accept the result,\" study researcher Deirdre Lyell, MD, assistant professor of obstetrics and gynecology at Stanford University School of Medicine, says in a news release.\nAll of the women received therapy for eight weeks and were interviewed at the four- and eight-week marks by someone who did not know which treatment they were getting.\nSome received depression-specific acupuncture treatments, others had needles inserted in acupuncture points not known to relieve depression, and a third group received massage therapy.\nMany pregnant women who have symptoms of depression worry that taking antidepressants might harm their unborn babies -- so they stop taking their medications, say researchers at the Stanford University School of Medicine.\nRemission rates were not significantly lower in the depression-specific acupuncture group compared to the other two groups.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\nNo independent experts were interviewed for this story.\u00a0\u00a0 \n", "answer": 0}, {"article": "I can't do this.'\nThis was another small study -- 20 dyslexic volunteers and 21 participants without the condition -- testing how people identify shapes, navigate a virtual environment, and do other tasks involving spatial reasoning.\nThe most important intervention is a direct, explicit teaching of phonics, or how symbols correspond with sounds, Branstetter said.\nHere's another insight about dyslexia: men with the condition may have enhanced visual-spatial abilities, according to a study in the journal Learning and Individual Differences.\nAnother important limitation in the study is that some children in the study did receive tutoring or reading interventions, to which they were not randomly assigned.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\n\nThe story does include independent experts. Although it does not discuss conflicts of interest, the authors of the main study declared no conflicts and reported that their study was supported by a number of grants from public agencies and foundations, though the baseline assessment of the participants was supported by a company that markets treatment interventions for people with dyslexia. One troubling point: the story describes one person who claims to have been helped by \u201ctraining at a learning development center.\u201d If this individual was associated with the company that helped sponsor this research, the story should have disclosed that connection.", "answer": 1}, {"article": "For its part, the pediatricians group hopes the new recommendations will encourage more parents to circumcise their sons \u2014 and more insurance plans to pay for it.\n\"Those families who choose circumcision should have access to circumcision.\nThey liken the procedure to female genital mutilation.\n\"They act as though there's this huge body of literature.\nOnly about 56 percent of newborn males are circumcised.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Both advocates for circumcision and opponents were quoted within the story.", "answer": 1}, {"article": "Adding Victoza to insulin therapy quickly eliminated these peaks and dips in blood sugar.\n\"Some patients have now been treated for up to a year, and the effect is as good as it was at the beginning,\" Dandona said at a news conference webcast from Boston.\nAt the annual meeting of the Endocrine Society in Boston, Dandona reported the results of a study in which 14 adults, whose type 1 diabetes was well controlled with insulin given via an insulin pump, received once-daily Victoza for either one week or 24 weeks.\nJune 7, 2011 - People with well-controlled type 1 diabetes had even better sugar control, used less insulin, and lost an average of 10 pounds in six months when taking the type 2 diabetes drug Victoza in a small clinical study.\n\"Over a protracted period of time, as their diabetes continues to be well controlled, there is delightful improvement in patients' well-being.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story notifies readers that this study was conducted without drug company support, but that a corporate-funded trial is in the works. The story could also have notified readers that the lead researcher, Dr. Dandona, disclosed numerous relationships with pharmaceutical companies in the abstract for this study \u2014 although none with Victoza manufacturer Novo Nordisk.\nThe story fell short of the bar when it failed to obtain feedback from an expert who wasn\u2019t involved with the research. Context is everything, and even hearing from a practicing diabetes expert would have been helpful.", "answer": 0}, {"article": "Adding small amounts of powdered ginger to food may help take the edge off seasonal allergy symptoms, according to an animal study published online in the Journal of Nutritional Biochemistry. Daily intake of dried ginger significantly reduced sneezing and other signs of allergy in rodents with induced allergic rhinitis, or hay fever.\n\nA major component in ginger, 6-gingerol, suppresses the activation of T lymphocytes, or T cells, a type of white blood cell that plays an important role in sensitizing people to specific allergens,...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not quote any sources, either independent or connected to the scientific paper. We realize that space and length limitations may make it difficult to include such sources in a brief story such as this one. Nevertheless, we wanted to hear more context for this study. Ginger has already been studied for relationships to cardiovascular disease and cancer. A comment from someone in nutritional biochemistry, or an allergist, might have helped readers take better stock of the findings.", "answer": 0}, {"article": "This is in line with some of our recent studies which indicate that the GI tract microbiome in Alzheimer's is significantly altered in composition when compared to age-matched controls, and that both the GI tract and blood-brain barriersbecome significantly more leaky with aging, thus allowing GI tract microbial exudates (e.g.\nWalter Lukiw, Professor of Neurology, Neuroscience and Ophthalmology and Bollinger Professor of Alzheimer's disease at Louisiana State University, who reviewed the study but was not involved in the research, said: \"This early study is interesting and important because it provides evidence for gastrointestinal (GI) tract microbiome components playing a role in neurological function, and indicates that probiotics can in principle improve human cognition.\nBut scientists have long hypothesized that probiotics might also boost cognition, as there is continuous two-way communication between the intestinal microflora, the gastrointestinal tract, and the brain through the nervous system, the immune system, and hormones (along the so-called \"microbiota-gut-brain axis\").\nAt the beginning and the end of the 12-week experimental period, the scientists took blood samples for biochemical analyses and tested the cognitive function of the subjects with the MMSE questionnaire, which includes tasks like giving the current date, counting backwards from 100 by sevens, naming objects, repeating a phrase, and copying a picture.\n\"In a previous study, we showed that probiotic treatment improves the impaired spatial learning and memory in diabetic rats, but this is the first time that probiotic supplementation has been shown to benefit cognition in cognitively impaired humans,\" says Professor Mahmoud Salami from Kashan University, the senior author of the study.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release states that the research was supported by a grant from the Deputy of Research of Kashan University of Medical Sciences, and that the probiotic supplements were produced and provided by Tak Gen Zist Pharmaceutical Company in Tehran, Iran. The authors declared no commercial or financial relationships that could be construed as a potential conflict of interest.", "answer": 1}, {"article": "University of Miami cardiologists last week reported success in a small, preliminary human clinical trial of a new stem cell therapy they hope some day will routinely mend human hearts and reduce the need for lifelong medication, even for transplants.\nThe study shed new light on a question of prime interest to cardiologists: whether the injected stem cells actually transformed themselves into heart muscle, or improved heart function in some other way.\nThe hope was that the immature adult stem cells would turn into heart muscle, replacing the scar tissue.\nIn the study, stem cells were taken from the patient's own bone marrow and injected by catheter into scar tissue in the patient's heart caused by an earlier heart attack.\n\u201cThat's the Holy Grail, the quest the whole field has been pursuing for close to a decade, and this is evidence we're on the right track,\u201d said Dr. Joshua Hare, director of the University of Miami Medical School's Interdisciplinary Stem Cell Institute.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story does not interview any independent sources, nor does it reveal that some of the study authors received funding from BioCardia, the company that manufactures a device used to inject the stem cells into the participants\u2019 hearts. In addition, the story should have noted that the study was funded in part by BioCardia.\n", "answer": 0}, {"article": "The requested URL /2011-08-30/business/29945941_1_mark-kris-cancer-cases-lung was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\nWhile the story notes the conflicts of some sources, it appears that all the experts quoted were participants in a conference call arranged by Pfizer.", "answer": 0}, {"article": "THURSDAY, Feb. 24, 2011 (HealthDay News) -- Blood tests that indicate prostate-specific antigen (PSA) levels are rising rapidly over time are of little use in detecting aggressive prostate cancer and should not be done, a new study indicates.\nMen with both high and low levels of PSA can have cancer or not have cancer.\nPSA is a protein produced by cells of the prostate gland.\nThe men in the study were all from the placebo arm, meaning they had not received the drug.\n\"It's something that has become almost a community standard.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two independent sources were quoted.", "answer": 1}, {"article": "(CNN) A saliva test may someday be able to diagnose a concussion and predict how long symptoms last, according to a study published Monday in the JAMA Pediatrics.\nThe study was funded in part by Quadrant Biosciences, a biotech company that hopes to bring a saliva test for concussion to market in the next 12 to 24 months, Hicks said.\n\"Fortunately, the technology required to measure saliva RNA is already employed in medicine; we use it to check patients for upper respiratory viruses in our hospitals and clinics every day,\" Hicks said.\nThe saliva biomarker may be showing that neurons experienced force and not that a there is a concussion, with which the brain cannot perform its typical functions within a normal range, he said: \"I would hesitate to assign too much potential groundbreaking science.\"\n\"We found three microRNAs that were highly associated with specific symptoms one month after injury, such as headache, fatigue and memory difficulties,\" Hicks said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes two independent sources: the JAMA Pediatrics editorial and a neurologist, Dr. Jeffrey Kutcher, who directs The Sports Neurology Clinic at The CORE Institute in Michigan. In addition, the story explains that Quadrant Biosciences, which is hoping to market a saliva test for concussions, provided part of the funding for the original study. It also notes that Kutcher is consulting for a company working on an alternative approach to testing for concussion severity using electroencephalograms (EEG).", "answer": 1}, {"article": "This story has been updated with additional information.\nThe data could represent a \u201cparadigm shift in how the disease is thought about,\u201d CEO Jeff Jonas said in a conference call.\nThe drug has a \u201cvery, very short half-life\u201d in the body, Jonas said, meaning that it can be metabolized quickly.\nIn cases of severe depression, that equilibrium gets out of whack, and Sage\u2019s drug is meant to restore it, modulating those GABA receptors to allow NMDA to do its job.\nThere\u2019s a natural push and pull between neurotransmitters called NMDA receptors and the GABA receptors that regulate their flow in the brain.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although the story notes that the results were released in a news release and a company conference call, and were not peer reviewed (thus making it clear that the source is only the company and that the results have not been independently reviewed), the story should have included comments from independent experts.", "answer": 0}, {"article": "This new approach to drug discovery is a promising technology that is rapidly moving in the translational research space , .\nAmong these, the abstract \"Tivanisiran a new treatment for Dry Eye Disease, that improved signs and symptoms in clinical trials\" (Posterboard number: 925 - B0103) is highlighted, the compound improving the ocular inflammatory parameters, tear quality and a reduction in ocular pain associated with dry eye disease is also underlined1.\nThe presentation has taken place within the framework of the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) that has been held from the 29th of April to the 3rd of May in Honolulu, Hawaii.\nThe novel mechanism of action of tivanisiran, based on genetic silencing through RNA interference (RNAi), is targeted at the treatment of the signs and symptoms of this pathology, making it a firm candidate for the treatment of dry eye disease.\nDry eye can be treated with cyclosporin drops or autologous serum, but there is as yet no specific product for chronic treatment of the ocular pain related to dry eye syndrome; oral analgesics or anaesthetics are used in general.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "PharmaMar, the parent company of he drugmaker, is listed as the study funder on the EurkekAlert! website which hosts the news release. We encourage news releases to include sponsors and conflict of interest information in the body of the news release so that information follows when the release is picked up verbatim by news aggregators.", "answer": 1}, {"article": "Antioxidants neutralize unstable forms of oxygen called reactive oxygen species that can damage cells throughout the body.\nBut the finding is in line with a previous study of U.S. adults that found that a higher intake of vitamin E, but not vitamin C or beta-carotene, was related to a lower risk of developing Alzheimer\u2019s over two years.\nReactive oxygen species are produced naturally in the body, as byproducts of metabolism; because the brain is an area of high metabolic activity, it is thought to be particularly vulnerable to accumulating oxidative damage over a lifetime.\nResearchers found that among 5,400 Dutch adults age 55 and older, the one-third who reported the highest vitamin E intake from food were 25 percent less likely to develop dementia, including Alzheimer\u2019s disease, over the next decade than the third with the lowest intakes.\nThe one-third of study participants with the highest vitamin E consumption typically got 18.5 milligrams (mg) per day, just over the recommended daily intake of 15 mg.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although the story is generally well balanced, it could have benefited from the inclusion of an independent\u00a0comment on the findings. Valuable context about prior studies and the serious limitations of the current study would have been\u00a0helpful.", "answer": 0}, {"article": "LONDON (Reuters) - In an analysis that set off a fierce debate over the health effects of salt, researchers said on Wednesday they had found no evidence that small cuts to salt intake reduce the risk of developing heart disease or dying prematurely.\nThis gave the researchers enough data to be able to start drawing conclusions, they said.\nThe Cochrane review attracted sharp criticism from nutrition experts.\nHigh blood pressure, or hypertension, is a major risk factor for cardiovascular diseases \u2014 the leading causes of death worldwide.\n\u201cThe people in the trials we analyzed only reduced their salt intake by a moderate amount, so the effect on blood pressure and heart disease was not large,\u201d he said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Quotes from several independent sources were included as part of this story.", "answer": 1}, {"article": "The effect, however, typically lasts only about seven months before the cancer starts to grow again, though some patients benefit for more than two years.\nDoctors are eager to try the two drugs together.\n\u201cIf it weren\u2019t for the trial I wouldn\u2019t be here,\u201d she said.\nIt has not been all good.\n(The drug\u2019s name comes from V600E mutation in RAF.)\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several independent sources cited.", "answer": 1}, {"article": "Participants had an average starting cholesterol of about 230 milligrams per deciliter of blood.\n\u201cIn a sense it\u2019s a necessary micronutrient and we need it, but we might be (in) a situation where we have enough \u2014 we might even have too much.\u201d\n\nSelenium is found in meat, bread, and some nuts.\nWhile Guallar said the results are \u201cgood news\u201d in showing that high selenium intake is probably not a risk for high cholesterol, he wanted to add a note of caution.\n\u201cIn a population like the U.S. where selenium levels are adequate, there\u2019s no reason to take extra selenium in supplements.\u201d\n\nThe question of the link between selenium and health outcomes, Guallar said, \u201cis a very interesting story that\u2019s still developing.\u201d\nStill, the finding is \u201creassuring\u201d because previous research had linked high selenium with higher cholesterol levels, said study author Dr. Eliseo Guallar, from the Johns Hopkins Bloomberg School of Public Health in Baltimore.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only expert source for this story was a co-author on the study being discussed. Although his comments are appropriately cautious, they are not sufficient to satisfy this criterion.", "answer": 0}, {"article": "But the triggers are different for different people.\n\"The majority of them have really been suffering a number of years and they're really miserable with the pain,\" Bernstein says.\nThere is just no single reason why people get chronic headaches, although we do know that migraines have a genetic component and usually a trigger.\nThat testing is expensive, it may not be necessary and it could even be harmful, says lead researcher Dr. John Mafi, of Beth Israel Deaconess Medical Center in Boston.\n\"If you are a migraine sufferer and I expose you to the right trigger, you're going to have a migraine,\" Bernstein says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "It\u2019s not clear whether either of the clinical sources in this story have any conflicts of interest or particular agendas. But in both cases they are commenting on areas where they couldn\u2019t be considered objective. In one case, the source discusses a study that he coauthored, and in the other case, the source discusses the treatment of one of her patients. We\u2019ll give the benefit of the doubt, because the second source speaks mainly about headaches in general rather than the patient discussed in the story. Ideally, a completely independent expert would have been tapped to question and evaluate the evidence presented.", "answer": 1}, {"article": "The study\u2019s conclusions contrast with those of a report last year by the United States Preventive Services Task Force, an independent group that issues guidelines on cancer screening, questioning the benefit of screening women younger than 50.\nThe new study took advantage of circumstances in Sweden, where since 1986 some counties have offered mammograms to women in their 40s and others have not, according to the lead author, Hakan Jonsson, professor of cancer epidemiology at Umea University in Sweden.\nTheir paper is published online in the journal Cancer and will be presented on Friday at a meeting sponsored by the American Society for Clinical Oncology and five other organizations.\nThe study\u2019s authors include Dr. Stephen Duffy, an epidemiologist at the University of London, and Dr. Laszlo Tabar, professor of radiology at the University of Uppsala School of Medicine in Sweden, who have long been advocates of mammography screening.\nBut their results were greeted with skepticism by some experts who say they may have overestimated the benefit.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\nA strong point of this story is the inclusion of comments from several independent experts with a variety of perspectives on the meaning of the latest study results. The story does not mention any potential conflicts of interest, but the researchers did not list any in their journal article.", "answer": 1}, {"article": "\"This is a groundbreaking study of extreme importance,\" Joshua Hare, MD, director of the University of Miami's Interdisciplinary Stem Cell Institute, tells WebMD via email.\nHare was not involved in the study.\n\"The improvement we have seen in patients is quite encouraging,\" he says.\nI saw him this morning.\nIt's early -- results are in for only the first 16 patients -- but the results already are drawing praise from experts not easily impressed by first reports.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story presented one independent perspective and a quote from an editorial that accompanied the study.  ", "answer": 1}, {"article": "The official suggested that the baby might be \u201cwhat a baby girl looks like on the outside,\u201d but that \u201cwe\u2019re giving you the results on the inside.\u201d\n\nMs. Lewis, who sued Acu-Gen, said she ultimately received a refund.\nIt also helped her plan, she said.\nIf the Y chromosome is detected, the fetus is male.\nAbsence of a Y chromosome would probably mean the fetus is female, but could mean that fetal DNA was not found in that sample.\nFor the blood tests, women prick their fingers and send blood samples to labs.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted four sources, in addition to the study\u2019s lead author.", "answer": 1}, {"article": "Mumford, who's now 30, says he's never felt better.\nIf collected and stored for private use, the procedure can cost as much as $2,000 or more, plus annual storage fees.\nCord blood stem cell transplants have the same risks as adult bone marrow transplants: the new blood rejecting the host, called graft-versus-host disease.\nThe nonprofit, named for his mother, who died of breast cancer while he was being treated, provides emotional and financial assistance to cancer patients.\nOn Saturday, her husband, Jake, finally wore the suit he had been saving for his wife's funeral -- at a family wedding.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The online story quotes only one physician.\u00a0 Another independent expert might have raised some of the questions that we have raised throughout this review. ", "answer": 0}, {"article": "\"Dislocation is a common reason for a total hip replacement to fail, and when it happens, sufferers can experience significant pain and require another surgery to fix the problem,\" explains lead study author Jonathan Vigdorchik, MD, an assistant professor of orthopedic surgery at NYU School of Medicine and associate fellowship director of the Division of Adult Reconstructive Surgery at NYU Langone Orthopedic Hospital.\nMore than 310,000 hip replacements are performed in the United States each year, and an estimated 2.5 million Americans are currently living with hip replacements.\nIn a hip replacement, an artificial joint comprising a ball and socket is implanted to replace the natural ball and socket in the pelvis, enabling movement that is typical of the hip joint.\nIn addition to Vigdorchik and Buckland, study authors in NYU Langone's Department of Orthopedic Surgery include Ameer Elbuluk, BA, and Richard Iorio, MD.\nA novel risk assessment tool helps identify which patients undergoing total hip replacement may be at higher risk for an implant dislocation after surgery, according to a new study from researchers at NYU Langone Health and described in the Best Poster in the Adult Reconstruction Hip at the American Academy of Orthopaedic Surgeons (AAOS) 2018 Annual Meeting in New Orleans.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t discuss funding for the study or possible conflicts of interest among the study authors. A quick search of the federal Open Payments database shows that the lead author, Dr. Jonathan Vigdorchik, receives payments from a number of device companies, including those that make dual mobility hip implants.", "answer": 0}, {"article": "The pre-clinical results have encouraged CGT and Aberdeen University to create a spin-out company, called Islexa.\nAround the world, 21 million people have type 1 diabetes.\nIt employs more than 100 people and has government backing through Innovate UK but also gets private funding through partnerships.\nIt will manufacture lab-grown islets, the organoids responsible for insulin production, by reprogramming donated pancreatic tissue.\nThey are looking for investors to take Islexa all the way as a fully fledged external company.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Every source in this story was also quoted in the news release.", "answer": 0}, {"article": "But there are still a lot of unanswered questions about immune therapy.\n\"It is early days for the successes of immune therapy,\" said Mark Fishman, president of the Novartis Institutes for BioMedical Research, a research arm of drug company Novartis, which is taking a different approach to turning the immune system against cancer.\n\"We as a lung cancer community are incredibly excited about the activity of immunotherapy in various aspects of the disease,\" said Pasi Janne, director of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute in Boston.\nThere have been no other recent treatment breakthroughs in squamous cancer, which most commonly occurs in smokers or former smokers, so this advance is particularly welcome, said Janne.\nIn addition to melanoma and lung cancer, this brake-release approach has been shown effective in early trials against bladder, kidney, head and neck cancers, and some blood cancers.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although the story quotes three different experts who comment on this area of cancer research, we would be hard-pressed to call any of them independent or unconflicted. The main source \u2014 Pasi Janne \u2014 is the director of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute, which recently entered into a\u00a0partnership with Bristol Myers Squibb to explore cancer immunotherapy. The other two sources are with competing drug companies who are developing their own cancer immunotherapies. Had any of these sources been able to give some type of evaluation of the study that\u2019s supposedly being reported on, we might have rated this satisfactory. A surefire way to earn a satisfactory would have been to quote an independent expert oncologist with no horse in this race.", "answer": 0}, {"article": "(With HIV, 50 to 60 percent is about the efficacy range researchers hope for.)\n\u201cIt\u2019s a step forward toward getting another candidate into trial that could have some promise.\u201d It\u2019s too soon to say if and when the mosaic vaccine might work to prevent the virus from spreading in humans, he added.\n(Some of that access is now in jeopardy, however, given that President Donald Trump has proposed cutting $800 million from a key US government AIDS program called PEPFAR in the 2018 budget.)\n\u201cThe mosaic strategy is one way to attempt to deal with the global virus diversity.\u201d\n\nA word of caution, though: We\u2019re only in the early phase of human testing, and the vaccine could ultimately fail to prevent the virus from spreading among people.\nResearchers from the National Institutes of Health and Johnson & Johnson at the International AIDS Society conference in Paris Monday morning presented data on a clinical trial of what\u2019s called the \u201cAd26-env mosaic vaccine.\u201d\n\nThe mosaic vaccine was developed using a computer algorithm to analyze HIV data from around the world and select a range of HIV sequences to include in a shot.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Barouch, the lead investigator, is only identified with the vaccine center but his previous disclosures show he has licensed patents to Crucell Holland, a subsidiary of Johnson & Johnson, which is funding the current research. The extent of his financial involvement with them should\u2019ve been made more clear.", "answer": 0}, {"article": "A complex and expensive pacemaker-defibrillator can significantly improve the chance for survival among the tens of thousands of heart-failure patients with only mild symptoms, according to a major, multiyear clinical study.\n\nThe research, regarded as likely to change medical practice, showed that the device to \"resynchronize\" the hearts of such patients lowered the death rate by 29% in such patients over 40 months, compared to those who had a standard defibrillator implanted.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does a good job quoting outside sources, but we wish it had done a better job identifying how many of these folks have conflicts.", "answer": 1}, {"article": "Still, the big questions surrounding sauna bathing\u2019s safety have always centered on its occupant\u2019s (and her heart\u2019s) ability to withstand the heat.\n\u201cAs infrared heat penetrates more deeply than warmed air, users develop a more vigorous sweat at a lower temperature than they would in traditional saunas,\u201d says Dr. Richard Beever, a clinical assistant professor of family medicine at the University of British Columbia.\nFrom the Jewish to Mesoamerican \u201chouses of heat,\u201d people all over the world have long associated a good sweat with a wide assortment of health benefits.\n\u201cSauna bathing leads to a significant increase in heart rate and reduction in total vascular resistance, thereby decreasing blood pressure,\u201d says Dr. Ernst van der Wall, chief of cardiology at the Netherlands Leiden University Medical Centre.\nPeople who spent 15 minutes a day for two weeks in an infrared sauna enjoyed a significant drop in blood pressure compared to a control group who spend the same amount of time in a \u201croom-temperature\u201d space, one Japanese study reported.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Both of the sources have direct ties to the research mentioned. \u00a0One of the sources, Dr. Beever, appears in advertisements/advertorials for the Sunlighten brand\u00a0of infrared saunas. The story would have been strengthened by including an expert independent of the research.", "answer": 0}, {"article": "But testimonials are not scientific proof.\nMark Crislip, an infectious-disease doctor in Portland, Ore., who recently wrote about dry needling for Science-Based Medicine \u2014 a website critical of alternative medicine \u2014 says the version practiced by physical therapists doesn\u2019t \u201ccome with the mystical baggage that accompanies acupuncture.\u201d But he says it may well be a \u201ctheatrical placebo.\u201d\n\nWhat do published studies say?\nFor now, here\u2019s what consumers should know:\n\nPhysical therapists say it is not, \u201cthough superficially, it may look the same,\u201d says Justin Elliott, vice president of government affairs for the American Physical Therapy Association.\nWhile some studies have shown promise, he says, \u201cthe quality of the evidence is not strong.\u201d That\u2019s why Briggs and his colleagues are starting a study looking at dry needling in \u201crunner\u2019s knee,\u201d the condition that has plagued Pierce.\n\u201cWhat is being called dry needling is clearly a form of acupuncture\u201d and should be done only by professionals extensively trained in that discipline, says Thomas Burgoon, a West Chester, Pa., physician who is president of the American Academy of Medical Acupuncture.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story should be commended for its extensive sourcing. There are many sources packed into this piece and likely more sources who were interviewed and not quoted given the amount of reporting that clearly went into it.\nAt the same time, most of the sources have a potential conflict of interest\u00a0in some way:\nAll of these potential conflicts\u00a0are called out in the piece, which is commendable.\nThe one person who brings a fairly down-the-middle view is Matt Briggs, a physical therapist who is studying the technique to see whether it works. But our question about him is whether he also is a practitioner of the technique.", "answer": 1}, {"article": "In Manhattan some raw-milk drinkers hire a mule to bring the white stuff to an agreed-upon location in...\nNo biggie--just zip to your local supermarket and pick up a carton.\nCarol Peterson, an IT manager at Xerox, drives almost two hours each month to her favorite farm in upstate New York for her unpasteurized supply.\nAnd they consider themselves lucky.\nNow that's trickier.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story has quotes from \u2018fans\u2019 of raw milk, a scientist with expertise in food safety, and material from the FDA.\u00a0", "answer": 1}, {"article": "But there are dangers to this approach.\n\u201cThe challenge for the next few years is to find out the limitations, the boundaries, the real mechanisms.\u201d\n\nStill, whatever the role of inflammation in epilepsy, Elisa Moller says that anti-inflammatories were a miracle intervention for her son.\n\u201cIt was not known that inflammation was a common feature of different types of epilepsy.\u201d\n\nNormal brain function is regulated by the glial cells, which protect neurons and induce an inflammatory response if the brain is injured.\nIt\u2019s not known what sets off a seizure, but lately scientists like Dr. Devinsky have been gathering evidence that inflammation, the immune system\u2019s response to injuries or foreign organisms, plays a pivotal role.\nAt William\u2019s worst point, a night in July 2010, he had a seizure every time he fell asleep, suffering 23 grand mals between midnight and 6 a.m.\n\nDr. Devinsky had prescribed weekly doses of prednisone, a steroid, and in desperation Ms. Moller decided to administer a mega dose.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We applaud the reporter for talking to so many people for this piece. It must be noted, though, that most of the sources quoted in the story have a stake in the outcome of research on anti-inflammatories for drugs. The first is William Moller\u2019s mother, Elisa, who has elected to give her sun mega-doses of steroids, unproven to show long-term efficacy without significant side effects. The second is William Moller\u2019s doctor, Orrin Devinsky, director of the Comprehensive Epilepsy Center at the New York University Langone Medical Center. He, too, must be hoping that his treatment protocol for William and other patient\u2019s is justified. Then there are Eleonora Aronica, a neuropathologist at the University of Amsterdam, and Annamaria Vezzani, a neuroscientist at the Mario Negri Institute for Pharmacological Research in Milan, both of whom have made inflammation\u2019s relationship to epilepsy the central focus of their research. Dr. Jacqueline French, a neurologist at the N.Y.U. Comprehensive Epilepsy Center, is leading a drug trial for treating epileptics with anti-inflammatories. Only one expert appears to be speaking from a place of academic objectivity: Dr. Tallie Z. Baram, an epilepsy expert at the University of California, Irvine, who says, \u201cLike any new field, there\u2019s a lot of enthusiasm and almost a bit of religion involved.\u201d Indeed. And the religion in this story wins out, with it ending on Elisa Moller being paraphrased saying, \u201canti-inflammatories were a miracle intervention for her son.\u201d", "answer": 1}, {"article": "In the Swiss research, animals took a drug that dissolved a barrier around the part of the brain where mammals store their fear memories. Afterward, they stopped being afraid of noises that were linked to electric shocks, which meant their bad memories had been erased, according to the Mail. Human brains, explains NYU neuroscience Prof. Joseph LeDoux, could actually \"overwrite\" memories with happier thoughts if the medication is developed for people, according to the Daily Mail.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story provided comments from two independent sources, including a neurologist and a neuroscientist; however, they contributed only hypothetical statements. Perhaps commentary from someone in the mental health profession would have been useful. Additionally, the story may have also mentioned that this research took place in an institute associated with the pharmaceutical company, Novartis. ", "answer": 1}, {"article": "TUESDAY, Oct. 16, 2018 (HealthDay News) -- Stimulating a specific set of nerves that are nestled along the spine may deliver relief to those who suffer from chronic back pain and cut the need for opioid painkillers, new research suggests.\n\"The results of this study are very significant,\" said Dr. Kiran Patel, director of neurosurgical pain at Lenox Hill Hospital in New York City.\n\"In certain patients who have not gotten relief from other treatments, this therapy may give sustained pain relief and may allow them to reduce opioids for at least 18 months and perhaps longer,\" said lead researcher Robert McCarthy.\nThe therapy, which targets the root ganglion nerves, is more effective than other spine stimulation procedures because it places tiny leads precisely at the area where pain originates, unlike other devices that provide more generalized stimulation, the researchers said.\n\"In my pain practice and career, dorsal root ganglion stimulation therapy has been one of the most effective technologies available to combat chronic pain,\" Patel said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The authors of this study reported no conflicts of interest in the abstract. However, the story didn\u2019t mention that a doctor who\u2019s quoted, Kiran Patel, MD, received nearly $12,000 in 2017 from Abbott Laboratories, which makes a DRG device. Kiran is also listed as a \u201cDRG specialist\u201d on Abbott\u2019s web site.\nFurther, the story didn\u2019t say who funded this study.", "answer": 0}, {"article": "After taking into account other factors that might affect health and disease risk, like smoking, researchers found women who drank light or moderate amounts of alcohol were less likely to develop chronic diseases as they aged.\nThe women filled out questionnaires about what they ate and drank at midlife, about age 58.\nFor example, compared to nondrinkers, women who drank up to one alcoholic drink per day were 20% more likely to be disease-free at age 70 than nondrinkers.\nA new study shows women who drank the equivalent of a beer or small glass of wine each day were less likely to develop chronic diseases like heart disease, cancer, and diabetes as they got older compared to nondrinkers or those who drink four or more drinks at one time.\nResearchers then analyzed health status information collected after the women turned 70.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes from the study, but includes no independent perspectives.", "answer": 0}, {"article": "Revenues from pharmaceutical and device corporations are available at http://www.\n\"The biggest problem we face in preventing stroke in patients with atrial fibrillation is that almost half of patients don't take any blood thinner at all,\" Bernstein said.\nLOS ANGELES, Feb. 19, 2016 - A new medication reverses the blood-thinning effects of the anticoagulant dabigatran in patients suffering a brain bleed, potentially limiting the extent of bleeding, according to research presented at the American Stroke Association's International Stroke Conference 2016.\nIn patients who received two 2.5-gram of idarucizumab infusions in a 15-minute period, blood tests revealed that dabigatran's blood-thinning effect was 100 percent reversed in all 18 patients with brain bleed.\nAn interim analysis of the first 90 patients in a study called RE-VERSE AD (REVERSal Effects of idarucizumab in patients on Active Dabigatran) showed that idarucizumab effectively reversed dabigatran's anticoagulant effects, said Richard A. Bernstein, M.D., Ph.D., lead study author and director of the stroke program at Northwestern Memorial Hospital in Chicago, Illinois.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does tell readers that the study was funded by Boehringer Ingelheim, which markets both Praxbind and Pradaxa. However, it tells readers that study author disclosures (i.e., conflicts of interest) \u201care on the abstract.\u201d Given that there is no link to the abstract, and we couldn\u2019t find it when we looked (and we did look), that\u2019s not very useful. We did look up Richard Bernstein, who is the lead study author, and his faculty page lists Boehringer Ingelheim under \u201cIndustry Relationships.\u201d Readers shouldn\u2019t have to hunt down an abstract (or look an author up online) to learn that.", "answer": 0}, {"article": "The requested URL was not found on this server. That\u2019s all we know.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story includes commentary from several experts, including those not involved with the new study. \u00a0The writer also points out that the CDC sponsored the study. ", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070603/11back.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The news story cites two noted authorities on spine care, the lead author of the study on degenerative spondylolisthesis and the physician who wrote the accompanying editorial in the New England Journal of Medicine. ", "answer": 1}, {"article": "This is something the study\u2019s authors readily acknowledge.\n\u201cOne day in June, in my inbox were 42 deaths.\u201d\n\nThe findings show the balancing act of opioid policy: Even if doctors need to pull back opioids, they must be careful to ensure patients suffering from debilitating pain and other problems can still meet their other care needs.\nMaybe the opioids themselves caused problems that negatively impacted function or quality of life, \u201csuch as constipation, fatigue, poor sleep, and depressed mood.\u201d It\u2019s possible that opioid dose reduction also resolved what\u2019s known as opioid-induced hyperalgesia, \u201ca paradoxical response in which patients receiving opioids become more sensitive to painful stimuli.\u201d\n\nOr, the researchers suggested, the observational studies simply showed reverse causation \u2014 \u201cthat is, patients successfully tapered opioids because pain severity decreased.\u201d\n\nThe findings do not mean that doctors can now simply yank patients off opioids and expect them to get better.\nThere\u2019s good evidence this happened to many \u2014 but not all \u2014 opioid painkiller users: A 2014 study in JAMA Psychiatry found 75 percent of heroin users in treatment started with painkillers, and a 2015 analysis by the CDC found people who are addicted to painkillers are 40 times more likely to be addicted to heroin.\nBased on his reading of the data, \u201cit\u2019s John with PTSD on the 10 milligrams.\u201d\n\nBut as is true for addiction and pain treatments, adequate mental health care is also out of reach for many patients \u2014 showing just another way that the US health care system isn\u2019t built to adequately address the full needs of patients.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A refreshing number of outside experts are quoted or cited in this story, and their remarks weren\u2019t the typical \u201cthe study was intriguing\u201d variety. Their quotes added some helpful context, such as how long it can take doctors to wean people off opioids (\u201cmonths or even years\u201d) and how everyone responds differently to tapering \u2014 and how some do poorly with it.", "answer": 1}, {"article": "A three-year-old Silicon Valley start-up, Counsyl Inc., won the Bronze Innovation Award for its simple, low-cost genetic test that can alert prospective parents who might be carrying genes that could cause hereditary diseases in their children.\n\nCounsyl's technology promises a \"high quality-of-life impact for families at risk for conceiving children with familial diseases,\" says Larry Bock, an Innovation Awards judge and special limited partner at venture firm Lux Capital. \"This technology bundles previously...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0One outside voice was included in the story \u2013 that of a judge in the Innovation Awards competition. The judge, a venture capital executive, is not a medical expert, and it\u2019s not made clear that he is not an investor in the company or in that technological field. Presumably the awards are not judged by people with a financial interest in the outcome, though the story does not say so. We hunted throughout the Journal\u2019s quite interesting package but could not find any \"how we did it\" story or anything about the judges. We think this weakened the story and the overall package. It would have been nice to hear from an obstetrician who would consider using such a test.", "answer": 0}, {"article": "NEW YORK (Reuters) - Johnson & Johnson\u2019s Stelara helped a significantly higher percentage of Crohn\u2019s disease sufferers than those who received a placebo, according to a study of patients who had not been helped by other commonly used drugs.\n\u201cThey\u2019ll feel measurably better.\u201d\n\n\u201cThe patient population was really quite ill and had very high disease activity, and despite that we saw nice response rates,\u201d Sandborn said.\nAfter 22 weeks, 69.4 percent of the Stelara patients maintained a clinical response and 41.7 percent were deemed to be in clinical remission.\n\u201cIt\u2019s effective in the patient population that has the greatest unmet need at this point in time,\u201d Sandborn said of patients who do not respond to anti-TNF drugs.\nCommon symptoms are abdominal pain and diarrhea, and it can lead to bowel perforations.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only source is the primary investigator. And who funded the study? Presumably it was Johnson and Johnson.", "answer": 0}, {"article": "Guadecitabine works to reverse a so-called epigenetic change in cancer cells known as methylation, which may alter genetic activity in cells in a way that can block the action of tumor-suppressing genes, pushing cells to become cancerous and resistant to therapy.\nBy reversing this change in cancer cells, the drug restores cancer cells' vulnerability to drugs such as irinotecan.\nThere was one death during the study, possibly resulting from febrile neutropenia caused by the treatment.\nIt is manufactured by Astex Pharmaceuticals, a supporter of the Johns Hopkins-led study.\nThe patients were divided into four groups, each receiving different doses of guadecitabine in combination with irinotecan, over an average period of four months.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release clearly states that the study was supported by Astex Pharmaceuticals, which manufactures guadecitabine.", "answer": 1}, {"article": "The population studied was relatively homogenous, and \"the [body mass] findings were not the object of the study (wheezing or asthma in children was the primary objective), growth was a secondary finding,\" Rabin explained.\n\"Certainly, however, this solid paper adds to the literature and paves the way for additional research on this interesting topic.\"\n\"For the past decade, the importance of fish oil and the omega-3 fatty acids have been stressed to patients,\" explained Wu, who was not involved in the study.\nHowever, the findings only showed an association and did not prove that fish oil pills caused healthier growth in children.\n\"The use of fish oil in the latter part of the pregnancy has an impact on bone and muscle mass.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story provides comments from independent sources unaffiliated with the research. We did not detect any conflicts of interest that should have been disclosed.", "answer": 1}, {"article": "Chemotherapy and other cancer therapies can wreak havoc on the taste buds and olfactory senses, depriving recipients of the intricate interplay between taste and smell that is critical to grasping flavors and enjoying foods.\nThe substance is well-known as a first-line defense, aiding the body's immune response, but little is known about its ability to impact salivary proteins.\nCancer patients and their supporting family and friends may again find comfort in enjoying a meal together. \"\nOral infections, such as thrush, also may be diminished.\nTheir most recent study builds on the previous body of work through the application of lactoferrin supplements in treating taste and smell abnormalities.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources are excluded.\nCareful review of the author disclosures included in the study reveal no significant conflicts of interest.", "answer": 0}, {"article": "The new circulating tumor cell (CTC) chip identified such cells in nearly half of 20 people with early-stage prostate cancer and in two-thirds of people with advanced cancer, providing important prognostic information, researchers at Massachusetts General Hospital reported.\nThe test is awaiting approval by the U.S. Food and Drug Administration and already is approved for use in Europe, Catalona said.\nThe new PSA test is given twice a year, along with a digital rectal exam to determine the size of the tumor, and a yearly biopsy.\nIn a study of 2,000 men in the Chicago area, \"we found it to be more accurate than the tests now available, and it also seems to identify the more aggressive prostate cancers,\" he said.\nThe presence of circulating cells can indicate spread of the cancer to other parts of the body, but they are so rare that they are invisible to current technology.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The experts quoted in the story appear to have an association with Beckman Coulter, Inc, the company planning to market the test reported on.\u00a0 This was not made clear in the story. ", "answer": 0}, {"article": "New medtech apps put specialist knowledge in patients' pockets\n\nDeep-learning networks have already been applied to produce algorithms capable of diagnosing diseases like melanoma and blindness caused by diabetes.\n\u201cHowever, some of these parameters may be unavailable\u2026We therefore explored whether additional signals for cardiovascular risk can be extracted from retinal images, which can be obtained quickly, cheaply and non-invasively in an outpatient setting.\u201d\n\nRead more: Can smartphones replace your GP?\nThe method\u2014detailed in a paper published on Monday in the Nature journal Biomedical Engineering\u2014involves analyzing blood vessels in an area of the eye called the retinal fundus.\n\u201cMost cardiovascular risk calculators use some combination of these parameters to identify patients at risk of experiencing either a major cardiovascular event or cardiac-related mortality within a pre-specified time period, such as 10 years,\u201d the paper states.\nThe researchers concluded: \u201cThe opportunity to one day readily understand the health of a patient\u2019s blood vessels, key to cardiovascular health, with a simple retinal image could lower the barrier to engage in critical conversations on preventive measures to protect against a cardiovascular event.\u201d\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does point out that the researchers work for \u201cGoogle\u2019s parent company Alphabet\u201d and for the company Verily, which used to be Google Life Sciences, so the conflict of interest is obvious.\u00a0 But it fails to identify any of the researchers, even though it includes two quotes from a nameless source.\u00a0 No independent sources are quoted.", "answer": 0}, {"article": "This showed that they \u201cvalue the relationship more than being right,\u201d Williams said.\nIn analyzing the recordings, Williams identified 10 communication patterns that caregiving spouses used to connect with their partners and show affection.\nThey included sharing news about friends or relatives or plans for the day as a way to involve their spouse in day-to-day events; waiting patiently and keeping eye contact while spouses searched for words; and finding alternate ways to communicate \u2014 for example, singing songs together when attempts to engage the spouse in certain topics failed.\nPrevious research has found that communication decline among people with dementia is a significant source of stress to caregivers, and most say they need education about communication.\nA relationship is obviously so much more than that.\u201d\n\nMembers of Williams\u2019s research team visited 15 couples in their home once a week for 10 weeks.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes only a single source, the lead investigator, and offers no additional independent sources.\u00a0 It fails to mention funding for the study, nor does it offer any information that would allow readers to gauge potential conflicts.", "answer": 0}, {"article": "\u201cAnd, with autism, gastrointestinal symptoms are often severe, so we thought this could be potentially valuable.\n\u201cWe have to be mindful of the placebo effect, and we have to take [the findings] with a grain of salt,\u201d Matthew Sullivan, an associate professor of microbiology at The Ohio State University, said in the release.\nThe study, which was published in the journal Microbiome, included 18 children with autism and moderate to severe gastrointestinal problems.\nOn average, the score on a scale for ranking gastrointestinal symptoms dropped 82 percent from the beginning to the end of treatment, while average developmental age increased by 1.4 years, according to the release.\nA small study claims children with autism may benefit from fecal transplants, which involves introducing donated microbes into people with gastrointestinal disease to rebalance the gut.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There is no independent source quoted in the story.\nUpon further investigation of the original journal publication on the study, we found a statement about several of the authors holding patents related to fecal transplantation. These seven authors have \u201cpending/approved patents related to the use of FMT and or probiotics\u201d for a variety of conditions, including autism. Five authors have received research funding from Crestovo and several are advisors for Crestovo. None of these were quoted in the story. Crestovo is a for-profit biotech company.\nThe story and the news release should both have made note of these conflicts.", "answer": 0}, {"article": "The average age of the participants was 11.\n\"This receptor has several effects, but one of them may be to modulate the calcium inside and outside the neuron, which is very much related to the excitability of nerve cells,\" he explained.\n\"This was a very, very treatment-resistant group, and the response was very promising,\" Devinsky said.\nA second study from the University of California, San Francisco, explored the long-term effectiveness of cannabidiol for children with epilepsy, by adding the marijuana-derived oil to the regular drug regimen of about 25 kids for one year.\nThe study found that after a year, the treatment resulted in a 50 percent reduction in seizures for 10 participants -- about 40 percent of the group.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although the story does make clear the distinction between researchers involved in the studies discussed and those not involved, there is no mention of funding. Who funded the study is a very important question. It would also be important to know if any of the researchers involved/quoted were consultants/paid by this company. A news release issued in advance of the American Epilepsy Society meeting, where these studies were scheduled to be presented, notes that the medicine used (called Epidiolex) and was supplied by manufacturer GW Pharmaceutical. That information didn\u2019t make it into the story.", "answer": 0}, {"article": "She cited a 2010 review estimating that 11 million to 12 million women a year will suffer from a UTI, accounting for 1.6 billion antibiotic prescriptions a year.\nWhat's more, the amount of time that passed before a woman's next UTI and between recurrent infections was longer in the water group than in the control group.\n\"It is the urine output which is of course the key factor leading to the effect seen in the study,\" said Wessells, chair of the department of urology at the University of Washington School of Medicine in Seattle.\nThey also called the women each month to assess compliance and counsel them to return to the clinic for evaluation and possible treatment if they were experiencing UTI symptoms.\nThe women were followed for a year, with clinic visits at the beginning of the study as well as 6 and 12 months later.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included an independent source. However, it unfortunately left out that Danone, which sells several brands of bottled water, was heavily involved in the study. This is disclosed in the study abstract.", "answer": 0}, {"article": "One such tool is called a CT chest scan, which produces detailed images with high-dose x-rays and is being used in millions of patients every year in the U.S.\n\u201cI think doctors should think carefully about the pretest probability of a pulmonary embolism before they order this test,\u201d Wiener told Reuters Health.\n\u201cRather than an epidemic of disease, we think the increased incidence of PE reflects an epidemic of diagnostic testing that has created overdiagnosis,\u201d the researchers write in the Archives of Internal Medicine.\nIt\u2019s been estimated that more than 600,000 Americans have a pulmonary embolism each year.\nThe condition usually occurs when a blood clot travels from the legs to the lungs, sometimes with fatal results.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent source was quoted. It would have been interesting to solicit opinions from radiologists, for example, that might have placed some of this in a different light.", "answer": 0}, {"article": "\u2022 Surgery should be followed by intraperitoneal, or localized, chemotherapy delivered to the abdomen.\nThe possibility of a 50 per cent cure rate would be a significant improvement over the current 20 per cent survival rate resulting from more conventional treatment options offered to patients, which consist of a combination of different methods including: chemotherapy before surgery; post-operative chemotherapy delivered intravenously to the whole body (as opposed to localized into the abdomen); and surgery that leaves minimal residual disease in the abdomen, rather than removing all visible cancer cells.\n\"Women need support to endure surgery and the rigours of intraperitoneal chemotherapy, but should be encouraged to do so whenever possible, considering the potential survival benefits,\" said Narod.\n\"For decades, women have been treated with a combination of treatment options, resulting in poor prognosis for most women with advanced-stage ovarian cancer, but there are many survivors as well,\" said Dr. Narod, senior scientist at Women's College Research Institute.\nBased on an analysis of existing evidence, published in an opinion article in the Nature Reviews Clinical Oncology journal on January 20, Dr. Narod argues that to achieve a cure, rather than simply delay progression or reoccurrence of the disease, women should be first treated with aggressive surgery to remove all clinically-detectable cancer cells, followed by targeted chemotherapy to the abdomen (intraperitoneal chemotherapy).\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t mention funding sources and conflicts of interest, but there do not appear to be any conflicts of interest since the release is highlighting an opinion piece that analyzes previous research studies. Because the research isn\u2019t advocating use of a specific drug or technology and because the published review states the author has no competing interests, we\u2019ll give them the benefit of the doubt.", "answer": 1}, {"article": "Eye and Ear specializes in ophthalmology (eye care) and otolaryngology\u2013head and neck surgery (ear, nose and throat care).\n\u201cThe development of cochlear implants, for example, didn\u2019t really accelerate until someone placed an electrode in the cochlea of a patient and found that the patient heard a frequency of some type.\u201d\n\nSmell loss, or anosmia, has an estimated prevalence of 5 percent of the general population.\n\u201cNow we know that electrical impulses to the olfactory bulb can provide a sense of smell \u2014 and that\u2019s encouraging.\u201d\n\nIn addition to Dr. Holbrook, authors on the International Forum of Allergy & Rhinology study include co-first author Sidharth V. Puram, MD, PhD, of Washington University School of Medicine, Reiner B.\nReporting online today in International Forum of Allergy & Rhinology, the research team describes their results, which provide a proof of concept for efforts to develop implant technology to return the sense of smell to those who have lost it.\nThis breakthrough in human patients opens the door for a \u201ccochlear implant for the nose\u201d to be developed \u2014 though the study authors caution that the concept of an olfactory stimulator is more challenging than existing technologies.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not mention any sources of funding or potential conflicts of interest. To be clear, even if the work was internally funded and there are no conflicts of interest, that is worth noting. The release acknowledges previous work of \u201cresearch colleagues\u201d at the Virginia Commonwealth University but should have gone further in explaining that the researchers hold a patent for an olfactory implant system and have formed a company to develop the technology.", "answer": 0}, {"article": "\u201cWe have taken the job done by this equipment, which is the size of a large photocopier, and shrunk it down to a USB chip.\u201d\n\nThe test, which uses a mobile phone chip, requires a drop of blood to be placed onto a spot on the USB stick.\nAny HIV in the sample triggers an acidity change, which the chip transforms into an electrical signal.\n\u201cMonitoring viral load is crucial to the success of HIV treatment.\nThis is sent to the USB stick, which shows the result on a computer or electronic device.\nSome 36 million people worldwide are infected with the human deficiency virus (HIV) that causes AIDS, and the majority of them live in sub-Saharan Africa.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We did see any original quotes from an independent source, nor the study\u2019s authors.", "answer": 0}, {"article": "Parkinson's is a disease that affects nerve cells in the brain that control the movement of muscles.\nHe cautioned that persistent use of ibuprofen can lead to gastritis, or inflammation of the stomach lining, but said that, in comparison, \"there is very little to lose when measuring its side effects against the effects of Parkinson's,\" which can include loss of balance, stiffness, hallucinations and dementia.\n\"It's intriguing [that the finding applied to] just ibuprofen and not aspirin or acetaminophen or other commonly prescribed medications for inflammation because it implies something more specific to ibuprofen that should be investigated,\" Tagliati said.\nWEDNESDAY, Feb. 17, 2010 (HealthDay News) -- Regular use of ibuprofen, a common anti-inflammatory drug, significantly lowers the risk for developing Parkinson's disease, Harvard researchers report.\nBut in the meantime, Tagliati said, he would \"definitely discuss ibuprofen use\" with his patients because, if it works to protect against the disease, it could very well benefit those who already have it.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One independent source was quoted.\u00a0 But we\u2019re troubled by the story letting that source get away with saying he would \"definitely discuss ibuprofen use\" with his patients \u2013 because it would be very easy to find other sources who would say it\u2019s far too early to discuss ibuprofen use with their patients.\u00a0 In fact, a MedPageToday.com story stated that the lead researcher himself said \"that it\u2019s too early to make any clinical recommendations based on the observational data, which not only need confirmation in prospective trials but also cannot prove causality.\"", "answer": 1}, {"article": "Doctors tell patients who are at risk of developing stones to drink lots of water and avoid foods rich in oxalate, such as rhubarb, okra, spinach and almonds.\nIn addition to Rimer and Asplin, authors on the paper include Giannis Mpourmpakis and his graduate student, Michael G. Taylor, of the University of Pittsburgh; Ignacio Granja of Litholink Corporation, and Jihae Chung, a UH graduate student working in Rimer's lab.\nThe work offers the first evidence that the compound hydroxycitrate (HCA) is an effective inhibitor of calcium oxalate crystal growth that, under certain conditions, is actually able to dissolve these crystals.\nHCA was also tested in human subjects, as seven people took the supplement for three days, allowing researchers to determine that HCA is excreted through urine, a requirement for the supplement to work as a treatment.\nThe project grew out of preliminary work done by collaborator John Asplin, a nephrologist at Litholink Corporation, who suggested HCA as a possible treatment.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release fails to disclose that the study\u2019s lead author has patented the use of a molecule for kidney stone treatment, nor does it identify the study\u2019s funding source. The study was funded by grants from federal, foundation and university sources according to the acknowledgements section of the journal article. In addition, the patent disclosure was included in supplementary material posted on the Nature website.", "answer": 0}, {"article": "\u201cThere\u2019s a sizable demand, but the hype around efficacy far exceeds available evidence,\u201d notes Doraiswamy, adding that, for healthy young people such as Silicon Valley go-getters, \u201cit\u2019s a zero-sum game.\n\u201cThere\u2019s pretty conclusive evidence from animal studies that intermittent fasting is beneficial for brain function and resistance to aging from neurogenerative diseases,\u201d he says.\nHis office is located in the heart of the city\u2019s tech boom and he is increasingly sought out by young, male tech workers who tell him they are interested in cognitive enhancement.\nPlease don\u2019t take it, people!\u201d\n\nFor Burke and other brain hackers, the evidence for nootropics is strong enough.\nMark Mattson, chief of the Laboratory of Neurosciences at the National Institute on Aging, has overseen a lot of the animal studies on fasting and is impressed with the evidence \u2014 so much so that he has personally adopted a regimen of intermittent fasting.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story lacks comment from an independent expert who\u2019s not involved with selling, prescribing or taking nootropics or some other cognition-boosting product.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/12/national/a180226S32.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes input from researchers, editorial writer, and from drug maker. However, it is not clear if the story included any input from any independent source not directly tied to the study. ", "answer": 1}, {"article": "Last Wednesday, the F.D.A.\n\u201cThere are very few treatments in all of cardiovascular medicine that could claim that \u2014 I can think of heart transplant, and that\u2019s it.\u201d\n\nThe results were even more notable, he said, because the early versions of the devices were clunky, stiff and difficult to use.\nThe result was a requirement that a hospital should be doing at least 50 surgical aortic valve replacements a year to have access to the technology.\nThe consensus of the group, he said, was that \u201cnot every one of the 1,150 cardiac surgery programs or the 1,600 cath labs in the U.S. should be able to do it.\u201d\n\nIn June 2014, after another company, Medtronic, did similar studies, its device was approved, too, for high-risk patients.\n\u201cThis technology is expensive and high risk,\u201d Dr. Mack said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article features in-depth reporting with plenty of expert testimony \u2014 a rarity in health news today and a delight to these reviewers. It might have been nice to include a source who could better explain some of the harms of TAVR.", "answer": 1}, {"article": "Some 68% of the country is either overweight or obese, but there\u2019s not much clinical evidence on the best way to lose weight, outside of research on bariatric surgery. (True, \u201cEat less and exercise more\u201d is great advice if you can manage to follow it, but public-health authorities have repeated that line until they\u2019re blue in the face and as a population we\u2019ve only gotten fatter.)\n\nResearch presented over the weekend at the annual meeting of the Obesity Society and published online in the Journal of the American Medical Association suggests a few specific strategies that may help \u2026", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not quote any \"live\" sources, but it does make good use of an editorial that accompanied the study. It also points out that the study was finded by diet giant Jenny Craig and that the editorial writer, Rena Wing, a professor of psychiatry at Brown University called for \"cost-effectiveness studies, conducted by researchers without any financial ties to the companies involved, that compare different commercial programs with each other.\"", "answer": 1}, {"article": "\"What we look for are shelves of books that have gone missing, which represent a missing fragment of a chromosome, or extra fragments of chromosome, that could contain genes related to autism.\"\nBetween 10 percent and 15 percent of autism cases can be traced to a known genetic cause, the researchers noted.\n\"Part of that is because of the technology that's been available.\nThe U.S. National Institute of Neurological Disorders and Stroke has more on autism.\n\" said Dr. Robert Marion, a pediatric geneticist at Children's Hospital at Montefiore Medical Center in New York City.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story included perspective from a pediatric geneticist unaffiliated with the research. ", "answer": 1}, {"article": "Obesity-related health conditions include high blood pressure, type 2 diabetes and high cholesterol.\nThe people who initially will use the ReShape are people who can afford to pay for it out-of-pocket and need to drop some pounds quickly, Roslin said.\n\"I don't think it's going to be part of the medical algorithm for treating obesity,\" he added.\nIn the clinical trial, the 187 participants who used the device lost an average of more than 14 pounds, or about 7 percent of their total body weight.\nThat clinical trial was funded by the company that makes the ReShape system, according to a presentation from the Obesity Society annual meeting in Boston.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story identifies the device manufacturer, ReShape, as the financial sponsor of the clinical research on their own device. \u00a0And it includes extensive quotes with an obesity surgeon who provides expert perspective on some of the limitations of the intervention.\n\u00a0", "answer": 1}, {"article": "For further information, please contact:\n\"When the benefits of phospholipids on PMS and PMDD came to light through Lipogen's research, we immediately explored its potential,\" says David Rutenberg, CEO for Lipogen.\nThe previously unrecognized PMS/PMDD benefit of PS Plus came about when 2,000 volunteers received and consumed Lipogen's PS Plus for brain health and stress management.\nAt the end of the 2-month study, out of 220 women under the age of 40 who consumed the product regularly, 23 women (10.45%) reported that they noticed relief of premenstrual syndromes.\n\"We also have begun an ongoing, double-blind, randomized, placebo-controlled clinical trial with daacro GmbH, Trier, Germany, to learn more how Lipogen's formulation can help alleviate PMS and PMDD symptoms.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "It\u2019s clear from the release that Lipogen, the company that issued the release, also funded the study. According to the release:\n\u201cWhen the benefits of phospholipids on PMS and PMDD came to light through Lipogen\u2019s research, we immediately explored its potential,\u201d says David Rutenberg, CEO for Lipogen.", "answer": 1}, {"article": "The Claim: Red palm oil, a deep orange fat pressed from the palm tree fruit, is a superfood\u2014packed with healthy antioxidants and good for the heart, say companies who sell it.\n\nThe Verdict: The colorful oil is rich in tocotrienols, nutrients in the vitamin E family, and carotenoids, which the body converts into vitamin A. Several studies suggest possible benefits in stroke and liver disease from vitamin extracts made from the oil, but so far there isn\u2019t proof that consuming the oil can ward off disease, scientists say.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A strength of the story is that there are quotes from several sources. It\u2019s nice to see that in a story that offers a broad overview of a topic, valuable space is still given to conflicts; in this case, pointing out that the studies hinting at some potential health benefits were funded by industry groups and that the lead author is a paid consultant to a manufacturer.", "answer": 1}, {"article": "For Brittany Scott, a Cortland resident whose husband took the SpermCheck Fertility test, however, it seemed a little more complicated than a pregnancy test.\n\"It may provide (an opportunity for) both physicians and couples to take a closer look at ways for men to step up to the plate and optimize their reproductive potential,\" said Dr. Robert Brannigan, urologist at Northwestern University Feinberg School of Medicine.\nThere are several characteristics of sperm alone \u2014 at least three that aren't addressed by SpermCheck \u2014 that affect male fertility.\nThe test is not intended to be a complete semen analysis or an overall indicator of a man's fertility, Lopez said.\nThe result showed that the father of four's sperm count was below the test's threshold.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story extensively quotes Dr. Robert Brannigan, a urologist at Northwestern University Feinberg School of Medicine. And Brannigan provides much needed context for the test. For example: \u201cThe male reproductive system should not be oversimplified, Brannigan said. There are several characteristics of sperm alone \u2014 at least three that aren\u2019t addressed by SpermCheck \u2014 that affect male fertility. In addition, hormones and the delivery of the sperm play a part.\u201d The story also quotes\u00a0Brad Imler, the president of the American Pregnancy Association, who provided good comments.", "answer": 1}, {"article": "\u201cBut there were other components to it -- there was oppositional defiant disorder, there were some [autism] spectrum-like behaviors, and difficulty later on socializing with other children.\u201d\n\nOppositional defiant disorder is one of the most common conditions linked to ADHD in children and is characterized by anger, tantrums, opposition to authority and, sometimes, aggressive behavior.\n\u201cThe easiest way to get their brain to become coordinated is by making their body coordinated, so a large part of what we're doing is this sensory motor interaction, building their muscle tone, building their strength, building their body spatial awareness.\u201d\n\nThe program also incorporates what Melillo calls \u201cbionutritional\u201d guidelines to make sure children are getting the proper nutrition for optimal learning.\n\u201cShe couldn't do anything to stop it, and I really began to realize that her brain wouldn't let her, even if she wanted to be good, her brain wasn't allowing her to.\u201d\n\nMallory\u2019s oppositional behavior reached a fever pitch when the family moved from their home in Hoboken, N.J. to the suburb of Glen Rock, N.J. in 2014.\n\u201cI think I knew from very early on that she was different, but she was my first child, so I figured anything that I saw, there was a chance that she would grow out of it,\u201d Amy Oakes told FoxNews.com.\nThe spectrum of ADHD and related disorders is broad, and there is no one-size-fits-all treatment.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not quote any sources independent of the franchise that sells the \u201ctraining\u201d to families. The fact that the story ends with a link to the commercial Brain Balance Centers website reinforces the notion that this is more promotion than journalism.", "answer": 0}, {"article": "Current evidence definitely supports screening, he said.\nThe higher rates, coupled with the majority of cases being found in early, treatable stages, point toward the need for ongoing, accessible free screening in high-risk populations and underserved regions, say researchers at the Georgia Cancer Center at Augusta University.\nThe researchers note that a percentage of the patients presenting at screening had early symptoms, like a persistent cough, so the rate of cancer detection in patients who showed no indication of disease was 2.2 percent, still double the rates of previous studies.\nThe pioneering National Lung Screening Trial, which began in 2002 and included 33 largely urban centers, found 292 cases of lung cancer among the 26,722 high-risk individuals screened in the first year, for a rate of 1.1 percent.\nThe combination technology is often used to visualize other tumor types throughout the body and many patients require an injection of sugar dye, which will be taken up by the tumor but must first circulate for about an hour before the scan is done.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "While the story doesn\u2019t explicitly state where the funding for the initiative came from, it\u2019s also not clear whether there was any external source of funding. Based on the description, the study comes across as a clinician-driven initiative designed to make use of down time on diagnostic equipment. There does not appear to be a conflict of interest.", "answer": 1}, {"article": "Analytics firm GlobalData has forecast that CGRP antibodies will generate combined sales of $4 billion by 2026.\nSimilar drugs are under development at companies including Eli Lilly & Co and Teva Pharmaceutical Industries Ltd, but Amgen emphasizes that Aimovig is the only one that targets the CGRP receptor pathway, rather than CGRP itself.\n\u201cThis is a trial in really difficult to treat patients,\u201d professor Uwe Reuter, trial investigator and managing medical director at Charit\u00e9 Universit\u00e4tsmedizin in Berlin, told Reuters in a telephone interview.\nThe 12-week trial, presented this week at the annual meeting of the American Academy of Neurology, involved 246 patients suffering four to 14 migraine headaches a month who had tried two to four preventive treatments that either did not work for them or had intolerable side effects.\nAmgen has partnered with Novartis AG to co-commercialize Aimovig in the United States, while Amgen has rights to the drug in Japan and Novartis has rights to commercialize in rest of world.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only sources in the story are the trial\u2019s lead investigator and an Amgen official. Many aspects of this coverage could have been improved with an independent voice.", "answer": 0}, {"article": "It may actually help you live longer, according to new research from the Harvard T.H.\nHowever, they note, \u201cthere is no clear basis for believing that the effects of optimism on health differ by sex or race.\u201d\n\nFinally, the researchers emphasize that while some people may think they\u2019re just not optimistic, it is something that is modifiable.\nOptimistic people are likely to have better diets, they\u2019re exercising more, and they\u2019re getting better sleep.\u201d\n\nHowever, even after the researchers accounted for these factors, the results still suggest that optimism itself is linked to a longer life.\n\u201cOptimism is linked with lower inflammation and healthier biomarker levels and lipid levels, so there could be an independent effect on optimism.\u201d\n\nShe said her team plans to focus more on the potential impact of optimism on biological functioning in future research.\nTo measure levels of optimism, participants were asked to use a five-point scale to either agree or disagree with six statements, such as, \u201cIn uncertain times, I usually expect the best.\u201d\n\nThe results showed that the most optimistic women \u2013 those in the top 25 percent \u2013 had a nearly 30 percent lower risk of dying from any of the diseases analyzed in the study when compared to the least optimistic participants in the lowest 25 percent.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two of the study\u2019s authors are interviewed. Chatting with an outside source would definitely have strengthened this story, and may have exposed the reverse causation issue we\u00a0previously\u00a0brought.", "answer": 0}, {"article": "Contact: Paul R. Sanberg at psanberg@health.usf.edu, Shinn-Zong Lin at shinnzong@yahoo.com.tw, or Associate Editor Samantha Portis at celltransplantation@gmail.com\n\"There are an increasing number of patients with advanced coronary artery disease that are not amenable to surgical or percutaneous revascularization,\" said study co-author Dr. Timothy D. Henry of the Cedars-Sinai Heart Institute.\nIn addition, there was a significant reduction in the time to first hospitalization in cell-treated patients, with a trend toward reduction in mortality as well.\n\"The results of our study are even more provocative given that the outcomes represent the effect of a single treatment,\" wrote the researchers.\nAccording to the researchers, the study demonstrated that CD34+ cells have the ability to restore the microcirculation and improve myocardial tissue perfusion.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not mention funding sources or address potential conflicts of interest. For example, as the relevant journal article notes: \u201cBaxter Healthcare sponsored the study and was responsible for the conduct of the investigation.\u201d At least two study co-authors were former Baxter employees. Another author is listed in the paper as being an employee of Caladrius Biosciences, but a cursory search finds that he was previously a vice president at Baxter. Yet another author has received an honoraria from Baxter, and another has received research funding from Baxter. The paper was not as transparent about these conflicts of interest as it should have been, and the release fails to address them at all. In addition, the release appears to have been issued by the \u201cCell Transplantation Center of Excellence for Aging and Brain Repair.\u201d\u00a0 Given that the researcher cited in the release is based at the Cedars-Sinai Heart Institute, one could assume that the center is located there. But that would be wrong. There is no center by that name. Instead it appears to be a hybrid of the journal name and the name of the center where it is housed. This is confusing (at best) and misleading (at worst), since the center had nothing to do with the research. Frankly, this is very confusing for readers.", "answer": 0}, {"article": "June 30, 2010 -- A drug used in Europe as emergency contraception may also treat painful uterine fibroids, researchers say.\nIt is effective for up to five days after unprotected sex.\nThe new drug is manufactured by HRA Pharma, a European pharmaceutical company, which provided funding for the new study.\nSurgery is often the only way to treat painful, bleeding fibroids, but surgery too can sometimes compromise fertility.\nAs many as 80% of all women have uterine fibroids (noncancerous growths in the uterus), according to the nonprofit National Uterine Fibroids Foundation.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted multiple independent experts.", "answer": 1}, {"article": "Years later, on the surface.\n\"The idea is when you get the treatment and it is successful and the pain gets better then you can start cutting down the on the medication, and see how low you can go\" said Dr. Richard Cruciani.\nThis therapy is being tested at several centers around the world and more study is needed, but this new variation on an ancient concept is promising -- using electricity to try to zap the perception of pain.\n\"I am in a lot less pain today and now it just feels as though I have a sunburn that is a few days old,\" he said.\nNow he's trying something that might seem shocking: an electrical current applied to his head - part of a clinical trial at Beth Israel Medical Center in New York.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Both sources interviewed are interested parties. At least one of them is a clinical investigator for the trial, the other his colleague at the same institution. \nThe reporter should have interviewed at least one independent expert on chronic pain for some context.\nIn addition, the only subject interviewed reports a positive outcome. \u00a0", "answer": 0}, {"article": "May 17, 2012 -- An extract from the Chinese herb kudzu may help drinkers cut down on drinking, according to a new pilot study.\nIt is one of the substances known as isoflavones found in kudzu.\nThe study is published in Drug and Alcohol Dependence.\nHe studied the extract puerarin.\n\"It didn't stop the drinking,\" says researcher David M. Penetar, PhD, assistant professor of psychology at McLean Hospital and Harvard Medical School.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story points out the extensive links between the manufacturer of the supplement and the study authors. It consults an independent expert who injects an important note of skepticism into the coverage.", "answer": 1}, {"article": "Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.\nArticle: \"Classification of Newborn Ear Malformations and their Treatment with the EarWell Infant Ear Correction System\" (doi: 10.1097/PRS.0000000000003150)\n\nFor more than 70 years, Plastic and Reconstructive Surgery\u00ae (http://www. )\nThe official journal of the American Society of Plastic Surgeons, Plastic and Reconstructive Surgery\u00ae brings subscribers up-to-the-minute reports on the latest techniques and follow-up for all areas of plastic and reconstructive surgery, including breast reconstruction, experimental studies, maxillofacial reconstruction, hand and microsurgery, burn repair, and cosmetic surgery, as well as news on medico-legal issues\n\nThe American Society of Plastic Surgeons is the largest organization of board-certified plastic surgeons in the world.\nFebruary 28, 2017 - For infants with congenital malformations of the ear, a treatment system called EarWell can gently reshape the ear--avoiding the pain and cost of later surgery, reports a study in the March issue of Plastic and Reconstructive Surgery\u00ae, the official medical journal of the American Society of Plastic Surgeons (ASPS).\nDr. Byrd comments, \"The EarWell system is effective in eliminating or reducing the need for surgery in all but the most severe congenital ear malformations.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release refers to study co-author H. Steve Byrd four times, but never mentions that he has a financial interest in EarWell systems. In fact, as the journal article states: \u201cDr. Byrd has a royalty agreement with Becon Medical [which markets EarWell] for his work designing the EarWell device.\u201d And Byrd isn\u2019t the only one. Another of the co-authors is also listed in the journal article as having an investment in Becon Medical. This sort of conflict-of-interest information needs to be disclosed in a news release.", "answer": 0}, {"article": "NEW YORK (Reuters Life!)\nThe study, led by Hung Fu Tseng, a research scientist at Kaiser Permanente in Southern California, compared about 75,000 vaccinated members of the Kaiser Permanente Health plan with about 225,000 similarly aged members who weren\u2019t vaccinated.\n- The herpes zoster vaccine could prevent tens of thousands of cases of shingles each year if it was offered to everyone who is eligible, with vaccinated adults half as likely to develop shingles, a study said.\nCost is one hurdle, with the vaccine sometimes costing up to $200 for people whose insurance doesn\u2019t cover it.\nEveryone in the study, published in the Journal of the American Medical Association, was at least 60 years old, and the researchers didn\u2019t include anybody for whom the live vaccine is not recommended.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\n\nThere is a source who is independent of this study; however, Dr. Oxman was the lead researcher of the clinical trial that led to the approval of this vaccine. The description of him as being \u201cinvolved in a previous study of the vaccine\u201d is inadequate to describe his perspective on this vaccine. This story also fails to tell readers about study funding (from the Kaiser Permanente health plan) or support that the vaccine maker has given to some of the researchers for other research projects.\nThe comments from Dr. Oxman dealt only with benefits of vaccination. The story would have been better if there had been independent comment on the study itself, both what it adds to what we know and what potential weakness or limits there are in this sort of study. There\u2019s still a strong shared decision-making message that should be the take-home, but that didn\u2019t come across in the story \u2013 perhaps because of who was interviewed.\n", "answer": 0}, {"article": "Without such interactions, language and social skills do not develop.\nThe treatment, dubbed Early Start Denver Model or ESDM, offers a child 20 hours a week of one-on-one treatment with a trained therapist.\nAs measured by an electroencephalogram (EEG), small children's brains show a specific pattern of activity when they look at a picture of a human face.\n\"We jump-started and improved the responses of children's brains to social information,\" says Dawson, professor of psychiatry at the University of North Carolina and chief science officer at Autism Speaks.\nBut that's not all, researchers Geraldine Dawson, PhD, and colleagues report.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We thought the story spent too much time with the lead author of the study, but we appreciated the comments from Arthur L. Beaudet, MD, professor of molecular and human genetics, pediatrics, and molecular and cellular biology at Baylor College of Medicine, Houston. He said, \u201cTo the extent early intervention helps brain development, it is more likely to help by letting the brain compensate and get around the problems rather than reverse them. \u2026We do know if you damage the brain of a young child, like in an accident, the infant brain has a tremendous ability to recover and get around the problem.\u201d More voices like this would have helped readers understand the importance of the findings and the likelihood that they would have a broad application for children with autism.\nIt is a low bar to get one outside source but at least this was done.", "answer": 1}, {"article": "Taiwanese scientists say a blood thinner drug based on venom from the Wagler's pit viper was effective in mice, and might prove safer than current anti-clotting meds for humans one day.\n\"The potential development of a new agent based on snake venom that could have similar beneficial effects on preventing blood clotting, and potentially cause less bleeding side effects, is an exciting discovery that warrants future investigation,\" Marzo added.\nWhen mixed with blood, the new compound prevented blood cells called platelets from clotting.\nStill, experiments in animals often don't translate to success in humans, so further research is needed.\nAlso, mice that received the drug had slower blood clot formation than untreated mice, but the treated mice did not bleed longer than untreated mice.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There was at least one independent source. But the story didn\u2019t disclose that the researcher interviewed in the story has a patent application for the compound, and other financial interests that are related.", "answer": 0}, {"article": "But the scientific evidence has been slim.\nWhat was lacking was clear evidence that taking melatonin in supplement form had the same sleep-inducing effect.\nThere's no question that the hormone helps the brain tell a.m. from p.m.--regulating sleep cycles and circadian timing--when it is produced naturally by the body at night.\nMillions of jet-lagged and sleep-deprived Americans--citing countless self-help articles--insist they do.\nThat's why there's so much interest in a study in the current issue of the journal Sleep.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only sources of information appear to be related to the single study mentioned and the lead author of the paper on that study. ", "answer": 0}, {"article": "LONDON (Reuters) - Scientists in Canada and Sweden have used laboratory-made biosynthetic corneas to restore vision to patients in a small human trial, and shown for the first time that they can help to repair damaged eye tissue.\nThe researchers found that, eventually, the cells and nerves from nine of the 10 patients regrew completely and packed themselves into the implant, resulting in a kind of \u201cregenerated\u201d cornea that looked and functioned like normal, healthy eye tissue.\n\u201cThe results were pretty encouraging and there is great potential here,\u201d Fagerholm said in a telephone interview.\nAlthough the fragile film is easily destroyed by trauma or infection, replacement human corneas can be used to restore vision, although this depends on a steady supply of donors.\n\u201cWith further research, this approach could help restore sight to millions of people who are waiting for a donated human cornea for transplantation.\u201d\n\nThe cornea is a tiny piece of transparent, film-like tissue that covers the surface of our eyes.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources. The story does make the effort of explaining that a biotech company provided the substance used to create the corneas, giving readers a hint that this could be primarily a commercial enterprise.", "answer": 0}, {"article": "AMD, the No.\n\"Results suggest a new path forward in our fight against AMD that may even include a strategy to prevent those at risk of the disease from ever developing it,\" said Brian McKay, Ph.D., associate professor, Department of Ophthalmology and Vision Science, University of Arizona.\nThis research, titled \"Mining Retrospective Data for Virtual Prospective Drug Repurposing: L-DOPA and Age-related Macular Degeneration,\" was supported by National Center for Advancing Translational Sciences, National Human Genome Research Institute, Research to Prevent Blindness, Bright Focus Foundation, The Edward N. & Della L. Thome Memorial Foundation, Wisconsin Genomics Initiative, National Eye Institute, Marshfield Clinic and University of Arizona.\nTo test this, researchers examined health records of 37,000 Marshfield Clinic patients looking for those with AMD, those taking L-DOPA and those with both L-DOPA and AMD.\nThe retrospective study was led by researchers at Marshfield Clinic Research Foundation, University of Arizona, Medical College of Wisconsin, University of Miami, Essentia Health, Stanford University and University of Southern California.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release identifies the funding sources of this research but does not alert readers to the conflict of interest disclosure found in the published results. While the lead author has not yet received income from the drug application, he is the patent holder. \u201cDr. McKay is an inventor on an approved patent for the use of L-DOPA to treat or delay AMD,\u201d according to the published paper. Just because he hasn\u2019t received royalties yet doesn\u2019t mean he or his institution will never accept royalties if and when L-DOPA is approved for treating AMD. The release should have called attention to this.\u00a0 ", "answer": 0}, {"article": "Staying sexually active\u2014and considering sexuality an important part of life\u2014may be linked to higher cognitive functioning as people age, according to a study in the March issue of the American Journal of Geriatric Psychiatry.\n\nOlder men and women who were satisfied with their sexual relationships and considered sexuality an essential component of aging performed better on tests of cognitive function than those who felt sexuality and intimacy were unimportant, the research showed.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources are quoted. An expert would likely have emphasized the limitations of a study like this.", "answer": 0}, {"article": "Abaloparatide works differently from Forteo and improves bone density more than Forteo, Miller said.\n\"If this gets approved, and there is no reason to think it won't, this will be the second drug available for the treatment of high-risk osteoporosis,\" said lead researcher Dr. Paul Miller of the Colorado Center for Bone Research.\nThe editorial was co-written by Dr. Anne Cappola of the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, associate editor of JAMA, and Dr. Dolores Shoback of the University of California, San Francisco.\n\"I am hoping that having a second drug available, that it will help reduce the cost,\" he said.\n\"Everybody is going to want to know if this is inferior or superior to Forteo,\" she said, adding that this is an early study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Dr. Caroline Messer of the Center for Pituitary and Neuroendocrine Disorders at Lenox Hill Hospital was interviewed as an independent source. She correctly pointed out that a head-to-head trial directly comparing Forteo and abaloparatide is needed in the next step of research.\nThe story also discloses that the research study was\u00a0funded by the maker of abaloparatide, Radius Health.\nHowever, the story doesn\u2019t\u00a0point out that the study author (whom they quote extensively) also serves on a Radius Health Advisory Board.", "answer": 0}, {"article": "In the study in Nature, investigators show that HIF-2 inhibition was able to control metastatic kidney cancer even after 7 lines of prior therapy.\nAs sometimes happens in patients, mice on sunitinib were sickly and lost weight, whereas mice on the HIF-2 inhibitor gained weight while on the study,\" he said.\nNearly 400,000 Americans are now living with a diagnosis of kidney cancer and more than 60,000 people are expected to be diagnosed with kidney cancer this year, according to the National Cancer Institute.\nIn a previous report, Dr. Kevin Courtney, Assistant Professor of Internal Medicine and a coauthor of the current study, reported at the American Association of Clinical Oncology annual meeting that HIF-2 inhibitors were safe in patients and had activity even in heavily pretreated patients.\nThe Harold C. Simmons Comprehensive Cancer Center is the only NCI-designated comprehensive cancer center in North Texas and one of just 47 NCI-designated comprehensive cancer centers in the nation.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release was particularly fulsome in explaining the multiple, overlapping conflicts of the researchers, the sponsoring pharmaceutical company and the academic institution that has a financial stake in this discovery. Well done.", "answer": 1}, {"article": "\"Mindfulness-based therapeutic interventions promote the use of meditative practices to increase present-moment awareness of conscious thoughts, feelings, and body sensations in an effort to manage negative experiences more effectively.\u201d\n\nChildren who are at a high risk for bipolar disorder or other anxiety disorders, such as the participants, often have poor coping skills when confronted by stress, and only a lucky few get help.\nBoth findings reaffirm the potential that mindfulness therapy could bring to the table.\nBut a team of researchers from the University of Cincinnati set out to explore other treatment options that focus more on the mind and less on pharmaceutical solutions.\nJournal of Child and Adolescent Psychopharmacology.\nSome mental health professionals have suggested that mindfulness exercises can help bridge the treatment gap, and there is some encouraging, if early, evidence showing that these techniques can be used to prevent relapses of depression or anxiety.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes only two researchers \u2014 and both were authors of the paper being discussed.", "answer": 0}, {"article": "A growing body of evidence suggests that weight-loss surgery is more effective than diet and exercise at getting rid of Type 2 diabetes.\n\nA small but rigorous randomized trial published Wednesday in JAMA Surgery provides the latest evidence showing the superiority of bariatric surgery over lifestyle changes in resolving the chronic condition involving high blood sugar.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The Not Satisfactory rating here doesn\u2019t tell the whole story. The article makes good and broad use of sources, beyond the authors of the research publication. The article has some input from those who point out the need for longer term follow-up. And it does an especially good job of bringing out information about clinical guidelines and how they might change in response to the growing evidence for the benefits of weight loss surgery. Alas, the editorialist quoted at the end of the study, who very enthusiastically endorses wider use of bariatric surgery,\u00a0acknowledged speaking fees from a number of companies who manufacture bypass surgery equipment. The story does not alert readers to this conflict of interest, which triggers an automatic Not Satisfactory rating here.", "answer": 0}, {"article": "\"All our patients considered the [treatment] to be worthwhile and beneficial, though some patients experienced side effects,\" study head Weiqiong Gu, MD, of Ruijin Hospital in Shanghai, tells WebMD.\n\"We now have a unique approach with some positive findings, but it's still early.\nThe study was very small, and the procedure is not ready for widespread use.\nOne patient has gone without insulin injections for 3.5 years.\nThe blood stem cells are then removed from the body and frozen.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The chief scientific and medical officer of the American Diabetes Association was quoted with independent perspective.", "answer": 1}, {"article": "For more information about Wolters Kluwer's solutions and organization, visit http://www.\n\"It seems that migraine surgery patients can recover function and ability to cope with pain very well after surgery, in stark contrast to what has been shown in other pain conditions,\" Dr. Austen and coauthors write.\nThe new study shows \"continued positive outcomes\" after migraine surgery in appropriately selected patients, including large improvements in migraine-related disability.\nJanuary 2, 2018 - In addition to reducing headache frequency and severity, surgical treatment for migraine leads to significant improvements in everyday functioning and coping ability, according to a study in the January issue of Plastic and Reconstructive Surgery\u00ae, the official medical journal of the American Society of Plastic Surgeons (ASPS).\n\"Pain questionnaires used in the evaluation of better-understood and more common pain syndromes have not been applied to migraine surgery,\" Dr. Austen and coauthors write.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release does not mention the funding sources, and that earns a Not Satisfactory rating here. The study does disclose that none of the researchers have conflicts of interest.", "answer": 0}, {"article": "While a growing body of evidence has linked tree nuts such as pecans to reduced risk of CVD, this is the first study to look at the effects of pecan consumption on factors other than blood lipid levels and specifically those related to T2D.\nThe study was funded by the National Pecan Shellers Association.\nObesity is a risk factor for T2D, and both obesity and T2D increase CVD risk.\nWhat's really interesting is that just one small change - eating a handful of pecans daily - may have a large impact on the health of these at-risk adults.\"\nFor four weeks at a time, subjects ate either a control diet with no nuts or the same diet with pecans substituted for 15 percent of the total calories.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release made it clear that the study was funded by the National Pecan Shellers Association. The published study also noted that the researchers had no conflicts of interest.", "answer": 1}, {"article": "Related: CDC study finds opioid dependency begins within a few days of initial use\n\u201cIt\u2019s an avenue that shows some promise.\u201d\n\nAlthough research on humans is not yet planned, study authors Kim Janda and Paul Bremer, chemists at the Scripps Research Institute, are encouraged about this next step.\nThe current study of the vaccine, published in the Journal of the American Chemical Society, follows eight years of laboratory research and studies in rodents that indicated the compound could neutralize heroin at different doses.\nIn this case, the vaccine introduces a piece of the heroin molecule to the immune system.\n\u201cWe believe this vaccine candidate will prove safe for human trials,\u201d said Janda in a statement.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The comments of an independent knowledgable\u00a0source provide balance to the story. However, the story did not disclose that the researcher, Kim D. Janda, has filed a\u00a0 patent application on this technology. See \u201cHeroin Haptens, Immunoconjugates and Related Uses.\u201d", "answer": 0}, {"article": "(Philadelphia, PA) - Reversing memory deficits and impairments in spatial learning is a major goal in the field of dementia research.\n\"This is an old drug for a new disease,\" he added.\nMicroscopic examination revealed vast differences in synaptic integrity between the groups of mice.\n\"The research could soon be translated to the clinic, to human patients with Alzheimer's disease.\"\nEach TUHS member organization is owned and operated pursuant to its governing documents.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources are named.", "answer": 1}, {"article": "So, the investigators asked, could a scan identify those whose actual risk is lower than what was calculated?\nBut if that person has a calcium score of zero, the actual risk turned out to be 4 percent, below the 7.5 percent threshold for recommending a statin according to the guidelines and below the 5 percent risk for considering a statin.\nFor example, a person who, according to the current risk calculator, has a 12 percent risk of a heart attack in the next decade should take a statin, the guidelines say.\nAccording to today\u2019s guidelines, half had risk scores high enough that a statin would be recommended or should be considered.\nDr. Krumholz and Dr. Khurram Nasir, a preventive cardiologist at Baptist Health South Florida, who conceived the new study, reasoned that research on heart scans had not been designed to help doctors make treatment decisions they face today.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This was a split decision that we ultimately ruled Not Satisfactory. There are multiple independent sources in the story, so it clearly addresses that element of the criterion. However, the story does not report the financial relationships some of the study authors have with manufacturers of scanners and other medical devices. One of our reviewers argued that these scanning machines are essentially generic and that therefore a conflict of interest disclosure is not relevant in this case. Two others voted that the potential conflict, minimal though it might be, was still directly relevant to the story and merited a brief mention. This is an instance where a binary Satisfactory/Not Satisfactory rating does not capture the nuance involved in our decision-making, which is why we always encourage readers to pay more attention to the comments than the ratings.", "answer": 0}, {"article": "For more information, please visit http://www.\nThe research, conducted at LA BioMed, found a reduction in the amount of low-attenuation plaque, or \"soft plaque,\" in the arteries of patients with metabolic syndrome who took Aged Garlic Extract.\n\"We have completed four randomized studies, and they have led us to conclude that Aged Garlic Extract can help slow the progression of atherosclerosis and reverse the early stages of heart disease.\"\nA follow-up screening conducted a year after the initial screening found those who had taken Aged Garlic Extract had slowed total plaque accumulation by 80%, reduced soft plaque and demonstrated regression (less plaque on follow-up) for low-attenuation plaque.\n\"This study is another demonstration of the benefits of this supplement in reducing the accumulation of soft plaque and preventing the formation of new plaque in the arteries, which can cause heart disease,\" said Matthew J. Budoff, MD, an LA BioMed lead researcher.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "While this release does mention that the study was funded by a company that produces the garlic supplement and that the study\u2019s main author received payments from that company, it doesn\u2019t go nearly far enough with disclosures. The paper, published as a paid supplement to the Journal of Nutrition, needed to be labeled as such. Paid supplement articles differ from routine, peer-reviewed\u00a0 papers published in the journal. The work was presented at a symposium sponsored primarily by commercial interests from the nutrition industry and the main author served as the paid chair of that meeting. All of this is information that readers should have to properly evaluate the value of the information.", "answer": 0}, {"article": "Overall, research is suggesting that CT scans of people at risk of lung cancer might make a dent in cancer mortality, and it\u2019s possible that more frequent screening might make an even bigger dent, Hanley noted.\nThat previous finding was \u201cvery good news in the field,\u201d said Dr. Bruce Johnson of the Dana Farber Cancer Institute, who treats lung cancer patients and reviewed the results for Reuters Health.\nThe data are \u201cconsistent\u201d with earlier studies but there are still many issues to resolve regarding lung cancer screening, Johnson said.\nIn 2006, Dr. Claudia Henschke, currently based at Mount Sinai School of Medicine and Arizona State University, caused a stir when she published a study concluding that 80 percent of lung-cancer deaths could be prevented through widespread use of spiral CT.\nA total of 64 people died in the screened population, the authors report \u2014 but applying the death rate among people with the same underlying characteristics in one of the unscreened populations, they estimated that the number of deaths would have been 100.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\n\nThe story quotes two independent experts who provide valuable perspectives on this study. We wish more stories provided similar attention to independent experts. It also notes that Dr. Henschke has been criticized in the past for accepting funding from tobacco companies and that this study was supported in part by manufacturers of CT scanners.", "answer": 1}, {"article": "MONDAY, Dec. 17, 2012 (HealthDay News) -- For patients whose high blood pressure cannot be controlled despite taking several medications, a short burst of radio waves at the nerves around the kidneys may do the trick, a small new study says.\nThe findings could be a significant step in treating people with resistant hypertension, which is a major risk factor for heart attack and stroke, the researchers said.\nFor the study, an international team lead by Dr. Murray Esler, professor and senior director of the Baker IDI Heart and Diabetes Institute in Melbourne, Australia, assigned 35 patients to renal denervation and compared them to 47 patients who had already had the procedure.\n\"Participants' kidneys were not damaged or functionally impaired,\" Esler said in a journal news release.\nIf it is applicable, it could mean patients need not take blood-pressure drugs, Esler suggested.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Medtronic funding\u00a0 was disclosed.\nThere was an independent expert who provided some needed balance \u2013 although that expert was not quoted about any real critical analysis of the evidence.\nNonetheless, enough to get a satisfactory score.", "answer": 1}, {"article": "We're sorry, but we seem to have lost this page.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does use some independent sources, but it does not identify conflicts of interest. Again, this is a big missed opportunity because the authors of this paper have potential conflicts. They have worked with many drug and device makers, including Siemens, one of the big MRI\u00a0makers, as well as: Boehringer Ingelheim, ImaRx Therapeutics, Photothera, Cerevast, CoAxia, Sanofi, Solvay Pharmaceuticals, GlaxoSmithKline, Wyeth, Genentech, LifeCycle Pharma A/S, ReNeuron, Novovision, NeuroLogica Corporation, Avanir Pharmaceuticals, Micromedex, AstraZeneca, Bayer Schering Pharma, Takeda Pharmaceutical Company Limited, Embrella Cardiovascular, Millennium Pharmaceuticals, Novo Nordisk, Otsuka Pharmaceutical Co., Pfizer, Mitsubishi Tanabe Pharma Corporation, PDL BioPharma, Inc., Terumo Neurovascular Monitoring, Guidant, Cordis, Bard Peripheral Vascular, Inc., Abbott, Boston Scientific, Olea Medical, Lantheus Medical Imaging, and, believe it or not, even more.\u00a0Two hold patents on MR devices. Might they stand to beneft?", "answer": 0}, {"article": "Researchers say future studies should look more closely at the benefits of massage and focus on cost-benefit analysis.\nFor an active person, this was devastating.\nOnly about one-third of patients receiving the usual care experienced similar relief.\nPeggy O'Brien-Murphy was among the study participants.\nSooner or later, back pain seems to get most of us.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No truly independent source was interviewed \u2013 only two researchers involved in the study.", "answer": 0}, {"article": "Aug. 10, 2011 -- Two of three patients dying of chronic lymphocytic leukemia (CLL) appear cured and a third is in partial remission after infusions of genetically engineered T cells.\nMoreover, the signal does not call down the deadly all-out immune attack -- the feared \"cytokine storm\" -- that can do more harm than good.\n\"Here's this guy, the handwriting is on the wall, any hematologist will tell you he is a goner -- this guy was essentially cured,\" Galipeau tells WebMD.\nThe treatment success came in a pilot study that was only meant to find out whether the treatment was safe, and to determine the right dose to use in later studies.\n\"Within three weeks, the tumors had been blown away, in a way that was much more violent than we ever expected,\"June says in a news release.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Both stories could have used more outside sources. In each case, only one outside source was quoted. In the WebMD case, the outside source was overly effusive. In the Reuters case, the outside source did a better job tempering some of the enthusiasm of the authors with a realistic assessment of the treatment\u2019s prospects.", "answer": 1}, {"article": "Autism is a group of complex brain developmental disorders characterized by impairments in social interaction, communication, and stereotypical and repetitive behaviours.\n\"We used some of the most widely used assessments of social responsiveness for children with autism,\" said autism expert, Associate Professor Adam Guastella of the Brain and Mind Centre.\nThe study, led by researchers at the University's Brain and Mind Centre, is thought to be the first evidence of a medical treatment for social impairments in children with autism.\n\"We found that following oxytocin treatment, parents reported their child to be more socially responsive at home, and our own blind independent clinician ratings also supported improved social responsiveness in the therapy rooms of the Brain and Mind Centre,\" he said.\nIt is also the first clinical trial investigating the efficacy, tolerability and safety of intranasal-administered oxytocin in young children with autism.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funders of the study aren\u2019t named in the release. In addition to Australian government and foundation grants, the project was supported by a private individual, and the lead investigator\u2019s research work is currently supported by Servier Australia and Pfizer (manufacturer of Pitocin), according to the published study.", "answer": 0}, {"article": "CHICAGO \u2013 Initial findings from a randomized phase III clinical trial show that patients with advanced squamous non-small-cell lung cancer (NSCLC) benefit more from initial treatment with PD-L1 targeted immunotherapy atezolizumab (Tecentriq\u00ae) and chemotherapy than from chemotherapy alone -- 29% had a reduced risk of disease worsening or death compared with those who received chemotherapy alone.\nOutcomes for only two of the groups, however, are being reported in this presentation:\n\nOutcome data for the third treatment group, which received atezolizumab with a slightly different chemotherapy regimen (carboplatin and paclitaxel), are not yet available.\nThe findings will be featured in a press briefing today and presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.\nThis study received funding from F. Hoffmann-La Roche Ltd.\n\nView the disclosures for the 2018 ASCO Annual Meeting News Planning Team.\nThe researchers will explore tumor PD-L1 expression and other molecular markers, such as tumor mutational burden (TMB), that may predict whether a patient will benefit from this treatment regimen.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that the trial received funding from F. Hoffmann-La Roche. We will give the package of release and abstract a satisfactory rating because the abstract includes a long list of ties between the researchers and industry. The disclosure statement is almost as long as the description of the trial and its results.", "answer": 1}, {"article": "Moscona said tests were needed that would show the drug actually helped reduce disease symptoms in animals.\n\u201cDevelopment of effective antiviral drugs and vaccines for human parainfluenza virus has lagged far behind influenza, despite the recognized impact of these diseases in children\u201d and adults, \u201cparticularly the elderly, immunocompromised and patients with underlying airway disease.\u201d\n\nParainfluenza viruses are not closely related to flu but belong to another family of viruses called paramyxoviruses.\nThe researchers said that means patients with flu-like symptoms could get the drug without the need for a test to show whether their infection was caused by influenza or parainfluenza.\nA spokesman for NexBio, David Wurtman, said the company would seek Food and Drug Administration approval to test Fludase in people with parainfluenza.\nBecause Fludase affects the human cells that viruses infect, not the virus itself, it is less likely to cause the virus to develop resistance, the company believes.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "       \n \nThe story fails in just about every aspect of this criterion.\u00a0No experts  in the field other than those involved in the research study are  quoted.\u00a0Interestingly, 6 of the 9 authors of the study are employees of  NexBio, the company that produces the drug.\u00a0One of the authors is listed  as the inventor of the drug in an approved patent for its use in the  treatment of influenza and parainfluenza.\u00a0While these facts do not necessarily impugn the study result, failure to note them in the story is a major  omission.\n ", "answer": 0}, {"article": "An ongoing study will evaluate the product over two years.\nThere are as yet no plans to market Souvenaid, so the cost hasn't been established, company spokesman William Green said.\n\"There isn't a clear diet that prevents you from getting Alzheimer's disease or improves your memory,\" Thies said.\nIf it appears to have a positive effect, then it may be something that could benefit patients even before definitive symptoms of Alzheimer's appear, Wurtman said.\nThe new drink, called Souvenaid, may actually stimulate the growth of new synapses, said the drink's inventor, Massachusetts Institute of Technology scientist Dr. Richard Wurtman.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The Alzheimer\u2019s Association spokesman added some needed perspective. Manufacturer support for the study, and MIT\u2019s patent on the product, were disclosed. It would have been better to additionally have a scientist who studies nutrition and neurodegenerative disease comment on the study.", "answer": 1}, {"article": "\"In the absence of treatment alternatives, reverse total shoulder arthroplasty [RTSA] is a justifiable treatment for patients with a massive, irreparable rotator cuff tear before the age of 60,\" according to the report by Christian Gerber, MD, of the University of Zurich and colleagues.\nThe RTSA technique--using an implant in which the natural locations of the shoulder \"ball and socket\" are reversed--uses other muscles to move the shoulder, providing an alternative when the rotator cuff is severely damaged or destroyed.\nThe new study focused on long-term outcomes of RTSA in patients under age 60.\nThe company, headquartered in Alphen aan den Rijn, the Netherlands, serves customers in over 180 countries, maintains operations in over 40 countries and employs 19,000 people worldwide.\nThe results alleviate concerns that the clinical benefits of RTSA might not hold up over time in younger, more active patients.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release never mentions funding for this study, nor does it mention that the corresponding author has been paid by two joint replacement manufacturers, information that was readily available in the scientific paper.", "answer": 0}, {"article": "They wrote up a plan to test what they called \u201csuperselective intra-arterial cerebral infusion\u201d of Avastin in 30 patients with glioblastomas that had recurred after standard treatment.\nDespite a beautiful scan, the first patient who was treated died in October, from pneumonia and the spread of glioblastoma to his brainstem.\n\u201cThis will substantially alter the way that chemotherapy is given in the future,\u201d said Dr. John Boockvar, the brain surgeon who devised the trial.\nHe had the standard treatment: surgery, temozolomide pills and six weeks of radiation, which ended on June 25.\nEach patient would receive just one treatment directed into the brain, followed weeks later by a series of intravenous treatments with Avastin.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The reporter draws on three principal sources: two physicians involved with the research and an independent expert on glioblastoma from NIH. ", "answer": 1}, {"article": "The earliest trials with patients who developed POCD were performed after the 1950s.\nIf so, the use of an anti-inflammatory drug may have a protective effect,\" said Maria Jos\u00e9 Carvalho Carmona, a professor of anesthesiology at the University of S\u00e3o Paulo's Medical School (FM-USP) and principal investigator for the study.\n\"The results reinforce recent evidence of the importance of avoiding deep anesthesia,\" Carmona said.\nThe good news, according to a Brazilian study published by the journal PLoS One, is that two relatively simple measures can help to reduce the incidence of POCD: administering a small dose of the anti-inflammatory drug dexamethasone immediately before an operation and avoiding profound anesthesia during the operation.\nThe researchers evaluated 140 patients aged between 60 and 87 who underwent surgery under propofol-induced general anesthesia at the Central Institute of Hospital das Cl\u00ednicas, FM-USP's teaching hospital, in most cases for removal of gallstones.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not explicitly note who funded the study. However, the study does not appear to have received any external funding. According to the ClinicalTrials.gov page for the study, the work was sponsored primarily by the University of S\u00e3o Paulo and Duke University (where the authors work), with additional support from the Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo (or S\u00e3o Paulo Research Foundation), which is public. It\u2019s not unusual for universities to avoid mentioning funding for projects that they funded themselves. But it would have been a stronger release if it didn\u2019t leave readers wondering who paid for the work.", "answer": 1}, {"article": "\"Now they tell me, 'You never say 'What?'\n\"There are little things that I probably heard when I was younger, before my hearing loss, but I don't remember them,\" she said.\nUnlike a hearing aid, which amplifies sounds, Esteem is a prosthetic inner-ear stimulator.\n\"This really fills a need for adults with moderate to severe sensorineural hearing loss,\" Marzo said.\n\"When I wore a hearing aid, I turned it off when I got home because all the background noise was so agitating,\" said Merlo, 40.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article appropriately points out that the surgeon was trained by the device\u2019s manufacturer, Envoy Medical Corp. An independent source would have greatly helped to put the implant\u2019s effectiveness into perspective.", "answer": 0}, {"article": "MONDAY, Oct. 25, 2010 (HealthDay News) -- One of the world's most ubiquitous and pedestrian drugs -- aspirin -- may cut the risk of dying for men who have prostate cancer that has not yet spread beyond the gland, a new study suggests.\n\"We feel these results are practice changing,\" Mason added.\nAspirin also comes with some risks of its own, including stomach bleeding, Choe pointed out.\n\"This benefit was seen whether these patients were treated with surgery or radiotherapy,\" Choe added.\nThis protects them from immune cells and also helps them stick to their next location, Choe explained.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\nThe story does not quote any independent sources. ", "answer": 0}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\nIt could also become useful as a non-invasive way to assess breast cancer treatment progress.\u201d\n\nThe team plans to complete safety testing of the imaging agent during the next three years.\nAs the name implies, they are often too small to be detected with standard screening.\nTheir testing showed that the agent is readily cleared from the body and has a low level of retention in tissues.\nTherefore, they expect it will be safe if ultimately developed for clinical use.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The article noted that the research was partially funded through an NIH grant. There are no conflicts of interest.", "answer": 1}, {"article": "\"A key question now is to work out which patients will benefit from the drug -- clearly, some patients do and some don't,\" Johann de Bono, MD, PhD, of the U.K.'s Royal Marsden NHS Foundation Trust, says in a news release.\nIt blocks an enzyme crucial to the production of male hormones, which spur the growth and spread of advanced prostate cancers.\nThe study was funded by Johnson & Johnson, which is developing the drug.\nIt appears that abiraterone is able to shut down androgen production not only in the testes, but also from the adrenal gland and from within prostate tumors themselves.\nThe treatment gave patients with metastatic, castration-resistant prostate cancer only an extra four months of life.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There is no independent voice or perspective in the piece. ", "answer": 0}, {"article": "MONDAY, Oct. 10, 2011 (HealthDay News) -- An experimental Alzheimer's disease drug, gantenerumab, may help lower levels of amyloid plaque in the brains of people with the disease, an early clinical trial indicates.\n\"They are all extremely exciting and promising in animals,\" he said.\nAlzheimer's disease is the most common form of dementia.\nThe need for a drug to delay the onset or slow progression of Alzheimer's disease can't be underestimated, Aggrawal said.\nMany in the Alzheimer's research community are awaiting these drugs with bated breath, but \"none are ready for prime time,\" he said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Independent experts perspectives were helpful.\u00a0 Funding by the drug\u2019s manufacturer was disclosed.", "answer": 1}, {"article": "Actually, nitrous is making a comeback in U.S. maternity circles. It has remained a staple of childbirth in Canada, Australia, and Britain \u2014 Catherine, Duchess of Cambridge (the former Kate Middleton), who welcomed her third royal baby, Louis Arthur Charles, last month, reportedly has used it. But it basically disappeared in the United States in the 1970s. American women preferred to be numbed below the waist with epidural anesthesia, or at least that became the gold standard for pain relief.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story employs several independent sources. A minor point, but it would have been helpful to hear from a source from one of the countries where using nitrous oxide during labor is far more commonplace, and for an ACOG spokesperson to comment on the lack of guidance on using it during labor.\nAlthough not strictly conflict of interest issues, the article rightly points out two advocacy considerations. First, that many midwives are advocating for nitrous as a low-tech option at a time when labor and delivery are becoming increasingly medicalized. Second, that some hospitals are approaching nitrous as a marketing tool; presumably to position themselves as low-tech-friendly.", "answer": 1}, {"article": "Remember, Senay urged: Most people can achieve the recommended calcium intake by eating three or four servings of dairy products and other foods that contain calcium per day.\nAdults over 50 need 1,200 milligrams per day.\nThe maximum recommended intake of calcium is 2,500 milligrams.\nCalcium recommendations vary according to age.\nSupplements are an additional tool to be used when needed.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources are quoted.", "answer": 0}, {"article": "For more information, recipes and facts about pasta, please visit http://www.\nCertain grain foods, like pasta, are a great complement to a healthy well-balanced meal and provide plenty of opportunities for improving the diet,\" explains registered dietitian Diane Welland, Nutrition Communications Manager for the National Pasta Association.\nFrom the analysis, researchers identified a number of key positive nutritional dietary patterns associated with children and adolescents who eat pasta as part of their diet compared to those who don't eat pasta.\nThe research, which was presented at the 2017 Experimental Biology conference at the end of April in Chicago, demonstrated that young pasta-eaters have greater intakes of important vitamins and minerals and lower intakes of saturated fat and total fat in the diet compared to their peers who do not consume pasta.\nTo learn more about the research, please contact Kara Yacovone at kyacovone@kellencompany.com.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release clearly states that an industry financed association paid for the research. Readers should be able to take the hint (without being told explicitly) that the association has a financial interest in selling more pasta.", "answer": 1}, {"article": "A new study finds that supplementing the Mediterranean diet with more olive oil or more nuts helps diminish age-related decline in cognitive function. Photo: Getty Images\n\nThe Mediterranean diet, supplemented with a handful of nuts or a few tablespoons of olive oil a day, can counteract the effects of aging on the brain\u2019s ability to function, a new clinical study suggests.\n\nThe study, published online Monday in JAMA Internal Medicine, was unusual in that it employed rigorous scientific practices to test the effect of the diet on health. Most previous evidence showing benefits from the Mediterranean diet was gathered through observational studies, a less conclusive research technique.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story gets valuable input from a clinical neuropsychologist from the Mayo Clinic who was not involved in the research. It also notes the role of the California Walnut Commission in funding some of Dr. Ros\u2019 previous work. We\u2019ll call that good enough for a Satisfactory rating, but we\u2019d note that the donation of nuts and olive oil by commercial concerns in this study is more than a trivial contribution. The acknowledgment of that donation is buried in the original paper under \u201cAdditional Contributions,\u201d below mention of the statistics analyst. We think that contribution deserved a more prominent acknowledgment than either the original study or this story gave to it.", "answer": 1}, {"article": "April 9, 2012 -- Taking soy to relieve hot flashes has received mixed reviews over the years.\nNow, researchers who took another look at 19 published studies find that soy supplements may help, at least over time.\n\"What this study shows is that ingesting soy isoflavones will help you,\" she says.\nTwo co-authors, not including Melby, have ties to the soy industry.\n\"I personally think foods [containing soy] are better.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Perhaps the only saving grace of the story:\u00a0 One clearly skeptical independent expert and one other who noted limitations.", "answer": 1}, {"article": "If you'd like more information about the ONCOblot\u00ae Test, please visit http://www.\n\"The completion of this trial is an exciting new chapter for our work,\" says Nick Miner, Vice President of Business Development.\nor e-mail info@oncoblotlabs.com\n\nIf you'd like to read the clinical study, please visit http://clinicalproteomicsjournal.\nAlthough the fight against cancer often appears to be an overwhelmingly intransigent problem, significant progress is being made regarding the development of additional tools for cancer detection, such as the ONCOblot Test.\nIn this study, the serum presence of a mesothelioma-specific form of the ENOX2 protein (a recently identified marker of malignancy) was found within the serum of asbestos-exposed individuals an average of 6.2 years in advance of clinical symptoms by using the ONCOblot tissue of origin cancer detection test.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release states that the study was done by MorNuCo, the company that developed the ONCOblot test.\nAnother useful flag apparent to close readers is that the only person quoted in the release is not a researcher, but the company\u2019s vice president of business development.", "answer": 1}, {"article": "...\nIn response to such concerns, researchers revised their consent forms \u2014 the documents that explain a study's risks and benefits to patients \u2014 which had failed to mention the risk of death in chelation therapy.\nIn a statement after the study was presented, Antman, a cardiologist at Boston's Brigham and Women's Hospital and professor of medicine at Harvard Medical School, added, \"Intriguing as the results are, they are unexpected and should not be interpreted as an indication to adopt chelation therapy into clinical practice.\"\n\"A definitive answer on chelation therapy will take much additional research,\" Gervasio Lamas, chief of the Columbia University division of cardiology at Mount Sinai Medical Center in Miami Beach, Fla., said in a statement.\nA taxpayer-funded study tested whether it could reduce heart attacks\n\nA heart disease study presented Sunday is being called a $32 million waste of time \u2014 and even a danger to public health \u2014 by some of the country's leading health experts.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Plenty of independent sources contribute to this piece.\u00a0If there\u2019s one thing we question,\u00a0it\u2019s\u00a0the\u00a0description of possible bias among the investigators.\u00a0The story quotes a source who says that \u201cmore than half the trial sites were led by doctors who practice chelation,\u201d\u00a0which \u201ccould lead to a bias in favor of chelation.\u201d\u00a0That may well be true, but aren\u2019t a lot of trials\u00a0led by physicians\u00a0and surgeons who use the treatment that they\u2019re supposed to be studying\u2013whether it\u2019s a drug or surgical procedure? We agree that this is a\u00a0form of bias, but it\u2019s one that\u2019s endemic to\u00a0medical research.\u00a0It feels like a double standard\u00a0to flag the study for this particular shortcoming.", "answer": 1}, {"article": "(Reuters) - Dermira Inc said its experimental topical therapy for excessive underarm sweating was successful in two late-stage studies, bringing it one step closer to providing an easy-to-use therapy for the often embarrassing condition.\nWhile the function of sweating is to prevent overheating, those affected sweat even when the body does not need cooling.\nOral medicines can be used to systemically limit sweating.\nThe first line of defense are anti-perspirants.\nFor instance, a class of drugs called anticholinergics are commonly used off-label for this purpose, but they are linked with the risk of dementia.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A spokesperson from the company is quoted. However,\u00a0no independent sources are used.", "answer": 0}, {"article": "Might non-opioid painkillers work just as well as these addictive drugs?\nThe study involved 416 adults (average age, 37) who had gone to an emergency department with an extremity injury causing moderate to severe pain (averaging 8.7 on a scale of 1 to 10).\nResearch has shown that even short-term opioid use, such as that stemming from an initial prescription for pain from an injury or surgery, can make people predisposed to a dependence on the powerful drugs \u2014 partly from their effectiveness at relieving pain and partly from the euphoria they produce.\nEven for people who initially had rated their pain as a 10 (for the worst pain possible) or had broken a bone, there was virtually no difference in pain reduction between those who had and had not taken an opioid.\nAbuse of opioids has become an epidemic in the United States, with opioids now causing 60 percent of drug overdose deaths.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources cited in the story, nor does the story address potential conflicts of interest. We get that this story is part of a series that aims to present brief \u201csnapshots\u201d of recent research findings that are interesting or important \u2014 little news nuggets you can read in the amount of time it takes you to wait for the elevator.\nBut we think getting outside input is sort of a threshold issue for journalism, and perhaps especially so for health care journalism. It could simply be a sentence from an independent source noting whether this is valuable information for clinical decision-making in emergency rooms. Are opioids regularly prescribed to patients with these types of injuries?\nLikewise, there don\u2019t appear to be any conflicts of interest related to the paper. A few words to that effect would have been very welcome.", "answer": 0}, {"article": "Both drugs could win approval from the Food and Drug Administration by this summer.\n(However, the PCSK9 drugs are taken by injection every two weeks or four weeks, which could deter some users.)\nStill, the findings could help smooth the way for regulatory approval, wider use of the drugs by doctors and possibly reimbursement by insurers.\nThe drugs, evolocumab from Amgen and alirocumab from Sanofi and Regeneron, inhibit a protein in the body called PCSK9 that helps regulate cholesterol.\nAnalysts say the drugs will have billions of dollars in annual sales and will be taken by millions of people who cannot lower their cholesterol enough using statins alone or cannot tolerate statins.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted two independent doctors \u2013 Dr. Steven E. Nissen and Dr. Sanjay Kaul \u2013 both of whom pointed out the limitations in the studies. The piece also did an excellent job in disclosing potential conflicts of interest, since pharmaceutical companies often finance the development and research of their drugs. The article stated that lead study authors \u201cDr. Sabatine and Dr. Robinson have been paid consultants to the companies sponsoring the trials they led.\u201d It also made clear the fact early in the story that these studies were \u201csponsored by manufacturers.\u201d", "answer": 1}, {"article": "Streicher, an associate professor of clinical obstetrics and gynecology at the Northwestern University Feinberg School of Medicine, said the study drew \"erroneous conclusions.\"\nAccording to the FDA, which looked at three clinical trials of Addyi that included about 2,400 women, about 10% more patients treated with Addyi reported meaningful improvements in satisfying sexual events, sexual desire, or reduced distress compared to women taking a placebo.\n\"The data presented in this review suggests that the meaningful change caused by flibanserin is minimal,\" according to the team of Dutch researchers.\nDr. Lauren Streicher, medical director of the Center for Sexual Medicine at Northwestern Memorial Hospital in Chicago, said the results cited in the Dutch study are averages, and while Addyi doesn't work for everyone, many of her patients have benefited from it.\nThey said for women using the drug, the number of additional \"satisfying sexual events\" averaged out to about 0.5 per month.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "It was unfortunate not to have included the many and direct ties between those attacking the review (such as the International Society for the Study of Women\u2019s Sexual Health, which is supported by pharmaceutical manufacturers) and one of their board members, Dr. Lauren Streicher, who has declared ties to\u00a0Noven Pharmaceuticals, Inc and Shionogi & Co., Ltd. We know that patient testimony at the flibanserin hearings at the FDA was supported by Sprout, the maker of flibanserin, which gave financial support to those attending the hearings. But it is unclear if the patient mentioned in this story received such support.", "answer": 0}, {"article": "As part of the new study, published online Monday in the journal Lancet, researchers examined the cancer death rates of 25,570 patients who had participated in eight different randomized controlled trials of aspirin that ended up to 20 years earlier.\n\u201cThis is important as a proof of principle that a single simple compound like aspirin can reduce the risk of cancer substantially,\u201d said the study\u2019s lead author, Dr. Peter M. Rothwell, professor of neurology at the University of Oxford.\nThe risk of lung cancer death was 30 percent lower, the risk of colorectal cancer death was 40 percent lower and the risk of esophageal cancer death was 60 percent lower, the study reported.\nMany Americans take aspirin to lower their risk of heart disease, but a new study suggests a remarkable added benefit, reporting that patients who took aspirin regularly for a period of several years were 21 percent less likely decades later to die of solid tumor cancers, including cancers of the stomach, esophagus and lung.\nThe specific dose of aspirin taken did not seem to matter \u2014 most trials gave out low doses of 75 to 100 milligrams \u2014 but the participants in the longest lasting trials had the most drastic reductions in cancer death years later.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does quote some outside experts and includes this important comment: \u201c\u201cMany people may wonder if they should start taking daily aspirin, but it would be premature to recommend people starting taking aspirin specifically to prevent cancer,\u201d said Eric J. Jacobs, an epidemiologist with the American Cancer Society.\u201d We think that, on balance, comments like that were overshadowed by the comments from the study\u2019s author. \u201c\u201cThis is important as a proof of principle that a single simple compound like aspirin can reduce the risk of cancer substantially,\u201d said the study\u2019s lead author, Dr. Peter M. Rothwell, professor of neurology at the University of Oxford. \u201cThere\u2019s been a lot of work over the years showing that certain compounds can increase the risk of cancer, but it\u2019s not been shown before that we can reduce the risk with something as simple as aspirin.\u201d\u201d Nevertheless, it meets the basic requirement on this criterion. However, it should have noted that while there was no outside funding for this study, some of the authors have ahd consulting relationships with pharmaceutical companies.", "answer": 1}, {"article": "Buck scientists strive to discover new ways of detecting, preventing and treating age-related diseases such as Alzheimer\u2019s and Parkinson\u2019s, cancer, cardiovascular disease, macular degeneration, osteoporosis, diabetes and stroke.\n\u201cWe think addressing multiple targets within the molecular network may be additive, or even synergistic, and that such a combinatorial approach may enhance drug candidate performance, as well.\u201d\n\nWhile encouraged by the results of the study, Bredesen admits more needs to be done.\n\u201cFollow up testing showed some of the patients going from abnormal to normal.\u201d\n\nOne of the more striking cases involved a 66-year old professional man whose neuropsychological testing was compatible with a diagnoses of MCI and whose PET scan showed reduced glucose utilization indicative of AD.\nBy 2050, it\u2019s estimated that 160 million people globally will have the disease, including 13 million Americans, leading to potential bankruptcy of the Medicare system.\nNow we\u2019re recommending that people find out their genetic status as early as possible so they can go on prevention.\u201d Sixty-five percent of the Alzheimer\u2019s cases in this country involve APOE4; with seven million people carrying two copies of the ApoE4 allele.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release notes that the National Institutes of Health (NIH) provided some funding, but it does not list all of the study\u2019s funding sources. Those include the Accelerate Fund, an early-stage investment fund based in Canada. The researcher also apparently stands to benefit from sales of a book set to be released in May 2017 through a mainstream book publisher.", "answer": 0}, {"article": "This diet excludes many compounds found in wheat, certain fruits and vegetables, garlic, onions and sugar substitutes.\nMeanwhile, we strongly recommend that IBS patients work with their physician and a registered dietitian to navigate the Low-FODMAP diet to take control of their IBS symptoms.\u201d\n\nEswaran received funding to conduct the research from the University of Michigan Nutritional and Obesity Center and Prometheus Diagnostics.\nMany practitioners and patients have turned to diet as a possible treatment, but many of the dietary recommendations have not been backed by clinical trials.The study, the largest of its kind, measured the degree of relief from low FODMAP, a frequently recommended diet, which stands for Fermentable Oligo-Di-Monosaccharides and Polyols.\n\u201cThis is the only methodically rigorous clinical trial to show that diet-based therapy can not only improve symptoms, but also quality of life in patients with IBS,\u201d says U-M assistant clinical professor and gastroenterologist Shanti Eswaran, M.D., who researches the role of diet and food in functional bowel diseases such as IBS.\nThe results were impressive: More than 50 percent of the patients on the low FODMAP diet had major improvement of their abdominal pain, compared with 20 percent of the control group.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release says the research was funded by the University of Michigan Nutritional and Obesity Center and Prometheus Laboratories Inc. It might have disclosed that Prometheus Laboratories is owned by the global food and beverage giant Nestl\u00e9, and that it sells diagnostic tests for IBS.", "answer": 1}, {"article": "You know your cholesterol, your blood pressure ... your heart gene score?\n\"This is the first time polygenic scores have really been shown to reach the level of precision where they can have an impact\" on patient health.\n\"There are things you can do to lower the risk,\" Kathiresan said \u2014 the usual advice about diet, exercise, cholesterol medication and not smoking helps.\nThey estimated that up to 25 million Americans may have triple the average person's risk for coronary artery disease even if they haven't yet developed warning signs like high cholesterol.\nOn the flip side, a low-risk score \"doesn't give you a free pass,\" he added.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does quote one source unaffiliated with the research effort and also points out that two of the researchers \u201care co-inventors on a patent application for the system,\u201d so their potential for conflicts is clear to the reader.", "answer": 1}, {"article": "The biopharma company Amarin is making some heart-medicine history Monday with its proprietary, prescription formulation of fish oil, called Vascepa.\n\nIn a stunning clinical trial result that upends years of skepticism about the long-term heart benefit of products containing omega-3 fatty acids, Amarin\u2019s Vascepa significantly reduced the risk of deaths, heart attacks, strokes, and other serious cardiovascular events compared to a placebo.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes comments from experts who were not involved in this trial and it identified others as being researchers for this trial or working for Amarin. However, when the first quote calls this drug \u201cabsolutely the most significant study in the field of cardiovascular risk reduction since the statins were introduced\u201d, it is not enough to identify the source as \u201ca Vascepa study investigator\u201d when that researcher, Matthew Budoff, received over $120,000 in 2017 from Amarin, including payments of more than $4000 per appearance for speaking and teaching engagements on behalf of the company.\n[Note: The text has been corrected to indicate that the\u00a0quoted source\u2019s name is Matthew Budoff, not Martin Budoff as it initially appeared.]", "answer": 0}, {"article": "Dr. Bried, who implanted Mr. Mueller\u2019s hip last year, said he was concerned that squeaking might be \u201ca harbinger of something similar.\u201d\n\nMr. Mueller said Dr. Bried had told him to consider getting the hip replaced \u201csooner rather than later.\u201d\n\nStryker says such fears are overblown.\nWhile there have been no reported cases of serious mishaps, some surgeons fear that the ceramic material might shatter at some point, leaving a patient with so many inflammatory shards in the hip that a doctor could never find them all.\nWhatever the actual frequency, some investigators who have looked at the problem say the squeaking seems to be associated with extreme flexing of the ceramic implants, but exactly how is unclear.\n\u201cThere is no evidence that the wear associated with squeaking would lead systems to fail,\u201d said Dr. James A. D\u2019Antonio, an orthopedic surgeon outside Pittsburgh, who was a chief investigator on the clinical trials that led to regulatory approval for Stryker\u2019s Trident.\nNor is there a clear relationship between squeaking and hip pain or other conditions some patients say they have encountered, like the sensation that the hip disengages slightly when a patient walks.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites 4 patients, 4 surgeons, a spokesperson for implant maker Stryker, and a lawyer representing aggrieved patients. All in all, they provide a balance of viewpoints. The story mentions a conflict of interest for one surgeon. It appears that 2 of the patients are clients of the lawyer.", "answer": 1}, {"article": "His father\u2019s eventful medical history included a serious stroke and coronary bypass surgery.\nHe wanted to be able to go to the beach.\u201d\n\nA nephrologist at the University of North Carolina School of Medicine, Dr. Hladik understood better than most how kidney dialysis could consume a patient\u2019s days.\nSo after considerable discussion, Mr. Hladik decided to skip the three weekly trips to a renal center, along with the resulting fatigue and dietary and travel restrictions.\n\u201cDialysis may have prolonged his life, but I suspect only by a couple of months,\u201d Dr. Hladik said.\nGerald J. Hladik was 74 when the day long anticipated by his doctors arrived: His kidneys, damaged years earlier by a viral infection, had lost 85 percent of their function.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are numerous sources both quoted and cited in the story, so we are giving it a pass here. At the same time, we would have liked to have heard the evidence-based opinion of a strong advocate for end-of-life dialysis. The counterpoint in this case might have been a doctor saying that patients have a hard time sharing in decisions or sometimes do not want to do so.", "answer": 1}, {"article": "In fiscal year 2014, Penn Medicine provided $771 million to benefit our community.\n\"It is also important for clinicians to confirm that a woman's complaints of worsening memory are in the executive function domains, are temporally related to the transition to menopause, and are not indicative of some other pathological cognitive impairment before prescribing a trial of LDX.\"\n\"There are approximately 90 million post-menopausal women living in the US alone, and with the average age of onset occurring at 52, the great majority of those women will live in the postmenopausal state for at least one-third of their lives.\n\"Although we observed that short-term use of LDX was well tolerated and effective in several subjective and objective areas, long-term studies of menopausal women receiving LDX are needed, similar to those conducted for ADHD patients,\" said Epperson.\n\"Reports of cognitive decline, particularly in executive functions, are widespread among menopausal women,\" said lead author, C. Neill Epperson, MD, professor of Psychiatry and Obstetrics and Gynecology at the Perelman School of Medicine at the University of Pennsylvania, and director of the Penn Center for Women's Behavioral Wellness.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "While the release does identify the four funding entities underwriting the research, it fails to point out what the research paper actually does: That two authors receive grant support from Shire, the drug\u2019s manufacturer, and that that the lead author has stock holdings with five different pharmaceutical firms (although not with the manufacturer of the drug used in the study). Readers need this information to be able to interpret the evidence.", "answer": 0}, {"article": "They found that patients on lithium had a higher risk of suffering kidney function problems and developing hypothyroidism or hyperthyroidism and also hypercalcemia.\nThere should be more sensible use of it.\u201d\n\nStephen Buckley, head of information at the charity Mind, said: \u201cWe welcome research which adds to our understanding of treatments and medications for people experiencing mental health problems, including bipolar disorder.\nPatients say that the downsides include emotional numbing \u2013 feeling that you aren\u2019t connected with your feelings \u2013 as well as tremors,\u201d said Dr Joseph Hayes, a psychiatrist at University College London.\nThat superseded its previous view, outlined in 2006, that any of the four drugs were useful first lines of treatment for the condition, which affects about one in 100 people.\nTo me as a doctor that\u2019s a big worry because my main aim is to help people to be well and if you aren\u2019t doing that with the best available evidence then you are failing patients,\u201d said Hayes.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although the majority of the quotes come from a senior author of the research, the comments of\u00a0Stephen Buckley, head of information at the charity Mind were welcomed and provided an important second voice. \u00a0A few words from other clinicians would have been a bonus.", "answer": 1}, {"article": "But this is where it gets more complicated.\nThis is an evolving field, and our goal is to better discern who is at high and low risk of breast cancer and develop a greater range of prevention strategies.\u201d\n\nAn individual risk analysis should prompt conversation between doctor and patient about the potential benefits and the risk of the therapy.\nKenneth Lin, a family physician at Georgetown University who worked on developing the task force\u2019s SERM guidelines, notes that while SERMs may have reduced new cases, they \u201chave not been shown to reduce breast cancer mortality in any study or meta-analysis.\u201d One possible explanation, he says, is that \u201cthese drugs are effective at preventing nonlethal cancers rather than the more serious ones.\u201d\n\nNot used enough?\nAt that point, the panel said, women \u201care likely to have more benefit than harm from using tamoxifen or raloxifene.\u201d\n\nASCO\u2019s lower cutoff worries some experts.\nOther medications, including raloxifene and a class of drugs called aromatese inhibitors, do much the same thing, though the Food and Drug Administration has not yet approved aromatese inhibitors for this use.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story makes good use of actual interviews with more than one source. The perspective these experts provide is crucial.\nSince the story emphasizes patient decision-making surrounding preventative drug treatment, it would have been useful to include the voices of some actual patients who did and did not opt for drug treatment.", "answer": 1}, {"article": "Two new devices\u2014one that deflates fat cells, one that destroys them\u2014have just been cleared for \"body contouring\" in doctors' offices by the Food and Drug Administration.\n\nZeltiq grabs onto love handles and belly pouches and freezes the fat cells inside, causing them to self-destruct over several months. Zerona...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0The story included comments from a number of clinicians and adipose tissue researchers who had no connection with the highlighted devices.", "answer": 1}, {"article": "In prior studies, they found that far-UVC light killed methicillin-resistant S. aureus (MRSA) bacteria -- a common and dangerous \"superbug\" -- without harming human or mouse skin.\nHe noted that the technology's cost \"is not prohibitive, and it is safe.\nMONDAY, Feb. 12, 2018 (HealthDay News) -- As a particularly nasty flu season rages across the United States, scientists have found a powerful new disinfectant that makes \"light\" work of the virus.\nBut he believes \"the use of overhead, low-level far-UVC light in public locations would be a safe and efficient method for limiting the transmission and spread of airborne-mediated microbial diseases, such as influenza and tuberculosis.\"\nIt could offer a new, inexpensive way to eliminate airborne flu viruses in indoor public spaces such as hospitals, doctors' offices, schools, airports and aircraft, said the team from Columbia University Medical Center in New York City.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The lead researcher, as well as two physicians not affiliated with the study, are quoted. But, the story did not reveal the researcher\u2019s conflict of interest,\u00a0which the TIME Health story did disclose:\n\u201cBrenner says his team is working with a company to develop a commercially available version of the lamp..\u201d", "answer": 0}, {"article": "\"PSA can identify those at low risk of prostate cancer and once you have done that, you can remove almost 50 percent of men in the age group 55 to 74 [from undergoing biopsies],\" said study senior author Monique Roobol, an epidemiologist in the department of urology at Erasmus University Medical Center in Rotterdam.\nFor this study, about 20,000 men aged 55 to 74 in the Rotterdam area were screened, with those having PSA scores at or above the cut-off of 3.0 sent for biopsies and additional screenings every four years.\nThis compares with 15.7 percent of those with scores from 2 percent to 2.9 percent developing a malignancy and 0.36 percent dying of the disease.\nA second study also being presented at the symposium found that a drug already used to treat enlarged prostate gland may delay the progression of low-risk, early prostate cancer among men who choose a wait-and-see approach to treatment.\nA final study of almost 4,000 patients found that surgeons needed to perform 1,600 procedures known as robotic-assisted laparoscopic radical prostatectomies (RALP) to become adept at the procedure.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There do not appear to have been any independent sources used to verify the veracity of the information presented at the meeting or to provide context for the details reported.", "answer": 0}, {"article": "\"In health as elsewhere, if something looks too good to be true, it should be treated with great caution,\" says an editorial published this week in the medical journal BMJ.\nAlso, a recent Swedish study found that middle-aged people having more than two drinks a day \u2013 just above the moderate level for men \u2014 had a markedly increased stroke risk.\n\"At those ages, any benefit we get from moderate drinking is only to the extent that someone who is moderately drinking is not heavily drinking,\" Mukamal says.\n\"I cannot prove and I don't think anyone can prove that alcohol consumption can prevent anyone from dying or prevent heart attacks,\" says Kenneth Mukamal, an associate professor of medicine at Harvard Medical School, Boston.\nAnd heavy drinking is not good for anyone: It has long been linked with stroke, heart failure and many non-cardiovascular hazards, including car crashes.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article interviewed four solid sources at reputable academic centers \u2013 an associate professor at Harvard Medical School, a cardiologist at Cleveland Clinic, a professor of medicine at Columbia University Medical Center, and a neurological surgeon at Rush University Medical Center.", "answer": 1}, {"article": "For more nutrition information and to access a vast collection of healthy potato recipes, please visit http://www.\n\"It's important that consumption of all vegetables, particularly those that are good sources of potassium and dietary fiber, be encouraged in children,\" says Theresa A. Nicklas, DrPH, USDA/ARS Children's Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine, and one of the supplement's authors.\nThe executive summary \"Science and Policy: Adopting a Fruitful Vegetable Encounter for Our Children,\" is available online at http://advances.\nStorey ML, Anderson PA. Nutrient Intake and Vegetable and White Potato Consumption by Children 1 to 3 Years.\nThe supplement is the outcome of a November 2014 USDA/ARS Children's Nutrition Research Center at Baylor College of Medicine roundtable on vegetable consumption in children.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes:\nThe supplement is the outcome of a November 2014 USDA/ARS Children\u2019s Nutrition Research Center at Baylor College of Medicine roundtable on vegetable consumption in children. The forum was supported by the Alliance for Potato Research and Education, a not-for-profit organization dedicated to expanding and translating scientific research into evidence-based policy and education initiatives that recognize the role of all forms of the potato\u2013a nutritious vegetable\u2013in promoting health for all age groups.\nThat\u2019s good information as far as it goes, but the release does not acknowledge that the authors of the main study that is the basis for the release are both paid by the Alliance (one is an employee, the other a consultant), which is a membership group for potato growers.", "answer": 0}, {"article": "Griffiths says his team's new study grew out of a decade of research at Johns Hopkins on the effects of psilocybin in healthy volunteers, which found that psilocybin can consistently produce positive changes in mood, behavior and spirituality when administered to carefully screened and prepared participants.\nHalf of the participants were female with an average age of 56.\nOne-third of the participants had transient increases in blood pressure.\nSome 67 percent of participants reported the experience as one of the top five meaningful experiences in their lives, and about 70 percent reported the experience as one of the top five spiritually significant lifetime events.\nTo minimize expectancy effects, the participants and the staff members supervising the sessions were told that the participants would receive psilocybin on both sessions, but they did not know that all participants would receive one high and one low dose.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release clearly lists the sources of funding for the research. That\u2019s enough to earn it a satisfactory rating.", "answer": 1}, {"article": "LONDON -- Sanofi-Aventis SA's obesity drug Acomplia can improve blood-sugar levels and weight loss in diabetic patients, according to a study presented at the World Diabetes Congress in South Africa.\n\nThe findings from the clinical trial have shown newly diagnosed patients with type-two diabetes who weren't taking antidiabetic drugs had significantly improved blood-sugar levels and lost more weight with Acomplia, compared with a dummy pill over a period of six months. In addition, Acomplia -- also known as rimonabant -- helped...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although the story did include the thoughts of two analysts, this story would have been more useful to readers if it had included comments from a clinician or scientist not involved in the study who could have commented on why the benefits of this drug differ from those of others currently used for treating this condition.", "answer": 0}, {"article": "What if doctors had a pill that prevents breast cancer and nobody wanted to take it? That has pretty much been the situation with tamoxifen, an estrogen-like drug that was proved in 1998 to cut in half the chance of developing breast cancer if taken for five years by women with increased risk of the malignancy. The trouble is, tamoxifen also triggers menopausal symptoms like hot flashes and slightly increases the chances that a woman will develop blood clots and uterine cancer. As a result, women haven't been too eager to take the medication--nor have many doctors been all that enthusiastic...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This study was partially funded by Eli Lilly and AstraZenaca, makers of Evista and tamoxifen, though this is not mentioned. There is also no mention of whether the breast cancer expert cited from the American Cancer Society has financial ties with these drug companies. ", "answer": 0}, {"article": "Similar training is an effective component in treating amblyopia, also called \u201clazy eye,\u201d which is the most frequent cause of vision loss in infants and children, affecting 3 percent of the population.\nReading at our normal pace, the brain has only about 250 milliseconds to do this work until the eyes automatically move onto the next letter or word.\nHowever, other studies with no commercial links obtained similar results, and several scientists I spoke to, including those without ties to GlassesOff, thought the science behind the app was credible.\nOne study also examined functions of the eye itself and found none of these improvements were because of changes in the eye.\nIf we haven\u2019t yet processed the prior set of information, we can\u2019t understand it.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "In-depth reporting was clearly undertaken (and independent research is cited) in the process of putting together this piece. Also,\u00a0the column discloses conflicts of interest within the industry, which is important.\nHowever, the story didn\u2019t include direct quotes from independent sources. The author states that he consulted with experts in this field as part of his research, and that\u2019s another check in the \u201cplus\u201d column. But on the downside, readers don\u2019t know who those sources are or what expertise they bring to bear. From a reader standpoint, this would be useful information to include and it\u2019s important information to look for. Considering all aspects of the issue, we\u2019ll rate this a borderline satisfactory.", "answer": 1}, {"article": "That was not statistically significant.\nJanuvia, an oral medication known chemically as sitagliptin that helps lower blood sugar levels, had sales of about $4 billion in 2014, plus another $1.8 billion for the related combination product Janumet\n\nOn the study\u2019s main focus, after about three years 11.4 percent of Januvia patients had experienced cardiovascular death, non-fatal heart attack, non-fatal stroke or hospitalization for unstable angina versus 11.6 percent in the placebo group.\nThe detailed results also showed no increase in hospitalization for heart failure, which had been a particular concern with DPP-4 inhibitors, the class to which Januvia belongs.\n\u201cWe can be reassured we can use this drug for glucose lowering without affecting the already high cardiovascular risk in people with type 2 diabetes,\u201d said Professor Rury Holman, the study\u2019s lead investigator, who presented the data at the American Diabetes Association meeting in Boston.\nThere were 228 such hospitalizations for Januvia and 229 in the placebo group, according to data also published in the New England Journal of Medicine.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were several problems here. First, the story offered no independent expert perspective on the findings \u2014 only one of the study authors is quoted. And, as explained above, it is a little unclear where all the information in the story had its origin, and that connects to conflicts of interest. The story says, incorrectly it seems, that \u201cthe Tecos heart safety study was conducted by an independent academic research collaboration between the University of Oxford Diabetes Trials Unit and the Duke University Clinical Research Institute.\u201d But it also talks about Merck making announcements about the study\u2019s findings before they were published. The study itself says at the end, \u201cSupported by Merck Sharp & Dohme, a subsidiary of Merck.\u201d And the study authors reported on their disclosure forms conflicts of interest with Merck and other diabetes drug makers. While the study authors may describe their work as an \u201cindependent collaboration,\u201d we expect stories to dig deeper and explain what exactly that means.", "answer": 0}, {"article": "So, how best to reach these targets?\nGiven the known benefits of high-fiber diets and the growing evidence that fiber may play a role in preventing disease, the government's Dietary Guidelines for Americans also say most people need to consume more.\nIn a commentary accompanying the study in Pediatrics, Blackwell writes, \"There is longstanding evidence that dietary fibers may reduce circulating estrogen levels.\"\n\"This is a really important study ... [suggesting] that the more fiber you eat during your high school years, the lower your risk is in developing breast cancer,\" says Kimberly Blackwell, a breast cancer specialist at the Duke Cancer Center.\nThe researchers found that women who consumed high levels of fiber (28 grams per day, on average) had a 24 percent lower risk of developing breast cancer before menopause, compared with women who ate low levels of fiber (14 grams per day, on average).\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quotes two researchers in regard to the study. One was the study\u2019s lead author, and the other was the author of a commentary on the study that was published in the same issue of Pediatrics. A third source is quoted in regard to what can be done to get teens to eat more fiber, but that source doesn\u2019t address the study in question. We\u2019ll give the story credit for reaching beyond the authors of the study, but we think the story would be much stronger if it had incorporated more expert analysis on the study itself.", "answer": 1}, {"article": "The first placebo-controlled study of two vaccines against the Ebola virus found they both successfully created a powerful antibody response for a year, suggesting they both could be tools to save lives in a future epidemic of the deadly disease.\n\nThe research, by doctors from the U.S. and Liberian governments and elsewhere, was published Wednesday in the New England Journal of Medicine. The study looked at 1,500 patients in Liberia, and took place amid and after the outbreak of Ebola in Liberia from 2014 into 2015.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included information from an unaffiliated expert, and it alerts readers that pharmaceutical companies developed the two vaccines. That\u2019s good reporting and useful context. However, the story also says that the latest study was conducted by the \u201cU.S. and Liberian governments and elsewhere,\u201d while neglecting to mention that \u201celsewhere\u201d includes GlaxoSmithKline and Merck (which employs several of the researchers). The story also doesn\u2019t mention that several of the researchers have other economic ties to the companies. This one\u2019s a close call, but there\u2019s not quite enough information to clear our bar.", "answer": 0}, {"article": "\u2022 Available multimedia including photos and an audio interview are on the right column of the release link - https:/\n\u2022 Story on previous JAHA study (June 21, 2018): Breastfeeding may reduce a mother's heart attack and stroke risk\n\u2022 For updates and new science from JAHA, follow @JAHA_AHA\n\nStatements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association's policy or position.\nAt the time of recruitment, the average age was 63.7 years and the follow-up period was 12.6 years.\nStroke is the fourth leading cause of death among women aged 65 and older, and is the third leading cause of death among Hispanic and black women aged 65 and older, according to the study.\nHowever, because the Women's Health Initiative is large, researchers were able to adjust for many characteristics, and the effects of breastfeeding remained strong, Jacobson said.\nFollow us on Facebook and Twitter.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release clearly discloses the source of research funding. The release also notes that \u201cauthor disclosures [regarding potential conflicts of interest] are on the manuscript.\u201d It would have been much better to simply disclose the conflicts on the release itself by saying: \u201cThe authors report no potential conflicts of interest.\u201d", "answer": 1}, {"article": "Newswise \u2014 SEATTLE (March 24, 2017) \u2013 The U.S. Food and Drug Administration yesterday granted accelerated approval to the checkpoint inhibitor Bavencio (avelumab) for the treatment of patients with metastatic Merkel cell carcinoma (MCC), including those who have not received prior chemotherapy.\nBecause of the data from this clinical trial, avelumab (brand name Bavencio) has become the first systemic therapy approved by the FDA for MCC, and the first treatment of any kind approved for metastatic MCC.\nWithin six weeks of that first infusion, more than one-third of the cancer throughout his body was gone, and today, more than 90 percent of his tumor mass has disappeared.\nDr. Paul Nghiem, affiliate investigator of the Clinical Research Division at Fred Hutch, and the George F. Odland Endowed Chair in Dermatology at the University of Washington School of Medicine, is a senior investigator on the clinical trial that led to the FDA approval and the senior author on the Lancet Oncology article that preceded the approval.\nHis team foundational work on the role of immune cells in MCC paved the way for immunotherapy trials in the disease, including one he leads of another immunotherapy drug with a similar mechanism of action (Merck\u2019s Keytruda), whose results were published last year and changed the field overnight.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release appropriately explains that the clinical trial in question was for a drug made by Merck and that the lead scientist in the clinical trial receives ongoing funding from other companies. (We should note, too, that one of the reviewers on this news release, Bill Heisel, works at the University of Washington where some of the researchers on the clinical trial work as faculty.)", "answer": 1}, {"article": "WASHINGTON\u2014The Food and Drug Administration questioned the clinical benefit of using GlaxoSmithKline PLC's Avodart to cut the risk of prostate cancer.\n\nAvodart is currently approved to treat benign enlargement of the prostate. The company is seeking FDA approval to market the drug to certain men to reduce the risk of prostate cancer. The drug will be reviewed by an FDA advisory panel on Wednesday along with Merck & Co.'s Proscar, a drug similar to Avodart.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only delivers information from an FDA documented posted online and from a drug company spokesperson. So, in fact, we don\u2019t hear from a truly independent voice and not from any expert in clinical care either.", "answer": 0}, {"article": "Prostate cancer recurrence happens in about 30 percent of patients after surgery.\n\u201cIt really builds on some prior data and combines prior findings to ask and answer a new question that is quite relevant for men affected by prostate cancer.\u201d\n\nSome patients benefitted from adding the drugs more than others.\nThe findings should trickle down to clinical settings \u201cpretty quickly,\u201d said Dr. William Shipley, chair of the genitourinary oncology unit at Massachusetts General Hospital and one of the researchers behind the study, which was published Wednesday in the New England Journal of Medicine.\nThe specific ADT drug used in the study, bicalutamide, has since been largely replaced by another kind of drug that decreases the amount of testosterone the body produces.\nThe results were especially dramatic for men who had prostate-specific antigen (PSA) levels above .07 ng/ml when they started the trial.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An independent source was included. And this STAT story noted an important detail that the NYTimes missed: how AstraZeneca \u2014 a maker of a hormone-blocking drug for men \u2014 was a study sponsor.", "answer": 1}, {"article": "So when the government advisory panel \u2014 the U.S. Preventive Services Task Force \u2014 recommends against routine PSA testing, it\u2019s making a judgment call.\nIt\u2019s saying that, for most men, the (albeit small) risk of sexual dysfunction and urinary leakage from eventual treatment is not worth it, given the even smaller chance that PSA testing could save your life.\nAs a patient, if you\u2019re deciding whether to get a PSA test, or whether not to get a PSA test, remember you do have a right to your own opinion too.\nThen, if the patient does have cancer, the available treatments for it \u2014 surgery, radiation, as well as other options \u2014 also have side effects, chief among them impotence, incontinence, and urinary incontinence.\nHowever, prostate cancer is one of the few cancers that\u2019s not strongly linked to smoking (and falling cigarette consumption over the past 40 years is a major reason for falling cancer rates).\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "It is clear that the writer brings a lot of reporting depth to the story and has a clear understanding of the topic. An independent voice or two might have helped the story show readers where the preponderance of the evidence now lies instead of making it look as if this is merely a debate between \u201cbetween public health experts who have largely turned away from PSA screening, and many practicing clinicians who feel the test has helped their patients immensely.\u201d That is a simplistic dichotomy and the story never really answers the question it poses of \u201cWhy Can\u2019t Doctors Agree?\u201d", "answer": 0}, {"article": "They were also asked about their medical histories.\n\u201cThe bottom line is we showed evidence that increased consumption of white rice \u2013 even at this low level of intake \u2014 is still associated with increased risk,\u201d said Dr. Sun, who was at the Harvard School of Public Health when the study was done.\nBut the Harvard study is one of the first to distinguish between brown rice and white rice consumption in the United States, where rice is not a staple food and relatively little is eaten overall, said Dr. Qi Sun, an instructor in medicine at Brigham and Women\u2019s Hospital, which is affiliated with Harvard Medical School.\nThe researchers tried to control for the fact that Americans who eat brown rice tend to be more healthy overall \u2014 they eat more fruits and vegetables and less red meat and trans fats, and they also tend to be thinner, more active and less likely to smoke than those who don\u2019t eat brown rice.\nAnd correlation does not necessarily mean a cause-and-effect relationship, since factors other than brown rice consumption may have accounted for the decreased diabetes risk that was observed.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0No independent sources were quoted to give perspective about the results of the study presented. Single source medical science stories are not a good idea \u2013 not even for (especially not for?) the New York Times. ", "answer": 0}, {"article": "But as for whether they\u2019ll help a client prepare for an important presentation?\nThere is a published review on the use of Myers\u2019 cocktail \u2014 but it\u2019s just a collection of anecdotal evidence.\nThe other \u2014 which was also missing a placebo group \u2014 involved just seven patients and showed only short-term improvement in symptoms.\nThe infusion treatments can be traced back to an intravenous supplement known as the Myers\u2019 cocktail, a slurry of magnesium, calcium, B vitamins, and other products developed decades ago by a Baltimore physician.\nThe author, Dr. Alan Gaby, has long promoted the use of intravenous vitamins for a wide range of clinical conditions.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story chose sources who were outside the retail industry selling supplements, and we didn\u2019t detect any potential conflicts of interest.", "answer": 1}, {"article": "So why weren't they all cured?\n\"This study really underscores the fact that children who have other issues with sleep should be looked at for bedwetting because anything that depresses sleep at night can lead to bedwetting,\" said AUA spokesman Dr. Anthony Atala, a urologist at Wake Forest University in Winston-Salem, N.C.\n\n\"If a child has bedwetting, pay close attention to their sleep patterns, and observe them while they are asleep and you can see whether they are breathing at a regular pace, and if not, seek additional help,\" Atala said.\n\"There are several potential causes of bedwetting, and sleep apnea is clearly one of them,\" said Dr. Lane S. Palmer, chief of pediatric urology at the Cohen Children's Medical Center in New Hyde Park, N.Y.\n\n\"There are secondary positive effects of this tonsil- or adenoid-removing surgery, but I don't know that I would jump to have my child's tonsils or adenoids out as a primary treatment for bedwetting,\" he said.\n\"If they haven't seen an ear, nose and throat specialist, see one to see if the child who wets the bed has OSA that can be cured by tonsil or adenoid removal,\" said study author Dr. Yegappan Lakshmanan, chief of pediatric urology at Children's Hospital of Michigan, in Detroit.\n\"Bedwetting is multifactorial even within these groups, and eventually we should be able to pinpoint the cause for every single child,\" Lakshmanan said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story has more sources than most. It quotes the lead researcher on the study and then four independent sources from a range of specialties.\u00a0They bring some great perspectives to the story and help people understand the connections between different behaviors. \u201cChildren with sleep apnea can be difficult to rouse, which may cause the bedwetting, said Dr. Dennis Kitsko, an otolaryngologist at the Children\u2019s Hospital of Pittsburgh. \u2018But not every child with sleep apnea will wet the bed, and not every bedwetter will have sleep apnea.'\u201d", "answer": 1}, {"article": "Still, the failure rate was similar to the failure rate of the IUD when used during the five-year period (which is under 1%).\nThe women were informed of the pregnancy risk associated with using their device longer than recommended, and the researchers called them for followup every 6 months for 36 months or until the women had their device removed.\nThough the data is preliminary, the researchers say they believe that the hormonal IUD and the implant can both be used for an additional year longer than the FDA recommends.\nThe study is still ongoing, and the researchers plan to recruit up to 800 women and ultimately test whether the IUDs and implants were effective for up to three years after their current FDA-approved duration.\n(There is also a non-hormonal IUD that is approved for 12 years, but it was not included in the current study.)\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No one is quoted by name in the story, not even from among the researchers. We would have liked an independent comment from someone who was not part of this study about its implications.", "answer": 0}, {"article": "It has been 51 years since the first birth-control pill became available in the U.S., bringing dozens of contraceptive options for women in its wake. There are currently two options on the market for men\u2014vasectomy or a condom.\n\nThe research pipeline is full of possibilities, though. Scientists at Columbia University Medical Center have halted sperm production and started it again in mice with no apparent side effects, using a drug that blocks receptors for vitamin A. An injectable synthetic substance, in Phase 3 clinical trials...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Good sourcing.", "answer": 1}, {"article": "reconstructions\u201d currently being conducted on injured knees \u201ccould be avoided without adversely affecting outcomes.\u201d\n\nThis possibility should reverberate across playing fields nationwide, where, at the moment, preseason high school, collegiate and adult-league sports practices are under way, with a concomitant surge in A.C.L.\ntreatment is \u201ccontroversial,\u201d The New England Journal study\u2019s authors, Richard Frobell, Ph.D., and Stefan Lohmander, M.D., Ph.D., of Lund University, wrote in their e-mail.\nIn the current study, most of the group members who had reconstructive surgery reported that their injured knees felt healthy after two years and that they had returned to activity \u2014 not, in most cases, at the same level as before their injuries, but they were active.\nThe \u201cbelief among most surgeons and patients is that surgery is a \u2018must,\u2019 at least if you aim to go back into an active lifestyle,\u201d the Swedish authors of the study e-mailed in response to questions.\n\u201cOn the basis of our study results, we\u2019d tell patients\u201d that \u201cthere is no apparent downside of starting a good rehab program and waiting with the surgery decision to see if it is needed or not,\u201d the authors wrote to me.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "It cites the opinions of orthopedic surgeons, including one who seems clearly uninvolved in the NEJM study, and the author of the 2009 British Journal of Sports Medicine study.\u00a0It also tells us the affiliations of interviewees who were involved and not involved in the two studies. \nNote that the study publication discloses that the research was funded by a number of organizations in Sweden as well as Pfizer. As this wasn\u2019t a drug study, we\u2019re not sure what Pfizer\u2019s interest were and point it out as an FYI.", "answer": 1}, {"article": "Post-traumatic stress disorder (PTSD) is a term for a broad range of psychological symptoms that can develop after someone experiences or witnesses a traumatic event.\nThe work was supported by the Swiss National Science Foundation, University of Zurich and Wellcome.\nThis time there were no electric shocks, but a loud sound played after either colour was shown.\nIn the first session, participants were given either doxycycline or a placebo and learnt to associate a certain colour with an electric shock.\nMatrix enzymes are found throughout the body, and their over-activity is involved in certain immune diseases and cancers.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes the funding sources and the study stated that there were no conflicts of interest.", "answer": 1}, {"article": "To learn more about the Society and the field of endocrinology, visit our site at http://www.\nThe study was funded by Radius Health, Inc.\n\nEndocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers.\nThe results of the pre-specified subgroup analysis within the ACTIVE clinical trial will be presented Friday, April 1, at ENDO 2016, the annual meeting of the Endocrine Society, in Boston.\nThe data suggest that abaloparatide appears to be an effective treatment for a broad group of postmenopausal women with osteoporosis.\nThe Society, which is celebrating its centennial in 2016, has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release prominently and early notes that the research is \u201cindustry sponsored,\u201d and names the company (Radius Health, Inc.). It also notes that the investigator quoted in the release is a consultant to the company. Kudos!", "answer": 1}, {"article": "CLEVELAND, Ohio (May 17, 2017)--Fennel, an anise-flavored herb used for cooking, has long been known for its health benefits for a variety of issues, including digestion and premenstrual symptoms.\n\"A larger, longer, randomized study is still needed to help determine its long-term benefits and side effect profile.\"\nIn the end, fennel was concluded to be a safe and effective treatment to reduce menopause symptoms without serious side effects.\nA new study confirms that it is also effective in the management of postmenopause symptoms such as hot flashes, sleeplessness, vaginal dryness, and anxiety, without serious side effects.\nThe use of complementary and alternative medicine for the management of menopause symptoms has surged in recent years as women have attempted to identify alternatives to hormone therapy (HT).\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t tell us who funded the study. According to the Iranian Registry of Clinical Trials, the study was funded by Tehran University.", "answer": 0}, {"article": "FDA approves breakthrough cholesterol drug, but only for certain high-risk patients\n\nOvereating may be caused by a hormone deficiency, scientists say\n\nCDC report: Lyme disease is spreading to new territories\n\nResearchers retract study claiming marriages fail more often when wife falls ill\nThe study reported that \"taking aromatase inhibitors for 5 years reduced the risk of postmenopausal women with breast cancer dying of their disease by 40 percent within 10 years of starting treatment, compared with no hormonal treatment.\"\nThe results were part of the Early Breast Cancer Trialists' Collaborative Group, a collaboration based at the University of Oxford, that collects and analyzes information about randomized clinical trials every few years.\n\u201cThe drugs are complementary, because the main side effect of aromatase inhibitors is an increase in bone loss and fractures, while bisphosphonates reduce bone loss and fractures as well as improving survival,\" he said.\nIf this had not happened, \"the benefit of aromatase inhibitors over tamoxifen would probably have been somewhat greater,\" they surmised.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This is a two-source story, with quotes from two professors who had ties to the studies. The report desperately needed an independent expert, who could talk about some of the missing details \u2013 like the design and limitations of the studies, the quality of evidence and harms of the interventions.", "answer": 0}, {"article": "Use of osteoporosis drugs, once heavily advertised by celebrity spokeswomen, has dropped by more than 50% in recent years amid reports of such serious side effects as sudden bone fractures.\n\nYet many experts say the benefits of the drugs, known as bisphosphonates, far outweigh the risks for many users.\n\nAn analysis in the New England Journal...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story incorporates input from several sources, and tells readers precisely what sort of financial ties each source has to relevant drug companies. Kudos.", "answer": 1}, {"article": "CHICAGO - A minimally invasive procedure in which pulses of energy from a probe are applied directly to nerve roots near the spine is safe and effective in people with acute lower back pain that has not responded to conservative treatment, according to a study being presented today at the annual meeting of the Radiological Society of North America (RSNA).\nThe one-year outcomes demonstrated that CT-guided pRF was superior to the injection-only strategy.\nTo ensure you are using the most up-to-date information, please contact us.\nIn some cases, the entire disk must be removed and the vertebra fused together for stability.\nToday, therapy for spine disorders allows for definitive treatment of symptoms and conditions using different techniques and technologies.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Study funding is not included.\nA review of the meeting abstract reveals no conflicts of interest disclosed by the seven authors.", "answer": 0}, {"article": "Johnson, who runs the Institute of Endocrinology and Preventive Medicine in Dallas, says she only trusts the quality-controlled, safety-tested pharmaceutical bio-identical hormones that are made by drug companies and approved by the Food and Drug Administration.\nIt\u2019s no longer that you need to stay away from hormone replacement therapy, it\u2019s that you need to use it wisely.\u201d\n\nThat wisdom comes from a careful medical assessment and ongoing surveillance of blood pressure, blood work, breast changes, side effects and effectiveness.\nIt\u2019s a process, but hormone replacement therapy is helping women have a better life in an era when they live longer.\u201d\n\nJohnson, Firouzbakht and other experts will tell you that hormone therapy protects against heart disease, a much more common killer of women than breast cancer, as well as against dementia, colon cancer, osteoporosis and other health issues.\nThe doctors emphasized not just the medical benefits, but that the treatment can enable and boost a woman\u2019s overall day-to-day existence, too.\nIn the late 1990s, the treatment became standard for menopausal symptoms \u2014 the hot flashes, night sweats, headaches, incontinence and other problems that eventually strike almost all women.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There was clear imbalance in the story. The article only presents quotes from two doctors who were supportive of HRT. It also failed to identify sources for some of the claims in the article.", "answer": 0}, {"article": "\u201cModels are models,\u201d Lin said.\nSome experts in cancer screening and statistics said its novel approach was \u201con shaky ground\u201d and used a \u201ccompletely unverifiable\u201d methodology that they had \u201cnever seen before,\u201d but others praised its \u201cintriguing and innovative approach.\u201d There was one area of agreement, however: \u201cI imagine it\u2019s going to generate some buzz,\u201d said biostatistician Ted Karrison of the University of Chicago.\nAs a result, when researchers counted deaths in each group, it wasn\u2019t a clean comparison: Rather than comparing screened to unscreened men, they were comparing assigned-to-screening men to not-assigned-to-screening men.\nThis is a screening test that saves lives.\u201d\n\nThose gains come at some cost to health, though: For every life saved, she estimated, five men will be told they have cancer when in fact their abnormal cells would never grow, spread, or harm them.\nThe finding that assigned-to-screening men were no more likely to avoid death from prostate cancer might therefore have been because their screening behavior wasn\u2019t different enough from the \u201cunscreened\u201d (but in fact partly screened) men\u2019s, not because PSA screening doesn\u2019t save lives.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A wide range of outside voices give this article depth and heft. The inclusion of voices of researchers who chose to remain anonymous reminds us of the very controversial and potentially career-altering aspects of this research.\nHowever, as with the Los Angeles Times story, this story didn\u2019t note the financial disclosures of the study authors, including the senior author, Ruth Etzioni, who disclosed she owns equity in a company developing medical imaging technology that it says could be applied in prostate cancer patients. Dr. Etzioni stated that she does not consider the equity ownership to be a conflict of interest, but considering that an increase in PSA screening would boost demand for more precise and less invasive follow-up testing, it appears that her company would benefit.\nThe study was funded by the National Cancer Institute. While that source does not raise any red flags, and the study stated that the funder had no role in the study, news stories are more informative when they note study funding.", "answer": 0}, {"article": "Jason Dragoo\u2019s Stanford University research team gets 100 to 200 inquiries every day from people interested in joining its clinical trial studying the use of stem cells to treat knee injuries.\n\nThe interest highlights a growing demand for the use of stem cells derived from a person\u2019s own bone marrow or fat to treat orthopedic injuries. Osteoarthritis, a degenerative joint disease where the protective tissue or cartilage around a joint wears down, is a particular focus of inquiry.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Four different physicians are quoted in the story. However, according to Dollars for Docs, three of these physicians have recent financial ties to companies actively involved in stem cell product development. This was not disclosed.", "answer": 0}, {"article": "I would be in my 60s when I had to do this again, and who wants to have surgery unnecessarily when you are 60 something?\"\nIt also turns out that the longer a woman has the implants, the more likely she is to experience these complications.\n\"They may leak, they may rupture, you may decide you want a different size.\nAlthough the long-term effects of silicone in the body are still uncertain, many plastic surgeons don't see the leaking of modern implants as a health concern.\n\"The silicone implants of today are what we call a cohesive gel \u2014 it's essentially like a jelly.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two independent experts were quoted.\u00a0 (Sidney Wolfe\u2019s name was misspelled.) However, the article could have benefited from:", "answer": 1}, {"article": "For more information, visit http://www.\n\"The existing totality of evidence suggests an urgent need to increase the use of varenicline in the general population as well as in those with serious mental illness who on average die about 20 years earlier than the general population, in part, because their smoking rates may be as high as 75 percent,\" said Hennekens.\nIn a commentary published in the current issue of the American Journal of Medicine, researchers from the Charles E. Schmidt College of Medicine at Florida Atlantic University reassure clinicians and their patients that varenicline, whose brand name is Chantix, is a safe and effective way to achieve smoking cessation and that failure to use this drug has caused preventable heart attacks and deaths from cardiovascular disease.\nThe trial was conducted for 12 weeks on about 8,000 long-term smokers and included equal subgroups of those without as well as with psychiatric disorders.\nWith more than 70 full and part-time faculty and more than 1,300 affiliate faculty, the college matriculates 64 medical students each year and has been nationally recognized for its innovative curriculum.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release includes an entire paragraph about the commentary\u2019s senior author, but it fails to note that the author serves \u201cin an advisory role\u2026to Pfizer and their legal counsel\u201d \u2014 as noted in the commentary itself. Pfizer is the company that markets Chantix. Note: this does not mean that the author is doing anything untoward, but it does raise the potential for a conflict of interest, and a release needs to make that clear.", "answer": 0}, {"article": "Outside of heart attacks, doctors are often too quick to use a common $20,000 procedure to treat patients suffering from coronary artery disease, a new study suggests.\n\nAbout 600,000 angioplasty procedures, which almost always involve placement of a tiny metal tube called a stent, are done in the U.S. each year. Roughly 70% of these procedures are performed on patients suffering symptoms of a heart attack and aren't medically controversial. But the remainder are done on stable patients who are suffering mild symptoms or no symptoms...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several independent sources gave helpful perspectives in the story.", "answer": 1}, {"article": "Nivolumab unleashes an immune system attack on cancer by blocking activation of a protein called PD-1 on T cells, white blood cells that find and attack cells, viruses or bacteria that have specific targets.\n\"We can get good results without choosing to treat patients based on PD-L1 status,\" said Sharma, who also is scientific director of MD Anderson's immunotherapy platform and an investigator with the Parker Institute for Cancer Immunotherapy at MD Anderson.\n\"The response rate is better than we've seen for other potential second-line treatments and nivolumab is really well-tolerated, which is important because bladder cancer patients are a fragile group after frontline treatment with platinum chemotherapy,\" said Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology at MD Anderson.\nBoth nivolumab, known as Opdivo, and ipilimumab, known as Yervoy, were developed and marketed by Bristol-Myers Squibb, which funded the clinical trial.\nIt was based on the research of Jim Allison, Ph.D., chair of Immunology, executive director of the immunotherapy platform and director of the Parker Institute for Cancer Immunotherapy at MD Anderson.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that the clinical trial was funded by Bristol-Myers Squibb, which developed and markets both nivolumab and ipilimumab. However, the release doesn\u2019t note that the lead author has served as a consultant to the Bristol-Myers Squibb Immuno-Oncology Network, among several others.", "answer": 0}, {"article": "You've probably heard about it \u2014 maybe you even remember seeing it once \u2014 but you're not really sure what it is or even where to find it.\n\nThe female condom (FC2), or internal condom, is a non-hormonal barrier method of birth control. But instead of going on a penis, it goes in a vagina, which is why it's also sometimes referred to as an internal condom. For more information, BuzzFeed Health spoke with two experts who could demystify this lesser-known contraceptive:\n\n* Dr. Harry Fisch, clinical professor of urology and reproductive medicine at Weill Cornell Medical College, and chief corporate officer of Veru Healthcare, which distributes FC2\n\n* Dr. Lauren Streicher, associate clinical professor of obstetrics and gynecology at Northwestern University\u2019s Feinberg School of Medicine", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story makes it clear that one of the sources is chief corporate officer of Veru Healthcare, which distributes the female condom known as FC2.\u00a0 ", "answer": 1}, {"article": "But stimulating the vagus nerve requires surgery to implant a device near the collarbone.\nThe approach, which is not yet approved by the FDA, could offer an alternative or enhancement to treatment with drugs, says Christopher DeGiorgio, the neurologist at UCLA who invented the new approach.\n\"For me it's extremely effective,\" says Jennifer Rees, 49, who lives in the Los Angeles area and has been using the nerve stimulator for six years.\nThe trigeminal nerve stimulator, in contrast, never penetrates the skin and is powered by an external device about the size of a large cell phone, DeGiorgio says.\n\"For me, all it involved was putting two gel pads above my eyebrows, one on each eyebrow,\" she says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not use any independent sources. It also does not make it clear whether Christopher DeGiorgio, a UCLA doctor who invented the device, will benefit from it financially. One can presume that he will, but the story should have made that clear.", "answer": 0}, {"article": "Bissada is now conducting follow-up research to support the first study's findings.\nThe researchers reported their findings in the Dentistry article, \"Periodontal Treatment Improves Prostate Symptoms and Lowers Serum PSA in Men with High PSA and Chronic Periodontitis.\"\n\"This study shows that if we treat the gum disease, it can improve the symptoms of prostatitis and the quality of life for those who have the disease,\" said Nabil Bissada, chair of Case Western Reserve's Department of Periodontics and the new study's corresponding author.\nTreating gum disease reduced symptoms of prostate inflammation, called prostatitis, report researchers from Case Western Reserve University School of Dental Medicine and the Departments of Urology and Pathology at University Hospitals Case Medical Center.\nThe men were assessed for symptoms of prostate disease by answering questions on the International-Prostate Symptom Score (IPSS) test about their quality of life and possible urination issues.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t discuss funding, but the paper says that the study was sponsored by the authors\u2019 departments at the university. There\u2019s really no harm in leaving this information out, so we\u2019ll rule this Satisfactory.", "answer": 1}, {"article": "This was not statistically different.\nSince then, the shift has become even more distinct: Aspirin prescribing has risen to 70 percent among Michigan surgeons, says Hallstrom, who is co-director of the initiative and a health services researcher at U-M's Institute for Healthcare Policy and Innovation.\nThe critical care specialists who make up the American College of Chest Physicians favor heparin to reduce the risk of blood clots, while the American Academy of Orthopaedic Surgeons guidelines state that no one drug is better than another for preventing clots.\n\"The most important way to prevent blood clots is getting moving,\" says Hallstrom, noting that people are at risk for blood clots when they sit or lie in one position for too long, such as on an airplane or a hospital bed.\nDuring the two-year study period from 2013 to 2015, aspirin use rose from 10 percent to 50 percent among the patients cared for by orthopaedic surgeons in the Michigan Arthroplasty Registry Collaborative Quality Initiative, a statewide effort to give patients the best possible recovery and outcomes after hip and knee replacements.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The disclosure statements included with the journal article reporting on this study note that Blue Cross and Blue Shield of Michigan support the quality improvement group that did this study and pay some of the salaries of key researchers. Even though the disclosure statements say Blue Cross and Blue Shield did not specifically fund the work on this study, the release should have noted the funding relationship.", "answer": 0}, {"article": "The findings offer important guidance to the growing number of women who face planned C-sections -- one in three babies in the United States, estimates the National Center for Health Statistics.\nAll of the women had previously had C-sections.\nThe Associated Press and McClatchy Newspapers contributed to this story.\nOf those, more than 13,000 had elective C-sections.\n\"This happens to me every day,\" Lavin said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes multiple experts.", "answer": 1}, {"article": "This press release contains forward-looking statements.\nAs featured in the ASTRO Scientific Session poster titled \"High Dose Adaptive MRI Guided Radiation Therapy Improves Overall Survival of Inoperable Pancreatic Cancer,\" key data points and findings from the presentation include the following:\n\u2022 The study detailed a retrospective review of 42 locally-advanced pancreatic cancer patients treated with MRIdian at four institutions (University of California Los Angeles, University of Wisconsin, VU University Medical Center, Washington University).\nAs a result, MRIdian's on-table adaptive radiation therapy allows doctors to respond to subtle anatomical changes observed on a day-to-day basis and reshape the dose to better match the current contours of the tumor.\nViewRay, Inc. (Nasdaq: VRAY), maker of the world's first and only clinical MRI-guided radiation therapy system, announced today outcomes data presented during the recent 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO).\nCoupled with new adaptive radiation therapy software tools, we create new customized plans in minutes, all while the patient is on the treatment table,\" said Percy Lee, M.D., senior author and Associate Professor and Vice Chair of Education for the Department of Radiation Oncology at the David Geffen School of Medicine at UCLA.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "This research was sponsored by ViewRay, the company that developed the MRIdian system, and the release does a good job calling attention to this. However, according to the published study, at least one of the co-authors received honoraria from ViewRay Medical Systems. Since this was not included in the release we\u2019re rating this criteria Not Satisfactory.", "answer": 0}, {"article": "Scientists are inching closer to a drug that may protect peanut allergy sufferers from potentially life-threatening complications that can occur due to accidental consumption.\n\u201cWe\u2019re excited about the potential to help children and adolescents with peanut allergy protect themselves against accidentally eating a food with peanut in it,\u201d said allergist Stephen Tilles, MD, ACAAI former president, study co-author and consulting advisor for Aimmune Therapeutics, according to EurekAlert.\nIn addition, the symptoms caused by the 100-fold higher dose at the end of the study were milder than the symptoms on the lower dose at the beginning of the study.\u201d\n\nEXPERTS: CHILDREN AT RISK OF LEAD POISONING IN CHATTANOOGA\n\nWith FDA approval this drug would mark the first treatment available by prescription for peanut allergies.\nWhile the drug is not being hailed as a cure for peanut allergy, it has proven successful in building up patients\u2019 tolerance to peanuts over time, lessening the potential for life-threatening complications.\n\u201cThis is not a quick fix, and it doesn\u2019t mean people with peanut allergy will be able to eat peanuts whenever they want,\u201d Jay Lieberman, MD, vice chair of the ACAAI Food Allergy Committee and study co-author, said, according to EurekAlert.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only sources quoted were authors of the study who had relationships with the company that makes the treatment. Independent sources could have provided more context, including a more balanced view of how this treatment might affect the care of people with peanut allergies.", "answer": 0}, {"article": "For more information about the symposium, visit www.thoracicsymposium.org.\n\u201cElderly patients, who are otherwise doing well, should not have treatment withheld based solely on concerns about side effects and age.\u201d\n\nThe abstract, \u201cStereotactic body radiotherapy for early stage non-small cell lung cancer in patients 80 years and older: A multi-center analysis,\u201d will be presented in detail during the poster session at the 2017 Multidisciplinary Thoracic Cancers Symposium in San Francisco (full details below).\nAbstract and Presentation Details\n\u2022 Stereotactic Body Radiotherapy for Early Stage Non-Small Cell Lung Cancer in Patients 80 Years and Older: A Multi-Center Analysis\n\u2022 News Briefing: Friday, March 17, 1:00 \u2013 1:45 p.m. Pacific time, Foothill F, http://bit.do/thoracic2\n\u2022 Poster Session, Thursday, March 16, and Friday, March 17, Yerba Buena Salons 7 and 8\n\u2022 This news release contains additional and/or updated information from the study author(s).\nABOUT ASTROThe American Society for Radiation Oncology (ASTRO) is the premier radiation oncology society in the world, with more than 10,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals who specialize in treating patients with radiation therapies.\nThe advanced form of radiation therapy (RT) was well tolerated among this relatively understudied elderly population, indicating that SBRT is a viable option for patients who may otherwise be offered no curative treatment.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not report anything about the funding of the study or any disclosures by the researchers. There is a note about how to seek information about the author disclosures, but this information should be contained in the release itself.", "answer": 0}, {"article": "\u201cThere are still lots of patients in need of transplants that are not getting them because of lack of matched donors, and that is unacceptable in the year 2016.\u201d\n\nJones estimates that about 7,500 transplants of donated stem cells were done in 2014 \u2014 primarily for leukemia and lymphoma but also for nonmalignant blood disorders such as sickle cell and aplastic anemia \u2014 but that more than 15,000 could easily be done annually if more doctors embraced the new methods now available.\nHe also will be five years cancer-free in September.\nIt was extraordinarily shocking to us that it was impossible,\u201d Caryn recalled.\nIn fact, when she and her doctors scoured the registry for a match for her, only one name came up: her own.\nA larger trial using umbilical cord blood that had been expanded in a lab is underway.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Every source in the piece is either directly involved in the types of treatments being discussed or is a patient who has undergone treatment.", "answer": 0}, {"article": "This study received funding from the Divers Alert Network and U.S.\n\"It appears that the drug, which dilates the blood vessels, could be creating more capacity in the blood vessels in the arms and legs, reducing the tendency for blood to redistribute to the thorax, and therefore reducing the high pressure in the pulmonary vessels.\"\nIt dilates blood vessels, giving it the potential to ease an abrupt cold water-induced constriction of blood vessels in the arms and legs that can lead to blood pooling in the heart and lungs.\n\"During immersion in water, particularly cold water, susceptible people have an exaggerated degree of the normal redistribution of blood from the extremities to the chest area, causing increased pressure in the blood vessels of the lungs and leakage of fluid into the lungs,\" said Richard Moon, M.D., an anesthesiologist and medical director of the Duke Center for Hyperbaric Medicine & Environmental Physiology.\nThe drug -- best known as Viagra\u2122 -- is normally used for treatment of male impotence, but also for pulmonary arterial hypertension.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funders are mentioned, although the release makes no effort to clarify possible conflicts of interest. The study on which this news release\u00a0is based states\u00a0that the principle investigators have no conflicts of interest.", "answer": 1}, {"article": "Which sounds worse to you?\nThere is no correlation between getting the Gardasil vaccine and seriously adverse effects such as \u201cautoimmune diseases (including Guillain-Barre Syndrome and multiple sclerosis), anaphylaxis, venous thromboembolism, and stroke.\u201d\n\nMind you, all these things and more have been used by people who attack vaccines as an argument against it.\nThe study, published in the Pediatric Infectious Disease Journal, looked at the published data about effects from the vaccine and found that it has a \u201cfavorable safety profile.\u201d This study comes after many other previous studies that show essentially the same thing.\nEven more frustrating about this vaccine is that it\u2019s being fought by an unusual group of people; while most anti-vax leanings are not affiliated with any particular political persuasion, Gardasil gets attacked additionally by conservatives who think that girls getting it will become more promiscuous, because HPV is a sexually transmitted disease.\nThe Gardasil vaccine, on the other hand, caused some people to faint after getting it, and others got mild skin infections\u2014both of which occur somewhat rarely with other vaccines too, as you might expect.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There is no independent voice included, nor does the story alert readers to the fact that Merck funded the study. Drug company funding is obligatory for post-marketing surveillance data of this type. So while it\u2019s worth mentioning, such funding is arguably not as important as when a company funds a study with glowing findings on a new unapproved device or drug.", "answer": 0}, {"article": "Trying to diagnose prostate cancer is one of the most maddening tasks a doctor has.\nIt is a string of RNA that does not appear to have any function but that is overexpressed, or overactive, in prostate cancer.\nThe test had a sensitivity of 49 percent, meaning it correctly identified 49 percent of cancers.\nA blood test for prostate specific antigen or PSA shows when PSA rises, but PSA goes up with either cancer or just normal enlargement of the prostate \u2014 or even if the gland is inflamed, such as from an infection.\n\u201cIf the PCA3 is abnormal, above about 35, you have got an 80 percent chance of having cancer,\u201d Crawford said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Only a single conflicted source was quoted: one of the principal investigators of the study reported on. \u00a0Considering this study was presented at the annual meeting of the American Urological Association, it seems that there were many around who could have offered expert opinion and insight about this test.", "answer": 0}, {"article": "However, some patients developed new tumors in that time period, the researchers noted.\nFunding for their work was provided by Galil Medical, a medical device manufacturer based in Arden Hills, Minn.\n\nBecause this study was presented at a medical meeting, the conclusions should be considered preliminary until published in a peer-reviewed journal.\nFor his part, Dr. David Carbone, a professor and director of the James Thoracic Center at the Ohio State University Wexner Medical Center, said that the findings regarding cryoablation are \"not incredibly novel,\" given that the procedure has been around for years.\nAt least in the short-run -- meaning three months after the procedure -- the intervention known as \"cryoablation\" appeared to kill all targeted tumors that had spread to the lung from elsewhere, preliminary results suggest.\nThe study authors cautioned that while the initial findings are encouraging, the treatment should not be seen as a cure for this type of metastatic (spreading) lung disease.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The one \u201cindependent\u201d expert quoted provided another valid perspective, although it seems that we may simply have dueling physician preferences at play here \u2013 the study authors possibly preferring cryoablation and the other expert quoted preferring stereotactic radiosurgery.\u00a0 And not enough evidence was provided to help readers/patients decipher where the weight of the evidence aligns.", "answer": 1}, {"article": "The findings were reported Monday in an American Heart Association online conference.\n\"The study highlights that if one chooses to use ticagrelor in subjects with acute coronary syndromes, it would be logical to use aspirin 81 milligrams per day (and not 325 mg daily),\" said Dr. Jeffrey S. Berger, assistant professor of medicine and director of cardiovascular thrombosis at NYU Langone Medical Center in New York City.\nThe panel's recommendation was based in part on prior findings from this study, called the Platelet Inhibition and Patient Outcomes (PLATO) trial.\n\"Of note, there is little reason to ever use aspirin 325 mg except in the acute setting of a heart attack or stroke,\" he added.\n\"Patients with acute coronary syndrome have options to prevent recurrent events,\" study lead author Dr. Kenneth W. Mahaffey, co-director of cardiovascular research at the Duke Clinical Research Institute, and associate professor of medicine at Duke University Medical Center, said in an AHA news release.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Our biggest bone to pick with the story is its failure to mention that the study was funded by the maker of drug. Keep in mind that Brilinta is going up against Plavix, shortlisted\u00a0with the best-selling drugs on the planet, and at US sites of PLATO, Plavix \u201cwon\u201d (kind of). With FDA approval influenced by the results of this PLATO follow-up, AstraZeneca\u2019s funding was a pretty important conflict of interest to disclose.  One independent source was cited, Dr. Berger. Further sources may have revealed more of the history and controversy in the field. In the discussion at the AHA conference where this new study was announced, at least one panelist said he thought the results were \u201cspurious,\u201d emphasizing the study\u2019s conclusion that the result could have been due to chance.", "answer": 0}, {"article": "Griffith said a German study recently found that donated corneas cost about $2,500.\n\"The patients' own cells and nerves grew back, and there was an overall improvement in vision,\" said study co-author May Griffith.\n\"This is true cutting-edge work and brings an exciting new option to the repertoire of corneal transplant surgeons,\" he said.\nAn estimated 5 million people in the world have an eye disease called trachoma that affects the cornea, and another 1.5 million to 2 million are thought to have developed cornea-related blindness through other diseases or trauma.\nThe shortage means trouble for many of those whose corneas -- the clear surface at the front of the eye -- have been injured or damaged by illness.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes one independent source who is basically a booster for the research. He also, though, raises an issue that underscores some of the information lacking in the story. The story also\u00a0could have explained what the funding sources were.", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/29/national/w155455S59.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Quotes from an accompanying editorial, a member of the panel monitoring the vaccine\u2019s safety and the head of National Institute of Allergy and Infectious Disease of the National Institutes of Health augment the information presented in the article in the New England Journal of Medicine upon which the story was based.", "answer": 1}, {"article": "What if we told you that a guy with no background in science or medicine - not even a college degree - has come up with what may be one of the most promising breakthroughs in cancer research in years?\nIt was the worst kind of luck that gave Kanzius the idea to use radio waves to kill cancer cells: six years ago, he was diagnosed with terminal leukemia and since then has undergone 36 rounds of toxic chemotherapy.\nHere's the important part: if clinical trials pan out - and there's still a long way to go - the Kanzius machine will zap cancer cells all through your body without the need for drugs or surgery and without side effects.\nIt's not something that a layman like me should be in, it should be left to doctors and research people,\" he told Stahl.\nHis name is John Kanzius, and as correspondent Lesley Stahl first reported last April, he's a former businessman and radio technician who built a radio wave machine that has cancer researchers so enthusiastic about its potential they're pouring money and effort into testing it out.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The segment draws exclusively on the inventor and three credible but potentially self-interested supporters, one of whom is dead. \nThis is unsatisfactory: One or more independent cancer researchers should have been interviewed, including one who is currently doing other research with nanoparticles and one expert radiologist.\nThese sources could have provided necessary context for this history and outcomes of previous promised \"breakthroughs,\" the implications of novelty and the many things which remain unknown.\nThe segment should have reported whether the researchers interviewed have a financial or other interest in the procedure. ", "answer": 0}, {"article": "The back of the Snooz'n bottle says the beverage will \"combat stress, energy drinks and sleeplessness\" and takes about 30 minutes to take effect.\nSome say they aren't intended for people younger than 18 or for pregnant or nursing women - a warning that the Food and Drug Administration has also made about melatonin.\nThe chief ingredient in many of these beverages is melatonin, a hormone that induces sleepiness and helps coordinate the body's biological clock.\nHowever, a study published in January in the Journal of the American Geriatrics Society found that a pre-bedtime cocktail of magnesium, zinc and a five-milligram dose of melatonin significantly improved sleep among a group of 43 elderly Italian insomniacs.\nIt's typically released by the pineal gland around 10 p.m.; secretion stops around 4 or 5 a.m., helping to trigger the body to wake up, Scharf says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes a physician sleep expert, a dietitian, and an employee of one of the beverage companies. There don\u2019t appear to be any conflicts of interest that weren\u2019t properly disclosed.", "answer": 1}, {"article": "\"Right then, I thought, \u2018Oh, why did I do this?\nThey sound different, but that's better than not hearing them at all.\u201d\n\nPriddy said that from his experience as a cochlear implant recipient, he has learned many valuable lessons about himself and the world around him.\nThe pain was so excruciating at that moment.\u201d\n\nBut the deafness typically results after the device is implanted because it has yet to be turned on.\n'\u201d\n\nBecause the sounds generated by cochlear implants are different from sounds received naturally by the ear, it takes time to learn to interpret what they mean.\nBerryhill said the cost of the implant and surgery is in excess of $60,000, but it is covered by most insurance companies as well as Medicare and Medicaid.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites several sources: a patient; the patient\u2019s mother, teacher, and physician; and a commercial website. The story should have included a trusted independent source with expertise on the subject who had no personal or economic interest in this patient or his treatment. ", "answer": 0}, {"article": "For more information, visit http://www.\n\"If you could imagine saving the cost from the number of patients whose readmission you were able to prevent, that result could provide significant savings to the health system,\" Dr. Gunter said.\nThe study results appear as an \"article in press\" on the website of the Journal of the American College of Surgeons ahead of print.\n\"We have demonstrated that a population of complex and high-risk patients, many of whom are older adults and novice smartphone users, can complete this protocol with high fidelity and satisfaction,\" the researchers concluded.\n\"We set out to come up with a protocol where patients could become active participants in their care and allow us to be in closer communication and monitor their wounds after they leave the hospital,\" said lead study author and general surgery resident Rebecca L. Gunter, MD.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release states that support came from the Agency for Healthcare Research and Quality and that lead author Rebecca L. Gunter, MD, is supported by the National Institutes of Health.", "answer": 1}, {"article": "WASHINGTON\u2014People with mild Alzheimer\u2019s disease who started taking an experimental Eli Lilly & Co. drug earlier in the course of their disease fared better than patients who started later in a clinical trial.\n\nThe outcome may bolster the company\u2019s case that the drug, solanezumab, can slow the decline of memory and function in mild Alzheimer\u2019s patients, despite prior studies with negative results. But the new data aren\u2019t final proof of the drug\u2019s benefit\u2014a separate, continuing study due to end in late 2016 is designed to...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two clearly independent sources are quoted, but both are market analysts who offered only global, annual sales estimates for the drugs. There seem to be no independent sources cited in regard to how promising the drugs are, what the clinical trial findings might mean, how far the drugs might be from reaching the market, etc. That\u2019s a significant oversight. Even if readers are interested in this solely as a business story, expert evaluations from independent sources on those issues would be enormously valuable. The conflicts of interest seem clear, with one exception. The story quotes Paul Aisen, director of the Alzheimer\u2019s Therapeutic Research Institute at the University of Southern California, \u201cwho presented the results\u201d on solanezumab.\u00a0Aisen is also a consultant to Eli Lilly and many other drug companies, which should have been mentioned.", "answer": 0}, {"article": "The Site is down for maintenance.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There was an important voice added from a breast cancer survivor.\nBut there was no independent expert perspective added.", "answer": 0}, {"article": "TUESDAY, Dec. 8, 2009 (HealthDay News) -- High-flow oxygen appears to be an effective treatment for cluster headaches, British researchers have found.\nHigh-flow oxygen also provided better pain relief at 30 and 60 minutes.\nThe National Pain Foundation has more about cluster headache.\nNo serious harmful side effects were reported after high-flow oxygen treatment, according to the report published in the Dec. 9 issue of the Journal of the American Medical Association.\nThe current treatment is injection with the drug sumatriptan, but frequent use of the drug isn't recommended because of the risk of adverse effects.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources were cited in the story. ", "answer": 0}, {"article": "\u201cThis is a very important claim for us to allow to be incorporated into food labels,\u201d said Dr. Scott Gottlieb, the commissioner of the F.D.A.\nThe product, called Hello, Peanut, can be mixed into pur\u00e9ed baby food to expose infants to peanuts starting around five months old.\nA new powdered peanut product is the first food item allowed to claim it may reduce peanut allergies in infants, though parents of susceptible babies are urged to consult a doctor before trying it.\nWhile many foods like whole grains, nuts and supplements carry qualified health claims stating that they may reduce the risk of diseases like cancer or heart disease, this is the first time a food product label will be allowed to make a qualified claim that it reduces the risk of an allergy, officials said.\n\u201cThe guidelines for how to approach allergens in children are changing, the science is changing, and it\u2019s important for parents to know.\u201d\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes the physician-developer of the product, government officials and physician-patient advocates. While we would have liked an expert source with no direct ties to industry or advocacy, we\u2019ll rate this Satisfactory.", "answer": 1}, {"article": "\u201cTraining peer counselors to do phone counseling is an effective, low-cost and non-stigmatizing way for new moms to get the help they need.\u201d\n\nParticularly for first-time mothers, postpartum depression can be hard to distinguish from the stress and fatigue that come with caring for a new infant around the clock, Letourneau said.\nFurthermore, at mid-point, 60 percent of the mothers had low depression scores; this percentage rose to 75 percent at end.\nOn average, they spoke about three times.\nThey also had nurses available for phone consults if they had concerns about anything the moms said during their conversations.\nBy midway through the study, 37 new moms had received at least one call from a peer counsellor.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two outside sources and notes explicitly that they were not involved in the current study. Gratifying!", "answer": 1}, {"article": "Could root canal procedures go by the wayside in the not-too-distant future?\n\"What we found is a material that can potentially regenerate components of a patients' tooth,\" Celiz told CBS News.\nThe process works by stimulating native stem cells inside teeth, triggering repair and regeneration of pulp tissues.\n\"We have tested it in cell cultures and we're moving it along into rodents,\" he said.\nInstead of the current dental materials used on fillings, which are toxic to cells, the new approach harnesses stem cells instead.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story lacks viewpoints from independent experts, such as someone from the American Association of Endodontists.", "answer": 0}, {"article": "According to a study published in the Online First edition of Anesthesiology, the official medical journal of the American Society of Anesthesiologists\u00ae (ASA\u00ae), patients who received a novel high frequency form of spinal cord stimulation (SCS) therapy experienced significantly greater, long-term relief for both chronic back and leg pain, when compared to a traditional low frequency form of SCS therapy.\u201cThis is the first long-term study to compare the safety and effectiveness of high frequency and traditional SCS therapy for back and leg pain,\u201d said Leonardo Kapural, M.D., lead study author and professor of anesthesiology at Wake Forest University School of Medicine and clinical director at Carolinas Pain Institute at Brookstown in Winston-Salem, N.C. \u201cChronic back and leg pain have long been considered difficult to treat and current pain relief options such as opioids have limited effectiveness and commonly known side effects.\nFor more information on the field of anesthesiology, visit the American Society of Anesthesiologists online at asahq.org.\nHF10 therapy remained more effective than traditional SCS over the 12 month study period.\nMore than 1.5 billion people worldwide suffer from chronic pain, with lower back pain being the most frequent condition affecting 23 to 26 percent of the population.\nIn the study, researchers examined 171 patients with chronic back or leg pain who were implanted at 10 comprehensive pain treatment centers.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not tell readers that the study was funded by the Nevro Corporation, which makes the device that was studied, nor that the study authors had ties to the company and other medical device makers.", "answer": 0}, {"article": "Warren says he wishes the solution were as simple as just taking folic acid.\nThe Norwegian study is the largest to date on the benefits of folic acid for autism prevention, and marks one of the first tangible things a woman can do to reduce her risk of giving birth to a child with the disorder.\n\"This is another piece of evidence that supports the beneficial uses of folic acid during pregnancy,\" said Halladay, who was not connected with the study.\n\"The reality is, autism is a complex disorder and our best answers about causes and treatment are going to be complex as well.\"\n\"This is pretty exciting,\" said Alycia Halladay, senior director for environmental and clinical sciences for Autism Speaks, an autism advocacy group.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes a nice mix of voices, including experts from an autism advocacy group, the March of Dimes, and in independent autism research program. This was a strong point of the story.", "answer": 1}, {"article": "New investigation advises doctors to recommend cranberry products as first line of defense against repeated urinary tract infections (UTIs)\n\nCARVER, Mass., September 19, 2017 - A thorough review of dozens of studies led scientists to conclude that healthcare professionals should be telling their patients to have cranberry products as a first step in reducing recurrent UTIs.\n\"Our investigation supports that cranberry products can be a powerful tool to fight off frequent UTIs,\" explains lead author, Dr. \u00c2ngelo Lu\u00eds.\nThe industry appreciates the efforts of these researchers and takes pride in the healthy attributes that cranberry products provide to consumers around the world,\" comments Terry Humfeld, executive director of the non-profit research and education-focused organization, The Cranberry Institute.\nLuis A, Domingues F and Pereira, L. Can cranberries contribute to reduce the incidence of urinary tract infections?\nThe Cranberry Institute is a not-for-profit organization founded in 1951 to further the success of cranberry growers and the industry in the Americas through health, agricultural and environmental stewardship research as well as cranberry promotion and education.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "This is satisfactory, yet the release could have been more transparent about the organization that issued the release. The study itself was supported by a Portuguese university and a Portuguese bank, which is noted in the release. However, the release lists a PR firm as the contact but includes a quote from the director of the Cranberry Institute and a summary of the Institute as background, without ever mentioning the group\u2019s relationship to the study.\u00a0 After looking at the Cranberry Institute\u2019s website it\u2019s clear that the trade group has worked with the PR firm previously on news releases. Why not explain the Cranberry Institute\u2019s interest in the research?", "answer": 1}, {"article": "The receiving operator characteristic (ROC) curve had an area under the curve (AUC) of 0.967.\nDr. Ashley Brenton, Associate Director of R&D for Proove states, \"This validation study builds on the peer-reviewed evidence supporting Proove Opioid Risk\u00ae and its components as an optimal model to predict opioid abuse risk.\"\nFurthermore, the sensitivity of the \"moderate risk\" cut-off score was 98%, while the specificity of the \"high risk\" score was 100%.\nThis study, entitled \"Evaluation of a Predictive Algorithm that Detects Aberrant Use of Opioids in an Addiction Treatment Centre\", is published in the peer-reviewed Journal of Addiction Research and Therapy (Impact Factor: 1.4).\nDiscovered by NIH-funded scientists, Proove\u00ae has translated into clinical practice the genetic variants and phenotypic factors contributing to pain sensitivity and chronic pain risk.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "No information is provided about who provided the funding for the study. The news release quotes three of the study\u2019s authors, including Dr. Ashley Brenton, who is identified as the \u201cAssociate Director of R&D for Proove.\u201d The two other authors quoted do not appear to work for Proove. The journal article on which the new release is based also omitted\u00a0 information about the funding source for the study.", "answer": 0}, {"article": "So, in a sense, [TMS is] not a treatment...for the ultimate cause of the disorder, but it\u2019s an intervention that improves how the patient is able to function.\u201d\n\nTMS has a lot in common with a traditional MRI scan.\nOnce the patient\u2019s thumb involuntarily twitches, the current is strong enough to affect the patient\u2019s brain activity.\nThose who struggle with depression have imbalanced levels of serotonin, which maintains mood, and dopamine, which controls the pleasure and reward zones.\nSome pill-averse patients have longed for a natural cure for depression, while others complain that the drugs they\u2019re on aren\u2019t enough.\nA physician then tests the machine to see how much power is needed to affect the patient\u2019s reflexes.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The one scientist quoted in this story holds patents on several brain stimulation methods and apparatuses, a potential conflict of interest that receives no attention in the story.", "answer": 0}, {"article": "It also found that the protective effect increases with age.\nDec. 6, 2010 -- Taking aspirin over a long period of time can substantially cut the risk of dying from a variety of cancers, according to a study showing that the benefit is independent of dose, gender, or smoking.\nThis 20-year follow-up established that the risk of cancer death remained 20% lower among those who had been allocated aspirin than those in the control group for all solid cancers, including lung, prostate, brain, bladder, and kidney cancers, and by 35% for gastrointestinal cancers.\nA previous study by the same authors showed that low doses of aspirin (75-300 milligrams) reduced the number of cases of colorectal cancer by a quarter and deaths caused by the disease by more than a third.\nFor instance, it only became apparent after about five years for esophageal, pancreatic, brain, and lung cancer; about 10 years for stomach and colorectal cancer; and about 15 years for prostate cancer.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two outside experts to good effect. One of them, Dr.\u00a0Peter Elwood, \u201can expert on aspirin from Cardiff University who was not involved in the study, says that doctors are often reluctant to recommend aspirin because \u201cthe risk of causing a bleed by what the doctor prescribes is going to be uppermost in a doctor\u2019s mind.\u201d A patient might interpret the risk differently, he says.\u201d", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Tens of thousands of kids may benefit from cholesterol-lowering medication, but no one would know because screening guidelines exclude too many children, U.S. doctors said Monday.\nIn a report published in the journal Pediatrics, they call for screening of all children, expanding one set of current recommendations that target only those whose parents or grandparents have heart disease or high cholesterol.\nScreening all children would \u201cidentify a number of children who are of very significant risk of premature heart disease,\u201d said Dr. William Neal of West Virginia University in Morgantown, who led the new study.\nThe new study tapped into data from more than 20,000 children who had been screened at public schools in West Virginia over five years.\nMore than seven in 10 school kids had first-degree relatives with heart disease, and about one percent of those had \u201cbad\u201d cholesterol (LDL cholesterol) levels that might require drug treatment in addition to diet changes and exercise, according to the researchers.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe journal Pediatrics stated that the study authors did not report any relevant financial interests. The story did include comments from an independent expert.", "answer": 1}, {"article": "But conventional germicidal lamps aren\u2019t safe for humans to be around.\n\u201cThink about doctor\u2019s waiting rooms, schools, airports and airplanes\u2014any place where there\u2019s a likelihood for airborne viruses.\u201d And unlike the flu vaccine, he says, far-UVC light is likely to be effective against all airborne microbes, including newly emerging virus strains.\n\u201cYou can sterilize a hospital room, but not when anyone\u2019s inside.\u201d\n\nAbout five years ago, Brenner says, the Columbia team came up with a potential solution.\n\u201cIf you have a lamp over the surgical site that can sterilize the air, you can prevent the bacteria from floating down and contaminating the wound.\u201d\n\nBrenner can\u2019t predict how long it might take for these lamps to be commercially available, but he says he\u2019s \u201cextremely optimistic\u201d about the technology.\nFor that reason, UV devices are often used for sterilization \u2014 for medical equipment in hospitals, for example, or drinking water for backcountry campers.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The lead author of the story is the only source cited, and we\u2019re not told if he has any conflicts of interest. The HealthDay story we reviewed rated better on this criteria.", "answer": 0}, {"article": "Cut It Out (Surgically)\n\nAt 32, it just didn't make sense that Daniel Sheiner was exhausted literally from the moment he woke up.\nThe only surgery proved effective more than 90 percent of the time is a significant and highly invasive surgery.\nSheiner is a software designer and programmer.\nHis job suffered as a result of his fatigue.\nNoninvasive measures are always the first lines of defense, she says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes the perspective of one independent expert.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070506/14healthwatch.lede.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not quote any independent researchers or clinicians who could comment on the impact of this new development on the management of osteoporosis.", "answer": 0}, {"article": "It's not really a problem,\" Mr.\nThe 106-year-old Children's Institute (formerly called the Rehabilitation Institute) plans to fund the room through the $30 million capital campaign it launched in 2005, after buying out its Shady Avenue site from the University of Pittsburgh Medical Center.\nUnder the plans -- developed with help from Duquesne University -- autistic patients would live for more than six weeks in a 1,000-square-foot room kept mostly free of harmful chemicals and pollutants, using special air-filtering systems, ultraviolet lights and air locks on doorways.\nThey think I am crazy, even a [Defeat Autism Now doctor] we once saw,\" said a message posted by a parent on the AutismWeb.com bulletin board in March\n\nParents \"research anything they can get their hands on and there are so many things saying 'Try this or try that' that aren't necessarily safe.\n\"We know that the data for this is just emerging, but we feel it's a very safe intervention, and it's empowering for families and very reasonable,\" he said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The main source of information for this article was the project\u2019s lead pediatrician.\u00a0 No other experts or expert opinions were included to provide balance to the story or to minimize potential bias.\u00a0 This\u00a0omission is particularly egregious in an article about a disorder that can be so heartbreakingly severe and recalcitrant, and about untested theory.\u00a0 The devotion of millions of dollars to a \"fringe\" therapy may mean these dollars are diverted away from compassionate, scientifically based care.\u00a0 ", "answer": 0}, {"article": "DALLAS - March 29, 2018 - A first-of-its-kind drug targeting a fused gene found in many types of cancer was effective in 93 percent of pediatric patients tested, researchers at UT Southwestern's Simmons Cancer Center announced.\nThe research appears in The Lancet Oncology.\nA next step in the research is a clinical trial involving a similar drug for those patients who developed resistance.\nBut the cancer started to grow again and no further treatments were available.\nThe nearly universal response rate seen with larotrectinib is unprecedented,\" Dr. Laetsch said.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release lists the funders of the trial and notes that the lead investigator is a paid consultant for Loxo Oncology.", "answer": 1}, {"article": "But many others are tough calls.\n\"The diagnosis of melanoma is the most serious one a dermatologist makes, and we have sleepless nights worrying about it,\" said Pariser, who consulted for the device's maker, Mela Sciences Inc. of Irvington, N.Y., on its presentation to FDA.\n\"There is no such thing as 100 percent certainty in medicine,\" said Dr. George Elias, a melanoma expert at Georgetown's Lombardi Comprehensive Cancer Center who had no ties to the company or the device.\n\"A biopsy takes a few minutes in my hands, so if there's an issue with any lesion we will always biopsy, whether we have a MelaFind picture or not,\" said Dr. Leonard Goldberg, a dermatologist at the Texas Medical Center and vice president of the Skin Cancer Foundation, a disease awareness group that accepts donations from makers of sunscreen.\nMore than 70,000 people in the U.S. will be diagnosed with melanoma this year, and 16 percent are diagnosed only after the disease has spread to other parts of the body, according to estimates from the National Institutes of Health.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not use a truly independent source because everyone appears to have some sort of conflict, but this is also one of the stories strengths. Rarely have we seen conflicts presented with this kind of detail. For example, the story says describes Dr. Leonard Goldberg as \u201ca dermatologist at the Texas Medical Center and vice president of the Skin Cancer Foundation, a disease awareness group that accepts donations from makers of sunscreen.\u201d", "answer": 1}, {"article": "The researchers from Harvard's T.H.\n\"The sexy headline is eat this and you'll have a lower risk of breast cancer, but I'd shift the focus to, eat more fiber because it's better for you and you'll be a healthier person and you're less likely to be obese and have chronic inflammation and other things that will reduce your risk for heart disease and cancer along the way,\" said Attai.\nDr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital, in New York, told CBS News, \"It lends support to the fact that we need to encourage people to start healthy habits earlier on.\"\n\"The results of this study emphasize the role of an early life high-fiber diet on prevention of breast cancer in later life.\nNevertheless, Blackwell said, \"It is reasonable for pediatricians to encourage a high-fiber diet and include decreasing breast cancer risk as one of the potential benefits.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story incorporates input from multiple independent sources who provide valuable perspective on the research. We particularly liked this line from Dr. Deanna Attai.\u00a0(Full disclosure: Dr. Attai is also a reviewer for HealthNewsReview.org.)\n\u201cThe sexy headline is eat this and you\u2019ll have a lower risk of breast cancer, but I\u2019d shift the focus to, eat more fiber because it\u2019s better for you and you\u2019ll be a healthier person and you\u2019re less likely to be obese and have chronic inflammation and other things that will reduce your risk for heart disease and cancer along the way,\u201d\nAnd while the story does not address conflicts of interest, there do not appear to be any conflicts of interest to report.", "answer": 1}, {"article": "Assistant professor Mads Fiil Hjorth \n\nDepartment of Nutrition, Exercise and Sports, University of Copenhagen \n\nEmail: madsfiil@nexs.ku.dk \n\nTel.\nThe latest findings, as reported in AJCN, have garnered international support with further analysis conducted by researchers from the University of Colorado, Tufts University, and Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Fisiopatolog\u00eda de la Obesidad y Nutrici\u00f3n (CIBER OBN).\n\"Recognizing fasting plasma glucose as a key biomarker enables a new interpretation of the data from many previous studies, which could potentially lead to a breakthrough in personalized nutrition,\" said Arne Astrup, M.D., Head of Department of Nutrition, Exercise and Sports at University of Copenhagen.\nThe research analyzed data from three diet clinical trials which collectively looked at more than 1,200 individuals - Diet, Obesity, and Genes (DiOGenes); the OPUS Supermarket intervention (SHOPUS); and the Nutrient-gene interactions in human obesity (NUGENOB).\nThe findings suggest that for most people with prediabetes, a diet rich with vegetables fruits and wholegrains should be recommended for weight loss and could potentially improve diabetes markers.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not state the funder of the research. A deeper dive into the full-text publication of the research revealed that the study was funded by Gelesis Inc.,\u00a0a biotechnology company working to develop therapies to induce weight loss and improve glycemic control in overweight and obese patients.", "answer": 0}, {"article": "CHAPEL HILL - University of North Carolina Lineberger Comprehensive Cancer Center researchers have found that mailing self-collection kits to test for high-risk human papillomavirus infection has the potential to boost cervical cancer screening - especially for low-income women who are overdue for testing.\nThe home self-collection test indicated that 12.4 percent of women were infected with high-risk HPV, the self-collection tests used in the clinic found 15.5 of the women had high-risk HPV infection, and the clinician-collected test identified 11.4 percent of the women had high-risk HPV infection.\n\"We found in this sample, all of the women who had high-grade lesions had HPV-positive home self-collection results,\" Smith said.\nFinancial disclosure: High-risk HPV and sexually transmitted disease tests, sample preservation media, ThinPrep processor slides, and other equipment were donated by Hologic, Inc. Self-collection brushes were donated by Rovers Medical Devices.\nThis will allow us to determine the effect that self-collection has on screening uptake.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release includes information about not only sources of funding, but also sources of research equipment \u2014 which is really good to see. The release also includes clear information regarding potential conflicts of interest.", "answer": 1}, {"article": "Washington, DC - September 18, 2018 - An international team of researchers has successfully deployed a Zika virus vaccine to target and kill human glioblastoma brain cancer stem cells, which had been transplanted into mice.\nIt provides a network for scientists in academia, industry and clinical settings.\nASM's mission is to promote and advance the microbial sciences.\nMice that got the injection of the GSCs only rapidly developed tumors.\nFinally, the team investigated the cellular mechanisms that the modified Zika virus used to kill the GSCs.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding source for the study is not mentioned.", "answer": 0}, {"article": "And studies suggest that fortifying corn masa with folic acid could prevent an additional 40 to 120 cases of neural tube defects among babies born to Hispanic mothers each year.\nThe exact cause of this discrepancy isn't known.\nThe petitioners filed the results of that study in October.\nBut the FDA might have more questions related to the study before making a final ruling.\nIt renders the corn more pliable for grinding into masa flour and gives the masa its distinctive aroma and flavor.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes independent sources.", "answer": 1}, {"article": "Before the trial, one 40-year-old, who said he had fears starting at age 10 that he was going to die in his sleep, rated his certainty that he was suffering from a serious illness as an 8 on a scale of 1 to 10.\nThe study found that hypochondriacs who got cognitive behavior therapy, which encourages people to challenge the validity of their disabling beliefs, also improved -- as much as those given the drug.\nAccording to the standard manual of mental disorders, hypochondriasis is a potentially serious condition that can prompt people to go doctor shopping, abuse sick time at work and become complete invalids.\nIn the first controlled study that compared a group of hypochondriacs given the drug with a group that got psychological talk therapy and another group that received sugar pills, the medication significantly reduced people's fears about imaginary illnesses.\nIn general, there was a 40 percent increase in prostate cancer in men who had no sons.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The source of information for this study appears to be a journal article.\u00a0 No one is quoted. There is no evidence of any input sought from any source independent of the study. \u00a0 ", "answer": 0}, {"article": "The United States Preventive Service Task Force (USPSTF) currently recommends that physicians screen patients for dysglycemia (prediabetes or type 2 diabetes) when they are 40 to 70 years old and are overweight or obese.\nThe study also touches on the financial implications of these guidelines.\n\"The earlier patients are diagnosed with these conditions, the sooner they can begin to combat them,\" O'Brien said.\nUnder a provision in the Affordable Care Act, all services recommended by the USPSTF must be fully covered by insurers.\nOnly 23 percent of patients with prediabetes or diabetes would be missed if expanded screening criteria were used to make screening decisions, the study found.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding sources are satisfactorily explained and detailed.", "answer": 1}, {"article": "THURSDAY, June 28, 2012 (HealthDay News) -- A new drug for type 2 diabetes causes significantly less weight gain and may carry lower risks for hypoglycemia (low blood sugar), heart attack and stroke than standard medications, a new study indicates.\nResearchers in Germany noted that the new drug, linagliptin (Tradjenta), is intended for use in patients that do not fare well with metformin, the most common first-line drug used to treat the disease.\nThe study, which was funded by linagliptin's maker, Boehringer Ingelheim, involved 1,500 people from 16 countries with type 2 diabetes.\nThe researchers found that 7 percent of patients on linagliptin experienced hypoglycemia, compared to 38 percent of patients treated with glimepiride.\nAlthough the effectiveness of the drugs were similar, the study showed the side effects of linagliptin were much less severe than those of glimepiride.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story says quite high that the study \u201cwas funded by linagliptin\u2019s maker, Boehringer Ingelheim,\u201d and it quotes one independent source. More sources would have been better.", "answer": 1}, {"article": "We suspect this strategy could benefit other cancer patient populations.\"\nThe findings were presented Dec. 6 at the 57th annual meeting of the American Society of Hematology in Orlando, Florida.\nThe high-dose vaccine (Fluzone High-Dose) was approved in 2009 by the FDA as a single dose for adults over 65.\nThis study was supported by the Arthur R. Sekerak Cancer Research Fund a Yale Cancer Center philanthropic fund.\n\"Using an approved flu vaccine in a novel dosing schedule yielded promising results for a group patients at high risk for infection,\" Branagan said.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release discloses that the study was funded by the Yale Cancer Center\u2019s Arthur R. Sekerak Cancer Research Fund.", "answer": 1}, {"article": "The research was funded by an Incubator grant from MS Research Australia.\n\"This, in turn may lead to fewer relapses and a slower loss of brain volume, resulting in slowing or potentially halting progression of the disease for the person living with MS.\nGiven exosomes can cross the blood-brain barrier, it is likely that some of the circulating exosomes in MS patients come from affected central nervous system cells or the associated inflammatory milieu.\n\"This is the first demonstration that micro-RNAs associated with circulating exosomes in blood are informative biomarkers not only for the diagnosis of MS, but in predicting disease subtypes with a high degree of accuracy,\" said Associate Professor Michael Buckland, Head of the Department of Neuropathology at RPA Hospital and the Brain and Mind Centre, University of Sydney.\nThe research was made possible through the generosity of patients at the Brain & Mind Centre's multidisciplinary Multiple Sclerosis Clinic, a collaborative service offered by Royal Prince Alfred Hospital, and the University of Sydney.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding source is identified. Since the goal is to devise a commercial diagnostic test, we would also encourage releases to point out any potential conflicts of interest. In this case, there doesn\u2019t appear to be any.", "answer": 1}, {"article": "Others have such high cholesterol that taking statins alone is not enough.\n\"It seems that the group that takes them, compared to the group that doesn't, has half the rate of cardiovascular events and mortality as those that don't,\" Dr. Seth S. Martin of the Johns Hopkins School of Medicine told CBS News.\nIn an editorial published along with the study, experts note that although the results are promising, more long-term research is needed to make definitive conclusions about the drug.\nThese new drugs \"could be for someone who needs an addition to statin, or it could be instead of statin,\" Martin said.\nOne in six American adults lives with high cholesterol, and millions have trouble getting it under control, according to the Centers for Disease Control and Prevention.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes Seth Martin of Johns Hopkins School of Medicine, who is one of the authors of an accompanying editorial in the same journal. We salute the quote from someone independent of the study and who appears to have no conflict of interest \u2014 but wish he had been identified better. Readers can\u2019t tell who he is from the story itself.", "answer": 1}, {"article": "Lanctot and Fargo do not recommend that relatives or friends of those with agitated Alzheimer's provide them medical marijuana to ease their suffering.\n\"We would love to see this study done in a larger group of people, to see if it continues to be effective in a larger group, and how worried we need to be about this sedation side effect,\" Fargo said.\nFor example, only one person out of five to 14 treated with antipsychotics actually experiences a decrease in agitation, Lanctot said.\n\"This is the first clinical trial to show that a cannabinoid can decrease agitation,\" said lead researcher Krista Lanctot, a senior scientist at Sunnybrook Health Sciences Center in Toronto.\nDuring the clinical trial, 39 patients with moderate to severe Alzheimer's disease received nabilone for six weeks to treat their clinically significant agitation, followed by six weeks with an inactive placebo.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A lead researcher and a source from the Alzheimer\u2019s Association were quoted. Since this research was presented at the Alzheimer\u2019s Association meeting, this does not meet the bar for an independent source.", "answer": 0}, {"article": "Arjmandi was to present the findings Tuesday at the Experimental Biology meeting in Washington D.C.\nIt's kind of like nature's toothbrush, and it's brushing the bad stuff out,\" she explained.\nThe addition of apples to the diet probably kept the women feeling fuller because of the fiber content in the apples, she explained.\nDespite the addition of several hundred calories a day to their diet, the apple-eating women didn't gain weight over the course of the study.\n\"Some people are predisposed because of their genes to having high cholesterol, and a healthy diet may not be enough.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We\u2019ll give the story credit for seeking the input from an independent clinical nutritionist, although she apparently only had a news release and/or an abstract to comment on \u2013 which is incomplete basis for comment much less a story.", "answer": 1}, {"article": "As this study has shown in a randomized, double-blind, double-dummy, placebo-controlled manner, exogenous testosterone therapy with Androgel can clearly decrease sperm production and potentially impact fertility,\" said Dr. Kim.\nThe findings, which are published in BJU International, could change the way men are treated for low testosterone.\nAn alternative approach to testosterone replacement is based on restoring the body's natural production of testosterone with drugs similar to those used to help women ovulate.\nThis can result in a significant decrease in sperm count--leading to infertility--because the body needs its own testosterone to produce sperm.\nThe Professional Development segment provides digital and print books, online assessment and training services, and test prep and certification.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Two of the three researchers, co-authors of the journal manuscript,\u00a0are consultants to Repros Therapeutics. This is disclosed in the journal manuscript but not mentioned in the news release. \u00a0Enclomiphene is in their product pipeline.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070520/28healthwatch.lede.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only source quoted in this story was the senior author of the paper reported on.\u00a0 It would have been helpful to have an independent source comment on the results presented.", "answer": 0}, {"article": "Johnson & Johnson and Bavarian Nordic have a vaccine in early-stage clinical tests.\nThe vaccine is being developed by the U.S. National Institutes of Health (NIH) and GSK against the Zaire strain of Ebola \u2014 the one circulating in West Africa \u2014 and the first doses for a larger trial arrived in Liberia last week.\nThe data, published in the New England Journal of Medicine, were from 60 healthy volunteers given the vaccine in Britain between Sept. 17 and Nov. 18 last year.\nHowever, the antibody response was weaker than was found in a trial of the same Ebola vaccine in macaque monkeys, in which the animals were also found to be protected.\nThat trial is the first of several mid-stage studies planned for West Africa and aims to test GSK\u2019s vaccine and one from Merck and NewLink.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story utilized quotes from the lead author and a representative of the sponsoring organization. \u00a0Both were clearly identified as such so the the reader could place their comments into perspective. The two individuals quoted provided a very balanced view of the study results. However, our standard is to include the perspective of at least one person not affiliated with the research, so the story rates unsatisfactory on this criterion.", "answer": 0}, {"article": "LOS ANGELES (Embargoed Until Oct. 18, 2018 @ 10:05AM ET) -- A surgical technique called EDAS (encephaloduroarteriosynangiosis) significantly decreases the rate of stroke recurrence and death for patients with severe atherosclerosis of the brain arteries, according to findings of a Phase IIa clinical trial presented today at the World Stroke Congress in Montreal.\nDespite advances in medical care, annual rates of recurrent stroke and death are remain high, at 15 percent or more for ICAD patients, according to published research.\nWhile this Phase IIa trial selected patients from previous studies as the control group, the Phase III study would enroll new ICAD patients for both the control and experimental groups, he explained.\n\"This clinical trial moves us significantly closer to preventing strokes and death in high-risk populations,\" said Keith Black, MD, professor and chair of the Department of Neurosurgery.\nTwo of the EDAS patients had small wound openings that required additional surgical interventions, but there were no intracranial hemorrhages or other serious adverse events, the researchers reported.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release explains that the study was funded by grants from the National Institutes of Neurological Disorders and Stroke of the National Institutes of Health.", "answer": 1}, {"article": "Researchers at Brigham and Women's Hospital in Boston looked at 3.8 million pregnant women nationwide and found that those taking popular antidepressants, called SSRIs, did not appear to be at significantly increased risk of having a baby with pulmonary hypertension.\n\"The risk increase of taking antidepressants late in pregnancy, if present, is much more modest than previous studies have found,\" says Krista Huybrechts, Ph.D., an epidemiologist at Brigham and Women's Hospital.\nBOSTON -- In 2006, the FDA warned the public that the use of common antidepressants, like Prozac and Paxil, late in pregnancy could put a baby at risk for respiratory failure.\nDr. Economy warns patients about the potential risks like withdrawal in the newborn and a small risk of heart defects, but says for many women, the worst time to stop their medications is at the end of pregnancy when postpartum depression becomes a concern.\n\"My basic message is that, overall, there may be some slight risks associated with the medication, but in balancing risks and benefits for most women, I would suggest they stay on their medication,\" she said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We didn\u2019t find one of the sources quoted in the story \u2014 Dr. Katherine Economy \u2014 on the list of study authors, nor in the acknowledgements, which suggests she wasn\u2019t involved in the study. But as the story points out, she works at the same institution as several of the authors and could therefore be less objective than some other independent observers. Her comments are certainly valuable and add important perspective to the piece. But to be consistent with our standard, we are obligated to rule this Not Satisfactory. We feel that it\u2019s always a good idea to reach an outside source for comment.", "answer": 0}, {"article": "Fried said sensory experiences that eventually become memories pass through this hub before they are stored in the hippocampus, the brain\u2019s chief memory center.\n\u201cThe entorhinal cortex is the golden gate to the brain\u2019s memory mainframe,\u201d Dr. Itzhak Fried, professor of neurosurgery at the David Geffen School of Medicine at UCLA, who worked on the study, said in a telephone interview.\nDespite costly efforts, no drug has been found that can keep Alzheimer\u2019s from progressing, and policymakers are growing increasingly worried about the swelling ranks of dementia patients as the population ages.\n\u201cAlthough the current evidence is preliminary, is based on small samples and requires replication, the potential application of deep-brain stimulation in amnestic disorders is enticing,\u201d Black wrote.\nThe current study was done at the University of California at Los Angeles in seven epileptic patients awaiting surgery who had electrodes implanted deep in their brains to help pinpoint the source of their seizures.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an independent source and includes a comment from an editorial that appears along with the research report in the New England Journal of Medicine. It does not refer to any conflicts of interest, but the authors reported no conflicts in the disclosure forms posted online by the journal.", "answer": 1}, {"article": "Gage BF, Bass AR, Lin H, Woller SC, Stevens SM, Al-Hammadi N, Li J, Rodriguez Jr. T, Miller JP, McMillin GA, Pendleton RC, Jaffer AK, King CR, DeVore B, Porche-Sorbet R, Napoli L, Merritt K, Thompson AM, Hyun G, Anderson JL, Hollomon W, Barrack RL, Nunley RM, Moskowitz G, Davila-Roman V and Eby CS for the GIFT investigators.\nNo patient died during the trial.\nVariants in another gene affect warfarin sensitivity.\nVariants in one gene affect vitamin K recycling.\nIn the future, we hope to quantify how these variants affect warfarin.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Nicely done and quite complete.", "answer": 1}, {"article": "Megan L. Kavanaugh, a senior research scientist at the Guttmacher Institute, which studies reproductive health, said in an interview that \u201call new insurance plans obtained through the act\u2019s exchanges fully cover all contraceptive methods without any co-payments or other out-of-pocket costs.\u201d Title X family planning clinics and Planned Parenthood clinics are more likely than other sources to offer LARC methods, she said.\nOnly about half of obstetrician-gynecologists offer the implant, the committee said, and many physicians use \u201coverly restrictive criteria\u201d when deciding whether to recommend an IUD, especially for adolescents and women who have not yet been pregnant.\nThe hormone, a form of progesterone, prevents ovulation and thickens the cervical mucus, making it harder for sperm to reach and fertilize an egg.\n\u2022 The More We Learn on Nutrition, the More We Ignore\n\u2022 Ask Well: Catching Up on Lost Sleep\n\nFor more fitness, food and wellness news, follow us on Facebook and Twitter, or sign up for our newsletter.\nThere are few contraindications; nearly all women are eligible for an implant or IUD, according to guidelines from the Centers for Disease Control and Prevention and the American College of Obstetricians and Gynecologists.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes one expert, Megan Kavanaugh, who is one of the authors of one of the studies referenced in the article. Kavanaugh works for the Guttmacher Institute, and has declared no conflicts in other publications on contraception. It would have been nice to hear from someone who is totally independent of the studies and report covered in the column, but we think Dr. Kavanaugh qualifies as sufficient for a Satisfactory rating here.", "answer": 1}, {"article": "A rare malignancy known as squamous cell carcinoma of the anal canal (SCCA) is on the increase, and now researchers have reported results of the first-ever phase II clinical trial results for treatment with the immunotherapy drug nivolumab.\nThe phase II study, for which findings are being presented at this week's American Association for Cancer Research's annual meeting in New Orleans, was designed and led by researchers at The University of Texas MD Anderson Cancer Center's Human Papillomavirus-Related (HPV) Cancers Moon Shot Program.\nStudy team members for the correlative analysis included Armeen Mahvash, M.D., Interventional Radiology; Luis Vence, Ph.D., Jorge Blando, D.V.M., and James Allison, Ph.D., all of Immunology; Robert Wolff, Cancer Medicine; Aki Ohinata, GI Medical Oncology; Chimela Ohaji, Investigational Cancer Therapeutics; and Padmanee Sharma, M.D., Ph.D., Genitourinary Medical Oncology.\nOf note, patients who scored as responders had higher frequency of CD8 T-cells and PD-L1 CD45 immune cells in pre-treatment samples.\n\"This study demonstrated responses in five of 18 patients treated at MD Anderson, and many of the patients had significant reductions in their tumor size.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release could have been transparent about financial backing. Funding sources are listed, but there is no mention of whether individual researchers have potential conflicts of interest. In our review of MD Anderson\u2019s kidney cancer news release last fall, we noted that one of the researchers involved in that study is a paid consultant to the maker of nivolumab, Bristol-Myers Squibb. That researcher, Padmanee Sharma, M.D., is also part of the anal cancer study team. Neither news release noted her financial tie, and the reader is left to wonder whether any of the researchers have vested interests in the study outcome.", "answer": 0}, {"article": "Potluri cautioned, however, that this study can't prove that statins actually extended life in cancer patients.\n\"We need to further investigate the reasons for patients with high cholesterol having improved mortality in four of the most common cancers,\" said senior researcher Dr. Rahul Potluri, a clinical lecturer at Aston University School of Medicine in Birmingham.\nThe results were to be presented Friday at the European Society of Cardiology meeting in Florence, Italy.\n\"Regardless of whether or not a person has cancer, statin use should be discussed with a health care provider,\" said Eric Jacobs, strategic director of pharmacoepidemiology at the American Cancer Society.\nAmong the patients in the study, nearly 8,000 had lung cancer, 5,500 had breast cancer, 4,600 had prostate cancer and 4,500 had colon cancer, the researchers found.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not identify whether there are any conflicts for the study authors, but they do not appear to have any when we researched them ourselves. We are glad the story included a quote from an independent source\u00a0at\u00a0the American Cancer Society.", "answer": 1}, {"article": "In one of his own studies, Wong found no effect on soy germ isoflavones among women who took the supplements for two years.\nSoy supplements also have side effects such as nausea, bloating, and constipation, according to the National Institutes of Health.\n\u201cThe majority of them are showing no benefit,\u201d said William W. Wong, a nutrition researcher at Baylor College of Medicine in Houston who wasn\u2019t involved in the new work.\nThe work was supported by Frutarom Netherlands, which also donated the supplements.\nThe new study, published in the journal Menopause, is based on 90 Chinese women.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The journalist interviewed an American researcher who did not agree with the study results and had conducted other studies using soy supplements and did not find any significant effects. \u00a0Also, it was stated the supplements in the study were provided by Frutarom Netherlands \u2013 a private company that sells soy supplements over the counter in the U.S.", "answer": 1}, {"article": "The quality of life survey measured overall functioning (physical, emotional, cognitive, etc.\n\u201cThe net benefit of pleurectomy and decortication justifies the procedure in the majority of patients with malignant pleural mesothelioma,\u201d Dr. Vigneswaran concluded.\nThe study is titled \u201cQuality of Life in Patients Undergoing Pleurectomy and Decortication for Malignant Pleural Mesothelioma.\u201d The surgeries were performed by Dr. Vigneswaran at University of Chicago Medicine, where he practiced before recently joining Loyola.\nNewswise \u2014 MAYWOOD, IL \u2013 Although surgery can prolong the lives of patients with an aggressive type of cancer called malignant pleural mesothelioma, many patients avoid the operation for fear it will degrade their quality of life.\nPrior to surgery, 31 percent of the patients had a performance status score of 0 (fully functional); 65 percent had a performance status score of 1 (able to do light house work or office work); and 4 percent had a performance status of 2 (ambulatory and capable of self-care, but unable to work).\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release does not mention any funding sources for the study but we\u2019ll rate this \u201cNot Applicable\u201d since the surgeries described were performed in one surgeon\u2019s practice. There are also no new drugs or devices in play and the procedures are not new or novel.", "answer": 2}, {"article": "The study was to be presented Sunday at the Alzheimer's Association International Conference in Washington, D.C.\n\"This is a very preliminary study with a small number of subjects and the results are far from conclusive,\" said Dr. Allison Reiss, head of the Inflammation Section at Winthrop-University Hospital in Mineola, N.Y.\n\nShe believes the current study lacks information on possible confounding factors -- things such as \"coexisting illnesses, medications, hydration state, tobacco use and multiple other variables\" that could influence what's found in the saliva samples.\nIn the study, Sapkota's team tested the saliva of 22 people with Alzheimer's disease, 25 people with what's known as mild cognitive impairment (a decline in memory and thinking that's sometimes a precursor to dementia), as well as 35 people whose mental skills were normal for their age.\nSUNDAY, July 19, 2015 (HealthDay News) -- It's still very early, but scientists say a test based on a patient's saliva might someday help detect Alzheimer's disease.\n\"It is uncertain whether the strength and consistency of the relationship between these metabolites [in saliva] and Alzheimer's risk will be maintained in a large multicenter study.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Nice job here. Two of the three sources quoted in the story are apparently unaffiliated with the institution conducting the research, suggesting independent voices. A comparison with a Time story about the same study makes this story seem exceptionally well-sourced.", "answer": 1}, {"article": "WASHINGTON -- The Food and Drug Administration on Wednesday approved ImClone Systems Inc. and Bristol-Myers Squibb Co.'s Erbitux as a treatment for head and neck cancer, the agency said Wednesday.\n\nThe drug, which is designed to block proteins involved with cancer growth, was first approved in 2004 as a colon cancer treatment.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Only a single source \u2013 the FDA \u2013 is quoted.", "answer": 0}, {"article": "Recent tests show the cancerous nodules in Mejia's lungs are shrinking, and she hopes for more good news after scans later this summer.\n\"If there is cancer, the tumor is shedding DNA into the mother's blood as well and that is what is accounting for this imbalance,\" study author Dr. Diana Bianchi, who serves on an advisory panel for the company, told CBS News.\nThe study, funded by Illumina, a maker of one non-invasive prenatal test, looked at eight women with abnormal test results.\nWhile prenatal testing is widely used for pregnant women at risk of having babies with chromosome disorders such as Down syndrome, new research shows certain types of tests may also reveal markers of cancer in mothers.\nThe findings are published in the Journal of the American Medical Association.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story noted that the study was funded by the manufacturer of the test and that the study author quoted has a relationship with the company. That\u2019s useful context, but we require an independent voice to meet our standard on this criterion. No one was quoted except one of the study\u2019s authors.", "answer": 0}, {"article": "ABOUT CLEARPOP\n\nClearPop for Rapid Earache Relief represents a simple, safe, pediatrician recommended, clinically effective and fun way to treat earaches.\nDue to increasing concern about antibiotic overuse and its links to obesity, celiac disease, and Superbugs, the American Academy of Pediatrics now recommends against the use of antibiotics to treat routine ear infections in children over 2.\nIn light of this, Morehouse developed a lollipop with a patented shape optimized to pull congestion out of the middle ear and into the mouth.\nFull study report at http://clearpop.com \n\n\n\nEAR INFECTION AND ANTIBIOTICS\n\nEar infections are the Number One reason kids aged 5 and under receive oral antibiotics.\nClearPop for Rapid Earache Relief has been shelved by Raley's (CA, NV) select RiteAid locations, and is available at boutique drugstores and Amazon.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "No confusion here. The release is clearly a promotional vehicle for ClearPop which is noted in the dateline and throughout the copy. It also provides links back to the ClearPop website and states that the creator of Clearpop also started and leads the company.", "answer": 1}, {"article": "She tried decongestants, antihistamines and steroid nasal sprays.\nTo avoid poking through to the brain or into the orbit of an eye, there's a device around the patient's head with a guidance system that tells Metson, in three dimensions, exactly where his sharp instruments are on a CT scan of Butler's head.\n\"And if we can use those as novel targets for, let's say, nasal sprays or medications, we may be able to treat people like Judy without surgery,\" Metson says.\n\"I read an article about people feeling less tired all the time after having had surgery, and I thought, boy, I would really like that,\" she says.\nOn the monitor, you can see the miniature instruments he's using to cut away inflamed tissue and snip away pieces of eggshell-thin bone that block Butler's sinuses and give her nonstop headaches.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story relies\u00a0heavily on the perspective of Judy Foreman, the health columnist and patient, and her surgeon,\u00a0Ralph Metson, neither of whom have any conflicts of interest that we could identify. While it would have been nice to hear from an expert who wasn\u2019t involved in this particular case,\u00a0the story does enough to satisfy the criterion.\u00a0", "answer": 1}, {"article": "EMBARGOED UNTIL AUG. 14, 2017, AT 10 A.M. EDT\n\"Our previous lab studies and human clinical trials have shown promise in treating heart failure using cardiac stem cell infusions,\" said Eduardo Marb\u00e1n, MD, PhD, director of the Cedars-Sinai Heart Institute and the primary investigator of the study.\nSince Marb\u00e1n's team completed the world's first cardiac stem cell infusion in 2009, the Cedars-Sinai Heart Institute has made significant contributions to decoding and understanding how cardiac stem cells regenerate damaged heart muscle.\nFrom cardiac imaging and advanced diagnostics to surgical repair of complex heart problems to the training of the heart specialists of tomorrow and research that is deepening medical knowledge and practice, the Cedars-Sinai Heart Institute is known around the world for excellence and innovations.\n\"We have much to study, including whether CDCs need to come from a young donor to have the same rejuvenating effects and whether the extracellular vesicles are able to reproduce all the rejuvenating effects we detect with CDCs.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release states that \u201cgeneral support\u201d for Marban\u2019s lab is provided by the National Institutes of Health, and that Cedars-Sinai along with its heart institute chief Eduardo Marban, a co-author of the study, have financial interests in Capricor, which own the process to grow cardiac-derived stem cells.", "answer": 1}, {"article": "THURSDAY, Feb. 3, 2011 (HealthDay News) -- A special restrictive diet may significantly reduce symptoms of attention-deficit hyperactivity disorder (ADHD) in young children, a new study suggests.\n\"We think that dietary intervention should be considered in all children with ADHD, provided parents are willing to follow a diagnostic restricted elimination diet for a five-week period, and provided expert supervision is available,\" they concluded.\n\"If parents have noticed that a child's behavior seems to get worse with certain foods, it may be worth considering,\" said Ghuman, who is an associate professor of psychiatry and pediatrics at the University of Arizona in Tucson.\nIgG is an antibody made by the immune system that some alternative medicine practitioners believe is linked to food hypersensitivities; however, IgG testing is controversial among many mainstream physicians and even some naturopaths, according to background information in the study.\n\"Since none of the children stayed on the diet beyond five weeks, it is hard to know if this dietary intervention offers sustained benefit,\" he said, adding, \"Since it is more difficult to enforce restricted diets in older children, this approach may not be suitable for the majority of older children with ADHD.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes one outside expert and one expert who wrote an accompanying editorial.\u00a0Dr. Andrew Adesman, chief of developmental and behavioral pediatrics at the Steven and Alexandra Cohen Children\u2019s Medical Center of New York in New Hyde Park, said, \u201cSince none of the children stayed on the diet beyond five weeks, it is hard to know if this dietary intervention offers sustained benefit. \u2026Since it is more difficult to enforce restricted diets in older children, this approach may not be suitable for the majority of older children with ADHD.\u201d Jaswinder Ghuman, MD, associate professor of psychiatry and pediatrics at the University of Arizona, who wrote a commentary, says, \u201c\u201dBut, for this diet to work, you have to be very consistent with it, and you have to pay attention to nutrition. It should be done under the supervision of a primary care doctor, and if possible, a dietician.\u201d These cautious voices are very different from the more exultant opinions in the WebMD piece.", "answer": 1}, {"article": "Researchers say breast cancer survivors often experience side effects from cancer treatments that can persist months or years after completion of treatment.\nIn the study, published in Breast Cancer Research and Treatment, higher intake of cruciferous vegetables and soy foods were associated with fewer reports of menopausal symptoms.\nHigher soy intake was also associated with less reported fatigue.\n\"Understanding the role of life style factors is important because diet can serve as a modifiable target for possibly reducing symptoms among breast cancer survivors.\"\nThe authors report having no personal financial interests related to the study.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There was disclosure of the funding sources, and the release tells us that the study authors had no financial conflicts of interest. Good job.", "answer": 1}, {"article": "(CNN) Experts have proposed using medical marijuana to help Americans struggling with opioid addiction.\n\"There is a great deal of movement in the Northeast, with New Hampshire and New Jersey being well-positioned to legalize adult use,\" Moore said.\nThe details of the medical cannabis laws were found to have a significant impact on opioid prescription patterns, the researchers found.\n\"This study adds one more brick in the wall in the argument that cannabis clearly has medical applications,\" said David Bradford , professor of public administration and policy at the University of Georgia and a lead author of the Medicare study.\n'This crisis is very real'\n\n\"We have had overuse of certain prescription opioids over the years, and it's certainly contributed to the opioid crisis that we're feeling,\" he added.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted the lead authors of each of the studies. It also quoted the independent co-author of the invited commentary. Another source was Melissa Moore, New York deputy state director for the Drug Policy Alliance. The article did not mention that the Drug Policy Alliance advocates for legalizing and regulating marijuana. There is one brief paragraph in the article that described \u201csome skeptics\u201d who \u201cargue that medical marijuana could actually worsen the opioid epidemic\u201d but no one is quoted.", "answer": 0}, {"article": "The combination contraceptive needs to undergo further testing before it is commercially available.\nThe results of the study, funded by the U.S. National Institutes of Child Health and Human Development, were presented at the recent Endocrine Society annual meeting, held in Houston.\nThe study, conducted in conjunction with the University of Washington, involved 56 men who were assigned to receive one of three types of gels: one gel containing both testosterone plus a gel containing one of two doses of the synthetic progestin; or a gel containing testosterone on its own plus a \"placebo\" gel with no progestin.\nThis is the first time that a combination of testosterone and a synthetic progestin called Nestorone has been tested as a gel that could be applied topically.\nBecause the new study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We\u2019re going to take a hard line on this criterion. The comments from the one independent source appear to be confined to potential for men using a contraceptive and not to the study or the results and their implications.\u00a0 So, while there is an independent source, the comments were not relevant to the study per se.\u00a0 SInce surrogate measures were sought as an outcome measure, the comments of an independent expert related to the study results would have been informative.", "answer": 0}, {"article": "SATURDAY, Sept. 29, 2012 (HealthDay News) -- Researchers say they've discovered a two-drug combination that delays treatment resistance in patients with advanced melanoma.\nBut the response is temporary in most cases, and tumor growth resumes in six or seven months, the researchers explained.\nThe study was conducted at 14 sites in the United States and Australia and included 162 patients who received different dose combinations of the drugs: two daily 150 milligram (mg) doses of dabrafenib plus one 2 mg dose of trametinib; the same dabrafenib dose with a 1 mg dose of trametinib; or treatment with dabrafenib alone.\nThe study was scheduled for presentation Saturday at the European Society for Medical Oncology meeting in Vienna and simultaneous publication in the New England Journal of Medicine.\nAfter one year of treatment, 41 percent of patients receiving the full-dose combination treatment had no progression of their melanoma, compared with 9 percent of those receiving dabrafenib alone.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story informs readers that both drugs studied are being developed by GSK, which sponsored the studies. And we hear from an independent dermatologist who was not involved with the study.", "answer": 1}, {"article": "Women were defined as light drinkers if they had no more than one or two drinks a week.\nIn the U.S., pregnant women are strongly advised not to drink at all, says Eva Pressman, MD, director of maternal/fetal medicine at the University of Rochester, N.Y.\n\nPressman points out that women who are light drinkers during pregnancy tend to be from households with relatively high incomes.\n\"Our results suggest that children born to mothers who drank at low levels were not at any risk of social or emotional difficulties or any risk of emotional impairments compared to mothers who did not drink,\" Kelly tells WebMD.\nOct. 5, 2010 - Pregnant women who have up to two alcoholic drinks per week do not harm their children, a U.K. study shows.\nIn the U.K., women are advised not to drink at all during the first trimester of their pregnancy and to drink no more than a drink or two a week after that.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "On this criterion, this story did better than the other one we reviewed. It includes an independent source: Dr. Eva Pressman, director of maternal/fetal medicine at the University of Rochester. She serves as the voice of moderation, and she says some things that are actually pointed out in the study itself. One thing missing from both of these stories is any mention of who funded the research, but since the funding came from a public agency, we won\u2019t penalize the story. Of course, if the funding had come from an entity connected to the alcoholic beverage industry, disclosure (and heightened skepticism) would have been imperative.", "answer": 1}, {"article": "\"Although there was no significant difference in either physician visits or antibiotic use, as might be expected over only a 6-month follow-up period, our findings concerning consultations are important in the longer term, given antibiotic use increases the risk of antimicrobial resistance.\"\n\"We found potentially important changes in other outcomes; in particular, fewer participants in the nasal irrigation group than in the no-irrigation group had headaches, used over-the-counter medications and intended to consult a doctor in future episodes,\" write the authors.\nThe study involved 871 patients from 72 primary care practices in England who were randomly assigned to 1 of 4 advice strategies: usual care, daily nasal and saline irrigation supported by a demonstration video, daily steam inhalation, or combined treatment with both interventions.\n\"We have found that even a very brief intervention of a video showing patients how to use saline nasal irrigation can improve symptoms, help people feel they do not need to see the doctor to manage the problem, and reduce the amount of over-the-counter medication they need to use,\" said Dr. Paul Little, Primary Care and Population Sciences Unit, University of Southampton, Southampton, United Kingdom.\nSteam inhalation did not appear to alleviate symptoms of sinusitis.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "This release does not make any comment on the study funders. According to the UK clinical trial registry, the study was sponsored by the University of Southampton (UK).", "answer": 0}, {"article": "(CNN) -- The use of mammograms has dipped since a medical task force made controversial recommendations that women in their 40s may not need to get breast cancer screenings every year, according to one of three small studies to be presented Monday.\nRoughly 15% of women in their 40s detect breast cancer through mammography.\n\"There are whole lots of assumptions that are not supported by the data they presented.\"\n\"This is a decision that should belong to the woman with appropriate info on hand.\"\n\"There is a real, but rather modest benefit.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Good sourcing, including \u2013 unlike the competing Denver Post story \u2013 input from the chair of the US Preventive Services Task Force.", "answer": 1}, {"article": "Thousands of breast cancer patients at risk of developing aggressive secondary tumours could benefit from a potential new genetic test.\nProfessor Coleman said: \"If the test is negative for this gene, then they can be offered this bone strengthening treatment, which can give them a better chance of surviving their cancer.\u201d\n\nA test for the gene, known as MAFTest, has been developed by a Spanish medical company called Inbiomotion following work conducted at the Institute for Research in Biomedicine (IRB) in Barcelona.\n\u201cIt only seems to be effective in some patients, particularly older women, while others show no response and in some younger women it may even be harmful.\u201d\n\nThe new study, which is published in the journal Lancet Oncology, has shown it may be possible to identify women who will benefit from bisphosphonates by using a test that looks for a gene known as MAF.\n\u201cThe discovery made at IRB Barcelona and tested in the current study could be of great use to clinicians and would avoid unnecessary treatment of patients who would not benefit or could be harmed by the treatment,\" added Professor Roger Gomis, leader of the growth control and cancer metastasis group at IRB Barcelona, who was a co-author on the study.\nThe new study, which is published in the journal Lancet Oncology, was part of an international phase 3 clinical trial involving 3,360 women with stage II or III breast cancer.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release didn\u2019t note any funding sources. The published study stated that the study was funded by Novartis, which makes the bisphosphonate drug Zometa, and by Inbiomotion which developed the MAFTest that tests for amplification of the MAF gene. (The release does mention that the test was developed by Inbiomotion.)\nClearly, both companies would benefit from positive study results and positive news coverage and thus must be mentioned in the news release as funders of the study in the interest of transparency.", "answer": 0}, {"article": "Researchers at Georgia State analyzed clinical data from a large cohort of breast cancer patients treated at Northside Hospital in Atlanta from 2005 to 2015.\nCo-authors of the study include Jun Xia, Sergey Klimov, Pranay Neema, Dr. Dora Il'yasova, Dr. Padmashree C. G. Rida, Dr. Remus Osan and Dr. Aneja of Georgia State; Dr. Guilherme Cantuaria and Dr. Mildred Jones of the Northside Hospital Cancer Institute; Dr. Uma Krishnamurti, Dr. Xiaoxian (Bill) Li and Dr. Michelle D. Reid of Emory University; and Dr. Meenakshi Gupta of West Georgia Hospitals.\n\"We found that, in general, African-American breast cancer patients exhibit increased likelihood for tumor recurrence, particularly to regional and distant sites, after receiving any combination of adjuvant therapy (treatment following surgery) compared to European-American breast cancer patients.\nThis higher incidence of tumor recurrence can contribute to a poorer prognosis,\" said Nikita Wright, first author of the study and a senior Ph.D. student in Dr. Ritu Aneja's laboratory in Georgia State's Biology Department.\nDespite a similar number of reported cases of breast cancer among African-American and European-American women, African-Americans experience a more aggressive clinical course and a 40 percent higher death rate than European-Americans among premenopausal and menopausal breast cancer patients.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release clearly states the funder: \u201cThe study was funded by the National Cancer Institute of the National Institutes of Health.\u201d\nAs far as conflicts of interest, one of the authors, Padmashree C. G. Rida, disclosed receiving a salary from Novazoi Theranostics, which is described in one business directory as a \u201cDiagnostic Substances business / industry within the Chemicals and Allied Products sector.\u201d It doesn\u2019t appear that the tie represents a potential conflict relative to this study, but we think it\u2019s always prudent to disclose such commercial affiliations in news releases.", "answer": 1}, {"article": "\"The truth is that quit smoking programs, like other programs that treat addictions, often have fairly low success rates. But that doesn't mean they're not worthwhile or that you should be discouraged. Your own success in quitting and staying that way is what really counts, and you have some control over that. Even if you don't succeed the first few times, keep trying. You can learn from your mistakes so that you'll be ready for those pitfalls next time.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story does not include any comments from independent sources\u2013or even from one of the researchers themselves. It only refers to the original journal article. Why does this matter? It\u2019s always a good idea to consult an outside source because it\u2019s likely to yield insights and context that otherwise would be lacking. But overall, this is a case where the story\u00a0is still fairly strong, regardless of the lack of sourcing or interviews.", "answer": 0}, {"article": "What causes the disc to herniate in the first place?\n\"I think that it be important for people to have good information,\" he adds.\n\"However what was really interesting is that patients who decided not to have surgery who could wait also did very well.\"\nHe says he thinks that sometimes people are too quick with surgery.\nIn an effort to determine which approach is best, Dr. Weinstein's launched a major study of over 1,200 patients with back pain.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quotes the study's lead author. The story should have quoted other clinicians/researchers who could have provided other perspectives.", "answer": 0}, {"article": "Tecentriq is marketed by Genentech based in San Francisco, California.\nThe study also looked at the difference in effect based on \"positive\" versus \"negative\" expression of the PD-L1 protein on patients' tumor-infiltrating immune cells.\nThese are distinct programs intended to facilitate and expedite the development and review of certain new drugs in light of their potential to benefit patients with serious or life-threatening conditions.\nThe most common side effects of treatment with Tencentriq were fatigue, decreased appetite, nausea, urinary tract infection, fever (pyrexia) and constipation.\n\"Tecentriq provides these patients with a new therapy targeting the PD-L1 pathway,\" said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "This release describes the approval of a new drug by a regulatory agency, but we\u2019d still like to know who sponsored the study that\u2019s the basis for the approval. It\u2019s not enough to state who markets the drug.", "answer": 0}, {"article": "It's a \"close call,\" says H. Gilbert Welch, MD, MPH, of the Dartmouth Institute in Lebanon, N.H.\n\n\"This is a test that women who want it should be able to have,\" Welch tells WebMD.\nHow many lives?\n\"Because we don't know which cancers these are, all cancers are treated.\n\"Some will benefit in a very large way.\n\"The vast majority will turn out not to have cancer, but all of them will worry.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 1}, {"article": "Most recently, the F.D.A.\nAlthough smoking rates in the United States have declined in recent decades, tens of millions of adults continue to smoke, and the habit causes more than 440,000 deaths a year, according to the Centers for Disease Control and Prevention.\nThe most widespread therapies currently available are nicotine-replacement products, like nicotine patches and gum, which are designed to wean the smoker by administering trickles of nicotine to the body, replacing the surges delivered by cigarettes.\nWhile the market for smoking cessation therapies is estimated to be more than $1 billion annually, many smokers continue to fail in their efforts to quit even while using the available products, with long-term success rates generally peaking at about 20 percent.\n\"It's the period between four-week abstinence and one-year abstinence that's the critical period,\" said Dr. Victor I. Reus, a professor of psychiatry at the University of California, San Francisco, and a lead investigator on the NicVax study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Only sources affiliated with the study and Nabi Biopharmaceuticals are cited. The National Institute of Drug Abuse (NIDA) funded early phases of the study with a $4.1 million grant so the director of NIDA pharmacotherapies has an interest in the outcome of the trials. Sources not affiliated with the NicVax trials are needed for perspective on this new therapy for smoking cessation. ", "answer": 0}, {"article": "Although the technique's potential to identify brain disorders and diseases was noted years ago, fcMRI-based diagnostic tests have yet to make their way into doctors' offices.\nThe answer?\nThanks to this work, we know we have a reliable tool to study these possibilities.\"\n\"Brain networks captured by fcMRI are really about the individual,\" Gratton said.\nFunctional MRI scans generate a dynamic map of the outer surface of the brain, showing changing hot spots of activity over time.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funders of the study are listed on a sidebar of the news release hosting site, EurekAlert!", "answer": 1}, {"article": "But they can be deadly in the modern era.\nThe underlying research, from Immunomic Therapeutics and Johns Hopkins University, involves attaching a fragment of DNA from, say, cedar pollen to a template vaccine that can embed itself inside the cell.\nIf it works, it\u2019d be fairly easy to swap out the cedar pollen DNA for a different allergen \u2014 for instance, the genetic material that codes for peanut or cat antigens \u2014 and tack it onto this vaccine template.\nAs many as 10 percent of children suffer from hay fever, nearly 12 percent have skin allergies, and 5 percent have food allergies, most commonly peanuts, dairy, and shellfish, according to the 2014 National Health Interview Survey.\nThe capsules are science\u2019s answer to previous efforts from allergists, who would concoct \u201chome brews\u201d of peanut protein to desensitize patients under the table.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article casts a pretty wide net of sources, including interviews with allergy researchers at Stanford and at Mass General Hospital in Boston, as well as investigators with drug companies.", "answer": 1}, {"article": "The study's third co-author is Julie-Andr\u00e9e Marinier, from the Centre de recherche interdisciplinaire en r\u00e9adaptation du Montr\u00e9al m\u00e9tropolitain and \u00c9cole d'optom\u00e9trie at the Universit\u00e9 de Montr\u00e9al.\nIn Canada, that\u2019s roughly 3.6 million people.\nAnd that could help with stigmatization of the elderly and disabled.\nFor the study, the Concordia-based research team recruited 100 participants who ranged in age from 24 to 97.\n\u201cWhat was interesting to note was that it didn\u2019t matter what technology was used to do the magnification: an iPad worked just as well as a traditional device like a closed circuit television system (CCTV),\u201d he says.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release names several sources of funding.", "answer": 1}, {"article": "However, Reid believes theirs is the first study to model the long-term effects of eating dark chocolate in reducing cardiovascular risk.\nThey did not study actual people eating actual chocolate.\nReid and his team constructed a mathematical model to predict the long-term health effects of eating dark chocolate daily in high-risk people.\nThe researchers also computed whether it would be cost-effective to spend money on a public education campaign about dark chocolate's benefits.\nSeveral studies have found that dark chocolate, with its heart-healthy flavonols, can lower blood pressure and improve cholesterol.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The Harvard nutritionist/epidemiologist provided vital perspectives.\n\u00a0", "answer": 1}, {"article": "So Friedman opted for a less invasive procedure to make her stomach smaller again.\nThe problem is that over the years the stomach stretches, and when that happens, Watson says, \"Patients are able to eat more at one sitting and they feel hungrier more often.\"\nWatson says we don't know for sure, but it's possible the body begins to adapt to those changes, which is why the weight loss is reversed over time.\nIf the stomach pouch has stretched, new sutures are put in place to once again reduce the size of the stomach.\n\"It was the first time in my life that I've ever lost a lot of weight and was able to maintain it.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an independent expert who provides useful context about this type of surgery. While it clearly meets our standard, the story could have offered a few more details about this source. Is he a bariatric surgeon? Has he used this device? That would give readers a better perspective from which to evaluate his comments about the procedure.", "answer": 1}, {"article": "This determined the most effective treatment frequency.\nFurthermore, adding the MES+HS treatment to a DPP-4 inhibitor, which is the most often used therapeutic drug for diabetes in Japan, showed an even stronger blood glucose improvement.\n\"This device is very easy to use since it simply attaches to the abdomen, and it has a low-impact on the patient.\nIn the researcher's next clinical trial, 60 obese patients with type 2 diabetes from both genders were given a 12-week treatment with the belt-shaped MES+HS medical device.\nThe heat shock response (HSR) is activated as a response to stress in the human body, but its function decreased in those with type 2 diabetes.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release notes that the study was funded by the Japan Agency for Medical Research and Development, Grants-in-Aid for Scientific Research. The journal article in Scientific Reports also acknowledges the belt device was provided by the Tsuchiya Rubber Co., Ltd. (Kumamoto, Japan).", "answer": 1}, {"article": "Abroms and her team wanted to find out if a more intensive mobile phone program called Quit4baby would be more effective.\n\"Our findings show that a text messaging program helped some groups of pregnant women quit smoking during pregnancy,\" says lead author Lorien C. Abroms, ScD, MA, an associate professor of prevention and community health at Milken Institute School of Public Health (Milken Institute SPH) at the George Washington University.\nThe school also offers an online Master of Public Health MPH@GW, an online Executive Master of Health Administration MHA@GW, and an online Master of Science in Management of Health Informatics and Analytics, HealthInformatics@GW, which allow students to pursue their degree from anywhere in the world.\nDr. Abroms has stock in Wellpass Inc. (formerly Voxiva, Inc.) and has licensed Text2quit and Quit4baby to Wellpass.\nThe messages help educate the women about the health risks associated with smoking and they are interactive--allowing a woman to text back for more help if she is experiencing a craving or goes back to smoking.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release offers information about both funding and conflicts of interest. It notes that the lead author, \u201cDr. Abroms has stock in Wellpass Inc. (formerly Voxiva, Inc.) and has licensed Text2quit and Quit4baby to Wellpass.\u201d This is a real strength of the release.", "answer": 1}, {"article": "MONDAY, March 19, 2012 (HealthDay News) -- New research finds that a minimally invasive surgical procedure to treat hernias results in less chronic pain and a faster recovery when compared to a traditional approach.\nAlmost all the patients were men, and their average age was around 55.\nIt was developed in the 1990s, Brunt said.\nThe findings appear in the March issue of the Archives of Surgery.\nFor more about hernias, try the U.S. National Library of Medicine.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An independent source provided useful context about the important continuing role of the traditional \u201copen\u201d procedure.", "answer": 1}, {"article": "Bathing-suit season is here and with it, anxiety over cellulite. A new laser device that burrows under the skin is getting praise from some doctors who say it gives more dramatic and longer-lasting results than previous treatments, but others caution that more research is needed.\n\nCellulite is a dimpled, uneven appearance of skin caused by fat underneath. It affects some 85% of women and about 5% of men. Until recently, the main treatments to battle cellulite have been external treatments such as creams and radio-frequency and...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were two apparently independent sources quoted.", "answer": 1}, {"article": "\"The low rate of serious adverse events and significant interventions supports the safety of procedural sedation in the hands of emergency department physicians,\" said Dr. Bhatt.\nThe overall incidence of adverse events in the study population was 11.7%.\nThe CHEO Research Institute makes discoveries today for healthier kids tomorrow.\nIt includes children from six emergency departments across Canada, sedated with six different medication combinations.\nSignificant interventions in response to an adverse event were rare, occurring in only 1.4% of children.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release clearly notes that the study was funded by a federal Canadian program.", "answer": 1}, {"article": "The ability to control the tightness is presumably part of the reason that patients who opt for banding lose less weight, at least initially, than gastric bypass patients -- an average of 50 to 65 percent of their excess weight in the first three years.\nAnother difference between the band and the bypass that proves both a plus and a minus is that the band doesn't cause the dumping syndrome.\nThus, when food empties from the stomach, it bypasses a few feet of upper intestine, which means that fewer nutrients (including fewer calories) are absorbed by the body.\nThe thing is, for about 20 to 40 percent of patients, the operation fails over the long term.\nIn addition, there's no nutrient malabsorption as there is with the bypass, because the small intestine is left intact; banding patients do not have to take nutrient supplements for the rest of their lives, the way bypass patients do.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several clinicians were quoted as part of this story indicating that they were seeing an increased number of individuals seeking to have a second weight loss procedure because they felt gastric bypass was not sufficient to enable them to maintain their weight loss. \u00a0Beyond this, the story included no expert commenting with concrete information about the risks and benefits associated with this approach to weight control.", "answer": 0}, {"article": "Here's the scientific proof.\nOne major limitation of the study is that it ends when the men are in their 30s \"which may be too early for decrements in health to emerge,\" the authors acknowledge.\nHowever, the reanalysis regarding psychotic disorders contradicted the earlier conclusions -- that there indeed appeared to be a higher risk of psychotic disorders among marijuana users in the study versus non-users that approached statistical significance when using a more liberal test.\nWith the widespread availability of marijuana in recent years thanks to its legalization in a growing number of states, there has been increasing concern about the long-term health consequences on teens who might be able to get easier access to it illegally.\nUpdate: The study's findings generated significant controversy along with requests for supplemental analysis, according to the editors of the Psychology of Addictive Behaviors.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story badly needed an independent source. It would have been possible and helpful\u00a0to choose from among many researchers whose work points to potential\u00a0harm from chronic marijuana exposure. Again, letting the researcher get away with saying \u2013 unchallenged- that he wanted to \u201chelp inform the debate about legalization of marijuana\u201d in a single source story is problematic.", "answer": 0}, {"article": "+3582944 54542\n\nIntake of fermented and nonfermented dairy products and risk of incident CHD: the Kuopio Ischaemic Heart Disease Risk Factor Study Timo T. Koskinen, Heli E. K. Virtanen, Sari Voutilainen, Tomi-Pekka Tuomainen, Jaakko Mursu, Jyrki K. Virtanen.\nWhen the study participants were divided into four groups on the basis of their consumption of fermented dairy products with less than 3.5% fat, the risk of incident coronary heart disease was 26% lower in the highest consumption group compared to the lowest consumption group.\nMilk was the most commonly used product in this category, and a very high consumption was defined as an average daily milk intake of 0.9 litres.\nTheir dietary habits were assessed at the beginning of the study in 1984-1989, and they were followed up for an average of 20 years.\nThe study participants were divided into groups on the basis of how much they ate different dairy products, and the researchers compared the groups with the highest and lowest consumption, while also taking various lifestyle and nutrition factors into consideration.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding for the study is not mentioned.\nReview of the authors does not reveal any major conflicts of interest.", "answer": 0}, {"article": "\"That's a huge achievement,\" Kopans noted, adding that \"it may not be a big deal to an epidemiologist who's looking at huge numbers and doesn't take care of women with breast problems.\"\n\"It's clearly muddying the waters,\" he said.\nLearn more about screening mammograms by visiting the U.S. National Cancer Institute.\nBut some cancer organizations reject the panel's advice.\nBut since the advent of routine mammograms in the 1990s, the rate of death from breast cancer has dropped 30 percent, he observed.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 0}, {"article": "Maia Szalavitz is a health writer at TIME.com.\nThey\u2019re more able to go outside their comfort zone and to better resist their habits and rituals.\u201d One participant in Hollander\u2019s study was previously too anxious to take the subway or eat in a restaurant, but, when taking Prozac, was able to tolerate these unpredictable environments.\n\u201cThe clinicians could tell that people were doing better not only in terms of OCD symptoms but overall distress and ability to function.\u201d\n\nMORE: Why Are So Many Foster Care Children Taking Antipsychotics?\nFor example, they like to line up their toys and they get very bent out of shape if there is any deviation.\u201d\n\nMORE: What Does a 400% Increase in Antidepressant Use Really Mean?\nA previous, larger study of a similar medication, Celexa (citalopram), in autistic children did not find a reduction in repetitive behaviors, but the drug did reduce irritability and was superior to placebo among children who had the highest levels of irritability.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story briefly quotes another story in which Yale Child Study Center director Fred Volkmar commented on the study, indicating that more research was needed. We would have liked to have seen more independent voices helping readers understand whether there was anything new here. The story also says, \u201cHollander has previously received funding from pharmaceutical companies, but the current study was paid for by a grant from the Food and Drug Administration\u2019s \u201corphan\u201d drug program.\u201d\n\u00a0\n\u00a0", "answer": 1}, {"article": "Women receiving five more years of letrozole also had greater loss of bone in their hip, worse osteoporosis, and more fractures.\nThe study, which was also published Sunday in the New England Journal of Medicine, was partially funded by Novartis, which sells letrozole \u2014 the aromatase inhibitor used in the trial \u2014 as the branded drug Femara.\nThe trial included 1,918 postmenopausal women who had what\u2019s called hormone-receptor positive breast cancer, in which the hormones estrogen or progesterone fuel the proliferation of cells.\nDr. Debra Patt, a breast cancer specialist at Texas Oncology who was not involved in the study, called the difference of a few percentage points in the risk of recurrence (95 percent vs. 91 percent) \u201csubstantial.\nSeveral of the authors have received speaking fees or consulting payments from Novartis, AstraZeneca (which makes letrozole), and Pfizer (maker of the aromatase inhibitor exemestane).\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Kudos here, too. Dr. Richard Schilsky was interviewed as an independent source. Conflicts of interest were also disclosed: The study was funded by\u00a0Novartis which sells letrozole, and several of the study authors are connected to pharmaceutical companies.", "answer": 1}, {"article": "\u2018What insanity is that?\u2019 Hundreds of NC children are being killed or injured by guns.\n\nDid you realize that in the past five years, hundreds of teens and youth have been killed or hurt by gunfire in North Carolina? Here\u2019s what some say you can do about it.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story includes a quote from a single university-based vaccine expert, but it does not state whether he has any potential conflicts of interest. The story fails to note that two researchers received consulting fees from one or more pharmaceutical companies\u2013including MedImmune, which manufactures the FluMist inhaled vaccine in partnership with the researchers\u2019 employer, the University of Michigan. ", "answer": 0}, {"article": "But the mind is a powerful thing.\nThe second study, published in 2013, had a similar set up \u2014 37 people complaining of gastrointestinal problems, randomized into high-gluten, low-gluten and no-gluten groups.\nAnd in a large Italian study of people who complain of gastrointestinal problems, the authors conclude that NCGS is slightly more common than celiac disease, putting it at a prevalence of a bit above 1 percent of the population.\nWhat is less clear is whether there is another group of individuals whose digestive systems have some \u201cgluten sensitivity\u201d and who would, therefore, benefit from avoiding gluten.\nThe authors found that 40 percent of patients on the entirely gluten-free diet reported a continuation of symptoms, compared with 68 percent of those who had consumed gluten.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story offers an excellent overview of the literature on NCGS and gluten-free diets, but includes no input from sources other than the author \u2014 an economist who has done extensive work on the economics of health-related issues. We think the story stands up pretty well without that independent perspective, but it certainly couldn\u2019t hurt, and would likely have helped, to hear from experts in related health fields, such as a nutritionist or gastroenterologist.", "answer": 0}, {"article": "When it made its recommendation, the Academy of Pediatrics admitted \u201cit is clear that additional research is needed to further document the effects of changes in school start times over time.\u201d\n\nWell, there\u2019s some new (but still incomplete) evidence that later start times do help teens get more sleep.\nPeople with a lot of social jet lag also tend to get fewer hours of sleep, which exacerbates these same health problems.\nMore work needs to be done to confirm these findings.\nTeens tend to be night owls, and forcing them to be early birds can mess with their health\n\nTeens tend to go to sleep a bit later and wake up a bit later than the average adult \u2014 something called a \u201cdelayed\u201d sleep phase.\nA new meta-analysis in the Journal of Clinical Sleep Medicine analyzed 18 studies on start times.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No sources appear to have been interviewed for this story, though it contains a lot of citations to studies and quotes used in past stories.", "answer": 0}, {"article": "The study found that, among the women treated with the hormones, there was an increased risk of heart attacks, strokes, blood clots and, most frightening of all to many women, a slightly higher risk of breast cancer among those randomized to take the leading H.R.T.\n\u201cWomen today have so many options \u2014 a wide array of doses, from low to traditional, and ways to use them.\u201d In addition to pills, there are patches, gels and sprays applied to the skin.\n\u201cThe cardiovascular protection found in observational studies involved women who were younger and within a few years of menopause when they started taking H.R.T.,\u201d he said.\nThere are also lots of products now available and different ways to use them that enhance the safety of hormone replacement.\nFor women without a history of cancer, blood clots or heart disease, most professional medical societies concerned with women\u2019s health now recommend treatment for menopausal symptoms for up to five years using therapy that combines estrogen and progesterone and even longer for those who take estrogen alone.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The Danish trial referenced in the study was partially funded by drug companies and the authors disclose a long list of drug company affiliations not mentioned in the story. In addition, the first author of the 2013 study showing harm from avoiding hormone therapy has served as a consultant Noven Therapeutics, which makes hormone therapies.\nThe two experts quoted in the story are JoAnn Manson and Howard Hodis. Manson is one of the authors of the editorial about the mobile phone app, and the paper says she has no conflicts. Hodis is a member of the board of the North American Menopause Society. The NAMS receives support from a long list of pharmaceutical companies. Links to some of them here.", "answer": 0}, {"article": "There aren't strong guidelines regarding the use of tonsillectomy to treat sleep disorders, so the doctors reviewed the evidence to see whether the surgery outperformed so-called watchful waiting -- monitoring the situation.\nThe study results showed \"there may be new evidence that supports expanding the criteria and opening up the procedure to more individuals,\" said Dr. Alyssa Hackett, an otolaryngologist with the New York Eye and Ear Infirmary of Mount Sinai in New York City.\nAn evaluation of current medical evidence suggests more kids would receive significant short-term improvement in their daily life if the guidelines were relaxed, said Chinnadurai, a pediatric otolaryngologist with Vanderbilt University Medical Center in Nashville.\nThe researchers decided to review whether the throat infection guidelines are too stringent, ruling out patients who potentially could benefit but don't meet the high threshold of recurring infections, Chinnadurai said.\nThere's an even clearer benefit for kids whose sleep is disturbed due to inflamed tonsils, Chinnadurai said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes a quote from a clinician not affiliated with the study, which adds some useful context. It does not mention any possible conflict of interest but none are expected from a large Agency for Healthcare Research and Quality (AHRQ)-commissioned evidence review, which this was.", "answer": 1}, {"article": "Soy may keep breast cancer from coming back\nThe findings, published in the Journal of Clinical Oncology, lends support to the idea that adding soy foods to the diet can help people in multiple ways, says Dr. Jyoti Patel, a lung cancer specialist at Northwestern University in Chicago, who was not involved in the study.\n\u201cThere are probably 30,000 people in the U.S. who never smoked and who have lung cancer.\u201d\n\nLung cancer kills 160,000 Americans a year.\nMost of the women in the study had never been smokers, and there\u2019s a lot of evidence to suggest that lung cancer is a different disease in smokers versus non-smokers.\n\u201cAlthough the risks are probably different for American women for developing lung cancer, I do think it is a call to action for more research about how we develop lung cancer,\u201d Patel said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Barely satisfactory \u2013 only because the story quotes a lung cancer expert\u00a0who was not involved with the study.\u00a0\u00a0 But that expert did not provide any useful criticism of this minimally important study, including the fact that all the findings could have been related to other non-dietary factors.", "answer": 1}, {"article": "Feb. 3, 2011 -- Children with attention deficit hyperactivity disorder (ADHD) should be offered a special ADHD diet to see if eliminating certain foods might reduce their symptoms, Dutch researchers say.\nThe diet studied, known as the restricted elimination diet (RED), can work, the researchers say, because they believe ADHD symptoms in some children might be affected by eating specific foods.\nU.S. experts had some caveats, saying that the results of the study, which included 100 children, should be repeated in other populations to see if the findings hold up.\n''I am of the opinion that every child deserves this diagnostic intervention,\" researcher Lidy Pelsser, PhD, of the ADHD Research Centre in Eindhoven, the Netherlands, tells WebMD.\nIn five weeks of trying the diet, Pelsser says, parents will know if their child is responding or not; if not, they can move on to other treatments.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes one outside expert and one expert who wrote an accompanying editorial.\u00a0Eugene Arnold, MD,\u00a0\u00a0professor emeritus of psychiatry at Ohio State University\u2019s Nisonger Center, Columbus, says\u00a0\u201cThere is a risk of malnutrition if you don\u2019t pay attention to the balance of nutrients.\u201d But he also gives the impression that the diet is worth trying, even based on the limited evidence of efficacy. \u201cIf there is no improvement in two to five weeks, forget it,\u201d\u00a0he says.\u00a0Jaswinder Ghuman, MD, associate professor of psychiatry and pediatrics at the University of Arizona, who wrote a commentary, says, \u201cIt is very difficult to carry out,\u201d and added,\u00a0these are interesting findings and it does present an alternative treatment option for the children.\u201d Taken together, these comments tend to underscore the idea that people should try this diet, a very different take away from the HealthDay story, which said high up \u201cthe evidence isn\u2019t yet conclusive.\u201d", "answer": 1}, {"article": "But there\u2019s one big stumbling block for both of them, a problem that has dogged medical genetics for decades: Data for non-white populations is sorely lacking.\nThere just aren\u2019t.\u201d (Today there is that resource, based on Muenke and the NIH\u2019s work.)\n\u201cWe are not a diagnostic tool, and we will never be a diagnostic tool,\u201d said FDNA CEO Dekel Gelbman.\n(The program is funded by the NIH\u2019s Fogarty International Center; President Trump eliminated funding for the center in his 2018 \u201cskinny\u201d budget proposal announced in March.)\nFor one thing, it can be the factor that sends someone to get a genetic test in the first place.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "It\u2019s not exactly clear where the NIH work and the company\u2019s work begin and end. It talks about NIH-funded researchers gathering photos and uploading those to Face2Gene. That should be made more clear.\nAn outside expert to comment on whether this is useful would have been helpful.", "answer": 0}, {"article": "More information can be found at http://www.\n\"This could ultimately change the way we diagnose concussions, not only in children, but in anyone who sustains a head injury,\" said Papa.\n\"Symptoms of a concussion, or a mild to moderate traumatic brain injury, can be subtle and are often delayed, in many cases by several days,\" said Linda Papa, MD, MSC, an emergency medicine physician and NIH funded researcher at Orlando Health and lead author of the study.\n\"Not only were they present in the bloodstream, we were able to detect measurable levels of GFAP up to a week after the injury,\" said Papa.\n\"We have so many diagnostic blood tests for different parts of the body, like the heart, liver and kidneys, but there's never been a reliable blood test to identify trauma in the brain.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release mentions that a lead researcher is \u201cNIH funded\u201d but does not specify funders for this study nor does it include a statement about potential conflicts of conflicts. (Just to clarify \u2014 we\u2019re always pleased to see a statement even if no conflicts are known to exist.) The journal article itself has a disclosure footnote that states Papa is an unpaid consultant to Banyan Biomarkers, Inc., while Welch and Lewis disclosed receiving contract research funding from Banyan. Banyan is a for-profit biotech company in Florida seeking to commercialize a biomarker for head injury. We think this connection between the research and the biotech should have been mentioned in the release.", "answer": 0}, {"article": "But that the rise of the chronic diseases was actually linked to higher sugar consumption is a challenge.\nNow, in a paper published Tuesday, he and his colleagues believe they have come up with the definitive evidence that sugar, as Lustig says, \u201cis toxic.\u201d\n\nIn most lab studies, the doses of sugar that scientists test are quite high; they want to see what the effect is quickly and, depending on the research, they may not have time to wait to study the more gradual effects that might emerge.\nBut I worry that people are going to hang everything on this when we still need to reduce consumption.\u201d\n\nLustig hopes that won\u2019t happen as more data emerges that details how sugar is altering the body in unhealthy ways outside of its caloric contribution.\n\u201cWe know that a healthy diet and weight loss cause good metabolic changes, and although this study tries to attribute its effects to low fructose, in fact it is impossible to do that because of the study design.\u201d\n\nSome experts are concerned for other reasons.\n\u201cThis is causation.\u201d\n\nThe diet he provided the children isn\u2019t considered ideal from a health perspective \u2014 starches are still a considerable source of calories and can contribute to weight gain.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes restraining comments from two independent experts, although those comments come far down in the story and should have been placed higher. The story perhaps also could have mentioned that Dr. Lustig is author of a 2012 book called \u201cFat chance:\u00a0Beating the Odds Against Sugar, Processed Food, Obesity, and Disease,\u201d and so may have an intellectual and financial conflict of interest when it comes to sugar. \u00a0The study was funded by\u00a0the NIH and Touro University, as well as UCSF \u2014 another aspect that could have been mentioned for context.", "answer": 1}, {"article": "CDC To Doctors: Anti-HIV Pill No Magic Bullet Against Virus\n\nIn November, researchers revealed a encouraging finding: taking a pill can greatly reduce the risk of getting HIV.\nIt's the first time anybody's shown that taking a pill can prevent HIV \u2013 and it was the first new weapon against HIV unveiled in many years.\nBut the landmark study, involving 2,500 men who have sex with men, showed that taking Truvada faithfully can reduce the risk of infection by as much as 92 percent.\nSome insurers might pay, but some might balk.\nWhen researchers tested the blood of patients for traces of Truvada, they found many who claimed to have taken the pill regularly weren't telling the truth.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story is based on the CDC\u2019s evaluation and warnings about proper use of the drug.\nWe would have liked to have seen a clinician-researcher\u2019s perspective \u2013 someone not affiliated with the CDC analysis.", "answer": 0}, {"article": "The unique ability for CURATE.AI to rapidly identify the drug doses that result in the best possible treatment outcomes allows for actionable, and perpetually optimised personalised medicine,\" explained Professor Dean Ho, Director of the Singapore Institute for Neurotechnology (SINAPSE) at NUS, who led the study.\nThe research team successfully utilised CURATE.AI to continuously identify the optimal doses of each drug to result in a durable response, allowing the patient to resume a completely normal and active lifestyle.\nCURATE.AI is applicable to all diseases and all patients, and a first generation of the platform was previously validated in the clinic for single drug optimisation in post-transplant immunosuppression.\nThe CURATE.AI team expects to broadly deploy the platform for the prevention of transplant rejection, adult and paediatric cancers, cardiovascular medicine, diabetes management, infectious diseases, and many other applications.\nHowever, CURATE.AI has shown that patients can still respond to the therapies that have seemingly stopped working by continuously identifying the patient's optimal dosing parameters.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "It is not made clear who funded the relevant study, who funded the creation of CURATE.AI, or whether CURATE.AI has been patented or is under consideration for being marketed as a for-profit medical tool.", "answer": 0}, {"article": "But a 2012 Cochrane review of randomized clinical trials found there's no evidence that removing wisdom teeth will prevent or reduce crowding of other teeth down the line.\n(The same thing happened with tonsils, which doctors no longer remove just to get rid of the chance of infection later on.)\nThe question comes down to which side of the fence medical professionals fall on\n\nIt's worth noting that oral surgeons make a good chunk of their paychecks by removing wisdom teeth, so there is a financial incentive involved.\nThe risks and benefits of removing your wisdom teeth\n\nThere's a chance that if you opt not to have your wisdom teeth taken out, they might be fine for the rest of your life.\nThe American Association of Oral and Maxillofacial surgeons says, \"There is no pat answer, cookbook recipe, or flow chart that is universally accepted regarding the decision making process\" in these cases.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Sources include a dentist and two oral surgeons as well as numerous published reports and professional association position reports. The story also reminds us\u00a0that \u201coral surgeons make a good chunk of their paychecks by removing wisdom teeth, so there is a financial incentive involved.\u201d", "answer": 1}, {"article": "This news-agency article is no longer available on nytimes.com.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "While the story does include a couple of independent sources, it could have done a better job identifying the connections between other sources and industry. The story does not tell readers that Dr. Judith Tsui is an advisor to the company developing the app she is studying. Another quoted source, Alain Litwin, appears to have received consulting fees from several pharmaceutical companies. The story does identify one proponent of smartphone apps, Dr. Richard Garfein, as a co-developer of an app.", "answer": 0}, {"article": "THURSDAY, May 24, 2018 (HealthDay News) -- Because vertigo can have many causes, treating it can be difficult, but researchers have identified a new type that may be effectively treated with medication.\nThe researchers noticed that uncontrolled eye movements, called nystagmus, lasted longer in people with this new form of vertigo.\nFor the study, researchers recruited 338 people who had vertigo with an unknown cause.\nThe findings were published online May 23 in Neurology.\nThey then moved each patient's head forward and shook it from side to side for about 15 seconds.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story provides only one source \u2014 a member of the research team \u2014 and no independent sources.\u00a0 It doesn\u2019t disclose who funded the study, either.", "answer": 0}, {"article": "Breast cancer test kits by genetic testing company 23andMe just received Food and Drug Administration approval.\nMore: Breast cancer: Study finds tumor risk increased by use of oral contraceptives\n\nBut \u201cit has a lot of caveats,\u201d warned Donald St. Pierre, acting director of the FDA's Office of In Vitro Diagnostics and Radiological Health.\n\u201cThe test should not be used as a substitute for seeing your doctor for cancer screenings or counseling on genetic and lifestyle factors that can increase or decrease cancer risk,\u201d he said.\nThe prescription-free test is the first to report on three specific BRCA1 and BRCA2 breast cancer gene mutations, according to the FDA.\nStill, the company, which already tests DNA for other health risks as well as ancestry, said this cancer test is \"a step in the right direction.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story provides useful information from an FDA news release and clearly notes that the relevant testing is a test being marketed by a specific company. That said, the story lacks\u00a0 actual interviews with third-party expert sources not connected with the FDA or the gene testing company.", "answer": 0}, {"article": "WASHINGTON -- A new study shows patients taking the anticlotting drug Plavix along with a type of drug used to block stomach acid have an increased risk of a subsequent hospitalization for heart trouble.\n\nThe study, which is being published in this week's Journal of the American Medical Association, adds to other recent studies that suggest proton pump inhibitors like Aciphex, Nexium, Prevacid and Protonix reduce the effectiveness of Plavix, which is marketed by Bristol-Myers Squibb Co. and Sanofi-Aventis SA.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included quotes from the lead author of the study and from a drug company representative.\u00a0 We wish the story had included the input of a clinician not connected to the study.\u00a0 However, we give credit because the story noted that one of the researchers received honoraria and research support from two drug companies. \u00a0 ", "answer": 1}, {"article": "\u201c[PRP] works, and the results have been amazing,\u2019\u2019 says John Ferrell, the sports medicine physician who treated me.\nWe will be able to treat ailments noninvasively, and at an earlier stage.\u2019\u2019\n\nThe procedure involves collecting several ounces of blood from a patient\u2019s arm, spinning the blood in a centrifuge to concentrate the platelets and injecting the concentrated platelets into the injury site to stimulate healing.\nThe researchers call the results \u201cclinically relevant,\u2019\u2019 despite the study\u2019s small size, and say the next step should be a larger, controlled clinical trial.\nThe American Academy of Orthopaedic Surgeons \u2014 which says PRP \u201cholds great promise\u2019\u2019 \u2014 describes the risk as minimal.\n\u201cI\u2019ve heard some skeptics call PRP a cure looking for a disease, but it is being used in so many areas of medicine now with promising outcomes,\u201d says Marni Wesner, a sports medicine physician at the clinic and one of the study\u2019s authors.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Along with quotes from\u00a0the author\u2019s physician (who\u00a0has already posted the story\u00a0on his website)\u00a0there are quotes from\u00a0a researcher who was involved in one small clinical trial on PRP. The inclusion of the researcher just barely squeaks by as sufficient to earn a Satisfactory rating here.\nHowever, the story would have been much stronger had the author interviewed an expert who disagrees with these two sources, which wouldn\u2019t be hard to find given the Cochrane review and other systematic reviews that cast a less rosy glow on PRP.", "answer": 1}, {"article": "Whether these differences are big enough to cause women to take the drug for twice as long remains to be seen.\nThe difference came in later years, suggesting that tamoxifen has a carry-over effect that lasts long after women stop taking it.\n\u201cI have patients who agonize about this, people who are coming to the end of their tamoxifen.\u201d\n\nEmily Behrend, who is a few months from finishing her five years on tamoxifen, said she would definitely consider another five years.\n\u201cThey don\u2019t feel well on them, but it\u2019s their safety net,\u201d said Dr. Garber, who added that the news would be welcomed by many patients who would like to stay on the drug.\n\u201cThe treatment effect is real, but it\u2019s modest,\u201d said Dr. Paul E. Goss, director of breast cancer research at the Massachusetts General Hospital.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Excellent use of sources.\u00a0 A variety of researchers, clinicians, and a patient were represented.\nThe story clearly stated that AstraZeneca, which makes a form of tamoxifen, helped finance the study.", "answer": 1}, {"article": "Risk reduction [was] probably in the range of 80 to 95 percent,\" said researcher Timothy Rebbeck, an epidemiologist at the University of Pennsylvania.\nA new study in the Journal of the American Medical Association shows the clearest evidence yet that women carrying the BRCA1 and BRCA2 genes should consider preventive surgery because they are at a very high risk for breast and ovarian cancers.\nThe study findings are extremely reassuring to Rebbeck -- no breast cancer diagnoses among women who had double mastectomies after three years of follow-up.\n\"My mother left me when I was 26, and it was extremely painful and traumatic for my entire life,\" she says.\nIt confirms what smaller studies have suggested in the past: Women who have a family history of breast cancer can greatly reduce their chances of getting the disease by having a double mastectomy.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story includes comments from an author of an editorial in the journal who was not involved in this study. Although the story does not report financial or other information about the sources, the study was funded by a variety of grants from public agencies and foundations and neither the researchers nor the editorial writers reported any relevant financial disclosures.", "answer": 1}, {"article": "Master said each participant was asked to carry an accelerometer to record movements and an iPod Touch loaded with an app that would ping them prompts at intervals during each day to report any symptoms they were feeling. They also completed activity questionnaires and summaries. In addition, they wore a device called an ActiGraph to monitor sleep.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not use any independent sources such as an outside concussion expert. There do not appear to be any conflicts of interest, but the story could have let readers know that the work was funded by the Penn Medicine Translational Neuroscience Center.", "answer": 0}, {"article": "\u201cDr.\n\u201cHere at Valley, we are proud to offer this option for our patients and are excited about its potential for vastly improving patient care for women with breast cancer.\u201d The technique involves placing tissue expanders (interim implants) under the skin on top of a woman\u2019s pectoralis muscles after her breast tissue has been removed.\n\u201cIt\u2019s important to listen to each woman\u2019s needs and then to decide together what is the best approach to treatment, so that in the end the cancer will be gone and the woman can move on with her life,\u201d says Dr. Wilson.\nIn addition to exceptional cosmetic results, the technique is likely to improve clinical outcomes as evidenced by ongoing research that shows women who undergo this procedure experience less pain and a shorter recovery period.\nAfter consulting with several breast surgeons and reconstructive surgeons, Ms. Burt opted for a nipple-sparing mastectomy performed by breast surgeon Tihesha Wilson, M.D., Assistant Medical Director of Valley\u2019s Breast Center.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The Valley Breast Center is listed at the end of the release. But due to the overwhelmingly positive comments from the patient who received the procedure, it would have helped to make clear whether or not she was compensated in any form by the hospital system.", "answer": 1}, {"article": "It found that bariatric surgery:\n\u2022 produced a mean weight loss of more than 100 pounds\n\nCHARLOTTESVILLE, Va., Oct. 1, 2015 - A study evaluating the effects of bariatric surgery on obese women most at risk for cancer has found that the weight-loss surgery slashed participants' weight by a third and eliminated precancerous uterine growths in those that had them.\n\"We're talking about small numbers, really tiny numbers\" of study participants, Modesitt said, noting one limitation of the study.\nA total of 68 participants underwent the procedure; two opted out of the surgery, and another died of a heart condition prior to surgery.\nThe study looked at the effects of bariatric surgery in a relatively short timeframe, one to three years after surgery.\nThe findings have been published as a lead article in the scientific journal Gynecologic Oncology.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The authors declared no conflicts of interest in the paper. But one of the study authors was an employee from the company that provided the technology for some of the analyses in the study. This probably was worth a mention.", "answer": 0}, {"article": "Yet the study suggests the opposite has happened.\nThe study found that among all opioid users, concurrent use of benzodiazepines more than doubled the risk of an emergency room or inpatient visit for a drug overdose.\nThe study also only looked at legally prescribed opioid painkillers and benzodiazepines, missing the effects of concurrent use of illegally obtained pills or drugs.\nThe study also found that eliminating concurrent benzodiazepine and opioid use could reduce the risk for an opioid overdose\u2013related emergency room or inpatient visit by 15 percent.\nFrom 2001 to 2013, co-prescriptions to opioids and benzodiazepines among the studied pool of patients increased from 9 percent to 17 percent \u2014 a nearly 89 percent jump.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story quotes one source, an author of the study. It would have benefitted from\u00a0comments from independent physicians and public health experts on the challenges of changing prescribing patterns, as well as adequately treating pain and/or anxiety.", "answer": 0}, {"article": "The biggest variable is patients themselves.\n\"There is, to be honest, some irrational exuberance out there,\" says Daniel Berry, chief of orthopedic surgery at the Mayo Clinic in Rochester, Minn., and president of the American Academy of Orthopedic Surgeons.\nIn the past, many doctors assumed implants would wear out in about 10 or 15 years, and they urged young patients to put off surgery as long as possible to minimize the risk of needing a costly and difficult revision surgery\u2014or even two.\n\"If you have a brand new sports car and leave it in the garage, it will last forever and you won't have any fun,\" says Thomas Schmalzried, an orthopedic surgeon at St. Vincent Medical Center in Los Angeles.\n\"There's a happy medium, and it's not necessarily the same for every patient,\" says Dr. Berry.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article included comments from several independent sources. It was not clear, however, whether any of the expert sources had conflicts of interest with implant manufacturers. Information on financial conflicts would have aided in the interpretation of their comments. Though several of the experts made comments that were intended to curb the enthusiasm expressed by the patients, it would have been helpful to know whether any of the physicians receive payments from device manufacturers\u2014given the widespread conflicts-of-interest that have affected this field in recent years.\n\n \n", "answer": 0}, {"article": "This is one of the first few studies that suggests a different mechanism.\nIt\u2019s a medication that works differently than everything else.\u201d\n\nThe study was funded by a grant from the National Institutes of Mental Health, but the SAMe pills and placebo pills were provided by the dietary supplement maker Pharmavite.\nThat\u2019s probably the best hypothesis.\u201d\n\nOther studies have suggested that SAMe can relieve symptoms of depression.\n\u201cIt provides clues to new treatments, and it provides clues to understanding what causes depression as well as what goes on biochemically when people get better from depression.\u201d\n\nThe researchers studied the use of SAMe or a placebo in 73 adults with depression who were not responding to prescription antidepressant treatment.\nAnd about 26 percent of patients in the SAMe group experienced a complete remission of symptoms, compared to just 12 percent in the placebo group, according to a report published in The American Journal of Psychiatry.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An independent source was cited, the author of the editorial that accompanied the study. And all conflicts of interest were clearly pointed out. While, by the letter, it meets the standard for this criteria, we note two flaws:\n1) The piece could\u2019ve used a lot more balance to the lead investigator\u2019s hopes and excitement for his research. His quotes aren\u2019t challenged\n2) A more independent source could\u2019ve been used because Dr. Nelson and Dr. Papkostas have coauthored 3 recent studies together.", "answer": 1}, {"article": "\"CMS made the right decision,\" said John Petrini, a Santa Barbara, Calif., gastroenterologist who heads the American Society for Gastrointestinal Endoscopy.\nBut no test is.\"\nLike other mass screening tests including mammography, the overarching question is whether the benefits of virtual colonoscopy outweigh the risks.\nThe prospects for significant expansion of the procedure, which is covered by a growing number of insurance companies, have collided with a large and unexpected roadblock.\nKlein disagrees.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes multiple sources with differing persepctives.", "answer": 1}, {"article": "But by the end, those who had been in the combined program had more symptom relief, and were functioning better as well.The researchers expect to have lowered average doses in the combined program but had not yet finished analyzing that data.\nAbout half got the combined approach and half received treatment as usual.\nThe team trained staff members at the selected clinics to deliver that package, and it included three elements in addition to the medication.\nSecond, education for family members to increase their understanding of the disorder.\nOver two years, both groups showed steady improvement.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes experts who were not authors on the study.", "answer": 1}, {"article": "MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation.\nEvery year, 1.3 million men in the U.S. undergo a prostate biopsy.i Although a biopsy is the only way to diagnose prostate cancer, the procedure is invasive and results in complications in 18 percent of patients, with 3 percent hospitalized for infection within 30 days.ii,iii,iv Common complications from a prostate biopsy may include bleeding, infection, sepsis/bacteremia, urinary symptoms/retention, and sexual dysfunction.\n\"While biopsy is the only path to prostate cancer diagnosis, no man wants to, nor should have to, go through the uncomfortable, costly procedure if it can be avoided,\" said Dr. Jan Groen, Chief Executive Officer of MDxHealth.\nThe primary objective was to characterize changes in health outcomes, measured in quality-adjusted life years, and a secondary objective was evaluating healthcare costs.\n\"We believe that this strategy improves the value of conventional risk assessment strategies through improvements in both quality and cost, the numerator and denominator of the health care value equation.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Neither element shows up in the text.\u00a0 Since the news release comes from the company MDxHealth, which is marketing the test, one might assume that the company paid for the study.\u00a0 But the text of the research report suggests otherwise, indicating funding from the American Cancer Society and a foundation focused on urological research. That would have been a useful addition to the release.", "answer": 0}, {"article": "American veterans coping with PTSD are traveling to lodges in the Amazon that offer ayahuasca, a hallucinogenic brew. Some say it has helped them manage emotional trauma from war, but others say it\u2019s not worth the journey. Photo: Ryan Dube/WSJ\n\nAfter surviving firefights and a roadside bomb in Afghanistan, U.S. Army veteran Asa Barrett tried antidepressant drugs and therapy to overcome depression and bouts of anger. Nothing worked.\n\nBut then, like many other foreigners, he journeyed to Peru\u2019s remote Amazonian jungle to drink ayahuasca, a centuries-old, sacred indigenous brew that some Western scientists think can help to heal psychological traumas.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Aside from the Navy official, the story lacks input from independent mental health experts and patient advocacy groups. However, his inclusion in the story is sufficient to rate Satisfactory.\nWe do want to point out that the California-based advocacy group that\u2019s mentioned as wanting to seek funding for studies (the Multidisciplinary Association for Psychedelic Studies) states on its website that it has created a subsidiary that may generate profits in the sale of legal MDMA (\u201cecstasy\u201d or \u201cmolly\u201d) if and when it gains FDA approval. So beyond\u00a0selling newspapers, there may be other financial incentives for the promotion of hallucinogens-as-therapy.", "answer": 1}, {"article": "Joslin has one of the largest diabetes training programs in the world, educating 150 M.D.\nIn an earlier study, Joslin researchers reported that VEGF, a major growth factor for blood vessels, is elevated in the eye fluids of patients with proliferative diabetic retinopathy and DME, causing leakage and the growth of abnormal blood vessels.\nOver the past few years, drugs that target VEGF have become a standard treatment for DME, providing a preferred alternative or adjunct to laser treatment.\nIn light of these positive results, \u201cit is more important than ever for patients with diabetes to be evaluated on a regular basis for eye disease and receive treatment promptly once indicated as we now have excellent success in treating patients with DME,\u201d says Dr. Aiello.\nThe trial was supported through a cooperative agreement from the National Eye Institute and the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, U.S. Department of Health and Human Services.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding sources and the donation of drugs from the pharmaceutical companies are clearly stated. The Joslin researchers quoted in the article don\u2019t appear to have any direct conflicts of interest with companies involved in the research.", "answer": 1}, {"article": "William E. Pelham Jr., director of the Center for Children and Families at Florida International University, called neurofeedback \u201ccrackpot charlatanism.\u201d He warned that exaggerated claims for it might lead parents to favor it over proven options like behavioral therapy and medication.\nNeurofeedback in general is a largely unregulated, with practitioners often devising their own protocols about where on the scalp to place electrodes.\nA major attraction of the technique is the hope that it can help patients avoid drugs, which often have side effects.\nBrain cells communicate with one another, in part, through a constant storm of electrical impulses.\nTheir patterns show up on an electroencephalogram, or EEG, as brain waves with different frequencies.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0The story included quotes from advocates as well as skeptics about benefit to be obtained through neurofeedback treatment.", "answer": 1}, {"article": "When left untreated, however, B.P.H.\nSurprisingly, his case is not unique.\u201d\n\nMany doctors are now urging men to become proactive earlier to prevent chronic problems in the future.\nBut for patients who have trouble getting back to sleep, \u201cthere are many effective options, and patients almost always end up with less bothersome symptoms once they choose to do something,\u201d he said.\n\u201cMy father used to be up 10 times a night and said it wasn\u2019t a problem for him,\u201d said Dr. Franklin C. Lowe, professor of urology at Columbia University College of Physicians and Surgeons.\n\u201cSome men go to the bathroom several times a night, get right back to sleep and are not bothered,\u201d he said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Three urologists were quoted for this story.\u00a0 It would have been helpful to include the perspective of a clinician who would have made the point that postponing active treatment is a viable option. ", "answer": 1}, {"article": "\"Our research could help develop policies that make the service more accessible to low-income women,\" added senior author Nazeem Muhajarine, a professor in community health and epidemiology at the University of Saskatchewan and McRae's supervisor while she conducted the research.\n\"Waitlists for midwives can be quite long, so women who are educated and health-conscious typically access midwives early on in their pregnancies,\" said McRae.\nCompared to those who received care from an OB, low-income women receiving midwifery care had a 41 per cent reduction in odds for small-for-gestational age birth, the researchers found.\n\"But more vulnerable women might not be as aware of the services available to them, so expanding midwifery to make it available for all women is important.\"\nMidwives are experts in the care of women having healthy pregnancies, and tend to spend more time with their patients with a focus on the overall physical, emotional and psychological wellbeing of mothers and their newborns.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release did not state how the study was funded, which was through scholarships. It also did not mention that the lead author disclosed in the published study that as of May, she had been providing consulting services to the Midwives Association of BC.", "answer": 0}, {"article": "Source: Brightling C, et al.\nWe already know that using treatments to target eosinophilic airway inflammation can substantially reduce asthma attacks.\u201d\n\nUltimately, the researchers hope that the drug \u201ccould likewise help to stop preventable asthma attacks, reduce hospital admissions and improve day-to-day symptoms \u2013 making it a \u2018game changer\u2019 for future treatment,\u201d said Brightling.\nAs the researchers tracked the participants over the course of 12 weeks, they found that those taking the drug saw a decrease in their sputum eosinophil reading from an average of 5.4 percent to 1.1 percent.\nBy measuring the sputum eosinophil \u2014 the inflammation marker that shows how white blood cells increase during asthma attacks \u2014 the researchers were able to track the effects of the drug.\nIn the study, the researchers examined 61 participants who were divided into two groups: The first was given 225mg of the drug twice a day for 12 weeks, and the second group was given a placebo.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There\u2019s no comment from an independent source, leaving unchallenged a researcher\u2019s assertion that fevipiprant may be a \u201cgame changer for the future treatment of asthma.\u201d\u00a0 The story could have let readers know that funding came from Novartis, as well as a European Union grant program, and the Leicester (U.K.) National Institute for Health Research Respiratory Biomedical Research unit. Several researchers involved in the trial reported receiving financial compensation from Novartis and other drug companies.", "answer": 0}, {"article": "(Reuters) - Vanda Pharmaceuticals Inc said its experimental drug for a rare sleep disorder proved effective in a second late-stage trial, and the company now plans to apply for a U.S. approval for the drug in mid-2013.\nThey have gained nearly 8 percent since December 18.\nWhile the first two are efficacy studies, the remaining two are intended to establish the safety profile of the drug.\nThe drug is being tested for \u2018non-24-hour disorder\u2019 that has no approved treatment.\nAn orphan drug, if approved, can usually fetch a premium pricing in the market.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only source appears to be the drug company CEO.", "answer": 0}, {"article": "Further,Dr.\n\u201cIt\u2019s wonderful to have this option to offer this special set of patients.\u201d About UT Southwestern Medical CenterUT Southwestern, one of the premier academic medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education.\nFrank Brown of Dallas, grandfather of six and the owner of Frank\u2019s Wrecker Service in Dallas, has familial hypercholesterolemia, an inherited condition that causes high levels of cholesterol, especially low-density lipoprotein (LDL) cholesterol or \u201cbad cholesterol.\u201d High levels of LDL cholesterol are strongly associated with heart disease.\nNewswise \u2014 DALLAS \u2013 Feb. 25, 2016 \u2013 A 59-year-old heart patient with dangerously high levels of cholesterol that could not be adequately reduced by statin drugs now has near-normal cholesterol levels, thanks to a new class of drugs that grew out of work done by UT Southwestern Medical Center researchers.\nTheir research led to the development by drug companies of evolocumab and alirocumab, the two approved PCSK9 inhibitors, which are delivered by monthly or semimonthly injections.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t talk about funding for this individual patient, which is fine. But it does talk about a number of researchers who were involved in developing evolocumab and alirocumab. Were those researchers supported by the relevant drug companies? Does the medical school itself have partnerships with these companies? It\u2019s not clear. If those potential conflicts do not exist, it would have been good to make that clear \u2014 particularly in a case like this, where the rationale for the news release is not clear to readers.", "answer": 0}, {"article": "\"The mice were exposed to the different omega-3s even before tumours developed, which allowed us to compare how effective the fatty acids are at prevention,\" said Ma.\n\"This study is the first to compare the cancer-fighting potency of plant- versus marine-derived omega-3s on breast tumour development,\" said the professor in the Department of Human Health and Nutritional Sciences.\nThere are three types of omega-3 fatty acids: a-linolenic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).\n\"Seeing the significant benefits omega-3s can have in combatting a highly aggressive form of breast cancer means omega-3s will likely be beneficial for other types of cancer.\"\nThe next step is to investigate the effects of omega-3s on other forms of breast cancer.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources and conflicts of interest aren\u2019t mentioned. According to the study, which is behind a paywall, funding came from the Public Health Agency of Canada, the Canadian Institutes of Health Research-Institute of Cancer Research, the Canada Foundation for Innovation, and the Ontario Research Fund, Ontario Graduate Scholarship. Canada is a world leader in both seafood and flax seed exports. The authors reported no competing interests.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - When symptom-free people have heart scans to look for clogged arteries, they can end up with overtreatment and side effects, researchers said Monday.\nPeople who got scans also had more additional tests and major heart procedures.\nIn those who tested negative for atherosclerosis or didn\u2019t get scanned, less than 10 percent used the medications.\nIf they get big enough, such buildups may cut the blood flow and cause a heart attack.\n\u201cWith these new imaging techniques, we are left with the dilemma of what to do with the results,\u201d he said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An author of the paper, and the author of an accompanying editorial were quoted.", "answer": 1}, {"article": "Bleier said the device, which consists of a lead wire and a neurostimulator the size of a stopwatch, is implanted on top of a buttock muscle. Patients don't feel it when they sit down and you can't see its imprint under a tight pair of pants. Patients can try the stimulation for two weeks with the pacemaker outside the body before deciding whether to have it implanted, an outpatient procedure. Medicare pays about $21,500 for the device and treatment.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We\u2019ll give the story the benefit of the doubt, although the end result was imperfect.\nWe would have liked to hear an independent expert\u2019s evaluation of the InterStim device which, by word count, got most of the attention in the story.\u00a0 We only heard from a surgeon who uses it.\nBut at various times in the story 4 other sources were interviewed, although only one of them offered any critical analysis of the evidence.", "answer": 1}, {"article": "Last year 61.5m prescriptions for antidepressants were issued in England.\nIt would accelerate our therapeutic interventions and make them more tailored to the needs of the patient.\u201d\n\nBut further clinical research is needed to see if the findings can be applied in a clinical setting, Hallstrom added.\nThese initial findings are interesting, but, as with all areas of mental health, there is still more research to be done.\u201d\n\nMental health problems, including depression, are estimated to cost \u00a3105bn a year in England.\nThe Royal College of Psychiatrists said that, if it worked, the test could prove to be a key moment in the quest for the holy grail of biological psychiatry.\nThe scientists at King\u2019s College London behind the development claim that their test \u201caccurately and reliably predicts whether depressed patients will respond to common antidepressants, which could herald a new era of personalised treatment for people with depression\u201d.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes two independent sources, but does not mention study funding or conflicts of interest. The research was funded by the government-run Medical Research Council and the National Institute for Health Research Maudsley Biomedical Research Centre, according to the King\u2019s College London news release.\nOne researcher, Carmine Pariante, M.D., received funding directly or indirectly from pharmaceutical firms Johnson & Johnson, Lundbeck, GSK, and Pfizer as well as the UK-based Wellcome Trust, according to the study.\nJ&J has a vested interest in developing drugs that might be used after this blood test is given, so this was\u00a0important\u00a0to disclose.", "answer": 0}, {"article": "The surgery she's upset about may be archaic - but it's very common.\n\"You would think in today's age and the way that we've improved in so many areas of medicine, women would begin questioning this, but we're finding that they're not,\" said Beth Cahill of the National Womens Health Resource Center.\nIt's all over in about an hour, and patients are usually home within a day and back to normal within a week or two.\nLike all laparoscopic procedures, a camera is inserted through a tiny incision to see into the abdomen; two other small incisions are made so that tools can be inserted to perform the surgery.\n\"If patients really know that they have options when it comes to hysterectomy, we will start seeing some of the changes that I feel need to happen,\" Warren said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although the story does\u00a0quote more than one expert, it is not clear that these are actual independent experts. Dr Cahill is the Executive Director of the National Women\u2019s Health Resource Center, whose campaign \"What\u2019s going on down there?\" was supported by Ethicon, Inc, a manufacturer of surgical equipment. And it is not clear what Dr Warren\u2019s credentials are.", "answer": 0}, {"article": "While the most pressing need, from the perspective of the global burden of disease, is low-and middle-income countries, it's equally relevant in a country like Australia where we're still achieving only 40%-50% control rates for high blood pressure.\"\nCompared with patients receiving usual care, a significantly higher proportion of patients receiving the Triple Pill achieved their target blood pressure of 140/90 or less (with lower targets of 130/80 for patients with diabetes or chronic kidney disease).\nA trial led by The George Institute for Global Health revealed that most patients - 70 per cent - reached blood pressure targets with the 'Triple Pill', compared to just over half receiving normal care.\nAt six months, 83 percent of participants in the Triple Pill group were still receiving the combination pill compared to the majority of patients in the usual-care group still receiving only one and only one third receiving two or more blood-pressure-lowering drugs.\nDr Ruth Webster, of The George Institute for Global Health, said this was a major advance by showing that the Triple Pill was not only more effective than standard care, it was also safe.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Although this is mentioned \u2026\nThe study was funded by the National Health and Medical Research Council of Australia\n\u2026 what\u2019s not mentioned is that the two lead authors quoted in the news release both receive a salary from George Health Enterprises (GHE is the product commercialization arm of The George Institute for Global Health). According to disclosures cited in the published study:\nGeorge Health Enterprises has received investment funds to develop fixed-dose combination products containing aspirin, statin, and blood pressure-lowering drugs and has submitted a patent for the treatment of hypertension", "answer": 0}, {"article": "\"There is some limited evidence from my study and others that fish oil may be good for preventing breast cancer, but there is not sufficient evidence to make a public health recommendation right now,\" cautions study researcher Emily White, PhD, an epidemiologist at the Fred Hutchinson Cancer Research Center in Seattle.\nLobular breast cancer forms in the milk glands.\nDuctal breast cancer is the most common type of breast cancer and forms in the milk ducts.\nIn the study, 880 women developed breast cancer during six years of follow-up.\nExactly how fish oil may affect breast cancer risk is not fully understood, but it may be related to its strong anti-inflammatory properties.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Four different sources were quoted \u2013 a strength of the story. ", "answer": 1}, {"article": "Check out more than one clinic and make sure you know what it defines as a \u201csuccess\u2019\u2019 \u2014 a viable transferring of an egg leading to a baby, or just a safely thawed egg.\nShe owns her eggs, no question.\nFreezing eggs now is no guarantee of a baby later.\nThings to consider before freezing your eggs\n\n\u25a0 Beware of a false sense of security.\nDiscarding an unused embryo, which has the potential to develop into a baby, has weightier implications for many than discarding unused eggs.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several good independent sources cited. ", "answer": 1}, {"article": "Former NASA astronaut Mark Kelly announced that he is running for John McCain's Senate seat in Arizona in the 2020 election.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story failed to point out that the Dr. Castro, who led the study discussed in this story, is a paid consultant for Asthmatx, which manufactures the thermoplasty device tested in the study and which provided funding\u00a0for the study. \u00a0", "answer": 0}, {"article": "The average age of people in both groups was 73.\nThe findings, presented Sunday, Nov. 25 at the Radiological Society of North America meeting in Chicago, suggest that doctors may one day be able to use widely available tests to tell people their risk of developing dementia before symptoms arise.\n\"We could tell that the individuals who went on to develop dementia have these differences on diffusion MRI, compared with scans of cognitively normal people whose memory and thinking skills remained intact,\" Raji said.\n\"Right now it's hard to say whether an older person with normal cognition or mild cognitive impairment is likely to develop dementia,\" said lead author Cyrus A. Raji, MD, PhD, an assistant professor of radiology at Washington University's Mallinckrodt Institute of Radiology.\nAlthough there are no drugs available yet to prevent or delay the onset of Alzheimer's disease, identifying those at high risk of developing dementia within the next few years could still be beneficial, the researchers said.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funder \u2014 the Boerger Research Fund for Alzheimer\u2019s Disease and Neurocognitive Disorders from the Foundation of the American Society of Neuroradiology \u2014 is noted on the sidebar of the release hosting site, EurekAlert! We encourage news release writers to include funders in the body of the news release text as well.\nWe didn\u2019t observe any conflicts of interest among the researchers.", "answer": 1}, {"article": "The U.S. Institute of Medicine says the amount of weight women should gain during pregnancy varies depending on their non-pregnancy weight.\nThe women were randomly assigned to a diet, exercise, a combination of the two or standard care.\nThen, during the next pregnancy the woman is already heavier and that may increase the risk of complications.\nThe women who took part in diet, exercise and combination programs were also less likely to develop high blood pressure during pregnancy, compared to those in the standard care group.\nThe diets and exercise programs varied, but could include low-glycemic diets and unsupervised exercise.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites an independent source and makes it clear when quoting from the paper itself.", "answer": 1}, {"article": "Jan. 13, 2010 (Coronado, Calif.) -- A blood test under study to help diagnose lung cancer looks promising, researchers reported Tuesday at a cancer meeting in California.\nHe is the senior author on the study, presented at the American Association for Cancer Research-International Association for the Study of Lung Cancer's joint conference in Coronado, Calif.\n\nAbout 219,000 new cases of lung cancer were expected to be diagnosed in the U.S. in 2009, according to the American Cancer Society, and about 159,000 deaths were expected.\nAccording to Dubinett, about one in 500 chest X-rays shows a lung nodule of ''indeterminant significance.\"\n''Currently, 20% to 25% of surgeries done for suspected lung cancer turn out to be benign diagnoses,\" says Steven Dubinett, MD, professor of medicine and pathology and director of the Lung Cancer Research Program at the Jonsson Comprehensive Cancer Center at the David Geffen School of Medicine, University of California, Los Angeles.\nWhen that occurs, the next step is to examine the suspicious area, with the physician ordering a biopsy or inserting a scope into the lungs to evaluate further.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An independent source was cited, a meeting attendant, and the SomaLogic quotes were added for context. The latter were good for illustrating that the Dubinett group is not the only game in town working on this type of blood test.\nIdeally, the article would have had more independent analysis of the specific results.\u00a0No independent source was used to assess the SomaLogic employee\u2019s claims of their experimental test\u2019s sensitivity.\u00a0Although\u00a0the\u00a0MedPage Today coverage of the study\u00a0is aimed at a professional medical audience, it provides a good example of some of the critical points outside sources can provide about these type of very early results.\nAlthough the article does not identify conflicts of interest, from the MedPage Today article it\u2019s not clear that the investigators disclosed any conflicts of interest in their abstract.", "answer": 1}, {"article": "Women who ate walnuts tended to weigh less, consume more fish and exercise more than those who did not.\nWalnuts may have some unique benefits.\u201d\n\nThe study was supported with grants from the National Institutes of Health and the California Walnut Commission.\n\u201cThere\u2019s been a lot of research on nuts in general in relation to cardiovascular health,\u201d said the senior author, Dr. Frank B. Hu, a professor of medicine at Harvard.\nThe scientists, writing in the April issue of The Journal of Nutrition, used dietary and health data on 138,000 women participating in a large continuing study of women\u2019s health.\n\u201cThis is the first on walnuts and diabetes.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent source was quoted \u2013 only the author of the study was quoted.\u00a0 The story did note that the study was partially funded by the California Walnut Commission. It did not mention that the researcher quoted in the story has received funding support from that commission.", "answer": 0}, {"article": "A recent study has found evidence suggesting text messages could reduce one\u2019s odds of a second heart attack.\n\nA six-month clinical trial in Australia found that patients recovering from a heart attack were more likely to maintain lower blood pressure, less body fat and lower cholesterol levels than a control group when the patients received text messages asking and giving suggestions about their health routines. Patients receiving the texts also were more likely to be active and to quit smoking than the patients in the control...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story clearly identifies one source as the leader of the study and includes a second source who appears to be independent of the research.\u00a0 Funding sources are missing from the story, but the study\u2019s declarations of funding do not seem eyebrow-raising.", "answer": 1}, {"article": "The team recruited 45 healthy participants aged 21-70 years who were either obese or overweight.\nModerate-fat diet with one avocado a day lowered 'bad' cholesterol by 13.5 mg/dL\n\nThe researchers found that participants' levels of low-density lipoprotein (LDL) - referred to as the \"bad\" cholesterol - were an average of 8.3 milligrams per deciliter (mg/dL) lower after following the lower-fat diet without an avocado and 7.4 mg/dL lower after following the moderate-fat diet without an avocado, compared with their baseline average.\nIt is well known that avocados are high in fat, but the majority of an avocado's fat is monounsaturated, which is deemed a \"good\" type of fat.\nWhat is more, the team found that a number of additional blood measurements - such as total cholesterol, small dense LDL, triglycerides and non-HDL (high-density lipoprotein) - were better after participants followed the moderate-fat diet with one avocado a day, compared with the other two diets.\nThe researchers, including senior author Penny M. Kris-Etherton, PhD, distinguished professor of nutrition at Pennsylvania State University, publish their findings in the Journal of the American Heart Association.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes quotes from the principal author that help place the study in context, and it notes that the story was funded by Haas Avocado Board. However, the researcher\u2019s quotes are taken directly from a press release, whereas the other outlets that covered this story all spoke directly with the study author. Additional useful information could have (and, we think, should have) been gleaned by speaking with someone who was not affiliated with the study. That\u2019s why we\u2019re rating this unsatisfactory.", "answer": 0}, {"article": "George E. Jordan may be reached at gjordan@starledger.com or (973) 392-1801.\nThe study said there were still many unanswered questions about Pfizer's pill, torcetrapib, the first in a new class of heart medicines known as a CETP inhibitors, which raise HDL, or good cholesterol, and lower LDL, or bad cholesterol.\n\"It is still possible that CETP inhibitors without off-target effects of torcetrapib could be viable as a therapy for cardiovascular disease,\" said an editorial published in today's edition of the New England Journal of Medicine, which concluded: \"It is possible that CETP inhibition might be better suited to certain subgroups of patients, such as those with impaired clearance of LDL cholesterol or low levels of HDL cholesterol at base line,\" the editorial said.\nOf the 15,067 patients in seven countries taking part in the randomized clinical trial, called Illuminate, 82 patients taking a combination of torcetrapib and Lipitor died, compared with 51 taking Lipitor alone, which was the control group, according to the study.\nThe study, presented by Australian heart researcher Philip Barter, who oversaw Pfizer's torcetrapib clinical trials, concluded torcetrapib caused \"off-target\" effects, including deaths, elevated blood pressure, cardiovascular problems and a possible link to cancers.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not quote any independent experts or researchers, a major flaw of this story. It\u2019s not clear that anyone was actually interviewed, since only a study and an editorial were cited.\u00a0 Perhaps an independent expert could have put into perspective for the reader the fact that this story focuses on a small, theoretical part of the overall story at the expense of the facts.", "answer": 0}, {"article": "This new way of testing fetal DNA seemed to have already become fairly common where Seitz used to live, in Washington, D.C.\nShe didn't want an invasive procedure like amniocentesis or chorionic villus sampling.Those are considered the gold standard for prenatal genetic testing, but doctors must put a needle into the womb to collect cells that contain fetal DNA, which means a small risk of miscarriage.\n\"Many women are very excited by the idea that as part of their blood testing, they could find out pretty definitively if the baby is a boy or a girl,\" says Dr. Diana Bianchi, an expert on prenatal diagnostics at Tufts University School of Medicine.\nIt's only been on the market since October 2011 and is not regulated by the Food and Drug Administration \u2014 the FDA does not regulate this type of genetic testing service.\nUntil the new testing technology came along, the only less invasive option was for an expectant mother to get an ultrasound, plus have her blood tested for specific proteins.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story sought out several expert sources for their opinions about the testing, and it appropriately noted that one of these sources (Dr. Lee Shulman) is a consultant to firms selling the new screening tests. However, it failed to note that another of these expert sources (Dr. Diana Bianchi) was also a paid consultant to a testing company. In addition, it didn\u2019t caution readers that the study the story links to was paid for by a testing company.", "answer": 0}, {"article": "In an earlier pilot study supported by Life Extension, Drs.\n\"It's an important trial,\" says Dr. Steven Hirsh, director of clinical research for Life Extension in Fort Lauderdale, Fla. \"The findings are very noteworthy and support further study in randomized controlled trials with larger sample sizes and durations.\nThe team of researchers, led by Dr. Rafael de la Torre, program director of IMIM Hospital del Mar Medical Research Institute and study co-principal investigator, and Dr. Mara Dierssen, group leader at Center for Genomic Regulation, Barcelona, Spain, and study co-principal investigator, proposed that EGCG might have conferred these benefits by inhibiting an enzyme called DYRK1A, which has been implicated in Down syndrome and neurodegenerative conditions including Alzheimer disease.\nIn acknowledging the novelty of their findings and calling for more research, the Spanish research team noted that \"\u2026this study is the first well-powered trial that shows improvement in adaptive behavior (functional academics) and brain-related changes in young adults with Down's syndrome.\nThe level of DYRK1A-positive cells is elevated in certain regions of Alzheimer disease patients' brains, and is roughly 20-fold higher in the frontal cortex, compared to normal brains.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release makes it clear that the study was supported by Life Extension and discloses Life Extension\u2019s involvement in an earlier pilot study. The two sources quoted in the news release have ties to Life Extension \u2013 a fact the news release also makes clear in their titles.\nWe applaud the news release for disclosing this information, which is why we give it a Satisfactory rating here.", "answer": 1}, {"article": "Algase rates the device as about as accurate as the MMSE.\n\u201cWhat we are all about is making cognitive care part of primary care.\u201d\n\nMore than 5 million Americans have Alzheimer\u2019s disease, the leading cause of dementia.\nWith the United States shifting toward an older society, the hope is that earlier detection can lead to earlier intervention to slow or arrest the disease, perhaps through medications working their way to the market or changes in lifestyle.\nThe federal government\u2019s approval to market the device comes as Alzheimer\u2019s researchers everywhere step up the pursuit for easier and more inexpensive ways to identify dementia in its earliest stages.\nThe 10-minute, non\u00adinvasive examination can detect subtle lapses in the brain\u2019s perceptual ability that may signal the early stages of mental decline caused by dementia.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This was a difficult call. The story includes extensive comments from a company source and two clinicians who are early adopters of the device. The comments of the two users especially are quite helpful and demonstrate thorough reporting. With that being said, we hesitate to call any of these sources truly independent. Although the story qualifies that one of the physician users has no ties to the company, the fact that she\u2019s been using the system for several years, presumably with the equipment and support being supplied by the company at no cost, suggests a close relationship between the source and the manufacturer. The intent of this criterion is encourage a truly outside perspective. We think that comments from other sources not as close to the work and who could speak to other diagnostic approaches would have been helpful. The Not Satisfactory rating is not meant to suggest a lack of thoroughness on the part of the story or that the sources provided were not appropriate. It reflects our desire and hope that stories will always also include the perspective of at least one impartial expert.", "answer": 0}, {"article": "However, the treatment failed to improve secondary goals of the trial, such as heart-pumping efficiency and six-minute walking distance, and Vericel shares fell more than 31 percent by afternoon trading on Monday.\n\u201cFor patients, this is a really hopeful thing.\u201d\n\nHenry, who presented the data at the ACC meeting, stressed the need for larger trials to prove the benefit of ixmyelocel-T\n\nFor the treatment, bone marrow is taken from the patient and enhanced over two weeks to increase two types of cells associated with healing.\n\u201cPeople were looking for downside and they had one.\u201d\n\nThe data compared Vericel\u2019s bone marrow-derived ixmyelocel-T stem cells with placebo in 109 well-treated patients with advanced heart failure who had exhausted medical and device therapies.\n\u201cIt\u2019s a little baffling that you\u2019re keeping patients alive, but not having any effect on those secondary endpoints,\u201d said Needham & Co analyst Chad Messer.\nWith advanced heart failure, a leading cause of hospitalizations, blood-pumping ability is diminished as the heart\u2019s left ventricle becomes enlarged and weakened.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The doctor quoted in the story was identified as the lead investigator for the study. However, the story didn\u2019t include his potential conflict of interest\u2013that he received funding\u00a0from the drug company\u2013which was stated and easy to find in the study. For this reason, we\u2019re rating this Not Satisfactory.\nWe were please to see the story included an additional outside source, even if it was a financial analyst. A second, independent medical source would have made the story stronger.", "answer": 0}, {"article": "Boutot and Bertone-Johnson suggest that more prospective studies of their findings are warranted, including studies that compare soy-based and non-soy vegetable proteins.\nEarly menopause, the cessation of ovarian function before age 45, affects about 10 percent of women and is associated with higher risk of cardiovascular disease, osteoporosis and early cognitive decline, the authors note.\nThey observed that women consuming approximately 6.5 percent of their daily calories as vegetable protein had a significant 16 percent lower risk of early menopause compared to women whose intake was approximately 4 percent of calories.\n\"A better understanding of how dietary vegetable protein intake is associated with ovarian aging may identify ways for women to modify their risk of early onset menopause and associated health conditions,\" write first author and then-graduate student Maegan Boutot, with her advisor, professor Elizabeth Bertone-Johnson.\nFew studies have evaluated how protein intake is associated with menopause timing, they add, and to their knowledge this is the first to look specifically at early menopause.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release states that the study was supported by a grant from NIH\u2019s Eunice Kennedy Shriver National Institute of Child Health and Human Development. The researchers reported no conflicts.", "answer": 1}, {"article": "One was a low-fat diet that included lots of fruits, low-fat dairy, poultry, whole grains and small amounts of red meat.\nIt was also supported by a grant from the Hass Avocado Board, an industry group that the researchers say had no role in the design of the study or the interpretation of the data.\nThe only difference between the two was the avocado \u2014 the other diet had the same amount of fat from other sources.\nAnd given the reduction in funds available for research, it's become increasingly common for researchers to carry out these kinds of industry-supported studies.\nNew research finds that eating an avocado per day, as part of an overall diet rich in healthy fats, may help cut the bad kind cholesterol, known as LDL.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story relies entirely on one source, who was an author of the study. It would have been good to get additional input from other experts in the field. However, the story not only makes clear that the study was partially funded by an avocado industry organization, but discusses the issue at length.", "answer": 0}, {"article": "Call 911 or your doctor for all medical emergencies.Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.\nThere was no significant association between healthy dietary patterns and risk of kidney failure.\nThis content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition.\nThe content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN).\nIn 6 studies, healthy dietary patterns were consistently associated with a 20% to 30% lower rate of mortality, with 46 fewer deaths per 1000 people over 5 years.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release says that the authors had no financial conflicts of interest.", "answer": 1}, {"article": "Two drugs once widely used to treat Parkinson's disease sharply increase the risk of heart-valve damage, researchers have found. The studies immediately prompted calls for the treatments to be discontinued or patients more closely monitored.\n\nPatients who take the drugs, pergolide or cabergoline, are four to seven times as likely to suffer damage to their heart valves as patients who don't take either one, according to two studies published in today's New England Journal of Medicine.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article enlists a variety of sources to balance its commentary on the drugs implicated in the new research, and includes sufficient information for readers to assess the sources\u2019 potential conflicts of interest. ", "answer": 1}, {"article": "By doing both, the ability of imaging to accurately plot a tumor\u2019s location is increased and there is a more refined sense of the tumor\u2019s extent, said Nathan White, PhD, assistant project scientist at UC San Diego, study co-author and co-inventor of the RSI-MRI technique.\nIt corrects for magnetic field distortions and focuses upon water diffusion within tumor cells.\nGreater blood flow is often a requirement of growing cancer cells.\nAn imaging technique called diffusion MRI measures the diffusion of water and has been a standard imaging technique in the brain and an emerging technique in the prostate.\n\u201cThis new approach is a more reliable imaging technique for localizing tumors.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding sources are fully listed. There is no indication of a conflict of interest.", "answer": 1}, {"article": "The change comes amid sharp controversy over new recommendations from a federal task force that women wait until age 50 before they begin having routine mammograms and that women age 50 to 74 scale back to getting the exams routinely every two years.\nThese recommendations are sound,\" she said.\n\"More testing is not always more intelligent testing.\"\nThe National Cervical Cancer Coalition, a patient advocacy group, endorsed the recommendations.\nBut in this case, if anything, we're taking money out of our own pockets.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Sourcing is excellent. Sources include: ", "answer": 1}, {"article": "[On average] \"22 grams (about .78 ounces) of new heart tissue grew,\" which he says is quite remarkable considering this had never been done before and the average weight of the part of the heart that is responsible for pumping the blood through the body is about 150 grams (about 5.3 ounces).\n\"This is the first instance of therapeutic regeneration,\" says Dr. Eduardo Marb\u00e1n, director of the Cedars-Sinai Heart Institute.\nTo qualify for this clinical trial, patients had to have suffered a recent heart attack and \"had to have a significant amount of damage to begin with and weren't squeezing [blood into the body] as well as they should have,\" says Dr. Peter Johnston, one of the study authors who injected the new heart cells into patients treated at Johns Hopkins Hospital.\nThe damaged area also doesn't conduct electric current as well, leading to an abnormal heart rhythm, which can cause more problems.\n\"By preventing the consequences of a heart attack you may be able to prevent further down the heart failure that happens in [many of these] patients.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story could have sought a little wider circle of independent experts. But we thought the reporter elicited good comments from Sonia Skarlatos, Ph.D and deputy director of the Division of Cardiovascular Sciences at the NIH\u2019s National Heart, Lung, and Blood Institute, which funded the study. We have to give an \u201cunsatisfactory\u201d here, though, because the story failed to mention the financial interest that the lead researcher has in the stem cell therapy. The press release for the study mentions this, as does a competing WebMD story.\n\u00a0", "answer": 0}, {"article": "Current mammography testing works well for detecting breast cancer in women over 50 with results of up to 95% accuracy.\nThe most effective screening tool for detecting breast cancer is mammography and for women of all ages to remain breast aware, reporting any changes to their [doctor].\u201d\nThe Manchester team says it is far less effective for younger women, where the detection rate could be as low as 60% for women under the age of 50.\nWu says in a news release: \u201cThe system we have is portable and as soon as you lie down you can get a scan -- it\u2019s real-time.\nOct. 28, 2010 -- A University of Manchester, England, engineering professor has invented a portable breast scanner that could lead to more accurate tests for younger women without the need for X-rays.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An independent source was consulted. Talking to more of them, or giving more space to Ms. Rogers\u2019s keen caveats about the uncertainty and context, instead of burying them like an appendix, may have reversed some of our unsatisfactory ratings.\nThe article is honest, at least, that it sourced a news release. Ideally it would have acknowledged that all the factoids and forward-looking upside in the article came from Dr. Wu and the university, those who presumably hold the patent on this tool and stand to profit financially from good press or success in the IET awards competition. ", "answer": 1}, {"article": "April 12, 2012 -- The next new acne treatment may be found in the produce section of your food store.\nLargely due to its anti-inflammatory and anti-bacterial properties, the herb thyme -- which is found with other herbs in the produce section of most food stores -- may well earn itself a place in the skin care section of your local drug store.\n\"If thyme tincture is proven to be as clinically effective as our findings suggest, it may be a natural alternative to current treatments,\" researcher Margarita Gomez-Escalada, PhD, says in a news release.\nIn fact, the thyme tincture was more powerful than standard concentrations of benzoyl peroxide, which is the active ingredient in many acne products.\nBut some U.S. dermatologists are quick to caution that while intriguing, this research is still preliminary, and thyme-tinged acne treatments are not yet ready for prime time.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This is an example of how simply seeking independent experts\u2019 quotes isn\u2019t sufficient.\u00a0 Yes, there were four independent physicians quoted.\u00a0 But none was quoted directly addressing the evidence with any substance.\u00a0 Instead, they were quoted giving only vague reactions such as:\nThe closest thing to a helpful independent perspective was this quote: \u201cHow it works in the lab setting is very different than how it works on your skin.\u201d\nWe will give the story a BARELY satisfactory score on this one, and that\u2019s being generous.", "answer": 1}, {"article": "This is relatively new thinking.\n\u201cIt is not clear that it is the specific early introduction of an allergenic food that renders immunological protection, rather than the accompanying increased diversity in the diet that occurs as a by-product,\u201d writes Dr. Matthew Greenhawt, an allergy and immunology specialist at Children\u2019s Hospital Colorado, in the accompanying editorial.\nWhen babies eat certain foods early in life\u2014the kinds so many end up allergic to, like eggs and peanuts\u2014they\u2019re less likely to develop allergies to those foods later on, finds a new analysis published in the ( ).\nBut, as an editorial published in the same issue of points out, in the next decade, food allergy prevalence nearly doubled in the United States.\nEarly introduction didn\u2019t seem to make a difference for autoimmune diseases, at least according to the available evidence; eating gluten young wasn\u2019t associated with the risk of developing celiac disease.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes only one scientist, and that is his written comment from an editorial accompanying the study, not an interview.\nThis source, Dr. Matthew Greenhawt, has a potential conflict of interest that wasn\u2019t disclosed: He\u2019s a member of the scientific advisory council for the National Peanut Board, among other affiliations clearly stated in the study\u2019s editorial.", "answer": 0}, {"article": "\u201cThis is really a teachable moment.\u201d\n\nThe skills taught in the course are useful at many stressful moments, Porter said, not just when cancer is diagnosed.\n\u201cThese are really good life skills,\u201d Porter said.\nIt makes biological sense, Stagl said.\n\u201cIt\u2019s quite amazing,\u201d she said.\nBut most people aren\u2019t explicitly trained how to cope with stressful events.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes quotes from at least one independent source and clearly identifies quotes from researchers associated with the recent study.", "answer": 1}, {"article": "Reiki, a therapy in which hands are placed lightly on the body or just above it, is increasingly being used to reduce cancer-related fatigue, anxiety, nausea and pain. Several studies suggest a benefit to patients, but scientists say more large, rigorous studies are needed.\n\nCancer patients\u2014due to the disease and to side effects of chemotherapy\u2014often suffer from severe mental and physical fatigue, doctors say. Anxiety, nausea and pain are also common. In recent years, many cancer centers have been offering Reiki, a form of...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted many experts.\u00a0 Most, however, were used to at least hint at the idea that Reiki has some benefit. We do appreciate some of the candor, though. \u201cBarrie Cassileth, chief of the Integrative Medicine Service at Memorial Sloan-Kettering Cancer Center in New York, calls the energy theory \u2018absurd\u2019 but says light-touch therapy can have a \u2018great relaxing effect\u2019 on cancer patients \u2018who are constantly poked, prodded and given needles.'\u201d", "answer": 1}, {"article": "(Reuters Health) - Leaving a bedroom door or window open may help people sleep better, a study from the Netherlands suggests.\nThe study participants were asked not to drink alcoholic beverages or caffeinated drinks, which could influence sleep.\nThey each slept alone, and the bedroom layout with furniture arrangement was kept consistent.\nOpen windows and doors helped reduce carbon dioxide levels and improve ventilation and air flow, which was related to better sleep quality for the healthy young adults in the study.\nClosed environments tended to have less background noise \u2013 but they also had significantly higher carbon dioxide levels, which indicated lower ventilation levels.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A sleep researcher who wasn\u2019t involved in the study was interviewed, and we could detect no conflicts of interest.", "answer": 1}, {"article": "These weekend warriors cram the recommended amount of exercise into one or two days, while the rest of us faithfully head to the gym multiple times a week for a half-hour hamster run on the treadmill.\nThe information about physical activity was reported by the participants, and it\u2019s likely that many were too generous in their estimates of how much time they spent at the gym.\nOne study, published in 2014 in the journal Heart, suggests that in people with existing heart disease, the risk for cardiac arrest and stroke was the same for people who exercised more than an hour a day compared with those who didn\u2019t exercise at all.\nThis could be something as simple as a brisk walk or other low-impact options for vigorous exercise about 20 minutes a day.\n\u201cI would be more concerned about what\u2019s happening at the point of exercise\u2014not the long-term benefits,\u201d says Dr. Howard Andrew Selinger, chair of family medicine at Quinnipiac University.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does provide some precautionary words from an independent expert in the field related to the risks associated with strenuous exercise. We would have liked to have seen an expert in the field provide comments on the study, the inherent limitations and on the conclusions drawn.", "answer": 1}, {"article": "The F.D.A.\nNovartis said that about 2.2 million Americans would be eligible for the drug, which was approved for patients with so-called Class II to Class IV chronic heart failure with so-called reduced ejection fraction.\nTimothy Anderson, pharmaceutical analyst at Sanford C. Bernstein & Company, said in a recent note that Entresto was \u201clikely to become a mega-brand over time\u201d but that the initial uptake was \u201clikely to be on the slower side given the entrenched nature of off-patent ACE inhibitors.\u201d He said it was highly unusual that there were no major competitors for Entresto on the way, giving it a \u201clong runway.\u201d\n\nIn a clinical trial with more than 8,400 participants, patients were randomly assigned to take either Entresto or enalapril, an ACE inhibitor.\nThe other ingredient, sacubitril, inhibits an enzyme known as neprilysin, a new mechanism of action for a heart failure drug.\nIt said there were also cases of angioedema, an allergic reaction that usually results in swelling of the lips or face but can be life threatening if swelling interferes with breathing.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two people are quoted in the story. One is an analyst at an investment firm, with no clear ties to Novartis, who was quoted in regard to the drug\u2019s potential to generate revenue for Novartis. The other is the head of Novartis\u2019s pharmaceutical division. An outside perspective on the potential health impact of the drug would have been very welcome.", "answer": 0}, {"article": "\"It's a very fragile organ to begin with,\" Kavaler said, \"and if you start to do all these things to it you can disfigure it...\n\"However, most men complaining of inadequate penile size do have associated sexual problems even if their penile dimensions fall within the normal range -- so-called dysmorphophobic penis,\" said Gontero, an associate professor of urology at the University of Turin.\nIn a review of five evidence-based surgical studies of 121 men and six non-surgical studies of 109 men published between 2000 and 2009, the researchers found that penile extenders -- which stretch the organ over a period of months through traction -- were the most effective among non-invasive methods.\nStudy co-author Dr. Paolo Gontero said urologists are constantly approached by men concerned about their penis size, despite the fact that the majority are average, with a flaccid length of 1 to 4 inches.\n\"All procedures aimed to increase the penile girth should be considered unsafe, leading to potentially poor cosmetic and functional results,\" Gontero added.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story uses independent sources, and we applaud that. We wish that the second independent source quoted had not been a penile enhancement practitioner.\u00a0The story did not, however, note that the co-author of the study has conducted research for a European company that produces a penile traction device and is a member of the company\u2019s medical advisers (http://www.andromedical.com/medical-committee/committee-members/). This was not included in the conflict of\u00a0interest statement that\u00a0was published with the study,\u00a0but this is a reminder that reporters should perform basic\u00a0background checks when covering research and quoting experts.", "answer": 1}, {"article": "Funding of this work was supported by the Nemours Foundation along with the regional economic development initiative of the Florida High Tech Corridor.\nThis research demonstrates a novel method of treating this tumor without the toxicity of aggressive therapy that can also have late effects on the patient's health,\" said Tamarah J. Westmoreland, MD, PhD, a pediatric surgeon at Nemours Children's Health System and senior author of the study.\nThe study, conducted in partnership by researchers at Nemours Children's Hospital and the University of Central Florida, demonstrates a potentially novel treatment for neuroblastoma, the most common cancer in infants.\nOverall, the nano-therapeutic treatments showed a more pronounced effect in MYCN-amplified cells, which are traditionally more resistant to drug therapies.\nIn the study, researchers loaded Cerium oxide nanoparticles with curcumin and coated them with dextran to test in cell lines of a high-risk form of neuroblastoma, known as MYCN-amplified, as well as non-amplified neuroblastoma.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release discloses the study\u2019s funding sources, which include the Nemours Foundation and the regional economic development initiative of the Florida High Tech Corridor.\nWe were not able to find any potential conflicts of interests.\nWe rate this one Satisfactory.", "answer": 1}, {"article": "\"The consistency among the results lead to the unequivocal conclusion that there is no clinical benefit of the use of folic acid and vitamin B12 (with or without the addition of vitamin B6) in patients\" with heart disease, wrote Joseph Loscalzo of the Brigham and Women's Hospital in Boston in an editorial that will be published with the studies.\n\"There are hundreds, if not thousands, of papers showing that.\"\nThe new study, involving more than 15,000 high-risk patients, did not find any overall benefit and even suggested the combination may be dangerous for some patients.\nAlthough the new studies did show that the vitamins cut homocysteine levels, that did not translate into a reduction in the risk for heart attacks or strokes.\n\"The homocysteine theory really isn't getting much attention anymore,\" he said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "In addition to the discussion of the studies, a quote was pulled from an editorial in the journal that published the studies. ", "answer": 1}, {"article": "Obesity puts children at greater risk of developing preventable conditions like heart disease and diabetes at a younger age, and suffering poor health later in life.\nProfessor Mary Fewtrell, assistant officer for health promotion at the U.K.-based Royal College of Paediatrics and Child Health, told Newsweek: \"Although the effect sizes are not given, these outcomes are certainly positive.\nVitamin D is most commonly associated with the development and maintenance of strong bones as the body needs it to absorb calcium.\nThe team measured participants' vitamin D levels, body fat percentage, as well as their markers of liver and heart function at the start of the study, and again 12 months later.\nEarlier this year, researchers in the Netherlands published a study indicating higher levels of belly fat are linked to lower vitamin D levels.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There appears to be at least one expert, Mary Fewtrell (of the Royal College of Paediatrics and Child Health), who comments on the study yet is not involved in the research.", "answer": 1}, {"article": "Servan-Schreiber offered more words of wisdom to LaPook -- words he says doctors rarely impart to their patients -- and LaPook discussed with co-anchor Harry Smith on The Early Show Friday why he thinks it is that cancer survivors aren't offered more guidance by the medical establishment:\n\nServan-Schreiber appears in the joint CBS, NBC, ABC special \"Standing Up To Cancer\" Friday night.\n\"There's tremendous evidence that physical exercise helps prevent cancer, and also helps people who already have cancer prevent a recurrence,\" he says.\nHe has penned the best-selling book, \"Anti-Cancer: A New Way of Life,\" about his past and on-going battle, and offers suggestions to fellow cancer patients.\n\"Help it with the right nutrition, with physical exercise, with managing stress better, and avoiding contaminants that feed cancer.\nAnd if you do these things, which are very simple, you're greatly increasing your chance of beating the odds.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quotes one physician, who is also a patient. The story could have been greatly improved by quoting an expert or researcher in this field who is not so emotionally involved. ", "answer": 0}, {"article": "Acupuncture designed to treat depression appears to improve symptoms in pregnant women, suggesting it as an alternative to antidepressant medication during pregnancy, a study found.\n\nThe study, published Monday in the journal Obstetrics & Gynecology, is the largest to date examining the effectiveness of acupuncture to treat depression in pregnant women. It was funded by a grant from the government's Agency for Healthcare Research and Quality. \"Acupuncture that we have tested works for pregnant, depressed women,\"...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes only the lead author on the study. The story should have quoted additional, independent experts who could have provided much needed perspective on the importance of \u2013 or limitations of \u2013 these new findings.", "answer": 0}, {"article": "\u201cI hope insurance companies will look at this and realize that early detection and surgery, if appropriate, will ultimately save them money in the long term.\u201d\n\nSOURCE: bit.ly/2gVClQv The New England Journal of Medicine, online October 25, 2017.\nThe researchers said that was to be expected and, without surgery, patients probably would have experienced similar problems as a result of their continuing seizures.\nThe surgery \u201chad a transforming effect on how they get along in life,\u201d Dr. Tripathi said.\nBut with physical therapy, all regain the lower and upper limb function within six months.\n\u201cThe child may not be able to ambulate by his- or herself.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article does quote a Boston specialist who was not a part of the study, which was conducted in India.", "answer": 1}, {"article": "Jan. 25, 2010 -- A low-carbohydrate diet may have health benefits that go beyond weight loss.\nA new study shows that a low-carbohydrate diet was equally good as the weight loss drug orlistat (the active ingredient in Alli and Xenical) at helping overweight and obese people lose weight, but people who followed the low-carb diet also experienced a healthy drop in their blood pressure levels.\n\"I expected the weight loss to be considerable with both therapies but we were surprised to see blood pressure improve so much more with the low-carbohydrate diet than with orlistat,\" researcher William S. Yancy, Jr., MD, an associate professor of medicine at Duke University Medical Center, says in a news release.\n\"It's important to know you can try a diet instead of medication and get the same weight loss results with fewer costs and potentially fewer side effects,\" Yancy says.\nResearchers say studies have already shown that the two weight loss methods are effective at promoting weight loss, but it's the first time the health effects of each have been compared head to head.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story\u2019s only quotes come from Dr. Yancy, a researcher affiliated with the study. The story also does not inform\u00a0readers that Dr. Yancy and another co-author on the study have received funding from the Robert C. Atkins Foundation, which promotes\u00a0research on low-carb diets.\u00a0", "answer": 0}, {"article": "Asked if the 34% improvement in cognitive decline is meaningful to a patient, Carrillo said, \"I have a family member with AD.\nThe latest results come from a combined analysis of a 1,012-patient study and a 646-patient study, both of which involved people with mild to moderate Alzheimer's disease.\nThere was even a hint that the drug helped to slow the decline in functioning.\nThe drug is designed to prevent those clumps from forming.\nI would be happy with a sustained cognitive benefit for my mother-in-law.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes independent experts, although their independence from the drug maker\u2019s research is implied rather than clearly declared. AP, though, did a better job.", "answer": 1}, {"article": "Papa and her team expanded on that work by studying how levels of these two proteins, or biomarkers, change immediately after head trauma.\n\u201cI don\u2019t think a blood will be the be-all and end-all but it would be a beautiful tool for us to have in the clinic to support a lot of our decision making.\u201d\n\nTesting for levels of UCH-L1, for example, might be helpful for emergency medical teams in an ambulance trying to assess whether a patient has any serious head injuries, since its levels peak in the hours immediately after a trauma.\nThere\u2019s growing evidence that concussions may have more lasting effects than previously thought, and that monitoring people with head injuries, no matter how apparently minor, is crucial to ensuring they receive proper treatment and minimize the effects of the trauma.\nWhen Papa then looked just at people who showed signs of TBI on CT scans, she found that their levels of GFAP and UCH-L1 were significantly higher than those of people with other types of trauma, suggesting that the two markers can be relatively specific to TBI and not trauma in general.\nMORE: A New Blood Test to Diagnose Concussions On The Field\n\nIn the emergency room, a blood test for UCH-L1 could also help doctors decide which patients should get a CT scan \u2014 the higher their levels of the protein are, the more likely they are to have TBI and would benefit from a scan, while those with lower levels probably don\u2019t need one.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story included no independent sources, and failed to mention a potential conflict of interest with the only source quoted in the story. As stated in the JAMA Neurology\u00a0study, lead researcher\u00a0Dr. Linda Papa was listed as one of several researchers who have consulted or received contract research funding from Banyan Biomarkers, Inc. Banyan is a for-profit biotech company in Florida seeking to commercialize a biomarker for head injury.", "answer": 0}, {"article": "To learn more about the Society and the field of endocrinology, visit our site at http://www.\nBefore and at the end of treatment, subjects provided stool samples for microbiota analysis.\n\"Despite numerous preventive and therapeutic interventions, none has stopped obesity from reaching epidemic proportions.\"\nFollow us on Twitter at @TheEndoSociety and @EndoMedia.\nInstead, an electromagnetic coil is placed on the scalp and sends magnetic pulses to stimulate specific deep regions of the brain.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "No funding sources or conflicts of interest are described in the news release.", "answer": 0}, {"article": "The blood test is developed on a so-called antibody microarray that consists of hundreds of recombinant antibody fragments.\nThere is currently no cure and few treatment options for advanced pancreatic cancer, which is the late stage when pancreatic cancer is usually diagnosed\", explains Carl Borrebaeck, professor at the department of Immunotechnology at Lund University.\nIn the future, the screening method could be used to screen people who are at a higher risk of developing pancreatic cancer, such as those with a hereditary risk, newly onset diabetes patients and patients with chronic inflammation of the pancreas.\nSince the immune system is the first to respond to threats like complex diseases, such as cancer, autoimmune diseases and infections, the microarray was designed to mirror this early response.\n\"Our test can detect pancreatic cancer with 96% accuracy at stage I and II, while there is still the possibility of successful surgical intervention.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "It should have been shared with readers that nearly half the study authors have financial ties to Immunovia AB, the biotech company developing this IMMray\u2122 blood test for detecting pancreatic cancer.\nThe lead author quoted in the news release is a co-founder of the company and the chairman of its board of directors.", "answer": 0}, {"article": "\"It is a huge step\" and a first for the field of genetics, said John Rossi, a researcher at City of Hope in Duarte, Calif., where he and Zaia plan another study to test Sangamo's approach.\nThe only side effect was two days of flulike symptoms.\nHe treated his first patient with it in July 2009.\nThe sixth man also had modified cells, but fewer than expected.\nThis is the first time researchers have permanently deleted a human gene and infused the altered cells back into patients.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several independent sources were quoted.", "answer": 1}, {"article": "(Reuters Health) - Getting too little sleep during the week can increase some risk factors for diabetes, but sleeping late on weekends might help improve the picture, a small U.S. study suggests.\n\u201cBy catching up on sleep on the weekends, people are reducing average extent and severity of the effects of sleep deprivation,\u201d Gangwisch added by email.\nThe volunteers were given a calorie-controlled diet to limit the potential for their food and drink choices to influence the outcomes.\nIn the real world, when people don\u2019t get enough sleep they tend to overeat, which may limit how much results from this lab experiment might happen in reality, the authors note in a report scheduled for publication in the journal Diabetes Care.\nOn another occasion, the same men were allowed to sleep 8.5 hours for four nights.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article did a good job, as noted earlier, of highlighting the limitations of the study, and quotes an outside researcher saying as much. Kudos!", "answer": 1}, {"article": "\u201cShould he take a statin?\n\u201cFinasteride has to be recognized as the first clearly demonstrated way to prevent prostate cancer with any medication or any oral agent at all.\u201d\n\nFinasteride has had its ups and downs.\nWith finasteride, Dr. Logothetis added, \u201cwe\u2019re trying to overcome our other sins.\u201d\n\nOther experts say, Not so fast.\nThe amount of benefit he\u2019ll get is not much, but his risk reduction still is 25 or 30 percent.\u201d\n\nDr. Thompson knows what he will do about finasteride.\nBut the reality is that people are being operated on.\u201d\n\n\u201cWe are trying to avoid a diagnosis to avoid a prevention whose value is disputed,\u201d he said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cited several highly-credentialed prostate cancer clinician-researchers.\u00a0 However, the only one expressing a somewhat more negative tone got the least space.\u00a0 ", "answer": 1}, {"article": "Sometimes patients get stents when they have no pain at all, just blockages.\nHeart disease is still the leading killer of Americans \u2014 790,000 people have heart attacks each year \u2014 and stenting is a mainstay treatment in virtually every hospital.\nBut they are most often used in patients who have a blocked artery and chest pain that occurs, for example, walking up a hill or going up stairs.\nTheir study focused on the insertion of stents, tiny wire cages, to open blocked arteries.\nA procedure used to relieve chest pain in hundreds of thousands of heart patients each year is useless for many of them, researchers reported on Wednesday.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We were pleased to see discussion from many experts, however, the story left out two important potential conflicts of interest. The story states that:\nDr. William E. Boden, a cardiologist and professor of medicine at Boston University School of Medicine, called the results \u201cunbelievable.\u201d\nReaders should have been informed that Boden has received fees from Abbott, a major stent device maker.\nAlso, the story states that:\nDr. David Maron, a cardiologist at Stanford University, praised the new study as \u201cvery well conducted\u201d but said that it left some questions unanswered. The participants had a profound blockage but only in one artery, he noted, and they were assessed after just six weeks.\u00a0\nThe story didn\u2019t disclose that Dr. Maron is an \u201cemployee of and stockholder in Cardiovascular Services of America, which provides outpatient cardiac catheterization and computed tomography angiography services,\u201d which was disclosed here.", "answer": 0}, {"article": "While the disease is rare, with about 3,100 new diagnoses and 330 deaths in the United States each year, it often goes undiagnosed until it affects vision. Sacks \u2014 known for books including Awakenings and The Mind's Eye, in which he tells the story of his own cancer \u2014 said his symptoms hit suddenly, wiping out a triangular chunk of the vision in his right eye.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources in the story. The only sources are the initial clinical trial patient, the doctor who is conducting the clinical trial and the founding CEO of Aura Biosciences, the drug\u2019s developer.", "answer": 0}, {"article": "Those medications can produce adverse side effects like gastrointestinal distress and fractures of the femur.\n\u201cBy opposing one group of muscles against another, it stimulates osteocytes, the bone-making cells.\u201d\n\nMost experts argue that it\u2019s difficult, perhaps impossible, for adults to gain significant bone mass.\nAt the time the study was submitted for publication, \u201cwith more than 90,000 hours of yoga practiced largely by people with osteoporosis or osteopenia, there have been no reported or X-ray detected fractures or serious injuries of any kind related to the practice of yoga in any of the 741 participants,\u201d Dr. Fishman and his colleagues wrote.\nThe average age of the 227 participants upon joining the study was 68, and 83 percent had osteoporosis or its precursor, osteopenia.\nIf you don\u2019t fall, you greatly reduce your risk of a serious fracture.\u201d\n\nFor more fitness, food and wellness news, follow us on Facebook and Twitter, or sign up for our newsletter.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Dr. Fishman invested a \u2018significant chunk\u2019 of his own money into the research and we appreciate that the story put that financial interest out in the open. Apart from the selling of the DVDs used, it hard to imagine how there could be a significant financial gain from the study. However, given that investment, it wold have been valuable to have comments from others in the field speaking to the study results and the basic premise entailed. This kind of research might be more influenced by more subtle\u00a0intellectual conflicts of interest, where the researchers are intellectually identified with an idea (yoga=good) and would have difficulty accepting alternative hypotheses. The lack of a control group becomes somewhat problematic as it is possible that a similar group of non-yoga performing people would also see increases in their bone density.", "answer": 1}, {"article": "\"We think it will be a very important tool in the toolbag of surgeons and physicians treating obesity and its co-morbidities,\" said Gregory S. Lea, senior vice president and chief financial officer of EnteroMedics. \"When patients leave the diet, counseling and drug world and have nothing more, they turn to surgical procedures, and only 1% to 2% of patients who might be eligible for bariatric surgery are getting it.\"", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We commend the story for actually talking with two experts who are knowledgeable about the device and related research. That being said, these experts were a senior executive with the device manufacturer and a researcher who conducted some of the studies leading to development of the device. They both have a vested interest in the success of the device. The story would have been stronger if it had chosen to interview an outside expert in gastroenterology, endocrinology or a related specialty to give an unbiased perspective on the device.\nHealthNewsReviews.org offers a list of independent experts in many fields who are willing to provide an outside perspective on health news stories.", "answer": 0}, {"article": "So, should we be referring to physical therapists, osteopaths or chiropractors from the ER?\"\n\"This study shows that basically neck pain will get better on its own,\" said Dr. Victor Khabie, chief of the departments of surgery and sports medicine at Northern Westchester Hospital in Mount Kisco, N.Y. \"It would've been good if they had a no-treatment group, too,\" he added.\nSpinal manipulation is one type of treatment that's offered for neck pain, and it can be administered by chiropractors, physical therapists, osteopaths and other health care providers, according to the study.\n\"For me, as an ER doctor, this study offers an interesting perspective,\" said Dr. Robert Glatter, an attending physician in emergency medicine at Lenox Hill Hospital in New York City.\nAll are probably still viable treatment options, but what we don't know is what each particular patient will need,\" Bronfort said, adding that it's possible a combination of treatments might be helpful, too.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes quotes from multiple independent sources. It reports that funding for this trial was provided by \u201cU.S. National Center for Complementary and Alternative Medicine.\u201d It might have been helpful to point out that the center is part of the National Institutes of Health, so that it would be clear to readers that it is a public institution. Although the story does not report on any potential conflicts of interest on the part of the researchers, the article authors did not disclose any conflicts in their journal article.", "answer": 1}, {"article": "A new study has an intriguing finding: Advanced cancer patients who received early palliative care in conjunction with standard care for their disease not only reported better quality of life, but lived a few months longer than patients who received only standard care.\n\nThe research, published in the New England Journal of Medicine, included 151 patients diagnosed with metastatic non-small-cell lung cancer who were randomly assigned to one of those treatment plans. At 12 weeks, 86% of those who were still alive filled out assessments \u2026", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although it didn\u2019t include the breadth of perspectives included in some of the other stories about this study,\u00a0this story\u00a0did include an interview with an expert not affiliated with the study\u2013enough for\u00a0a satisfactory.\u00a0Since this source is the past president of American Academy of Hospice and Palliative Medicine\u2013 a professional group that obviously supports increased awareness and use of palliative care\u2013we wish it had also included a comment from someone without these industry ties. \u00a0\u00a0", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070715/23knee.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article cites one source\u2014the chief of the knee service at a major New York hospital that performed 2500 knee replacements in 2006. It offers no independent sources who might have balanced his enthusiasm with information on harms, costs, and other treatment options.", "answer": 0}, {"article": "Research on a bacterial toxin first discovered in Adelaide has led to the development a new blood test for the early diagnosis of ovarian cancer - a disease which kills over 1000 Australian women and 150,000 globally each year.\nThe new blood test has the potential to dramatically improve early detection of the disease, although it will require further testing before it is available for clinicians.\nThe team has now engineered a harmless portion of the toxin to enhance its specificity for the cancer glycan and used this to detect it in blood samples from women with ovarian cancer.\nA paper published this month in Biochemical and Biophysical Research Communications has shown that the new test detected significant levels of the cancer glycan in blood samples from over 90% of women with stage 1 ovarian cancer and in 100% of samples from later stages of the disease, but not in any of the samples from healthy controls.\nProfessor Michael Jennings, Deputy Director of the Institute for Glycomics at Griffith University, said: \"Detection of this tumour marker may also play a role in a simple liquid biopsy to monitor disease stage and treatment.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "A major weakness of this news release is failing to mention that four out of six of the authors are \u201cnamed inventors on a patent\u201d related to this screening test.\nAlso, the funding for this study is not included.", "answer": 0}, {"article": "Merck filed in February for FDA approval of Keytruda for both initial and secondary treatment of advanced urothelial cancer, the most common type of bladder cancer.\nThe Merck drug is awaiting U.S. Food and Drug Administration approval, but Tecentriq was approved by the agency last year, contingent on verification of its clinical benefit.\nAfter 18 months, 36 percent of Keytruda patients were alive, compared with 20.5 percent of chemotherapy patients, according to research published by ASCO.\nIn addition to Tecentriq\u2019s approval for bladder cancer patients whose disease has stopped responding to chemotherapy, the FDA last month approved the Roche drug as an initial treatment for people with a specific type of advanced bladder cancer and in people whose cancer progressed despite at least one prior platinum-containing chemotherapy.\nThe agency has also granted contingent approval to AstraZeneca Plc\u2019s Imfinzi, Bristol-Myers Squibb\u2019s Opdivo and Bavencio, developed by Pfizer Inc and Merck KGaA, as second-line bladder cancer treatments.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story has no sources. It needed\u00a0an independent voice to provide comment on what it means to see survival increase by only a handful of months, particularly for such an expensive treatment. Is the trade-off worth it? Will doctors readily prescribe this treatment?", "answer": 0}, {"article": "The body mass index, or BMI, associated with the lowest risk of death has increased since the 1970s, a study finds, from 23.7, in the \"normal\" weight category, to 27, which is deemed \"overweight.\"\nSo he and his colleagues sliced and diced the data to see what could account for the shift.\nBut when they looked at the mortality rates in nonsmokers who had never had cancer or heart disease, it also became associated with a higher BMI over time.\nThe BMI has been vilified as a poor measure of an individual's health.\nBy 2013, 56 percent of the Danes had a BMI of 25 or higher.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were no apparent conflicts of interest. However, only one researcher was quoted, but nobody else independent of the work.", "answer": 0}, {"article": "TUESDAY, Jan. 31, 2017 (HealthDay News) -- A breath test to detect stomach and esophageal cancers shows promise, researchers say.\nThe researchers said they are planning a larger trial of the breath test over the next three years.\nFindings from the study were presented Monday at the European Cancer Congress (ECC).\nThe U.S. National Cancer Institute has more on stomach cancer.\nIn the longer term this could also mean earlier diagnosis and treatment, and better survival,\" Markar said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not appear to include input from independent sources.", "answer": 0}, {"article": "The results were just published online by the medical journal The Lancet.\nAlso, there was no difference in deaths from clots blocking blood vessels in either group, a potential safety concern for the medicine.\nA study of more than 20,000 patients with traumatic injuries and at risk of bleeding to death found those who were treated with tranexamic acid were significantly less likely to die than those who got a placebo.\nThat improvement may not seem so dramatic, but drug is pretty easy to give -- an initial 10-minute infusion within 8 hours of injury, followed by a second infusion over 8 hours.\nThe drug is used to reduce bleeding during surgery and is also approved in the U.S. to prevent bleeding in hemophiliacs who have teeth pulled.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "It\u2019s difficult to find room for an independent perspective in a 245-word brief, and this story didn\u2019t find the room. ", "answer": 0}, {"article": "Colic occurs during the first three months of an infant's life in which an otherwise healthy child cries and cannot be comforted for three hours or more every day.\nThe infants' mothers were also advised to avoid cow's milk in their own diets during the study period.\nColic affects up to 28% of infants and has no known cause or cure.\nThe findings were published online today in Pediatrics.\nAll the infants were diagnosed with colic, born full-term at a healthy gestational weight, had no history of gastrointestinal disorders, were breastfed, not formula fed, and did not receive any other probiotic supplements during the week prior to the study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A real shortcoming. No independent perspective\u00a0was provided nor were the\u00a0researchers themselves interviewed for the story. In addition, the story failed to point out that the study was funded by probiotic manufacturer BioGaia. \u00a0\u00a0", "answer": 0}, {"article": "You know, they go to rehab and there\u2019s not much more [more] they can recover usually.\u201d\n\nFor the study, Steinberg and his team recruited 18 patients who had suffered their first and only stroke six months to three years prior to the trial.\nIn Steinberg's study, it did not \u201ccause problems by differentiating into unwanted tissues or forming tumors.\u201d And even when the stem cells came from an unrelated donor, the participants did not experience a strong immune reaction.\nResults showed that the implanted stem cells didn\u2019t survive very long in the brain, disappearing about one to two months after injections; however, patients still showed significant motor recovery at six and 12 months post-surgery.\nThe findings suggest that stroke-damaged areas of the brain, once thought to be dead or irreversible, can actually be \u201cresurrected.\u201d\n\nSource: Steinberg G, Kondziolka D, Wechsler L, et al.\n\u201cThe recovery some patients showed was not just minimal, it was significant,\u201d said Steinberg, who has researched stem cell therapies for more than 15 years.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "As noted above, this article appears to have been drawn substantially if not exclusively from the news release, although the writer appears to have interviewed the principal investigator; but it\u00a0offers not a single source outside of the investigators who presumably approved the news release issued by Stanford.\nThere is disclosure about industry funding in the news release, but none at all in the article. The article would have gone a long way to put credibility and context into a genuinely promising experimental therapy if it had sought comment from an independent stem cell therapy researcher.", "answer": 0}, {"article": "For more information about NIH and its programs, visit http://www.\nThe study, funded by the National Heart, Lung, and Blood Institute's (NHLBI) asthma network (AsthmaNet), appears in the August 18, 2016, issue of the New England Journal of Medicine.\n\"Previous observational studies had suggested that acetaminophen use was associated with asthma symptoms,\" says Kristie Ross, MD, MS, Clinical Director, Division of Pediatric Pulmonology, Allergy/Immunology and Sleep Medicine at University Hospitals Rainbow Babies & Children's Hospital (UH Rainbow) and co-author on the study.\nAbout the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services.\nAs the primary pediatric affiliate of Case Western Reserve University School of Medicine and the only Level I Pediatric Trauma Center in the region, UH Rainbow Babies & Children's Hospital offers access to novel therapies, advanced technologies and clinical discoveries long before they are available nationwide.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "University Hospitals Case Medical Center discloses in its first paragraph the fact that the National Institutes of Health and the National Heart, Lung and Blood Institute\u2019s Asthma Network (AsthmaNet) funded the study.\nHowever, according to the published study, several of the researchers have ties to Pfizer, the maker of Children\u2019s Advil, and to McNeil Consumer Healthcare and Johnson & Johnson, makers of Tylenol. These are important ties to mention in a news release.", "answer": 0}, {"article": "The reviewers point out that some of the differences found, such as the longer operation times for robotic-assisted surgery, may be due to surgeons\u2019 inexperience with the new tool and could improve over time.\nThe researchers found that the two advanced minimally invasive techniques led to similar results, and both appeared to be generally superior to the traditional open procedure.\nHowever, about half as much blood was lost when robots were enlisted than with standard laparoscopy.\nAt the same time, lymph nodes are often removed to determine the stage of the cancer and whether further treatment is necessary.\nThe closed procedure, known as laparoscopy, requires a much smaller cut, through which small instruments and a video camera are inserted.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted two physicians who were not involved in the study.", "answer": 1}, {"article": "Behind that common piece of advice is a complex series of physiological processes that calm the body, slow the heart and help control pain.\n\nBreathing and controlling your breath is one of the easiest ways to improve mental and physical health, doctors and psychologists say. Slow, deep and consistent breathing...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "While this story does identify which of the quoted experts stand to make money from products or classes, it should have let readers hear from more than just the boosters of breathing exercises. A quick look at the medical literature produces a long list of reviews that note the poor quality and inconsistent results of research on this topic. The story could have included comments from researchers on the gap between the rosy claims of promoters and what the available evidence actually shows.", "answer": 0}, {"article": "A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer's disease, stroke, migraine, multiple sclerosis, brain injury, Parkinson's disease and epilepsy.\n\"While such changes may be detected with MRI, we believe there may be a less expensive and portable way to measure these changes with a transcranial Doppler (TCD) device.\"\n\"This important work provides insight into a tool that may yet prove useful in the recognition and management of concussion,\" said Jeffrey Kutcher, MD, FAAN, with the The Sports Neurology Clinic in Brighton, Michigan.\nVANCOUVER, British Columbia, April 13, 2016 /PRNewswire-USNewswire/ -- Mapping blood flow in the brain of athletes using an advanced form of ultrasound may make it easier to more accurately recognize concussions, according to a study released today that will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016.\nThis is in contrast to traditional TCD ultrasound measurements like change in cerebral blood flow reactivity which differentiated between the two 60 percent of the time, average blood flow speed which differentiated 55 percent of the time and blood flow resistance which differentiated 53 percent of the time.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "While the news release makes clear that the National Institutes of Health and the National Science Foundation funded the study, it does not illuminate the potential conflict of interest of the lead investigator. The lead investigator is identified in the release as the co-founder of Neural Analytics which developed the technology, and a journalist or other reader must then infer that the company may well be a beneficiary of the adoption of this technology. At minimum, some acknowledgement of the financial prospects for the company would be appropriate.", "answer": 0}, {"article": "Dr. Ellen Marmur, the chief of the division of dermatologic and cosmetic surgery at Mount Sinai Medical Center in Manhattan, did say Algenist could fairly claim that alguronic acid offers protection against ultraviolet damage to cells, and that she might use the product as \u201ca nice sun protection on top of S.P.F.\nDr. Dana Sachs, an associate professor of dermatology at the University of Michigan, Ann Arbor, wrote in an e-mail after looking at Algenist\u2019s dossier that \u201cthe claims on cell regeneration and elastin synthesis are based on in vitro models, which is hard to extrapolate to in vivo, and again no statistical significance is presented, so this is a weak claim.\u201d\n\nDr. Day, who has a doctorate in biochemistry, said that statistical significance was found but not included in press materials.\nBut Dr. McDaniel, who does research into using plant-derived products to lengthen the life of cells, says he thinks the comparative data must be viewed with caution because the studies that yielded it are \u201cchallenging to do accurately, hard to interpret and not necessarily predictive of final products.\u201d\n\nSoon, consumers will judge whether Algenist products are a breakthrough.\nAfter reviewing press materials and Solazyme\u2019s 84-page patent application, Dr. David McDaniel, a dermatologist and the director of the Institute of Anti-Aging Research in Virginia Beach, Va., said he was impressed by the in-vitro testing of alguronic acid.\n\u201cWe want to give it a lot of visibility all at the same time.\u201d But Mr. Burke knows that marketing has its limits.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Again,we love that the story took this company\u2019s marketing materials and attempted to have them independently analyzed. But the story chose poorly when picking experts. After 10 paragraphs of effusive language about a new wave of ocean-derived anti-aging products, the first ostensibly critical voice in the story is given to Dr. David McDaniel, who is described as \u201ca dermatologist and the director of the Institute of Anti-Aging Research in Virginia Beach, Va.\u201d what does McDaniel say? He \u201csaid he was impressed by the in-vitro testing of alguronic acid. \u201cIn the petri dish, their data seems to show some substantial benefits to their active ingredient,\u201d he said. But he cautioned that in-vitro testing does not demonstrate how a final formulation works off the shelf.\u201d The story does not point out that the institute is a contract research organization that provides service to manufacturers including study design, laboratory testing, clinical testing and media consultations.", "answer": 0}, {"article": "Devenish manufactures pre-mix and special feed for pigs, poultry, cattle, sheep, equine, game, companion animals and aquaculture.\n\"Therefore, in this project we studied the recently developed alternatives to oily fish or supplementation, namely chicken meat and eggs, naturally enriched with sustainable algae-based omega-3 PUFA.\nProfessor Chris Elliott, Founder of the Institute for Global Food Security & Pro Vice Chancellor, Faculty of Medicine, Health & Life Sciences, Queens University Belfast said:\n\n\"The cost to the health service of treating cardiovascular related illness in the UK is \u00a310billion/year.\n\"International guidelines recommend eating oily fish at least once per week, however, many people do not eat fish at all and less than 20% of the world's population have optimal omega-3 PUFA levels.\nThe findings were presented by Professor Alice Stanton of The Royal College of Surgeons in Ireland:\n\n\"Greater consumption of oily fish has long been linked to a reduced incidence of heart attack, stroke, diabetes and cancer and improved brain health, vision, muscle and joint health,\" said Professor Alice Stanton.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release never specifically says who funded the research, although most readers would assume it was Devenish, the manufacturer of the chicken feed being touted and the company that issued the release. The release does disclose that \u201cThe chicken meat and eggs used in the study came from birds offered OmegaPro, a sustainable and algae-based source of omega-3 PUFA, developed by Devenish.\u201d \nThe release should have noted whether there were any financial ties between the researchers and Devenish. Without a published study this is hard for us to verify.", "answer": 1}, {"article": "While 19.5 percent of patients who received only the placebo injections were judged to have met the trial\u2019s specified clinical endpoint \u2014 at least a 20 percent reduction in the number of tender and swollen joints \u2014 the response rate among those getting the real drug every four weeks was 53.3 percent.\nThe drug, an injectable monoclonal antibody, is already commercially available for the treatment of psoriasis, for which it has been remarkably effective, said Genovese.\nThose getting the drug every two weeks didn\u2019t do any better and were slightly more prone to side effects, such as a mild reaction at the injection site.\nFor the last decade or so, Genovese said, another pro-inflammatory substance called IL-17 has been drawing the attention of immunologists focusing on psoriasis and psoriatic arthritis.\nHowever, despite the availability of TNF inhibitors, \u201conly about half of psoriatic arthritis patients who are given TNF inhibitors get better,\u201d said Genovese.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release states that the manufacturer paid for the trial and the key spokesperson, the principle investigator served as a consultant to Eli Lilly.", "answer": 1}, {"article": "According to Kramer, \"This randomized study concludes that [aspirin's] use is not only effective for reducing the incidence of preeclampsia at term, but also preterm.\nThe reduction in risk was even greater for early deliveries.\nPreeclampsia is a serious high blood pressure disorder.\nThis is important because it will reduce the need for preterm delivery, which is risky for the baby.\"\nA baby aspirin dose is 81 milligrams.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included an independent source and we could find no conflicts of interest.", "answer": 1}, {"article": "The original form of vancomycin is an ideal starting place for developing better antibiotics.\nEven if they found a solution to one of those, the organisms would still be killed by the other two.\u201d\n\nTested against Enterococci bacteria, the new version of vancomycin killed both vancomycin-resistant Enterococci and the original forms of Enterococci.\nThe researchers, led by Dale Boger, co-chair of TSRI\u2019s Department of Chemistry, discovered a way to structurally modify vancomycin to make an already-powerful version of the antibiotic even more potent.\nCombined with the previous modifications, this alteration gives vancomycin a 1,000-fold increase in activity, meaning doctors would need to use less of the antibiotic to fight infection.\nThe next step in this research is to design a way to synthesize the modified vancomycin using fewer steps in the lab, as the current method takes 30 steps.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding source is clearly identified, and there does not appear to be a conflict of interest for the researchers. The release would have been stronger if it had clearly stated that there was no conflict of interest.", "answer": 1}, {"article": "This study was presented at a medical conference.\nBut if the findings are confirmed, \"patients who are taking aspirin for other reasons may see an added benefit,\" says study head Kevin Choe, MD, a radiation oncologist at the University of Texas Southwestern Medical School in Dallas.\nThe study involved 5,275 men with localized cancer whose disease had not spread beyond the prostate gland; 1,982 of the men were taking anticlotting medications: aspirin, Lovenox, Plavix, and/or warfarin.\nThe findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\nThe risk that cancer spread was also reduced by anticlotting medications, from 7% to 3%.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\n\nIt was easy to meet the basic requirement of this criterion, because the news briefing was moderated by an expert who was not involved in this study. Also, the researchers did not declare any conflicts of interest. However, it is possible that the moderator (who is also the president of the medical association sponsoring the meeting) may have had some role in selecting or shaping this study presentation and so it is hard to know for sure how independent he is.", "answer": 1}, {"article": "Both types are thought to be beneficial.\nThe MRIs showed higher white matter hyperintensity volume, tiny lesions in the brain, raising the risk for death, stroke and dementia for the low omega-3 fatty acids group.\n\u201cThis is an important new finding that supports omega-3 for brain health and brain size,\u201d said Dr. Majid Fotuhi, chairman of the Neurology Institute for Brain Health and Fitness and assistant professor of neurology at Johns Hopkins University School of Medicine.\nPeople with diets short on omega-3 fatty acids \u2013 the kind found in fish oil \u2013 were more likely to experience accelerated brain aging, a new study found.\nVegetable and canola oils, soybeans, flaxseed, walnuts and vegetables including spinach, kale and salad greens are also a source of omega-3 fatty acids.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did consult an independent expert. However, this expert\u2019s recommendations opened the door to a lot of questionable statements about the benefits of DHA. So this is a rare case where the story probably would have been better without this outside perspective.", "answer": 0}, {"article": "Results of the vaccine were not as good in the other 25 patients.\nAs exciting as that is, he says, \"a lot of work needs to be done to prove whether this can be effective [for more patients].\"\n\"In January, it will be four years [for her],\" he tells WebMD.\nOne woman who got the investigational vaccine now has no X-ray evidence of cancer, says study researcher James Gulley, MD, PhD.\n\"That time frame is not anything to write home about,\" Gulley says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This is the root of the story\u2019s main shortcoming. Almost all of the information in the story comes from one source: Dr. James\u00a0Gulley, who oversaw the study. Gulley is quite enthusiastic about this vaccine, despite the evidence, and the story needed more perspectives to put this vaccine into a broader context. At the very end, there are a few comments from Dr. Vincent K. Tuohy, who also is working on a breast cancer vaccine. Because of his competing research, he seems to have a conflict, but even putting that aside, his comments were not used to their best effect.", "answer": 0}, {"article": "\"Many would have predicted that tendon healing is inflammation-linked,\" said Thoru Pederson, Ph.D., Editor-in-Chief of The FASEB Journal, \"but that the anti-inflammatory roles of TSCs could be so potent, and so amplifiable, is a striking finding.\"\nIt is the world's most cited biology journal according to the Institute for Scientific Information and has been recognized by the Special Libraries Association as one of the top 100 most influential biomedical journals of the past century.\nOur mission is to advance health and welfare by promoting progress and education in biological and biomedical sciences through service to our member societies and collaborative advocacy.\nThe researchers found that CTGF stimulation induced TSCs' production of anti-inflammatory cytokines, consequently leading to improved tendon healing and matrix remodeling.\n\"Our findings represent an important foundation for the development of a new treatment that would regulate overwhelmed inflammation for tendon ruptures and tears, tendonitis, tendinopathy, and other tendon injuries and diseases.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The quoted expert source in the release is identified clearly as a co-investigator of the study, but we can find no information in the release about funding sources or possible conflicts of interest.", "answer": 0}, {"article": "MONDAY, June 19, 2017 (HealthDay News) -- Acupuncture is a safe and effective alternative to pain medications for some emergency room patients, a new study reports.\nBut he noted that more research is needed because some patients remained in pain no matter what treatment they received.\nThe study participants were seen at four Australian emergency departments for acute low back pain, migraines or ankle sprains.\nOne hour after treatment, less than 40 percent of all patients had significant pain reduction, meaning at least a 2-point decline on the 10-point scale.\nThe study was published June 18 in the Medical Journal of Australia.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story offers quoted statements only from the lead investigator for the trial. No independent sources or quoted, nor are we told who funded the study.", "answer": 0}, {"article": "But for now this category is useful only to researchers.\nThe guidelines say, for instance, that newly developed \"biomarker\" tests, such as assays for proteins in spinal fluid, and some specialized brain scans can be used for early diagnosis of Alzheimer's.\nBut, the guidelines say, the tests are to be used only for research, and not for diagnosing Alzheimer's in the general public.\nRather, the goal in creating this category is to see if scientists can define when the disease starts, and track it through biomarker tests, brain imaging, or other yet-to-be-invented tests.\nBut the new criteria, which were developed by the National Institute on Aging and the Alzheimer's Association, are almost guaranteed to prompt confusion, even in people who are thinking quite clearly.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\n\nAlthough the overall tone of this story is cautious and balanced, only one expert is quoted. Readers don\u2019t get any sense of how widely accepted the panels conclusions are or what dissenting opinions other experts might hold.\nMore importantly, this story does not tell readers about the links between panel members and companies that are developing tests or treatments for Alzheimer\u2019s disease. The journal article announcing the new guidelines includes this note about the expert quoted in this story: \u201cDavid Knopman serves on a Data Safety Monitoring Board for Lilly Pharmaceuticals, is an investigator for clinical trials sponsored by Elan Pharmaceuticals, Forest Pharmaceuticals, and Baxter Healthcare, is deputy editor of Neurology, and receives compensation for editorial activities\u201d. ", "answer": 0}, {"article": "\"I think this may be changing in health care,\" said Spears, \"but because migraine affects women more than men, there is a stigma around the stereotype of a patient who comes in with multiple complaints, calls frequently and wants to see the doctor frequently.\" Men, on the other hand, have been stereotyped as going to the doctor \"only when something he has is real.\"", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does include one statement by a physician not part of the research team. But it doesn\u2019t point out that all of the researchers are either the employees of the pharmaceutical firm, Teva Pharmaceuticals, which makes the new drug, or they are consultants to dozens of other pharmaceutical firms. These ties should have been disclosed.", "answer": 0}, {"article": "News releases can also be found at http://www.\nThe air pressure in the treadmill can be adjusted to take the patient from 100 per cent of their body weight to only 20 per cent, the same feeling as walking on the moon, and reducing the impact and pressure on joints during the run.\nNot only does the tailored anti-gravity treadmill programme provide a great environment for healing, it also helps the person restore their belief that they can make a successful return to the sport they love.\nThe case report highlights the journey a 39-year-old female endurance runner took from the end of her post-knee surgery rehabilitation to taking part in her sport again.\nThe Sports Ready clinic is student-led under supervision of experienced practitioners, with patients self-referring or sent by private clinics and NHS orthopaedic consultants.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t say if the author received funding to complete the case study. It also doesn\u2019t give readers any information about potential conflicts of interest, or the absence of any, between the study authors and anti-gravity treadmill manufacturers.", "answer": 0}, {"article": "One recent analysis of previous studies found that people who took a low dose of aspirin every day for several years reduced their risk of developing Alzheimer\u2019s by 13 percent.\nBut what about Alzheimer\u2019s?\nIt\u2019s believed that aspirin, and possibly other nonsteroidal anti-inflammatory drugs, may reduce or head off that process.\nAnother study in 2003 in The European Journal of Clinical Pharmacology found a similarly beneficial effect for aspirin and other nonsteroidal anti-inflammatory drugs.\nThe claim that aspirin can prevent the disease stems from the notion that Alzheimer\u2019s is caused by inflammation that disrupts proteins in the brain.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story did not appear to contain material obtained from individuals with expertise in this area.\u00a0 No one was quoted.", "answer": 0}, {"article": "All were treated with medicines that improve chest pain and heart and artery health such as aspirin, cholesterol-lowering statins, nitrates, ACE inhibitors, beta-blockers and calcium channel blockers.\nBut most angioplasties are done on a non-emergency basis, to relieve chest pain caused by clogged arteries crimping the heart's blood supply.\nTo the surprise of the researchers, both groups fared about the same: approximately 19 percent had a heart attack or died within seven years, adds LaPook.\n\"We deliberately chose to enroll a sicker, more symptomatic group\" to give angioplasty a good chance to prove itself, Boden said.\nIf that does not help, they can consider angioplasty or bypass surgery, which unlike angioplasty, does save lives, prevents heart attacks and gives lasting relief of chest pain.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quotes one cardiologist not associated with the study and gives no rationale for why he was chosen. (Is it because he's in New York and readily available?) The story could have quoted other clinicians or experts who could have provided some valuable perspective on the impact of this new development on the management of heart disease.", "answer": 0}, {"article": "Instead, the chief usefulness of the \"ALVAC-AIDSVAX\" vaccine is likely to be what it can teach virologists about what is happening in the immune system when a person is even somewhat protected from HIV.\n\"I just think it's too early really,\" said one, who spoke on the condition of anonymity for that reason.\nOther researchers were less sanguine about the study but did not want to be quoted by name as being skeptical when only a few details of the results have been released.\nAn experiment in Thailand involving more than 16,000 men and women has demonstrated for the first time a small but measurable protective effect of an AIDS vaccine.\nThe results were barely significant on statistical grounds, perplexing for scientific reasons and unanticipated by most researchers.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Interviews with Dr. Fauci of NIH, with one of the investigators, and with an unnamed skeptic.\u00a0 ", "answer": 1}, {"article": "\"The saddest day for me had to be the day of (baseball) try-outs,\" Jordan says.\nJordan was one of the more serious cases.\nVictims often show no earlier symptoms, looking the picture of health.\nAnd he got a summer job at Great American Ballpark.\nJordan took his doctor's advice and quit the sports he loved.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No experts other than the researchers doing this study are quoted.", "answer": 0}, {"article": ", and receive monthly highlights by signing up at http://www.\n\"The bitter taste receptors that we have found on uterine muscle could be one more piece of the puzzle to understand the onset of labor, both at term and preterm, and develop new therapeutics for preterm labor.\"\nThis could be good news for those trying to prevent preterm labor: New research published online in The FASEB Journal suggests that exposing bitter taste receptors in the uterus to certain substances can stop many unwanted contractions that occur during premature labor.\nIt is the world's most cited biology journal according to the Institute for Scientific Information and has been recognized by the Special Libraries Association as one of the top 100 most influential biomedical journals of the past century.\n\"The biological mechanism of labor initiation remains unknown, and a large percentage of preterm pregnancies do not respond well to current medications,\" said Ronghua Zhuge, Ph.D., associate professor within the University of Massachusetts Medical School's Department of Microbiology and Physiological Systems in Worcester, Massachusetts.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release does not list the funding sources, although the paper does list them. There is no mention of conflict of interest in either the published study or the news release.", "answer": 0}, {"article": "Dr. Warren was puzzling over how to recreate that synaptic traffic cop when, because of a scheduling conflict, he showed up in 2001 at the wrong scientific conference and happened to sit next to Mark F. Bear, a neuroscience professor at M.I.T.\n\u201cThis may be the key to solving the mystery of autism and other developmental disorders.\u201d\n\nGeraldine Dawson, chief science officer at Autism Speaks, the world\u2019s largest autism advocacy organization, said that a growing body of research suggests that the many genetic causes of autism all seem to affect synapses, suggesting that a treatment for one form of the disease might help others.\nDr. Scolnick has not seen the results of the Novartis trial, but was told of them and concluded that if the drugs work in fragile X, \u201cthere\u2019s nothing to say that they won\u2019t work in some cases of broader autism-spectrum disorders.\u201d\n\nThe roots for the Novartis results began in 1982 when Stephen T. Warren, then a graduate student in genetics at Michigan State University, was looking for a job and something to research.\nIf authenticated in further, larger trials, the results could also become a landmark in the field of autism research, since scientists speculated that the drug may help some patients with autism not caused by fragile X, perhaps becoming the first medicine to address autism\u2019s core symptoms.\nThe results of the trial were something of a jumble until Novartis scientists noticed that patients who had a particular, undisclosed biological trait improved far more than others.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "While the story does collect feedback from a number of independent expert sources, we think the way these sources were used was inappropriate and potentially misleading. The reporter seems to have approached many of the sources\u00a0and asked them to comment\u2013 without the benefit of any actual data\u2013on\u00a0the reporter\u2019s second-hand description of the apparent positive results of Novartis\u2019s research. The sources all respond with a variation on, \"Wow, that sounds\u00a0wonderful.\" And really, who wouldn\u2019t say the same thing? Nobody doubts\u00a0that a drug effective for fragile X syndrome would represent a huge\u00a0medical breakthrough. But the\u00a0more important question\u00a0prompted by the\u00a0article is whether such a breakthrough has in fact\u00a0occurred.\u00a0Although there are some cautions and caveats sprinkled throughout the article, we think the extremely positive tone of the expert quotes far outweighs these nuggets of restraint. What bears repeating (and what we\u00a0think\u00a0gets lost in this story)\u00a0is that\u00a0these experts are enthusiastic about the concept of an effective treatment; they are not endorsing\u00a0Novartis\u2019s\u00a0claim\u00a0that the drug caused \"clear improvements\" in behavior. \u00a0", "answer": 0}, {"article": "WASHINGTON (Jan. 11, 2015) -- Symptoms of mild to minimal depression were associated with early indicators of heart disease in a research letter published today in the Journal of the American College of Cardiology, but the study found regular exercise seems to reduce the adverse cardiovascular consequences of depression.\n1 among cardiovascular journals worldwide for its scientific impact.\nThey also looked a several early indicators of heart disease.\nResearchers used questionnaires to evaluate patients for depression and levels of physical activity.\nThe American College of Cardiology is a 49,000-member medical society that is the professional home for the entire cardiovascular care team.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Neither the funding source nor any conflicts of interest are disclosed.", "answer": 0}, {"article": "\"Experimental studies suggest that fructans may be beneficial in diabetes, obesity, stimulating the immune system of the body, decreasing levels of disease-causing bacteria in the intestine, relieving constipation and reducing the risk of colon cancer,\" Mercedes Lopez, of the National Polytechnic Institute in Guanajuato, said in the news release.\nThe fructans turn into alcohol when agave is processed into tequila, they said.\nBut drinking tequila won't help, the study authors noted.\nThe National Osteoporosis Foundation has more about osteoporosis prevention.\n\"They can be used in many products for children and infants to help prevent various diseases, and can even be used in ice cream as a sugar substitute.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources. ", "answer": 0}, {"article": "\"Wow!\"\nAnd the drug hasn't been submitted for review by the Food and Drug Administration, though Vertex expects to do that later this year.\nUltimately, the drug might be used by around 3,000 patients worldwide, if approved, and Schoenebaum expects it would be command a very high price, perhaps $250,000 a year.\nThe foundation has championed the development of drugs, including VX-770, and has provided $75 million to Vertex to get the medicine this far.\nBut a key takeaway is that the medicine gets at a root cause of cystic fibrosis in some people rather than just relieving their symptoms.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Includes interview with CF Foundation president \u2013 not the most independent of sources since they have funded this work \u2013 but the story appropriately notes that the foundation will receive royalties from sales if the drug makes it to market.\nThe story also interviewed a biotech and drug analyst.", "answer": 1}, {"article": "Australian researchers have discovered that an existing medication could have promise in preventing breast cancer in women carrying a faulty BRCA1 gene.\n\"We therefore investigated what effect RANK inhibition had on the cancer precursor cells in BRCA1-mutant breast tissue.\"\nThe research, which also involved researchers at the Australian familial cancer consortium kConFab and US biotechnology company Amgen was published today in Nature Medicine.\n\"We think this strategy could delay or prevent breast cancer in women with an inherited BRCA1 gene mutation,\" Professor Lindeman said.\n\"By thoroughly dissecting how normal breast tissue develops, we have been able to pinpoint the precise cells that are the culprits in cancer formation,\" she said.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release includes Amgen in the sections of the release that list all of the organizations that were involved with conducting the research and which supported the work financially. However, the release does not tell readers that Amgen is the company that currently markets denosumab (under the trade names XGEVA and Prolia).", "answer": 0}, {"article": "The latest trial success follows Roche\u2019s announcement last week about a separate study in which Tecentriq mixed with chemotherapies carboplatin and Abraxane boosted progression-free survival, compared with chemotherapy alone, in first-line treatment of patients with advanced squamous non-small cell lung cancer.\nThe Basel-based company, which had previously announced Tecentriq, Avastin and chemotherapy had reduced the risk of disease progression or death, said on Monday it hopes for a quick approval from authorities for the cocktail.\nShe also said the survival benefit was observed across key subgroups, including those with varying levels of a protein called PD-L1 that can help tumors avoid detection.\nThis could help Roche make the case that its cocktail is suitable for broad patients groups, not just those with specific biomarkers.\n\u201cWe are pleased the IMpower150 study demonstrated a clinically meaningful survival benefit for people receiving their initial treatment for this type of advanced lung cancer,\u201d said Sandra Horning, Roche\u2019s chief medical officer.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes an unattributed quote lifted from the Roche news release, and a quote from a financial analyst, who discusses the drug\u2019s shifting market share\u2013not the science. This was not sufficient sourcing.", "answer": 0}, {"article": "However, they say these findings \u201craise questions that warrant investigation\u201d and call for verification in randomised studies \u201cbefore recommending a change to current practice.\u201d\n\nNotes to Editors\n\n Research: Antenatal nutritional supplementation and autism spectrum disorders in the Stockholm youth cohort: population based cohort study\n\n Journal: The BMJ\nAfter adjusting for several potentially influencing factors in both mothers and children, the researchers found that multivitamin use, with or without additional iron and/or folic acid, was associated with a lower likelihood of child ASD with intellectual disability relative to mothers who did not use folic acid, iron, and multivitamins.\nGiven the current understanding and strength of evidence supporting the importance of nutritional supplementation during pregnancy, \u201cit is impossible to imagine that these results, on their own, should change current practice,\u201d they write.\nThe results of the various analyses seemed to be consistent with each other, say the authors, suggesting that the association between multivitamins and ASD might not be fully explained by confounding.\nThere was no consistent evidence that either iron or folic acid use were associated with a reduced risk of ASD.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release makes no mention of either funding sources or potential conflicts of interest involving the study authors. This information is plainly provided in the journal article\u2019s footnotes which\u00a0 lists the government funding sources and notes that \u201cResearchers were independent from funders.\u201d", "answer": 0}, {"article": "Multigene testing is not more expensive than testing for the BRCA mutations alone, he said.\n\u201cThe interpretation of these tests is not a simple color-by-numbers thing.\u201d The vast majority of uncertain genes will be benign, but a misinterpretation could lead a patient to a drastic, unnecessary surgical procedure, he said.\nEven among all appropriate candidates who are sent for genetic testing, only nine percent will test positive for the BRCA mutations, so an additional four percent who have non-BRCA mutations is a significant number, Ellisen said.\nBut new tests for breast cancer risk mutations beyond the well-known BRCA genes would offer actionable information for many women and their doctors, a new study finds.\nThe BRCA1 and BRCA2 gene mutations put women at high risk for breast, ovarian and other cancers, but mutations of other genes are believed to confer extra risk as well.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article mentions that several of the study\u2019s authors have links to the industry and to companies that produce the genetic test panels. The story also quotes from an editorial written by an expert who wasn\u2019t involved with the study. Conducting an interview with an outside expert might have unearthed additional useful context, but the story is pretty solid here as it stands.", "answer": 1}, {"article": "\"Our preliminary results are a first step in developing much-needed empirical data for clinicians and caregivers on how to use technology such as tablets as tools to enhance care and also for app developers working to serve the technologic needs of this population.\"\nHe became more interactive.\n\"The biggest advantage is versatility,\" said Vahia.\nResearchers loaded a menu of 70 apps onto the tablets for the study.\n\"His mood improved.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not mention who funded the study.", "answer": 0}, {"article": "\u201cIf used perfectly, how much HIV protection could there be?\n\u201cThat individual control of prevention is so powerful.\u201d\n\nThe dapivirine ring has been in development for more than a decade, and the the new studies are the first to show that it prevents HIV transmission.\nBut 1 in 3 infections were prevented overall \u2014 and that\u2019s huge.\u201d\n\nWarren noted that other rings with antiretrovirals are also being developed, as well as rings that could offer multipurpose protection, against not only HIV but pregnancy.\nThe other study, which has not yet been published but was presented on Monday at the Conference on Retroviruses and Opportunistic Infections meeting in Boston, studied 2,000 women in South Africa and Uganda.\nLike the other study, in this one the ring had no visible effect in women younger than 21, whereas new HIV cases dropped by 37% in women over 21.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story doesn\u2019t mention the makers of the device or any potential conflicts of interest. However, one of the authors of the study presented in abstract form (the \u201cSPIRE\u201d study) is affiliated with the International Partnership for Microbicides, Silver Spring, MD, which is involved with product development, partnerships with pharmaceutical companies, and marketing of this and related devices. The device is licensed from Janssen Sciences, a large pharmaceutical company. The International Partnership for Microbes describes itself this way: \u201cAs a nonprofit product developer, IPM partners with a variety of organizations to facilitate strategic planning from the earliest stages of product design to ensure future access to products.\u201d\nThere are two people quoted in the story, the lead author of the study and the head of AVAC, a global HIV-prevention advocacy group. (AVAC issued a news release on the two studies.) While the story includes insightful comments from these two sources, both have some investment (even if only on an intellectual level) in the project. The story would have been been stronger if it had included an expert with no relationship at all to the device studies, ideally someone active in providing health care in sub-Saharan Africa, who might have provided insights into adherence, product acceptance or any practical obstacles (such as costs) in the way.", "answer": 0}, {"article": "If it gets to that point, then clearly things will change.\u201d\n\nStroke is the fourth-leading cause of death in the United States.\nWe wanted the superiority of endovascular treatment.\u201d\n\nWhether the findings will cause physicians to abandon the practice is uncertain.\nOne study took eight years to complete because it was so difficult to enroll patients willing to take the chance that they would be randomly assigned to get the older treatment.\nFurther, many practitioners think that newer clot-retrieving devices work better than the ones used in the three trials.\nIt had permission to run the study in 30 hospitals but found only 22 that were willing to participate.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The\u00a0deputy director of the National Institute of Neurological Disorders and Stroke provided some perspective, plus the reporter worked to include statements from investigators from each of the three trials and we credit that effort as satisfactory.", "answer": 1}, {"article": "\"More than 30 years since the discovery of the antidepressant effects of sleep deprivation, we still do not have an effective grasp on precisely how effective the treatment is and how to achieve the best clinical results,\" said study senior author Philip Gehrman, PhD, an associate professor of Psychiatry and member of the Penn Sleep Center, who also treats patients at the Cpl.\nThe findings of this meta-analysis hope to provide relief for the estimated 16.1 million adults who experienced a major depressive episode in 2014.\n\"Regardless of how the response was quantified, how the sleep deprivation was delivered, or the type of depression the subject was experiencing, we found a nearly equivalent response rate.\"\nReviewing more than 2,000 studies, the team pulled data from a final group of 66 studies executed over a 36 year period to determine how response may be affected by the type and timing of sleep deprivation performed (total vs early or late partial sleep deprivation), the clinical sample (having depressive or manic episodes, or a combination of both), medication status, and age and gender of the sample.\nMichael J. Crescenz VA Medical Center, and Hengyi Rao, David F. Dinges, Namni Goel, John A. Detre, Mathias Basner, Yvette I. Sheline, and Michael E. Thase, all from Penn.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release listed the federal grants and two medical device companies that provided funding for the study. One of the device companies manufactures devices for sleeping and respiratory care. There does not appear to be any direct conflict, but we would have liked a statement saying that.", "answer": 1}, {"article": "But the fact that the fewest recurrences were seen in men who took the highest statin doses is compelling, says senior investigator Stephen J. Freedland, MD, of the Duke Prostate Center.\n\u201cStatin users may see their doctors more often and may be more health conscious in general, and it has been suggested that this could explain the observed reduction in risk,\u201d Freedland tells WebMD.\nIn a new study from Duke University Medical Center, men who took statins for their hearts were 30% less likely to have their cancers come back after their prostates were removed than men who did not take the drugs.\n\u201cIf this is the case, dosage shouldn\u2019t matter.\nThose who took the highest doses saw their recurrence risk drop by half.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Durado Brooks provides some great context at the end, and it would have been nice if this were higher up.", "answer": 1}, {"article": "In a new paper published on May 31 in the journal PLOS One, researchers from Duke believe they have found a better way.\n\"The mortality rate of cervical cancer should absolutely be zero percent because we have all the tools to see and treat it,\" said Nimmi Ramanujam, the Robert W. Carr, Jr., Professor of Biomedical Engineering at Duke.\nWhile more than 4,000 American women die of the disease each year, the mortality rate has dropped more than 50 percent in the past four decades, largely due to the advent of well-organized screening and diagnostic programs.\n\"We recruited 15 volunteers on Duke's campus to try out the new integrated speculum-colposcope design,\" said Mercy Asiedu, a graduate student working on the project in Ramanujam's lab.\nThe colposcope is a magnified telescopic device and camera designed to allow medical professionals to look through the speculum to see the cervix, which is located three to six inches inside the vagina.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release acknowledges in a footnote that the research was\u00a0funded by the National Institutes of Health. That\u2019s enough to meet our standard, but putting this information in the body of the release would make it more likely to be picked up by syndicators and others who might redistribute this content.", "answer": 1}, {"article": "TUESDAY, Feb. 23, 2010 (HealthDay News) -- A popular nutritional supplement -- extract of bitter melon -- may help protect women from breast cancer, researchers say.\n\"We didn't see any death in the normal cells,\" she said.\nThe next step is to see if the team can repeat these findings in animals, Ray said.\nThe bitter melon extract killed only the cancer cells, not the healthy breast cells.\nFor more information on breast cancer, visit the American Cancer Society.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One independent source was quoted.", "answer": 1}, {"article": "For more information or to arrange an interview with Dr. Vuksan, please contact:\n\"The findings are most important for populations at high risk for cardiovascular disease, such as Type 2 diabetics, who have normal levels of LDL cholesterol, but elevated levels of non-HDL or apo B,\" said Dr. Vladimir Vuksan, research scientist and associate director of the Risk Factor Modification Centre of St. Michael's.\nIt is the first study to look at the effects of barley and barley products on both LDL and non-HDL cholesterol in addition to apolipoprotein B, or apoB, a lipoprotein that carries bad cholesterol through the blood.\nThe review also indicated that barley had similar cholesterol-lowering effects as oats, which is often the go-to grain for health benefits.\n\"After looking at the evidence, we can also say that barley is comparably effective as oats in reducing overall risk of cardiovascular disease\" said Dr. Vuksan.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There\u2019s no mention of funders and financial ties to industry which should always be disclosed as a potential conflict of interest. Several of the researchers involved have financial ties to both trade groups and corporations, according to the published report. For example, one of the authors holds Canadian and U.S. patents on a medical use of viscous fiber for certain health conditions.", "answer": 0}, {"article": "But that may be changing.\nIt\u2019s functioning in your day-to-day life.\u201d\n\nEkstadt has the privilege of being the first person in the nation to get the Raindrop outside of a clinical trial.\nThe other eye will be for seeing distance, explains Dr. D. Rex Hamilton, director of the Laser Refractive Center at the Stein Eye Institute at the University of California, Los Angeles, and a clinical professor of ophthalmology at the David Geffen School of Medicine at UCLA.\n\u201cSo the other eye needs to have good distance vision without glasses,\u201d Hamilton says, adding that sometimes people have laser surgery to improve the distance vision in the eye that won\u2019t be getting an implant to improve vision close-up.\n\u201cThere\u2019s a healing process after the inlay is put in that requires eye drops be put in on a daily basis for around three months,\" says Hamilton.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "It was not clear from the story whether either one of the experts quoted \u2013 Ralph Chu or D. Rex Hamilton \u2013 had any conflicts. In fact, Chu is one of the researchers\u00a0in a clinical study of the Raindrop implant, according to a peer-reviewed journal article we found.", "answer": 0}, {"article": "\u201cHowever, this study shows a substantial benefit for athletes undergoing surgery to prevent recurrent instability down the road.\u201d\n\nThe research data was collected between 2003 and 2013 from eight fellowship trained surgical practices, with patient ages ranging from 16 to 30 years old.\nAfter treatment with an arthroscopic bankart repair, the postoperative dislocation rate in the first-time injury group was 29%, compared to 62% in those who did not have surgery after their initial injury.\n\u201cWhile young athletes and parents may be wary of surgery, our study shows the advantages of this treatment approach,\u201d commented Marshall.\nThe average age of patients was 19 years old.\nThe study examined 121 patients at an average of 51 months post-surgery.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "It would have been helpful had the news release noted that\u00a0Alabama Orthopedic Spine & Sports Medicine Associates carried out the surgeries.", "answer": 0}, {"article": "Neither treatment prompted significant side effects, the authors said.\nHowever, while this approach is often successful in younger children (between the ages of 3 and 7), it is successful among only about a third of older children (between the ages of 7 and 12).\nAnd while theorizing that the apparent success of this alternative approach may have something to do with stimulating blood flow, retinal nerve growth and visual cortex activity, the authors acknowledged that the exact mechanism by which it works remains poorly understood.\nMONDAY, Dec. 13, 2010 (HealthDay News) -- Acupuncture may be an effective way to treat older children struggling with a certain form of lazy eye, new research from China suggests, although experts say more studies are needed.\nThe team nonetheless pointed out that their study's tracking period was relatively short, and that acupuncture is a complicated system that may lend itself to different success rates, depending on the skills of the particular acupuncturist.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story deserves praise for seeking out comments from two experts who provide valuable perspective on the results. Unfortunately, though, the story didn\u2019t point out that the researchers in this study have filed\u00a0a patent application\u00a0for vision-related acupuncture points.\u00a0This constitutes a significant potential financial conflict that should have been disclosed to readers. ", "answer": 0}, {"article": "TMS treats conditions by delivering brief, powerful magnetic field pulses that stimulate nerve cells in the brain.\nThe procedure is noninvasive and doesn't require anesthesia, and the pulses are delivered via an electromagnetic device or coil that is placed or worn on the head.\nOverall, 38% of the people with the real device responded to the treatment compared with 11% of those with the sham device.\nThe approval was based on a clinical trial of 100 people with obsessive-compulsive disorder, where roughly half received treatment with TMS and the other half had a sham treatment that didn't deliver the electromagnetic pulses.\nThe Food and Drug Administration made the announcement on Friday, expanding the use of a technology that has been around for decades.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article is weakened by the absence of expert comment and attribution of claims made by the company and the FDA. Nor does the reader learn anything about whether those who conducted the clinical trial have or had any ties to Brainsway or other conflicts of interest.", "answer": 0}, {"article": "How miserable is combing a child's hair, lock by lock, to pick off head lice? So miserable that some parents are buying $30 shampoos and other washes that promise to ward off the tiny, grayish bugs.\n\nThe parents get peace of mind that they are doing something. Conveniently for the product makers, there's no way to tell if they kept lice at bay, or if children wouldn't have gotten lice anyway. Makers say sales are growing fast.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Excellent sourcing.", "answer": 1}, {"article": "The researchers found that overall 30-day mortality decreased from 1.6 percent (84 of 5,275 patients) to 0.7 percent (26 of 3,878 patients) after FSI implementation.\nOn the basis of this review, clinicians from surgery, anesthesia, critical care, and palliative care were notified of the patient\u2019s frailty and associated surgical risks; if indicated, perioperative plans were modified based on team input.\nIt also suggests the potential to improve postoperative survival among the frail through systematic administrative screening, review, and optimization of perioperative plans.\nThe absolute reduction in 180-day mortality among frail patients was more than 19 percent, with improvement remaining robust even after controlling for age, frailty, and predicted mortality.\u201d\n\n: This investigation was supported by a grant from the U.S. Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development.\n\u201cThe ultimate cause of the survival benefit is likely multifactorial, including changes in preoperative decision making, intraoperative management, and postoperative rescue,\u201d the authors write.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We learn that the study \u201cwas supported by a grant from the U.S. Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development. We did not detect any conflicts of interest that should have been disclosed.", "answer": 1}, {"article": "Mango consumption helped relax blood vessels in as little as two hours after intake.\nThe honey mango (also referred to as Ataulfo) was chosen for the study due to the high concentration of polyphenols in this popular variety.\n\"Our results build on previous animal and cell studies that point to the potential benefits of mangos to promote health.\"\nMangos contain a mix of polyphenols, including mangiferin, quercetin, gallotannins, and gallic acid, that have been the focus of previous investigations exploring the potential health-protecting properties of mangos.\nSix of the 24 participants produced methane, and of these six, three shown significant reduction after consuming mango, which is considered a favorable outcome for gut health.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release clearly notes that the research was partially funded by the National Mango Board. We were unable to access the published study to check whether any conflicts of interest were disclosed.", "answer": 1}, {"article": "Some people do need supplements.\n\u201cThe public has been receiving very confusing and alarming messages about calcium supplements,\u201d says JoAnn Manson, a professor of medicine at Harvard Medical School and chief of preventive medicine at Brigham and Women\u2019s Hospital, Boston.\nA second, wider-ranging study found no heart risks and was the basis of new guidelines from two medical groups saying that calcium supplements should be considered heart safe.\nAmong others who might need a boost: Vegans, people with lactose intolerance and anyone who, for whatever reason, does not consume enough calcium, says Taylor Wallace, an affiliate professor of nutrition at George Mason University in Fairfax, Va., and a co-author of the new cardiovascular statement.\nBut the study, published in the Journal of the American Heart Association, was not designed in a way that could prove the supplements caused the artery changes.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This is a strong point. The story not only incorporates input from multiple sources, but clearly identifies any affiliation that could be perceived as influencing their perspective (e.g., noting that one source wrote an editorial that was published in conjunction with the JAHA paper). In addition, the story clearly notes that the meta-analysis was done with support from a pharmaceutical company that manufactures calcium supplements.", "answer": 1}, {"article": "Among the children born during the study, Pan and his colleagues found no significant differences between the tenofovir-treated group and the control group with regard to fetal development and infant growth.\n\u201cWe believe that these findings will not only save many lives, but could also help to eradicate hepatitis B nationally and abroad.\u201d\n\nThe study was conducted in five locations in China, where HBV infection is endemic.\nThe study focused on the most common way that children become infected with hepatitis B, an incurable viral infection that causes liver disease and cancer, which is through infection during the perinatal period.\n\u201cPreventing mother-to-child transmission is the most effective way to reduce the global burden of chronic hepatitis B infection and liver cancer,\u201d says Calvin Pan, MD, lead author of the study and a clinical professor of medicine at NYU Langone.\n\u201cThis study provides strong evidence on how best to care for women infected with hepatitis B during pregnancy and reduce the rate of disease transmission,\u201d says Mark Pochapin, MD, the Sholtz/Leeds Professor of Gastroenterology and director of the Division of Gastroenterology and Hepatology at NYU Langone.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that the research is funded by Gilead Sciences. It should also have mentioned that a corresponding author disclosed speaking and advising fees from Gilead, according to the published study.", "answer": 0}, {"article": "She worries about the small chance of benefit in light of the larger chance of finding and treating a cancer that did not need to be treated.\n\u201cWe were surprised,\u201d said Dr. Mette Kalager, the lead author of the paper who is a breast surgeon at University and a visiting scientist at the Harvard School of Public Health.\nThe decision to be screened, she says, \u201cis a matter of personal preference.\nIn the study, which is continuing, women were followed for a maximum of 8.9 years.\nAnd, starting in 1996, Norway began offering mammograms to women ages 50 to 69 and assigning multidisciplinary treatment teams to all women with breast cancer, similar to the teams at many major medical centers in the .\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\nThe story includes comments from several independent sources offering a variety of perspectives. It does not mention that the study was funded by the Cancer Registry of Norway and the Research Council of Norway.", "answer": 1}, {"article": "The study did not follow people over time.\nThe use of replacement products made no difference, whether they were taken for the recommended two-month period (they usually were not), or with the guidance of a cessation counselor.\nThe researchers argue that while nicotine replacement appears to help people quit, it is not enough to prevent relapse in the longer run.\nDr. Fiore, who has reported receiving payments from drug makers, said that \u201cthere are millions of smokers out there desperate to quit, and it would be a tragedy if they felt, because of one study, that this option is ineffective.\u201d\n\nIn the new study, conducted in , the researchers followed a representative sample of 1,916 adults, including 787 people who said at the start of the study that they had recently quit smoking.\nThey interviewed the participants three times, about once every two years during the 2000s, asking the smokers and quitters about their use of gum, patches and other such products, their periods of not and their relapses.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This is the only one of the three stories we reviewed that did not quote someone directly connected to GlaxoSmithKline, the maker of some of the best selling tobacco replacement products. Several independent sources were quoted.", "answer": 1}, {"article": "However, oral pills cause side effects such as bleeding between periods, mood swings and nausea in women.\n\u201cThese results pave the way for Amphora\u2019s disruption of the contraception market as a novel, highly effective, non-hormonal and woman-controlled method that finally answers women\u2019s long-awaited desire to avoid hormones,\u201d Roth Capital Partners analyst Yasmeen Rahimi said.\n\u201cOur research and current understanding of women suggests the time is now for there to be a new non-hormonal category in contraception,\u201d Chief Executive Saundra Pelletier said on a conference call with analysts.\n(Reuters) - Shares of Evofem Biosciences Inc jumped as much as 38 percent on Monday after its birth control gel showed effectiveness in a late-stage study, bringing the first hormone-free contraceptive close to approval.\nThe company plans to resubmit the marketing application for Amphora in the second quarter next year and if approved, plans to launch the product in January 2020.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "With a new birth control product, we\u2019d like to see comments from independent physicians or researchers that are experts in the field\u2013and we think this is something investors would value seeing, too. However, this story quotes the CEO of the product\u2019s maker, as well as two business analysts.", "answer": 0}, {"article": "It\u2019s easy to get into the habit of popping a pill to have a good night\u2019s sleep. Insomnia, which affects a third of adults, becomes more common as we age.\n\nBut as evidence has mounted about the risks of drugging the brain to induce or maintain slumber, more doctors are steering patients away from sleep aids, including over-the-counter medications, and are offering innovative behavioral-change solutions.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story had several independent sources and we detected no conflicts of interest.", "answer": 1}, {"article": "Botox is now being used by men, some of whom did not even run for President. The number of men in the U.S. who paid to get a series of tiny injections in their face nearly tripled from 2001 to 2007--to 300,000, or about 7% of the total Botoxed population. And despite the recession, those numbers aren't going down yet; one of the many things the laid-off cannot afford is to look their age.\n\nMen usually get Botox to remove those two vertical lines between their eyebrows that make them look angry and confused and thus, one could argue, masculine. They...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites statistics showing increased use among males, but cites no source. \nThe reporter interviewed one enthusiastic practitioner who services Hollywood stars, an enthusiastic paid celebrity spokesman, one enthusiastic patient and his even more enthusiastic wife. \nNo dissenting voice, even a comic one, is included.\u00a0 ", "answer": 0}, {"article": "Neck pain was assessed by the Northwick Park Questionnaire (NPQ) at 3, 6, and 12 months.\nAcupuncture is a procedure in which patients have thin needles inserted into specific points on the body to relieve pain and the Alexander Technique is an educational process that teaches people how to avoid unnecessary muscular and mental tension in everyday activities.\nBoth acupuncture and Alexander Technique prove effective for long-term relief of chronic neck pain\n\nIn a randomized, controlled trial, both acupuncture and the Alexander Technique led to long-term significant reductions in neck pain and associated disability compared with usual care alone.\nTo speak with the lead author, Dr. Hugh MacPherson, please contact David Garner at david.garner@york.ac.uk or +44 (0) 1904 322153.\nIn addition, persons with chronic neck pain often seek complimentary care to manage their condition, such as acupuncture or the Alexander Technique.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release does not disclose funding sources for the study. In addition, the study was more transparent than the release in disclosing\u00a0potential\u00a0conflicts of interest. Two of the authors of the original study, Drs. Woodman and Ballard, are both on the Society of Teachers of the Alexander Technique and contributed toward obtaining funding for the study. Coincidentally, all practitioners recruited in the study for the Alexander Technique came from the same society. The fact that the study authors and practitioners were all closely allied with the Alexander Technique was worth disclosing to readers, especially journalists, who were relying on the release.", "answer": 0}, {"article": "\"Research has shown that subtle markers of autism are identifiable in the first year of life,\" explained Dr. Ron Marino, associate chair of pediatrics at Winthrop-University Hospital in Mineola, N.Y. \"Video feedback seems like a natural and potentially very potent extension of intervention when it can be most effective,\" he added.\nThe goal of the therapy -- delivered over five months while the infants were ages 7 to 10 months -- was to improve the infant's attention, communication, early language development, and social engagement.\nSome of the families were assigned to a therapy program in which a therapist used video feedback to help parents understand and respond to their infant's individual communication style.\nAfter five months, infants in the families in the video therapy group showed improvements in attention, engagement and social behavior, according to the study published Jan. 22 in The Lancet Psychiatry.\nThose studies \"will need to include a larger, more diverse sample population and need to look at developmental outcomes over a much longer period of time.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We commend the story for including interviews with the lead author of the study as well as two experts who appeared to be unaffiliated with the research. However, only a sentence would have been needed to alert readers to the fact that the funders of the research included autism advocacy groups.", "answer": 0}, {"article": "The regular use of statins was associated with a 42% reduction in rheumatoid arthritis (RA) risk in a newly reported study of patients enrolled in one of Israel's largest health plans .\nThere is also a suggestion that statins reduce systemic inflammation and may be protective against RA and other chronic inflammatory diseases.\nSeveral studies have suggested a role for statins in slowing the progression of disease among patients with rheumatoid arthritis, but others failed to find a protective benefit for statin use.\nThe analysis revealed that patients who took statins for at least eight years during the decade-long study period were roughly 40% less likely to develop rheumatoid arthritis than people who did not take statins at all or who took them less persistently.\nBetween 1998 and 2007, 2,578 new cases of rheumatoid arthritis were identified in this group.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\nThe story includes comments from an independent source. Although the story does not mention any potential conflicts of interest, none were disclosed by the study authors.", "answer": 1}, {"article": "New research is helping Pfizer Inc. build a case for getting an important drug in its portfolio approved to treat a mysterious pain condition that could offer a big additional source of sales.\n\nThe New York drug maker said Tuesday that Lyrica, already on the market to treat certain types of pain, reduced painful symptoms among sufferers of fibromyalgia, a chronic and controversial condition that may affect as many as six million Americans. And today, it will unveil results from another study that it says shows Lyrica has a lasting...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent experts are quoted.\u00a0 The story appears to rely heavily on Pfizer input:\u00a0", "answer": 0}, {"article": "NEW ORLEANS \u2014 Eighty-year-olds with clogged arteries or leaky heart valves used to be sent home with a pat on the arm from their doctors and pills to ease their symptoms.\nThe answer: Average survival was roughly six years \u2014 almost the same as similarly aged people who do not have heart disease.\nThis improved dramatically as the study went on, from 85 percent in the early years to 98 percent by its end.\nBut today \u201cwe have elderly folks who are extremely viable\u201d who want to decide for themselves whether to take the risk, he said.\nThat led more doctors to operate on older patients for everything from bum knees to bad backs.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included comments from individuals involved in the study reported on. \u00a0It failed to provide insight from experts who could comment objectively about the results of the study.", "answer": 0}, {"article": "In the past couple of years a couple of brands have figured out the right angle \u2014 electrolytes and hydration.\u201d\n\nCraven estimated the coconut-water market at about $100 million annually right now, but companies are doubling their sales year after year.\nI was meeting with a cardiologist recently, and he said he doesn\u2019t advise (coconut oil) for any clients.\u201d\n\nThe fat issue is complicated by the types of fatty acids found in coconut, versus other saturated fats.\n\u201cIt\u2019s trickling down to the mass market.\u201d\n\nThe company is growing so quickly, he said, it had to hunt for coconuts from outside of Brazil, where it previously harvested most of its fruit.\n\u201cThe volume is going through the roof,\u201d said Laura Sauls, a spokeswoman for Hermosa Beach, Calif.-based Zico.\n\u201cDemand has increased exponentially, primarily in mainstream groceries like Walmart and Costco,\u201d said Arthur Gallego, a spokesman for the New York-based Vita Coco.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes a lot of people. Unfortunately, most of them are connected to the sales or marketing of coconut products in some way.\u00a0Daniel Fabricant, vice president for government and scientific affairs at the Natural Products Association, a trade association in Washington says coconut products have everything a healthy consumer would want. \u201cIt\u2019s a holistic approach.\u201d\u00a0\u201cIt\u2019s an effective drink for rehydration that doesn\u2019t bring in the added sugars and the additives,\u201d says Dani Little, dietitian for a Whole Foods Market in Boulder. Also quoted are:\u00a0John Craven, the founder of Bevnet.com, a trade publication for the beverage industry.\u00a0Arthur Gallego, a spokesman for the New York-based Vita Coco;\u00a0Laura Sauls, a spokeswoman for Hermosa Beach, Calif.-based Zico and\u00a0Kevin Conrad, a sales executive with GoFast, a Denver energy drink that now includes a version containing coconut-water concentrate.That leaves just\u00a0Jessica Crandall, a Denver dietitian who is president of the Colorado Dietetic Association. The closest we get to any medical sources is Crandall saying that she \u201cwas meeting with a cardiologist recently, and he said he doesn\u2019t advise (coconut oil) for any clients.\u201d Note the use of the word \u201cclients.\u201d Everyone is being sold coconut oil or not sold something in this story. The last word goes to a Whole Foods executive. \u201cIt\u2019s healthy \u2014 and simple, too. That\u2019s one of the attractions, said Tom Rich, who is in charge of grocery operations for Whole Foods Rocky Mountain region.\u00a0\u201cIt\u2019s something you don\u2019t have to figure out,\u201d he said. \u201cPeople know what it is and where it grows. It\u2019s simple all the way around.\u201d \u201c", "answer": 0}, {"article": "They all drank caffeine regularly.\nWe are able to point, with a much higher resolution picture, at aging and the things that should be markers for inflammation.\u201d\n\nThe key will be to figure out when the inflammatory response starts to spiral out of control.\n\u201cThere was no boundary, apparently.\u201d\n\nIn the study, Furman and his colleagues analyzed blood samples from 100 young and old people.\n\u201cThe more caffeine people consumed, the more protected they were against a chronic state of inflammation,\u201d says study author David Furman, consulting associate professor at the Institute for Immunity, Transplantation and Infection at Stanford University.\nIn an upcoming study, Furman and others will soon investigate the immune systems of 1,000 people; he hopes to use that information to develop a reference range of immune-system components to tell people whether their levels are normal, or if they\u2019re at higher risk for developing chronic conditions driven by inflammation.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes only researchers associated with the study and does not tell readers who funded the work. In this case, all of the funding appears to come from well-regarded research institutions, such as NIH and the Howard Hughes Medical Institute. Input from third-party experts may have helped better place the findings in context.", "answer": 0}, {"article": "Both countries have tried to make it easier to be tested.\nWhen asked if any test similar to BioSure\u2019s new take-home test was in development, Tara Goodin, a press officer for the Food and Drug Administration, said: \u201cThe FDA cannot confirm the existence of or comment on any current/pending product applications.\u201d\n\nThe FDA has approved two take-home HIV tests, but neither has all the strengths of the BioSure test.\nIt adjusted the raw data to mirror the demographics of the U.K. as a whole and estimated that in 2012, 22 percent of all residents with HIV were undiagnosed.\nAnd because the incidence of other sexually transmitted infections declined for these men, after the diagnosis, the scientists had reason to believe the self-reports of condom usage were accurate.\nOraQuick, on the other hand, is an oral-based at-home test that does let users see their results immediately, but it has an 8.3 percent chance of a false negative.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources identified in this story. That would be ok for an op-ed, which is how this story reads. But the byline is from a news writer, so our standard of at least one independent source applies here. Again, the independent studies reported on did not actually look at self-testing at home.", "answer": 0}, {"article": "Strokes had a higher impact on the patient\u2019s quality of life, the study reported.\nThe European trial, which included 1,713 patients randomly assigned to either stent or endarterectomy, found that stent patients were at much higher risk of stroke, death or heart attack in the first 30 days after surgery, with 7.4 percent suffering one of these adverse events, compared with 4 percent of the surgery group.\n\u201cPrior to the Crest trial, we really did not have the best evidence, but these results indicate that we have two very safe and effective methods to prevent stroke.\u201d\n\nThough there are differences in risk between the two procedures and individual variations, he said, \u201cthe results from stenting are very comparable to those for carotid surgery.\u201d\n\nBut Dr. Martin M. Brown, chief investigator for the European trial, the International Carotid Stenting Study, said that although differences in the groups studied might explain the disparate results, \u201cnobody has really shown stenting is better than surgery, so why choose a stent?\u201d\n\nDr. Brown added, \u201cEven if Crest shows little difference between the two, there are three other trials that suggest surgery is safer.\u201d\n\nStrokes are the third leading cause of death in the United States and a major cause of disability among adults.\nLong-term follow-up of patients, which was two and a half years on average but is continuing, found both groups at equal risk of suffering a stroke that should have been prevented by the procedure: 2 percent of those in the stent group compared with 2.4 percent of the surgical patients.\nThe most important message is that the overall death rate was extremely low, 0.6 percent, said one of the study\u2019s principal investigators, Dr. Gary S. Roubin, the chairman of cardiovascular medicine at Lenox Hill Hospital in New York.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "It would have been nice to see some perspective from someone who was in no way affiliated with either of these studies\u2013something which the LA Times, in its defense, did provide in its coverage. Nevertheless, in the hierarchy\u00a0of sourcing priorities, we felt it was most important that the\u00a0coverage include some kind of European perspective to counterbalance the American voices advocating for stents. The New York Times managed to get a hold of the lead investigator for\u00a0the European ICSS trial. He made a\u00a0pretty good case for why one might think twice before\u00a0opting for a stent instead of open surgery.\u00a0\u00a0", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061008/16organ.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although several sources are quoted, all of them have some connection to organ swapping and all of them praise it. It\u2019s not clear if the reporter sought any independent opinion from physicians not directly tied to organ-swapping transplant efforts. The story does not obtain any perspective from someone who may think organ swapping may violate current laws, which is the reason stated for needing clarifying legislature. ", "answer": 0}, {"article": "For more information, visit http://www.\nThe Journal of Medical Entomology is published by the Entomological Society of America, the largest organization in the world serving the professional and scientific needs of entomologists and people in related disciplines.\nIn order to test the effectiveness of the device, Christopher Bibbs and Rui-De Xue of the Anastasia Mosquito Control District in Florida studied how the device performed against hungry Aedes aegypti mosquitoes.\n\"Just look at all the bug zappers, repellent bracelets, sonic bug repellents, and other zany creations that wax and wane in popularity.\n\"In vector control, we see more often than not that tools available for consumers don't work for the intended purpose,\" said Bibbs.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We wish the release was more clear about sponsorship. The release doesn\u2019t explicitly say who funded the study but the implication is that it was sponsored by the Anastasia Mosquito Control District in Florida. An acknowledgement in the study states that readers shouldn\u2019t view the study as a product endorsement. \u201cThis is a research report only and mention of specific names of commercial products does not imply endorsement by the Anastasia Mosquito Control District.\u201d", "answer": 0}, {"article": "\"If a cell phone company told you they tested all the models and their model came out the best, would you believe it?\nAccording to a study by the FTC, this halo effect can even lead people to overlook warning statements -- about the high sodium content of a product, for example.\nThat's the paradox of products such as POM, Silverglade says: The health claims on these products strain the imagination, yet studies have repeatedly shown that health claims sell food.\nOne of the most prominent claims, that POM can decrease arterial plaque by 30 percent, was taken from a single pilot study that included just 19 people and was funded by the makers of POM.\nHealth.com: 25 diet-busting foods you should never eat\n\nNot all of the products were drinks, but \"the beverage category stands out,\" says Bruce Silverglade, director of legal affairs at the Center for Science in the Public Interest, a consumer advocacy group based in Washington, D.C. \"At first blush it seems that beverage products are certainly a large proportion of food products that make bogus health-related claims.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The diversity of voices in this story is a strong point. We hear from consumer advocates, industry and independent researchers, as well nutrition experts. One quibble is that comments from the industry-funded researchers are relegated to the very end of the story and they are made to sound like shills for POM. There\u2019s nothing inherently wrong with industry-funded research, and these researchers can\u2019t necessarily be held responsible for how the funding company\u00a0portrays\u00a0their findings. Whether pomegranate juice\u00a0has health benefits is a question worth exploring; the problems arise\u00a0when companies\u00a0oversell or\u00a0distort the\u00a0results.", "answer": 1}, {"article": "In an average follow-up of five years, they found that the rate of unusable donor kidneys and the long-term outcomes of recipients varied little among the first three age groups \u2014 around 18 percent of the organs had to be discarded, and the five-year survival was about 88 percent\nOld age is not necessarily a barrier to kidney donation.\nThe study is in the Clinical Journal of the American Society of Nephrology.\nRecipients were at most seven years older or younger than the donors.\nItalian researchers retrospectively studied 647 kidney transplants, grouping the donors according to whether they were in their 50s, 60s, 70s or 80s.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The post included no independent sources.", "answer": 0}, {"article": "Co-authors on the paper, all from Boston University, are T.A.\nThe UV LED device also emits a much narrower band of UVB light and thereby decreasing likelihood of skin damage that can occur when the skin is exposed to higher wavelengths of UV radiation.\n\"We tested ultraviolet LEDs from different sources and at different wavelengths.\nThanks to the work of the research team and the pioneering work of the Boston University Photonics Center on UV LEDs, we may soon see innovative treatment options like simple integration with a wearable device could aid millions of people.\"\n\"Dr. Holick's research with our UVB LEDs demonstrates the potential for new applications that can potentially improve and save hundreds of thousands of lives.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release discloses the study\u2019s funding sources, which include the Boston University School of Medicine and a Boston University Ignition Award.\nThe original journal article states the study authors have no competing interests.\nWe rate this one Satisfactory.", "answer": 1}, {"article": "Of these, 40% (574) were nulliparous women, 870 (60%) women completed 3 years of the study, 707 (49%) elected to enroll in an extension phase up to a total of 5 years, and 550 (38%) completed 5 years of use.\nThe clinical trial had no upper or lower weight or BMI limit.\nFor the first 3 to 6 months, a woman's period may become irregular and the number of bleeding days may increase.\nKyleena is available by prescription only.\nIf Kyleena comes out, use back-up birth control.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release is clearly marked as being from the manufacturer of Kyleena.", "answer": 1}, {"article": "And Maxwell stressed that their preliminary findings need to be replicated in the future.\n\"We would wish to point out that, at the moment, that our findings are preliminary, and would not recommend that patients drink alcohol with the specific purpose of treating their arthritis,\" said Dr. James Maxwell, lead author of the study and a consultant rheumatologist at The Rotherham NHS Foundation Trust in England.\nBecause the researchers assessed drinking frequency, rather than the amount of alcohol consumed, it is not clear how much alcohol might be helpful, they said.\n\"There's a little information that alcohol can suppress the immune system,\" added Fiocco.\nThe benefit of ethanol exposure for these rodents seemed to be due to higher levels of testosterone, the researchers wrote.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One apparently independent expert was quoted. \u00a0 We weren\u2019t told why he was quoted or whether he was involved in the research. But he\u2019s not listed as an author of the study, so we\u2019ll give the story the benefit of the doubt \u2013 by a hair.\u00a0 ", "answer": 1}, {"article": "TUESDAY, March 29, 2011 (HealthDay News) -- A minimally invasive treatment for enlarged prostate that limits blood supply to the prostate seems to be just as effective as surgery but without the risk of debilitating side effects, such as impotence and urinary incontinence.\nCurrent surgical procedures typically require no more than one night in the hospital and complications such as incontinence and impotence are uncommon, he said.\nThe procedure is performed under general anesthesia and involves a hospital stay.\nOther minimally invasive treatments for enlarged prostate that are currently available are less effective and have a greater risk of a need for reoperation, according to background materials that accompanied the study.\nAfter nine months, none had experienced sexual dysfunction and 25 percent still reported improvements.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Clinicians with expertise in treating benign prostatic hyperplasia and without apparent ties to the study reported on were quoted in this story.", "answer": 1}, {"article": "\"Doctors are already doing these [glucose and HbA1c] tests together -- if a patient is obese, for example, and has other risk factors for diabetes, the physician is likely to order tests for both glucose and HbA1c from a single blood sample.\nThe study began in the 1980s, and along the way has recorded valuable data from participants, including diabetes test data.\nBut taking the test twice takes up time and money and could still result in missed diagnoses, said a team from the Johns Hopkins Bloomberg School of Public Health in Baltimore.\nThe new study \"helps us move quicker to treat diabetes,\" he said.\nThis could change care, \"potentially allowing a major simplification of current clinical practice guidelines,\" Selvin said in a university news release.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story tapped independent diabetes experts.\nWhile the study was funded by government grants, one of the authors disclosed grants and personal fees from industry, unrelated to the study.", "answer": 1}, {"article": "FRANKFURT (Reuters) - Merck KGaA said that its immunotherapy Bavencio, jointly developed with Pfizer, delayed the progression of kidney cancer when used in combination with Pfizer\u2019s Inlyta drug in a late-stage study.\n\nThe drug combination led to longer progression-free survival in patients with advanced renal cell carcinoma (RCC) when compared with a control group on older Pfizer drug Sutent, the German drugmaker said in a statement on Tuesday.\n\nThe trial will continue to show whether Bavencio plus Inlyta also prolongs patients\u2019 lives.\n\nWhile the company said the benefit was statistically significant, they did not specify the duration of progression-free survival. A detailed analysis would be submitted for presentation at a medical congress, it added.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does make clear that the information about the ongoing study came from a company that makes one of the relevant drugs. That\u2019s good. However, the story does not incorporate input from any independent sources.", "answer": 0}, {"article": "The ACC leads in the formation of health policy, standards and guidelines.\nBecause the study involved women who received both mammography and CT scan for clinical indications, these women may have been more likely than the average woman to have coexisting conditions, although Hecht said these were unrelated to heart disease.\n\"The message is if a woman is getting a mammogram, look for breast arterial calcification.\nIt's a freebie and provides critical information that could be lifesaving for some women,\" Hecht said, adding he hopes these findings will prompt clinicians, who rarely report breast arterial calcification, to routinely report not just the presence or absence of breast arterial calcifications but also to estimate and note the amount.\n\"The more breast arterial calcification a women has, the more likely she is to have calcium in her heart's arteries as well.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release states that the Flight Attendants Medical Research Foundation was a partial funder. We aren\u2019t told who else sponsored the research or if there were any potential conflicts of interest.", "answer": 1}, {"article": "Strawberries have the potential to prevent esophageal cancer, according to a preliminary study released Wednesday.\n\nResearchers, led by Ohio State University, were able to show that freeze-dried strawberries slowed the growth of dysplastic, or precancerous, lesions in about 30 people who consumed the fruit for six months.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent source is cited.", "answer": 0}, {"article": "The U.S. Food and Drug Administration approved the first therapy to treat an underlying cause of cystic fibrosis, a pill that targets a genetic mutation affecting a small minority of patients suffering from the life-threatening breathing disorder.\n\nThe drug, Kalydeco, from Vertex Pharmaceuticals Inc., will be among the most expensive therapies on the market, costing $294,000 a year.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There was no independent medical expert interviewed for the story.\u00a0 The story also quoted the same patient we saw profiled in other stories.\u00a0 Did the drug company provide access to her for all who quoted her?", "answer": 0}, {"article": "AstraZeneca PLC's cholesterol drug Crestor sharply lowered risk of heart attacks among apparently healthy patients in a major study that challenges longstanding heart-disease prevention strategies. The findings could substantially broaden the market for statins, the world's best-selling class of medicines.\n\nHeart experts said the findings, presented Sunday at the annual scientific meeting of the American Heart Association in New Orleans, could reshape cholesterol-treatment guidelines used for more than a decade to fight cardiovascular...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included comments from several individuals who were not involved in the study and provided some cautionary perspective about the implications of the study. \u00a0And while this piece relied heavily on comments from Dr. Ridker, the story did mention that he was an inventor of the test for CRP was also the recipient of funding from the manufacturer of the study drug.", "answer": 1}, {"article": "Fear of doctors, the prospect of being poked and prodded in strange places, a lack of insurance to cover the costly test -- or a combination of all three -- are to blame for as many as half of the over-50 crowd putting off or avoiding the screening test altogether.\nThey then created techniques for detecting the DNA change when it expelled from the body in feces.\nIt will be geared toward use in the privacy of one's home.\nAnd you've probably heard about how early screening means early detection and removal of polyps before they turn into cancer.\nNot since 1998, when the FDA approved the PSA test for early detection of prostate cancer, had new technology been created in early cancer detection until the stool DNA test.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only source cited in the news story is the researcher whose team developed the stool DNA test. There are no independent sources.", "answer": 0}, {"article": "\"The approach we used here could be applied to any number of other conditions, and may reveal new and important uses for thousands of already approved drugs, without large investments in additional clinical trials,\" Makunts said.\nThe research team focused on patients in the database who received ketamine, narrowing their study population down to approximately 41,000.\nFor financial and ethical reasons, ketamine has never been tested for its safety and effectiveness in treating depression in a large-scale clinical trial, but it reportedly works much more rapidly than standard antidepressants.\nThey applied a mathematical algorithm to look for statistically significant differences in reported depression symptoms for each patient.\nThe researchers hypothesize that the antidepressant effects of diclofenac and minocycline may be due, at least in part, to their abilities to reduce inflammation.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release names the funder, not in the release text itself but on the EurekaAlert! website which hosts the news release.", "answer": 1}, {"article": "But then a few years later she started noticing something interesting.\n\"There hasn't been much action in this area, and that certainly has to come up when a company is thinking about dumping money into researching a drug for female sexual dysfunction,\" says Phyllis Greenberger, president of the Society for Women's Health Research, which received money from Boehringer Ingelheim, the company that makes flibanserin.\nYou can find a practitioner through the National Certification Commission for Acupuncture and Oriental Medicine, or if you prefer a medical doctor, visit the website of the American College for Advancement in Medicine, where you can put in your ZIP code and find a doctor who specializes in integrative medicine.\nThe greatest hope for a so-called \"female Viagra\" was a drug called flibanserin, but it was nixed by a panel of Food and Drug Administration experts on Friday, who said the drug didn't seem to really help women with sexual dysfunction.\nIn 2008, a survey of more than 30,000 U.S. women in the journal Obstetrics & Gynecology found that nearly 40 percent reported that they'd had a sexual problem at some point in their lives, most often a lack of desire.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "When there are two sides to an issue, it\u2019s not enough to source a story with three views from the same side, as this story did. While it is undeniable that many patients find great comfort and benefit from alternative medicine approaches\u00a0such as those discussed in this article, it is equally clear that many of these treatments have very little\u00a0evidence to support their use, and have the potential to cause harm. Of course, the same is true for many \"conventional\" medical practices, which is why we always think it\u2019s a good idea to include at\u00a0least one truly independent source to comment on claims made in a health story. \u00a0", "answer": 0}, {"article": "Yin Cao, an instructor in the Medicine, Clinical and Translational Epidemiology Unit at Massachusetts General Hospital and Harvard Medical School, presented the information Monday at the American Association for Cancer Research meeting in Washington.\n\"This study found strong evidence that aspirin use may reduce cancer death.\nThe study was well conducted and was able to control for a number of important confounders.\nEven the ancient Egyptians used the natural form of it for pain relief centuries ago.\nMen's risk of dying from lung cancer was also lower.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources in this story.", "answer": 0}, {"article": "TUESDAY, March 13, 2018 (HealthDay News) -- A pill that combines three blood pressure-lowering drugs improves people's chances of lowering their high blood pressure, researchers report.\nAll had high blood pressure.\nThe findings, she said, \"should prompt reconsideration of recommendations around the use of combination therapy.\"\nThe rate of side effects was no greater among those who took the three-in-one pill than among the usual care group.\nUsual care meant taking whatever blood pressure medicine their doctor prescribed.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources in the story.", "answer": 0}, {"article": "PERMP was not measured in the SHP465-305 study.\nThe risks and uncertainties include, but are not limited to, the following:\n\u2022 the proposed combination with Baxalta may not be completed due to a failure to satisfy certain closing conditions, including any shareholder or regulatory approvals or the receipt of applicable tax opinions;\n\u2022 disruption from the proposed transaction with Baxalta may make it more difficult to conduct business as usual or maintain relationships with patients, physicians, employees or suppliers;\n\u2022 the combined company may not achieve some or all of the anticipated benefits of Baxalta's spin-off from Baxter International, Inc. (\"Baxter\") and the proposed transaction may have an adverse impact on Baxalta's existing arrangements with Baxter, including those related to transition, manufacturing and supply services and tax matters;\n\u2022 the failure to achieve the strategic objectives with respect to the proposed combination with Baxalta may adversely affect the combined company's financial condition and results of operations;\n\u2022 products and product candidates may not achieve commercial success;\n\u2022 product sales from ADDERALL XR and INTUNIV are subject to generic competition;\n\u2022 the failure to obtain and maintain reimbursement, or an adequate level of reimbursement, by third-party payers in a timely manner for the combined company's products may affect future revenues, financial condition and results of operations, particularly if there is pressure on pricing of products to treat rare diseases;\n\u2022 supply chain or manufacturing disruptions may result in declines in revenue for affected products and commercial traction from competitors; regulatory actions associated with product approvals or changes to manufacturing sites, ingredients or manufacturing processes could lead to significant delays, an increase in operating costs, lost product sales, an interruption of research activities or the delay of new product launches;\n\u2022 the successful development of products in various stages of research and development is highly uncertain and requires significant expenditures and time, and there is no guarantee that these products will receive regulatory approval;\n\u2022 the actions of certain customers could affect the combined company's ability to sell or market products profitably, and fluctuations in buying or distribution patterns by such customers can adversely affect the combined company's revenues, financial condition or results of operations;\n\u2022 investigations or enforcement action by regulatory authorities or law enforcement agencies relating to the combined company's activities in the highly regulated markets in which it operates may result in significant legal costs and the payment of substantial compensation or fines;\n\u2022 adverse outcomes in legal matters and other disputes, including the combined company's ability to enforce and defend patents and other intellectual property rights required for its business, could have a material adverse effect on the combined company's revenues, financial condition or results of operations;\n\u2022 Shire is undergoing a corporate reorganization and was the subject of an unsuccessful acquisition proposal and the consequent uncertainty could adversely affect the combined company's ability to attract and/or retain the highly skilled personnel needed to meet its strategic objectives;\n\u2022 failure to achieve the strategic objectives with respect to Shire's acquisition of NPS Pharmaceuticals Inc. or Dyax Corp. (\"Dyax\") may adversely affect the combined company's financial condition and results of operations;\n\u2022 the combined company will be dependent on information technology and its systems and infrastructure face certain risks, including from service disruptions, the loss of sensitive or confidential information, cyber-attacks and other security breaches or data leakages that could have a material adverse effect on the combined company's revenues, financial condition or results of operations;\n\u2022 the combined company may be unable to retain and hire key personnel and/or maintain its relationships with customers, suppliers and other business partners;\n\u2022 difficulties in integrating Dyax or Baxalta into Shire may lead to the combined company not being able to realize the expected operating efficiencies, cost savings, revenue enhancements, synergies or other benefits at the time anticipated or at all; and other risks and uncertainties detailed from time to time in Shire's, Dyax's or Baxalta's filings with the Securities and Exchange Commission (\"SEC\"), including those risks outlined in \"ITEM 1A: Risk Factors\" in Shire's and Baxalta's Annual Reports on Form 10-K for the year ended .\nThe completion of SHP465-305 addresses an FDA requirement to evaluate the safety and efficacy of SHP465 in children and adolescents prior to filing a Class 2 resubmission of the medicine for FDA approval.\nDr. Matthew Brams, M.D., Clinical Assistant Professor at Baylor College of Medicine and principal investigator for study 305, added: \"The study of SHP465 in children and adolescents is an essential next step to progressing the clinical program.\n\"We are pleased with the positive results of the SHP465-305 study,\" said Philip J. Vickers, Ph.D., Head of Research & Development, Shire.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "It\u2019s clear that the drug sponsor issued the news release and sponsored the study. We\u2019re provided a quote from the study\u2019s principal investigator (PI), Matthew Brams, an assistant professor at Baylor College of Medicine, but we\u2019re not told what financial arrangements the PI had with Shire. According to ProPublica\u2019s \u201cDollars for Docs\u201d database, Brams (one of ProPublica\u2019s designated top earners of speaking and consulting fees from drug companies) has received payments for serving as a consultant for Shire. That\u2019s a disclosure we\u2019d like to see in the news release.", "answer": 0}, {"article": "MONDAY, July 6, 2015 (HealthDay News) -- A scan of calcium deposits inside your arteries can help doctors deduce how long you're likely to live, a new study has found.\n\"This is not a new test, but these results emphasize the importance of looking at this marker in addition to the traditional risk factors,\" said Dr. William Zoghbi, past president of the American College of Cardiology and head of cardiovascular imaging for Houston Methodist Hospital.\n\"If you had no calcium or very small amounts, we were able to track over a very long time that you actually had a very outstanding survival,\" Shaw said.\nIn this new study, doctors referred 9,715 healthy patients in the Nashville area between 1996 and 1999 to a cardiology outreach screening program provided by the military's Tricare Healthcare System.\nThe results of a calcium scan can be reassuring for people with few or no calcium deposits, and can provide people with high calcium levels with added impetus to take better care of themselves, Shaw said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story goes a long way toward satisfying this criterion by including comments from an expert who was not connected to the research. But it fails to tell readers that some of the researchers receive funding from General Electric Healthcare, which sells scanners used for CAC tests, or from pharmaceutical companies who stand to garner more patients if CAC testing is expanded.", "answer": 0}, {"article": "(Edmonton, AB) Groundbreaking research from the University of Alberta and McGill University has opened the door towards the future prevention of cardiac fibrosis--a condition leading to heart failure for which there is currently no treatment.\nThis research was supported by the Canadian Institutes of Health Research.\nInevitably it leads to heart failure and eventually death.\nFibrosis is an early step on the path to heart failure.\nThe team is now pushing forward with additional studies to see if the same therapeutic effect can be achieved in humans.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release clearly notes the funding source, the Canadian Institute for Health Research.", "answer": 1}, {"article": "\"Although it is not clear if bisphosphonates are the cause, these unusual femur fractures have been predominantly reported in patients taking bisphosphonates,\" the FDA says.\nThat's obviously a lot more benefit than risk.\nAnd they can be complex breaks that are difficult to fix and slow to heal.\nThat's called the relative risk, and it seems alarming.\nAgain, Merck disputes the connection.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "NPR provides us with three fresh sources beyond the JAMA article itself.", "answer": 1}, {"article": "\u201cNo one should die of hypertension.\n\u201cThe electronic counseling (e-Counseling) intervention had an effect similar to that of adding an additional blood-pressure-lowering medication,\u201d said Robert P. Nolan, the lead author of the study, a senior scientist at the Peter Munk Cardiac Center at the University Health Network and an associate professor at the University of Toronto.\nThe study also measured changes in risk scores of developing heart disease and stroke in the next 10 years, diastolic blood pressure, dietary changes, smoking cessation, cholesterol levels excluding the good cholesterol (HDL) and pulse pressure, which is the difference between the higher and lower (diastolic) numbers on the blood pressure reading.\nIn part, most of the studies here today show what to do \u2014 not how to achieve it,\u201d said Eric Peterson, a professor at Duke University School of Medicine and an associate editor of the Journal of the American Medical Association, during the conference.\nThe randomized, double-blind study included 264 participants with an average age of 58, of whom 58 percent were women.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes quotes from two experts who spoke at the conference session where this research was presented. They do not appear to have any conflicts of interest. However, it\u2019s unclear if the reporter interviewed the sources directly, or used statements they made to the entire audience at the session. The former is more suitable for obtaining comments that pertain to a lay audience like the Post\u2019s.", "answer": 1}, {"article": "Your skin vs. the sun: A sunscreen pill?\nA cautionary note:The damning evidence against vitamin A, which has long been used as a skin-cancer treatment, came from experiments done on mice, which have a far higher susceptibility to skin cancers than humans.\nThe basics: Almost everybody would love to have a \"healthy\" bronze glow, but almost everybody now also understands that the sun isn't our friend and that our skin needs to be protected from its stealthy attacks.\nAs an alternative, there's a relatively new product called Fernblock, which claims to protect the skin internally by systemically inhibiting the absorption of ultraviolet rays.\nOur two cents' worth:There's no reason not to take a flyer on Fernblock \u2014 actress Reese Witherspoon gives it a hearty endorsement - but keep slathering up, too.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The sources independent from Fernblock\u2019s manufacturer and Reese Witherspoon are anonymous. There are\u00a0vague references to the opinions of \u201cmost\u201d dermatologists and to those dermatologists \u201cwho have experience with Fernblock.\u201d These generalizations are unverifiable, and thus of uncertain accuracy. Making a sweeping statement does not substitute for evidence or flesh-and-blood sources.\u00a0A comment about this product from a dermatologist or even someone versed in herbal medicine would have given helpful context. There was also a link to an Environmental Working Group page about sunscreen, but we don\u2019t see information about sun pills, the point of this story.", "answer": 0}, {"article": "For instance, dietary guidelines recommend limiting sugar consumption to no more than 10 percent of daily calories.\n\"Relying on evidence from observational studies...carries the potential limitation of confounding bias,\" states an editorial that was published alongside the study.\nIn addition, diets low in seafood, whole grains and fruits and vegetables were found to contribute to about 6-8 percent of the deaths.\nScientists use statistical methods to try to tease apart the impact of diet as part of people's overall lifestyle.\nSo, think of it this way: You can start consuming more of the foods that are protective.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes from an accompanying editorial, which leads to some useful discussion of the limitations of observational research.", "answer": 1}, {"article": "The therapy continued with the parents for the next six months with less intensity.\nThe absence of any hope, as well as the very sudden regression in children\u2019s behaviour, led many parents to believe in the discredited theory of Andrew Wakefield that the MMR (measles, mumps and rubella) vaccine was the cause of autism.\n\u201cThis is not a cure, in the sense that the children who demonstrated improvements will still show remaining symptoms to a variable extent, but it does suggest that working with parents to interact with their children in this way can lead to improvements in symptoms over the long term.\u201d\n\nThe trial involved 152 children aged two to four.\nThere are no drugs to treat the condition, which typically sets in around the age of two, and many families have tried intensive training of their children by therapists, with mixed results.\nThese results look promising for the many thousands of parents who want to find early interventions for their children based on solid science.\u201d\n\nThe researchers said children\u2019s communication with their parents was improved at the end of the six years.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Outside sources were included in evaluating the impact of the study, including one from an autism\u00a0advocacy group. But none of the experts noted limitations or cautions about over-interpreting the data in the long-term follow up. Almost every source was cheerleading.", "answer": 1}, {"article": "nutritional guidelines, which I\u2019ve discussed before, says that coffee is not only O.K.\nIt\u2019s important to remember that we usually conduct those trials to see if what we are observing in epidemiologic studies holds up.\nIf any other modifiable risk factor had these kind of positive associations across the board, the media would be all over it.\nMost of us aren\u2019t drinking coffee because we think it will protect us, though.\nToo much of anything can be bad.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An independent expert would have added valuable context here, but no such voice is provided.\nAre studies of coffee consumption which find themselves as part of meta-analyses of coffee consumption funded by, tied to, or otherwise linked to Big Coffee in any way that suggests commercial biases in this research? \u00a0We don\u2019t know, and we don\u2019t learn about any such conflicts of interest in the story. Is it a conflict of interest if the reporter, plus most of the researchers and meta-analyzers are routine, habitual coffee consumers?", "answer": 0}, {"article": "Sha says it\u2019s not clear what might be found in plasma from young people that might help the symptoms of Alzheimer\u2019s.\nThe work made headlines and launched a company, Alkahest, that\u2019s working to develop young human plasma into treatments for aging-related diseases.\n\u201cWe need to do the next steps to understand what is in the young plasma.\u201d\n\nPlasma is the liquid part of blood, with the red cells and immune cells removed.\nAnd, McCracken says, the company is working to figure out just what it is in the plasma that might affect aging and disease.\n\u201cThere are things you can do but right now there is no drug that is actually going to slow down the progression of the brain disease in Alzheimer\u2019s,\u201d said Keith Fargo, director of scientific programs for the Alzheimer\u2019s Association.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We\u2019ll give the story a Satisfactory here since it does quote one source unaffiliated with the research and points out that earlier work led to the formation of a private company which intends to market a product derived from the research. However, the story would have been stronger if it had commentary from an independent expert with a more skeptical perspective.", "answer": 1}, {"article": "The HSRx product demonstrated superior treatment performance throughout the entire clinical study.\n\"Acne is among the 10 most prevalent human infectious diseases and recent studies show it has a significant long-term psychological impact on many of the 80+% of teenagers and young adults who suffer from it,\" he added.\n\"Acne sufferers' number one priority is getting rid of inflammatory lesions \u2013 pimples \u2013 fast,\" Sullivan said.\nAfter 48 hours, the percentage of subjects with unsightly acne-associated redness was reduced nearly three times as much with HSRx 2121 as with the competing product.\nAfter 24 hours treatment, the percentage of subjects with reduced acne count was 64% greater for those using HSRx 2121 than for subjects using the competing product.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We\u2019ll give the benefit of the doubt here. The release states that the trial was conducted by their pharma company HSRx Group and speaks openly about marketing. In fact, most of the release talks about what a great business opportunity it is and the potential for profit (vs. how it might impact the millions of sufferers): \u201cThe HSRx product demonstrated superior treatment performance throughout the entire clinical study.\u201dThat makes for a powerful marketing advantage,\u201d Sullivan said.\u201d And: \u201cOur acne treatment product has enormous commercial potential, evidenced by the significant licensee interest it has attracted. As with each of our\u00a0next generation\u00a0OTC drug products, we intend to license HSRx 2121 to a leading marketing entity that has the resources and expertise to maximize sales, here and abroad,\u201d Parise said.\u201d\nIf you go to the website of the research organization you will find their acne study summaries (which interestingly DO mention the types of acne formulations used). Makes one wonder even more why the news release neglected to mention this.", "answer": 1}, {"article": "Palliative Care Consults for Patients with Advanced Cancers Reduces Hospitalization and Improves Quality of Care\n\nIntegration of Palliative Care Improves Many Measures of Quality\n\nNewswise \u2014 (NEW YORK \u2014 March 15, 2017/Embargoed until March 17, 4:00 pm ET) Cancer patients admitted to the hospital with advanced stages of disease who were referred early to palliative care had decreased health care utilization and increased use of support services following discharge, according to a new study led by researchers at the Icahn School of Medicine at Mount Sinai.\nThe integration of palliative care improves symptom control and decreases unwanted health care use, yet many patients are never offered these services.\nSuch interventions drive escalating costs and are often directly in conflict with patients\u2019 prior stated wishes,\u201d said Dr. Smith.\n\u201cOur results highlight the need to adopt this practice at acute care hospitals across the nation,\u201d said Dr. Smith.\n15 nationally in the 2016-2017 \u201cBest Hospitals\u201d issue of U.S. News & World Report.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding source is not identified.", "answer": 0}, {"article": "WEDNESDAY, Aug. 17, 2011 (HealthDay News) -- People who have narrowed carotid arteries in the neck and show no symptoms may be at risk for stroke and not know it, but a simple ultrasound test can identify the problem, a new study suggests.\nThe patients who are at high risk are candidates for surgery, he said.\nThe report was published in the Aug. 17 online edition of Neurology.\nThe problem is identifying the patients at the highest risk for stroke, he said.\n\"If they are too sick or frail for surgery, it makes no sense to do the ultrasound,\" he said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Quotes from two individuals who were not involved in the study reported on were included in this story.", "answer": 1}, {"article": "\"It is very big.\n\"This new technology has the potential to facilitate an easy-to-administer, noninvasive blood test that would allow us to count tumor cells, and to characterize the biology of the cells,\" said Robert McCormack, Veridex's head of technology innovation and strategy.\n\"It is appropriate to view announcements such as the one today with enthusiasm, but recognize that we must temper that excitement with the realization that there is still much research to be done to determine the true impact of this test on the treatment of patients with cancer.\"\n\"The challenging goal of sorting extremely rare circulating tumor cells from blood requires continuous technological, biological and clinical innovation to fully explore the utility of these precious cells in clinical oncology,\" Toner said.\nDr. Mehmet Toner, director of the BioMicroElectroMechanical Systems Resource Center in Massachusetts General's Center for Engineering in Medicine, says while it will take at least five years before the test is on the market, it's another step toward personalized medicine and the implications for patients are significant.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Too much of the story comes from conflicted sources.\u00a0 There is input from Dr. Len Lichtenfeld of the American Cancer Society at the very end.\u00a0 But the story fails to mention that the American Cancer Society has supported research in this area.\u00a0 And the story didn\u2019t even include the much stronger types of comments Lichtenfeld made on his own blog, such as:\u00a0\n\u201c\u2026this is an announcement of a research deal.\u00a0 Nothing more, nothing less.\u00a0 It is not a new breakthrough. It is not something that has been proven effective in improving cancer detection and treatment.\u00a0 Not that it is anything less than stunning to develop and demonstrate that this technology works \u2013 but as with all research it is a giant step to go successfully from the laboratory phase of development to the clinical phase of making a real difference in patients\u2019 lives. So that in essence is what the fuss is all about: the researchers have signed a contract with a company to further develop this research and determine whether in fact it can be applied successfully to large numbers of patients in a more efficient and less expensive manner.\u201d  ", "answer": 0}, {"article": "But he also sees a lot of patients who cannot be candidates.\n\"In order to implant this device, we need to remove the natural lens, or the cataract, and then use a portion of the natural lens to position and support the telescope,\" says Williams.\nThat's why Orr saw blank spots where people's noses and eyes should be in their faces, sort of like \"holes in the film,\" says Colby.\nSo the take-home message: If you're over 60 and you begin to experience visual loss, get yourself to an eye specialist as soon as possible to see if you can be treated with medication to stabilize and even reverse the vision loss you've experienced.\nBut if they're scanning the room to see exactly where the clock is, they use the other eye, which also has end-stage macular degeneration.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The bottom third of the story relies heavily, perhaps too much so, on Dr. George Williams, a retinal surgeon given the vague title of \"associated with the American Academy of Ophthalmology.\" Those quibbles aside, Williams provides some great insight and counterbalancing information. It also explains that the other expert in the story, Dr. Kathryn A. Colby, was one of the principal investigators in the story.", "answer": 1}, {"article": "A 33-year-old Queens woman who was treated by Batzofin last week fits that bill. Married for two years, she failed to get pregnant through intercourse, with and without drugs. When Batzofin told her about his new procedure, she said, \"Let's go for it.\"", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not do a good job finding unbiased sources to speak to the difference between IVF and IVM treatments\u2013only one person is cited. An additional\u00a0 researcher or fertility expert could provide a balanced review of the evidence (both benefits and harms) of these and additional fertility treatments, which might also be appropriate for women who cannot take hormones typical of IVF regimens.\u00a0 The story does interview women who serve mainly to promote Dr. Batzofin\u2019s clinic. ", "answer": 0}, {"article": "TUESDAY, May 4, 2010 (HealthDay News) -- Noninvasive stool DNA testing can detect two types of colorectal precancers and could play a larger role in colon cancer prevention, say two new studies.\n\"This study shows that cancer and precancer in IBD can be detected noninvasively,\" senior investigator Dr. David Ahlquist said in a Mayo news release.\nThe first study found that stool DNA testing detected five out of five cases of colon cancer and four out of five cases of a precancerous lesion called dysplasia in 10 patients with inflammatory bowel disease (IBD).\nIt's important for people with IBD because they are at much higher risk for colorectal cancer than the general population.\nSome of the study authors and the Mayo Clinic have a financial interest related to technology used with this research.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Only the Mayo Clinic researcher quoted in the news release is quoted in the story.\u00a0 Given all of the competing approaches to colon cancer screening, someone independent of this work needed to comment to put this research into perspective. ", "answer": 0}, {"article": "MONDAY, Feb. 15, 2010 (HealthDay News) -- People with high-functioning autism or Asperger's syndrome were better able to \"catch\" social cues after inhaling the hormone oxytocin, new research shows.\nIt doesn't make a whole lot of sense,\" he pointed out.\nThe long-term effects of the hormone are also uncertain.\nThere were, however, wide variations in individual responses, the team noted.\nIt involved 13 adults, most of them men, aged 17 to 39.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites several independent sources and provides several quotes for balance. The study authors themselves identified no conflicts of interest.", "answer": 1}, {"article": "NEW ORLEANS (Reuters) - Abbott Laboratories Inc\u2019s experimental Absorb heart stent, designed to dissolve and thereby restore the blood vessel\u2019s natural flexibility, has proven safe and effective a year after being implanted in patients, researchers said.\n\u201cThe baby will grow and the biodegradable material will disappear,\u201d he said.\nDuring the same period, no blood clots were reported among patients who were far enough along in testing to be evaluated in the 101-patient study.\nIt hopes to seek U.S. approval for the product in 2015, several years before any competitor.\nHe said Absorb and stents like it will likely be the next generation of stents and ultimately improve outcomes for patients.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent source was quoted. And the story never stated who paid for the study or whether the quoted researcher has any financial ties to the manufacturer.", "answer": 0}, {"article": "Elevated sweat chloride confirms that an infant actually has CF.\n\"We set out to discover whether there were chemical indicators detected in sweat that could complement the gold standard for CF diagnosis: the sweat chloride test.\"\n\"Sweat contains lots of information related to human health that researchers have not fully analyzed and we found some unexpected chemicals associated with CF,\" he says.\nBut there are some obstacles that complicate clinical decision-making, explains Britz-McKibbin, because sweat chloride can result in ambiguous diagnoses in some borderline cases and does not reveal how the disease might progress for individual patients.\nThe findings, published in the journal ACS Central Science, shed new light on the underlying mechanisms of CF and could lead to improved prognosis and better therapies for a disease which is quite variable, affecting different children in different ways, say researchers.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding source is clearly marked and there does not appear to be a conflict of interest. However, it\u2019s not clear whether the \u201cspecialized technique developed at McMaster\u201d is being patented for use in the marketplace, or if it is being made freely available to other researchers. Either way, that would be a valuable point to make in the release.", "answer": 1}, {"article": "The way it works: A doctor draws a vial of your blood and separates it into its key components, the red blood cells, the clear serum and the platelets. The physician then adds vitamins and amino acids to the mix, and the enriched serum is injected into your face.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources; no evidence of any independent reporting.\u00a0 ", "answer": 0}, {"article": "Their editorial accompanies the Marban report in the Feb. 14 advance online issue of The Lancet.\n\"We have been trying as doctors for centuries to find a treatment that actually reverses heart injury,\" Eduardo Marban, MD, PhD, tells WebMD.\n\"These findings suggest that this therapeutic approach is feasible and has the potential to provide a treatment strategy for cardiac regeneration after [heart attack],\" write University of Hong Kong researchers Chung-Wah Siu and Hung-Fat Tse.\n\"That is what we seem to have been able to achieve in this small number of patients.\nThe finding, just in time for Valentine's Day, is the clearest evidence yet that literally broken hearts can heal.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No interviews with independent sources are in evidence in the story. There is one quote from an accompanying editorial. The bulk of the story is given over to effusive quotes from the lead researcher, Eduardo Marban. We appreciate that the story made note of the fact that \u201cHe invented the \u201ccardiosphere\u201d culture technique used to create the stem cells and founded the company developing the treatment.\u201d We think, though, that his conflict of interest should have prompted a few calls to independent sources.", "answer": 0}, {"article": "Injections of botulinum toxin, best known as a wrinkle treatment, are now being used increasingly to prevent chronic migraine sufferers. Scientific data are mixed, but two large recent studies show Botox can reduce the number of headache days in chronic sufferers.\n\nMigraine headache is a debilitating neurological condition that manifests itself as an intense throbbing pain on one or both sides of the head, according to the Migraine Research Foundation, a New York nonprofit. Some 14 million people experience migraine attacks...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "It is not clear that any of the experts who commented in this study were independent, disinterested sources. All appeared to have some kind of relationship with the developer of Botox. How hard can it be to find a headache specialist who is not on the company payroll?\nThe article did not adequately describe the relationships of the quoted experts with the company that manufacturers and markets Botox. For instance, the article noted that one of the quoted experts is the principal investigator of one of the Botox trials. However, the journalist didn\u2019t reveal that this expert has also been a consultant to the drug company.", "answer": 0}, {"article": "The bar was developed over the past 10 years by a team of scientists led by Drs.\nThe CHORI-bar is intended to fill these gaps with components present in the bar in normal dietary amounts.\nThe CHORI-team thinks the broad scale improvements observed with the CHORI-bar may be the result of \"oiling\" multiple joints by the complex nutrient mixture.\nThe full potential of food-based supplements to do the work of some drugs without their negative side effects is just beginning to be seriously investigated.\n6 McCann, J. C., and Ames, B. N. (2009) Vitamin K, an example of triage theory: is micronutrient inadequacy linked to diseases of aging?\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "One can find no information about either funding or potential conflicts of interest.\u00a0A brief look at the manuscript reveals that the investigators were funded by the CHORI itself, a charitable foundation, and the lab company Quest Diagnostics. A number of industry sponsors provided the materials for the bars, including Dow Chemical.The study authors reportedly have a patent on the CHORI bar concept.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Coffee, tea, or decaf-no matter what your choice, drinking any of these beverages may reduce your risk of diabetes, according to a new analysis of 18 studies including hundreds of thousands of people.\nFor every additional cup of coffee a person consumed each day, the study\u2019s authors found, a person\u2019s risk of diabetes was reduced by 7 percent.\nThe current analysis could have overestimated the effect of these beverages on diabetes risk due to statistical issues with the smaller studies, Huxley and her colleagues note.\nA 2005 research review concluded that people who drank the most coffee were one-third less likely to develop diabetes than those who drank the least, Dr. Rachel Huxley of The University of Sydney, Australia, and colleagues note.\nIn the six studies that looked at decaf coffee, the researchers found, people who consumed more than three or four cups a day were at 36 percent lower risk of diabetes.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0No independent sources were quoted in the story.\u00a0 We especially feel that this was warranted given the inclusion of the researcher\u2019s bold claims of potential impact\u00a0 of the findings. ", "answer": 0}, {"article": "This test might help.\nThe study was funded by the March of Dimes and other nonprofit sources, although Quake and his colleagues have filed for a patent on the test.\n\"Those molecules will circulate in the blood for some time, they can be measured, and you can see the contributions from essentially every tissue in the body,\" senior investigator Stephen Quake told BuzzFeed News.\nIn a subgroup of women, the test accurately classified 4 of 5 preterm deliveries as being at-risk, and incorrectly suggested that 3 of 18 women who had a full-term pregnancy were at risk for early labor.\nHowever, a new blood test \u2014 which is still experimental and not yet available outside of a research lab \u2014 can pick up on gene activity in the body that suggests a pregnancy is at risk for preterm delivery, according to a study published Thursday in the journal Science .\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We don\u2019t get a crucial outside perspective on the study; the only source named in the story is one of the lead authors. On the plus side, the story is very thorough given its short length, and it offers a blunt if not skeptical summary on the research. It also helps that we\u2019re told the study was funded by the March of Dimes and \u201cother nonprofit sources,\u201d and that the authors have applied to patent the blood test, implying they stand to profit from its approval and widespread use.", "answer": 0}, {"article": "\u201cKangaroo mother care is care of preterm infants carried skin-to-skin with the mother.\n\u201cKangaroo mother care may change the behavior of less well-educated mothers by increasing their sensitivity to the needs of their children, thus making them equivalent to mothers in more favorable environments.\u201d\n\nTwenty million babies are born at a low birth weight every year around the globe, the World Health Organization reports.\nRelated: More U.S. Moms are Breastfeeding Their Babies\n\n\u201cThe effects of kangaroo mother care at one year on IQ and home environment were still present 20 years later in the most fragile individuals, and kangaroo mother care parents were more protective and nurturing,\u201d Dr. Nathalie Charpak and colleagues at the Kangaroo Foundation in Bogota, Colombia, wrote in their report.\nIts key features are: early, continuous and prolonged skin-to-skin contact between the mother and the baby; exclusive breastfeeding (ideally); it is initiated in hospital and can be continued at home; small babies can be discharged early; mothers at home require adequate support and follow-up,\u201d WHO said.\nThe U.S. has one of the highest rates of pre-term and low-weight births \u2014 about one in 12 births, according to the March of Dimes.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story lacked comment from independent sources. While there are some statements about KMC attributed to the World Health Organization, those statements don\u2019t address the findings of this study. An independent source likely could have provided some context and important reassurances to parents who had premature babies but either weren\u2019t offered kangaroo care or weren\u2019t able to because of birth complications, which is a growing problem in the U.S.", "answer": 0}, {"article": "For the study, Lumeng's team collected data on more than 43,700 Michigan preschool-age children between 2005 and 2013.\nThe daily routine might translate into less TV time and more regular sleep schedules, she said.\n\"Perhaps the program fosters better mental health in the children, which in turn leads to better eating,\" he said.\n\"Even though children in the Head Start group began the observation period more obese, equally overweight, and moreunderweight than children in the comparison groups, at the end of the observation period the initially obese and overweight Head Start children were substantially less obese andoverweight than the children in the comparison groups,\" the authors wrote.\nIn their first year in Head Start, obese and overweight kids lost weight faster than two comparison groups of children who weren't in the program, researchers found.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story provides comments by a source who was not involved in the study, Dr. David Katz of Yale University, explaining the value of the Head Start Program.", "answer": 1}, {"article": "The researchers believe that adding probiotics to the peanut allergens may be important in improving the children\u2019s tolerance to the food, but Dr. Anna Nowak-Wegrzyn, an associate professor of pediatrics at Icahn School of Medicine at Mt.\n\u201cThe question for me would be if there is a difference between patients who were treated with [both] immunotherapy [in the form of low doses of peanuts] and probiotics, and those who were treated with just immunotherapy.\u201d\n\nThat may have to wait for another study.\nMORE: Babies Should Eat Eggs and Peanuts Early to Avoid Food Allergies\n\nIn the follow-up, which tracked the children for four years after they were treated with the combination therapy, 67% of those who got the combination probiotic and peanut therapy were comfortable eating peanuts, compared to only 4% of those who did not get the treatment.\nThe study, published in the journal , follows up on children enrolled in an earlier study of an immunotherapy treatment, which combined probiotics with small doses of peanuts that were designed to gradually train the children\u2019s immune systems to accept the peanut allergen rather than treat it as something foreign.\nBut the new findings provide even more evidence that using peanuts to treat peanut allergy, and to re-train the immune system to be less allergic, can be effective.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does include input from one independent source, and that source highlights some significant questions regarding the study. For example, as the source notes, it\u2019s not clear what role (if any) the probiotics played in the study outcomes. In other words, it\u2019s not clear if the combination therapy achieved better results than would have been achieved using only immunotherapy without the probiotics.\nBut while the story did touch base with an independent source, it did not clearly address conflicts of interest. Here\u2019s a line from the Aug. 16 news release issued by the Murdoch Childrens Research Institute (MCRI), where the relevant clinical trials were conducted: \u201cThis follow up study was initially funded by MCRI and the Australian Food Allergy Foundation. It then received a $15 million funding commitment in 2016 from capital investment firm, OneVentures. A biotech company Prota Therapeutics, was jointly set up by the MCRI and OneVentures to develop [a combined probiotics and oral immunotherapy treatment] towards an FDA approved product with a plan to make the vital treatment available globally to people with peanut allergy.\u201d That\u2019s the sort of thing readers should know.", "answer": 0}, {"article": "Furthermore, these tumor cells were sensitive to an experimental drug, neratinib.\nTo identify the patients in this study who carried the new HER2 mutation, the researchers required tissue from the tumor, a biopsy, from which they could extract and sequence the genetic material to determine the presence of the HER2 mutation.\nThe results of the clinical trial were encouraging in that about 30 percent of the 16 patients treated with neratinib had a meaningful clinical response showing significant disease stabilization or regression.\nThere is a group of metastatic breast cancers that has the HER2 gene amplified - the cells have many copies of it - which leads to enhanced activity of the product enzyme, a tyrosine kinase.\nHER2 has been established as a therapeutic target in breast cancer, and breast cancers in which the HER2 gene is not amplified do not, in general, respond to HER2-directed therapeutic approaches.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release didn\u2019t name funders or discuss any potential conflicts of interest, instead referring readers to the full study, for which a journal subscription is required. The published study on which the release is based does list the full funding sources and the study authors\u2019 conflicts of interest. Puma Biotechnology Inc, the maker of neratinib, was one of the study funders. This should have been disclosed in the release. All three corresponding authors of the study have multiple financial ties with Puma Biotechnology and other pharmas. This, too, should have been noted in the release.", "answer": 0}, {"article": "What does a heart attack look like in women?\nThe study can't say specifically what about the berries seemed to result in a lower risk of heart attack among these women, or that there was a direct cause-and-effect link between eating the berries and lowered heart attack risk.\n\"Berries were the most commonly consumed sources of these substances in the U.S. diet, and they are one of the best sources of these powerful bioactive compounds,\" said study lead author Aedin Cassidy.\nMONDAY, Jan. 14, 2013 (HealthDay News) -- Eating three or more servings of blueberries and strawberries each week may help reduce a woman's risk of heart attack, a large new study suggests.\nDana Greene, a nutritionist in Boston, regularly tells her patients to consume more fruits and vegetables, including berries.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two independent experts, preventive cardiologist Dr. Suzanne Steinbaum and nutritionist Dana Greene. We wish that the experts were quoted on a more analytical view of the study, instead of talking so much about berry diets. Greene is even quoted as saying, \u201c[Berries] are so good for you,\u201d and \u201cThere is no downside\u201d to eating berries. Again, too much of anything could become more of a harm than a benefit, as mentioned above. It\u2019s interesting that Steinbaum was also interviewed in the competing TIME story.\u00a0 Why?", "answer": 1}, {"article": "Dr Fabiansen , the main author of the paper appearing in PLOS Medicine today, underscores the importance of the findings:\n\n\"Previous studies of nutritional supplements have mainly looked at the effect on weight gain.\nThe study was primarily funded by Danida, MSF-Denmark and MSF-Norway, and USAID via the World Food Programme.\nThe study found that children who received LNS experienced greater weight gain, and the large majority of the weight gain was healthy lean tissue.\nEarlier peer-reviewed articles from the study have appeared in the American Journal of Clinical Nutrition, BMC Nutrition, and Appetite.\nIf we can treat children with moderate acute malnutrition with the scientifically proven most effective food aid product, and thereby prevent severe acute malnutrition, then many lives can be saved\"\n\nDr Susan Shepherd, a paediatrician who heads ALIMA's Operational and Clinical Research, says:\n\n\"ALIMA is very proud of its participation in this study.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The major funding sources for the study are listed, but financial relationships between two of the authors and Nutriset, a producer of LNS products, were not included in the release. According to the published study they are Nutriset patent holders.", "answer": 0}, {"article": "WEDNESDAY, Sept. 8, 2010 (HealthDay News) -- Statins, lauded for their ability to lower cholesterol and prevent heart attacks and strokes, may also reduce the risk of developing rheumatoid arthritis, Israeli researchers report.\nThis work received no outside or corporate finding, the researchers noted.\n\"The effect was stronger in younger patients and in patients using more effective statins.\"\n\"Patients who were covered for more than 80 percent of the time, had a 40 percent lower risk of developing rheumatoid arthritis,\" Chodick said.\nFor more information on statins, visit the U.S. National Library of Medicine.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\nThe story includes both an independent source and the information that the researchers did not receive any outside funding for their work.", "answer": 1}, {"article": "\"These treatments really have the potential to transform people's lives,\" Vickery said, \"and I have seen it happen firsthand: the sense of relief [families] get when a child becomes desensitized.\"\nEven though she dislikes the medicine's taste, Ellis also believes it is worth it.\nThey can help you get through it,\" she said.\nIt would still be worth it to many, he said.\nI would say it's been some work to go through this study, just in terms of a time commitment.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes several expert sources, including a doctor who was not involved in the study and who does not appear to be funded by potential treatment-makers.", "answer": 1}, {"article": "The games are based on the work of Japanese neuroscientist Ryuta Kawashima, M.D.\n\"Functional MRI allows you to study which brain areas are simultaneously active and gives information on the participation of certain areas with specific brain circuits,\" Dr. De Giglio said.\n\"This increased connectivity reflects the fact that video gaming experience changed the mode of operation of certain brain structures,\" Dr. De Giglio said.\nAt follow-up, the 12 patients in the video-game group had significant increases in thalamic functional connectivity in brain areas corresponding to the posterior component of the default mode network, which is one of the most important brain networks involved in cognition.\nDamage to the thalamus, a structure in the middle of the brain that acts as a kind of information hub, and its connections with other parts of the brain play an important role in the cognitive dysfunction many MS patients experience.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t share any information on how the research was funded, while in fairness, neither does the original research paper. Neither does it discuss any potential conflict of interest, although the research paper suggests there is none. Given the mention of the use of a commercial game, information about funding and conflict of interest is relevant.", "answer": 0}, {"article": "LONDON (Reuters) - A 15-minute brain scan could in future be used to test for autism, helping doctors diagnose the complex condition more cheaply and accurately.\nCognitive behavioral therapy and educational treatment can be highly effective for some patients and the impact of a more certain prognosis would be especially beneficial for children.\nAutism spectrum disorders are diagnosed in one percent of the population in Britain and the United States, and the condition affects four times as many boys as girls.\nThe new scanning method \u2014 which picks up on structural changes in the brain\u2019s grey matter \u2014 could be ready for general use in a couple of years.\nIt could be a boon for patients and their doctors by reducing reliance on time-consuming and emotionally trying assessments based on interviews and behavioral observation.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One of the sources for this story was not involved in the research and has no obvious conflicts of interest.", "answer": 1}, {"article": "A blood test conducted as early as the 10th week of pregnancy may help identify women at risk for gestational diabetes, a pregnancy-related condition that poses potentially serious health risks for mothers and infants, according to researchers at the National Institutes of Health and other institutions.\nExercise and a healthy diet may lower blood glucose levels during pregnancy.\nIf these measures are not successful, physicians may prescribe insulin to bring blood glucose under control.\nIn middle pregnancy, HbA1c levels declined for both groups.\nThe test approximates the average blood glucose levels over the previous 2 or 3 months, based on the amount of glucose that has accumulated on the surface of red blood cells.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Although not explicit, it seems clear the research was funded by NIH.", "answer": 1}, {"article": "But confirmation would be good news for the prevention and control of gonorrhea.\n\u201cGonorrhea rates have been going down in the vaccine group whereas in the non-vaccine group it\u2019s following the rest of the province.\u201d\n\nIt is not clear how long the protection \u2014 if it\u2019s real \u2014 will actually last.\nThe research, conducted in New Zealand, found that the gonorrhea rate among teens and young adults there who had received a meningitis B vaccine during an emergency campaign in the early 2000s was significantly lower than the rate seen in people of the same age who weren\u2019t vaccinated.\n\u201cMathematical modeling has shown that even a vaccine of moderate efficacy and duration could have a substantial effect on the transmission and prevalence of gonorrhea, if coverage in the population is high and protection lasts during the highest risk period,\u201d Kate Seib, of Australia\u2019s Institute for Glycomics, wrote in a commentary that accompanied the study.\nThe study, published Monday in the Lancet, was funded by GSK and Auckland Uniservices, the commercialization arm of the University of Auckland.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story reports that the study was funded by GSK and Auckland Uniservices, the commercialization arm of the University of Auckland. It does not mention that one of the researchers in the study has been a paid consultant for GSK and other drugmakers.\nThe story appears to use one independent source, Dr. Jean Longtin, head of Quebec\u2019s public health laboratory. It also quotes from an accompanying editorial by Kate Seib, of Australia\u2019s Institute for Glycomics, who declared no conflicts.", "answer": 1}, {"article": "A surgically implanted electrical device that stimulates the sacral nerve can calm an overactive bladder, according to a company that sells it. Physicians say sacral neural stimulation works well for many patients, but a test period with an external device is recommended first.\n\nMillions of Americans suffer from \"urge incontinence,\" accidents caused by a strong, sudden need to get to the bathroom, or overly frequent urination, defined as eight or more times a day. Quality of life is affected, as sufferers must...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes multiple experts. The story points out that one of the experts is a researcher on a Medtronic-sponsored trial of the device but does not mention any conflicts for the other experts, leaving the reader questioning the validity of some of their statements.", "answer": 1}, {"article": "JACKSONVILLE, Fla. \u2014 Researchers at Mayo Clinic\u2019s campus in Florida have conducted the world\u2019s first prospective, blinded and placebo-controlled clinical study to test the benefit of using bone marrow stem cells, a regenerative medicine therapy, to reduce arthritic pain and disability in knees.\n\u201cWe actually counted all of the stem cells with markers that are accepted by the FDA, and we made sure they would be able to survive inside the patient,\u201d Dr. Shapiro says.\nThe solution, which contained tens of thousands of stem cells, was injected into a patient\u2019s knee using ultrasound-guided imagery.\n\u201cThat could be, but both this idea and the notion that a placebo effect could be involved would be surprising, given that some patients are still doing very well years after their study treatment ended,\u201d says Dr. Shapiro.\n\u201cWe feel that if we are going to offer any stem cell procedures to our patients, the science needs to be worked out,\u201d Dr. Shapiro says.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release duly notes that funding was by the Mayo Clinic in Florida\u2019s Center for Regenerative Medicine.", "answer": 1}, {"article": "THURSDAY, Jan. 5, 2012 (HealthDay News) -- Preliminary findings suggest a drug used to treat another disease might also reduce painful flare-ups in gout patients starting new medication regimens.\n\"This is a very expensive drug,\" he said.\n\"And insurance will be an issue.\nHowever, he cautioned that the high cost of rilonacept will most likely curtail its use.\nFor more on gout, visit the U.S. National Library of Medicine.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One independent expert is quoted.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - People who took a newer type of pain pill over a three-year period were less likely to develop polyps that could lead to colorectal cancer \u2014 but at the expense of a higher risk of heart problems, new study findings report.\nMore than half had received Celebrex for approximately 3 years, before concerns over the increased risk of cardiovascular problems caused researchers to discontinue the study.\nBut to people who have no underlying cardiovascular problems and a particularly high risk of colon cancer - they were diagnosed with it before perhaps, or have a strong family history - regular screening may not be enough, Chan noted.\nThe study, published in the American Journal of Gastroenterology, received financial support from Pfizer, which sells Celebrex.\nThose who had been on Celebrex were also more likely to develop advanced polyps during that final year.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story notes that the study was funded by Pfizer, maker of Celebrex, and includes commentary from an independent expert who didn\u2019t participate in the study.", "answer": 1}, {"article": "WEDNESDAY, April 4, 2012 (HealthDay News) -- Regularly consumption of food and drink rich in substances called flavonoids, such as berries, apples, tea and red wine, can lower a man's risk of developing Parkinson's disease by 40 percent, new research suggests.\nHe also said it will be important to confirm these findings in other studies and learn the mechanism of how berries and other flavonoids appear to offer some protection against Parkinson's disease.\nFor women, however, a reduction in risk was only seen when they ate at least several servings of berries a week, according to the study.\nThere are no harmful effects from berry consumption, and they lower the risk of hypertension too,\" Gao added.\nGao said it wasn't clear why only men benefited from the extra flavonoid intake, but he noted that other studies have also found differences between men and women.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted an independent expert, who cautioned that people who already have Parkinson\u2019s disease won\u2019t benefit from eating berries or other flavonoid-rich foods.", "answer": 1}, {"article": "All of the treatments involved chemotherapy combined with the targeted anti-cancer drugs bevacizumab and/or cetuximab.\nNo significant differences were seen with regard to the type of therapy the patients received.\nFor more on vitamin D and cancer, visit the U.S. National Cancer Institute.\nThe U.S. National Institutes of Health funded the study.\nIt promotes the intestines' ability to absorb calcium and other important minerals, and is essential for maintaining strong, healthy bones, according to the U.S. National Institutes of Health.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an outside expert offering an important piece of context and caution about the findings. And it includes a statement from a second outside source with expertise in oncology who underscores the important finding about progression-free survival. Yes!", "answer": 1}, {"article": "Overweight people on low-carbohydrate and Mediterranean diets lost more weight and got greater cardiovascular benefits than people on a conventional low-fat diet, according to a study that endorses alternative diets published in a major medical journal.\n\nThe study, which tracked 322 Israelis for two years, surprisingly found that a low-carb diet, often associated in the U.S. with high levels of meat consumption -- was better than a low-fat diet in boosting blood levels of \"good\" cholesterol, or high-density lipoproteins...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This study accurately summarized the results of the New England Journal of Medicine article on weight loss with three popular diets.\u00a0 This article provided a good balance of commentary by independent experts\u00a0representing alternative opinions and interpretation of the results.", "answer": 1}, {"article": "Fighting bacteria with drugs designed to kill them helps fuel the problem of antibiotic resistance if stronger bacteria can survive and evolve to become \u201csuperbugs.\u201d\n\n\u201cBut instead of always setting a bomb off to kill an infection, there are situations where using an anti-virulence method may be just as effective, while also helping to restore balance to the health of the patient,\u201d said Quave.\nThe extracts from the fruit repress a gene that allows the bacterial cells to communicate with one another.\n\u201cIt weakens the bacteria so the mouse\u2019s own defenses work better\u201d to clear the infection, she said.\nThe medicines include antibiotics, which act on bacteria, as well as drugs to fight fungal, viral or parasitic infections.\nThe plant extracts didn't harm the skin tissues or the normal, healthy bacteria found on skin.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story had no independent sources, and it didn\u2019t disclose that the researcher interviewed in the story has a provisional patent on the application of these extracts.", "answer": 0}, {"article": "LONDON (Reuters) - An \u201celectronic nose\u201d could be used as a simple breath test to detect lung, breast, bowel and prostate cancers, Israeli scientists said Wednesday.\n\u201cIf we can confirm these initial results in large-scale studies, this new technology could become a simple tool for early diagnosis of cancer along with imaging,\u201d said Abraham Kuten of Technion Israel Institute of Technology.\nKuten and his colleagues studied the breath of 177 people \u2014 some healthy and some with various types of cancer \u2014 to detect the different chemicals emitted from the surface of cancer cells as they grow.\nUsing the sensor to pinpoint chemical variations, the team found they could not only distinguish between healthy and malignant breath but also identify the four different common tumor types.\nTheir findings, published in the British Journal of Cancer, build on earlier research published by scientists at the same institute last year showing that a sensor made with gold nanoparticles could detect lung cancer in breath.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": " ", "answer": 0}, {"article": "Heart disease and colorectal cancer are among the most common causes of death in the U.S.\n\"The evidence shows that there's really no incremental benefit of going over 81 milligrams, and in fact, you may increase bleeding risk by going over,\" CBS News medical contributor Dr. Tara Narula, a cardiologist at Lenox Hill Hospital in New York City, told \"CBS This Morning\" when the draft guidelines were released last September.\n\"As with any drug, patients and their doctors must balance the benefits and risks of taking aspirin,\" Dr. Kirsten Bibbins-Domingo, chair of the task force and professor of medicine, epidemiology and biostatistics at the University of California, San Francisco, told CBS News.\n\"The task force recommends that all patients talk to their doctor to evaluate their risk for cardiovascular disease and bleeding before making a decision about aspirin use, but this is particularly important for people in their 60s,\" Bibbins-Domingo said.\nColorectal cancer is the third most common cancer diagnosed in both men and women (excluding skin cancers) and a leading cause of cancer death, the American Cancer Society reports.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This was a close call, and just barely squeaked by as Satisfactory. The story included quotes from two interviewees, the chair of the task force and from another physician. However, that quote is lifted from a CBS TV interview from last year, and not regarding this latest report.", "answer": 1}, {"article": "But study author Dong Wang, a graduate student with the departments of nutrition and epidemiology at Harvard T.H.\nDr. Sonia Anand, a professor of medicine and epidemiology at McMaster University in Hamilton, Canada, praised the study, saying it's \"reasonable\" to link changes in diet to death rates in this way.\nAs a result, she said, it's crucial to look at a variety of studies and see if trends hold up.\nBut, she said, nutrition research like this has limitations because it relies on people's memories of what they ate.\nAccording to Wang, the study findings suggest that healthier diets lower the risk of death in a variety of ways.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "As noted, the article would have been stronger if it had quoted more senior authors of the paper and more outside experts, but it does quote one and the quote is strong.", "answer": 1}, {"article": "\"Cluster headache is a rare, debilitating and difficult to treat disorder with few effective acute therapies,\" Dr. Stephen Silberstein, director of the headache center at Jefferson University in Philadelphia, said in a statement.\nThere aren\u2019t many specific treatments but they include the migraine drug sumatriptan, delivered via auto-injector, and inhaled oxygen.\nThe idea is to disrupt signals that run along the vagus nerve, a giant nerve that runs from the brain all the way to the colon.\nBoth approaches are limited \u2014 it\u2019s not safe to use the injection more than twice a day \u2014 and inconvenient.\nThe device is a vagus nerve stimulator and it\u2019s not entirely clear how it works.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story doesn\u2019t quote any independent\u00a0sources \u2013 not even from\u00a0the editorial in the journal that offered a critique\u00a0about the study\u2019s limitations and conclusions.", "answer": 0}, {"article": "Cowen & Co estimates that use of DNA blood tests for cancer screening will exceed $10 billion a year by the end of the decade.\nBut the move by Pathway, a privately owned maker of genetic tests ranging from cancer risk and heart health to drug response, underscores a growing debate over how much genetic information should be made available to healthy people if it is not yet clear how it can improve their health.\n\u201cFor any given test, the rate of false positives causing unnecessary alarm and false negatives that provide false security should be known,\u201d said Dr. Keith Stewart, an oncologist who heads Mayo Clinic\u2019s Center for Individualized Medicine.\n\u201cIf we are relying on a test that can only detect cancer after it has formed, we miss a huge opportunity to intervene,\u201d said Dr. Scott Kopetz of the University of Texas MD Anderson Cancer Center.\nThe company is focusing on mutations that are relatively well-understood, and for which there are specific treatments, said Chief Executive Jim Plante.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted more independent sources than the competing Bloomberg story, and it also did a good job of identifying where people had conflicts. For example, the last expert quoted says that the test should undergo a large clinical trial, a point of agreement among multiple experts quoted in the press. But then the story says that this expert, \u201cis advising two companies developing liquid biopsy tests for cancer screening: Sysmex and Personal Genome Diagnostics.\u201d", "answer": 1}, {"article": "He struggled to sleep.\n\u201cThe MDMA seems to act as a catalyst that allows the healing to happen.\u201d\n\nWhat do patients say about it?\nThe current protocol calls for patients to take MDMA two or three times, each a month apart, interspersed with psychotherapy.\nThe drug floods the brain with hormones and neurotransmitters that evoke feelings of trust and well-being, users report.\nIt was a turning point, and for the next year I continued to get better.\u201d\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The unique funding for this project, as well as \u201cwho cashes in if MDMA becomes legal\u201d is thoroughly covered and a very nice addition to the article.\nThe lead authors appear to have no financial conflicts of interest, and multiple sources were tapped.", "answer": 1}, {"article": "The Society is based in Oak Brook, Ill. (RSNA.org)\nIf a lesion was evident, then clinicians could employ a nuclear scan to assess ischemia and take advantage of both modalities by fusing the results together to make a hybrid image.\nRadiology is edited by David A. Bluemke, M.D., Ph.D., University of Wisconsin School of Medicine and Public Health, Madison, Wis., and owned and published by the Radiological Society of North America, Inc.\n\nRSNA is an association of over 54,200 radiologists, radiation oncologists, medical physicists and related scientists promoting excellence in patient care and health care delivery through education, research and technologic innovation.\nHowever, the degree of stenosis on ICA is not always an accurate predictor of heart attack risk because it gives no information on perfusion, or the flow of blood into the heart muscle.\nOAK BROOK, Ill. - Cardiac hybrid imaging with CT and nuclear stress testing is an excellent long-term predictor of adverse cardiac events like heart attacks in patients being evaluated for coronary artery disease, according to a study published in the journal Radiology.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The study\u2019s first author disclosed that he is on the speaker\u2019s bureau for GE Healthcare, which manufactures the nuclear imaging machines discussed in the news release. Although the author claims that this relationship is not relevant to the current study, we don\u2019t see how that can be accurate. If the author has a financial relationship with a company that stands to benefit from the approach advocated in the study, that certainly seems relevant to disclose and the news release should have done so.", "answer": 0}, {"article": "First published on September 5, 2007 at 12:00 am\nMany who trained to use robots to do coronary bypass run out of patience after three or four procedures, Jeevanandam said, which is why he decided to hire Dr. Sudhir Srivastava, who performed hundreds of robotic bypasses while working at a center in Odessa, Texas.\nThe maker of the robotic systems, Intuitive Surgical Inc. of Sunnyvale, Calif., is an enthusiastic backer of the University of Chicago's initiative.\nThe robots have proven popular for urologic, gynecologic and some general surgery, Pappas said, but few coronary surgeons use them for valve repairs and fewer still do bypass procedures.\n\"The exactness of bypass surgery is so high that many people are reluctant to do it without tactile as well as visual feedback.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article\u2019s sources\u00a0include a physician who has devoted\u00a0the last five years of his career to the robotic surgery, three satisifed patients, a marketing representative of the company that makes the device and one doctor who is skeptical about the device\u2019s utility in heart bypass surgery. Interviewing additional dispassionate sources would have strengthened the story.\u00a0\nThe article makes a brief refererence to the device maker being an \"enthusiastic backer\" of the Chicago program, but fails to indicate whether there is a financial relationship beyond that of customer and vendor. The\u00a0subject of\u00a0whether\u00a0Srivastava has\u00a0financial ties to the maker should have been explored, or, if it was, should have been addressed in the story. ", "answer": 0}, {"article": "An international team of scientists found that Montmorency tart cherries helped to positively impact the gut microbiome - a collection of trillions of bacteria and other microbes that live in the intestinal tract.\nThe Cherry Marketing Institute, a not-for-profit organization funded by U.S. tart cherry growers and processors, provided financial support for the study.\nThe laboratory experiments were set up to mimic the conditions within the human digestive system, specifically the stomach, small intestine and three regions of the colon, to study how polyphenols are broken down and absorbed.\nThe individuals who ate a more plant-based diet, with higher intakes of carbohydrates and fiber, responded with an increase in Bacteroides and Bifidobacterium, presumably because of the specific combination of polysaccharides and polyphenols.\nHowever, when concentrated juices were fermented, this bifidogenic effect appeared to be leveled out by the larger increase of polysaccharides utilizing bacteria.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "It\u2019s mentioned that The Cherry Marketing Institute \u201cprovided financial support for the study.\u201d\nIt\u2019s not clear if any of the researchers involved have financial ties to the institute.", "answer": 1}, {"article": "Prozac was developed by Eli Lilly and is now available in a cheaper generic form as fluoxetine.\nThe cost of caring for its victims, who often have motor function difficulties like paralysis or weakness on one side, puts a heavy burden on already stretched healthcare systems.\nHemiplegia \u2014 paralysis to one side of the body \u2014 and hemiparesis \u2014 weakness on one side of the body \u2014 are the most common disabilities after stroke and scientists believe SSRIs might help improve movement by increasing the level of the brain chemical serotonin in the central nervous system.\nSignificantly greater improvements in motor function were recorded after three months in patients taking Prozac, where the average test score improved by 34.0 points, than in the placebo group, where the average improvement was 24.3 points.\n\u201cThe positive effect of the drug on motor function... suggests that the neuronal ... action of SSRIs provides a new pathway that should be explored further,\u201d said Francois Chollet of Toulouse University Hospital, who led this research.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The journal\u2019s editorial and one outside source, Roger Bonomo, were cited. The article would have benefited from independent quotes that counterbalanced the forward-looking statements about this preliminary study, as opposed to only using quotes that reinforced the authors\u2019 conclusions.\nDr. Chollet\u2019s conflict of interest was identified. We see no other relevant conflicts in the research that warranted disclosure in this story.", "answer": 1}, {"article": "Newswise \u2014 Eating a type of powdered food supplement, based on a molecule produced by bacteria in the gut, reduces cravings for high-calorie foods such as chocolate, cake and pizza, a new study suggests.\nAt the moment, the UK average is 15g.\"\nThis study illustrates very nicely that signals produced by the gut microbiota are important for appetite regulation and food choice.\nThe volunteers also had to rate how appealing they found the foods.\nProfessor Gary Frost, senior author of the study from the Department of Medicine at Imperial, said: \"Our previous findings showed that people who ate this ingredient gained less weight -- but we did not know why.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release discloses funding sources.", "answer": 1}, {"article": "\u201cSo this is a possible fringe benefit.\u201d\n\nResearchers studied 2,447 men over 12 years, examining them every other year.\nTaking aspirin every day may lower the risk for prostate enlargement, a new study has found.\n\u201cWe were pretty surprised by the strong association with objective things like the 49 percent reduction,\u201d he said.\n\u201cAt least half the patients I see are taking a daily aspirin for other health reasons,\u201d said Dr. Michael M. Lieber, an author of the study and a Mayo Clinic urologist.\nOther nonsteroidal anti-inflammatory drugs, or Nsaids, like naproxen (Aleve) or ibuprofen (Advil or Motrin), have the same effect.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article only quotes the lead investigator, which can be biasing. The article did not quote an independent source of information. ", "answer": 0}, {"article": "The report concluded that both are necessary for bone health but that as for preventing cancer, heart disease, diabetes and autoiummune disorders, the evidence was \u201cinconsistent, inconclusive as to causality, and insufficient to inform nutritional requirements.\u201d Even so, the committee recommended that children and adults up to age 70 get 600 IU of vitamin D daily \u2014 from food and, if necessary, supplements \u2014 and that adults age 71 and older get 800 IU.\nThese studies are as consistent as we have ever seen with any nutrient.\u201d\n\nBut, he adds, \u201cthose studies do not prove cause and effect.\nI just don\u2019t know which one.\u201d\n\nHurley is a science journalist and author of \u201cNatural Causes: Death, Lies and Politics in America\u2019s Vitamin and Herbal Supplement Industry\u201d (Broadway Books, 2007).\nSome studies have found no ill effects from taking far higher amounts, and many of the prospective but not proven benefits against cancer and other diseases are believed to require doses ranging from 2,000 to 5,000 IU.\nThe one thing the research leaders are certain of is that the public\u2019s faith in vitamin D as a modern panacea has far outpaced what the scientific evidence proves.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The experts cited are leaders in the field. (Well done on the part of the story to entice these folks to comment.) There do not appear to be any major conflicts among the sources quoted.", "answer": 1}, {"article": "Doctors say bronchial thermoplasty has given them a new weapon in the battle against severe asthma, and many patients call it life-changing.\n\u201cI\u2019m a language therapist,\u201d she said, \u201cbut I can\u2019t even think of the word to describe how much better this has made my life.\u201d\n\nAcross the country, about 24 million people suffer from asthma.\nAnd researchers at Washington University School of Medicine found that compared with a control group, bronchial thermoplasty patients saw their asthma attacks drop by a third, their emergency room visits fall by 84 percent, and the number of days they lost from work and school drop by 66 percent.\n\u201cFor those of us in the field who work with severe asthmatics and see how limited they are, it\u2019s frustrating because we have this new therapy, we\u2019ve seen it work, and the data says it works,\u201d said Dr. Roy St. John, a pulmonary disease specialist at Columbus Pulmonary and Critical Care in Ohio.\nThe one-time cost of $20,000, they say, is dwarfed by the tens of thousands of dollars in hospital bills and medication costs that a severe asthmatic can easily accumulate in a single year.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes quotes from several independent sources and from an insurance industry spokesperson, thereby satisfying our criteria. As noted above, however, we don\u2019t think it would have been difficult to find a clinical expert with a more skeptical view of the evidence supporting bronchial thermoplasty.", "answer": 1}, {"article": "There\u2019s ample reason for caution.\n\u201cIt\u2019s like a rocket that landed on Jupiter, rather than the moon.\u201d Still, Eckel warned it\u2019s too soon to say whether ancetrapib would actually prevent disease over the long run.\n\u201cIt appears to be safe and to not raise blood pressure,\u201d Shah told CNN, \u201cbut it\u2019s not a slam-dunk.\u201d For one thing, despite improved cholesterol levels, patients did not see less inflammation in their blood vessels.\nIf the same benefit were seen in all patients at risk of heart disease \u2013 far from a sure thing \u2013 it would translate to hundreds of thousands of fewer deaths and heart attacks over a five-year period, according to Dr. Christopher Cannon, the lead study author and a cardiologist at Brigham and Women\u2019s Hospital in Boston.\nThe first patients will be enrolled in April, according to Dr. Rory Collins of Oxford University, where the research will be overseen.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\n\nThis is a strong point of the story. It offers readers comments from several independent experts who highlight some of the key questions that still need to be investigated. (However, the story leaves all the caveats out of the lead paragraphs, so readers have to dig down to find the vital context.) It also points out that the trial was sponsored by the company developing this drug.\nThe story should have pointed out that the lead researcher has financial ties to this drug company and others, including board membership and grants.", "answer": 1}, {"article": "Information on breast cancer is available at cancer.gov.\nThe study did not find similar links between regular-dose aspirin or other NSAIDs and the risk for breast cancer.\nThe researchers analyzed data on 57,164 women, most in their early 60s, who had no history of breast cancer.\nAll were taking the medication at least three times a week.\nThose taking low-dose aspirin were 16 percent less likely to have developed any type of breast cancer, compared with women who took no NSAID.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story doesn\u2019t note who funded the research, nor does it incorporate input from independent sources.", "answer": 0}, {"article": "Her report is the latest warning from researchers who suspect that stents are being overused and may even be causing heart attacks and deaths.\nThey were in stable condition and free of chest pain, and were picked at random to receive either heart medicines only or balloon treatment and stents with heart medicines.\nAfter a few days have passed, though, there is little or no chance of preventing heart damage.\nThe people who generally do best are those who arrive at the hospital and have angioplasty within 90 minutes of the heart attack.\nThe 2,166 patients in the study had all suffered heart attacks 3 to 28 days before, caused by a completely blocked coronary artery.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The first author of the study discussed, the director of the NIH institute funding the study, and an expert in the field not associated with the study all appeared to be sources of information for this story.", "answer": 1}, {"article": "Previous studies of other antidepressants have yielded mixed results, according to Freeman.\n''We believe escitalopram provides an option for treating moderate to severe hot flashes that are disrupting people's lives and quality of life,\" says study researcher Ellen Freeman, PhD, a research professor in the department of obstetrics-gynecology and psychiatry at the University of Pennsylvania School of Medicine, Philadelphia.\nJan. 18, 2011 -- Low doses of the antidepressant Lexapro (escitalopram) cooled off hot flashes better than placebo in about 200 menopausal women, according to a new study.\nThe new study findings suggest Lexapro can provide an option for women reluctant to take hormone therapy.\nIn the study, Freeman found the antidepressant reduced both the number and severity of hot flashes compared to placebo.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an independent expert who seems generally supportive of antidepressant therapy for hot flashes. While we don\u2019t think it would have been difficult to find someone\u00a0with a more skeptical take\u00a0on the results, which would have added value for readers,\u00a0the story\u00a0did enough to satisfy this aspect\u00a0of the criterion.\n(UPDATED COMMENT INSERTED ON 2/24/11:\u00a0 We originally but erroneously wrote that this story failed to disclose potential conflicts of interest. But it actually did, when it stated:\u00a0\u201cThe study was funded by the National Institute on Aging and other sources. Freeman reports having received research support from Forest Laboratories Inc., and other pharmaceutical companies that make antidepressants. For this study, Forest, which makes escitalopram, provided the drug and placebo pills but no funding.\u201d)", "answer": 1}, {"article": "It was not present in the healthy volunteers.\n\u201cIt kills people and it kills them quickly.\u201d\n\nA screening test could have a huge effect, said Dr. Timothy Donahue, an associate professor of surgery and molecular and medical pharmacology and chief of pancreas and gastrointestinal surgery at the University of California, Los Angeles.\nIt is a good example of how this disease sneaks up on people and gives no warning.\u201d\n\nA test for pancreatic cancer could save lives, perhaps even Flippo-Morton\u2019s, Raghavan said.\nBut, he said, \u201cthis is just a speculation based on the current strength of the study.\u201d\n\nHad such a test been available, it might have save the life of Dr. Teresa Flippo-Morton, a prominent breast surgeon from Charlotte, N.C.\n\n\u201cShe was an expert in oncology,\u201d said Dr. Derek Raghavan, a colleague and president of the Levine Cancer Institute where Flippo-Morton worked.\n\u201cUsing this test we were 100 percent accurate at identifying all cancer patients.\u201d\n\nIn 2015 48,960 Americans will be diagnosed with pancreatic cancer, according to estimates by the National Cancer Institute.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We give the story a pass here because there are multiple voices in the piece. But it should be noted that there was only one dissenting opinion, at the very end, from Dr. Brian Wolpin, of the Dana Farber Cancer Institute. He brought up the point that should have been in the second paragraph of the story: \u201cIn this study the patients were known to have cancer or not to have cancer. In this kind of sample sensitivity and specificity tend to look good.\u201d", "answer": 1}, {"article": "NEW YORK (Reuters Health) - New findings add to confusion over whether taking aspirin, ibuprofen or related painkillers reduces the risk of developing melanoma.\nThe findings are interesting, but should not lead people to conclude that popping a few painkillers will reduce their risk of skin cancer, cautioned Dr. Maryam Asgari of Kaiser Permanente Northern California and the University of California San Francisco, who co-authored the 2008 study.\nAnimal experiments have suggested that the class of painkillers known as nonsteroidal anti-inflammatory drugs (NSAIDs) could play a role in preventing melanoma, but a large 2008 study failed to find any evidence to support this possibility.\n\u201cI think it\u2019s just too early\u201d to say NSAIDs offer any protection, she said.\nAs a result, \u201cI wouldn\u2019t recommend (taking NSAIDs to reduce melanoma) just based on this\u201d new study, Asgari noted.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story turned to Dr. Maryam Asgari of Kaiser Permanente Northern California and the University of California San Francisco, who co-authored a 2008 study.\u00a0 Oddly, no author/researcher on the new study was quoted.", "answer": 1}, {"article": "Research has shown that giving statins to patients who already have Alzheimer's does not seem to help.\n\"It seems as though the statins because they lower cholesterol reduce production of these plaques,\" said Dr. Gayatri Devi.\n\"But statins as prevention for Alzheimers is not indicated at this time.\"\n\"What it tells us is that statins might not be effective in slowing the progression of disease, but they might ... prevent disease,\" said Mary Haan of the University of Michigan.\nThose who were taking a cholesterol-lowering statin such as Lipitor, had a surprising result.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The reporter talks to one of the researchers on the study, and an expert with no relationship to the study. \nThis is adequate sourcing. A third source would have improved the story.\u00a0 ", "answer": 1}, {"article": "Saline \u2014 salt dissolved in water \u2014 has been the most widely used fluid in the U.S. for more than a century even as evidence has emerged that it can harm kidneys, especially when used a lot.\n\u201cWe\u2019ve been sounding the alarm for 20 years\u201d about possible harms from saline, said Dr. John Kellum, a critical care specialist at the University of Pittsburgh.\nChemotherapy is administered to a cancer patient via intravenous drip in Durham, N.C. IVs are one of the most common things in health care.\nSince there are about 30 million people hospitalized in the U.S. alone each year, \u201cthere are tens or hundreds of thousands of patients who would be spared death or severe kidney problems by using balanced fluids instead of saline,\u201d said one study leader, Vanderbilt\u2019s Dr. Matthew Semler.\nThey\u2019re widely used in Europe and Australia.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two sources: One not involved with the study, and one who\u2019s a study leader.\nIt\u2019s mentioned \u201cfederal grants helped pay for the work,\u201d which is sufficient.", "answer": 1}, {"article": "\"It is extremely common for patients with AF to seek treatment that does not involve the use of chronic oral anticoagulants therapy, as there are other risks associated with their long term use,\" said co-author Francis E. Marchlinski, MD, FHRS, director of Electrophysiology for the University of Pennsylvania Health System and Richard T. and Angela Clark President's Distinguished Professor in the Perelman School of Medicine at the University of Pennsylvania.\nOf these patients, 84 had been ablated, sixteen were being treated with drug therapy, and three had implanted devices that served as a quality control check.\nPatients were provided with novel oral anticoagulants and were instructed to start taking the medication if they suspected or detected an AF episode lasting longer than one hour.\n\"These are patients who were actively seeking, preparing for and are committed to the alternate treatment method, and who are informed about how to diligently and effectively monitor their pulse throughout the day.\"\n\"While this is an observational study with a relatively small patient sample, further research is certainly needed to better understand alternate treatment options,\" said Pammer.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "It seems that the funding sources are very transparent as is the involvement of the researchers.", "answer": 1}, {"article": "But a new study suggests an existing medication may help.\nFor example, the drugs may raise the risk for problems with short-term memory, reasoning and confusion, and may also hike the risk for dementia among older patients, studies indicate.\n\"This study makes me hopeful that these patients may have a way out of their dilemma,\" Police said.\nThe study found that women taking the medicine had an average of five fewer hot flashes a week, compared with three fewer among women taking a placebo.\nAnd oxybutynin doesn't interfere with the metabolism of tamoxifen, Leon-Ferre said, calling that an important consideration for breast cancer survivors.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article quotes Dr. Alice Police, regional director of breast surgery at the Northwell Health Cancer Institute in Sleepy Hollow, NY, who was not affiliated with the study. We did not detect any conflicts of interest that should have been disclosed.", "answer": 1}, {"article": "It is \"a significant problem in the military,\" said Taylor, who noted that military personnel often develop insomnia because of rapidly changing schedules and deployments that keep them constantly on alert.\nA third control group of participants was contacted by the researchers every other week during the six weeks, but did not receive cognitive behavioral therapy.\nAll completed one week of sleep monitoring by keeping sleep diaries and wearing activity monitors.\n\"Successful treatment has a real impact on patients' daily lives.\nFor deployed military personnel, the side effects such as grogginess, slowed cognitive processing and slowed reaction time can be dangerous,\" Taylor said.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release names the funding source. The researchers reported no conflicts of interest.", "answer": 1}, {"article": "Interval cancers are those found between mammograms, either through additional tests or symptoms.\n\"Screening mammography does work well in women with a history of breast cancer, so they should continue to get their annual screening mammogram,\" said Diana Miglioretti, senior investigator at Group Health Research Institute in Seattle and a co-author of the new research.\nIn their study, published in the Feb. 23 issue of the Journal of the American Medical Association, Miglioretti and her colleagues found that false positives and interval cancers were both higher in women with a history of breast cancer than in those without such history.\nThe interval cancer rate was 3.6 per 1,000 screenings in those with a history and 1.4 per 1,000 in those without, the investigators found.\nIt points to the need, she said, for women to remain vigilant about screening after their breast cancer treatment -- and to report any symptoms to their doctor immediately.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Quotes from two independent sources are included in the article.\u00a0 Dr. William Audeh, director of the Wasserman Breast Cancer Risk Reduction Program at Cedars-Sinai Medical Center,\u00a0presents possible explanations for\u00a0some of the higher false positives among\u00a0women with a\u00a0personal history of breast cancer.\u00a0 Quotes from both Dr. Audeh and\u00a0Dr. Robert Smith, director of cancer screening for the American Cancer Society,\u00a0point out that screening mammography may not have been as effective among women with\u00a0a personal history of breast cancer as it was\u00a0in those without a breast\u00a0cancer\u00a0diagnosis but that most of the cancers detected were stage I or ductal carcinoma in situ, a non-invasive breast cancer. The article could have noted that study authors declared no conflicts of interest\u00a0and\u00a0\u00a0that the study was funded by a grant from the National Cancer Institute.", "answer": 1}, {"article": "With the memory of Memorial Day cheeseburgers and bratwursts still lingering, many of us may be relieved to hear that a new study suggests that a meaty, high-fat, Atkins-style diet can do more than contribute to rapid weight loss.\nThe volunteers, all of whom exercised, generally became more physically fit during the study, Dr. Stewart said.\nThe full study will monitor the volunteers for six months and include additional measures of cardiovascular health after both diets.\nBut so did the low-carbohydrate, high-fat group.\n\u201cThose on the high-fat diets showed no harmful impacts\u201d after 45 days or so, she said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several individuals who were not connected with the study reported provided comments and context for thinking about the diets discussed.", "answer": 1}, {"article": "Merck & Co. and Schering-Plough Corp. said a long-awaited trial showed their cholesterol drug Vytorin failed to slow progression of heart disease better than a cheaper drug, threatening the companies' $5 billion-a-year cholesterol-fighting franchise.\n\nSchering-Plough's shares fell 8% to $25.52 and Merck declined 1.3% to $59.78 at 4 p.m. in New York Stock Exchange composite trading.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story included interview quotes from individuals involved in the field of cardiovascular outcomes research, cardiologists, and company spokespeople.", "answer": 1}, {"article": "LONDON (Reuters) - British scientists conducting early-stage research have found that a potential new drug from GlaxoSmithKline could treat mixed-lineage leukemia(MLL) \u2014 the most common form of leukemia in babies.\n\u201cEven though this is still lab-based ... it validates the idea of developing small molecules against epigenetic switches,\u201d he said in an emailed comment.\nKevin Lee, head of epigenetics discovery research at GSK, who also worked on the study, said he too was excited about the findings, although it will probably be many years before the drug could potentially reach the market.\n\u201cWe urgently need better ways to treat children with more aggressive forms of leukemia, such as MLL,\u201d said Lesley Walker, CRUK\u2019s director of information.\nAccording to Cancer Research UK, eight out of 10 children with leukemia in Britain now survive for five years or more, compared with one in 10 in the late 1960s.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources quoted in the story.", "answer": 0}, {"article": "A minimally invasive procedure designed to shrink prostate tissue with a series of nine-second blasts of steam offers men a new treatment for urinary symptoms commonly associated with enlarged prostates.\n\nThe procedure, called Rez\u016bm (pronounced \u201cresume\u201d) and developed by NxThera Inc. of Maple Grove, Minn., became widely available in the U.S. in the second half of 2016. Thermal energy in the form of steam is applied to the prostate with a needle. As it cools it releases heat energy into the tissue, killing cells and shrinking...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources here. Claus G. Roehrborn, who is referred to as a co-author on studies of enlarged prostate treatments, is a paid consultant to the study\u2019s funder, NxThera (see\u00a0this 2015 paper), but the story didn\u2019t disclose that. As noted above, input from an independent source would have made this story much stronger.", "answer": 0}, {"article": "Alexander Technique is a series of posture lessons, devised by a 19th century Australian actor named F.M.\n\"We look at what you are doing that causes that problem in the first place, so how you sit at the computer or how you pick up your child or what you do when you're driving,\" says Gray.\n\"The people who had 24 lessons had gone down from about 21 days of pain that the usual care group reported to about 3 days in pain,\" says Little.\n\"The whole point is that you understand the process so that you can arrive there yourself,\" says Gray.\n\"The fact of having your arms up and carrying the weight of this instrument and pushing the instrument toward you and so you have this stress, this wall you're pushing against,\" says Rodriguez.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article did not include commentary from an independent expert source\u2014to its detriment. Independent commentary might have allowed readers to come to a much better understanding of the potential benefits of the Alexander Technique, and the level of evidence supporting it. The journalist did not provide any information on potential conflicts-of-interest.\n\n \n", "answer": 0}, {"article": "Patel says that makes the impact of the case study \u201cstartling and exciting\u201d because if studies bear the findings out, deep brain stimulation may one day help people with hypertension whose blood pressure remains uncontrolled on multiple medications.\n\u201cWhat their case report shows is that blood pressure can be reduced in a sustained fashion in a patient with unsuccessful deep brain stimulation for pain,\u201d says Erlick Pereira, MD, a neurosurgeon at the University of Oxford.\n\u201cPain creates stress and that can have an effect on one\u2019s blood pressure,\u201d says Nikunj J. Patel, MD, a neurosurgeon at Frenchay Hospital in Bristol, U.K., and an author of the case study.\nDoctors in the U.K. made the discovery after implanting a device that works as an electric stimulator of a region of the brain in a 55-year-old man who had developed chronic pain on the left side of his body following a stroke.\nThat was a surprise because experts had long thought that pain had to be reduced to see a reduction in blood pressure.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story features two interviews, one with an author of this case report, and another with an expert who also reported observing a blood pressure lowering-effect of DBS in a patient (though this may have been related to the patient\u2019s pain relief and not directly attributable\u00a0to the DBS device). While these individuals are clearly knowledgeable, they both are sympathetic to the idea that DBS may lower blood pressure, and neither could be called truly independent. One of these experts \u2014 Erlick Pereira \u2014\u00a0has done work sponsored by Medtronic, one of the leading DBS implant makers (as discussed here).\u00a0 In addition, according to coverage of this most recent case report in MedPageToday,\u00a0Patel and some of his coauthors disclosed financial relationships\u00a0with manufacturers of DBS devices.", "answer": 0}, {"article": "Nov. 5, 2012 (Los Angeles) -- An IV infusion of \"good\" HDL cholesterol seems to rapidly remove cholesterol out of plaque-clogged arteries following a heart attack, a small, early study suggests.\nIn the year after a heart attack, about 12% of people have a second heart attack or stroke.\nAnd half of them happen in the first month, says researcher Andreas Gille, MD, PhD.\nHDL removes cholesterol from artery walls, but current HDL-boosting drugs, such as niacin and fibrates, take years to work, according to Gille.\nStandard heart attack medications, such as aspirin and anti-clotting drugs, prevent clotting but don\u2019t eliminate an underlying factor: cholesterol that has built up on artery walls, he says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One independent expert provided the only balance and the only caveat in the story.", "answer": 1}, {"article": "In late July, Sen. David Vitter, R-Louisiana, wrote a letter to the FDA saying that there are no new safety concerns and that \"the [FDA advisory] committee's concerns appear to have been based on cost-effectiveness.\"\nIf it's not available, Blackwell says, \"I'm going to have to give older drugs with the exact same toxicity.\nSusan Pisano, a spokeswoman for the Association of Health Insurance Plans, the largest trade group, said insurers would wait for guidance from the FDA, but adds, \"If the FDA pulls back its approval for this particular indication, it would trigger a review of plan policies.\nAnother breast cancer specialist, Dr. Edith Perez, deputy director of the Mayo Clinic Cancer Center in Jacksonville, Florida, says many chemotherapy drugs, such as Gemzar -- which is substantially less expensive than Avastin -- have previously been approved without showing they can lengthen survival.\n\"There was a delay in progression of the tumor, but it had no effect on quality of life, or survival,\" Visco says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes interviews with individuals who are for and against revoking Avastin\u2019s approval, providing some counterbalance; however, the focus on the personal success story of one patient tips this balance.\u00a0 Because of the strong comments by people like Fran Visco and some of the physicians quoted, we\u2019ll give this story a satisfactory score on this criterion. \nHowever, if you\u2019re going to play the personal anecdote game, we think you have an obligation to balance the glowing positive story with the more representative story of people who didn\u2019t benefit. The plural of anecdote is not data. \nAlso, from a balance perspective, why wasn\u2019t the statement of Senator David Vitter \u2013 who has politicized breast cancer a number of times without showing a concern for evidence \u2013 balanced by a statement from a politician who is more evidence-based?\u00a0 Again, if you\u2019re going to play the politics game, how about leveling the playing field a bit? ", "answer": 1}, {"article": "The testing is done under medical supervision.\n\"We found that 14 percent of the patients challenged had mild or moderate allergic reactions,\" explains study author Carla Davis, an allergist and director of the Food Allergy Program at Texas Children's Hospital.\nAs we've reported, people sometimes misinterpret the symptoms of a condition such as lactose intolerance for a food allergy.\nThis Test Can Determine Whether You've Outgrown A Food Allergy\n\nAn estimated 4 percent of Americans have food allergies, and the Centers for Disease Control and Prevention has concluded that allergies are a growing public health concern.\nBut the only way to confirm that it was safe for Jula to eat egg was to take the food challenge test.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites one expert not involved in the research, and we could find no potential conflicts of interest that should have been disclosed. The independent source provided a quote that we wished had been explored more in-depth: \u201cBut it\u2019s also possible [some of them] never truly had a food allergy.\u201d This is an important point\u2013how much did the study help actually overturn incorrect diagnoses?", "answer": 1}, {"article": "You have to take your temperature every morning and record that, because without all that data it's not really any use to you,\" Bekki Burbidge, head of communications at the FPA, told BuzzFeed News.\nAnd if the app gives you a \"red day\" \u2013 meaning you could be fertile \u2013 you have to abstain from sex, or use another method of protection such as condoms.\nTaking your temperature is what sets Natural Cycles and other apps like it apart from standard period-tracking apps.\n\"Our typical user is in a stable relationship a few years before wanting to have kids.\nThe app was approved as a class IIb medical device by T\u00fcv S\u00fcd, a notified body in Sweden where it is based.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "In addition to talking to the founder of the company that produces\u00a0the app, the story includes two independent experts who comment on the app and on aspects of sexual biology.", "answer": 1}, {"article": "According to the new analysis, published online Jan. 4 in the Mayo Clinic Proceedings, the only difference between the medications is that ARBs are more easily tolerated.\n\"We believe that our study ends the debate and gives physicians the option to prescribe either drug for their patients,\" added Bangalore, an associate professor in the division of cardiology, in the department of medicine at NYU Langone.\nAlthough ACE inhibitors were developed 10 years earlier, both types of drugs showed similar effects in the analysis, challenging previous findings that suggest ACE inhibitors have greater benefits.\n\"There has been debate for many years over the safety and efficacy of ACE inhibitors compared to ARBs, with many of them using an 'ACE inhibitor-first' approach, with ARBs regarded as less effective,\" study author Dr. Sripal Bangalore said in a medical center news release.\n\"This is the first time that we have a clear and consistent message from the three buckets of trials of ACE inhibitors and ARBs, all of which show that there is no outcome difference between the two agents, except for better tolerability of ARBs,\" Bangalore said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story quotes only the primary author as a source, failing to offer additional perspectives.\u00a0 It also fails to mention that some of the authors have ties to major pharmaceutical firms which, while not directly impacting the quality of the research, is information that readers should be aware of in cases of stories about medications made by such companies.", "answer": 0}, {"article": "One of the top research universities in the world, MSU focuses its vast resources on creating solutions to some of the world\u2019s most pressing challenges, while providing life-changing opportunities to a diverse and inclusive academic community through more than 200 programs of study in 17 degree-granting colleges.\nUp until then, it was unclear how these compounds, also known as cannabinoids, affected the immune system.\n\u201cIt might not be people smoking marijuana,\u201d Kaminski said.\nYet, even with this therapy, certain white blood cells can still be overly stimulated and eventually become inflammatory.\nWith antiretroviral therapy \u2013 a standard form of treatment that includes a cocktail of drugs to ward off the virus \u2013 these cells have a better chance of staying intact.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding sources of the study are not mentioned.", "answer": 0}, {"article": "While the cause of Alzheimer's remains elusive, it is clear that maintaining a healthy blood-brain barrier is a critical preventative measure.\nFox Foundation and the Osteopathic Heritage Foundation.\nIt is among the top 10 causes of death in America.\nIn Alzheimer's, the brain begins to change years before symptoms emerge.\nOMED 15 is a five-day event offering clinical and research updates in 15 specialties, with an emphasis on osteopathic principles and practices.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Two funding sources for the research are disclosed.", "answer": 1}, {"article": "TUESDAY, Jan. 12, 2010 (HealthDay News) -- Blood pressure drugs that block the protein angiotensin appear to reduce the risk of developing Alzheimer's disease and other forms of dementia, a new study finds.\n\"Any study like this is hypothesis-generating,\" he said.\nCalled angiotensin receptor blockers, these drugs have a greater protective effect against dementia than ACE inhibitors, the study found.\nIt is produced when enzymes act to convert a precursor molecule, angiotensinogen.\nAngiotensin causes blood vessels to constrict, raising blood pressure.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did quote one independent expert who injected a cautionary note \u2013 in addition to the lead researcher. ", "answer": 1}, {"article": "The World Health Organization estimates that more than 300 million people suffer from clinical depression world-wide. But cost, time, stigma, distance to travel, language barriers and other factors prevent many from seeking help.\n\nNow, a growing group of health-care providers are betting that technology\u2014from web-based courses to mobile apps that send prompts via text\u2014can help bridge that gap.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Another cautious \u201cSatisfactory.\u201d One source is clearly identified as someone independent of one of the studies cited.\u00a0 Two others experts are not so identified but are not listed as coauthors on any of the studies.\u00a0 Funding for those studies is not mentioned.\nIt\u2019s worth noting here that two of the sources seem to be heads of institutes that are involved in the development of technological/Internet-based treatment approaches; both could benefit financially from being able to treat many more\u00a0patients online.\n\u00a0", "answer": 1}, {"article": "For more information, visitwww.asmbs.org.\nInaddition to Dr. Chuttani, study authors of the abstract entitled,\u201cThe First Procedureless Gastric Balloon: A Prospective StudyEvaluating Safety, Weight Loss, Metabolic Parameters and Quality ofLife,\u201d include, Evzen Machytka MD, PhD, Martina Bojkova MD, TomasKupka MD, and Marek Buzga MSc, PhD from the University of Ostrava,Ioannis Raftopoulos MD, Andreas Giannakou MD, and Kandiliotis IoannisMD from the Iatriko Medical Center, and Kathy Stecco MD, Samuel LevyMD, and Shantanu Gaur MD, from Allurion Technologies.\nThetreatment involves patients swallowing a capsule that quicklydissolves in the stomach to reveal a deflated gastric balloon inside.With a thin catheter attached to the device, but long enough toremain outside the patient\u2019s mouth, a physician fills the balloonwith fluid (550 mL) to about the size of a grapefruit.\n\u201cFor many struggling with theirweight, procedureless gastric balloon devices may serve as atreatment option that bridges the gap between weight-loss drugs andsurgery.\u201d\n\nTheU.S.\n\u201cOur findings demonstrate that Elipseprovides individuals and their caregivers with a safe, effective, andnon-invasive weight loss intervention that does not require surgery,endoscopy, or anesthesia.\u201d\n\nResearcherspresented interim results for the first 34 patients of a multi-centerstudy that showed individuals lost an average of 22 pounds after fourmonths or 37 percent of their excess weight.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release states that the manufacturer is \u201cstudying what it says is the first procedureless gastric balloon.'\u201d It isn\u2019t exactly clear what role the the manufacturer had in the study but the release does disclose that one of the quoted study co-authors \u201cholds an equity position in Allurion Technologies,\u201d the manufacturers of the device. This means he has an ownership interest in the company and will profit if the device is approved and adopted.", "answer": 1}, {"article": "After several trips to the doctor, the Mullins received the worst possible news.\n\"It's wonderful to go and talk to a parent, whose child has just diagnosed with an advanced neuroblastoma and say the odds of being cured has increased dramatically,\" said Dr. M. Fevzi Ozkaynak with the Maria Fareri Children's Hospital at the Westchester Medical Center in New York.\n\"I've been through it, it was the past, time to move on,\" he said.\nBut then his doctor offered an additional step: an experimental treatment called immunotherapy, in which antibodies that target the cancer are injected into the bloodstream and attach to the tumor cell.\nOne tagged with antibody, the cancer can be more easily recognized and attacked by the body's own white blood cells.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The experience of one patient, and the thoughts of his parents and his doctor (who was also a co-author of the abstract) were included in the story. \u00a0There was no interview with independent experts in childhood cancers or neuroblastoma specifically. This would have help provide context for viewers about the likely impact of this treatment. \u00a0", "answer": 0}, {"article": "But should a woman undergoing natural menopause try acupuncture for hot flashes?\nThe results with the sham acupuncture, which bested gabapentin, suggest that \"there is more than a placebo effect with the sham acupuncture,\" said Dr. Gary Deng, interim chief of the integrative medicine service at Memorial Sloan Kettering Cancer Center in New York City.\nFurthermore, the effects of acupuncture were \"significant and enduring for hot flashes while gabapentin's effect only happened when a patient was taking the medication,\" said study first author Dr. Jun Mao, an associate professor of family medicine and community health at the University of Pennsylvania in Philadelphia.\nOne big distinction between the two populations, though, is that breast cancer survivors do not have the option of hormone replacement therapy open to them because those hormones are linked to breast cancer.\n\"For patients suffering symptoms, they can look for all kinds of possible solutions and are better off talking to their doctor to find out what's most appropriate for them,\" Deng said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The fact that two of the study authors consult for Pfizer, which makes gabapentin, merited a brief disclosure/acknowledgment in the story, and the lack of such disclosure is the basis for our Not Satisfactory rating here. We did enjoy the observations of outside expert Dr. Gary Deng, who was consulted about the effects of placebo and had some interesting comments to share with readers. We wish the story had also included a direct expert comment regarding the quality of the study and the patient-care implications of the findings.", "answer": 0}, {"article": "\"The positive effects of bariatric surgery on health outcomes -- such as diabetes and cardiovascular disease -- are reasonably well-studied, but less is known about the effects on pregnancy and [post-delivery] outcomes,\" Johansson pointed out.\nHowever, the weight-loss surgery group was twice as likely to give birth to babies considered small for their gestational age, and their pregnancies were also of slightly shorter duration.\n\"I don't think pregnancy should be the thing that tips the scale,\" said Caughey.\nThey recommended any pregnancy after weight-loss surgery be considered high-risk and receive stricter monitoring.\n\"Also, many women in our study may have been continuing to lose weight when they became pregnant.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article quotes the independent source who wrote the editorial that came with the research article. This is a strong point of the story\u2019s coverage.", "answer": 1}, {"article": "People with painfully damaged knees and hips have increasingly turned to \"minimally invasive\" joint-replacement surgery. But these relatively new procedures, though they promise shorter recuperation times, are raising concerns about potential complications.\n\nMany surgeons in recent years have performed joint replacements with ever smaller incisions. In minimally invasive surgery, the incision is typically about three to four inches long, roughly half that of traditional surgery. By cutting less of the surrounding tissue...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\nThe story cites three patients, three orthopaedic surgeons, and one spokesperson for a company that manufactures the implants and tools used in the new procedure.\u00a0 ", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061008/16healthwatch.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story included a comment from the first author of the study from which the results were derived. There was no obvious attempt to get independent insight about the study results. A quote from a nutritional epidemioloigst not associated with the study would have given some perspective on the observations reported on in the story.", "answer": 0}, {"article": "The research, published online in Alzheimer's & Dementia: The Journal of the Alzheimer's Association, studied participants in the Baltimore Experience Corps, a program that brings retired people into public schools to serve as mentors to young children, working with teachers to help them learn to read in understaffed school libraries.\nThe control arm of the study, those not involved in Experience Corps, exhibited age-related shrinkage in brain volumes.\nExperience Corps is a national program, however it can be costly and isn't available everywhere.\nThey took MRI scans of their brains at enrollment and then again after 12 and 24 months.\nParticipants were an average of 67.2 years old, predominantly African-American, were in good health, came from neighborhoods with low socioeconomic status and had some college education.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release clearly lists the funding sources.", "answer": 1}, {"article": "He is an associate professor in the department of infection and obesity at the Pennington Biomedical Research Center in Baton Rouge, La.\nThe research was funded by the American Egg Board, and will be presented at the19th European Congress on Obesity in Lyon, France.\n\"This study shows that diets with higher protein quality may enhance satiety, leading to better compliance and success of a weight loss diet,\" researcher Nikhil Dhurandhar, PhD, says in a news release.\nFor people hoping to shed some pounds, changing the type of protein in the diet, rather than the amount of it, is an idea the researchers think deserves more study as a weight loss strategy.\nIn a small study, it took longer for people who ate eggs for breakfast to show signs of hunger than it did for those who had a bowl of ready-to-eat cereal.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story notes that the study was funded by egg producers, but the only source quoted is the study author. This story would have benefited immensely from an independent perspective.", "answer": 0}, {"article": "[2] This number is expected to double every 20 years, reaching 74.7 million in 2030 and 131.5 million in 2050.\nSince its establishment, evidence has been accumulated to support the hypothesis that certain nutritional molecules are beneficial in reducing disease progression in Alzheimer's.\nDuring its years of activity, preclinical and epidemiological evidence was accumulated to support the hypothesis that certain nutritional molecules could be beneficial in reducing disease progression in Alzheimer's.\nAnd for those who start the intervention early and consumed it regularly, it can help to conserve memory and the ability to think and perform everyday tasks.\nThe primary outcome parameter was selected to assess the effect on cognitive function (a broad measure of thinking) during 24 months intake of Fortasyn Connect compared with a control product.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release focuses on the involvement of the European Commission, but it omits the involvement of Dannon, the massive food company, which holds the patent on the nutritional drink being studied.", "answer": 0}, {"article": "\"In addition, it is unknown whether bevacizumab [Avastin] increases survival when added to cisplatin-based chemotherapy in patients with advanced non-squamous non-small-cell lung cancer,\" Pirker said.\nThe funder was involved in study design, coordination of data collection, data analysis, data interpretation, and writing of the report, the journal noted.\n\"So, the researchers and sponsors are to be congratulated for doing this study.\nIt's possible the FDA will withdraw approval of Avastin as a breast cancer treatment.\nThe patients were treated at centers in 40 countries around the world.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0Several sources were quoted who did not have a direct connection to the study reported on or to the company. \u00a0The story indicated clearly that the study reported on was funded by the maker of the drug studied.", "answer": 1}, {"article": "What does that mean for men today?\nStill, growing numbers of doctors are using the method already to help decide when to order a biopsy, and \"I think the study does raise the question as to whether PSA velocity may at some point be a helpful factor in determining prognosis,\" he said.\nThose with a higher PSA velocity \u2014 the level rose more than a count of 0.35 a year \u2014 had a 54 percent survival rate, while those whose PSA rose more slowly had a 92 percent survival rate.\nWASHINGTON \u2014 Prostate cancer is more likely to be life-threatening if the man's PSA level rose rapidly during the years before he was diagnosed, says a new study that may help change how PSA tests are used.\nHow fast a man's PSA was rising a decade before his cancer was diagnosed \u2014 even before it reached that biopsy-triggering level of 4 \u2014 predicted his survival 25 years later, regardless of his ultimate cancer treatment, Carter concluded.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article quotes the lead author, who has very encouraging things to say about using PSA velocity to screen men for prostate cancer.\u00a0 The author even goes so far as to encourage men have a baseline PSA test at age 40, which is not currently part of any guidelines.\u00a0 The article also obtains independent input from a physician who cautions readers about the value of PSA velocity, providing balance to the lead author's comments.\u00a0 The line \"The study is far from proof that making health decisions based on the so-called PSA velocity can really save lives\" also helps provide balance to\u00a0the lead author's\u00a0enthusiasm.", "answer": 1}, {"article": "\"You're going through all this suffering and stuff and you want to know, am I going to survive?\nThe researchers reported that just one week after treatment began, they could tell with 93 percent certainty which patients would eventually respond to the drug and which would not.\nThe new research tests both standard PET scans and a newer approach that involves injecting a different tracer substance.\n\"Our hope ... is you might be able to give a single dose of a chemotherapy agent and within a day or two figure out whether the tumor is going to respond,\" says Dr. Michael Graham of the University of Iowa.\nUnlike CT scans or MRIs, PET scans can show a tumor's internal activity, not just its size.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Sources include: \nNo independent sources are consulted to provide context or less enthusiastic viewpoints.\nThe story did not report whether any of the sources has a financial conflict of interest. \u00a0 ", "answer": 0}, {"article": "Frustrated by the high relapse rate of traditional addiction treatments, scientists are working on a strategy that recruits the body's own defenses to help addicts kick drug habits.\n\nThe new approach uses injected vaccines to block some addictive substances from reaching the brain. If a vaccinated addict on the path to recovery slips and indulges in a drug, such as tobacco or cocaine, no pleasure will result.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The sourcing of this story was good. We hear from\u00a0academics, government researchers, and industry executives. Their voices provide balance and give texture to the coverage.\u00a0It should be noted, however, that most of these experts have a vested interest in the field or the success of a particular treatment, whether because of industry ties or because they are leading experiments on\u00a0a particular approach. Even the government experts might be biased by their provision of significant financial support for research in this area. It would have been nice to hear\u00a0a comment about the vaccines from someone\u00a0who is certifiably free of all potential conflicts.\u00a0\u00a0But we can\u2019t justify docking points\u00a0since there is no voice that is overly enthusiastic about the concept.", "answer": 1}, {"article": "The moderate dose also prompted a drop in the ability to accurately recognize fear in other people's faces, determined by having the participants look at a range of photos, the study found, but it did not affect the ability to perceive the shifting cues in a person's eyes or voice, determined by having the participants listen to a series of audio clips.\nThe study, funded by the U.S. National Institute on Drug Abuse and conducted at the Human Behavioral Pharmacology Laboratory at the University of Chicago, was published in the Dec. 15 issue of Biological Psychiatry.\nIn fact, those who took the drug actually rated themselves as more sociable than those taking MDMA.\n\"Many things can be life-threatening or dangerous if used incorrectly.\nA moderate dose of MDMA was found to significantly increase feelings of loving, friendliness and playfulness, the researchers said, whereas the low dose of MDMA boosted feelings of loneliness.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There was no truly independent source quoted.\u00a0 The only quote coming from anyone outside the current research team came from a researcher who also reported on MDMA research months ago.\nWhat about the observation of someone who does not have a dog in the hunt?", "answer": 0}, {"article": "MORE: A Cheaper Way to Quit Smoking?\nThe research was funded by the National Institute on Aging, but some of the authors also receive pharmaceutical industry funding and one reported funding from Philip Morris.\nThe randomized controlled trial included 74 people, mainly in their late 70\u2019s, with mild cognitive impairment (MCI).\nThe authors conclude, \u201cThis initial study provides evidence for nicotine-induced cognitive improvement in subjects with MCI; however, whether these effects are clinically important will require larger studies.\u201d\n\nThe study found no problematic side effects associated with the nicotine patch and none of the patients had withdrawal symptoms when it was stopped.\nHowever, patients on nicotine did lose a few pounds, which is a known side effect.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We can\u2019t give this a satisfactory score because, unlike the MSNBC story, this one does not include any information from clinical experts not involved in the study.\nIt does, however, note that some of the authors on the study have received drug company funding and funding from tobacco makers. It also noted that the nicotine patches themselves were provided by Pfizer.", "answer": 0}, {"article": "Schubiner also acknowledged that this general \u201cmodel\u201d for understanding and addressing fibromyalgia pain is controversial.\nThe precise cause of fibromyalgia is unknown \u2014 there are no physical signs, such as inflammation and tissue damage in the painful area \u2014 but some researchers believe the disorder involves problems in how the brain processes pain signals.\nThat is not to say that the pain people with fibromyalgia feel is \u201call in their head,\u201d stressed Dr. Howard Schubiner, of St. John Health/ Providence Hospital and Medical Centers in Southfield, Michigan.\nAnother difference is that, right now, only a small number of healthcare providers practice affective self-awareness, according to Schubiner.\nThat is important because it is possible for patients to benefit from simply receiving attention from a healthcare provider, or being part of small-group sessions with other people suffering from the same condition, for example.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included only one expert source, Dr. Howard Schubiner, who in addition to being\u00a0an author on the paper\u00a0is also the original developer of affective self-awareness therapy. While these credentials no doubt make him an authority on the treatment and an important\u00a0interview subject, they\u00a0also create the appearance that he\u00a0could be biased in\u00a0favor of the approach. Another expert perspective would have been useful, for example, to explain why some professionals disagree with Schubiner\u2019s approach to fibromyalgia treatment. Schubiner suggests that\u00a0his ideas are \"controversial,\" but we never\u00a0learn what it is that other experts in the field object to. \u00a0", "answer": 0}, {"article": "With this in mind, researchers developed a probiotic supplement aimed at reducing inflammation caused by microbial imbalances in the gut.\nThe results showed that the group receiving the probiotic supplement, on average, didn't return to the hospital as quickly and required less in-patient treatment time compared to the placebo group.\nThe patients were randomly selected to receive either the probiotic supplement or a placebo in addition to their usual medications.\nAbout 3 million people in the US are diagnosed every year with bipolar disorder, a psychiatric condition characterized by dramatic shifts in mood from depression to mania.\nIn recent years, research has demonstrated a strong link between the gastrointestinal tract and the central nervous system.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding is not mentioned.\nA version of the study published in April 2018 noted that the lead author had no conflicts of interest to disclose.", "answer": 0}, {"article": "Investigators conducted a randomized controlled trial in the pediatric Emergency Department at The Mount Sinai Hospital comparing lung ultrasound to chest X-ray in 191 children from birth to 21 years of age.\nFurthermore, the reduction in chest X-rays in the investigational arm resulted in an overall cost savings of $9,200, and length of stay in the Emergency Department was decreased by 26 minutes.\n\"In the era of precision medicine, lung ultrasound may also be an ideal imaging option in children who are at higher risk for radiation-induced cancers or have received multiple radiographic or CT imaging studies,\" says Dr. Tsung.\nThe Mount Sinai Hospital is ranked as one of the nation's top 10 hospitals in Geriatrics, Cardiology/Heart Surgery, and Gastroenterology, and is in the top 25 in five other specialties in the 2014-2015 \"Best Hospitals\" issue of U.S. News & World Report.\nThe research team was led by James Tsung, MD, MPH, Associate Professor in the Department of Emergency Medicine and Department of Pediatrics at the Icahn School of Medicine at Mount Sinai, and former clinical fellow Brittany Pardue Jones, MD, who's currently Assistant Professor in the Department of Pediatrics at Vanderbilt University School of Medicine.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that the study was conducted at the Icahn School of Medicine at Mount Sinai but doesn\u2019t disclose sponsors or potential conflicts of interest. According to the journal article, one of the researchers has a consulting relationship with an ultrasound company. This should have been included in the release.", "answer": 0}, {"article": "www.uhn.ca\n\nTo download video and photos of the ex vivo kidney perfusion circuit and kidney transplant, please visit:\n\u2022 Preparing ex vivo kidney circuit in the OR\n\u201cWorking on this project has been one of the most rewarding experiences of my professional career,\u201d says Dr. Lisa Robinson, Division Head of Nephrology at SickKids.\nThe scope of research and complexity of cases at Toronto General Hospital have made it a national and international source for discovery, education and patient care.\nIt has one of the largest hospital-based research programs in Canada, with major research in transplantation, surgical innovation, cardiology, infectious diseases, genomic medicine and liver disease.\nDr. Selzner, a clinician-scientist at the Toronto General Hospital Research Institute and Associate Professor of Surgery at the University of Toronto, previously modified the preservation solution and supervised the research on a successful warm perfusion technique for the deceased donor liver organ.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "It\u2019s not disclosed that Dr. Markus Selzner has an existing relationship with Veritas Therapeutics (an offshoot of the\u00a0University Health Network Toronto Transplant Institute) and is one of the inventors of an assigned patent.", "answer": 0}, {"article": "The recommendations also support the position of the American College of Cardiology and the American Heart Association, which in 2013 radically shifted their advice from suggesting that doctors focus on the level of a patient\u2019s low-density lipoproteins (LDL) or \u201cbad cholesterol\u201d to looking at a more comprehensive picture of risk based on things such as weight and blood pressure, as well as lifestyle factors.\nThe task force and AHA groups carry tremendous influence in medical practice and in what insurance companies will cover.\nThey are more likely to not only get to the hospital and survive until they are discharged but also survive in greater numbers a year after their hospitalization than those who do not use statins.\nIt is also slightly more conservative when it comes to determining the benefits of taking the medications, which include Lipitor, Crestor and Zocor.\nStatin intolerance is real, researchers find.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes independent sources and we didn\u2019t see any apparent conflicts of interest.", "answer": 1}, {"article": "ASTRO publishes three medical journals, International Journal of Radiation Oncology\n\u2022 Biology\n\u2022 Physics (www.redjournal.org), Practical Radiation Oncology (www.practicalradonc.org) and Advances in Radiation Oncology (www.advancesradonc.org); developed and maintains an extensive patient website, RT Answers (www.rtanswers.org); and created the Radiation Oncology Institute (www.roinstitute.org), a nonprofit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment.\nThe median patient age was 63 years (range 43-73), and 91 percent of the patients presented with stage T1 disease.\n\u201cThis study illustrates that a potentially curative dose of radiation may be delivered safely to the prostate entirely in a single administration,\u201d said Dr. Krauss.\nTypically, HDR brachytherapy is administered in four to as many as nine treatment sessions, which generally requires multiple invasive procedures to insert the implants.\nThe study is available online in the International Journal of Radiation Oncology \u25cf Biology \u25cf Physics, the flagship journal of the American Society for Radiation Oncology (ASTRO).\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t tell us who sponsored the study. The published report indicated there were no conflicts of interest.", "answer": 0}, {"article": "Scientists have used a form of stem-cell therapy to improve survival rates for the most severely sick lupus patients, a group that usually has no remaining treatment options.\n\nLupus is an autoimmune disease that attacks an individual's own organs, causing symptoms that range from swollen joints and skin rashes to severe damage to kidneys, lungs and other parts of the body.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Only a quote from the first author of the study was included. No \nindependent second source. ", "answer": 0}, {"article": "PhD candidate Alexandra Wade says the new MedDairy diet challenges popular perceptions of what is considered healthy.\n\u201cThis study shows that the new MedDairy works better than a generic low-fat diet, ensuring better health outcomes for people at risk of cardiovascular disease.\u201d\n\nImportantly, the MedDairy diet also meets additional calcium requirements recommended by Australia\u2019s national health bodies.\n\u201cThe new MedDairy diet allows for three to four servings with dairy, which means Australians can more sustainably meet their recommended daily nutrient intakes while also maintaining the significant health benefits offered through the MedDiet.\nIt also includes 1-2 servings of dairy foods (700-820mg calcium), which is less than half the dairy recommended by the Australian National Health and Medical Research Council (NHMRC) for older Australians.\nIn Australia, it is the single leading cause of death in Australia, affecting 4.2 million Australians and killing one Australian every 12 minutes.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release didn\u2019t include funding information. It should have noted that the research received funding from Dairy Australia, an industry trade group, as well as government and foundation grants.", "answer": 0}, {"article": "March 31, 2010 -- A widely prescribed drug used to shrink enlarged prostates appears to reduce the incidence of prostate cancer in men with an increased risk for the disease.\nA total of 8,231 men between the ages of 50 and 75 took part in the study, published in the New England Journal of Medicine.\nAll of the men had elevated blood levels of prostate specific antigen (PSA), which indicated an increased risk for prostate cancer.\n\"But we don't have studies saying that they decrease the risk of death from prostate cancer.\"\nScheduled biopsies were performed two and four years after they entered the trial.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes several independent sources, including an expert from the American Cancer Society.", "answer": 1}, {"article": "This study will be presented at a medical conference.\nThe participants were followed for 20-22 years and filled out questionnaires about the foods they ate.\nThe cause of the disease is unknown, and the risk of developing it increases with age.\nNor is it clear why the results differed for men and women.\nThe results showed that men who ate the most foods rich in flavonoids had a 35% lower risk of Parkinson\u2019s disease compared with those who ate the least.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only quote comes from the researcher from a news release.\u00a0 No independent perspective appears in the story.", "answer": 0}, {"article": "The results are chronicled in Robison\u2019s new book, \u201cSwitched On: A Memoir of Brain Change and Emotional Awakening.\u201d\n\nIn a moving, often harrowing narrative reminiscent of \u201cAwakenings\u201d and other popular works by the late neurologist and writer Oliver Sacks, Robison writes of the transformations these sessions helped unlock, the welcome ones \u2014 and the not so welcome.\nBut his book does illustrate that the consequences can be long-lasting, and detrimental.\u201d\n\nRobison remains optimistic that as research continues, the potential benefits will outweigh the risks.\nIt didn\u2019t occur to me that most of the news out there, most of the emotion, is, if not bad, at least not all good.\n\u201cAnd what I wrote about in the book isn\u2019t 10 percent of what they\u2019re doing now.\u201d\n\n\u201cSwitched On\u201d ends in 2013.\nI can\u2019t.\u201d\n\nEven a 1 percent chance at success seemed worth the odds, Robison went on.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Given that this is primarily an interview with a book author, we\u2019ll rate this N/A. However, a source who is independent of the book author (the only other person quoted is one of the research doctors), could have provided important perspectives\u00a0on the treatment being discussed anecdotally.", "answer": 2}, {"article": "An experimental spray improved sex for some men who regularly experience premature ejaculation, according to the results of two studies set to be presented Tuesday at a urology conference.\n\nMen who applied the aerosol spray, a mixture of the anesthetics lidocaine and prilocaine, reached orgasm a mean of 3 minutes 18 seconds after beginning sex, compared with about 56 seconds for those who got a placebo spray. The 539 men completing the two studies, who were randomly assigned to the real drug or the fake version, had an average...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The reporter clearly read a lot about the problem and the potential treatments and does a fairly good job synthesizing this information. The story makes it clear that the two outside sources were not involved in this research. It is unclear whether these doctors are involved in any competing research or research into a similar product.", "answer": 1}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\nThe new study, supported by NIH\u2019s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), provides strong evidence that even a partial course can have some benefit.\nAbout the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services.\nSteroids improve survival and reduce the chances of certain birth defects for extremely premature infants, even if the treatment course is not finished before delivery, according to a study funded by the National Institutes of Health (NIH).\nThe study team also found evidence that the better outcomes likely were due to lower rates of bleeding in the brain and of a brain injury called cystic periventricular leukomalacia.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release identifies the funding source in its headline and first sentence \u2013 the National Institutes of Health. It later adds that NIH\u2019s National Center for Advancing Translational Sciences also provided funding for the study.\nThere was no mention of conflicts of interest, since there were none reported in the original journal article.", "answer": 1}, {"article": "NEW YORK (Reuters Health) \u2014 Could one hour be all you need to quit smoking, without cravings or side effects?\n\u201cWe can hope that this is going to be a method that is going to help people.\u201d But, Daviglus said, \u201cWe need more research and more evidence.\u201d\n\u201cThey want to get this thing approved, obviously.\u201d\n\nBut, he said of the initial evidence in favor of the treatment, \u201cthis one is only a single study, which of course the people who believe in lasers will jump on ... (but) things have got to be confirmed.\nThe treatment also targets other points that are thought to suppress appetite \u2014 to prevent the weight gain that often comes with quitting smoking \u2014 and promote relaxation, according to Innovative Laser Therapy.\nAnd while the laser device used by clinics including Innovative Laser Therapy has been approved by the Food and Drug Administration for temporary pain relief, the agency has not cleared it to be marketed for smoking cessation.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story makes extensive use of independent sources and the scientific literature. This story could be a lesson plan for someone wanting to teach a course in how to cover \"breakthrough\" treatments. 1. Find the studies being used to make these claims. 2. Read them. 3. Talk to the authors. 4. Talk to others who have done research in a similar vein.", "answer": 1}, {"article": "\u201cThe findings published today substantially increase our optimism for the potential for the development of a Zika vaccine for humans.\u201d\n\nBeyond that, \u201cthis is a promising [vaccine] candidate that can be easily produced in large quantities,\u201d said coauthor, Col. Nelson Michael, an Army doctor who specializes in flaviviruses, such as Zika and dengue.\nRight now, just one of those three vaccines will be progressing to clinical trials.\nMonkeys that got a sham vaccine developed no antibodies.\nThen the monkeys were exposed to active forms of the virus.\nOne vaccine had just the man-made proteins in it, the other wrapped a common cold virus around the proteins.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes only sources directly involved with the research.", "answer": 0}, {"article": "You should go through six to eight weeks of conservative management.\u2019 \u201d\n\nAt the Partners Healthcare System in Boston, spine experts have the same struggle to convince patients that an M.R.I.\n\u201cIf you\u2019re going to look at a spine, you need to know what that spine might look like in a normal patient,\u201d said Dr. Michael Modic, chairman of the Neurological Institute at the Cleveland Clinic.\nIt\u2019s that they get the imaging in the first place.\u201d\n\nThat was what happened with Mrs. Weinstein.\n\u201cWe thought, \u2018What\u2019s going to be the reaction among referring physicians?\u2019 \u201d Dr. Jarvik said.\n\u201cI feel that I have come full circle,\u201d she said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes multiple experts. The story quotes Dr Jarvik but does not describe his speciality or institutional affiliation. [Note: the NYT later added this]", "answer": 1}, {"article": "Marion Nestle, a nutrition professor at New York University, says longer studies conducted among people in their own environments, not with such controlled meals, have shown \"little difference in weight loss and maintenance between one kind of diet and another.\"\nThe diets had the same number of calories, but the fat, protein and carbohydrate content varied.\nA new study is raising questions about the age-old belief that a calorie is a calorie.\nParticipants were fed food that was prepared for them by diet experts.\nMore research is needed to show that interesting results like these are applicable in real life, she says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story provides comments from 3 outside experts who have differing takes on the research. It notes that one of the experts is the author of an Atkins diet book.", "answer": 1}, {"article": "The findings appeared online Feb. 5 in the BMJ.\nDespite the fact the American Heart Association (AHA) currently recommends that 5 percent to 10 percent of all calories come from polyunsaturated fat (principally from omega-6), the NIH team found no evidence to support the notion that linoleic acid confers health benefits.\n\"And so, we were interested in trying to evaluate just one of these compounds, linoleic acid, by looking at this old trial using modern statistical methods, and also by re-including some original data that had gone missing from the first analysis,\" Ramsden explained.\n\"There is more than one type of polyunsaturated fatty acid,\" explained Dr. Christopher Ramsden, who headed the re-analysis and is a clinical investigator with the laboratory of membrane biophysics and biochemistry at the National Institute on Alcohol Abuse and Alcoholism, part of the U.S. National Institutes of Health.\nThe original \"Sydney Diet Heart Study,\" was initially conducted between 1966 and 1973, at a time when the cholesterol-lowering benefits of all polyunsaturated vegetable acids (PUFAs) were touted with a broad brush.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes comments from an American Heart Association expert, who provides some common-sense advice. It is worth noting, though, that the AHA spokesperson quoted in this story did not hint at the AHA \u201cconsidering re-evaluating its dietary recommendations\u201d as did the AHA spokesperson in the competing TIME story.", "answer": 1}, {"article": "These results have helped eliminate pre-term birth and hospitalizations for pre-term labor, and patients and families have better outcomes, he added.\n\u201cThey\u2019ve lost family members generation after generation after generation, or they\u2019ve had family members who\u2019ve suffered from chronic disease that\u2019s totally preventable.\u201d\n\nThese procedures not only help limit the passing on of diseases\u2014 they may also help couples get pregnant faster.\n\u201cWhen we do pre-implantation genetic screening, we can ensure that the embryos are chromosomally normal before transferring them back to the intended mother\u2019s uterus, and that increases the likelihood of implantation,\u201d Dr. Jared Robbins, an associated professor in obstetrics and gynecology-reproductive endo & infertility at Northwestern University Feinberg School of Medicine, told Fox News.\nAccording to the Centers for Disease Control and Prevention (CDC), birth defects caused by genetic disorders affect one in every 33 births in the United States.\n\u201cWe can\u2019t fix the embryos yet, but we can determine which embryos are affected by the disease and which aren\u2019t and only transfer back those that are not affected,\u201d Robbins, who is also a fertility doctor at Northwestern Memorial Hospital, said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are two sources cited here, both of whom appear to offer these fertility services in clinics where they work. The story is upfront about that. And while this type of screening is fairly controversial, that is largely due to debates over the morality of terminating an embryo. And that debate is not the focus of the story, at least not directly.", "answer": 1}, {"article": "For advice, information and support, visit http://www.\nDr Arthur Roach, Director of Research at Parkinson's UK, which funded the study said:\n\n\"People affected by Parkinson's, their carers, and health and social care professionals have said that preventing falls and improving balance is the biggest unmet need for people living with the condition, other than finding a cure.\nThe research, published today in The Lancet Neurology (1), shows people with Parkinson's who were given the oral drug rivastigmine were 45% less likely to fall and were considerably steadier when walking, compared to those on the placebo.\n\"We already know that rivastigmine works to treat dementia by preventing the breakdown of acetylcholine, however our study shows for the first time that it can also improve regularity of walking, speed, and balance.\nParkinson's UK Research Fellow Dr Emily Henderson and principal researcher on the study, based at the University of Bristol, said:\n\n\"With the degeneration of dopamine producing nerve cells, people with Parkinson's often have issues with unsteadiness when walking.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release states that the study was funded by the Parkinson\u2019s UK organization. When we looked at the published study we noted that the second author describes a conflict of interest with a company that manufactures fall risk assessment tools: \u201cSRL declares that the FallScreen fall risk assessment tool is commercially available through Neuroscience Research Australia (NeuRA); any profits from sales of the assessment are shared equally between the inventor (SRL), the falls and balance research group at NeuRA, and the NeuRA central fund. All other authors declare no competing interests.\u201d\u00a0 In addition, the charity\u2019s website states that about 0.5% of its income comes from pharmaceutical companies but that \u201cOur industry supporters don\u2019t have any input into the content of\u00a0our information.\u201d While not critical, because these connections may not have any relationship to the pharmacological intervention, it would have been nice to have that spelled out.", "answer": 1}, {"article": "TUESDAY, June 26, 2012 (HealthDay News) -- Electroencephalogram (EEG), a test that shows the electrical activity of the brain, might be used to spot autism in children, a new study suggests.\nShe said the findings are important because, \"they help us understand why individuals with autism have difficulty with complex behaviors, such as social interaction and language.\nThe use of EEG-based testing may help diagnose autism in children and may improve early detection in infants, leading to more effective treatments and coping strategies, the researchers said.\n\"What was unique about this study is the very large number of children studied,\" Dawson noted.\n\"This reduced functional connectivity in the brain helps us understand impairments associated with autism,\" she added.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We\u2019re giving this one a pass here, but we thought that more time could have been spent with the only other independent expert quoted in the story, who was given one sentence to offer perspective.", "answer": 1}, {"article": "Viagra is one of three licensed drugs to treat erectile dysfunction, Davies explained. The other two are Cialis and Levitra. They can take from half an hour to several hours to work, and they're not for everyone: Men who've had a stroke or heart attack are told to use the drugs with caution, reports the Daily Mail. Even those without medical issues simply don't like the wait.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The lead researcher of this rat study was interviewed. And a urologist was quoted briefly \u2013 but only about the potential of the idea. \nNo independent expert opinion appeared to evaluate the research and to judge the story\u2019s claims that this animal study \"promises instant anti-impotence with no side effects.\" ", "answer": 0}, {"article": "These infant siblings were compared with 33 infants with no known family history of autism.\nHe said that, judging by the differences in brain activity, he and his colleagues could detect which babies were in the high-risk group.\nResearchers strapped a net of 64 electrodes all over a baby's head while it was sitting in its mom's lap and a research assistant was blowing bubbles to hold the child's attention.\nThis will now allow the researchers to evaluate them for autism and then look back at the brain activity patterns of the children who do fit the clinical criteria for autism.\nThey say they were nearly 100% accurate when the boys were 9 months old.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story made good use of outside experts, although we were dismayed to see the cliched \u201choly grail\u201d reference, so beloved by researchers and journalists.", "answer": 1}, {"article": "In its marketing campaign, Cyberonics notes that VNS treatment does not cause the weight gain associated with antidepressants and the confusion and memory loss common after electroconvulsive therapy (ECT), psychiatry's term for shock treatments.\nCyberonics officials testified that 30,000 people commit suicide annually, most of whom were diagnosed with severe depression.\nMany FDA \"regulators, politicians and third-party payers\" know little about resistant depression, Cummins said.\nA report by Harvard Pilgrim Health Care, an influential mental health insurer in Boston, called it \"experimental, investigational and unproven.\"\n\"You get desperate when you've been depressed for years,\" she said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Patients, providers, FDA spokesperson, device manufacturer, skeptics and supporters are interviewed or cited.", "answer": 1}, {"article": "For every one point increase in processed foods consumption, they lost 1.67 points in IQ.\nThe researchers identified three basic diets: \"processed,\" crammed with fats, sugar and convenience foods; a \"traditional\" diet high in meats and vegetables; and a \"health conscious\" diet with lots of fruit, vegetables, salads, fish, rice and pasta.\nThe key seemed to be the diet at age 3, since diet at 4 and 7 seemed to have no effect on IQ, the research team noted.\n\"Fast and junk food seem like an easy and affordable option for busy parents, but defaulting to high-fat, high-sugar, high-calorie foods is putting their children's health and future at risk,\" Heller said.\nFor the study, published online Feb. 7 in the Journal of Epidemiology and Community Health, Northstone's team collected data from the Avon Longitudinal Study of Parents and Children on 3,966 children born in 1991 and 1992.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included comments from an dietitian\u00a0who spoke about the potential detrimental effects of poor nutrition on cognitive development. It would have been helpful to hear\u00a0from an expert on neurodevelopment, who could have commented on the size of the effects observed and their\u00a0relevance to real world\u00a0performance.\u00a0\u00a0A comment from a pediatrician about counseling families on healthy diets also would have been\u00a0helpful.", "answer": 1}, {"article": "Inside the brightly lit storefront in Brooklyn, N.Y., business was brisk as employees combed, washed and blow-dried little heads.\n\n\u201cDo I have a lot of lice?\u201d a boy asks the woman combing his hair slathered in Pantene conditioner.\n\nIt\u2019s the busiest time of the year for companies like Lice Busters, a family-run business Dalya Harel started in...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article does a very good job of noting the conflicts of interest of those quoted.", "answer": 1}, {"article": "Qi Sun of the Harvard School of Public Health and his colleagues analyzed data collected from 13.984 female nurses participating in the Nurses\u2019 Health Study, an ongoing study examining a variety of health issues.\nThat was after accounting for other factors, such as smoking.\nThose who drank between one-third and 1 drink per day five to seven days a week were almost 50 percent more likely to be in good health when they got older compared with those who did not imbibe.\nNow, the researchers stressed that wasn\u2019t the case for women who consumed more than two drinks a day or four drinks or more at a time.\n\u201cThese data suggest that regular, moderate consumption of alcohol at midlife may be related to a modest increase in overall health status among women who survive to older ages,\u201d the researchers wrote.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were no independent sources cited.", "answer": 0}, {"article": "Texas rep expects Trump to make case for a border wall at State of the Union\n\n\"We're going to keep working to secure the border, and not blink until we either get it done or the voters get to speak in 2020\"", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Only one source, a physician at the National Cancer Institute, is quoted. In a story of this potential magnitude, other sources and perspectives are needed. It doesn\u2019t add that much time to a story, even in broadcast. ", "answer": 0}, {"article": "Aug. 12, 2012 -- Daily aspirin use, long recommended for people at high risk of heart attack, may also reduce the risk of dying from cancer, according to new research.\nThe benefit, however, may not be as great as believed, says researcher Eric Jacobs, PhD, of the American Cancer Society.\nThe new analysis is published in the Journal of the National Cancer Institute.\n\"In our analysis, daily aspirin use was associated with about a 16% lower risk of dying from cancer overall,\" Jacobs says.\nHe found an association, not cause and effect.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Again, we\u2019ll take a hard-line approach.\nYes, the story had an additional source, an editorial writer.\u00a0 And yes, it disclosed the industry ties of that editorial writer and the fact that he holds a patent for chemoprevention use of aspirin.\nIt is understandable that the story would turn to Dr. Baron\u2019s comments, since he wrote the accompanying editorial and since he has published extensively on this topic.\nBut, by definition, since he was the only other source used, there was no independent source used in the story.\nBy contrast, Reuters had no problem finding a truly independent source.\n\u00a0", "answer": 0}, {"article": "Dr. Lazova is currently the Director of Dermatopathology at California Skin Institute in San Jose, California.\n\u201cThis test integrates anatomic pathology and analytical chemistry in a very useful and meaningful way.\u201d\n\nThe finding suggests that IMS analysis, based on proteomic signatures, may improve both diagnosis and prediction of outcomes for patients with ambiguous moles, the researchers said.\nThe researchers found that in nearly all cases, the IMS analysis was a more accurate predictor, both of benign lesions and melanomas, than standard microscopic examination.\nThe test, which analyzes proteins in cells, could provide more reliable results for clinicians with patients who might be at risk for this deadly cancer.\n\u201cInstead of pathologists being dependent solely upon the physical appearance of the cells, they now have the additional advantage of molecular information regarding the protein makeup [of cells] provided by mass spec imaging,\u201d said Dr. Lazova, who is corresponding author on the study.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release states that the study was \u201csupported\u201d in part by the National Institutes of Health. However, neither the news release nor the study explains where other funding was obtained. The news release does not say whether any of the researchers had conflicts of interest, although no conflicts of interest were declared in the study.", "answer": 1}, {"article": "\"Previous patients got sick, but it wasn't clear at the time whether it was due to the T cells or an infection,\" said pediatric oncologist Stephan Grupp, who oversaw Emily's care at Children's Hospital of Philadelphia. \"Now we know the main reason they were sick was the cells. But now we can intervene. She taught us.\"", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only expert sources were physicians/researchers involved in the development of the experimental treatment or the care of patients receiving it. A perspective from someone not affiliated with this research would have helped identify the caveats and limitations that we felt were missing from this report.", "answer": 0}, {"article": "\"CCSVI equals hope and a lot of MS patients just are completely devoid of hope,\" Stecker says.\nHowever, Zamboni suggests that the disease instead is the result of blocked blood veins \u2014 leading to inflammation, which, in turn, causes the immune system to attack nerves in the brain and spinal cord.\n\"Even if the treatment is not useful for patients with MS, I don't think that we can abandon the idea of vascular involvement in MS,\" Zivadinov says.\nThese discrepancies, and growing public controversy, prompted the National Multiple Sclerosis Society in the U.S. and the Multiple Sclerosis Society of Canada to take Zamboni's claims seriously.\nIt's so seductive, in fact, that Canadians and Americans with MS have been flocking overseas to get the \"liberation procedure.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two experts who are involved in studies of vein abnormalities and potential links to MS, and their perspectives are a valuable addition to the story. However, both of these researchers (Dr. Robert Fox and Dr. Robert Zivadinov) have reported relationships with\u00a0companies that make\u00a0drugs to treat MS. To avoid the appearance of any conflict, the story should have alerted readers\u00a0to these relationships.", "answer": 0}, {"article": "For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email mediarelations@jamanetwork.org.\nThe many potential preventive health benefits of breastfeeding should also be communicated openly to the general public, not only to mothers, so breastfeeding can be more socially accepted and facilitated.\nThe authors suggest several biological mechanisms of breast milk may explain their results, including that breast milk contains many immunologically active components and anti-inflammatory defense mechanisms that influence the development of an infant\u2019s immune system.\nIn addition, more high-quality studies are needed to clarify the biological mechanisms underlying this association between breastfeeding and lower childhood leukemia morbidity,\u201d the study concludes.\nEfrat L. Amitay, Ph.D., M.P.H., and Lital Keinan-Boker, M.D., Ph.D., M.P.H., of the University of Haifa, Israel, reviewed the evidence in 18 studies on the association between breastfeeding and childhood leukemia.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Neither the news release nor the study cited any outside sponsors. The study was completed by epidemiologists at the School of Public Health in Haifa, Israel, and the Ministry of Health in Ramat Gan, Israel.", "answer": 1}, {"article": "For more information, visit http://www.\n\"This is the largest clinical study done in the world on conventional electrodes and will have major implications for doctors and their patients who need their long-term hearing restored,\" said the study's lead investigator, George Wanna, MD, Site Chair, Department of Otolaryngology-Head and Neck Surgery at New York Eye and Ear Infirmary of Mount Sinai (NYEE) and Mount Sinai Beth Israel; Chief, Division of Otology-Neurotology and Director of the Center for Hearing and Balance and Ear Institute at Mount Sinai Health System.\nThe Mount Sinai Hospital is also ranked as one of the nation's top 20 hospitals in Geriatrics, Gastroenterology/GI Surgery, Cardiology/Heart Surgery, Diabetes/Endocrinology, Nephrology, Neurology/Neurosurgery, and Ear, Nose & Throat, and is in the top 50 in four other specialties.\nThe results, published in the June 23, 2017, online edition of The Laryngoscope, may transform how doctors approach cochlear implant procedures to give patients the best possible outcomes.\nDr. Wanna and the researchers also looked at the impact of two major surgical approaches used to insert the electrodes in the inner ear: \"round window\" (where surgeons open the membrane without bone removal or drilling in the inner ear) and \"cochleostomy\" (which requires drilling into the bone to get inside the inner ear).\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We know that the lead researcher is with the\u00a0Department of Otolaryngology-Head and Neck Surgery at New York Eye and Ear Infirmary of Mount Sinai (NYEE) and Mount Sinai Beth Israel, as well as the Center for Hearing and Balance and Ear Institute at Mount Sinai Health System and that he had a team of researchers from Vanderbilt University.\nThe release doesn\u2019t tell us if any any of the researchers or their institutions have any conflicts of interest in either the surgical technique or the type of cochlear implants studied in this trial.\nAccording to the published study, four of the authors, including the first author and the senior author, have financial conflicts of interest in the form of consulting arrangements with cochlear device companies.", "answer": 0}, {"article": "\"While reductions in [cardiovascular] death still trump these bleeding events, if rivaroxaban is approved, we should expect a number of bleeding events that will require medical attention,\" Hicks wrote.\nA final decision is expected by the end of June, according to the documents.\nOf those patients, 136 had bleeding in the brain.\nThe U.S. National Institute of Neurological Disorders and Stroke has more about stroke.\n\"Carefully selecting patients for rivaroxaban therapy will be necessary to mitigate these bleeding risks.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent source was quoted.", "answer": 0}, {"article": "It appears to be that fasting is causing some major stress, and the body responds to that by some protective mechanisms that potentially have a beneficial long-term effect on risk of chronic disease.\u201d\n\nDr. Horne noted that patients shouldn\u2019t take up fasting without discussing it first with their doctor.\nRegular fasting may be good for your heart.\nThe scientists used blood tests before and after the fasting period to look at a number of different metabolic markers.\nThe patients were asked if they engaged in regular fasting, and the researchers compared the answers to whether they eventually received a diagnosis of heart disease.\n\u201cBut what it does suggest is that fasting is not a marker for other healthy lifestyle behaviors.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent expert was quoted, something sorely lacking in the story.", "answer": 0}, {"article": "A new asthma drug being developed by Sanofi and Regeneron Pharmaceuticals may help patients whose condition is not well controlled by existing medicines, according to the results of a small clinical trial released Tuesday.\n\nIn the 12-week study, the number of asthma attacks or other outbreaks of symptoms decreased by 87 percent in those getting the drug, dupilumab, compared with those getting a placebo.\n\nOther measures of lung function and disease control also improved, according to the study results, which were published online Tuesday in The New England Journal of Medicine and presented at the annual meeting of the American Thoracic Society in Philadelphia.\n\nDupilumab blocks the action of interleukin-4 and interleukin-13, two inflammatory chemicals made by the body that are believed to contribute to asthma. Sanofi and Regeneron say there are also preliminary signs dupilumab works against the skin condition atopic dermatitis, suggesting it can be blocking a biological pathway that contributes to multiple allergic conditions.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did not cast a very wide net for sourcing, relying entirely on the contents of the New England Journal of Medicine paper and an accompanying editorial. But we give the story points for at least presenting a diversity of views. For one, both the Times story and a competing Reuters story referred to the editorial, but only the Times story used the editorial to note the study\u2019s limitations and failure to prove the drug\u2019s efficacy.\n\u201cIn the commentary, Dr. Michael E. Wechsler of National Jewish Health in Denver, said that in actual medical practice, patients would not be taken off their existing medications. The real need, he wrote, is for drugs to help control asthma when used in addition to the existing medications, and the study had not demonstrated that dupilumab could fulfill that role.\u201d\nThe Times also did something that Reuters did not do. It pointed out that the lead author on the story \u2013 quoted liberally by Reuters by not quoted here \u2013 \u201chas been a consultant to Regeneron.\u201d", "answer": 1}, {"article": "Utian is now an independent consultant and was a co-author of one of the studies.\nHormone therapy is the only FDA-approved treatment for hot flashes related to menopause, but many women are reluctant to undergo hormone therapy because its long-term use has been linked to an increased risk for breast cancer and stroke .\nIn one study, the number of daily hot flashes experienced by postmenopausal women taking 1,800 milligrams of the drug per day declined from around 10 to around 2.\n\u201cThese side effects, when they did occur, tended to occur early in treatment and disappear within a few weeks,\u201d Sweeney says.\nNAMS founder and former executive director Wulf Utian, MD, says Serada does not appear to be as effective as hormonal therapy, but it may be a useful alternative treatment for women who can\u2019t take hormones or don\u2019t want to.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article is up-front about where this information is coming from and the potential conflicts the sources may have. Still, the story relies heavily on comments from company representatives or researchers involved with the study. The only comment from a truly independent observer doesn\u2019t address the research itself and is about the general need for non-hormonal treatments for hot flashes.\u00a0A close one, but we\u2019ll call it satisfactory.", "answer": 1}, {"article": "The average age was 53 when the study began.\nThe government study found no benefit from a mega-veggie-and-fruit diet over the U.S. recommended serving of five fruits and vegetables a day -- more than most Americans eat.\nDuring the next seven years, the cancer returned in 256 women (16.7 percent) in the special diet group and 262 women (16.9 percent) in the comparison group.\nHopes that a diet low in fat and chock-full of fruit and vegetables might prevent the return of breast cancer have been dashed by a seven-year experiment in more than 3,000 women.\nThat led some experts to suggest that weight loss and exercise should be the next frontier for cancer prevention research.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quotes the author of an editorial on the newly published data.\u00a0 Her comment needs further explanation, so more information from her or from other researchers or clinicians not affliated with the study would have been useful, especially regarding a discussion of other benefits associated with a high-fiber low-fat diet focusd largely on plant-based foods. ", "answer": 0}, {"article": "Lona Sandon, a registered dietitian and assistant professor of clinical nutrition at the University of Texas Southwestern Dallas, reacted with cautious optimism to the findings.\nThe authors concluded that fish oil supplementation appears to be a safe and effective way to prevent malnutrition among cancer patients, and may ultimately prove to be of benefit for other groups of people, such as elderly patients who also face a significant ongoing risk for muscle loss.\nTo explore the therapeutic potential of fish oil supplements, the authors offered 16 cancer patients undergoing an initial 10-week chemotherapy regimen a daily dose of 2.2 grams of a particular omega-3 fatty acid called eicosapentaenoic (EPA).\nNevertheless, it raises hope that a simple, noninvasive intervention might go a long way towards countering the fatigue, poorer prognosis and impaired quality of life that can result from chemo-induced muscle mass loss.\n\"Fish oil may prevent loss of weight and muscle by interfering with some of the pathways that are altered in advanced cancer,\" study author Dr. Vera Mazurak, of the University of Alberta in Edmonton, Canada, said in a news release.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Despite what we just said in the \u201cnews release\u201d criterion above, we will give the story a satisfactory score for seeking an independent perspective, but we wonder what that dietitian reacted to:\u00a0 the study itself or just a news release?\u00a0 Barely satisfactory.", "answer": 1}, {"article": "\u201cAn aneurysm in no way means that you're going to die.\nWhen they would open me up [the aorta] could just blow.\u201d\n\nThe bulge in the large artery that carries blood away from the heart can be immediately life-threatening if it grows large enough to rupture.\nWe can anticipate challenges by practicing the procedure beforehand.\u201d\n\nSo far doctors at Mayo Clinic have done this personalized procedure on more than 450 patients.\nAnd even if the stent does fit, patients often undergo a long, painful recovery.\nThe deadly condition is called an abdominal aortic aneurysm (AAA) and Berg had not one but two of them \u2014 measuring 5 centimeters and 6.5 centimeters wide \u2014 making surgery dangerous.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One of the sources, Gustavo Oderich, MD,\u00a0has reported being a consultant\u00a0for Cook Medical and W.\u00a0L. Gore, both makers of endovascular grafts. The story did not disclose this.", "answer": 0}, {"article": "Researchers conducted a systematic review of existing peer-reviewed research evaluating infusion care for several conditions, including cystic fibrosis, antibiotics following orthopedic surgery and several cancers requiring infused chemotherapies.\n\"At CVS Health, we provide important home infusion services to patients through Coram, which is just one of the ways we are expanding our clinical delivery model and helping to move important health services to lower cost sites of care,\" added Alan Lotvin, MD, Executive Vice President, CVS Specialty.\n\"As the U.S. health care payment system shifts from volume to value, we are focused on identifying new approaches to health service delivery that provide better care and improve patient outcomes while lowering costs,\" said Troyen A. Brennan, MD, study author and Chief Medical Officer, CVS Health.\nThe CVS Health Research Institute is focused on contributing to the body of scientific knowledge related to pharmacy and health care through research collaborations with external academic institutions, participation in federally-funded research, analysis and sharing of CVS Health data sources and coordination of pilot programs and initiatives.\nWhile many commercial health plans provide comprehensive coverage for home infusion services, Medicare has limited reimbursement for this type of care, and Congress is discussing how to implement a comprehensive home infusion benefit for Medicare beneficiaries.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release is clear that the study was done by the CVS Health Research Institute. Since this is a news release from a profit-making company that operates directly to sell services under study, we hope the readers quickly understand there is an inherent conflict. This is the equivalent of a Coca Cola study about the benefits of drinking their product.", "answer": 1}, {"article": "\u201cUsually everything is developed first for adults,\u201d he noted recently, \u201cand children are an afterthought.\u201d\n\n\u2018This is not the end\u2019: Using immunotherapy and a genetic glitch to give cancer patients hope\n\nThis 8-year-old is free of cancer \u2014 for now \u2014 after a \u2018breakthrough\u2019 treatment\n\nFor a 6-year-old with cancer, a future staked on medicine\u2019s hottest field\n\u201cNobody was hoping for zero cancer.\u201d\n\nThe pioneering therapy administered to Ludwig and a few other adults at the University of Pennsylvania hospital paved the way for clinical trials with children.\n\u201cI said, \u2018Surely, this has been tried on kids somewhere else in the world,\u2019 \u201d recalled her father, Thomas Whitehead of Philipsburg, Pa. \u201cBut Steve said, \u2018Nope, some adults got it, but that was a different kind of leukemia.\u2019 \u201d\n\nAfter she received the therapy, Emily\u2019s fever soared, her blood pressure plummeted, and she ended up in a coma and on a ventilator for two weeks in the hospital\u2019s intensive care unit.\n\u201cThis is truly pushing the envelope and at the cutting edge of science.\u201d\n\nThe biggest concerns, however, center on safety.\n\u201cThe efficacy takes care of itself, but safety takes a lot of attention.\u201d\n\nOne of the most common side effects is called cytokine release syndrome, which causes high fever and flulike symptoms that in some cases can be so dangerous that the patient ends up in intensive care.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "All of the sources in the story are patients, parents of patients, are associated with the pharmaceutical industry, or were involved with the relevant research being discussed. That said, the sources \u2014 and their conflicts of interest \u2014 were all clearly identified. Still, the story would have benefited from some independent, expert input.", "answer": 0}, {"article": "This decrease was largely confined to women with hormone receptor-negative tumors and women who were not treated with anti-estrogen therapy such as tamoxifen (which blocks the effects of estrogen).\nThis is because in hormone receptor-positive cancer, the most common form of the disease, there are some concerns that high estrogen levels help cancer cells grow and spread, though this remains controversial.\nIn an accompanying editorial, Omer Kucuk, MD, of the Winship Cancer Institute of Emory University, noted that the United States is the number 1 soy producer in the world and is in a great position to initiate changes in health policy encouraging soy intake.\n\"Based on our results, we do not see a detrimental effect of soy food intake among women who were treated with endocrine therapy,\" said Dr. Zhang.\nMore than 20 percent of all new breast cancer cases with known estrogen and progesterone receptor status are receptor-negative, and they have poorer survival rates than hormone receptor-positive cases.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The study was funded by the National Cancer Institute; noting that would have strengthened the release.\nSophisticated health news consumers appreciate knowing whether a study was government funded or funded by a special interest such as the soybean industry. Readers should also be told that this research is part of a larger study that has been ongoing since 1995.", "answer": 0}, {"article": "To raise awareness about CDE and help other people find relief, the \u201cMy Cousin Vinny\u201d and \u201cThe Wrestler\u201d star has teamed up with pharmaceutical company Allergan and Guide Dogs for the Blind, an organization that trains dogs and pairs them with visually impaired individuals.\nWhen you visit the website, you\u2019ll see a pop-up window with a portal to take the quiz.\nThe quiz on Restasis.com can help individuals learn whether they\u2019re a candidate for the drug.\nIf you think you may be suffering from CDE, Tomei advised visiting your doctor to receive a diagnosis.\n\u201cA whole world of freedom opens up [for these individuals] because you can move about a city like this (New York City) or anywhere much more easily, and the dogs can become your eyes,\u201d she said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Presumably the celebrity in question, Marisa Tomei, is working for the company, but even that detail was not presented.", "answer": 0}, {"article": "\u201cI had one guy that came crawling into my practice and handed me his MRI, and I put him on the table.\nThe new beds, Fuh said, are much different than similar beds made 20 years ago where patients would lie on their stomachs, put a strap around their pelvis and \u201chold onto handle bars for dear life.\u201d\n\n\u201cThe table now, you just lay on your back, and the machine does all of the work.\nI would say a quarter of my patients fall asleep.\u201d\n\nThe decompression therapy is used to treat herniated discs, ruptured discs, sciatica, bulging discs, degenerative discs, posterior facet syndrome and spinal stenosis/arthritis.\nThe space agency noticed astronauts, who did not have gravity compressing their spines in space, reporting the disappearance of neck and back pain.\nThe back is gently stretched over a number of treatments, allowing the disc to rehydrate and heal.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quotes one physician, the owner of a center that provides spinal decompression. This is a major flaw in the story. The story should have quoted other clinicians or researchers to provide some context for the claims being made.", "answer": 0}, {"article": "Using information from the VITamins and Lifestyle study, Dibaba and the other co-authors analyzed an enormous trove of data on over 66,000 men and women, ages 50 to 76, looking at the direct association between magnesium and pancreatic cancer and whether age, gender, body mass index, non-steroidal anti-inflammatory drugs use and magnesium supplementation play a role.\nTheir study, \"Magnesium intake and incidence of pancreatic cancer: The VITamins and Lifestyle study,\" recently appeared in the British Journal of Cancer.\n\"Pancreatic cancer is really unique and different from other cancers,\" said study co-author Ka He, chair of the Department of Epidemiology and Biostatistics at the IU School of Public Health-Bloomington.\nThe overall occurrence of pancreatic cancer has not significantly changed since 2002, but the mortality rate has increased annually from 2002 to 2011, according to the National Cancer Institute.\nBut few studies have explored the direct association of magnesium with pancreatic cancer; of those that did, their findings were inconclusive, said Daniel Dibaba, a Ph.D. student at the School of Public Health-Bloomington, who led the IU study.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funders of the study aren\u2019t named in the release. According to the published findings, the research was supported by grants from the National Cancer Institute and the National Institute of Health Office of Dietary Supplements.", "answer": 0}, {"article": "The Lung EpiCheck blood test detects changes in DNA methylation in 6 markers in cfDNA associated with lung cancer.\nIt is estimated that there are about 1.8 million new cases of lung cancer annually worldwide and about 1.55 million die from the disease each year.\nThe reason for the high mortality rate is that currently most cases are detected when the patient becomes symptomatic, which is usually at late stages of the disease.\nThe results will be presented in a poster presentation titled Lung EpiCheck \u2122 - Results of the Training and Test Sets of a Methylation-Based Blood Test for Early Detection of Lung Cancer at the IASLC 19th World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer, to take place on September 22-26, 2018 in Toronto, Canada.\nSuch promising results combined with the simplicity of the test, could allow us to detect lung cancer at the early stages and hence improve 5-year survival from about 15% to about 50-70%.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "It\u2019s clear from the release that the research was\u00a0supported by the company that makes the proposed lung cancer screening tool.\u00a0 Neither the release or abstract provide information on whether or not there are financial conflicts of interest between the investigators and the company that makes the test.", "answer": 2}, {"article": "But therapies have been improving steadily.\n``The proof of the pudding is always what happens when you give it to people and look at what the potency of the antiviral effect is,\" said Dr. Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.\n``We desperately need new compounds with novel mechanisms of action,\" said Eric Freed, chief of the virus-cell interaction section of the HIV Drug Resistance Program of the National Cancer Institute.\nThat hints at the opportunity to use bevirimat in potent combination with existing drugs, said Dr. Daniel R. Kuritzkes, director of AIDS research at Brigham and Women's Hospital and an associate professor of medicine at Harvard Medical School.\n``It's only when we started giving people three drugs from at least two different classes that we really started making an impact,\" said Kenneth Mayer, medical research director at Boston's Fenway Community Health and a Brown University professor of medicine.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Researchers and physicians who work with HIV/AIDS therapies are cited to provide perspective on this potential new drug treatment. Sources who are paid consultants for Panacos Pharmaceuticals are appropriately noted. Some appropriate attempt at balance is provided by the concluding quote from Dr. Anthony Fauci of the National Institutes of Health. ", "answer": 1}, {"article": "The method enables researchers to identify and define the glymphatic pathway, where cerebrospinal fluid (CSF) filters through the brain and exchanges with interstitial fluid (ISF) to clear waste, similar to the way the body\u2019s lymphatic system clears waste from organs.\n\u201cThe analysis showed us consistently that glymphatic transport was most efficient in the lateral position when compared to the supine or prone positions,\u201d said Dr. Benveniste.\nBy using dynamic contrast magnetic resonance imaging (MRI) to image the brain\u2019s glymphatic pathway, a complex system that clears wastes and other harmful chemical solutes from the brain, Stony Brook University researchers Hedok Lee, PhD, Helene Benveniste, MD, PhD, and colleagues, discovered that a lateral sleeping position is the best position to most efficiently remove waste from the brain.\n\u201cIt is interesting that the lateral sleep position is already the most popular in human and most animals \u2013 even in the wild \u2013 and it appears that we have adapted the lateral sleep position to most efficiently clear our brain of the metabolic waste products that built up while we are awake,\u201d says Dr. Nedergaard.\nIt is increasing acknowledged that these sleep disturbances may accelerate memory loss in Alzheimer\u2019s disease.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not tell us who funded the study. According to the study, the work was supported by \u201cFBRI\u201d (not clear what that stands for), the National Institutes of Health,\u00a0and the Department of Anesthesiology at Stony Brook Medicine.", "answer": 0}, {"article": "She noted that medicine\u2019s veterinary counterparts have been using water therapy for years with injured racehorses.\n\u201cWe\u2019ve been using hydrotherapy to help decrease any sort of gravity that can affect joint function,\u201d said Rao, who is also with the department of family medicine at Plainview Hospital in Plainview, New York.\nIt\u2019s just an all-around good aerobic conditioner for athletes, too, sports medicine expert Dr. Naresh Rao, told CBS News.\n\u201cI personally prescribe it for knee issues and low back issues.\u201d\n\nHydrotherapy uses a water-friendly treadmill that can be placed in a pool.\nThe nice thing about it, said Johnson, is that people can step right into the tank at ground level and then the water fills up around them.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes four experts, making this a strong point. It would have been helpful for one of these experts to point out that there is very little evidence supporting water-based PT compared to standard PT.", "answer": 1}, {"article": "Surgery for a painful, common back condition known as spinal stenosis resulted in significantly reduced back pain and better physical function than treatment with drugs and physical therapy, according to the latest findings from a large federally funded research effort.\n\nThe results from the Spine Patient Outcomes Research Trial, or Sport, echo findings it reported last April involving degenerative spondylolisthesis, another common spinal problem. A separate, earlier report from the same study found nonsurgical treatment for...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quoted one source \u2013 the study\u2019s lead investigator.\u00a0 The story should have included some input from observers not directly involved the study about their interpretation of the results. ", "answer": 0}, {"article": "MONDAY, March 12, 2012 (HealthDay News) -- People taking popular cholesterol-lowering drugs called statins may have a slightly lower risk than others of developing Parkinson's disease, new research suggests.\nThe study had some limitations, the authors acknowledged.\nBut there is some good news, he added.\nIt's thought these drugs may have potent anti-inflammatory effects, which could protect the brain.\nPeople taking cholesterol-lowering drugs, especially those younger than 60, were less likely to develop the neurological disorder than those not using cholesterol drugs, the researchers found.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two independent experts, providing good balance for the story.", "answer": 1}, {"article": "SUNDAY, Aug. 28, 2011 (HealthDay News) -- An experimental drug, apixaban (Eliquis), appears better than the old standby warfarin in preventing strokes in people with the abnormal heart rhythm called atrial fibrillation, a new study finds.\nThe issue of cost remains a factor, however.\nCommenting on the latest study, Dr. Gregg C. Fonarow, a professor of cardiology at the University of California, Los Angeles agreed that \"atrial fibrillation substantially increases the risk of stroke and death.\"\nThe study was funded by Bristol-Myers Squibb and Pfizer, the makers of apixaban.\n\"This represents a very important therapeutic advance in the care of patients with atrial fibrillation.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted a study researcher, a company spokesperson, and a cardiologist who did not appear to have ties to the study reported on.", "answer": 1}, {"article": "Oparil is a consultant for Qnexa manufacturer Vivus.\nThe people who took the lowest dose of the drug dropped about 5.1% of body weight at six months, and, on average, gained some back by one year.\n\u201cWhen the hunger comes back, the topiramate kicks in,\u201d says study author Suzanne Oparil, MD, a professor of medicine, physiology, and biophysics and director of the vascular biology and hypertension program at the University of Alabama at Birmingham.\nThe higher the dose, the more substantial the weight loss, and the more likely it was to be maintained over time, the study shows.\nAt six months, people who took the full dose of Qnexa once daily lost nearly 10% of their body weight; by one year, it was up to 10.4%.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story mention that the study author and Dr. Aronne received funding from the manufacturer of this drug. \u00a0It also included a quote from the president of the American Society of Hypertension who does not appear to have a financial tie to this product.", "answer": 1}, {"article": "Tensions ran so high at one point that two prostate cancer specialists, who had urged the F.D.A.\nThe only approved treatment for them now is the chemotherapy drug Taxotere, from Sanofi-Aventis, which extended median survival by about three months in trials.\nThe F.D.A.\u2019s decision two years ago ignited an outcry from some prostate cancer patients and from investors in Dendreon, who said the agency was being unreasonable and denying patients a treatment that might work.\nCancer vaccines of the type represented by Provenge, known as immunotherapy, are different from conventional vaccines in that they do not aim to prevent disease, but to enlist the body\u2019s defenses in attacking the disease after it occurs.\nJudy Leon, a spokeswoman for the F.D.A., said the agency sympathized with patients but that it was necessary for drugs to meet agency standards for safety and efficacy.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes six sources:\nToo many sources are biased in favor of the company and its product, and they are given signficantly more space in the story than independent voices.\u00a0 \nThere is no source who is openly skeptical or even ambivalent about the findings. There is no one who suggests that conclusions made before findings are published may be premature. ", "answer": 0}, {"article": "\u201cMen don\u2019t say, \u2018Let me go to the urologist and give a semen sample.\u2019\u201d That reluctance has created a $440 million-a-year market for male fertility tests in the U.S., Lopez says.\nWhen it comes to infertility, the burden seems to often fall on women.\n\u201cIn our society, the woman carries the burden of trying to determine the issues surrounding infertility,\u201d Ray Lopez, CEO of SpermCheck, told Bloomberg News.\nThey\u2019re poked and prodded and scoped in an effort to figure out what\u2019s complicating conception.\nA new at-home sperm-analysis test allows men to assess their babymaking abilities.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There is no independent perspective in the story.\u00a0 The only sources quoted are the CEO and the chairman of the company making the test.\n\u00a0", "answer": 0}, {"article": "However, the N.Y.U.\nThe upshot, Dr. Galetta believes, is that parents and coaches \u201cshould absolutely consider\u201d familiarizing themselves with the King-Devick test and administering it to young athletes before the season starts, then having those baseline numbers and the test itself handy on the sidelines.\nThe Standardized Assessment of Concussion had performed rather miserably, correctly identifying only two of the concussed athletes, missing 10, and finding that three of the uninjured control athletes had supposedly sustained a concussion, since their scores had declined compared with their baseline (almost certainly, the study\u2019s authors believe, because these young athletes were physically tired).\nIt is still too early to say, however, whether the King-Devick test can replace other, more conventional concussion evaluations for young athletes, including the standardized assessment, despite its shortcomings in this study, Dr. Galetta cautioned.\nThe test is so simple and inexpensive that any coach or parent potentially could administer it, the study\u2019s authors believe, and any league afford to provide it as a way to help evaluate and safeguard players.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes only one source \u2014 the lead author of the study. Considering there are numerous resources now devoted to sports-related concussion research, diagnostics and treatment, and considering there is quite a bit of disagreement among experts as to what are the best methods, this story would have been a lot stronger with additional voices.", "answer": 0}, {"article": "The U.S. Food and Drug Administration approved the vaccine for girls in 2008 and for boys aged 9 through 26 in 2009.\n\"Studies like this underscore the 'human' in human papillomavirus,\" said Fred Wyand, director of the HPV Resource Center at the American Social Health Association.\nThe researchers also saw some reduction in the number of precancerous penile lesions, although at this point they said it's impossible to know whether this will result in a lower rate of penile cancers.\n\"It's a similar efficacy to what we've seen in females,\" said Giuliano, who is chair of cancer epidemiology and genetics at the H. Lee Moffitt Cancer Center in Tampa.\nHPV is almost ubiquitous in males and females, but experts note that most people will clear the virus naturally so that it does not result in any harm.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Barely satisfactory. The story notes that the research was partially funded by Merck, the manufacturer of the vaccine. It quotes only one expert not affiliated with the study, and would have been stronger if that single expert was not from the American Social Health Association, which lists advocacy for these vaccines as one of its stated positions.", "answer": 1}, {"article": "LOS ANGELES -- Researchers have demonstrated for the first time that the progression of Type-1 diabetes can be halted -- and possibly reversed -- by a stem cell transplant that preserves the body's diminishing ability to make insulin, according to a study published today.\nIt was funded by the Brazilian Ministry of Health and other sources.\nAbout two weeks later, the patients checked into the hospital and received chemotherapy and other drugs to kill off their immune systems over five days.\nThe researchers also cautioned that the process is not without risk, with patients vulnerable to infection during part of the therapy.\nThe treatment had no effect on one patient, whose disease had already progressed too far, doctors decided.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article quotes a source associated with the research and also quotes a source not associated with the research.\u00a0 ", "answer": 1}, {"article": "Newswise \u2014 Multiple myeloma is the second most common type of blood cancer in the United States, impacting more than 25,000 people each year and disproportionatly affecting African-American men.\n\u201cI believe for the first time that we have treatments that are effective enough to make it possible to eradicate multiple myeloma definitively in a substantial proportion of patients, along with having the technology to detect that the disease has been targeted and that treatment can be stopped,\u201d said Luciano Costa, M.D., Ph.D., scientist at the UAB Comprehensive Cancer Center, lead of the Hematologic-Malignancy Working Group, and principal investigator of the MASTER study.\nThe hope is that the therapies will eradicate the disease in a significant proportion of patients and measure disease response more accurately than ever before.\nAs it stands, patients with billions of cancer cells in their bodies and patients with true disease eradication will both appear to be in complete remission using current methods to measure disease response to therapy.\nThe MASTER trial is supported by Amgen and Janseen, both with drug and finaincial support.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release reports that this trial is supported by Amgen and Janssen, makers of two of the drugs it uses. (Executives at Janssen may not be happy that the release misspelled the company\u2019s name as \u201cJanseen\u201d.) The disclosure would have been more complete if it had noted that the lead investigator, Luciano Costa, MD, PhD, has also received speaking fees and other personal payments from Amgen and Celgene (which sells another one of the drugs being tested).", "answer": 0}, {"article": "Routledge added that current evidence shows that not smoking, only consuming alcohol within recommended limits, staying active, monitoring cholesterol levels and eating a balanced diet can all help with the health of the heart and brain.\n\"Getting a diagnosis of dementia can be time consuming and quite frustrating for many people, so it's promising that earlier indicators of cognitive decline are in development,\" said Paul Edwards, Director of Clinical Services at Dementia UK.\n\"What we do know is that the blood supply in the brain is incredibly important, and that maintaining a healthy heart and blood pressure is associated with a lower risk of developing dementia,\" said Carol Routledge, Director of Research at Alzheimer's Research UK, who was not involved in the research.\nVascular dementia is directly caused by reduced blood flow to the brain, and this can also play a role in the development of Alzheimer's disease, studies have found.\nIn the United States, the condition is the sixth biggest cause of death among all adults, according to the US Centers for Disease Control and Prevention, while in the UK it has overtaken heart disease as the leading cause of death, according to the Office for National Statistics.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not address conflicts of interest. The study abstract notes that several researchers have ties to The Brain Protection Company. It is not clear to what extent that company may potentially benefit from the findings, if at all. The company does have patents related to dementia treatment (such as this one).", "answer": 0}, {"article": "Antidepressants frequently prescribed to help treat bipolar depression do little to help patients recover, according to a new study that adds fuel to a long-running debate over how to best treat an affliction that affects an estimated eight million Americans.\n\nBipolar disorder, also known as manic depression, is a serious mental illness that involves dramatic swings in mood, including frequent and lengthy periods of depression. Along with mood-stabilizing drugs like lithium, many physicians also treat the disorder with common...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes information from an author of the study cited, as well as from a researcher not involved in the study, but who specializes in bipolar treatment. The story mentions that the study was sponsored by the National Institute of Mental Health, and the authors disclose the potential conflicts.\u00a0\u00a0", "answer": 1}, {"article": "Researchers said challenges in measuring the effectiveness of mammography screenings include increases in breast-cancer awareness and advances in treatment.\n\"Among women in the screening group, there was a 28 percent reduction in mortality from breast cancer during the same period.\nThus, the relative reduction in mortality that was causally related to the screening program alone was 10 percent.\"\nThe study, published in the New England Journal of Medicine, analyzed data from more than 40,000 women with breast cancer.\nResearchers from Norway and Harvard University compared the death rates from breast cancer in four groups: one group of women from 1996 through 2005 who were living in Norwegian counties with screening; another group in the same time period who were living in counties without screening; and two similar groups from 1986 through 1995.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 0}, {"article": "Editor's note: To obtain a copy of the Cancer Prevention Research paper, \"Effect of vitamin D3 supplementation in combination with weight loss on inflammatory biomarkers in postmenopausal women: a randomized controlled trial,\" or to arrange an interview with corresponding author Catherine Duggan, please contact: Kristen Woodward in Fred Hutch media relations, kwoodwar@fredhutch.org or 206-667-5095.\nFor more information visit fredhutch.org or follow Fred Hutch on Facebook, Twitter or YouTube.\nVitamin D is a steroid hormone that has multiple functions beyond its widely recognized role in regulating calcium levels and bone metabolism.\n\"Weight loss reduces inflammation, and thus represents another mechanism for reducing cancer risk,\" Duggan said.\n\"That suggests vitamin D can augment the effect of weight loss on inflammation.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources are well documented.", "answer": 1}, {"article": "Tucatinib is a small molecule inhibitor of the HER2 growth factor receptor.\n\"I think this drug has an extremely high likelihood of being approved for women with HER2+ breast cancer for use after previous treatments,\" Borges says.\nThe fact that it is a small molecule means the drug is able to pass through the blood-brain barrier to act against brain metastases of the disease.\nBecause the drug is taken in pill form and has a very favorable side effect profile, Borges points out that it is relatively patient-friendly, allowing women to avoid treatments in infusion centers and also many of the side-effects associated with chemotherapies.\nThe forthcoming trial lead by Shagisultanova will be a multi-center clinical trial with CU Cancer Center as the lead site, testing the combination of three drugs - tucatinib plus the anti-estrogen receptor drug letrozole and the cell cycle inhibitor palbociclib - against breast cancers positive for both HER2 and estrogen receptors.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release mentions Array BioPharma, which originally developed tucatinib, but it does not state specifically that Array provided the funding for this study, nor does it explain that three of the authors of the original paper are Array employees. It does note that its only source, Dr. Virginia Borges, director of the Breast Cancer Research Program and Young Women\u2019s Breast Cancer Translational Program at the University of Colorado Cancer Center, \u201chas been a major driver of the drug\u2019s development from its invention at Array Biopharm in Boulder, CO and now through clinical trials of the drug, which is licensed to Cascadian Therapeutics of Seattle, WA.\u201d", "answer": 0}, {"article": "Newswise \u2014 DURHAM, N.C. -- Patients suffering from noninfectious uveitis, a group of diseases that causes eye inflammation, can get effective treatment from a corticosteroid alternative that has previously been approved for treatment of arthritis and Crohn\u2019s disease, according to a study led by a Duke Health researcher.\nThe studies also looked at whether an alternative would be better tolerated or more effective, yet still safe.\u201d\n\nThe study consisted of 217 adults who had active, non-infectious intermediate or posterior uveitis, or panuveitis.\n\u201cThe hope is that by delaying or eliminating recurrences, the symptoms will be minimized or eliminated.\u201d\n\nThe researchers found that median time to treatment failure was 24 weeks in the adalimumab group and 13 weeks in the placebo group.\n\u201cSince each of these signs can be associated with different types of uveitis, the study\u2019s results broaden the applicability of treatment for patients.\u201d\n\nThe study authors note, however, that patients in the adalimumab group reported serious adverse effects, such as respiratory tract infections and allergic reactions, more frequently than those in the placebo group.\nPatients in the adalimumab group were also significantly less likely to experience treatment failure during the duration of the study (80 weeks) and they were at lower risk of treatment failure due to each of the four signs.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release dedicates a whole paragraph to summarizing potential conflicts of interest, which is welcome and we hope to see this kind of transparency showing up in more releases in the future. It further directs readers to the published study\u2019s supplementary documents for more extensive disclosure information.\nIn the PDF of supplementary materials we learned that only two out of the 17 authors had no conflicts of interest to declare. ", "answer": 1}, {"article": "The majority of cases are caught at around 66.\nThe resulting test hones in on these and the existing 100 known markers to pinpoint the 1 percent of men who are at six times greater risk of developing the condition, and the 10 percent of men who have a threefold greater risk of developing the disease, a study author told The Guardian.\nThe next steps should be to understand how this research can be developed into tests that could identify men who might be more likely to develop aggressive cancers, and how this could be rolled out to patients.\u201d\n\nDr. Iain Frame, the director of research at the charity Prostate Cancer UK, highlighted that men with a family history of prostate cancer are two-and-a-half times more likely to be diagnosed with the disease compared to a man with no family history.\nThe new method is being trialed on 300 men in doctors' offices across London, and is due to be expanded to 5,000 next year, according to BBC News.\nAlthough prostate cancer is the second leading cause of cancer death in the U.S. after lung, few risk factors have been found, and it is difficult to accurately diagnose.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story would have benefited from more sources who weren\u2019t connected to the research (both of the advocate sources were from organizations that helped fund the study). Also, most of the information wasn\u2019t cribbed from other news outlets (in this case, the Guardian and BBC News).", "answer": 0}, {"article": "CHICAGO (Reuters) - The common diabetes drug metformin may hold promise as a way to keep smokers from developing lung cancer, U.S. researchers said on Wednesday.\n\u201cThis important laboratory study, together with prior laboratory and epidemiology research, suggests that metformin may be useful in cancer prevention and treatment,\u201d said Dr. Michael Pollak of McGill University in Montreal, who wrote a review on metformin research in the same journal.\n\u201cAlthough smoking cessation is the most important step for current smokers, over half of lung cancer cases are diagnosed in former smokers, raising the importance of identifying those at highest risk and identifying effective preventive treatments,\u201d Dennis, whose findings were published in the journal Cancer Prevention Research, said in a statement.\nThe findings were so strong the team now wants to test it in smokers to see if it can keep then from developing tumors.\nOther studies have shown that metformin can cut diabetics\u2019 risk of pancreatic and breast cancers, and the latest finding now suggests it may defend the body against smoking-induced lung tumors.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A hesitant satisfactory on this one only because it quoted a comment from an expert \"who wrote a review on metformin research in the same journal.\" There was no evidence of any interview having been conducted, though. ", "answer": 1}, {"article": "It hopes setting such a standard would also help prevent teenagers who experiment with tobacco from becoming addicted.\nThe FDA estimates that setting such a standard would help 5 million smokers quit within a year and prevent more than 33 million teens and young adults from becoming regular smokers by the year 2100.\nThe FDA will continue to take enforcement actions against companies that inappropriately target children, including through the promotion of e-cigarettes, Gottlieb said.\nThe comment period will be open through mid-June, said Mitch Zeller, director of FDA\u2019s Center for Tobacco Products.\nJames Figlar, executive vice president of research and development for R.J. Reynolds Tobacco Company, part of British American Tobacco, said the company would work with the agency to create a path for alternative, less harmful tobacco products to reach the market.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story contained information from two FDA officials, one quote from an antismoking group (the identical quote was found in several different news stories), and a comment from a cigarette maker. We only wished that there was an outside source commenting on the quality of the projected benefits or of the possible harms of this plan.", "answer": 1}, {"article": "First published on June 22, 2006 at 12:00 am\nThe study he led randomly assigned 395 men and women ages 65 to 84 with mild functional limitations to receive either sugar pills or various oral doses of the growth hormone stimulator capromorelin, an investigational medication developed by Pfizer Global Research and Development.\nThe government has approved use of growth hormone for a limited array of conditions in adults and children, Dr. Merriam said.\nCompared to placebo, the medication stimulated growth hormone secretion and was associated with an increase in lean muscle mass, improved balance as demonstrated by heel-to-toe walking, and a better ability to climb stairs.\nDr. Julia Zehr, a Michigan State University researcher who led the study, said the findings suggest that biological factors may influence those behaviors, not just the psychological effect of changes in body composition during puberty.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only sources of information appear to be researchers who presented their work at a scientific meeting. (There can be problems with such reporting. See \u201cMedia reporting on research presented at scientific meetings: more caution needed,\u201d at: http://www.mja.com.au/public/issues/184_11_050606/wol10024_fm.html) The story does mention that the study was sponsored by Pfizer, maker of the growth hormone drug capromorelin. ", "answer": 0}, {"article": "New research analyzing more than 22,000 U.S. cases of aortic aneurysm repair is likely to hasten the trend toward more procedures being done with a device called a stent-graft instead of the typical surgery that requires up to eight weeks of recovery.\n\nThe study by doctors at Harvard Medical School and the federal Centers for Medicare and Medicaid Services found the death rate in surgery, 4.8%, was four times that of the 1.2% death rate in placing stent-grafts to seal off the aneurysm. Surgery tended to provide a more permanent...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Though most of the story was about the advantages of endovascular repair of aortic aneurysms, the story did include a quote from a surgeon who does open repair indicating that he felt that open repair was a better fix.", "answer": 1}, {"article": "Medical device makers have been working for years to develop a so-called artificial pancreas to deliver insulin to patients with type 1 diabetes, an autoimmune disease in which the body destroys its own ability to make insulin.\nThe ultimate goal is to create a device that can check patients blood day and night, during and between meals, and deliver insulin as required.\nThe bodies of type 1 diabetes sufferers become unable to properly break down sugar and if untreated, blood vessels and nerves are destroyed, organs fail and patients die.\nThe Cambridge study found their device performed better than a conventional pump, which delivers insulin at pre-set rates and which kept blood sugar levels around normal for 40 percent of the time compared with 60 percent for the artificial pancreas.\nThe Cambridge study, published in The Lancet medical journal on Friday, used devices and sensors from Smiths Medical, a unit of Smiths Group, Abbott Diabetes Care, a unit of Abbott Laboratories, and Medtronic.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites one interview with a study researcher and provides no other independent perspective. It does not inform us that this source had financial ties to one of the study sponsors.", "answer": 0}, {"article": "U.S. News & World Report consistently names Cleveland Clinic as one of the nation's best hospitals in its annual \"America's Best Hospitals\" survey.\nThe former indication is potentially useful for using IsoPSA for screening by primary care physicians, while the second is helpful for urologists in identifying patients who would benefit from curative intent therapy and other applications.\nThe study directly compared the clinical performance of a new test based on PSA, called IsoPSA, to PSA itself with patients already scheduled for prostate biopsy.\n\"The methodology used in the IsoPSA assay represents a significant departure from conventional ways to define biomarkers in blood, and may be applicable to improving other cancer biomarkers,\" said Dr. Klein.\nDr. Stovsky has a leadership position (Chief Medical Officer) and investment interest in Cleveland Diagnostics, Inc.\n\nCleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The IsoPSA test was developed by Cleveland Diagnostics, which also funded, designed and conducted the study. The principal investigator is a co-founder and chief medical officer of Cleveland Diagnostics and has investment interest in the company.\nSince the news release disclosed these facts, we give it a Satisfactory rating here.", "answer": 1}, {"article": "The robot-surgeon team might not have outperformed the surgeon alone because the procedure was a relatively simple one.\nWith the surgeon alone, \u201cthe incision is smaller (and) the manipulations are more controlled,\u201d Dr. Ceana Nezhat, an author on the study and the chair of Obstetrics & Gynecology at Northside Hospital in Atlanta, told Reuters Health.\nBut all I need to do is add 5 and 5.\u201d\n\nEspecially in a time of concern over rising medical costs, \u201cwe should not simply use the highly sophisticated technology just because it\u2019s there,\u201d Falcone said.\n\u201cWe were surprised that (surgery with the robot) did not have better outcomes than (the surgeon alone), as we have always believed if you can see more and see better you can do more and do better,\u201d the authors write.\nSurgeons treating women with endometriosis - a chronic condition that affects more than 5 million women and adolescent girls in the U.S. - didn\u2019t get better or faster results when they used a robotic system.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "As noted above, the comments from Falcone were essential. It might have been worth noting that both the hospitals mentioned in the story actually promote robotic surgery for endometriosis quite heavily. Here\u2019s one example:http://www2.northside.com/RoboticSurgery/Robotic-Surgery-At-Northside/Gynecologic-Surgeries/Robotic-Endometriosis.aspx", "answer": 1}, {"article": "TUESDAY, Aug. 17, 2010 (HealthDay News) -- Less invasive biopsies done with the help of imaging to guide the needle now make up the majority of biopsies being done, a new study finds.\nIn fact, the use of these minimally invasive biopsies increased from 59 percent to 67 percent of all biopsies between 1997 and 2008, a trend which is likely to continue, one expert noted.\nThe only two areas where needle biopsies were not the majority of biopsies done were biopsies of lymph nodes and soft tissues.\n\"Doing image-guided biopsy allows more definitive diagnosis and shorter hospital stays,\" said Dr. Robert Quencer, chair of radiology at the University of Miami Miller School of Medicine, who was not involved on the study.\n\"We also found that the use of imaging guidance increased over this time period, most likely because the technique enables more efficient and safe targeting of lesions,\" Kwan said in a news release.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One independent expert was quoted, although not to provide any data-driven evidence.\u00a0 And his quote, \"I doubt there is variation to this in any major medical center\" begs verification. ", "answer": 1}, {"article": "Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others: the ability of HETIOZ\u00ae to provide significant benefit in the treatment of the symptoms of jet lag disorder; Vanda's ability to obtain marketing approval for the use of HETLIOZ\u00ae in the treatment of jet lag disorder; and other factors that are described in the \"Risk Factors\" and \"Management's Discussion and Analysis of Financial Condition and Results of Operations\" sections of Vanda's annual report on Form 10-K for the fiscal year ended December 31, 2017, which is on file with the SEC and available on the SEC's website at www.sec.gov.\nJet lag disorder symptoms are more severe during eastward travel.\nHETLIOZ\u00ae has not been studied in patients with severe hepatic impairment and is not recommended in these patients.\nThere are no adequate and well-controlled studies of HETLIOZ\u00ae in pregnant women.\nHETLIOZ\u00ae should be used during pregnancy only if the potential benefit justifies the potential risks.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Information and references for further information about financial support are contained at the end of the release and it\u2019s clear that Vanda sponsored the trial.", "answer": 1}, {"article": "\"Compared to childhood vaccines, people would [probably] think 55% is not too impressive, because many childhood vaccines are in the range of 80% to 90% [effective],\" says researcher Hung Fu Tseng, PhD, MPH, a research scientist at Kaiser Permanente Southern California.\nAnother new study, published in the American Journal of Preventive Medicine, finds that by 2008, less than 7% of U.S. adults aged 60 and older had gotten the vaccine, which has been available just since 2006.\nGetting the vaccine makes it less likely that adults will get the painful rash that can occur when the varicella zoster virus, which causes childhood chickenpox, reactivates to cause shingles.\nHowever, he tells WebMD, the 55% risk reduction ''is pretty high compared to other adult vaccines.\"\nThe new study is published in the Journal of the American Medical Association.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\n\nThe story includes an independent source. However, the comments of the independent source don\u2019t address the specific methods or findings of this study. Instead, they begin to wander off into a discussion of the relationship between stress and shingles attacks.\nThe story does tell readers that this study was funded by the Kaiser Permanente health plan and that the lead author has received support from the vaccine\u2019s maker for other research.", "answer": 1}, {"article": "Is that a big difference?\nAlthough the pro-surgery outcome is not a game-changer, Weintraub says it might cause some doctors and patients to consider surgery.\n\"We would hope a study as powerful as this one will inform decision-makers to rethink the direction they're going in,\" the NHLBI's Dr. Michael Lauer told Shots.\n\"It's a very big deal to recommend coronary surgery to patients,\" Weintraub says.\nThe National Heart, Lung and Blood Institute, which funded the study with new \"stimulus\" money from the American Recovery and Reinvestment Act, is more bullish on the implications.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Dr. Laura Mauri, who wrote\u00a0an accompanying editorial, has a few words of caution about patients switching from stents to open-heart surgery. And the story nicely points out that \u201cMauri is an interventional cardiologist \u2013 i.e., a specialist who does coronary stenting \u2013 at Brigham and Women\u2019s Hospital in Boston.\u201d That doesn\u2019t mean that Mauri would recommend stents against the evidence, but it helps readers understand her perspective.", "answer": 1}, {"article": "April 28, 2010 -- Federal researchers say a new treatment can reverse vision loss in many patients with diabetic macular edema, a leading cause of blindness in people with diabetes.\n\nIn a news conference yesterday, researchers announced findings from a government study comparing treatments for swelling of the retina caused by leaking blood vessels in the eye.\n\nNearly 50% of patients given eye injections of the drug Lucentis along with laser treatments showed improvement in vision after a year of treatment, compared to just over a fourth of patients treated with laser alone.\n\nFor several decades, laser has been the standard treatment for diabetic macular edema, or DME, in which fluid builds up near the center of the retina.\n\n\u201cFor the first time in 25 years we have definitive proof that a new treatment can lead to better results for the eye health of people with diabetes,\u201d said Neil M. Bressler, MD, who oversaw the study as chairman of the Diabetic Retinopathy Clinical Research Network.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One quote from the head of the National Eye Institute.\u00a0 But he didn\u2019t really evaluate evidence \u2013 only talked about hope. \nMeantime, no mention that Genentech funded\u00a0 the trial (a strength of the NYT story was its discussion of the \"pay for play\" aspect of the research) \u2013 and no mention that Dr. Bressler disclosed financial ties to Genentech.\u00a0 From the Times: \nSome doctors criticized the organizers of the trial for testing Lucentis rather than another Genentech drug, Avastin, which works in the same way as Lucentis.\nAlthough it is a cancer drug, Avastin is often used off-label for eye diseases because it is far cheaper than Lucentis, costing only $20 to $100 a dose, compared with $2,000 for Lucentis.\nAvastin is undercutting sales of Lucentis, which totaled $1.1 billion in the United States last year.\nOrganizers of the trial conceded that a major reason Lucentis was chosen was that Genentech, which is now owned by Roche, agreed to provide the drug free of charge and to contribute $9 million in additional financing \u2014 but only if Lucentis were used.\n\u201cObviously you can\u2019t underplay $9 million,\u201d said Dr. Ferris of the eye institute, which is part of the part of the National Institutes of Health. But he said there were other factors as well, like a belief that Lucentis might have been the better drug.\nDr. Philip J. Rosenfeld, a professor of ophthalmology at the University of Miami, said the decision was \u201cclearly a case of pay to play\u201d since Genentech\u2019s money dictated the choice of drugs.", "answer": 0}, {"article": "LONDON (Reuters) - The first new asthma pill in decades has produced promising results in a small clinical trial, potentially paving the way for another treatment option for patients by the end of the decade.\nThe latest research, published in the journal Lancet Respiratory Medicine, comes at a time of considerable innovation in asthma care, with the recent launch of new injectable drugs for severe asthma that also target eosinophils.\nAt the same time, many drugmakers are developing improved asthma inhalers, including \u201csmart\u201d devices with sensors that monitor use.\nNovartis believes the medicine could be filed for regulatory approval in around 2019.\nLarger and longer studies are now needed to prove that the twice-daily pill can also reduce severe asthma attacks, known as exacerbations.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story doesn\u2019t contain comments from outside experts who could put some perspective on the trial results and explain what this might mean for patients.\nThe story could have let readers know that funding came from Novartis, as well as a European Union grant program, and the Leicester (U.K.) National Institute for Health Research Respiratory Biomedical Research unit. Several researchers involved in the trial reported receiving financial compensation from Novartis and other drug companies.", "answer": 0}, {"article": "In the study, the research team profiled blood samples collected in a blinded study from children and adolescents 9-19 years to explore whether patients with spastic CP showed differences at the cellular level that routine orthopedic patients (needing ACL repairs, spinal fusions or other surgeries) did not.\nIf successful, the researchers say the type of blood test in development also may be useful for other disorders, such as infant leukemia.\nWhen we find that epigenetic response, or signal, in the genetic sequencing, it provides another line of evidence for clinicians to use in making decisions,\" said Marsh.\nSubtle changes in a patient's physical health are paralleled by changes in DNA methylation, making it a useful tool to understand disease.\nIn a second study, using samples from children aged 2-5 years, the researchers were able to validate their results and predict with 73 percent accuracy whether the blood samples came from children who had CP.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release names the various funding sources for this work and is clear in pointing out the commercial role, and potential economic benefit,\u00a0to some of the authors.", "answer": 1}, {"article": "Chicago (CNN) -- For the first time, patients with the deadliest form of skin cancer have two new treatment options that prolong survival, according to new research presented at a cancer conference in Chicago on Sunday.\nPatients with and without the BRAF mutation were eligible to participate.\nThis is very unusual in the world of drug development, he said.\nThat is what is so remarkable here,\" Schuchter said.\nIt doesn't target a specific part of the cell.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two independent experts were quoted.", "answer": 1}, {"article": "The results were published in January in Nature Medicine.\nThese antibodies are a major area of study in the laboratory of Rockefeller University investigator Michel Nussenzweig, who is Zanvil A. Cohn and Ralph M. Steinman Professor and head of the Laboratory of Molecular Immunology.\nThe majority of the people in the trial were enrolled at The Rockefeller University Hospital, while some of the HIV-1 infected participants received the antibody at the University of Cologne, in Germany.\nThe purpose was to determine whether the antibody was safe and whether it had antiviral activity in humans.\nIn an effort to accomplish this, the investigators are looking into modified variants of the antibodies with prolonged activity, so that they would need to be given less often in the PrEP setting.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The major funding sources for the study are listed at the end of the release. The online version of the published study notes that Tibor Keler, one of the study authors, is employed by Celldex Therapeutics which manufactures 10-1074. This should have been noted in the release.", "answer": 0}, {"article": "Dr. Michael Schwartz is director of laparoscopy and minimally invasive surgery at North Shore-LIJ Health System in Lake Success, N.Y.\nBoth methods have their limits and, \"while this study is very preliminary, if this radiotracer technology can prove to detect very early recurrence or metastasis in human patients, it could become extremely useful in either the pre- or post-treatment setting in selecting a treatment algorithm,\" Schwartz said.\n\"The ultimate goal is to be able to predict the response of patients to new and existing therapies at an early stage, thereby personalizing their treatment and improving outcomes,\" Michael J. Evans, research fellow in the Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center, explained in meeting news release.\nHe noted that, as of now, doctors typically rely on results of the PSA blood test and/or standard diagnostic scans to help guide treatment decisions.\nHowever, Goluboff also noted that research from animal-based studies does not always pan out in humans and \"further, larger studies are of course required to confirm these findings.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Perhaps the only thing that salvaged the story was the story-ending caveat from an independent expert:\n\u2026research from animal-based studies does not always pan out in humans and \u201cfurther, larger studies are of course required to confirm these findings.\u201d", "answer": 1}, {"article": "Dennis believes the ReavillMED CV shows a \"tremendous amount of promise,\" and he wants to test the first 50 catheters Reavill can provide.\nThe catheter is inserted into the arm and travels to the heart within 20 to 30 seconds via the bloodstream.\nIt can be inserted in a nonsterile environment such as an emergency room.\nIt remains to be seen whether that saved time will result in saved lives.\nHe plans to bear the cost of any prostheses the veterans need to work on the catheters.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story at least turns to two physicians who are considering use of the catheter at their hospitals.", "answer": 1}, {"article": "Abbott Laboratories is betting heart patients will benefit from a new type of arterial stent that dissolves away when it is no longer needed.\n\nStents are scaffold-like devices used to prop open clogged heart arteries. Most stents are made of metal. But Abbott's new device, called Absorb, is made from a plastic-like material called polylactide that is commonly used in surgical sutures. The Absorb scaffold\u2014Abbott doesn't call it a stent\u2014is designed to completely fade away in two years and to cease supporting arteries at six...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The statements made by\u00a0a company representative\u00a0are counterbalanced by comments from Dr. Virmani, an independent expert in coronary artery disease and a very outspoken individual.", "answer": 1}, {"article": "The Ache: In cold and flu season, pathogens spread when people are crammed into close quarters, such as airplanes and cars.\n\nThe Claim: Personal air purifiers worn around the neck clean the air in the wearer\u2019s breathing zone of viruses and bacteria as well as allergens, say companies that sell them.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "While the story does quote representatives from the device manufacturers, as well as a university professor conducting the lab tests, it also quotes an environmental scientist from the National Institutes of Health and an infectious disease specialist from an unaffiliated medical center.", "answer": 1}, {"article": "Leone-Bay said that cancer studies have been conducted on Afrezza in rats.\n\"They have done the required safety studies and come out clean, but it's only been tested for six months, so long-term isn't known,\" said Sanjoy Dutta, director of the insulin initiative at the Juvenile Diabetes Research Foundation.\n\"Afrezza is an ultra-rapid-acting insulin, and clinical studies have shown us that it has the potential to change diabetes therapy, because in the body, Afrezza looks like the insulin that's normally in a person's body,\" said Andrea Leone-Bay, vice president of pharmaceutical development for MannKind Corp., manufacturer of Afreeza.\nThe new drug, Afrezza, which is awaiting approval from the U.S. Food and Drug Administration, works faster, keeps blood sugar levels at a closer to normal level and has less risk of causing low blood sugar levels (hypoglycemia) than currently available injectable insulins, researchers say.\nTUESDAY, March 23, 2010 (HealthDay News) -- A new form of inhaled insulin appears to help people with diabetes who must use insulin, with fewer potential risks than an earlier form of inhaled insulin that is no longer on the market.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One independent source was quoted, who pointed out that safety studies \"came out clean\" and that we don\u2019t have long-term safety data. He also confirmed the formulation\u2019s mechanism of action and associated hypoglycemia profile.\u00a0Dr. Leone-Bay\u2019s affiliation with MannKind is identified, as is Dr. Dutta\u2019s role at the Juvenile Diabetes Research Foundation. (The article should have indicated, however, whether Dr. Dutta has any financial relationships with the company that is trying to bring this product to market.)\n Nevertheless, the lack of evidence sources, balance, evaluation, and any independent analysis save for one quote precludes a Satisfactory rating on this criterion. Much more of the claims, many explicitly from the VP\u2019s mouth, needed the counterweight of independent eyes.\u00a0\nReporters have to be more cautious when using the senior executives of pharma companies for the main source of information on a new product. \u00a0These stories in particular should try to find objective, senior scientists in the field who do not work for the company to give an assessment of the new therapy.", "answer": 0}, {"article": "For those at high risk, doctors recommend blood pressure medicine, quitting smoking, exercising more and eating a healthier diet \u2014 but so far chocolate isn\u2019t on the list.\n\u201cAs dark chocolate contains more cocoa and less sugar than milk chocolate, consumption of dark chocolate would be more beneficial.\u201d\n\nLarsson and her colleagues, whose findings appear in the Journal of the American College of Cardiology, tapped into data from a mammography study that included self-reports of how much chocolate women ate in 1997.\nNEW YORK (Reuters Health) - A sweet tooth isn\u2019t necessarily bad for your health\u2014 at least not when it comes to chocolate, hints a new study.\nAccording to Larsson, flavonoids have been shown to cut high blood pressure, a risk factor for stroke, and improve other blood factors linked to heart health.\n\u201cGiven the observational design of the study, findings from this study cannot prove that it\u2019s chocolate that lowers the risk of stroke,\u201d Susanna Larsson from Karolinska Institutet in Stockholm told Reuters Health in an email.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This was the only major shortcoming \u2014 no independent perspective. An expert in epidemiology might have\u00a0pointed out,\u00a0for example,\u00a0that the data on chocolate consumption were collected from\u00a0subject self-reports, and therefore should be viewed cautiously.", "answer": 0}, {"article": "And the chunky monkeys?\nThe important thing is that we passed a milestone where we can now make drugs based on this knowledge and we can potentially slow down aging itself,\" Sinclair explains.\n\"Our goal is to prevent and forestall many of the diseases that strike us as we reach 50, 60, and 70.\nMost researchers agreed that there was something in the wine that offered protection, and a few years later, even the highly cautious federal dietary guidelines say that moderate consumption of red wine can be beneficial.\n\"When I Googled this resveratrol, I was shocked to find that red wine was the top hit,\" Sinclair remembers.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quotes individuals or researchers who are heavily invested in the claims made, both financially and with their personal involvement. The story does a disservice by not quoting other experts who could have provided some badly needed perspective.", "answer": 0}, {"article": "\"We estimate that use of [Brilinta] instead of [Plavix] for one year in 1,000 patients with acute coronary syndromes and who are planning to undergo an invasive strategy at the start of drug treatment would lead to 11 fewer deaths, 13 fewer myocardial infarctions, and six fewer cases of stent [clotting] without an increase in the rates of major bleeding or transfusion,\" conclude study researcher Christopher P. Cannon, MD, and colleagues.\nThat's probably why the 6,732 study patients who got Brilinta were 16% less likely to die, or have a heart attack or stroke, than were the 6,676 patients who got Plavix.\nAnd since the drugs irreversibly bind to blood-clotting platelets, a patient has to stop taking these drugs for five to seven days before the body can make enough new platelets.\nThe new kid on the block is AstraZeneca's ticagrelor, to be named Brilinta if the experimental drug gets FDA approval.\nStone has in the past received honoraria from the makers of both Plavix and Brilinta and serves on the advisory boards of Boston Scientific and Abbott Vascular.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0The story quotes one independent source and identifies potential conflicts of interest. It would have been better if the \"independent\" commenter didn\u2019t have industry ties. ", "answer": 1}, {"article": "\"In addition to providing important support for using SBRT to treat early-stage lung cancer in elderly patients, these findings highlight the value of multi-institutional collaborations and large data sets that can provide statistically meaningful answers to critical questions about treatment outcome and guide clinical decision making.\"\nThe results, which were based on data from more than 1,000 patients across five institutions that comprise the Elekta Lung Research Group, are available online and will be published in the July 15 print issue of International Journal of Radiation Oncology\n\u2022 Biology\n\u2022 Physics.\nDisclosure: This research was partially supported by Elekta through a research grant with all institutions being members of the Elekta Lung Research Group.\nThe results of our study clearly support the use of SBRT for elderly patients, especially those who may not be able to tolerate longer courses of radiotherapy or more invasive treatment options,\" says Meredith Giuliani, MBBS, FRCPC, MEd, a radiation oncologist in the Cancer Clinical Research Unit at Princess Margaret Cancer Centre, University Health Network in Toronto and lead study author.\nThe study evaluated safety and efficacy outcomes of 1,083 patient reports collected in a multi-institutional database.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release makes it clear that the findings were produced with funding from Elekta. However, it does not make it clear that Elekta is a large medical technology company that manufactures SBRT and other equipment used in radiation oncology.", "answer": 0}, {"article": "Thousands of heart-failure patients die each year because they aren't able to get a transplanted organ. Now, many medical experts are touting the benefits of a new mechanical pump that gives a patient's own heart a new lease on life.\n\nPatients surgically implanted with the new pump, known as a left-ventricular assist device, or LVAD, had a survival rate of 58% after two years, according to a recent study. That's not as good as a heart transplant, which offers a survival rate of about 70% after 10 years. But it surpasses the...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites three medical sources; it reveals the financial connection between the first source and the maker of the Heartmate II device.\nPresumably the two other sources have no conflicts of interest, but it would have been useful to state that. ", "answer": 1}, {"article": "Probably not.\nBut the numbers came out this way: People who drink more than four cups of coffee each day have 39% lower odds of getting mouth or throat cancer, compared to people who don't drink coffee.\nThe protection was seen for oral and pharyngeal cancer, but not for cancer of the larynx.\nThat's probably not what University of Milan researchers Carlotta Galeone, ScD, PhD, and colleagues thought they'd find when they analyzed nine studies comparing 5,139 people with head and neck cancer to 9,028 people without cancer.\nThough there weren't enough data on decaf drinkers to draw conclusions, drinking tea -- even massive quantities -- was not protective.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent source was quoted.\u00a0 Someone could have commented on study methods.\u00a0 Someone could have commented on the context of all of the other coffee-cancer studies that have been done.\u00a0 Someone should have been interviewed for such perspective, but it doesn\u2019t appear that anyone was \u2013 at least no such interviews appear in the story. We don\u2019t like single-source stories in any form of journalism, least of all in health/medical stories. ", "answer": 0}, {"article": "\"In making effective treatments easier for patients, the hope is that we can reduce vision loss from glaucoma, and possibly other diseases,\" said study author James D. Brandt, M.D., director of the UC Davis Medical Center Glaucoma Service.\nThe authors receive financial support from ForSight VISION5, manufacturer of the bimatoprost ring.\nThe authors noted the device could also be used for non-glaucoma medications, with potential applications for dry eye, allergies and inflammation.\nThe ring became dislodged in 15 patients but was replaced each time, allowing therapy to continue.\nSome patients experienced itchiness and eye redness, which is not unusual for patients taking glaucoma medication.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release states that the authors of the study receive financial support from ForSight VISION5, which makes the ring.", "answer": 1}, {"article": "According to Hegde, yoga may curb oxidative stress because it stimulates the parasympathetic nervous system \u2014 the part of the nervous system that basically acts as a brake against the gas pedal of the sympathetic nervous system.\nIn the real world, yoga classes vary widely.\nLong-term oxidative stress is believed to contribute to a host of chronic diseases.\nSome are vigorous work-outs involving complicated poses that would not be appropriate for older adults with chronic health conditions.\nThe significance of that is not clear.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did not quote any independent sources.", "answer": 0}, {"article": "Gerdes has published 32 animal studies showing a link between improvements in thyroid hormone levels and heart health in rats and mice.\n\"What we have tried to do here is show the effect of safe doses of thyroid hormones and we're seeing amazing results in multiple studies, with dramatic improvements in heart function, gene expression, and collagen levels, just by restoring depressed thyroid levels in the heart,\" said Gerdes.\n\"This low dose of thyroid hormone safely restored depressed cardiac tissue T3 levels to normal while largely preventing the accumulation of collagen, or scar tissue, resulting from sustained high blood pressure,\" said Gerdes.\n\"The studies demonstrate that we should be able to implement a similar, safe treatment and monitoring program for use in human clinical trials.\nThyroid hormones administered to female rats with high blood pressure led to encouraging cardiac improvements, according to a study in the American Journal of Physiology led by NYIT College of Osteopathic Medicine researcher Martin Gerdes.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not mention either how the study was funded or whether there were conflicts of interest for the authors. The study was funded by the National Heart, Lung, and Blood Institute, and there don\u2019t appear to be any conflicts of interest \u2014 but it\u2019s important to tell readers that.", "answer": 0}, {"article": "\u201cOver the next couple of years, we will find out what it means.\u201d\n\nOn Oct. 23, 2008, Avid and two other companies, and , that are developing fluorine 18-based dyes for amyloid scans, got a pointed question from an advisory committee to the F.D.A.\n\u201cSomething bad happens, and now something good happens.\u201d\n\nLate last year, Avid saw the initial results of its hospice study \u2014 data from the first six patients.\nOther tests are being studied \u2014 ones that look for amyloid in cerebrospinal fluid that bathes the brain; scans that look for shrinkage of the brain in areas needed for memory and reasoning; PET scans that look for uptake of glucose, a cellular fuel, to show areas where the brain was active and where it was not.\n\u201cThe 20 percent who had amyloid, though they were still statistically in the normal range, did worse on every memory test than the control group.\u201d\n\nWhat, Dr. Skovronsky asked, did that mean?\nMost of the time, the scans were as expected \u2014 those with Alzheimer\u2019s had lots of plaque, those with normal memories had little if any and those with mild memory impairment were in between.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are outside sources, but they aren\u2019t used to good effect. The comment from \"Dr. Michael Weiner of the University of California, San Francisco, who is not part of the company\u2019s study and directs a federal project to study ways of diagnosing Alzheimer\u2019s\" is couched in such a way that it makes us think he could be commenting on any breakthrough that would lead to sharper detection of Alzheimer\u2019s, not necessarily this study. Did he actually review the study results? Has he seen the results of similar studies? Does this work perhaps advance his work in some way? None of that is clear. Dr. Mathis is really only used to create another eureka moment. A\u00a0good question for both Weiner and Mathis would have been, \"What is it exactly about this scan that makes you think it rises above all the other detection methods being studied? And how many years away from a clinical application are we in the best and worst case scenarios? Ten to 20 years? 20 to 30 years? Not in our lifetime?\" Nonetheless, we\u2019ll give the story the benefit of the doubt on at least approaching independent sources. ", "answer": 1}, {"article": "Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.\nCoolSculpting for the double chin is already clinically proven to reduce fat up to 20 percent in the treated area after one treatment.1\n\n\"Allergan is committed to advancing innovation for CoolSculpting\u00ae to meet the needs of patients seeking non-invasive aesthetic treatments,\" said David Nicholson, Chief Research and Development Officer at Allergan.\n\"A 2017 American Society for Dermatologic Surgery (ASDS) survey revealed that 73 percent of patients are bothered by excess fat under the chin.2 We are pleased this patient concern can successfully be addressed by CoolSculpting through a non-invasive approach, and furthermore improve the appearance of lax tissue in the treated area.\"\nThese factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS\u00ae, on our financial results; uncertainty associated with financial projections, projected cost reductions, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2016 and Allergan's Quarterly Report on Form 10-Q for the period ended September 30, 2017.\nAn 18-week clinical study of CoolSculpting in submental fat treatment found that 77 percent of patients showed improved appearance of lax tissue and 75 percent of patients reported their chin looked more toned following treatment.3\n\n\"In my own patients, I have noticed the improved appearance of lax tissue when using the CoolMini\u00ae applicator for the CoolSculpting\u00ae system to treat the submental area,\" said Jeffrey S. Dover, MD, FRCPC, Co-Director of SkinCare Physicians of Chestnut Hill, Mass.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The 2015 clinical study we found online states that Zeltiq Aesthetics, then manufacturers of the CoolSculpting System, sponsored the research. All three authors of the study were on the medical advisory boards for\u00a0Zeltiq and received research support and grants from the company. One of the investigators also owned Zeltiq stock.\nJust for clarification, Dublin-based Allergan acquired Zeltiq Aesthetics in April this year.\nSince none of this is explicitly disclosed, we rate this one Not Satisfactory.", "answer": 0}, {"article": "About the University of Louisville Physicians Group and The James Graham Brown Cancer Center:\n\nThe James Graham Brown Cancer Center is a key component of the University of Louisville Health Sciences Center.\nThe centers that collaborated on the study included University of Louisville, Louisville, KY; Henry Ford Hospital, Detroit, MI; Cleveland Clinic, Cleveland, OH; Piedmont Hospital, Atlanta, GA; Swedish Medical Center, Denver, CO; and Cancer Treatment Centers of America, Atlanta, GA.\n\nFrom July 2010 to October 2014, patients with radiographic Stage III LAPC were treated with IRE and monitored under a multicenter, prospective IRB-approved registry.\nAs part of the region's leading academic, research and teaching health center, the cancer center provides the latest medical advances to patients, often long before they become available in non-teaching settings.\n\"The STAR data adds to the growing body of evidence that IRE ablation may represent a new treatment paradigm for patients with locally advanced pancreatic cancer,\" said Robert Martin, M.D., Ph.D., F.A.C.S., director of the Division of Surgical Oncology, and Professor, Department of Surgery, University of Louisville, James Graham Brown Cancer Center.\nPancreatic cancer has one of the highest mortality rates of all cancers and is expected to climb from the fourth leading cause of cancer-related death in the U.S. to the second by 2020.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We aren\u2019t told what the funding sources are, nor whether there\u2019s any conflict of interest. This information is also missing from the abstract itself. But by digging just a little bit, we learned that the lead author of the study and the primary source for this release (Dr. Martin) is a paid consultant to Angiodynamics\u00a0(scroll to the bottom for disclosure info),\u00a0which makes the NanoKnife system. This is critical information to disclose with these results.", "answer": 0}, {"article": "The new study was presented at the annual meeting of the American Pain Society.\nXyrem, which is approved by the FDA for the treatment of narcolepsy, corrects the same disturbed sleep patterns that studies have shown are common in fibromyalgia patients, Jones says.\nMay 12, 2010 (Baltimore) -- The powerful sleeping medication Xyrem can help relieve the hallmark symptom of pain in people with fibromyalgia, suggests a study that pitted the drug against a placebo.\nThe National Fibromyalgia Association estimates that about 10 million Americans, mostly women, have fibromyalgia, an unexplained condition characterized by chronic pain and fatigue.\nAlso, small, preliminary studies suggested the drug can reduce pain and fatigue in people with fibromyalgia.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A source was interviewed, and conflicts of interest are identified, including the drug company that funded the study. Although we are told the source was not involved in the study per se, the story suggests that he is a consultant for the drug company.\u00a0 IF this is in fact the case, there is a question about the independence of the source.\u00a0 Furthermore, no source provides analysis of the research itself. The consultant is quoted downplaying the abuse observed for Xyrem in narcolepsy and the potential role of a new product in the management of this disease. We don\u2019t necessarily dispute his underlying points, and there\u2019s evidence in the literature supporting his characterization of the abuse. But these points would mean a lot more coming from someone who is an independent source.\nThe drug is sometimes used off-label for fibro, as we can deduce from the\u00a0patient anecdote talking about her success with the drug. We\u2019re also not sure this selective anecdote was appropriate to include:\u00a0without any other quotes or independent analysis to balance it, it paints an overly heroic picture of the drug. \u00a0As a bit of background, note that Jazz has gotten into trouble in the past in this arena: its subsidiary\u00a0plead guilty\u00a0to a federal\u00a0indictment\u00a0of promoting Xyrem for off-label uses, including fibromyalgia.\nPerhaps a more minor issue, we\u2019re not sure that the article ever says explicitly that Jones was the investigator on this study. \u00a0It will be obvious to some readers, while others may feel she is an expert commenting on the research.", "answer": 0}, {"article": "The U.S. Preventive Services Task Force (USPSTF) says there is no proof that the benefits of routine mammogram screening outweigh the risks for average-risk women in their 40s.\n\"What we are seeing is that women with mammogram -detected breast cancer require less treatment,\" Malmgren tells WebMD.\n\"Let's say 10,000 women in the world were going to die of breast cancer that developed in their 40s,\" Brawley tells WebMD.\nThe finding comes from a careful study of nearly 2,000 women diagnosed with first-time breast cancer at age 40 to 49.\nThe women were carefully followed since their diagnosis in 1990 to 2008, says study co-leader Judith A. Malmgren, PhD, president of Seattle's HealthStat Consulting.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did include helpful quotes from Dr. Otis Brawley of the American Cancer Society.\nHowever, for a story that mentions the US Preventive Services Task Force (USPSTF) three times, it failed to include any response from anyone on the USPSTF!", "answer": 0}, {"article": "The average reduction in blood pressure caused by a single anti-hypertension drug is 9/5 mmHg.\n\"The possibility of using a natural product, rather than another pill, to help lower blood pressure, is very appealing,\" adds Dr. Amoils.\nBeetroot contains high levels of dietary nitrate (NO3), which the body converts into biologically active nitrite (NO2) and nitric oxide (NO).\nThe first figure is systolic pressure, generated when the heart is pumping, and the second figure is diastolic pressure, created when the heart is relaxing and filling with blood.\n\"It is hugely beneficial for people to be able to take steps in controlling their blood pressure through non-clinical means, such as eating vegetables,\" Prof. Ahluwalia adds.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story offers comments from only two sources: One, a research leader at the British Heart Foundation, which funded the study, and the second, the apparent principal investigator conducting the trial.\u00a0 The story borrows liberally from a news release (more on that later) and offers no insight from individuals not connected to the project.", "answer": 0}, {"article": "Spinal fluid can also reveal the disease but that can be a difficult and painful test.\nAccording to a paper published in the online edition of the British journal Nature Medicine, preliminary studies by a team of scientists led by a Stanford neurology professor show the test is yielding promising results in predicting which patients with mild memory loss are at high risk of developing Alzheimer's disease.\nThere is still plenty of lab work to be done, more rigorous research before it's proven a simple blood test can diagnose Alzheimer's, but those working on the test are hopeful it can be approved for use by 2009, adds Blackstone.\nIn a study of 259 blood samples, the test identified early markers for Alzheimer's with 90 percent accuracy, reports CBS News correspondent John Blackstone.\nBrain scans and spinal taps are helpful but they're not certain.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted someone from the company developing the test and quoted only one \"expert\" but he did not comment on the test but only on the subtlety of the disease. This is insufficient sourcing for a story that states: \"For millions who worry their forgetfulness could be the first sign of something worse, a blood test could, in the future, provide answers.\"", "answer": 0}, {"article": "A study believed to be the largest of its kind suggests that the physical aspects of yoga are effective at relieving low back pain, but it didn't find any evidence that yoga provided broader mental benefits.\n\nThe study, funded by the National Institutes of Health's National Center for Complementary and Alternative Medicine, was published online Monday in the Archives of Internal Medicine. It was lead by researchers at Seattle's Group Health Research Institute.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story could have benefitted substantially from independent commentary by a researcher or healthcare provider not associated with the study. There were no stated conflicts-of-interest in the study. So none needed to be identified in the article.\n\n\n\n\n\n\n", "answer": 0}, {"article": "For more information visit http://www.\nThe development of olaparib, which is now owned by AstraZeneca, was underpinned by scientific research carried out with funding from Cancer Research UK at The Institute of Cancer Research (ICR) and the University of Cambridge, and clinical trials led by the ICR and The Royal Marsden, and other institutions in the UK and overseas.\nIt also proves the principle that we can detect prostate cancers with specific targetable mutations using genomic sequencing to deliver more precise cancer care by matching treatment to those men most likely to benefit.\nThe drug, a type of treatment called a PARP inhibitor, was licensed last year for women with ovarian cancer and inherited BRCA mutations, but so far has not been approved for use on the NHS by NICE or the Cancer Drugs Fund.\nThe results have led on to the start of TOPARP-B, a second part of this trial in which only men whose prostate cancers have detectable DNA repair mutations will receive olaparib.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We recognize that it can be challenging to sort out and explain complex partnerships in a brief news release but it is better to point out that potential conflicts exist.\nAlthough the release mentions a pharmaceutical backer of the study (AstraZeneca) and lists other funders, we rated this Not Satisfactory because the vast majority of investigators had multiple, complex ties to pharmaceutical makers including\u00a0some who have patents and other commercial interests in the success of these treatments. These are mostly highly financially conflicted researchers whose\u00a0conflicts are never mentioned in the news release, even though we know that such financial entanglement will mean that any news release will put the best possible face on the outcome of their research.", "answer": 0}, {"article": "Aug. 17, 2011 -- German researchers say that highly trained dogs are able to reliably sniff out lung cancer in human breath.\nBut that test has caused controversy because it falsely detects cancer in about one out of four people, leading to further invasive procedures.\nRecently a large, government-funded study found that longtime smokers at high risk for lung cancer who received annual rapid computed tomography (CT) scans of their lungs cut their risk of dying of the disease by 20%.\n\"The whole field is focused on using something that's readily available that does not involve an expensive surgery or scan that would allow us to find early cancers,\" says Ramalingam, who is developing technology that aims to replicate the ability of dogs to smell trace amount of chemicals produced by cancerous tumors.\nIn its early stages, lung cancer has few symptoms, making it difficult for doctors to catch it early, when it's still treatable.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes independent sources and identifies that one expert, who is not tied to the European research, is also working in a related area \u2013 developing technology to mimic the canine sniff test.", "answer": 1}, {"article": "To learn more about the Society and the field of endocrinology, visit our site at http://www.\nThe most important thing to remember is that therapy must be individualized based on each woman's needs and goals.\"\nThe study, \"Managing Menopausal Symptoms and Associated Clinical Issues in Breast Cancer Survivors\" is published online at https:/ , ahead of print.\nThe Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries.\n\u2022 Smoking cessation, weight loss (if indicated), limiting or avoiding alcohol, maintaining adequate levels of vitamin D and calcium, eating a healthy diet, and regular physical activity are suggested for all women with prior breast cancer\n\u2022 Non-pharmacologic therapies for VMS such as cognitive behavioral therapy, hypnosis, and acupuncture may be helpful as are vaginal lubricants and moisturizers\n\u2022 Several emerging approaches such as selective estrogen receptor modulators (SERMs), Tissue selective estrogen complex (TSECs), estetrol, and neurokinin B inhibitors show promise as useful agents to expand options for symptom relief with less breast cancer risk but have not yet been tested to confirm safety in women with prior breast cancer\n\nOther authors of the study include: Cynthia A. Stuenkel of the University of California, San Diego in La Jolla, Calif.; Susan R. Davis of the School of Public Health and Preventative Medicine, Monash University in Australia; JoAnn V. Pinkerton of the University of Virginia in Charlottesville, Va.; Ann Gompel of Paris Descartes University in France; and Mary Ann Lumsden of the University of Glasgow School of Medicine, Dentistry, and Nursing in Scotland.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t state any funding sources. Several of the review authors have received industry funding and any relevant industry funding should be noted in the release.", "answer": 0}, {"article": "[Added June 10] So Gokhale studied findings from anthropologists, such as Noelle Perez-Christiaens, who analyzed postures of indigenous populations.\nAnd it doesn't bother her that the method hasn't been tested in a clinical trial.\nIt's good design,\" Gokhale says.\nThe first thing that popped out was the shape of their spines.\nEach year, doctors in the Bay Area refer hundreds of patients to Gokhale.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "In addition to Esther Gokhale, the story cites two physicians. The story clearly notes that one of the physicians refers patients to Gokhale.", "answer": 1}, {"article": "The U.S. Food and Drug Administration today approved Siliq (brodalumab) to treat adults with moderate-to-severe plaque psoriasis.\n\"Moderate-to-severe plaque psoriasis can cause significant skin irritation and discomfort for patients, and today\u2019s approval provides patients with another treatment option for their psoriasis,\" said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA\u2019s Center for Drug Evaluation and Research.\nSiliq is intended for patients who are candidates for systemic therapy (treatment using substances that travel through the bloodstream, after being taken by mouth or injected) or phototherapy (ultraviolet light treatment) and have failed to respond, or have stopped responding to other systemic therapies.\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nThe Agency also is responsible for the safety and security of our nation\u2019s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release does not disclose funding sources for the clinical trials. A 2016 FDA briefing document online (page 6, second paragraph) implies that the drug company funded the clinical trials to support its application for FDA approval.\nSince none of this is mentioned, we give the news release a Not Satisfactory rating.", "answer": 0}, {"article": "WEDNESDAY, Nov. 30, 2011 (HealthDay News) -- Eating baked or broiled fish as little as once a week may boost brain health and lower the risk for mild cognitive impairment and Alzheimer's disease, new brain scan research suggests.\nIn those people with larger brain volume, \"the risk for Alzheimer's and mild cognitive impairment went down by fivefold within five years following the brain scans we conducted,\" he said.\nThe study authors found that eating baked and broiled fish -- but not fried -- helps to preserve gray matter neurons, strengthening them in areas of the brain deemed critical to memory and cognition.\n\"Those who eat baked or broiled fish had larger brains,\" noted study author Dr. Cyrus Raji, a resident in the department of medicine at the University of Pittsburgh Medical Center, Mercy Hospital.\nWith that information, the authors found that regardless of age, gender, physical activity routines, and/or educational achievement, race or weight, those who ate baked or broiled fish had larger mass in the hippocampus, precuneus, posterior cingulate and orbital frontal cortex regions of their brains.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "At least the story had one independent source, a NY neurologist who said, \u201cOne has to wonder if there are other factors\u2026 that they didn\u2019t measure.\u201d\u00a0 But his comments were buried deep in the story, as was the line \u201cFor now, the connection must be viewed as an association, rather than a cause-and-effect.\u201d\u00a0 That should have been in the second paragraph at the latest.\n ", "answer": 1}, {"article": "About half of all patients should be suitable for a partial replacement, but an analysis of data routinely collected by the National Joint Registry showed that of 98,147 knee replacements undertaken in 2016, only 9% were partial.\nThe NHS, however, needs to get the support of surgeons, many of whom rarely carry out the less invasive procedure.\nThey can be carried out with a smaller incision using minimally invasive surgery, but they are only suitable for people whose ligaments inside the knee are strong.\n\u201cFor patients and the NHS to see the benefits of partial replacements, we need the buy-in of surgeons, who would need to feel comfortable performing a greater proportion of their knee replacements as partials,\u201d he said.\nThe main reason for the surgery is osteoarthritis.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not appear to incorporate input from any independent sources. All the quotes were taken from the news release, without attribution.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Testing women for human papillomavirus (HPV) may catch more pre-cancerous growths than standard cervical cancer screening does \u2014 but more evidence is needed before the newer tests become routine, a study published Monday concludes.\nIt has not been clear exactly how HPV testing, or liquid-based Pap tests, measure up against standard Pap tests.\nA lot of research has been done since the 2003 recommendations, said Dr. Evelyn P. Whitlock, a senior investigator with Kaiser Permanente Northwest in Portland, Oregon, who led the review.\nBut there are still questions about the effects of HPV screening, and \u201cmore complete evidence\u201d is needed before it becomes widely used, Whitlock and her colleagues write.\n\u201cIt\u2019s reassuring to know that they perform equivalently,\u201d Whitlock told Reuters Health.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There was only a single source quoted \u2013\u00a0 the lead reviewer and author, Evelyn Whitlock, a senior investigator with Kaiser Permanente in Portland, Oregon.", "answer": 0}, {"article": "Dec. 20, 2010 -- Scientists using brain scanning technologies say they have been able to predict with 90% accuracy which children with dyslexia will be able to improve reading skills over a period of a few years.\n\nResearchers say their findings reveal activity in specific brain regions during reading that could eventually lead to new treatments for people with dyslexia.\n\n\u201cAt this time, we cannot say which treatment type will each child benefit from,\u201d study researcher Fumiko Hoeft, MD, PhD, an imaging expert at Stanford University, tells WebMD in an email. \u201cBut with more research, and if researchers combine it with intervention studies, then we should be able to identify brain patterns that are predictive of responding to one type of intervention or another.\u201d\n\nShe says in a news release that the study \u201cgives us hope that we can identify which children might get better over time\u201d and that the findings represent \u201ca huge step forward.\u201d\n\nThe discovery of brain regions involved in the learning disorder \u201cmay provide a mechanism for enduring improvement that promotes relatively successful reading development,\u201d according to the study, published in the Dec. 20 issue of the Proceedings of the National Academy of Sciences.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\n\nThe only comments from an expert who was not a member of the research team come from the director of the Eunice Kennedy Shriver National Institute of Child Health and Human Development. The story fails to tell readers that this institute provided funding for the study and issued a news release praising the results, thus the source doesn\u2019t seem to be as independent as readers deserve.", "answer": 0}, {"article": "Newswise \u2014 Fresh thyme and oregano offer a savory touch to a tasty dish, but a University of Iowa researcher recently discovered natural compounds in the herbs that may offer a treatment for cachexia or \u201cwasting syndrome\u201d as it is more commonly known.\n\u201cThis same calcium signal also activates signaling pathways to increase skeletal muscle endurance and also skeletal muscle size.\u201d\n\nSah\u2019s research team hypothesized that low level calcium cycling induced by these natural compounds might promote improved exercise capacity and overall metabolic health associated with healthy muscle mass.\nThe intellectual property associated with this discovery was recently licensed by the UI Research Foundation to Innovus Pharma, an over-the-counter consumer goods and specialty pharmaceutical company that commercializes non-prescription medicine and consumer care products.\nThe discovery was a \u201cserendipitous finding\u201d in the lab of Rajan Sah, M.D., Ph.D., assistant professor of Internal Medicine and Molecular Physiology and Biophysics at the University of Iowa.\n\u201cThe oncology supportive care market is a very large unmet medical market with limited choices to both physicians and patients,\u201d said Bassam Damaj, chief executive officer of Innovus Pharma.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There is no mention in the release of who funded this research, nor is there a journal paper which we could find that might offer that information.\u00a0 The release does say that the \u201cdiscovery\u201d has been licensed to a pharmaceutical firm that plans on developing an over-the-counter drug, and quotes a company official praising the work.\u00a0 There is no information that suggests the researchers are free from any potential conflicts of interest, with that company or other firms.\nA search of the Google Patents database shows that the lead investigator and the University of Iowa Research Foundation have applied for a patent for the compound.", "answer": 0}, {"article": "To him, diet underpins longevity.\nAccording to Toribio-Mateas, the results confirm earlier theories that \"some hormone-like growth factors that are required during development to grow, then become promoting agents of aging after development and sexual maturity have been reached\".\nThe idea of caloric control improving your health, and therefore your lifespan, is nothing new, but researchers are now hoping to accurately determine the type of diet that could make you live longer.\n\"When you make IGF less active, it reduces risk factors linked to diabetes and cardiovascular disease,\" says Miguel Toribio-Mateas, Chairman of the British Association for Applied Nutrition and Nutritional Therapy.\n\"The results of the study are encouraging and warrant more research in this area,\" says Toribio-Mateas.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Whoo boy. We\u2019re giving this a satisfactory rating since the story does let us know there is a potential conflict of interest\u2013one of the researchers plans to sell nutrition products promoting this type of dieting. However, we wish this fact would have raised more red flags for CNN, and led to a more critical analysis of the piece.\nA second source quoted in the story \u2014 nutritionist\u00a0Miguel Toribio-Mateas \u2014 espouses some unorthodox views on his website, including that one can\u00a0\u00a0\u201cgrow younger from inside by providing the necessary building blocks that enable cellular processes to keep us looking and feeling our best as we age.\u201d\nWhile we question the source\u2019s expertise, we think the story meets the standard for a Satisfactory rating. But readers should be wary of the guidance being provided, which doesn\u2019t seem to be based on particularly strong evidence.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Older people who use olive oil in their cooking and on their salads may have a lower risk of suffering a stroke, researchers reported Wednesday.\nAnd after they did, olive oil was still linked to a lower stroke risk.\nSuch clinical trials are considered the \u201cgold standard\u201d of medical evidence.\nOlive oil is one part of the Mediterranean diet that has been tied to heart benefits.\n\u201cWe need to remember that this is an observational study,\u201d said Dr. Nikolaos Scarmeas, a neurologist at Columbia University Medical Center in New York who wrote an editorial published with the study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included strong input from a researcher who wrote in an editorial on the study.", "answer": 1}, {"article": "For more information, go to http://www.\nOakland, CA (January 3, 2017) - A new study by researchers from the UCSF Benioff Children's Hospital Oakland Research Institute (CHORI) shows that a modest 4 milligrams of extra zinc a day in the diet can have a profound, positive impact on cellular health that helps fight infections and diseases.\nIn addition to King, the study's other authors are Sarah J Zyba, Swapna V Shenvi, David W Killilea, Tai C Holland, Elijah Kim, Adrian Moy, Barbara Sutherland, Virginia Gildengorin, and Mark K Shigenaga, conducting the research at CHORI's Nutrition and Metabolism Center.\nThe study, published in the American Journal of Clinical Nutrition, was led by CHORI Senior Scientist Janet King, PhD.\n\"We were pleasantly surprised to see that just a small increase in dietary zinc can have such a significant impact on how metabolism is carried out throughout the body,\" says King.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "None of the authors reported conflicts of interest related to the study. The research was supported by a grant from HarvestPlus, a research program advocating for biofortification to breed higher levels of micronutrients \u2014 like iron, zinc and vitamin A \u2014 directly into staple food crops. Additional funding came from the NIH Office of Dietary Supplements.\nThe news release does not disclose these funding sources, which is why we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "Newswise \u2014 The first laser treatments used to treat skin conditions such as benign vascular birthmarks and port-wine stains were developed more than 40 years ago.\n\u201cThis new technology may also provide physicians with a safer, more controllable option for treating patients.\u201d\n\nThe team co-authored the paper, \u201cUltrasonic modulation of tissue optical properties in ex vivo porcine skin to improve transmitted transdermal laser intensity,\u201d which recently was accepted for publication by the society\u2019s journal, Lasers in Surgery and Medicine.\n\u201cWe\u2019ve named the technique \u2018sonoillumination,\u2019 and we\u2019re hopeful that the procedure will be available widely in the near future.\u201d\n\nWhiteside and his team, including adviser, Heather K. Hunt, an assistant professor of bioengineering in the MU College of Engineering, tested the sonoillumination system on porcine skin tissue samples.\n\u201c\u2018Sonoillumination\u2019 will be extremely beneficial for clinicians and the ASLMS presentation allowed us to demonstrate the system to the people who actually will be using the technology once it\u2019s commercialized.\u201d\n\nNicholas Golda, associate professor of dermatology and director of dermatology surgery at the MU School of Medicine, echoed the merits of the sonoillumination system and the effect it will have on dermatology.\nIn 2016, the Office of Technology Management and Industry Relations reported that Mizzou received $14.9 million in revenue from more than 40 technology licenses.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We applaud the inclusion of a link to a patent application, which both highlights a potential benefit to the researchers and provides a great deal more detail about the device itself. The application states that the patent has been assigned to the University of Missouri, but it is reasonable to assume that commercialization of this device would benefit the careers of the researchers. The release says the research was funded by a University of Missouri program called FastTrack, which is intended to support the development and commercialization of technologies.", "answer": 1}, {"article": "Other expert groups have made similar statements.\nIf you are allergic to mold spores or to pollen from trees, grasses or ragweed, that means knowing when levels are high (by checking pollen.com or the National Allergy Bureau) and then taking steps such as these recommended by the American Academy of Allergy, Asthma and & Immunology:\n\u2022 Keep windows closed at home and in your car.\nIt's a myth, he adds, that older, sedating antihistamines, such as Benadryl, are extra effective against nasal allergies.\n\"These are first-line treatments\" that can prevent allergy symptoms, not just treat them, says Jackie Eghrari-Sabet, an allergist in Gaithersburg, Md.\nIt's also important to administer the sprays correctly, so that they end up inside your nasal passages, not just your nose, where they might cause irritation, Sublett says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were some obvious conflicts of interest with one of the expert sources quoted in this story.\nDr. James Sublett is not only a Louisville allergist and president of the American College of Allergy, Asthma & Immunology, but he is also a \u201cspeaker for numerous pharmaceutical and medical device companies,\u201d says his profile on the digital media company Everyday Health. A bit more digging finds that Sublett \u201chas received payment for lectures from GlaxoSmithKline, Merck, Sunovion, and Teva and has stock/stock options with AllergyZone LLC,\u201d according to disclosure statement for a 2013 study on cockroaches in The Journal of Allergy and Clinical Immunology.\nWe believe such conflicts of interests are troubling and should be disclosed, especially when the first product mentioned by the story includes a nasal steroid spray from GlaxoSmithKline \u2013 the same pharmaceutical company that engages Sublett as a speaker. That, together with the lead quote from the allergy group (where Sublett is president) claiming steroid nasal sprays are the \u201csingle most effective drug class,\u201d throws the story somewhat off balance. We\u2019re glad a second, seemingly independent expert was also consulted for her opinion.", "answer": 0}, {"article": "The IVC required cross-clamping in 24 cases.\n\"This is a complex condition and the complication rate with open surgery is 12% to 47%, depending on the thrombus level, with a mortality rate of 5% to 10%,\" explained lead investigator Ronney Abaza, MD, Robotic Surgery Director at OhioHealth Dublin Methodist Hospital.\nRobotic nephrectomy for inferior vena cava tumor thrombus has favorable outcomes and reproducibility when performed by surgeons with adequate robotic experience, according to first multi-institutional report, published in the journal of urology\n\nNew York, NY, Feb. 7, 2016 - Renal cell carcinoma can sometimes spread to the inferior vena cava (IVC), the body's largest vein, posing a threat to the heart and brain.\n\"Using robotic nephrectomy, our complication rate and lack of mortalities compare reasonably with open series with no grade III to V complications, according to the Clavien system, in any patient, including no deaths.\"\nRenal vein surgery can often be managed with minimally invasive laparoscopic techniques, but this is not typically advisable for an IVC thrombus (a fibrous clot), which is surgically far more complex with potentially fatal complications that can occur in the course of removing the thrombus and reconstructing the IVC.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t tell us who funded the study or if there were any potential conflicts of interest.\nThe lead author, Ronney Abaza, MD, Robotic Surgery Director at Ohio Health Dublin Methodist Hospital, has conducted training programs on behalf of the manufacturer of the robotic device.", "answer": 0}, {"article": "The Food and Drug Administration cleared silver diamine fluoride for use as a tooth desensitizer for adults 21 and older.\nIt\u2019s been used for decades in Japan, but it\u2019s been available in the United States, under the brand name Advantage Arrest, for just about a year.\nBut studies show it can halt the progression of cavities and prevent them, and dentists are increasingly using it off-label for those purposes.\nNow there\u2019s an alternative: an antimicrobial liquid that can be brushed on cavities to stop tooth decay \u2014 painlessly.\nNobody looks forward to having a cavity drilled and filled by a dentist.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This is a real strong point. The story draws on input from a variety of experts, and clearly marks their relevant affiliations. What\u2019s missing, though, is commentary from an expert on the research behind the method.", "answer": 1}, {"article": "The journal that published the new paper, Science, promoted the finding in a news release, but added a \u201cspecial note\u201d citing the Schiavo case and warning that the finding \u201cshould not be used to generalize about all other patients in a vegetative state, particularly since each case may involve a different type of injury.\u201d\n\nThe brain researchers, led by Adrian Owen at the Medical Research Council Cognition and Brain Sciences Unit in Cambridge, England, performed scans on the patient\u2019s brain five months after her accident.\nAn estimated 100,000 Americans exist in this state of partial consciousness, and some of them eventually regain full awareness.\nDoctors from the University of Cambridge and the University of Li\u00e8ge in Belgium collaborated on the research.\nWhen presented with sentences containing ambiguous words, like \u201cThe creak came from a beam in the ceiling,\u201d additional language processing areas also became active, as in normal brains.\nAbout 50 percent of people with such injuries recover some awareness in the first year after the injury, studies find; very few do so afterward.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes multiple, independent sources who were not directly involved in the research study and who provided valuable perspectives.", "answer": 1}, {"article": "\"Based on the current safety and clinical benefit data, the dose of the vaccine was increased to 40 million dendritic cells per injection and the trial opened to patients who have previously been treated with a HER2-targeted therapeutic, including patients with breast cancer,\" said Berzofsky.\nIn the dose escalation portion of the phase I clinical trial, patients were injected with the vaccine on weeks 0, 4, 8, 16, and 24 after enrollment in the study.\n\"We hope that one day the vaccine will provide a new treatment option for patients with these cancers.\"\nOne patient with ovarian cancer had a complete response that lasted 89 weeks, one patient with gastroesophageal cancer had a partial response that lasted 16 weeks, and four patients (two with colon cancer, one with prostate cancer, and one with ovarian cancer) had stable disease.\nAmong the six patients who received the lowest dose of the vaccine, 5 million dendritic cells per injection, no clinical benefit was seen.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that the research was funded by the National Cancer Institute at NIH.\u00a0The study abstract states the lead scientist declared no conflicts of interest.", "answer": 1}, {"article": "The Food and Drug Administration approved Provenge this spring to treat advanced prostate cancer.\nBut, as the study's lead author Dr. Philip Kantoff acknowledges, \"It's not a home run; this is not going to cure prostate cancer.\"\nProvenge is supposed to work by, in effect, vaccinating patients against their own cancers using a patient's own white blood cells.\n\"Can't say,\" replies Dendreon COO Hans Bishop.\nMeanwhile, Dendreon, the Seattle-based company that makes Provenge, says there's a waiting list for the drug.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Solid quotes from the written editorial accompanying the study in the New England Journal of Medicine and even an appropriately cautious quote from the lead author of the study. ", "answer": 1}, {"article": "Data from more than 18,000 patients also found that apixaban was safer overall than warfarin, and tended to cause less bleeding in the skull in patients who faced the highest risk of bleeding.\n\"This analysis provides further support for the benefit of apixaban, but given the very low risk of bleeding with apixaban, it also suggests that the current stroke and bleeding risk scores may not be sensitive enough to tease out those patients with the very lowest risk of stroke who might benefit from apixaban therapy,\" said Ansell, who is chairman of the department of medicine at Lenox Hill Hospital in New York City and a consultant to Bristol-Myers Squibb and Pfizer, the companies that are marketing the drug as Eliquis.\n\"The benefits of apixaban are preserved, regardless of the risk score used and regardless of the patient risk category,\" study author and cardiologist Dr. Renato Lopes said in a Duke news release.\nThe findings suggest that the current risk scoring systems for tailoring anti-clotting (anticoagulant) treatment to individual patients may be less relevant when using apixaban for patients with atrial fibrillation who have at least one risk factor for stroke, according to the Duke University Medical Center researchers.\n\"With new oral anticoagulants, such as apixaban, we might not need risk scores to guide treatment decisions for stroke prevention in patients with atrial fibrillation.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were no independent sources in the story, as the story itself says at the bottom: \u201cSOURCES: Jack Ansell, M.D., chairman, department of medicine, Lenox Hill Hospital, New York City; Duke Medicine, news release, Oct. 1, 2012\u201d The story does point out that Ansell is \u201ca consultant to Bristol-Myers Squibb and Pfizer, the companies that are marketing the drug as Eliquis.\u201d But it does not point out the more important fact that those companies funded the study.\nThe article was accompanied by an editorial that provided both context and balance.\u00a0 Regrettably, the story did not provide either.", "answer": 0}, {"article": "The game, \u201cWizard\u201d, is designed to help so-called episodic memory \u2014 the type of memory needed to remember where you left your keys several hours ago, or to remember a few hours later where you parked your car in a multi-storey car park.\n\u201cWe need a way of treating the cognitive symptoms of schizophrenia, such as problems with episodic memory, but slow progress is being made toward developing a drug treatment,\u201d said Barbara Sahakian from the department of psychiatry at Cambridge University.\nThis study, published in the journal Philosophical Transactions of the Royal Society B, found that 22 patients who played the memory game made significantly fewer errors and needed significantly fewer attempts to remember the location of different patterns specific tests.\nThere is increasing evidence that computer-assisted training can help people with schizophrenia overcome some of their symptoms, with better outcomes in their daily lives.\nThe researchers said this was important, since lack of motivation is a common feature of schizophrenia.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources in the article. And, while there don\u2019t appear to be any conflicts of interest, it would likely have been worth noting that the \u201cbrain game\u201d research was funded by Janssen/Johnson & Johnson \u2014 a large pharmaceutical company.", "answer": 0}, {"article": "Lee is a professor of medicine and director of the electrophysiology laboratories and clinics at UCSF.\nAccording to Dr. Byron Lee of the University of California, San Francisco (UCSF), \"There is a growing body of literature supporting the connection between atrial fibrillation and dementia.\"\nThe researchers said that the key is to start blood thinners, such as warfarin, soon after atrial fibrillation is diagnosed.\nThe researchers looked at when treatment began: either within 30 days of atrial fibrillation diagnosis, which was considered immediate; or after a year, which was considered delayed.\n\"Therefore,\" he said, \"we need to be extremely aggressive in treating atrial fibrillation patients with anticoagulants [blood thinners] when indicated.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A second source appears to be independent of the study, although readers are not given enough information to determine that. It\u2019s not clear who funded the study, and we think that should have been included.", "answer": 0}, {"article": "At a recommended dose of two gel caps daily, a month\u2019s supply of Basis will cost $60 ($50 with a membership) and will be available online only.\n\u201cBut we will be data-driven and will communicate the complexities of science in simple ways.\u201d\n\u201cWhat does it mean, to improve metabolic health?\n\u201cWhat interests me in this is that it is a different challenge, to apply what we are learning through basic research, not just to curing disease but to keeping people healthy,\u201d said Szostak, who runs a research lab at Massachusetts General Hospital.\n\u201cAs soon as we have analyzed the data, we will publish them on our website,\u201d he said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article quotes a reputable source who provides an appropriately skeptical view \u2014 one of the strongest aspects of this piece", "answer": 1}, {"article": "Testing cholesterol in toddlers and babies?\nAn expert panel in the United States recommends this test for children between the ages of 9 and 11, but many aren\u2019t tested now unless they are obese or have other heart risk factors such as diabetes or high blood pressure.\n\u201cI hadn\u2019t heard of it before.\u201d\n\nThe study did not address whether screening is cost-effective.\nThe study also revealed parents who had the condition but didn\u2019t know it, and had passed it on to their children.\nThe study authors in England estimated that if cholesterol testing costs $7 and gene testing costs $300, it would cost $2,900 for every person identified as having the disorder.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included independent sources. Also, the story discloses this: \u201cThe study was led by Dr. David Wald at Queen Mary University of London. He and another author founded a company that makes a combination pill to prevent heart disease. The work was funded by the Medical Research Council, the British government\u2019s health research agency.\u201d", "answer": 1}, {"article": "MILAN (Reuters) - An established targeted therapy for bowel cancer may also help women with an aggressive form of breast cancer, a mid-stage clinical study revealed on Monday, opening up a potential new market for the medicine.\nNo question,\u201d he said.\nSales last year were $1.7 billion.\n\u201cThis study clearly opens the field ...\n\u201cWe are very excited by these results,\u201d lead researcher Jose Baselga of the Massachusetts General Hospital Cancer Center in Boston told the European Society for Medical Oncology (ESMO) \u2014 Europe\u2019s biggest cancer meeting.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 1}, {"article": "And on a Tuesday evening earlier this summer, the company partnered with a women\u2019s group to host a conversation about \u201cproactive steps you can take today to reach your future family building goals.\u201d Appetizers, wine, and beer were served \u2014 and, in a gesture to the crowd full of women with pregnancy on their minds, non-alcoholic beverages were on the menu, too.\nMany of the other conditions that the test screens for are also quite rare.\nBut the report doesn\u2019t explain the prevalence.\nWe\u2019re not claiming we\u2019re there,\u201d Beim said.\nShe was 1.54 times more likely to have primary ovarian insufficiency.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The company\u2019s CEO is clearly identified. Physicians who serve as sources and who have used the test are distinguished from those who have not.", "answer": 1}, {"article": "Kjersti Aagaard, vice chair of obstetrics and gynecology at Baylor College of Medicine and Texas Children's Hospital, is more skeptical.\n\"The most important thing for parents to be talking with their provider about is how will we adapt to the delivery as it emerges,\" she said.\nBut those doctors overestimated the benefit to the mother and didn't look at the impact their change had on the babies, said Heike Rabe, a researcher at Brighton and Sussex Medical School and University Hospitals, in the United Kingdom, who wrote an editorial accompanying the study.\nMany countries and professional organizations, including the American Congress of Obstetricians and Gynecologists, have called on obstetricians to delay cord clamping in premature babies when feasible.\nIn the new study, Andersson found that healthy, full-term newborns whose umbilical cords were left attached for three extra minutes had better fine motor control when they reached preschool than those clamped immediately.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted a separate source not involved in the study with a different point of view. And\u00a0while we applaud the story\u2019s inclusion of that voice, we think the air time could have been used more fruitfully. Asking the reader to talk to a doctor/make an individual choice [Dr. Ishani speaking here as someone such people are sent to], without more explanation as to why they would choose one route or another, misses an opportunity to deliver succinct, useful information about the downsides of delayed clamping.", "answer": 1}, {"article": "Beyond walking, weight lifting and other resistance training may improve bone mineral density in the lower back, and maintain bone density in the hips.\nIf a person simply stands, the muscles accommodate and do most of the work, he said - with no benefit to the bone.\nAnother 34 million are at risk because they have low bone density.\n\"All bones - spine bones and big leg bones - will respond to pressure from weight by forming more bone.\"\n\"Anything that makes bone bear weight is good for bone quality,\" said Dr. Kirkham Wood, head of orthopedic spine surgery at Massachusetts General Hospital.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Quotes from two clinicians with an expertise in exercise and bone health were included in this piece.", "answer": 1}, {"article": "Newswise \u2014 CHAPEL HILL, NC \u2013 UNC researchers say the results from the multi-site phase 2 and 3 trials of brexanolone injection are not only promising, but could change the way postpartum depression (PPD) is treated.\n\u201cWith our latest results, we believe that brexanolone, if approved, could provide relief for women with a range of postpartum severity.\u201d\n\nThe paper, published in The Lancet, includes a new integrated analysis of results from three double-blind, placebo-controlled trials that took place at 30 sites in the U.S., including UNC\u2019s Perinatal Psychiatry Unit.\nIn the brexanolone trials, we saw patients starting to feel better within days,\u201d said the trial\u2019s academic principal investigator, Samantha Meltzer-Brody, MD, MPH, director of Perinatal Psychiatry Program at the UNC School of Medicine.\nThe integrated analysis looked at results of the trials which randomized 209 women to receive a double-blinded 60-hour infusion of either brexanolone injection 90 \u00b5g/kg/hr or placebo.\nDavid Rubinow, MD, chair of the Department of Psychiatry at the UNC School of Medicine and a coauthor of the paper, says time is especially crucial for new mothers experiencing postpartum depression because the weeks and months following birth are a critical period for mother-infant bonding.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that Sage Therapeutics funded the research.\nSage Therapeutics is the developer of brexanolone injection and sponsor of the trials. A New Drug Application is currently under review by the FDA and brexanolone injection has been granted Breakthrough Therapy Designation. The FDA has assigned a Prescription Drug User Fee Act target date of December 19, 2018.\nWhat the release doesn\u2019t tell us is that both quoted researchers disclosed financial ties with Sage Therapeutics.\u00a0 This information was included in the studies published in the Lancet.\nSM-B reports personal fees from MedScape and grants from Sage Therapeutics, awarded to the University of North Carolina \u2026 DRR reports personal fees and has stock options in Sage Therapeutics\u2026.", "answer": 0}, {"article": "Feb. 15, 2011 -- Taking zinc, either as a syrup or lozenge, through the first few days of a cold may shorten the misery of an upper respiratory infection, a new research review shows.\n\u201cThe evidence from the recent trials does support the use of zinc lozenges in treatment of common cold,\u201d says study researcher Meenu Singh, MD, a pediatric pulmonologist at the Post Graduate Institute of Medical Research in Chandigarh, India.\n\u201cWe really don\u2019t have interventions for colds that work.\u201d\n\nThe review of 15 studies with 1,360 participants was published by the Cochrane group, an international collaboration of researchers that reviews evidence behind therapeutic interventions.\n\u201cThis is great news,\u201d says Kay Dickersin, PhD, an epidemiologist with the Johns Hopkins School of Public Health and director of the U.S. Cochrane Center.\nThe review also found that zinc cut the number of days that kids missed school because of being sick and reduced the use of antibiotics by cold sufferers.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included commentary from \u201cAnanda Prasad, MD, PhD, a professor of internal medicine at Wayne State University School of Medicine in Detroit, who has spent his career researching zinc\u2019s effects on the immune system.\u201d\u00a0 But, since two of his studies were included in the Cochrane report (something noted by the NY Times story), it\u2019s not truly an independent perspective. And, as noted above, his comments added to some of the confusion in the story.", "answer": 0}, {"article": "Second induction for VYXEOS-treated patients was 100u/m2 on days 1 and 3 and the control arm was cytarabine 100mg/m2/day by continuous infusion for 5 days and daunorubicin 60mg/m2 on days 1 and 2 (5+2).\nFor a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see Celator's Form 10-K for the year ended December 31, 2014, subsequent reports on Form 10-Q and 8-K, and other filings by the company with the U.S. Securities and Exchange Commission.\n\"The successful outcome of this Phase 3 trial represents an important advance for AML patients, their families and clinicians,\" said Scott Jackson, Chief Executive Officer of Celator Pharmaceuticals.\nThe live webcast of the call can be accessed in the Investors section of Celator's website at www.celatorpharma.com.\nCelator Pharmaceuticals, Inc., with locations in Ewing, N.J., and Vancouver, B.C., is an oncology-focused biopharmaceutical company that is transforming the science of combination therapy, and developing products to improve patient outcomes in cancer.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We aren\u2019t told anything about the relationship between the study\u2019s principal investigator, Dr. Jeffrey E. Lancet, and Dr.\u00a0Gail Roboz and Celator, the\u00a0company whose drug they are discussing. If there is or isn\u2019t a financial conflict of interest, that needed to be spelled out in the news release. We do know that Scott Jackson, chief executive officer of Celator Pharmaceuticals, has obvious financial ties to the company whose drug he is praising.", "answer": 0}, {"article": "A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website: http://www.\nThe article is available free on the Journal of Child and Adolescent Psychopharmacology website.\nThe Journal is dedicated to child and adolescent psychiatry and behavioral pediatrics, covering clinical and biological aspects of child and adolescent psychopharmacology and developmental neurobiology.\nThe drug formulation, which consists of two layers of microbeads with an inner drug-loaded core, delays release of the active ingredient for 8-10 hours and then provides controlled extended release designed to cover the early morning into the evening.\n\"Developing new formulations of effective medications for patients with ADHD improves the lives of children with the disorder,\" says Harold S. Koplewicz, MD, Editor-in-Chief of the Journal of Child and Adolescent Psychopharmacology and President of the Child Mind Institute in New York.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There is no mention in the release about the funding for the research or any information about potential conflicts of interest among the researchers. The published research paper, however, readily discloses that the study was supported by a pharmaceutical manufacturer and that the lead researcher is a paid consultant to that company. Numerous other potential conflicts among the research team are also outlined in the paper. All of these financial ties should have been mentioned in the release. ", "answer": 0}, {"article": "Celgene\u2019s drug Abraxane prolonged the lives of patients with advanced pancreatic cancer by almost two months in a clinical trial, researchers reported Tuesday, signifying an advance in treating a notoriously difficult disease but not as big a leap as some doctors and investors had hoped.\n\n\u201cIt was not the breakthrough we were anticipating,\u201d said Dr. Andrea Wang-Gillam, an assistant professor and pancreatic cancer specialist at Washington University in St. Louis, who was not involved in the trial.\n\nStill, Dr. Wang-Gillam and others said any progress was welcome against metastatic pancreatic cancer, which has defied most treatments, with patients tending to live only about six months after diagnosis.\n\nPancreatic cancer is the fourth most common cause of cancer death, with 38,000 Americans expected to die this year, almost as many deaths as from breast cancer, according to the American Cancer Society. Yet there are only 45,000 new cases of pancreatic cancer a year compared with more than 230,000 new breast cancer cases.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Excellent use of independent sources, including the \u201cnot the breakthrough we were anticipating\u201d quote from one of them in the story\u2019s second sentence.", "answer": 1}, {"article": "We are excited to announce that FibromyalgiaTreating.com is now part of RedOrbit.com. All of the same great people, writers and editors but now with more firepower. We now have access to an enormous amount of additional research information from doctors and scientists. We can now extend to other conditions that may be part of your everyday lives and help you on a broad level if that is what you need. We are here for you and now, better than ever so sit back and enjoy the new Fibromyalgia Treating by RedOrbit!", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story provides many clinical perspectives\u00a0on the CAD technology.\u00a0 The reporter interviews not only the study author and the author of an accompanying NEJM editorial, but also clinicians and radiologists who talk about use of CAD in practice. Interviews with clinicians who provide their rationale for not using the CAD technology provide excellent balance to the story. ", "answer": 1}, {"article": "This version has been corrected.\nHe called the technology \"a canary in the coal mine\" for lung cancer, which kills about 160,000 people in the United States each year.\nCorrection: The original version of this post incorrectly named the company that is distributing the Bronchial Genomic Classifier.\nThat has left only two ways to determine whether the abnormality is cancerous: inserting a needle through the chest wall and into the tumor, or surgically opening a patient's chest to find it (and remove it if necessary).\nBut now, according to a study published Sunday in the New England Journal of Medicine, there appears to be a new, much less invasive way of determining whether a growth is malignant.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The good news is that the study\u2019s publication in a peer reviewed journal of high reputation suggests that the data have been vetted and the information is valid. That said, however, news articles that rely on journal articles and statements by commercial interests are greatly\u00a0strengthened by comments from independent sources. This article clearly outlines the commercial interests of the primary investigator and developer of the genomic test. But readers might have learned more about the limitations of the study and the test if other experts had been interviewed.", "answer": 0}, {"article": "New research now shows that resistance training may protect the nervous system and thus slow the progression of the disease.\nThis is the main finding of a study conducted by a research partnership between Aarhus University, Aarhus University Hospital, the University of Southern Denmark and the University Medical Center Hamburg-Eppendorf, that has just been published in Multiple Sclerosis Journal.\n\"Over the past six years, we have been pursuing the idea that physical training has effects on more than just the symptoms, and this study provides the first indications that physical exercise may protect the nervous system against the disease,\" says one of the researchers behind the study, Associate Professor Ulrik Dalgas from the Department of Public Health at Aarhus University.\n\"For the past 15 years, we have known that physical exercise does not harm people with multiple sclerosis, but instead often has a positive impact on, for example, their ability to walk, their levels of fatigue, their muscle strength and their aerobic capacity, which has otherwise often deteriorated.\nBut the fact that physical training also seems to have a protective effect on the brain in people with multiple sclerosis is new and important knowledge,\" says Ulrik Dalgas.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release names the study\u2019s funders in a sidebar on the EurekAlert! website as the Augustinus Foundation, Hestehandler Ole Jacobsens Mindelegat and Biogen Idec. We encourage news release writers to include funders in the text of the release as well.", "answer": 1}, {"article": "Tests were conducted starting from seven to nine days after the device was implanted.\n\u201cTo go from being completely blind for many years, to being able to read a few letters and see shapes is an amazing step.\u201d\n\nRetinitis pigmentosa in a genetic eye condition that leads to blindness and affects about 1 in 4,000 people worldwide.\nHe was cautious about possible wider applications, but said that if it was developed further, the device may someday be used to help people with severe cases of age-related macular degeneration, the leading cause of blindness in older people.\nEberhart Zrenner, chairman of the University of Tuebingen Eye Hospital in Germany and director of a small company called Retinal Implant AG which is developing the device, said the trial results were a \u201cproof of concept\u201d and would now be taken into further trials in around 25 to 50 patients in Europe.\nAccording to the study published in the Proceedings of the Royal Society B journal, one blind patient who had the device implanted was able to identify and find objects placed on a table in front of him, and was able to walk around a room independently.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does quote one presumed independent source, Robert Maclaren, a professor of Ophthalmology at Britain\u2019s Oxford University. In the above mentioned Medical Technology Alert, the manufacturer announced that Dr. Maclaren will be the lead investigator on a clinical study expected to enroll\u00a0six subjects to advance this same retinal implant technology. As a result, Dr. Maclaren can hardly be described as an independent expert. Overall, we felt that the story was missing a strong, independent analysis. Had the reporter talked with more researchers in the field or more clinicians, perhaps the story would have had a more thoughtful tone.", "answer": 0}, {"article": "The low-fat diet was not easy to follow, said Dr. Rowan T. Chlebowski, a medical oncologist at Harbor-U.C.L.A.\nThe idea is that a high-carbohydrate, low-fat diet leads to weight gain, higher insulin and blood glucose levels, and more diabetes, even if the calories are the same as in a higher-fat diet.\nThe women on low-fat diets had a 9 percent lower rate of breast cancer; the incidence was 42 per thousand per year in women in the low-fat diet group, compared with 45 per thousand per year in women consuming their regular diet.\nBut the current study, asking if a low-fat diet could protect women from breast cancer in the first place, had findings that fell short of statistical significance, meaning they could have occurred by chance.\nFor decades, many scientists have said, and many members of the public have believed, that what people eat -- the composition of the diet -- determines how likely they are to get a chronic disease.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Scientists with a variety of different perspectives and interests are quoted. It is unfortunate that the quotes used focused more on personal beliefs than on evaluation of the evidence. ", "answer": 1}, {"article": "Five patients were previously diagnosed with colorectal cancer and one with cholangiocarcinoma.\nThe main advantage is that the new technique does not rely on pre-amplification, which can introduce errors and biases.\nThe test, which is called single color digital PCR, requires only a fraction of a tube of blood and can detect as few as three mutation-bearing molecules in a single reaction.\nThe single-color digital PCR test offers several advantages over other methods of circulating tumor DNA analysis, compared to next-generation targeted sequencing and fluorescent probe-based digital PCR assays.\nMoreover, the test's rapid turnaround and relatively low cost, especially compared to next-generation DNA sequencing, provide a potential opportunity for universal monitoring of more patients than is currently done,\" explained lead investigator Hanlee P. Ji, MD, Associate Professor in the Department of Medicine at Stanford University and Senior Associate Director of the Stanford Genome Technology Center.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funders are noted in the sidebar where this release is hosted on EurekAlert! but not in the release itself. We encourage news release writers to include funders in the body of the release. There is no mention of conflicts of interest in the release, nor in the study itself.", "answer": 1}, {"article": "Please use our search feature and update your bookmarks. Thank you!", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release goes into significant detail about the funders and their mission. Funders include the National Institutes of Health, the National Multiple Sclerosis Society, and a private foundation. The drugs and placebo used in the study were provided by Synthetic Biologics, the manufacturer. The release also notes, somewhat vaguely, that Synthetic Biologics has licensed some rights from UCLA. ", "answer": 1}, {"article": "The people who do this are specially trained.\nThe guidelines provide added incentive to quickly transfer stroke victims from a local hospital to a major stroke center capable of advanced treatment, said Powers and Dr. David Kandzari, director of interventional cardiology and chief scientific officer for the Piedmont Heart Institute in Atlanta.\nBut when those drugs don't work, doctors now can turn to a new catheter-based device that will physically remove the blood clot, said Dr. William Powers, lead author of the updated AHA guidelines and chair of neurology at the University of North Carolina at Chapel Hill.\nA number of other medical societies have endorsed the AHA's new guidelines, including the American Association of Neurological Surgeons and the Society of Vascular and Interventional Neurology.\nThe procedure must start within six hours of the onset of a stroke, which means that emergency teams and hospitals will have to move fast, Powers said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two experts, one of whom chaired the committee that wrote the guidelines (Powers) and the other (Kandazari) who was apparently independent of the guideline-writing process. The solicitation of an outside expert opinion is commendable, but the story should have notified readers that Dr. Kandazari is a paid consultant for companies, such as Medtronic and Boston Scientific, that make the devices that are used in these procedures. See this Wall Street Journal report and the disclosures on this online CME program.", "answer": 0}, {"article": "The Watchman is a catheter-delivered device that is permanently implanted in the opening of the left atrial appendage (LAA), a small appendage of tissue that projects off one of the upper chambers of the heart.\nIt has been suggested that as treatment for atrial fibrillation, the Watchman device may be preferable to standard blood thinning medications, such as warfarin, which raise the risk of bleeding.\nThe researchers found that while results from the trials varied, the device did appear to be more cost-effective in the larger, longer-term trial.\nNew Haven, Conn.-- A new study by a Yale researcher may support the use of a device for patients suffering from irregular heart rhythms.\n\"Based on that, the study may provide more certainty in terms of cost-effectiveness.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release does not say who paid for the work or whether any of those involved in the studies cited had conflicts of interest.", "answer": 0}, {"article": "Repatha, with a list price of more than $14,000 a year, was approved based on its ability to dramatically lower \u201cbad\u201d LDL cholesterol in patients who require more intensive therapy on top of widely-used statins, such as Lipitor, or who are unable to tolerate statins.\nAt the heart meeting in March, researchers will also provide details on risk reduction for each of the components, such as non-fatal heart attack, non-fatal stroke, and heart-related death.\nThe data should pave the way for greater acceptance by health insurers and pharmacy benefit managers, who have been rejecting about 75 percent of prescriptions written for the expensive medicine despite multiple appeals by physicians.\n\u201cThese results show unequivocally the connection between lowering LDL cholesterol with Repatha and cardiovascular risk reduction, even in a population already treated with optimized statin therapy,\u201d Amgen research chief Sean Harper said in a statement.\nThe trial was widely expected to be positive, especially after a smaller study presented in November showed Repatha therapy led to regression of artery-clogging plaque, an underlying cause of heart disease.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only source mentioned in the story is an official from Amgen, the drugmaker.\u00a0 Therefore, there is an assumed conflict of interest since the company is touting the success of their product, even without any substantive data to back that up.\u00a0 No independent source is included in the story.", "answer": 0}, {"article": "Now Dr.\nFor years, the study\u2019s principal investigator, Suzanne Craft, has studied insulin\u2019s effects in Alzheimer\u2019s.\nIn her field, cardiovascular medicine, she has seen many exciting findings in small studies that fall apart in larger or longer ones.\nAnd conditions in which the body makes too little insulin or is resistant to its effects \u2014 diabetes, prediabetes, even untreated high-blood pressure \u2014 are associated with an increased risk of Alzheimer\u2019s.\nThe problem was to find a way to get more insulin to the brain but not to the body.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes quotes from the lead researcher on the study as well as an expert who was not affiliated with the research. The comments from the independent expert help drive home the need for caution when interpreting these results.", "answer": 1}, {"article": "A doctor suggested the gene test and she scored very low for recurrence risk.\n\u2018\u2018There is no chance that for these patients, that chemotherapy would have any benefit.\u2019\u2019\n\nDr. Karen Beckerman, a New York City obstetrician diagnosed with breast cancer in 2011, said she was advised to have chemo but feared complications.\nThe study involved the most common type of breast cancer \u2014 early stage, without spread to lymph nodes; hormone-positive, meaning the tumor\u2019s growth is fueled by estrogen or progesterone; and not the type that the drug Herceptin targets.\nThe test accurately identified a group of women whose cancers are so likely to respond to hormone-blocking drugs that adding chemo would do little if any good while exposing them to side effects and other health risks.\nMany women with early-stage breast cancer can skip chemotherapy without hurting their odds of beating the disease \u2014 good news from a major study that shows the value of a gene-activity test to gauge each patient\u2019s risk.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The Associated Press interviews five experts for the article \u2013 one is the study\u2019s lead author and the rest are independent sources. This is a strong point in the story.\nBut while the story also mentions the funding source (National Cancer Institute), there was a relevant conflict of interest that was overlooked here. Dr. Joseph Sparano, the study\u2019s lead author, reported a patent \u201crelated to tests to predict responsiveness of cancer patients to chemotherapy treatment options\u201d in his NEJM disclosure forms (p.79-80). Since we feel this is significant enough conflict of interest that should have been touched upon in the story, we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "\u201cDoes everybody need to practice at least 20 minutes a day three times a week?\nThis is a much larger study, and the findings are robust.\u201d\n\nAbout four out of five people experience low back pain at some point in their lives, prompting Americans to spend $50 billion a year on medications, physical therapy and related costs.\nThe study is the largest and most thorough to date to look at whether yoga has an effect on chronic low back pain, a problem that affects millions and has no surefire long-term remedy.\n\u201cAt a certain point in time you learn what your back needs.\u201d\n\nAs an alternative to yoga, stretching may be a viable option.\n\u201cMore participants in the yoga and stretching groups were very satisfied with their overall care for back pain.\u201d\n\nDr. Sherman said that like many other therapies for low back pain, yoga probably would not work for everyone.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The New York Times article did not offer commentary from an independent source. The evidence on chronic back pain is complex and challenging, as is the evidence on yoga and stretching. So the article would have benefited from additional expert input. The authors of the clinical trial did not disclose any conflicts-of-interest, so there was no need to report on this criterion in the article.\n", "answer": 0}, {"article": "\u201cThis test looks very promising, but it is also very expensive,\u201d\n\nWhile there are risks attached to amniocentesis and CVS screens, these are minimized when the test is performed by a skilled obstetrician, she says.\n\u201cWe are not quite there yet, but it may become a real possibility for finding out real information without having to risk a pregnancy.\u201d\n\nFor example, \u201cIf this comes back negative, you don\u2019t need an amniocentesis, but if it comes back positive, we would probably still do an amniocentesis to confirm the results,\u201d she says.\nStill, he adds, \u201cit\u2019s an important step forward.\u201d\n\nThe technology is likely prohibitively expensive and time-consuming at this point, he says.\nWhile the new screen only looks for Down syndrome, Sullivan says that some of the other trisomy birth defects can be more easily identified on an ultrasound exam.\n\u201cPatients are very concerned about loss rates with aminocentesis and CVS and want reassurance about their pregnancies, so we are always looking for a better test,\u201d says Jennifer Wu, an obstetrician/gynecologist Lenox Hill Hospital in New York City.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story provides a wealth of outside experts who provide great commentary and context about the study\u2019s findings. We wish more stories about screenings had quotes like these:\u00a0\u201cIn a year or two, this test may be available, but it won\u2019t replace existing technologies, it will nudge its way into our armamentarium of available methodologies,\u201d says Mark I. Evans, MD,\u00a0\u00a0director of Comprehensive Genetics in New York City, and an obstetrician/gynecologist at Mount Sinai School of Medicine, also in New York City.\u00a0\u201cThe bad news is that prenatal diagnosis is not just about Down syndrome\u2026Down syndrome represents about 50% of what we find, and this new test can help with that, but it may also give women a false sense of reassurance.\u201d", "answer": 1}, {"article": "\n\u2022 Medimetriks, in collaboration with Otsuka, announces the successful completion of a Phase 2 trial of MM36 (previously known as OPA-15406) in Atopic Dermatitis (AD)\n\u2022 MM36 is a topical phosphodiesterase 4 (PDE4) inhibitor under development for the treatment of AD\n\u2022 Results showed a therapeutic benefit as measured by percentage change in EASI score and improvement in IGA score\n\u2022 MM36 is expected to be the 2nd topical PDE4 inhibitor available in the US and may offer unique benefits for patients suffering from AD\n\nMedimetriks Pharmaceuticals, Inc. today announces the publication of Phase 2 results for MM36 (previously referred to as OPA-15406), a novel topical non-steroidal phosphodiesterase IV (PDE4) inhibitor for the treatment of mild-to-moderate atopic dermatitis.\nThe majority of affected individuals have resolution of disease during childhood, although 10% to 30% of patients maintain the condition throughout their lives.\nA small percentage of the population develops first symptoms as adults.\nTheir use can be limited by local adverse reactions such as burning and stinging.\nThese effects were sustained through week 8 of the study.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t include any information about how the study was funded. The study itself discloses that several authors are paid consultants for the companies making the drug.", "answer": 0}, {"article": "More About: The Study\n\nNathalie Scheers had looked at parvalbumin before in another context.\nWe already knew that they can meet in the gut, the blood, or the brain,\" explains Pernilla Wittung-Stafshede.\nA study from Chalmers University of Technology, Sweden, shines more light on the link between consumption of fish and better long-term neurological health\n\nA new study from Chalmers University of Technology, Sweden, shines more light on the link between consumption of fish and better long-term neurological health.\nIt was Nathalie who first had the inspiration to investigate parvalbumin more closely, after a previous study she did looking at biomarkers for fish consumption.\nWhat the Chalmers researchers have now discovered, is that parvalbumin can form amyloid structures that bind together with the alpha-synuclein protein.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding sources for the study and any potential conflicts among the researchers are not mentioned in the release. The published article acknowledges funding from the Knut and Alice Wallenberg Foundation, the Swedish Research Council, the Olle Engqvist Foundation and the Chalmers Foundation.", "answer": 0}, {"article": "Professor Bartlett said researchers are constantly looking at new treatment strategies for alcohol abuse and addiction, which is characterised by extended periods of heavy alcohol use, binges and abstinence, and anxiety and depression which contribute to relapse.\nTheir studies in adult mice show that two weeks of daily treatment with the drug tandospirone reversed the effects of 15 weeks of binge-like alcohol consumption on neurogenesis - the ability of the brain to grow and replace neurons (brain cells).\nIt is commonly used there and shown to be highly effective in treating general anxiety and well tolerated with limited adverse effects.\"\n\"This opens the way to look at if neurogenesis is associated with other substance-abuse deficits, such as in memory and learning, and whether this compound can reverse these.\"\n\"Other studies in mice have shown that tandospirone improves brain neurogenesis, but this is the first time it has been shown that it can totally reverse the neurogenic deficits induced by alcohol.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release makes no mention of the funding sources of this research, nor does it provide any information on potential conflicts of interest.", "answer": 0}, {"article": "TUESDAY, June 5, 2012 (HealthDay News) -- A simple blood test may help gauge prognosis and tailor treatments for women who have been diagnosed with early stage breast cancer.\nOne area for study is how well these circulating cells predict recurrence and death in patients who have already had chemotherapy.\nThe more tumor cells a woman had in her bloodstream, the higher the likelihood of relapsing or dying, according to the report.\nThe problem is that just having circulating tumor cells may not be enough information to foretell the future, she noted.\nWhether or not cancer has spread to the lymph nodes is currently the best way to predict survival in women with breast cancer.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two experts not connected with the study are quoted.\u00a0 Both provide valuable perspective on the clinical\u00a0usefulness of the blood test to current patients.", "answer": 1}, {"article": "The study's authors acknowledged that their preliminary data offers \"promise for the use of time-restricted feeding as a weight loss technique in obese adults, but longer-term, large-scale randomized controlled trials [are needed].\"\nFollowers of the popular regime eat during an eight-hour window, in this case between 10 a.m. and 6 p.m. And for the 16 hours in between, they consume only calorie-free drinks, such as water.\nThe authors noted that the results mirror those from previous studies of other forms of intermittent fasting, including alternate day fasting, where an individual eats normally every other day.\nFurther research is now needed to uncover whether 16:8 works better than other fasting diets in terms of weight loss and health benefits.\n\"There are also many studies that either report no overall effect or sometimes the opposite.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included quotes from a previous story from an independent expert, who spoke on the general topic of fasting diets. More comments from independent sources about this particular study would have strengthened the story.\nThe story should have noted that two of the authors have recently written books about fasting and weight loss.", "answer": 0}, {"article": "And the study had one particularly unexpected outcome.\n\u201cYou will get a relative change, even though it might not be as accurate as a chest strap,\u201d said Clue co-founder Mike LaVigne.\nAs the researchers had hypothesized, the participants' Fitbits captured a portion of this fertile window by showing that their resting heart rates rose one or two days before ovulation, as well as during ovulation itself.\nFitbits aren't the only wearables that can track fertility-related biometrics in the background.\nDepending on the device, it could even help you go one step further and actually conceive.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources in the story. Only two sources are quoted, and each of them works for a tech company whose products address fertility issues.", "answer": 0}, {"article": "For those who have resolved to get fit in the New Year, O\u2019Donovan recommends to start with moderate exercise, such as brisk walking, and then to set realistic, incremental goals to boost confidence without running the risk of setbacks due to injury.\n\u201cThe novel finding is that it appears the duration, and possibly the intensity, of leisure time physical activity is more important than the frequency,\u201d Ekelund said.\nTheir overall risk of death was 30% lower than the sedentary adults, with the risk of cardiovascular and cancer deaths lower by 40% and 18% respectively.\nIn the study, those who exercised a little had a 29% lower risk of death than those who did no exercise at all.\nNearly 9,000 of the study participants died in the period.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The sources don\u2019t appear to have any conflicts of interest, and there was one additional source included beyond the lead researcher.", "answer": 1}, {"article": "Newly published research in the Journal of the American College of Nutrition showed that a hearty bowl of instant oatmeal helped curb food intake at lunch better than a leading oat-based, cold cereal -- even when each bowl provided the same number of calories.\nThe lunches offered ranged from 2,600 to 2,800 calories and participants were told to \"eat to satisfaction.\"\nAfter an analysis of the types of fiber in each cereal, the researchers suspected that the higher molecular viscosity of the beta-glucan in the instant oatmeal contributed to its satiating effect over the oat-based, cold cereal.\nFor more information, please visit www.QuakerOats.com, www.Facebook.com/Quaker or follow us on Twitter @Quaker.\nAuthors stated that the processing of the cold cereal might lead to changes in the oat fiber that reduced its ability to enhance satiety.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding sources for the study are not made clear in the release, nor does the release tell us that the study researchers included PepsiCo employees. The journal article discloses all of this information so it would have been easy enough to find and include.", "answer": 0}, {"article": "Current treatments target the immune cells involved in the disease and none are specific for FLS.\n\"Here, we investigated whether this venom component, called iberiotoxin, would be able to specifically block the FLS potassium channel and reduce the severity of the rheumatoid arthritis in rat models of the disease.\"\n\"We think that this venom component, iberiotoxin, can become the basis for developing a new treatment for rheumatoid arthritis in the future.\"\nA group of researchers led by Dr. Christine Beeton at Baylor College of Medicine has found that one of the hundreds of components in scorpion venom can reduce the severity of the disease in animal models, without inducing side effects associated with similar treatments.\nIn some cases they reversed the signs of established disease, meaning that the animals had better joint mobility and less inflammation in their joints.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release reports that the study was supported by Peptide International, makers of the peptide iberiotoxin, the Arthritis Foundation and the National Institutes of Health. We didn\u2019t find any undisclosed conflicts of interest.", "answer": 1}, {"article": "* Researchers involved in this study are affiliated to the following:\n\nSchool of Medicine, University of East Anglia, Norwich, UK \n\nNorfolk and Norwich University Hospital, Norwich, UK \n\nBristol Medical School, University of Bristol, Bristol, UK \n\nDepartment of Rheumatology, University Hospitals Bristol, Bristol, UK \n\nMedical Research Council Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, UK \n\nCollege of Medical and Dental Sciences, University of Birmingham, UK \n\nCentre for Endocrinology, Diabetes and Metabolism, Queen Elizabeth Hospital, Birmingham, UK \n\nLeicester Medical School, Centre for Medicine, University of Leicester, UK \n\nNational Institute of Health Research Manchester Musculoskeletal BRU, Central Manchester University Hospitals NHS Foundation Trust & \n\nArthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, UK \n\nDepartment of Health Sciences, University of York, York, UK \n\nCentre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK \n\nMellanby Centre for Bone Research, Centre for Integrated Research into Musculoskeletal Ageing, University of Sheffield, Sheffield, UK \n\nAustralian Catholic University, Melbourne, VIC, Australia\nThe study suggests that one hip fracture could be prevented for every 111 women screened and early analysis suggests the approach is likely to be cost-effective.\nHalf of the women were screened to compare screening with routine care.\n\"We welcome this community based screening programme and any other research that reduces the likelihood of fractures.\"\nWhile screening did not reduce the incidence of all osteoporosis-related fractures, there was strong evidence for a reduction in hip fractures.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The source of funding and universities involved in the study are clearly stated.", "answer": 1}, {"article": "Prescribing testosterone for age-related deficiency \u2014 which is only vaguely defined \u2014 took off in 2000. The trend was driven not by solid scientific evidence, but by the introduction of convenient, rub-on testosterone products, the first being Androgel. Many men are put on testosterone with no tests of their levels or despite tests showing normal levels, a study of Medicare claims found.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does an exemplary\u00a0job of citing credible, outside sources about the study. We did not detect any conflicts of interest that were overlooked.", "answer": 1}, {"article": "With better drugs and radiation techniques available, the proportion of women with Stage 4 breast cancer who had surgery dropped from 67.8 percent in 1988 to 25.1 percent in 2011, according to a study published Wednesday in the journal JAMA Surgery.\nHere's how he survived]\n\nPrevious research has reached the same conclusion, but a significant problem with this study and others like it is that they rely on retrospective data, looking back over any number of years, said Michael S. Sabel, the chief of surgical oncology at the University of Michigan, who was not involved in the newly published study.\nIn their study, Schroeder; Alexandra Thomas, a professor at Iowa's Carver College of Medicine, and others looked at 21,372 women from 1988 to 2011 who had Stage 4 breast cancer at the time of their original diagnosis and did not receive radiation as part of their first course of therapy.\n\"Theoretically...patients with metastatic breast cancer might benefit from surgery to remove the cancerous breast tumor in combination with medical therapies as a more complete reduction of their total body cancer burden,\" she added.\nIn retrospective research, it's impossible to filter out the countless reasons that a woman and her doctor might have made the decision to treat the cancer with or without surgery, leaving the conclusions unreliable for clinical decision-making, he said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The Washington Post report interviews two independent sources \u2013 the chief surgical oncologist at the University of Michigan and the medical director of a breast cancer center \u2013 and their comments bring a much needed critical perspective to the piece.\nNo conflicts of interests are reported, both in the original research article and in the Washington Post story.", "answer": 1}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\nThe test correctly excluded all the 31 controls and diagnosed both Parkinson\u2019s disease and dementia with Lewy bodies with 93 percent accuracy.\nAbout the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services.\nThe diseases typically progress for years before symptoms appear, and once they do, distinguishing one disease from another can be difficult.\nNIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release mentions that the research was supported by the NIH but doesn\u2019t mention other significant funders such as the Parkinson\u2019s and Movement Disorder Foundation and the Shiley-Marcos Alzheimer\u2019s Disease Research Center at the University of California San Diego.\nIt also doesn\u2019t note (as the published article does) that four study authors have applied for a US provisional patent application on the technology. ", "answer": 0}, {"article": "A drug-coated stent made by Abbott Laboratories that is awaiting U.S. regulatory approval is as safe as, and potentially more effective than, the market-leading version of the heart device made by Boston Scientific Corp., according to findings presented Tuesday at the EuroPCR conference in Barcelona.\n\nClinical-trial data analyzed by Abbott two years after its Xience V stents were implanted in patients are likely to reassure investors and regulators about the product's long-term safety and could restore some investor confidence...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story would have benefited greatly by including comment(s) from someone other than a company spokesperson or someone involved in the study. This could have provided readers with some insight about what this new product might add to the field.", "answer": 0}, {"article": "June 2, 2010 (San Francisco) -- A quick spray of a new drug may help men who suffer from premature ejaculation last nearly six times longer, new research suggests.\nAll used the product for three months, for a total of 23,000 doses.\n1 sexual health problem in men.\nHe consults for Shionogi Pharma Inc., which makes the spray and funded the work.\nThe numbers aren't huge.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One researcher\u2019s financial links to the drug company were disclosed.\u00a0 One independent expert was interviewed. ", "answer": 1}, {"article": "This is often not enough to make a meaningful improvement.\nThe tests measured line crossing and figure- and shape-copying ability.\nEveryone took tests that measured their abilities after the study and then again two weeks later.\nThere were no improvements seen in test scores of those who got the other treatment.\nAfter a stroke, one side of the brain can become overactive and its circuits can get overloaded.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story had excellent sourcing and included comments from four different experts.", "answer": 1}, {"article": "A first-of-its-kind osteoporosis drug lowers the risk of bone fractures better than some existing treatments, two studies suggest, and could soon add a more expensive but easier to manage treatment option to the booming market.\n\"You're going to have blowback by insurers\" over how much they will pay, he said, but Amgen might try to charge more than $10,000 per year.\n\"It'll find a particular niche where it'll be used, but I don't see it as taking over the market,\" said Dr. Sundeep Khosla, a professor and osteoporosis researcher at the Mayo Clinic.\nThe second study included 1,468 men with prostate cancer at increased fracture risk due to cancer hormone therapy, although 556 dropped out for reasons from side effects and cancer progression to the study being extended from two to three years.\nIn this case, it targets a molecule in bones that drives formation of cells called osteoclasts that break down bone, a strategy that greatly reduces bone loss.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several independent sources were interviewed for this story.\u00a0 The writer also points out that both trials were paid for by Amgen, the manufacturer of denosumab, and nearly all the researchers were employed by the company or received consulting or advisory fees from them.\u00a0 ", "answer": 1}, {"article": "Matthews: \u2018It\u2019s only going to get better\u2019\n\nIn his first game with the Pacers, he only made two shots but they came in the fourth quarter to pull out the victory vs. the Hornets.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No interview material from independent experts was included in this story.", "answer": 0}, {"article": "D'Onofrio is also a co-author of several studies based on patient data from Sweden that found similarly lower risk for substance abuse and transport accidents in people with ADHD who used medication.\nThe results, based upon nearly 3 million people with ADHD in the United States, are reported in the American Journal of Psychiatry.\nThe larger number of people in the two more recent studies -- as well as the use of U.S. patients in the new analyses -- strengthens this earlier evidence.\nThe majority of the ADHD medicines used in the study were stimulants such as Adderall, an amphetamine, and Ritalin, or methylphenidate.\n\"Many factors can influence who receives ADHD treatment, including socioeconomic factors, health care access, the strength of support networks and disorder severity,\" Quinn said.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release noted the funders but did not mention any of the authors\u2019 conflicts of interest. One of the authors has served as a speaker for\u00a0Eli Lilly and Shire, and was awarded a research grant from Shire. Shire produces ADHD medications, including\u00a0Vyvanse and Adderall. Eli Lilly also produces an ADHD medication, Strattera. This is a big conflict of interest that should have been noted in the release, particularly since both Adderall and Strattera were mentioned by brand name in the release.", "answer": 0}, {"article": "Water jets also were linked with a decrease in the amount of half-pints of milk students bought, which could be a potential mechanism of weight reduction, the researchers found.\nThe study, published in JAMA Pediatrics, analyzed data collected from 1,227 elementary and middle schools across New York City - some with and some without \"water jets.\"\n\"The study by Schwartz and colleagues in this issue of JAMA Pediatrics adds to a growing body of evidence supporting the importance of providing drinking water access in schools.\n\"We associated these water dispensers with almost a one percentage point reduction in the likelihood of being overweight for boys and a little over a half a percentage point reduction for girls,\" said lead researcher Brian Elbel, an associate professor of population health and health policy at NYU School of Medicine.\nSchools with water dispensers saw a modest weight drop among students, according to the study by researchers from NYU Langone Medical Center, New York University's Institute for Education and Social Policy, and the Center for Policy Research at Syracuse University's Maxwell School of Citizenship and Public Affairs.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No conflicts of interests were reported in the original journal article. The study was funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development.\nThe CBS report only quoted comments from the study\u2019s lead researcher and then excerpts from the accompanying JAMA Pediatrics editorial. Technically, these editorial comments are sufficient to clear our bar, but we\u2019d note that the thrust of the quote is mainly to confirm what the researchers are reporting. We would have liked to have seen a quote from someone willing to provide a more critical perspective on the study, such as the significance of its limitations and their impact on the research.\nWhile we give the benefit of the doubt here as we always do, the story didn\u2019t really fulfill the spirit of this criterion.", "answer": 1}, {"article": "The research was published online in the journal Neuropsychology.\n\"The study findings are exciting because they demonstrate that it's never too late to take action to maximize the cognitive capacity of your brain,\" said lead researcher Megan Lenehan, PhD.\nThe participants completed the same cognitive tests each year during the four-year study, with 92 percent of the college-studies group displaying a significant increase in cognitive capacity, while the remaining 8 percent generally maintained their cognitive capacity.\nThe study was too short to reveal any long-term effects so the researchers plan to follow the participants as they age to provide additional evidence of whether college studies may reduce the risk or delay the onset of dementia.\nFull text of the article is available from the APA Public Affairs Office and at\n\nThe American Psychological Association, in Washington, D.C., is the largest scientific and professional organization representing psychology in the United States.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources weren\u2019t noted, nor conflicts (which could have been covered if just noted that it was a largely government-funded study). The published article\u00a0is also silent on the matter. Given the subject, it is difficult to identify any meaningful potentials for a conflict of interest. But we think all news releases should discuss funding as a matter of course. That\u2019s our line in the sand.", "answer": 0}, {"article": "The paid for the study.\nIt\u2019s hard for us as surgeons and medical oncologists and radiation oncologists to accept that you don\u2019t have to remove the nodes in the armpit.\u201d\n\nDr. Grant W. Carlson, a professor of surgery at the Winship Cancer Institute at , and the author of an editorial accompanying the study, said that by routinely taking out many nodes, \u201cI have a feeling we\u2019ve been doing a lot of harm.\u201d\n\nIndeed, women in the study who had the nodes taken out were far more likely (70 percent versus 25 percent) to have complications like infections, abnormal sensations and fluid collecting in the armpit.\n\u201cIt\u2019s a little frustrating.\u201d\n\nEventually, he said, genetic testing of breast tumors might be enough to determine the need for treatment, and eliminate the need for many node biopsies.\nThe complications \u2014 and the fact that there was no proof that removing the nodes prolonged survival \u2014 inspired Dr. Giuliano to compare women with and without axillary dissection.\n\u201cThis is such a radical change in thought that it\u2019s been hard for many people to get their heads around it,\u201d said Dr. Monica Morrow, chief of the breast service at Sloan-Kettering and an author of the study, which is being published Wednesday in The Journal of the American Medical Association.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Good quotes including from Dr. Monica Morrow, chief of the breast service at Sloan-Kettering and an author of the study, but also a few fromindependent experts toward the end.\u00a0Dr. Grant W. Carlson, a professor of surgery at the Winship Cancer Institute at Emory University, and the author of an editorial accompanying the study, provides some soul-searching context by saying that, in taking out so many lymph nodes, \u201cI have a feeling we\u2019ve been doing a lot of harm.\u201d\u00a0Dr. Elisa R. Port, the chief of breast surgery at Mount Sinai Medical Center in Manhattan, said, \u201cIt\u2019s definitely practice-changing.\u201d And\u00a0Dr. Alison Estabrook, the chief of the comprehensive breast center at St. Luke\u2019s-Roosevelt hospital in New York said, \u201cIn the past, surgeons thought our role was to get out all the cancer. \u2026 Now he\u2019s saying we don\u2019t really have to do that.\u201d", "answer": 1}, {"article": "To place an electronic embedded link to this study in your story This link will be live at the embargo time: http://jamanetwork.\n\"Results lend support to current national initiatives from the National Academies, White House, and bipartisan legislation requesting that the U.S. Food and Drug Administration create a new regulatory classification for hearing devices meeting appropriate specifications to be available over the counter,\" the authors write.\nPersonal sound amplification products (PSAPs) are less-expensive, over-the-counter devices not specifically labeled for hearing loss treatment, but some are technologically comparable with hearing aids and may be appropriate for mild to moderate hearing loss.\nNicholas S. Reed, Au.D., of the Johns Hopkins School of Medicine, Baltimore, and colleagues compared five of these devices (costs, approximately $350 to $30) with a conventional hearing aid (cost, $1,910) among 42 adults (average age, 72 years) with mild to moderate hearing loss.\nEditor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release asks the reader to see the study for \u201cauthor contributions and affiliations, financial disclosures, funding and support,\u201d which is better than nothing, yet doesn\u2019t make it easy for readers to draw conclusions about any potential bias.", "answer": 0}, {"article": "\u201cThe journal knew it.\u201d\n\n\u201cThe question for the journal, given that the authors worked for the company, is, \u2018Do we publish something like that?\u2019\u201d\n\nJohnston said there was an ongoing debate about whether or not scientists who review studies should know about potential industry interests.\nHe pointed out it was hard to draw any conclusions from this part of the study because it didn\u2019t include any data.\n\u201cScientifically there are no data there,\u201d he said about one of the company\u2019s experiments.\nBut the researchers never compared the response directly between the two groups, the whole point of a randomized controlled trial.\n\u201cIt wasn\u2019t being hidden that they worked for the company,\u201d Johnston told Reuters Health.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story identified conflicts of interest that even a publishing journal did not \u2013 and it showed how this happened.\u00a0 And it quoted several skeptical expert sources. ", "answer": 1}, {"article": "Reuters - A nicotine addiction pill can help smokers quit gradually when they can\u2019t go cold turkey, a study finds, suggesting that it may be time to revisit practice guidelines that focus primarily on immediate cessation.\n\u201cThis is very strong support for changing clinical practice to include gradual reduction aided by medication.\u201d\n\nSmoking is the leading cause of preventable death in the U.S., according to the Centers for Disease Control and Prevention.\n\u201cThis is the first study of its kind to enroll a group of smokers who are not traditionally enrolled in clinical trials because they are not ready to quit,\u201d said Dr. Caryn Lerman, professor of psychiatry and deputy director of the Abramson Cancer Center at the University of Pennsylvania in Philadelphia.\n\u201cThis allows us to reach a much broader population of smokers who aren\u2019t willing to quit abruptly or set a quit date, and it shows that people can quit without going cold turkey,\u201d said lead study author Dr. Jon Ebbert, a professor in primary care and internal medicine at the Mayo Clinic in Rochester, Minnesota.\nWhile the study shows that Chantix, which is known generically as varenicline, can be effective for some smokers, the group taking the pill also experienced more side effects such as nausea, abnormal dreams, insomnia, constipation, vomiting, and weight gain.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story notes that Chantix is made by Pfizer \u2014 but does not tell readers that Pfizer funded the study. Also, the story quotes two experts. One is an author of the study. The other is Dr. Caryn Lerman of Penn\u2019s Abramson Cancer Center. According to declarations in her published work, Lerman has served as a consultant/advisor to Pfizer regarding medications for nicotine dependence. The story would have benefited from including an expert without (real or perceived) ties to Pfizer.", "answer": 0}, {"article": "But Gee believes reimbursing patients to play games could cut other health costs \u2014 by promoting exercise and preventing disease, for example, or even reducing the amount of expensive drugs people take.\nIf it becomes proprietary, the only people who can do unfettered research on it are the people who own the procedure,\" he says.\n\"If it says 'FDA approval needed' in the business plan, I myself scream in fear and run away,\" says Tim Chang, managing director at Mayfield Fund, a venture capital firm.\n\"I'd like to think we could cut down standard clinical trials, in size and length of time, by half or more,\" he says.\n\"As an industry, we're going to have to reorient ourselves around what it is we're really trying to do,\" he says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This is a key strength of the story. Several different experts and viewpoints are presented, so that readers are shown a range of opinions and perspectives. The affiliations of key sources are identified, so that readers can see how their interests might influence their outlook.", "answer": 1}, {"article": "But Cao doesn't think people should start taking aspirin to prevent cancer until more research is done.\nThe association of aspirin with reduced cancer risk was the same for women and men regardless of race, history of diabetes, family history of cancer, weight, smoking, regular use of other painkillers or taking multivitamins, the study authors added.\n\"Although aspirin is recommended for most people who have had a heart attack, and has some benefits for cancer risk as well, at this point the American Cancer Society does not recommend that people use aspirin specifically to prevent cancer because it is not clear that the benefits with respect to cancer outweigh the risks,\" Jacobs said.\nThere was a 20 percent lower risk of cancers of the gastrointestinal tract, especially in the colon and rectum, among people taking aspirin, said lead researcher Yin Cao, a postdoctoral research fellow at the Harvard School of Public Health in Boston.\n\"The results of ongoing research to develop more tailored treatment based upon a personalized assessment of risks and benefits is critical before recommending aspirin for preventing cancer,\" she said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes an independent source from the American Cancer Society. But it\u00a0makes no mention of possible conflicts of interest, even though they would not have been hard to find: The American Association for Cancer Research news release notes that Yin\u2019s team includes Andrew Chan of Harvard Medical School, \u201cwho has previously served as a consultant for Bayer Healthcare [which makes aspirin], Pfizer Inc., and Pozen Inc.\u201d", "answer": 0}, {"article": "In another study released during the Wednesday press conference, researchers from M.D.\nLast year, the U.S. Preventive Services Task Force recommended that women in their 40s not at high risk for breast cancer could forego mammograms until they turned 50 and, even then, it said they only needed to undergo screening once every two years.\nThat recommendation met with outrage from breast cancer specialists, while other organizations, including the American Cancer Society, continued to recommend annual mammograms for women in their 40s.\nThe findings will no doubt do little to quell a controversy that has existed since the 1980s over the value of mammography screenings for women in their 40s.\nWEDNESDAY, Sept. 29, 2010 (HealthDay News) -- Another study evaluating the value of mammograms for younger women finds that screening can lower the risk of dying from breast cancer for women in their 40s.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites independent sources, including the Swedish study author and chair of the American Society of Clinical Oncology\u2019s communications committee, as well as other breast cancer researchers who found a benefit in screening younger women and a decline in breast cancer mortality.\u00a0 However, these sources do not\u00a0 discuss the downsides of treatment. No one is cited to discuss the downsides of mass screening in a group where the risks may outweigh the benefits.\u00a0 Risks of screening low to average risk women in their early 40s include: overtreatment, false positive biopsies, anxiety, and in some cases, a fear and avoidance of future screening when mammography may be of greater benefit. Why not interview a member of the USPSTF to discuss their reaction to this recently published data? The USPSTF guidelines also do note that women at low-average risk discuss screening with their doctor. There is no mandate that women 40-49 not have access to annual screening. \nQuotes from both Dr. Jennifer Obel of ASCO and from study co-author Hakan Jonsson apparently came from an ASCO teleconference.\u00a0 There was no evidence of any independent research to find independent experts to comment on the study. \n", "answer": 0}, {"article": "S. Raman; M. Pless; A. Cubillo; A. Calvo; R. Hecht; C. Liu; E. Chan; J. Chesney; A. Prat; David Geffen School of Medicine, University of California, Los Angeles, CA;, Department of Oncology, Kantonsspital Winterthur, Winterthur, Switzerland; HM Universitario Sanchinarro, CIOCC, Madrid, Spain; Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain; Amgen Inc., Thousand Oaks, CA; James Graham Brown Cancer Center, University of Louisville, Louisville, KY; Hospital Cl\u00ednic, University of Barcelona, Barcelona, Spain.\nAmgen, the pharmaceutical company that makes T-VEC, was a sponsor of the trial.\nPatients were given escalating doses of T-VEC, up to the maximum FDA-approved dose for melanoma.\n\"This minimally invasive treatment offers patients a novel way to directly and indirectly attack the cancer cells.\"\nAdditional investigation is also planned to test the therapy in combination with a checkpoint inhibitor to activate a stronger immune response.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release identified Amgen, the pharmaceutical company that makes T-VEC, as a sponsor of the trial.", "answer": 1}, {"article": "Genes that are associated with asthma risk are located on chromosome 17 and called 17q21.\nIt is already known that environmental factors have a modifying effect on specific genetic risk, so the aim of this new study was to find out whether this could also be true for breastfeeding and this specific gene related to asthma with the respect to respiratory symptoms in early infancy.\n\"Our study is the first to show that breastfeeding can modify the effect of asthma-related genetic profiles on respiratory symptoms in the first year of life\", commented Dr Olga Gorlanova, from the University Children's Hospital Basel (UKBB), and the University of Basel, Basel, Switzerland.\nThis is the first time that we were able to show the effect of the 17q21 variants on respiratory symptoms during the 1st year of life, depending on breastfeeding status.\nThe study is presented today (4 September, 2016) at the European Respiratory Society's International Congress.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release provides no information as to the funders of this research, nor does it provide any information on possible conflicts of interest involving the researchers, only one of which is mentioned in the release.\u00a0 Additionally, neither the abstract nor the full research paper was available when the news release was published, so other information describing the research was unavailable.", "answer": 0}, {"article": "The process can take several years.\nThe study was funded by Acorda Therapeutics, the maker of cimaglermin, and the report was published online Dec. 26 in the journal JACC: Basic to Translational Science.\nTUESDAY, Dec. 27, 2016 (HealthDay News) -- Heart failure patients have weakened hearts, but researchers say an experimental drug used for the first time in humans may repair heart cells and improve heart function.\nBefore cimaglermin could be used to treat patients, it must prove its worth in a series of progressively larger and challenging trials and then be approved by the U.S. Food and Drug Administration.\n\"These findings need to be replicated in larger trials, and you have to be able to predict whether improved heart function from cimaglermin will help people live longer and feel better,\" she noted.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does get credit for quoting a researcher not affiliated with this project, but it neglects to mention some obvious potential conflicts of interest among the members of the research team. According to the research paper, eight of the 13 researchers have some linkage to pharmaceutical firms and seven of them have a connection to the sponsor of the study, Acorda Therapeutics, Inc., either as consultants, employees, or stockholders, and two of them have had research funded by the company.", "answer": 0}, {"article": "After replacement surgery and months of physical therapy, patients can lift no more than 15 or 20 pounds, he said.\n\"The last time I had an injection in my wrist, it was so painful, I thought I was going to have to pull over coming home and have someone else come and drive,\" she recalled.\n\"The cost is that you don't have the ability to lift heavy objects,\" Collins said.\nMore than a dozen bones lie beneath the skin and muscles of the hand and wrist, compared with two or three for those larger joints.\nWrist replacement surgery is a last resort for some Delighted to be making her own bed once again\n\nWrist replacement surgery is a last resort for those who wish to save hand's range of motion\n\nMaking a bed may seem like a small task, but being able to do it means a lot to 79-year-old Ruby Chambers.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story relies on one patient and one \u201cexpert,\u201d a surgeon who performs wrist replacements. It provides no information on potential conflicts of interest and no conflicting points of view. Input from experts outside of this institution would provide balance and potentially clarify the risks and benefits of this procedure.", "answer": 0}, {"article": "DBS has been used to treat tremors associated with Parkinson\u2019s disease, but Machado said the new approach, if successful, will achieve something novel.\nClose to 800,000 Americans have a stroke each year and estimates suggest about half of those people will be disabled from it.\n\u201cThe big difference is that when we are treating the motor symptoms of Parkinson\u2019s disease, we\u2019re trying to make the symptom, like a tremor, go away,\u201d he said.\nSomeone has a stroke in the United States every 40 seconds, and it has become the leading cause of serious long-term disability among Americans.\nIf all goes as planned, Machado will insert the electrodes in the brain of someone severely disabled by stroke who has exhausted all other options without improvement.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quotes a single source\u2013the head of the clinical trial who will also be the person leading the DBS surgery. There is no discussion\u00a0about potential conflicts of interest.", "answer": 0}, {"article": "\u201cExercise is a good way to counteract the negative effects of sitting, but just incorporating physical activity into one part of our day may not be enough to overcome the damage caused by prolonged sitting and an otherwise sedentary lifestyle.\u201d\n\nBecause the workday is a major contributor to sedentary behavior, with more than 20 percent of workers in the U.S. reporting more than 8 hours each day, tactics that promote workstation activity have emerged in recent years, including standing desks, as well as dynamic pedal and treadmill workstations.\nThe findings are published in WORK, a journal affiliated with the Canadian Association of Occupational Therapists and endorsed by the International Ergonomics Association.\nUp to 7 percent of deaths have been attributed to sitting alone.\nThe researchers found that modest movement while seated elevated the metabolic rate more than sitting and more than standing, by 17 and 7 percent respectively, and had no detrimental effect on cognitive function.\nSitting has been identified as a risk factor for early mortality, independent of the presence of a disease, such as cancer or diabetes.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release notes in the last sentence that the research was funded by the company that makes the HOVR device used in the intervention.", "answer": 1}, {"article": "What's that like for Mason?\nIf I would have survived through that, I wouldn't have been able to live with myself,\" he said.\nMore research will be needed to try to establish whether they actually repair damage to the spinal cord.\n\"There was nothing we could have done to change that night,\" said Bob Gambuti.\nToday, the company sponsoring the trial reported four of the six patients experienced improvement in both motor strength and function.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does tell viewers that the physician who performed the procedure \u201cis not affiliated with the company\u201d sponsoring the trial. However, it should have included an independent expert and named\u00a0the trial sponsor.", "answer": 0}, {"article": "Prostate cancer begins when cells in a man\u2019s prostate gland mutate and start to grow uncontrollably.\nThe fusion of MRI and ultrasound imaging technology that we use to accurately identify and diagnose the cancer, combined with the extreme precision of the gold nanoshells in targeting the diseased cells, allows us to be incredibly accurate at obliterating them.\nLooking back, the experience was even better than I was expecting, and I hope to see nanoparticle therapy advance into an option for anyone diagnosed with prostate cancer in the future.\u201d\n\nThe gold nanoparticles were invented by Naomi Halas, the head of Rice University\u2019s Laboratory for Nanophotonics.\nI am excited as we continue tracking the progress of this groundbreaking improvement to prostate cancer care.\u201d\n\nDoug Flewellen, the first patient in Texas to receive the new method of care, says for him, the procedure was a no-brainer.\nThis new technology holds the potential to eliminate those life-altering effects, while still removing the cancer tissue and reducing hospital and recovery time,\u201d Canfield said.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funder(s) of the study aren\u2019t mentioned. We don\u2019t know how heavily the lead researcher, his research center or partners, or even the patient could be conflicted with the company developing the technology. That information would have been very helpful.", "answer": 0}, {"article": "TRENTON, N.J. (AP) - GlaxoSmithKline PLC on Wednesday applied for approval in the U.S. and Europe to sell an existing breast-cancer drug as a first-line treatment.\nIt's also been approved for that use in the 27 European Union countries and several others.\nApproval as an initial treatment likely would boost that sharply.\nThis material may not be published, broadcast, rewritten or redistributed.\nAbout two-thirds of breast cancers are hormone sensitive.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only source interviewed in the story is an employee of the drugmaker.\u00a0 Where was any perspective from an independent clinician? ", "answer": 0}, {"article": "Cardinal says older adults need to realize that exercise can greatly improve their quality of life by maximizing function as long as possible.\nPrevious findings from the same study showed that the exercise program lowered the risk of becoming disabled in the first place; this one showed that it sped recovery from an episode of disability and lowered the risk of subsequent episodes.\nThe authors called on medical schools to \"start preparing students to prescribe exercise as effectively as they prescribe statins, and for health systems to support physicians in addressing inactivity just as they provide support in addressing other health risks.\"\n\"Prescribing exercise may be just as important as prescribing medications \u2014 perhaps even more important in some cases,\" the editorial said.\nPrevious research has suggested that exercise can improve memory and reverse muscle loss in older adults, among other benefits.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an independent source, and doesn\u2019t appear to have missed any conflicts of interest.", "answer": 1}, {"article": "\"The risk of MS among daughters whose mothers consumed four glasses of milk per day was 56% lower than daughters whose mothers consumed less than three glasses of milk per month,\" Harvard researcher Fariba Mirzaei, MD, says in a news release.\nHowever, few foods naturally contain the vitamin.\nIt revealed that women born to mothers who had the highest intake of vitamin D had a much lower risk of developing MS as an adult.\nThe disease most often strikes adults after age 20, but it can develop in children.\nVitamin D is found in certain foods and beverages such as fortified milk and cereals, and fatty fish such as salmon.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent experts were interviewed for this story.\u00a0\u00a0\u00a0", "answer": 0}, {"article": "\"Sixty to 80 percent [success] for something that somebody's not going to get guaranteed pain relief -- in my mind, it's not something I would go for,\" Duggal says.\nAfter a few months, she's back to running -- but shorter distances.\nThe healing process takes place over several months after the shock-wave therapy, which Theodore does in a single treatment.\nSuddenly the room is filled with the rhythmic click-click-click of a metronome.\nThe plantar fascia is a tough, rubber-band-like structure on the bottom of the foot.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story finds experts on both sides of this issue and gives them each a reasonable amount of air time.", "answer": 1}, {"article": "TUESDAY, Nov. 2, 2010 (HealthDay News) -- MRI images can serve as a \"surrogate clock\" to pinpoint stroke onset in patients whose symptoms began during sleep, increasing the number of patients eligible for highly effective clot-busting therapy, according to a new study.\nare managed as urgently as those with known stroke onset time,\" she said.\nis that they get there too late,\" he said.\nA couple of hours later [after therapy], they can walk and talk.\nReview the warning signs of stroke at the American Stroke Association.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included quotes from independent experts.", "answer": 1}, {"article": "\u2022 Keep up to date with Tenovus Cancer Care by following them on Twitter @tenovuscancer or Liking their page on Facebook http://www.\n\u2022 The Centre for Performance Sciences is a partnership between the Royal College of Music, London and Imperial College London.\nDr Daisy Fancourt, Research Associate at the Centre for Performance Science, a partnership between the Royal College of Music and Imperial College London and co-author of the research, said: \"Many people affected by cancer can experience psychological difficulties such as stress, anxiety and depression.\nSinging in a choir for just one hour boosts levels of immune proteins in people affected by cancer, reduces stress and improves mood, which in turn could have a positive impact on overall health, a new study by Tenovus Cancer Care and the Royal College of Music published today in ecancermedicalscience has found.\nIt will look at mental health, wellbeing, social support and ability to cope with cancer, alongside measuring stress hormones and immune function amongst patients, carers, staff and people who have lost somebody to cancer.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that the non-profit Tenovus conducted the research, in collaboration with The Centre for Performance Science, which is a new partnership of the Royal College of Music and Imperial College London.", "answer": 1}, {"article": "But researchers say the preliminary findings could one day lead to diabetes treatments.\nWhen researchers compared patients who had gastric bypass surgery to those who lost the same amount of weight by dieting, they found that the surgery patients had lower levels of amino acids that have been linked to insulin resistance.\nAnd the patients in both groups had lost just a fraction of the weight they needed to lose at the time of the analysis.\nMost of the research has focused on changes in gut hormones, but we have shown that a decline in specific circulating amino acids also occurs.\u201d\nThe study was small, including just 10 patients who had the surgery and 11 patients who followed severely calorie-restricted diets.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "In addition to two authors of the study reported on, a spokesperson from the American Diabetes Association commented on the impact of gastric bypass on type II diabetes.", "answer": 1}, {"article": "A downloadable photo of Dr. Mark Loeb is available here\nThe original intention of the study was to show that nasal spray vaccines would provide better protection than flu shots, but Loeb says the conclusions of the study are now especially important, given the ACIP's recommendations.\nFor the study, Loeb's team conducted a three-year trial in a Hutterite colony, where people live communally and are relatively isolated from cities and towns, to determine whether vaccinating children and adolescents with the flu nasal spray provided better direct and community protection than the standard flu shot.\n\"Our study is the first blinded randomized controlled trial to compare the direct and indirect effect of the live vaccine versus the inactivated vaccine,\" said Loeb, a professor in McMaster's Department of Pathology and Molecular Medicine.\nThe researchers randomly assigned 1,186 children in 52 Hutterite colonies in Alberta and Saskatchewan, Canada to receive either the nasal spray vaccine or the flu shot and also followed 3,425 community members who did not receive a flu vaccine.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does identify the chief funder of the study, the Canadian Institutes for Health Research, although it offers no information on possible conflicts of interest among any of the researchers. The abstract\u00a0of the study does state that two of the researchers do have links to pharmaceutical firms, but not in relation this study.", "answer": 1}, {"article": "This trial represents an expansion of the Abramson Cancer Center's integrative medicine and wellness services that are available to patients and survivors.\n\"We offer several ways to enhance quality of life, minimize or reduce side effects of cancer and cancer treatment, and promote healing and recovery,\" Vapiwala said.\n\"There may also be a psychosocial benefit that derives from participation in a group fitness activity that incorporates meditation and promotes overall healthiness.\nMost yoga participants reported a sense of well-being at the end of each class, and upon finishing the yoga program and concluding their study involvement, many patients requested and received an at-home practice routine to fit their needs, Ben-Josef said.\nFurthermore, erectile dysfunction is reported in 21 to 85 percent of all prostate cancer patients, while urinary incontinence is reported in 24 percent of men with this disease.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release makes no mention of funding or possible conflicts of interest. It does say that the oral abstract was presented at the\u00a0Society of Integrative Oncology\u2019s 12th International Conference.", "answer": 0}, {"article": "\u201cThe important point was the intensity of the activity,\u201d Erin Richman, a postdoctoral fellow at UCSF, said in a statement.\nProstate cancer is the second leading cause of cancer death in men.\nThe patients\u2019 average age at diagnosis was 65.\nMore than 2.2 million men in the U.S. are living with prostate cancer.\nMen who took acetaminophen for less than five years saw no protective benefit.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent expert source was cited to comment on either finding.", "answer": 0}, {"article": "On The Early Show Friday, Family Circle magazine Editor in Chief Linda Fears discussed everyday lessons that can make a big difference.\nNow, there's new information showing how important folic acid is.\nIt's a tremendous challenge for parents to teach their teenagers and \"tweens\" everything they ought to know.\nIn fact, according to a recent survey we conducted on the emotional lives of tweens and teens, kids want more time just hanging out with their parents, and more time talking about important issues.\"\nYou can't see or smell it.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were no comments from experts in B vitamins or prenatal development.\u00a0 We really don't what sources were used.\u00a0 ", "answer": 0}, {"article": "Representative Rosa DeLauro, Democrat of Connecticut, said that the new guidelines would have no effect on federal policy and that \u201cRepublicans are using these new recommendations as a distraction.\u201d\n\n\u201cMaking such arguments, especially at this critical point in the debate, merely clouds the very simple issue that our health reform bill would increase access to care for millions of women across the country,\u201d she said.\nOnly some people who are exposed to it develop cancer; in most, the immune system fights off the virus.\nIt is by no means clear that doctors or patients will follow the new guidelines.\nCervical cancer is caused by a sexually transmitted virus, human papillomavirus, or HPV, that is practically ubiquitous.\nIf cancer does develop, it can take 10 to 20 years after exposure to the virus.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Sourcing is excellent. Sources include:", "answer": 1}, {"article": "Want to embed a link to this study in your story?\nThe following related elements also are available on the For The Media website:\n\nThe editorial, \"Opioid vs Nonopioid Acute Pain Management in the Emergency Department,\" by Demetrios N. Kyriacou, M.D., Ph.D., Senior Editor, JAMA, Chicago; Northwestern University Feinberg School of Medicine, Chicago.\nThe findings suggest that ibuprofen-acetaminophen is a reasonable alternative to opioid management of acute extremity pain due to sprain, strain, or fracture, but further research to assess longer-term effect, adverse events and dosing is warranted.\nBottom Line: For adults coming to the emergency department for arm or leg pain due to sprain, strain, or fracture, there was no difference in pain reduction after 2 hours with ibuprofen-acetaminophen vs three comparison opioid-acetaminophen (paracetamol) combinations.\nStudy Conclusions: There were no important differences in pain reduction after 2 hours with ibuprofen-acetaminophen or opioid-acetaminophen combination pills in emergency department patients with acute extremity pain.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release says only that information about financial disclosures and funding are available in the JAMA article itself \u2014 which isn\u2019t very helpful. For the record, the study was funded (at least in part) by the National Institute on Aging, and there don\u2019t appear to be any conflicts of interest \u2014 but the news release could have said as much.", "answer": 0}, {"article": "Sales of herbal cleansing products tripled last year to $28 million, according to Spins, a market research company.\nIt includes no caffeine, sugar, animal products, gluten or alcohol.\n\"I want to keep doing it for the rest of my life,\" she added.\n\"They're very, as a whole, low in calories.\nOne night, the pair saw an infomercial for The Almighty Cleanse.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There did not appear to be anyone knowledgeable about weight, weight loss, or anything medical consulted for this segment.", "answer": 0}, {"article": "But Riddle soon heard that certain compounds in cannabis\u2014cannabinoids\u2014have been shown to induce cancer cell death.\nIt\u2019s very apparent that he\u2019s dying.\u2019\u201d\n\nLandon began to refuse chemotherapy and turn into a \u201clittle psychopath,\u201d says Riddle.\nThe shape of the receptor mirrors the shape of the compound, enabling the CBD to land and attach to the cell.\nShe had up to 300 seizures per day.\nShe was willing to do whatever it took to keep him on cannabis.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are quotes from multiple experts. Those who are proponents of cannabis oil treatment are identified as working for marijuana businesses.", "answer": 1}, {"article": "But the lower doses used in this study (1.5 or 0.75 mcg) \"may help to improve the overall safety profile, particularly for geriatric patients,\" he said.\nPeople who reported higher levels of exercise were less likely to suffer from nocturia, Dagenais found.\n\"However, there have been concerns about safety, particularly in elderly patients.\"\n\"Other researchers have examined the utility and safety of desmopressin for the treatment of nocturia in the past,\" he said.\nThere's more on nocturia at the National Association for Continence.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An outside source was used in this story. We\u2019re also told that the was paid for by the drug company.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070225/5laser.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does an excellent job providing multiple balanced perspectives on current trends in laser eye surgery. The story includes perspectives from ophthalmologist researchers, laser eye surgeons and patients who have had the procedures. ", "answer": 1}, {"article": "THURSDAY, May 3, 2018 (HealthDay News) -- Much of the debate over when to start having mammograms has focused on lives saved, but new research suggests that early screening might also translate into smaller tumors and less aggressive breast cancer treatments.\nAnd the women who were screened earlier had smaller tumors.\nThe other group had a screening 25 months or more before their diagnosis.\nAll of the women were older than 40.\nBut only 29 women fell into the \"never had a mammogram\" group.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes the study author and an outside source.", "answer": 1}, {"article": "Previous research by Mayberg and others suggested that deep brain stimulation had potential as a treatment for depression.\nStill, he said, it's important to note that \"we seem to be making progress and hopefully those who are suffering the most can find solace in that and not give up hope.\"\nMONDAY, Jan. 2, 2012 (HealthDay News) -- A small study suggests that deep brain stimulation, which is currently being investigated as a treatment for general depression, may also help patients with bipolar disorder.\nThe St. Jude Medical Neuromodulation company, which has provided consulting fees to Mayberg and some of the other study authors, is currently recruiting patients for a study that could pave the way for its approval as a treatment for depression, Mayberg said.\nStill, the study suggests that brain stimulation \"not only just helps patients who haven't been able to recover from depression, but it seems to be associated with the absence of relapses.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story says that the St. Jude Medical Neuromodulation company \u201cprovided consulting fees to Mayberg and some of the other study authors\u201d and \u201cis currently recruiting patients for a study that could pave the way for its approval as a treatment for depression.\u201d The story also quotes\u00a0Samuel James Collier, M.D., assistant professor of psychiatry, University of Texas Southwestern Medical Center at Austin, who provides a welcome dose of skepticism to the story, saying \u201cMedications and ECT \u2014 electroconvulsive therapy \u2014 are clearly safer, better tolerated, and do not embody a large surgical risk. \u2026I can\u2019t think of a scenario where deep brain stimulation would be considered even remotely before medications and ECT were exhausted.\u201d\n\u00a0", "answer": 1}, {"article": "Sabourin Lussier, born with spina bifida, faced the possibility of kidney failure when she was just 19 years old. Her bladder, damaged by the devastating birth disorder, leaked uncontrollably and often backed urine up into her kidneys.\n\nA conventional surgery to reconstruct her bladder with intestinal tissue threatened further health complications. So in May 2000, Ms. Lussier and her mother, Gail Johnston, agreed to an experiment under which she and eight other patients with spina bifida would receive partial, laboratory-built...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No mention of sources' potential conflict of interest or sources of funding for this procedure. The cost may be free to the patients currently undergoing the transplantation, but someone is paying for the research and surgeons' efforts. ", "answer": 0}, {"article": "But the supplement has largely failed to show benefits in human athletes.\n\u201cIt can be speculated that the training frequency could be higher (with shorter breaks after vigorous training sessions)\u201d in those drinking beer, he wrote in an e-mail response.\n\u201cFurthermore, it is not possible to drink one to one and a half liters of alcoholic beer per day, especially not during strenuous training.\u201d We all knew that, right?\n\u201cWe do not know whether the side effects of alcoholic beer would cancel out the positive effects caused by the polyphenols,\u201d he wrote.\n\u201cIncidence of upper respiratory tract infections was 3.25-fold lower\u201d in the nonalcoholic beer drinkers, the scientists reported, in the journal Medicine & Science in Sports & Exercise.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes the lead author extensively.\u00a0 Unfortunately, no other independent perspectives are provided. No potential conflicts of interest are noted.", "answer": 0}, {"article": "Foods to avoid\n\n Dairy: Milk, ice cream, yogurt, cottage and ricotta cheeses (except for lactose-free versions)\n\n Fruits: Apples, peaches, pears, watermelon, cherries, figs\n\n Vegetables: Garlic, onions, leeks, asparagus, cauliflower or large servings (more than \u00bd cup) of broccoli and Brussels sprouts\n\n Grains: Wheat (except in sourdough bread), rye, barley\n\n Legumes and nuts: Cashews, kidney beans, soy beans and soy milk\n\n Sweeteners: Honey, fructose, xylitol, agave syrup\n\nFoods to include \n\n Dairy and dairy substitutes: Kefir, almond milk, coconut milk\n\n Fruits: Bananas, blueberries, grapes, oranges, strawberries\n\n Vegetables: Carrots, green beans, bell peppers, potatoes, tomatoes\n\n Grains: Rice, oats, gluten-free bread (but check labels for high-FODMAP ingredients)\n\n Legumes and nuts: Peanuts, pecans, walnuts\n\n Sweeteners: Cane sugar, aspartame, stevia\n\u201cBut I think it\u2019s a reasonable thing to try.\u201d\n\nThe largest study so far, with 92 patients, was conducted at University of Michigan.\nIt found that 52% of low-FODMAP patients and 41% of patients on a less-restrictive diet reported \u201cadequate relief.\u201d The difference was not statistically significant, says study co-author William Chey, a professor of gastroenterology.\nThe undigested carbohydrates can draw extra fluid into the digestive tract and end up in the colon, where they are \u201cfeasted upon\u201d and fermented by gut microbes, leading to all sorts of misery, says Lauren Van Dam, a registered dietitian at the University of Michigan.\n\u201cOur goal is for them to be on the most varied, nutritious diet possible.\u201d\n\nThe trickiest part is avoiding onions and garlic, the dietitians say.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "William Chey, a professor of gastroenterology,\u00a0is listed as a consultant to Nestle on one of the studies.\u00a0Nestle Health Science markets low-FODMAP products. Also, another source, dietitian Kate Scarlata, has a forthcoming book on FODMAP. We think both of these details should have been in the story.\nWe were\u00a0glad to see that the story does note that the University of Michigan\u2019s website for low-FODMAP diet resources, which is referenced in the article, receives funding from Nestle Health Science.", "answer": 0}, {"article": "The alternative therapy reduced hot flashes by as much as 74% in the study conducted by researchers at Baylor University\u2019s Mind-Body Medicine Research Laboratory and funded by the National Institutes of Health.\n\u201cThere is certainly a need for non-pharmacologic treatments for hot flashes and night sweats,\u201d says North American Menopause Society (NAMS) Executive Director Margery Gass, MD.\nThey are linked to declining estrogen levels, but it remains unclear just why the sudden lack of estrogen sends the body into thermal mayhem, and why some women are more affected than others.\nIn the newly published study, they set out to determine if the alternative treatment would do the same in women whose symptoms were related to menopause.\nA total of 187 postmenopausal women who reported having at least seven hot flashes a day, or 50 a week, were recruited for the trial.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The WebMD quotes a researcher tied to the study and the\u00a0Executive Director of the\u00a0North American Menopause Society (NAMS). The study was published in Menopause, which is the journal of NAMS. A comment from an independent source would have been welcome, especially if he/she discussed the study\u2019s limitations and significance. Furthermore, any potential conflicts of interest are not mentioned.", "answer": 0}, {"article": "Any opinions, findings, conclusion, or recommendations expressed in this publication are those of the authors and do not necessarily reflect the view of the U.S. Dept.\nThe Lifestyle Interventions and Independence for Elders Study is supported by a National Institutes of Health/National Institute on Aging Cooperative Agreement (U01AG22376) and a supplement from the National Heart, Lung and Blood Institute (3U01AG022376-05A2S), and sponsored in part by the Intramural Research Program, National Institute on Aging, National Institutes of Health.\nThe content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.\nWe wanted the physical activity sessions to include exercise that participants could do outside of the study, and we hope that learning of these results might motivate others to try to make safe, incremental changes to their activity levels.\nFor the LIFE study, the researchers analyzed data from 1,635 men and women age 70-89 over an average of 2.6 years.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release is clear that the research was supported by the National Institutes of Health.\nWhile some of the researchers disclosed pharma funding in the published study, that funding wasn\u2019t relevant to this research and we agree with the decision not to include it in the release.", "answer": 1}, {"article": "TUESDAY, March 27, 2012 (HealthDay News) -- When taken as a supplement, unroasted -- or green -- coffee-bean extract can help people shed pounds, according to a small preliminary study.\nThe study was conducted in India and funded by Applied Food Sciences, the American manufacturer of two green-coffee-extract products.\nIt has not been published in a journal, and therefore has yet to undergo peer review.\n\"First of all, you need more than 16 people to have any statistical significance attached to these findings,\" Sandon said.\nAll the patients were instructed to maintain their usual dietary habits, while the study team monitored them for weight loss over a period of nearly six months.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An independent expert commented on the wisdom (or lack thereof) of basing this story on a 16-person study described only in a yet-to-be-presented meeting abstract. It also mentions that the study was funded by the supplement manufacturer.", "answer": 1}, {"article": "In both breast and other cancer trials, palbociclib has been shown to be safe with once-daily dosing, and its main adverse effect is reversible neutropenia, an abnormally low count of neutrophils, a type of white blood cell that helps fight infections.\nAlthough, median progression-free survival was four months, five patients had progression-free survival greater than one year.\nThe lower their neutrophil count, the more vulnerable patients are to infectious diseases.\nIn such cases the drug is temporarily discontinued and reintroduced at a lower dose.\n\"In tumors, it can cause shrinkage, or more commonly, arrest of growth.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that Pfizer and the National Institutes of Health funded the review.", "answer": 1}, {"article": "The heightened connectivity to spirituality has also been demonstrated to curb suicidal thoughts and attempts.\nThe study, published recently in the Journal of Pharmacology, analyzed data from an annual survey conducted by the National Survey on Drug Use and Health that measures substance abuse in relation to mental illness.\nThe results showed that those who had taken these substances in their lifetime had a 19% less likelihood of exhibiting psychological distress in the past month, and their reports of suicidal thoughts in the past year were likely to be 14% lower.\nAdditionally, the effects of psychedelics on the developing brain are still largely unknown, meaning they could pose a threat to people with a predisposition to schizophrenia.\nIn recent years, some scientists, such as this study\u2019s lead researcher, Peter S. Hendricks, have been pioneering innovative treatments to help decrease the suicide rate.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article\u2019s sole source is the lead author of the study. Especially for a controversial topic such as this one, we think it\u2019s important to include feedback from experts with differing perspectives.", "answer": 0}, {"article": "U.S.\nFigure 1a shows a tear at baseline on the posterior horn of the medial meniscus, while Figure 1b, taken 9 months after the first injection shows complete resolution of the tear.\nResults are published in the scientific publication the Journal of Medical Cases, and is authored by USRM Chief Science Officer Dr. Kristin Comella and colleagues Dr. Scott Greenberg of the Magaziner Center for Wellness, and Dr. Laura Ross of Ross Orthopedic.\nStem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product Adipocell\u2122, as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.\nThe paper outlines the case study of a 56-year-old male with a chronic meniscus injury.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "While it isn\u2019t explicitly stated, readers probably assume that this research was funded by US Stem Cell, Inc. The lead investigator is identified as the company\u2019s chief science officer, so her potential conflict is clear.\u00a0 There is no additional information offered on the remaining two investigators.", "answer": 2}, {"article": "Doctors use brain imaging, evaluation of behavior, psychiatric tests, and other means to diagnose the disease.\n''This is a simple test that has high accuracy and can be run from a single drop of blood,\" says Robert Nagele, PhD, a professor of medicine at the University of Medicine and Dentistry of New Jersey School of Osteopathic Medicine.\nHis test is one of numerous such tests under study, says Heather Snyder, PhD, a spokesperson for the Alzheimer's Association, who reviewed the research results.\nLast month at the Alzheimer's Association International Conference, Australian researchers reported good results for another blood test for Alzheimer's under development.\nAn estimated 5.4 million Americans have Alzheimer's disease, the most common form of dementia, according to the Alzheimer's Association.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\nThe story includes a spokesperson from the Alzheimer\u2019s Association. It does not appear that this group was involved with this study. We would have preferred hearing from an independent scientist rather than someone from an advocacy group. Nonetheless the Association spokesman adds some important perspectives. The story does point out near the top that the lead researcher is the founder of the company developing the test.", "answer": 1}, {"article": "The U.S. Food and Drug Administration today approved Nuplazid (pimavanserin) tablets, the first drug approved to treat hallucinations and delusions associated with psychosis experienced by some people with Parkinson\u2019s disease.\nEarly symptoms of the disease are subtle and occur gradually.\nNuplazid was shown to be superior to placebo in decreasing the frequency and/or severity of hallucinations and delusions without worsening the primary motor symptoms of Parkinson\u2019s disease.\nThe neurological disorder typically occurs in people over age 60, when cells in the brain that produce a chemical called dopamine become impaired or die.\nBreakthrough therapy designation is a program designed to expedite the development and review of drugs that are intended to treat a serious condition and where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release\u00a0tells us Nuplazid is marketed and funded by Acadia Pharmaceuticals.", "answer": 1}, {"article": "Surgical removal of cancerous tissue also can spur the spread of cancer in the body.\nWhile there are drugs given to patients after surgery to prevent cancer cells from adhering to each other or other tissues, these drugs do not rid the body of cancer cells or collect them to allow an assessment of the patient\u2019s status.\n\u201cThis method is effective for both diagnosing and treating metastasis cancer and can be used in combination with traditional chemotherapy and radiation therapy,\u201d he added.\n\u201cWe have made a nano-sized device that we can put under the skin using an injection needle to recruit the cancer cells into a small area where we can treat them with less overall side effects to the whole body,\u201d Tang said.\n\u201cOur cancer trap works just like a roach motel, where you put in some bait and the roach goes there and dies,\u201d said Liping Tang, UTA bioengineering professor and leader of the research.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "While the release does mention the institution\u2019s overall level of funding for cancer research, it does not say where any of that funding came from \u2014 much less who funded the \u201ccancer trap\u201d research. Federal agencies? The private sector? Nonprofit organizations?", "answer": 0}, {"article": "Animal models had skin injuries infected with Pseudomonas aeruginosa, Staphylococcus aureus or Acinetobacter baumannii, three different types of bacteria that commonly infect wounds and develop biofilms that are treatment resistant.\nThe team\u2019s next move is to focus on the bioelectric bandage as a treatment for chronic wounds in a patient population; however, the technology could also be used to treat acute injuries.\nWorking with a mechanical and aerospace engineering team led by Shaurya Prakash, PhD and Vish Subramaniam, PhD, the scientists have optimized the bandage\u2019s design and the amount of electrical current delivered.\n\u201cWe\u2019re hoping this new design may allow electric fields and currents to penetrate more deeply into wounds, and really get to where these biofilms may be hiding,\u201d said Subramaniam, chair of the Department of Mechanical and Aerospace Engineering at Ohio State.\nThe immune system cannot penetrate the biofilm, and antibiotics can\u2019t get in either \u2013 causing constant inflammation and low-level infection that can further dampen the healing process.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release identifies the funder of this work as the National Institute of Health, and notes that \u201cthe team already has interest from several industry partners.\u201d", "answer": 1}, {"article": "Other Phase 2 data presented over the weekend showed that treatment with cabozantinib led to significant tumor shrinkage in 24 percent of patients with metastatic ovarian cancer.\n\u201cFor the first time, cabo is showing dramatic activity against both soft tissue and metastatic bone lesions,\u201d said Exelixis Chief Executive Officer Michael Morrissey.\nThe disease remained stable in 23 other patients, or 21 percent, and worsened in three.\n\u201cMen with late-stage prostate cancer usually die from bone disease.\u201d\n\nAfter 12 weeks of treatment, 31 patients were randomly selected to receive either a placebo or cabozantinib.\nExcluding patients on placebo, the median survival without disease progression was 29 weeks.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No physician or researcher was interviewed \u2013 only the drug company CEO.\u00a0 Not good form in reporting on health news.\u00a0 With thousands of cancer specialists in Chicago for the ASCO conference, was none available?", "answer": 0}, {"article": "Joslin has one of the largest diabetes training programs in the world, educating 150 M.D.\nThe use of anti-VEGF treatment rather than laser for PDR could help prevent these symptoms.\u201d\n\nAdditionally, the need for vitrectomy surgery was lower in the Lucentis group (8 of 191 eyes) than in the laser group (30 of 203 eyes).\nThe trial results \u201cprovide crucial evidence for a safe and effective alternative to laser therapy against PDR,\u201d said NEI Director Paul A. Sieving, M.D., Ph.D.\n\n\u201cPatients who received Lucentis showed a little bit better central vision, much less loss of their side vision, and substantially less risk for surgery than patients who received laser treatment,\u201d said Lloyd Paul Aiello, M.D., Ph.D., director of the Beetham Eye Institute at Joslin Diabetes Center and Professor of Ophthalmology at Harvard Medical School.\n\u201cLaser still has a role in the treatment of PDR for some patients, but anti-VEGF therapy gives us another tool in our search for better vision outcomes in our patients with diabetes.\u201d\n\nFounded in 1898, Joslin Diabetes Center is world-renowned for its deep expertise in diabetes treatment and research.\n\u201cThese findings will change the available treatment options for patients with PDR.\u201d\n\nDiabetic retinopathy damages blood vessels in the light-sensitive retina in the back of the eye.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does tell readers that the study was funded by the National Eye Institute. However, it does not make clear that Lloyd Paul Aiello \u2014 who is quoted in the release \u2014 was also a co-author of the journal article. The release also fails to mention that several co-authors receive research funding or consulting fees from Genentech, which developed ranibizumab and markets it in the U.S., and Novartis, which markets the drug outside the U.S.", "answer": 0}, {"article": "Larsson and her colleagues combed through research databases spanning the last 45 years to find studies that tracked how much magnesium people took and how many of them had a stroke over time.\nOther experts said the results were consistent with dietary recommendations.\nAbout 6,500 of them, or three percent, had a stroke in the time they were followed.\nThose are things that have low sodium, high potassium and high magnesium,\u201d said Larry Goldstein, director of the stroke center at the Duke University Medical Center in Durham, North Carolina.\n\"It's again the diet per se, not any one individual component of the diet.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included one independent expert\u2019s perspective.", "answer": 1}, {"article": "After 10 months of following the prescribed protocol, his hippocampal volume increased to the 75th percentile.\nThe MEND protocol, outlined in a 2014 study in the journal Aging, calls for interventions to treat conditions that could be associated with Alzheimer's such as inflammation, stress and diabetes.\nThe study noted that some of the patients who had to quit working as a result of their memory decline, were able to return to work after adopting MEND and participants who were struggling at their jobs reported an improvement in job performance.\nA cure for Alzheimer's disease (AD), a condition marked by progressive, debilitating cognitive decline that affects more than 5.4 million Americans, is the holy grail in disease research.\nBut Bredesen believes that the only way to treat Alzheimer's is to treat all of the underlying problems, which may require intervention with supplements.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does include an independent source, Florida Atlantic University professor James E. Galvin, M.D., M.P.H., who\u2019s quoting saying that personalized approaches are promising, but more study is needed. \u201cNot all things from the (MEND) approach have a lot of scientific support behind them,\u201d he says in the story.\nBut, the story does not describe funding sources, which include the National Institutes of Health (NIH) and the Accelerate Fund, an early-stage investment fund based in Canada. As we reported in our earlier news release review, lead researcher Bredesen also apparently stands to benefit from sales of a book set to be released in May 2017 through a mainstream book publisher.", "answer": 0}, {"article": "The only once-and-be-done-with-it option for women has been tubal ligation (\"tying the tubes\") -- surgery that renders a woman sterile.\nThe nonsurgical approach uses a hysteroscope -- a camera-tipped instrument -- to thread two small wires through the vagina, cervix and uterus and into the fallopian tubes.\nThere is the risk of infection or a puncture of the vagina or uterus while inserting the hysteroscope.\nThere is very little bleeding, and no stitches are needed to close the tiny openings (one on each side).\nAs with tubal ligation, there is also an increased risk of ectopic pregnancy -- a pregnancy that develops outside the uterus.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does quote\u00a0an expert who describes the risks and benefits of the procedure fairly well. The story could have quoted another clinician\u00a0or expert to comment on the roll of Essure in clinical practice.", "answer": 1}, {"article": "People who don\u2019t get this type of minimally invasive surgery may instead get a more invasive procedure that involves surgeons cutting open the chest to repair a damaged valve.\nThe analysis focused on people with what\u2019s known as aortic stenosis, which occurs when the large blood vessels leading away from the heart narrow, forcing it to work much harder to pump blood.\nResults of the current study reaffirm that a minimally-invasive procedure can be a viable option, even for elderly people who are high-risk surgical patients, said Dr. Samir Kapadia, a cardiovascular medicine researcher at the Cleveland Clinic in Ohio.\nThe smaller studies in the analysis ranged in size from 36 to 484 patients, and most of them followed patients for as long as six to 12 months after surgery.\nOne limitation of the current analysis is that many of these smaller studies were not controlled experiments designed to prove whether or how transcatheter aortic valve replacement might improve quality of life, lead study author Nicola Straiton of the University of Sydney and colleagues note in Age and Ageing.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two experts who weren\u2019t involved in the analysis, which is good. However, both have received payments from companies that make heart valves, according to CMS\u2019 Open Payments search tool. Those connections were not disclosed in the story.", "answer": 0}, {"article": "It's the first study to specifically examine...\nJennifer Corbett Dooren has details on Lunch Break.\nNow, it may be good for the brain as well.\nNow, it may be good for the brain as well.\nWe've long known that the Mediterranean diet is good for the heart.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent perspective provided and \u2013 if the journalist isn\u2019t going to do a critical analysis of the evidence \u2013 then an independent perspective is sorely needed in such stories.", "answer": 0}, {"article": "The U.S. Food and Drug Administration today approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis).\nThe Agency also is responsible for the safety and security of our nation\u2019s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.\nBy binding to this protein, Dupixent is able to inhibit the inflammatory response that plays a role in the development of atopic dermatitis.\nThe safety and efficacy of Dupixent have not been established in the treatment of asthma.\nOverall, participants who received Dupixent achieved greater response, defined as clear or almost clear skin, and experienced a reduction in itch after 16 weeks of treatment.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There is no mention of who funded the research leading to the FDA approval, although many readers will assume it was supported by the manufacturer Regeneron.", "answer": 0}, {"article": "The study, \"Efficacy and Safety of an Injectable Combination Hormonal Contraceptive for Men,\" will be published online at http://press.\nThe research was co-sponsored and funded by UNDP/UNFPA/UNICEF/WHO/World Bank Special Program of Research, Development, and Research Training in Human Reproduction in Geneva, Switzerland, and CONRAD (using funding from the Bill & Melinda Gates Foundation and the U.S. Agency for International Development).\nOther authors of the study include: Hermann M. Behre of Martin Luther University of Halle-Wittenberg in Halle, Germany; Michael Zitzmann of the University of M\u00fcnster in M\u00fcnster, Germany; Richard A. Anderson of The University of Edinburgh in Edinburgh, United Kingdom; David J. Handelsman of the University of Sydney and Concord Hospital in Sydney, Australia; Silvia W. Lestari of the University of Indonesia in Jakarta, Indonesia; Robert I. McLachlan of Monash Medical Centre in Melbourne, Australia; M. Cristina Meriggiola of the University of Bologna in Bologna, Italy; Man Mohan Misro of the National Institute of Health & Family Welfare in New Dehli, India; Gabriela Noe of the Instituto Chileno de Medicina Reproductiva in Santiago, Chile; Frederick C. W. Wu of Manchester Royal Infirmary in Manchester, U.K.; Ndema A. Habib and Kirsten M. Vogelsong of the World Health Organization of Geneva, Switzerland; and Marianne M. Callahan, Kim A. Linton and Doug S. Colvard of CONRAD, East Virginia Medical School, a reproductive health organization based in Arlington, VA.\nThe hormones were effective in reducing the sperm count to 1 million/ml or less within 24 weeks in 274 of the participants.\n\"The study found it is possible to have a hormonal contraceptive for men that reduces the risk of unplanned pregnancies in the partners of men who use it,\" said one of the study's authors, Mario Philip Reyes Festin, MD, of the World Health Organization in Geneva, Switzerland.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release states that the research was co-sponsored and funded by UNDP/UNFPA/UNICEF/WHO/World Bank Special Program of Research, Development, and Research Training in Human Reproduction in Geneva, Switzerland, and CONRAD, using funding from the Bill & Melinda Gates Foundation and the U.S. Agency for International Development. It also states that the hormones were provided by drugmaker Schering, which has since merged with Bayer.", "answer": 1}, {"article": "These findings held for every geographical region.\nNow here\u2019s the interesting part: eating more foods thought to be less healthy \u2014 those typical of Western diets \u2014did not link to an increase in heart attacks, strokes, or deaths.\nIn fact, every one-point increase in a participant\u2019s Mediterranean diet score was linked with a 7 percent reduction in risk of heart attack, stroke, or death.\nLook at it this way: if 100 people ate the highest proportion of Mediterranean foods and 100 ate the least, there would be three fewer heart attacks, strokes, or deaths among those who ate more foods from the Mediterranean diet.\nThey answered questions about their diet and reported how many times a week they consumed servings from separate food groups.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story would have been stronger if it had included analysis from at least one independent source who had no connection to this study. Especially considering that many of the study\u2019s authors, including the source who was indirectly quoted in the story, received support from a variety of pharmaceutical companies, including GlaxoSmithKline, which is mentioned in this story.", "answer": 0}, {"article": "Though CA125 is valuable to look for recurrence of cancer, it is not recommended for screening because it can surge, for example, during menstruation. However, guidelines from the American College of Obstetricians and Gynecologists and the National Comprehensive Cancer Network (NCCN) recommend a CA125 test plus vaginal ultrasound imaging for a woman with nonspecific symptoms that could signal ovarian cancer, such as bloating and pain. A CT or MRI scan may be added, although these are expensive. A biopsy is usually avoided because it could spread cancer cells.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The companies responsible for developing and marketing these two tests are front and center in this story, with scientists affiliated with the companies clearly identified. At least two sources in the story\u2014one of them a scientist affiliated with the National Comprehensive Cancer Network\u2014appear to be independent of the companies.", "answer": 1}, {"article": "A formerly controversial high-fat diet has proved highly effective in reducing seizures in children whose epilepsy does not respond to medication, British researchers are reporting.\n\u201cThis is the first time that we\u2019ve really got Class 1 evidence that this diet works for treatment of epilepsy,\u201d said Dr. J. Helen Cross, professor of pediatric neurology at University College London and Great Ormond Street Hospital.\nFor the British trial, the researchers enrolled 145 children ages 2 to 16 who had never tried the diet, who were having at least seven seizures a week and who had failed to respond to at least two anticonvulsant drugs.\nAs the first randomized trial of the diet, the new study lends legitimacy to a treatment that has been used since the 1920s but has until recently been dismissed by many doctors as a marginal alternative therapy.\nThough its exact mechanism is uncertain, the diet appears to work by throwing the body into ketosis, forcing it to burn fat rather than sugar for energy.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Apparently a not-yet-published journal article was one source. \u00a0\u00a0 Another was an interview with the principal investigator of the study reported on. \u00a0In addition, there was an interview with a clinician with expertise in the area but who was not directly associated with the story reported on.", "answer": 1}, {"article": "Links will be live at the embargo time http://jamanetwork.\nWho and When: More than 140,000 U.S. women who had DCIS between 1998 and 2014; this study compared lumpectomy plus radiation vs. lumpectomy alone, lumpectomy vs. mastectomy, and lumpectomy plus radiation vs. mastectomy\n\nWhat (Study Measures and Outcomes): Use of radiation and/or extent of surgery (exposures); breast cancer mortality rates within 15 years (outcomes)\n\nHow (Study Design): This was an observational study.\nAuthors: Steven A. Narod, M.D., of Women's College Research Institute, in Ontario, Canada, and co-authors\n\nResults: A small improvement in breast cancer survival was associated with radiation plus lumpectomy for DCIS.\nStudy Limitations: Some data were missing; investigators didn't have information on tamoxifen use; treatments in the study population weren't randomly assigned; and the possibility remains that the decision to undergo radiotherapy was associated with other favorable prognostic factors.\nRelated Material: The invited commentary, \"Systemic Effects of Radiotherapy in Ductal Carcinoma In Situ,\" by Mira Goldberg, M.D., and Timothy J. Whelan, B.M., B.Ch., of McMaster University, Ontario, Canada, also is available on the For The Media website.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The style of this news release was to punt the question of funders and \u201cconflicts\u201d into a web link where the reader has to chase it down. It would better serve readers to have funders and any conflicts of interest spelled out in the release.\nHere is what the release states:\nEditor\u2019s Note:\u00a0The article contains conflict of interest disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.\nThe study notes that researchers received funding from Canadian government agencies.", "answer": 0}, {"article": "Most bills do allow parents to opt out, because the question remains: Where to make this decision - at the statehouse ... or your house.\nThe vaccine promises to reduce the number of HPV related cervical cancers by more than 70 percent, CBS News correspondent Cynthia Bowers reports.\nBut is it something that we are in position to sort of ramrod down people's throats?\n\"You may do things that you don't think you're going to do now that may happen and you get cervical cancer.\"\n\"Even if you think you aren't at risk, you are,\" adds Audrey.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quotes one expert, the father of a young girl being vaccinated. The story should have quoted additional experts or clinicians who could provide some additional perspective.", "answer": 0}, {"article": "Dong, an expert in vitamin D and a professor in the MCG Department of Population Health Sciences, says about 15 minutes daily in the \"young\" sun - between 10 a.m. and 2 p.m. - but before your skin starts to get pink, is the best source of vitamin D.\n\nFoods like milk, milk products like cheese and yogurt, fatty fish like mackerel and sardines, some greens like kale and collards and fortified cereals also are good sources.\nTwo thousand IUs decreased stiffness by 2 percent in that timeframe.\nThere were no measurable differences in weight or blood pressure measurements over the 16-week study period.\n\"It significantly and rapidly reduced stiffness,\" Raed says.\nThe American Heart Association considers this the primary outcome measurement of arterial stiffness.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not mention any particular funding source.", "answer": 0}, {"article": "The blisters heal in a week or two to form crusty scabs that eventually fall off.\nAnother difference is that Zostavax contains a live, weakened virus, making it unsuitable for people with poor immunity, whereas Shingrix contains a nonliving virus particle and may eventually be approved for those with compromised immunity, who are especially susceptible to a severe case of shingles.\nWhat makes Shingrix so much better is the inclusion of a substance called an adjuvant that boosts the body\u2019s immune response to the vaccine.\nThe shot itself is painful and can cause a sore arm for a day or two.\nIf you\u2019re lucky you may detect the onset of shingles before the rash appears.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Study funding is not mentioned. Perhaps more importantly, the story takes an advocacy position in favor of vaccination\u2013and presents the reporter\u2019s opinion as medical advice.", "answer": 0}, {"article": "Without strong evidence for its efficacy, the American Congress of Obstetricians and Gynecologists does not include the treatment in its Practice Bulletin for Urinary Incontinence in Women. L. Elaine Waetjen, professor of obstetrics and gynecology at the University of California, Davis Medical Center, who has spent more than 15 years treating women for this problem, said that there is \"no scientific evidence that the O-Shot works for incontinence and there is also no clear biological mechanism for why it should treat this condition.\"", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes important backstopping from an independent source. We did not detect any conflicts of interest that should have been disclosed.", "answer": 1}, {"article": "Uterine fibroids are benign tumors that grow in and around the uterus.\n\u201cIt\u2019s nice to have some additional tools in the toolbox.\u201d\n\nEarlier in October the U.S. Food and Drug Administration accepted Allergan \u2019s new drug application for ulipristal acetate (UA) to treat abnormal uterine bleeding caused by uterine fibroids.\nShe says UA appears to have fewer side effects than Lupron, the only medication, an injectable, available in the U.S. that shrinks fibroids.\n\u201cFor the longest time we have not really had good options from an oral medication standpoint to treat fibroids,\u201d says Arnold Advincula, vice chairman of women\u2019s health and chief of gynecology at Sloane Hospital for Women at NewYork-Presbysterian/Columbia University Medical Center.\n\u201cThis particular drug also works directly on the lining of the uterus\u2014the endometrium\u2014so it also quite fast and dramatically decreases and stops the vaginal bleeding,\u201d says Ayman Al-Hendy, director of interdisciplinary translational research at Augusta University in Georgia and a member of Allergan\u2019s advisory board.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article quotes one outside expert whose comments focused on the use of an injectable alternative to the oral drug, and the downsides of this alternative. But it also has a comment from Allergan\u2019s researcher noting that longer-time follow up is needed for UA. These source\u2019s commercial relationships are appropriately disclosed.\n[Editor\u2019s note: Following publication of this review, we learned that Allergan provides financial support to the White Dress Project. The story would have done well to acknowledge this relationship.]", "answer": 1}, {"article": "\"Our study should help generate further research into developing a test that clinicians - like psychologists, psychiatrists or nurses - can use in their offices to diagnose, treat and monitor the condition of people with schizophrenia.\"\nA tiny skin electrode was placed on the skin under the eye to record the retina's electrical activity.\nThe participants were tested in normal light and after sitting in the dark for 10 minutes to assess activity in different types of retinal cells.\n\"Since the retina is part of the nervous system, what is happening in the retina is likely reflective of what is occurring in the brain,\" Silverstein said.\nIn the study, published in the May 2018 issue of the Journal of Abnormal Psychology, researchers used RETeval, a hand-held device developed to record electrical activity from the retina, to replicate and extend prior studies showing that people with schizophrenia had abnormal electrical activity in the retina.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release did not mention who funded this study, and it which wasn\u2019t mentioned in the study itself, as far as we could tell. The release also didn\u2019t mention that one of the authors is employed by LKC Technologies, which makes these devices.", "answer": 0}, {"article": "This study wasn't long enough.\nHe also pointed out that the study involved infants, and that adults -- the most common cataract patients -- have a different regenerative capacity of lens epithelial stem cells.\nIn addition, we are testing if this approach can be used in treating other leading causes of blindness, such as macular degeneration and glaucoma,\" said Zhang.\n\"The main excitement for me is the ability to regenerate an organ or a tissue within an organ,\" said Canto-Soler, a retina specialist.\n\"As a glaucoma specialist, the way we do congenital cataracts, there's a great risk these babies will develop glaucoma for a lifetime and maybe with this new surgery, they won't have that glaucoma risk.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We were pleased to see multiple independent sources interviewed for this story. Seeking out multiple viewpoints can often surface new details about the illness or field of study, and place it in the context of wider research efforts and the typical patient experience.", "answer": 1}, {"article": "MONDAY, March 21, 2011 (HealthDay News) -- While the majority of morbidly obese patients who undergo gastric banding say they are generally satisfied years later, almost 40 percent are saddled with major complications, while about half have to have their bands removed, a small, new Belgian study reveals.\nThe current observations stem from a research effort led by Dr. Jacques Himpens, of the European School of Laparoscopic Surgery at the Saint Pierre University Hospital in Brussels, whose team assessed the status of 82 patients that had undergone the procedure known as \"laparoscopic adjustable gastric banding\" (LABG) more than a decade prior to the study launch.\nThe finding comes on the heels of a recent study out of the University of California, San Francisco that suggested gastric bypass surgery is superior to alternative surgical methods (such as gastric banding) for promoting weight loss and/or eliminating type 2 diabetes.\nSince its introduction in 2001, the banding approach has become a popular alternative to \"Roux-en-Y gastric by-pass\" surgery, which involves the literal stapling of the stomach in order to redirect food past part of the small intestine to instigate reduced food absorption as well as a quicker sensation of satiety.\nThe results: 12 years or more later, more than 60 percent of the banding patients said they were \"satisfied\" with their experience.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story\u00a0quoted an author of the study, the author of a critique on that study, and a surgeon who did not appear to have ties with the study. But the story missed a key fact that WebMD found in the study and reported, which is the conflicts of interest for the study\u2019s lead author, who, as WebMD pointed out, \u201creports consultant work for Ethicon Endosurgery, which makes another gastric band, Realize, and for Covidien, a health care products company.\u201d Not pointing out that the author has worked for a competing gastric band maker is a significant drawback to the story.", "answer": 0}, {"article": "MONDAY, Feb. 21, 2011 (HealthDay News) -- When it comes to shedding pounds and improving or eliminating type 2 diabetes, gastric bypass surgery may be better than other surgical weight-loss procedures, two new studies find.\nIn the bypass group, patients lost an average of 64 percent of their excess weight, vs. 36 percent for those in the lap-banding group.\n\"Everyone thinks that all weight-loss operations are the same, even the doctors and the surgeons.\nAn editorial accompanying the studies noted the results should be interpreted with caution since longer-term data is not yet available.\nLater complications may include malnutrition, hernias and a tendency in about one in 10 people to regain much of the weight they lost as a result of the procedure.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an independent expert source and weaves his comments into the coverage nicely. Remarks from a second source would have been even better.", "answer": 1}, {"article": "Feb. 1, 2012 -- A new drug appears to be effective for shrinking uterine fibroids and controlling the heavy menstrual bleeding they often cause, according to new research from Europe.\nIf trials now under way in the U.S. prove positive, New Jersey-based Watson Pharmaceuticals Inc. and Swiss-based PregLem hope to market ulipristal acetate as a fibroid treatment under the trade name Esmya, says Watson spokesman Charlie Mayr.\nIn one study, the drug ulipristal acetate proved to be much more effective than a placebo for shrinking the non-malignant uterine tumors.\nIn another, ulipristal acetate was found to be as effective as monthly injections of the drug Lupron for reducing heavy bleeding in women with uterine fibroids.\nUlipristal acetate is the active chemical in the emergency contraceptive sold in the U.S. as Ella, but the daily doses taken by the fibroid patients in the studies were much smaller than those in the contraceptive.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We were happy to see this story explain which drugmakers were interested in Esmya as a product line, but the story failed to make the same connection made in the AP story. The AP pointed out that the study was funded by these drug companies and that the researchers had worked as advisers for the companies. This is a big omission. The independent commentary from the researcher who wrote the accompanying editorial was welcome.", "answer": 0}, {"article": "It is for use only in those aged 12 or more, the F.D.A.\nThe pill will cost $150, according to a spokeswoman for Genentech, which will sell Xofluza in this country.\nThe new antiviral, generically known as baloxavir marboxil but sold under the brand name Xofluza, is a single dose treatment.\nFlu season has already begun, and last year\u2019s was one of the most lethal in decades; about 80,000 Americans died of flu or its consequences, the Centers for Disease Control and Prevention said earlier this month .\nGenentech will offer coupons that lower the price to $30 for patients with health insurance and to about $90 for the uninsured.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story incorporates input from two sources at the FDA, but the information appears to stem from an FDA statement. Information from pharmaceutical companies is clearly marked, but we really look for news stories to incorporate input from independent sources \u2014 beyond what may be available in a news release.", "answer": 0}, {"article": "At the meeting, Ahlquist presented the results of the first clinical evaluation study, which enrolled 1,100 patients.\n''One in every 17 of us will have colon cancer in our lifetime,\" says David Ahlquist, MD, professor of medicine and a consultant in gastroenterology at the Mayo Clinic in Rochester, Minn., who presented his findings on the new colon cancer screening test.\nAlthough colon cancer is the second leading cause of cancer death for men and women in the U.S., many adults don't undergo the screenings once they reach age 50 (or earlier for those with a family history), Ahlquist told a news conference.\nAhlquist called the 85% figure ''very high\" and adds: \"It would be very hard to find a noninvasive approach that could get that range.\"\nThe new test, a next-generation stool test known as a DNA methylation test, detects tumor-specific alterations or methylations in the DNA in the cells shed into the stool from cancerous or precancerous lesions.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Mixed bag:\u00a0 The story did include comments from two independent experts, which was good.\nBut the story never fully explained the lead researcher\u2019s true ties to the company making the test.\u00a0 There was only this vague and unhelpful line:\u00a0 \u201cAhlquist and Mayo Clinic are working in collaboration with Exact Sciences Corp. of Madison, Wis., to develop the test.\u201d\nNonethless, we\u2019ll give the story the benefit of the doubt on this criterion.", "answer": 1}, {"article": "The results of the Women's Health Initiative (WHI)--the largest, most scientifically rigorous study of older women's medical issues ever conducted--continue to startle researchers, confuse the public and frustrate headline writers. Case in point: last week's report that taking estrogen for seven years does not increase the risk of breast cancer for many women. There is a lot of good news in that finding, as well as some important caveats.\n\nIn many ways, the story began four years ago when researchers halted a different part of the WHI--one that looked at the long-term health effects of taking the hormone combination estrogen and progestin...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Cites a lead researcher from the trial and the National Heart, Lung, and Blood Institute. Missing the perspective of an independent expert without ties to the study. ", "answer": 1}, {"article": "The FDA granted this application Priority Review, Fast Track (for the mastocytosis indication) and Breakthrough Therapy (for the AML indication) designations.\n\u201cRydapt is the first targeted therapy to treat patients with AML, in combination with chemotherapy,\u201d said Richard Pazdur, M.D., acting director of the Office of Hematology and Oncology Products in the FDA\u2019s Center for Drug Evaluation and Research and director of the FDA\u2019s Oncology Center of Excellence.\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nIn addition, patients who received Rydapt in combination with chemotherapy in the trial went longer (median 8.2 months) without certain complications (failure to achieve complete remission within 60 days of starting treatment, progression of leukemia or death) than patients who received chemotherapy alone (median three months).\nCommon side effects of Rydapt in patients with AML include low levels of white blood cells with fever (febrile neutropenia), nausea, inflammation of the mucous membranes (mucositis), vomiting, headache, spots on the skin due to bleeding (petechiae), musculoskeletal pain, nosebleeds (epistaxis), device-related infection, high blood sugar (hyperglycemia) and upper respiratory tract infection.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t mention who funded the research leading to the approval, although some readers might be able to guess that Novartis Pharmaceuticals, the manufacturer of Rydapt, and Invivoscribe Technologies, the makers of the LeukoStrat CDx FLT3 Mutation Assay, sponsored the trials since the approval was given to them.", "answer": 0}, {"article": "Christian\u2019s team studied 676 school-age children whose mothers had been in a clinical trial in which some got iron and folic acid supplements and other nutrients while they were pregnant.\n\u201cIron is essential for the development of the central nervous system,\u201d said Parul Christian, an expert in international health at the Johns Hopkins University Bloomberg School of Public Health, whose study appears in the Journal of the American Medical Association.\nCHICAGO (Reuters) - Children in rural Nepal whose mothers were given iron and folic acid supplements during pregnancy were smarter, more organized and had better fine motor skills than children whose mothers did not get them, U.S. researchers said on Tuesday.\n\u201cIt had an impact across a range of function, including intellectual function, executive function and fine motor function,\u201d factors that could affect a child\u2019s later academic success, Christian said.\nThe World Health Organization estimates that in developing countries, every other pregnant woman is anemic and about 40 percent of preschool children are anemic.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does point out how the study was funded, but it does not make use of any experts other than one of the study\u2019s authors. This is too bad because certainly another researcher in the field could have provided some context for how widely applicable a program like this would be. There are always significant barriers to scaleup for public health interventions in poor countries, and something as simple in theory as vitamin supplementation may not be simple on the ground.\u00a0Another researcher or clinician with global health experience could have provided perspective.", "answer": 0}, {"article": "He'd read about advances in targeted therapies \u2014 drugs that go after cancer cells at the molecular level.\nBut in the meantime, patients like Anselmo are grateful to have time they wouldn't have had otherwise.\nOur series is produced with member station WNYC, and with Ken Burns Presents: Cancer: The Emperor of All Maladies, which will air on PBS starting March 30.\nWhy Doctors Are Trying A Skin Cancer Drug To Treat A Brain Tumor\n\nMaryAnn Anselmo feared for the worst when she was diagnosed with a brain tumor called a glioblastoma in late 2013.\n\"It's like you're in a parking lot,\" Hyman says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Both sources quoted in this story\u2013the patient and her doctor\u2013have interests that are arguably aligned. It would have been helpful to hear from a second neurooncologist who has experience with the disease, drug, and/or genetic targeting technique. However, because the neurooncologist clearly describes the limitations of highly targeted cancer-treating drugs, i.e. how they can and probably will eventually resist the drug, we\u2019ll rate this sourcing satisfactory.", "answer": 1}, {"article": "\"There is very little in a doctor's arsenal to battle ARI, especially since most are viral infections where antibiotics don't work.\nHe cautioned that the study is not definitive proof that vitamin D can prevent ARI but it suggests that it can and at little risk to the patient.\nAt the same time, Ginde found that those who received higher doses of vitamin D also saw an increase in falls.\nBut vitamin D can reinforce it and prevent illnesses like pneumonia, influenza and bronchitis.\nThose with higher doses saw ARIs cut nearly in half.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not make any mention of funding sources. The published study lists government agencies, including the Veterans Administration, as sponsors.\u00a0\u00a0  ", "answer": 0}, {"article": "Twenty-seven percent in the intervention group experienced depression compared with 41 percent in the control group.\n\"I was surprised by the big response to our study,\" Buntrock wrote.\nIn this experiment, half of the participants were asked to do six half-hour-long exercises that were based on cognitive behavioral therapy and problem-solving therapy, which are techniques commonly used for in-person therapy.\n\"More studies are needed to evaluate the preventive effects of unguided web-based interventions on the onset of major depressive disorder,\" Buntrock wrote in an email.\n\"And of course, I'm surprised about what happens now; that a health insurance company offers the intervention to its members.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does tell readers who funded the work, which is great. However, the only source quoted in the article is the lead author of the relevant study. An independent expert opinion would have been extremely valuable.", "answer": 0}, {"article": "It turns out that the melanoma really cares if we block the gene BRAF.\n\"I don't want to say this is going to change survival rates but they're working with the most ill people, so you can't really generalize [to other patient populations],\" said Dr. Alice Pentland, chair of dermatology at the University of Rochester Medical Center.\nThe study, which is published in the Aug. 26 issue of the New England Journal of Medicine, was funded by drug makers Plexxikon and Roche Pharmaceuticals.\nThe average survival time for someone diagnosed with melanoma is nine to 11 months, added Chapman, who is an attending physician in the Melanoma Sarcoma Service at Memorial Sloan-Kettering Cancer Center in New York City.\nWEDNESDAY, Aug. 25, 2010 (HealthDay News) -- By probing deeper into the biological mechanisms that go awry in melanoma, scientists have come up with an experimental drug that has had an effect in a surprising number of patients with advanced melanoma.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes a dermatologist\u00a0with no links to the research. Not coincidentally, she\u00a0is the only person in any\u00a0of the three stories we reviewed\u00a0about\u00a0this study to point out the lack of conclusive data on survival.\u00a0The story also notes that the trial was funded by drug maker Roche.", "answer": 1}, {"article": "Israel is director of the respiratory therapy department at Brigham and Women's Hospital in Boston.\n\"By blocking the signal that helps keep mast cells alive, we were hoping to reduce the number of these cells,\" Israel said.\n\"This is a very early work that in no way should encourage asthmatics,\" Maniatis said.\nFor more on asthma, visit the U.S. National Heart, Lung, and Blood Institute.\n\"It has been a while since a new approach and treatment for severe asthma has emerged,\" Horovitz said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not disclose that the study\u2019s senior researcher,\u00a0Dr. Elliot Israel, has worked as a consultant for Novartis, which makes Gleevec. It also didn\u2019t mention who funded the study. In this case, it was primarily the National Institutes of Health.", "answer": 0}, {"article": "Intermittent fasting in mice helped to kick-start the animals' metabolism and to burn fat by generating body heat.\nThe research team in this study wanted to better understand the reactions that interventions such as fasting trigger on a molecular level in the body.\nIntermittent fasting promotes adipose thermogenesis and metabolic homeostasis via VEGF-mediated alternative activation of macrophage, Cell Research DOI: 10.1038/cr.2017.126\n\nNote: Kyoung-Han Kim's current affiliation is the University of Ottawa Heart Institute, Canada.\nThere are changes in certain gene pathways involved in the immune system and the body's reaction to inflammation.\nThrough an analysis into the underlying biology involved, the researchers found that such intermittent fasting tempers an immune reaction in fat cells.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The research was funded by a variety of grants which were listed in the sidebar of the EurekAlert! site, but not in the news release text. The authors declared in the journal article that they had no conflicts of interest.", "answer": 1}, {"article": "Holick and others say there is little or no downside to ingesting even high levels of vitamin D.\n\n\"I've been treating patients with 50,000 units of vitamin D once a week for eight weeks followed by 50,00 every other week for over a decade, and I've not seen any untoward toxicity,\" Holick says.\nAn Institute of Medicine panel is working on a vitamin D update, which may come out this summer.\nThe National Institutes of Health is devoting $22 million for a five-year study.\nThat is, they compare people with high and low levels of vitamin D and correlate those levels with whether or not the person has a disease.\nSun exposure is key for vitamin D, known as the sunshine vitamin.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0Several respected experts in the field of vitamin D research and the epidemiology of disease were quoted for this story.", "answer": 1}, {"article": "\"If your immune system has been educated by the vaccine to recognize the tumor cells, we think it will allow the immune system to take care of any individual [cancer] cells trying to set up shop,\" explained Dr. Elizabeth Mittendorf, a surgical oncologist at the University of Texas M.D.\nThe goal of the vaccine, Hale said, is to educate the body to respond to that HER2-based peptide, so it will recognize the cancer when it recurs and attack it.\nThe vaccine, known as the \"HER2-based peptide vaccine AE37,\" is designed to harness the power of the patient's immune system, based on its reaction to a cancer-linked peptide (protein).\n\"For the controls, even without having their immune systems 'educated' towards HER2 specifically, they may still mount a response because they have previously seen HER2 within their own cancer,\" Hale said.\nThe science is early, Hale stressed, and it will take at least five years before the vaccine could conceivably be available if ongoing studies bear out.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article contained quotes from a different researcher who was very cautious about drawing conclusions from the current study\u2019s findings.\nWe do wonder,\u00a0 though, what it means when the story says that the independent expert \u201creviewed the findings.\u201d\u00a0 What did he review?\u00a0 Since the researcher\u2019s findings hadn\u2019t even been presented yet when the story was written, did the independent observer review the short abstract that appeared in the conference program?\u00a0 Did he have access to a more complete data set or a more complete description of the work?", "answer": 1}, {"article": "\u201cIt\u2019s just a phenomenal tool.\u201d\n\nThere is a downside, though: \u201cInformation overload is a very serious problem\u201d for the doctors, said Dr. Lynne Warner Stevenson, director of the Heart Failure Program at Brigham and Women\u2019s Hospital in Boston and a professor at Harvard Medical School, who counts herself as a proponent of smart devices.\nHalf of them had not been enrolled for remote monitoring and served as a control group.\nPatients can see what is happening to their own bodies and act accordingly.\nPatients, who often are frail or live far from their doctors, can be spared frequent office visits.\nSuddenly, she felt a pain in her chest.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0Clinicians who were involved with the makers of the devices discussed were quoted in this piece.", "answer": 1}, {"article": "Investigators in the Netherlands report the results of a three-year follow-up of a randomized controlled trial that compared three noninvasive treatments that included imiquimod and fluorouracil cream.\n\"Both creams have an equal cosmetic outcome and risk of local adverse events.\nFluorouracil has the advantage of being less expensive than imiquimod.\nOur evidence indicates that a personalized treatment approach is necessary,\" added Dr. Roozeboom.\nEssers, PhD, Michette J.M.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t mention funding sources.", "answer": 0}, {"article": "Seventy-four subjects with type 2 diabetes were randomly assigned to follow either a vegetarian diet or a conventional anti-diabetic diet.\nThe vegetarian diet consisted of vegetables, grains, legumes, fruits and nuts, with animal products limited to a maximum of one portion of low-fat yoghurt per day; the conventional diabetic diet followed the official recommendations of the European Association for the Study of Diabetes (EASD).\nLosing muscle fat improves glucose and lipid metabolism so this finding is particularly important for people with metabolic syndrome and type 2 diabetes, says lead author, Dr. Hana Kahleov\u00e1, Director of Clinical Research at the Physicians Committee for Responsible Medicine in Washington DC.\nThe vegetarian diet was found to be almost twice as effective in reducing body weight, resulting in an average loss of 6.2kg compared to 3.2kg for the conventional diet.\nUsing magnetic resonance imaging, Dr. Kahleov\u00e1 and colleagues then studied adipose (fat-storage) tissue in the subjects' thighs to see how the two different diets had affected subcutaneous, subfascial and intramuscular fat (that is, fat under the skin, on the surface of muscles and inside muscles).\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release did not discuss the funding source for the research. However, the organization that the\u00a0researchers are representing is the Physicians Committee for Responsible Medicine, a group that is a proponent of vegetarian and vegan diets and of dietary management of diseases (where appropriate).", "answer": 0}, {"article": "The Ache: In the digital age, many people spend hours daily bent over computers, phones and tablets\u2014our necks craned forward. Some scientists say this unnatural position can lead to pain, headaches and other symptoms, sometimes collectively called \u201ctext neck.\u201d\n\nThe Claim: Technology itself comes to the rescue. An Android app called the Text Neck Indicator measures the angle of your phone and lets you know when you\u2019re holding it in a favorable viewing position. And a new wearable device, Alex, monitors the angle of your neck...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story clearly notes relevant conflicts of interest and is very well-sourced for a story of this length, quoting authors of both studies as well as two independent sources. If those independent sources had been asked about the studies, and not just the products, the story would have been stronger.", "answer": 1}, {"article": "Total hip replacement surgery is increasingly common, with more than 300,000 procedures done every year in the U.S.\n\"The people who are against the whole idea for same-day discharge for hip replacement are concerned about the very rare instances where somebody could develop a blood clot that goes to the lung, or a fracture of some sort,\" said Davidovitch.\n\"The option to go home the same day and have that family around me was something that I wanted to do,\" said Spina.\nAnd to be quite honest, if the pain is controlled and the patient is healthy and medically completely stable there is no reason for them to be in the hospital.\nAccording to research done by the American Academy of Orthopaedic Surgeons, there are no significant differences between either approach in recovery outcomes six months after surgery.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story does include a surgeon who is skeptical of the benefits of \u201csame-day\u201d hip replacements. However, as noted above, the surgeon advocating the \u201csame-day\u201d procedure is featured far more prominently, likely creating an imbalance in reader perceptions. But the main reason for marking down the story on this criterion is that it fails to tell readers that NYU Langone has a marketing campaign tied to \u201csame-day\u201d hip surgery. The result is that the story supports the promotional efforts of the hospital and its surgeons without alerting readers to the commercial aspects of the matter.\nThe hospital tweeted an image of an earlier story on \u201csame-day\u201d hip replacement, indicating the marketing department understands the value of friendly coverage. HealthNewsReview.org also reviewed that Wall Street Journal story.", "answer": 0}, {"article": "A 6-month supply of vitamin D supplements can be bought for less than $10, and many multivitamins contain the recommended daily dose of vitamin D.\n\nAs for calcium, the NIH advises 1,000 mg per day for men ages19-70, and then 1,200 mg per day for men older than 70.\nIn animal studies, a lack of vitamin D has been linked to several diseases, such as multiple sclerosis and some types of cancer.\nAt the end of the study, men who exercised had higher bone density than those who had supplemented their diet with 1000 milligrams of calcium and 800 international units (IU) of vitamin D per day.\nTo build bone density, weight-bearing exercise is needed, such as running or weight-lifting, according to the NIH.\n\u201cYou\u2019ve got to have it to build a wall,\u201d he said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites the researchers\u2019 published findings, then turns in large part to an independent expert to evaluate the evidence.", "answer": 1}, {"article": "Bethany, who manages occupational therapists for a nursing-home chain, and Jay, a rural mail carrier, shuttled between the Twin Cities visiting their daughters.\n\u201cI couldn\u2019t walk up the steps very well.\u201d Almost three years of treatment, including punishing chemotherapy, provided a couple of years of remission.\nIt\u2019s too soon.\u201d\n\nScientists have wanted for decades to marshal the immune system to vanquish cancer, but their attempts have mostly been frustrated.\n\u201cWe\u2019re kind of up against the edge.\u201d\n\nFry thinks she might be able to undergo a second round of her latest immunotherapy, as long as her cancer is still producing CD22 proteins.\nHer mother added, \u201cWe just need this to work and to stay working.\u201d\n\nNCI\u2019s Fry is careful not to make any promises about an extended remission.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This is a tricky one. There are multiple sources in the article who speak to the research itself, and most of them are clearly identified as being involved with the research in some way. There appears to be at least one expert source who is not affiliated with any of the clinical trials, but that is inferred, rather than explicitly stated. What makes this tricky is that the story discusses multiple trials, without clearly identifying most of them. That makes it difficult to provide a judgment call here. When it\u2019s a toss-up, we try to err on the side of the story, so we\u2019ll give this a Satisfactory.", "answer": 1}, {"article": "Lona Sandon, a registered dietitian and assistant professor of clinical nutrition at the University of Texas Southwestern Medical Center at Dallas, agreed.\n\"The question was to see if more weight loss could be achieved if we provided decent quality lifestyle intervention, mostly dietary counseling, along with this medication,\" said study lead author Dr. Kishore Gadde, director of the Obesity Clinical Trials Program at Duke University Medical Center in Durham, N.C.\n\n\"And the answer was yes,\" Gadde said.\n\"The important thing to keep in mind is that although we diagnose obesity on the basis of a mathematical formula -- a BMI of 30 and up -- the basis for obesity may differ from one individual to another.\"\n\"But for many people, this kind of drug might absolutely be of great help, by doing something that helps the regulation of these appetite hormones and the regulatory pathway,\" she said.\nJust a few prescription medications are approved in the United States for long-term treatment of obesity, including orlistat (brand name Xenical) and lorcaserin hydrochloride (Belviq).\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story is almost entirely reliant on one source, the lead author of the story. It does quote one independent expert, but it\u2019s at the very end of the story and, in effect, is an endorsement of the study\u2019s findings. We are certain that other weight loss experts would have had more insightful or critical comments to make.", "answer": 0}, {"article": "Back in April the WSJ wrote about the race to develop ways of detecting Alzheimer\u2019s disease using a brain scan. Currently only a post-mortem sampling of brain tissue can provide a definitive diagnosis. But the hope is that a technology that could be used in living patients could help rule out Alzheimer\u2019s in some patients and for those that have the disease, allow its \u2026", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0There are no experts or independent sources that were quoted as part of this story.", "answer": 0}, {"article": "No more than a few days later, the samples were transported to labs at the university, where they remained frozen until they were processed by researchers. This ensured that none of the bacteria had a chance to grow or change from the time the sample was collected. Also, it guaranteed that all samples were treated the same way.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There do not appear to be any conflicts of interest. However, this story did not include independent sources.", "answer": 0}, {"article": "The key asset Pfizer wanted?\nThe field is so hot that over the summer, Pfizer agreed to spend an eye-popping $14 billion to buy San Francisco-based biotech Medivation.\nBut the data it presented at the European conference showed that the drug may not actually be more effective than Lynparza, the PARP inhibitor that\u2019s been marketed by AstraZeneca since 2014.\n\u201cWe found a significant decrease in the tumors with only two months of therapy,\u201d said Dr. Jennifer Litton, the lead investigator.\n\u201cAt this time, there\u2019s nothing available that has been approved by regulatory agencies for these women who have recurrence to their ovarian cancer.\u201d\n\nThe company aims to use its PARP inhibitor, rucaparib, to treat only patients with BRCA mutations who have had two or more chemotherapies.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes commentary from a researcher from the National Cancer Institute who has studied the currently available drug, Lynparza. That\u2019s good. However, the story does not adequately disclose the affiliations of an investigator focused on another drug (Dr. Kristeleit) whose consulting and advisory roles with Clovis and several of drug companies were not made clear.", "answer": 0}, {"article": "UW-Madison radiology professor Weibo Cai is also a senior author on the study.\n\"One potential advantage of the new device over existing vagus nerve stimulators is that it does not require external battery charging, which is a significant advantage when you consider the inconvenience that patients experience when having to charge a battery multiple times a week for an hour or so.\"\nThat existing unit, \"Maestro,\" approved by the Food and Drug Administration in 2015, administers high-frequency zaps to the vagus nerve to shut down all communication between the brain and stomach.\n\"Our expectation is that the device will be more effective and convenient to use than other technologies,\" says Wang.\nThat ongoing maintenance can be a big barrier to use, says Luke Funk, a surgery professor in UW-Madison's Division of Minimally Invasive, Foregut and Bariatric Surgery.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release states that funding was provided by grants from the National Institutes of Health. It\u2019s noteworthy that the journal article reporting the trial results states the authors declared no competing interests. However, the release discloses that the researchers patented the device. This is a glimpse at the varying and incomplete ways in which conflicts of interest are (or are not) reported in journals and in downstream news coverage.", "answer": 1}, {"article": "Before the introduction of whooping cough vaccine in the 1940s, more than 200,000 cases a year were reported in the U.S. By 1965, that number plummeted to fewer than 10,000 a year. But the disease made a comeback in the 1990s, as the newer \"acellular\" vaccine \u2014 containing only cellular material but not whole cells \u2014 was phased in. While it is safer and has fewer side effects than the old version, studies have found that its protective effects wane more quickly than originally expected.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Included in the story is a quote from vaccine expert Dr. Paul A. Offit, and we detected no potential conflicts of interest.", "answer": 1}, {"article": "SOURCE: bit.ly/zZIYa1\nThe analysis, which appeared in the Journal of Urology, compared increasingly common robotic surgery with two other techniques for the same surgery and found that direct costs can be up to several thousand dollars higher for the robotic type.\nThe results were similar for people who had kidneys removed.\n\u201cI think the take home message is that robotic (surgery), looking at our study, had certain beneficial outcomes compared to open and laparoscopic procedures,\u201d said study leader Jim Hu at Brigham and Women\u2019s Hospital in Boston.\nWe were going to get patients out of the hospital quicker, have better potency and incontinence outcomes,\u201d he told Reuters Health.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included some input from the editorial writer \u2013 although, as stated above in the \u201cEvidence\u201d criterion \u2013 perhaps not to its greatest effectiveness.\n\u00a0", "answer": 1}, {"article": "But there are other theories about how fluoride works.\nIf you pay out of pocket, a varnish treatment costs from $23 to $55, compared with a filling, which ranges from $86 to $606, according to the American Dental Association.\n\"Prevention has always been a part of the world of dentistry,\" says Richard Valachovic, president of the American Dental Education Association.\n\"OK, Alice, we are going to put the fluoride varnish on your teeth,\" says Marion Manski, director of the dental hygiene program at the University of Maryland School of Dentistry.\n\"Some of the stuff in our study has been known for 50 years,\" Evans says, referring to the use of fluoride treatments.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes a number of sources discussing this trend in dentistry, instead of just relying on one dentist.\nBut the piece would be more balanced had it included at least one source pointing out that some of the techniques advocated in the story could be overkill or wasteful for many people who are at just average risk for tooth decay. As the piece was written, all the sources are very rosy about more aggressive preventive dental care.\u00a0We also found via an internet search that source\u00a0John Featherstone\u00a0has accepted consultation fees from dental companies that make products for these purposes. However, since he wasn\u2019t specifically endorsing one of these products\u00a0in this story,\u00a0we\u2019ll\u00a0give this a pass.", "answer": 1}, {"article": "ASTHMA According to conventional wisdom, asthma and other allergic diseases like hay fever are made worse by dirty environments. Recent evidence has suggested, however, that children exposed to dirt and germs early in life may have a lower risk of developing asthma and other allergies. Studies have found that the children of farmers -- who presumably are exposed to a ... (Full article: 838 words)", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Less than optimum: The sole source of this article appears to be a New England Journal of Medicine article. No additional sources were apparent. \nStrong point: The story stated, \u201cCAUTIONS: This study was funded by AstraZeneca the maker of candesartan and the company was also involved in the analysis of the data.\u201d ", "answer": 1}, {"article": "\"Observing this, we asked ourselves if it was possible to pharmacologically induce immune quiescence with medication that was better assured of reaching the point of infection,\" said Ho.\nThe tool, a vaginal implant, decreases the number of cells that the HIV virus can target in a woman's genital tract.\nThe implants were tested in an animal model and the team observed a significant reduction in T cell activation, meaning that the vaginal tract was demonstrating an immune quiescent state.\nThe implant is composed of a hollow tube and two pliable arms to hold it in place.\nUnlike conventional methods of HIV prevention, such as condoms or anti-HIV drugs, the implant takes advantage of some people's natural immunity to the virus.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not mention funding sources.\nThe published study does not include any disclosures of financial conflicts of interest by the authors.", "answer": 0}, {"article": "\"It's difficult to predict what will happen next, but they are on the right track,\" Mironov said.\nThe vessels failed in three of the patients, which experts said was not surprising in patients so seriously ill. One other patient withdrew from the study and another died of unrelated causes.\n\"This technology is very, very promising,\" said Vladimir Mironov of the Medical University of South Carolina, who co-wrote an accompanying commentary in the Lancet that praised the study as \"a revolutionary milestone.\"\nIn the five remaining patients, the vessels worked for at least 6 to 20 months after they were implanted.\nIn 2007, the scientists published preliminary findings for another 4 patients in the New England Journal of Medicine.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included quotes from a journal commentator and a comment from the president of the National Kidney Foundation, who was not connected with the study. The story noted that the lead researcher is an employee of the company developing the tissue-engineered blood vessel grafts and that the company funded the study.", "answer": 1}, {"article": "Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to tumor characteristics.\nThis study brought together the principal investigators from the groundbreaking 2014 study on 3D MAMMOGRAPHY\u2122 exams, also published in JAMA, this time led by Elizabeth Rafferty, MD, a co-author on the prior study.3 A total of 452,320 examinations (278,906 conventional mammograms compared to 173,414 Genius\u2122 3D MAMMOGRAPHY\u2122 exams), were analyzed.\nWomen with heterogeneously dense breasts make up about 40 percent of the U.S. screening population (women ages 40-74) \u2014 approximately 25 million women in the U.S.\n\n\"Utilizing Genius\u2122 3D MAMMOGRAPHY\u2122 exams for breast cancer screening will reduce the need for subsequent unnecessary testing, and decrease the number of unnecessary breast biopsies\u2014 addressing concerns that were previously raised as limitations of conventional mammography while also reducing costs for health systems,\" said Pete Valenti, Hologic's Division President, Breast and Skeletal Health Solutions.\n\"Density creates challenges for conventional mammography by obscuring the images, which often results in additional visits and exams for women,\" said Edward Evantash, MD, board certified OB/GYN and Medical Director for Hologic.\nIn addition, there can be no assurance that the systems will achieve any expected level of sales or market share.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release is distributed by the company that makes the 3D mammography so we can assume it played a role in funding the study. What\u2019s troubling is that the release gives no mention of potential conflicts of interest \u2014 or the absence of conflict \u2014 among the many investigators involved with the study. The published research notes that none of the researchers reported a potential conflict but that five of the researchers received research grant funding from Hologic. Also concerning is a note included with the disclosure section of the study: \u201cThe study contracts and data sharing agreements specified that Hologic had the right to review all publications prior to submission, but could not mandate any revision of the manuscript or prevent submission for publication.\u201d\nAt bare minimum the release should have noted that at least some of the researchers received grant funding from the manufacturer.", "answer": 0}, {"article": "For more industry information, health research and recipe ideas, visit http://www.\n\"There's a lot of research that looks at specific health conditions in aging, such as diabetes and heart disease, but less attention to research on quality of life and ability to maintain independence with aging,\" said Dr. Francine Grodstein, ScD, professor of medicine at Brigham and Women's Hospital and Harvard Medical School.\nConsuming walnuts and select other whole foods as part of a healthy diet may be associated with a reduced risk of physical function impairments throughout the aging process in women\n\nFolsom, Calif., (June 22, 2016) - A new study published in the Journal of Nutrition suggests that consuming 1-2 servings of walnuts per week (1/4 cup per serving) was associated with reduced risk of developing impairments in physical function, which helps enable older women to maintain independence throughout the aging process.\n\"The simple message from this study is that eating an overall healthy diet, including certain foods, such as walnuts and other whole foods, may help women with the ability to do key everyday tasks as they age, like carrying groceries or dressing themselves.\"\nWhile the CWC does provide funds and/or walnuts for various projects, the actual studies are conducted independently by researchers who design the experiments, interpret the results and write the manuscripts.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release discloses that the study was funded in part by the California Walnut Commission. However, it should also have mentioned that funding for the 30-year Nurses Health Study came from the National Institutes of Health and that one researcher involved in the study has received a grant from the International Nut and Dried Fruit Council to study nuts and cognitive function in aging.", "answer": 0}, {"article": "Carmichael and Segura collaborated on the study.\nThe study was supported by funds from the National Institutes of Health.\n\"This study indicated that new brain tissue can be regenerated in what was previously just an inactive brain scar after stroke.\"\nThe brain has a limited capacity for recovery after stroke and other diseases.\nThe gel is infused with molecules that stimulate blood vessel growth and suppress inflammation, since inflammation results in scars and impedes regrowth of functional tissue.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding is listed as from the NIH. The authors stated they had no financial conflicts of interest.", "answer": 1}, {"article": "\"I think people should consider it [TXA] following trauma on the basis of this study,\" he said.\nAlthough there was some worry that TXA might lead to more heart attacks, strokes or clots in the lungs, the researchers observed no such increase among patients getting the drug.\nIt works by significantly reducing the rate at which blood clots break down, the researchers explained.\nAmong patients receiving TXA, the rate of death from any cause was cut by 10 percent compared to patients receiving placebo, the researchers found.\nUsing this drug to treat trauma patients is a completely new idea, Levy said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes the author of an accompanying editorial who was not affiliated with the study and does not appear to have conflicts regarding the research.", "answer": 1}, {"article": "Flavonoids have been found to relax blood vessels and thereby improve blood flow, inhibit platelets from sticking together in the blood, and have a beneficial antioxidant effect. What still is not known is whether regularly eating dark chocolate, especially with its high sugar and fat content, eventually will lead to an unhealthy weight gain that would erase the beneficial effects of the flavonoids found in the cocoa.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The report cites three sources and their credentials, but mentions a potential conflict of interest for only the lead author, who received funding from Hershey and the CDC. It is impossible to judge the independence of the other sources. Nonethless, we'll give the story the benefit of the doubt. ", "answer": 1}, {"article": "Varicose veins are one of the more unsightly signs of aging. But new, less-invasive treatments are making it easier to remove them painlessly, bypassing a difficult surgical procedure that was often the only option in the past.\n\nAs many as 25% of women and 15% of men suffer from varicose veins; over the age of 50, one out of two people are affected. Heredity plays a part, but obesity, prolonged standing on the job and hormone therapy increase the risks. Sometimes, varicose veins have no signs or symptoms and require no treatment,...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does a good job talking with experts who recommend a cautious approach to the new therapies. There is no cheerleading in this piece.", "answer": 1}, {"article": "My entire head throbbed and stung.\u201d\n\nKaufman, who lives in Los Angeles, visited dozens of doctors, trying every option, including pain clinics, holistic remedies, Botox shots, and even hypnotherapy.\nThe aim of the medication is to stop a migraine before it even starts.\nHowever, the price tag could be as much as $10,000 a year.\nAnother advantage: it could lead to a decrease in the amount of medications used by patients to handle headaches acutely.\nIf approved by the FDA, the drug could be available in 2018.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story had no independent sources. Including some would have likely strengthened the story.", "answer": 0}, {"article": "\"With my technique, there is a much more limited scar and it limits the scarring in the fold of the breast, which is usually the most uncomfortable. By the third day, most women are up and around and doing most of their activities.\"", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes comments from four plastic surgeons linked to credible institutions. \nHaving said that, all of the sources are biased in favor of the procedure for reasons of economic self-interest.\u00a0\nIt\u2019s also worth noting that all four are men. \n\u00a0", "answer": 1}, {"article": "A colonoscopy isn\u2019t something you get just for giggles. Beyond the obvious unpleasantness, there\u2019s the small but real risk of complications that in rare cases can lead to hospitalization or even death.\n\nThat\u2019s why the American Cancer Society and other groups recommend that people screened for colorectal cancer using a colonoscopy wait a decade in between tests if no polyps or other signs of potential cancer are found. Polyps are slow-growing, and the benefits of being screened more frequently than that don\u2019t seem to outweigh the risks \u2026", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story used an American Cancer Society spokesman as an independent source.", "answer": 1}, {"article": "\"Prostate cancer, unfortunately, is a common cancer, and more than 27,000 men are estimated to have died from the disease in 2015,\" said Naveen Pokala, M.D., an assistant professor in the Division of Urology at the MU School of Medicine and lead author of the study.\n\"However, this study shows that it is a viable treatment option.\nThe procedure is challenging because tissue that surrounds the prostate is scarred during radiation treatment, making it difficult for the surgeon to identify and cut out tissue that needs to be removed.\nUsing the Surveillance, Epidemiology and End Results (SEER) program database, Pokala and his research team studied 364 patients who underwent a salvage radical prostatectomy surgery after unsuccessful radiation treatments.\nLooking at survival rates, the researchers found that 88.6 percent of men were still alive 10 years later and 72.7 percent of men were still alive 20 years later.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There\u2019s no mention of who funded the study or if there were potential conflicts of interest in the release. The journal article stated there were no conflicts of interest.", "answer": 0}, {"article": "THIS STUDY randomly assigned 60 adults with mild cognitive impairment or mild to moderate Alzheimer\u2019s disease to be given, via nasal spray, 20- or 40-milligram doses of insulin detemir (Levemir), a man-made insulin that is longer acting than natural insulin, or a placebo daily for three weeks.\n3 (in press)\u201d and search for \u201cinsulin.\u201d\n\nLEARN MORE ABOUT dementia at ninds.nih.gov/disorders and www.familydoctor.org.\nAlso, among those in the 40-milligram group, people carrying what is sometimes called the Alzheimer\u2019s gene (APOE-e4) showed more improvement than non-carriers.\nMemory loss is often the first sign of dementia, which in later stages can interfere with such things as the ability to solve problems, control emotions or do such daily tasks as eating and dressing.\nCAVEATS The study involved a relatively small number of participants and lasted a short time; a larger and longer study would be needed to adequately test effectiveness and safety.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We give the story credit for recommending that readers go to two independent sources for more information about dementia:\u00a0ninds.nih.gov/disorders\u00a0and\u00a0www.familydoctor.org. However, we think that all health stories could use some perspective \u2014 in the text of the actual story \u2014 from an independent expert. We realize that a 300-word column like this may never meet our standard here. But we\u2019ll continue hold out for that ideal.", "answer": 0}, {"article": "Knee surgery for a torn meniscus is done about half a million times each year in the U.S.\n\"Within a month I was healed,\" Dvorkin said.\nThe treatment involved two to three hour-long sessions a week, including strengthening exercises, balancing and massage.\n\"I felt better within two weeks\" on physical therapy, he said.\nResults were published online by the New England Journal of Medicine.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted two study leaders, an editorial author, and two patients.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - An infusion of the anesthetic ketamine can lift mood within minutes in patients suffering from severe bipolar depression, according to a small study out this month in the Archives of General Psychiatry.\nBut, according to Zarate, more research is needed on how to use the drug in the safest and most effective way.\nThose rights would be assigned to his employer, the National Institutes of Health.\n\u201cWe want to alleviate the suffering and get them back to their life,\u201d he said.\nAll of the patients were on lithium or valproate - two drugs commonly used for bipolar illness - but had not responded to treatment.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story needed independent voices to comment on the size of the study, the study design, the potential harmful effects, etc.", "answer": 0}, {"article": "A limitation of the study is that the evidence on acetaminophen was mainly for acute low back pain, but as the University of Leeds's Philip Conaghan explained, \"There is very little long-term data [on chronic back pain], and if a drug doesn't work in the acute problem, it seems unlikely to work in the chronic phase \u2014 though back pain may be even more complex than osteoarthritis pain.\"\nThe study also noted that patients on acetaminophen \"are nearly four times more likely to have abnormal results on liver function tests compared with those taking oral placebo.\"\nLike all good evidence-based medicine thinkers, he was able to provide a very practical answer: \"If you\u2019re talking about aspirin in doses of 500 to 1,000 mg or two tablets, 30 percent of people get relief from acute pain.\nEither the outcomes in studies are badly defined, the studies have too few participants to say anything concrete, or many people in the studies actually seem to have chronic headaches as opposed to the ordinary ones the researchers are allegedly studying.\nI asked him to describe the overall success rates for the most common three: acetaminophen (like Tylenol), ibuprofen (like Advil), and aspirin.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Sourcing is a very strong component of the article. The story quotes three pain experts from three different institutions as sources. No conflicts of interest were apparent.", "answer": 1}, {"article": "\u201cI\u2019m thinking, is this the way it\u2019s going to be for the rest of my life?\n\u201cIt also made me afraid to do things.\nI didn\u2019t know how a heart attack felt.\nIf the patient answers yes to one or both, a questionnaire is recommended to determine if the patient is depressed and the severity.\nSince I\u2019ve had a heart event, is my life over?\u201d she said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes multiple experts.", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/12/national/a131601S24.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Research was discussed at an American College of Cardiology meeting. No abstract was available on-line. A quote from an American Heart Association spokesman, reported to have no role in the study, was included as part of the story. However, it does report on the use of a proprietary software and machine, and the story gave no details regarding the author\u2019s relationship to the company. ", "answer": 0}, {"article": "MONDAY, Dec. 6, 2010 (HealthDay News) -- Long-term use of a daily low-dose aspirin dramatically cuts the risk of dying from a wide array of cancers, a new investigation reveals.\nThe current observations follow prior research conducted by the same study team, which reported in October that a long-term regimen of low-dose aspirin appears to shave the risk of dying from colorectal cancer by a third.\nThe potential impact of aspirin on pancreatic, stomach and brain cancer death rates was more problematic to gauge, the authors noted, due to the relative paucity of deaths from those specific diseases.\n\"These findings provide the first proof in man that aspirin reduces deaths due to several common cancers,\" the study team noted in a news release.\nThe protective impact of low-dose aspirin on stomach and colorectal cancer death was not seen until 10 years out, and for prostate cancer, the benefits first appeared 15 years down the road.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes comments from an independent cancer expert. That\u2019s the most important factor in this case, so we will pass this story on this criterion. However, while the study itself did not receive outside funding, readers should have been told that some of the authors have had consulting relationships with pharmaceutical companies.", "answer": 1}, {"article": "Scientists say they have created a new drug that can attack ovarian and lung cancers in patients for whom other treatments have failed.\nCommenting on the next stage of the research, she said: \u201cIn the larger phase II trial we\u2019ve recruited 140 women with relapsed ovarian cancer across the U.K. to standard chemotherapy (paclitaxel) or paclitaxel in combination with vistusertib.\nOver half of patients with ovarian cancer and over a third with lung cancer saw their tumors shrink, according to the study, which was published in the Annals of Oncology.\nIt built on previous research by the ICR that showed ovarian cancer cells resistant to treatment generally have higher levels of a molecule called p-S6K, which aids the growth of the disease.\nConfirmatory studies will be essential and if positive would broaden our armamentarium for fighting this cancer.\u201d\n\nThis article has been updated with comment from Professor Udai Banerji\u200b.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There was no information about conflicts of interest. The study was funded by drugmaker AstraZeneca with support from the UK-based Institute of Cancer Research (ICR) and The Royal Marsden. Some of the researchers reported ties with AstraZeneca.", "answer": 0}, {"article": "So researchers have been looking for alternatives.\nIn a separate analysis of the same study group, Carpenter\u2019s team found that women on Lexapro also reported bigger improvements in sleep problems: half saw their insomnia symptoms drop by at least 50 percent, versus 35 percent of placebo users.\nAfter four weeks, the study found, women on the antidepressant saw their score on the interference scale fall by half, on average.\nBesides antidepressants, doctors sometimes prescribe certain blood pressure medications or the anti-seizure drug gabapentin, which some studies suggest may be helpful.\nAnd for now, he noted, it\u2019s also not clear why antidepressants would have effects on hot flashes.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article does appear to use independent sources including interviewing Dr Robert Freedman, a psychiatrist who was skeptical of the true benefits of using antidepressants to treat hot flashes.", "answer": 1}, {"article": "So why do routine lab tests that doctors order often come back negative or not informative in ME/CFS patients?\nThe link to gradation in severity, rather than simply seeking a positive versus negative result, represents a new approach to the search for biological markers for the illness.\nThe multidisciplinary Stanford team is now working on developing a panel that could be used commercially, that would test for around five of the 17 cytokines and would likely involve the doctor first classifying patients by severity in order to interpret the results.\nThe symptoms can range from mild to extremely severe, with about a quarter of patients so ill they're mostly or completely confined to bed.\nResearch findings from Stanford University released Monday could point the way to a long-sought diagnostic laboratory test for the condition, and possibly a first-ever treatment.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story reports that the researchers are \u201cworking on developing a panel that could be used commercially,\u201d thus at least implying that they stand to financially or professionally benefit from positive research results.\nThe story includes comments from one of the reviewers of the study, but should have noted that the reviewer and the lead author of the study also collaborate on other research. This connection was clearly noted in the footnotes of the journal article.\nThe story would have been better if it had included comments from at least one expert not closely associated with the authors of this journal article, and more strongly pointed out the potential conflict of interest.", "answer": 0}, {"article": "The studies also varied in quality, with only nine of 26 considered \"low [in] bias,\" according to background information accompanying the study.\n\"In short, no single therapy is better than another, although some individuals are likely to have more success with one therapy than another,\" said study author Sidney Rubinstein, a research fellow at VU University Medical Center in Amsterdam.\nThe analyses indicated that SMT -- which involves manual manipulation of the spine and surrounding muscles -- has only a short-term impact on pain relief, although it eases pain faster than other treatments.\nMore than 6,000 patients were included in the compilation of results, which the study authors said were sparse in data indicating participants' overall recovery, quality of life and ability to return to work.\nBut which treatment is right for any patient depends not only on their specific pain, but their doctor's recommendations and their own comfort level with various options, said Stephen Perle, a spokesman for the American Chiropractic Association.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article did include expert commentary by a spokesman for the American Chiropractic Association. He offered reasonable and interesting comments.\nHowever, one could argue that a spokesman for a professional organization that is heavily involved in the provision of spinal manipulation is not a truly independent and impartial source. That spokesman might be viewed as having a conflict-of-interest in offering commentary on this topic. So it would have been useful for the article to include the views of another expert commentator as well.", "answer": 0}, {"article": "Researchers reintroduced the drug to 32 patients who were initially treated as part of a study of 634 patients.\nThe study is the first to test ipilimumab in patients whose skin cancer had spread to the brain, and the findings, released in an abstract or brief summary, support its potential use in these patients, the researchers said.\nThe team found that in patients whose cancer initially progressed while on ipilimumab, whose who were reintroduced to the drug had a disease control rate of 65 to 75 percent, compared to zero in the patient who got the vaccine only.\nIn the phase 2 trial, researchers said four out of 51 patients with at least one brain lesion had a partial response to the drug, and in 5 out of 51 patients, both brain and other tumors in the body stabilized after 12 weeks of treatment.\nResults of a late-stage study of the drug in melanoma patients will be detailed in a \u201clate-breaker\u201d session at ASCO\u2019s annual meeting in June.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "1clip_filelist.xml\"/>\n\n\n\n \nNot only were there no independent sources, the reporter did not include comments from any experts at all. The story appears to be based entirely on reading presentation abstracts.\nEven though disclosures about study funding and other potential conflicts of interest are posted on the same web site as the meeting abstracts, this story failed to report that both trials and the study authors received funding from Bristol-Myers Squibb, the company developing the drug, and that one of the trials was also supported by a second company, Medarex. The abstracts themselves also mention that some of the researchers are employees of Bristol-Myers Squibb or Medarex. Readers deserve to be told about these financial relationships.\n", "answer": 0}, {"article": "Commenting on the Nature Medicine study, he tells Newsweek the paper is \u201cvery interesting on a number of levels.\u201d\n\n\u201cFirst of all there\u2019s clearly growing interest in the potential therapeutic role of cannabinoids and in this particular case THC on various human conditions,\u201d he says.\nWith a cannabinoid like THC, which does have adverse effects in certain individuals, there would be worries about the chronic dosing of this kind of medicine.\nThis is a challenge faced by anyone wanting to develop a therapy for a human disorder such as dementia.\nScientists discovered low doses of its main psychoactive ingredient\u2014cannabinoid THC\u2014can reverse the age-related decline in cognitive abilities, a finding that could lead to scientists figuring out a way of slowing brain aging in humans.\nThe team argues that while they do not yet know if these findings would be same in humans, it could lead to new treatments to prevent cognitive decline in older people: \u201cCannabis preparations and THC are used for medicinal purposes,\u201d they write.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although the outside principal source of commentary is an Oxford University scientist with skin in the game of cannabis research, his words are\u00a0temperate and cautionary about any eventual therapeutic use of cannabinoids to duplicate the mouse finds in people.", "answer": 1}, {"article": "Overall, more than half of people who run will experience some sort of injury from doing so, while the percentage of walkers who will get hurt is around 1 percent.\nIt was immediately apparent that running can lead to more injuries, and the risk goes up as running programs get more intense.\nYou're also more likely to trip and fall while running than you are during a walk.\nOr alternatively: \"One could choose running because the health benefits are larger and come faster, in a shorter period of time.\"\nA good walking regimen can have similar benefits, he noted.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes independent sources, and there were no potential conflicts of interests that we could detect.", "answer": 1}, {"article": "In this new study, researchers found an increased amount of the protein CCL11 in patients previously diagnosed with CTE.\nWhile it is hoped that this will be one avenue to help detect the disease in the living, McKee believes that it will just be one part of a larger process.\nHowever, there is a potential bias in that study, as relatives of these players may have submitted their brains for diagnosis due to clinical symptoms noticed while the players were alive.\nMore exposure to football increases likeliness of CCL11\n\nThe paper evaluated the brains of 23 deceased football players with CTE, and compared them to the brains of 50 deceased people diagnosed with Alzheimer's disease and the brains of 18 deceased non-athletes.\n\"This is an inflammatory marker that may be non-specific and may not be diagnostic of CTE,\" he said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does incorporate input from one independent source \u2014 who raised valuable points about the limitations of this discovery and the amount of work that remains to be done. There do not appear to be any conflicts of interest.", "answer": 1}, {"article": "Frank Ruschitzka, MD, of Zurich University Hospital, tells WebMD that ideas that at first seem \"crazy\" can turn out to be lifesaving.\nThe new study involved 27 people with heart failure so severe that they were comfortable only at rest, 25 people with less severe heart failure, and 28 healthy people.\n\"We saw two distinct patterns, one of which correlated with heart failure,\" says study leader Vasileios Kechagias, a PhD candidate at the University Hospital Jena.\nThe goal of the project is to develop a simple, accurate, noninvasive, and reproducible method for early identification of chronic heart failure, he tells WebMD.\nThe researchers are now testing more than 1,000 patients and trying to identify the odorous molecules unique to heart failure patients, Kechagias says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One indepedent source is quoted. The story was based on a news briefing at a research conference, and we understand the need to file under deadline pressure. At the same time, we think the story would have benefited from at least one discussion with an expert outside of the study or the news briefing, perhaps another expert on a panel at the same conference. The story could have noted that a patent application has been filed for the device.", "answer": 1}, {"article": "\u201cThere\u2019s definitely a major need for a permanent, total artificial heart,\u201d Laman A.\nThe Lasker Foundation, which is based in New York, praised their work in the development of artificial heart valves, saying they had \u201cprolonged and enhanced the lives of millions of people with heart disease.\u201d\n\nIn the November 2009 bulletin of the Acad\u00e9mie Nationale de M\u00e9decine, Dr. Carpentier wrote that, instead of picking up from older models of artificial hearts built on animal research, the developers of the new device had sought to use the tools of the digital revolution, namely computer-assisted design, hemodynamic modeling, regulation algorithms and simulations.\nThe United States Food and Drug Administration has designated the AbioCor as a \u201chumanitarian use device,\u201d meaning its use is restricted to people who are ineligible for transplants and would otherwise be facing imminent death.\nCiting World Health Organization data that shows heart disease is the world\u2019s leading cause of death, Mr. Conviti, the Carmat chief executive, estimated the potential market at \u201ca minimum\u201d of 100,000 patients a year in the United States and Europe.\nIn the United States, the National Heart, Lung and Blood Institute, a unit of the National Institutes of Health, is supporting efforts by two separate groups, one led by Dr. O. H. Frazier of the Texas Heart Institute in Houston, the other by Dr. Leonard A. R. Golding of the Cleveland Clinic.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Besides quotes from the company executive, there was only one quote from an independent expert.\u00a0 But since he was not commenting on any evidence or track record for the French\u00a0 heart \u2013 or even any comment on its concept or design \u2013 we rule this unsatisfactory.\u00a0 No independent expert was quoted on the real \"heart of the story.\" ", "answer": 0}, {"article": "\u201cNow that you can just write a prescription, I use them in my practice a lot more.\u201d\n\nSince the Food and Drug Administration approved the first topical Nsaid in 2007, sales in the United States have soared \u2014 to more than $264 million in 2009, according to IMS Health, a health care research company.\nThe risks in the most vulnerable population \u2014 people with other illnesses, like liver disease, or those on blood thinners \u2014 are not known, because these patients are generally excluded from studies.\nAnd young, healthy patients may not want to bother with creams or gels, which have their maximum effect if applied four times a day.\nThe main advantage of a skin cream is that it bypasses the stomach and much of the bloodstream, theoretically minimizing serious side effects.\nAnd some, including Vioxx and Bextra, were taken off the market after they were linked to heart attacks and strokes.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story includes quotes from several experts and points out that two of them have accepted consulting fees or research support from pharmaceutical companies.", "answer": 1}, {"article": "\"They have a lot of promise and are potentially very important,\" said Katherine Hamilton, a headache specialist at Penn Medicine. The drugs, which are injected under the skin, offer hope for patients who have not responded to other treatments, but Hamilton said that what is \"potentially even more clinically relevant is they have a lower side-effect profile\" than other medications commonly used for migraine. She added, though, that it remains to be seen how patients who take them for long periods will fare. As new drugs, their long-term impact is not yet known.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story used one source who appears to be independent, Katherine Hamilton, MD, of Penn State.\nHowever, it didn\u2019t disclose that another source, Stephen Silberstein, MD,\u00a0 has substantial conflicts of interest. He personally received more than $620,000 from companies that make those and other migraine drugs from 2013 to 2017, according to CMS\u2019s Open Payments database. Most of the payments were for consulting, but he also pocketed money for such things as travel, food and beverages, and speaking fees.\nThe story did mention that Silberstein was involved in testing one of the drugs \u2014 erenumab \u2014 and helped design and run the trial for another \u2014 fremanezumab. But that didn\u2019t fully inform readers.", "answer": 0}, {"article": "CHICAGO, Dec. 2, 2015 /PRNewswire/ -- An analysis of clinical data from over 200 patients treated by Dr. Michael Stehling found that a new procedure that uses MR and ultrasound to guide treatment to the precise tumor location allows for faster recovery times and lower side effects in all stages of prostate cancer.\nUnlike other treatment procedures for prostate cancer therapy, image guided or irreversible electroporation (IRE) only destroys cells; vital tissue structures are not affected, making IRE the first tissue-selective form of therapy.\nIRE is precision guided and reliably destroys cells within the treatment field, but important anatomical structures in and around the prostate such as nerves, the intestinal wall, the sphincter, veins and arteries are spared.\nIncontinence is one of the most common adverse side effects of current treatments for localized prostate cancer and can have a substantial impact on the quality of life.\nThroughout the study, there were no cases of IRE-related incontinence, even when the lower urinary sphincter was included in the treatment field.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release did not identify funding sources for the research. Frehling is the director of a for-profit treatment center, Prostata.", "answer": 0}, {"article": "\u201cI don\u2019t think you can necessarily just make comparisons to existing benchmarks, such as the PCSK9s.\u201d\n\nEven so, Tim Anderson, a Bernstein analyst, said the \u201cmarginal\u201d data are not compelling enough to dispel what for Novartis will remain a pricing conundrum, should canakinumab\u2019s approval be expanded for heart patients.\n\u201cIn view of the additional oncology findings, we don\u2019t think you should just think about this as a cardiovascular drug,\u201d Narasimhan said.\nIlaris now costs about $200,000 per patient annually for treating rare immune conditions and brings in some $400 million in yearly sales for the Swiss company, though its price is likely to be slashed should it win approval in the heart setting.\nNovartis had said in June that the drug met its goal in the study but details were only unveiled at European Society of Cardiology meeting in Barcelona.\n\u201cSome have wondered whether a particularly high-risk subgroup could be identified where canakinumab\u2019s current price can be justified,\u201d he said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story, which is more of a \u201cbusiness of medicine\u201d story, uses a drug industry analyst source to good effect, and included commentary from the study\u2019s accompanying editorial.", "answer": 1}, {"article": "Dubbed Stop-af, the Medtronic trial showed that almost 70 percent of patients who had cryoablation remained free of the condition after one year, compared with just 7 percent of patients who received drug therapy, according to data presented at the American College of Cardiology meeting in Atlanta.\nDuring the follow-up period, 97 percent of patients who got the procedure and 92 percent of the drug therapy patients did not suffer heart attack, stroke or death.\nWhen it reaches the area of the heart that causes abnormal rhythms, the tissue is ablated, or destroyed.\nThe Medtronic device, which the company added to its portfolio with the 2008 acquisition of CryoCath, has been approved in Europe and Australia.\nOver the past decade, more patients have been referred for ablation procedures when drugs proved ineffective.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0There were no independent sources interviewed to discuss the potential of this device to affect outcomes and patient care. \u00a0This is a problem.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070225/5disease.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quotes one expert and one satisfied patient who happens to be a physician. The story should have quoted other clinicians/researchers who could have provided some additional perspective.", "answer": 0}, {"article": "For men with advanced prostate cancer, the news for decades has been mostly bleak. Until recently, only two treatments had been shown to prolong survival.\n\nResearchers reported Monday that the drug abiraterone, being developed by Johnson & Johnson, extended survival by an average of 3.9 months among men with cancer that has spread beyond the prostate and for whom other treatments have failed. Among men, prostate cancer is the second-leading cancer killer, behind only lung cancer.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\nAlthough the story includes an independent expert and notes that the drug is being developed by Johnson & Johnson, it does not tell readers that the trial researcher quoted in the story has had a financial relationship with the drug\u2019s commerical developers. Journal articles about earlier phases of research into this drug noted the researchers\u2019 financial disclosures. The fact that such disclosures may not be included in materials distributed at medical meetings is one more reason to be wary of these presentations.", "answer": 0}, {"article": "\u2022 The study compared the results of RCTs, which explore interventions under strict clinical conditions, to those of prospective cohort studies that are observational, and followed larger populations for longer periods of time.\nThe study was supported by a grant from GOED, which played no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.\nCurrent RCTs have varying durations, different baseline CHD status for study participants, and utilize several methods for patient selection and randomization.\n\"The meta-analyses of Alexander and colleagues suggests that omega-3 fatty acid intake may reduce risk of adverse CHD events, especially among people with elevated levels of TGs or LDL-C....omega-3 fatty acid intake of at least 1 gram of EPA+DHA per day, either from seafood or supplementation (as recommended by the American Heart Association), continues to be a reasonable strategy,\" said the authors.\n\"There are important public health implications related to reducing the risk of coronary heart disease, and therefore we are encouraged by the results of this comprehensive analysis,\" said Dr. Harry Rice, Vice President of Regulatory and Scientific Affairs for the Global Organization for EPA and DHA Omega-3s (GOED), which funded the study.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "This is a really close call. The story makes clear that the research was funded by the Global Organization for EPA and DHA Omega-3s (GOED) \u2014 which also issued this news release, through AAAS\u2019s EurekAlert! news service. The release also quotes two GOED employees, and clearly identifies them as such. However, the release doesn\u2019t include any language explaining what GOED is, what it does, or who its members are. And that\u2019s important, because GOED is not an independent research organization, it\u2019s an industry group that exists to promote consumer use of products that contain omega-3 fatty acids.", "answer": 0}, {"article": "For more information, visit http://www.aaojournal.org.\n\u201cWhile we cannot totally avoid developing cataracts, we may be able to delay their onset and keep them from worsening significantly by eating a diet rich in vitamin C.\u201d \u201cGenetic and Dietary Factors Influencing the Progression of Nuclear Cataract,\u201d Yonova-Doing, et al.\nAbout OphthalmologyOphthalmology, the official journal of the American Academy of Ophthalmology, publishes original, peer-reviewed, clinically-applicable research.\nDespite the advent of modern cataract removal surgery, cataracts remain the leading cause of blindness globally.1 Researchers at King\u2019s College London looked at whether certain nutrients from food or supplements could help prevent cataract progression.\nFor more than 120 years, we have been educators, innovators and advocates for the public and our profession to ensure the highest-quality medical and surgical eye care.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t mention its funders or potential conflicts of interest. Just because a funder has no apparent conflicts of interest does not mean that that information need not be included. In this case, inclusion of the fact that the Wellcome Trust and the Guide Dogs for the Blind Association paid for the work would have strengthened the release\u2019s credibility. Instead, a reader is left to wonder whether perhaps a group representing citrus growers is behind the study (it wasn\u2019t).", "answer": 0}, {"article": "I\u2019d rather have done 10 rounds with Mike Tyson.\u201d\n\nRichard Burt of Northwestern University in Chicago, who carried out the first HSCT for MS in 1995 and is coordinating the international trials, told the BBC: \u201cThere has been resistance to this in the pharma[ceutical] and academic world.\nThis is not a technology you can patent and we have achieved this without industry backing.\u201d\n\nEmma Gray, the head of clinical trials at the MS Society, said: \u201cOngoing research suggests stem cell treatments such as HSCT could offer hope, and it\u2019s clear that in the cases highlighted by Panorama, they\u2019ve had a life-changing impact.\n\u201cIt is important to stress, however, that this treatment is only suitable for patients with relapsing remitting multiple sclerosis disease who have had two or more significant relapses in the past 12 months, failed to respond to standard drug treatment and who have had the illness for at least 10 years.\u201d\n\nOne patient who has undergone the treatment, known as autologous haematopoietic stem cell transplant (HSCT), told the BBC\u2019s Panorama programme that he had made incredible progress.\nThe treatment has traditionally been used to treat bone and blood cancers.\u201d\n\nBasil Sharrack, a consultant neurologist at Sheffield teaching hospitals NHS foundation trust, said: \u201cThe new treatment is showing some remarkable results in the small number of patients we have treated so far.\nAt one point, I couldn\u2019t even hold a spoon and feed myself.\u201d\n\nWithin a few days of the transplant, he was able to move his toes, and after four months could stand unaided, although he still needs a wheelchair.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Funding sources are not identified, but the principal investigator for the international trial notes that \u201cwe have achieved this [the international clinical trial] without industry backing,\u201d which is helpful. \u00a0Most of the sources in the story are either doctors involved with the trial or patients participating in the trial.\u00a0 One potentially independent source, who heads clinical trials at the MS Society in the UK, reacts cautiously to the testimonials, reminding readers that HSCT \u201cneeds to be carried out at an accredited centre or as part of a clinical trial.\u201d\nAlthough It isn\u2019t clear that anyone quoted doesn\u2019t have a vested interest in this trial, including the head of clinical trials for the MS society, we\u2019ll give the story the benefit of the doubt since it does at least specify no involvement from industry. The story would have been better had it commented on involvement from other vested interests.", "answer": 1}, {"article": "In traditional transplants, hair follicles are taken from an area that runs an inch or two above the ears and temples to the back of the head.\n\u201cThe hairline was fully grown and soft-looking by nine months\u201d in the 35-year-old, he wrote, \u201cat which time the patient started combing his hair backward and sporting a ponytail, exposing his hairline comfortably.\u201d\n\nSince then, Dr. Umar has done eight more of the procedures, including one in a woman.\n\u201cHe had resorted to cropping his hair short to obscure the problem.\u201d\n\nWith the patients under local anesthesia, Dr. Umar used a device that creates microscopic wounds around hair follicles in the back of the leg; the follicles were then removed and transplanted to the hairline.\nIf you take that hair and use it in the hairline, it can end up looking harsh and pluggy, because the hair is too thick.\u201d\n\nDr. Umar was inspired to develop the procedure in part from personal experience.\nThe procedure has the potential to restore the hairlines of millions of men with male pattern baldness, the most common cause of hair loss and often an enormous source of stress.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There is not a single independent voice in this piece. Instead, it ends with a sales pitch from the surgeon marketing this technique. In a story about a review of a cosmetic procedure in just two patients, a story should never include a phrase like this: \u201cIt\u2019s life-altering for them when they realize that this is possible.\u201d Yet, this is the message that readers are given as a take home.\n\u00a0", "answer": 0}, {"article": "Jill adds: \"Anal cancer is on the increase and those of us who have been through what at times was gruelling radiotherapy regimen, welcome this study and the impact it will have on the treatment plans of patients in the future.\"\nThe results will be crucial to future large scale trials looking at optimum care for anal cancer patients.\nFunded by the Bowel Disease Research Foundation (BDRF) charity, the work has been published in the Lancet Oncology journal.\nIt is crucial that we tackle what is becoming an increasingly common form of cancer through research studies like this.\nThe findings of this project will play a crucial role in these efforts going forward.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes funding is from the Bowel Disease Research Foundation (BDRF).", "answer": 1}, {"article": "Her team of 12, including study co-author and U of A post-doctoral fellow Hein Min Tun, take the science one step closer to understanding the connection by identifying that exposure to pets in the womb or up to three months after birth increases the abundance of two bacteria, Ruminococcus and Oscillospira, which have been linked with reduced childhood allergies and obesity, respectively.\nThe study, funded by the Canadian Institutes of Health Research and the Allergy, Genes and Environment Network (AllerGen NCE), was published in the journal Microbiome, along with an editorial in Nature.\nThe study also showed that the immunity-boosting exchange occurred even in three birth scenarios known for reducing immunity, as shown in Kozyrskyj's previous work: C-section versus vaginal delivery, antibiotics during birth and lack of breastfeeding.\n\"It's not far-fetched that the pharmaceutical industry will try to create a supplement of these microbiomes, much like was done with probiotics,\" she said.\nIn other words, even if the dog had been given away for adoption just before the woman gave birth, the healthy microbiome exchange could still take place.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release tells us that the Canadian Institutes of Health Research and the Allergy, Genes and Environment Network (AllerGen NCE) funded the study.", "answer": 1}, {"article": "THURSDAY, April 14, 2011 (HealthDay News) -- In the latest research to test the concept of an artificial pancreas for the management of type 1 diabetes, British researchers report that they were able to improve blood sugar control and reduce the risk of dangerous low blood sugars overnight.\nBoth groups were monitored twice overnight in each study.\nLearn more about type 1 diabetes from the Nemours Foundation.\nThe study found no serious low blood sugar events after midnight.\nResults were published online in the British Journal of Medicine on April 14.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources quoted in this story.", "answer": 0}, {"article": "HAB recently created a series of simple, quick to prepare interactive meal makeovers to show people how to make small shifts in their diets by substituting fresh avocados for other foods or ingredients higher in saturated fats.\n\"This study supports the body of research showing the many benefits that fresh avocados have to offer when consumed in everyday healthy eating plans,\" says Emiliano Escobedo, Executive Director, HAB.\n(See conclusion of study)\n\n\"Interestingly, our results indicate that even healthy subjects with a relatively normal baseline TC (100 to 240 mg/dL), LDL-C (75 to 150 mg/dL), and TG (50 to 175 mg/dL) had significant reductions,\" says Sachin Shah, PharmD, corresponding author and expert in cardiovascular health.\nThe Hass Avocado Board (HAB) is an agriculture promotion group established in 2002 to promote the consumption of Hass Avocados in the United States.\n\"Fresh avocado, as part of a balanced diet, and as a cholesterol-free substitute for solid fats, can help be part of the solution for maintaining normal cholesterol levels,\" says Nikki Ford, PhD, Director of Nutrition, Hass Avocado Board.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release states that the research was \u201cconducted at the University of the Pacific and independently funded.\u201d The published study doesn\u2019t tell us who funded the study either.\u00a0 Under \u201cFinancial disclosures\u201d it states \u201cThe views expressed in this material are those of the authors and do not reflect the official policy or position of the U.S. Government, the Department of Defense, the Department of the Air Force or University of the Pacific.\u201d That statement has nothing to do with financing the study.", "answer": 0}, {"article": "Researchers agreed that until there\u2019s clearer evidence for benefit, men with healthy hearts shouldn\u2019t seek out statin prescriptions for the purpose of lowering their prostate cancer risks.\nClose to one in four of the men in both groups combined had ever taken a statin.\nMost of the men were white and in their mid- to late-60s, on average.\n\u201cIt gets very, very tricky to sort out,\u201d Freedland told Reuters Health.\n\u201cIf a person\u2019s on the fence about taking a statin medication for their heart, this is another potential benefit they may have by taking one of these,\u201d he told Reuters Health.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Important perspective added by independent expert from Duke who was not involved in the study.", "answer": 1}, {"article": "When it comes to the most popular type of osteoporosis treatment, bisphosphonates, the question is not so much about how much to take, but whether there are harmful consequences from long-term use.\nThe task force offers no advice for women younger than 60 or for men of any age, though men account for at least 20 percent of US patients with osteoporosis.\nBut in September, a different group of scientists used the same database and concluded in an article in the British Medical Journal that bisphosphonates appeared to double the risk of esophageal cancer after about 5 years of use.\nThe US Preventive Services Task Force, which sets standards on disease prevention and primary care, suggests that all women get a bone density screening by age 65, or by 60 if a patient might be at high risk for fractures.\nIt found no significant reduction in fractures in the study population, which received supplements of 1,000 milligrams of calcium and 400 international units of vitamin D daily.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article included commentary from several independent experts who provided useful insights. The article did not discuss potential conflicts of interest among these experts. However, the journalist\u2019s hard work in soliciting a diversity of comments outweighs the lack of discussion of financial conflicts.\u00a0\n\u00a0\n ", "answer": 1}, {"article": "Intrarosa is marketed by Quebec-based Endoceutics Inc.\nIntrarosa is the first FDA approved product containing the active ingredient prasterone, which is also known as dehydroepiandrosterone (DHEA).\nThe U.S. Food and Drug Administration approved Intrarosa (prasterone) to treat women experiencing moderate to severe pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\n\"Pain during sexual intercourse is one of the most frequent symptoms of VVA reported by postmenopausal women,\" said Audrey Gassman, M.D., deputy director of the Division of Bone, Reproductive, and Urologic Products (DBRUP) in the Office of Drug Evaluation III in the FDA\u2019s Center for Drug Evaluation and Research (CDER).\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t disclose the funders of the studies the drug approval was based on. In the one study we could find via an online search, it disclosed that EndoCeutics sponsored the research. The first author of the Menopause journal article is also the President and CEO of EndoCeutics, while the second author is an EndoCeutics consultant and receives grants for clinical studies.\nWe feel this is a major conflict of interest that should have been highlighted in the news release.", "answer": 0}, {"article": "January 30, 2018 - For older women undergoing mastectomy for breast cancer, direct-to-implant (DTI) breast reconstruction provides good outcomes in a single-step procedure, while avoiding some of the inconvenience and risks of staged approaches to breast reconstruction, reports a study in the February issue of Plastic and Reconstructive Surgery\u00ae, the official medical journal of the American Society of Plastic Surgeons (ASPS).\nHowever, DTI had some important advantages.\nPlastic and Reconstructive Surgery\u00ae is published by Wolters Kluwer.\nSo far, however, most studies of DTI have focused on younger women.\nhas been the one consistently excellent reference for every specialist who uses plastic surgery techniques or works in conjunction with a plastic surgeon.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding sources for the study are not disclosed.", "answer": 0}, {"article": "(Reuters Health) - - People were less likely to go to the hospital with heart attacks or strokes after several counties in New York State restricted the use of trans fats, according to a new study.\nAdmissions for heart attacks were nearly 8 percent lower in counties with restrictions.\n\u201cWe still found the same thing,\u201d Brandt said.\nAfter three years or more, the combined rate of hospitalizations for heart attacks or strokes was about 6 percent lower in the counties with trans fat regulations.\nBy 2018, those fats will be nearly eliminated from American diets, they add.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This was a weak point in the story\u2013no independent sources were quoted.", "answer": 0}, {"article": "That\u2019s consistent with the findings of the National Lung Screening Trial in the U.S., which in November released data \u2014 published online in the New England Journal of Medicine last week \u2014 showing that 20 percent fewer middle-aged heavy smokers died of lung cancer when they were screened annually with a CT scan compared to a standard, less detailed chest X-ray.\nMost of the tumors found via CT scans were small, whereas those found through X-ray screening or in patients with symptoms were more often further advanced, according to the findings published in the journal Lung Cancer.\nLung cancer kills more people in the U.S. than any other cancer \u2014 over 150,000 each year.\nCT scanning uses X-rays and computers to produce a clearer image than traditional X-ray techniques, but CT also uses higher radiation doses to generate those images.\nEast Asian countries are more likely to regularly screen non-smokers for lung cancer because biological differences seem to put Asians at a higher risk than other non-smokers, researchers explained.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Good perspective added from one of the leaders of US lung screening studies.", "answer": 1}, {"article": "Dr. Jae Jung, a dermatologist at City of Hope cancer center in Duarte, California, agreed.\nFor the study, researchers in Australia looked at nearly 400 people who had had at least two non-melanoma skin cancers.\nThe two most common forms of the disease, basal cell carcinoma and squamous cell carcinoma, can usually be treated successfully.\n\"It's safe, it's almost obscenely inexpensive, and it's already widely commercially available,\" Dr. Diona Damian, the senior author of the study and a professor of dermatology at the University of Sydney, told HealthDay.\nResearchers say vitamin B3 gives skin cells an energy boost -- \"turns back on the immune system,\" in Agus's words -- helping them repair the damage.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two\u00a0independent sources are quoted in this story about the study. But as with AP\u2019s coverage, the quotes offered here provide little in the way of substantive analysis.\nBut that\u2019s one of the pitfalls of reporting on abstracts that haven\u2019t even been presented to a scientific conference yet, much less published. It\u2019s almost impossible to get truly substantive analysis because the data haven\u2019t been adequately scrutinized.\nWe\u2019ll award a borderline Satisfactory, however, since their comments do relate specifically to the expected impact of the benefit reported in the study.", "answer": 1}, {"article": "\"To address inconsistencies in prior studies on vitamin D and to investigate associations in population subgroups, we analyzed participant-level data, collected before colorectal cancer diagnosis, from 17 prospective cohorts and used standardized criteria across the studies,\" said Stephanie Smith-Warner, PhD, an epidemiologist at the Harvard T.H.\nChan School of Public Health, the U.S. National Cancer Institute, and more than 20 other medical centers and organizations finds that higher circulating vitamin D concentrations are significantly associated with lower colorectal cancer risk.\n\"In the past, substantial differences between assays made it difficult to integrate vitamin D data from different studies,\" explained Regina G. Ziegler, PhD, a National Cancer Institute epidemiologist and co-senior author on the article.\nVitamin D, known for its role in maintaining bone health, is hypothesized to lower colorectal cancer risk via several pathways related to cell growth and regulation.\nOptimal vitamin D concentrations for colorectal cancer prevention may be higher than the current National Academy of Medicine recommendations, which are based only on bone health.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Vitamin D supplement manufacturers appeared to play no role in the analysis, and the funders are from the American Cancer Society, the Harvard T.H. Chan School of Public Health, and the U.S. National Cancer Institute.", "answer": 1}, {"article": "Some of the complaints related to the placement of the device.\nThis test is an alternative to the generally-prescribed modified hysterosalpingogram (HSG) test in which an x-ray of the uterus and fallopian tubes is used to check for proper device placement.\nBut since its approval in 2002, women using the device have sent the FDA more than 5,000 complaints, ranging from pain and menstrual problems to pregnancies and even deaths.\nThe training will start in September, the same month the FDA will hold a public panel meeting to discuss the safety and effectiveness of Essure.\n(Reuters) - Bayer Healthcare said on Wednesday the U.S. Food and Drug Administration approved using transvaginal ultrasound as an alternate test to confirm if the company\u2019s Essure permanent birth control device has been placed properly.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story is little more than a re-worked news release. It alludes to the announcement made by Bayer Healthcare. None of the other statements of fact are attributed.\nThis story would have benefited from feedback from an independent expert, who could have explained the harms associated with the device and helped readers understand whether or not a new test might help improve outcomes for patients electing to undergo the Essure procedure.\nReporters needing to find independent voices for their stories are invited to refer to an extensive list of experts maintained by HealthNewsReview.org. All of these experts are free of industry ties \u00a0and sensitive to reporter deadlines.", "answer": 0}, {"article": "CHICAGO (Reuters) - Measuring certain proteins in spinal fluid can accurately diagnose Alzheimer\u2019s and predict which patients with memory problems will develop the fatal brain-wasting disease, Belgian researchers said on Monday.\n\u201cThe unexpected presence of the Alzheimer\u2019s disease signature in more than one-third of cognitively normal subjects suggests that Alzheimer\u2019s disease pathology is active and detectable earlier than has heretofore been envisioned,\u201d Geert De Meyer of Ghent University in Belgium and colleagues wrote.\nWhen they looked to see how accurate these signatures were at spotting the disease, they found 90 percent of those with Alzheimer\u2019s had the disease pattern in their spinal fluid.\nThey said measuring traces of beta amyloid and tau \u2014 two proteins associated with the telltale plaques and tangles that form in the brains of patients with Alzheimer\u2019s \u2014 accurately detected Alzheimer\u2019s in 90 percent of patients with the disease.\nLast month, experts at the National Institute on Aging and the Alzheimer\u2019s Association proposed new guidelines for diagnosing Alzheimer\u2019s even before patients have symptoms.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story does not include comments from an independent source and it fails to tell readers that several of the study authors are or were employees of the company that developed key components of the test. It also does not mention that the study was funded by an institute that receives funding from pharmaceutical companies, including the company that makes the test.", "answer": 0}, {"article": "(Forget to weigh in or track your meals?\n\"The data really does confirm that when you give people tools and help, instead of just preaching to them, it really does help.\"\nA recent pilot study with Utah-based Intermountain Healthcare that included about 200 people, all of whom were at high risk of Type 2 diabetes, found that 75 percent of the participants completed the Omada program and lost at least 5 percent of their body weight.\n\"Homemade breads and croissants, pasta and pizza,\" Speranza ticks off the list of baked treats with a mix of reverence and resolve in his voice.\nThe Centers for Disease Control and Prevention recognizes many diabetes prevention lifestyle change programs, delivered both in-person and online, including Vida, which bills itself as a \"health transformation team\" that is data and tech-driven.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two people who have tried the program, the company CEO, and a doctor who helped run the Utah study. We think readers deserve to hear from independent experts in the field of weight loss or those involved in motivating patients to improve their diets and exercise routines. Their voices would add needed context for this ever-vexing area of health care.\nWe did want to commend the story for including a personal story about the program that wasn\u2019t fully positive, which helps balance the story out.", "answer": 0}, {"article": "THURSDAY, May 27, 2010 (HealthDay News) -- A new approach to treating irregular heartbeats appears to have demonstrated success in halting abnormal electrical pulses in both patients and pigs, new research indicates.\nThe traditional means for getting at misfiring cells relies on pre-intervention X-rays for a much less precise snapshot form of visual guidance.\nThe current study focused on 27 patients (66 percent men), all of whom were diagnosed with a form of atrial fibrillation.\nIn fact, with this new approach, the study team found that physicians could destroy such cells with 100 percent accuracy.\nThe investigators found that after just one laser treatment, misfiring ceased in 84 percent of the treated veins, and 90 percent remained inactive three months after treatment.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There\u2019s actually no interview \u2013 only a rehash of what was published in a journal, restated from a news release.\u00a0 No independent source cited. ", "answer": 0}, {"article": "Sonata uses a probe that is inserted through the cervix into the uterus. The probe not only allows the doctor to see the fibroid using ultrasound, but it also has a radio-frequency device at the tip. The doctor hits a foot pedal to send energy through the probe to heat the fibroid, shrinking it over time. The body absorbs the dead tissue, so it does not have to be surgically removed.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes two independent sources and clearly identifies those sources who are affiliated with the industry-funded Sonata trial or the manufacturer of the technology used in Sonata.", "answer": 1}, {"article": "Male infertility has a range of root causes, from low or abnormal sperm production to blockages to illness.\nAs things stand now, men have to provide samples \u201cin these specific rooms in hospitals under so much stress and embarrassment,\u201d the study\u2019s principal investigator, Hadi Shafiee, PhD, told CBS News.\nThat\u2019s the question researchers at Brigham and Women\u2019s Hospital and Massachusetts General Hospital tried to answer when they went about developing a smartphone-based test that men could use to test their semen in the comfort of their homes.\n\u201cThe accuracy of this approach was very similar to that of computer-assisted laboratory analysis, even when it was performed by untrained users with no clinical background,\u201d they wrote in the study.\nThe app\u2019s user experience is hard to forget: users can see vivid moving images of their sperm right on the screen.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources were included, and the story didn\u2019t disclose that the one source who was interviewed\u2013researcher Hadi Shafiee\u2013holds a patent on the technology.", "answer": 0}, {"article": "\"We estimated that 47 percent of lethal prostate cancer cases would be prevented in the United States if men over 60 had five or more of these healthy habits,\" said Kenfield, assistant professor in the Department of Urology at UCSF Medical Center, and formerly of the Department of Medicine at Harvard Medical School in Boston, where the study was initiated.\nCases were confirmed through medical records and pathology reports, and cause of death was determined by death certificate and medical record, and secondarily by next of kin.\nReducing intake of processed meats would cut the risk by 12 percent, they reported.\nTo gage the effects of lifestyle habits, the researchers developed a score based on the results of the health professionals survey, then applied it to the physicians' study.\nChan School of Public Health, and Brigham and Women's Hospital.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources were clearly identified, and there are no clear conflicts of interest.", "answer": 1}, {"article": "IBS is considered a functional gastrointestinal disorder without a known physiologic cause, with the symptoms recurring and often worsened by stress.\nWith the drug treatment, Pimentel says, those with the IBS ''can enjoy social outings without the worry of having to run to the bathroom and having diarrhea.\"\nWith the new antibiotic treatment, Pimentel tells WebMD, many participants ''say they are 80% improved, 90% improved, that kind of results.\n''The major finding was that all IBS symptoms improved,\" says Mark Pimentel, MD, director of the GI Motility Program at Cedars-Sinai Medical Center, Los Angeles, who led the clinical trial of the drug at Cedars.\nThe drug is approved by the FDA only for traveler's diarrhea and hepatic encephalopathy, a brain disorder caused by chronic liver failure.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This is where the story excels in one way and fails in another. It excels by taking pains to point out the conflicts of interest of everyone it quotes. It nearly gives the lead author, Mark Pimentel,\u201d a pass by calling him \u201cdirector of the GI Motility Program at Cedars-Sinai Medical Center, Los Angeles, who led the clinical trial of the drug at Cedars\u201d in the second paragraph and waiting until paragraph 14 to tell readers, \u201cThe studies were funded by Salix Pharmaceuticals Inc., which makes rifaximin. Pimentel serves as a consultant to Salix and serves on its scientific advisory board. He discovered the use of the antibiotic for IBS. Cedars-Sinai holds the patent and has licensed the rights to Salix.\u201d It goes on to quote Jan Tack and says, \u201cTack has served as a scientific adviser to companies evaluating IBS drugs.\u201d Its last source is\u00a0Christine Frissora, of whom the story says, \u201cFrissora reports research funding from Tioga Pharmaceuticals for a study of an IBS drug and serving on the speakers bureaus for Prometheus Therapeutics and Diagnostics, Salix Pharmaceuticals, and Takeda Pharmaceuticals North America.\u201d See a pattern here? Where are the independent voices in the story?\nSo, for example, when Dr. Frissora says the findings \u201cwill probably encourage other doctors to try it, especially primary care doctors who may not [yet] know about this data\u201d \u2013 why don\u2019t we hear from an evidence-based primary care doc about whether he/she will change practice based on this info?", "answer": 0}, {"article": "\"The electronic nose discriminates between patients with asthma and healthy subjects and its performance is increased when combined with FENO,\" wrote the Italian team led by Dr. Paolo Montuschi of the Catholic University of the Sacred Heart in Rome.\nEach test is non-invasive, requiring only the use of exhaled air.\nThese VOCs produce a unique smell print for each individual and specific patterns are seen in people with asthma.\nIn some diseases, you use blood markers to monitor treatment response.\nNone of the study volunteers had a history of smoking.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites two independent sources and identifies their affiliations.", "answer": 1}, {"article": "With knee-replacement surgery on the rise, more patients with two bad knees are opting for a controversial procedure that replaces both at the same time.\n\nSimultaneous bilateral knee replacement, as the surgery is known, is a subject of debate among orthopedic surgeons, with conflicting evidence about the risks and benefits. Proponents say it eliminates the need for a second hospital stay and grueling rehabilitation period, reduces time spent under anesthesia and costs less.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story talked to multiple sources and clearly identified those who played a role in studies that were cited in the story.", "answer": 1}, {"article": "Drinking concentrated blueberry juice improves brain function in older people, according to research by the University of Exeter.\nThe study excluded anyone who said they consumed more than five portions of fruit and vegetables per day, and all participants were told to stick to their normal diet throughout.\nThe research was carried out in association with the University of the West of England, and the concentrated blueberry juice (BlueberryActive) and some funding for the study was provided by CherryActive Ltd, which produces cherry, beetroot and blueberry products in concentrate and capsule form.\nThe new paper, \"Enhanced task-related brain activation and resting perfusion in healthy older adults after chronic blueberry supplementation\", is published in the journal Applied Physiology, Nutrition and Metabolism.\nOf the 26 healthy adults in the study, 12 were given concentrated blueberry juice - providing the equivalent of 230g of blueberries - once a day, while 14 received a placebo.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release included the important fact that a commercial enterprise selling blueberry juice concentrate and blueberry capsules provided the samples and some of the funding for the study.\nThe published paper states the authors declared they had no conflicts of interest.", "answer": 1}, {"article": "In years past, \"the message was that chocolate consumption might be associated with higher LDL [bad] cholesterol or perhaps higher incidence of cardiovascular disease,\" he said.\nFor one thing, it's possible that some factor other than chocolate could be helping lower the risk of stroke.\nSaposnik said more studies will help clarify the association between chocolate and stroke risk.\nBoth are good for heart health,\" he said.\nThe National Stroke Association has more on stroke.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0A dietitian and a nutrition researcher \u2013 both apparently unaffiliated with the research \u2013 were quoted. ", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/02/15/national/a141001S34.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 1}, {"article": "And the fact that there isn't ... medical treatments for obesity, including pharmaceuticals, really is a challenge, considering how big the problem is in this country.\"\nWe see improvements in quality of life.\nWe see improvements in sleep apnea.\nWe see decreased rates of progression to diabetes.\nShe's gained back half of the weight she lost.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several independent sources were cited.", "answer": 1}, {"article": "So his team designed a randomized controlled clinical trial to see if short-term use of a curcumin supplement could reduce inflammation in people with metabolic syndrome, a cluster of risk factors for heart disease.\nThe researchers didn\u2019t examine the effect of curcumin on any diseases, and it was a fairly brief study, so it\u2019s not clear what the long-term implications may be they caution in their report.\nThe study team also analyzed data from eight previous studies and confirmed that curcumin had shown a significant reduction of CRP concentrations in a total of 281 patients.\n\u201cThe findings of our studies, along with clinical findings reported by other groups, indicate the usefulness of daily use of curcumin supplement for the prevention and treatment of several diseases,\u201d Sahebkar said.\nThey found that the people who took curcumin had improved blood levels of all three biomarkers as well as reduced fasting blood sugar and hemoglobin A1c, a measure of long-term blood sugar levels.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does acknowledge that one of the study authors is the CEO of two companies that manufacture curcumin supplements. However, it includes no independent sources. Given the obvious potential for industry influence, this story really needed an independent voice to help evaluate claims for readers.", "answer": 0}, {"article": "\"As the kids with cystic fibrosis are living longer and longer, a lot of these ancillary problems are become more apparent,\" said C. Michael White, director of the Evidence-based Practice Center and lead author of the study.\nBut with antibiotics and other medical advances, the median age for people with the disease increased to 37 by 2008.\nLungs are clogged with a thick mucus, which can lead to lung infections.\nIn the 1950s, children with cystic fibrosis generally died before age 8.\nCaused by defective genes, cystic fibrosis affects multiple organs.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 0}, {"article": "\"What we found was a very coherent pattern of less cervical cancer among people who\u2019ve used the IUD based on thousands of women \u2014 and the pattern wasn't subtle at all, it was stunning,\" Dr. Victoria Cortessis, the study's lead author and associate professor of clinical preventive medicine at the Keck School of Medicine at the University of Southern California, told BuzzFeed Health.\n\nIUDs are small, T-shaped devices that are placed in the uterus to prevent sperm from reaching an egg. They are a highly effective form of birth control and they can offer protection against pregnancy for up to three, five, or ten years.\n\nThe study is the first of its kind to combine and analyze data from multiple studies to look at the issue. \"We went through all of the relevant human epidemiological data on this topic and narrowed it down to 16 high-quality observational studies of over 12,000 women from all over the world,\" Cortessis says.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Unfortunately, the story depended on quotes only from the lead author of the study. Verification of the significance of study findings by an independent expert would have strengthened credibility of the story.", "answer": 0}, {"article": "CHICAGO\u2014For patients facing a choice between bypass surgery and a popular, less-invasive procedure to treat heart blockages, surgery improves chances of long-term survival, researchers said Tuesday.\n\nIn a study that analyzed data on nearly 190,000 Medicare patients treated between 2003 and 2007, 16.4% of surgery patients had died after four years, compared with 20.8% treated with angioplasty and a stent to prop open diseased vessels.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story sought out a variety of views and, even in quoting the lead researcher, emphasized how nobody \u201cwould say the results will completely change the way we do things.\u201d\nThe comments of the experts are balanced and provide the reader with some semblance of the difficulties that are inherent in this type of decision making.", "answer": 1}, {"article": "Half of the patients were given a scan called a computed tomography angiogram, or CTA, in addition to standard diagnostic tests.\nThe research is published in the New England Journal of Medicine and is being presented at the European Society of Cardiology Annual Congress in Munich.\nLead researcher Professor David Newby, of the BHF Centre for Cardiovascular Science at the University of Edinburgh, said: \"This relatively simple heart scan ensures that patients get the right treatment.\nThis is the first study to look at the impact of the scans on long-term survival rates.\nThe study had previously found that around a quarter of patients had their diagnoses reclassified after receiving the scan, prompting new treatments in many cases.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "National funding sources of the study are mentioned.\nWhat\u2019s not mentioned is that the lead author quoted in the release receives grant funding from Siemens, a major manufacturer of CTA scanners.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Blood drawn from expectant mothers could offer parents an earlier sneak peek at their baby\u2019s sex than methods currently used in the U.S., researchers said Tuesday.\n\u201cIt could reduce the number of invasive procedures that are being performed for specific genetic conditions,\u201d said Dr. Diana Bianchi of Tufts University School of Medicine, who worked on the new study.\nBut other researchers voiced concerns, saying it could be misused to terminate a pregnancy if the baby isn\u2019t of the desired sex.\nBecause such disorders mostly strike boys, knowing that the baby is a girl could spare the mother diagnostic procedures, such as amniocentesis, that carry a small risk of miscarriage.\nIn those procedures, doctors either extract a small amount of the fluid that surrounds the fetus (amniocentesis) or they take a sample of the placenta (chorionic villus sampling).\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story uses independent sources, and notes that the lead author of the JAMA\u00a0study, Diana Bianchi, is an investor in a related cell-free fetal DNA test for Down syndrome.", "answer": 1}, {"article": "Funding: National Cancer Institute grants P50 CA097248 and P30 CA046592, and the Sinabaldo and Diane Tozzi Research Fund\n\"This adds ammunition to the idea that we need to pick individual therapies more carefully.\nThe responders can continue with combination chemotherapy and radiation.\nAfter a decade of using this approach, researchers are reporting \"exceptional\" survival rates nearing 80 percent, even for the most advanced patients.\nIf the tumor did not respond after that first dose, patients would likely fail on the chemotherapy and would do better going straight to surgery.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources are clearly noted in the release and there do not appear to be relevant conflicts of interest.", "answer": 1}, {"article": "Prior to this, Yu\u2019s team had performed targeted MRI biopsies with the patient being moved in and out of the MRI scanner as the needle was guided to the target area \u2014 a sort of stop-motion procedure that could take up to an hour.\nHe ends up diagnosed with cancer only after the tumor has spread to his bone or lymph nodes years later.\u201d\n\nMagnetic resonance imaging and targeted biopsy for the prostate have provided relief for patients like Harder who have not been able to get an accurate diagnosis.\n\u201cIf we put those characteristic features together from each sequence then we can say with a high degree of confidence that this area is concerning for cancer and potentially target it for biopsy,\u201d said Sarah Winks, M.D., an attending physician in the Department of Radiology.\nThat\u2019s one of our strengths.\u201d\n\nYu has seen how MRI technology has changed prostate patients\u2019 care.\nNow, with the support of Massey Cancer Center, Urology and Radiation Oncology, they are doing about 1,200 multiparametric-MRI and 200 imaging guided biopsies per year.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t name a funding source, but it\u2019s not based on one study. It focuses heavily on selected outcomes and patient anecdotes from a single treatment center, the VCU Massey Cancer Center.\nThere are no apparent undisclosed conflicts of interest or funding sources related to VCU. However, two authors of the NCI\u2019s Center for Cancer Research study (briefly referenced in the release) had reported holding a patent related to the MRI biopsy platform, and a third reported holding multiple patents in the field. That research was supported by the National Institutes of Health, the National Cancer Institute, the Center for Cancer Research, and Center for Interventional Oncology. The NIH, Philips Healthcare, and devicemaker Invivo Corp. have a cooperative research and development agreement.", "answer": 1}, {"article": "Powered by a small wireless device, this circular array of nanowires mimics densely packed retinal cells to help achieve \"functional vision,\" says Gabriel A. Silva, professor of bioengineering and ophthalmology at UC San Diego.\nThese promise that patients could become more independent.\u201d\n\nWhen healthy, retinal cells transmit visual information to the brain.\nThe researchers were unable to determine how well the rats were able to see, if at all, but they noted that the animals\u2019 eyes continued to react to light more than six months after the implant was installed.\nThe findings were reported in the Journal of Neural Engineering.\nThe devices are only experimental prototypes with many years of additional research and development likely before they might be ready for commercial use.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Three sources are quoted in the story. One researcher from the Italian team, one researcher from the Californian team, and one researcher who is independent of both research groups.", "answer": 1}, {"article": "MONDAY, May 16, 2011 (HealthDay News) -- A daily dose of the antioxidant selenium doesn't appear to elevate \"bad\" cholesterol levels, and may in fact prompt a very modest boost in \"good\" cholesterol, a new British study reveals.\nNone of the patients experienced any serious side effects as a result of selenium supplementation.\nHowever, the safety of selenium has not been studied, and the authors said the findings weren't significant enough to recommend supplementation of the trace mineral.\nBut an association is only that; it doesn't mean one thing causes another.\nGood cholesterol (HDL) levels rose a bit solely among those assigned to the highest selenium dosage.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An independent expert source was quoted and there were no obvious conflicts of interest that weren\u2019t disclosed.", "answer": 1}, {"article": "There are clear philosophical differences.\nThe question was presented in May at the yearly ACOG meeting in Washington: \u201cWhy not induce everyone at 39 weeks?\u201d Two doctors had been asked to debate: Errol Norwitz, chairman of obstetrics and gynecology at Tufts University School of Medicine, and Charles Lockwood, dean of the Morsani College of Medicine at the University of South Florida.\nRather, he said, the latest literature suggests that the drugs available to soften the cervix in preparation for contractions help to decrease the Caesarean risk, adding a small caveat: For a small number of first-time mothers with \u201cunfavorable, long and hard cervixes\u201d \u2014 as opposed to cervixes that are soft and receptive to induction \u2014 the risk of Caesarean is increased.\nBut the question has some doctors reconsidering their assumptions about induction and has sparked criticism by women who contend there is already too much interference with uncomplicated pregnancies.\nShe called it \u201cconcerning and rash\u201d for doctors at the meeting to make \u201cbroad conclusions\u201d that \u201ccould potentially affect at least 3 million women a year in the United States alone.\u201d\n\nNorwitz said that the presentations were evidence-based.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "As noted above, the story includes several sources who criticize the proposition that labor should be induced earlier routinely. The story also quotes an opponent who charges that obstetricians have a philosophical bias in favor of medical intervention, which in a way flags a potential conflict of interest for readers.", "answer": 1}, {"article": "European regulatory bodies recommend pharmaceutical-grade chondroitin sulfate as well as pharmaceutical-grade glucosamine sulfate as first-line treatments for osteoarthritis, Reginster said by email, because of the side effects associated with celecoxib and other non-steroidal inflammatory drugs (NSAIDs) including stomach ulcers, bleeding, liver and kidney problems.\n\u201cStudies like this highlight that medicine is still an art - we do not have perfect answers, and we have to individualize for each patient.\u201d\n\nThe study was sponsored by IBSA Institut Biochimique SA, a pharmaceutical company based in Lugano, Switzerland, that makes the chondroitin sulfate supplements used in the test.\nDr. Michael Shepard of Hoag Orthopedic Institute in Orange, California, noted that the study had a relatively low number of participants and that most U.S. studies of this type would run two years rather than six months.\nReginster told Reuters Health the findings are in line with earlier studies showing pharmaceutical-grade chondroitin sulfate could significantly decrease the progression of knee osteoarthritis over a period of three years.\nThose who took chondroitin sulfate or celecoxib had similar levels of pain relief at the end of the study, and in both groups the improvement was greater than for those taking just a placebo, according to the report in Annals of the Rheumatic Diseases.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two American experts, neither of whom seem to be associated with this European study. We applaud the effort to get outside perspective, but wish the article made clear if these sources do or do not\u00a0have conflicts of interest with pharmaceutical companies that make any kind of arthritis pain medication.", "answer": 1}, {"article": "Cocaine use is widespread in the Western World.\nThe results of this pilot study, published in the peer-reviewed journal European Neuropsychopharmacology, suggest that this may become an effective medical treatment for patients with cocaine addiction, although a larger trial is needed to confirm the initial findings.\nIn addition, 69% (11/16) patients) in the experimental group showed no relapse to cocaine use, whereas only 19% (3/16) patients) in the control group showed a similar positive result (the results are adjusted for patients who dropped out of the trial).\nAt the end of the first 29 days of the experiment, the experimental group was given the option of continuing the treatment, whereas those in the control group were given the possibility of receiving the same rTMS treatment as the experimental group for 63 days.\nAs author, Dr Antonello Bonci (Scientific Director, National Institute on Drug Abuse, and Adjunct Professor, John Hopkins University, Baltimore) said:\n\n\"Despite the fact that more than 20 million people worldwide suffer from cocaine use disorders2, there are no effective neurobiological treatments for patients with this devastating condition\".\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release fails to point out the funding sources for this work, or to address any possible information on potential conflicts of interest, even though that information is readily available in the research paper.\nThe published study states that funding was provided by several public and private sources in Italy and the National Institute on Alcohol Abuse (US), and that the study authors had no financial or potential conflicts of interest.", "answer": 0}, {"article": "Despite all the headlines about swine flu, which has become the main influenza strain circulating in the world, doctors do expect some garden-variety flu to hit this fall too \u2013 the kind that every year kills 36,000 Americans and hospitalizes 200,000.\nOn Friday, the NIH is set to release results of its own studies of hundreds of adults that confirm that one shot works, Fauci said.\nU.S. data to be released Friday confirm those findings and show the protection starts rapidly, Dr. Anthony Fauci of the National Institutes of Health told The Associated Press.\nThe highest concentrations of flu cases are in the Southeast and a few other states.\nWaiting to get the first inoculation out of the way \"is not in anybody's best interest,\" added Dr. Nancy Nielsen, past president of the American Medical Association.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\nThis story points out that several of the trials were done by vaccine manufacturers. It quotes government officials who were not directly involved in those trials. However, as noted above, the story is a primarily summary of official statements. There are no quotes from independent experts in infectious diseases.", "answer": 1}, {"article": "A common heart drug called a beta blocker was associated with a striking increase in survival for women with ovarian cancer in a study that suggests a possible new strategy for treating a variety of tumors.\n\nResearchers analyzing a database of 1,425 women with the tough-to-treat cancer found those who had taken a certain type of beta blocker lived more than four years longer on average than those who hadn\u2019t been prescribed the drug. The women were taking the medicine to treat high blood pressure or another heart problem, not...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes an independent source who wasn\u2019t affiliated with the research. Christina Annunziata, a director with the Center for Cancer Research at the National Institutes of Health, said that while she found the study \u201cinteresting\u201d and \u201cthought-provoking,\u201d she cautioned that \u201cI don\u2019t think it\u2019s practice-changing quite yet.\u201d Annunziata co-authored an editorial accompanying the report which were both published in the American Cancer Society\u2019s Cancer journal.\nThe story would have been even stronger had it outlined the funding sources for this study, which included government and foundation grants. However, since we didn\u2019t find any significant conflicts in the list of funding sources, we didn\u2019t think this omission unbalanced the coverage.", "answer": 1}, {"article": "\u201cThe number of dementia cases could drop by half.\u201d\n\nNov. 20: MRI scan may predict which people will develop Alzheimer's disease\n\nLambracht-Washington said the study marks major progress toward a safe and effective vaccine.\nTesting in mice showed that the vaccine safely prevents the buildup of substances in the brain associated with the fatal disease, the team reported this week in the journal Alzheimer's Research & Therapy.\nThere has been research in monkeys and rabbits as well, and the researchers hope the vaccine will progress to human trials.\nAbout 5.7 million Americans have Alzheimer's disease, according to the University of Texas.\nThe number could double by 2050.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story has no independent sources. The authors asserted no conflicts in the published paper.", "answer": 0}, {"article": "P.S.A.\n\u201cThey often don\u2019t appreciate the downside of screening,\u201d Dr. Brooks said, \u201cand they don\u2019t appreciate the delay in benefit.\u201d In addition, Dr. Brooks said, primary care doctors often \u201coverestimate the likelihood that early detection of prostate cancer will lead to survival benefits.\u201d\n\nAdded to that, Dr. Brooks said, is the length of time it takes to discuss the pros and cons of screening with patients.\nScreening, he added, \u201cis promoted by hospitals and industry.\u201d And, he added, \u201cmany patients demand it.\u201d\n\nDr. Brooks of the cancer society says he travels the country and talks to primary care doctors about screening, and has learned that many have misconceptions about the test\u2019s benefits.\n\u201cIt is not all pure data that is promoting aggressive screening.\u201d Dr. Andriole is directing a National Cancer Institute study of 76,000 men that failed to find a screening benefit after 10 years.\nThe new study only included national data through 2005, the most recent year they were available, but, said Dr. Durado Brooks, director of prostate and colorectal cancers for the American Cancer Society, \u201cthere is no reason to believe it has changed significantly since 2005.\u201d Doctors said there are several reasons screening seems to continue indefinitely as men age.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Numerous independent sources without ties to the study reported on were quoted as part of this story.\nOne thing that does concern us is the way the piece ended.\u00a0 The story profiled two men \u2013 and both choose to be screened.One recently found a small cancer, and is thinking of \u201chaving the whole thing taken out.\u201d\u00a0 Why was there no balancing profile of a man who chooses not to be screened?", "answer": 1}, {"article": "Thourani V, Jensen H, Babaliaros V, Kodali S, Rajeswaran J, Ehrlinger J, Blackstone E, Suri R, Don C, Aldea G, Williams M, Makkar R, Svensson L, McCabe J, Dean L, Kapadia S, Cohen D, Pichard A, Szeto W, Herrmann H, Devireddy C, Leshnower B, Ailawadi G, Maniar H, Hahn R, Leon M, Mack M. Outcomes in Nonagenarians Undergoing Transcatheter Aortic Valve Replacement in the PARTNER-I Trial.\nWhile the current study did not evaluate other alternative options for TAVR, these techniques may include transaortic, transcaval, transcarotid, or trans-subclavian.\nAs part of the PARTNER-I trial, Vinod H. Thourani, MD, from Emory University in Atlanta, and colleagues from 12 other institutions in the United States found that transcatheter aortic valve replacement (TAVR) is a safe and effective way to treat aortic stenosis in nonagenarians who qualify for the surgical technique.\nFor the study, the researchers used two different approaches: transfemoral TAVR (TF-TAVR), which is the traditional approach performed via the groin, and transapical TAVR (TA-TAVR), which is performed via the heart muscle.\nIn the largest series published to date, between April 2007 and February 2012, 531 nonagenarians underwent TAVR: 329 with TF-TAVR and 202 with TA-TAVR.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not mention funding sources or conflicts of interest. This is particularly problematic for a release that leads with a statement that valve replacement surgery should be an option for older patients \u2014 given that the relevant journal article makes clear that six of the study authors have financial relationships with companies who have a vested interest in valve replacement surgeries.", "answer": 0}, {"article": "The ChemMedChem study is available at http://dx.\nThe best inhibitor in this group, SCA-50, showed strong activity against MRSA Mu50 strain and an inhibitory effect on MRSA Mu50 that was two-to-60 times more potent than all commonly used antibiotics, including vancomycin, the last resort option for treating MRSA-related infections.\nThe RB analogs inhibited the ATPase activities of two SecA isoforms identified in S. aureus, SaSecA1 and SaSecA2, as well as the SaSecA1-dependent protein-conducting channel.\nCommunity-acquired MRSA often begins as a skin boil and is spread by skin-to-skin contact.\nATLANTA--A novel class of antimicrobials that inhibits the function of a key disease-causing component of bacteria could be effective in fighting methicillin-resistant Staphylococcus aureus (MRSA), one of the major drug-resistant bacterial pathogens, according to researchers at Georgia State University.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes the study\u2019s funding sources are the National Institutes of Health and Georgia State\u2019s Center for Biotechnology and Drug Design and Molecular Basis of Diseases Program.\nNo conflicts of interest are disclosed in the release or published study results.", "answer": 1}, {"article": "The American Heart Association recommended more than a year ago using induced hypothermia for cardiac arrest patients who are stable.\n\"We know that people's neurologic outcomes are likely to be better if they get it but we don't completely understand what's happening in the brain for sure when the body is cooled.\"\n\"Anytime you can take someone who comes into the hospital after having cardiac arrest, who may not ever wake up, and you can potentially change that to someone who can wake up and become back the person they were the day before, it's an amazing thing,\" says Dr. David Likosky, a neurologist.\n\"This is ice, and it's a treatment that's very simple, and it's a treatment that makes a big difference: the difference between waking up and not.\"\nIn medicine, in general, we have many very expensive treatments that may make a marginal difference \u2014 treatments that are potentially painful, that cost a lot,\" Likosky says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A patient who underwent this treatment and had a good outcome as well as two physicians (a neurologist and a cardiologist) at a hospital which uses this treatment were interviewed for this story.\nIt would have been helpful to understand why only a limited number of hospitals include this treatment in their management of heart attack.", "answer": 1}, {"article": "Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities.\nThe School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2016 fiscal year.\nIn addition to Weinstein, additional authors include Mitchell D. Schnall, Elizabeth S. McDonald, Alice Chong, and Emily F. Conant.\nOne in eight women in the United States will develop breast cancer at some point during their life.\nThe most common exam offered for asymptomatic patients seeking supplemental screening is a whole breast screening ultrasound examination.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release did not mention any source of funding for the study. Nor did it address whether there were any conflicts of interest among the researchers at the University of Pennsylvania.", "answer": 0}, {"article": "[1]\n\nWriting in a linked Comment, Dr Nahid Bhadelia from Boston University School of Medicine and Boston Medical Center, Boston, USA says, \"[This study] validates the accuracy of the ReEBOV RDT in patients who are well into their illness...suggesting it could be used to triage this subset of patients if RT-PCR is not available, particularly in those with a high index of clinical suspicion for a differential diagnosis...the data presented provide crucial information about the point of-care function of this rapid diagnostic test, such as ease of use, quality of samples taken at the bedside, and the concordance with venous samples...the results raise caution regarding the performance of the widely used altona RT-PCR assay, which the authors suggest might have underperformed because of laboratory specific technical and performance factors.\"\nBoth the RDT and altona assays failed to detect a small number of EVD cases that tested positive by the Trombley test, all with very low amounts of virus.\nA new test can accurately predict within minutes if an individual has Ebola Virus Disease (EVD), according to new research published in The Lancet.\nThe altona RT-PCR assay failed to detect a small number of EVD cases that tested positive by both RDT and by an alternative RT-PCR test (Trombley), all with relatively low amounts of virus.\nThis method poses substantial risks to the healthcare workers responsible for blood collection, transport, and testing, and efforts to contain the Ebola epidemic in west Africa have been hampered by this slow and complex diagnostic test.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We\u2019re told the Abundance Foundation funded the test and the maker of the rapid-diagnostic test, Corgenix, provided the kits.", "answer": 1}, {"article": "Newswise \u2014 Omega-3 fatty acids may lower the risk of breast cancer in postmenopausal obese women, according to researchers.\nThe researchers plan to test the effect of DHA alone in obese subjects, potentially in combination with weight loss, in a future trial.\nAt the conclusion of the two-year study, the researchers found that increasing levels of omega-3 in the blood were associated with reduced breast density\u2014but only in women with a body mass index above 29, bordering on obesity.\nSome epidemiological data supports the idea that omega-3s protect against breast cancer, but the findings have been inconsistent.\nAlthough Lovaza contains both of the fatty acids DHA -- 375 milligrams -- and EPA -- 465 milligrams, only DHA blood levels were associated with breast density reduction.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does identify the funding sources for this research as well as the suppliers of the drugs used in this study so possible conflicts of interest are adequately addressed.", "answer": 1}, {"article": "The devices had been developed at EV3 Inc., a Plymouth med-tech company that Covidien acquired in 2010.\nIt's a key finding, because patients with diabetes usually suffer from more advanced PAD and the blood vessels re-clog faster than for those who do not.\nThe company says this is a major step forward in treating PAD because, unlike stents, atherectomy \"leaves no metal behind.\"\nThe results showed that atherectomy, the practice of trimming away the plaque that causes peripheral artery disease (PAD), is just as effective at restoring blood flow as traditional angioplasty and stents.\nThe study is the largest to look at the effectiveness of atherectomy, Covidien said, and enrolled 800 patients at 47 centers in the U.S. and Europe.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were comments from the principal investigator\u00a0 \u2013 but they only addressed business prospects \u2013 not clinical efficacy questions\u00a0 And there was a stock analyst\u2019s perspective.\nBut we expect more: independent clinical experts\u2019 perspectives on what the data on harms and benefits mean for patients \u2013 especially when the headline claims \u201ctools shown effective against PAD.\u201d", "answer": 0}, {"article": "Minimally invasive procedures increased to 31 percent of all radical prostatectomies in 2005 from 12.2 percent in 2003.\n\u201cThis paper,\u201d Dr. Hu said, \u201cdemonstrates that there are hidden risks for patients who opt for laparoscopic or robotic surgery.\u201d\n\nIn laparoscopy, a surgeon inserts instruments through small cuts in the skin instead of making large incisions to expose the organs.\nThe study, published on May 10 in The Journal of Clinical Oncology, examined a sample of 2,702 Medicare patients undergoing radical prostatectomy, the complete removal of the prostate, from 2003 to 2005.\nLaparoscopic operations for prostate cancer, a minimally invasive surgery that is in rising demand, result in fewer immediate complications and quicker recovery than the more common open procedure, a new study reports.\nThe widely advertised procedure is becoming more popular, said Dr. Jim C. Hu, the lead author of the study and an instructor in surgery at Harvard.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article uses as sources the study itself, the lead author, and two independent medical specialists. This is sufficient sourcing.\nIt is not known if any of the researchers had ties to interested parties such as device makers. The published abstract does not include this information. ", "answer": 1}, {"article": "Diseases like Alzheimer\u2019s start years, even decades, before the first symptoms of memory loss shows up.\n\u201cBut what\u2019s nice about it is that it\u2019s a nice non-cognitive, motor factor so it\u2019s looking at another aspect of brain function.\u201d\n\nMORE: This Alzheimer\u2019s Breakthrough Could Be a Game Changer\n\nPetersen suggests that every physician should get this information on their patients at age 65; that way, they can have a baseline against which to compare any changes as their patients age.\nCurrently, the only way to truly separate out those on the road to Alzheimer\u2019s is to conduct expensive imaging tests of the brain, or to do a spinal tap, an invasive procedure that extracts spinal fluid for signs of the amyloid protein that builds up in the disease.\nAnd with rates of those diseases rising, experts say that more primary care physicians\u2014not neurology experts\u2014will have the task of identifying these patients early so they can take advantage of whatever early interventions might be available.\nMORE: New Test May Predict Alzheimer\u2019s 10 Years Before Diagnosis\n\nWhile his test is a possible solution to that problem, he acknowledges that the results need be repeated before it\u2019s recommended on a wide scale to physicians across the country.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story provides quotes and comments by one of the authors of the study. An independent expert would likely have identified many of the coverage gaps we discuss in this review. HealthNewsReview.org provides a list of independent experts who are willing to talk with journalists who need help fleshing out their stories.", "answer": 0}, {"article": "\"That didn't result in clostridium seeding anywhere else outside the injected region, but it's a theoretical possibility since we were able to detect it in the blood culture of one or two patients,\" Janku said.\nThe trial results were to be presented Sunday at the International Cancer Immunotherapy Conference, in New York City.\nWhen both injected and uninjected lesions were included, the stable disease rate was 86 percent, the researchers reported.\nIn 2000, the U.S. Centers for Disease Control and Prevention reported that a handful of drug users in the United Kingdom fell ill or died after their injection sites became infected with the bacteria.\n\"What would be interesting is if this could prime an immune response that would eventually also take care of the non-injected tumors.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted two researchers who were involved in the trial, with no independent sources. It did not say that the trial was sponsored by a company called BioMed Valley Discoveries.", "answer": 0}, {"article": "As this Lancet study points out, because annual flu shots were recommended for the elderly since the 1960s, it has been unethical to conduct high-quality randomized controlled trials where you give only one group the shot in order to compare it with another group that didn't get the vaccine.\nIn kids, the highest-quality evidence \u2014 a randomized controlled trial \u2014 suggests the vaccine works well enough: On average, if you give six kids under the age of 6 a flu shot, you can expect to prevent one case of the flu.\nIt's true that flu vaccines don't work spectacularly well, at least according to the best evidence we have (and most of the evidence on flu vaccines is of poor methodological quality).\nThe flu shot is designed to protect people against three or four strains of the A and B viruses that researchers believe will be most common that year, leading to the nasty fevers, headaches, coughs, and runny noses that make many people miserable in the fall and winter.\nIn a good year, when the WHO guesses correctly and the flu shot matches the strains in circulation, you need to give 33 adults flu shots, on average, to prevent one case of illness.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The author of this story compiles ample evidence from reliable and respected independent sources concerning influenza.\u00a0\u00a0 It does not, however, offer any information concerning conflicts of interest, but with this type of story, we\u2019re hard pressed to see how there would be a conflict.", "answer": 1}, {"article": "In a study suggesting that red wine might be the next big thing in breast cancer prevention, a study has found that women who drank just under two servings of red wine daily experienced hormonal changes that mimic the effects of a drug used to prevent malignant breast tumors from coming back.\n\nThe study, published Friday in the Journal of Women's Health, found that consuming the same amount of white wine did not have the same effect in premenopausal women participating in the study.\n\nWomen intent on warding off breast cancer have been warned about alcohol consumption: as recently as November, a study found that women who consumed as few as three servings of alcohol a week increased their risk of developing the disease, which strikes one in eight American women at some point in life.\n\nWhite wine and other alcoholic beverages are believed to promote the conversion of androgens--\"male hormones\" such as testosterone, which circulate in all women's blood--into estrogen. And the greater a woman's lifetime exposure to estrogen--whether her own or estrogen that comes from medication or environmental sources--the higher her risk of developing breast cancer.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There was no second source, no independent source.\u00a0 That would have helped.", "answer": 0}, {"article": "A type of sleeping pill that several major pharmaceutical companies are racing to develop received good news yesterday when Swiss biotech company Actelion Ltd. reported positive clinical data.\n\nSleep experts say the drug class needs further study but could potentially offer some benefits beyond Ambien, the top-selling drug in the $3.8 billion global market for sleeping pills. While Ambien and similar drugs, called nonbenzodiazepine drugs, are effective and easily tolerated by most people, some insomniacs don't respond to the...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did not appear to make use of any independent sources of information regarding the clinical efficacy of this drug.", "answer": 0}, {"article": "But there\u2019s a problem with a low-FODMAP diet.\nGluten is not a carbohydrate; it\u2019s a mix of proteins found in wheat and its close relatives (including spelt, kamut and farro), as well as in barley and rye.\nIf your gut can handle FODMAPs, foods that contain a lot of them can be very good choices \u2014 partly because the fermentation helps your gut biome and partly because the way FODMAPs are digested means you\u2019re absorbing fewer calories than indicated on a FODMAP-rich product\u2019s label.\nIt\u2019s what gives bread its elasticity, but it also sets off the immune system of people with celiac disease, damaging the small intestine and sometimes producing painful and unpleasant symptoms.\nA low-FODMAP diet eased their symptoms, as it does for about 70 percent of people who suffer from irritable bowel syndrome, a condition that causes abdominal pain and bowel changes.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only source quoted is Dr. GIbson, one of the creators of the low-FODMAP diet and an author of a book entitled, The Complete Low FODMAP Diet: A revolutionary Plan for Managing IBS and Other Digestive Disorders.", "answer": 0}, {"article": "But previous studies suggest more than 50 percent of these biopsies are unnecessary and can result in pain, worry, infertility and higher health care costs.\nThe next step, the researchers report, was to verify that the four-gene test worked using freely circulating DNA from blood and urine, rather than DNA taken directly from cervical tissue.\nThe researchers then compared the number of methyl groups attached to each gene in samples from the 34 healthy women to 53 samples with a specific subset of precancerous markers.\n\"Our urine test would serve as a molecular triage,\" he says, \"at times supplementing Pap test information.\nUsing methylation as a value to diagnose malignancy, the three genes together showed a 90 percent sensitivity, meaning that their presence was able to predict a true positive cancer sample this percentage of the time.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Although the release offers no information about possible conflicts of interest (the article on which the release was based indicates the absence of such conflicts), it does provide information about funding. And it does disclose the start of a collaboration between the team and a company that intends to design and market a urine test product.", "answer": 1}, {"article": "The new study followed participants for three years.\n\u201cA 5 percent loss of weight is associated with a 50 percent lower risk of diabetes and a 10 percent loss is associated with an 80 percent lower risk.\u201d\n\nPatients in Bohula\u2019s study did see improvements in hypertension and blood sugar levels with weight loss.\nThat\u2019s how we need to start looking at drugs for obesity.\u201d\n\nWhat many don\u2019t understand is that weight gain leads to changes in the brain that may not be reversible, Aronne said.\nThere are probably a few reasons for this, including cost, if not covered by insurance, and a perception that these agents are not safe in light of the history with weight loss agents.\u201d\n\nIn fact, a 2017 report that examined the medical records of 2.2 million patients found that fewer than one in 50 patients who were eligible for a diet pill prescription received one.\n\u201cMost prior studies of weight loss only followed patients for a year, and a few out to two years,\u201d said the study\u2019s lead author, Dr. Erin Bohula, an assistant professor of medicine at Harvard Medical School and a cardiologist and investigator with the TIMI Study Group at Brigham and Women\u2019s Hospital in Boston.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story didn\u2019t disclose that two physician sources, Erin Bohula and Louis Aronne, received payments in the tens of thousands of dollars in connection with weight drugs, according to ProPublica\u2019s Dollars for Docs database.\nA third physician quoted in the story, Vijaya Surampudi, has received smaller payments from Novartis that were not tied to a weight-loss drugs.\nThe story would have benefited from more independent sources.", "answer": 0}, {"article": "The frequency of screening mammograms -- and the appropriate age to begin them -- has been debated since the U.S. Preventive Services Task Force in 2009 recommended that women routinely get screening mammograms every other year starting at age 50.\n\"Hopefully, there will be less anxiety about getting a recall.\"\nInformation about the women and their mammograms came from the Breast Cancer Surveillance Consortium, funded by the National Cancer Institute.\nThose false-positives may cause inconvenience and anxiety, and biopsies can cause pain and scarring, the researchers note.\nAfter 10 years of annual screening, more than half of women will be called back at least once for another mammogram.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent experts were quoted.", "answer": 0}, {"article": "Dry eye in the Beaver Dam Offspring Study: prevalence, risk factors, and health-related quality of life.\nJerry St. Peter, Vice President and Head of Sun Ophthalmics, added: \"A key strategic imperative for our ophthalmic business is to participate in the rapidly growing, underserved, and dynamic Dry Eye market, which is expected to reach $5 billion by 2020.\nBased on published data, the efficacy and safety endpoints in these trials compared favorably to other formulations of cyclosporine A with the advantage of early onset.\nNational Health and Wellness Survey: The Global Health and Wellness Report - 2014.http://www.kantarhealth.com/docs/ebooks/global-health-and-wellness-report.pdf.\n[1]\n\nAccording to Dilip Shanghvi, Managing Director, Sun Pharma, \"We are happy to see the early onset of action and strong efficacy results for Seciera\u2122.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There is no mention in the release of who funded the study. Also, there is no information about where the study was conducted, or which institutions were involved, although it identifies the study as \u201cmulticenter.\u201d There is a quote from an individual identified as a \u201cstudy investigator\u201d but no other information is offered, including any disclosures as to possible conflicts of interest.", "answer": 0}, {"article": "URBANA, Ill. - Nearly every American who has become a parent in the last decade has heard the slogan, \"breast milk is best,\" and has likely been encouraged to offer breast milk to newborns.\nIn their new study, the team concentrated solely on the effects of prebiotics.\nAfter 33 days, blood, brain, and intestinal tissues were collected for analysis.\nYet for many families, breastfeeding is difficult or impossible.\nThe work was supported by Mead Johnson Nutrition.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that the research was funded by Mead Johnson Nutrition, the manufacturer of a prebiotic infant formula.", "answer": 1}, {"article": "While many different types of cancer were present in both groups, the team found that breast and prostate cancers were less common among those with thrombocytosis than in the general population, while lung and colorectal cancers were more common.\nResearchers say that raised platelet counts are as good a predictor of getting any cancer as a lump in the breast is for breast cancer.\nFor about a third of cases of lung and colorectal cancer in patients with thrombocytosis, there had been no other symptoms that raised the suggestion of cancer.\nIn total, over 31,000 patients found to have a raised platelet count, and nearly 8,000 without, were included in the analysis.\nPlatelets are tiny blood cells that circulate in the body, helping wounds to clot.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story used\u00a0information and quotes from those not associated with the study, and we detected no conflicts of interest.", "answer": 1}, {"article": "In a study presented Tuesday at the American Chemical Society's spring national meeting in San Diego, 16 overweight young adults took, by turns, a low dose of green coffee bean extract, a high dose of the supplement, and a placebo.\nA larger trial involving 60 people is being planned.\nIt would be difficult to take without a lot of water, Vinson reported.\nBut the more extract they consumed, the more weight and fat they lost.\nOf the 16 volunteers, six wound up with a body mass index in the healthful range.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two independent experts added important perspectives to the story.", "answer": 1}, {"article": "In 2012, a federally funded panel of experts on preventive care concluded there are more risks than benefits to screening American men for prostate cancer with the PSA test. And in April 2017, the U.S. Preventive Services Task Force dumped the decision squarely into the laps of patients and their doctors. Some men between 55 and 69 years of age might well decide to get their PSA checked, the task force said. After hearing the ledger of pros and cons, however, others in that age bracket might just as reasonably skip the screening test, the panel concluded.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "As with the STAT News story, this one didn\u2019t note the financial disclosures of the study authors, including the senior author, Ruth Etzioni, who disclosed she owns equity in a company developing medical imaging technology that it says could be applied in prostate cancer patients. Dr. Etzioni stated that she does not consider the equity ownership to be a conflict of interest, but considering that an increase in PSA screening would boost demand for more precise and less invasive follow-up testing, it appears that her company would benefit.\nWhile the story does quote an independent source, it would have been helpful to note that he consults for the medical industry.\nThe study was funded by the National Cancer Institute. While that source does not raise any red flags, and the study stated that the funder had no role in the study, news stories are more informative when they note study funding.", "answer": 0}, {"article": "The study shows that eating foods rich in antioxidants, like vegetables and fruits, fights disease and may prolong life.\n\"These findings support increasing fruit and vegetable consumption as a means of preventing premature death,\" write researcher Chaoyang Li, MD, PhD, of the CDC and colleagues in the Archives of Internal Medicine.\nAlthough previous studies have suggested eating more fruits and vegetables is associated with a lower risk of disease, studies have not shown that taking beta-carotene supplements reduces the risk of dying from heart disease or cancer.\nResearchers found that people with the highest levels of the antioxidant alpha-carotene in their blood had a 39% lower risk of death from any cause, including heart disease and cancer, than those who had the lowest levels of the antioxidant during the 14-year study.\nNov. 22, 2010 -- Eat your veggies and you may live longer, a study suggests.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\n\nThe story does not include comments from any independent sources. The lack of perspective deprives readers of the context needed to appreciate what this study says\u2026 and does not say. Since the researchers are employees of federal agencies, not associated with the supplement or food industries, and they reported no financial disclosure, it is of less concern that the story does not address potential conflicts of interest.", "answer": 0}, {"article": "In one of two related studies published Monday, Anderson and his colleagues described in the journal Nature Biotechnology how they had tested 774 variations of alginate in rodents and monkeys and identified a handful that elicited a greatly reduced foreign body response.\n\u201cOur goal is to bring that kind of biological cure across the spectrum of type 1 diabetes.\u201d\n\nThe potential of the approach has attracted interest from both small startups and large biopharmaceutical companies that are looking at stem cell-based therapies for diabetes.\nThe human beta cells survived exquisitely well.\u201d\n\nThe studies show \u201cyou can take stem cells and make a limitless supply of [human beta cells] and put them in a device and cure an entirely different species of animal,\u201d Anderson said.\nThe MIT team has developed tiny capsules for the cells, but ViaCyte, for example, has created a larger device outfitted with the cells that gets inserted under the skin.\n\u201cThis is really the first demonstration of the ability of these novel materials in combination with a stem-cell derived beta cell to reverse diabetes in an animal model,\u201d said Julia Greenstein, vice president of discovery research at JDRF, an organization trying to end type 1 diabetes that provided some funding for the studies.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Most of the sources are connected to the study, either from the research institutions involved or the funders. But we give the story points for taking the next step and talking to people in the pharmaceutical research world who would be among those actually taking a discovery like this and making it therapeutic. The story quotes someone from Semma and someone from VitaCyte, both of whom provide a good dose of realistic context. While ideally we would\u2019ve heard from someone with no stake at all in this line of research, we think there are enough voices with enough distance from the studies to earn the story a Satisfactory rating. And to the article\u2019s credit, the sources\u2019 affiliations are all clearly stated.", "answer": 1}, {"article": "The researchers focused on blueberries and strawberries because these are the most widely consumed varieties in the U.S.\n\u201cAlthough we know about the effects of antioxidants and flavonoids, and their effects in wine and chocolate, it is interesting to look at their effects in such a large group of women over a long period of time,\u201d says Dr. Suzanne Steinbaum, director of women and heart disease at Lenox Hill Hospital in New York City, who was not involved in the study.\nThe women who ate more berries also tended to eat healthier overall, consuming more vegetables and fruits than those who didn\u2019t eat as many berries; but when the scientists broke down the women\u2019s diets, they found that the highest consumers of berries even had a lower risk of heart attack compared with women who still ate plenty of fruits and vegetables but fewer berries.\nThe results are particularly encouraging because they showed that a change in diet could affect heart-disease risk for relatively young women.\nIn the study, researchers from the Harvard School of Public Health and the University of East Anglia in the U.K. analyzed data from 93,600 women ages 25 to 42 enrolled in the Nurses\u2019 Health Study II.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes one independent expert, preventive cardiologist Dr. Suzanne Steinbaum, who is the same doctor quoted in the HealthDay article.\u00a0 (Hmm, why is that?) We wish that she could have talked more on the limitations of the study, although her comment on benefits later in life more of an endorsement than a critical analysis: \u201c\u2026even if you are eating these early in life, you\u2019re getting benefits that last for life.\u201d\nNonethless, because an independent expert was quoted, we\u2019ll give the story the benefit of the doubt.", "answer": 1}, {"article": "Dec. 2, 2011 (Chicago) -- An experimental approach in which penile nerve tissue is frozen to knock out overactive nerves helped men with premature ejaculation last three times longer.\nIts supporters say the technique, or a similar one involving heat therapy, could someday become a standard treatment for the condition.\n\"That's about what you see with standard drug therapy,\" says researcher J. David Prologo, MD, assistant professor of interventional radiology at Case Western Reserve University\u2019s School of Medicine in Cleveland.\nThey lasted an average of 110 seconds before ejaculation, or nearly two minutes, over the three months they were followed, compared with 36 seconds before treatment.\nThe findings were presented here at the annual meeting of the Radiological Society of North America.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story notifies us that the study was funded by Galil Medical, and that one of the sources consults for them. It also obtains a comment from an independent expert, who\u00a0adds some important context regarding the uncertain long-term safety of the procedure.", "answer": 1}, {"article": "What does that mean?\nIn general, they also had less disability, a reduced fear of moving, and improvement in mental and physical outlook, according to the study authors.\nThe regimen included the best known exercises for back pain and general exercises, she said.\nPhysical therapists and doctors can guide patients in this process, she added.\nThe new exercises are designed to help overcome that fear, Malfliet said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An outside expert was quoted and we detected no conflicts of interest that should have been disclosed.", "answer": 1}, {"article": "One innovative aspect of the study was the measurement of bone texture of the lumbar spine using trabecular bone score (TBS) - the first use of this technique in adolescent athletes.\nThe research was funded by the EU via a Marie-Sklodowska-Curie fellowship awarded to principal investigator Dr Luis Gracia-Marco, also of the University of Exeter.\n\"This raises a question about whether swimming and cycling are good for bone development,\" Dr Gracia Marco said.\n\"Our research shows that playing football can improve bone development in comparison to swimming and cycling,\" said first author Dimitris Vlachopoulos, of Sport and Health Sciences at the University of Exeter.\nThe paper, entitled: \"Longitudinal Adaptations of Bone Mass, Geometry and Metabolism in Adolescent Male Athletes.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release notes that funding for the study came from a Marie Sklodowska-Curie fellowship, provided by the European Union. The researchers do not appear to have any conflicts of interest in connection with this study.", "answer": 1}, {"article": "March 15, 2010 -- A common pain reliever may help people with type 2 diabetes control their blood sugar levels.\nHowever, it also has been shown to increase protein in the urine and its long-term safety will need further investigation.\nThe results showed those who took salsalate at each of the dosage levels experienced a beneficial decrease in blood sugar A1c levels of 0.5% or more.\nAlthough only minor side effects of salsalate use were reported, researchers say salsalate users tended to develop more protein in their urine.\nA preliminary study shows salsalate reduced blood sugar levels and helped with glycemic control at a variety of doses in people with type 2 diabetes.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources were used. \nThe investigators didn\u2019t disclose\u00a0any substantial conflicts of interest related to the study.", "answer": 0}, {"article": "These findings are published in FASEB BioAdvances journal.\nHowever, in their two most recent clinical trials of the test involving over 700 blood samples from colorectal and prostate cancer patients (and further breast and lung cancer samples that were available), they were unable to distinguish those with cancer from healthy patients in 60 cases.\nCo-first author Dr Mojgan Najafzadeh from the University of Bradford said: \"We feel that we've taken it as far as we can in proving that the test works with high predictability for cancer outcome, and IMSTAR are the right partners to improve it still further.\"\nThe research team believes that the test could be the first screening tool to 'rule in, or rule out' cancer in patients under suspicion of the disease, alongside other traditional diagnostics methods.\nDr Francoise Soussaline, PhD, DSc, IMSTAR's president said: \"To bring a universal 'liquid biopsy' blood test for cancer to market, it must achieve a number of criteria, including high sensitivity and specificity and be fully automated with high throughput for a medical routine use.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "While it is not clear who is funding this latest study, the company, IMSTAR, which has licensed the test, identifies the University of Bradford as a \u201cpartner\u201d on its website.\u00a0 Additionally, the PI quoted most extensively in the release appears to co-own a 2010 patent for a similar test.", "answer": 0}, {"article": "Researchers compared 136 women with rheumatoid arthritis with 544 healthy women of similar age.\nThe community-based approach and the fact that data on breast-feeding was collected before the onset of disease give the study strength.\nBut they found that the number of children born to a mother did not affect the results.\nAfter controlling for factors including smoking and education level, they found that women who breast-fed for 1 to 12 months reduced their risk of arthritis by 25 percent, and that those who breast-fed for more than a year cut their risk in half.\nThe authors acknowledge that it is difficult to separate the effect of breast-feeding from childbirth itself.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\nThis story cites a single source, the lead researcher of the study summarized in the news brief. No independent source is cited.\n", "answer": 0}, {"article": "So mystery and grief hung heavy when he collapsed from a cardiac arrest Jan. 6 inside the Teutonia M??\nFor 24 hours, his body temperature was kept at 91 degrees Fahrenheit, which put him in a state of hibernation.\n\"We believe the people who do go home have fewer neurological problems that impair the quality of life,\" Dr. Callaway said.\n\"My goal is to get back to a normal life,\" he said, noting he hates cold weather and is surprised he withstood hypothermic therapy.\nWithout the therapy, cardiac-arrest patients have a greater risk of suffering dementia, loss of memory or severe devastation of mental capacity, Dr. Tayal said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "While quotes from several physicans were included in this story as well as quotes from a patient who had had the treatment, the sources of the background information about the treatment and the studies about its benefit were not mentioned. So readers get the perspectives of \"believers\" minus any hard evidence.\u00a0 ", "answer": 0}, {"article": "Photo/Video: Emily Prapuolenis/The Wall Street Journal\n\nYvonne Felix\u2019s eyes don\u2019t work well enough on their own for her to read, recognize faces or cross the street without help.\nGeoffrey A. Fowler discusses the headset with Yvonne Felix, a blind artist and supporter of the technology.\nThe visor that allows legally blind people to see is no longer Star Trek fiction.\nA next-generation visor from eSight can improve vision for many legally blind people.\nLeaps in augmented-reality technology are being used to help people with severely low vision gain back enough sight to function, and then some.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story discloses\u00a0that the featured patient, Yvonne Felix, is an eSight spokesperson. The story adds\u00a0some needed backstopping from Walter Wittich, a researcher at the University of Montreal. However, the story didn\u2019t disclose that his lab has accepted grants from eSight.", "answer": 0}, {"article": "\u201cDiet is a complicated business,\u201d he said.\n\u201cThey do not tell you what will happen if you change peoples\u2019 sodium intake.\u201d\n\nWhat is needed, Dr. Alderman said, is a large study in which people are randomly assigned to follow a low-sodium diet or not and followed for years to see if eating less salt improves health and reduces the death rate from cardiovascular disease.\n\u201cYou can say, \u2018O.K., let\u2019s dismiss the observational studies because they have all these problems.\u2019 \u201d But, he said, despite the virtues of a randomized controlled clinical trial, such a study \u201cwill never ever be done.\u201d It would be impossible to keep people on a low-sodium diet for years with so much sodium added to prepared foods.\n\u201cIf the goal is to prevent hypertension\u201d with lower sodium consumption, said the lead author, Dr. Jan A. Staessen, a professor of medicine at the University of Leuven, in Belgium, \u201cthis study shows it does not work.\u201d\n\nBut among the study\u2019s other problems, Dr. Briss said, its subjects who seemed to consume the smallest amount of sodium also provided less urine than those consuming more, an indication that they might not have collected all of their urine in an 24-hour period.\nThe investigators found that the less salt people ate, the more likely they were to die of heart disease \u2014 50 people in the lowest third of salt consumption (2.5 grams of sodium per day) died during the study as compared with 24 in the medium group (3.9 grams of sodium per day) and 10 in the highest salt consumption group (6.0 grams of sodium per day).\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did a better job than USA Today finding experts who could give readers a broad context for the findings. We also appreciated how it noted that one of the experts had worked for the Salt Institute, which is the leading advocacy organization for more salt consumption.\n[Addendum on May 6: It\u2019s very difficult to find an \u201cindependent\u201d expert to comment on the evidence base on salt. Dr. Alderman, who is quoted in the Times story and frequently weighs in on this controversy, has an asterisk next to his name (appropriately so) because of his previous ties to the salt industry. But it\u2019s worth noting that the independent experts in this field, such as Dr. Appel and Dr. Sacks (who are also quoted in the Times story), are closely affiliated with NHLBI which funds much of the research on sodium. And as Gary Taubes posited many years ago in Science magazine, the NHLBI may not be a dispassionate arbiter of the evidence. (The full text of his story can be accessed at the National Association of Science Writers website: http://www.nasw.org/1999-science-society-awards.) ]", "answer": 1}, {"article": "July 7, 2010 -- The FDA says it has approved the use of micro-sized implantable telescopes to improve vision in patients with end-stage, age-related macular degeneration.\nTraining would also be needed to verify that there is sufficient peripheral vision in the untreated eye.\nThere are two forms of AMD, a wet form and a dry form.\nIt damages the center of the retina, or macula, and results in a loss of vision in the center of the visual field.\nIt is designed to magnify and project images onto a healthy portion of the afflicted person's retina.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent experts were quoted \u2013 only quotes from a company news release. ", "answer": 0}, {"article": "* Average reductions of 0.8 pct seen in levels of A1C\n\nCHICAGO, June 29 (Reuters) - Medtronic Inc\u2019s (MDT.N) insulin pump and monitoring device controlled blood glucose levels better than multiple daily injections in patients with Type 1 diabetes, according to a large post-market study.\n\u201cWhat we\u2019ve been able to show is that by combining this technology, you can lower the A1C, which reduces your risk of complications, and you can do it safely without increasing your rate of hypoglycemia,\u201d said study author Dr. Richard Bergenstal, executive director of the International Diabetes Center at Park Nicollet Health Services in Minneapolis.\nAdult and pediatric patients using the pump and continuous glucose monitoring device saw reductions in levels of A1C, a commonly used measure of blood sugar, that were four times greater than those who received regular insulin injections in the study of 485 patients ranging from age 7 to 70.\nIn the study, patients on pump therapy saw a reduction in average A1C levels of 0.8 percent, compared with a 0.2 percent average reduction for those who received multiple injections.\nPatients in the study, which was presented at a meeting of the American Diabetes Association in Orlando, Florida, and sponsored by Medtronic, achieved better glucose control over a one-year period without an increase in hypoglycemia, or dangerously low blood sugar.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nNot only does this story lack an independent source, it makes no mention of the ties between the researchers and manufacturers of insulin pumps and blood glucose sensors. Indeed, the disclosure summary included in the New England Journal of Medicine is 30 percent longer than the news report about the study. The story does note that the trial was sponsored by Medtronic, which manufactures the pump used by researchers.(Disclosures are summarized at the end of the article posted online at: http://content.nejm.org/cgi/content/full/NEJMoa1002853Disclosure statements provided by each auther are available at: http://content.nejm.org/cgi/content/full/NEJMoa1002853/DC3 ", "answer": 0}, {"article": "And other research has raised new concerns.\n\u201cOnly a minority of these parents mentioned medication.\u201d\n\nKatherine Ellison is a Pulitzer Prize-winning former foreign correspondent and author and co-author of seven books, including the forthcoming \u201cWhat Everyone Needs to Know about A.D.H.D.\u201d (Oxford University Press), co-authored with Stephen Hinshaw, Vice-Chair for Psychology, Department of Psychiatry, University of California, San Francisco.\nOne possible reason, as the report noted, was that many children refuse to continue taking medication after a year or so, something most parentsof such children well know.\nRecent research, he says, suggests the pills may \u201cnormalize\u201d the child\u2019s brain over time, rewiring neural connections so that a child would feel more focused and in control, long after the last pill was taken.\nAlthough the studies had different methods and goals, the authors said that, together, they suggested that stimulants \u201care associated with attenuation of abnormalities in brain structure, function, and biochemistry in subjects with A.D.H.D.\u201d\n\nBut other A.D.H.D.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The best feature of this story is the presentation of experts with different perspectives who outline the reasons for their views. It also notes concerns about financial ties between some experts and the pharmaceutical industry.\nWhile we\u2019ll award a satisfactory rating, we wish the story had put more emphasis on some of these researchers\u2019 checkered history with respect to conflict disclosure. Notably, the lead author of the study cited as evidence for a normalizing effect on brains reportedly failed to disclose payments totaling more than $1.6 million dollars from drug companies. And the source citing that study,\u00a0Dr. Timothy E. Wilens, failed to disclose similar payments.", "answer": 1}, {"article": "UT Southwestern, one of the premier academic medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education.\nTo reap the most benefit, the exercise regimen should begin by late middle age (before age 65), when the heart apparently retains some plasticity and ability to remodel itself, according to the findings by researchers at the Institute for Exercise and Environmental Medicine (IEEM), which is a collaboration between UT Southwestern Medical Center and Texas Health Presbyterian Hospital Dallas.\nThe more than 50 participants in the study were divided into two groups, one of which received two years of supervised exercise training and the other group, a control group, which participated in yoga and balance training.\nHowever, the researchers also found that the heart chamber in competitive masters-level athletes remains large and elastic, and that even four to five days of committed exercise over decades is enough for noncompetitive athletes to reap most of this benefit.\nAt the end of the two-year study, those who had exercised showed an 18 percent improvement in their maximum oxygen intake during exercise and a more than 25 percent improvement in compliance, or elasticity, of the left ventricular muscle of the heart, Dr. Levine noted.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release mentions the funding sources for the study (NIH and American Heart Association). There are no conflicts of interest listed in the news release or study.", "answer": 1}, {"article": "These studies used tablet computers to test navigational tasks.\n\u201cBy pinpointing those who are beginning to lose their navigational skills, we hope to show that we can target people at a much earlier stage of the condition and one day become far more effective in treating them.\u201d\n\nThe discovery that loss of navigational skills was associated with Alzheimer\u2019s disease was made several years ago by Chan and colleagues based at several centres in the UK.\n\u201cThe entorhinal cortex is the first brain region to show degeneration when you get Alzheimer\u2019s, and that is where we shall be focusing our research,\u201d said Chan, whose work is funded by the Alzheimer\u2019s Society.\n\u201cThe aim of the study is very simple: can we detect changes in brain function before people are aware that they have them?\u201d\n\nResearchers recently pinpointed the significance of a tiny area of the brain known as the entorhinal cortex, which acts as a hub in a widespread brain network that controls navigation.\n\u201cIt is usually thought memory is the first attribute affected in Alzheimer\u2019s,\u201d said project leader Dennis Chan, a neuroscientist based at Cambridge University.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story notes that the forthcoming study has received funding from the Alzheimer\u2019s Society. However, the only source cited in the story is one of the researchers who will be conducting the study. Input from an independent expert about the viability of such a study would have been very welcome.", "answer": 0}, {"article": "Those drugs could not be used, however, until they received emergency use authorizations from the F.D.A.\nAlthough there are still questions about peramivir\u2019s true effectiveness, some critics say the government moved too slowly to make the drug available, and that even now, access is too restricted.\nLate Thursday, the government announced orders for intravenous versions of Tamiflu and Relenza, which are much cheaper \u2014 a development that could force shares of BioCryst to give up some of their gains on Friday.\nThe federal government said late Thursday that it had also ordered 10,000 treatment courses each of intravenous versions of Tamiflu and Relenza, with options to buy 30,000 more courses of each.\nDr. Lurie, the federal official, said there had been 237 requests to use the drug since the emergency use authorization was granted nearly two weeks ago.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\n\nThe story did not point out that one of the supporters of faster and broader access to peramivir, Dr. Richard Whitley, has long been a booster of the drug, which is being commercially developed by a spin-off of the University of Alabama department he works in. \nSee Whitley comments in a 2005 article promoting the potential of peramivir: \nhttp://main.uab.edu/show.asp?durki=87834\nHere we also point out that the story profiled only one patient and includes a quote from the patient\u2019s father crediting peramivir with saving his daughter\u2019s life. The story does not give any examples of similar patients who either survived after getting approved drugs or who received peramivir and yet did not survive. Despite the clear caveats in the story, the reliance on only a single anecdote may give readers a skewed sense of the benefits of the unapproved drug. ", "answer": 0}, {"article": "The other half got a heart health education program.\nThe Chinese developed tai chi thousands of years ago, but it has recently piqued the interest of Western medicine as an alternative mind-body therapy to treat disease.\nThe study authors say there's a usually a strong relationship between depression and heart failure, so the fact that tai chi helped cheer people up was an especially good sign.\nThe movement is tai chi, an ancient martial art turned exercise, and a study out this week in Archives of Internal Medicine says it may help people suffering from heart failure feel better about life.\nThe Archives of Internal Medicine study is the first large clinical trial to look at whether a tai chi program can do anything for people with heart failure.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were no independent perspectives provided in the story. At the very least, the story could have incorporated some\u00a0comments from an editorial that accompanied the study\u00a0(subscription required), which raised questions about the size and statistical power of the study as well as other\u00a0issues.", "answer": 0}, {"article": "Ulcerative colitis is a chronic inflammatory bowel disease.\nFor more information on ulcerative colitis, visit the U.S. National Institute of Diabetes and Digestive and Kidney Diseases.\n\"There is still a substantial unmet need for new treatments for patients with ulcerative colitis,\" said study lead author Dr. William Sandborn.\nWhether Xeljanz should be used as a first treatment is still not clear, said Dr. Arun Swaminath, director of the inflammatory bowel disease program at Lenox Hill Hospital in New York City.\n\"Treatment with oral tofacitinib is potentially a new treatment option for patients with moderate to severe ulcerative colitis, pending review by the [U.S. Food and Drug Administration],\" Sandborn said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story handles this very well. The study\u2019s lead author is clearly identified, the story clearly states that Pfizer (which makes Xeljanz) funded the study, and that the lead author has consulted for Pfizer. In addition, two independent sources are included in the article. One of those sources was also the author of an editorial on the NEJM paper, which the story notes.", "answer": 1}, {"article": "Three years later, researchers continue to detect the presence of the cloned cells they infused into the patient, 61-year-old high school history teacher Gardiner Vinnedge of North Bend, Wash.\n\nFor six years, Vinnedge endured painful rounds of chemotherapy, only to have his melanoma return.\nSeveral independent researchers said the study results were promising.\nThe last step was to infuse the resulting army of cancer-fighting clones back into the patient.\nThe only side effect, he said, was a raging rash that lasted for three days.\nIt aims to charge up the patient's immune system to attack cancer cells and halt their out-of-control growth.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several independent sources were quoted.", "answer": 1}, {"article": "MONDAY, Feb. 22, 2010 (HealthDay News) -- Women who experience depression during pregnancy may have another treatment option, new research suggests.\nMany women are cautious about using medications during pregnancy, reports the study.\nAll were between 12 and 30 weeks of gestation.\nInterpersonal psychotherapy is an option for women who are depressed during pregnancy, but this type of therapy isn't always available, according to the study.\nThe treatments lasted an average of 25 minutes.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes one independent expert who provides valuable commentary on the importance of the new findings. ", "answer": 1}, {"article": "\"Guidelines changed based on this study,\" Jolly noted.\nThe results of the study were published online March 16 in the New England Journal of Medicine to coincide with a planned presentation of the findings at the American College of Cardiology's annual meeting in San Diego.\nFor the study, Jolly and colleagues randomly assigned 10,732 patients undergoing an angioplasty after a heart attack to have clots manually removed or to not have them removed.\n\"These findings will likely have important implications for clinical practice,\" Fonarow said.\n\"There has been some controversy about removing blood clots during the treatment of heart attacks,\" said lead researcher Dr. Sanjit Jolly, an associate professor of cardiology at McMaster University in Hamilton, Ontario.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The information was released simultaneously in the New England Journal of Medicine and presented at a conference. The story references data from the study and quotes an expert who was not affiliated with the study. While the story meets our standard, we wish that the independent expert had been pressed for a more meaningful evaluation, as discussed above.", "answer": 1}, {"article": "The page you are looking for has moved. Please go to the main EurekAlert! homepage to locate the section you are interested in and reset your bookmarks.\n\nFor further assistance, please contact webmaster@eurekalert.org.", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There is no specific trial referenced, just a review of the author\u2019s past work relating to blood and saliva screening tests and his opinions that AD can be prevented through \u201cself treatment by consumption of non-steroidal anti-inflammatory drugs, adhering to a Mediterranean diet, and consuming antioxidants such as quercitin which is contained in coffee.\u201d\nThe release makes many claims and cites a lot of research, but as readers we have no idea who may stand to gain what. It\u2019s not clear who funded the studies, nor what stake Dr. Greer,\u00a0the president and CEO of Aurin Biotech, may have in any products that eventually result from this research.", "answer": 0}, {"article": "CHICAGO -- Many patients treated with Byetta, a diabetes drug by Amylin Pharmaceuticals Inc. and Eli Lilly & Co., were able to maintain good blood-sugar control and also lose weight after three years on the drug, according to a study.\n\nThe study, described at the American Diabetes Association's annual meeting here, examines clinical data from the longest trial involving Byetta presented to date.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only uses one source of information, and he is the lead author of the study. There were many other diabetes specialists at the American Diabetes Association meeting \u2013 where these data were presented \u2013 who could have helped put this in perspective for readers. ", "answer": 0}, {"article": "Cooked tomatoes tend to have a greater effect on blood levels of lycopene than raw tomatoes or tomato juice.\nOct. 8, 2012 -- Men who eat lots of tomatoes and tomato-based products may have a lower risk for stroke, a new study suggests.\nMen who had the highest lycopene levels were 59% less likely to have this kind of stroke than men with the lowest levels.\nThe findings appear in the Oct. 9, 2012, issue of Neurology.\nResearchers measured the level of lycopene in their blood when the study began and followed the men for about 12 years.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The sourcing was strong. We hear from three different experts on stroke, who add some valuable context.", "answer": 1}, {"article": "The work builds on the success of the team's pioneering research to tackle antimicrobial resistance over the past 18 months.\nThe breakthrough by researchers at the University of Lincoln, UK, marks another important step to realising the potential of teixobactin in aiding the global fight against antibiotic-resistant pathogens.\nWith this new knowledge, synthesised versions of teixobactin can be more easily developed, taking the process from up to 30 hours to just ten minutes for a single coupling step - a significant step towards turning teixobactin into a viable new drug.\nImportantly, the two new simplified forms of teixobactin have also proven to have identical potency against superbugs as the natural form of teixobactin.\nThese amino acids lack the 'binding' part, over-turning the prior understanding that enduracididine is essential for to so-called 'target binding' to be highly potent against superbugs.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not discuss either funding or conflicts of interest. Readers would have to go to the journal article to learn:\nSince other researchers investigating teixobactin have submitted patent applications and commercialization of basic research has become a routine part of academic science, it would have been nice to see this news release directly address the potential financial interest the researchers may have in the development of their work.", "answer": 0}, {"article": "The new research, reported Oct. 10 in the journal Nature Communications, was led by Charles Brenner, PhD, professor and Roy J.\nThe biggest surprise from his metabolomic analysis was an increase in a metabolite called NAAD, which was multiplied by 45 times, from trace levels to amounts in the micromolar range that were easily detectable.\nThe study showed for the first time that oral NR is superior to nicotinamide, which is better than niacin in terms of the total amount of NAD+ produced at an equivalent dose.\nThe next step will be to study the effect of longer duration NR supplementation on NAD+ metabolism in healthy adults, but Brenner also has plans to test the effects of NR in people with diseases and health conditions, including elevated cholesterol, obesity and diabetes, and people at risk for chemotherapeutic peripheral neuropathy.\nIn particular, the researchers compared the ability of all three NAD+ precursor vitamins - NR, niacin, and nicotinamide - to boost NAD+ metabolism and stimulate the activity of certain enzymes, which have been linked to longevity and health benefits.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release lists the funders and states that the manufacturer, ChromaDex, supplied NR for use in the trial and that lead researcher, Charles Brenner, is a consultant for ChromaDex and co-counder and chief scientific advisor of ProHealthspan, which sells NR supplements under the trade name Tru NIAGEN.\nThe release does not state that Brenner has other conflicts including owning stock in ChromaDex, or that four of the other nine researchers have financial conflicts.", "answer": 1}, {"article": "Natural remedies have an obvious appeal, but how do you know which ones to choose and whether the claims are backed by science?\nThe thinking is that sweet substances of any kind help soothe the back of the throat and break up mucus in the airways.\nThe Risks: According to the National Institute of Allergy and Infectious Diseases, honey may be useful in relieving coughing, but it should never be given to children under a year of age because in rare cases it can cause infantile botulism.\nThe subjects were randomly divided into three groups: one that received no treatment, another that received one or two teaspoons of buckwheat honey, and a third that received a dose of honey-flavored dextromethorphan.\nThe study was carried out by pediatricians at the Pennsylvania State University medical school and supported by a grant from the National Honey Board, an industry-backed agency of the Department of Agriculture.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This is such a brief summation of various studies that we don\u2019t feel this category applies. No one was quoted or cited.", "answer": 2}, {"article": "Sixty percent of the people who considered pets to be a part of their social networks placed them in the central, most important circle \u2014 the same place many people put close family and social workers.\nThe interviews with participants are poignant, and reveal the struggle and isolation that can come with mental illness.\nMany of the study participants are unemployed because of their illness, she notes.\nThe scientists asked who they went to when they needed help or advice, where they gained emotional support and encouragement and how they spent their days.\nHaving a pet that was well taken care of was a source of pride for them.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story clearly highlights one source\u2019s role in the research and incorporates input from a second source who was not associated with the research.", "answer": 1}, {"article": "Hepatitis C is a viral disease that causes inflammation of the liver that can lead to diminished liver function or liver failure.\nThe safety and efficacy of Epclusa for 12 weeks was evaluated in three Phase III clinical trials of 1,558 subjects without cirrhosis or with compensated cirrhosis (mild cirrhosis).\nThe safety and efficacy of Epclusa was also evaluated in a clinical trial of 267 subjects with decompensated cirrhosis (moderate to severe cirrhosis), of whom 87 subjects received Epclusa in combination with ribavirin for 12 weeks, and 94 percent of these patients had no virus detected in the blood 12 weeks after finishing treatment.\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nApproximately 75 percent of Americans with HCV have genotype 1; 20-25 percent have genotypes 2 or 3; and a small numbers of patients are infected with genotypes 4, 5 or 6.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release did not identify funding sources or state whether there were any conflicts of interest.This release describes the approval of a new drug by a regulatory agency, but we\u2019d still like to know who sponsored the study that\u2019s the basis for the approval. It\u2019s not enough to state who manufactures and markets the drug.", "answer": 0}, {"article": "So far, however, there is little scientific proof of their effectiveness\u2014many studies of probiotics have involved less-than-rigorous...\nOne of the fastest-growing dietary supplements, probiotics are now prominent on drug and big-box store shelves.\nThey are live microorganisms\u2014or \"good\" bacteria\u2014that when consumed in capsules or yogurt are said to confer a health benefit.\nBut some researchers are investigating the beneficial bugs for conditions that have nothing to do with the digestive tract.\nSumathi Reddy has details on Lunch Break.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A number of expert sources are quoted. We question the value of comments from a blogger who attributes many personal\u00a0health benefits to probiotics, but we suppose those comments do help to characterize the business side of the story and explain why sales are growing.\u00a0 And despite the number of sources quoted, the story never really delivered an independent expert\u2019s evaluation of evidence.\u00a0The Children\u2019s Hospital source did not address the efficacy of probiotics, only what a microbiome is.\u00a0 Gerard Mullin from Hopkins is an author and presumably stands to gain if people want to learn more about probiotics.\u00a0 There are no sources without a conflict of interest who comment on the efficacy issue, which is what the main value of this story could be. Nonetheless, because some of the quotes at least danced around the edges, we\u2019ll rate this as borderline Satisfactory.", "answer": 1}, {"article": "In 2008 Sciencewatch (Thomson Reuters http://sciencewatch.com/ana/st/hpv/08julHPVWheler/) ranked her global citation contributions over the past decade, 7th in human papillomavirus contributions and in the top 1% in the field of clinical medicine.\nIn the US, only about 40 percent of girls and 21 percent of boys receive the three-dose vaccination series.\nThey found that the vaccine protected the women against HPV infections during the follow-up period and that the women were protected from many types of HPV across a broad age range.\nIt treats about 60 percent of adults and virtually all the children in New Mexico diagnosed with cancer \u2014 more than 10,000 people\u2014 from every county in the state in more than 135,000 clinic visits each year.\nOne of the premier cancer centers nationwide, the UNM CCC has more than 125 board-certified oncology physicians, forming New Mexico\u2019s largest cancer care team.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The study was funded by GlaxoSmithKline, the vaccine manufacturer, but that\u2019s not mentioned in the news release.", "answer": 0}, {"article": "To learn more about NAMS, visit http://www.\n\"This study shows that, for women who need or choose to avoid medications, electro-acupuncture may be an option because it has minimal risks, but blinded controlled trials are needed,\" says Dr. JoAnn Pinkerton, NAMS executive director.\nCLEVELAND, Ohio (November 28, 2016)--It's somewhat of a little-known adverse effect of having breast cancer, but studies suggest that approximately 30% to 40% of women with breast cancer report persistent hot flashes.\nThe study showed electro-acupuncture to be comparable to, if not better than, gabapentin in helping to reduce hot flash severity and frequency and improving overall sleep quality (including falling asleep faster and fewer sleep disruptions).\nAlthough it is not exactly understood how acupuncture affects sleep, it has been shown to affect a number of neurotransmitters associated with sleep, such as serotonin and melatonin.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that the research was funded in part by the National Cancer Institute but it makes no mention of potential conflicts of interest on the part of the researchers involved. We\u2019ll give them the benefit of the doubt here since we don\u2019t have access to the full published study to verify who the funders are or assess whether there are financial conflicts of interest.\u00a0 We encourage news releases to always disclose whether or not there are conflicts.", "answer": 1}, {"article": "What if, her team began to think, it could come up with a blood test for schizophrenia?\n\u201cAs the development costs of a test are very high, there is a risk that the test will not be commercially viable.\u201d For severe mental illnesses like schizophrenia, it\u2019s also the case that even if a test made it through development and hit the market, it may not be successfully integrated into psychiatric practice.\n\u201cThe problem with schizophrenia is that although about 1 percent of the population suffers from schizophrenia, the number of new patients per year is quite low, at 0.02 percent,\u201d says Bahn.\nThe test, says Bahn, can accurately predict whether someone will \u201cdevelop schizophrenia over the next two years.\u201d\n\nBahn\u2019s finding is one of several recent advancements toward a comprehensive system of biological mental health diagnostic tools.\nIt took a few years to find the right \u2018formula\u2019 of meds.\u201d While the doctors recommended some medication that helped, it was a matter of trial and error, since Orlando still doesn\u2019t have a concrete diagnosis today.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story interviews a patient, a professor who is an expert in mental disorders, and a researcher looking at one avenue for biomarker identification. It\u2019s also clear that the reporter read through a lot of studies to develop this piece.\nHowever, the story doesn\u2019t point out that source Dr. Sabine Bahn has apparent financial stakes in the success of this blood test.", "answer": 0}, {"article": "In the first seven months on market, about four in five cardiologists and two in five primary care doctors had prescribed it to more than 250,000 people, Wa\u2019el Hashad, Boehringer\u2019s vice president for cardiovascular marketing, said in an interview last week.\nThe drug acts on an enzyme that leads to blood clots.\nAs many as 12 million people will have it by 2020 because of an aging population with longer life expectancy.\nThere is great appeal and demand for new drugs that do not vary so much and deliver the same stroke-preventing benefits.\nAs many as half of people with the condition, however, are untreated, by varying estimates.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story mentioned that the study reported on had been funded by the drug maker. \u00a0It included comments from a clinician who had no ties to the study reported on.", "answer": 1}, {"article": "Before undergoing surgery, cancer patients could be given the Zika vaccine to \"let the viruses hunt down the GSCs [glioblastoma stem cells] and eliminate them,\u201d said virologist Dr. Cheng-Feng Qin of the Chinese Academy of Military Medical Sciences in Beijing, who worked on the study.\n\u201cWe still need to further improve the specificity of the cancer-killing ability, while retain the safety of the vaccine strain,\u201d Shi explained.\nBut those injected with the combination lived to around 50 days, 20 days longer than the stem cell mice.\nCurrently, most people diagnosed with the condition die within two years.\nThe majority of Zika cases result in a mild fever, rash, aches and pains, conjunctivitis and a headache.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does include an independent source though we wish the source had been tapped more to explain the very limited human implications of the research.", "answer": 1}, {"article": "The study was part of the ongoing Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) project, through which Mukherjee and study co-author Geoffrey Manley, MD, PhD, vice chairman of neurological surgery at UCSF and chief of neurosurgery at Zuckerberg San Francisco General Hospital, along with collaborators from many other research institutions are leading studies and gathering common data across research sites to more quickly advance TBI research.\nThe study revealed telltale patterns of brain activity that, six months later, were associated with worse performance on behavioral and cognitive tests and were different from patterns seen in healthy control subjects.\nThey also exhibited less connectivity within several other networks, including those known as the executive control network, the fronto-parietal network, the dorsal attentional network, and the orbitofrontal network; they showed an increase in connectivity in the visual network.\nFor concussion sufferers, even those who never lost consciousness, physicians may now be able to predict early on who is more likely to continue experiencing symptoms months or years after the head-jarring event, using a new non-invasive magnetic resonance imaging (MRI) method devised by a consortium of researchers led by UC San Francisco scientists.\nIn their new study, published online January 13, 2017 in the Journal of Neurotrauma, the researchers used a technique called functional MRI (fMRI), coupled with sophisticated statistical analysis, to track activity in the brain networks of 75 patients, aged 18 to 55, within the first two weeks of their having experienced concussions.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding sources for this research project included the National Institutes of Health and the Department of Defense. In the original journal article, all authors stated they were free of competing financial interests.\nSince the news release disclosed the funding sources, we give it a Satisfactory rating here.", "answer": 1}, {"article": "It was used to carry a chimeric antigen receptor targeting CD-19 coupled with receptors for two other components of T-cell activity.\nThe results provide \u201ca tumor-attack roadmap for the treatment of other cancers,\u201d including those of the lung and ovaries as well as myeloma and melanoma, researchers said.\nFurther study will show whether the latest results \u201creflect an authentic advance toward a clinically applicable and effective therapy or yet another promising lead that runs into a barrier that cannot be easily overcome,\u201d Urba said in an NEJM editorial.\nThe engineered T-cells were detected in patients\u2019 blood for several months afterward, and a portion of them turned into \u201cmemory T-cells,\u201d which could provide ongoing protection against cancer recurrence, researchers surmised.\nThe leukemia patients in the Phase I trial had to be treated with an immunity-boosting drug since the targeted molecule, CD-19, is also present on certain normal immune-system cells.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Both stories cited just one outside source. The Reuters story, though, did a superior job here by quoting someone who had some words of caution. Dr. Walter Urba of the Providence Cancer Center in Portland warned that \u201cthe long-term viability of the treatment is still unknown.\u201d", "answer": 1}, {"article": "Imperial Health Charity (formerly Imperial College Healthcare Charity) raises funds for five London hospitals within Imperial College Healthcare NHS Trust: Charing Cross, Hammersmith, Queen Charlotte's & Chelsea, St Mary's and Western Eye hospitals.\nNow, for the first time, we have been able to show individual cell death and detect the earliest signs of glaucoma.\nThe technique developed is called DARC, which stands for detection of apoptosing retinal cells.\nWe were the first English university established after Oxford and Cambridge, the first to open up university education to those previously excluded from it, and the first to provide systematic teaching of law, architecture and medicine.\nUCL Business, the commercialisation company of UCL, holds the patents for the technology.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funder is named and we are told that \u201cUCL Business, the commercialisation company of UCL, holds the patents for the technology.\u201d", "answer": 1}, {"article": "\"There are 150,000 new cases of colon cancer each year in the United States, treated at an estimated cost of $14 billion,\" noted Dr. David A. Ahlquist, professor of medicine and a consultant in gastroenterology at the Mayo Clinic in Rochester, Minn.\n\n\"The dream is to eradicate colon cancer altogether and the most realistic approach to getting there is screening,\" he said.\nFor more information on colon cancer, visit the American Cancer Society.\nIt is expected to cost more than a fecal occult blood test, but far less than a colonoscopy.\nAhlquist hopes that the test will be approved and available within two years.\nCologuard is not yet available for sale.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "At least the input of the director of colorectal cancer for the American Cancer Society was important.", "answer": 1}, {"article": "The folks who carried out this egg industry-funded research were from the Pennington Biomedical Research Center in Baton Rouge, La.\nBoth types of breakfasts had the same number of calories, but the egg breakfasts contained \u201chigher protein quality,\u201d according to an abstract for the study, posted online here.\nSo to assess whether people who ate egg breakfasts were better off than their counterparts who ate cereal, they took blood samples and measured the concentration of two key hunger hormones: acylated ghrelin (which stimulates hunger) and PYY3-36 (which is how the intestines let the brain know that you\u2019re full).\nInstead, they recruited 20 volunteers who were overweight or obese and assigned them to a week of either egg breakfasts or ready-to-eat cereal breakfasts.\nThat\u2019s right \u2013 the folks who sell eggs paid for a study that comes to the shocking conclusion that eggs are an ideal breakfast food.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story makes clear that the study\u2019s funding source was the American Egg Board, but doesn\u2019t seek out a comment from an expert who might be able to put the findings in perspective or show us how the funding conflict may have led to a warped result.", "answer": 0}, {"article": "Statins, such as Pfizer Inc\u2019s Lipitor and AstraZeneca\u2019s Crestor, work by preventing the liver from making cholesterol.\nThe most common side effects seen in the trial were injection-site reactions, cold-like symptoms and headache.\nThe disorder is estimated to affect about one in 500 people and causes extremely high cholesterol.\nPatients treated with a placebo saw a 1 percent increase in LDL cholesterol.\nAMG145, along with other PCSK9 inhibitors being developed by companies like Pfizer, Regeneron Pharmaceuticals Inc in partnership with Sanofi and Roche, is a man-made antibody.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Not only are independent voices absent from this story, there is no mention that the study was funded by Amgen and the researchers were either company employees or receive consulting fees or other compensation from Amgen.", "answer": 0}, {"article": "A lot changed in between the births of my second and third daughters. For one thing, this time around I really am getting no sleep; for another, the pediatrician recommended something for our 1-month-old that is different from what had been suggested for our other children. She said we needed to pick up a liquid multivitamin that contains 400 international units (IUs) of vitamin D. It was a little confusing, because with our first daughter, now almost 4, the doctor told us to simply get her out in the sun from time to time to let her body produce vitamin D,...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The sources of information for this story were inadequate. \u00a0We learn the practice recommendations of one pediatrician (as reported by a parent) and a clinician who was reported to chair the Academy of Pediatrics nutrition committee. \u00a0There were no individuals with particular expertise in vitamin D who appeared to have been interviewed for this piece.", "answer": 0}, {"article": "What is the effect of Topical Curcumin Gel for treating burns and scalds?\nThe author of the study believes that the effectiveness of curcumin gel on the skin - or topical curcumin - is related to its potent anti-inflammatory activity.\nThe process goes through a sequence of acute and chronic inflammatory events, during which there is redness, swelling, pain and then healing, often with scarring in the case of burns and scalds of the skin.\nThe sequence is started by the release of phosphorylase kinase about 5 mins after injury, which activates over 200 genes that are involved in wound healing.\n\"Curcumin gel appears to work much better when used on the skin because the gel preparation allows curcumin to penetrate the skin, inhibit phosphorylase kinase and reduce inflammation,\" explains Dr Heng.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The journal article (but not the news release) states that Dr. Heng has shares in Omnicure Inc., a company that manufactures and markets topical curcumin gel. We also found that Dr. Heng is the founder and practicing research physician of this US-based company. Its main product line Psoria-Gold has been used as an anti-inflammatory gel in various spas, health stores and medical clinics in the US and Canada, according to its website. Did the company also help fund the research? That isn\u2019t made transparent in either the news release or the journal article.\nSince the news release does not disclose funding sources and conflicts of interest, we give it a Not Satisfactory rating.", "answer": 0}, {"article": "The trial was funded by Mayo Clinic.\nIn this group, the rate of heart attack, stroke and revascularization and death was 3.7 percent among those with a low ceramide score, but 16.4 percent in people with the highest ceramide levels.\n\u201cOur research suggests that evaluating ceramide levels in patients who are not at immediate risk for coronary artery disease events may help cardiologists decide who could benefit from proactive and preventive treatment, such as statins, or lifestyle changes to prevent a serious cardiac event down the road,\u201d says Jeff Meeusen, Ph.D., a clinical chemist, co-director of Cardiovascular Laboratory Medicine at Mayo Clinic and the study\u2019s lead author.\nThis test seems to provide such information,\u201d says Allan S. Jaffe, M.D., senior author of the study, cardiologist at Mayo Clinic and chair of the Division of Clinical Core Laboratory Services.\nThe test, released commercially by Mayo Medical Laboratories in August 2016, measures blood concentrations of plasma ceramides, a class of lipids that are highly linked to cardiovascular disease processes.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release states that Mayo Clinic funded the trial and notes in the same paragraph that the ceramide test is available through Mayo Medical Laboratories, making the potential conflict of interest quite clear. It also notes that the study\u2019s senior author is a Mayo Clinic cardiologist and chair of the \u201cDivision of Clinical Core Laboratory Services\u201d and that Mayo Medical Laboratories collaborated with Finland-based Zora Biosciences to develop the test.", "answer": 1}, {"article": "Revenues from pharmaceutical and device corporations and health insurance providers are available at http://www.\nPrevious separate studies have shown that a Mediterranean diet reduces certain risk factors for cardiovascular disease, as does a vegetarian diet; however, this was the first study to compare effects of the two distinct eating patterns\n\nCurrent study authors said they wanted to evaluate whether switching to a lacto-ovo-vegetarian diet would also be heart-healthy in people who were used to eating both meat and fish.\nThe study included 107 healthy but overweight participants, ages 18-75, who were randomly assigned to follow for three months either a low-calorie vegetarian diet, which included dairy and eggs, or a low-calorie Mediterranean diet for three months.\nThe vegetarian diet was more effective at reducing LDL (the \"bad\") cholesterol, while the Mediterranean diet resulted greater reductions in triglycerides, high levels of which increase the risk for heart attack and stroke.\nStill, \"the take-home message of our study is that a low-calorie lacto-ovo-vegetarian diet can help patients reduce cardiovascular risk about the same as a low-calorie Mediterranean diet,\" Sofi said.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release noted \u201cthis research received no specific grant from any funding agency, commercial, or not-for-profit sectors.\u201d No conflicts of interest are identified in the published study.", "answer": 1}, {"article": "\u201cFor moving your system to an earlier time, such as would be necessary when traveling West-to-East, light during the last few hours of the night is ideal.\u201d\n\nThe night flashes require special technology and equipment, beyond just a smartphone, which are still in development, Zeitzer said.\nZeitzer was on the committee that removed jet lag as a \u201cdisease\u201d from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), the guide that psychiatrists use to diagnose mental illnesses.\nIn experiments, the technique \u2013 which is based on the way non-visual parts of the brain respond to light \u2013 was much more effective than sustained bright light similar to that from devices sometimes used to combat sleep disorders or seasonal depression.\nThe study included 39 people, 31 of whom were exposed to a series of two-millisecond light flashes with changing intervals while sleeping, and eight of whom were exposed to 60 minutes of continuous bright light.\nIn a previous study, the short flashes of light at night did not interrupt sleep or reduce its quality, he added.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This article scores well on consulting an independent source by quoting a researcher who was not part of the study,\u00a0Anna Wirz-Justice, professor emeritus at the Center for Chronobiology at the University of Basel in Switzerland.", "answer": 1}, {"article": "\"Off-label\" refers to the practice of prescribing medicines to treat conditions not been specifically approved by the FDA.\nCyclobenzaprine, marketed in higher doses by others as Amrix, Fexmid, and Flexeril, is already widely used ''off-label'' for patients with fibromyalgia, Lederman says.\nAbout 5 million Americans have fibromyalgia.\nThe results of the study are published online in The Journal of Rheumatology.\nTONIX is developing a lower-dose version and improving the formula, Lederman says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\nThe story does report that the researcher quoted is the president of the company hoping to market this pill, and that the company funded the study. The story also quotes an independent source. But as noted above, the overall presentation is out of balance, because the boosterism of the company president is given top billing, while the skeptical comments of the independent source are almost entirely relegated to an addendum at the bottom of the story.", "answer": 1}, {"article": "Body temperature, heart and breathing rate normalize more quickly.\nThis was a \"serendipitous magical finding,\" says Gray, suggesting that skin-to-skin contact acted something like a \"natural incubator.\"\nAnd unlike Elias, who cried a lot after delivery, Shabaik says Ali stopped crying \"within seconds\" after being placed on her chest.\nThe benefits are many, according to Dr. Lydia Kyung-Min Lee, an ob-gyn at UCLA.\nIt's not just that mother and baby are together, Gray says, but also that the mother is in some way \"programming the baby, the breathing, temperature and heart rate.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story appears to have at least one independent medical source, and there are no apparent conflicts of interest.\nThat said, the story would have benefited from an expert discussing research on kangaroo care. As we noted in our review of NBC News\u2019s story on the follow-up study, there are some nuances worth pointing out to parents.", "answer": 1}, {"article": "The human collagen used to develop the corneas was provided by biotechnology company FibroGen Inc.\n\u201cThis is the first time we have been able to regenerate a cornea in humans,\u201d researcher May Griffith, PhD, of the Ottawa Hospital Research Institute and the University of Ottawa tells WebMD.\n\u201cWe are still in the prototype stage, but this shows that regenerating a human cornea is possible.\u201d\n\nTwo years after having the corneas implanted, six of the 10 patients had improved vision .\nIn a newly released study, investigators from Canada and Sweden reported results from the first 10 people in the world treated with the biosynthetic corneas.\nA shortage of human donor tissue coupled with the threat of graft rejection from donor corneal transplants has driven the search for other ways of treating corneal damage.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story uses one independent voice. As with many stories of this nature, it waits until the very end to bring in the independent voice of reason. Still, because the researcher\u2019s comments in this story are so cautious, Dr. Walter Stark\u2019s comments only help to bolster the sense that more research is necessary to draw any conclusions about benefits of biosynthetic corneas.", "answer": 1}, {"article": "WHAT'S NEXT: Researchers said they want to see whether moderate drinking also benefits women with hypertension.\nCAUTIONS: The study included only male healthcare providers, so it might not be generalizable to a broader population.\nThe researchers found that people who drank moderate amounts of beer, wine, or liquor had fewer heart attacks, though their risk of death was not significantly different from that of the other subjects in the study.\nBefore the test, one group was exposed to a negative stereotype: They were told that women do not perform well at spatial reasoning.\nOverall, the results suggest that a change in societal messages could spur changes in actual performance.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quotes one expert, the lead author on the study. The story should have quoted multiple experts who could provide more perspective.", "answer": 0}, {"article": "Cancer Treatment Centers was among the first to adopt brachytherapy for breast cancer patients a decade ago, Kelly said.\nThe advantages of brachytherapy, also called \"accelerated partial breast irradiation,\u201d are shorter treatment time and a smaller area that is exposed to radiation.\nBecause the prostate is small and tiny shifts in position can make accurately targeting tumors difficult, OU Physicians has software and a real-time machine that allow doctors to place the seeds exactly where they are needed.\nAlthough standards depend somewhat on doctors' preferences, candidates for breast brachytherapy typically have early-stage tumors with a margin of healthy tissue around the tumor site after removal and minimal or no migration of cancer cells to nearby lymph nodes.\nAlthough there are no large-scale national results, doctors say studies have shown brachytherapy to be as effective as traditional radiation therapy.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The portion of the article on breast cancer includes an interview with one patient who was treated with apparent success, a physician employed by the cancer treatment chain that treated her, and a radiologist from a local university. \nThe reporter should have spoken to one or two nationally recognized experts on radiation therapy and brachytheraphy specifically in order to put the generally positive information in the story in context. The American Society of Breast Surgeons has written guidelines about the appropriate use of brachytherapy. One of its authors would have made an excellent source.\u00a0\nThe section on prostate cancer treatement includes only one source\u2013a urologist who performs the procedure and uses the new software he is enthusiastic about. As with the rest of the story, the article here uses comments about popularity but none about effectiveness or risk. \u00a0", "answer": 0}, {"article": "This is the first to correct an inherited genetic mutation.\n\"For a one-time therapy, like Luxturna, a non-traditional payment and distribution model is necessary to ensure needs of all parties -- patients, payers and providers -- are addressed,\" said Jennifer Luddy, a spokeswoman for Express Scripts.\nThe mutation affects both eyes, usually at the same pace, so most patients would need treatment for both eyes, a Spark Therapeutics spokeswoman said.\nThe company's offer of unusual payer models, including rebates and installment payments, will \"help ensure patients' individual financial situation does not hinder access to treatment,\" da Silva said.\nThe drug will be available in the United States in early spring, with an estimated 1,000 to 2,000 people in the US standing to benefit from this treatment, according to Spark.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story squeaked by on this criterion, because it quoted\u00a0a news release\u00a0by the Patients for Affordable Drugs group that provides important counterbalance to the drug company\u2019s claims. The story would have been stronger if it had contained more input from an independent medical expert who could comment on the veracity of the evidence itself.\n[Editor\u2019s note: This criterion was updated on 1/11/18 to reflect the correct rating. It was previously rated \u201cNot Satisfactory.\u201d This change does not affect the overall rating.]", "answer": 1}, {"article": "First author is Dipen Parekh, MD, of the University of Miami.\nBut apart from the RAZOR trial, there have been no prospective, randomized multicenter trials to assess how robotic surgery compares to open surgery in cancer survival.\nThe RAZOR trial found that two years after surgery, 72.3 percent of patients in the robotic surgery group were alive, with no disease progression and essentially cured, compared with 71.6 percent in the open surgery group.\n\"It is important to conduct these trials before widespread adoption of technology, as has been the case with robotic prostatectomy (removal of the prostate),\" he said.\nThe study is titled \"Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomized, phase 3, non-inferiority trial.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Although the release reports that the study was supported by the National Cancer Institute, it fails to note the financial disclosures several researchers made about money they have received from companies relevant to this study.", "answer": 0}, {"article": "Can a high-tech scan reveal whether Alzheimer's disease is the cause of your forgetfulness? Advocates of Positron Emission Tomography scans for the diagnosis of Alzheimer's say the scans significantly aid in the early and accurate diagnosis of the memory-robbing disease. Neurologists say PET is useful in distinguishing between Alzheimer's and a similar-acting dementia. However, opinions differ on whether the scans are useful in predicting the likelihood of Alzheimer's in people with only mild memory problems.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does quote two directors of major Alzheimer\u2019s research centers. The story could have quoted other clinicians or researchers who may have provided some additional perspective.", "answer": 1}, {"article": "CHICAGO - The majority of patients were pain free after receiving a new image-guided pulsed radiofrequency treatment for low back pain and sciatica, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).\nEven without touching the disc, the pulsation serves to resolve the herniation.\nIt is the most common cause of job-related disability.\nSix patients required a second pulsed radiofrequency session.\nThe patients underwent a minimally invasive interventional radiology procedure in which, with the help of CT imaging, a needle is guided to the location of the bulging disc and nerve root.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "It\u2019s not obvious from the release who funded this work.", "answer": 0}, {"article": "Rosenfeld says it's never wrong to prescribe an antibiotic for a well-diagnosed ear infection.\nAccording to one of the studies, ear infection, or acute otitis media, is the most frequently diagnosed illness in children in the United States, and most children with these ear infections are routinely given antibiotics.\nThe foundation for the \"watchful waiting\" treatment recommendation instead of taking drugs is based on this and previous studies that did not have very many children under age 2 in the clinical trials.\n\"If you received a placebo and you have a 74% chance of having symptoms go away or improvement [of illness]\" \u2013 compared with the 80% in the antibiotic group ... \"as a parent, how impressed are you about a 6% difference?\"\n\"More young children with a certain diagnosis of acute otitis media recover more quickly when they are treated with an appropriate antimicrobial agent,\" Klein wrote.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The\u00a0prominence of the independent voices in this story is a real strength of the coverage. It was nice to see lengthy comments from Dr. Richard Rosenfeld, who literally wrote the book (or at least edited it) on evidence-based treatment of ear infections. There\u2019s also input from a doctor who is a stronger proponent of early antibiotic use.", "answer": 1}, {"article": "\u2022 4.9 million babies are born with a serious birth defect worldwide every year\n\u2022 3.3 million children under five die from serious birth defects annually\n\u2022 Congenital heart disease is the most common form of birth defect, affecting 1 in 100 babies\n\u2022 42 babies are born with a heart defect in Australia every week\n\u2022 30 babies will undergo heart surgery in Australia every week\n\u2022 Heart defects account for 30% of deaths in children under five\n\n[1] Baker H, DeAngelis B, Holland B, Gittens-Williams L, Barrett T Jr. Vitamin Profile of 563 Gravidas during Trimesters of Pregnancy.\nThe findings have been released today by the New England Journal of Medicine \u2013 the most prestigious clinical research publication in the world.\nThis could change the way pregnant women are cared for around the world,\u201d said Professor Graham.\nIt\u2019s extremely rare to discover the problem and provide a preventive solution at the same time.\nThis will enable doctors to identify those women who are at greatest risk of having a baby with a birth defect, and ensure they are getting sufficient vitamin B3.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t name any of the study\u2019s many public or private foundation funders. ", "answer": 0}, {"article": "Such an analysis is months away.\n\u201cThe challenge now shifts from proving the efficacy of the method to developing the proper quality standards, infrastructure and guidelines to bring this needed benefit to those at high risk for the disease \u2014 now,\u201d Ms. Fenton said.\n\u201cNo one should come away from this thinking that it\u2019s now safe to continue to smoke,\u201d said Dr. Harold E. Varmus, director of the National Cancer Institute.\nThe study, called the National Lung Screening Trial, was conducted by the American College of Radiology Imaging Network and the cancer institute.\nBut health officials involved in the study refused to endorse widespread screening of current or former smokers, saying more analysis of the study\u2019s results is needed to further identify who benefited most.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\n\nThere is an independent source and the story reports that the trial was government-financed. \nHowever, the story does not tell readers that the independent source, Dr. Claudia Henschke, has been a loud critic of this trial. Dr. Henschke has been criticized both for making claims about benefits of CT screening that went beyond the available evidence, for having ties to a leading manufacturer of CT scanners, and for taking funding from a tobacco company. She should have been identified as someone who has frequently clashed with those who have supported this trial.\n", "answer": 1}, {"article": "2 Barnes DE, Yaffe K (2011) The projected effect of risk factor reduction on Alzheimer's disease prevalence.\n\"I believe neuroradiology, and especially quantitative MRI technology, will have a huge impact in the future of diagnosis and treatment of Alzheimer's disease, since there is compelling evidence for the baseline size of hippocampus as a key determinant of risk for future cognitive decline, and since many lifestyle factors can cause atrophy or expansion in the volume of this critical brain structure,\" says neurologist Majid Fotuhi, M.D., Ph.D., of Johns Hopkins University.\n\"We are working closely with neuroradiologists to redefine how we can reduce risk for Alzheimer's with quantitative neuroimaging that helps us pinpoint symptom-relevant volume loss in the brain and subsequent targets for tracking our lifestyle-based interventions,\" says Dr. David Merrill, a geriatric psychiatrist at UCLA Medical Center.\nThe American Journal of Neuroradiology (AJNR) is published monthly by the American Society of Neuroradiology (ASNR), a professional association of more than 5,000 members who specialize in diagnostic radiology of the central nervous system, brain, head and neck through the use of X-ray, MRI, CT and angiography.\nThe concept that cognitive decline can be identified early and prevented by applying quantitative brain imaging techniques is the focus of \"Hot Topics in Research: Preventive Neuroradiology in Brain Aging and Cognitive Decline,\" a review published online in American Journal of Neuroradiology (AJNR).\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not specify funding sources for the work, which included the National Institute of Biomedical Imaging and Bioengineering and the National Institutes of Health. Many of the authors are consultants for medical device and pharmaceutical companies, including Toshiba (cited as \u201crelated\u201d or relevant in the original research report). The release does not disclose this.", "answer": 0}, {"article": "The page you are looking for has either moved or is not available (error 404).\n\nPlease return to the homepage or use the search box above to see if the page is available in a new location.\n\nIf you think this message is in error or need assistance, please email the webmaster.", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release makes no mention of funding sources or conflicts of interest. The study itself states that it was funded by the NIH and notes that 13 of the authors, including the primary investigator, have ties to drug companies.", "answer": 0}, {"article": "Also, can we distinguish autism from other forms of developmental delay?\"\nWhile the children were undergoing the fMRI, the researchers played recordings of their parents talking to them and watched for brain activity in areas of the brain responsible for hearing and understanding language.\nAnother expert, Dr. Robert F. Lopez-Alberola, chief of pediatric neurology at the University of Miami Miller School of Medicine, said that \"it's nice to have an objective measure, but it doesn't really do much.\"\n\"It is possible that children who have delayed language but not autism would also show the same pattern.\n\"It is during the toddler/preschool years that autism typically presents and needs to be diagnosed,\" he explained.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "HealthDay continues its laudable tradition of listing the story\u2019s sources at the end of the piece.. We thought the quotes from independent experts were great and provided some strong context.", "answer": 1}, {"article": "While the value of CT scans for screening remains the focus of debate, no one questions the value of the tests for allowing doctors to quickly diagnose a wide variety of health problems, including head injuries, heart problems, cancer, appendicitis, fractures and gallstones.\nThe individual risk varies depending on the age of the patient and the type of scan.\nYounger people face more risk than older people because they have more time for a cancer to develop.\nYou can't get that kind of information any other way.\nThese are X-rays from a CT scan.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes multiple, independent experts who can provide differing perspectives.", "answer": 1}, {"article": "Learn more about brain health at http://www.\nOn the other hand, the more closely people followed a Western diet--a diet that is high in saturated fats and red meats and low in fruits and vegetables--the more likely they were to develop depression.\n\"Depression is common in older adults and more frequent in people with memory problems, vascular risk factors such as high blood pressure or high cholesterol, or people who have had a stroke,\" said study author Laurel Cherian, MD, of Rush University Medical Center in Chicago and a member of the American Academy of Neurology.\nThe study found that people whose diets adhered more closely to the Dietary Approaches to Stop Hypertension (DASH) diet were less likely to develop depression than people who did not closely follow the diet.\nMINNEAPOLIS - People who eat vegetables, fruit and whole grains may have lower rates of depression over time, according to a preliminary study released today that will be presented at the American Academy of Neurology's 70th Annual Meeting in Los Angeles, April 21 to 27, 2018.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that the study was supported by the National Institute on Aging, which is good. However, conflicts of interest are not explicitly addressed. Given that only one of the researchers involved with the study was named, it is impossible for readers to determine if there are any conflicts of interest. For example, one can buy any number of DASH diet cookbooks online \u2014 are any study co-authors associated with those? Given the paucity of information in the release, it\u2019s impossible to tell. (As noted above, we obtained a copy of the study abstract and didn\u2019t see any obvious conflicts of interest \u2014 but the information isn\u2019t readily available in the release.)", "answer": 1}, {"article": "\"It's the first time in the history of Type 1 diabetes where people have gone with no treatment whatsoever ... no medications at all, with normal blood sugars,\" said study co-author Dr. Richard Burt of Northwestern University's medical school in Chicago.\nBurt and other diabetes experts called the results an important step forward.\nIt is less common than Type 2 diabetes, which is associated with obesity.\nBut it didn't work for two of them.\nOne patient was as young as 14.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two experts \u2013 one of whom was apparently not involved in the study. \u00a0\u00a0", "answer": 1}, {"article": "But that could finally change with the introduction of two simple new blood tests for spotting the disease.\nThe tests, which measure antibodies in the blood, were based on research suggesting that IBS may develop after infection from a bacterial toxin found in food poisoning.\n\"We now have a test to say, you have a disease,\" Pimentel told CBS News.\n\"There's always kind of a 'trend of the week' that you had to go and get tested for and rule out, and at the end of the day you don't feel better,\" she said.\n\"I'm not saying the symptoms went away,\" she said, but she \"started to feel more whole.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The quoted CBS news correspondent casts a sufficiently critical view of the test, yet it is hard to say if he is conflicted or not, seeing as he works for the same news outlet the news story has appeared in. \u00a0It would have been relatively easy to discuss the tests with an outside expert unconnected to the test manufacturer or the\u00a0news network.\nIn addition, Dr. Pimental is quoted in the story as \u201cthe developer of the tests.\u201d Most people will probably understand that he has a financial interest, but this could have been made more clear by saying so \u2014 disclosing that he\u2019s a paid consultant of the companies developing the tests commercially.", "answer": 0}, {"article": "THURSDAY, May 9, 2013 (HealthDay News) -- Scientists report positive results in early testing of a wireless pacemaker that's placed in the heart instead of being connected to it via wires from the upper chest.\nStill, he said, the new device will probably be more expensive than other pacemakers, and may pose special risks of its own.\nAnd the existing version of the device won't work for most pacemaker patients because it lacks some key features.\nIt's also not clear when the pacemaker may be publicly available, and its cost is unknown.\nIn the new study, researchers implanted the pacemaker in 32 people for the first time through a puncture in the skin; in 10 patients, they had to reposition it.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The independent experts who were quoted added important cautionary perspectives to the story.\nAnd the story mentioned that the study author receives grant funding from the manufacturer, works for them as a consultant, and has received stock options from the company.", "answer": 1}, {"article": "Drugs such as aspirin and ibuprofen treat inflammation, the body's immune response to infections or pathogens.\nTheir potential side effects also must be investigated, Khandaker said, adding that \"we and other research groups from both sides of the Atlantic are currently planning and conducting such randomized control trials.\"\nThe findings also suggest that \"anti-inflammatory drugs may be helpful in treating patients with depression who are chronically inflamed.\"\nThe immune system acts like a thermostat, turned down low most of the time but cranked up when we have an infection, according to Khandaker.\nIn some people, the thermostat is always set slightly higher, behaving as if they have a persistent low-level infection.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The CNN story offers a quote from a source not associated with the research; and it offers links to websites and other sources where readers could find out more about funding and sponsorship of the study. This is a strong point of the story.", "answer": 1}, {"article": "Get to know how you can help save and improve kids' lives at http://www.\nThe technology is subject to a patent application filed through WORLDiscoveries\u00ae, the joint technology transfer office of Lawson and Western.\n\"This novel approach, to use blood testing of metabolites as a diagnostic tool for concussions, was exploratory and we were extremely pleased with the robustness of our initial results,\" says Dr. Fraser, also an Associate Professor in Western's Departments of Paediatrics, Physiology & Pharmacology and Clinical Neurological Sciences at the Schulich School of Medicine & Dentistry.\n\"We looked at a host of patterns and it appears that those who suffered a concussion have a very different pattern than those who have not had a concussion.\"\nThis new method, fully funded by the Children's Health Foundation and conducted by the Western Concussion Study Group, is unique in that previous attempts have looked unsuccessfully for a single highly accurate protein biomarker that can distinguish concussed from non-concussed adolescent patients.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release notes the funder and acknowledges that the \u201cThe technology is subject to a patent application filed through WORLDiscoveries\u00ae, the joint technology transfer office of Lawson and Western.\u201d", "answer": 1}, {"article": "Chavarro and colleagues studied 926 men who had prostate cancer that hadn\u2019t spread.\nIt\u2019s yet another piece of evidence showing that the so-called Western diet can worsen the risks for cancer, as well as all sorts of other diseases from heart disease to Alzheimer\u2019s.\n\u201cOur findings with Western diet and prostate cancer-specific mortality, however, were surprising, in part because there are very little data regarding how diet after diagnosis may impact disease prognosis.\u201d\n\nThe findings could be important for many men.\n\u201cOur results suggest that the same dietary recommendations that are made to the general population primarily for the prevention of cardiovascular disease may also decrease the risk of dying from prostate cancer among men initially diagnosed with nonmetastatic disease (cancer that has not spread),\u201d said Dr. Jorge Chavarro of Brigham and Women\u2019s Hospital and Harvard Medical School, who led the study.\n\u201cBecause cardiovascular disease is one of the top causes of death among prostate cancer survivors, our findings regarding all-cause mortality are what we anticipated and closely align with the current knowledge of the role of diet on cardiovascular disease,\u201d he said in a statement.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "News articles always come out stronger when sources other than those with a stake in a study\u2019s findings are sought out and quoted. In this case, an additional comment from a nutritional epidemiologist not involved in this study would have provided context.", "answer": 0}, {"article": "\"We want this to be true, we hope that this is true, but we have learned through 30, 40, 50 years of cancer screening that we have to do the right studies at the outset to know that it's true,\" Prasad says.\nFirst, he notes, the Hopkins team will need to demonstrate that the test will be useful in patients without symptoms.\nOf course, the ultimate goal of this test is to find cancer in people who haven't already been diagnosed.\nThey're hoping to make it economical, so that each test could cost about $500.\nAnother problem is that the test results find signs of cancer, but often fail to pinpoint which part of the body is affected.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The two independent sources cited provide important context for understanding the strengths, limitations, and clinical context of the screening test.", "answer": 1}, {"article": "It affects cells that play important roles in helping the immune system battle bacteria, viruses and fungi that can cause infections.\n\"I had a baby to compare her to and I just knew, something was wrong with her,\" Vaccaro told CBS News.\n\"Those stem cells are given back to the patient where they can go back to the bone marrow and make the blood cells for the rest of the patient's life,\" Kohn said.\nThat means an actual cure for the disease, said Kohn, who is also director of the Human Gene Medicine Program at UCLA.\nThe Vaccaros turned to Dr. Donald Kohn at the Broad Stem Cell Research Center at UCLA, where Kohn focuses on the development of new methods to treat genetic diseases of blood cells.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only two people quoted are the clinical investigator and the parent of a child treated. \u00a0A comment or two from other experts in the field would have rounded out the reporting.", "answer": 0}, {"article": "(Reuters) - A combination of two Bristol-Myers Squibb drugs that help the immune system fight melanoma led to significantly greater tumor shrinkage than treatment with one of the medicines, according to a midstage study presented on Monday.\n\u201cThe response rates and the depth of responses are quite impressive,\u201d Dr. Stephen Hodi, director of the Melanoma Center at Dana-Farber Cancer Institute and co-lead author of the study, said in an interview.\n\u201cLonger follow-up will be helpful to see the durability of these responses and what happens to patients who had complete responses,\u201d said Hodi, who presented data from the Checkpoint-069 study at the American Association for Cancer Research meeting in Philadelphia.\nThe overall response rate, defined as tumors that shrank by at least 30 percent, was 61 percent for the 72 patients who received the combination versus 11 percent among the 27 who got Yervoy alone.\n\u201cMost of the patients who stopped for toxicity continued to benefit,\u201d said Fouad Namouni, Bristol\u2019s head of development for Yervoy and Opdivo.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "While the story says\u00a0that both drugs are made by Bristol-Myers Squibb, it fails to note that the study itself was supported by Bristol-Myers Squibb. That\u2019s a significant oversight. Also, while the story quotes two people, one of them is\u00a0a co-author on the study and the other is the Bristol-Myers Squibb employee who was responsible for developing the relevant drugs. An independent perspective would have been very welcome.", "answer": 0}, {"article": "He reviewed the findings for WebMD.\n\"There certainly seems to be a benefit to using the laser,\" says American Academy of Ophthalmology (AAO) spokesman James Salz, MD, clinical professor of ophthalmology at the University of Southern California in Los Angeles.\n\"The idea is that all the surgeon will have to do is remove the pieces with a vacuum,\" says researcher Mark Packer, MD, of Oregon Health and Sciences University in Portland.\nAlthough approved by the FDA, the femtosecond laser procedure is not widely used in the U.S., according to the American Academy of Ophthalmology.\n\"If you have a technique to soften the cataract, there appears to be less chance of damage [to the eye ],\" Salz says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "While the story appropriately discloses that\u00a0an author of one of the studies \u2014 Mark\u00a0Packer, MD \u2014\u00a0consults for a manufacturer that makes lasers, it did not mention that the lead author of the second study\u00a0\u2014 William Culbertson, MD \u2014 also has relationships\u00a0with laser\u00a0manufacturers, as disclosed in this recent Medscape CME article\u00a0(login required). \u00a0In addition \u2014 and more troubling \u2014 it did not disclose the fact that an\u00a0\u00a0American Academy of Ophthalmology spokesman quoted in the story \u2014 James Salz, MD \u2014 has received clinical research grants from another laser manufacturer (as disclosed in a different Medscape CME article\u00a0\u00a0\u2014 login required). Since readers may justifiably assume that Salz\u00a0is presenting disinterested views on behalf of the association, the failure to discuss his industry ties is a significant shortcoming of the piece.", "answer": 0}, {"article": "The higher the result the more eggs, the lower the result the fewer eggs.\n\u201cMy tests were really below normal and that was an indicator to me that I needed to move ahead with taking control of my fertility at that time and doing something, which was egg freezing.\u201d\n\nGold finished her graduate studies, and soon after met her future husband.\n\u201cI was very career-minded and very focused and had relationships throughout my 20s and early 30s, but still wasn't in that forever relationship.\u201d\n\nWomen are born with a finite number of eggs: they start out with roughly one to two million in their ovaries.\n\u201cThere's no way you should lose hope, there's so many things we can do these days and starting early enough we can use this information to keep options open, no matter what the result is you're going to be okay.\u201d\nThe test has traditionally been offered to women who are struggling to get pregnant and helps assess the possible next steps, such as getting pregnant sooner or freezing eggs.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The doctor interviewed in this story stands to gain from positive news coverage of this blood test, especially considering the clinic he works for is actively trying to get women to take the test, which will result in an increase in patient referrals. We think that\u2019s suspect enough that the journalists reporting the story should have sought out additional, independent opinions.", "answer": 0}, {"article": "ASTRO publishes three medical journals, International Journal of Radiation Oncology\n\u2022 Biology\n\u2022 Physics (www.redjournal.org), Practical Radiation Oncology (www.practicalradonc.org) and Advances in Radiation Oncology (www.advancesradonc.org); developed and maintains an extensive patient website, RT Answers (www.rtanswers.org); and created the Radiation Oncology Institute (www.roinstitute.org), a nonprofit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment.\nThe 2016 Annual Meeting is expected to attract more than 11,000 attendees from across the globe, including oncologists from all disciplines and members of the entire radiation oncology team.\nThe technique has become the standard of care for many non-surgical lung cancer patients, as it limits exposure to the heart and surrounding lungs.\nThere were no reported grade four or five toxicities nor any grade three GI toxicities.\nAs the leading organization in radiation oncology, the Society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research, and advocacy.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release does not say how the study was funded or whether any of the investigators have conflicts of interest. In papers on the topic published in 2015, the researchers declared no conflicts of interest.", "answer": 0}, {"article": "\u201cI've responded great.\n\u201cWe have two drugs here so it\u2019s hard to dissect which drug did what, but we do think the vaccine played a key role.\u201d\n\n\u201cIt was shocking to me,\u201d said Diamond.\nI think the prognosis is going to be good now.\u201d\n\nThe most frequent mutation across all cancers occurs in a gene called p53, which contributes to cells becoming oncogenic when they produce a mutant form of the p53 protein (p53 gene mutations are present in about 50% of malignancies).\nIn a subsequent laboratory study, the COH researchers showed that these patients\u2019 immune cells could be reactivated by treatment with a PD1 inhibitor that is a biosimilar to the clinical drug called pembrolizumab.\nThe researchers tested this vaccine, known as p53MVA, in a 2013 clinical trial and found it to be safe in patients with advanced gastrointestinal cancers.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There was no mention of where the funding for the vaccine research came from, but the researcher who\u00a0developed the vaccine was quoted\u00a0in the release saying they were seeking funding for a larger vaccine trial. There was also mention of several drug companies expressing interest in the vaccine, but it\u2019s unclear if any of those same companies have given any money for testing.", "answer": 0}, {"article": "The compound WAY-316606 could therefore be used to treat baldness, without patients suffering the same side effects as they would on CsA.\nDr. Hawkshaw said in a statement: \u201cThe fact this new agent, which had never even been considered in a hair-loss context, promotes human hair growth is exciting because of its translational potential: It could one day make a real difference to people who suffer from hair loss.\u201d\n\n\u201cClearly though, a clinical trial is required next to tell us whether this drug or similar compounds are both effective and safe in hair-loss patients.\u201d\n\nA British Association of Dermatologists spokesperson said in a statement the results were interesting.\n\u201cIt is also important to realize that this is being proposed as a treatment for hair loss, not a cure as such.\u201d\n\nThis piece has been updated with a comment from the British Association of Dermatologists.\nThe scientists were then able to identify that WAY-316606, a compound used to treat osteoporosis, has a similar effect on how SFRP1 is expressed.\nAn existing drug used to treat a common bone disorder could hold the key to the cure for baldness, according to a new study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story had an independent source \u2014 a \u201cstatement\u201d from the British Association of Dermatologists. However, the story didn\u2019t explain that the study was sponsored by Giuliani SpA, an Italian pharmaceutical company that makes dermatology products.\nAn independent source knowledgeable about research and drug development\u2013rather than a professional association\u2019s spokesperson statement\u2013would have helped here.", "answer": 0}, {"article": "Ralph Sacco and Tatjana Rundek of the University of Miami in an accompanying editorial.\nIt didn\u2019t include a comparison group, which would offer the best evidence, but it \u201chelps build the evidence base for the importance of getting in for early treatment,\u201d said Dr. Donna Arnett, dean of public health at the University of Kentucky and past president of the American Heart Association.\nThe researchers also found that the one-year stroke risk doubled when multiple blood vessel clogs were seen with brain imaging, a large artery was narrowed by heart disease and the patient scored a 6 or 7 on a seven-point scale that assesses stroke risk factors.\nThe findings, reported in the New England Journal of Medicine, are more evidence of the benefits of sending someone to a hospital even if muscle weakness or slurred speech has only lasted for a few seconds, lead author Dr. Pierre Amarenco of Bichat Hospital in Paris told Reuters Health by phone.\nBut in the new study, Amarenco and his colleagues found stroke risks of 1.5 percent at two days, 2.1 percent at seven days and 3.7 percent at 90 days when mini-strokes were treated aggressively.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites an independent expert source, as well as drawing on the third-party editorial published in NEJM. However, the story does not tell readers that the study was supported by pharmaceutical companies Sanofi and Bristol-Myers Squibb, which is an important oversight.", "answer": 0}, {"article": "Doctors said Thursday that the increased risk did not outweigh the benefits of the drugs.\n\u201cWhat\u2019s really important to say is that bipolar disorder is very difficult to treat, the burden is enormous, and these medications help keep people free of mood and anxiety symptoms and allow them to function,\u201d said Andrew A. Nierenberg, medical director of the bipolar clinic and research program at Massachusetts General Hospital.\nThe Food and Drug Administration undertook a combined analysis of 199 clinical trials with 43,892 patients and found 4 suicides and 105 reports of suicidal symptoms among the 27,863 patients who were given the drugs compared to no suicides and 35 reports of suicidal symptoms among the 16,029 patients treated with placebos.\nThe drugs, which include Depakote, Lamictal, Topamax, Keppra, Lyrica and Neurontin, are sometimes prescribed for chronic pain and headaches, as well.\nDrugs for epilepsy, bipolar illness and mood problems double the risks of suicidal thoughts and behavior, and patients taking them should be watched for sudden behavioral changes, drug regulators have said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does a good job citing a range of clinicians, patients and pharmaceutical spokespeople.\u00a0 Regarding the latter, the story notes that findings from pharma-sponsored research were either more positive, or similar to that of the FDA\u2019s review. The interviews in this story provide context for the new information; however, Dr. Nierenberg makes a blanket statement about the risks not outweighing the benefits. For some of these drugs, the benefit in bipolar disorder has not been shown.We are not told if Dr. Nierenberg or Dr. Harden receive pharmaceutical funding. ", "answer": 1}, {"article": "Why so few?\nMedicines backed by the strongest evidence include anti-seizure drugs (divalproex sodium, sodium valproate and topiramate), blood pressure drugs (metoprolol, propranolol and timolol) and, for menstrual-related migraines, a medicine called frovatriptan, the guidelines say.\n\"You have a lot of gun-shy patients because of a lot of bad experiences,\" says Michael John Coleman, founder of the patient group MAGNUM, also known as the National Migraine Association.\n\"Migraine is one of the most disabling conditions known to man, but patients need to know that there is hope,\" says Stephen Silberstein, a neurologist at Thomas Jefferson University in Philadelphia and lead author of the guidelines from the American Academy of Neurology and the American Headache Society.\nOne reason is that it's hard to persuade people to take medicines on days when they feel fine, says Elizabeth Loder, a neurologist at Brigham and Women's Hospital in Boston.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included an independent expert source and had some valuable input from a patient advocate group. It also included the perspective of a patient \u2014 a rarity in health stories \u2014 who said she didn\u2019t get much benefit from her medication and experienced signficant adverse effects.\nUnfortunately, however, the story failed to mention the extensive commercial conflicts of the panel that wrote the guidelines, including the author quoted in the story, Dr. Stephen Silberstein. Here is what he disclosed to readers in the guidelines text:\u00a0 \u201cDr. Silberstein is on the advisory panel of and receives honoraria from AGA, Allergan, Amgen, Capnia, Coherex, Colucid, Cydex, GlaxoSmith-Kline, Lilly, MAP, Medtronic, Merck, Minster, Neuralieve, NINDS, NuPathe, Pfizer, St. Jude Medical, and Valeant. He is on the speakers\u2019 bureau of and receives honoraria from Endo Pharmaceuticals, GlaxoSmithKline, and Merck. He serves as a consultant for and receives honoraria from Amgen and Novartis. His employer receives research support from AGA, Allergan, Boston Scientific, Capnia, Coherex, Endo Pharmaceuticals, GlaxoSmithKline, Lilly, MAP, Medtronic, Merck, NINDS, NuPathe, St.Jude Medical, and Valeant Pharmaceuticals.\u201d\n\u00a0", "answer": 0}, {"article": "Lucentis (ranibizumab) was originally developed to treat age-related macular degeneration.\nThe study of 691 patients with DME found that 50 percent of those who received Lucentis eye injections, plus laser treatment if necessary, had substantial improvement in vision one year after treatment, compared with 28 percent of patients who received laser treatment alone.\nThis is a \"seminal\" study,\" added Dr. George A. Williams, a board member of the American Academy of Ophthalmology and chair of the ophthalmology department at Oakland University William Beaumont School of Medicine.\nThe study, published online in the journal Ophthalmology, was conducted by the Diabetic Retinopathy Clinical Research (DRCR) Network.\nThe American Academy of Ophthalmology will review the study findings and make recommendations on whether Lucentis plus laser treatment should be the preferred treatment for a large number of patients with DME.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Quotes come directly from an American Academy of Opthalmology news release.\u00a0 No discussion of whether either of the quoted experts has financial ties to the company making the drug \u2013 but one of them reported in the study that he had ties to the manufacturer. ", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070902/10healthwatch.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quotes one expert who is the lead author on the study.", "answer": 0}, {"article": "But after treatment, the group exposed to the bright light was scoring sexual satisfaction scores of around 6.3.\nAfter taking baseline readings, they divided the men into two groups and gave one regular treatment with a bright light box, while the control, or placebo, group was treated with a light box adapted to give out significantly less light.\n\u201cBefore treatment, both groups averaged a sexual satisfaction score of around 2 out of 10.\nIn contrast, the control group only showed an average score of around 2.7 after treatment.\u201d\n\u201cThe increased levels of testosterone explain the greater reported sexual satisfaction,\u201d he said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not use any independent source and does not address conflicts of interest, though we could not identify any.", "answer": 0}, {"article": "Researchers have found strong evidence that adenotonsillectomy \u2014 the surgery to remove the tonsils and adenoids \u2014 can help relieve childhood behavioral or attention problems, including attention-deficit hyperactivity disorder, or A.D.H.D.\nResearchers studied 78 children who were scheduled for the operation, and a control group of 27 children having other surgery.\nAll the children spent one night in a sleep laboratory to record their sleep and breathing patterns.\nAccording to the paper, which was published yesterday in Pediatrics, it has been known that children with sleep disorders often have behavior problems.\nAlthough the surgery has become less common with antibiotics, more than 400,000 children under 15 have their tonsils, adenoids or both removed every year, according to estimates by the Metropolitan Insurance Company.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "In the story, only a single expert is quoted, the author of the research article in the journal Pediatrics.", "answer": 0}, {"article": "Oct. 26, 2011 -- An experimental drug called briakinumab appears to be more effective than a standard medication for treating psoriasis, a new study shows.\n\"This is the single most effective drug we've had in psoriasis, ever,\" says Kenneth B. Gordon, MD, a dermatologist and clinical associate professor at the University of Chicago's Pritzker School of Medicine.\nReich, a partner at Dermatologikum Hamburg and professor of dermatology, venerology, and allergology at Georg-August-University in Gottingen, Germany, says that after a year of therapy, roughly 60% of the 154 patients in the briakinumab group had near or complete clearance of their skin lesions.\nAt that time, the company said it wanted to evaluate the \"next steps\" for briakinumab and might try for approval again at a later date.\n\"Many of us were disappointed it was withdrawn because there would be a subset of patients who wouldn't respond to anything else and it would have been nice to have for them.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included a second source, but he can\u2019t be viewed as an independent source since he, too, has been involved in research of the drug and has been a paid consultant and investigator for Abbott. \nThe story also did not disclose what is clearly disclosed in the journal article \u2013 that the principal investigator:\n\u00a0\nIt also didn\u2019t disclose what the journal article disclosed, that Abbott personnel helped write the manuscript and helped with the statistical analyses.\n\u00a0\n The Statement of Principles of the Association of Health Care Journalists includes these clauses:\u00a0 ", "answer": 0}, {"article": "Those levels rose in study participants who received vitamin C to become comparable to women who do not smoke.\n\u201cSmoking during pregnancy reflects the highly addictive nature of nicotine that disproportionately affects the most vulnerable populations,\u201d said Dr. McEvoy, lead study author and professor of pediatrics at Oregon Health & Science University.\nSumming up the findings of the current study, Dr. McEvoy said that a relatively low dosage of vitamin C may present \u201ca safe and inexpensive intervention that has the potential to help lung health of millions of infants worldwide.\u201d\n\nHowever, she added, helping mothers quit smoking should remain the primary goal for health professionals and public health officials.\n#Nosmokingduringpregnancy.\u201d\n\nAbout the American Journal of Respiratory and Critical Care Medicine\n\nThe AJRCCM is a peer-reviewed journal published by the American Thoracic Society.\nIn \u201cOral Vitamin C (500 mg/day) to Pregnant Smokers Improves Infant Airway Function at 3 Months: A Randomized Trial,\u201d Cindy T. McEvoy, MD, MCR, and her co-authors report that at three months of age, the infants whose mothers took 500 mg of vitamin C in addition to their prenatal vitamin had significantly better forced expiratory flows (FEFs).\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding is very clearly attributed to the National Heart, Lung, and Blood Institute and the Office of Dietary Supplements.\nConflicts of interest are not mentioned, and none were found.\n\u00a0", "answer": 1}, {"article": "And for this, patients should do their part.\n\u201cTherefore, it is important to study the factors associated with the diagnosis of colon cancer occurring after colonoscopy.\u201d\n\nDuring a colonoscopy, a flexible camera is passed through the colon in search of abnormal growths known as polyps and other warning signs of early tumors.\n\u201cThe key to maximizing protection against colorectal cancer after colonoscopy is performance by an operator with excellent examination\u201d and growth-removal technique, \u201cin a well-prepped colon,\u201d Kahi told Reuters Health by e-mail.\n\u201cThis is very different from a population undergoing screening.\u201d\n\nColonoscopy would probably miss a smaller percentage of cancers in such a large population, Lieberman said, because the rate would be lower.\nGiven the wide variation in colonoscopy training, the researchers call for standardizing it, including credentialing and re-credentialing.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story includes two independent sources to great effect. Without their commentary, readers might be inclined to doubt the results of their colonscopies or seek repeated screenings beyond the recommended schedule. In a short amount of space, this story was able to bring in some valuable perspective on an important study.", "answer": 1}, {"article": "The Duke results were published online Tuesday by the New England Journal of Medicine to coincide with their presentation at the 22nd International Conference on Brain Tumor Research in Norway.\nThe scientists removed one of the virus's genes to prevent it from causing polio and replaced that gene with one from a harmless virus known as a rhinovirus, which ordinarily causes the common cold.\nThe modified virus retains the ability to infect and kill brain tumor cells, and also appears to trigger the patient's own immune system cells to attack the tumors, the researchers say.\nIn addition, the researchers are planning to try the approach on children with brain cancer, as well as other types of cancer, including melanoma and breast cancer.\nThe Duke researchers decided to try to use a genetically modified version of the poliovirus, which can cause a devastating form of paralysis, because of the virus's ability to infect nervous system cells.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did have an independent source, but did not mention that seven of the researchers on the study reported financial interests in the company that holds the license for the treatment.", "answer": 0}, {"article": "Adverse reactions associated with UroLift System treatment were comparable to other minimally invasive surgical therapies as well as standard cystoscopy.\n\"We are committed to providing patients with the highest quality, most effective options to address their urology needs,\" said Matthias Hofer, MD , urologist at Northwestern Memorial Hospital.\nThe most common adverse events reported during the study included pain or burning with urination, blood in the urine, pelvic pain, urgent need to urinate, and the inability to control urine because of an urgent need to urinate.\nPerformed through the urethra, an urologist uses the UroLift System to push aside the obstructive prostate lobes and positions small, tailored permanent UroLift implants to hold the prostate lobes in the retracted position.\nWhile current surgical options, such as the 'gold standard' surgery, Transurethral Resection of the Prostate (TURP), can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction and retrograde ejaculation (dry orgasm).\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release is silent on issues related to conflict of interest. The studies cited in the release were funded by the device manufacturer. The Northwestern urologist quoted in the release has received small payments (amounting to $121.50) from the manufacturer for food and beverages. These could have been acknowledged in a footnote.", "answer": 0}, {"article": "TUESDAY, March 29, 2011 (HealthDay News) -- If you're looking to lose those extra pounds, you should probably add reducing stress and getting the right amount of sleep to the list, say researchers from Kaiser Permanente's Center for Health Research in Portland.\nThose in the second phase of the trial continued their diet and exercise program.\nDuring this part of the trial, the participants lost an average of almost 14 pounds.\nAnd the extra calories mostly came from saturated fat, which can spell trouble for waistlines.\nSimilarly, weight loss reduced stress and depression.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story included expert quotes and also some insight from the results of a recently presented study.", "answer": 1}, {"article": "\"Although media coverage of the early release of data from the STAR trial suggests a clear 'winner' in raloxifene, the data from clinical endpoints and patient-reported symptoms suggest a less clear conclusion,\" Dr. William J. Gradishar and David Cella of Northwestern University wrote in an editorial in the medical journal.\nThe new information presented here and published in the medical journal included a detailed analysis of the side effects of the drugs and the results of a survey of about 10 percent of the 19,747 women in the trial concerning their physical and mental well-being.\nAs for the data on vaginal and vulvar cancer prevention, they came from combining data from three trials used to test the ability of the vaccine, Gardasil, made by Merck & Company, to prevent cervical cancer.\nWhile both drugs reduced cases of breast cancer by about half from what would have been expected for the women in the study, raloxifene caused fewer cases of blood clots, cataracts and uterine cancers, making it initially appear the winner.\nThe editorial in the journal said the new data \"still may not be enough to convince primary care physicians to be more aggressive than they have been to date in breast cancer chemoprevention.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites information from both the editorial that accompanied these studies as well as the researcher who presented the results at a professional meeting. It might have been helpful to note that neither the authors of the editorial nor the presenter appear to have any financial relationship with either drug manufacturer; this information was available in the published articles. ", "answer": 1}, {"article": "NEW YORK -- Scientists acknowledged that an HIV vaccine recently tested in Thailand may be less effective than they originally suggested, but said it still provided valuable leads for further research.\n\nWhen first publicly disclosing the outcome of the vaccine trial in September, researchers said the vaccine had lowered the risk of infection by about 31%. That result was modest but statistically significant. Coming after two decades of failed HIV-vaccine trials, the announcement was welcomed by researchers around the world.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story does not provide commentary from any independent sources. In this case, a single comment from a biostatistical consultant would have provided helpful perspective.\u00a0 ", "answer": 0}, {"article": "\"In this long-term study of lorcaserin for treating patients for obesity, there was good weight loss, outstanding safety profile and the drug was extremely well-tolerated,\" said lead researcher Dr. Steven Smith from the Translational Research Institute for Metabolism and Diabetes in Winter Park, Fla.\n\n\"As patients are looking for additional options and physicians are looking for new tools, [lorcaserin] provides us with a look into the future for what's going to be available for helping patients lose weight,\" he added.\nThe report is published in the July 15 issue of the New England Journal of Medicine, and was sponsored by Arena Pharmaceuticals, of San Diego, Calif., which used its own doctors as part of the study group.\nThe third new drug is Orexigen Therapeutic's Contrave, which is a combination of the antidepressant Wellbutrin and the addiction drug naltrexone.\n\"If weight-loss drugs are tailor-made to hit only the right receptor, based on physiological knowledge, it seems to be possible to develop weight-loss medications that do not possess any serious adverse effects,\" Astrup added.\n\"Among those who remained, lorcaserin produced relatively modest weight loss when combined with diet and exercise counseling, and that weight loss was maintained in over half of the participants only so long as they kept taking the drug.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Of the three, this story makes the best use of outside sources and does the best job of identifying conflicts of interest. It should have taken the extra step of noting Arne Astrup\u2019s conflicts of interest, given that he is the chief \"independent\" booster of the drug. But in the first two paragraphs it says \"industry-funded research,\" \"work was sponsored by the drug manufacturer\" and \"was sponsored by Arena Pharmaceuticals.\"", "answer": 1}, {"article": "For more information about the AACR, visit http://www.\nAmong the 36 patients with hormone receptor-positive breast cancer, 11 had a partial response, with four of the 11 responders having continued prior endocrine therapy, and an additional 18 patients had stable disease.\nFor example, abemaciclib has greater selectivity for CDK4 compared with palbociclib, which may explain why it does not affect white blood cell counts as severely, allowing it to be taken on a continuous schedule without treatment holidays, he said.\nIn addition, the AACR publishes eight prestigious, peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers.\nAuthor Comment: \"These data show that abemaciclib is an oral drug that can be taken on a continuous schedule and achieve durable clinical activity against multiple tumors including breast and lung cancers,\" said Shapiro.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release includes a \u201cFunding & Disclosures\u201d paragraph. It lists funding by Eli Lilly and Company. It also lists some of the payments and other connections between key researchers and the company. We like the format used for this EurekAlert version of the release, which also notes the funder in a box just to the right of the release\u2019s headline.", "answer": 1}, {"article": "A female testosterone patch showed promise at boosting older women's enjoyment of sex, but concerns about the cancer risk of hormone therapies mean U.S. women won't be getting an equivalent of Viagra anytime soon.\n\nProcter & Gamble Co., the Cincinnati consumer-products giant, has worked since 1999 to secure U.S. approval for its Intrinsa patch, intended to increase sex drive and satisfaction in women after menopause.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only sources contacted for this story are representatives of two companies involved with development of female sexual satisfaction products, including the one studied in the journal report. \nThe viewpoints of independent clincians and researchers would have been valuable.\u00a0 ", "answer": 0}, {"article": "Hartmann said doctors could take pressure off women by performing lumpectomies first to eliminate their cancer tumors.\nIt\u2019s an emotional decision that women often make quickly, considering that surgeries often take place within days of their cancer diagnosis.\n\u201cIf I didn\u2019t do as much as possible to eliminate the cancer, I would feel like I was almost waiting for the other shoe to drop.\u201d\n\nWomen removing a single cancerous breast have a 1 percent chance per year of suffering cancer in the other breast.\nThen the women can have genetic tests and assess their risks for follow-up cancers before deciding whether to have one or both breasts removed.\n\u201cI\u2019m worried about the women who are on the fence and make a very quick decision before really considering the other options or the fact that it is an irreversible procedure,\u201d said Dr. Todd Tuttle, the U\u2019s chief of surgical oncology and lead author of the study in the Journal of Clinical Oncology.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The reporter interviews the lead author of the study, two additional credible medical experts and one patient. The patient, a nurse, is a more credible source than one often finds in news stories.\u00a0\u00a0 ", "answer": 1}, {"article": "But, lead author Dr. Giacomo Koch said, \u201cWhat we found is that the improvement was more marked in those patients that were more impaired.\u201d\n\nKoch, from the Santa Lucia Foundation in Rome, told Reuters Health he thinks those patients with more severe problems would likely see a benefit outside of just test results.\nThe \u201creal\u201d magnetic stimulation group improved by about 16 percent right after the treatment and 23 percent at the later time point, while there was no significant benefit seen in patients given the fake stimulation.\nAbout half of people who have a stroke end up with difficulty processing or reacting to things on one side of their body, most often on the left side after a stroke in the right side of the brain, said Dr. Anna Barrett, director of stroke rehabilitation research at the Kessler Foundation in West Orange, New Jersey, who wasn\u2019t involved in the new study.\nThe researchers said that it\u2019s not clear what the amount of improvement they observed would mean for patients in their daily lives.\nIn a new, small study published in the journal Neurology, patients who were given quick bursts of stimulation over a couple of weeks improved by about 20 percent on tests of vision and attention, while those who got a fake stimulation treatment didn\u2019t improve significantly.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an author of the new study as well as a neurologist who wasn\u2019t involved with the research.\u00a0 In fact, that independent expert was quoted before the study author was.  ", "answer": 1}, {"article": "The boxes are a new idea for many Americans.\n\u2018\u2018They do it because they want to be nurturing and they are, but it\u2019s not safe.\u2019\u2019\n\nTo get the boxes, prospective moms can register through babyboxuniversity.com, watch a handful of videos on sleep safety and pass a quiz.\nThe idea for baby boxes started in Finland in the 1930s, and is tied to a sharp drop in sudden infant deaths, according to Dr. Kathryn McCans, a pediatrician who chairs New Jersey\u2019s Child Fatality and Near Fatality Review Board.\nBut when they\u2019re linked to a practice that started in Finland decades ago to help babies sleep safely, they\u2019re taking on a new purpose as so-called baby boxes make their way to the U.S.\n\nParents are beginning to take baby boxes home from hospitals along with their newborns.\nMcCans says the complimentary items like diapers and onesies are nice, but the more important objective behind the boxes is bringing down infant deaths and grounding parents on safe sleep practices: Place babies on their backs to sleep; Don\u2019t use bumpers in cribs; Keep stuffed animals and blankets out of infants\u2019 sleep spaces; Avoid sleeping in the same bed as infants.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story tells readers that the Baby Box Co. is a \u201cfor-profit\u201d company. But they don\u2019t give us any details about the company\u2019s relationship with the pediatrician, Kathryn McCans, who is the only physician quoted in the story.\nDoes Dr. McCans receive any funding or payment from The Baby Box Company? We can\u2019t tell from the story. At the company\u2019s own website, she is listed as one of \u201cour experts\u201d on this page. \nShe may have donated her time, but that isn\u2019t made clear. At the very least, it should have been clarified that that McCans has a relationship with the company and is not totally independent.", "answer": 0}, {"article": "If that feels a little onerous, consider new findings out of Baylor College of Medicine in Houston suggesting that love of physical activity may start in the womb.\nBut in the human studies, it wasn\u2019t always clear whether active mothers who have active children simply raised their kids to exercise a lot or whether there might have been a genetic predisposition to physical activity.\nThe offspring of those mothers turned out to be about 50 percent more physically active than those born to mothers that hadn\u2019t had the exercise wheel option.\nThe mice with running wheels voluntarily ran an average of more than six miles a night, decreasing to about two miles late in pregnancy.\nObservational studies of active pregnant women and their babies have reported \u201cresults consistent with ours,\u201d Waterland said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There appear to be no overlooked conflicts of interest in this story. However, because there were no independent sources, this falls under Not Satisfactory.", "answer": 0}, {"article": "Other studies are further along.\nThe message for patients, he added, is that heart failure can be treated, and researchers are looking for \"innovative\" ways to improve that treatment.\nHowever, experts cautioned that while the results are encouraging, there's a lot of work left ahead before stem cells can be used to treat heart failure.\nIn an early study of 27 patients, Japanese researchers used patients' own muscle stem cells to create a \"patch\" that was placed on the heart.\nSo it's possible, Gorodeski explained, that the \"modest\" symptom improvements would have happened anyway.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story uses an independent source to good effect, which we are always glad to see. However, the story misses a key point in terms of conflicts of interest. While this specific study was funded by Japanese government agencies, the journal article notes that the research team also receives funding from TERUMO Company. TERUMO Company makes a product called HeartSheet, which Nature described in 2015 as being \u201cmade of skeletal-muscle stem cells that are taken from a patient\u2019s thigh and grown in the lab. The sheet\u2026is then applied to the hearts of people who have severe cardiac failure.\u201d\nIn other words, the researchers receive funding from the company whose product they were testing \u2014 even though they don\u2019t explicitly explain in the paper that what they are doing is virtually identical (if not identical) to TERUMO\u2019s product.", "answer": 0}, {"article": "\u201cBut if adults believe in echinacea, they\u2019re going to get benefits \u2014 maybe from placebo \u2014 but they\u2019ll get benefits.\u201d\n\nDr. Coleman, who described himself as \u201cnot much of a pill taker,\u201d hedged a bit when asked if he planned to use echinacea himself.\nIn addition, some studies might not use large enough doses of the herb; others might use a species of echinacea that is less effective.\n\u201cIf you\u2019re testing the same intervention on the same population using the same outcome measures, then meta-analysis is a very good technique,\u201d Dr. Barrett said.\n\u201cI\u2019ll probably consider taking it if I feel a cold coming on,\u201d he said.\nSome might not have a large enough sample to find a small but statistically significant effect.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The reporter does an excellent job describing the rigor of the study and getting the author, an interested party, and a disinterested party to provide perspective. ", "answer": 1}, {"article": "\"The bottom-line finding of the Alpha Omega Trial is that [omega]-3 fatty acids did not reduce the primary endpoint major cardiovascular events,\" Kromhout said, noting that the ALA finding needs further confirmation.\nAll had experienced a heart attack at some point in the decade leading up to the study, and all were taking blood pressure medications, anti-clotting drugs and statins.\nNone of the low-dose supplements seemed to stave off such events in most of the patients.\nAnd they're also not just looking at preventable fatalities but all heart-related events that follow.\nIt is during this acute post-attack period, he explained, when patients are most vulnerable to a subsequent event.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0The story included comments from several individuals without direct ties to the study reported on but with active research programs examining the potential of benefit from omega-3 fatty acids.", "answer": 1}, {"article": "Chattoo also offers patients a nutritionist and trainer with the procedure.\nShe told FoxNews.com that the balloon \u201cmakes you feel full all the time to the point where you\u2019re not angry about having to lose things like chocolate and cake.\u201d\n\nBrown said that the balloon acted like a \u201crestart button\u201d and retrained her body to adapt to a new lifestyle of healthy eating and exercise.\n\u201cThe beauty of the procedure is that it is a nonsurgical procedure,\u201d Chattoo said.\nNow, there is a new solution for people with a body mass index (BMI) between 30 and 40 that want to lose weight called the Orbera gastric balloon.\nThe balloon remains in the patient\u2019s stomach for six months and is then removed the same way it was inserted, through the mouth.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites two sources. One is a pleased former patient who used Orbera. The other is a doctor who provides Orbera to his clients. There are no outside sources who can an offer impartial assessment of Orbera: it\u2019s effectiveness, safety or novelty. And the story does not tell readers that the doctor offers Orbera to his clients (though a critical news consumer would probably guess). We only know because we went to his website (which the story links to).", "answer": 0}, {"article": "Silberstein was the lead author of new migraine treatment guidelines presented Monday at the annual meeting of the American Academy of Neurology in New Orleans.\nThe authors also noted that frovatriptan (Frova), which is used to treat migraine symptoms, can also help prevent menstrual migraines.\nIn a summary of the guidelines written for patients and their families, this is how migraines are described:\n\nPreventive treatment involves taking a seizure drug and a beta-blocker every day to reduce the frequency, severity and duration of migraines.\nThese medications \u201care effective for migraine prevention and should be offered to patients with migraine to reduce migraine attack frequency and severity,\u201d Silberstein and colleagues wrote in the new guidelines, which were based on a review of 284 publications.\nNew guidelines\u2026 (Photo illustration by Gary\u2026)\n\n\u201cMigraine is a condition that involves recurring headaches.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story noted that 5 of the 6 guideline authors disclosed relationships with drug companies. However, the only source quoted in the article is one of the guideline authors \u2014 no independent perspective was included.", "answer": 0}, {"article": "MONDAY, Aug. 6, 2012 (HealthDay News) -- Treatment with growth hormone-releasing hormone improves memory and focus in healthy adults and in those who already show some signs of mental decline, new research finds.\nBenefits from the treatment lasted as long as people stayed on the treatment.\nResults of the study are published in the Aug. 6 issue of the Archives of Neurology.\nLearn more about mild cognitive impairment from the Alzheimer's Foundation.\nAll of these hormones are believed to play a role in brain health, and decreasing levels of these hormones are suspected to play a role in the development of Alzheimer's disease.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One independent expert\u2019s input was important at the end of the story.", "answer": 1}, {"article": "None did.\nMeanwhile, in Philadelphia, radiologists examined the scans and calculated how much plaque was present in the patients\u2019 brains and, independently, used a computer to analyze the amount of plaque in the scans.\nIn addition, the company scanned the brains of 76 younger people who would not be expected to have plaque in their brains.\nDr. Reisa A. Sperling, an Alzheimer\u2019s expert at Brigham and Women\u2019s Hospital in Boston and co-chairwoman of the session where the results were presented, said, \u201cPersonally, I found the data quite convincing.\u201d\n\nDr. Sperling, an investigator on a different AVID study but who is not paid by the company, said the challenge now will be to see whether the scans can accurately predict whether people are developing Alzheimer\u2019s before they have symptoms.\nAnd the data showed that the scans were completely accurate in ruling out Alzheimer\u2019s pathology: unlike doctors, they never said people had Alzheimer\u2019s pathology when they did not.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0The story quotes three clinicians, all of whom had ties to the company involved with promoting the test reported on or the study of that test. \u00a0So while conflicts of interest were identified, there did not appear to be any independent sources interviewed on the topic. The story mentioned that \u2018experts who attended said the data persuaded them that the method works\u2019 but were they all in some way connected with the company? ", "answer": 0}, {"article": "The findings were presented Monday at the American Heart Association (AHA) annual meeting in Orlando, Fla.\n\"Even though statins are so effective at lowering cholesterol and reducing risk for heart disease and stroke, they do need to be taken every day and they can have certain side effects in some people,\" said Sacco, who is also chairman of neurology at the University of Miami.\n\"There are still plenty of people who can't achieve adequate LDL levels with existing drugs, including statins,\" he noted.\nThe study was funded by AMG145 manufacturer Amgen Inc.\n\nHigh cholesterol is a major risk factor for heart disease.\n\"This new shot may provide a more long-lasting approach, especially if it could be given once a month,\" Sacco said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story alerted readers to the fact that the study was funded and conducted by Amgen. However, at least one of the researchers who comments on the findings \u2014 Daniel Rader \u2014 consults for numerous pharmaceutical companies that produce or are developing new cholesterol-based therapies, including drugs that target the PCSK9 pathway discussed in the article.\u00a0To avoid any appearance of a conflict, the story should have disclosed these relationships.", "answer": 0}, {"article": "While the proton therapy market is expected to more than double by 2018, with an estimated 300 proton therapy rooms, Jongen's Brussels-based company IBA is working on a smaller and cheaper model they hope will make proton therapy more accessible.\nWhen I feel a bit depressed, for whatever reason, I go back to those letters and they are very exciting.\"\n\"There are a number of cancers which are not localized,\" he said.\n\"It does a lot less collateral damage to the patient,\" Jongen said.\nOnce the proton beam has been generated, it's piped into a treatment room where patients receive a powerful dose of targeted radiation that kills only those cancerous cells.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "It would not have been difficult find an independent source to give perspective on the claims in this story.\nBut no independent source appeared in this story.", "answer": 0}, {"article": "But this could take a few years to develop.\n\"This is the earliest phase, and you now have to show that it actually breaks down the gluten peptides that trigger a response in the stomach at a speed that will protect the human,\" said Dr. Joseph Murray, a professor of medicine in the division of gastroenterology and the department of immunology at the Mayo Clinic, in Rochester, Minn. \"Let's see how it goes with a whole slice of bread.\"\nIn this case, the researchers re-engineered the natural enzyme to recognize the peptide that triggers celiac disease and modified the protein in the laboratory so it would survive the acidic stomach environment.\nIf the researchers opt to make a prescription drug, the process of clinical trials and obtaining U.S. Food and Drug Administration approval could take a decade or more, he said.\n\"It will probably be helpful to someone who gets a low-level exposure [to glutens] by accident,\" he said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The expert source quoted at the end of the article provides some very important context. This is the major strength of the story. However, the story should have mentioned that Dr. Murray is on the scientific advisory board of a company testing a competing treatment for celiac disease. His comments should be viewed with that perspective.", "answer": 0}]